10 Nov 2022 29 June 2023 8 Jul 2021 January 17, 2025 March 9, 2023 May 12, 2023 May 30, 2025 Contact: Stephan Schurer schurer at med dot miami dot edu Contact: Stephan Schurer stephan dot schurer at gmail dot com Contact: Stephan Schurer stephan dot schurer at med dot miami dot edu Contact: Stephan Schurer stephan dot schurer at med dot miami dot edu Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Nicolette Ross, Joan Glenny-Pescov, Jiaming Hu, Caty Chung, Stephan Schurer* Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, add_name, Stephan Schurer* Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner,colette Ross, Joan Glenny-Pescov, Jiaming Hu, Caty Chung, Stephan Schurer* Created by: Saminda Abeyruwan, Caty Chung, Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Nicolette Ross, Joan Glenny-Pescov, Jiaming Hu, Stephan Schurer* Created by: Caty Chung, Nicolette Ross, Joan Glenny-Pescov, Jiaming Hu, Stephan Schurer* There is a one-to-one correspondance with rdf:label value and concept descriptions. Concept description starts with the prefix BAO_. contact: Stephan Schurer: stephan dot schurer at gmail dot com created by: Uma Vempati, Hande Küçük, Ubbo Visser, Saminda Abeyruwan, Kunie Sakurai, Vance Lemmon, Stephan Schurer* BAO BioAssay Ontology Bioassay ontology bioassay ontology 2.1 2.7.2 2.7.4 2.7.5 2.8.12 2.8.15 2.8.2 2.8.6 An annotation property that represents an ID used in the NIH LINCS project. Oliver He, Jiangan Xie, Jie Zheng LINCS ID An annotation property that represents a PubMed BioAssay Identifier accession number. Oliver He https://pubchem.ncbi.nlm.nih.gov/help.html PubChem AID editor preferred label editor preferred term The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English) PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> editor preferred label editor preferred label editor preferred term editor preferred term editor preferred term~editor preferred label example example of usage A phrase describing how a class name should be used. May also include other kinds of examples that facilitate immediate understanding of a class semantics, such as widely known prototypical subclasses or instances of the class. Although essential for high level terms, examples for low level terms (e.g., Affymetrix HU133 array) are not A phrase describing how a term should be used and/or a citation to a work which uses it. May also include other kinds of examples that facilitate immediate understanding, such as widely know prototypes or instances of a class, or cases where a relation is said to hold. PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> IAO:0000112 uberon example_of_usage true example_of_usage example of usage example of usage has curation status PERSON:Alan Ruttenberg PERSON:Bill Bug PERSON:Melanie Courtot OBI_0000281 has curation status has curation status definition A property representing the English language definitions of what NCI means by the concept. They may also include information about the definition's source and attribution in a form that can easily be interpreted by software. The official OBI definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. The official definition. 2012-04-05: Barry Smith The official OBI definition, explaining the meaning of a class or property: 'Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions' is terrible. Can you fix to something like: A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property. Alan Ruttenberg Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can't be evaluated by those criteria. On the specifics of the proposed definition: We don't have definitions of 'meaning' or 'expression' or 'property'. For 'reference' in the intended sense I think we use the term 'denotation'. For 'expression', I think we you mean symbol, or identifier. For 'meaning' it differs for class and property. For class we want documentation that let's the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let's the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The 'intended reader' part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition. Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable. We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with. 2012-04-05: Barry Smith The official OBI definition, explaining the meaning of a class or property: 'Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions' is terrible. Can you fix to something like: A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property. Alan Ruttenberg Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can't be evaluated by those criteria. On the specifics of the proposed definition: We don't have definitions of 'meaning' or 'expression' or 'property'. For 'reference' in the intended sense I think we use the term 'denotation'. For 'expression', I think we you mean symbol, or identifier. For 'meaning' it differs for class and property. For class we want documentation that let's the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let's the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The 'intended reader' part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition. Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable. We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with. PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> DEFINITION definition definition textual definition editor note An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology. PERSON:Daniel Schober GROUP:OBI:<http://purl.obfoundry.org/obo/obi> IAO:0000116 uberon editor_note true editor_note editor note editor note term editor Name of editor entering the term in the file. The term editor is a point of contact for information regarding the term. The term editor may be, but is not always, the author of the definition, which may have been worked upon by several people 20110707, MC: label update to term editor and definition modified accordingly. See http://code.google.com/p/information-artifact-ontology/issues/detail?id=115. PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> term editor term editor alternative term An alternative name for a class or property which means the same thing as the preferred name (semantically equivalent) PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> alternative term alternative term definition source formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007 PERSON:Daniel Schober Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w GROUP:OBI:<http://purl.obolibrary.org/obo/obi> definition source definition source An administrative note of use for a curator but of no use for a user IAO:0000232 uberon curator_notes true curator_notes curator note curator note curator notes the URI for an OBI Terms ticket at sourceforge, such as https://sourceforge.net/p/obi/obi-terms/772/ An IRI or similar locator for a request or discussion of an ontology term. IAO:0000233 external uberon term_tracker_item true true term_tracker_item The 'tracker item' can associate a tracker with a specific ontology term. term tracker item term tracker item imported from For external terms/classes, the ontology from which the term was imported PERSON:Alan Ruttenberg PERSON:Melanie Courtot GROUP:OBI:<http://purl.obolibrary.org/obo/obi> imported from imported from IAO_0000125 Use on obsolete terms, relating the term to another term that can be used as a substitute Add as annotation triples in the granting ontology Person:Alan Ruttenberg term replaced by An association that specifies one of three data types for a particular variable, String, Code or Number. A23 Conceptual Entity Has_PCDC_Data_Type Has_PCDC_Data_Type Has_PCDC_Data_Type An association that shows which Permissible Values are possible for a specific PCDC EWS Variable concept. A29 Conceptual Entity Has_PCDC_EWS_Permissible_Value Has_PCDC_EWS_Permissible_Value Has_PCDC_EWS_Permissible_Value An association that that connects a concept representing a GDC value to any associated GDC property concept(s). A32 Conceptual Entity Is_Value_For_GDC_Property Is_Value_For_GDC_Property Is_Value_For_GDC_Property An association that shows which Permissible Values are possible for a specific PCDC GCT Variable. A34 Conceptual Entity Has_PCDC_GCT_Permissible_Value Has_PCDC_GCT_Permissible_Value Has_PCDC_GCT_Permissible_Value An association that shows which Permissible Values are possible for a specific PCDC OS Variable. A38 Conceptual Entity Has_PCDC_OS_Permissible_Value Has_PCDC_OS_Permissible_Value Has_PCDC_OS_Permissible_Value An association that shows which Permissible Values are possible for a specific PCDC HL Variable. A39 Conceptual Entity Has_PCDC_HL_Permissible_Value Has_PCDC_HL_Permissible_Value Has_PCDC_HL_Permissible_Value An association that shows which Permissible Values are possible for a specific DIPG/DMG Variable. A40 Conceptual Entity Has_DIPG_DMG_Permissible_Value Has_DIPG_DMG_Permissible_Value Has_DIPG_DMG_Permissible_Value true A property representing a concept unique identifier within the NCI Enterprise Vocabulary Service's NCI Thesaurus. NHC0 Conceptual Entity code code code A property that represents a description of the sort of thing or category to which a concept belongs in the context of the UMLS semantic network. P106 Conceptual Entity Semantic Type Semantic_Type In general, applying semantic types aids in allowing users (or computer programs) to draw conclusions about concepts by virtue of the categories to which they have been assigned. We use a set of semantic types developed for the UMLS Metathesaurus. There are currently 134 semantic types in the UMLS. Semantic_Type Semantic_Type A property representing an alternative Preferred Name for use in some NCI systems. P107 Conceptual Entity Display Name Display_Name Display Name Display_Name Display_Name A property representing the word or phrase that NCI uses by preference to refer to the concept. P108 Conceptual Entity Preferred Name Preferred_Name Preferred Name Preferred Term Preferred_Name Preferred_Name A property representing the concept unique identifier (CUI) assigned by the National Library of Medicine (NLM). If a concept in any NCI-maintained knowledgebase exists in the NLM Unified Medical Language System (UMLS), NCI includes the NLM CUI among the information we provide about the concept. P207 Conceptual Entity UMLS CUI UMLS_CUI UMLS_CUI UMLS_CUI A property representing the concept unique identifier (CUI) for those concepts that appear in NCI Metathesaurus but not in the National Library of Medicine Unified Medical Language System (NLM UMLS). P208 Conceptual Entity NCI Metathesaurus CUI NCI_META_CUI NCI_META_CUI NCI_META_CUI A property is used to indicate when a non-EVS entity has contributed to, and has a stake in, a concept. This is used where such entities, within or outside NCI, have indicated the need to be able to track their own concepts. A single concept can have multiple instances of this property if multiple entities have such a defined stake. P322 Conceptual Entity Contributing Source Contributing_Source Contributing_Source Contributing_Source A property representing the English language definition of a concept from a source other than NCI. P325 Conceptual Entity [source] Definition ALT_DEFINITION ALT_DEFINITION ALT_DEFINITION true A property representing a retired unique concept identifier created and stored as Concept Name by legacy EVS software. Use of these values was long discouraged, but continued as late as 2009 when creation of new values ceased and Concept Name was retired. Legacy values are intended solely to help resolve and update earlier coding. P366 Conceptual Entity Legacy Concept Name Legacy Concept Name Legacy_Concept_Name Legacy Concept Name A property representing that a term in another terminology has been mapped to a term in NCIt and describes the relationship between the mapped terms. P375 Conceptual Entity Maps_To Maps_To Maps_To A property representing notations made by NCI vocabulary curators. They are intended to provide supplemental, unstructured information to the user or additional insight about the concept. P98 Conceptual Entity DesignNote DesignNote DesignNote DesignNote An alternative term used by the IEDB. IEDB alternative term tooth SubClassOf 'never in taxon' value 'Aves' x never in taxon T if and only if T is a class, and x does not instantiate the class expression "in taxon some T". Note that this is a shortcut relation, and should be used as a hasValue restriction in OWL. PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#> PREFIX owl: <http://www.w3.org/2002/07/owl#> PREFIX in_taxon: <http://purl.obolibrary.org/obo/RO_0002162> PREFIX never_in_taxon: <http://purl.obolibrary.org/obo/RO_0002161> CONSTRUCT { in_taxon: a owl:ObjectProperty . a owl:Restriction ; owl:onProperty in_taxon: ; owl:someValuesFrom ?taxon ] . ?x rdfs:subClassOf [ a owl:Restriction ; owl:onProperty in_taxon: ; owl:someValuesFrom [ a owl:Class ; owl:complementOf ?taxon ] ] . } WHERE { ?x never_in_taxon: ?taxon . } RO:0002161 uberon never_in_taxon true true never_in_taxon never in taxon A is mutually_spatially_disjoint_with B if both A and B are classes, and there exists no p such that p is part_of some A and p is part_of some B. PREFIX owl: <http://www.w3.org/2002/07/owl#> PREFIX part_of: <http://purl.obolibrary.org/obo/BFO_0000050> PREFIX mutually_spatially_disjoint_with: <http://purl.obolibrary.org/obo/RO_0002171> CONSTRUCT { part_of: a owl:ObjectProperty . [ a owl:Restriction ; owl:onProperty part_of: ; owl:someValuesFrom ?x ; a owl:Restriction ; owl:onProperty part_of: ; owl:someValuesFrom ?y ] ] } WHERE { ?x mutually_spatially_disjoint_with: ?y . } RO:0002171 uberon mutually_spatially_disjoint_with true true mutually_spatially_disjoint_with mutually spatially disjoint with mutually spatially disjoint with https://github.com/obophenotype/uberon/wiki/Part-disjointness-Design-Pattern S present_in_taxon T if some instance of T has some S. This does not means that all instances of T have an S - it may only be certain life stages or sexes that have S PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#> PREFIX owl: <http://www.w3.org/2002/07/owl#> PREFIX in_taxon: <http://purl.obolibrary.org/obo/RO_0002162> PREFIX present_in_taxon: <http://purl.obolibrary.org/obo/RO_0002175> CONSTRUCT { in_taxon: a owl:ObjectProperty . ?witness rdfs:label ?label . ?witness rdfs:subClassOf ?x . ?witness rdfs:subClassOf [ a owl:Restriction ; owl:onProperty in_taxon: ; owl:someValuesFrom ?taxon ] . } WHERE { ?x present_in_taxon: ?taxon . BIND(IRI(CONCAT( "http://purl.obolibrary.org/obo/RO_0002175#", MD5(STR(?x)), "-", MD5(STR(?taxon)) )) as ?witness) BIND(CONCAT(STR(?x), " in taxon ", STR(?taxon)) AS ?label) } RO:0002175 uberon present_in_taxon true true present_in_taxon The SPARQL expansion for this relation introduces new named classes into the ontology. For this reason it is likely that the expansion should only be performed during a QC pipeline; the expanded output should usually not be included in a published version of the ontology. present in taxon present in taxon 'anterior end of organism' is-opposite-of 'posterior end of organism' 'increase in temperature' is-opposite-of 'decrease in temperature' x is the opposite of y if there exists some distance metric M, and there exists no z such as M(x,z) <= M(x,y) or M(y,z) <= M(y,x). RO:0002604 quality is_opposite_of true true is_opposite_of is opposite of is_opposite_of An alternate textual definition for a class taken unmodified from an external source. This definition may have been used to derive a generalized definition for the new class. UBPROP:0000001 uberon external_definition true external_definition This annotation property may be replaced with an annotation property from an external ontology such as IAO external_definition A textual description of an axiom loss in this ontology compared to an external ontology. UBPROP:0000002 uberon axiom_lost_from_external_ontology true axiom_lost_from_external_ontology This annotation property may be replaced with an annotation property from an external ontology such as IAO axiom_lost_from_external_ontology Notes on the homology status of this class. UBPROP:0000003 uberon homology_notes true homology_notes This annotation property may be replaced with an annotation property from an external ontology such as IAO homology_notes Used to connect a class to an adjectival form of its label. For example, a class with label 'intestine' may have a relational adjective 'intestinal'. UBPROP:0000007 uberon has_relational_adjective true has_relational_adjective has_relational_adjective Notes on the how instances of this class vary across species. UBPROP:0000008 uberon taxon_notes true taxon_notes taxon_notes Notes on the evolved function of instances of this class. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000009 uberon function_notes true function_notes function_notes Notes on the structure, composition or histology of instances of this class. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000010 uberon structure_notes true structure_notes structure_notes Notes on the ontogenic development of instances of this class. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000011 uberon development_notes true development_notes development_notes Notes on how similar or equivalent classes are represented in other ontologies. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000012 uberon external_ontology_notes true external_ontology_notes external_ontology_notes FMA has terms like 'set of X'. In general we do not include set-of terms in uberon, but provide a mapping between the singular form and the FMA set term UBPROP:0000202 uberon fma_set_term true fma_set_term fma_set_term http://purl.org/dc/terms/contributor uberon dc-contributor true dc-contributor contributor consider created_by creation_date has_alternative_id An alternative label for a class or property which has a more general meaning than the preferred name/primary label. https://github.com/information-artifact-ontology/ontology-metadata/issues/18 has broad synonym has_broad_synonym https://github.com/information-artifact-ontology/ontology-metadata/issues/18 disease characteristic (MONDO:0021125) has cross-reference (http://www.geneontology.org/formats/oboInOwl#hasDbXref) "NCIT:C41009"^^xsd:string An annotation property that links an ontology entity or a statement to a prefixed identifier or URI. Reference database or publication source. database_cross_reference has cross-reference A property representing a fully qualified synonym, contains the string, term type, source, and an optional source code if appropriate. Each subfield is deliniated to facilitate interpretation by software. An alternative label for a class or property which has the exact same meaning than the preferred name/primary label. An alternative label for a given entity such as a commonly used abbreviation or synonym. https://github.com/information-artifact-ontology/ontology-metadata/issues/20 FULL_SYN Synonym with Source Data alternative_term has exact synonym has exact synonym has_exact_synonym https://github.com/information-artifact-ontology/ontology-metadata/issues/20 An alternative label for a class or property which has a more specific meaning than the preferred name/primary label. https://github.com/information-artifact-ontology/ontology-metadata/issues/19 has narrow synonym has_narrow_synonym https://github.com/information-artifact-ontology/ontology-metadata/issues/19 Name space of the ontology. disease_ontology has_obo_namespace An alternative label for a class or property that has been used synonymously with the primary term name, but the usage is not strictly correct. https://github.com/information-artifact-ontology/ontology-metadata/issues/21 has related synonym has_related_synonym https://github.com/information-artifact-ontology/ontology-metadata/issues/21 An identifier for an individual entity. An identifier is an information content entity that is the outcome of a dubbing process and is used to refer to one instance of entity shared by a group of people to refer to that individual entity. id An association that connects the concept defining a particular terminology subset with concepts that belong to this subset. Concept_In_Subset in subset in_subset shorthand Comment. comment Is defined by. rdfs:isDefinedBy A human readable name for this class. label label http://www.w3.org/2000/01/rdf-schema#seeAlso seeAlso spatial uberon seeAlso true seeAlso see also A skos concept mapping used to link two concepts, indicating a high degree of confidence that the concepts can be used interchangeably. has exact match A skos concept mapping used to state a hierarchical mapping link between two concepts where the DO concept is narrow (DO represents subtypes) and the xref is broad. has narrower match http://xmlns.com/foaf/0.1/depiction uberon depiction true depiction depiction has temperature unit has marker is substrate of is marker of stains has orthogonal assay design has response unit has concentration unit has perturbagen has mode of action has assay format has detection method has endpoint has measure group has assay stage has target has assay method has specification is orthogonal assay design of has assay kit has curve fit specification has percent response has concentration is perturbagen of is assay method of has inducer is regulated by has transcription factor is measure group of is related assay to Assay performed to confirm activity of compounds identified in the primary screen. It can be performed as replicate measurements at a single screening concentration or as concentration-response assay. is confirmatory assay of Counter assays typically follow concentration-response assays to confirm the biological activity of chemical entities identified in the primary assays. Counter assays eliminate active compounds that do not act on the intended target. They are performed using related targets, e.g. a receptor isoform, a homologous gene, etc which are functionally distinct from the intended target. Counter assays are also performed to eliminate cytotoxic compounds. The actives from the primary assay are tested on cultured cells and the cell death is estimated commonly by measuring ATP concentration. Other example for a counter assays a FRET assay when the primary assay used absorption readout; luminescence readout when the primary assay measured fluorescence intensity, etc. is counter assay of Same target, design, technology, format, but not necessarily the same throughput. For example primary, confirmatory, and concentration-response could be related by 'is identical to' is identical assay of is alternate assay format of is assay format of is endpoint of is regulator of is specification of has alternate assay format is target of is detection method of has manufacturer has assay control has primary assay has confirmatory assay has counter assay has summary assay has variant construct assay is variant construct assay of has parental cell line assay is parental cell line assay of has compound toxicity assay is compound toxicity assay of is primary assay of has selectivity assay is selectivity assay of has alternate target assay is alternate target assay of has alternate cell line assay is alternate cell line assay of has alternate organism assay is alternate organism assay of has alternate confirmatory assay is alternate confirmatory assay of has orthogonal assay technology is orthogonal assay technology of has alternate assay type is alternate assay type of has alternate assay conditions is alternate assay conditions of has lead optimization assay is lead optimization assay of has physicochemical profiling assay is physicochemical profiling assay of has compound fluorescence assay is compound fluorescence assay of has compound aggregation assay is compound aggregation assay of has compound redox-activity assay is compound redox-activity assay of is summary assay of has identical assay based on normalization has measured entity detects catalyzed by has cell line has form involves biological process has assay phase characteristic is indicator of has purity unit encodes is measured entity of has quality uses assay kit has assay kit component uses as substrate has time unit has substrate is binding site of tagged with has detected entity is cell line of has assay protocol is assay protocol of has associated disease is associated disease of has assay readout content has assay readout content parametricity has assay source has assay title has bioassay type is bioassay type of has assay readout type has signal direction has endpoint modifier has phenotype is phenotype of is localized in has concentration throughput has repetition throughput uses detection instrument has assay footprint silences has gene symbol is role of is unit of has unit is detected by has antibody source recombinantly expressed in has preparation method has organism has assay medium has assay serum is grown in is transfected into has role reports has binding site has function involves molecular function phenotype of c stands in this relationship to p if and only if there exists some p' such that c is capable_of p', and p' is part_of p. has function in http://www.obofoundry.org/ro/#OBO_REL:part_of part of has phenotype has part derives into See also BFO_0001009 derives from occurs in bearer of inheres in contains process X connected_to Y if and only if X and Y share a fiat boundary. connected to http://www.obofoundry.org/ro/#OBO_REL:has_participant has participant participates in is derived from detects phenotype has indicator is described by quantifies has molecular phenotype has morphological phenotype has positive control has negative control has experimental setting has response value has temperature value has percent response value has id value has DNA sequence has ID has display info has date has purity value has concentration value has time value has concentration-point number has passage number has cell count This describes the number of repeats of an entity (e.g., artificial regulatory element, cDNA, etc.) present in a DNA construct. has copy number This describes the number of repeats of a gene of interest cloned in a DNA construct. has gene copy number This describes the number of repeats of a cDNA of interest cloned in a DNA construct. has cDNA copy number This describes the number of repeats of an artificial regulatory element present in a DNA construct. has artificial regulatory region copy number has sequence has protein sequence has nucleic acid sequence has RNA sequence has shRNA sense sequence has enzyme reaction temperature value has sense strand sequence has anti-sense strand sequence has assay deposition date A biosafety level is the level of biocontainment required to isolate hazardous biological agents in an enclosed facility. The levels of containment range from the lowest biosafety level of 1 to the highest at level 4. The levels are as follows: BSL1: Suitable for work involving well-characterized agents not known to consistently cause disease in immunocompetent adult humans, and present minimal potential hazard to laboratory personnel and the environment (definition from CDC). BSL2: Suitable for work involving agents that pose moderate hazards to personnel and the environment. It differs from BSL-1 in that 1) laboratory personnel have specific training in handling pathogenic agents and are supervised by scientists competent in handling infectious agents and associated procedures; 2) access to the laboratory is restricted when work is being conducted; and 3) all procedures in which infectious aerosols or splashes may be created are conducted in BSCs or other physical containment equipment (definition from CDC). BSL3: Suitable for clinical, diagnostic, teaching, research, or production facilities where work is performed with indigenous or exotic agents that may cause serious or potentially lethal disease through inhalation route exposure. Laboratory personnel must receive specific training in handling pathogenic and potentially lethal agents, and must be supervised by scientists competent in handling infectious agents and associated procedures. All procedures involving the manipulation of infectious materials must be conducted within BSCs, other physical containment devices, or by personnel wearing appropriate personal protective equipment (definition from CDC). BSL4: has biosafety level pH approximates the negative logarithm (base 10) of the molar concentration of dissolved hydronium ions in a solution. has assay pH value It is the force per unit area applied in a direction perpendicular to the surface of an object in an assay. has assay pressure value has cell modification temperature value has perturbagen incubation temperature value has substrate incubation temperature value It is the temperature at which the biological experiment was conducted. has assay temperature value It is the interval of time between the addition of a perturbagen, substrate or cell modification and the measurement of change, as observed by a detection method in the bioassay. has incubation time value It is the interval of time between the cell modification, namely transient transfection of plasmid DNA/ siRNA, viral transduction, etc and the measurement of change, as observed by a detection method in the bioassay. has cell modification time value has coupled substrate incubation time value It is the interval of time between the enzyme activity measurement in a kinetic assay. has enzyme reaction time value It is the interval of time between the addition of a perturbagen and the measurement of change, as observed by a detection method in the bioassay. has perturbagen incubation time value It is the interval of time between the addition of an enzyme substrate and the measurement of change, as observed by a detection/ readout in a bioassay. has substrate incubation time value has coupled substrate incubation temperature value The number of replicate measurements (repetitions) per concentration value used. has repetition point-number has wavelength value is input data value of has sequence position The nucleotide number in the sense strand of a gene that marks the beginning and end of the shRNA probe. has shRNA probe sense sequence position The nucleotide number in the sense strand of a gene that marks the beginning and end of the siRNA probe. has siRNA probe sense sequence position has ligand incubation time value The value (in conjunction with the signal direction) used to determine perturbagens of interest (hits.) Perturbagens with a readout value beyond the threshold in the direction of interest are considered active in the assay. has activity threshold value has excitation wavelength value has emission wavelength value has absorbance wavelength value has recommended name has value reports assay measurment value CHEBI:101086 EC 5.4.99.7 (lanosterol synthase) inhibitor EC 5.4.99.7 (lanosterol synthase) inhibitor CHEBI:101090 EC 5.4.99.* (intramolecular transferase transferring other groups) inhibitor EC 5.4.99.* (intramolecular transferase transferring other groups) inhibitors EC 5.4.99.* inhibitor EC 5.4.99.* inhibitors inhibitor of intramolecular transferase transferring other groups inhibitors of intramolecular transferase transferring other groups intramolecular transferase transferring other groups inhibitor intramolecular transferase transferring other groups inhibitors EC 5.4.99.* (intramolecular transferase transferring other groups) inhibitor CHEBI:10110 zidovudine 3'-azido-3'-deoxythymidine AZT Azidothymidine Retrovir Zidovudin Zidovudinum zidovudine zidovudine CHEBI:102248 EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitors EC 1.14.11.29 inhibitor EC 1.14.11.29 inhibitors HIF hydroxylase inhibitor HIF hydroxylase inhibitors hypoxia-inducible factor-L-proline, 2-oxoglutarate:oxygen oxidoreductase (4-hydroxylating) inhibitor hypoxia-inducible factor-L-proline, 2-oxoglutarate:oxygen oxidoreductase (4-hydroxylating) inhibitors prolyl 4-hydroxylase inhibitor prolyl 4-hydroxylase inhibitors EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor CHEBI:102368 EC 2.6.1.40 [(R)-3-amino-2-methylpropionate--pyruvate transaminase] inhibitor (R)-3-amino-2-methylpropanoate:pyruvate aminotransferase inhibitor (R)-3-amino-2-methylpropanoate:pyruvate aminotransferase inhibitors (R)-3-amino-2-methylpropionate transaminase inhibitor (R)-3-amino-2-methylpropionate transaminase inhibitors (R)-3-amino-2-methylpropionate--pyruvate aminotransferase inhibitor (R)-3-amino-2-methylpropionate--pyruvate aminotransferase inhibitors D-3-aminoisobutyrate--pyruvate aminotransferase inhibitor D-3-aminoisobutyrate--pyruvate aminotransferase inhibitors D-3-aminoisobutyrate--pyruvate transaminase inhibitor D-3-aminoisobutyrate--pyruvate transaminase inhibitors D-3-aminoisobutyrate-pyruvate aminotransferase inhibitor D-3-aminoisobutyrate-pyruvate aminotransferase inhibitors D-3-aminoisobutyrate-pyruvate transaminase inhibitor D-3-aminoisobutyrate-pyruvate transaminase inhibitors D-AIBAT inhibitor D-AIBAT inhibitors D-beta-aminoisobutyrate:pyruvate aminotransferase inhibitor D-beta-aminoisobutyrate:pyruvate aminotransferase inhibitors EC 2.6.1.40 [(R)-3-amino-2-methylpropionate--pyruvate transaminase] inhibitors EC 2.6.1.40 inhibitor EC 2.6.1.40 inhibitors beta-aminoisobutyrate--pyruvate aminotransferase inhibitor beta-aminoisobutyrate--pyruvate aminotransferase inhibitors beta-aminoisobutyrate--pyruvate transaminase inhibitor beta-aminoisobutyrate--pyruvate transaminase inhibitors beta-aminoisobutyrate-pyruvate aminotransferase inhibitor beta-aminoisobutyrate-pyruvate aminotransferase inhibitors EC 2.6.1.40 [(R)-3-amino-2-methylpropionate--pyruvate transaminase] inhibitor CHEBI:110725 EC 2.1.1.8 (histamine N-methyltransferase) inhibitor EC 2.1.1.8 (histamine N-methyltransferase) inhibitors EC 2.1.1.8 inhibitor EC 2.1.1.8 inhibitors S-adenosyl-L-methionine:histamine N-tele-methyltransferase inhibitor S-adenosyl-L-methionine:histamine N-tele-methyltransferase inhibitors S-adenosylmethionine-histamine N-methyltransferase inhibitor S-adenosylmethionine-histamine N-methyltransferase inhibitors histamine 1-methyltransferase inhibitor histamine 1-methyltransferase inhibitors histamine methyltransferase inhibitor histamine methyltransferase inhibitors histamine-methylating enzyme inhibitor histamine-methylating enzyme inhibitors imidazolemethyltransferase inhibitor imidazolemethyltransferase inhibitors EC 2.1.1.8 (histamine N-methyltransferase) inhibitor CHEBI:130181 calmodulin antagonist calmodulin antagonist CHEBI:131186 IP3 receptor antagonist D-myo-inositol 1,4,5-trisphosphate receptor antagonist D-myo-inositol 1,4,5-trisphosphate receptor antagonists IP3 antagonist IP3 antagonists IP3 receptor antagonists InsP3R antagonist InsP3R antagonists inositol trisphosphate receptor antagonist inositol trisphosphate receptor antagonists IP3 receptor antagonist CHEBI:131359 adenosine A2B receptor agonist A2B agonist A2B agonists A2B receptor agonist A2B receptor agonists adenosine A2B receptor agonists adenosine A2B receptor agonist CHEBI:131492 Wnt signalling activator Wnt signaling activator Wnt signaling activators Wnt signalling activators Wnt signalling activator CHEBI:131495 formyl peptide receptor agonist FPR agonist FPR agonists formyl peptide receptor agonists formyl peptide receptor agonist CHEBI:131509 EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor AOF2 inhibitor AOF2 inhibitors BHC110 inhibitor BHC110 inhibitors CPRF inhibitor CPRF inhibitors EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitors EC 1.14.99.66 inhibitor EC 1.14.99.66 inhibitors KDM1A inhibitor KDM1A inhibitors KIAA0601 inhibitor KIAA0601 inhibitors LSD1 inhibitor LSD1 inhibitors [histone H3]-dimethyl-L-lysine(4)FAD-dependent demethylase 1A inhibitor [histone H3]-dimethyl-L-lysine(4)FAD-dependent demethylase 1A inhibitors amine oxidase (flavin containing) domain 2 inhibitor amine oxidase (flavin containing) domain 2 inhibitors lysine (K)-specific demethylase 1A inhibitor lysine (K)-specific demethylase 1A inhibitors lysine demethylase 1A inhibitor lysine demethylase 1A inhibitors lysine-specific demethylase 1A inhibitor lysine-specific demethylase 1A inhibitors lysine-specific histone demethylase 1A inhibitor lysine-specific histone demethylase 1A inhibitors EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor CHEBI:131561 hyaluronic acid synthesis inhibitor HA inhibitor HA inhibitors HA synthesis inhibitor HA synthesis inhibitors hyaluronic acid inhibitor hyaluronic acid inhibitors hyaluronic acid synthesis inhibitors hyaluronic acid synthesis inhibitor CHEBI:131604 Mycoplasma genitalium metabolite Mycoplasma genitalium metabolites Mycoplasma genitalium metabolite CHEBI:131611 teichoic acid biosynthesis inhibitor TarO inhibitor TarO inhibitors teichoic acid biosynthesis inhibitors teichoic acid biosynthesis inhibitor CHEBI:131699 EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor DNA duplicase inhibitor DNA duplicase inhibitors DNA nucleotidyltransferase (DNA-directed) inhibitor DNA nucleotidyltransferase (DNA-directed) inhibitors DNA nucleotidyltransferase inhibitor DNA nucleotidyltransferase inhibitors DNA polymerase I inhibitor DNA polymerase I inhibitors DNA polymerase II inhibitor DNA polymerase II inhibitors DNA polymerase III inhibitor DNA polymerase III inhibitors DNA polymerase alpha inhibitor DNA polymerase alpha inhibitors DNA polymerase beta inhibitor DNA polymerase beta inhibitors DNA polymerase gamma inhibitor DNA polymerase gamma inhibitors DNA polymerase inhibitor DNA polymerase inhibitors DNA replicase inhibitor DNA replicase inhibitors DNA-dependent DNA polymerase inhibitor DNA-dependent DNA polymerase inhibitors DNA-directed DNA polymerase (EC 2.7.7.7) inhibitor DNA-directed DNA polymerase (EC 2.7.7.7) inhibitors EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitors EC 2.7.7.7 inhibitor EC 2.7.7.7 inhibitors Klenow fragment inhibitor Klenow fragment inhibitors Taq DNA polymerase inhibitor Taq DNA polymerase inhibitors Taq Pol I inhibitor Taq Pol I inhibitors Tca DNA polymerase inhibitor Tca DNA polymerase inhibitors deoxynucleate polymerase inhibitor deoxynucleate polymerase inhibitors deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase (DNA-directed) inhibitor deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase (DNA-directed) inhibitors deoxyribonucleate nucleotidyltransferase inhibitor deoxyribonucleate nucleotidyltransferase inhibitors deoxyribonucleic acid duplicase inhibitor deoxyribonucleic acid duplicase inhibitors deoxyribonucleic acid polymerase inhibitor deoxyribonucleic acid polymerase inhibitors deoxyribonucleic duplicase inhibitor deoxyribonucleic duplicase inhibitors deoxyribonucleic polymerase I inhibitor deoxyribonucleic polymerase I inhibitors deoxyribonucleic polymerase inhibitor deoxyribonucleic polymerase inhibitors duplicase inhibitor duplicase inhibitors sequenase inhibitor sequenase inhibitors EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor CHEBI:131734 EC 2.7.11.20 (elongation factor 2 kinase) inhibitor ATP:[elongation factor 2] phosphotransferase inhibitor ATP:[elongation factor 2] phosphotransferase inhibitors Ca/CaM-kinase III inhibitor Ca/CaM-kinase III inhibitors CaM kinase III inhibitor CaM kinase III inhibitors EC 2.7.11.20 (elongation factor 2 kinase) inhibitors EC 2.7.11.20 inhibitor EC 2.7.11.20 inhibitors EF2K inhibitor EF2K inhibitors STK19 inhibitor STK19 inhibitors calmodulin-dependent protein kinase III inhibitor calmodulin-dependent protein kinase III inhibitors eEF2 kinase inhibitor eEF2 kinase inhibitors eEF2K inhibitor eEF2K inhibitors elongation factor 2 kinase (EC 2.7.11.20) inhibitor elongation factor 2 kinase (EC 2.7.11.20) inhibitors elongation factor 2 kinase inhibitor elongation factor 2 kinase inhibitors EC 2.7.11.20 (elongation factor 2 kinase) inhibitor CHEBI:131770 EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor ATP phosphohydrolase (channel-conductance-controlling) inhibitor ATP phosphohydrolase (channel-conductance-controlling) inhibitors CFTR inhibitor CFTR inhibitors EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitors EC 3.6.3.49 inhibitor EC 3.6.3.49 inhibitors channel-conductance-controlling ATPase (EC 3.6.3.49) inhibitor channel-conductance-controlling ATPase (EC 3.6.3.49) inhibitors channel-conductance-controlling ATPase inhibitor channel-conductance-controlling ATPase inhibitors cystic fibrosis conductance regulator inhibitor cystic fibrosis conductance regulator inhibitors cystic fibrosis transmembrane conductance regulator inhibitor cystic fibrosis transmembrane conductance regulator inhibitors cystic-fibrosis membrane-conductance-regulating protein inhibitor cystic-fibrosis membrane-conductance-regulating protein inhibitors EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor CHEBI:131787 dopamine receptor D2 antagonist D2 receptor antagonist D2R antagonist dopamine receptor D2 antagonist CHEBI:131789 RUNX1 inhibitor AML1 inhibitor AML1 inhibitors CBFA2 inhibitor CBFA2 inhibitors RUNX1 inhibitors acute myeloid leukemia 1 protein inhibitor acute myeloid leukemia 1 protein inhibitors core-binding factor subunit alpha-2 inhibitor core-binding factor subunit alpha-2 inhibitors core-binding factor subunit alpha2 inhibitor core-binding factor subunit alpha2 inhibitors runt-related transcription factor 1 inhibitor runt-related transcription factor 1 inhibitors RUNX1 inhibitor CHEBI:131790 melatonin receptor antagonist melatonin receptor antagonists melatonin receptor antagonist CHEBI:131791 HIV-1 Tat inhibitor HIV-1 Tat antagonist HIV-1 Tat antagonists HIV-1 Tat inhibitors HIV-1 trans-activator of transcription antagonist HIV-1 trans-activator of transcription antagonists human immunodeficiency virus type 1 Tat antagonist human immunodeficiency virus type 1 Tat antagonists human immunodeficiency virus type 1 Tat inhibitor human immunodeficiency virus type 1 Tat inhibitors human immunodeficiency virus type 1 trans-activator of transcription antagonist human immunodeficiency virus type 1 trans-activator of transcription antagonists HIV-1 Tat inhibitor CHEBI:131794 EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor ATP:caldesmon O-phosphotransferase inhibitor ATP:caldesmon O-phosphotransferase inhibitors ATP:protein phosphotransferase ((2+)/calmodulin-dependent) inhibitor ATP:protein phosphotransferase ((2+)/calmodulin-dependent) inhibitors CAM PKII inhibitor CAM PKII inhibitors Ca(2+)/calmodulin-dependent microtubule-associated protein 2 kinase inhibitor Ca(2+)/calmodulin-dependent microtubule-associated protein 2 kinase inhibitors Ca(2+)/calmodulin-dependent protein kinase (EC 2.7.11.17) inhibitor Ca(2+)/calmodulin-dependent protein kinase (EC 2.7.11.17) inhibitors Ca(2+)/calmodulin-dependent protein kinase 1 inhibitor Ca(2+)/calmodulin-dependent protein kinase 1 inhibitors Ca(2+)/calmodulin-dependent protein kinase II inhibitor Ca(2+)/calmodulin-dependent protein kinase II inhibitors Ca(2+)/calmodulin-dependent protein kinase IV inhibitor Ca(2+)/calmodulin-dependent protein kinase IV inhibitors Ca(2+)/calmodulin-dependent protein kinase inhibitor Ca(2+)/calmodulin-dependent protein kinase inhibitors Ca(2+)/calmodulin-dependent protein kinase kinase beta inhibitor Ca(2+)/calmodulin-dependent protein kinase kinase beta inhibitors Ca(2+)/calmodulin-dependent protein kinase kinase inhibitor Ca(2+)/calmodulin-dependent protein kinase kinase inhibitors CaM kinase II inhibitor CaM kinase II inhibitors CaM kinase inhibitor CaM kinase inhibitors CaM-regulated serine/threonine kinase inhibitor CaM-regulated serine/threonine kinase inhibitors CaMKI inhibitor CaMKI inhibitors CaMKII inhibitor CaMKII inhibitors CaMKIV inhibitor CaMKIV inhibitors CaMKKalpha inhibitor CaMKKalpha inhibitors CaMKKbeta inhibitor CaMKKbeta inhibitors EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitors EC 2.7.11.17 inhibitor EC 2.7.11.17 inhibitors STK20 inhibitor STK20 inhibitors caldesmon kinase (phosphorylating) inhibitor caldesmon kinase (phosphorylating) inhibitors caldesmon kinase inhibitor caldesmon kinase inhibitors calmodulin-dependent kinase II inhibitor calmodulin-dependent kinase II inhibitors microtubule-associated protein 2 kinase inhibitor microtubule-associated protein 2 kinase inhibitors EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor CHEBI:131795 dopamine receptor D1 agonist D1 agonist D1 agonists dopamine D1 receptor agonist dopamine D1 receptor agonists dopamine receptor D1 agonists dopamine receptor D1 agonist CHEBI:131809 SMO receptor agonist SMO receptor agonists smoothened agonist smoothened agonists smoothened receptor agonist smoothened receptor agonists SMO receptor agonist CHEBI:131844 EC 1.14.11.1 (gamma-butyrobetaine dioxygenase) inhibitor 4-trimethylammoniobutanoate,2-oxoglutarate:oxygen oxidoreductase (3-hydroxylating) inhibitor 4-trimethylammoniobutanoate,2-oxoglutarate:oxygen oxidoreductase (3-hydroxylating) inhibitors BBOX inhibitor BBOX inhibitors EC 1.14.11.1 (gamma-butyrobetaine dioxygenase) inhibitors EC 1.14.11.1 inhibitor EC 1.14.11.1 inhibitors alpha-butyrobetaine hydroxylase inhibitor alpha-butyrobetaine hydroxylase inhibitors butyrobetaine hydroxylase inhibitor butyrobetaine hydroxylase inhibitors gamma-butyrobetaine hydroxylase inhibitor gamma-butyrobetaine hydroxylase inhibitors EC 1.14.11.1 (gamma-butyrobetaine dioxygenase) inhibitor CHEBI:13193 hydrogen acceptor A hydrogen acceptor CHEBI:131961 EC 1.13.11.11 (tryptophan 2,3-dioxygenase) inhibitor EC 1.13.11.11 (tryptophan 2,3-dioxygenase) inhibitors EC 1.13.11.11 inhibitor EC 1.13.11.11 inhibitors L-tryptophan 2,3-dioxygenase inhibitor L-tryptophan 2,3-dioxygenase inhibitors L-tryptophan pyrrolase inhibitor L-tryptophan pyrrolase inhibitors L-tryptophan:oxygen 2,3-oxidoreductase (decyclizing) inhibitor L-tryptophan:oxygen 2,3-oxidoreductase (decyclizing) inhibitors L-tryptophan:oxygen 2,3-oxidoreductase (ring-opening) inhibitor L-tryptophan:oxygen 2,3-oxidoreductase (ring-opening) inhibitors TDO inhibitor TDO inhibitors indolamine 2,3-dioxygenase inhibitor indolamine 2,3-dioxygenase inhibitors indoleamine 2,3-dioxygenase inhibitor indoleamine 2,3-dioxygenase inhibitors tryptamin 2,3-dioxygenase inhibitor tryptamin 2,3-dioxygenase inhibitors tryptamine 2,3-dioxygenase inhibitor tryptamine 2,3-dioxygenase inhibitors tryptophan 2,3-dioxygenase (EC 1.13.11.11) inhibitor tryptophan 2,3-dioxygenase (EC 1.13.11.11) inhibitors tryptophan 2,3-dioxygenase inhibitor tryptophan 2,3-dioxygenase inhibitors tryptophan oxygenase inhibitor tryptophan oxygenase inhibitors tryptophan peroxidase inhibitor tryptophan peroxidase inhibitors tryptophan pyrrolase inhibitor tryptophan pyrrolase inhibitors tryptophanase inhibitor tryptophanase inhibitors EC 1.13.11.11 (tryptophan 2,3-dioxygenase) inhibitor CHEBI:132272 herbicide safener herbicide safeners herbicide safener CHEBI:132365 EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitors EC 1.14.11.2 inhibitor EC 1.14.11.2 inhibitors collagen proline hydroxylase inhibitor collagen proline hydroxylase inhibitors hydroxylase, collagen proline inhibitor hydroxylase, collagen proline inhibitors peptidyl proline hydroxylase inhibitor peptidyl proline hydroxylase inhibitors procollagen-L-proline,2-oxoglutarate:oxygen oxidoreductase (4-hydroxylating) inhibitor procollagen-L-proline,2-oxoglutarate:oxygen oxidoreductase (4-hydroxylating) inhibitors procollagen-proline 4-dioxygenase inhibitor procollagen-proline 4-dioxygenase inhibitors procollagen-proline dioxygenase (EC 1.14.11.2) inhibitor procollagen-proline dioxygenase (EC 1.14.11.2) inhibitors procollagen-proline dioxygenase inhibitor procollagen-proline dioxygenase inhibitors procollagen-proline,2-oxoglutarate-4-dioxygenase inhibitor procollagen-proline,2-oxoglutarate-4-dioxygenase inhibitors proline hydroxylase inhibitor proline hydroxylase inhibitors proline protocollagen hydroxylase inhibitor proline protocollagen hydroxylase inhibitors proline, 2-oxoglutarate dioxygenase inhibitor proline, 2-oxoglutarate dioxygenase inhibitors proline,2-oxoglutarate 4-dioxygenase inhibitor proline,2-oxoglutarate 4-dioxygenase inhibitors prolyl 4-hydroxylase inhibitor prolyl 4-hydroxylase inhibitors prolyl hydroxylase inhibitor prolyl hydroxylase inhibitors prolyl-glycyl-peptide, 2-oxoglutarate:oxygen oxidoreductase, 4-hydroxylating inhibitor prolyl-glycyl-peptide, 2-oxoglutarate:oxygen oxidoreductase, 4-hydroxylating inhibitors prolylprotocollagen dioxygenase inhibitor prolylprotocollagen dioxygenase inhibitors prolylprotocollagen hydroxylase inhibitor prolylprotocollagen hydroxylase inhibitors protocollagen hydroxylase inhibitor protocollagen hydroxylase inhibitors protocollagen proline 4-hydroxylase inhibitor protocollagen proline 4-hydroxylase inhibitors protocollagen proline dioxygenase inhibitor protocollagen proline dioxygenase inhibitors protocollagen proline hydroxylase inhibitor protocollagen proline hydroxylase inhibitors protocollagen prolyl hydroxylase inhibitor protocollagen prolyl hydroxylase inhibitors EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor CHEBI:132518 EC 3.2.1.23 (beta-galactosidase) inhibitor EC 3.2.1.23 (beta-galactosidase) inhibitors EC 3.2.1.23 inhibitor EC 3.2.1.23 inhibitors S 2107 inhibitor S 2107 inhibitors beta-D-galactanase inhibitor beta-D-galactanase inhibitors beta-D-galactoside galactohydrolase inhibitor beta-D-galactoside galactohydrolase inhibitors beta-D-lactosidase inhibitor beta-D-lactosidase inhibitors beta-lactosidase inhibitor beta-lactosidase inhibitors exo-(1->4)-beta-D-galactanase inhibitor exo-(1->4)-beta-D-galactanase inhibitors hydrolact inhibitor hydrolact inhibitors lactase inhibitor lactase inhibitors lactozym inhibitor lactozym inhibitors maxilact inhibitor maxilact inhibitors oryzatym inhibitor oryzatym inhibitors sumiklat inhibitor sumiklat inhibitors trilactase inhibitor trilactase inhibitors EC 3.2.1.23 (beta-galactosidase) inhibitor CHEBI:132608 TRPM4 channel inhibitor TRPM4 channel inhibitors Transient receptor potential cation channel subfamily M member 4 inhibitor Transient receptor potential cation channel subfamily M member 4 inhibitors melastatin 4 inhibitor melastatin 4 inhibitors TRPM4 channel inhibitor CHEBI:132710 xenoantigen xenoantigens xenoantigen CHEBI:132717 bleaching agent bleaching agent CHEBI:132771 EC 3.6.5.* (hydrolases acting on GTP; involved in cellular and subcellular movement) inhibitor EC 3.6.5.* (hydrolases acting on GTP; involved in cellular and subcellular movement) inhibitors EC 3.6.5.* (hydrolases acting on GTP; involved in cellular and subcellular movement) inhibitor CHEBI:132772 EC 3.6.5.5 (dynamin GTPase) inhibitor EC 3.6.5.5 (dynamin GTPase) inhibitors EC 3.6.5.5 inhibitor EC 3.6.5.5 inhibitors GTP phosphohydrolase (vesicle-releasing) inhibitor GTP phosphohydrolase (vesicle-releasing) inhibitors dynamin GTPase (EC 3.6.5.5) inhibitor dynamin GTPase (EC 3.6.5.5) inhibitors dynamin GTPase inhibitor dynamin GTPase inhibitors EC 3.6.5.5 (dynamin GTPase) inhibitor CHEBI:132972 farnesoid X receptor agonist BAR agonist BAR agonists FXR agonist FXR agonists bile acid receptor agonist bile acid receptor agonists farnesoid X receptor agonists farnesoid X receptor agonist CHEBI:132992 radiosensitizing agent radiosensitiser radiosensitisers radiosensitising agent radiosensitising agents radiosensitizer radiosensitizers radiosensitizing agents radiosensitizing agent CHEBI:133016 5-hydroxytryptamine 2A receptor inverse agonist 5-hydroxytryptamine (2A) receptor inverse agonist 5-hydroxytryptamine (2A) receptor inverse agonists 5-hydroxytryptamine 2A receptor inverse agonists 5HT(2A) inverse agonist 5HT(2A) inverse agonists 5HT2A inverse agonists 5HT2Ainverse agonist 5-hydroxytryptamine 2A receptor inverse agonist CHEBI:133022 B-cell lymphoma 2 inhibitor B-cell lymphoma 2 inhibitors Bcl-2 inhibitor Bcl-2 inhibitors B-cell lymphoma 2 inhibitor CHEBI:133024 lymphocyte function-associated antigen-1 antagonist LFA-1 antagonist LFA-1 antagonists lymphocyte function-associated antigen-1 antagonists lymphocyte function-associated antigen-1 antagonist CHEBI:133106 chemical hybridisation agent chemical hybridisation agents chemical hybridization agent chemical hybridization agents chemical hybridisation agent CHEBI:133190 fatty acid oxidation inhibitor fatty acid oxidation inhibitors fatty acid oxidation inhibitor CHEBI:133811 EC 2.4.1.17 (glucuronosyltransferase) inhibitor 1-naphthol glucuronyltransferase inhibitor 1-naphthol glucuronyltransferase inhibitors 1-naphthol-UDP-glucuronosyltransferase inhibitor 1-naphthol-UDP-glucuronosyltransferase inhibitors 17-OH steroid UDPGT inhibitor 17-OH steroid UDPGT inhibitors 17beta-hydroxysteroid UDP-glucuronosyltransferase inhibitor 17beta-hydroxysteroid UDP-glucuronosyltransferase inhibitors 3-OH androgenic UDPGT inhibitor 3-OH androgenic UDPGT inhibitors 3alpha-hydroxysteroid UDP-glucuronosyltransferase inhibitor 3alpha-hydroxysteroid UDP-glucuronosyltransferase inhibitors 4-hydroxybiphenyl UDP-glucuronosyltransferase inhibitor 4-hydroxybiphenyl UDP-glucuronosyltransferase inhibitors EC 2.4.1.17 (glucuronosyltransferase) inhibitors EC 2.4.1.17 inhibitor EC 2.4.1.17 inhibitors UDP glucuronic acid transferase inhibitors UDP glucuronosyltransferase inhibitor UDP glucuronosyltransferase inhibitors UDP glucuronyltransferase inhibitor UDP glucuronyltransferase inhibitors UDP-alpha-D-glucuronate beta-D-glucuronosyltransferase (acceptor-unspecific; conformation-inverting) inhibitor UDP-alpha-D-glucuronate beta-D-glucuronosyltransferase (acceptor-unspecific; conformation-inverting) inhibitors UDP-glucuronate beta-D-glucuronosyltransferase (acceptor-unspecific) inhibitor UDP-glucuronate beta-D-glucuronosyltransferase (acceptor-unspecific) inhibitors UDP-glucuronyltransferase inhibitor UDP-glucuronyltransferase inhibitors UDPGA transferase inhibitor UDPGA transferase inhibitors UDPGA-glucuronyltransferase inhibitor UDPGA-glucuronyltransferase inhibitors UDPGT inhibitor UDPGT inhibitors glucuronosyltransferase inhibitor glucuronosyltransferase inhibitors uridine 5'-diphosphoglucuronyltransferase inhibitor uridine 5'-diphosphoglucuronyltransferase inhibitors uridine diphosphate glucuronyltransferase inhibitor uridine diphosphate glucuronyltransferase inhibitors uridine diphosphoglucuronosyltransferase inhibitor uridine diphosphoglucuronosyltransferase inhibitors uridine diphosphoglucuronyltransferase inhibitor uridine diphosphoglucuronyltransferase inhibitors EC 2.4.1.17 (glucuronosyltransferase) inhibitor CHEBI:133878 neuropeptide Y receptor antagonist neuropeptide Y receptor antagonists neuropeptide Y receptor antagonist CHEBI:133891 salt-inducible kinase 2 inhibitor SIK2 inhibitor SIK2 inhibitors SNF1LK2 inhibitor SNF1LK2 inhibitors salt-inducible kinase 2 inhibitors serine/threonine-protein kinase SIK2 inhibitor salt-inducible kinase 2 inhibitor CHEBI:133895 EC 2.5.1.46 (deoxyhypusine synthase) inhibitor (4-aminobutyl)lysine synthase inhibitor (4-aminobutyl)lysine synthase inhibitors DHS inhibitor DHS inhibitors EC 2.5.1.46 (deoxyhypusine synthase) inhibitors EC 2.5.1.46 inhibitor EC 2.5.1.46 inhibitors [eIF-5A]-deoxyhypusine synthase inhibitor [eIF-5A]-deoxyhypusine synthase inhibitors [eIF5A-precursor]-lysine:spermidine 4-aminobutyltransferase (propane-1,3-diamine-forming) inhibitor [eIF5A-precursor]-lysine:spermidine 4-aminobutyltransferase (propane-1,3-diamine-forming) inhibitors spermidine dehydrogenase inhibitor spermidine dehydrogenase inhibitors spermidine:eIF5A-lysine 4-aminobutyltransferase (propane-1,3-diamine-forming) inhibitor spermidine:eIF5A-lysine 4-aminobutyltransferase (propane-1,3-diamine-forming) inhibitors EC 2.5.1.46 (deoxyhypusine synthase) inhibitor CHEBI:134083 hypoxia-inducible factor pathway activator HIF pathway activator HIF pathway activators hypoxia activator hypoxia activators hypoxia-inducible factor pathway activators hypoxia-inducible factor pathway activator CHEBI:134084 EC 1.15.1.1 (superoxide dismutase) inhibitor EC 1.15.1.1 (superoxide dismutase) inhibitor CHEBI:134108 lipopolysaccharide biosynthesis inhibitor lipopolysaccharide biosynthesis inhibitors lipopolysaccharide biosynthesis inhibitor CHEBI:134109 EC 3.5.1.108 (UDP-3-O-acyl-N-acetylglucosamine deacetylase) inhibitor EC 3.5.1.108 (UDP-3-O-acyl-N-acetylglucosamine deacetylase) inhibitors EC 3.5.1.108 inhibitor EC 3.5.1.108 inhibitors LpxC deacetylase inhibitor LpxC deacetylase inhibitors LpxC enzyme inhibitor LpxC enzyme inhibitors LpxC inhibitor LpxC inhibitors UDP-(3-O-(R-3-hydroxymyristoyl))-N-acetylglucosamine deacetylase inhibitor UDP-(3-O-(R-3-hydroxymyristoyl))-N-acetylglucosamine deacetylase inhibitors UDP-(3-O-acyl)-N-acetylglucosamine deacetylase inhibitor UDP-(3-O-acyl)-N-acetylglucosamine deacetylase inhibitors UDP-3-O-((R)-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase inhibitor UDP-3-O-((R)-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase inhibitors UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase inhibitor UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase inhibitors UDP-3-O-[(3R)-3-hydroxymyristoyl]-N-acetyl-alpha-D-glucosamine amidohydrolase inhibitor UDP-3-O-[(3R)-3-hydroxymyristoyl]-N-acetyl-alpha-D-glucosamine amidohydrolase inhibitors UDP-3-O-[(3R)-3-hydroxymyristoyl]-N-acetylglucosamine amidohydrolase inhibitor UDP-3-O-[(3R)-3-hydroxymyristoyl]-N-acetylglucosamine amidohydrolase inhibitors UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase inhibitor UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase inhibitors UDP-3-O-acyl-GlcNAc deacetylase inhibitor UDP-3-O-acyl-GlcNAc deacetylase inhibitors deacetylase LpxC inhibitor deacetylase LpxC inhibitors EC 3.5.1.108 (UDP-3-O-acyl-N-acetylglucosamine deacetylase) inhibitor CHEBI:134173 antidote to barbiturate poisoning antidote to barbiturate overdose antidote to barbiturate poisoning CHEBI:134182 platelet-activating factor receptor antagonist PAF antagonist PAF antagonists platelet-activating factor receptor antagonists platelet-activating factor receptor antagonist CHEBI:134545 EC 1.8.1.4 (dihydrolipoyl dehydrogenase) inhibitor E3 component of alpha-ketoacid dehydrogenase complexes inhibitor E3 component of alpha-ketoacid dehydrogenase complexes inhibitors EC 1.8.1.4 (dihydrolipoyl dehydrogenase) inhibitors EC 1.8.1.4 inhibitor EC 1.8.1.4 inhibitors L-protein inhibitor L-protein inhibitors LDP-Glc inhibitor LDP-Glc inhibitors LDP-Val inhibitor LDP-Val inhibitors dehydrolipoate dehydrogenase inhibitor dehydrolipoate dehydrogenase inhibitors diaphorase inhibitor diaphorase inhibitors dihydrolipoamide dehydrogenase inhibitor dihydrolipoamide dehydrogenase inhibitors dihydrolipoamide:NAD(+) oxidoreductase inhibitor dihydrolipoamide:NAD(+) oxidoreductase inhibitors dihydrolipoic dehydrogenase inhibitor dihydrolipoic dehydrogenase inhibitors dihydrothioctic dehydrogenase inhibitor dihydrothioctic dehydrogenase inhibitors glycine-cleavage system L-protein inhibitor glycine-cleavage system L-protein inhibitors lipoamide dehydrogenase (NADH) inhibitor lipoamide dehydrogenase (NADH) inhibitors lipoamide oxidoreductase (NADH) inhibitor lipoamide oxidoreductase (NADH) inhibitors lipoamide reductase (NADH) inhibitor lipoamide reductase (NADH) inhibitors lipoamide reductase inhibitor lipoamide reductase inhibitors lipoate dehydrogenase inhibitor lipoate dehydrogenase inhibitors lipoic acid dehydrogenase inhibitor lipoic acid dehydrogenase inhibitors lipoyl dehydrogenase inhibitor lipoyl dehydrogenase inhibitors protein-6-N-(dihydrolipoyl)lysine:NAD(+) oxidoreductase inhibitor protein-6-N-(dihydrolipoyl)lysine:NAD(+) oxidoreductase inhibitors protein-N(6)-(dihydrolipoyl)lysine:NAD(+) oxidoreductase inhibitor protein-N(6)-(dihydrolipoyl)lysine:NAD(+) oxidoreductase inhibitors EC 1.8.1.4 (dihydrolipoyl dehydrogenase) inhibitor CHEBI:136537 EC 2.4.2.8 (hypoxanthine phosphoribosyltransferase) inhibitor 6-hydroxypurine phosphoribosyltransferase inhibitor 6-mercaptopurine phosphoribosyltransferase inhibitor EC 2.4.2.8 (hypoxanthine phosphoribosyltransferase) inhibitors EC 2.4.2.8 inhibitor EC 2.4.2.8 inhibitors GMP pyrophosphorylase inhibitor GPRT inhibitor HGPRTase inhibitor HPRT inhibitor IMP pyrophosphorylase inhibitor IMP-GMP pyrophosphorylase inhibitor IMP:diphosphate phospho-D-ribosyltransferase inhibitor guanine phosphoribosyltransferase inhibitor guanine-hypoxanthine phosphoribosyltransferase inhibitor guanosine 5'-phosphate pyrophosphorylase inhibitor guanosine phosphoribosyltransferase inhibitor guanylate pyrophosphorylase inhibitor guanylic pyrophosphorylase inhibitor hypoxanthine phosphoribosyltransferase (EC 2.4.2.8) inhibitor hypoxanthine phosphoribosyltransferase (EC 2.4.2.8) inhibitors hypoxanthine phosphoribosyltransferase inhibitor hypoxanthine phosphoribosyltransferase inhibitors hypoxanthine-guanine phosphoribosyltransferase inhibitor inosinate pyrophosphorylase inhibitor inosine 5'-phosphate pyrophosphorylas inhibitore inosinic acid pyrophosphorylase inhibitor inosinic pyrophosphorylase inhibitor purine-6-thiol phosphoribosyltransferase inhibitor transphosphoribosidase inhibitor EC 2.4.2.8 (hypoxanthine phosphoribosyltransferase) inhibitor CHEBI:136558 EC 1.11.1.7 (peroxidase) inhibitor Arthromyces ramosus peroxidase inhibitor Arthromyces ramosus peroxidase inhibitors Coprinus cinereus peroxidase inhibitor Coprinus cinereus peroxidase inhibitors EC 1.11.1.7 (peroxidase) inhibitors EC 1.11.1.7 inhibitor EC 1.11.1.7 inhibitors HRP inhibitor HRP inhibitors Japanese radish peroxidase inhibitor Japanese radish peroxidase inhibitors extensin peroxidase inhibitor extensin peroxidase inhibitors guaiacol peroxidase inhibitor guaiacol peroxidase inhibitors heme peroxidase inhibitor heme peroxidase inhibitors horseradish peroxidase (HRP) inhibitor horseradish peroxidase (HRP) inhibitors horseradish peroxidase inhibitor horseradish peroxidase inhibitors lactoperoxidase inhibitor lactoperoxidase inhibitors oxyperoxidase inhibitor oxyperoxidase inhibitors peroxidase (EC 1.11.1.7) inhibitor peroxidase (EC 1.11.1.7) inhibitors peroxidase inhibitor peroxidase inhibitors phenolic donor:hydrogen-peroxide oxidoreductase inhibitor phenolic donor:hydrogen-peroxide oxidoreductase inhibitors plant peroxidase inhibitor plant peroxidase inhibitors protoheme peroxidase inhibitor protoheme peroxidase inhibitors pyrocatechol peroxidase inhibitor pyrocatechol peroxidase inhibitors scopoletin peroxidase inhibitor scopoletin peroxidase inhibitors soybean peroxidase (SBP) inhibitor soybean peroxidase (SBP) inhibitors EC 1.11.1.7 (peroxidase) inhibitor CHEBI:136580 LRH-1 antagonist LRH-1 antagonists NR5A2 antagonist NR5A2 antagonists liver receptor homolog-1 antagonist liver receptor homolog-1 antagonists liver receptor homologue-1 antagonist liver receptor homologue-1 antagonists nuclear receptor subfamily 5 group A member 2 antagonist nuclear receptor subfamily 5 group A member 2 antagonists LRH-1 antagonist CHEBI:136643 propesticide pro-pesticide pro-pesticides propesticides propesticide CHEBI:136644 proinsecticide pro-insecticide pro-insecticides proinsecticides proinsecticide CHEBI:136645 profungicide pro-fungicide pro-fungicides profungicides profungicide CHEBI:136646 proherbicide pro-herbicide pro-herbicides proherbicides proherbicide CHEBI:136647 proacaricide pro-acaricide pro-acaricides proacaricides proacaricide CHEBI:136648 prosafener pro-safener pro-safeners prosafeners prosafener CHEBI:136651 S100 calcium-binding protein B inhibitor S100 calcium-binding protein B inhibitors S100B inhibitor S100B inhibitors S100 calcium-binding protein B inhibitor CHEBI:136859 pro-agent pro-agents proagent proagents pro-agent CHEBI:136860 antidote to sarin poisoning antidote to sarin poisoning CHEBI:136984 EC 4.4.1.14 (1-aminocyclopropane-1-carboxylate synthase) inhibitor 1-aminocyclopropane-1-carboxylate synthase inhibitor 1-aminocyclopropane-1-carboxylate synthase inhibitors 1-aminocyclopropane-1-carboxylate synthetase inhibitor 1-aminocyclopropane-1-carboxylate synthetase inhibitors 1-aminocyclopropane-1-carboxylic acid synthase inhibitor 1-aminocyclopropane-1-carboxylic acid synthase inhibitors 1-aminocyclopropanecarboxylate synthase inhibitor 1-aminocyclopropanecarboxylate synthase inhibitors ACC synthase inhibitor ACC synthase inhibitors EC 4.4.1.14 (1-aminocyclopropane-1-carboxylate synthase) inhibitors EC 4.4.1.14 inhibitor EC 4.4.1.14 inhibitors S-adenosyl-L-methionine methylthioadenosine-lyase (1-aminocyclopropane-1-carboxylate-forming) inhibitor S-adenosyl-L-methionine methylthioadenosine-lyase (1-aminocyclopropane-1-carboxylate-forming) inhibitors S-adenosyl-L-methionine methylthioadenosine-lyase inhibitor S-adenosyl-L-methionine methylthioadenosine-lyase inhibitors aminocyclopropanecarboxylate synthase inhibitor aminocyclopropanecarboxylate synthase inhibitors aminocyclopropanecarboxylic acid synthase inhibitor aminocyclopropanecarboxylic acid synthase inhibitors EC 4.4.1.14 (1-aminocyclopropane-1-carboxylate synthase) inhibitor CHEBI:137079 eukaryotic initiation factor 4F inhibitor eIF4F inhibitor eIF4F inhibitors eukaryotic initiation factor 4F inhibitors eukaryotic initiation factor 4F inhibitor CHEBI:137114 bromodomain-containing protein 4 inhibitor BRD4 inhibitor BRD4 inhibitors bromodomain-containing protein 4 inhibitors bromodomain-containing protein 4 inhibitor CHEBI:137123 EC 2.7.11.30 (receptor protein serine/threonine kinase) inhibitor ATP:[receptor-protein] phosphotransferase inhibitor ATP:[receptor-protein] phosphotransferase inhibitors EC 2.7.11.30 (receptor protein serine/threonine kinase) inhibitors EC 2.7.11.30 inhibitor EC 2.7.11.30 inhibitors STK13 inhibitor STK13 inhibitors TGF-beta kinase inhibitor TGF-beta kinase inhibitors activin receptor kinase inhibitor activin receptor kinase inhibitors inhibitor of receptor protein serine/threonine kinase receptor protein serine/threonine kinase (EC 2.7.11.30) inhibitor receptor protein serine/threonine kinase (EC 2.7.11.30) inhibitors receptor protein serine/threonine kinase inhibitor receptor protein serine/threonine kinase inhibitors receptor serine/threonine protein kinase inhibitor receptor serine/threonine protein kinase inhibitors receptor type I serine/threonine protein kinase inhibitor receptor type I serine/threonine protein kinase inhibitors receptor type II serine/threonine protein kinase inhibitor receptor type II serine/threonine protein kinase inhibitors EC 2.7.11.30 (receptor protein serine/threonine kinase) inhibitor CHEBI:137401 capsaicin receptor agonist TRPV1 agonist TRPV1 agonists capsaicin agonist capsaicin agonists capsaicin receptor agonists transient receptor potential cation channel subfamily V member 1 agonist transient receptor potential cation channel subfamily V member 1 agonists vanilloid receptor 1 agonist vanilloid receptor 1 agonists capsaicin receptor agonist CHEBI:137431 antihypotensive agent antihypotensive agents pressor pressors vasopressor agent vasopressor agents antihypotensive agent CHEBI:137514 TRPA1 channel agonist TRPA1 channel agonists transient receptor potential ankyrin 1 agonist transient receptor potential ankyrin 1 agonists transient receptor potential cation channel A1 agonist transient receptor potential cation channel A1 agonists TRPA1 channel agonist CHEBI:137566 EC 2.5.1.48 (cystathionine gamma-synthase) inhibitor 4-O-succinyl-L-homoserine:L-cysteine S-(3-amino-3-carboxypropyl)transferase inhibitor 4-O-succinyl-L-homoserine:L-cysteine S-(3-amino-3-carboxypropyl)transferase inhibitors EC 2.5.1.48 (cystathionine gamma-synthase) inhibitors EC 2.5.1.48 inhibitor EC 2.5.1.48 inhibitors O(4)-succinyl-L-homoserine:L-cysteine S-(3-amino-3-carboxypropyl)transferase inhibitor O(4)-succinyl-L-homoserine:L-cysteine S-(3-amino-3-carboxypropyl)transferase inhibitors O-succinyl-L-homoserine succinate-lyase (adding cysteine) inhibitor O-succinyl-L-homoserine succinate-lyase (adding cysteine) inhibitors O-succinylhomoserine (thiol)-lyase inhibitor O-succinylhomoserine (thiol)-lyase inhibitors O-succinylhomoserine synthase inhibitor O-succinylhomoserine synthase inhibitors O-succinylhomoserine synthetase inhibitor O-succinylhomoserine synthetase inhibitors cystathionine gamma-synthase inhibitor cystathionine gamma-synthase inhibitors cystathionine synthase inhibitor cystathionine synthase inhibitors cystathionine synthetase inhibitor cystathionine synthetase inhibitors homoserine O-transsuccinylase inhibitor homoserine O-transsuccinylase inhibitors homoserine transsuccinylase inhibitor homoserine transsuccinylase inhibitors EC 2.5.1.48 (cystathionine gamma-synthase) inhibitor CHEBI:137626 EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor 11beta-hydroxy steroid dehydrogenase inhibitor 11beta-hydroxy steroid dehydrogenase inhibitors 11beta-hydroxysteroid dehydrogenase inhibitor 11beta-hydroxysteroid dehydrogenase inhibitors 11beta-hydroxysteroid dehydrogenase type 1 inhibitor 11beta-hydroxysteroid dehydrogenase type 1 inhibitors 11beta-hydroxysteroid:NADP(+) 11-oxidoreductase inhibitor 11beta-hydroxysteroid:NADP(+) 11-oxidoreductase inhibitors EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitors EC 1.1.1.146 inhibitor EC 1.1.1.146 inhibitors beta-hydroxysteroid dehydrogenase inhibitor beta-hydroxysteroid dehydrogenase inhibitors corticosteroid 11-reductase inhibitor corticosteroid 11-reductase inhibitors corticosteroid 11beta-dehydrogenase inhibitor corticosteroid 11beta-dehydrogenase inhibitors dehydrogenase, 11beta-hydroxy steroid inhibitor dehydrogenase, 11beta-hydroxy steroid inhibitors EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor CHEBI:137684 Papio hamadryas metabolite P. hamadryas metabolite P. hamadryas metabolites Papio hamadryas metabolites Papio hamadryas metabolite CHEBI:137736 anxiogenic anxiogenics panicogenic panicogenics anxiogenic CHEBI:138014 EC 3.4.22.56 (caspase-3) inhibitor CASP-3 inhibitor CASP-3 inhibitors CPP32 inhibitor CPP32 inhibitors EC 3.4.22.56 (caspase-3) inhibitors EC 3.4.22.56 inhibitor EC 3.4.22.56 inhibitors apopain inhibitor apopain inhibitors caspase-3 (EC 3.4.22.56) inhibitor caspase-3 (EC 3.4.22.56) inhibitors caspase-3 inhibitor caspase-3 inhibitors yama protein inhibitor yama protein inhibitors EC 3.4.22.56 (caspase-3) inhibitor CHEBI:138015 endocrine disruptor endocrine disrupting chemical endocrine disrupting chemicals endocrine disrupting compound endocrine disrupting compounds endocrine disruptors endocrine-disrupting chemical endocrine-disrupting chemicals hormonally active agent hormonally active agents endocrine disruptor CHEBI:138090 ATPase motor cytoplasmic dynein inhibitor ATPase motor cytoplasmic dynein inhibitors ATPase motor cytoplasmic dynein inhibitor CHEBI:138103 inorganic acid inorganic acids mineral acid mineral acids inorganic acid CHEBI:138168 neuropeptide Y2 receptor agonist neuropeptide Y2 receptor agonist CHEBI:138208 carotenoid biosynthesis inhibitor carotenogenesis inhibitor carotenogenesis inhibitors carotenoid biosynthesis inhibitors carotenoid-biosynthesis inhibitor carotenoid-biosynthesis inhibitors carotenoid biosynthesis inhibitor CHEBI:138380 RhoA inhibitor Ras homolog gene family, member A inhibitor Ras homolog gene family, member A inhibitors RhoA GTPase inhibitor RhoA GTPase inhibitors RhoA inhibitors RhoA inhibitor CHEBI:138381 RhoC inhibitor Ras homolog gene family, member C inhibitor Ras homolog gene family, member C inhibitors RhoC GTPase inhibitor RhoC GTPase inhibitors RhoC inhibitors RhoC inhibitor CHEBI:138390 EC 1.1.1.159 (7alpha-hydroxysteroid dehydrogenase) inhibitor 7alpha-HSDH inhibitor 7alpha-HSDH inhibitors 7alpha-hydroxy steroid dehydrogenase inhibitor 7alpha-hydroxy steroid dehydrogenase inhibitors 7alpha-hydroxysteroid dehydrogenase inhibitor 7alpha-hydroxysteroid dehydrogenase inhibitors 7alpha-hydroxysteroid:NAD+ 7-oxidoreductase inhibitor 7alpha-hydroxysteroid:NAD+ 7-oxidoreductase inhibitors EC 1.1.1.159 (7alpha-hydroxysteroid dehydrogenase) inhibitors EC 1.1.1.159 inhibitor EC 1.1.1.159 inhibitors EC 1.1.1.159 (7alpha-hydroxysteroid dehydrogenase) inhibitor CHEBI:138416 angiotensin receptor agonist angiotensin receptor agonists angiotensin receptor agonist CHEBI:138880 autophagy inducer autophagocytosis inducer autophagocytosis inducers autophagy inducers autophagy inducer CHEBI:138887 prostaglandin receptor antagonist prostaglandin receptor antagonists prostanoid receptor antagonist prostanoid receptor antagonists prostaglandin receptor antagonist CHEBI:138920 EC 6.3.5.* (carbon-nitrogen ligases with glutamine as amido-N-donor) inhibitor EC 6.3.5.* (carbon-nitrogen ligases with glutamine as amido-N-donor) inhibitors EC 6.3.5.* (carbon-nitrogen ligases with glutamine as amido-N-donor) inhibitor CHEBI:138921 EC 6.3.5.5 [carbamoyl-phosphate synthase (glutamine-hydrolysing)] inhibitor CAD inhibitor CAD inhibitors CPS inhibitor CPS inhibitors EC 6.3.5.5 [carbamoyl-phosphate synthase (glutamine-hydrolysing)] inhibitors EC 6.3.5.5 inhibitor EC 6.3.5.5 inhibitors GD-CPSase inhibitor GD-CPSase inhibitors HCO3(-):L-glutamine amido-ligase (ADP-forming, carbamate-phosphorylating) inhibitor HCO3(-):L-glutamine amido-ligase (ADP-forming, carbamate-phosphorylating) inhibitors carA inhibitor carA inhibitors carB inhibitor carB inhibitors carbamoyl phosphate synthetase inhibitor carbamoyl phosphate synthetase inhibitors carbamoyl-phosphate synthase (glutamine-hydrolysing) (EC 6.3.5.5) inhibitor carbamoyl-phosphate synthase (glutamine-hydrolysing) (EC 6.3.5.5) inhibitors carbamoyl-phosphate synthetase (glutamine-hydrolysing) inhibitor carbamoyl-phosphate synthetase (glutamine-hydrolysing) inhibitors carbamoylphosphate synthetase II inhibitor carbamoylphosphate synthetase II inhibitors carbamyl phosphate synthetase (glutamine) inhibitor carbamyl phosphate synthetase (glutamine) inhibitors carbon-dioxide:L-glutamine amido-ligase (ADP-forming, carbamate-phosphorylating) inhibitor carbon-dioxide:L-glutamine amido-ligase (ADP-forming, carbamate-phosphorylating) inhibitors glutamine-dependent carbamoyl-phosphate synthase inhibitor glutamine-dependent carbamoyl-phosphate synthase inhibitors glutamine-dependent carbamyl phosphate synthetase inhibitor glutamine-dependent carbamyl phosphate synthetase inhibitors hydrogen-carbonate:L-glutamine amido-ligase (ADP-forming, carbamate-phosphorylating) inhibitor hydrogen-carbonate:L-glutamine amido-ligase (ADP-forming, carbamate-phosphorylating) inhibitors EC 6.3.5.5 [carbamoyl-phosphate synthase (glutamine-hydrolysing)] inhibitor CHEBI:138924 EC 6.3.4.* (other carbon--nitrogen ligases) inhibitor EC 6.3.4.* (other carbon--nitrogen ligases) inhibitors EC 6.3.4.* inhibitor EC 6.3.4.* inhibitors EC 6.3.4.* (other carbon--nitrogen ligases) inhibitor CHEBI:138925 EC 6.3.4.2 [CTP synthase (glutamine hydrolyzing)] inhibitor CTP synthase (glutamine hydrolyzing) (EC6.3.4.2) inhibitor CTP synthase (glutamine hydrolyzing) (EC6.3.4.2) inhibitors CTP synthase (glutamine hydrolyzing) inhibitor CTP synthase (glutamine hydrolyzing) inhibitors CTP synthetase inhibitor CTP synthetase inhibitors CTPS inhibitor CTPS inhibitors EC 6.3.4.2 [CTP synthase (glutamine hydrolyzing)] inhibitors EC 6.3.4.2 inhibitor EC 6.3.4.2 inhibitors UTP--ammonia ligase inhibitor UTP-ammonia ligase inhibitors UTP:L-glutamine amido-ligase (ADP-forming) inhibitor UTP:L-glutamine amido-ligase (ADP-forming) inhibitors cytidine triphosphate synthetase inhibitor cytidine triphosphate synthetase inhibitors pyrG inhibitor pyrG inhibitors uridine triphosphate aminase inhibitor uridine triphosphate aminase inhibitors EC 6.3.4.2 [CTP synthase (glutamine hydrolyzing)] inhibitor CHEBI:138927 EC 6.3.5.3 (phosphoribosylformylglycinamidine synthase) inhibitor 2-N-formyl-1-N-(5-phospho-D-ribosyl)glycinamide:L-glutamine amido-ligase (ADP-forming) inhibitor 2-N-formyl-1-N-(5-phospho-D-ribosyl)glycinamide:L-glutamine amido-ligase (ADP-forming) inhibitors 5'-phosphoribosylformylglycinamide:L-glutamine amido-ligase (ADP-forming) inhibitor 5'-phosphoribosylformylglycinamide:L-glutamine amido-ligase (ADP-forming) inhibitors EC 6.3.5.3 (phosphoribosylformylglycinamidine synthase) inhibitors EC 6.3.5.3 inhibitor EC 6.3.5.3 inhibitors FGAM synthase inhibitor FGAM synthase inhibitors FGAM synthetase inhibitor FGAM synthetase inhibitors FGAR amidotransferase inhibitor FGAR amidotransferase inhibitors FGARAT inhibitor FGARAT inhibitors N(2)-formyl-N(1)-(5-phospho-D-ribosyl)glycinamide:L-glutamine amido-ligase (ADP-forming) inhibitor N(2)-formyl-N(1)-(5-phospho-D-ribosyl)glycinamide:L-glutamine amido-ligase (ADP-forming) inhibitors formylglycinamide ribonucloetide amidotransferase inhibitor formylglycinamide ribonucloetide amidotransferase inhibitors formylglycinamide ribotide amidotransferase inhibitor formylglycinamide ribotide amidotransferase inhibitors phosphoribosylformylglycinamidine synthase inhibitor phosphoribosylformylglycinamidine synthase inhibitors phosphoribosylformylglycinamidine synthetase inhibitor phosphoribosylformylglycinamidine synthetase inhibitors phosphoribosylformylglycineamidine synthetase inhibitor phosphoribosylformylglycineamidine synthetase inhibitors EC 6.3.5.3 (phosphoribosylformylglycinamidine synthase) inhibitor CHEBI:138928 EC 6.3.5.2 [GMP synthase (glutamine-hydrolysing)] inhibitor EC 6.3.5.2 [GMP synthase (glutamine-hydrolysing)] inhibitors EC 6.3.5.2 inhibitor EC 6.3.5.2 inhibitors GMP synthase (glutamine-hydrolysing) inhibitor GMP synthase (glutamine-hydrolysing) inhibitors GMP synthetase (glutamine-hydrolysing) inhibitor GMP synthetase (glutamine-hydrolysing) inhibitors guanosine 5'-monophosphate synthetase inhibitor guanosine 5'-monophosphate synthetase inhibitors guanosine monophosphate synthetase (glutamine-hydrolyzing) inhibitor guanosine monophosphate synthetase (glutamine-hydrolyzing) inhibitors guanylate synthetase (glutamine-hydrolyzing) inhibitor guanylate synthetase (glutamine-hydrolyzing) inhibitors xanthosine 5'-phosphate amidotransferase inhibitor xanthosine 5'-phosphate amidotransferase inhibitors xanthosine-5'-phosphate:L-glutamine amido-ligase (AMP-forming) inhibitor xanthosine-5'-phosphate:L-glutamine amido-ligase (AMP-forming) inhibitors EC 6.3.5.2 [GMP synthase (glutamine-hydrolysing)] inhibitor CHEBI:138931 glutamine antagonist glutamine antagonists glutamine antagonist CHEBI:138938 EC 4.1.1.39 (ribulose-bisphosphate carboxylase) inhibitor 3-phospho-D-glycerate carboxy-lyase (dimerizing) inhibitor 3-phospho-D-glycerate carboxy-lyase (dimerizing) inhibitors 3-phospho-D-glycerate carboxy-lyase (dimerizing; D-ribulose-1,5-bisphosphate-forming) inhibitor 3-phospho-D-glycerate carboxy-lyase (dimerizing; D-ribulose-1,5-bisphosphate-forming) inhibitors D-ribulose 1,5-bisphosphate carboxylase inhibitor D-ribulose 1,5-bisphosphate carboxylase inhibitors D-ribulose 1,5-diphosphate carboxylase inhibitor D-ribulose 1,5-diphosphate carboxylase inhibitors EC 4.1.1.39 (ribulose-bisphosphate carboxylase) inhibitors EC 4.1.1.39 inhibitor EC 4.1.1.39 inhibitors RuBP carboxylase inhibitor RuBP carboxylase inhibitors RuBisCO inhibitor RuBisCO inhibitors carboxydismutase inhibitor carboxydismutase inhibitors diphosphoribulose carboxylase inhibitor diphosphoribulose carboxylase inhibitors ribulose 1,5-bisphosphate carboxylase inhibitor ribulose 1,5-bisphosphate carboxylase inhibitors ribulose 1,5-bisphosphate carboxylase/oxygenase inhibitor ribulose 1,5-bisphosphate carboxylase/oxygenase inhibitors ribulose 1,5-diphosphate carboxylase inhibitor ribulose 1,5-diphosphate carboxylase inhibitors ribulose 1,5-diphosphate carboxylase/oxygenase inhibitor ribulose 1,5-diphosphate carboxylase/oxygenase inhibitors ribulose bisphosphate carboxylase/oxygenase inhibitor ribulose bisphosphate carboxylase/oxygenase inhibitors ribulose diphosphate carboxylase inhibitor ribulose diphosphate carboxylase inhibitors ribulose diphosphate carboxylase/oxygenase inhibitor ribulose diphosphate carboxylase/oxygenase inhibitors ribulose-bisphosphate carboxylase inhibitor ribulose-bisphosphate carboxylase inhibitors rubisco inhibitor rubisco inhibitors EC 4.1.1.39 (ribulose-bisphosphate carboxylase) inhibitor CHEBI:138952 EC 2.4.2.14 (amidophosphoribosyltransferase) inhibitor 5'-phosphoribosylpyrophosphate amidotransferase inhibitor 5'-phosphoribosylpyrophosphate amidotransferase inhibitors 5-phospho-beta-D-ribosylamine:diphosphate phospho-alpha-D-ribosyltransferase (glutamate-amidating) inhibitor 5-phospho-beta-D-ribosylamine:diphosphate phospho-alpha-D-ribosyltransferase (glutamate-amidating) inhibitors 5-phosphoribosyl-1-pyrophosphate amidotransferase inhibitor 5-phosphoribosyl-1-pyrophosphate amidotransferase inhibitors 5-phosphoribosylamine:diphosphate phospho-alpha-D-ribosyltransferase (glutamate-amidating) inhibitor 5-phosphoribosylamine:diphosphate phospho-alpha-D-ribosyltransferase (glutamate-amidating) inhibitors 5-phosphororibosyl-1-pyrophosphate amidotransferase inhibitor 5-phosphororibosyl-1-pyrophosphate amidotransferase inhibitors EC 2.4.2.14 (amidophosphoribosyltransferase) inhibitors EC 2.4.2.14 inhibitor EC 2.4.2.14 inhibitors alpha-5-phosphoribosyl-1-pyrophosphate amidotransferase inhibitor alpha-5-phosphoribosyl-1-pyrophosphate amidotransferase inhibitors amidophosphoribosyltransferase (EC 2.4.2.14) inhibitor amidophosphoribosyltransferase (EC 2.4.2.14) inhibitors amidophosphoribosyltransferase inhibitor amidophosphoribosyltransferase inhibitors glutamine 5-phosphoribosylpyrophosphate amidotransferase inhibitor glutamine 5-phosphoribosylpyrophosphate amidotransferase inhibitors glutamine phosphoribosyldiphosphate amidotransferase inhibitor glutamine phosphoribosyldiphosphate amidotransferase inhibitors glutamine phosphoribosylpyrophosphate amidotransferase inhibitor glutamine phosphoribosylpyrophosphate amidotransferase inhibitors glutamine ribosylpyrophosphate 5-phosphate amidotransferase inhibitor glutamine ribosylpyrophosphate 5-phosphate amidotransferase inhibitors phosphoribose pyrophosphate amidotransferase inhibitor phosphoribose pyrophosphate amidotransferase inhibitors phosphoribosyl pyrophosphate amidotransferase inhibitor phosphoribosyl pyrophosphate amidotransferase inhibitors phosphoribosyldiphosphate 5-amidotransferase inhibitor phosphoribosyldiphosphate 5-amidotransferase inhibitors phosphoribosylpyrophosphate glutamyl amidotransferase inhibitor phosphoribosylpyrophosphate glutamyl amidotransferase inhibitors EC 2.4.2.14 (amidophosphoribosyltransferase) inhibitor CHEBI:138953 EC 6.3.5.1 [NAD(+) synthase (glutamine-hydrolysing)] inhibitor DPN synthetase inhibitor DPN synthetase inhibitors EC 6.3.5.1 [NAD(+) synthase (glutamine-hydrolysing)] inhibitors EC 6.3.5.1 inhibitor EC 6.3.5.1 inhibitors NAD synthetase (glutamine-hydrolysing) inhibitor NAD synthetase (glutamine-hydrolysing) inhibitors NAD(+) synthase (glutamine-hydrolysing) (EC 6.3.5.1) inhibitor NAD(+) synthase (glutamine-hydrolysing) (EC 6.3.5.1) inhibitors NAD(+) synthase (glutamine-hydrolysing) inhibitor NAD(+) synthase (glutamine-hydrolysing) inhibitors NAD(+) synthetase (glutamine-hydrolyzing) inhibitor NAD(+) synthetase (glutamine-hydrolyzing) inhibitors deamido-NAD(+):L-glutamine amido-ligase (AMP-forming) inhibitor deamido-NAD(+):L-glutamine amido-ligase (AMP-forming) inhibitors desamidonicotinamide adenine dinucleotide amidotransferase inhibitor desamidonicotinamide adenine dinucleotide amidotransferase inhibitors nicotinamide adenine dinucleotide synthetase (glutamine) inhibitor nicotinamide adenine dinucleotide synthetase (glutamine) inhibitors EC 6.3.5.1 [NAD(+) synthase (glutamine-hydrolysing)] inhibitor CHEBI:138956 EC 6.3.5.4 [asparagine synthase (glutamine-hydrolysing)] inhibitor AS inhibitor AS inhibitors AS-B inhibitor AS-B inhibitors EC 6.3.5.4 [asparagine synthase (glutamine-hydrolysing)] inhibitors EC 6.3.5.4 inhibitor EC 6.3.5.4 inhibitors L-aspartate:L-glutamine amido-ligase (AMP-forming) inhibitor L-aspartate:L-glutamine amido-ligase (AMP-forming) inhibitors asparagine synthase (glutamine-hydrolysing) (EC 6.3.5.4) inhibitor asparagine synthase (glutamine-hydrolysing) (EC 6.3.5.4) inhibitors asparagine synthase (glutamine-hydrolysing) inhibitor asparagine synthase (glutamine-hydrolysing) inhibitors asparagine synthetase (glutamine-hydrolysing) inhibitor asparagine synthetase (glutamine-hydrolysing) inhibitors asparagine synthetase B inhibitor asparagine synthetase B inhibitors glutamine-dependent asparagine synthetase inhibitor glutamine-dependent asparagine synthetase inhibitors EC 6.3.5.4 [asparagine synthase (glutamine-hydrolysing)] inhibitor CHEBI:138977 quorum sensing inhibitor QS inhibitor QS inhibitors QSI QSIs quorum sensing inhibitors quorum sensing inhibitor CHEBI:139044 thromboxane A2 agonist TXA2/PGH2 agonist TXA2/PGH2 agonists TXA2/PGH2 receptor agonist TXA2/PGH2 receptor agonists thromboxane A2 agonists thromboxane A2 receptor agonist thromboxane A2 receptor agonists thromboxane A2 agonist CHEBI:139055 PERK inhibitor PERK inhibitors PKR-like endoplasmic reticulum kinase inhibitor PKR-like endoplasmic reticulum kinase inhibitors protein kinase R-like endoplasmic reticulum kinase inhibitor protein kinase R-like endoplasmic reticulum kinase inhibitors PERK inhibitor CHEBI:139074 LIM kinase inhibitor LIM kinase inhibitors LIM kinase inhibitor CHEBI:139084 cis-Golgi ArfGEF GBF inhibitor cis-Golgi ArfGEF GBF inhibitor CHEBI:139109 IP3 receptor agonist D-myo-inositol 1,4,5-trisphosphate receptor agonist D-myo-inositol 1,4,5-trisphosphate receptor agonists IP3 agonist IP3 agonists IP3 receptor agonists InsP3R agonist InsP3R agonists inositol trisphosphate receptor agonist inositol trisphosphate receptor agonists IP3 receptor agonist CHEBI:139153 EC 2.4.1.255 (protein O-GlcNAc transferase) inhibitor EC 2.4.1.255 (protein O-GlcNAc transferase) inhibitors EC 2.4.1.255 inhibitor EC 2.4.1.255 inhibitors O-GlcNAc transferase inhibitor O-GlcNAc transferase inhibitors O-linked N-acetylglucosaminyltransferase inhibitor O-linked N-acetylglucosaminyltransferase inhibitors OGTase inhibitor OGTase inhibitors UDP-N-acetyl-D-glucosamine:protein-O-beta-N-acetyl-D-glucosaminyl transferase inhibitor UDP-N-acetyl-D-glucosamine:protein-O-beta-N-acetyl-D-glucosaminyl transferase inhibitors protein O-GlcNAc transferase (EC 2.4.1.255) inhibitor protein O-GlcNAc transferase (EC 2.4.1.255) inhibitors protein O-GlcNAc transferase inhibitor protein O-GlcNAc transferase inhibitors protein O-linked beta-N-acetylglucosamine transferase inhibitor protein O-linked beta-N-acetylglucosamine transferase inhibitors uridine diphospho-N-acetylglucosamine:polypeptide beta-N-acetylglucosaminyltransferase inhibitor uridine diphospho-N-acetylglucosamine:polypeptide beta-N-acetylglucosaminyltransferase inhibitors EC 2.4.1.255 (protein O-GlcNAc transferase) inhibitor CHEBI:139155 melanin-concentrating hormone receptor antagonist MCHR agonist MCHR agonists melanin-concentrating hormone receptor antagonists melanin-concentrating hormone receptor antagonist CHEBI:139180 nicotinic acid adenine dinucleotide phosphate receptor antagonist NAADP antagonist NAADP antagonists NAADP receptor antagonist NAADP receptor antagonists nicotinic acid adenine dinucleotide phosphate receptor antagonists nicotinic acid adenine dinucleotide phosphate receptor antagonist CHEBI:139246 peptide probe peptide probe CHEBI:139338 EC 1.14.17.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen and with reduced ascorbate as one donor, and incorporation of one atom of oxygen) inhibitor EC 1.14.17.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen and with reduced ascorbate as one donor, and incorporation of one atom of oxygen) inhibitor CHEBI:139339 EC 1.14.17.1 (dopamine beta-monooxygenase) inhibitor (3,4-dihydroxyphenethylamine)beta-mono-oxygenase inhibitor (3,4-dihydroxyphenethylamine)beta-mono-oxygenase inhibitors 3,4-dihydroxyphenethylamine beta-oxidase inhibitor 3,4-dihydroxyphenethylamine beta-oxidase inhibitors 3,4-dihydroxyphenethylamine,ascorbate:oxygen oxidoreductase (beta-hydroxylating) inhibitor 3,4-dihydroxyphenethylamine,ascorbate:oxygen oxidoreductase (beta-hydroxylating) inhibitors 4-(2-aminoethyl)pyrocatechol beta-oxidase inhibitor 4-(2-aminoethyl)pyrocatechol beta-oxidase inhibitors DbetaH inhibitor DbetaH inhibitors EC 1.14.17.1 (dopamine beta-monooxygenase) inhibitors EC 1.14.17.1 inhibitor EC 1.14.17.1 inhibitors MDBH (membrane-associated dopamine beta-monooxygenase) inhibitor MDBH (membrane-associated dopamine beta-monooxygenase) inhibitors SDBH (soluble dopamine beta-monooxygenase) inhibitor SDBH (soluble dopamine beta-monooxygenase) inhibitors dopa beta-hydroxylase inhibitor dopa beta-hydroxylase inhibitors dopamine beta-hydroxylase inhibitor dopamine beta-hydroxylase inhibitors dopamine beta-monooxygenase (EC 1.14.17.1) inhibitor dopamine beta-monooxygenase (EC 1.14.17.1) inhibitors dopamine beta-monooxygenase inhibitor dopamine beta-monooxygenase inhibitors dopamine beta-oxidase inhibitor dopamine beta-oxidase inhibitors dopamine hydroxylase inhibitor dopamine hydroxylase inhibitors dopamine-B-hydroxylase inhibitor dopamine-B-hydroxylase inhibitors oxygenase, dopamine beta-mono-phenylamine beta-hydroxylase inhibitor oxygenase, dopamine beta-mono-phenylamine beta-hydroxylase inhibitors EC 1.14.17.1 (dopamine beta-monooxygenase) inhibitor CHEBI:139361 TRP channel blocker TRP channel blockers transient receptor potential channel blocker transient receptor potential channel blockers TRP channel blocker CHEBI:139492 sensitiser sensitisers sensitizer sensitizers sensitiser CHEBI:139503 vitamin D receptor agonist VDR agonist VDR agonists calcitriol receptor agonist calcitriol receptor agonists vitamin D nuclear receptor agonist vitamin D nuclear receptor agonists vitamin D receptor agonists vitamin D receptor agonist CHEBI:139512 EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitors EC 1.3.1.9 inhibitor EC 1.3.1.9 inhibitors ENR inhibitor ENR inhibitors NADH-enoyl acyl carrier protein reductase inhibitor NADH-enoyl acyl carrier protein reductase inhibitors NADH-specific enoyl-ACP reductase inhibitor NADH-specific enoyl-ACP reductase inhibitors acyl-[acyl-carrier-protein]:NAD+ oxidoreductase inhibitor acyl-[acyl-carrier-protein]:NAD+ oxidoreductase inhibitors enoyl-ACP reductase inhibitor enoyl-ACP reductase inhibitors enoyl-[acyl carrier protein] reductase inhibitor enoyl-[acyl carrier protein] reductase inhibitors EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor CHEBI:139556 EC 4.1.1.17 (ornithine decarboxylase) inhibitor EC 4.1.1.17 (ornithine decarboxylase) inhibitors EC 4.1.1.17 inhibitor EC 4.1.1.17 inhibitors L-ornithine carboxy-lyase (putrescine-forming) inhibitor L-ornithine carboxy-lyase (putrescine-forming) inhibitors L-ornithine carboxy-lyase inhibitor L-ornithine carboxy-lyase inhibitors ODC inhibitor ODC inhibitors SpeC inhibitor SpeC inhibitors EC 4.1.1.17 (ornithine decarboxylase) inhibitor CHEBI:139566 Jacobaea metabolite Jacobaea metabolites Jacobaea metabolite CHEBI:139584 lysophosphatidic acid receptor 3 agonist LPA3 agonist LPA3 agonists LPAR3 agonist LPAR3 agonists lysophosphatidic acid receptor 3 agonists lysophosphatidic acid receptor 3 agonist CHEBI:139609 survivin suppressant survivin suppressants survivin suppressor survivin suppressors survivin suppressant CHEBI:140061 TRPV4 agonist OSM9-like transient receptor potential channel, member 4 agonist OSM9-like transient receptor potential channel, member 4 agonists OTRPC4 agonist OTRPC4 agonists TRPV4 agonists VR-OAC agonist VR-OAC agonists transient receptor potential +agonist transient receptor potential cation channel subfamily V member 4 agonist transient receptor potential cation channel subfamily V member 4 agonists transient receptor potential vanilloid 4 agonists transient receptor vanilloid-4 agonist transient receptor vanilloid-4 agonists vanilloid-receptor related osmotically activated channel agonist vanilloid-receptor related osmotically activated channel agonists TRPV4 agonist CHEBI:140160 Camellia sinensis metabolite C. sinensis metabolite C. sinensis metabolites Camellia sinensis metabolites Camellia sinensis metabolite CHEBI:140165 Brassica napus metabolite Brassica napus metabolites rapeseed metabolite rapeseed metabolites Brassica napus metabolite CHEBI:140190 calcium-dependent antibiotics Ca(2+)-dependent antibiotic Ca(2+)-dependent antibiotics Ca-dependent antibiotic Ca-dependent antibiotics calcium-dependent antibiotic calcium-dependent antibiotics CHEBI:140378 EC 1.1.1.37 (malate dehydrogenase) inhibitor (S)-malate:NAD(+) oxidoreductase inhibitor (S)-malate:NAD(+) oxidoreductase inhibitors EC 1.1.1.37 (malate dehydrogenase) inhibitors EC 1.1.1.37 inhibitor EC 1.1.1.37 inhibitors L-malate dehydrogenase inhibitor L-malate dehydrogenase inhibitors L-malate-NAD(+) oxidoreductase inhibitor L-malate-NAD(+) oxidoreductase inhibitors MDH inhibitor MDH inhibitors NAD-L-malate dehydrogenase inhibitor NAD-L-malate dehydrogenase inhibitors NAD-dependent malate dehydrogenase inhibitor NAD-dependent malate dehydrogenase inhibitors NAD-dependent malic dehydrogenase inhibitor NAD-dependent malic dehydrogenase inhibitors NAD-linked malate dehydrogenase inhibitor NAD-linked malate dehydrogenase inhibitors NAD-malate dehydrogenase inhibitor NAD-malate dehydrogenase inhibitors NAD-malic dehydrogenase inhibitor NAD-malic dehydrogenase inhibitors NAD-specific malate dehydrogenase inhibitor NAD-specific malate dehydrogenase inhibitors malate (NAD) dehydrogenase inhibitor malate (NAD) dehydrogenase inhibitors malate dehydrogenase (EC 1.1.1.37) inhibitor malate dehydrogenase (EC 1.1.1.37) inhibitors malate dehydrogenase inhibitor malate dehydrogenase inhibitors malic acid dehydrogenase inhibitor malic acid dehydrogenase inhibitors malic dehydrogenase inhibitor malic dehydrogenase inhibitors EC 1.1.1.37 (malate dehydrogenase) inhibitor CHEBI:140399 specialised pro-resolving mediator SPM SPMs specialised pro-resolving mediators specialised proresolving mediator specialised proresolving mediators specialized pro-resolving mediator specialized pro-resolving mediators specialized proresolving mediator specialized proresolving mediators specialised pro-resolving mediator CHEBI:140482 neurokinin-3 receptor antagonist NK-3 receptor antagonist NK-3 receptor antagonists NK3 receptor antagonist NK3 receptor antagonists NK3R antagonist NK3R antagonists neurokinin-3 receptor antagonists neurokinin-3 receptor antagonist CHEBI:140489 tropomyosin-related kinase B receptor agonist TrkB receptor agonist TrkB receptor agonists tropomyosin-related kinase B receptor agonists tropomyosin-related kinase B receptor agonist CHEBI:140535 TRPV1 agonist TRPV1 agonists capsaicin receptor agonist capsaicin receptor agonists transient receptor potential cation channel subfamily V member 1 agonist transient receptor potential cation channel subfamily V member 1 agonists transient receptor potential vanilloid 1 agonist transient receptor potential vanilloid 1 agonists vanilloid receptor 1 agonist vanilloid receptor 1 agonists TRPV1 agonist CHEBI:140602 Arabidopsis thaliana metabolite Arabidopsis thaliana metabolites Arabidopsis thaliana metabolite CHEBI:140701 secreted frizzled-related protein 1 inhibitor SFRP1 inhibitor SFRP1 inhibitors sFRP-1 inhibitor sFRP-1 inhibitors secreted frizzled-related protein 1 inhibitors secreted frizzled-related protein-1 inhibitor secreted frizzled-related protein-1 inhibitors secreted frizzled-related protein 1 inhibitor CHEBI:140921 Hedgehog signaling pathway inhibitor Hedgehog pathway inhibitor Hedgehog pathway inhibitors Hedgehog signaling pathway inhibitors Hedgehog signaling pathway inhibitor CHEBI:140922 glioma-associated oncogene inhibitor GLI inhibitor GLI inhibitors glioma-associated oncogene inhibitors glioma-associated oncogene inhibitor CHEBI:140982 neuropeptide FF receptor antagonist NPFF receptor antagonist NPFF receptor antagonists NPFFR antagonist NPFFR antagonists neuropeptide FF receptor antagonists neuropeptide FF receptor antagonist CHEBI:141000 neuropeptide FF receptor agonist NPFF receptor agonist NPFF receptor agonists neuropeptide FF receptor agonists neuropeptide FF receptor agonist CHEBI:141001 kisspeptin receptor agonist kisspeptin receptor agonists kisspeptin receptor agonist CHEBI:141153 quinone outside inhibitor QOI QOIs Qo inhibitor Qo inhibitors quinone outside inhibitors quinone outside inhibitor CHEBI:141301 pronematicide pronematicides pronematocide pronematocides pronematicide CHEBI:142184 5-hydroxytryptamine 2B receptor agonist 5-HT2B agonist 5-HT2B agonists 5-HT2B receptor agonist 5-HT2B receptor agonists 5-hydroxytryptamine 2B receptor agonists 5-hydroxytryptamine receptor 2B agonist 5-hydroxytryptamine receptor 2B agonists serotonin receptor 2B agonist serotonin receptor 2B agonists 5-hydroxytryptamine 2B receptor agonist CHEBI:142185 5-hydroxytryptamine 2C receptor agonist 5-HT2C receptor agonist 5-HT2C receptor agonists 5-HT2c agonist 5-HT2c agonists 5-hydroxytryptamine 2C receptor agonists 5-hydroxytryptamine receptor 2C agonist 5-hydroxytryptamine receptor 2C agonists serotonin receptor 2C agonist serotonin receptor 2C agonists 5-hydroxytryptamine 2C receptor agonist CHEBI:142480 EC 1.14.14.94 (leukotriene-B4 20-monooxygenase) inhibitor (6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate,[reduced NADPH-hemoprotein reductase]:oxygen oxidoreductase (20-hydroxylating) inhibitor (6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate,[reduced NADPH-hemoprotein reductase]:oxygen oxidoreductase (20-hydroxylating) inhibitors CYP4F2 inhibitor CYP4F2 inhibitors CYP4F3 inhibitor CYP4F3 inhibitors EC 1.14.13.30 inhibitor EC 1.14.13.30 inhibitors EC 1.14.14.94 (leukotriene-B4 20-monooxygenase) inhibitors EC 1.14.14.94 inhibitor EC 1.14.14.94 inhibitors LTB4 20-hydroxylase inhibitor LTB4 20-hydroxylase inhibitors LTB4 omega-hydroxylase inhibitor LTB4 omega-hydroxylase inhibitors leucotriene-B4 omega-hydroxylase inhibitor leucotriene-B4 omega-hydroxylase inhibitors leukotriene-B4 20-hydroxylase inhibitor leukotriene-B4 20-hydroxylase inhibitors leukotriene-B4 20-monooxygenase (EC 1.14.14.94) inhibitors leukotriene-B4 20-monooxygenase inhibitor leukotriene-B4 20-monooxygenase inhibitors EC 1.14.14.94 (leukotriene-B4 20-monooxygenase) inhibitor CHEBI:142481 EC 1.14.15.3 (alkane 1-monooxygenase) inhibitor 1-hydroxylase inhibitor 1-hydroxylase inhibitors EC 1.14.15.3 (alkane 1-monooxygenase) inhibitors EC 1.14.15.3 inhibitor EC 1.14.15.3 inhibitors alkane 1-hydroxylase inhibitor alkane 1-hydroxylase inhibitors alkane 1-monooxygenase (EC 1.14.15.3) inhibitor alkane 1-monooxygenase (EC 1.14.15.3) inhibitors alkane 1-monooxygenase inhibitor alkane 1-monooxygenase inhibitors alkane hydroxylase inhibitor alkane hydroxylase inhibitors alkane monooxygenase inhibitor alkane monooxygenase inhibitors alkane,reduced-rubredoxin:oxygen 1-oxidoreductase inhibitor alkane,reduced-rubredoxin:oxygen 1-oxidoreductase inhibitors fatty acid omega-hydroxylase inhibitor fatty acid omega-hydroxylase inhibitors omega-hydroxylase inhibitor omega-hydroxylase inhibitors EC 1.14.15.3 (alkane 1-monooxygenase) inhibitor CHEBI:142581 EC 4.1.1.15 (glutamate decarboxylase) inhibitor EC 4.1.1.15 (glutamate decarboxylase) inhibitors EC 4.1.1.15 inhibitor EC 4.1.1.15 inhibitors L-aspartate-alpha-decarboxylase inhibitor L-aspartate-alpha-decarboxylase inhibitors L-glutamate 1-carboxy-lyase (4-aminobutanoate-forming) inhibitor L-glutamate 1-carboxy-lyase (4-aminobutanoate-forming) inhibitors L-glutamate 1-carboxy-lyase inhibitor L-glutamate 1-carboxy-lyase inhibitors L-glutamate alpha-decarboxylase inhibitor L-glutamate alpha-decarboxylase inhibitors L-glutamic acid decarboxylase inhibitor L-glutamic acid decarboxylase inhibitors L-glutamic decarboxylase inhibitor L-glutamic decarboxylase inhibitors aspartate 1-decarboxylase inhibitor aspartate 1-decarboxylase inhibitors aspartic alpha-decarboxylase inhibitor aspartic alpha-decarboxylase inhibitors cysteic acid decarboxylase inhibitor cysteic acid decarboxylase inhibitors gamma-glutamate decarboxylase inhibitor gamma-glutamate decarboxylase inhibitors glutamate decarboxylase (EC 4.1.1.15) inhibitor glutamate decarboxylase (EC 4.1.1.15) inhibitors glutamate decarboxylase inhibitor glutamate decarboxylase inhibitors EC 4.1.1.15 (glutamate decarboxylase) inhibitor CHEBI:142738 tau aggregation inhibitor TAI tau aggregation inhibitor tau aggregation inhibitors tau protein aggregation inhibitor tau protein aggregation inhibitors tau-aggregation inhibitor tau-aggregation inhibitors tau aggregation inhibitor CHEBI:142781 EC 2.5.1.117 (homogentisate solanesyltransferase) inhibitor EC 2.5.1.117 (homogentisate solanesyltransferase) inhibitor CHEBI:142782 TRPV channel modulator TRPV channel modulators transient receptor potential (vanilloid) channel modulator transient receptor potential (vanilloid) channel modulators TRPV channel modulator CHEBI:142783 TRP channel modulator TRP channel modulators TRP channel modulator CHEBI:142790 EC 3.3.2.10 (soluble epoxide hydrolase) inhibitor sEHi soluble epoxide hydrolase inhibitor soluble epoxide hydrolase inhibitors EC 3.3.2.10 (soluble epoxide hydrolase) inhibitor CHEBI:143001 GABAB receptor agonist GABAB receptor agonist CHEBI:143002 EC 2.1.3.* (carboxy- and carbamoyltransferases) inhibitor EC 2.1.3.* (carboxy- and carbamoyltransferases) inhibitors EC 2.1.3.* (carboxytransferase and carbamoyltransferase) inhibitor EC 2.1.3.* (carboxytransferase and carbamoyltransferase) inhibitors EC 2.1.3.* inhibitor EC 2.1.3.* inhibitors carboxy- and carbamoyltransferase (EC 2.1.3.*) inhibitor carboxy- and carbamoyltransferase (EC 2.1.3.*) inhibitors EC 2.1.3.* (carboxy- and carbamoyltransferases) inhibitor CHEBI:143003 EC 2.1.3.3 (ornithine carbamoyltransferase) inhibitor EC 2.1.3.3 (ornithine carbamoyltransferase) inhibitors EC 2.1.3.3 inhibitor EC 2.1.3.3 inhibitors L-ornithine carbamoyltransferase inhibitor L-ornithine carbamoyltransferase inhibitors L-ornithine carbamyltransferase inhibitor L-ornithine carbamyltransferase inhibitors L-ornithine transcarbamylase inhibitor L-ornithine transcarbamylase inhibitors OTC inhibitor OTC inhibitors carbamoyl-phosphate:L-ornithine carbamoyltransferase inhibitor carbamoyl-phosphate:L-ornithine carbamoyltransferase inhibitors carbamylphosphate-ornithine transcarbamylase inhibitor carbamylphosphate-ornithine transcarbamylase inhibitors citrulline phosphorylase inhibitor citrulline phosphorylase inhibitors ornithine carbamoyltransferase (EC 2.1.3.3) inhibitor ornithine carbamoyltransferase (EC 2.1.3.3) inhibitors ornithine carbamoyltransferase inhibitor ornithine carbamoyltransferase inhibitors ornithine carbamyltransferase inhibitor ornithine carbamyltransferase inhibitors ornithine transcarbamylase inhibitor ornithine transcarbamylase inhibitors EC 2.1.3.3 (ornithine carbamoyltransferase) inhibitor CHEBI:143130 impurity contaminant contaminants impurities impurity impurity CHEBI:143204 peptide allergen allergenic peptide peptide allergen CHEBI:143231 carbohydrate allergen allergenic carbohydrate allergenic carbohydrate derivative carbohydrate allergen CHEBI:143252 ceramide allergen allergenic ceramide ceramide allergen CHEBI:143828 EC 1.14.14.154 (sterol 14alpha-demethylase) inhibitor CYP51 inhibitor CYP51 inhibitors EC 1.14.14.154 (sterol 14alpha-demethylase) inhibitors EC 1.14.14.154 inhibitor EC 1.14.14.154 inhibitors ERG11 inhibitor ERG11 inhibitors cytochrome P450 51 inhibitor cytochrome P450 51 inhibitors lanosterol 14-demethylase inhibitor lanosterol 14-demethylase inhibitors lanosterol 14alpha-demethylase inhibitor lanosterol 14alpha-demethylase inhibitors obtusufoliol 14-demethylase inhibitor obtusufoliol 14-demethylase inhibitors oxidoreductase (14-methyl cleaving) inhibitors sterol 14-demethylase inhibitor sterol 14-demethylase inhibitors sterol 14alpha-demethylase (EC 1.14.14.154) inhibitor sterol 14alpha-demethylase (EC 1.14.14.154) inhibitors sterol 14alpha-demethylase inhibitor sterol 14alpha-demethylase inhibitors sterol,[reduced NADPH--hemoprotein reductase]:oxygen inhibitor sterol,[reduced NADPH--hemoprotein reductase]:oxygen oxidoreductase (14-methyl cleaving) inhibitor EC 1.14.14.154 (sterol 14alpha-demethylase) inhibitor CHEBI:143909 EC 2.7.1.40 (pyruvate kinase) inhibitor EC 2.7.1.40 inhibitor EC 2.7.1.40 inhibitors phosphoenol transphosphorylase inhibitor phosphoenol transphosphorylase inhibitors phosphoenolpyruvate kinase inhibitor phosphoenolpyruvate kinase inhibitors pyruvate kinase inhibitor pyruvate kinase inhibitors EC 2.7.1.40 (pyruvate kinase) inhibitor CHEBI:144064 EC 1.14.15.6 cholesterol monooxygenase (side-chain-cleaving) inhibitor C27-side chain cleavage enzyme inhibitor C27-side chain cleavage enzyme inhibitors EC 1.14.15.6 inhibitor EC 1.14.15.6 inhibitors cholesterol 20-22-desmolase inhibitor cholesterol 20-22-desmolase inhibitors cholesterol C20-22 desmolase inhibitor cholesterol C20-22 desmolase inhibitors cholesterol desmolase inhibitor cholesterol desmolase inhibitors cholesterol monooxygenase (side-chain-cleaving) inhibitor cholesterol monooxygenase (side-chain-cleaving) inhibitors cholesterol side-chain cleavage enzyme inhibitor cholesterol side-chain cleavage enzyme inhibitors cholesterol side-chain-cleaving enzyme inhibitor cholesterol side-chain-cleaving enzyme inhibitors cytochrome P-450scc inhibitor cytochrome P-450scc inhibitors steroid 20-22 desmolase inhibitor steroid 20-22 desmolase inhibitors steroid 20-22-lyase inhibitor steroid 20-22-lyase inhibitors EC 1.14.15.6 cholesterol monooxygenase (side-chain-cleaving) inhibitor CHEBI:144097 EC 1.4.3.2 (L-amino-acid oxidase) inhibitor EC 1.4.3.2 (L-amino-acid oxidase) inhibitors EC 1.4.3.2 inhibitor EC 1.4.3.2 inhibitors L-amino-acid oxidase inhibitor L-amino-acid oxidase inhibitor (EC 1.4.3.2) inhibitor L-amino-acid oxidase inhibitor (EC 1.4.3.2) inhibitors L-amino-acid oxidase inhibitors L-amino-acid:oxygen oxidoreductase (deaminating) inhibitor L-amino-acid:oxygen oxidoreductase (deaminating) inhibitors ophio-amino-acid oxidase inhibitor ophio-amino-acid oxidase inhibitors EC 1.4.3.2 (L-amino-acid oxidase) inhibitor CHEBI:144099 EC 2.6.1.2 (alanine transaminase) inhibitor EC 2.6.1.2 (alanine transaminase) inhibitor CHEBI:144387 EC 2.7.1.105 (6-phosphofructo-2-kinase) inhibitor (6-phosphofructo-2-kinase) inhibitors 6-phosphofructo-2-kinase (phosphorylating) inhibitor 6-phosphofructo-2-kinase (phosphorylating) inhibitors 6-phosphofructo-2-kinase inhibitor 6-phosphofructo-2-kinase inhibitors 6-phosphofructose 2-kinase inhibitor 6-phosphofructose 2-kinase inhibitors EC 2.7.1.105 inhibitor EC 2.7.1.105 inhibitors fructose 6-phosphate 2-kinase inhibitor fructose 6-phosphate 2-kinase inhibitors phosphofructokinase 2 inhibitor phosphofructokinase 2 inhibitors EC 2.7.1.105 (6-phosphofructo-2-kinase) inhibitor CHEBI:144455 EC 3.1.1.64 (retinoid isomerohydrolase) inhibitor EC 3.1.1.64 (retinoid isomerohydrolase) inhibitors EC 3.1.1.64 inhibitor EC 3.1.1.64 inhibitors RPE65 inhibitor RPE65 inhibitors all-trans-retinol isomerase:hydrolase inhibitor all-trans-retinol isomerase:hydrolase inhibitors all-trans-retinyl-palmitate hydrolase inhibitor all-trans-retinyl-palmitate hydrolase inhibitors all-trans-retinylester 11-cis isomerohydrolase inhibitor all-trans-retinylester 11-cis isomerohydrolase inhibitors retinoid isomerohydrolase inhibitor retinoid isomerohydrolase inhibitors retinol isomerase inhibitor retinol isomerase inhibitors EC 3.1.1.64 (retinoid isomerohydrolase) inhibitor CHEBI:144829 tumour antigen tumour antigens tumour antigen CHEBI:144895 C5a receptor antagonist C5AR1 antagonist C5AR1 antagonists C5a receptor antagonists CD88 antagonist CD88 antagonists cluster of differentiation 88 antagonist cluster of differentiation 88 antagonists complement component 5a receptor 1 antagonist complement component 5a receptor 1 antagonists C5a receptor antagonist CHEBI:144981 EC 3.6.5.2 (small monomeric GTPase) inhibitor EC 3.6.5.2 (small monomeric GTPase) inhibitor CHEBI:144987 sphingosine-1-phosphate receptor antagonist EDG receptor antagonist S1P receptor antagonist S1P receptor antagonists SIP antagonist SIP antagonists sphingosine 1-phosphate receptor antagonist sphingosine 1-phosphate receptor antagonists sphingosine-1-phosphate receptor antagonists sphingosine-1-phosphate receptor antagonist CHEBI:144997 sphingosine-1-phosphate receptor 3 antagonist S1PR3 antagonist S1PR3 antagonists sphingosine-1-phosphate receptor 3 antagonists sphingosine-1-phosphate receptor 3 antagonist CHEBI:144998 sphingosine-1-phosphate receptor 1 antagonist S1PR1 antagonist S1PR1 antagonists sphingosine-1-phosphate receptor 1 antagonists sphingosine-1-phosphate receptor 1 antagonist CHEBI:145047 antispermatogenic agent antispermatogenic antispermatogenic agents antispermatogenics antispermatogenic agent CHEBI:145253 hyaluronan synthesis inhibitor HA synthesis inhibitor HA synthesis inhibitors hyaluronan synthesis inhibitors hyaluronic acid synthesis inhibitor hyaluronic acid synthesis inhibitors hyaluronan synthesis inhibitor CHEBI:145410 EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor EC 1.1.1.42 inhibitor EC 1.1.1.42 inhibitors IDH inhibitor IDH inhibitors IDP inhibitor IDP inhibitors IDP1 inhibitor IDP1 inhibitors IDP2 inhibitor IDP2 inhibitors IDP3 inhibitor IDP3 inhibitors NADP isocitric dehydrogenase inhibitor NADP isocitric dehydrogenase inhibitors NADP(+)-ICDH inhibitor NADP(+)-ICDH inhibitors NADP(+)-IDH inhibitor NADP(+)-IDH inhibitors NADP(+)-linked isocitrate dehydrogenase inhibitor NADP(+)-linked isocitrate dehydrogenase inhibitors NADP-dependent isocitrate dehydrogenase inhibitor NADP-dependent isocitrate dehydrogenase inhibitors NADP-dependent isocitric dehydrogenase inhibitor NADP-dependent isocitric dehydrogenase inhibitors NADP-linked isocitrate dehydrogenase inhibitor NADP-linked isocitrate dehydrogenase inhibitors NADP-specific isocitrate dehydrogenase inhibitor NADP-specific isocitrate dehydrogenase inhibitors dual-cofactor-specific isocitrate dehydrogenase inhibitor dual-cofactor-specific isocitrate dehydrogenase inhibitors isocitrate (NADP) dehydrogenase inhibitor isocitrate (NADP) dehydrogenase inhibitors isocitrate (nicotinamide adenine dinucleotide phosphate) dehydrogenase inhibitor isocitrate (nicotinamide adenine dinucleotide phosphate) dehydrogenase inhibitors isocitrate dehydrogenase (NADP(+)) inhibitor isocitrate dehydrogenase (NADP(+)) inhibitors isocitrate dehydrogenase (NADP-dependent) inhibitor isocitrate dehydrogenase (NADP-dependent) inhibitors isocitrate dehydrogenase inhibitor isocitrate dehydrogenase inhibitors oxalosuccinate decarboxylase inhibitor oxalosuccinate decarboxylase inhibitors oxalsuccinic decarboxylase inhibitor oxalsuccinic decarboxylase inhibitors triphosphopyridine nucleotide-linked isocitrate dehydrogenase-oxalosuccinate carboxylase inhibitor triphosphopyridine nucleotide-linked isocitrate dehydrogenase-oxalosuccinate carboxylase inhibitors EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor CHEBI:145425 EC 2.7.11.21 (polo kinase) inhibitor Cdc5 inhibitor Cdc5 inhibitors Cdc5p inhibitor Cdc5p inhibitors EC 2.7.11.21 (polo kinase) inhibitors EC 2.7.11.21 inhibitor EC 2.7.11.21 inhibitors PLK inhibitor PLK inhibitors Plk inhibitor Plk inhibitors Plk1 inhibitor Plk1 inhibitors Plo1 inhibitor Plo1 inhibitors STK21 inhibitor STK21 inhibitors polo kinase inhibitor polo kinase inhibitors polo serine-threonine kinase inhibitor polo serine-threonine kinase inhibitors polo-like kinase 1 inhibitor polo-like kinase 1 inhibitors polo-like kinase inhibitor polo-like kinase inhibitors serine/threonine-specific Drosophila kinase polo inhibitor serine/threonine-specific Drosophila kinase polo inhibitors EC 2.7.11.21 (polo kinase) inhibitor CHEBI:145437 uncoupling protein inhibitor UCP inhibitor UCP inhibitors mitochondrial uncoupling protein inhibitor mitochondrial uncoupling protein inhibitors uncoupling protein inhibitors uncoupling protein inhibitor CHEBI:145438 C-X-C chemokine receptor type 4 antagonist C-X-C chemokine receptor type 4 antagonists C-X-C motif chemokine receptor 4 antagonist C-X-C motif chemokine receptor 4 antagonists CD184 antagonist CD184 antagonists CXCR-4 antagonist CXCR-4 antagonists CXCR4 antagonist CXCR4 antagonists chemokine (C-X-C motif) receptor 4 antagonist chemokine (C-X-C motif) receptor 4 antagonists fusin antagonist fusin antagonists C-X-C chemokine receptor type 4 antagonist CHEBI:145515 GABAA receptor antagonist GABAA receptor antagonist CHEBI:145807 forkhead box protein O1 inhibitor FOXO1 inhibitor FOXO1 inhibitors Foxo1 inhibitor Foxo1 inhibitors forkhead box protein O1 inhibitors forkhead in rhabdomyosarcoma inhibitor forkhead in rhabdomyosarcoma inhibitors forkhead box protein O1 inhibitor CHEBI:145814 EC 1.2.1.11 (aspartate-semialdehyde dehydrogenase) inhibitor ASA dehydrogenase inhibitor ASA dehydrogenase inhibitors EC 1.2.1.11 (aspartate-semialdehyde dehydrogenase) inhibitors EC 1.2.1.11 inhibitor EC 1.2.1.11 inhibitors L-aspartate-4-semialdehyde:NADP+ oxidoreductase (phosphorylating) inhibitor L-aspartate-4-semialdehyde:NADP+ oxidoreductase (phosphorylating) inhibitors L-aspartate-beta-semialdehyde:NADP oxidoreductase (phosporylating) inhibitor L-aspartate-beta-semialdehyde:NADP oxidoreductase (phosporylating) inhibitors aspartate semialdehyde dehydrogenase inhibitor aspartate semialdehyde dehydrogenase inhibitors aspartate-semialdehyde dehydrogenase (EC 1.2.1.11) inhibitor aspartate-semialdehyde dehydrogenase (EC 1.2.1.11) inhibitors aspartate-semialdehyde dehydrogenase inhibitor aspartate-semialdehyde dehydrogenase inhibitors aspartic beta-semialdehyde dehydrogenase inhibitor aspartic beta-semialdehyde dehydrogenase inhibitors aspartic semialdehyde dehydrogenase inhibitor aspartic semialdehyde dehydrogenase inhibitors EC 1.2.1.11 (aspartate-semialdehyde dehydrogenase) inhibitor CHEBI:145947 antiatherosclerotic agent anti-atherosclerotic agent anti-atherosclerotic agents anti-atherosclerotic drug anti-atherosclerotic drugs antiatherosclerotic agent antiatherosclerotic agents antiatherosclerotic drug antiatherosclerotic drugs antiatherosclerotic agent CHEBI:145982 5-hydroxytryptamine 2A receptor agonist 5-HT2A agonist 5-HT2A agonists 5-HT2A receptor agonist 5-HT2A receptor agonists 5-hydroxytryptamine 2A receptor agonists 5-hydroxytryptamine receptor 2A agonist 5-hydroxytryptamine receptor 2A agonists serotonin receptor 2A agonist serotonin receptor 2A agonists 5-hydroxytryptamine 2A receptor agonist CHEBI:146222 ryanoid insecticide ryanoid insecticide CHEBI:146223 ryanodine receptor antagonist ryanodine receptor antagonist CHEBI:146246 CB2 receptor agonist CB2 receptor agonist CB2 receptor agonists CB2R agonist CB2R agonists cannabinoid receptor 2 agonist cannabinoid receptor 2 agonists cannabinoid receptor type 2 agonist cannabinoid receptor type 2 agonists type 2 cannabinoid receptor agonist type 2 cannabinoid receptor agonists CB2 receptor agonist CHEBI:146270 oneirogen oneirogens oneirogen CHEBI:147285 EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor 3C-like protease inhibitor 3C-like protease inhibitors 3cLpro inhibitor 3cLpro inhibitors EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitors EC 3.4.22.69 inhibitor EC 3.4.22.69 inhibitors Mpro inhibitor Mpro inhibitors SARS 3C-like protease inhibitor SARS 3C-like protease inhibitors SARS coronavirus 3CL protease inhibitor SARS coronavirus 3CL protease inhibitors SARS coronavirus main peptidase inhibitor SARS coronavirus main peptidase inhibitors SARS coronavirus main protease inhibitor SARS coronavirus main protease inhibitors SARS coronavirus main proteinase inhibitor SARS coronavirus main proteinase inhibitors SARS-CoV 3CLpro enzyme inhibitor SARS-CoV 3CLpro enzyme inhibitors SARS-CoV Mpro inhibitor SARS-CoV Mpro inhibitors SARS-CoV main protease inhibitor SARS-CoV main protease inhibitors coronavirus 3C-like protease inhibitor coronavirus 3C-like protease inhibitors severe acute respiratory syndrome coronavirus main protease inhibitor severe acute respiratory syndrome coronavirus main protease inhibitors EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor CHEBI:147289 EC 3.4.17.23 (angiotensin-converting enzyme 2) inhibitor ACE-2 inhibitor ACE-2 inhibitors ACE2 inhibitor ACE2 inhibitors EC 3.4.17.23 (angiotensin-converting enzyme 2) inhibitor EC 3.4.17.23 (angiotensin-converting enzyme 2) inhibitors EC 3.4.17.23 inhibitor EC 3.4.17.23 inhibitors angiotensin converting enzyme 2 inhibitor angiotensin converting enzyme 2 inhibitors angiotensin converting enzyme-2 inhibitor angiotensin converting enzyme-2 inhibitors angiotensin-converting enzyme 2 inhibitor angiotensin-converting enzyme 2 inhibitors hACE2 inhibitor hACE2 inhibitors EC 3.4.17.23 (angiotensin-converting enzyme 2) inhibitor CHEBI:147290 EC 3.4.17* (metallocarboxypeptidase) inhibitor EC 3.4.17* (metallocarboxypeptidase) inhibitor EC 3.4.17* (metallocarboxypeptidase) inhibitors EC 3.4.17.* inhibitor EC 3.4.17.* inhibitors metallocarboxypeptidase inhibitor metallocarboxypeptidase inhibitors EC 3.4.17* (metallocarboxypeptidase) inhibitor CHEBI:148436 nitrification inhibitor nitrification inhibitors nitrification inhibitor CHEBI:149497 spin trapping reagent spin trap spin trapping reagents spin traps spin trapping reagent CHEBI:149552 emetic emetics emetic CHEBI:149553 anticoronaviral agent anti-coronaviral agent anti-coronaviral agents anti-coronavirus agent anti-coronavirus agents anticoronaviral agent anticoronaviral agents anticoronaviral drug anticoronaviral drugs anticoronavirus agent anticoronavirus agents anticoronviral agent anticoronviral agents anticoronaviral agent CHEBI:149598 EC 2.3.3.8 (ATP citrate synthase) inhibitor ATP citrate (pro-S)-lyase inhibitor ATP citrate (pro-S)-lyase inhibitors ATP citrate lyase inhibitor ATP citrate lyase inhibitors ATP citrate synthase inhibitor ATP citrate synthase inhibitors ATP-citric lyase inhibitor ATP-citric lyase inhibitors ATP:citrate oxaloacetate-lyase [(pro-S)-CH2COO(-)->acetyl-CoA] (ATP-dephosphorylating) inhibitor ATP:citrate oxaloacetate-lyase [(pro-S)-CH2COO(-)->acetyl-CoA] (ATP-dephosphorylating) inhibitors EC 2.3.3.8 (ATP citrate synthase) inhibitor EC 2.3.3.8 (ATP citrate synthase) inhibitors EC 2.3.3.8 inhibitor EC 2.3.3.8 inhibitors acetyl-CoA:oxaloacetate acetyltransferase (isomerizing, ADP-phosphorylating) inhibitor acetyl-CoA:oxaloacetate acetyltransferase (isomerizing, ADP-phosphorylating) inhibitors adenosine triphosphate citrate lyase inhibitor adenosine triphosphate citrate lyase inhibitors citrate cleavage enzyme inhibitor citrate cleavage enzyme inhibitors citrate-ATP lyase inhibitor citrate-ATP lyase inhibitors citric cleavage enzyme inhibitor citric cleavage enzyme inhibitors EC 2.3.3.8 (ATP citrate synthase) inhibitor CHEBI:149639 EC 3.4.21.36 (pancreatic elastase) inhibitor EC 3.4.21.36 (pancreatic elastase) inhibitors EC 3.4.21.36 inhibitor EC 3.4.21.36 inhibitors elastase inhibitor elastase inhibitors elaszym inhibitor elaszym inhibitors pancreatic elastase (EC 3.4.21.36) inhibitor pancreatic elastase (EC 3.4.21.36) inhibitors pancreatic elastase I inhibitor pancreatic elastase I inhibitors pancreatic elastase inhibitor pancreatic elastase inhibitors pancreatopeptidase E inhibitor pancreatopeptidase E inhibitors serine elastase inhibitor serine elastase inhibitors EC 3.4.21.36 (pancreatic elastase) inhibitor CHEBI:149711 chemokine receptor 2 antagonist C-C chemokine receptor type 2 antagonist C-C chemokine receptor type 2 antagonists CCR-2 antagonist CCR-2 antagonists CCR2 antagonist CCR2 antagonists CD192 antagonist CD192 antagonists CKR-2B antagonist CKR-2B antagonists chemokine receptor 2 antagonists chemokine receptor 2 antagonist CHEBI:150006 SERCA activator EC 7.2.2.10 activator EC 7.2.2.10 activators SERCA activators Sarcoplasmic/Endoplasmic Reticulum Calcium-ATPase activator Sarcoplasmic/Endoplasmic Reticulum Calcium-ATPase activators SERCA activator CHEBI:15022 electron donor Elektronendonator donneur d'electron electron donor electron donor CHEBI:15339 acceptor A Acceptor Akzeptor Hydrogen-acceptor Oxidized donor accepteur acceptor CHEBI:156203 topoisomerase II inhibitor topoisomerase II inhibitor CHEBI:156211 MAIT cell agonist MAIT cell agonists mucosal associated invariant T cell agonist mucosal associated invariant T cell agonists MAIT cell agonist CHEBI:156295 G-15 (3Ar,4R,9bS)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline GPER antagonist G-15 CHEBI:156296 G-1 1-(4-(6-Bromobenzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)-ethanone GPER agonist G-1 CHEBI:156297 EC 3.4.21.75 (furin) inhibitor EC 3.4.21.75 (furin) inhibitors EC 3.4.21.75 inhibitor EC 3.4.21.75 inhibitors PACE inhibitor PACE inhibitors PC1 inhibitor PC1 inhibitors SPC3 inhibitor SPC3 inhibitors dibasic processing enzyme inhibitor dibasic processing enzyme inhibitors furin convertase inhibitor furin convertase inhibitors furin inhibitor furin inhibitors paired basic amino acid cleaving enzyme inhibitor paired basic amino acid cleaving enzyme inhibitors paired basic amino acid converting enzyme inhibitor paired basic amino acid converting enzyme inhibitors prohormone convertase inhibitor prohormone convertase inhibitors proprotein convertase inhibitor proprotein convertase inhibitors serine proteinase PACE inhibitor serine proteinase PACE inhibitors EC 3.4.21.75 (furin) inhibitor CHEBI:156527 EC 2.4.1.109 (dolichyl-phosphate-mannose-protein mannosyltransferase) inhibitor EC 2.4.1.109 (dolichyl-phosphate-mannose-protein mannosyltransferase) inhibitors EC 2.4.1.109 inhibitor EC 2.4.1.109 inhibitors PMT inhibitor PMT inhibitors dolichol phosphomannose-protein mannosyltransferase inhibitor dolichol phosphomannose-protein mannosyltransferase inhibitors dolichyl-D-mannosyl-phosphate:protein O-D-mannosyltransferase inhibitor dolichyl-D-mannosyl-phosphate:protein O-D-mannosyltransferase inhibitors dolichyl-phosphate-D-mannose:protein O-D-mannosyltransferase inhibitor dolichyl-phosphate-D-mannose:protein O-D-mannosyltransferase inhibitors dolichyl-phosphate-mannose--protein mannosyltransferase inhibitor dolichyl-phosphate-mannose--protein mannosyltransferase inhibitors protein O-D-mannosyltransferase inhibitor protein O-D-mannosyltransferase inhibitors EC 2.4.1.109 (dolichyl-phosphate-mannose-protein mannosyltransferase) inhibitor CHEBI:165840 Furafylline 3-(uran-2-ylmethyl)-1,8-dimethyl-7H-purine-2,6-dione Furafylline CHEBI:166822 EC 3.4.23.15 (renin) inhibitor EC 3.4.23.15 (renin) inhibitors EC 3.4.23.15 inhibitor EC 3.4.23.15 inhibitors angiotensin-forming enzyme inhibitor angiotensin-forming enzyme inhibitors angiotensinogenase inhibitor angiotensinogenase inhibitors renin inhibitor renin inhibitors EC 3.4.23.15 (renin) inhibitor CHEBI:166831 copper chelator copper chelate copper chelating agent copper chelating agents copper chelator copper chelators copper chelator CHEBI:166909 neuropilin receptor antagonist NRP antagonist NRP antagonists neuropilin receptor antagonists neuropilin receptor antagonist CHEBI:167165 kappa-opioid receptor antagonist kappa-opioid antagonist kappa-opioid antagonists kappa-opioid receptor antagonists kappa-opioid receptor antagonist CHEBI:167183 piscicide piscicides piscicide CHEBI:167523 ovicide ovicides ovicide CHEBI:167633 CPSF3 inhibitor CPSF-73 inhibitor CPSF-73 inhibitors CPSF3 inhibitors CPSF73 inhibitor CPSF73 inhibitors cleavage and polyadenylation specific factor 3 inhibitor cleavage and polyadenylation specific factor 3 inhibitors cleavage and polyadenylation specificity factor 73 KDa subunit inhibitor cleavage and polyadenylation specificity factor 73 KDa subunit inhibitors cleavage and polyadenylation specificity factor subunit 3 inhibitor cleavage and polyadenylation specificity factor subunit 3 inhibitors CPSF3 inhibitor CHEBI:167677 EC 6.1.1.6 (lysine--tRNA ligase) inhibitor EC 6.1.1.6 (lysine--tRNA ligase) inhibitors EC 6.1.1.6 inhibitor EC 6.1.1.6 inhibitors L-lysine-transfer RNA ligase inhibitor L-lysine-transfer RNA ligase inhibitors L-lysine:tRNA(Lys) ligase (AMP-forming) inhibitor L-lysine:tRNA(Lys) ligase (AMP-forming) inhibitors LysRS inhibitor LysRS inhibitors lysine translase inhibitor lysine translase inhibitors lysine--tRNA ligase inhibitor lysine--tRNA ligase inhibitors lysine-tRNA synthetase inhibitor lysine-tRNA synthetase inhibitors lysyl-tRNA synthetase inhibitor lysyl-tRNA synthetase inhibitors lysyl-transfer RNA synthetase inhibitor lysyl-transfer RNA synthetase inhibitors lysyl-transfer ribonucleate synthetase inhibitor lysyl-transfer ribonucleate synthetase inhibitors EC 6.1.1.6 (lysine--tRNA ligase) inhibitor CHEBI:167694 EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitors EZH2 inhibitor EZH2 inhibitors EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor CHEBI:167704 necroptosis inhibitor necroptosis inhibitors necroptosis inhibitor CHEBI:170010 EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor 3D polymerase inhibitor 3D polymerase inhibitors EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitors EC 2.7.7.48 inhibitor EC 2.7.7.48 inhibitors PB1 proteins inhibitor PB1 proteins inhibitors PB2 proteins inhibitor PB2 proteins inhibitors Q-beta replicase inhibitor Q-beta replicase inhibitors RDRP inhibitor RDRP inhibitors RNA nucleotidyltransferase (RNA-directed) inhibitor RNA nucleotidyltransferase (RNA-directed) inhibitors RNA replicase inhibitor RNA replicase inhibitors RNA synthetase inhibitor RNA synthetase inhibitors RNA transcriptase inhibitor RNA transcriptase inhibitors RNA-dependent RNA polymerase inhibitor RNA-dependent RNA polymerase inhibitors RNA-dependent RNA replicase inhibitor RNA-dependent RNA replicase inhibitors RNA-dependent ribonucleate nucleotidyltransferase inhibitor RNA-dependent ribonucleate nucleotidyltransferase inhibitors RNA-directed RNA polymerase inhibitor RNA-directed RNA polymerase inhibitors phage f2 replicase inhibitor phage f2 replicase inhibitors polymerase L inhibitor polymerase L inhibitors ribonucleic acid replicas inhibitor ribonucleic acid replicas inhibitors ribonucleic acid-dependent ribonucleate nucleotidyltransferase inhibitor ribonucleic acid-dependent ribonucleate nucleotidyltransferase inhibitors ribonucleic acid-dependent ribonucleic acid polymeras inhibitor ribonucleic acid-dependent ribonucleic acid polymeras inhibitors ribonucleic replicase inhibitor ribonucleic replicase inhibitors ribonucleic synthetase inhibitor ribonucleic synthetase inhibitors EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor CHEBI:171664 antiamoebic agent amebicide amebicides amoebicide amoebicides anti-amoebic agent anti-amoebic agents anti-amoebic drug anti-amoebic drugs antiamoebic antiamoebic agents antiamoebic drug antiamoebic drugs antiamoebics antiamoebic agent CHEBI:172326 EC 2.1.1.348 (mRNA m6A methyltransferase) inhibitor EC 2.1.1.348 (mRNA m6A methyltransferase) inhibitors EC 2.1.1.348 inhibitor EC 2.1.1.348 inhibitors METTL14 inhibitor METTL14 inhibitors METTL3 inhibitor METTL3 inhibitors EC 2.1.1.348 (mRNA m6A methyltransferase) inhibitor CHEBI:172919 EC 2.6.1.11 (acetylornithine transaminase) inhibitor 2-N-acetyl-L-ornithine:2-oxoglutarate 5-aminotransferase inhibitor 2-N-acetyl-L-ornithine:2-oxoglutarate 5-aminotransferase inhibitors ACOAT inhibitor ACOAT inhibitors EC 2.6.1.11 (acetylornithine transaminase) inhibitors EC 2.6.1.11 inhibitor EC 2.6.1.11 inhibitors N(2)-acetyl-L-ornithine:2-oxoglutarate aminotransferase inhibitor N(2)-acetyl-L-ornithine:2-oxoglutarate aminotransferase inhibitors N(2)-acetylornithine 5-transaminase inhibitor N(2)-acetylornithine 5-transaminase inhibitors N-acetylornithine aminotransferase inhibitor N-acetylornithine aminotransferase inhibitors N-acetylornithine-delta-transaminase inhibitor N-acetylornithine-delta-transaminase inhibitors acetylornithine 5-aminotransferase inhibitor acetylornithine 5-aminotransferase inhibitors acetylornithine aminotransferase inhibitor acetylornithine aminotransferase inhibitors acetylornithine delta-transaminase inhibitor acetylornithine delta-transaminase inhibitors acetylornithine transaminase inhibitor acetylornithine transaminase inhibitors succinylornithine aminotransferase inhibitor succinylornithine aminotransferase inhibitors EC 2.6.1.11 (acetylornithine transaminase) inhibitor CHEBI:172949 antimicrobial cosmetic preservative antimicrobial cosmetic preservatives antimicrobial cosmetic preservative CHEBI:173084 ferroptosis inhibitor ferroptosis inhibitors ferroptosis inhibitor CHEBI:173085 ferroptosis inducer ferroptosis inducers ferroptosis inducer CHEBI:173094 EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitors EC 3.1.3.25 inhibitor EC 3.1.3.25 inhibitors IMPase inhibitor IMPase inhibitors L-myo-inositol-1-phosphate phosphatase inhibitor L-myo-inositol-1-phosphate phosphatase inhibitors inositol 1-phosphatase inhibitor inositol 1-phosphatase inhibitors inositol monophosphatase inhibitor inositol monophosphatase inhibitors inositol monophosphate phosphatase inhibitor inositol monophosphate phosphatase inhibitors inositol phosphatase inhibitor inositol phosphatase inhibitors inositol phosphate phosphatase inhibitor inositol phosphate phosphatase inhibitors inositol-1(or 4)-monophosphatase inhibitor inositol-1(or 4)-monophosphatase inhibitors inositol-phosphate phosphatase inhibitor inositol-phosphate phosphatase inhibitors myo-inositol 1-phosphatase inhibitor myo-inositol 1-phosphatase inhibitors myo-inositol monophosphatase inhibitor myo-inositol monophosphatase inhibitors myo-inositol-1(or 4)-monophosphatase inhibitor myo-inositol-1(or 4)-monophosphatase inhibitors myo-inositol-1(or 4)-phosphate phosphohydrolase inhibitor myo-inositol-1(or 4)-phosphate phosphohydrolase inhibitors myo-inositol-1-phosphatase inhibitor myo-inositol-1-phosphatase inhibitors EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor CHEBI:173100 voltage-dependent anion channel inhibitor VDAC blocker VDAC blockers VDAC inhibitor VDAC inhibitors voltage-dependent anion channel blocker voltage-dependent anion channel blockers voltage-dependent anion channel inhibitors voltage-dependent anion-selective channel blocker voltage-dependent anion-selective channel blockers voltage-dependent anion-selective channel inhibitor voltage-dependent anion-selective channel inhibitors voltage-dependent anion channel inhibitor CHEBI:173108 thioredoxin inhibitor TRX inhibitor TRX inhibitors TRX1 inhibitor TRX1 inhibitors TXN inhibitor TXN inhibitors thioredoxin inhibitors thioredoxin inhibitor CHEBI:17347 testosterone 17beta-Hydroxy-4-androsten-3-one 17beta-hydroxy-4-androsten-3-one 17beta-hydroxyandrost-4-en-3-one 4-androsten-17beta-ol-3-one Androderm TESTOSTERONE Testosteron Testosterone testosterona testosterone testosteronum testosterone CHEBI:17499 hydrogen donor AH2 Donor Hydrogen-donor Reduced acceptor hydrogen donor CHEBI:176342 EC 1.11.1.9 (glutathione peroxidase) inhibitor EC 1.11.1.9 (glutathione peroxidase) inhibitors EC 1.11.1.9 inhibitor EC 1.11.1.9 inhibitors GSH peroxidase inhibitor GSH peroxidase inhibitors glutathione peroxidase inhibitor glutathione peroxidase inhibitors reduced glutathione peroxidase inhibitor reduced glutathione peroxidase inhibitors selenium-glutathione peroxidase inhibitor selenium-glutathione peroxidase inhibitors EC 1.11.1.9 (glutathione peroxidase) inhibitor CHEBI:176495 actin polymerisation inducer actin polymerisation enhancer actin polymerisation enhancers actin polymerisation inducers inducer of actin polymerization inducers of actin polymerization actin polymerisation inducer CHEBI:176497 geroprotector anti-aging agent anti-aging agents anti-aging drug anti-aging drugs geroprotective agent geroprotective agents geroprotectors geroprotector CHEBI:176508 ferroptosis suppressor protein 1 inhibitor AIFM2 inhibitor AIFM2 inhibitors FSP1 inhibitor FSP1 inhibitors apoptosis-inducing factor mitochondria-associated 2 inhibitor apoptosis-inducing factor mitochondria-associated 2 inhibitors ferroptosis suppressor protein 1 inhibitors ferroptosis suppressor protein 1 inhibitor CHEBI:17654 electron acceptor Elektronenakzeptor Oxidized donor electron acceptor electron acceptor CHEBI:176961 EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitors EC 2.7.11.2 inhibitor EC 2.7.11.2 inhibitors PDH kinase inhibitor PDH kinase inhibitors PDHK inhibitor PDHK inhibitors PDK inhibitor PDK inhibitors PDK1 inhibitor PDK1 inhibitors PDK2 inhibitor PDK2 inhibitors PDK3 inhibitor PDK3 inhibitors PDK4 inhibitor PDK4 inhibitors STK1 inhibitor STK1 inhibitors [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitors pyruvate dehydrogenase (acetyl-transferring) kinase inhibitor pyruvate dehydrogenase (acetyl-transferring) kinase inhibitors pyruvate dehydrogenase kinase (phosphorylating) inhibitor pyruvate dehydrogenase kinase (phosphorylating) inhibitors pyruvate dehydrogenase kinase activator protein inhibitor pyruvate dehydrogenase kinase activator protein inhibitors pyruvate dehydrogenase kinase inhibitor pyruvate dehydrogenase kinase inhibitors EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor CHEBI:177023 somatostatin receptor agonist SRIF agonist SRIF agonists SS-R agonist SS-R agonists SSR agonist SSR agonists SSTR agonist SSTR agonists somatostatin receptor agonists somatostatin receptor agonist CHEBI:17891 donor Donator Donor donneur donor CHEBI:179062 (S)-Mephenytoin (5S)-5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione (S)-Mephenytoin CHEBI:183050 neoantigen neoantigens neoantigen CHEBI:184301 EC 2.3.2.52 (beta-N-acetylhexosaminidase) inhibitor EC 2.3.2.52 (beta-N-acetylhexosaminidase) inhibitors EC 3.2.1.52 inhibitor EC 3.2.1.52 inhibitors N-acetyl-beta-D-hexosaminidase inhibitor N-acetyl-beta-D-hexosaminidase inhibitors N-acetyl-beta-hexosaminidase inhibitor N-acetyl-beta-hexosaminidase inhibitors N-acetylhexosaminidase inhibitor N-acetylhexosaminidase inhibitors beta-D-N-acetylhexosaminidase inhibitor beta-D-N-acetylhexosaminidase inhibitors beta-D-hexosaminidase inhibitor beta-D-hexosaminidase inhibitors beta-N-acetyl-D-hexosaminidase inhibitor beta-N-acetyl-D-hexosaminidase inhibitors beta-N-acetylglucosaminidase inhibitor beta-N-acetylglucosaminidase inhibitors beta-N-acetylhexosaminidase inhibitor beta-N-acetylhexosaminidase inhibitors beta-acetylaminodeoxyhexosidase inhibitor beta-acetylaminodeoxyhexosidase inhibitors beta-acetylhexosaminidinase inhibitor beta-acetylhexosaminidinase inhibitors beta-hexosaminidase inhibitor beta-hexosaminidase inhibitors hexosaminidase A inhibitor hexosaminidase A inhibitors hexosaminidase inhibitor hexosaminidase inhibitors EC 2.3.2.52 (beta-N-acetylhexosaminidase) inhibitor CHEBI:184380 EC 1.14.14.91 ( trans-cinnamate 4-monooxygenase) inhibitor CA4H inhibitor CA4H inhibitors EC 1.14.14.91 ( trans-cinnamate 4-monooxygenase) inhibitors EC 1.14.14.91 inhibitor EC 1.14.14.91 inhibitors cinnamate 4-hydroxylase inhibitor cinnamate 4-hydroxylase inhibitors cinnamate 4-monooxygenase inhibitor cinnamate 4-monooxygenase inhibitors cinnamate hydroxylase inhibitor cinnamate hydroxylase inhibitors cinnamic 4-hydroxylase inhibitor cinnamic 4-hydroxylase inhibitors cinnamic acid 4-hydroxylase inhibitor cinnamic acid 4-hydroxylase inhibitors cinnamic acid 4-monooxygenase inhibitor cinnamic acid 4-monooxygenase inhibitors cinnamic acid p-hydroxylase inhibitor cinnamic acid p-hydroxylase inhibitors cytochrome P450 cinnamate 4-hydroxylase inhibitor cytochrome P450 cinnamate 4-hydroxylase inhibitors t-cinnamic acid hydroxylase inhibitor t-cinnamic acid hydroxylase inhibitors trans-cinnamate 4-hydroxylase inhibitor trans-cinnamate 4-hydroxylase inhibitors trans-cinnamate 4-monooxygenase inhibitor trans-cinnamate 4-monooxygenase inhibitors trans-cinnamic acid 4-hydroxylase inhibitor trans-cinnamic acid 4-hydroxylase inhibitors EC 1.14.14.91 ( trans-cinnamate 4-monooxygenase) inhibitor CHEBI:189665 EC 3.4.21.61 (kexin) inhibitor EC 3.4.21.61 (kexin) inhibitors EC 3.4.21.61 inhibitor EC 3.4.21.61 inhibitors Kex 2p proteinase inhibitor Kex 2p proteinase inhibitors Kex2 endopeptidase inhibitor Kex2 endopeptidase inhibitors Kex2 endoprotease inhibitor Kex2 endoprotease inhibitors Kex2 endoproteinase inhibitor Kex2 endoproteinase inhibitors Kex2 protease inhibitor Kex2 protease inhibitors Kex2 proteinase inhibitor Kex2 proteinase inhibitors Kex2-like endoproteinase inhibitor Kex2-like endoproteinase inhibitors Kex2-like precursor protein processing endoprotease inhibitor Kex2-like precursor protein processing endoprotease inhibitors andrenorphin-Gly-generating enzyme inhibitor andrenorphin-Gly-generating enzyme inhibitors endoproteinase Kex2p inhibitor endoproteinase Kex2p inhibitors gene KEX2 dibasic proteinase inhibitor gene KEX2 dibasic proteinase inhibitors kexin inhibitor kexin inhibitors paired-basic endopeptidase inhibitor paired-basic endopeptidase inhibitors prohormone-processing KEX2 proteinase inhibitor prohormone-processing KEX2 proteinase inhibitors prohormone-processing endoprotease inhibitor prohormone-processing endoprotease inhibitors prohormone-processing proteinase inhibitor prohormone-processing proteinase inhibitors proprotein convertase inhibitor proprotein convertase inhibitors protease KEX2 inhibitor protease KEX2 inhibitors proteinase Kex2p inhibitor proteinase Kex2p inhibitors proteinase yscF inhibitor proteinase yscF inhibitors yeast KEX2 protease inhibitor yeast KEX2 protease inhibitors EC 3.4.21.61 (kexin) inhibitor CHEBI:189675 PAR2 negative allosteric modulator PAR2 negative allosteric modulator CHEBI:189676 protease-activated receptor-2 antagonist G-protein coupled receptor 11 antagonist G-protein coupled receptor 11 antagonists GPR11 antagonist GPR11 antagonists PAR-2 antagonist PAR-2 antagonists PAR2 antagonist PAR2 antagonists coagulation factor II (thrombin) receptor-like 1 antagonist coagulation factor II (thrombin) receptor-like 1 antagonists protease-activated receptor 2 antagonist protease-activated receptor 2 antagonists protease-activated receptor-2 antagonists protease-activated receptor-2 antagonist CHEBI:189683 sigma receptor modulator sigma receptor modulators sigma-receptor modulator sigma-receptor modulators sigma receptor modulator CHEBI:189684 sigma-2 receptor agonist sigma 2 receptor agonist sigma 2 receptor agonists sigma-2 receptor agonists sigma2 receptor agonist sigma2 receptor agonists sigma2R agonist sigma2R agonists sigma-2 receptor agonist CHEBI:190286 ceramide mimetic ceramide mimetics ceramide mimetic CHEBI:191196 EC 3.2.1.24 (alpha-mannosidase) inhibitor 1,2-alpha-D-mannosidase inhibitor 1,2-alpha-D-mannosidase inhibitors 1,2-alpha-mannosidase inhibitor 1,2-alpha-mannosidase inhibitors EC 3.2.1.24 (alpha-mannosidase) inhibitors EC 3.2.1.24 inhibitor EC 3.2.1.24 inhibitors alpha-D-mannopyranosidase inhibitor alpha-D-mannopyranosidase inhibitors alpha-D-mannosidase inhibitor alpha-D-mannosidase inhibitors alpha-mannosidase inhibitor alpha-mannosidase inhibitors exo-alpha-mannosidase inhibitor exo-alpha-mannosidase inhibitors p-nitrophenyl-alpha-mannosidase inhibitor p-nitrophenyl-alpha-mannosidase inhibitors EC 3.2.1.24 (alpha-mannosidase) inhibitor CHEBI:192269 CB1 receptor agonist CB1 receptor agonist CB1 receptor agonists CB1R agonist CB1R agonists cannabinoid receptor 1 agonist cannabinoid receptor 1 agonists cannabinoid receptor type 1 agonist cannabinoid receptor type 1 agonists type 1 cannabinoid receptor agonist type 1 cannabinoid receptor agonists CB1 receptor agonist CHEBI:192504 elicitor elicitors elicitor CHEBI:192999 EC 6.2.1.45 (E1 ubiquitin-activating enzyme) inhibitor E1 inhibitor E1 inhibitors E1 ubiquitin-activating enzyme inhibitor E1 ubiquitin-activating enzyme inhibitors EC 6.2.1.45 (E1 ubiquitin-activating enzyme) inhibitors EC 6.2.1.45 inhibitor EC 6.2.1.45 inhibitors ubiquitin activating enzyme inhibitor ubiquitin activating enzyme inhibitors ubiquitin-activating enzyme E1 inhibitor ubiquitin-activating enzyme E1 inhibitors EC 6.2.1.45 (E1 ubiquitin-activating enzyme) inhibitor CHEBI:194137 neurokinin-1 receptor agonist NK-1 receptor agonist NK-1 receptor agonists NK1 receptor agonist NK1 receptor agonists neurokinin-1 receptor agonists neurokinin-1 receptor agonist CHEBI:194153 protease-activated receptor-1 agonist PAR-1 agonist PAR-1 agonists PAR-1 receptor agonist PAR-1 receptor agonists PAR1 agonist PAR1 agonists coagulation factor II (thrombin) receptor agonist coagulation factor II (thrombin) receptor agonists coagulation factor II receptor agonist coagulation factor II receptor agonists coagulation factor II thrombin receptor agonist coagulation factor II thrombin receptor agonists protease activated receptor 1 agonist protease activated receptor 1 agonists protease-activated receptor 1 agonist protease-activated receptor 1 agonists protease-activated receptor-1 agonists proteinase-activated receptor 1 agonist proteinase-activated receptor 1 agonists protease-activated receptor-1 agonist CHEBI:194154 piezo1 agonist PIEZO1 agonist PIEZO1 agonists piezo type mechanosensitive ion channel component 1 agonist piezo type mechanosensitive ion channel component 1 agonists piezo-type mechanosensitive ion channel component 1 agonist piezo-type mechanosensitive ion channel component 1 agonists piezo1 agonists piezo1 agonist CHEBI:194181 mitochondrial calcium uniporter inhibitor MCU inhibitor MCU inhibitors mitochondrial calcium uniporter blocker mitochondrial calcium uniporter blockers mitochondrial calcium uniporter inhibitors mitochondrial calcium uniporter inhibitor CHEBI:194187 gastric inhibitory polypeptide receptor agonist GIP agonist GIP agonists GIP receptor agonist GIP receptor agonists GIP-R agonist GIP-R agonists GIPR agonist GIPR agonists gastric inhibitory polypeptide receptor agonists glucose-dependent insulinotropic polypeptide receptor agonist glucose-dependent insulinotropic polypeptide receptor agonists gastric inhibitory polypeptide receptor agonist CHEBI:194338 T-type calcium channel blocker T-type calcium channel antagonist T-type calcium channel antagonists T-type calcium channel blockers T-type calcium channel blocker CHEBI:194423 aquaretic aquaretic agent aquaretic agents aquaretics aquaretic CHEBI:194430 antimyopathic agent antimyopathic agents antimyopathic drug antimyopathic drugs antimyopathic agent CHEBI:194467 NOD1 agonist CARD4 agonist CARD4 agonists CLR7.1 agonist CLR7.1 agonists NOD1 agonists caspase recruitment domain-containing protein 4 agonist caspase recruitment domain-containing protein 4 agonists nucleotide binding oligomerization domain containing 1 agonist nucleotide binding oligomerization domain containing 1 agonists nucleotide-binding oligomerization domain-containing protein 1 agonist nucleotide-binding oligomerization domain-containing protein 1 agonists NOD1 agonist CHEBI:195251 activator activators activator CHEBI:195252 enzyme activator enzyme activators enzyme activator CHEBI:195299 Grace_C1_2023 Hezinglila Grace compound 1 Grace_C1_2023 CHEBI:195331 EC 2.6.1.13 (ornithine aminotransferase) inhibitor EC 2.6.1.13 (ornithine aminotransferase) inhibitors EC 2.6.1.13 inhibitor EC 2.6.1.13 inhibitors L-ornithine 5-aminotransferase inhibitor L-ornithine 5-aminotransferase inhibitors L-ornithine aminotransferase inhibitor L-ornithine aminotransferase inhibitors L-ornithine:alpha-ketoglutarate -aminotransferase inhibitor L-ornithine:alpha-ketoglutarate -aminotransferase inhibitors OAT inhibitor OAT inhibitors ornithine 5-aminotransferase inhibitor ornithine 5-aminotransferase inhibitors ornithine aminotransferase inhibitor ornithine aminotransferase inhibitors ornithine delta-transaminase inhibitor ornithine delta-transaminase inhibitors ornithine transaminase inhibitor ornithine transaminase inhibitors ornithine--oxo-acid transaminase inhibitor ornithine--oxo-acid transaminase inhibitors ornithine-2-oxoacid aminotransferase inhibitor ornithine-2-oxoacid aminotransferase inhibitors ornithine-alpha-ketoglutarate aminotransferase inhibitor ornithine-alpha-ketoglutarate aminotransferase inhibitors ornithine-keto acid aminotransferase inhibitor ornithine-keto acid aminotransferase inhibitors ornithine-keto acid transaminase inhibitor ornithine-keto acid transaminase inhibitors ornithine-ketoglutarate aminotransferase inhibitor ornithine-ketoglutarate aminotransferase inhibitors ornithine-oxo acid aminotransferase inhibitor ornithine-oxo acid aminotransferase inhibitors ornithine:alpha-oxoglutarate transaminase inhibitor ornithine:alpha-oxoglutarate transaminase inhibitors EC 2.6.1.13 (ornithine aminotransferase) inhibitor CHEBI:195444 insulin-like growth factor-binding protein inhibitor IGFBP inhibitor IGFBP inhibitors insulin-like growth factor-binding protein inhibitors insulin-like growth factor-binding protein inhibitor CHEBI:195525 EC 2.7.12.1 (dual-specificity kinase) inhibitor ADK1 inhibitor ADK1 inhibitors Arabidopsis dual specificity kinase 1 inhibitor Arabidopsis dual specificity kinase 1 inhibitors CLK1 inhibitor CLK1 inhibitors EC 2.7.12.1 (dual-specificity kinase) inhibitors EC 2.7.12.1 inhibitor EC 2.7.12.1 inhibitors Mps1p inhibitor Mps1p inhibitors dDYRK2 inhibitor dDYRK2 inhibitors dual-specificity kinase inhibitor dual-specificity kinase inhibitors EC 2.7.12.1 (dual-specificity kinase) inhibitor CHEBI:195530 PCNA inhibitor PCNA inhibitors proliferating cell nuclear antigen inhibitor proliferating cell nuclear antigen inhibitors PCNA inhibitor CHEBI:195542 sphingosine-1-phosphate receptor 2 antagonist EDG-5 antagonist EDG-5 antagonists EDG5 antagonist EDG5 antagonists S1P2 antagonist S1P2 antagonists S1PR2 antagonist S1PR2 antagonists sphingosine-1-phosphate receptor 2 antagonists sphingosine-1-phosphate receptor 2 antagonist CHEBI:195561 EC 3.5.3.1 (arginase) inhibitor EC 3.5.3.1 (arginase) inhibitors EC 3.5.3.1 inhibitor EC 3.5.3.1 inhibitors L-arginase inhibitor L-arginase inhibitors arginase inhibitor arginase inhibitors arginine amidinase inhibitor arginine amidinase inhibitors arginine transamidinase inhibitor arginine transamidinase inhibitors canavanase inhibitor canavanase inhibitors EC 3.5.3.1 (arginase) inhibitor CHEBI:195562 EC 3.5.3.* (non-peptide linear amidine C-N hydrolase) inhibitor EC 3.5.3.* (non-peptide linear amidine C-N hydrolase) inhibitors EC 3.5.3.* inhibitor EC 3.5.3.* inhibitors non-peptide linear amidine C-N hydrolase (EC 3.5.3.*) inhibitor non-peptide linear amidine C-N hydrolase (EC 3.5.3.*) inhibitors EC 3.5.3.* (non-peptide linear amidine C-N hydrolase) inhibitor CHEBI:196956 calcitonin gene-related peptide receptor antagonist CGRP antagonist CGRP antagonists calcitonin gene-related peptide receptor antagonists calcitonin gene-related peptide receptor antagonist CHEBI:197347 Rac1 inhibitor Rac-1 inhibitor Rac-1 inhibitors Rac1 inhibitors Ras-related C3 botulinum toxin substrate 1 inhibitor Ras-related C3 botulinum toxin substrate 1 inhibitors Rac1 inhibitor CHEBI:20569 EC 2.5.1.19 (3-phosphoshikimate 1-carboxyvinyltransferase) inhibitor 3-enol-pyruvoylshikimate-5-phosphate synthase inhibitor 3-enol-pyruvoylshikimate-5-phosphate synthase inhibitors 3-phosphoshikimate 1-carboxyvinyltransferase (EC 2.5.1.19) inhibitor 3-phosphoshikimate 1-carboxyvinyltransferase (EC 2.5.1.19) inhibitors 3-phosphoshikimate 1-carboxyvinyltransferase inhibitor 3-phosphoshikimate 1-carboxyvinyltransferase inhibitors 5-enolpyruvylshikimate-3-phosphate synthase inhibitor 5-enolpyruvylshikimate-3-phosphate synthase inhibitors EC 2.5.1.19 (3-phosphoshikimate 1-carboxyvinyltransferase) inhibitors EC 2.5.1.19 inhibitor EC 2.5.1.19 inhibitors EPSP synthase inhibitor EPSP synthase inhibitors phosphoenolpyruvate:3-phosphoshikimate 5-O-(1-carboxyvinyl)-transferase inhibitor phosphoenolpyruvate:3-phosphoshikimate 5-O-(1-carboxyvinyl)-transferase inhibitors EC 2.5.1.19 (3-phosphoshikimate 1-carboxyvinyltransferase) inhibitor CHEBI:20854 ATP synthase inhibitor ATP synthase inhibitor CHEBI:22153 acaricide Akarizid Akarizide acaricides miticide acaricide CHEBI:22180 EC 2.2.1.6 (acetolactate synthase) inhibitor EC 2.2.1.6 (acetolactate synthase) inhibitors EC 2.2.1.6 inhibitor EC 2.2.1.6 inhibitors acetohydroxy acid synthetase inhibitor acetohydroxy acid synthetase inhibitors acetohydroxyacid synthase inhibitor acetohydroxyacid synthase inhibitors acetolactate pyruvate-lyase (carboxylating) inhibitor acetolactate pyruvate-lyase (carboxylating) inhibitors acetolactate synthase (EC 2.2.1.6) inhibitor acetolactate synthase (EC 2.2.1.6) inhibitors acetolactate synthase inhibitor acetolactate synthase inhibitors acetolactic synthetase inhibitor acetolactic synthetase inhibitors alpha-acetohydroxy acid synthetase inhibitor alpha-acetohydroxy acid synthetase inhibitors alpha-acetohydroxyacid synthase inhibitor alpha-acetohydroxyacid synthase inhibitors alpha-acetolactate synthase inhibitor alpha-acetolactate synthase inhibitors alpha-acetolactate synthetase inhibitor alpha-acetolactate synthetase inhibitors pyruvate:pyruvate acetaldehydetransferase (decarboxylating) inhibitor pyruvate:pyruvate acetaldehydetransferase (decarboxylating) inhibitors EC 2.2.1.6 (acetolactate synthase) inhibitor CHEBI:22309 alicyclic antibiotics alicyclic antibiotics CHEBI:22311 aliphatic antibiotics aliphatic antibiotics CHEBI:22333 alkylating agent alkylating agent CHEBI:22368 alpha-1-microglobulin-Ig alpha complex chromophores alpha-1-microglobulin-Ig alpha complex chromophores CHEBI:22476 amino acid derivative antibiotics amino acid derivative antibiotics CHEBI:22581 antiauxins antiauxins CHEBI:22583 antifeedant antifeedants antifeedant CHEBI:22586 antioxidant antioxidants antioxydant antoxidant antioxidant CHEBI:22587 antiviral agent anti-viral agent anti-viral agents antiviral antiviral agents antivirals antiviral agent CHEBI:22676 auxin auxins auxin CHEBI:22695 base Base Base1 Base2 Basen Nucleobase base bases base CHEBI:22917 phytogenic insecticide botanical insecticide botanical insecticides phytogenic insecticides phytogenic insecticide CHEBI:22986 calcium ionophore calcium ionophores calcium ionophore CHEBI:23018 EC 4.2.1.1 (carbonic anhydrase) inhibitor EC 4.2.1.1 (carbonic anhydrase) inhibitors EC 4.2.1.1 inhibitor EC 4.2.1.1 inhibitors anhydrase inhibitor anhydrase inhibitors carbonate anhydrase inhibitor carbonate anhydrase inhibitors carbonate dehydratase inhibitor carbonate dehydratase inhibitors carbonate hydro-lyase (carbon-dioxide-forming) inhibitor carbonate hydro-lyase (carbon-dioxide-forming) inhibitors carbonate hydro-lyase inhibitor carbonate hydro-lyase inhibitors carbonic acid anhydrase inhibitor carbonic acid anhydrase inhibitors carbonic anhydrase (EC 4.2.1.1) inhibitor carbonic anhydrase (EC 4.2.1.1) inhibitors carbonic anhydrase A inhibitor carbonic anhydrase A inhibitors carbonic anhydrase inhibitor carbonic anhydrase inhibitors carboxyanhydrase inhibitor carboxyanhydrase inhibitors EC 4.2.1.1 (carbonic anhydrase) inhibitor CHEBI:23092 chemosterilant chemosterilants chemosterilant CHEBI:23100 chitin synthesis inhibitor chitin synthesis inhibitor CHEBI:23240 chromophore chromophore chromophores chromophore CHEBI:23354 coenzyme coenzyme coenzymes coenzyme CHEBI:23357 cofactor cofactor cofactors cofactor CHEBI:23366 compatible osmolytes compatible osmolytes CHEBI:23367 molecular entity entidad molecular entidades moleculares entite moleculaire molecular entities molecular entity molekulare Entitaet molecular entity CHEBI:23529 cytochrome-b6f complex inhibitor cytochrome-b6f complex inhibitor CHEBI:23530 cytokinin cytokinin CHEBI:23582 defoliant Defoliationsmittel Entlaubungsmittel defoliants defoliant CHEBI:23888 drug drugs medicine drug CHEBI:23891 ecdysone antagonists ecdysone antagonists CHEBI:23924 enzyme inhibitor enzyme inhibitor enzyme inhibitors inhibidor enzimatico inhibidores enzimaticos inhibiteur enzymatique inhibiteurs enzymatiques enzyme inhibitor CHEBI:23965 estradiol estra-1,3,5(10)-triene-3,17-diol oestradiol estradiol CHEBI:24002 ethylene releasers ethylene releasers CHEBI:24020 fat-soluble vitamin (role) fat-soluble vitamin fat-soluble vitamins fettloesliche Vitamine fat-soluble vitamin (role) CHEBI:24028 iron(3+) chelator iron(3+) chelator CHEBI:24127 fungicide fungicides fungicide CHEBI:24319 EC 6.3.1.2 (glutamate--ammonia ligase) inhibitor EC 6.3.1.2 (glutamate--ammonia ligase) inhibitors EC 6.3.1.2 inhibitor EC 6.3.1.2 inhibitors L-glutamate:ammonia ligase (ADP-forming) inhibitor L-glutamate:ammonia ligase (ADP-forming) inhibitors L-glutamine synthetase inhibitor L-glutamine synthetase inhibitors glutamate--ammonia ligase (EC 6.3.1.2) inhibitor glutamate--ammonia ligase (EC 6.3.1.2) inhibitors glutamate--ammonia ligase inhibitor glutamate--ammonia ligase inhibitors glutamine synthetase inhibitor glutamine synthetase inhibitors glutamylhydroxamic synthetase inhibitor glutamylhydroxamic synthetase inhibitors EC 6.3.1.2 (glutamate--ammonia ligase) inhibitor CHEBI:24430 group transfer coenzymes group transfer coenzymes CHEBI:24432 biological role biological function biological role CHEBI:24527 herbicide Herbizid Unkrautbekaempfungsmittel Unkrautvertilgungsmittel Wildkrautbekaempfungsmittel herbicides herbicide CHEBI:24621 hormone endocrine hormones hormone CHEBI:24850 insect attractant insect attractants insect attractant CHEBI:24851 insect growth regulator insect growth regulators insect growth regulator CHEBI:24852 insecticide insecticides insecticide CHEBI:24853 intercalator agente intercalante intercalating agent intercalating agents intercalating ligands intercalators intercalator CHEBI:24869 ionophore ionophore ionophores ionophore CHEBI:24874 iron ionophore iron ionophores iron ionophore CHEBI:24937 jasmonates jasmonates CHEBI:24941 juvenile hormone antagonists juvenile hormone antagonists CHEBI:24942 juvenile hormone mimic juvenile hormone mimic CHEBI:25078 luciferin luciferin CHEBI:25212 metabolite metabolite metabolites primary metabolites secondary metabolites metabolite CHEBI:25355 mitochondrial respiratory-chain inhibitor mitochondrial electron transport chain inhibitors mitochondrial electron-transport chain inhibitor mitochondrial respiratory chain inhibitors mitochondrial respiratory-chain inhibitor CHEBI:25435 mutagen mutagene mutagenes mutagenic agent mutageno mutagenos mutagens mutagen CHEBI:25442 mycotoxin fungal toxins mycotoxins mycotoxin CHEBI:25491 nematicide nematicides nematocide nematocides nematicide CHEBI:25512 neurotransmitter neurotransmitters neurotransmitter CHEBI:25540 neonicotinoid insectide neonicotinoid insectides nicotinoid insectide nicotinoid insectides neonicotinoid insectide CHEBI:25573 nodulation factor NF nod factor nodulation factors nodulation factor CHEBI:25605 nucleoside antibiotic nucleoside antibiotic CHEBI:25728 osmolyte osmolytes osmolyte CHEBI:25747 oxidized luciferins oxidized luciferins CHEBI:25943 pesticide synergist pesticide synergists pesticide synergist CHEBI:25944 pesticide Pestizid Pestizide pesticide pesticides pesticide CHEBI:26013 pheromone ectohormone feromone pheromone pheromones pheromone CHEBI:26083 phosphorus containing antibiotics phosphorus containing antibiotics CHEBI:26087 photosynthetic electron-transport chain inhibitor photosynthetic electron-transport chain inhibitor CHEBI:26088 photosystem-I inhibitor photosystem-I inhibitor CHEBI:26089 photosystem-II inhibitor photosystem-II inhibitor CHEBI:26115 phytoalexin phytoalexins phytoalexin CHEBI:26130 biological pigment pigments biological pigment CHEBI:26155 plant growth regulator plant growth regulators plant growth regulator CHEBI:26157 plant growth stimulator plant growth stimulators plant growth stimulator CHEBI:26220 precocenes precocenes CHEBI:26348 prosthetic group groupe prosthetique prosthetic group prosthetic groups prosthetic group CHEBI:26413 pyrethroid insecticide pyrethroid insecticides pyrethroid insecticide CHEBI:26645 semiochemical semiochemicals semiochemical CHEBI:26671 sideramine sideramine CHEBI:26672 siderophore ferrioxamine ferrioxamines ironophore siderochrome siderochromes siderophore siderophores siderophore CHEBI:2674 amodiaquine 4-[(7-chloroquinolin-4-yl)amino]-2-[(diethylamino)methyl]phenol Amodiaquine amodiaquina amodiaquine amodiaquinum amodiaquine CHEBI:26841 synthetic auxin synthetic auxins synthetic auxin CHEBI:26842 systemic acquired resistance inducing compounds systemic acquired resistance inducing compounds CHEBI:27026 toxin toxin toxins toxin CHEBI:27027 micronutrient micronutrients trace elements micronutrient CHEBI:27311 volatile oil component essential oil component essential oil components ethereal oil component ethereal oil components volatile oil components volatile oil component CHEBI:27314 water-soluble vitamin (role) wasserloesliche Vitamine water-soluble vitamin water-soluble vitamins water-soluble vitamin (role) CHEBI:27334 xenobiotic organic ethers xenobiotic organic ethers CHEBI:27780 detergent Detergents detergent detergent CHEBI:28593 quinidine (+)-Quinidine (+)-quinidine (8R,9S)-quinidine (9S)-6'-methoxycinchonan-9-ol (R)-(6-methoxyquinolin-4-yl)((3S,4R,7S)-3-vinylquinuclidin-7-yl)methanol (S)-(6-Methoxy-quinolin-4-yl)-((2R,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol (S)-(6-methoxyquinolin-4-yl)((2R,5R)-5-vinylquinuclidin-2-yl)methanol 6-methoxy-alpha-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol CIN-QUIN Chinidin Conchinin Kinidin Quinidine alpha-(6-methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol beta-quinine chinidinum conquinine pitayine quinidina quinidine quinidine CHEBI:3219 bupropion 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one Bupropion bupropion CHEBI:33229 vitamin (role) vitamin vitamina vitaminas vitamine vitamines vitamins vitaminum vitamin (role) CHEBI:33231 antitubercular agent antitubercular antitubercular agents antitubercular drug antitubercular drugs tuberculostatic agent antitubercular agent CHEBI:33232 application application CHEBI:33280 molecular messenger chemical messenger molecular messenger CHEBI:33281 antimicrobial agent Antibiotika Antibiotikum antibiotic antibiotics antibiotique antimicrobial antimicrobial agents antimicrobials microbicide microbicides antimicrobial agent CHEBI:33282 antibacterial agent antibacterial agents antibacterials bactericide bactericides antibacterial agent CHEBI:33284 nutrient nutrients nutrient CHEBI:33286 agrochemical agrichemical agrichemicals agricultural chemicals agrochemicals agrochemical CHEBI:33287 fertilizer fertiliser fertilizers fertilizer CHEBI:33288 rodenticide rodenticides rodenticide CHEBI:33289 avicide avicides avicide CHEBI:33290 food food material food materials food role foods foodstuff foodstuffs food CHEBI:33292 fuel fuel CHEBI:33295 diagnostic agent diagnostic aid diagnostic agent CHEBI:33893 reagent reactif reactivo reagent reagents reagent CHEBI:33904 molluscicide molluscicides molluscicide CHEBI:33937 macronutrient macronutrients macronutrient CHEBI:35195 surfactant surface active agent surfactant surfactants surfactant CHEBI:35197 lumiphore luminophore lumiphore lumiphore CHEBI:35204 tracer tracer tracer CHEBI:35205 chemical tracer chemical tracer chemical tracer CHEBI:35206 isotopic tracer isotopic tracer isotopic tracer CHEBI:35207 radioactive tracer radioactive tracer radioactive tracer CHEBI:35208 physical tracer physical tracer physical tracer CHEBI:35209 label label label CHEBI:35210 spin label spin label spin label CHEBI:35211 radioactive label radioactive label radioactive label CHEBI:35219 plant growth retardant plant growth inhibitor plant growth inhibitors plant growth retardants plant growth retardant CHEBI:35221 antimetabolite antimetabolite antimetabolites antimetabolite CHEBI:35222 inhibitor inhibidor inhibiteur inhibitor inhibitors inhibitor CHEBI:35223 catalyst Katalysator catalizador catalyseur catalyst catalyst CHEBI:35224 effector effector enzyme modulator effector CHEBI:35225 buffer buffer compound buffer compounds buffer CHEBI:35226 spin probe spin probe spin probe CHEBI:35230 fossil fuel fossil fuel fossil fuel CHEBI:35231 nuclear fuel nuclear fuel nuclear fuel CHEBI:35232 radiopharmaceutical radiopharmaceuticals radiopharmaceutical CHEBI:35337 central nervous system stimulant CNS stimulant analeptic analeptic agent analeptic drug analeptics central nervous system stimulant central stimulant central nervous system stimulant CHEBI:35441 antiinfective agent anti-infective agents anti-infective drugs antiinfective agents antiinfective drug antiinfective agent CHEBI:35442 antiparasitic agent antiparasitic drugs antiparasitics parasiticides antiparasitic agent CHEBI:35443 anthelminthic drug anthelminthic anthelminthics anthelmintic anthelmintics antihelminth antihelmintico vermifuge anthelminthic drug CHEBI:35444 antinematodal drug antinematodal agent antinematodal drugs antinematodals antinematodal drug CHEBI:35457 EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor ACE inhibitor ACE inhibitors DCP inhibitor DCP inhibitors EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitors EC 3.4.15.1 inhibitor EC 3.4.15.1 inhibitors PDH inhibitor PDH inhibitors angiotensin I-converting enzyme inhibitor angiotensin I-converting enzyme inhibitors angiotensin-converting enzyme inhibitor angiotensin-converting enzyme inhibitors carboxycathepsin inhibitor carboxycathepsin inhibitors dipeptidase inhibitor dipeptidase inhibitors dipeptide hydrolase inhibitor dipeptide hydrolase inhibitors dipeptidyl carboxypeptidase I inhibitor dipeptidyl carboxypeptidase I inhibitors dipeptidyl carboxypeptidase inhibitor dipeptidyl carboxypeptidase inhibitors endothelial cell peptidyl dipeptidase inhibitor endothelial cell peptidyl dipeptidase inhibitors kininase II inhibitor kininase II inhibitors peptidase P inhibitor peptidase P inhibitors peptidyl dipeptidase A inhibitor peptidyl dipeptidase A inhibitors peptidyl dipeptidase I inhibitor peptidyl dipeptidase I inhibitors peptidyl dipeptidase-4 inhibitor peptidyl dipeptidase-4 inhibitors peptidyl dipeptide hydrolase inhibitor peptidyl dipeptide hydrolase inhibitors peptidyl-dipeptidase A (EC 3.4.15.1) inhibitor peptidyl-dipeptidase A (EC 3.4.15.1) inhibitors peptidyl-dipeptidase A inhibitor peptidyl-dipeptidase A inhibitors peptidyl-dipeptide hydrolase inhibitor peptidyl-dipeptide hydrolase inhibitors peptidyldipeptide hydrolase inhibitor peptidyldipeptide hydrolase inhibitors EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor CHEBI:35469 antidepressant antidepressant drugs antidepressants thymoanaleptics thymoleptic drugs thymoleptics antidepressant CHEBI:35470 central nervous system drug CNS agent CNS drugs central nervous system agents central nervous system drug CHEBI:35471 psychotropic drug psychoactive agent psychoactive drugs psychopharmaceuticals psychotropic drugs psychotropic drug CHEBI:35472 anti-inflammatory drug anti-inflammatory drugs antiinflammatory agent antiinflammatory drug antiinflammatory drugs anti-inflammatory drug CHEBI:35473 tranquilizing drug ataractics tranquilising drug tranquilizing drugs tranquillising agent tranquillizing agents tranquilizing drug CHEBI:35474 anxiolytic drug anti-anxiety agents anti-anxiety drugs anxiolytic agents anxiolytics minor tranquilisers minor tranquilizers minor tranquilizing agents anxiolytic drug CHEBI:35475 non-steroidal anti-inflammatory drug NSAID NSAIDs non-steroidal anti-inflammatory agent non-steroidal anti-inflammatory drugs non-steroidal anti-inflammatory drug CHEBI:35476 antipsychotic agent Neuroleptikum antipsychotic agents antipsychotic drug antipsychotic drugs antipsychotics antipsychotiques grosser Tranquilizer major tranquilizers major tranquilizing agents neuroleptic neuroleptic agents neuroleptics neuroleptique neuroleptiques antipsychotic agent CHEBI:35477 antimanic drug antimanic agent antimanic drugs antimanics antimanic drug CHEBI:35480 analgesic analgesic CHEBI:35481 non-narcotic analgesic non-narcotic analgesic CHEBI:35482 opioid analgesic narcotic narcotic analgesic narcotic analgesics narcotics opioid analgesics opioid analgesic CHEBI:35487 EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor CoA-independent aldehyde dehydrogenase inhibitor CoA-independent aldehyde dehydrogenase inhibitors EC 1.2.1.3 (aldehyde dehydrogenase (NAD(+))) inhibitor EC 1.2.1.3 (aldehyde dehydrogenase (NAD(+))) inhibitors EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitors EC 1.2.1.3 inhibitor EC 1.2.1.3 inhibitors NAD-aldehyde dehydrogenase inhibitor NAD-aldehyde dehydrogenase inhibitors NAD-dependent 4-hydroxynonenal dehydrogenase inhibitor NAD-dependent 4-hydroxynonenal dehydrogenase inhibitors NAD-dependent aldehyde dehydrogenase inhibitor NAD-dependent aldehyde dehydrogenase inhibitors NAD-linked aldehyde dehydrogenase inhibitor NAD-linked aldehyde dehydrogenase inhibitors aldehyde dehydrogenase (NAD(+)) (EC 1.2.1.3) inhibitor aldehyde dehydrogenase (NAD(+)) (EC 1.2.1.3) inhibitors aldehyde dehydrogenase (NAD(+)) inhibitor aldehyde dehydrogenase (NAD(+)) inhibitors aldehyde dehydrogenase (NAD) inhibitor aldehyde dehydrogenase (NAD) inhibitors aldehyde dehydrogenase inhibitor aldehyde dehydrogenase inhibitors m-methylbenzaldehyde dehydrogenase inhibitor m-methylbenzaldehyde dehydrogenase inhibitors propionaldehyde dehydrogenase inhibitor propionaldehyde dehydrogenase inhibitors EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor CHEBI:35488 central nervous system depressant CNS depressants central nervous system depressants central nervous system depressant CHEBI:35493 antipyretic anti-pyretic antipyretic CHEBI:35497 androgen antagonist antiandrogen androgen antagonist CHEBI:35498 diuretic diuretics diuretic CHEBI:35499 hallucinogen hallucinogenic agents hallucinogenic drugs hallucinogens psychedelic agents psychedelics hallucinogen CHEBI:35522 beta-adrenergic agonist beta-adrenergic agonists beta-adrenergic receptor agonist beta-adrenoceptor agonists beta-adrenergic agonist CHEBI:35523 bronchodilator agent bronchodilator bronchodilator agents broncholytic agent bronchodilator agent CHEBI:35524 sympathomimetic agent sympathomimetic sympathomimetics sympathomimetic agent CHEBI:35526 hypoglycemic agent antidiabetic antihyperglycemic antihyperglycemic agent antihyperglycemic agents antihyperglycemic drug antihyperglycemic drugs antihyperglycemics hypoglycemic agents hypoglycemic drug hypoglycemic drugs hypoglycemic agent CHEBI:35530 beta-adrenergic antagonist beta-adrenergic antagonists beta-adrenergic blocker beta-adrenergic blockers beta-adrenergic receptor blockaders beta-adrenoceptor antagonists beta-blocker beta-blockers beta-adrenergic antagonist CHEBI:35544 EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate,hydrogen-donor:oxygen oxidoreductase inhibitor (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate,hydrogen-donor:oxygen oxidoreductase inhibitors (PG)H synthase inhibitor (PG)H synthase inhibitors COX inhibitor EC 1.14.99.1 (cyclooxygenase) inhibitor EC 1.14.99.1 (cyclooxygenase) inhibitors EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitors EC 1.14.99.1 inhibitor EC 1.14.99.1 inhibitors PG synthetase inhibitor PG synthetase inhibitors cyclooxygenase (EC 1.14.99.1) inhibitor cyclooxygenase (EC 1.14.99.1) inhibitors cyclooxygenase inhibitor cyclooxygenase inhibitors fatty acid cyclooxygenase inhibitor fatty acid cyclooxygenase inhibitors prostaglandin G/H synthase inhibitor prostaglandin G/H synthase inhibitors prostaglandin endoperoxide synthetase inhibitor prostaglandin endoperoxide synthetase inhibitors prostaglandin synthase inhibitor prostaglandin synthase inhibitors prostaglandin synthetase inhibitor prostaglandin synthetase inhibitors EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor CHEBI:35554 cardiovascular drug cardiovascular agent cardiovascular drugs cardiovascular drug CHEBI:35569 alpha-adrenergic agonist alpha-adrenergic agonists alpha-adrenergic receptor agonist alpha-adrenoceptor agonists alpha-adrenergic agonist CHEBI:35608 EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitors EC 3.1.3.48 inhibitor EC 3.1.3.48 inhibitors PPT-phosphatase inhibitor PPT-phosphatase inhibitors PTP-phosphatase inhibitor PTP-phosphatase inhibitors PTPase inhibitor PTPase inhibitors [phosphotyrosine]protein phosphatase inhibitor [phosphotyrosine]protein phosphatase inhibitors phosphoprotein phosphatase (phosphotyrosine) inhibitor phosphoprotein phosphatase (phosphotyrosine) inhibitors phosphotyrosine histone phosphatase inhibitor phosphotyrosine histone phosphatase inhibitors phosphotyrosine phosphatase inhibitor phosphotyrosine phosphatase inhibitors phosphotyrosine protein phosphatase inhibitor phosphotyrosine protein phosphatase inhibitors phosphotyrosylprotein phosphatase inhibitor phosphotyrosylprotein phosphatase inhibitors protein phosphotyrosine phosphatase inhibitor protein phosphotyrosine phosphatase inhibitors protein tyrosine phosphatase inhibitor protein tyrosine phosphatase inhibitors protein-tyrosine-phosphatase (EC 3.1.3.48) inhibitor protein-tyrosine-phosphatase (EC 3.1.3.48) inhibitors protein-tyrosine-phosphatase inhibitor protein-tyrosine-phosphatase inhibitors protein-tyrosine-phosphate phosphohydrolase inhibitor protein-tyrosine-phosphate phosphohydrolase inhibitors tyrosine O-phosphate phosphatase inhibitor tyrosine O-phosphate phosphatase inhibitors tyrosylprotein phosphatase inhibitor tyrosylprotein phosphatase inhibitors EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor CHEBI:35610 antineoplastic agent anticancer agent anticancer agents antineoplastic antineoplastic agents cytostatic antineoplastic agent CHEBI:35617 flavouring agent flavoring agent flavoring agents flavour enhancer flavour enhancers flavouring agents flavouring agent CHEBI:35620 vasodilator agent vasodilator vasodilator agents vasodilator agent CHEBI:35623 anticonvulsant Antiepileptika Antiepileptikum Antikonvulsiva Antikonvulsivum anti-convulsant anti-convulsants anti-convulsive agent anti-convulsive agents anticonvulsants anticonvulsive agent anticonvulsive agents antiepileptic antiepileptics antiepileptique antiepileptiques anticonvulsant CHEBI:35625 EC 3.5.2.6 (beta-lactamase) inhibitor EC 3.5.2.6 (beta-lactamase) inhibitors EC 3.5.2.6 inhibitor EC 3.5.2.6 inhibitors ampicillinase inhibitor ampicillinase inhibitors beta-lactam hydrolase inhibitor beta-lactam hydrolase inhibitors beta-lactamase (EC 3.5.2.6) inhibitor beta-lactamase (EC 3.5.2.6) inhibitors beta-lactamase A, B, C inhibitor beta-lactamase A, B, C inhibitors beta-lactamase AME I inhibitor beta-lactamase AME I inhibitors beta-lactamase I-III inhibitor beta-lactamase I-III inhibitors beta-lactamase inhibitor beta-lactamase inhibitors cephalosporin-beta-lactamase inhibitor cephalosporin-beta-lactamase inhibitors cephalosporinase inhibitor cephalosporinase inhibitors exopenicillinase inhibitor exopenicillinase inhibitors neutrapen inhibitor neutrapen inhibitors penicillin amido-beta-lactamhydrolase inhibitor penicillin amido-beta-lactamhydrolase inhibitors penicillin beta-lactamase inhibitor penicillin beta-lactamase inhibitors penicillinase I, II inhibitor penicillinase I, II inhibitors penicillinase inhibitor penicillinase inhibitors EC 3.5.2.6 (beta-lactamase) inhibitor CHEBI:35634 EC 1.17.3.2 (xanthine oxidase) inhibitor EC 1.17.3.2 (xanthine oxidase) inhibitors EC 1.17.3.2 inhibitor EC 1.17.3.2 inhibitors Schardinger enzyme inhibitor Schardinger enzyme inhibitors hypoxanthine oxidase inhibitor hypoxanthine oxidase inhibitors hypoxanthine-xanthine oxidase inhibitor hypoxanthine-xanthine oxidase inhibitors hypoxanthine:oxygen oxidoreductase inhibitor hypoxanthine:oxygen oxidoreductase inhibitors xanthine oxidase (EC 1.17.3.2) inhibitor xanthine oxidase (EC 1.17.3.2) inhibitors xanthine oxidase inhibitor xanthine oxidase inhibitors xanthine oxidoreductase inhibitor xanthine oxidoreductase inhibitors xanthine:O2 oxidoreductase inhibitor xanthine:O2 oxidoreductase inhibitors xanthine:oxygen oxidoreductase inhibitor xanthine:oxygen oxidoreductase inhibitors xanthine:xanthine oxidase inhibitor xanthine:xanthine oxidase inhibitors EC 1.17.3.2 (xanthine oxidase) inhibitor CHEBI:35640 adrenergic uptake inhibitor ARI NERI NRI adrenergic reuptake inhibitor adrenergic reuptake inhibitors adrenergic uptake inhibitors norepinephrine reuptake inhibitor norepinephrine reuptake inhibitors adrenergic uptake inhibitor CHEBI:35660 HIV protease inhibitor HIV protease inhibitors HIV protease inhibitor CHEBI:35664 EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor HMG-CoA reductase inhibitor HMG-CoA reductase inhibitors hydroxymethylglutaryl-CoA reductase inhibitor hydroxymethylglutaryl-CoA reductase inhibitors EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor CHEBI:35674 antihypertensive agent antihypertensive antihypertensive agents antihypertensive drug antihypertensive drugs antihypertensive agent CHEBI:35678 histamine agonist histamine agonists histamine agonist CHEBI:35679 antilipemic drug antihyperlipemic antihyperlipemics antihyperlipidaemic agent antihyperlipidaemic agents antihyperlipidaemic drug antihyperlipidaemic drugs antihyperlipidemic antihyperlipidemic agent antihyperlipidemic agents antihyperlipidemic drug antihyperlipidemic drugs antihyperlipidemics antilipemic antilipemic drugs antilipemics hypolipidemic agent hypolipidemic agents lipid-lowering agent lipid-lowering agents lipid-lowering drug lipid-lowering drugs antilipemic drug CHEBI:35684 antiplatyhelmintic drug antiplatyhelmintic agent antiplatyhelmintic drugs antiplatyhelmintic drug CHEBI:35703 xenobiotic Xenobiotic xenobiotic xenobiotic compounds xenobiotics xenobiotic CHEBI:35705 immunosuppressive agent immunosuppressant immunosuppressive agents inmunosupresor immunosuppressive agent CHEBI:35717 sedative hypnotics hypnotics and sedatives sedative drug sedatives sedatives and hypnotics sedative CHEBI:35718 antifungal agent antifungal antifungal agents antifungal drug antifungal drugs antifungals antifungal agent CHEBI:35816 leprostatic drug leprostatic leprostatic agent leprostatic drugs leprostatic drug CHEBI:35818 coccidiostat anticoccidial agent coccidiostats coccidiostat CHEBI:35820 antiprotozoal drug antiprotozoal agent antiprotozoal agents antiprotozoal drugs antiprotozoal drug CHEBI:35821 anticholesteremic drug anticholesteremic anticholesteremic agent anticholesteremic drugs antihypercholesterolemic antihypercholesterolemic agent antihypercholesterolemic agents antihypercholesterolemic drug antihypercholesterolemic drugs antihypercholesterolemics cholesterol inhibitor cholesterol-lowering agent cholesterol-lowering agents cholesterol-lowering drug cholesterol-lowering drugs hypocholesteremic agent anticholesteremic drug CHEBI:35841 uricosuric drug uricosuric agent uricosuric drugs uricosuric drug CHEBI:35842 antirheumatic drug anti-rheumatic drugs antirheumatic agent antirheumatic drugs antirheumatic drug CHEBI:35845 gout suppressant gout suppressants gout suppressant CHEBI:35846 renal agent renal agents renal agent CHEBI:35856 lipoxygenase inhibitor lipooxygenase inhibitor lipoxygenase inhibitors lipoxygenase inhibitor CHEBI:35941 serotonergic agonist 5-HT agonist 5-hydroxytryptamine agonist serotonergic agonists serotonin agonist serotonin agonists serotonergic agonist CHEBI:35942 neurotransmitter agent neurotransmitter agents neurotransmitter agent CHEBI:36043 antimicrobial drug antimicrobial drugs antimicrobial drug CHEBI:36044 antiviral drug anti-viral drug anti-virus drug antiviral drugs antiviral drug CHEBI:36047 antibacterial drug antibacterial drugs antibacterial drug CHEBI:36050 antitreponemal drug antitreponemal agent antitreponemal drugs antitreponemal drug CHEBI:36051 antisyphilitic drug antisyphilitic agent antisyphilitic agents antisyphilitic drugs antisyphilitics antisyphilitic drug CHEBI:36053 acaricide drug acaricide drugs acaricide drug CHEBI:36063 oxytocic oxytocic oxytocic agents oxytocic drugs uterine stimulants oxytocic CHEBI:36257 taurocholate 2-[(3alpha,7alpha,12alpha-trihydroxy-24-oxo-5beta-cholan-24-yl)amino]ethanesulfonate taurocholate taurocholate CHEBI:36333 local anaesthetic Lokalanaesthetikum anesthesique local local anaesthetic local anaesthetics local anesthetics local anaesthetic CHEBI:36335 trypanocidal drug antitrypanosomal agent antitrypanosomal agents antitrypanosomal drug antitrypanosomal drugs trypanocidal drugs trypanocide trypanosomicidal agents trypanocidal drug CHEBI:36413 anabolic agent anabolic agent CHEBI:36710 interferon inducer interferon inducers interferon inducer CHEBI:37153 EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor 3-hydroxy 3-methylglutaryl coenzymeA reductase phosphatase inhibitor 3-hydroxy 3-methylglutaryl coenzymeA reductase phosphatase inhibitors Aspergillus awamori acid protein phosphatase inhibitor Aspergillus awamori acid protein phosphatase inhibitors BCKDH phosphatase inhibitor BCKDH phosphatase inhibitors EC 3.1.3.16 (protein serine/threonine phosphatase) inhibitors EC 3.1.3.16 inhibitor EC 3.1.3.16 inhibitors HMG-CoA reductase phosphatase inhibitor HMG-CoA reductase phosphatase inhibitors branched-chain alpha-keto acid dehydrogenase phosphatase inhibitor branched-chain alpha-keto acid dehydrogenase phosphatase inhibitors calcineurin inhibitor calcineurin inhibitors casein phosphatase inhibitor casein phosphatase inhibitors phosphatase 2A inhibitor phosphatase 2A inhibitors phosphatase 2B inhibitor phosphatase 2B inhibitors phosphatase C-II inhibitor phosphatase C-II inhibitors phosphatase H-II inhibitor phosphatase H-II inhibitors phosphatase I inhibitor phosphatase I inhibitors phosphatase IB inhibitor phosphatase IB inhibitors phosphatase II inhibitor phosphatase II inhibitors phosphatase III inhibitor phosphatase III inhibitors phosphatase IV inhibitor phosphatase IV inhibitors phosphatase SP inhibitor phosphatase SP inhibitors phosphoprotein phosphatase (EC 3.1.3.16) inhibitor phosphoprotein phosphatase (EC 3.1.3.16) inhibitors phosphoprotein phosphatase inhibitor phosphoprotein phosphatase inhibitors phosphoprotein phosphohydrolase inhibitor phosphoprotein phosphohydrolase inhibitors phosphopyruvate dehydrogenase phosphatase inhibitor phosphopyruvate dehydrogenase phosphatase inhibitors phosphospectrin phosphatase inhibitor phosphospectrin phosphatase inhibitors polycation modulated (PCM-) phosphatase inhibitor polycation modulated (PCM-) phosphatase inhibitors protein D phosphatase inhibitor protein D phosphatase inhibitors protein phosphatase inhibitor protein phosphatase inhibitors protein phosphatase-1 inhibitor protein phosphatase-1 inhibitors protein phosphatase-2A inhibitor protein phosphatase-2A inhibitors protein phosphatase-2B inhibitor protein phosphatase-2B inhibitors protein phosphatase-2C inhibitor protein phosphatase-2C inhibitors protein serine/threonine phosphatase (EC 3.1.3.16) inhibitors protein serine/threonine phosphatase inhibitor protein serine/threonine phosphatase inhibitors serine/threonine specific protein phosphatase inhibitor serine/threonine specific protein phosphatase inhibitors EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor CHEBI:37334 diagnostic imaging agent diagnostic imaging agent CHEBI:37335 MRI contrast agent MRI contrast agent CHEBI:37336 radioactive imaging agent radioactive imaging agent CHEBI:37337 ultrasound contrast agent ultrasound contrast agent CHEBI:37338 radioopaque medium contrast media radiocontrast agent radiocontrast agents radioopaque media radiopaque media radiopaque medium radioopaque medium CHEBI:37416 EC 2.7.7.6 (RNA polymerase) inhibitor C RNA formation factors inhibitor C RNA formation factors inhibitors C ribonucleic acid formation factors inhibitor C ribonucleic acid formation factors inhibitors DNA-dependent RNA nucleotidyltransferase inhibitor DNA-dependent RNA nucleotidyltransferase inhibitors DNA-dependent RNA polymerase inhibitor DNA-dependent RNA polymerase inhibitors DNA-dependent ribonucleate nucleotidyltransferase inhibitor DNA-dependent ribonucleate nucleotidyltransferase inhibitors DNA-directed RNA polymerase inhibitor DNA-directed RNA polymerase inhibitors DNA-directed nucleoside-triphosphate:RNA nucleotidyltransferase inhibitor DNA-directed nucleoside-triphosphate:RNA nucleotidyltransferase inhibitors EC 2.7.7.6 (RNA polymerase) inhibitors EC 2.7.7.6 inhibitor EC 2.7.7.6 inhibitors RNA nucleotidyltransferase (DNA-directed) inhibitor RNA nucleotidyltransferase (DNA-directed) inhibitors RNA nucleotidyltransferase inhibitor RNA nucleotidyltransferase inhibitors RNA polymerase (EC 2.7.7.6) inhibitor RNA polymerase (EC 2.7.7.6) inhibitors RNA polymerase I inhibitor RNA polymerase I inhibitors RNA polymerase II inhibitor RNA polymerase II inhibitors RNA polymerase III inhibitor RNA polymerase III inhibitors RNA polymerase inhibitor RNA polymerase inhibitors RNA transcriptase inhibitor RNA transcriptase inhibitors deoxyribonucleic acid-dependent ribonucleic acid polymerase inhibitor deoxyribonucleic acid-dependent ribonucleic acid polymerase inhibitors directed RNA polymerase inhibitor nucleoside-triphosphate:RNA nucleotidyltransferase (DNA-directed) inhibitor nucleoside-triphosphate:RNA nucleotidyltransferase (DNA-directed) inhibitors ribonucleate nucleotidyltransferase inhibitor ribonucleate nucleotidyltransferase inhibitors ribonucleate polymerase inhibitor ribonucleate polymerase inhibitors ribonucleic acid nucleotidyltransferase inhibitor ribonucleic acid nucleotidyltransferase inhibitors ribonucleic acid polymerase inhibitor ribonucleic acid polymerase inhibitors ribonucleic acid transcriptase inhibitor ribonucleic acid transcriptase inhibitors ribonucleic polymerase inhibitor ribonucleic polymerase inhibitors ribonucleic transcriptase inhibitor ribonucleic transcriptase inhibitors transcriptase inhibitor transcriptase inhibitors EC 2.7.7.6 (RNA polymerase) inhibitor CHEBI:37527 acid Acid Saeure Saeuren acid acide acido acids acid CHEBI:37670 protease inhibitor protease inhibitors protease inhibitor CHEBI:37699 protein kinase inhibitor protein kinase inhibitors protein kinase inhibitor CHEBI:37700 EC 2.7.11.13 (protein kinase C) inhibitor ATP:protein phosphotransferase (diacylglycerol-dependent) inhibitor ATP:protein phosphotransferase (diacylglycerol-dependent) inhibitors EC 2.7.11.13 (protein kinase C) inhibitors EC 2.7.11.13 inhibitor EC 2.7.11.13 inhibitors PKC inhibitor PKC inhibitors PKCalpha inhibitor PKCalpha inhibitors PKCbeta inhibitor PKCbeta inhibitors PKCdelta inhibitor PKCdelta inhibitors PKCepsilon inhibitor PKCepsilon inhibitors PKCgamma inhibitor PKCgamma inhibitors PKCzeta inhibitor PKCzeta inhibitors PKN3 inhibitor PKN3 inhibitors Pkc1p inhibitor Pkc1p inhibitors STK24 inhibitor STK24 inhibitors cPKC inhibitor cPKC inhibitors cPKCalpha inhibitor cPKCalpha inhibitors cPKCbeta inhibitor cPKCbeta inhibitors cPKCgamma inhibitor cPKCgamma inhibitors calcium-dependent protein kinase C inhibitor calcium-dependent protein kinase C inhibitors calcium-independent protein kinase C inhibitor calcium-independent protein kinase C inhibitors calcium/phospholipid dependent protein kinase inhibitor calcium/phospholipid dependent protein kinase inhibitors nPKC inhibitor nPKC inhibitors nPKCdelta inhibitor nPKCdelta inhibitors nPKCepsilon inhibitor nPKCepsilon inhibitors nPKCeta inhibitor nPKCeta inhibitors nPKCtheta inhibitor nPKCtheta inhibitors protein kinase C (EC 2.7.11.13) inhibitor protein kinase C (EC 2.7.11.13) inhibitors protein kinase C inhibitor protein kinase C inhibitors protein kinase Cepsilon inhibitor protein kinase Cepsilon inhibitors EC 2.7.11.13 (protein kinase C) inhibitor CHEBI:37733 EC 3.1.1.8 (cholinesterase) inhibitor BChE inhibitor BChE inhibitors BtChoEase inhibitor BtChoEase inhibitors EC 3.1.1.8 (cholinesterase) inhibitors EC 3.1.1.8 inhibitor EC 3.1.1.8 inhibitors anticholineesterase inhibitor anticholineesterase inhibitors anticholinesterase anticholinesterases benzoylcholinesterase inhibitor benzoylcholinesterase inhibitors butyrylcholine esterase inhibitor butyrylcholine esterase inhibitors butyrylcholinesterase inhibitor butyrylcholinesterase inhibitors choline esterase II (unspecific) inhibitor choline esterase II (unspecific) inhibitors choline esterase inhibitor choline esterase inhibitors cholinesterase (EC 3.1.1.8) inhibitor cholinesterase (EC 3.1.1.8) inhibitors cholinesterase inhibitor non-specific cholinesterase inhibitor non-specific cholinesterase inhibitors propionylcholinesterase inhibitor propionylcholinesterase inhibitors pseudocholinesterase inhibitor pseudocholinesterase inhibitors EC 3.1.1.8 (cholinesterase) inhibitor CHEBI:37845 growth hormone GH Somatotropin Wachstumshormon growth hormones growth hormone CHEBI:37848 plant hormone phytohormone phytohormones plant growth factor plant growth factors plant growth hormone plant growth hormones plant hormones plant hormone CHEBI:37886 adrenergic agonist adrenergic agonists adrenergic receptor agonist adrenoceptor agonists adrenomimetic adrenomimetics adrenergic agonist CHEBI:37887 adrenergic antagonist adrenergic antagonists adrenergic blockaders adrenergic blocker adrenergic blockers adrenergic receptor blockaders adrenoceptor antagonists adrenergic antagonist CHEBI:37890 alpha-adrenergic antagonist alpha-adrenergic antagonists alpha-adrenergic blocker alpha-adrenergic blockers alpha-adrenergic receptor blockaders alpha-adrenoceptor antagonists alpha-adrenergic antagonist CHEBI:37930 phenothiazine antipsychotic drug phenothiazine antipsychotic drugs phenothiazine antipsychotics phenothiazine neuroleptics phenothiazine antipsychotic drug CHEBI:37955 H1-receptor antagonist H1 antihistaminics H1 receptor antagonists H1 receptor blockaders H1-receptor antagonists H1-receptor blocker H1-receptor blockers classical antihistamines classical antihistaminics H1-receptor antagonist CHEBI:37956 histamine antagonist antihistamine antihistamines antihistaminico antihistaminics histamine receptor blocker histamine receptor blockers histamine antagonist CHEBI:37957 histaminergic drug histamine agents histamine drugs histaminergic agent histaminergic agents histaminergic drugs histaminergic drug CHEBI:37958 dye Farbstoff Farbstoffe colorante colorantes dyes teinture teintures dye CHEBI:37961 H2-receptor antagonist H2 receptor antagonists H2 receptor blockaders H2-receptor blocker H2-receptor blockers histamine H2 receptor antagonist histamine H2 receptor antagonists H2-receptor antagonist CHEBI:37962 adrenergic agent adrenergic agents adrenergic drug adrenergic drugs adrenergic neuron agents adrenergics adrenergic agent CHEBI:38060 triazine insecticide triazine insecticide CHEBI:38068 antimalarial antimalarials antimalarial CHEBI:38070 anti-arrhythmia drug anti-arrhythmia agent antiarrhythmic agent anti-arrhythmia drug CHEBI:38147 cardiotonic drug cardiotonic drugs cardiotonic drug CHEBI:38155 phytosiderophore Phytosiderophor phytosiderophores phytosiderophore CHEBI:38157 iron chelator iron chelating agents iron chelators iron chelator CHEBI:38161 chelator Chelating agent Metal chelator chelating agents chelators complexon chelator CHEBI:38162 iron(2+) chelator iron(2+) chelator CHEBI:38215 calcium channel blocker calcium channel antagonist calcium channel antagonists calcium channel blockers calcium channel blocker CHEBI:38231 phytotoxin phytotoxins phytotoxin CHEBI:38234 DNA polymerase inhibitor DNA polymerase inhibitor CHEBI:38317 EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27) inhibitor 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27) inhibitors 4-hydroxyphenylpyruvate dioxygenase inhibitor 4-hydroxyphenylpyruvate dioxygenase inhibitors 4-hydroxyphenylpyruvate hydroxylase inhibitor 4-hydroxyphenylpyruvate hydroxylase inhibitors 4-hydroxyphenylpyruvate:oxygen oxidoreductase (hydroxylating, decarboxylating) inhibitor 4-hydroxyphenylpyruvate:oxygen oxidoreductase (hydroxylating, decarboxylating) inhibitors 4-hydroxyphenylpyruvic acid dioxygenase inhibitor 4-hydroxyphenylpyruvic acid dioxygenase inhibitors EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitors EC 1.13.11.27 inhibitor EC 1.13.11.27 inhibitors HPPD inhibitor HPPD inhibitors p-hydroxyphenylpyruvate dioxygenase inhibitor p-hydroxyphenylpyruvate dioxygenase inhibitors p-hydroxyphenylpyruvate hydroxylase inhibitor p-hydroxyphenylpyruvate hydroxylase inhibitors p-hydroxyphenylpyruvate oxidase inhibitor p-hydroxyphenylpyruvate oxidase inhibitors p-hydroxyphenylpyruvic acid hydroxylase inhibitor p-hydroxyphenylpyruvic acid hydroxylase inhibitors p-hydroxyphenylpyruvic hydroxylase inhibitor p-hydroxyphenylpyruvic hydroxylase inhibitors p-hydroxyphenylpyruvic oxidase inhibitor p-hydroxyphenylpyruvic oxidase inhibitors EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor CHEBI:38323 cholinergic drug cholinergic agent cholinergic drugs cholinomimetic cholinergic drug CHEBI:38324 cholinergic agonist acetylcholine agonist acetylcholine agonists acetylcholine receptor agonist cholinergic agonists cholinomimetic cholinomimetics cholinergic agonist CHEBI:38325 muscarinic agonist muscarinic acetylcholine receptor agonist muscarinic agonists muscarinic cholinergic agonist muscarinic cholinergic agonists muscarinic agonist CHEBI:38456 ecdysone agonist ecdysone agonists ecdysone mimetic ecdysone agonist CHEBI:38461 carbamate insecticide carbamate insecticides carbamate insecticide CHEBI:38462 EC 3.1.1.7 (acetylcholinesterase) inhibitor AChEI AcCholE inhibitor AcCholE inhibitors EC 3.1.1.7 (acetylcholinesterase) inhibitors EC 3.1.1.7 inhibitor EC 3.1.1.7 inhibitors acetyl.beta-methylcholinesterase inhibitor acetyl.beta-methylcholinesterase inhibitors acetylcholine acetylhydrolase inhibitor acetylcholine acetylhydrolase inhibitors acetylcholine esterase inhibitor acetylcholine hydrolase inhibitor acetylcholine hydrolase inhibitors acetylcholinesterase (EC 3.1.1.7) inhibitor acetylcholinesterase (EC 3.1.1.7) inhibitors acetylcholinesterase inhibitor acetylcholinesterase inhibitors acetylthiocholinesterase inhibitor acetylthiocholinesterase inhibitors choline esterase I inhibitor choline esterase I inhibitors cholinesterase inhibitor cholinesterase inhibitors true cholinesterase inhibitor true cholinesterase inhibitors EC 3.1.1.7 (acetylcholinesterase) inhibitor CHEBI:38496 electron-transport chain inhibitor electron-transport chain inhibitor CHEBI:38497 respiratory-chain inhibitor respiratory-chain inhibitor CHEBI:38498 mitochondrial NADH:ubiquinone reductase inhibitor mitochondrial NADH dehydrogenase inhibitor mitochondrial complex I inhibitor mitochondrial complex I inhibitors mitochondrial NADH:ubiquinone reductase inhibitor CHEBI:38499 mitochondrial cytochrome-bc1 complex inhibitor mitochondrial complex III inhibitor mitochondrial complex III inhibitors mitochondrial cytochrome-bc1 complex inhibitor CHEBI:38500 EC 1.9.3.1 (cytochrome c oxidase) inhibitor CcO inhibitor EC 1.9.3.1 (cytochrome c oxidase) inhibitors EC 1.9.3.1 inhibitor EC 1.9.3.1 inhibitors NADH cytochrome c oxidase inhibitor NADH cytochrome c oxidase inhibitors Warburg's respiratory enzyme inhibitor Warburg's respiratory enzyme inhibitors complex IV (mitochondrial electron transport) inhibitor complex IV (mitochondrial electron transport) inhibitors cytochrome a3 inhibitor cytochrome a3 inhibitors cytochrome aa3 inhibitor cytochrome aa3 inhibitors cytochrome c oxidase (EC 1.9.3.1) inhibitor cytochrome c oxidase (EC 1.9.3.1) inhibitors cytochrome c oxidase inhibitor cytochrome c oxidase inhibitors cytochrome oxidase inhibitor cytochrome oxidase inhibitors cytochrome-c oxidase inhibitor cytochrome-c oxidase inhibitors ferrocytochrome c oxidase inhibitor ferrocytochrome c oxidase inhibitors ferrocytochrome-c:oxygen oxidoreductase inhibitor ferrocytochrome-c:oxygen oxidoreductase inhibitors indophenol oxidase inhibitor indophenol oxidase inhibitors indophenolase inhibitor indophenolase inhibitors mitochondrial complex IV inhibitor mitochondrial complex IV inhibitors mitochondrial cytochrome-c oxidase inhibitors EC 1.9.3.1 (cytochrome c oxidase) inhibitor CHEBI:38502 cytochrome-bc1 complex inhibitor cytochrome-bc1 complex inhibitor CHEBI:38503 EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor DPNH-coenzyme Q reductase inhibitor DPNH-ubiquinone reductase inhibitor EC 1.6.5.3 (NADH:ubiquinone reductase (H(+)-translocating)) inhibitor EC 1.6.5.3 (NADH:ubiquinone reductase (H(+)-translocating)) inhibitors EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitors EC 1.6.5.3 inhibitor EC 1.6.5.3 inhibitors NADH coenzyme Q1 reductase inhibitor NADH coenzyme Q1 reductase inhibitors NADH dehydrogenase (ubiquinone) inhibitor NADH dehydrogenase (ubiquinone) inhibitors NADH-CoQ oxidoreductase inhibitor NADH-CoQ oxidoreductase inhibitors NADH-CoQ reductase inhibitor NADH-CoQ reductase inhibitors NADH-Q6 oxidoreductase inhibitor NADH-coenzyme Q oxidoreductase inhibitors NADH-coenzyme Q reductase inhibitor NADH-coenzyme Q reductase inhibitors NADH-ubiquinone oxidoreductase inhibitor NADH-ubiquinone oxidoreductase inhibitors NADH-ubiquinone reductase inhibitor NADH-ubiquinone reductase inhibitors NADH-ubiquinone-1 reductase inhibitor NADH-ubiquinone-1 reductase inhibitors NADH2 dehydrogenase (ubiquinone) inhibitor NADH:ubiquinone oxidoreductase complex inhibitor NADH:ubiquinone oxidoreductase inhibitor NADH:ubiquinone oxidoreductase inhibitors NADH:ubiquinone reductase (H(+)-translocating) inhibitor NADH:ubiquinone reductase (H(+)-translocating) inhibitors NADH:ubiquinone reductase (H+-translocating) inhibitor NADH:ubiquinone reductase inhibitor coenzyme Q reductase complex 1 dehydrogenase inhibitor complex I (NADH:Q1 oxidoreductase) inhibitors complex I (electron transport chain) inhibitors complex I (mitochondrial electron transport) inhibitors dihydronicotinamide adenine dinucleotide-coenzyme Q reductase inhibitor electron transfer complex I inhibitor electron transfer complex I inhibitors mitochondrial electron transport complex 1 inhibitor mitochondrial electron transport complex I inhibitor mitochondrial electron transport complex I inhibitors reduced nicotinamide adenine dinucleotide-coenzyme Q reductase inhibitor reduced nicotinamide adenine dinucleotide-coenzyme Q reductase inhibitors type 1 dehydrogenase inhibitor type 1 dehydrogenase inhibitors ubiquinone reductase inhibitor ubiquinone reductase inhibitors EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor CHEBI:38545 rosuvastatin (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid (3R,5S,6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid rosuvastatin rosuvastatin CHEBI:38623 EC 1.4.3.4 (monoamine oxidase) inhibitor EC 1.4.3.4 (monoamine oxidase) inhibitors EC 1.4.3.4 inhibitor EC 1.4.3.4 inhibitors MAO A inhibitor MAO A inhibitors MAO B inhibitor MAO B inhibitors MAO inhibitor MAO inhibitors MAO-A inhibitor MAO-A inhibitors MAO-B inhibitor MAO-B inhibitors adrenalin oxidase inhibitor adrenalin oxidase inhibitors adrenaline oxidase inhibitor adrenaline oxidase inhibitors amine oxidase (flavin-containing) inhibitor amine oxidase (flavin-containing) inhibitors amine:oxygen oxidoreductase (deaminating) (flavin-containing) inhibitor amine:oxygen oxidoreductase (deaminating) (flavin-containing) inhibitors amine:oxygen oxidoreductase (deaminating) inhibitor amine:oxygen oxidoreductase (deaminating) inhibitors epinephrine oxidase inhibitor epinephrine oxidase inhibitors monoamine oxidase (EC 1.4.3.4) inhibitor monoamine oxidase (EC 1.4.3.4) inhibitors monoamine oxidase A inhibitor monoamine oxidase A inhibitors monoamine oxidase B inhibitor monoamine oxidase B inhibitors monoamine oxidase inhibitor monoamine oxidase inhibitors monoamine:O2 oxidoreductase (deaminating) inhibitor monoamine:O2 oxidoreductase (deaminating) inhibitors serotonin deaminase inhibitor serotonin deaminase inhibitors tyraminase inhibitor tyraminase inhibitors tyramine oxidase inhibitor tyramine oxidase inhibitors EC 1.4.3.4 (monoamine oxidase) inhibitor CHEBI:38632 membrane transport modulator membrane transport modulators membrane transport modulator CHEBI:38633 sodium channel blocker Na channel blocker sodium channel blockers sodium channel blocker CHEBI:38634 voltage-gated sodium channel blocker Nav channel blocker Nav channel blockers voltage-dependent sodium channel blockers voltage-gated sodium channel blocker CHEBI:38637 tyrosine kinase inhibitor TKI inhibitor TKI inhibitors protein tyrosine kinase inhibitor protein tyrosine kinase inhibitors tyrosine kinase inhibitors tyrphostin tyrphostins tyrosine kinase inhibitor CHEBI:38706 pediculicide pediculicides pediculicide CHEBI:38807 calcium channel agonist calcium channel activator calcium channel activators calcium channel agonists calcium channel agonist CHEBI:38808 calcium channel modulator calcium channel modulators calcium channel modulator CHEBI:38809 ryanodine receptor modulator RyR modulator ryanodine receptor modulators ryanodine-sensitive calcium channel modulator ryanodine-sensitive calcium-release channel modulator ryanodine receptor modulator CHEBI:38828 nonionic surfactant non-ionic surfactant nonionic surfactants nonionic surfactant CHEBI:38849 blood substitute artificial blood blood substitutes oxygen carrier blood substitute CHEBI:38867 anaesthetic Anaesthetika Anaesthetikum anaesthetic anaesthetics anesthetic agent anesthetic drug anesthetics anaesthetic CHEBI:38869 general anaesthetic Allgemeinanaesthetika Allgemeinanaesthetikum general anaesthetic general anaesthetics general anesthetics general anaesthetic CHEBI:38870 inhalation anaesthetic Inhalationsanaesthetika Inhalationsanaesthetikum Inhalationsnarkotika Inhalationsnarkotikum anesthetic gases inhalation anesthetics inhalation anaesthetic CHEBI:38877 intravenous anaesthetic i.v.-Anaesthetika i.v.-Anaesthetikum intravenous anesthetics intravenous anaesthetic CHEBI:38941 schistosomicide drug antischistosoma antischistosomal drug schistosomicide schistosomicide drugs schistosomicides schistosomicide drug CHEBI:38956 ectoparasiticide ectoparasiticides ectoparasiticide CHEBI:38999 GABA-gated chloride channel antagonist GABA-gated chloride channel antagonists GABA-gated chloride channel antagonist CHEBI:39000 sodium channel modulator sodium channel modulators sodium channel modulator CHEBI:39011 Good's buffer substance Good buffer substance Good's buffer Good's buffers Good's buffer substance CHEBI:39116 pyrethroid ester insecticide pyrethroid ester insecticides pyrethroid ester insecticide CHEBI:39141 Bronsted acid Bronsted acid Bronsted-Saeure acide de Bronsted donneur d'hydron hydron donor Bronsted acid CHEBI:39142 Bronsted base Bronsted base Bronsted-Base accepteur d'hydron base de Bronsted hydron acceptor Bronsted base CHEBI:39143 Lewis acid Lewis acid Lewis-Saeure accepteur d'une paire d'electrons acide de Lewis electron acceptor electron-pair acceptor Lewis acid CHEBI:39144 Lewis base Lewis base Lewis-Base base de Lewis donneur d'une paire d'electrons electron donor Lewis base CHEBI:39208 antibiotic insecticide antibiotic insecticide CHEBI:39215 antibiotic pesticide antibiotic pesticide CHEBI:39216 antibiotic acaricide antibiotic acaricide CHEBI:39217 antibiotic nematicide antibiotic nematicide CHEBI:39259 pyrethroid ester acaricide pyrethroid ester acaricide CHEBI:39276 fumigant fumigant pesticide fumigants fumigant CHEBI:39277 fumigant insecticide fumigant insecticides fumigant insecticide CHEBI:39301 sulfite ester acaricide sulfite ester acaricide CHEBI:39316 mite growth regulator mite growth regulator CHEBI:39317 growth regulator growth regulators growth regulator CHEBI:39318 tetrazine acaricide tetrazine acaricide CHEBI:39351 pyrethroid ether insecticide pyrethroid ether insecticides pyrethroid ether insecticide CHEBI:39369 pyrethroid ether acaricide pyrethroid ether acaricides pyrethroid ether acaricide CHEBI:39378 homopteran inhibitor of chitin biosynthesis homopteran inhibitor of chitin biosynthesis CHEBI:39379 lepidopteran inhibitor of chitin biosynthesis lepidopteran inhibitor of chitin biosynthesis CHEBI:39412 bridged diphenyl acaricide bridged diphenyl acaricides bridged diphenyl acaricide CHEBI:39415 dinitrophenol insecticide dinitrophenol insecticides dinitrophenol insecticide CHEBI:39442 fluorescent probe fluorescent probe CHEBI:39456 antiglaucoma drug anti-glaucoma agent anti-glaucoma agents anti-glaucoma drug anti-glaucoma drugs antiglaucoma agent antiglaucoma drugs antiglaucoma drug CHEBI:4470 dextromethorphan (+)-3-methoxy-N-methylmorphinan (+)-dextromethorphan (4aS,10S,10aS)-6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene (9alpha,13alpha,14alpha)-3-methoxy-17-methylmorphinan 3-methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan Albutussin Antussan BA 2666 BA-2666 Balminil DM Benylin DM Calmylin D-methorphan DXM Delsym Dextromorphan Medicon Romilar Tusilan d-Methorphan destrometerfano dextromethorfan dextromethorphan dextromethorphane dextromethorphanum dextrometorfano dextromethorphan CHEBI:44915 propofol 2,6-BIS(1-METHYLETHYL)PHENOL 2,6-Diisopropylphenol 2,6-bis(1-methylethyl)phenol 2,6-bis(propan-2-yl)phenol Diprivan Disoprivan Disoprofol Propofol Rapinovet propofol propofolum propofol CHEBI:45735 troleandomycin (3R,5R,6S,7R,8R,11R,12S,13R,14S,15S)-12-[(4-O-acetyl-2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)oxy]-14-{[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy}-5,7,8,11,13,15-hexamethyl-4,10-dioxo-1,9-dioxaspiro[2.13]hexadecan-6-yl acetate Oleandocetine Oleandomycin triacetate Oleandomycin triacetyl ester Triacetyloleandomycin Triacetyloleandomycinum Tribiocillina Triocetin troleandomicina troleandomycin troleandomycine troleandomycinum troleandomycin CHEBI:45951 trifluoperazine 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine Trifluoperazine trifluoperazina trifluoperazine trifluoperazinum trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine trifluoroperazine trifluperazine trifluoperazine CHEBI:46787 solvent Loesungsmittel solvant solvents solvent CHEBI:47381 diclofenac 2-((2,6-dichlorophenyl)amino)benzeneacetic acid 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid Diclofenac [2-(2,6-dichloroanilino)phenyl]acetic acid diclofenac diclofenac acid diclofenaco diclofenacum diclofenamic acid {2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid diclofenac CHEBI:47867 indicator Indikator indicator CHEBI:47868 photosensitizing agent photosensitising agent photosensitizing agent CHEBI:47958 nicotinic acetylcholine receptor agonist muscarinic agonists nicotinic acetylcholine receptor agonists nicotinic agonist nicotinic agonists nicotinic acetylcholine receptor agonist CHEBI:48001 protein synthesis inhibitor protein synthesis antagonist protein synthesis antagonists protein synthesis inhibitors protein synthesis inhibitor CHEBI:48218 antiseptic drug antiseptic antiseptic agent antiseptic agents antiseptics local antiinfective agents local microbicides topical antiinfective agents topical microbicides antiseptic drug CHEBI:48219 disinfectant Desinfektionsmittel desinfectant disinfectants disinfecting agent disinfectant CHEBI:48278 serotonergic drug serotonergic agents serotonergic drugs serotonin drugs serotonergic drug CHEBI:48279 serotonergic antagonist 5-HT antagonists 5-hydroxytryptamine antagonists antiserotonergic agents serotonin antagonists serotonin blockaders serotonergic antagonist CHEBI:48318 fragrance Parfuem aroma arome essence parfum perfume scent fragrance CHEBI:48353 serine proteinase inhibitor serine proteinase inhibitors serine proteinase inhibitor CHEBI:48354 polar solvent polar solvent polar solvents polar solvent CHEBI:48355 non-polar solvent non-polar solvent CHEBI:48356 protic solvent protogenic solvent protic solvent CHEBI:48357 aprotic solvent aprotic solvent CHEBI:48358 polar aprotic solvent dipolar aprotic solvent polar aprotic solvent CHEBI:48359 protophilic solvent HBA solvent hydrogen bond acceptor solvent protophilic solvent protophilic solvent CHEBI:48360 amphiprotic solvent amphiprotic solvent amphiprotic solvent CHEBI:48406 EC 2.1.1.6 (catechol O-methyltransferase) inhibitor COMT inhibitor COMT inhibitors EC 2.1.1.6 (catechol O-methyltransferase) inhibitors EC 2.1.1.6 inhibitor EC 2.1.1.6 inhibitors S-adenosyl-L-methionine:catechol O-methyltransferase inhibitor S-adenosyl-L-methionine:catechol O-methyltransferase inhibitors catechol O-methyltransferase (EC 2.1.1.6) inhibitor catechol O-methyltransferase (EC 2.1.1.6) inhibitors catechol O-methyltransferase inhibitor catechol O-methyltransferase inhibitors catechol methyltransferase inhibitor catechol methyltransferase inhibitors catecholamine O-methyltransferase inhibitor catecholamine O-methyltransferase inhibitors EC 2.1.1.6 (catechol O-methyltransferase) inhibitor CHEBI:48407 antiparkinson drug antiparkinson agent antiparkinson drug CHEBI:48422 angiogenesis inhibitor angiogenesis antagonist angiostatic agents anti-angiogenic agent angiogenesis inhibitor CHEBI:48425 topical anaesthetic topical anaesthetics topical anesthetic topical anaesthetic CHEBI:48525 calcimimetic calcimimetics calcimimetic CHEBI:48539 alpha-adrenergic drug alpha-adrenergic drugs alpha-adrenergic drug CHEBI:48540 beta-adrenergic drug beta-adrenergic drugs beta-adrenergic drug CHEBI:48550 EC 1.1.1.21 (aldehyde reductase) inhibitor ALR2 inhibitor ALR2 inhibitors EC 1.1.1.21 (aldehyde reductase) inhibitors EC 1.1.1.21 inhibitor EC 1.1.1.21 inhibitors NADPH-aldopentose reductase inhibitor NADPH-aldopentose reductase inhibitors NADPH-aldose reductase inhibitor NADPH-aldose reductase inhibitors aldehyde reductase (EC 1.1.1.21) inhibitor aldehyde reductase (EC 1.1.1.21) inhibitors aldehyde reductase inhibitor aldehyde reductase inhibitors alditol:NAD(P)(+) 1-oxidoreductase inhibitor alditol:NAD(P)(+) 1-oxidoreductase inhibitors alditol:NADP oxidoreductase inhibitor alditol:NADP oxidoreductase inhibitors alditol:NADP(+) 1-oxidoreductase inhibitor alditol:NADP(+) 1-oxidoreductase inhibitors aldose reductase inhibitor aldose reductase inhibitors polyol dehydrogenase (NADP(+)) inhibitor polyol dehydrogenase (NADP(+)) inhibitors EC 1.1.1.21 (aldehyde reductase) inhibitor CHEBI:48560 dopaminergic agent dopamine agent dopamine agents dopamine drug dopamine drugs dopaminergic agents dopaminergic agent CHEBI:48561 dopaminergic antagonist dopamine antagonist dopamine blocker dopamine receptor antagonist dopaminergic antagonists dopaminergic antagonist CHEBI:48578 radical scavenger free radical scavengers free-radical scavenger radical scavenger CHEBI:48668 gamma-secretase modulator Gamma-secretase modulator Gamma-secretase modulators gamma secretase modulator gamma secretase modulators gamma-secretase modulator gamma-secretase modulators gamma-secretase modulator CHEBI:48675 antifibrinolytic drug antifibrinolytic agent antifibrinolytic agents antifibrinolytic drugs antifibrinolytic drug CHEBI:48676 fibrin modulating drug fibrin modulating agent fibrin modulating agents fibrin modulating drugs fibrin modulating drug CHEBI:48705 agonist agonist agonista agoniste agonists agonist CHEBI:48706 antagonist antagonist antagonista antagoniste antagonists antagonist CHEBI:4873 estropipate Estropipate Piperazine estrone sulfate estropipate CHEBI:48873 cholinergic antagonist Anticholinergika Anticholinergikum acetylcholine antagonists acetylcholine receptor antagonist agent anticholinergique agente anticolinergico agentes anticolinergicos anticholinergic agents anticholinergics anticholinergiques anticolinergicos cholinergic-blocking agents cholinergic antagonist CHEBI:48876 muscarinic antagonist Antimuskarinika Antimuskarinikum agente antimuscarinico agentes antimuscarinicos agents antimuscariniques antimuscarinic agents antimuscarinicos muscarinic acetylcholine receptor antagonist muscarinic antagonists muscarinic antagonist CHEBI:48878 nicotinic antagonist agente antinicotinico agentes antinicotinicos agents antinicotiniques antinicotinicos nicotinic acetylcholine receptor antagonist nicotinic acetylcholine receptor antagonists nicotinic antagonists nicotinic cholinergic antagonist nicotinic cholinergic antagonists nicotinic antagonist CHEBI:48887 bile acid metabolite bile acid metabolites bile salt metabolite bile acid metabolite CHEBI:49020 hormone antagonist hormone antagonists hormone antagonist CHEBI:49023 prostaglandin antagonist prostaglandin inhibitor prostaglandin antagonist CHEBI:49103 drug metabolite drug metabolites drug metabolite CHEBI:49110 peripheral nervous system drug peripheral nervous system agent peripheral nervous system drugs peripheral nervous system drug CHEBI:49159 leukotriene antagonist LTRA leukotriene antagonists leukotriene receptor antagonist leukotriene receptor antagonists leukotriene antagonist CHEBI:49167 anti-asthmatic drug anti-asthmatic agent anti-asthmatic agents anti-asthmatic drugs anti-asthmatic drug CHEBI:49200 EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor (K(+) + H(+))-ATPase inhibitor (K(+) + H(+))-ATPase inhibitors ATP phosphohydrolase (H(+)/K(+)-exchanging) inhibitor ATP phosphohydrolase (H(+)/K(+)-exchanging) inhibitors EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitors EC 3.6.3.10 inhibitor EC 3.6.3.10 inhibitors H(+)-K(+)-ATPase inhibitor H(+)-K(+)-ATPase inhibitors H(+)/K(+)-ATPase inhibitor H(+)/K(+)-ATPase inhibitors H(+)/K(+)-exchanging ATPase inhibitor H(+)/K(+)-exchanging ATPase inhibitors H,K-ATPase inhibitor H,K-ATPase inhibitors proton pump inhibitor proton pump inhibitors EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor CHEBI:49201 anti-ulcer drug anti-ulcer agent anti-ulcer agents anti-ulcer drugs anti-ulcer drug CHEBI:49205 CETP inhibitor CETP inhibitors cholesteryl ester transfer protein inhibitor CETP inhibitor CHEBI:49323 contraceptive drug contraceptive agent contraceptive drugs contraceptive drug CHEBI:49324 female contraceptive drug female contraceptive agent female contraceptive drugs female contraceptive drug CHEBI:49325 oral contraceptive oral contraceptives oral contraceptive CHEBI:49326 synthetic oral contraceptive synthetic oral contraceptives synthetic oral contraceptive CHEBI:50103 excitatory amino acid agonist excitatory amino acid agonists excitatory amino acid receptor agonist excitatory amino acid receptor agonists excitatory amino acid agonist CHEBI:50112 sex hormone Geschlechtshormon Geschlechtshormone Sexualhormon Sexualhormone hormone sexuelle hormones sexuelles sex hormones sex hormone CHEBI:50113 androgen Androgen Androgene androgene androgenes androgeno androgenos androgens androgen CHEBI:50114 estrogen Estrogene Oestrogen Oestrogene estrogene estrogenes estrogenes Hormon estrogeno estrogenos estrogens oestrogen oestrogene oestrogenes oestrogens estrogen CHEBI:50137 mu-opioid receptor antagonist mu-opioid antagonist mu-opioid antagonists mu-opioid receptor antagonists mu-opioid receptor antagonist CHEBI:50141 bronchoconstrictor agent bronchoconstrictor agents bronchoconstrictor drug bronchoconstrictor agent CHEBI:50176 keratolytic drug desquamating agent keratolytic agent keratolytic drugs skin-peeling agent keratolytic drug CHEBI:50177 dermatologic drug dermatologic agent dermatologic drugs dermatological agent dermatologic drug CHEBI:50183 P450 inhibitor CYP2D6 inhibitor CYP2D6 inhibitors P450 inhibitors cytochrome P450 inhibitor cytochrome P450 inhibitors P450 inhibitor CHEBI:50184 ion transport inhibitor ion transport inhibitors ion-transport inhibitor ion-transport inhibitors ion transport inhibitor CHEBI:50185 fatty acid synthesis inhibitor fatty acid synthesis inhibitors fatty acid synthesis inhibitor CHEBI:50188 provitamin provitamins provitamin CHEBI:50218 EC 3.1.4.* (phosphoric diester hydrolase) inhibitor EC 3.1.4.* (phosphoric diester hydrolase) inhibitors phosphodiesterase inhibitor phosphodiesterase inhibitors phosphoric diester hydrolase (EC 3.1.4.*) inhibitor phosphoric diester hydrolase (EC 3.1.4.*) inhibitors phosphoric diester hydrolase inhibitor phosphoric diester hydrolase inhibitors EC 3.1.4.* (phosphoric diester hydrolase) inhibitor CHEBI:50241 cholinesterase reactivator cholinesterase reactivators cholinesterase reactivator CHEBI:50242 enzyme reactivator enzyme reactivators enzyme reactivator CHEBI:50247 antidote antidotes antidote CHEBI:50248 hematologic agent hematologic agents hematologic agent CHEBI:50249 anticoagulant anticoagulante anticoagulants anticoagulant CHEBI:50266 prodrug Prodrugs prodrug CHEBI:50267 protective agent chemoprotectant chemoprotectants chemoprotective agent chemoprotective agents protective agents protective agent CHEBI:50268 GABA modulator GABA modulators GABA modulator CHEBI:50269 EC 1.1.1.1 (alcohol dehydrogenase) inhibitor ADH inhibitor ADH inhibitors EC 1.1.1.1 (alcohol dehydrogenase) inhibitors EC 1.1.1.1 inhibitor EC 1.1.1.1 inhibitors NAD-dependent alcohol dehydrogenase inhibitor NAD-dependent alcohol dehydrogenase inhibitors NAD-specific aromatic alcohol dehydrogenase inhibitor NAD-specific aromatic alcohol dehydrogenase inhibitors NADH-alcohol dehydrogenase inhibitor NADH-alcohol dehydrogenase inhibitors NADH-aldehyde dehydrogenase inhibitor NADH-aldehyde dehydrogenase inhibitors alcohol dehydrogenase (EC 1.1.1.1) inhibitor alcohol dehydrogenase (EC 1.1.1.1) inhibitors alcohol dehydrogenase (NAD) inhibitor alcohol dehydrogenase (NAD) inhibitors alcohol dehydrogenase inhibitor alcohol dehydrogenase inhibitors alcohol:NAD+ oxidoreductase inhibitor alcohol:NAD+ oxidoreductase inhibitors aldehyde reductase inhibitor aldehyde reductase inhibitors aliphatic alcohol dehydrogenase inhibitor aliphatic alcohol dehydrogenase inhibitors ethanol dehydrogenase inhibitor ethanol dehydrogenase inhibitors primary alcohol dehydrogenase inhibitor primary alcohol dehydrogenase inhibitors yeast alcohol dehydrogenase inhibitor yeast alcohol dehydrogenase inhibitors EC 1.1.1.1 (alcohol dehydrogenase) inhibitor CHEBI:50275 esomeprazole (-)-omeprazole (S)-(-)-omeprazole (S)-omeprazole 5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Alenia Escz Esofag Inexium paranova esomeprazol esomeprazole esomeprazolum esomeprazole CHEBI:50276 EC 5.99.1.2 (DNA topoisomerase) inhibitor DNA topoisomerase inhibitor DNA topoisomerase inhibitors EC 5.99.1.2 (DNA topoisomerase) inhibitors EC 5.99.1.2 (topoisomerase I) inhibitor EC 5.99.1.2 (topoisomerase I) inhibitors EC 5.99.1.2 inhibitor EC 5.99.1.2 inhibitors topoisomerase I (EC 5.99.1.2) inhibitor topoisomerase I (EC 5.99.1.2) inhibitors topoisomerase I inhibitor topoisomerase I inhibitors type I DNA topoisomerase inhibitor type I DNA topoisomerase inhibitors EC 5.99.1.2 (DNA topoisomerase) inhibitor CHEBI:50370 parasympatholytic parasympatholytics parasympatholytic CHEBI:50382 EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor EC 2.4.1.80 (ceramide glucosyltransferase) inhibitors EC 2.4.1.80 inhibitor EC 2.4.1.80 inhibitors UDP-glucose:N-acylsphingosine D-glucosyltransferase inhibitor UDP-glucose:N-acylsphingosine D-glucosyltransferase inhibitors UDP-glucose:ceramide glucosyltransferase inhibitor UDP-glucose:ceramide glucosyltransferase inhibitors ceramide glucosyltransferase (EC 2.4.1.80) inhibitor ceramide glucosyltransferase (EC 2.4.1.80) inhibitors ceramide glucosyltransferase inhibitor ceramide glucosyltransferase inhibitors ceramide:UDP-glucose glucosyltransferase inhibitor ceramide:UDP-glucose glucosyltransferase inhibitors ceramide:UDPGlc glucosyltransferase inhibitor ceramide:UDPGlc glucosyltransferase inhibitors glucosylceramide synthase inhibitor glucosylceramide synthase inhibitors uridine diphosphoglucose-ceramide glucosyltransferase inhibitor uridine diphosphoglucose-ceramide glucosyltransferase inhibitors EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor CHEBI:50390 EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor DT diaphorase inhibitor EC 1.6.5.2 (NAD(P)H dehydrogenase (quinone)) inhibitor EC 1.6.5.2 (NAD(P)H dehydrogenase (quinone)) inhibitors EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitors EC 1.6.5.2 inhibitor EC 1.6.5.2 inhibitors NAD(P)H dehydrogenase (quinone) (EC 1.6.5.2) inhibitor NAD(P)H dehydrogenase (quinone) (EC 1.6.5.2) inhibitors NAD(P)H dehydrogenase (quinone) inhibitor NAD(P)H dehydrogenase (quinone) inhibitors NAD(P)H dehydrogenase inhibitor NAD(P)H dehydrogenase inhibitors NAD(P)H menadione reductase inhibitor NAD(P)H menadione reductase inhibitors NAD(P)H-quinone dehydrogenase inhibitor NAD(P)H-quinone dehydrogenase inhibitors NAD(P)H-quinone oxidoreductase inhibitor NAD(P)H-quinone oxidoreductase inhibitors NAD(P)H2 dehydrogenase (quinone) inhibitor NAD(P)H2 dehydrogenase (quinone) inhibitors NAD(P)H: menadione oxidoreductase inhibitor NAD(P)H: menadione oxidoreductase inhibitors NAD(P)H:(quinone-acceptor)oxidoreductase inhibitor NAD(P)H:(quinone-acceptor)oxidoreductase inhibitors NAD(P)H:quinone oxidoreductase inhibitor NAD(P)H:quinone oxidoreductase inhibitors NADH-menadione reductase inhibitor NADH-menadione reductase inhibitors NQO1 inhibitor NQO1 inhibitors QR1 inhibitor QR1 inhibitors dehydrogenase, reduced nicotinamide adenine dinucleotide (phosphate, quinone) inhibitor dehydrogenase, reduced nicotinamide adenine dinucleotide (phosphate, quinone) inhibitors diaphorase inhibitor diaphorase inhibitors flavoprotein NAD(P)H-quinone reductase inhibitor flavoprotein NAD(P)H-quinone reductase inhibitors menadione oxidoreductase inhibitor menadione oxidoreductase inhibitors menadione reductase inhibitor menadione reductase inhibitors naphthoquinone reductase inhibitor naphthoquinone reductase inhibitors p-benzoquinone reductase inhibitor p-benzoquinone reductase inhibitors phylloquinone reductase inhibitor phylloquinone reductase inhibitors quinone reductase inhibitor quinone reductase inhibitors reduced NAD(P)H dehydrogenase inhibitor reduced NAD(P)H dehydrogenase inhibitors reduced nicotinamide-adenine dinucleotide (phosphate) dehydrogenase inhibitor reduced nicotinamide-adenine dinucleotide (phosphate) dehydrogenase inhibitors viologen accepting pyridine nucleotide oxidoreductase inhibitor viologen accepting pyridine nucleotide oxidoreductase inhibitors vitamin K reductase inhibitor vitamin K reductase inhibitors vitamin-K reductase inhibitor vitamin-K reductase inhibitors EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor CHEBI:50406 probe probe CHEBI:50407 acid-base indicator Saeure-Base-Indikator Saeure-Base-Indikatoren acid-base indicator indicador acido-base indicateur acide-base acid-base indicator CHEBI:50408 visual indicator indicador visual indicateur visuel visual indicator visual indicator CHEBI:50409 adsorption indicator adsorption indicator indicador de adsorcion indicateur par adsorption adsorption indicator CHEBI:50410 colour indicator colour indicator indicador de color indicateur colore indicateurs colores colour indicator CHEBI:50411 one-colour indicator indicador monocolor indicador monocromico indicateur monocolore one-colour indicator one-colour indicator CHEBI:50412 two-colour indicator indicador bicolor indicateur bicolore two-colour indicator two-colour indicator CHEBI:50423 EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor EC 1.6.3.1 inhibitor EC 1.6.3.1 inhibitors EC 1.6.3.1. (NAD(P)H oxidase (H2O2-forming)) inhibitor EC 1.6.3.1. (NAD(P)H oxidase (H2O2-forming)) inhibitors EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitors NAD(P)H oxidase (H2O2-forming) (EC 1.6.3.1) inhibitor NAD(P)H oxidase (H2O2-forming) (EC 1.6.3.1) inhibitors NAD(P)H oxidase (H2O2-forming) inhibitor NAD(P)H oxidase (H2O2-forming) inhibitors NAD(P)H oxidase inhibitor NAD(P)H oxidase inhibitors NAD(P)H:oxygen oxidoreductase (H2O2-forming) inhibitor NAD(P)H:oxygen oxidoreductase (H2O2-forming) inhibitors NAD(P)H:oxygen oxidoreductase inhibitor NAD(P)H:oxygen oxidoreductase inhibitors NADPH oxidase inhibitor NADPH oxidase inhibitors THOX2 inhibitor THOX2 inhibitors ThOX inhibitor ThOX inhibitors dual oxidase inhibitor dual oxidase inhibitors p138tox inhibitor p138tox inhibitors thyroid NADPH oxidase inhibitor thyroid NADPH oxidase inhibitors thyroid oxidase 2 inhibitor thyroid oxidase 2 inhibitors thyroid oxidase inhibitor thyroid oxidase inhibitors EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor CHEBI:50427 platelet aggregation inhibitor platelet aggregation inhibitors platelet aggregation inhibitor CHEBI:50433 platelet glycoprotein-IIb/IIIa receptor antagonist GPIIb/IIIa antagonist GPIIb/IIIa antagonists fibrinogen receptor antagonist fibrinogen receptor antagonists glycoprotein-IIb/IIIa receptor antagonist glycoprotein-IIb/IIIa receptor antagonists platelet glycoprotein-IIb/IIIa receptor antagonists platelet glycoprotein-IIb/IIIa receptor antagonist CHEBI:50444 adenosine phosphodiesterase inhibitor adenosine phosphodiesterase inhibitor CHEBI:50445 EC 3.5.4.4 (adenosine deaminase) inhibitor ADA inhibitor EC 3.5.4.4 (adenosine deaminase) inhibitors EC 3.5.4.4 inhibitor EC 3.5.4.4 inhibitors adenosine aminohydrolase inhibitor adenosine aminohydrolase inhibitors adenosine deaminase (EC 3.5.4.4) inhibitor adenosine deaminase (EC 3.5.4.4) inhibitors adenosine deaminase inhibitor adenosine deaminase inhibitors deoxyadenosine deaminase inhibitor deoxyadenosine deaminase inhibitors EC 3.5.4.4 (adenosine deaminase) inhibitor CHEBI:50469 EC 3.1.1.4 (phospholipase A2) inhibitor EC 3.1.1.4 (phospholipase A2) inhibitors EC 3.1.1.4 inhibitor EC 3.1.1.4 inhibitors lecithinase A inhibitor lecithinase A inhibitors phosphatidase inhibitor phosphatidase inhibitors phosphatidolipase inhibitor phosphatidolipase inhibitors phosphatidylcholine 2-acylhydrolase inhibitor phosphatidylcholine 2-acylhydrolase inhibitors phospholipase A inhibitor phospholipase A inhibitors phospholipase A2 (EC 3.1.1.4) inhibitor phospholipase A2 (EC 3.1.1.4) inhibitors phospholipase A2 inhibitor phospholipase A2 inhibitors EC 3.1.1.4 (phospholipase A2) inhibitor CHEBI:50502 EC 2.5.1.15 (dihydropteroate synthase) inhibitor (2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitor (2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitors 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitor 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitors 7,8-dihydropteroate synthase inhibitor 7,8-dihydropteroate synthase inhibitors 7,8-dihydropteroate synthetase inhibitor 7,8-dihydropteroate synthetase inhibitors 7,8-dihydropteroic acid synthetase inhibitor 7,8-dihydropteroic acid synthetase inhibitors DHPS inhibitor DHPS inhibitors EC 2.5.1.15 (dihydropteroate synthase) inhibitors EC 2.5.1.15 inhibitor EC 2.5.1.15 inhibitors dihydropteroate diphosphorylase inhibitor dihydropteroate diphosphorylase inhibitors dihydropteroate pyrophosphorylase inhibitor dihydropteroate pyrophosphorylase inhibitors dihydropteroate synthase (EC 2.5.1.15) inhibitor dihydropteroate synthase (EC 2.5.1.15) inhibitors dihydropteroate synthase inhibitor dihydropteroate synthase inhibitors dihydropteroate synthetase inhibitor dihydropteroate synthetase inhibitors dihydropteroic synthetase inhibitor dihydropteroic synthetase inhibitors EC 2.5.1.15 (dihydropteroate synthase) inhibitor CHEBI:50503 laxative aperient aperients laxante laxatives purgative purgatives laxative CHEBI:50504 osmotic diuretic osmotic diuretic CHEBI:50505 sweetening agent sweetener sweeteners sweetening agent CHEBI:50507 appetite depressant appetite depressant CHEBI:50509 potassium channel blocker potassium channel blocker CHEBI:50510 potassium channel modulator potassium channel modulator CHEBI:50513 mydriatic agent mydriatics mydriatic agent CHEBI:50514 vasoconstrictor agent vasoconstrictor agent CHEBI:50533 protein denaturant protein denaturant CHEBI:50566 nitric oxide donor NO donor NO donors NO generator NO generators NO releasing agent NO releasing agents nitric oxide donors nitric oxide generators nitric oxide releasing agent nitric oxide releasing agents nitric oxide donor CHEBI:50568 EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor 3',5'-cyclic nucleoside monophosphate phosphodiesterase inhibitor 3',5'-cyclic nucleoside monophosphate phosphodiesterase inhibitors 3',5'-cyclic-nucleotide 5'-nucleotidohydrolase inhibitor 3',5'-cyclic-nucleotide 5'-nucleotidohydrolase inhibitors 3',5'-cyclic-nucleotide phosphodiesterase inhibitor 3',5'-cyclic-nucleotide phosphodiesterase inhibitors 3',5'-cyclonucleotide phosphodiesterase inhibitor 3',5'-cyclonucleotide phosphodiesterase inhibitors 3',5'-nucleotide phosphodiesterase inhibitor 3',5'-nucleotide phosphodiesterase inhibitors 3': 5'-monophosphate phosphodiesterase (cyclic CMP) inhibitor 3': 5'-monophosphate phosphodiesterase (cyclic CMP) inhibitors 3':5'-cyclic nucleotide 5'-nucleotidohydrolase inhibitor 3':5'-cyclic nucleotide 5'-nucleotidohydrolase inhibitors EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitors EC 3.1.4.17 inhibitor EC 3.1.4.17 inhibitors PDE inhibitor PDE inhibitors cyclic 3',5'-mononucleotide phosphodiesterase inhibitor cyclic 3',5'-mononucleotide phosphodiesterase inhibitors cyclic 3',5'-nucleotide phosphodiesterase inhibitor cyclic 3',5'-nucleotide phosphodiesterase inhibitors cyclic 3',5'-phosphodiesterase inhibitor cyclic 3',5'-phosphodiesterase inhibitors cyclic 3',5-nucleotide monophosphate phosphodiesterase inhibitor cyclic 3',5-nucleotide monophosphate phosphodiesterase inhibitors cyclic AMP phosphodiesterase inhibitor cyclic AMP phosphodiesterase inhibitors cyclic nucleotide phosphodiesterase inhibitor cyclic nucleotide phosphodiesterase inhibitors cytidine 3':5'-monophosphate phosphodiesterase (cyclic CMP) inhibitor cytidine 3':5'-monophosphate phosphodiesterase (cyclic CMP) inhibitors nucleoside 3',5'-cyclic phosphate diesterase inhibitor nucleoside 3',5'-cyclic phosphate diesterase inhibitors nucleoside-3',5-monophosphate phosphodiesterase inhibitor nucleoside-3',5-monophosphate phosphodiesterase inhibitors phosphodiesterase III inhibitor EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor CHEBI:50627 EC 3.2.1.1 (alpha-amylase) inhibitor 1,4-alpha-D-glucan glucanohydrolase inhibitor 1,4-alpha-D-glucan glucanohydrolase inhibitors 4-alpha-D-glucan glucanohydrolase inhibitor 4-alpha-D-glucan glucanohydrolase inhibitors EC 3.2.1.1 (alpha-amylase) inhibitors EC 3.2.1.1 inhibitor EC 3.2.1.1 inhibitors Taka-amylase A inhibitor Taka-amylase A inhibitors alpha-amylase (EC 3.2.1.1) inhibitor alpha-amylase (EC 3.2.1.1) inhibitors alpha-amylase inhibitor alpha-amylase inhibitors endoamylase inhibitor endoamylase inhibitors glycogenase inhibitor glycogenase inhibitors EC 3.2.1.1 (alpha-amylase) inhibitor CHEBI:50629 cyclooxygenase 2 inhibitor COX-2 inhibitor COX-2 inhibitors PGHS-2 inhibitor PGHS-2 inhibitors cyclo-oxygenase 2 inhibitor cyclo-oxygenase 2 inhibitors cyclo-oxygenase-2 inhibitor cyclo-oxygenase-2 inhibitors cyclooxygenase 2 inhibitors cyclooxygenase-2 inhibitor cyclooxygenase-2 inhibitors prostaglandin H synthase-2 inhibitor prostaglandin H synthase-2 inhibitors prostaglandin-endoperoxide synthase 2 inhibitor prostaglandin-endoperoxide synthase 2 inhibitors cyclooxygenase 2 inhibitor CHEBI:50630 cyclooxygenase 1 inhibitor COX-1 inhibitor COX-1 inhibitors PTGS1 inhibitor PTGS1 inhibitors cyclo-oxygenase 1 inhibitor cyclo-oxygenase 1 inhibitors cyclooxygenase 1 inhibitors cyclooxygenase-1 inhibitor cyclooxygenase-1 inhibitors prostaglandin G/H synthase 1 inhibitor prostaglandin G/H synthase 1 inhibitors prostaglandin H2 synthase 1 inhibitor prostaglandin H2 synthase 1 inhibitors prostaglandin-endoperoxide synthase 1 inhibitor prostaglandin-endoperoxide synthase 1 inhibitors cyclooxygenase 1 inhibitor CHEBI:50635 EC 3.5.1.5 (urease) inhibitor EC 3.5.1.5 (urease) inhibitors EC 3.5.1.5 inhibitor EC 3.5.1.5 inhibitors urea amidohydrolase inhibitor urea amidohydrolase inhibitors urease (EC 3.5.1.5) inhibitor urease (EC 3.5.1.5) inhibitors urease inhibitor urease inhibitors EC 3.5.1.5 (urease) inhibitor CHEBI:50643 EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor (2E,6E)-farnesyl diphosphate synthetase inhibitor (2E,6E)-farnesyl diphosphate synthetase inhibitors DMAPP:IPP-dimethylallyltransferase inhibitor DMAPP:IPP-dimethylallyltransferase inhibitors EC 2.5.1.1 (dimethylallyltranstransferase) inhibitors EC 2.5.1.1 inhibitor EC 2.5.1.1 inhibitors dimethylallyl-diphosphate:isopentenyl-diphosphate dimethylallyltranstransferase inhibitor dimethylallyl-diphosphate:isopentenyl-diphosphate dimethylallyltranstransferase inhibitors dimethylallyltransferase inhibitor dimethylallyltransferase inhibitors dimethylallyltranstransferase (EC 2.5.1.1) inhibitor dimethylallyltranstransferase (EC 2.5.1.1) inhibitors dimethylallyltranstransferase inhibitor dimethylallyltranstransferase inhibitors diprenyltransferase inhibitor diprenyltransferase inhibitors geranyl pyrophosphate synthase inhibitor geranyl pyrophosphate synthase inhibitors geranyl pyrophosphate synthetase inhibitor geranyl pyrophosphate synthetase inhibitors geranyl-diphosphate synthase inhibitor geranyl-diphosphate synthase inhibitors prenyltransferase inhibitor prenyltransferase inhibitors trans-farnesyl pyrophosphate synthetase inhibitor trans-farnesyl pyrophosphate synthetase inhibitors EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor CHEBI:50646 bone density conservation agent anti-osteopenia agent anti-osteopenia agents anti-osteopenia drug anti-osteopenia drugs anti-osteoporosis agent anti-osteoporosis agents anti-osteoporosis drug anti-osteoporosis drugs anti-osteoporotic anti-osteoporotic agent anti-osteoporotic agents anti-osteoporotic drug anti-osteoporotic drugs anti-osteoporotics antiosteoporotic antiosteoporotics bone density conservation agents bone density conservation drug bone density conservation drugs bone density conservation agent CHEBI:50664 matrix metalloproteinase inhibitor MMPI matrix metalloproteinase inhibitors matrix metalloproteinase inhibitor CHEBI:50671 antithyroid drug antithyroid agent antithyroid agents antithyroid drugs antithyroid drug CHEBI:50683 EC 1.5.1.3 (dihydrofolate reductase) inhibitor 7,8-dihydrofolate reductase inhibitor 7,8-dihydrofolate reductase inhibitors DHFR inhibitor DHFR inhibitors EC 1.5.1.3 (dihydrofolate reductase) inhibitors EC 1.5.1.3 inhibitor EC 1.5.1.3 inhibitors NADPH-dihydrofolate reductase inhibitor NADPH-dihydrofolate reductase inhibitors dihydrofolate reductase (EC 1.5.1.3) inhibitor dihydrofolate reductase (EC 1.5.1.3) inhibitors dihydrofolate reductase inhibitor dihydrofolate reductase inhibitors dihydrofolic acid reductase inhibitor dihydrofolic acid reductase inhibitors dihydrofolic reductase inhibitor dihydrofolic reductase inhibitors folic acid reductase inhibitor folic acid reductase inhibitors folic reductase inhibitor folic reductase inhibitors tetrahydrofolate dehydrogenase inhibitor tetrahydrofolate dehydrogenase inhibitors EC 1.5.1.3 (dihydrofolate reductase) inhibitor CHEBI:50684 cross-linking reagent cross-linking reagents cross-linking reagent CHEBI:50685 antitrichomonal drug antitrichomonal agent antitrichomonal drug CHEBI:50689 reproductive control drug reproductive control agent reproductive control drugs reproductive control drug CHEBI:50691 abortifacient abortifacient agent abortifacient agents abortifacient drug abortifacient drugs abortifacients abortifacient CHEBI:50696 EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitors EC 2.4.1.129 inhibitor EC 2.4.1.129 inhibitors PBP3 inhibitor PG-II inhibitor PG-II inhibitors [poly-N-acetyl-D-glucosaminyl-(1->4)-(N-acetyl-D-muramoylpentapeptide)]-diphosphoundecaprenol:[N-acetyl-D-glucosaminyl-(1->4)-N-acetyl-D-muramoylpentapeptide]-diphosphoundecaprenol disaccharidetransferase inhibitor [poly-N-acetyl-D-glucosaminyl-(1->4)-(N-acetyl-D-muramoylpentapeptide)]-diphosphoundecaprenol:[N-acetyl-D-glucosaminyl-(1->4)-N-acetyl-D-muramoylpentapeptide]-diphosphoundecaprenol disaccharidetransferase inhibitors bactoprenyldiphospho-N-acetylmuramoyl-(N-acetyl-D-glucosaminyl)-pentapeptide:peptidoglycan N-acetylmuramoyl-N-acetyl-D-glucosaminyltransferase inhibitor bactoprenyldiphospho-N-acetylmuramoyl-(N-acetyl-D-glucosaminyl)-pentapeptide:peptidoglycan N-acetylmuramoyl-N-acetyl-D-glucosaminyltransferase inhibitors penicillin binding protein 1B inhibitor penicillin binding protein 1B inhibitors penicillin binding protein 3 inhibitor penicillin binding protein 3 inhibitors peptidoglycan glycosyltransferase (EC 2.4.1.129) inhibitor peptidoglycan glycosyltransferase (EC 2.4.1.129) inhibitors peptidoglycan glycosyltransferase inhibitor peptidoglycan glycosyltransferase inhibitors peptidoglycan transglycosylase inhibitor peptidoglycan transglycosylase inhibitors undecaprenyldiphospho-(N-acetyl-D-glucosaminyl-(1->4)-N-acetyl-D-muramoylpentapeptide):undecaprenyldiphospho-(N-acetyl-D-glucosaminyl-(1->4)-N-acetyl-D-muramoylpentapeptide) disaccharidetransferase inhibitor undecaprenyldiphospho-(N-acetyl-D-glucosaminyl-(1->4)-N-acetyl-D-muramoylpentapeptide):undecaprenyldiphospho-(N-acetyl-D-glucosaminyl-(1->4)-N-acetyl-D-muramoylpentapeptide) disaccharidetransferase inhibitors EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor CHEBI:50730 montelukast (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid 1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid MONTELUKAST Montelukast montelukast {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid montelukast CHEBI:50733 nutraceutical Dietary Supplement Food Supplementation Nutritional supplement nutraceutical CHEBI:50739 estrogen receptor modulator estrogen receptor modulator CHEBI:50741 retinoic acid receptor alpha/beta agonist RAR alpha/beta agonist retinoic acid receptor alpha/beta agonist CHEBI:50745 progestogen gestagen gestagens progestagen progestagens progestogens progestogen CHEBI:50748 antipsoriatic antipsoriatic agent antipsoriatic drug antipsoriatic CHEBI:50750 EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor DNA gyrase inhibitor DNA gyrase inhibitors DNA topoisomerase (ATP-hydrolysing) (EC 5.99.1.3) inhibitor DNA topoisomerase (ATP-hydrolysing) (EC 5.99.1.3) inhibitors DNA topoisomerase (ATP-hydrolysing) inhibitor DNA topoisomerase (ATP-hydrolysing) inhibitors DNA topoisomerase II inhibitor DNA topoisomerase II inhibitors EC 5.99.1.3 (DNA topoisomerase (ATP-hydrolysing)) inhibitor EC 5.99.1.3 (DNA topoisomerase (ATP-hydrolysing)) inhibitors EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitors EC 5.99.1.3 inhibitor EC 5.99.1.3 inhibitors inhibitor of type II topoisomerase inhibitors of type II topoisomerase topoisomerase II inhibitor topoisomerase II inhibitors topoisomerase-II inhibitor topoisomerase-II inhibitors type II DNA topoisomerase inhibitor type II DNA topoisomerase inhibitors EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor CHEBI:50751 anti-estrogen anti-estrogenic agent anti-estrogenic drug anti-oestrogen anti-oestrogenic agent anti-oestrogenic drug antiestrogen antiestrogenic agent antiestrogenic drug antioestrogen antioestrogenic agent antioestrogenic drug anti-estrogen CHEBI:50779 appetite enhancer appetite enhancing drug appetite stimulant orexigenic appetite enhancer CHEBI:50780 appetite regulator appetite regulators appetite regulator CHEBI:50781 EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor 3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+)) (EC 1.3.1.22) inhibitor 3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+)) (EC 1.3.1.22) inhibitors 3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+)) inhibitor 3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+)) inhibitors 3-oxo-5alpha-steroid 4-dehydrogenase inhibitor 3-oxo-5alpha-steroid 4-dehydrogenase inhibitors 3-oxo-5alpha-steroid:NADP+ Delta(4)-oxidoreductase inhibitor 3-oxo-5alpha-steroid:NADP+ Delta(4)-oxidoreductase inhibitors 3-oxosteroid 5alpha-reductase inhibitor 3-oxosteroid Delta4-dehydrogenase inhibitor 4-ene-3-oxosteroid 5alpha-reductase inhibitor 4-ene-5alpha-reductase inhibitor 5alpha-oxidoreductase inhibitor 5alpha-oxidoreductase inhibitors 5alpha-reductase inhibitor 5alpha-reductase inhibitors Delta(4)-3-ketosteroid 5alpha-oxidoreductase inhibitor Delta(4)-3-ketosteroid 5alpha-oxidoreductase inhibitors EC 1.3.1.22 (3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))) inhibitor EC 1.3.1.22 (3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))) inhibitors EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitors EC 1.3.1.22 inhibitor EC 1.3.1.22 inhibitors cholest-4-en-3-one 5alpha-reductase inhibitor cholestenone 5alpha-reductase inhibitor cholestenone 5alpha-reductase inhibitors reduced nicotinamide adenine dinucleotide phosphate:Delta(4)-3-ketosteroid 5alpha-oxidoreductase inhibitor reduced nicotinamide adenine dinucleotide phosphate:Delta(4)-3-ketosteroid 5alpha-oxidoreductase inhibitors steroid 5alpha-hydrogenase inhibitor steroid 5alpha-hydrogenase inhibitors steroid 5alpha-reductase inhibitor steroid 5alpha-reductase inhibitors testosterone 5alpha-reductase inhibitor testosterone 5alpha-reductase inhibitors testosterone Delta(4)-5alpha-reductase inhibitor testosterone Delta(4)-5alpha-reductase inhibitors testosterone Delta(4)-hydrogenase inhibitor testosterone Delta(4)-hydrogenase inhibitors EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor CHEBI:50788 EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor 3beta (or 20alpha)-hydroxysteroid dehydrogenase inhibitor 3beta (or 20alpha)-hydroxysteroid dehydrogenase inhibitors 3beta(or 20alpha)-hydroxysteroid dehydrogenase (EC 1.1.1.210) inhibitor 3beta(or 20alpha)-hydroxysteroid dehydrogenase (EC 1.1.1.210) inhibitors 3beta(or 20alpha)-hydroxysteroid dehydrogenase inhibitor 3beta(or 20alpha)-hydroxysteroid dehydrogenase inhibitors 3beta(or 20alpha)-hydroxysteroid:NADP(+) oxidoreductase inhibitor 3beta(or 20alpha)-hydroxysteroid:NADP(+) oxidoreductase inhibitors 3beta,20alpha-hydroxysteroid oxidoreductase inhibitor 3beta,20alpha-hydroxysteroid oxidoreductase inhibitors 3beta-HSD 3beta-hydroxysteroid dehydrogenase 3beta-hydroxysteroid dehydrogenase inhibitor EC 1.1.1.210 (3beta(or 20alpha)-hydroxysteroid dehydrogenase) inhibitor EC 1.1.1.210 (3beta(or 20alpha)-hydroxysteroid dehydrogenase) inhibitors EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitors EC 1.1.1.210 inhibitor EC 1.1.1.210 inhibitors dehydrogenase, 3beta,20alpha-hydroxy steroid inhibitor dehydrogenase, 3beta,20alpha-hydroxy steroid inhibitors progesterone reductase inhibitor progesterone reductase inhibitors EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor CHEBI:50790 EC 1.14.14.14 (aromatase) inhibitor EC 1.14.14.14 (aromatase) inhibitors EC 1.14.14.14 inhibitor EC 1.14.14.14 inhibitors aromatase (EC 1.14.14.14) inhibitor aromatase (EC 1.14.14.14) inhibitors aromatase inhibitor aromatase inhibitors estrogen synthase inhibitor estrogen synthase inhibitors estrogen synthetase inhibitor estrogen synthetase inhibitors oestrogen synthase inhibitor oestrogen synthase inhibitors oestrogen synthetase inhibitor oestrogen synthetase inhibitors EC 1.14.14.14 (aromatase) inhibitor CHEBI:50792 estrogen receptor antagonist estrogen receptor antagonists estrogen receptor antagonist CHEBI:50827 antiparathyroid drug antiparathyroid agent antiparathyroid agents antiparathyroid drugs antiparathyroid drug CHEBI:50837 estrogen antagonist oestrogen antagonist estrogen antagonist CHEBI:50843 antimineralocorticoid antimineralocorticoid CHEBI:50844 aldosterone antagonist aldosterone antagonist CHEBI:50846 immunomodulator Biomodulator Immune factor Immunologic factor Immunological factor immunomodulators immunomodulator CHEBI:50847 immunological adjuvant Immunoactivator Immunoadjuvant Immunologic adjuvant Immunopotentiator Immunostimulant immunological adjuvant CHEBI:50855 antiatherogenic agent anti-atherogenic agent anti-atherogenic agents anti-atherogenic drug anti-atherogenic drugs antiatherogenic agent antiatherogenic agents antiatherogenic drug antiatherogenic drugs antiatherogenic agent CHEBI:50857 anti-allergic agent anti-allergic agents anti-allergic drug anti-allergic drugs anti-allergic agent CHEBI:50864 insulin-sensitizing drug PPAR-gamma agonist PPAR-gamma agonists PPARgamma agonist PPARgamma agonists glitazonas glitazone drug glitazones insulin sensitisers insulin sensitizers insulin-sensitising drug insulin-sensitizing agent peroxisome proliferator-activated receptor gamma agonist peroxisome proliferator-activated receptor gamma agonists proliferator activated receptor gamma agonist proliferator activated receptor gamma agonists thiazolidinediones tiazolidinedionas insulin-sensitizing drug CHEBI:50902 genotoxin genotoxic agent genotoxic agents genotoxins genotoxin CHEBI:50903 carcinogenic agent agente carcinogeno cancerigene cancerogene carcinogen carcinogene carcinogenic agents carcinogeno carcinogens carcinogenic agent CHEBI:50904 allergen alergeno allergene allergenic agent allergen CHEBI:50905 teratogenic agent agent teratogene teratogen teratogeno teratogenic agent CHEBI:50907 deaminating agent deaminating agent CHEBI:50908 hepatotoxic agent agente hepatotoxico hepatotoxic agents hepatotoxicant hepatotoxicants hepatotoxin hepatotoxins hepatoxic agent hepatoxicant hepatotoxic agent CHEBI:50909 nephrotoxic agent agente nefrotoxico nephrotoxicant nephrotoxic agent CHEBI:50910 neurotoxin agente neurotoxico nerve poison nerve poisons neurotoxic agent neurotoxic agents neurotoxicant neurotoxins neurotoxin CHEBI:50912 cardiotoxic agent cardiotoxicant cardiotoxic agent CHEBI:50913 fixative fixating agent fixating agents fixation agent fixative CHEBI:50914 EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor 1-phosphatidylinositol 3-kinase inhibitor 1-phosphatidylinositol 3-kinase inhibitors ATP:1-phosphatidyl-1D-myo-inositol 3-phosphotransferase inhibitor ATP:1-phosphatidyl-1D-myo-inositol 3-phosphotransferase inhibitors EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitors EC 2.7.1.137 inhibitor EC 2.7.1.137 inhibitors PI(3)K inhibitor PI(3)K inhibitors PI-3 kinase inhibitor PI-3 kinase inhibitors PI3-kinase inhibitor PI3-kinase inhibitors PI3K inhibitor PI3K inhibitors PtdIns-3-kinase inhibitor PtdIns-3-kinase inhibitors Vps34p inhibitor Vps34p inhibitors phosphatidylinositol 3-kinase (EC 2.7.1.137) inhibitor phosphatidylinositol 3-kinase (EC 2.7.1.137) inhibitors phosphatidylinositol 3-kinase inhibitor phosphatidylinositol 3-kinase inhibitors phosphatidylinositol-3-OH kinase inhibitor phosphatidylinositol-3-OH kinase inhibitors phosphoinositide 3-kinase inhibitor phosphoinositide 3-kinase inhibitors type I phosphatidylinositol kinase inhibitor type I phosphatidylinositol kinase inhibitors type III phosphoinositide 3-kinase inhibitor type III phosphoinositide 3-kinase inhibitors EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor CHEBI:50916 lipid kinase inhibitor lipid kinase inhibitors lipid kinase inhibitor CHEBI:50919 antiemetic anti-emetic anti-emetics antiemetico antiemetics antiemetic CHEBI:50925 EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor A-kinase inhibitor A-kinase inhibitors AP50 kinase inhibitor AP50 kinase inhibitors ATP-protein transphosphorylase inhibitor ATP-protein transphosphorylase inhibitors ATP:protein phosphotransferase (non-specific) inhibitor ATP:protein phosphotransferase (non-specific) inhibitors BR serine/threonine-protein kinase 2 inhibitor BR serine/threonine-protein kinase 2 inhibitors CK-2 inhibitor CK-2 inhibitors CKI inhibitor CKI inhibitors CKII inhibitor CKII inhibitors EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitors EC 2.7.11.1 inhibitor EC 2.7.11.1 inhibitors HIPK2 inhibitor HIPK2 inhibitors Hpr kinase inhibitor Hpr kinase inhibitors M phase-specific cdc2 kinase inhibitor M phase-specific cdc2 kinase inhibitors MKNK2 inhibitor MKNK2 inhibitors PAK-1 inhibitor PAK-1 inhibitors PAK1 inhibitor PAK1 inhibitors PKA inhibitor PKA inhibitors Prp4 protein kinase inhibitor Prp4 protein kinase inhibitors Raf kinase inhibitor Raf kinase inhibitors Raf-1 inhibitor Raf-1 inhibitors STK32 inhibitor STK32 inhibitors T-antigen kinase inhibitor T-antigen kinase inhibitors WEE1Hu inhibitor WEE1Hu inhibitors Wee 1-like kinase inhibitor Wee 1-like kinase inhibitors Wee-kinase inhibitor Wee-kinase inhibitors betaIIPKC inhibitor betaIIPKC inhibitors cAMP-dependent protein kinase A inhibitor cAMP-dependent protein kinase A inhibitors cAMP-dependent protein kinase inhibitor cAMP-dependent protein kinase inhibitors cGMP-dependent protein kinase inhibitor cGMP-dependent protein kinase inhibitors calcium-dependent protein kinase C inhibitor calcium-dependent protein kinase C inhibitors calcium/phospholipid-dependent protein kinase inhibitor calcium/phospholipid-dependent protein kinase inhibitors casein kinase (phosphorylating) inhibitor casein kinase (phosphorylating) inhibitors casein kinase 2 inhibitor casein kinase 2 inhibitors casein kinase I inhibitor casein kinase I inhibitors casein kinase II inhibitor casein kinase II inhibitors casein kinase inhibitor casein kinase inhibitors cyclic AMP-dependent protein kinase A inhibitor cyclic AMP-dependent protein kinase A inhibitors cyclic AMP-dependent protein kinase inhibitor cyclic AMP-dependent protein kinase inhibitors cyclic monophosphate-dependent protein kinase inhibitor cyclic monophosphate-dependent protein kinase inhibitors cyclic nucleotide-dependent protein kinase inhibitor cyclic nucleotide-dependent protein kinase inhibitors cyclin-dependent kinase inhibitor cyclin-dependent kinase inhibitors dsk1 inhibitor dsk1 inhibitors epsilon PKC inhibitor epsilon PKC inhibitors glycogen synthase a kinase inhibitor glycogen synthase a kinase inhibitors glycogen synthase kinase inhibitor glycogen synthase kinase inhibitors hydroxyalkyl-protein kinase inhibitor hydroxyalkyl-protein kinase inhibitors mitogen-activated S6 kinase inhibitor mitogen-activated S6 kinase inhibitors non-specific serine/threonine protein kinase (EC 2.7.11.1) inhibitor non-specific serine/threonine protein kinase (EC 2.7.11.1) inhibitors non-specific serine/threonine protein kinase inhibitor non-specific serine/threonine protein kinase inhibitors p21 activated kinase-1 inhibitor p21 activated kinase-1 inhibitors p82 kinase inhibitor p82 kinase inhibitors phosphorylase b kinase kinase inhibitor phosphorylase b kinase kinase inhibitors protein glutamyl kinase inhibitor protein glutamyl kinase inhibitors protein kinase (phosphorylating) inhibitor protein kinase (phosphorylating) inhibitors protein kinase A inhibitor protein kinase A inhibitors protein kinase CK2 inhibitor protein kinase CK2 inhibitors protein kinase p58 inhibitor protein kinase p58 inhibitors protein phosphokinase inhibitor protein phosphokinase inhibitors protein serine kinase inhibitor protein serine kinase inhibitors protein serine-threonine kinase inhibitor protein serine-threonine kinase inhibitors protein-aspartyl kinase inhibitor protein-aspartyl kinase inhibitors protein-cysteine kinase inhibitor protein-cysteine kinase inhibitors protein-serine kinase inhibitor protein-serine kinase inhibitors protein-serine/threonine kinase inhibitors ribosomal S6 protein kinase inhibitor ribosomal S6 protein kinase inhibitors ribosomal protein S6 kinase II inhibitor ribosomal protein S6 kinase II inhibitors serine kinase inhibitor serine kinase inhibitors serine protein kinase inhibitor serine protein kinase inhibitors serine(threonine) protein kinase inhibitor serine(threonine) protein kinase inhibitors serine-specific protein kinase inhibitor serine-specific protein kinase inhibitors serine/threonine protein kinase inhibitor serine/threonine protein kinase inhibitors threonine-specific protein kinase inhibitor threonine-specific protein kinase inhibitors twitchin kinase inhibitor twitchin kinase inhibitors type-2 casein kinase inhibitor type-2 casein kinase inhibitors EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor CHEBI:50926 angiogenesis modulating agent angiogenesis modulating agent CHEBI:50949 serotonin uptake inhibitor SSRI serotonin reuptake inhibitor serotonin uptake inhibitor CHEBI:51039 dopamine uptake inhibitor DARI DRI dopamine reuptake inhibitor dopamine reuptake inhibitors dopamine uptake inhibitors dopamine uptake inhibitor CHEBI:51060 hormone agonist hormone agonist CHEBI:51061 hormone receptor modulator hormone receptor modulators hormone receptor modulator CHEBI:51065 dopamine agonist Agonista dopaminergico Dopamine receptor agonist Dopaminergic agonist dopamine agonist CHEBI:51068 miotic Miotico miotics miotic CHEBI:51076 antifouling biocide Antifoulant Antifouling agent Marine pesticide antifouling biocide CHEBI:51086 chemical role chemical role CHEBI:51087 protecting group Schutzgruppe Schutzgruppen groupe protecteur protective group protecting group CHEBI:51121 fluorescent dye fluorescent dyes fluorescent dye CHEBI:51166 Wittig reagent Wittig reagents reactif de Wittig reactivo de Wittig reactivos de Wittig Wittig reagent CHEBI:51177 antitussive anti-tussive cough suppressant cough suppressants antitussive CHEBI:51217 fluorochrome fluorochromes fluorochrome CHEBI:51237 Grignard reagent Grignards Reagens Grignard reagent CHEBI:51266 gelator gelator CHEBI:51267 swelling agent swelling agent CHEBI:51268 drying control chemical additive drying control chemical additive CHEBI:51371 muscle relaxant muscle relaxants muscle relaxant CHEBI:51372 neuromuscular agent neuromuscular agent CHEBI:51373 GABA agonist GABA agonists GABA receptor agonist GABA receptor agonists gamma-aminobutyric acid receptor agonist gamma-aminobutyric acid receptor agonists GABA agonist CHEBI:51374 GABA agent GABA agent CHEBI:51451 endothelin receptor antagonist ERA endothelin receptor antagonist CHEBI:51452 endothelin A receptor antagonist endothelin A receptor antagonist CHEBI:51577 partial prostacyclin agonist partial prostacyclin agonist CHEBI:52206 biochemical role biochemical role CHEBI:52208 biophysical role biophysical role CHEBI:52209 aetiopathogenetic role etiopathogenetic agent etiopathogenetic role aetiopathogenetic role CHEBI:52210 pharmacological role pharmacological role CHEBI:52211 physiological role physiological role CHEBI:52214 ligand ligands ligand CHEBI:52215 photochemical role photochemical roles photochemical role CHEBI:52216 photobiochemical role photobiochemical role CHEBI:52217 pharmaceutical farmaco medicament pharmaceuticals pharmaceutical CHEBI:52271 squaraine dye squaraine dye CHEBI:52290 mitogen mitogens mitogen CHEBI:52303 sterol methyltransferase inhibitor sterol methyltransferase inhibitor CHEBI:52424 EC 3.2.1.* (glycosidase) inhibitor EC 3.2.1.* (glycosidase) inhibitors EC 3.2.1.* inhibitor EC 3.2.1.* inhibitors glycosidase (EC 3.2.1.*) inhibitor glycosidase (EC 3.2.1.*) inhibitors glycosidase inhibitor glycosidase inhibitors glycoside hydrolase inhibitors EC 3.2.1.* (glycosidase) inhibitor CHEBI:52425 EC 3.2.1.18 (exo-alpha-sialidase) inhibitor EC 3.2.1.18 (exo-alpha-sialidase) inhibitors EC 3.2.1.18 inhibitor EC 3.2.1.18 inhibitors N-acylneuraminate glycohydrolase inhibitor N-acylneuraminate glycohydrolase inhibitors acetylneuraminidase inhibitor acetylneuraminidase inhibitors acetylneuraminyl hydrolase inhibitor acetylneuraminyl hydrolase inhibitors alpha-neuraminidase inhibitor alpha-neuraminidase inhibitors exo-alpha-sialidase (EC 3.2.1.18) inhibitor exo-alpha-sialidase (EC 3.2.1.18) inhibitors exo-alpha-sialidase inhibitor exo-alpha-sialidase inhibitors neuraminidase inhibitor neuraminidase inhibitors sialidase inhibitor sialidase inhibitors EC 3.2.1.18 (exo-alpha-sialidase) inhibitor CHEBI:52629 EC 3.1.26.13 (retroviral ribonuclease H) inhibitor EC 3.1.26.13 (retroviral ribonuclease H) inhibitors EC 3.1.26.13 inhibitor EC 3.1.26.13 inhibitors HIV RNase H inhibitor HIV RNase H inhibitors HIV-1 RNase H inhibitor HIV-1 RNase H inhibitors HIV-1 ribonuclease H inhibitor HIV-1 ribonuclease H inhibitors RT/RNase H inhibitor RT/RNase H inhibitors retroviral reverse transcriptase RNaseH inhibitor retroviral reverse transcriptase RNaseH inhibitors retroviral ribonuclease H (EC 3.1.26.13) inhibitor retroviral ribonuclease H (EC 3.1.26.13) inhibitors retroviral ribonuclease H inhibitor EC 3.1.26.13 (retroviral ribonuclease H) inhibitor CHEBI:52726 proteasome inhibitor proteasome inhibitors proteasome inhibitor CHEBI:52941 phosphate protecting group phosphate protecting groups phosphate protecting group CHEBI:52943 carboxylic acid protecting group carboxylic acid protecting groups carboxylic acid protecting group CHEBI:53000 epitope antigenic determinant epitope function epitope role epitope CHEBI:53121 adenosine A2A receptor antagonist adenosine A2A receptor antagonists adenosine A2A receptor antagonist CHEBI:53142 P2Y2 receptor agonist P2Y2 receptor agonists P2Y2 receptor agonist CHEBI:53337 tissue adhesive tissue adhesives tissue adhesive CHEBI:53353 GHB receptor agonist GHB receptor agonists GHB receptor agonist CHEBI:53431 chain carrier chain carriers chain carrier CHEBI:53559 topoisomerase IV inhibitor topoisomerase IV inhibitors topoisomerase IV inhibitor CHEBI:53659 EC 1.4.3.22 (diamine oxidase) inhibitor EC 1.4.3.22 (diamine oxidase) inhibitors EC 1.4.3.22 inhibitor EC 1.4.3.22 inhibitors diamine oxidase (EC 1.4.3.22) inhibitor diamine oxidase (EC 1.4.3.22) inhibitors diamine oxidase inhibitor diamine oxidase inhibitors histaminase inhibitor histaminase inhibitors histamine:oxygen oxidoreductase (deaminating) inhibitor histamine:oxygen oxidoreductase (deaminating) inhibitors EC 1.4.3.22 (diamine oxidase) inhibitor CHEBI:53746 EC 1.1.1.205 (IMP dehydrogenase) inhibitor EC 1.1.1.205 (IMP dehydrogenase) inhibitors EC 1.1.1.205 inhibitor EC 1.1.1.205 inhibitors IMP dehydrogenase (EC 1.1.1.205) inhibitor IMP dehydrogenase (EC 1.1.1.205) inhibitors IMP dehydrogenase inhibitor IMP dehydrogenase inhibitors IMP oxidoreductase inhibitor IMP oxidoreductase inhibitors IMP:NAD(+) oxidoreductase inhibitor IMP:NAD(+) oxidoreductase inhibitors inosinate dehydrogenase inhibitor inosinate dehydrogenase inhibitors inosine 5'-monophosphate dehydrogenase inhibitors inosine monophosphate dehydrogenase inhibitor inosine monophosphate dehydrogenase inhibitors inosine monophosphate oxidoreductase inhibitor inosine monophosphate oxidoreductase inhibitors inosinic acid dehydrogenase inhibitor inosinic acid dehydrogenase inhibitors EC 1.1.1.205 (IMP dehydrogenase) inhibitor CHEBI:53756 HIV-1 reverse transcriptase inhibitor HIV-1 reverse transcriptase inhibitors reverse transcriptase inhibitor reverse transcriptase inhibitors HIV-1 reverse transcriptase inhibitor CHEBI:53784 antispasmodic drug antispasmodics antispasmodic drug CHEBI:55322 mu-opioid receptor agonist mu opioid agonist mu-opioid agonists mu-opioid receptor agonists mu-opioid receptor agonist CHEBI:55323 antidiarrhoeal drug antidiarrheal antidiarrheal agent antidiarrheal agents antidiarrheal drug antidiarrheal drugs antidiarrheals antidiarrhoeal antidiarrhoeal agent antidiarrhoeal agents antidiarrhoeal drugs antidiarrhoeals antiperistaltic antiperistaltic agent antiperistaltic agents antiperistaltic drug antiperistaltic drugs antiperistaltics antidiarrhoeal drug CHEBI:55324 gastrointestinal drug gastrointestinal agent gastrointestinal agents gastrointestinal drugs gastrointestinal drug CHEBI:55347 vitamin K antagonist vitamin K antagonists vitamin K antagonist CHEBI:55350 neurokinin-1 receptor antagonist NK-1 receptor antagonist NK-1 receptor antagonists NK1 receptor antagonist NK1 receptor antagonists neurokinin-1 receptor antagonists neurokinin-1 receptor antagonist CHEBI:55351 substance P receptor antagonist substance P receptor antagonists substance P receptor antagonist CHEBI:59010 antiseborrheic antiseborrheic agent antiseborrheic agents antiseborrheic drug antiseborrheics antiseborrheic CHEBI:59105 EC 6.3.2.* (acid--D-amino-acid ligase) inhibitor EC 6.3.2.* (acid--D-amino-acid ligase (peptide synthase)) inhibitor EC 6.3.2.* (acid--D-amino-acid ligase (peptide synthase)) inhibitors EC 6.3.2.* (acid--D-amino-acid ligase) inhibitors EC 6.3.2.* (acid--amino-acid ligase) inhibitor EC 6.3.2.* (acid--amino-acid ligase) inhibitors EC 6.3.2.* [acid--D-amino-acid ligase (peptide synthase)] inhibitor EC 6.3.2.* [acid--D-amino-acid ligase (peptide synthase)] inhibitors EC 6.3.2.* inhibitor EC 6.3.2.* inhibitors acid--amino-acid ligase inhibitor acid--amino-acid ligase inhibitors peptide synthase inhibitor peptide synthase inhibitors EC 6.3.2.* (acid--D-amino-acid ligase) inhibitor CHEBI:59107 EC 3.4.24.* (metalloendopeptidase) inhibitor EC 3.4.24.* (metalloendopeptidase) inhibitors EC 3.4.24.* inhibitor EC 3.4.24.* inhibitors inhibitor of metalloendopeptidases inhibitor of metalloendopeptidases (EC 3.4.24.*) inhibitors of metalloendopeptidases inhibitors of metalloendopeptidases (EC 3.4.24.*) metalloendopeptidase (EC 3.4.24.*) inhibitor metalloendopeptidase (EC 3.4.24.*) inhibitors metalloendopeptidase inhibitors EC 3.4.24.* (metalloendopeptidase) inhibitor CHEBI:59132 antigen antigens antigen CHEBI:59163 biomarker biological marker biomarker CHEBI:59174 hapten haptens hapten CHEBI:59229 GnRH antagonist GnRH antagonists gonadotrophin-releasing hormone antagonist gonadotrophin-releasing hormone antagonists GnRH antagonist CHEBI:5924 EC 3.4.21.* (serine endopeptidase) inhibitor EC 3.4.21.* (serine endopeptidase) inhibitors EC 3.4.21.* inhibitor EC 3.4.21.* inhibitors inhibitor of serine endopeptidase (EC 3.4.21.*) inhibitor of serine endopeptidase (EC 3.4.21.*)s serine endopeptidase inhibitor serine endopeptidase inhibitors EC 3.4.21.* (serine endopeptidase) inhibitor CHEBI:59282 kappa-opioid receptor agonist kappa-opioid agonist kappa-opioid receptor agonists kappa-opioid receptor agonist CHEBI:59283 delta-opioid receptor antagonist delta-opioid antagonist delta-opioid antagonists delta-opioid receptor antagonist CHEBI:59285 EC 1.14.13.132 (squalene monooxygenase) inhibitor EC 1.14.13.132 (squalene monooxygenase) inhibitors squalene 2,3-oxidocyclase inhibitor squalene 2,3-oxidocyclase inhibitors squalene epoxidase inhibitor squalene epoxidase inhibitors squalene hydroxylase inhibitor squalene hydroxylase inhibitors squalene monooxygenase (EC 1.14.13.132) inhibitor squalene monooxygenase (EC 1.14.13.132) inhibitors squalene monooxygenase inhibitor squalene monooxygenase inhibitors squalene oxydocyclase inhibitor squalene oxydocyclase inhibitors squalene-2,3-epoxidase inhibitor squalene-2,3-epoxidase inhibitors squalene-2,3-epoxide cyclase inhibitor squalene-2,3-epoxide cyclase inhibitors EC 1.14.13.132 (squalene monooxygenase) inhibitor CHEBI:59321 EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor 5-hydroxytryptophan decarboxylase inhibitor 5-hydroxytryptophan decarboxylase inhibitors DOPA decarboxylase inhibitor DOPA decarboxylase inhibitors EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitors EC 4.1.1.28 inhibitor EC 4.1.1.28 inhibitors L-DOPA decarboxylase inhibitor L-DOPA decarboxylase inhibitors aromatic amino acid decarboxylase inhibitor aromatic amino acid decarboxylase inhibitors aromatic-L-amino-acid decarboxylase (EC 4.1.1.28) inhibitor aromatic-L-amino-acid decarboxylase (EC 4.1.1.28) inhibitors aromatic-L-amino-acid decarboxylase inhibitor aromatic-L-amino-acid decarboxylase inhibitors hydroxytryptophan decarboxylase inhibitor hydroxytryptophan decarboxylase inhibitors tryptophan decarboxylase inhibitor tryptophan decarboxylase inhibitors EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor CHEBI:59499 EC 3.4.13.* (dipeptidase) inhibitor EC 3.4.13.* (dipeptidase) inhibitors EC 3.4.13.* inhibitor EC 3.4.13.* inhibitors dipeptidase inhibitor dipeptidase inhibitors EC 3.4.13.* (dipeptidase) inhibitor CHEBI:59517 DNA synthesis inhibitor DNA synthesis inhibitors DNA synthesis inhibitor CHEBI:59544 phosphoantigen phosphoantigens phosphoantigen CHEBI:59647 EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor 3-oxosphinganine synthetase inhibitor 3-oxosphinganine synthetase inhibitors EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitors EC 2.3.1.50 inhibitor EC 2.3.1.50 inhibitors SPT inhibitor SPT inhibitors acyl-CoA:serine C-2 acyltransferase (decarboxylating) inhibitor acyl-CoA:serine C-2 acyltransferase (decarboxylating) inhibitors palmitoyl-CoA:L-serine C-palmitoyltransferase (decarboxylating) inhibitor palmitoyl-CoA:L-serine C-palmitoyltransferase (decarboxylating) inhibitors serine C-palmitoyltransferase (EC 2.3.1.50) inhibitor serine C-palmitoyltransferase (EC 2.3.1.50) inhibitors serine C-palmitoyltransferase inhibitor serine C-palmitoyltransferase inhibitors serine palmitoyltransferase inhibitor serine palmitoyltransferase inhibitors EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor CHEBI:59672 EC 2.4.1.16 (chitin synthase) inhibitor EC 2.4.1.16 (chitin synthase) inhibitors EC 2.4.1.16 inhibitor EC 2.4.1.16 inhibitors UDP-N-acetyl-D-glucosamine:chitin 4-beta-N-acetylglucosaminyl-transferase inhibitor UDP-N-acetyl-D-glucosamine:chitin 4-beta-N-acetylglucosaminyl-transferase inhibitors chitin synthase (EC 2.4.1.16) inhibitor chitin synthase (EC 2.4.1.16) inhibitors chitin synthase inhibitor chitin synthase inhibitors chitin synthesis inhibitor chitin synthesis inhibitors chitin synthetase inhibitor chitin synthetase inhibitors chitin-UDP N-acetylglucosaminyltransferase inhibitor chitin-UDP N-acetylglucosaminyltransferase inhibitors chitin-UDP acetyl-glucosaminyl transferase inhibitor chitin-UDP acetyl-glucosaminyl transferase inhibitors chitin-uridine diphosphate acetylglucosaminyltransferase inhibitor chitin-uridine diphosphate acetylglucosaminyltransferase inhibitors trans-N-acetylglucosaminosylase inhibitor trans-N-acetylglucosaminosylase inhibitors EC 2.4.1.16 (chitin synthase) inhibitor CHEBI:59680 vasopressin receptor antagonist antidiuretic hormone inhibitor antidiuretic hormone inhibitors arginine vasopressin receptor antagonist arginine vasopressin receptor antagonists argipressin receptor antagonist argipressin receptor antagonists vasopressin receptor antagonists vasopressin receptor antagonist CHEBI:59683 antipruritic drug anti-itching drug anti-itching drugs antipruritic agent antipruritic agents antipruritic drugs antipruritic drug CHEBI:59727 vasopressin receptor agonist antidiuretic hormone agonist antidiuretic hormone agonists arginine vasopressin receptor agonist arginine vasopressin receptor agonists argipressin receptor agonist argipressin receptor agonists vasopressin receptor agonists vasopressin receptor agonist CHEBI:59739 electrophilic reagent electrophile electrophiles electrophilic reagents electrophilic reagent CHEBI:59740 nucleophilic reagent nucleophile nucleophiles nucleophilic reagents nucleophilic reagent CHEBI:59745 chromatographic reagent derivatising reagents derivatizing reagent derivatizing reagents chromatographic reagent CHEBI:59752 bolaamphiphile alpha-omega-type surfactant bolaamphiphiles bolaform surfactant bolaphile bolaamphiphile CHEBI:59826 progestin progestins progestin CHEBI:59844 antihyperplasia drug antihypergenesis drug antihypergenesis drugs antihyperplasia drugs antihyperplastic antihyperplasia drug CHEBI:59864 depigmentation drug depigmentation agent depigmentation agents depigmentation drugs depigmentor depigmentors depigmentation drug CHEBI:59886 HIV fusion inhibitor HIV entry inhibitor HIV entry inhibitors HIV fusion inhibitors HIV fusion inhibitor CHEBI:59897 EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor DNA nucleotidyltransferase (RNA-directed) inhibitor DNA nucleotidyltransferase (RNA-directed) inhibitors EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitors EC 2.7.7.49 inhibitor EC 2.7.7.49 inhibitors RNA revertase inhibitor RNA revertase inhibitors RNA-dependent DNA polymerase inhibitor RNA-dependent DNA polymerase inhibitors RNA-dependent deoxyribonucleate nucleotidyltransferase inhibitor RNA-dependent deoxyribonucleate nucleotidyltransferase inhibitors RNA-directed DNA polymerase (EC 2.7.7.49) inhibitor RNA-directed DNA polymerase (EC 2.7.7.49) inhibitors RNA-directed DNA polymerase inhibitor RNA-directed DNA polymerase inhibitors RNA-instructed DNA polymerase inhibitor RNA-instructed DNA polymerase inhibitors RT inhibitor RT inhibitors deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase (RNA-directed) inhibitor deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase (RNA-directed) inhibitors reverse transcriptase inhibitor reverse transcriptase inhibitors revertase inhibitor revertase inhibitors telomerase inhibitor telomerase inhibitors EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor CHEBI:59941 amphiphile amphiphiles amphiphile CHEBI:59997 EC 1.14.18.1 (tyrosinase) inhibitor EC 1.14.18.1 (tyrosinase) inhibitors EC 1.14.18.1 inhibitor EC 1.14.18.1 inhibitors L-tyrosine,L-dopa:oxygen oxidoreductase inhibitor L-tyrosine,L-dopa:oxygen oxidoreductase inhibitors NN-acetyl-6-hydroxytryptophan oxidase inhibitor NN-acetyl-6-hydroxytryptophan oxidase inhibitors O-diphenol:O2 oxidoreductase inhibitor O-diphenol:O2 oxidoreductase inhibitors cresolase inhibitor cresolase inhibitors monophenol dihydroxyphenylalanine:oxygen oxidoreductase inhibitor monophenol dihydroxyphenylalanine:oxygen oxidoreductase inhibitors monophenol monooxidase inhibitor monophenol monooxidase inhibitors monophenol monooxygenase inhibitor monophenol monooxygenase inhibitors monophenol oxidase inhibitor monophenol oxidase inhibitors monophenol, dihydroxy-L-phenylalanine oxygen oxidoreductase inhibitor monophenol, dihydroxy-L-phenylalanine oxygen oxidoreductase inhibitors monophenolase inhibitor monophenolase inhibitors phenol oxidase inhibitor phenol oxidase inhibitors phenolase inhibitor phenolase inhibitors tyrosinase (EC 1.14.18.1) inhibitor tyrosinase (EC 1.14.18.1) inhibitors tyrosinase inhibitor tyrosinase inhibitors tyrosine-dopa oxidase inhibitor tyrosine-dopa oxidase inhibitors EC 1.14.18.1 (tyrosinase) inhibitor CHEBI:60186 EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor ATP phosphohydrolase (Ca(2+)-transporting) inhibitor ATP phosphohydrolase (Ca(2+)-transporting) inhibitors Ca(2+)-pumping ATPase inhibitor Ca(2+)-pumping ATPase inhibitors Ca(2+)-transporting ATPase (EC 3.6.3.8) inhibitor Ca(2+)-transporting ATPase (EC 3.6.3.8) inhibitors Ca(2+)-transporting ATPase inhibitor Ca(2+)-transporting ATPase inhibitors EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitors SERCA inhibitor SERCA inhibitors calcium pump inhibitor calcium pump inhibitors plasma membrane Ca-ATPase inhibitor plasma membrane Ca-ATPase inhibitors sarco(endo)plasmic reticulum Ca(2+)-ATPase inhibitor sarco(endo)plasmic reticulum Ca(2+)-ATPase inhibitors sarcoplasmic reticulum ATPase inhibitor sarcoplasmic reticulum ATPase inhibitors EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor CHEBI:60218 mimotope antigenic determinant mimic epitope mimic mimeotope mimeotope function mimeotope role mimetope mimotope function mimotope role mimotope CHEBI:60258 EC 3.4.* (hydrolases acting on peptide bond) inhibitor EC 3.4.* (hydrolase acting on peptide bond) inhibitor EC 3.4.* (hydrolase acting on peptide bonds) inhibitors EC 3.4.* (hydrolases acting on peptide bond) inhibitors EC 3.4.* (peptidase) inhibitor EC 3.4.* (peptidase) inhibitors EC 3.4.* inhibitor EC 3.4.* inhibitors inhibitor of hydrolases acting on peptide bond (EC 3.4.*) inhibitors of hydrolases acting on peptide bond (EC 3.4.*) peptidase inhibitors protease inhibitor protease inhibitors EC 3.4.* (hydrolases acting on peptide bond) inhibitor CHEBI:60280 EC 3.5.1.2 (glutaminase) inhibitor EC 3.5.1.2 (glutaminase) inhibitors EC 3.5.1.2 inhibitor EC 3.5.1.2 inhibitors L-glutaminase inhibitor L-glutaminase inhibitors L-glutamine amidohydrolase inhibitor L-glutamine amidohydrolase inhibitors glutaminase (EC 3.5.1.2) inhibitor glutaminase (EC 3.5.1.2) inhibitors glutaminase I inhibitor glutaminase I inhibitors glutaminase inhibitor glutaminase inhibitors glutamine aminohydrolase inhibitor glutamine aminohydrolase inhibitors EC 3.5.1.2 (glutaminase) inhibitor CHEBI:60311 thyroid hormone thyroid hormones thyroid hormone CHEBI:60575 phenoxy herbicide phenoxy herbicides phenoxy herbicide CHEBI:60598 opioid agent opioid agents opioid agent CHEBI:60599 mu-opioid agent mu-opioid agents mu-opioid agent CHEBI:60601 delta-opioid agent delta-opioid agents delta-opioid agent CHEBI:60603 kappa-opioid agent kappa-opioid agents kappa-opioid agent CHEBI:60605 opioid receptor antagonist opiate antagonist opiate antagonists opioid antagonist opioid antagonists opioid receptor antagonists opioid receptor antagonist CHEBI:60606 opioid receptor agonist opiate agonist opiate agonists opioid agonist opioid agonists opioid receptor agonists opioid receptor agonist CHEBI:60643 NMDA receptor antagonist N-methyl-D-aspartate receptor antagonist N-methyl-D-aspartate receptor antagonists NMDA receptor antagonists NMDAR antagonist NMDAR antagonists NMDA receptor antagonist CHEBI:60646 chiral reagent chiral reagent CHEBI:60649 glucagon receptor antagonist glucagon receptor antagonists glucagon receptor antagonist CHEBI:60688 EC 4.2.1.20 (tryptophan synthase) inhibitor EC 4.2.1.20 (tryptophan synthase) inhibitors EC 4.2.1.20 inhibitor EC 4.2.1.20 inhibitors L-serine hydro-lyase (adding indoleglycerol-phosphate) inhibitor L-serine hydro-lyase (adding indoleglycerol-phosphate) inhibitors L-tryptophan synthetase inhibitor L-tryptophan synthetase inhibitors indoleglycerol phosphate aldolase inhibitor indoleglycerol phosphate aldolase inhibitors tryptophan desmolase inhibitor tryptophan desmolase inhibitors tryptophan synthase (EC 4.2.1.20) inhibitor tryptophan synthase (EC 4.2.1.20) inhibitors tryptophan synthase inhibitor tryptophan synthase inhibitors tryptophan synthetase inhibitor tryptophan synthetase inhibitors EC 4.2.1.20 (tryptophan synthase) inhibitor CHEBI:60788 affinity label affinity labels affinity label CHEBI:60798 excitatory amino acid antagonist EAA receptor antagonist EAA receptor antagonists excitatory amino acid antagonists excitatory amino acid receptor antagonist excitatory amino acid receptor antagonists excitatory amino acid antagonist CHEBI:60807 anaesthesia adjuvant anaesthesia adjuvants anaesthestic adjuvant anaesthestic adjuvants anaesthesia adjuvant CHEBI:60809 adjuvant adjuvants adjuvant CHEBI:60816 immunogen immunogen CHEBI:60832 tubulin modulator tubulin modulators tubulin modulator CHEBI:60901 EC 2.5.1.9 (riboflavin synthase) inhibitor 6,7-dimethyl-8-(1-D-ribityl)lumazine:6,7-dimethyl-8-(1-D-ribityl)lumazine 2,3-butanediyltransferase inhibitor 6,7-dimethyl-8-(1-D-ribityl)lumazine:6,7-dimethyl-8-(1-D-ribityl)lumazine 2,3-butanediyltransferase inhibitors EC 2.5.1.9 (riboflavin synthase) inhibitors EC 2.5.1.9 inhibitor EC 2.5.1.9 inhibitors heavy riboflavin synthase inhibitor heavy riboflavin synthase inhibitors light riboflavin synthase inhibitor light riboflavin synthase inhibitors riboflavin synthase (EC 2.5.1.9) inhibitor riboflavin synthase (EC 2.5.1.9) inhibitors riboflavin synthase inhibitor riboflavin synthase inhibitors riboflavin synthetase inhibitor riboflavin synthetase inhibitors riboflavine synthase inhibitor riboflavine synthase inhibitors riboflavine synthetase inhibitor riboflavine synthetase inhibitors EC 2.5.1.9 (riboflavin synthase) inhibitor CHEBI:61015 nephrotoxin nephrotoxins nephrotoxin CHEBI:61016 angiotensin receptor antagonist angiotensin receptor antagonists angiotensin receptor antagonist CHEBI:61026 bile therapy drug bile therapy agent bile therapy agents bile therapy drugs bile therapy drug CHEBI:61115 EC 3.5.1.98 (histone deacetylase) inhibitor EC 3.5.1.98 (histone deacetylase) inhibitors EC 3.5.1.98 inhibitor EC 3.5.1.98 inhibitors HDAC inhibitor HDAC inhibitors HDACi HDACis HDI HDIs histone amidohydrolase inhibitor histone amidohydrolase inhibitors histone deacetylase (EC 3.5.1.98) inhibitor histone deacetylase (EC 3.5.1.98) inhibitors histone deacetylase inhibitor histone deacetylase inhibitors EC 3.5.1.98 (histone deacetylase) inhibitor CHEBI:61774 inositol phosphorylceramide synthase inhibitor inositol phosphorylceramide synthase inhibitor CHEBI:61908 EC 1.14.13.39 (nitric oxide synthase) inhibitor EC 1.14.13.39 (nitric oxide synthase) inhibitors EC 1.14.13.39 inhibitor EC 1.14.13.39 inhibitors NADPH-diaphorase inhibitor NADPH-diaphorase inhibitors NO synthase inhibitor NO synthase inhibitors endothelium-derived relaxation factor-forming enzyme inhibitor endothelium-derived relaxation factor-forming enzyme inhibitors endothelium-derived relaxing factor synthase inhibitor endothelium-derived relaxing factor synthase inhibitors nitric oxide synthase (EC 1.14.13.39) inhibitor nitric oxide synthase (EC 1.14.13.39) inhibitors nitric oxide synthase inhibitor nitric oxide synthase inhibitors nitric oxide synthetase inhibitor nitric oxide synthetase inhibitors nitric-oxide synthetase inhibitor nitric-oxide synthetase inhibitors EC 1.14.13.39 (nitric oxide synthase) inhibitor CHEBI:61950 microtubule-stabilising agent microtubule stabilising agent microtubule stabilising role microtubule stabilizing agent microtubule stabilizing agents microtubule stabilizing role microtubule-stabilising agents microtubule-stabilizing agent microtubule-stabilising agent CHEBI:61951 microtubule-destabilising agent microtubule destabilising agent microtubule destabilising agents microtubule destabilising role microtubule destabilizing role microtubule-destabilising agents microtubule-destabilizing agent microtubule-destabilizing agents microtubule-destabilising agent CHEBI:61966 metabotropic glutamate receptor agonist mGluRs agonist metabotropic glutamate receptor agonists metabotropic glutamate receptor agonist CHEBI:62049 acyl donor acyl donor CHEBI:62089 EC 1.4.7.1 [glutamate synthase (ferredoxin)] inhibitor EC 1.4.7.1 [glutamate synthase (ferredoxin)] inhibitors EC 1.4.7.1 inhibitor EC 1.4.7.1 inhibitors L-glutamate:ferredoxin oxidoreductase (transaminating) inhibitor L-glutamate:ferredoxin oxidoreductase (transaminating) inhibitors ferredoxin-dependent glutamate synthase inhibitor ferredoxin-dependent glutamate synthase inhibitors ferredoxin-glutamate synthase inhibitor ferredoxin-glutamate synthase inhibitors glutamate synthase (ferredoxin) (EC 1.4.7.1) inhibitor glutamate synthase (ferredoxin) (EC 1.4.7.1) inhibitors glutamate synthase (ferredoxin) inhibitor glutamate synthase (ferredoxin) inhibitors glutamate synthase (ferredoxin-dependent) inhibitor glutamate synthase (ferredoxin-dependent) inhibitors glutamate synthase inhibitor glutamate synthase inhibitors EC 1.4.7.1 [glutamate synthase (ferredoxin)] inhibitor CHEBI:62215 allelochemical allelochemicals allelochemical CHEBI:62434 EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor AATK inhibitor AATYK inhibitor AATYK2 inhibitor AATYK3 inhibitor ACH inhibitor ALK inhibitor ALK inhibitors ARK inhibitor ATP:[protein]-L-tyrosine O-phosphotransferase (receptor-type) inhibitor ATP:[protein]-L-tyrosine O-phosphotransferase (receptor-type) inhibitors AXL inhibitor BRT inhibitor Bek inhibitor Bfgfr inhibitor Bsk inhibitor C-FMS inhibitor CAK inhibitor CCK4 inhibitor CD115 inhibitor CD135 inhibitor CDw135 inhibitor CFD1 inhibitor CKIT inhibitor CSF1R inhibitor Cek1 inhibitor Cek10 inhibitor Cek11 inhibitor Cek2 inhibitor Cek3 inhibitor Cek5 inhibitor Cek6 inhibitor Cek7 inhibitor DAlk inhibitor DDR1 inhibitor DDR2 inhibitor DKFZp434C1418 inhibitor DRT inhibitor DTK inhibitor Dek inhibitor Drosophila Eph kinase inhibitor EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitors EC 2.7.10.1 inhibitor EC 2.7.10.1 inhibitors ECK inhibitor EDDR1 inhibitor EGFR inhibitor EPH inhibitor EPHA1 inhibitor EPHA2 inhibitor EPHA6 inhibitor EPHA7 inhibitor EPHA8 inhibitor EPHB1 inhibitor EPHB2 inhibitor EPHB3 inhibitor EPHB4 inhibitor EPHT inhibitor EPHT2 inhibitor EPHT3 inhibitor EPHX inhibitor ERBB inhibitor ERBB1 inhibitor ERBB2 inhibitor ERBB3 inhibitor ERBB4 inhibitor ERK inhibitor Ebk inhibitor Eek inhibitor Ehk2 inhibitor Ehk3 inhibitor Elk inhibitor EphB5 inhibitor Eyk inhibitor FGFR1 inhibitor FGFR2 inhibitor FGFR3 inhibitor FGFR4 inhibitor FLG inhibitor FLK1 inhibitor FLK2 inhibitor FLT1 inhibitor FLT2 inhibitor FLT3 inhibitor FLT4 inhibitor FMS inhibitor Fv2 inhibitor HBGFR inhibitor HEK11 inhibitor HEK2 inhibitor HEK3 inhibitor HEK5 inhibitor HEK6 inhibitor HEP inhibitor HER2 inhibitor HER3 inhibitor HER4 inhibitor HGFR inhibitor HSCR1 inhibitor HTK inhibitor IGF1R inhibitor INSR inhibitor INSRR inhibitor IR inhibitor IRR inhibitor JTK12 inhibitor JTK13 inhibitor JTK14 inhibitor JWS inhibitor K-SAM inhibitor KDR inhibitor KGFR inhibitor KIA0641 inhibitor KIAA1079 inhibitor KIAA1459 inhibitor KIT inhibitor KLG inhibitor Kil inhibitor Kin15 inhibitor Kin16 inhibitor LTK inhibitor MCF3 inhibitor MEN2A/B inhibitor MER inhibitor MERTK inhibitor MEhk1 inhibitor MST1R inhibitor MTC1 inhibitor MUSK inhibitor Mdk1 inhibitor Mdk2 inhibitor Mdk5 inhibitor Mep inhibitor Mlk1 inhibitor Mlk2 inhibitor Mrk inhibitor Myk1 inhibitor N-SAM inhibitor NEP inhibitor NET inhibitor NGL inhibitor NOK inhibitor NTRK1 inhibitor NTRK2 inhibitor NTRK3 inhibitor NTRK4 inhibitor NTRKR1 inhibitor NTRKR2 inhibitor NTRKR3 inhibitor NYK inhibitor Neu inhibitor Nsk2 inhibitor Nuk inhibitor PCL inhibitor PDGFR inhibitor PDGFRA inhibitor PDGFRB inhibitor PHB6 inhibitor PTK inhibitor PTK3 inhibitor PTK7 inhibitor RET inhibitor RON inhibitor ROR1 inhibitor ROR2 inhibitor ROS1 inhibitor RSE inhibitor RTK inhibitor RYK inhibitor SEA inhibitor SKY inhibitor STK inhibitor STK1 inhibitor Sek2 inhibitor Sek3 inhibitor Sek4 inhibitor Sfr inhibitor TEK inhibitor TIE inhibitor TIE1 inhibitor TIE2 inhibitor TIF inhibitor TKT inhibitor TRK inhibitor TRKA inhibitor TRKB inhibitor TRKC inhibitor TRKE inhibitor TYK1 inhibitor TYRO10 inhibitor TYRO3 inhibitor TYRO7 inhibitor Tyro11 inhibitor Tyro5 inhibitor Tyro6 inhibitor UFO inhibitor VEGFR1 inhibitor VEGFR2 inhibitor VEGFR3 inhibitor Vik inhibitor YK1 inhibitor Yrk inhibitor anaplastic lymphoma kinase inhibitor anaplastic lymphoma kinase inhibitors ephrin-B3 receptor tyrosine kinase inhibitor insulin receptor protein-tyrosine kinase inhibitor neurite outgrowth regulating kinase inhibitor nork inhibitor novel oncogene with kinase-domain inhibitor receptor protein tyrosine kinase inhibitor receptor protein-tyrosine kinase (EC 2.7.10.1) inhibitor receptor protein-tyrosine kinase (EC 2.7.10.1) inhibitors receptor protein-tyrosine kinase inhibitor receptor protein-tyrosine kinase inhibitors EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor CHEBI:62488 signalling molecule signal molecule signal molecules signaling molecule signaling molecules signalling molecules signalling molecule CHEBI:62530 EC 2.3.1.24 (sphingosine N-acyltransferase) inhibitor EC 2.3.1.24 (sphingosine N-acyltransferase) inhibitors EC 2.3.1.24 inhibitor EC 2.3.1.24 inhibitors acyl-CoA:sphingosine N-acyltransferase inhibitor acyl-CoA:sphingosine N-acyltransferase inhibitors ceramide synthase inhibitor ceramide synthase inhibitors ceramide synthetase inhibitor ceramide synthetase inhibitors sphingosine N-acyltransferase (EC 2.3.1.24) inhibitor sphingosine N-acyltransferase (EC 2.3.1.24) inhibitors sphingosine N-acyltransferase inhibitor sphingosine N-acyltransferase inhibitors sphingosine acyltransferase inhibitor sphingosine acyltransferase inhibitors EC 2.3.1.24 (sphingosine N-acyltransferase) inhibitor CHEBI:62608 EC 4.2.1.3 (aconitate hydratase) inhibitor 2-methylaconitate hydratase inhibitor 2-methylaconitate hydratase inhibitors 4.2.1.3 inhibitor 4.2.1.3 inhibitors AcnB inhibitor AcnB inhibitors EC 4.2.1.3 (aconitate hydratase) inhibitors aconitase inhibitor aconitase inhibitors aconitate hydratase (EC 4.2.1.3) inhibitor aconitate hydratase (EC 4.2.1.3) inhibitors aconitate hydratase inhibitor aconitate hydratase inhibitors cis-aconitase inhibitor cis-aconitase inhibitors citrate hydro-lyase inhibitor citrate hydro-lyase inhibitors citrate(isocitrate) hydro-lyase (cis-aconitate-forming) inhibitor citrate(isocitrate) hydro-lyase (cis-aconitate-forming) inhibitors citrate(isocitrate) hydro-lyase inhibitor citrate(isocitrate) hydro-lyase inhibitors EC 4.2.1.3 (aconitate hydratase) inhibitor CHEBI:62609 EC 3.11.1.3 (phosphonopyruvate hydrolase) inhibitor EC 3.11.1.3 (phosphonopyruvate hydrolase) inhibitors EC 3.11.1.3 inhibitor EC 3.11.1.3 inhibitors PPH inhibitor PPH inhibitors phosphonopyruvate hydrolase (EC 3.11.1.3) inhibitor phosphonopyruvate hydrolase (EC 3.11.1.3) inhibitors phosphonopyruvate hydrolase inhibitor phosphonopyruvate hydrolase inhibitors EC 3.11.1.3 (phosphonopyruvate hydrolase) inhibitor CHEBI:62754 glycine receptor antagonist glycine receptor antagonists glycine receptor antagonist CHEBI:62803 fuel additive fuel additives fuel enhancer fuel additive CHEBI:62868 hepatoprotective agent antihepatotoxic agent hepatoprotective agents hepatoprotector hepatoprotective agent CHEBI:62871 EC 4.3.1.24 (phenylalanine ammonia-lyase) inhibitor EC 4.3.1.24 (phenylalanine ammonia-lyase) inhibitors EC 4.3.1.24 inhibitor EC 4.3.1.24 inhibitors L-phenylalanine ammonia-lyase (trans-cinnamate-forming) inhibitor L-phenylalanine ammonia-lyase (trans-cinnamate-forming) inhibitors L-phenylalanine ammonia-lyase inhibitor L-phenylalanine ammonia-lyase inhibitors PAL inhibitor PAL inhibitors Phe ammonia-lyase inhibitor Phe ammonia-lyase inhibitors phenylalanine ammonia-lyase (EC 4.3.1.24) inhibitor phenylalanine ammonia-lyase (EC 4.3.1.24) inhibitors phenylalanine ammonia-lyase inhibitor phenylalanine ammonia-lyase inhibitors phenylalanine ammonium-lyase inhibitor phenylalanine ammonium-lyase inhibitors phenylalanine deaminase inhibitor phenylalanine deaminase inhibitors EC 4.3.1.24 (phenylalanine ammonia-lyase) inhibitor CHEBI:62872 EC 1.2.3.1 (aldehyde oxidase) inhibitor EC 1.2.3.1 (aldehyde oxidase) inhibitors EC 1.2.3.1 inhibitor EC 1.2.3.1 inhibitors aldehyde oxidase (EC 1.2.3.1) inhibitor aldehyde oxidase (EC 1.2.3.1) inhibitors aldehyde oxidase inhibitor aldehyde oxidase inhibitors aldehyde:oxygen oxidoreductase inhibitor aldehyde:oxygen oxidoreductase inhibitors quinoline oxidase inhibitor quinoline oxidase inhibitors retinal oxidase inhibitor retinal oxidase inhibitors retinoic acid synthase inhibitor retinoic acid synthase inhibitors EC 1.2.3.1 (aldehyde oxidase) inhibitor CHEBI:62873 odorant receptor agonist odorant receptor agonist CHEBI:62887 tankyrase inhibitor tankyrase inhibitors tankyrase inhibitor CHEBI:62913 EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor ADP-ribosyltransferase (polymerising) inhibitor ADP-ribosyltransferase (polymerising) inhibitors ADP-ribosyltransferase (polymerizing) inhibitor ADP-ribosyltransferase (polymerizing) inhibitors EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitors EC 2.4.2.30 inhibitor EC 2.4.2.30 inhibitors NAD(+) ADP-ribosyltransferase (EC 2.4.2.30) inhibitor NAD(+) ADP-ribosyltransferase (EC 2.4.2.30) inhibitors NAD(+) ADP-ribosyltransferase inhibitor NAD(+) ADP-ribosyltransferase inhibitors NAD(+):poly(ADP-D-ribosyl)-acceptor ADP-D-ribosyl-transferase inhibitor NAD(+):poly(ADP-D-ribosyl)-acceptor ADP-D-ribosyl-transferase inhibitors NAD(+):poly(adenosine-diphosphate-D-ribosyl)-acceptor ADP-D-ribosyl-transferase inhibitor NAD(+):poly(adenosine-diphosphate-D-ribosyl)-acceptor ADP-D-ribosyl-transferase inhibitors PARP PARPs poly(ADP-ribose) polymerase inhibitor poly(ADP-ribose) polymerase inhibitors poly(ADP-ribose) synthase inhibitor poly(ADP-ribose) synthase inhibitors poly(ADP-ribose) synthetase inhibitor poly(ADP-ribose) synthetase inhibitors poly(adenosine diphosphate ribose) polymerase inhibitor poly(adenosine diphosphate ribose) polymerase inhibitors EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor CHEBI:62914 axin stabilizer axin stabilizer CHEBI:62915 sialyltransferase inhibitor sialyltransferase inhibitors sialyltransferase inhibitor CHEBI:63046 emulsifier emulgent emulgents emulsifiers emulsifier CHEBI:63047 food emulsifier food emulsifiers food emulsifier CHEBI:63054 osteogenesis regulator osteogenesis regulators osteogenesis regulator CHEBI:63060 phase-transfer catalyst PTC phase transfer catalyst phase transfer catalysts phase-transfer catalysts phase-transfer catalyst CHEBI:63064 crystallisation adjutant crystallisation adjutants crystallization adjutant crystallization adjutants crystallisation adjutant CHEBI:63090 EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitors EC 2.4.2.1 inhibitor EC 2.4.2.1 inhibitors PNPase inhibitor PNPase inhibitors PUNPI inhibitor PUNPI inhibitors PUNPII inhibitor PUNPII inhibitors inosine phosphorylase inhibitor inosine phosphorylase inhibitors inosine-guanosine phosphorylase inhibitor inosine-guanosine phosphorylase inhibitors nucleotide phosphatase inhibitor nucleotide phosphatase inhibitors purine deoxynucleoside phosphorylase inhibitor purine deoxynucleoside phosphorylase inhibitors purine deoxyribonucleoside phosphorylase inhibitor purine deoxyribonucleoside phosphorylase inhibitors purine nucleoside phosphorylase inhibitor purine nucleoside phosphorylase inhibitors purine ribonucleoside phosphorylase inhibitor purine ribonucleoside phosphorylase inhibitors purine-nucleoside phosphorylase (EC 2.4.2.1) inhibitor purine-nucleoside phosphorylase (EC 2.4.2.1) inhibitors purine-nucleoside phosphorylase inhibitor purine-nucleoside phosphorylase inhibitors purine-nucleoside:phosphate ribosyltransferase inhibitor purine-nucleoside:phosphate ribosyltransferase inhibitors EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor CHEBI:63114 sphingosine-1-phosphate receptor agonist EDG receptor agonist S1P receptor agonist S1P receptor agonists SIP agonist SIP agonists sphingosine 1-phosphate receptor agonist sphingosine 1-phosphate receptor agonists sphingosine-1-phosphate receptor agonists sphingosine-1-phosphate receptor agonist CHEBI:63146 insulin release inhibitor insulin release inhibitor CHEBI:63156 EC 1.1.3.13 (alcohol oxidase) inhibitor EC 1.1.3.13 (alcohol oxidase) inhibitors EC 1.1.3.13 inhibitor EC 1.1.3.13 inhibitors alcohol oxidase (EC 1.1.3.13) inhibitor alcohol oxidase (EC 1.1.3.13) inhibitors alcohol oxidase inhibitor alcohol oxidase inhibitors alcohol:oxygen oxidoreductase inhibitor alcohol:oxygen oxidoreductase inhibitors ethanol oxidase inhibitor ethanol oxidase inhibitors EC 1.1.3.13 (alcohol oxidase) inhibitor CHEBI:63157 EC 4.2.1.22 (cystathionine beta-synthase) inhibitor EC 4.2.1.22 (cystathionine beta-synthase) inhibitors EC 4.2.1.22 inhibitor EC 4.2.1.22 inhibitors L-serine hydro-lyase (adding homocysteine) inhibitor L-serine hydro-lyase (adding homocysteine) inhibitors L-serine hydro-lyase (adding homocysteine; L-cystathionine-forming) inhibitor L-serine hydro-lyase (adding homocysteine; L-cystathionine-forming) inhibitors beta-thionase inhibitor beta-thionase inhibitors cystathionine beta-synthase (EC 4.2.1.22) inhibitor cystathionine beta-synthase (EC 4.2.1.22) inhibitors cystathionine beta-synthase inhibitor cystathionine beta-synthase inhibitors cystathionine-beta-synthase inhibitor cystathionine-beta-synthase inhibitors cysteine synthase inhibitor cysteine synthase inhibitors methylcysteine synthase inhibitor methylcysteine synthase inhibitors serine sulfhydrase inhibitor serine sulfhydrase inhibitors serine sulfhydrylase inhibitor serine sulfhydrylase inhibitors EC 4.2.1.22 (cystathionine beta-synthase) inhibitor CHEBI:63158 EC 2.3.1.21 (carnitine O-palmitoyltransferase) inhibitor CPT I (outer membrane carnitine palmitoyl transferase) inhibitor CPT I (outer membrane carnitine palmitoyl transferase) inhibitors CPT inhibitor CPT inhibitors CPT-A inhibitor CPT-A inhibitors CPT-B inhibitor CPT-B inhibitors CPTi inhibitor CPTi inhibitors CPTo inhibitor CPTo inhibitors CTP-1 inhibitor CTP-1 inhibitors EC 2.3.1.21 (carnitine O-palmitoyltransferase) inhibitors EC 2.3.1.21 inhibitor EC 2.3.1.21 inhibitors L-carnitine palmitoyltransferase inhibitor L-carnitine palmitoyltransferase inhibitors acylcarnitine transferase inhibitor acylcarnitine transferase inhibitors carnitine O-palmitoyltransferase (EC 2.3.1.21) inhibitor carnitine O-palmitoyltransferase (EC 2.3.1.21) inhibitors carnitine O-palmitoyltransferase inhibitor carnitine O-palmitoyltransferase inhibitors carnitine palmitoyltransferase II inhibitor carnitine palmitoyltransferase II inhibitors carnitine palmitoyltransferase inhibitor carnitine palmitoyltransferase inhibitors carnitine palmitoyltransferase-1 inhibitor carnitine palmitoyltransferase-1 inhibitors carnitine palmitoyltransferase-A inhibitor carnitine palmitoyltransferase-A inhibitors mitochondrial carnitine palmitoyltransferase-1 inhibitor mitochondrial carnitine palmitoyltransferase-1 inhibitors outer malonyl-CoA inhibitable carnitine palmitoyltransferase inhibitor outer malonyl-CoA inhibitable carnitine palmitoyltransferase inhibitors palmitoyl-CoA:L-carnitine O-palmitoyltransferase inhibitor palmitoyl-CoA:L-carnitine O-palmitoyltransferase inhibitors palmitoylcarnitine transferase inhibitor palmitoylcarnitine transferase inhibitors EC 2.3.1.21 (carnitine O-palmitoyltransferase) inhibitor CHEBI:63173 T-cell proliferation inhibitor T-cell proliferation inhibitors T-cell proliferation inhibitor CHEBI:63175 peptidomimetic peptidomimetics peptidomimetic CHEBI:63247 reducing agent reducer reducers reducing agents reductant reductants reducing agent CHEBI:63248 oxidising agent oxidant oxidants oxidiser oxidisers oxidising agents oxidizer oxidizers oxidizing agent oxidizing agents oxidising agent CHEBI:63330 sodium-dependent Pi-transporter inhibitor NPC inhibitor Na-Pi inhibitor sodium-dependent inorganic phosphate cotransporter inhibitor sodium-dependent inorganic phosphate transporter inhibitor sodium-dependent Pi-transporter inhibitor CHEBI:63332 EC 3.1.3.1 (alkaline phosphatase) inhibitor EC 3.1.3.1 (alkaline phosphatase) inhibitors EC 3.1.3.1 inhibitor EC 3.1.3.1 inhibitors alkaline phenyl phosphatase inhibitor alkaline phenyl phosphatase inhibitors alkaline phosphatase (EC 3.1.3.1) inhibitor alkaline phosphatase (EC 3.1.3.1) inhibitors alkaline phosphatase inhibitor alkaline phosphatase inhibitors alkaline phosphohydrolase inhibitor alkaline phosphohydrolase inhibitors alkaline phosphomonoesterase inhibitor alkaline phosphomonoesterase inhibitors glycerophosphatase inhibitor glycerophosphatase inhibitors orthophosphoric-monoester phosphohydrolase (alkaline optimum) inhibitor orthophosphoric-monoester phosphohydrolase (alkaline optimum) inhibitors phosphate-monoester phosphohydrolase (alkaline optimum) inhibitor phosphate-monoester phosphohydrolase (alkaline optimum) inhibitors phosphomonoesterase inhibitor phosphomonoesterase inhibitors EC 3.1.3.1 (alkaline phosphatase) inhibitor CHEBI:63457 fibroblast growth factor receptor antagonist FGFR inhibitor FGFR inhibitors fibroblast growth factor receptor antagonists fibroblast growth factor receptor inhibitor fibroblast growth factor receptor inhibitors fibroblast growth factor receptor antagonist CHEBI:63490 explosive explosive compound explosive compounds explosive material explosives explosives chemical explosives chemicals explosive CHEBI:63510 EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitors EC 3.6.3.9 inhibitor EC 3.6.3.9 inhibitors Na(+)/K(+)-ATPase inhibitor Na(+)/K(+)-ATPase inhibitors Na(+)/K(+)-pump inhibitor Na(+)/K(+)-pump inhibitors Na(+)/K(+)-transporting ATPase (EC 3.6.3.9) inhibitor Na(+)/K(+)-transporting ATPase (EC 3.6.3.9) inhibitors Na(+)/K(+)-transporting ATPase inhibitor Na(+)/K(+)-transporting ATPase inhibitors sodium pump inhibitor sodium pump inhibitors sodium-potassium adenosine triphosphatase inhibitor sodium-potassium adenosine triphosphatase inhibitors sodium-potassium pump inhibitor sodium-potassium pump inhibitors EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor CHEBI:63533 gonadotropin releasing hormone agonist GnRH agonist GnRH agonists GnRH-A gonadotrophin releasing hormone agonist gonadotrophin releasing hormone agonists gonadotropin releasing hormone agonists gonadotropin releasing hormone agonist CHEBI:63562 glucocorticoid receptor agonist glucocorticoid receptor agonists glucocorticoid receptor agonist CHEBI:63673 chemokine receptor 5 antagonist C-C chemokine receptor 5 antagonist C-C chemokine receptor 5 antagonists CCR-5 antagonist CCR-5 antagonists CCR5 antagonist CCR5 antagonists chemokine receptor 5 antagonists chemokine receptor 5 antagonist CHEBI:63674 EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor 4-aminobutanoate:2-oxoglutarate aminotransferase inhibitor 4-aminobutanoate:2-oxoglutarate aminotransferase inhibitors 4-aminobutyrate aminotransferase inhibitor 4-aminobutyrate aminotransferase inhibitors 4-aminobutyrate transaminase inhibitor 4-aminobutyrate transaminase inhibitors 4-aminobutyrate--2-ketoglutarate aminotransferase inhibitor 4-aminobutyrate--2-ketoglutarate aminotransferase inhibitors 4-aminobutyrate--2-oxoglutarate aminotransferase inhibitor 4-aminobutyrate--2-oxoglutarate aminotransferase inhibitors 4-aminobutyrate--2-oxoglutarate transaminase (EC 2.6.1.19) inhibitor 4-aminobutyrate--2-oxoglutarate transaminase (EC 2.6.1.19) inhibitors 4-aminobutyrate--2-oxoglutarate transaminase inhibitor 4-aminobutyrate--2-oxoglutarate transaminase inhibitors 4-aminobutyrate-2-oxoglutarate transaminase inhibitor 4-aminobutyrate-2-oxoglutarate transaminase inhibitors 4-aminobutyric acid 2-ketoglutaric acid aminotransferase inhibitor 4-aminobutyric acid 2-ketoglutaric acid aminotransferase inhibitors 4-aminobutyric acid aminotransferase inhibitor 4-aminobutyric acid aminotransferase inhibitors EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitors EC 2.6.1.19 inhibitor EC 2.6.1.19 inhibitors GABA aminotransferase inhibitor GABA aminotransferase inhibitors GABA transaminase inhibitor GABA transaminase inhibitors GABA transferase inhibitor GABA transferase inhibitors GABA--2-oxoglutarate aminotransferase inhibitor GABA--2-oxoglutarate aminotransferase inhibitors GABA--2-oxoglutarate transaminase inhibitor GABA--2-oxoglutarate transaminase inhibitors GABA--alpha-ketoglutarate aminotransferase inhibitors GABA--alpha-ketoglutarate transaminase inhibitor GABA--alpha-ketoglutarate transaminase inhibitors GABA--alpha-ketoglutaric acid transaminase inhibitor GABA--alpha-ketoglutaric acid transaminase inhibitors GABA--alpha-oxoglutarate aminotransferase inhibitor GABA--alpha-oxoglutarate aminotransferase inhibitors GABA--oxoglutarate aminotransferase inhibitor GABA--oxoglutarate aminotransferase inhibitors GABA--oxoglutarate transaminase inhibitor GABA--oxoglutarate transaminase inhibitors GabT inhibitor GabT inhibitors aminobutyrate aminotransferase inhibitor aminobutyrate aminotransferase inhibitors aminobutyrate transaminase inhibitor aminobutyrate transaminase inhibitors beta-alanine aminotransferase inhibitor beta-alanine aminotransferase inhibitors beta-alanine--oxoglutarate aminotransferase inhibitor beta-alanine--oxoglutarate aminotransferase inhibitors beta-alanine--oxoglutarate transaminase inhibitor beta-alanine--oxoglutarate transaminase inhibitors gamma-amino-N-butyrate transaminase inhibitor gamma-amino-N-butyrate transaminase inhibitors gamma-aminobutyrate aminotransaminase inhibitor gamma-aminobutyrate aminotransaminase inhibitors gamma-aminobutyrate transaminase inhibitor gamma-aminobutyrate transaminase inhibitors gamma-aminobutyrate--alpha-ketoglutarate aminotransferase inhibitor gamma-aminobutyrate--alpha-ketoglutarate aminotransferase inhibitors gamma-aminobutyrate--alpha-ketoglutarate transaminase inhibitor gamma-aminobutyrate--alpha-ketoglutarate transaminase inhibitors gamma-aminobutyrate:alpha-oxoglutarate aminotransferase inhibitor gamma-aminobutyrate:alpha-oxoglutarate aminotransferase inhibitors gamma-aminobutyric acid aminotransferase inhibitor gamma-aminobutyric acid aminotransferase inhibitors gamma-aminobutyric acid pyruvate transaminase inhibitor gamma-aminobutyric acid pyruvate transaminase inhibitors gamma-aminobutyric acid transaminase inhibitor gamma-aminobutyric acid transaminase inhibitors gamma-aminobutyric acid--2-oxoglutarate transaminase inhibitor gamma-aminobutyric acid--2-oxoglutarate transaminase inhibitors gamma-aminobutyric acid--alpha-ketoglutarate transaminase inhibitor gamma-aminobutyric acid--alpha-ketoglutarate transaminase inhibitors gamma-aminobutyric acid--alpha-ketoglutaric acid aminotransferase inhibitor gamma-aminobutyric acid--alpha-ketoglutaric acid aminotransferase inhibitors gamma-aminobutyric transaminase inhibitor gamma-aminobutyric transaminase inhibitors glutamate--succinic semialdehyde transaminase inhibitor glutamate--succinic semialdehyde transaminase inhibitors EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor CHEBI:63720 EC 2.1.1.45 (thymidylate synthase) inhibitor 5,10-methylenetetrahydrofolate:dUMP C-methyltransferase inhibitor 5,10-methylenetetrahydrofolate:dUMP C-methyltransferase inhibitors EC 2.1.1.45 (thymidylate synthase) inhibitors EC 2.1.1.45 inhibitor EC 2.1.1.45 inhibitors TMP synthetase inhibitor TMP synthetase inhibitors dTMP synthase inhibitor dTMP synthase inhibitors methylenetetrahydrofolate:dUMP C-methyltransferase inhibitor methylenetetrahydrofolate:dUMP C-methyltransferase inhibitors thymidylate synthase inhibitor thymidylate synthase inhibitors thymidylate synthetase inhibitor thymidylate synthetase inhibitors EC 2.1.1.45 (thymidylate synthase) inhibitor CHEBI:63721 EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor 10-formyltetrahydrofolate:5'-phosphoribosylglycinamide N-formyltransferase inhibitors 2-amino-N-ribosylacetamide 5'-phosphate transformylase inhibitor 5,10-methenyltetrahydrofolate:2-amino-N-ribosylacetamide ribonucleotide transformylase inhibitor 5,10-methenyltetrahydrofolate:2-amino-N-ribosylacetamide ribonucleotide transformylase inhibitors EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitors EC 2.1.2.2 inhibitor EC 2.1.2.2 inhibitors GAR TFase inhibitor GAR TFase inhibitors GAR formyltransferase inhibitor GAR formyltransferase inhibitors GAR transformylase inhibitor GAR transformylase inhibitors glycinamide ribonucleotide formyltransferase inhibitor glycinamide ribonucleotide formyltransferase inhibitors glycinamide ribonucleotide transformylase inhibitor glycinamide ribonucleotide transformylase inhibitors phosphoribosylglycinamide formyltransferase (EC 2.1.2.2) inhibitor phosphoribosylglycinamide formyltransferase (EC 2.1.2.2) inhibitors phosphoribosylglycinamide formyltransferase inhibitor phosphoribosylglycinamide formyltransferase inhibitors EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor CHEBI:63726 neuroprotective agent neuroprotectant neuroprotectants neuroprotective agents neuroprotective agent CHEBI:63794 retinoid X receptor agonist retinoid X receptor agonists retinoid X receptor agonist CHEBI:63908 film-forming compound film-forming agent film-forming agents film-forming compounds film-forming compound CHEBI:63923 sclerotherapy agent sclerotherapy agents sclerotherapy agent CHEBI:63932 EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitors EC 1.14.16.2 inhibitor EC 1.14.16.2 inhibitors L-tyrosine hydroxylase inhibitor L-tyrosine hydroxylase inhibitors L-tyrosine,tetrahydrobiopterin:oxygen oxidoreductase (3-hydroxylating) inhibitor L-tyrosine,tetrahydrobiopterin:oxygen oxidoreductase (3-hydroxylating) inhibitors tyrosine 3-hydroxylase inhibitor tyrosine 3-hydroxylase inhibitors tyrosine 3-monooxygenase (EC 1.14.16.2) inhibitor tyrosine 3-monooxygenase (EC 1.14.16.2) inhibitors tyrosine 3-monooxygenase inhibitor tyrosine 3-monooxygenase inhibitors tyrosine hydroxylase inhibitor tyrosine hydroxylase inhibitors EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor CHEBI:63936 alpha1B-adrenoceptor antagonist alpha1B-adrenoceptor antagonists alpha1B-adrenoceptor antagonist CHEBI:63951 estrogen receptor agonist estrogen receptor agonists estrogen receptor agonist CHEBI:63957 adenosine A1 receptor antagonist adenosine A1 receptor antagonists adenosine A1 receptor antagonist CHEBI:63958 cellulose synthesis inhibitor cellulose biosynthesis inhibitor cellulose biosynthesis inhibitors cellulose synthesis inhibitors cellulose synthesis inhibitor CHEBI:63962 Hsp90 inhibitor Hsp90 inhibitors heat shock protein 90 inhibitor heat shock protein 90 inhibitors Hsp90 inhibitor CHEBI:63963 metabotropic glutamate receptor antagonist mGluR antagonist mGluR antagonists metabotropic glutamate receptor antagonists metabotropic glutamate receptor antagonist CHEBI:64018 protein kinase C agonist protein kinase C agonists protein kinase C agonist CHEBI:64033 EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor EC 3.5.1.99 (fatty acid amide hydrolase) inhibitors EC 3.5.1.99 inhibitor EC 3.5.1.99 inhibitors FAAH inhibitor FAAH inhibitors anandamide amidohydrolase inhibitor anandamide amidohydrolase inhibitors arachidonoylethanolamide amidohydrolase inhibitor arachidonoylethanolamide amidohydrolase inhibitors fatty acid amide hydrolase (EC 3.5.1.99) inhibitor fatty acid amide hydrolase (EC 3.5.1.99) inhibitors fatty acid amide hydrolase inhibitor fatty acid amide hydrolase inhibitors fatty acylamide amidohydrolase inhibitor fatty acylamide amidohydrolase inhibitors oleamide hydrolase inhibitor oleamide hydrolase inhibitors EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor CHEBI:64047 food additive food additives food additive CHEBI:64049 food acidity regulator acidity regulator acidity regulators food acidity regulators pH control agent pH control agents food acidity regulator CHEBI:64054 delta-opioid receptor agonist delta-opioid receptor agonist CHEBI:64088 incretin mimetic incretin mimetics incretin mimetic CHEBI:64102 AMPA receptor agonist AMPA receptor agonists AMPAR agonist alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor agonist quisqualate receptor agonist AMPA receptor agonist CHEBI:64105 protein kinase G agonist protein kinase G agonists protein kinase G agonist CHEBI:64106 protein kinase agonist protein kinase agonists protein kinase agonist CHEBI:64133 EC 2.5.1.58 (protein farnesyltransferase) inhibitor EC 2.5.1.58 (protein farnesyltransferase) inhibitors EC 2.5.1.58 inhibitor EC 2.5.1.58 inhibitors FTase inhibitor FTase inhibitors farnesyl transferase inhibitor farnesyl transferase inhibitors farnesyl-diphosphate:protein-cysteine farnesyltransferase inhibitor farnesyl-diphosphate:protein-cysteine farnesyltransferase inhibitors farnesyltransferase inhibitor farnesyltransferase inhibitors protein farnesyltransferase (EC 2.5.1.58) inhibitor protein farnesyltransferase (EC 2.5.1.58) inhibitors protein farnesyltransferase inhibitor protein farnesyltransferase inhibitors EC 2.5.1.58 (protein farnesyltransferase) inhibitor CHEBI:64152 cysteine protease inhibitor cysteine protease inhibitors cysteine proteinase inhibitor cysteine proteinase inhibitors cysteine protease inhibitor CHEBI:64154 H3-receptor agonist H3-receptor agonists histamine H3-receptor agonist histamine H3-receptor agonists H3-receptor agonist CHEBI:64155 H4-receptor agonist H4-receptor agonists H4-receptor agonist CHEBI:64176 H3-receptor antagonist H3-receptor antagonists histamine H3-receptor antagonist histamine H3-receptor antagonists H3-receptor antagonist CHEBI:64237 EC 2.7.8.15 (UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase) inhibitor EC 2.7.8.15 (UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase) inhibitors EC 2.7.8.15 inhibitor EC 2.7.8.15 inhibitors GlcNAc-1-P transferase inhibitor GlcNAc-1-P transferase inhibitors N-acetylglucosamine phosphotransferase inhibitor N-acetylglucosamine transferase inhibitors N-acetylglucosamine-1-phosphate transferase inhibitor N-acetylglucosamine-1-phosphate transferase inhibitors UDP-D-N-acetylglucosamine N-acetylglucosamine 1-phosphate transferase inhibitor UDP-D-N-acetylglucosamine N-acetylglucosamine 1-phosphate transferase inhibitors UDP-GlcNAc:dolichyl-phosphate GlcNAc-1-phosphate transferase inhibitor UDP-GlcNAc:dolichyl-phosphate GlcNAc-1-phosphate transferase inhibitors UDP-N-acetyl-D-glucosamine:dolichol phosphate N-acetyl-D-glucosamine-1-phosphate transferase inhibitor UDP-N-acetyl-D-glucosamine:dolichol phosphate N-acetyl-D-glucosamine-1-phosphate transferase inhibitors UDP-N-acetyl-D-glucosamine:dolichyl-phosphate N-acetyl-D-glucosaminephosphotransferase inhibitor UDP-N-acetyl-D-glucosamine:dolichyl-phosphate N-acetyl-D-glucosaminephosphotransferase inhibitors UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase (EC 2.7.8.15) inhibitor UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase (EC 2.7.8.15) inhibitors UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase inhibitor UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase inhibitors UDP-acetylglucosamine--dolichol phosphate acetylglucosamine phosphotransferase inhibitor UDP-acetylglucosamine--dolichol phosphate acetylglucosamine phosphotransferase inhibitors UDP-acetylglucosamine--dolichol phosphate acetylglucosamine-1-phosphotransferase inhibitor UDP-acetylglucosamine--dolichol phosphate acetylglucosamine-1-phosphotransferase inhibitors chitobiosylpyrophosphoryldolichol synthase inhibitor chitobiosylpyrophosphoryldolichol synthase inhibitors dolichol phosphate N-acetylglucosamine-1-phosphotransferase inhibitor dolichol phosphate N-acetylglucosamine-1-phosphotransferase inhibitors uridine diphosphoacetylglucosamine--dolichyl phosphate acetylglucosamine-1-phosphotransferase inhibitor uridine diphosphoacetylglucosamine--dolichyl phosphate acetylglucosamine-1-phosphotransferase inhibitors EC 2.7.8.15 (UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase) inhibitor CHEBI:64297 reaction intermediate chemical intermediate reaction intermediate CHEBI:64338 K-ATP channel agonist ATP-sensitive K(+) channel agonist ATP-sensitive K(+) channel agonists ATP-sensitive K+ channel agonist ATP-sensitive K+ channel agonists ATP-sensitive K+ channel opener ATP-sensitive K+ channel openers K(ATP) channel agonist K(ATP) channel agonists K-ATP channel agonists K-ATP channel agonist CHEBI:64345 MALDI matrix material 'matrix-assisted laser desorption/ionization' matrix material 'matrix-assisted laser desorption/ionization' matrix materials MALDI matrix materials MALDI matrix solution MALDI matrix solutions MALDI matrix material CHEBI:64370 glutamate transporter activator excitatory amino-acid transporter activator excitatory amino-acid transporter activators glutamate transporter activators glutamate transporter activator CHEBI:64371 neurotransmitter transporter modulator neurotransmitter transporter modulators neurotransmitter transporter modulator CHEBI:64406 EC 3.4.22.38 (cathepsin K) inhibitor EC 3.4.22.38 (cathepsin K) inhibitors EC 3.4.22.38 inhibitor EC 3.4.22.38 inhibitors cathepsin K (EC 3.4.22.38) inhibitor cathepsin K (EC 3.4.22.38) inhibitors cathepsin K inhibitor cathepsin K inhibitors cathepsin O inhibitor cathepsin O inhibitors cathepsin O2 inhibitor cathepsin O2 inhibitors cathepsin X inhibitor cathepsin X inhibitors EC 3.4.22.38 (cathepsin K) inhibitor CHEBI:64411 EC 2.5.1.29 (geranylgeranyl diphosphate synthase) inhibitor (2E,6E)-farnesyl-diphosphate:isopentenyl-diphosphate farnesyltranstransferase inhibitor (2E,6E)-farnesyl-diphosphate:isopentenyl-diphosphate farnesyltranstransferase inhibitors EC 2.5.1.29 (geranylgeranyl diphosphate synthase) inhibitors EC 2.5.1.29 inhibitor EC 2.5.1.29 inhibitors GGPP synthase inhibitor GGPP synthase inhibitors farnesyltransferase inhibitor farnesyltransferase inhibitors geranylgeranyl diphosphate synthase (EC 2.5.1.29) inhibitor geranylgeranyl diphosphate synthase (EC 2.5.1.29) inhibitors geranylgeranyl diphosphate synthase inhibitor geranylgeranyl diphosphate synthase inhibitors geranylgeranyl pyrophosphate synthase inhibitor geranylgeranyl pyrophosphate synthase inhibitors geranylgeranyl pyrophosphate synthetase inhibitor geranylgeranyl pyrophosphate synthetase inhibitors geranylgeranyl-PP synthetase inhibitor geranylgeranyl-PP synthetase inhibitors EC 2.5.1.29 (geranylgeranyl diphosphate synthase) inhibitor CHEBI:64416 EC 1.3.1.43 (arogenate dehydrogenase) inhibitor EC 1.3.1.43 (arogenate dehydrogenase) inhibitors EC 1.3.1.43 inhibitor EC 1.3.1.43 inhibitors L-arogenate:NAD(+) oxidoreductase (decarboxylating) inhibitor L-arogenate:NAD(+) oxidoreductase (decarboxylating) inhibitors L-arogenate:NAD+ oxidoreductase (decarboxylating) inhibitor L-arogenate:NAD+ oxidoreductase (decarboxylating) inhibitors L-arogenate:NAD+ oxidoreductase inhibitor L-arogenate:NAD+ oxidoreductase inhibitors TyrA(a) inhibitor TyrA(a) inhibitors arogenate dehydrogenase (EC 1.3.1.43) inhibitor arogenate dehydrogenase (EC 1.3.1.43) inhibitors arogenate dehydrogenase inhibitor arogenate dehydrogenase inhibitors cyclohexadienyl dehydrogenase inhibitor cyclohexadienyl dehydrogenase inhibitors EC 1.3.1.43 (arogenate dehydrogenase) inhibitor CHEBI:64477 monolignol monolignols monolignol CHEBI:64570 EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor 5,10-methylenetetrahydrofolate:glycine hydroxymethyltransferase inhibitor 5,10-methylenetetrahydrofolate:glycine hydroxymethyltransferase inhibitors EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitors EC 2.1.2.1 inhibitor EC 2.1.2.1 inhibitors L-serine hydroxymethyltransferase inhibitor L-serine hydroxymethyltransferase inhibitors L-threonine aldolase inhibitor L-threonine aldolase inhibitors allothreonine aldolase inhibitor allothreonine aldolase inhibitors glycine hydroxymethyltransferase (EC 2.1.2.1) inhibitor glycine hydroxymethyltransferase (EC 2.1.2.1) inhibitors glycine hydroxymethyltransferase inhibitor glycine hydroxymethyltransferase inhibitors serine aldolase inhibitor serine aldolase inhibitors serine hydroxymethylase inhibitor serine hydroxymethylase inhibitors serine hydroxymethyltransferase inhibitor serine hydroxymethyltransferase inhibitors serine transhydroxymethylase inhibitor serine transhydroxymethylase inhibitors threonine aldolase inhibitor threonine aldolase inhibitors EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor CHEBI:64571 NMDA receptor agonist N-methyl-D-aspartate receptor agonist N-methyl-D-aspartate receptor agonists NMDA receptor agonists NMDAR agonist NMDAR agonists NMDA receptor agonist CHEBI:64577 flour treatment agent dough improver dough improvers flour treatment agent improving agent improving agents flour treatment agent CHEBI:64584 uremic toxin uremic toxins uremic toxin CHEBI:64588 glycine transporter 1 inhibitor GlyT1 inhibitor GlyT1 inhibitors glycine transporter 1 inhibitors glycine transporter 1 inhibitor CHEBI:64589 glycine receptor agonist glycine receptor agonists glycine receptor agonist CHEBI:64670 EC 1.8.1.9 (thioredoxin reductase) inhibitor EC 1.8.1.9 (thioredoxin reductase) inhibitors EC 1.8.1.9 inhibitor EC 1.8.1.9 inhibitors NADP-thioredoxin reductase inhibitor NADP-thioredoxin reductase inhibitors NADPH-thioredoxin reductase inhibitor NADPH-thioredoxin reductase inhibitors NADPH2:oxidized thioredoxin oxidoreductase inhibitor NADPH2:oxidized thioredoxin oxidoreductase inhibitors TrxR inhibitor TrxR inhibitors thioredoxin reductase (EC 1.8.1.9) inhibitor thioredoxin reductase (EC 1.8.1.9) inhibitors thioredoxin reductase (NADPH) inhibitor thioredoxin reductase (NADPH) inhibitors thioredoxin reductase inhibitor thioredoxin reductase inhibitors thioredoxin-disulfide reductase inhibitor thioredoxin-disulfide reductase inhibitors thioredoxin:NADP+ oxidoreductase inhibitor thioredoxin:NADP+ oxidoreductase inhibitors EC 1.8.1.9 (thioredoxin reductase) inhibitor CHEBI:64696 EC 2.3.1.26 (sterol O-acyltransferase) inhibitor ACAT inhibitor ACAT inhibitors EC 2.3.1.26 (sterol O-acyltransferase) inhibitors EC 2.3.1.26 inhibitor EC 2.3.1.26 inhibitors acyl coenzyme A-cholesterol-O-acyltransferase inhibitor acyl coenzyme A-cholesterol-O-acyltransferase inhibitors acyl-CoA:cholesterol O-acyltransferase inhibitor acyl-CoA:cholesterol acyltransferase inhibitor acyl-CoA:cholesterol acyltransferase inhibitors acylcoenzyme A:cholesterol O-acyltransferase inhibitor acylcoenzyme A:cholesterol O-acyltransferase inhibitors cholesterol acyltransferase inhibitor cholesterol acyltransferase inhibitors cholesterol ester synthase inhibitor cholesterol ester synthase inhibitors cholesterol ester synthetase inhibitor cholesterol ester synthetase inhibitors cholesteryl ester synthetase inhibitor cholesteryl ester synthetase inhibitors sterol O-acyltransferase (EC 2.3.1.26) inhibitor sterol O-acyltransferase (EC 2.3.1.26) inhibitors sterol O-acyltransferase inhibitor sterol O-acyltransferase inhibitors sterol-ester synthase inhibitor sterol-ester synthase inhibitors sterol-ester synthetase inhibitor sterol-ester synthetase inhibitors EC 2.3.1.26 (sterol O-acyltransferase) inhibitor CHEBI:64697 acyl-CoA:cholesterol acyltransferase 2 inhibitor ACAT-2 inhibitor ACAT-2 inhibitors acyl-CoA:cholesterol acyltransferase 2 inhibitors acyl-CoA:cholesterol acyltransferase 2 inhibitor CHEBI:64763 EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor 1-phosphatidyl-1D-myo-inositol-4,5-bisphosphate inositoltrisphosphohydrolase inhibitor 1-phosphatidyl-1D-myo-inositol-4,5-bisphosphate inositoltrisphosphohydrolase inhibitors 1-phosphatidyl-D-myo-inositol-4,5-bisphosphate inositoltrisphosphohydrolase inhibitor 1-phosphatidyl-D-myo-inositol-4,5-bisphosphate inositoltrisphosphohydrolase inhibitors 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase inhibitor 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase inhibitors EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitors EC 3.1.4.11 inhibitor EC 3.1.4.11 inhibitors PI-PLC inhibitor PI-PLC inhibitors monophosphatidylinositol phosphodiesterase inhibitor monophosphatidylinositol phosphodiesterase inhibitors phosphatidylinositol phospholipase C inhibitor phosphatidylinositol phospholipase C inhibitors phosphatidylinositol-specific phospholipase C inhibitor phosphatidylinositol-specific phospholipase C inhibitors phosphoinositidase C inhibitor phosphoinositidase C inhibitors phosphoinositide phospholipase C (EC 3.1.4.11) inhibitor phosphoinositide phospholipase C (EC 3.1.4.11) inhibitors phosphoinositide phospholipase C inhibitor phosphoinositide phospholipase C inhibitors triphosphoinositide phosphodiesterase inhibitor triphosphoinositide phosphodiesterase inhibitors EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor CHEBI:64857 cosmetic cosmetic component cosmetics cosmetic CHEBI:64909 poison poisonous agent poisonous agents poisonous substance poisonous substances poisons toxic agent toxic agents toxic substance toxic substances poison CHEBI:64911 antimitotic antimitotics mitosis inhibitor mitosis inhibitors mitotic inhibitor mitotic inhibitors antimitotic CHEBI:64912 antimycobacterial drug antimycobacterial agent antimycobacterial agents antimycobacterial drugs antimycobacterials antimycobacterium antimycobacterial drug CHEBI:64915 antiplasmodial drug antiplasmodial agent antiplasmodial agents antiplasmodial drugs antiplasmodium agent antiplasmodium agents antiplasmodium drug antiplasmodium drugs antiplasmodial drug CHEBI:64919 EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitor 1,2-diacylglycerol acyltransferase inhibitor 1,2-diacylglycerol acyltransferase inhibitors DGAT inhibitor DGAT inhibitors EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitors EC 2.3.1.20 inhibitor EC 2.3.1.20 inhibitors acyl-CoA:1,2-diacylglycerol O-acyltransferase inhibitor acyl-CoA:1,2-diacylglycerol O-acyltransferase inhibitors diacylglycerol O-acyltransferase (EC 2.3.1.20) inhibitor diacylglycerol O-acyltransferase (EC 2.3.1.20) inhibitors diacylglycerol O-acyltransferase inhibitor diacylglycerol O-acyltransferase inhibitors diacylglycerol acyltransferase inhibitor diacylglycerol acyltransferase inhibitors diglyceride O-acyltransferase inhibitor diglyceride O-acyltransferase inhibitors diglyceride acyltransferase inhibitor diglyceride acyltransferase inhibitors palmitoyl-CoA-sn-1,2-diacylglycerol acyltransferase inhibitor palmitoyl-CoA-sn-1,2-diacylglycerol acyltransferase inhibitors EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitor CHEBI:64920 EC 6.5.1.1 [DNA ligase (ATP)] inhibitor DNA joinase inhibitor DNA joinase inhibitors DNA ligase (ATP) (EC 6.5.1.1) inhibitor DNA ligase (ATP) (EC 6.5.1.1) inhibitors DNA ligase (ATP) inhibitor DNA ligase inhibitor DNA ligase inhibitors DNA repair enzyme inhibitor DNA repair enzyme inhibitors DNA-joining enzyme inhibitor DNA-joining enzyme inhibitors EC 6.5.1.1 (DNA ligase (ATP)) inhibitor EC 6.5.1.1 (DNA ligase (ATP)) inhibitors EC 6.5.1.1 [DNA ligase (ATP)] inhibitors EC 6.5.1.1 inhibitor EC 6.5.1.1 inhibitors deoxyribonucleate ligase inhibitor deoxyribonucleate ligase inhibitors deoxyribonucleic acid joinase inhibitor deoxyribonucleic acid joinase inhibitors deoxyribonucleic acid ligase inhibitor deoxyribonucleic acid ligase inhibitors deoxyribonucleic acid repair enzyme inhibitor deoxyribonucleic acid repair enzyme inhibitors deoxyribonucleic acid-joining enzyme inhibitor deoxyribonucleic acid-joining enzyme inhibitors deoxyribonucleic joinase inhibitor deoxyribonucleic joinase inhibitors deoxyribonucleic ligase inhibitor deoxyribonucleic ligase inhibitors deoxyribonucleic repair enzyme inhibitor deoxyribonucleic repair enzyme inhibitors deoxyribonucleic-joining enzyme inhibitor deoxyribonucleic-joining enzyme inhibitors polydeoxyribonucleotide synthase (ATP) inhibitor sealase inhibitor sealase inhibitors EC 6.5.1.1 [DNA ligase (ATP)] inhibitor CHEBI:64922 EC 3.4.21.37 (leukocyte elastase) inhibitor EC 3.4.21.37 (leukocyte elastase) inhibitors EC 3.4.21.37 inhibitor EC 3.4.21.37 inhibitors elastase inhibitor elastase inhibitors elaszym inhibitor elaszym inhibitors granulocyte elastase inhibitor granulocyte elastase inhibitors leukocyte elastase (EC 3.4.21.37) inhibitor leukocyte elastase (EC 3.4.21.37) inhibitors leukocyte elastase inhibitor lysosomal elastase inhibitor lysosomal elastase inhibitors neutrophil elastase inhibitor neutrophil elastase inhibitors polymorphonuclear leukocyte elastase inhibitor polymorphonuclear leukocyte elastase inhibitors serine elastase inhibitor serine elastase inhibitors EC 3.4.21.37 (leukocyte elastase) inhibitor CHEBI:64924 hepatitis C protease inhibitor hepatitis C protease inhibitors hepatitis C protease inhibitor CHEBI:64926 serine protease inhibitor serine protease inhibitors serine proteinase inhibitor serine proteinase inhibitors serine protease inhibitor CHEBI:64932 cathepsin B inhibitor EC 3.4.22.1 inhibitor EC 3.4.22.1 inhibitors cathepsin B inhibitors cathepsin B1 inhibitor cathepsin B1 inhibitors cathepsin II inhibitor cathepsin II inhibitors cathepsin B inhibitor CHEBI:64933 melanin synthesis inhibitor melanin biosynthesis inhibitor melanin biosynthesis inhibitors melanin synthesis inhibitors melanogenesis inhibitor melanogenesis inhibitors melanin synthesis inhibitor CHEBI:64943 EC 3.4.21.1 (chymotrypsin) inhibitor EC 3.4.21.1 (chymotrypsin) inhibitors EC 3.4.21.1 inhibitor EC 3.4.21.1 inhibitors alpha-chymar inhibitor alpha-chymar inhibitors alpha-chymar ophth inhibitor alpha-chymar ophth inhibitors alpha-chymotrypsin inhibitor alpha-chymotrypsin inhibitors avazyme inhibitor avazyme inhibitors chymar inhibitor chymar inhibitors chymotest inhibitor chymotest inhibitors chymotrypsin (EC 3.4.21.1) inhibitor chymotrypsin (EC 3.4.21.1) inhibitors chymotrypsin inhibitor chymotrypsin inhibitors chymotrypsins A and B inhibitor chymotrypsins A and B inhibitors chymotrypsins A inhibitor chymotrypsins A inhibitors chymotrypsins B inhibitor chymotrypsins B inhibitors enzeon inhibitor enzeon inhibitors quimar inhibitor quimar inhibitors quimotrase inhibitor quimotrase inhibitors EC 3.4.21.1 (chymotrypsin) inhibitor CHEBI:64946 anti-HIV agent anti-AIDS agent anti-AIDS agents anti-HIV agents anti-HIV agent CHEBI:64947 anti-HIV-1 agent anti-HIV-1 agents anti-HTLV-III agent anti-HTLV-III agents anti-LAV agent anti-LAV agents anti-HIV-1 agent CHEBI:64949 anti-HIV-2 agent anti-HIV-2 agents anti-HIV-2 agent CHEBI:64951 anti-HBV agent anti-HBV agents anti-hepatitis B virus agent anti-hepatitis B virus agents anti-HBV agent CHEBI:64952 anti-HSV agent anti-HHV agent anti-HHV agents anti-HSV agents anti-herpes simplex virus agent anti-herpes simplex virus agents anti-human herpes virus agent anti-human herpes virus agents anti-HSV agent CHEBI:64953 anti-HSV-1 agent anti-HHV-1 agent anti-HHV-1 agents anti-HHV-I agent anti-HHV-I agents anti-HSV-1 agents anti-HSV-I agent anti-HSV-I agents anti-human herpes virus-1 agent anti-human herpes virus-1 agents anti-human herpes virus-I agent anti-human herpes virus-I agents anti-HSV-1 agent CHEBI:64954 anti-HSV-2 agent anti-HHV-2 agent anti-HHV-2 agents anti-HHV-II agent anti-HHV-II agents anti-HSV-2 agents anti-HSV-II agent anti-HSV-II agents anti-human herpes virus-2 agent anti-human herpes virus-2 agents anti-human herpes virus-II agent anti-human herpes virus-II agents anti-HSV-2 agent CHEBI:64955 EC 3.2.1.166 (heparanase) inhibitor C1A heparanase inhibitor C1A heparanase inhibitors EC 3.2.1.166 (heparanase) inhibitors HPSE inhibitor HPSE inhibitors Hpa1 heparanase inhibitor Hpa1 heparanase inhibitors Hpa1 inhibitor Hpa1 inhibitors heparan sulfate N-sulfo-D-glucosamine endoglucanase inhibitor heparan sulfate N-sulfo-D-glucosamine endoglucanase inhibitors heparanase (EC 3.2.1.166) inhibitor heparanase (EC 3.2.1.166) inhibitors heparanase 1 inhibitor heparanase 1 inhibitors heparanase inhibitor heparanase inhibitors heparanase-1 inhibitor heparanase-1 inhibitors EC 3.2.1.166 (heparanase) inhibitor CHEBI:64957 EC 3.4.21.39 (chymase) inhibitor EC 3.4.21.39 (chymase) inhibitors EC 3.4.21.39 inhibitor EC 3.4.21.39 inhibitors SK protease inhibitor SK protease inhibitors chymase (EC 3.4.21.39) inhibitor chymase (EC 3.4.21.39) inhibitors chymase inhibitor chymase inhibitors mast cell protease I inhibitor mast cell protease I inhibitors skeletal muscle (SK) protease inhibitor skeletal muscle (SK) protease inhibitors skeletal muscle protease inhibitor skeletal muscle protease inhibitors skin chymotryptic proteinase inhibitor skin chymotryptic proteinase inhibitors EC 3.4.21.39 (chymase) inhibitor CHEBI:64964 EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor 5-LOX inhibitor 5-LOX inhibitors 5-lipoxygenase inhibitor 5-lipoxygenase inhibitors 5delta-lipoxygenase inhibitor 5delta-lipoxygenase inhibitors C-5-lipoxygenase inhibitor C-5-lipoxygenase inhibitors EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitors EC 1.13.11.34 inhibitor EC 1.13.11.34 inhibitors LTA synthase inhibitor LTA synthase inhibitors arachidonate 5-lipoxygenase (EC 1.13.11.34) inhibitor arachidonate 5-lipoxygenase (EC 1.13.11.34) inhibitors arachidonate 5-lipoxygenase inhibitor arachidonate 5-lipoxygenase inhibitors arachidonic 5-lipoxygenase inhibitor arachidonic 5-lipoxygenase inhibitors arachidonic acid 5-lipoxygenase inhibitor arachidonic acid 5-lipoxygenase inhibitors delta(5)-lipoxygenase inhibitor delta(5)-lipoxygenase inhibitors leukotriene A4 synthase inhibitor leukotriene A4 synthase inhibitors leukotriene-A4 synthase inhibitor leukotriene-A4 synthase inhibitors EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor CHEBI:64995 EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor 12-LOX inhibitor 12-LOX inhibitors 12-lipoxygenase inhibitor 12-lipoxygenase inhibitors 12S-lipoxygenase inhibitor 12S-lipoxygenase inhibitors 5delta-lipoxygenase inhibitor 5delta-lipoxygenase inhibitors C-5-lipoxygenase inhibitor C-5-lipoxygenase inhibitors EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitors EC 1.13.11.31 inhibitor EC 1.13.11.31 inhibitors LTA4 synthase inhibitor LTA4 synthase inhibitors arachidonate 12-lipoxygenase (EC 1.13.11.31) inhibitor arachidonate 12-lipoxygenase (EC 1.13.11.31) inhibitors arachidonate 12-lipoxygenase inhibitor arachidonate 12-lipoxygenase inhibitors delta(12)-lipoxygenase inhibitor delta(12)-lipoxygenase inhibitors leukotriene A4 synthase inhibitor leukotriene A4 synthase inhibitors EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor CHEBI:64996 EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor 15-LOX inhibitor 15-LOX inhibitors 15-lipoxygenase inhibitor 15-lipoxygenase inhibitors EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitors EC 1.13.11.33 inhibitor EC 1.13.11.33 inhibitors arachidonate 15-lipoxygenase (EC 1.13.11.33) inhibitor arachidonate 15-lipoxygenase (EC 1.13.11.33) inhibitors arachidonate 15-lipoxygenase inhibitor arachidonate 15-lipoxygenase inhibitors arachidonate:oxygen 15-oxidoreductase inhibitor arachidonate:oxygen 15-oxidoreductase inhibitors linoleic acid omega(6)-lipoxygenase inhibitor linoleic acid omega(6)-lipoxygenase inhibitors omega(6) lipoxygenase inhibitor omega(6) lipoxygenase inhibitors EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor CHEBI:65001 EC 3.1.1.3 (triacylglycerol lipase) inhibitor EC 3.1.1.3 (triacylglycerol lipase) inhibitors EC 3.1.1.3 inhibitor EC 3.1.1.3 inhibitors GEH inhibitor GEH inhibitors PPL inhibitor PPL inhibitors Tween hydrolase inhibitor Tween hydrolase inhibitors Tweenase inhibitor Tweenase inhibitors Tweenesterase inhibitor Tweenesterase inhibitors butyrinase inhibitor butyrinase inhibitors cacordase inhibitor cacordase inhibitors capalase L inhibitor capalase L inhibitors glycerol ester hydrolase inhibitor glycerol ester hydrolase inhibitors glycerol-ester hydrolase inhibitor glycerol-ester hydrolase inhibitors heparin releasable hepatic lipase inhibitor heparin releasable hepatic lipase inhibitors hepatic lipase inhibitor hepatic lipase inhibitors hepatic monoacylglycerol acyltransferase inhibitor hepatic monoacylglycerol acyltransferase inhibitors lipase inhibitor lipase inhibitors lipazin inhibitor lipazin inhibitors liver lipase inhibitor liver lipase inhibitors pancreatic lipase inhibitor pancreatic lipase inhibitors pancreatic triacylglycerol lipase inhibitor pancreatic triacylglycerol lipase inhibitors post-heparin plasma protamine-resistant lipase inhibitor post-heparin plasma protamine-resistant lipase inhibitors salt-resistant post-heparin lipase inhibitor salt-resistant post-heparin lipase inhibitors steapsin inhibitor steapsin inhibitors triacetinase inhibitor triacetinase inhibitors triacylglycerol ester hydrolase inhibitor triacylglycerol ester hydrolase inhibitors triacylglycerol lipase (EC 3.1.1.3) inhibitor triacylglycerol lipase (EC 3.1.1.3) inhibitors triacylglycerol lipase inhibitor triacylglycerol lipase inhibitors tributyrase inhibitor tributyrase inhibitors tributyrin esterase inhibitor tributyrin esterase inhibitors tributyrinase inhibitor tributyrinase inhibitors triglyceridase inhibitor triglyceridase inhibitors triglyceride hydrolase inhibitor triglyceride hydrolase inhibitors triglyceride lipase inhibitor triglyceride lipase inhibitors triolein hydrolase inhibitor triolein hydrolase inhibitors tween-hydrolysing esterase inhibitor tween-hydrolyzing esterase inhibitors EC 3.1.1.3 (triacylglycerol lipase) inhibitor CHEBI:65023 anti-asthmatic agent anti-asthmatic agents antiasthmatic agent antiasthmatic agents anti-asthmatic agent CHEBI:65053 EC 4.1.1.19 (arginine decarboxylase) inhibitor ADC inhibitor ADC inhibitors EC 4.1.1.19 (arginine decarboxylase) inhibitors EC 4.1.1.19 inhibitor EC 4.1.1.19 inhibitors L-arginine carboxy-lyase (agmatine-forming) inhibitor L-arginine carboxy-lyase (agmatine-forming) inhibitors L-arginine carboxy-lyase inhibitor L-arginine carboxy-lyase inhibitors SpeA inhibitor SpeA inhibitors arginine decarboxylase (EC 4.1.1.19) inhibitor arginine decarboxylase (EC 4.1.1.19) inhibitors arginine decarboxylase inhibitor arginine decarboxylase inhibitors EC 4.1.1.19 (arginine decarboxylase) inhibitor CHEBI:65056 EC 3.1.3.11 (fructose-bisphosphatase) inhibitor D-fructose 1,6-diphosphatase inhibitor D-fructose 1,6-diphosphatase inhibitors D-fructose-1,6-bisphosphate 1-phosphohydrolase inhibitor D-fructose-1,6-bisphosphate 1-phosphohydrolase inhibitors D-fructose-1,6-bisphosphate phosphatase inhibitor D-fructose-1,6-bisphosphate phosphatase inhibitors EC 3.1.3.11 (fructose-bisphosphatase) inhibitors EC 3.1.3.11 inhibitor EC 3.1.3.11 inhibitors FBPase inhibitor FBPase inhibitors fructose 1,6-bisphosphatase inhibitor fructose 1,6-bisphosphatase inhibitors fructose 1,6-bisphosphate 1-phosphatase inhibitor fructose 1,6-bisphosphate 1-phosphatase inhibitors fructose 1,6-bisphosphate phosphatase inhibitor fructose 1,6-bisphosphate phosphatase inhibitors fructose 1,6-diphosphatase inhibitor fructose 1,6-diphosphatase inhibitors fructose 1,6-diphosphate phosphatase inhibitor fructose 1,6-diphosphate phosphatase inhibitors fructose bisphosphate phosphatase inhibitor fructose bisphosphate phosphatase inhibitors fructose diphosphatase inhibitor fructose diphosphatase inhibitors fructose diphosphate phosphatase inhibitor fructose diphosphate phosphatase inhibitors fructose-bisphosphatase (EC 3.1.3.11) inhibitor fructose-bisphosphatase (EC 3.1.3.11) inhibitors fructose-bisphosphatase inhibitor fructose-bisphosphatase inhibitors hexose bisphosphatase inhibitor hexose bisphosphatase inhibitors hexose diphosphatase inhibitor EC 3.1.3.11 (fructose-bisphosphatase) inhibitor CHEBI:65057 adenosine A1 receptor agonist adenosine A1 receptor agonists adenosine A1 receptor agonist CHEBI:65064 EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor CFA synthase inhibitor CFA synthase inhibitors EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitors EC 2.1.1.79 inhibitor EC 2.1.1.79 inhibitors S-adenosyl-L-methionine:unsaturated-phospholipid methyltransferase (cyclising) inhibitor S-adenosyl-L-methionine:unsaturated-phospholipid methyltransferase (cyclising) inhibitors S-adenosyl-L-methionine:unsaturated-phospholipid methyltransferase (cyclizing) inhibitor S-adenosyl-L-methionine:unsaturated-phospholipid methyltransferase (cyclizing) inhibitors cyclopropane fatty acid synthase inhibitors cyclopropane fatty acid synthetase inhibitor cyclopropane fatty acid synthetase inhibitors cyclopropane synthase inhibitor cyclopropane synthase inhibitors cyclopropane synthetase inhibitor cyclopropane synthetase inhibitors cyclopropane-fatty-acyl-phospholipid synthase (EC 2.1.1.79) inhibitor cyclopropane-fatty-acyl-phospholipid synthase (EC 2.1.1.79) inhibitors cyclopropane-fatty-acyl-phospholipid synthase inhibitor cyclopropane-fatty-acyl-phospholipid synthase inhibitors unsaturated-phospholipid methyltransferase inhibitor unsaturated-phospholipid methyltransferase inhibitors EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor CHEBI:65065 EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor DNA adenine methyltransferase inhibitor DNA adenine methyltransferase inhibitors Dam inhibitor Dam inhibitors EC 2.1.1.72 (site-specific DNA-methyltransferase (adenine-specific)) inhibitor EC 2.1.1.72 (site-specific DNA-methyltransferase (adenine-specific)) inhibitors EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitors EC 2.1.1.72 inhibitor EC 2.1.1.72 inhibitors modification methylase inhibitor modification methylase inhibitors restriction-modification system inhibitor restriction-modification system inhibitors site-specific DNA-methyltransferase (adenine-specific) (EC 2.1.1.72) inhibitor site-specific DNA-methyltransferase (adenine-specific) (EC 2.1.1.72) inhibitors site-specific DNA-methyltransferase (adenine-specific) inhibitor site-specific DNA-methyltransferase (adenine-specific) inhibitors EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor CHEBI:65190 first generation antipsychotic first generation antipsychotic agent first generation antipsychotic agents first generation antipsychotic drug first generation antipsychotic drugs first generation antipsychotics typical antipsychotic typical antipsychotic agent typical antipsychotic agents typical antipsychotic drug typical antipsychotic drugs typical antipsychotics first generation antipsychotic CHEBI:65191 second generation antipsychotic atypical antipsychotic atypical antipsychotic agent atypical antipsychotic agents atypical antipsychotic drug atypical antipsychotic drugs atypical antipsychotics second generation antipsychotic agent second generation antipsychotic agents second generation antipsychotic drug second generation antipsychotic drugs second generation antipsychotics second generation antipsychotic CHEBI:65207 vascular endothelial growth factor receptor antagonist VEGF receptor inhibitor VEGF receptor inhibitors VEGFR inhibitor VEGFR inhibitors vascular endothelial growth factor receptor antagonists vascular endothelial growth factor receptor inhibitor vascular endothelial growth factor receptor inhibitors vascular endothelial growth factor receptor antagonist CHEBI:65232 EC 3.4.21.5 (thrombin) inhibitor E thrombin inhibitor E thrombin inhibitors EC 3.4.21.5 (thrombin) inhibitors EC 3.4.21.5 inhibitor EC 3.4.21.5 inhibitors activated blood-coagulation factor II inhibitor activated blood-coagulation factor II inhibitors beta-thrombin inhibitor beta-thrombin inhibitors blood-coagulation factor IIa inhibitor blood-coagulation factor IIa inhibitors factor IIa inhibitor factor IIa inhibitors fibrinogenase inhibitor fibrinogenase inhibitors gamma-thrombin inhibitor gamma-thrombin inhibitors thrombase inhibitor thrombase inhibitors thrombin (EC 3.4.21.5) inhibitor thrombin (EC 3.4.21.5) inhibitors thrombin inhibitor thrombin inhibitors thrombin-C inhibitor thrombin-C inhibitors thrombofort inhibitor thrombofort inhibitors tropostasin inhibitor tropostasin inhibitors EC 3.4.21.5 (thrombin) inhibitor CHEBI:65239 EC 3.2.1.114 (mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase) inhibitor (1->3)-(1->6)-mannosyl-oligosaccharide alpha-D-mannohydrolase inhibitor (1->3)-(1->6)-mannosyl-oligosaccharide alpha-D-mannohydrolase inhibitors 1,3(1,6)-alpha-D-mannosidase inhibitor 1,3(1,6)-alpha-D-mannosidase inhibitors 1,3-(1,6-)mannosyl-oligosaccharide alpha-D-mannohydrolase inhibitor 1,3-(1,6-)mannosyl-oligosaccharide alpha-D-mannohydrolase inhibitors EC 3.2.1.114 (mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase) inhibitors EC 3.2.1.114 inhibitor EC 3.2.1.114 inhibitors GlcNAc transferase I-dependent alpha1,3[alpha1,6]mannosidase inhibitor GlcNAc transferase I-dependent alpha1,3[alpha1,6]mannosidase inhibitors Golgi alpha-mannosidase II inhibitor Golgi alpha-mannosidase II inhibitors ManII inhibitor ManII inhibitors alpha-D-mannosidase II inhibitor alpha-D-mannosidase II inhibitors alpha-mannosidase II inhibitor alpha-mannosidase II inhibitors alpha1-3,6-mannosidase inhibitor alpha1-3,6-mannosidase inhibitors exo-1,3-1,6-alpha-mannosidase inhibitor exo-1,3-1,6-alpha-mannosidase inhibitors golgi alpha-mannosidase II inhibitor golgi alpha-mannosidase II inhibitors mannosidase II inhibitor mannosidase II inhibitors mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase (EC 3.2.1.114) inhibitor mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase (EC 3.2.1.114) inhibitors mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase inhibitor mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase inhibitors EC 3.2.1.114 (mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase) inhibitor CHEBI:65254 LRH-1 agonist LRH-1 agonists NR5A2 agonist NR5A2 agonists liver receptor homologue-1 agonist liver receptor homologue-1 agonists nuclear receptor subfamily 5 group A member 2 agonist nuclear receptor subfamily 5 group A member 2 agonists LRH-1 agonist CHEBI:65255 food preservative food preservatives food preservative CHEBI:65256 antimicrobial food preservative antimicrobial food preservatives antimicrobial preservative antimicrobial preservatives antimicrobial food preservative CHEBI:65259 GABA antagonist GABA antagonists gamma-aminobutyric acid receptor antagonist gamma-aminobutyric acid receptor antagonists GABA antagonist CHEBI:65265 antacid antacids antacid CHEBI:66894 erythropeotin receptor agonist erythropeotin receptor agonist erythropoiesis-stimulating agent erythropoiesis-stimulating agents erythropeotin receptor agonist CHEBI:66900 prostaglandin receptor agonist prostaglandin receptor agonists prostaglandin receptor agonist CHEBI:66902 CFTR potentiator CFTR potentiators cystic fibrosis transmembrane conductance regulator potentiator cystic fibrosis transmembrane conductance regulator potentiators CFTR potentiator CHEBI:66908 SMO receptor antagonist SMO receptor antagonists smoothened antagonist smoothened antagonists smoothened receptor antagonist smoothened receptor antagonists SMO receptor antagonist CHEBI:66956 antidyskinesia agent antidyskinesia agents antidyskinesia drug antidyskinesia drugs antidyskinetic agent antidyskinetic agents antidyskinetic drug antidyskinetic drugs antidyskinesia agent CHEBI:66980 nootropic agent cognitive enhancer cognitive enhancers intelligence enhancer intelligence enhancers memory enhancer memory enhancers neuro enhancer neuro enhancers nootropic nootropic agents nootropic drug nootropic drugs nootropics smart drug smart drugs nootropic agent CHEBI:66981 ophthalmology drug ophthalmic ophthalmic agent ophthalmic agents ophthalmics ophthalmological ophthalmologicals ophthalmology agent ophthalmology agents ophthalmology drugs ophthalmology drug CHEBI:66987 radiation protective agent radiation mitigation agent radiation mitigation agents radiation protective agents radiation protective drug radiation protective drugs radioprotective agent radioprotective agents radioprotector radioprotectors radiation protective agent CHEBI:66991 sympatholytic agent sympatholytic sympatholytic agents sympatholytic drug sympatholytic drugs sympatholytics sympatholytic agent CHEBI:66993 tocolytic agent anti-contraction drug anti-contraction drugs anti-contraction medication anti-contraction medications labour repressant labour repressants tocolytic tocolytic agents tocolytic drug tocolytic drugs tocolytics tocolytic agent CHEBI:67072 cannabinoid receptor agonist cannabinoid receptor agonists cannabinoid receptor agonist CHEBI:67079 anti-inflammatory agent anti-inflammatory agents antiinflammatory agent antiinflammatory agents anti-inflammatory agent CHEBI:67105 insect sterilant insect chemosterilant insect chemosterilants insect sterilants insect sterilant CHEBI:67114 ryanodine receptor agonist RyR activator RyR activators RyR agonist RyR agonists RyRs activator RyRs agonist ryanodine receptor activator ryanodine receptor activators ryanodine receptor agonist CHEBI:67126 colorimetric reagent color reagent color reagents colorimetric reagents colour reagent colour reagents colorimetric reagent CHEBI:67137 NMR shift reagent NMR shift reagents lanthanide shift reagent lanthanide shift reagents nuclear magnetic resonance shift reagent nuclear magnetic resonance shift reagents NMR shift reagent CHEBI:67189 EC 3.4.24.3 (microbial collagenase) inhibitor Achromobacter iophagus collagenase inhibitor Achromobacter iophagus collagenase inhibitors Clostridium histolyticum collagenase inhibitor Clostridium histolyticum collagenase inhibitors Clostridium histolyticum proteinase A inhibitor Clostridium histolyticum proteinase A inhibitors EC 3.4.24.3 (microbial collagenase) inhibitors EC 3.4.24.3 inhibitor EC 3.4.24.3 inhibitors MMP-1 inhibitor MMP-1 inhibitors MMP-8 inhibitor MMP-8 inhibitors aspergillopeptidase C inhibitor aspergillopeptidase C inhibitors azocollase inhibitor azocollase inhibitors clostridiopeptidase A inhibitor clostridiopeptidase A inhibitors clostridiopeptidase I inhibitor clostridiopeptidase I inhibitors clostridiopeptidase II inhibitor clostridiopeptidase II inhibitors collagen peptidase inhibitor collagen peptidase inhibitors collagen protease inhibitor collagen protease inhibitors collagenase A inhibitor collagenase A inhibitors collagenase I inhibitor collagenase I inhibitors collagenase MMP-1 inhibitor collagenase MMP-1 inhibitors collagenase inhibitor collagenase inhibitors interstitial collagenase inhibitor interstitial collagenase inhibitors kollaza inhibitor kollaza inhibitors matrix metalloproteinase-1 inhibitor matrix metalloproteinase-1 inhibitors matrix metalloproteinase-18 inhibitor matrix metalloproteinase-18 inhibitors matrix metalloproteinase-8 inhibitor matrix metalloproteinase-8 inhibitors metallocollagenase inhibitor metallocollagenase inhibitors metalloproteinase-1 inhibitor metalloproteinase-1 inhibitors microbial collagenase (EC 3.4.24.3) inhibitor microbial collagenase (EC 3.4.24.3) inhibitors microbial collagenase inhibitor microbial collagenase inhibitors nucleolysin inhibitor nucleolysin inhibitors soycollagestin inhibitor soycollagestin inhibitors EC 3.4.24.3 (microbial collagenase) inhibitor CHEBI:67195 gap junctional intercellular communication inhibitor gap junctional intercellular communication inhibitors gap junctional intercellular communication inhibitor CHEBI:67198 retinoic acid receptor agonist retinoic acid receptor agonists retinoic acid receptor agonist CHEBI:67199 AP-1 antagonist AP-1 antagonists activator protein-1 antagonist activator protein-1 antagonists AP-1 antagonist CHEBI:67200 provitamin A provitamin As provitamin A CHEBI:67230 EC 3.2.1.45 (glucosylceramidase) inhibitor D-glucosyl-N-acylsphingosine glucohydrolase inhibitor D-glucosyl-N-acylsphingosine glucohydrolase inhibitors EC 3.2.1.45 (glucosylceramidase) inhibitors EC 3.2.1.45 inhibitor EC 3.2.1.45 inhibitors GlcCer-beta-glucosidase inhibitor GlcCer-beta-glucosidase inhibitors acid beta-glucosidase inhibitor acid beta-glucosidase inhibitors acid-beta-glucosidase inhibitor acid-beta-glucosidase inhibitors beta-D-glucocerebrosidase inhibitor beta-D-glucocerebrosidase inhibitors beta-glucosylceramidase inhibitor beta-glucosylceramidase inhibitors ceramide glucosidase inhibitor ceramide glucosidase inhibitors glucocerebrosidase inhibitor glucocerebrosidase inhibitors glucosphingosine glucosylhydrolase inhibitor glucosphingosine glucosylhydrolase inhibitors glucosylceramidase (EC 3.2.1.45) inhibitor glucosylceramidase (EC 3.2.1.45) inhibitors glucosylceramidase inhibitor glucosylceramidase inhibitors glucosylcerebrosidase inhibitor glucosylcerebrosidase inhibitors glucosylsphingosine beta-D-glucosidase inhibitor glucosylsphingosine beta-D-glucosidase inhibitors glucosylsphingosine beta-glucosidase inhibitor glucosylsphingosine beta-glucosidase inhibitors psychosine hydrolase inhibitor psychosine hydrolase inhibitors EC 3.2.1.45 (glucosylceramidase) inhibitor CHEBI:67231 EC 3.2.1.48 (sucrose alpha-glucosidase) inhibitor EC 3.2.1.48 (sucrose alpha-glucosidase) inhibitors EC 3.2.1.48 inhibitor EC 3.2.1.48 inhibitors intestinal sucrase inhibitor intestinal sucrase inhibitors sucrase (invertase) inhibitor sucrase (invertase) inhibitors sucrase inhibitor sucrase inhibitors sucrase-isomaltase inhibitor sucrase-isomaltase inhibitors sucrose alpha-glucohydrolase inhibitor sucrose alpha-glucohydrolase inhibitors sucrose alpha-glucosidase (EC 3.2.1.48) inhibitor sucrose alpha-glucosidase (EC 3.2.1.48) inhibitors sucrose alpha-glucosidase inhibitor sucrose alpha-glucosidase inhibitors sucrose-alpha-D-glucohydrolase inhibitor sucrose-alpha-D-glucohydrolase inhibitors EC 3.2.1.48 (sucrose alpha-glucosidase) inhibitor CHEBI:67232 EC 3.2.1.10 (oligo-1,6-glucosidase) inhibitor EC 3.2.1.10 (oligo-1,6-glucosidase) inhibitors EC 3.2.1.10 inhibitor EC 3.2.1.10 inhibitors alpha-limit dextrinase inhibitor alpha-limit dextrinase inhibitors dextrin 6-glucanohydrolase inhibitor dextrin 6-glucanohydrolase inhibitors dextrin 6alpha-glucanohydrolase inhibitor dextrin 6alpha-glucanohydrolase inhibitors exo-oligo-1,6-glucosidase inhibitor exo-oligo-1,6-glucosidase inhibitors isomaltase inhibitor isomaltase inhibitors oligo-1,6-glucosidase (EC 3.2.1.10) inhibitor oligo-1,6-glucosidase (EC 3.2.1.10) inhibitors oligo-1,6-glucosidase inhibitor oligo-1,6-glucosidase inhibitors oligosaccharide alpha-1,6-glucohydrolase inhibitor oligosaccharide alpha-1,6-glucohydrolase inhibitors sucrase-isomaltase inhibitor sucrase-isomaltase inhibitors EC 3.2.1.10 (oligo-1,6-glucosidase) inhibitor CHEBI:67239 EC 3.2.1.20 (alpha-glucosidase) inhibitor EC 3.2.1.20 (alpha-glucosidase) inhibitors EC 3.2.1.20 inhibitor EC 3.2.1.20 inhibitors alpha-1,4-glucosidase inhibitor alpha-1,4-glucosidase inhibitors alpha-D-glucosidase inhibitor alpha-D-glucosidase inhibitors alpha-glucopyranosidase inhibitor alpha-glucopyranosidase inhibitors alpha-glucosidase (EC 3.2.1.20) inhibitor alpha-glucosidase (EC 3.2.1.20) inhibitors alpha-glucosidase inhibitor alpha-glucosidase inhibitors alpha-glucoside hydrolase inhibitor alpha-glucoside hydrolase inhibitors glucoinvertase inhibitor glucoinvertase inhibitors glucosidoinvertase inhibitor glucosidoinvertase inhibitors glucosidosucrase inhibitor glucosidosucrase inhibitors maltase inhibitor maltase inhibitors maltase-glucoamylase inhibitor maltase-glucoamylase inhibitors EC 3.2.1.20 (alpha-glucosidase) inhibitor CHEBI:67267 EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitors EC 2.5.1.59 inhibitor EC 2.5.1.59 inhibitors GGTase I inhibitor GGTase I inhibitors geranylgeranyl-diphosphate:protein-cysteine geranyltransferase inhibitor geranylgeranyl-diphosphate:protein-cysteine geranyltransferase inhibitors geranylgeranyltransferase type I inhibitor geranylgeranyltransferase type I inhibitors protein geranylgeranyltransferase type I (EC 2.5.1.59) inhibitor protein geranylgeranyltransferase type I (EC 2.5.1.59) inhibitors protein geranylgeranyltransferase type I inhibitor protein geranylgeranyltransferase type I inhibitors EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor CHEBI:67268 HIV-1 integrase inhibitor HIV-1 integrase inhibitor CHEBI:6801 metformin 1,1-dimethylbiguanide LA 6023 LA-6023 N(1),N(1)-dimethylbiguanide N,N-dimethylbiguanide N,N-dimethyldiguanide N,N-dimethylguanylguanidine N,N-dimethylimidodicarbonimidic diamide N,N-dimethyltriimidodicarbonic diamide dimethylbiguanide dimethyldiguanide metformin metformina metformine metforminum metformin CHEBI:68481 mTOR inhibitor mTOR inhibitors mammalian target of rapamycin inhibitor mammalian target of rapamycin inhibitors mTOR inhibitor CHEBI:68494 apoptosis inhibitor Type I cell-death inhibitor Type I cell-death inhibitors Type I programmed cell-death inhibitor Type I programmed cell-death inhibitors apoptosis inhibitors apoptosis inhibitor CHEBI:68495 apoptosis inducer Type I cell-death inducer Type I cell-death inducers Type I programmed cell-death inducer Type I programmed cell-death inducers apoptosis inducers apoptosis inducer CHEBI:68509 glutathione depleting agent glutathione depleting agents glutathione depletion agent glutathione depletion agents glutathione depletor glutathione depletors glutathione depleting agent CHEBI:68542 EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor (S)-dihydroorotate:fumarate oxidoreductase inhibitor (S)-dihydroorotate:fumarate oxidoreductase inhibitors DHODH inhibitor DHODH inhibitors EC 1.3.3.1 inhibitor EC 1.3.3.1 inhibitors EC 1.3.98.1 (dihydroorotate oxidase (fumarate)) inhibitor EC 1.3.98.1 (dihydroorotate oxidase (fumarate)) inhibitors EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitors EC 1.3.98.1 inhibitor EC 1.3.98.1 inhibitors dihydroorotate dehydrogenase inhibitor dihydroorotate dehydrogenase inhibitors dihydroorotate oxidase (fumarate) (EC 1.3.98.1) inhibitor dihydroorotate oxidase (fumarate) (EC 1.3.98.1) inhibitors dihydroorotate oxidase (fumarate) inhibitor dihydroorotate oxidase (fumarate) inhibitors EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor CHEBI:68543 pyrimidine synthesis inhibitor pyrimidine synthesis inhibitors pyrimidine synthesis inhibitor CHEBI:68553 guanylate cyclase 2C agonist GC-C agonist GC-C agonists guanylate cyclase 2C agonists guanylate cyclase 2C agonist CHEBI:68557 bradykinin receptor antagonist bradykinin receptor antagonists bradykinin receptor antagonist CHEBI:68563 P2Y12 receptor antagonist ADP receptor subtype P2Y12 antagonist ADP receptor subtype P2Y12 antagonists P2Y12 receptor antagonists purinergic receptor subtype P2Y12 antagonist purinergic receptor subtype P2Y12 antagonists P2Y12 receptor antagonist CHEBI:68581 EC 3.4.21.6 (coagulation factor Xa) inhibitor EC 3.4.21.6 (coagulation factor Xa) inhibitors EC 3.4.21.6 inhibitor EC 3.4.21.6 inhibitors Stuart factor inhibitor Stuart factor inhibitors activated Stuart-Prower factor inhibitor activated Stuart-Prower factor inhibitors activated blood-coagulation factor X inhibitor activated blood-coagulation factor X inhibitors activated factor X inhibitor activated factor X inhibitors autoprothrombin C inhibitor autoprothrombin C inhibitors coagulation factor Xa (EC 3.4.21.6) inhibitor coagulation factor Xa (EC 3.4.21.6) inhibitors coagulation factor Xa inhibitor coagulation factor Xa inhibitors factor Xa inhibitor factor Xa inhibitors plasma thromboplastin inhibitor plasma thromboplastin inhibitors prothrombase inhibitor prothrombase inhibitors prothrombinase inhibitor prothrombinase inhibitors thrombokinase inhibitor thrombokinase inhibitors thromboplastin inhibitor thromboplastin inhibitors EC 3.4.21.6 (coagulation factor Xa) inhibitor CHEBI:68612 EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor DPP IV/CD26 inhibitor DPP IV/CD26 inhibitors DPP-4 inhibitor DPP-4 inhibitors EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitors EC 3.4.14.5 inhibitor EC 3.4.14.5 inhibitors Gly-Pro naphthylamidase inhibitor Gly-Pro naphthylamidase inhibitors T cell triggering molecule Tp103 inhibitor T cell triggering molecule Tp103 inhibitors X-PDAP inhibitor X-PDAP inhibitors X-prolyl dipeptidyl aminopeptidase inhibitor X-prolyl dipeptidyl aminopeptidase inhibitors Xaa-Pro-dipeptidyl-aminopeptidase inhibitor Xaa-Pro-dipeptidyl-aminopeptidase inhibitors amino acyl-prolyl dipeptidyl aminopeptidase inhibitor amino acyl-prolyl dipeptidyl aminopeptidase inhibitors dipeptidyl aminopeptidase IV inhibitor dipeptidyl aminopeptidase IV inhibitors dipeptidyl peptidase IV inhibitor dipeptidyl peptidase IV inhibitors dipeptidyl peptidase-4 inhibitors dipeptidyl-aminopeptidase IV inhibitor dipeptidyl-aminopeptidase IV inhibitors dipeptidyl-peptidase IV (EC 3.4.14.5) inhibitor dipeptidyl-peptidase IV (EC 3.4.14.5) inhibitors dipeptidyl-peptidase IV inhibitor dipeptidyl-peptidase IV inhibitors dipeptidyl-peptide hydrolase inhibitor dipeptidyl-peptide hydrolase inhibitors glycoprotein GP110 inhibitor glycoprotein GP110 inhibitors glycylproline aminopeptidase inhibitor glycylproline aminopeptidase inhibitors glycylprolyl aminopeptidase inhibitor glycylprolyl aminopeptidase inhibitors glycylprolyl dipeptidylaminopeptidase inhibitor glycylprolyl dipeptidylaminopeptidase inhibitors leukocyte antigen CD26 inhibitor leukocyte antigen CD26 inhibitors lymphocyte antigen CD26 inhibitor lymphocyte antigen CD26 inhibitors pep X inhibitor pep X inhibitors postproline dipeptidyl aminopeptidase IV inhibitor postproline dipeptidyl aminopeptidase IV inhibitors EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor CHEBI:68640 EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor 17-alpha-hydroxylase/C17,20-lyase inhibitor 17-alpha-hydroxylase/C17,20-lyase inhibitors 17alpha-hydroxylase-C17,20 lyase inhibitor 17alpha-hydroxylase-C17,20 lyase inhibitors CYP17 inhibitor CYP17 inhibitors CYP17A1 inhibitor CYP17A1 inhibitors EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitors EC 1.14.99.9 inhibitor EC 1.14.99.9 inhibitors cytochrome P-45017alpha inhibitor cytochrome P-45017alpha inhibitors cytochrome P450 (P-45017alpha,lyase) inhibitor cytochrome P450 (P-45017alpha,lyase) inhibitors cytochrome P450 17-alpha-hydroxylase/C17,20-lyase inhibitor cytochrome P450 17-alpha-hydroxylase/C17,20-lyase inhibitors cytochrome p450 XVIIA1 inhibitor cytochrome p450 XVIIA1 inhibitors steroid 17alpha-hydroxylase inhibitor steroid 17alpha-hydroxylase inhibitors steroid 17alpha-monooxygenase (EC 1.14.99.9) inhibitor steroid 17alpha-monooxygenase (EC 1.14.99.9) inhibitors steroid 17alpha-monooxygenase inhibitor steroid 17alpha-monooxygenase inhibitors steroid 17alphahydroxylase/17,20 lyase inhibitor steroid 17alphahydroxylase/17,20 lyase inhibitors steroid,NADPH--hemoprotein reductase:oxygen oxidoreductase (17alpha-hydroxylating) inhibitor steroid,NADPH--hemoprotein reductase:oxygen oxidoreductase (17alpha-hydroxylating) inhibitors EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor CHEBI:68844 phosphodiesterase IV inhibitor PDE4 inhibitor PDE4 inhibitors phosphodiesterase 4 inhibitor phosphodiesterase 4 inhibitors phosphodiesterase IV inhibitors type 4 phosphodiesterase inhibitor type 4 phosphodiesterase inhibitors phosphodiesterase IV inhibitor CHEBI:6931 midazolam 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine Buccolam Dormicum mezolam midazolam midazolamum midazolam CHEBI:70709 progesterone receptor agonist PR agonist PR agonists progesterone receptor agonists progesterone receptor agonist CHEBI:70722 EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor ACC inhibitor ACC inhibitors ACCase inhibitor ACCase inhibitors EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitors EC 6.4.1.2 inhibitor EC 6.4.1.2 inhibitors acetyl coenzyme A carboxylase inhibitor acetyl coenzyme A carboxylase inhibitors acetyl-CoA carboxylase (EC 6.4.1.2) inhibitor acetyl-CoA carboxylase (EC 6.4.1.2) inhibitors acetyl-CoA carboxylase inhibitor acetyl-CoA carboxylase inhibitors acetyl-CoA:carbon-dioxide ligase (ADP-forming) inhibitor acetyl-CoA:carbon-dioxide ligase (ADP-forming) inhibitors EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor CHEBI:70724 cell dedifferentiation agent cell dedifferentiation agents cell dedifferentiation agent CHEBI:70725 adenosine A3 receptor antagonist adenosine A3 receptor antagonistS adenosine A3 receptor antagonist CHEBI:70727 topoisomerase inhibitor topoisomerase inhibitors topoisomerase inhibitor CHEBI:70728 actin polymerisation inhibitor actin polymerisation inhibitors actin polymerization inhibitor actin polymerization inhibitors inhibitor of actin polymerization inhibitors of actin polymerization actin polymerisation inhibitor CHEBI:70770 Aurora kinase inhibitor Aurora kinase inhibitors Aurora kinase inhibitor CHEBI:70774 capsaicin receptor antagonist TRPV1 antagonist TRPV1 antagonists TrpV1 antagonist TrpV1 antagonists capsaicin antagonist capsaicin antagonists capsaicin receptor antagonists transient receptor potential cation channel subfamily V member 1 antagonist transient receptor potential cation channel subfamily V member 1 antagonists vanilloid receptor 1 antagonist vanilloid receptor 1 antagonists capsaicin receptor antagonist CHEBI:70781 PPAR modulator PPAR modulators peroxisome proliferator-activated receptor modulator peroxisome proliferator-activated receptor modulators PPAR modulator CHEBI:70782 PPARalpha agonist PPAR-alpha agonist PPAR-alpha agonists PPARalpha agonist PPARalpha agonists peroxisome proliferator-activated receptor-alpha agonist peroxisome proliferator-activated receptor-alpha agonists PPARalpha agonist CHEBI:70817 EC 1.2.1.12 [glyceraldehyde-3-phosphate dehydrogenase (phosphorylating)] inhibitor 3-phosphoglyceraldehyde dehydrogenase inhibitor 3-phosphoglyceraldehyde dehydrogenase inhibitors D-glyceraldehyde-3-phosphate:NAD(+) oxidoreductase (phosphorylating) inhibitor D-glyceraldehyde-3-phosphate:NAD(+) oxidoreductase (phosphorylating) inhibitors EC 1.2.1.12 (glyceraldehyde-3-phosphate dehydrogenase (phosphorylating)) inhibitor EC 1.2.1.12 (glyceraldehyde-3-phosphate dehydrogenase (phosphorylating)) inhibitors EC 1.2.1.12 [glyceraldehyde-3-phosphate dehydrogenase (phosphorylating)] inhibitors EC 1.2.1.12 inhibitor EC 1.2.1.12 inhibitors GAPDH inhibitor GAPDH inhibitors NAD-dependent glyceraldehyde phosphate dehydrogenase inhibitor NAD-dependent glyceraldehyde phosphate dehydrogenase inhibitors NADH-glyceraldehyde phosphate dehydrogenase inhibitor NADH-glyceraldehyde phosphate dehydrogenase inhibitors dehydrogenase, glyceraldehyde phosphate inhibitor dehydrogenase, glyceraldehyde phosphate inhibitors glyceraldehyde phosphate dehydrogenase (NAD) inhibitor glyceraldehyde phosphate dehydrogenase (NAD) inhibitors glyceraldehyde-3-P-dehydrogenase inhibitor glyceraldehyde-3-P-dehydrogenase inhibitors glyceraldehyde-3-phosphate dehydrogenase (NAD) inhibitor glyceraldehyde-3-phosphate dehydrogenase (NAD) inhibitors glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) (EC 1.2.1.12) inhibitor glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) (EC 1.2.1.12) inhibitors glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) inhibitor glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) inhibitors glyceraldehyde-3-phosphate dehydrogenase inhibitor glyceraldehyde-3-phosphate dehydrogenase inhibitors phosphoglyceraldehyde dehydrogenase inhibitor phosphoglyceraldehyde dehydrogenase inhibitors triosephosphate dehydrogenase inhibitor triosephosphate dehydrogenase inhibitors EC 1.2.1.12 [glyceraldehyde-3-phosphate dehydrogenase (phosphorylating)] inhibitor CHEBI:70821 cathepsin L (EC 3.4.22.15) inhibitor Aldrichina grahami cysteine proteinase inhibitor Aldrichina grahami cysteine proteinase inhibitors EC 3.4.22.15 inhibitor EC 3.4.22.15 inhibitors cathepsin L (EC 3.4.22.15) inhibitor cathepsin L (EC 3.4.22.15) inhibitors cathepsin L inhibitor cathepsin L inhibitors cathepsin L1 inhibitor cathepsin L1 inhibitors cathepsin L (EC 3.4.22.15) inhibitor CHEBI:70822 EC 3.4.22.2 (papain) inhibitor EC 3.4.22.2 (papain) inhibitor EC 3.4.22.2 inhibitor EC 3.4.22.2 inhibitors papain (EC 3.4.22.2) inhibitor papain (EC 3.4.22.2) inhibitors papain inhibitor papain inhibitors papaine inhibitor papaine inhibitors papaya peptidase I inhibitor papaya peptidase I inhibitors papayotin inhibitor papayotin inhibitors summetrin inhibitor summetrin inhibitors velardon inhibitor velardon inhibitors EC 3.4.22.2 (papain) inhibitor CHEBI:70868 antileishmanial agent antileishmanial agents antileishmanial drug antileishmanial drugs antileishmanial agent CHEBI:70982 reactive oxygen species generator ROS generator ROS generators reactive oxygen species generators reactive oxygen species generator CHEBI:70998 G-protein-coupled receptor agonist G-protein-coupled receptor agonists GPCR agonist GPCR agonists G-protein-coupled receptor agonist CHEBI:71014 AMPA receptor antagonist AMPA receptor antagonists alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonists AMPA receptor antagonist CHEBI:71027 progesterone receptor modulator progesterone receptor modulators progesterone receptor modulator CHEBI:71031 orphan drug orphan drugs orphan drug CHEBI:71033 carbamylphosphate synthetase I activator carbamylphosphate synthetase I activators carbamylphosphate synthetase I activator CHEBI:71168 HIV-1 maturation inhibitor HIV-1 maturation inhibitors HIV-1 maturation inhibitor CHEBI:71173 H1-receptor agonist H1-receptor agonists histamine H1-receptor agonist histamine H1-receptor agonists H1-receptor agonist CHEBI:71178 EC 2.1.1.4 (acetylserotonin O-methyltransferase) inhibitor ASMT inhibitor ASMT inhibitors EC 2.1.1.4 (acetylserotonin O-methyltransferase) inhibitors EC 2.1.1.4 inhibitor EC 2.1.1.4 inhibitors N-acetylserotonin O-methyltransferase inhibitor N-acetylserotonin O-methyltransferase inhibitors N-acetylserotonin methyltransferase inhibitor N-acetylserotonin methyltransferase inhibitors S-adenosyl-L-methionine:N-acetylserotonin O-methyltransferase inhibitor S-adenosyl-L-methionine:N-acetylserotonin O-methyltransferase inhibitors acetylserotonin O-methyltransferase (EC 2.1.1.4) inhibitor acetylserotonin O-methyltransferase (EC 2.1.1.4) inhibitors acetylserotonin O-methyltransferase inhibitor acetylserotonin O-methyltransferase inhibitors acetylserotonin methyltransferase inhibitor acetylserotonin methyltransferase inhibitors hydroxyindole O-methyltransferase inhibitor hydroxyindole O-methyltransferase inhibitors hydroxyindole methyltransferase inhibitor hydroxyindole methyltransferase inhibitors EC 2.1.1.4 (acetylserotonin O-methyltransferase) inhibitor CHEBI:71181 Sir2 inhibitor Sir2 inhibitors Sir2 inhibitor CHEBI:71196 glucagon-like peptide-1 receptor agonist GLP-1 receptor agonist GLP-1 receptor agonists glucagon-like peptide-1 receptor agonists glucagon-like peptide-1 receptor agonist CHEBI:71212 prohormone prohormones prohormone CHEBI:71232 adenosine receptor antagonist adenosine receptor antagonists adenosine receptor antagonist CHEBI:71300 EC 2.* (transferase) inhibitor EC 2 inhibitor EC 2 inhibitors EC 2.* (transferase) inhibitors EC 2.* inhibitor EC 2.* inhibitors transferase inhibitor transferase inhibitors EC 2.* (transferase) inhibitor CHEBI:71338 autoinducer autoinducers autoinducer CHEBI:71476 EC 2.3.1.85 (fatty acid synthase) inhibitor (FAS) inhibitors EC 2.3.1.85 (fatty acid synthase) inhibitors EC 2.3.1.85 inhibitor EC 2.3.1.85 inhibitors acyl-CoA:malonyl-CoA C-acyltransferase (decarboxylating, oxoacyl- and enoyl-reducing and thioester-hydrolysing) inhibitor acyl-CoA:malonyl-CoA C-acyltransferase (decarboxylating, oxoacyl- and enoyl-reducing and thioester-hydrolysing) inhibitors fatty acid synthase (EC 2.3.1.85) inhibitor fatty acid synthase (EC 2.3.1.85) inhibitors fatty acid synthase inhibitor fatty acid synthase inhibitors EC 2.3.1.85 (fatty acid synthase) inhibitor CHEBI:71551 EC 3.5.1.23 (ceramidase) inhibitor AC inhibitor AC inhibitors EC 3.5.1.23 (ceramidase) inhibitors EC 3.5.1.23 inhibitor EC 3.5.1.23 inhibitors N-acylsphingosine amidohydrolase inhibitor N-acylsphingosine amidohydrolase inhibitors acid ceramidase inhibitor acid ceramidase inhibitors acylsphingosine deacylase inhibitor acylsphingosine deacylase inhibitors ceramidase (EC 3.5.1.23) inhibitor ceramidase (EC 3.5.1.23) inhibitors ceramidase inhibitor ceramidase inhibitors glycosphingolipid ceramide deacylase inhibitor glycosphingolipid ceramide deacylase inhibitors EC 3.5.1.23 (ceramidase) inhibitor CHEBI:71554 PPARgamma agonist PPAR-gamma agonist PPAR-gamma agonists PPARgamma agonist PPARgamma agonists peroxisome proliferator-activated receptor-gamma agonist peroxisome proliferator-activated receptor-gamma agonists PPARgamma agonist CHEBI:71692 insect repellent insect repellents insect repellent CHEBI:71942 EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor 3',5'-cyclic-GMP 5'-nucleotidohydrolase inhibitor 3',5'-cyclic-GMP 5'-nucleotidohydrolase inhibitors 3',5'-cyclic-GMP phosphodiesterase (EC 3.1.4.35) inhibitor 3',5'-cyclic-GMP phosphodiesterase (EC 3.1.4.35) inhibitors EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitors EC 3.1.4.35 inhibitor EC 3.1.4.35 inhibitors PDE5 inhibitor PDE5 inhibitors cGMP phosphodiesterase inhibitor cGMP phosphodiesterase inhibitors cGMP-PDE inhibitor cGMP-PDE inhibitors cyclic 3',5'-GMP phosphodiesterase inhibitor cyclic 3',5'-GMP phosphodiesterase inhibitors cyclic GMP phosphodiesterase inhibitor cyclic GMP phosphodiesterase inhibitors cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitor cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors cyclic guanosine 3',5'-phosphate phosphodiesterase inhibitor cyclic guanosine 3',5'-phosphate phosphodiesterase inhibitors guanosine cyclic 3',5'-phosphate phosphodiesterase inhibitor guanosine cyclic 3',5'-phosphate phosphodiesterase inhibitors phosphodiesterase 5 inhibitor phosphodiesterase 5 inhibitors phosphodiesterase V inhibitor phosphodiesterase V inhibitors type 5 phosphodiesterase inhibitor type 5 phosphodiesterase inhibitors EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor CHEBI:71951 EC 3.5.1.88 (peptide deformylase) inhibitor EC 3.5.1.88 (peptide deformylase) inhibitors EC 3.5.1.88 inhibitor EC 3.5.1.88 inhibitors PDF inhibitors formyl-L-methionyl peptide amidohydrolase inhibitor formyl-L-methionyl peptide amidohydrolase inhibitors peptide deformylase (EC 3.5.1.88) inhibitor peptide deformylase (EC 3.5.1.88) inhibitors peptide deformylase inhibitor peptide deformylase inhibitors EC 3.5.1.88 (peptide deformylase) inhibitor CHEBI:72294 nerve growth factor stimulator NGF stimulator NGF stimulators nerve growth factor stimulators nerve growth factor stimulator CHEBI:72298 MTP inhibitor MTP inhibitors MTTP inhibitor MTTP inhibitors microsomal triglyceride transfer protein inhibitor microsomal triglyceride transfer protein inhibitors MTP inhibitor CHEBI:72311 glucagon-like peptide-2 receptor agonist GLP-2 receptor agonist GLP-2 receptor agonists glucagon-like peptide-2 receptor agonists glucagon-like peptide-2 receptor agonist CHEBI:72316 virulence factor virulence factors virulence factor CHEBI:72470 provitamin B1 provitamin B1s provitamin B1 CHEBI:72483 vesicular glutamate transport inhibitor vesicular glutamate transport inhibitors vesicular glutamate transporter 1 inhibitor vesicular glutamate transporter 1 inhibitors vesicular glutamate transport inhibitor CHEBI:72571 pro-angiogenic agent angiogenesis inducing agent angiogenesis inducing agents pro-angiogenic agents proangiogenic agent proangiogenic agents pro-angiogenic agent CHEBI:72575 alarm pheromone alarm pheromones alarm signal alarm signals alarm substance alarm substances alarm pheromone CHEBI:72716 EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitors EC 2.3.2.13 inhibitor EC 2.3.2.13 inhibitors Factor XIIIa inhibitor R-glutaminyl-peptide:amine gamma-glutamyl transferase inhibitor TG-2 inhibitor TG-2 inhibitors TG2 inhibitor TG2 inhibitors TGase inhibitor TGase inhibitors fibrin stabilizing factor inhibitor fibrin stabilizing factor inhibitors fibrinoligase inhibitor fibrinoligase inhibitors glutaminylpeptide gamma-glutamyltransferase inhibitor glutaminylpeptide gamma-glutamyltransferase inhibitors polyamine transglutaminase inhibitor polyamine transglutaminase inhibitors protein-glutamine gamma-glutamyltransferase (EC 2.3.2.13) inhibitor protein-glutamine gamma-glutamyltransferase (EC 2.3.2.13) inhibitors protein-glutamine gamma-glutamyltransferase inhibitor protein-glutamine gamma-glutamyltransferase inhibitors protein-glutamine:amine gamma-glutamyltransferase inhibitor protein-glutamine:amine gamma-glutamyltransferase inhibitors tissue transglutaminase inhibitor tissue transglutaminase inhibitors transglutaminase inhibitor transglutaminase inhibitors transglutaminase-2 inhibitor transglutaminase-2 inhibitors EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor CHEBI:72768 aryl hydrocarbon receptor agonist AHR agonist AHR agonists AhR agonist AhR agonists aryl hydrocarbon receptor agonists aryl hydrocarbon receptor agonist CHEBI:72771 breast cancer resistance protein inhibitor ABCG2 inhibitor ABCG2 inhibitors breast cancer resistance protein inhibitors breast cancer resistance protein inhibitor CHEBI:72773 carotogenesis inhibitor carotogenesis inhibitors carotogenesis inhibitor CHEBI:72774 EC 1.3.99.29 [phytoene desaturase (zeta-carotene-forming)] inhibitor 15-cis-phytoene:acceptor oxidoreductase (zeta-carotene-forming) inhibitor 15-cis-phytoene:acceptor oxidoreductase (zeta-carotene-forming) inhibitors 2-step phytoene desaturase inhibitor 2-step phytoene desaturase inhibitors CrtIa inhibitor CrtIa inhibitors EC 1.3.99.29 [phytoene desaturase (zeta-carotene-forming)] inhibitors EC 1.3.99.29 inhibitor EC 1.3.99.29 inhibitors phytoene dehydrogenase inhibitor phytoene dehydrogenase inhibitors phytoene desaturase (zeta-carotene-forming) (EC 1.3.99.29) inhibitor phytoene desaturase (zeta-carotene-forming) (EC 1.3.99.29) inhibitors phytoene desaturase (zeta-carotene-forming) inhibitor phytoene desaturase (zeta-carotene-forming) inhibitors phytoene desaturase inhibitor phytoene desaturase inhibitors two-step phytoene desaturase inhibitor two-step phytoene desaturase inhibitors EC 1.3.99.29 [phytoene desaturase (zeta-carotene-forming)] inhibitor CHEBI:72854 EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor D-tryptophan:oxygen 2,3-oxidoreductase (decyclizing) inhibitor D-tryptophan:oxygen 2,3-oxidoreductase (decyclizing) inhibitors EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitors EC 1.13.11.52 inhibitor EC 1.13.11.52 inhibitors IDO inhibitor IDO inhibitors indoleamine 2,3-dioxygenase (EC 1.13.11.52) inhibitor indoleamine 2,3-dioxygenase (EC 1.13.11.52) inhibitors indoleamine 2,3-dioxygenase inhibitor indoleamine 2,3-dioxygenase inhibitors EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor CHEBI:73136 EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor ALR3 inhibitor ALR3 inhibitors EC 1.1.1.184 (carbonyl reductase (NADPH)) inhibitor EC 1.1.1.184 (carbonyl reductase (NADPH)) inhibitors EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitors EC 1.1.1.184 inhibitor EC 1.1.1.184 inhibitors NADPH2-dependent carbonyl reductase inhibitor NADPH2-dependent carbonyl reductase inhibitors aldehyde reductase 1 inhibitor aldehyde reductase 1 inhibitors carbonyl reductase (NADPH) (EC 1.1.1.184) inhibitor carbonyl reductase (NADPH) (EC 1.1.1.184) inhibitors carbonyl reductase (NADPH) inhibitor carbonyl reductase (NADPH) inhibitors carbonyl reductase (NADPH2) inhibitor carbonyl reductase (NADPH2) inhibitors carbonyl reductase inhibitor carbonyl reductase inhibitors nonspecific NADPH-dependent carbonyl reductase inhibitor nonspecific NADPH-dependent carbonyl reductase inhibitors prostaglandin 9-ketoreductase inhibitor prostaglandin 9-ketoreductase inhibitors secondary-alcohol:NADP+ oxidoreductase inhibitor secondary-alcohol:NADP+ oxidoreductase inhibitors xenobiotic ketone reductase inhibitor xenobiotic ketone reductase inhibitors EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor CHEBI:73181 EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor EC 1.11.1.11 (L-ascorbate peroxidase) inhibitors EC 1.11.1.11 inhibitor EC 1.11.1.11 inhibitors L-ascorbate peroxidase (EC 1.11.1.11) inhibitor L-ascorbate peroxidase (EC 1.11.1.11) inhibitors L-ascorbate peroxidase inhibitor L-ascorbate peroxidase inhibitors L-ascorbate:hydrogen-peroxide oxidoreductase inhibitor L-ascorbate:hydrogen-peroxide oxidoreductase inhibitors L-ascorbic acid peroxidase inhibitor L-ascorbic acid peroxidase inhibitors L-ascorbic acid-specific peroxidase inhibitor L-ascorbic acid-specific peroxidase inhibitors ascorbate peroxidase inhibitor ascorbate peroxidase inhibitors ascorbic acid peroxidase inhibitor ascorbic acid peroxidase inhibitors EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor CHEBI:73182 plant activator plant activators plant activator CHEBI:73189 brassinosteroid biosynthesis inhibitor brassinosteroid biosynthesis inhibitors brassinosteroid biosynthesis inhibitor CHEBI:73190 antimutagen antimutagenic agent antimutagenic agents antimutagens antimutagen CHEBI:73191 abscisic acid receptor agonist ABA agonist ABA agonists ABA receptor agonist ABA receptor agonists abscisic acid receptor agonists abscisic acid receptor agonist CHEBI:73192 EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitors EC 1.3.3.4 inhibitor EC 1.3.3.4 inhibitors HemG inhibitor HemG inhibitors HemY inhibitor HemY inhibitors PPO inhibitor PPO inhibitors Protox inhibitor Protox inhibitors protoporphyrinogen IX oxidase inhibitor protoporphyrinogen IX oxidase inhibitors protoporphyrinogen oxidase (EC 1.3.3.4) inhibitor protoporphyrinogen oxidase (EC 1.3.3.4) inhibitors protoporphyrinogen oxidase inhibitor protoporphyrinogen oxidase inhibitors protoporphyrinogen-IX:oxygen oxidoreductase inhibitor protoporphyrinogen-IX:oxygen oxidoreductase inhibitors protoporphyrinogenase inhibitor protoporphyrinogenase inhibitors EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor CHEBI:73193 gibberellin biosynthesis inhibitor gibberellin biosynthesis inhibitors gibberellin biosynthesis inhibitor CHEBI:73196 EC 4.4.1.11 (methionine gamma-lyase) inhibitor EC 4.4.1.11 (methionine gamma-lyase) inhibitors L-methioninase inhibitor L-methioninase inhibitors methioninase inhibitor methioninase inhibitors methionine gamma-lyase (EC 4.4.1.11) inhibitor methionine gamma-lyase (EC 4.4.1.11) inhibitors methionine gamma-lyase inhibitor methionine gamma-lyase inhibitors EC 4.4.1.11 (methionine gamma-lyase) inhibitor CHEBI:73214 EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor ATP phosphohydrolase (H(+)-transporting) inhibitor ATP phosphohydrolase (H(+)-transporting) inhibitors ATP synthase inhibitor ATP synthase inhibitors EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitors EC 3.6.3.14 inhibitor EC 3.6.3.14 inhibitors F1-ATPase inhibitor F1-ATPase inhibitors FoF1-ATPase inhibitor FoF1-ATPase inhibitors H(+)-transporting ATPase inhibitor H(+)-transporting ATPase inhibitors H(+)-transporting two-sector ATPase (EC 3.6.3.14) inhibitor H(+)-transporting two-sector ATPase (EC 3.6.3.14) inhibitors H(+)-transporting two-sector ATPase inhibitor H(+)-transporting two-sector ATPase inhibitors bacterial Ca(2+)/Mg(2+) ATPase inhibitor bacterial Ca(2+)/Mg(2+) ATPase inhibitors chloroplast ATPase inhibitor chloroplast ATPase inhibitors coupling factors (Fo, F1 and CF1) inhibitor coupling factors (Fo, F1 and CF1) inhibitors mitochondrial ATPase inhibitor mitochondrial ATPase inhibitors EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor CHEBI:73216 EC 3.6.* (hydrolases acting on acid anhydrides) inhibitor EC 3.6 inhibitor EC 3.6 inhibitors EC 3.6.* (hydrolases acting on acid anhydrides) inhibitors EC 3.6.* inhibitor EC 3.6.* inhibitors EC 3.6.*.* inhibitor EC 3.6.*.* inhibitors acid anhydride hydrolase inhibitor acid anhydride hydrolase inhibitors inhibitor of hydrolase acting on acid anhydride (EC 3.6.*) inhibitors of hydrolase acting on acid anhydride (EC 3.6.*) EC 3.6.* (hydrolases acting on acid anhydrides) inhibitor CHEBI:73240 NF-kappaB inhibitor NF-kappaB inhibitors nuclear factor kappa-light-chain-enhancer of activated B cells inhibitor nuclear factor kappa-light-chain-enhancer of activated B cells inhibitors NF-kappaB inhibitor CHEBI:73263 cyclooxygenase 3 inhibitor COX-3 inhibitor COX-3 inhibitors cyclo-oxygenase 3 inhibitor cyclo-oxygenase 3 inhibitors cyclooxygenase 3 inhibitors cyclooxygenase-3 inhibitor cyclooxygenase-3 inhibitors cyclooxygenase 3 inhibitor CHEBI:73267 oxidative phosphorylation inhibitor oxidative phosphorylation inhibitors oxidative phosphorylation inhibitor CHEBI:73273 sodium-glucose transport protein subtype 2 inhibitor SGLT2 inhibitor SGLT2 inhibitors sodium glucose co-transporter 2 inhibitor sodium glucose co-transporter 2 inhibitors sodium-glucose transport protein subtype 2 inhibitors sodium-glucose transport protein subtype 2 inhibitor CHEBI:73296 cholecystokinin antagonist CCK antagonist CCK antagonists cholecystokinin antagonists cholecystokinin antagonist CHEBI:73310 adenosine A2A receptor agonist A2A agonist A2A agonists A2A receptor agonist A2A receptor agonists adenosine A2A receptor agonists adenosine A2A receptor agonist CHEBI:73311 adenosine receptor agonist adenosine receptor agonist adenosine receptor agonist CHEBI:73319 adenosine A3 receptor agonist A3 agonist A3 agonists A3 receptor agonist A3 receptor agonists adenosine A3 receptor agonists adenosine A3 receptor agonist CHEBI:73333 scabicide scabicides scabicide CHEBI:73334 thyroid hormone agonist thyroid hormone agonists thyromimetic thyromimetics thyroid hormone agonist CHEBI:73335 ultraviolet filter UV filter UV filters ultraviolet filters ultraviolet filter CHEBI:73336 vulnerary vulneraries wound-healing agent wound-healing agents wound-healing drug wound-healing drugs vulnerary CHEBI:73352 protein-sequencing agent protein-sequencing agents sequencing agent sequencing agents protein-sequencing agent CHEBI:73354 EC 2.7.3.2 (creatine kinase) inhibitor CK inhibitor CK inhibitors CPK inhibitor CPK inhibitors EC 2.7.3.2 (creatine kinase) inhibitors creatine kinase (EC 2.7.3.2) inhibitor creatine kinase (EC 2.7.3.2) inhibitors creatine kinase inhibitor creatine kinase inhibitors creatine phosphokinase inhibitor creatine phosphokinase inhibitors EC 2.7.3.2 (creatine kinase) inhibitor CHEBI:73360 EC 3.4.11.18 (methionyl aminopeptidase) inhibitor EC 3.4.11.18 (methionyl aminopeptidase) inhibitors EC 3.4.11.18 inhibitor EC 3.4.11.18 inhibitors L-methionine aminopeptidase inhibitor L-methionine aminopeptidase inhibitors MAP inhibitor MAP inhibitors methionine aminopeptidase inhibitor methionine aminopeptidase inhibitors methionyl aminopeptidase (EC 3.4.11.18) inhibitor methionyl aminopeptidase (EC 3.4.11.18) inhibitors methionyl aminopeptidase inhibitor methionyl aminopeptidase inhibitors peptidase M inhibitor peptidase M inhibitors EC 3.4.11.18 (methionyl aminopeptidase) inhibitor CHEBI:73361 methionine aminopeptidase 2 inhibitor MAP2 inhibitor MAP2 inhibitors METAP2 inhibitor METAP2 inhibitors MetAP2 inhibitor MetAP2 inhibitors methionine aminopeptidase 2 inhibitors methionine aminopeptidase-2 inhibitor methionine aminopeptidase-2 inhibitors methionine aminopeptidase 2 inhibitor CHEBI:73413 cannabinoid receptor antagonist cannabinoid receptor antagonists cannabinoid receptor antagonist CHEBI:73416 CB1 receptor antagonist CB1 receptor antagonist CB1 receptor antagonists CB1R antagonist CB1R antagonists cannabinoid receptor 1 antagonist cannabinoid receptor 1 antagonists cannabinoid receptor type 1 antagonist cannabinoid receptor type 1 antagonists type 1 cannabinoid receptor antagonist type 1 cannabinoid receptor antagonists CB1 receptor antagonist CHEBI:73417 CB2 receptor antagonist CB2 receptor antagonist CB2 receptor antagonists CB2R antagonist CB2R antagonists cannabinoid receptor 2 antagonist cannabinoid receptor 2 antagonists cannabinoid receptor type 2 antagonist cannabinoid receptor type 2 antagonists type 2 cannabinoid receptor antagonist type 2 cannabinoid receptor antagonists CB2 receptor antagonist CHEBI:73472 kynuramine 2',3-diaminopropiophenone 3-amino-1-(2-aminophenyl)-1-propanone 3-amino-1-(2-aminophenyl)propan-1-one kynurenamine kynuramine CHEBI:73618 spectrophotometric reagent spectrophotometric reagents spectrophotometric reagent CHEBI:73623 tolerogen tolerogens tolerogen CHEBI:73668 peptide coupling reagent peptide coupling reagents peptide coupling reagent CHEBI:73730 PPARbeta/delta agonist NR1C2 agonist NR1C2 agonists PPAR(beta/delta) agonist PPAR(beta/delta) agonists PPAR-beta agonist PPAR-beta agonists PPAR-beta/delta agonist PPAR-beta/delta agonists PPAR-delta agonist PPAR-delta agonists PPARD agonist PPARD agonists PPARD receptor agonist PPARD receptor agonists PPARbeta agonist PPARbeta agonists PPARbeta/delta agonist PPARbeta/delta agonists PPARdelta agonist PPARdelta agonists nuclear receptor subfamily 1, group C, member 2 agonist nuclear receptor subfamily 1, group C, member 2 agonists peroxisome proliferator-activated receptor-beta agonist peroxisome proliferator-activated receptor-beta agonists peroxisome proliferator-activated receptor-delta agonist peroxisome proliferator-activated receptor-delta agonists PPARbeta/delta agonist CHEBI:73911 vibriostatic agent vibriostatic vibriostatics vibriostatic agent CHEBI:73913 antifolate antifolates folic acid antagonist folic acid antagonists antifolate CHEBI:73966 nitric oxide synthase activator NOS activator NOS activators nitric oxide synthase activators nitric oxide synthase activator CHEBI:74136 lachrymator lachrymators lachrymator CHEBI:74152 mordant mordant CHEBI:74213 EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor 2'-deoxyribonucleoside-diphosphate:thioredoxin-disulfide 2'-oxidoreductase inhibitor 2'-deoxyribonucleoside-diphosphate:thioredoxin-disulfide 2'-oxidoreductase inhibitors ADP reductase inhibitor ADP reductase inhibitors CDP reductase inhibitor CDP reductase inhibitors EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitors EC 1.17.4.1 inhibitor EC 1.17.4.1 inhibitors RR inhibitor RR inhibitors UDP reductase inhibitor UDP reductase inhibitors nucleoside diphosphate reductase inhibitor nucleoside diphosphate reductase inhibitors ribonucleoside diphosphate reductase inhibitor ribonucleoside diphosphate reductase inhibitors ribonucleoside-diphosphate reductase (EC 1.17.4.1) inhibitor ribonucleoside-diphosphate reductase (EC 1.17.4.1) inhibitors ribonucleoside-diphosphate reductase inhibitor ribonucleoside-diphosphate reductase inhibitors ribonucleotide diphosphate reductase inhibitor ribonucleotide diphosphate reductase inhibitors ribonucleotide reductase inhibitor ribonucleotide reductase inhibitors EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor CHEBI:74234 EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor 7,8-dihydrobiopterin:NADP(+) oxidoreductase 7,8-dihydrobiopterin:NADP(+) oxidoreductases EC 1.1.1.153 (sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)) inhibitor EC 1.1.1.153 (sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)) inhibitors EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitors L-erythro-7,8-dihydrobiopterin:NADP(+) oxidoreductase inhibitor L-erythro-7,8-dihydrobiopterin:NADP(+) oxidoreductase inhibitors sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming) (EC 1.1.1.153) inhibitor sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming) (EC 1.1.1.153) inhibitors sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming) inhibitor sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming) inhibitors sepiapterin reductase inhibitor sepiapterin reductase inhibitors EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor CHEBI:74236 polymerisation monomer polymerization monomer polymerisation monomer CHEBI:74352 quinol oxidation site inhibitor QP site inhibitor QP site inhibitors quinol oxidation site inhibitors quinol oxidation site inhibitor CHEBI:74440 epidermal growth factor receptor antagonist EGFR antagonoist EGFR antagonoists EGFR inhibitor EGFR inhibitors epidermal growth factor receptor antagonists epidermal growth factor receptor inhibitor epidermal growth factor receptor inhibitors epidermal growth factor receptor antagonist CHEBI:74518 anti-obesity agent anti-obesity agents anti-obestic agent anti-obestic agents anti-obesity agent CHEBI:74520 EC 1.1.1.44 (NADP(+)-dependent decarboxylating phosphogluconate dehydrogenase) inhibitor 6-phospho-D-gluconate dehydrogenase inhibitor 6-phospho-D-gluconate dehydrogenase inhibitors 6-phospho-D-gluconate:NADP+ 2-oxidoreductase (decarboxylating) inhibitor 6-phospho-D-gluconate:NADP+ 2-oxidoreductase (decarboxylating) inhibitors 6-phosphogluconate dehydrogenase (decarboxylating) inhibitor 6-phosphogluconate dehydrogenase (decarboxylating) inhibitors 6-phosphogluconic carboxylase inhibitor 6-phosphogluconic carboxylase inhibitors 6-phosphogluconic dehydrogenase inhibitor 6-phosphogluconic dehydrogenase inhibitors EC 1.1.1.44 (NADP(+)-dependent decarboxylating phosphogluconate dehydrogenase) inhibitors EC 1.1.1.44 inhibitor EC 1.1.1.44 inhibitors NADP(+)-dependent decarboxylating phosphogluconate dehydrogenase (EC 1.1.1.44) inhibitor NADP(+)-dependent decarboxylating phosphogluconate dehydrogenase (EC 1.1.1.44) inhibitors NADP(+)-dependent decarboxylating phosphogluconate dehydrogenase inhibitor NADP(+)-dependent decarboxylating phosphogluconate dehydrogenase inhibitors phosphogluconate dehydrogenase (NADP+ -dependent, decarboxylating) inhibitor phosphogluconate dehydrogenase (NADP+ -dependent, decarboxylating) inhibitors phosphogluconic acid dehydrogenase inhibitor phosphogluconic acid dehydrogenase inhibitors EC 1.1.1.44 (NADP(+)-dependent decarboxylating phosphogluconate dehydrogenase) inhibitor CHEBI:74529 antidote to paracetamol poisoning Tylenol poisoning antidote Tylenol poisoning antidotes acetaminophen poisoning antidote acetaminophen poisoning antidotes antidote to Tylenol poisoning antidote to acetaminophen poisoning antidotes to Tylenol poisoning antidotes to acetaminophen poisoning antidotes to paracetamol poisoning paracetamol poisoning antidote paracetamol poisoning antidotes antidote to paracetamol poisoning CHEBI:74530 antidote to curare poisoning antidote to curare antidote to tubocurarine antidote to tubocurarine poisoning antidotes to curare antidotes to curare poisoning antidotes to tubocurarine antidotes to tubocurarine poisoning curare antidote curare antidotes curare poisoning antidote curare poisoning antidotes tubocurarine antidote tubocurarine antidotes antidote to curare poisoning CHEBI:74570 EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor (5-L-glutamyl)-peptide:amino-acid 5-glutamyltransferase inhibitor (5-L-glutamyl)-peptide:amino-acid 5-glutamyltransferase inhibitors EC 2.3.2.2 (gamma-glutamyltransferase) inhibitors EC 2.3.2.2 inhibitor EC 2.3.2.2 inhibitors GGT inhibitor GGT inhibitors L-gamma-glutamyl transpeptidase inhibitor L-gamma-glutamyl transpeptidase inhibitors L-gamma-glutamyltransferase inhibitor L-gamma-glutamyltransferase inhibitors L-glutamyltransferase inhibitor L-glutamyltransferase inhibitors alpha-glutamyl transpeptidase inhibitor alpha-glutamyl transpeptidase inhibitors gamma-GPT inhibitor gamma-GPT inhibitors gamma-GT inhibitor gamma-GT inhibitors gamma-GTP inhibitor gamma-GTP inhibitors gamma-glutamyl peptidyltransferase inhibitor gamma-glutamyl peptidyltransferase inhibitors gamma-glutamyl transpeptidase inhibitor gamma-glutamyl transpeptidase inhibitors gamma-glutamyltransferase (EC 2.3.2.2) inhibitor gamma-glutamyltransferase (EC 2.3.2.2) inhibitors gamma-glutamyltransferase inhibitor gamma-glutamyltransferase inhibitors gamma-glutamyltranspeptidase inhibitor gamma-glutamyltranspeptidase inhibitors glutamyl transpeptidase inhibitor glutamyl transpeptidase inhibitors EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor CHEBI:74783 astringent adstringent adstringents astringents astringent CHEBI:74886 neoglycolipid probe neoglycolipid probe CHEBI:74914 microarray analysis reagent microarray analysis reagents microarray analysis reagent CHEBI:74925 EC 3.4.23.46 (memapsin 2) inhibitor BACE1 inhibitor BACE1 inhibitors EC 3.4.23.46 (memapsin 2) inhibitors EC 3.4.23.46 inhibitor EC 3.4.23.46 inhibitors Gamma-secretase inhibitor Gamma-secretase inhibitors beta-secretase inhibitor beta-secretase inhibitors beta-site APP-cleaving enzyme 1 inhibitor beta-site APP-cleaving enzyme 1 inhibitors beta-site Alzheimer's amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor beta-site Alzheimer's amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors beta-site Alzheimer's amyloid precursor protein cleaving enzyme 1 inhibitor beta-site Alzheimer's amyloid precursor protein cleaving enzyme 1 inhibitors gamma-secretase inhibitor gamma-secretase inhibitors memapsin 2 (EC 3.4.23.46) inhibitor memapsin 2 (EC 3.4.23.46) inhibitors memapsin 2 inhibitor memapsin 2 inhibitors membrane-associated aspartic protease 2 inhibitor membrane-associated aspartic protease 2 inhibitors EC 3.4.23.46 (memapsin 2) inhibitor CHEBI:74949 EC 3.1.27.3 (ribonuclease T1) inhibitor Aspergillus oryzae ribonuclease inhibitor Aspergillus oryzae ribonuclease inhibitors EC 3.1.27.3 (ribonuclease T1) inhibitors EC 3.1.27.3 inhibitor EC 3.1.27.3 inhibitors RNase F1 inhibitor RNase F1 inhibitors RNase G inhibitor RNase G inhibitors RNase N1 inhibitor RNase N1 inhibitors RNase N2 inhibitor RNase N2 inhibitors RNase Sa inhibitor RNase Sa inhibitors RNase T1 inhibitor RNase T1 inhibitors T1 inhibitor T1 inhibitors binase inhibitor binase inhibitors guanyl-specific RNase inhibitor guanyl-specific RNase inhibitors guanyloribonuclease inhibitor guanyloribonuclease inhibitors ribonuclease C2 inhibitor ribonuclease C2 inhibitors ribonuclease Ch inhibitor ribonuclease Ch inhibitors ribonuclease F1 inhibitor ribonuclease F1 inhibitors ribonuclease N1 inhibitor ribonuclease N1 inhibitors ribonuclease N3 inhibitor ribonuclease N3 inhibitors ribonuclease PP1 inhibitor ribonuclease PP1 inhibitors ribonuclease SA inhibitor ribonuclease SA inhibitors ribonuclease T1 (EC 3.1.27.3) inhibitor ribonuclease T1 (EC 3.1.27.3) inhibitors ribonuclease T1 inhibitor ribonuclease T1 inhibitors ribonuclease U1 inhibitor ribonuclease U1 inhibitors ribonuclease guaninenucleotido-2'-transferase (cyclising) inhibitor ribonuclease guaninenucleotido-2'-transferase (cyclising) inhibitors ribonuclease guaninenucleotido-2'-transferase (cyclizing) inhibitor ribonuclease guaninenucleotido-2'-transferase (cyclizing) inhibitors EC 3.1.27.3 (ribonuclease T1) inhibitor CHEBI:75047 B-Raf inhibitor B-Raf inhibitors BRAF inhibitor BRAF inhibitors human mutant serine/threonine kinase inhibitor human mutant serine/threonine kinase inhibitors B-Raf inhibitor CHEBI:75050 chromogenic compound chromogen chromogenic compounds chromogens chromogenic compound CHEBI:75174 EC 2.5.1.21 (squalene synthase) inhibitor EC 2.5.1.21 (squalene synthase) inhibitors EC 2.5.1.21 inhibitor EC 2.5.1.21 inhibitors SQS inhibitor SQS inhibitors farnesyl-diphosphate farnesyltransferase inhibitor farnesyl-diphosphate farnesyltransferase inhibitors farnesyl-diphosphate:farnesyl-diphosphate farnesyltransferase inhibitor farnesyl-diphosphate:farnesyl-diphosphate farnesyltransferase inhibitors farnesyltransferase inhibitor farnesyltransferase inhibitors presqualene synthase inhibitor presqualene synthase inhibitors presqualene-diphosphate synthase inhibitor presqualene-diphosphate synthase inhibitors squalene synthase (EC 2.5.1.21) inhibitor squalene synthase (EC 2.5.1.21) inhibitors squalene synthase inhibitor squalene synthase inhibitors squalene synthetase inhibitor squalene synthetase inhibitors EC 2.5.1.21 (squalene synthase) inhibitor CHEBI:75190 EC 5.4.3.2 (lysine 2,3-aminomutase) inhibitor EC 5.4.3.2 (lysine 2,3-aminomutase) inhibitors EC 5.4.3.2 inhibitor EC 5.4.3.2 inhibitors L-lysine 2,3-aminomutase inhibitor L-lysine 2,3-aminomutase inhibitors lysine 2,3-aminomutase (EC 5.4.3.2) inhibitor lysine 2,3-aminomutase (EC 5.4.3.2) inhibitors lysine 2,3-aminomutase inhibitor lysine 2,3-aminomutase inhibitors EC 5.4.3.2 (lysine 2,3-aminomutase) inhibitor CHEBI:75252 insulin-like growth factor receptor 1 antagonist IGF-1R antagonist IGF-1R antagonists insulin-like growth factor receptor 1 antagonists insulin-like growth factor receptor 1 antagonist CHEBI:75282 ergosterol biosynthesis inhibitor ergosterol biosynthesis inhibitors ergosterol biosynthesis inhibitor CHEBI:75298 histamine releasing agent histamine releasing agents histamine releasing compound histamine releasing compounds histamine releasing substance histamine releasing substances histamine releasing agent CHEBI:75324 excipient bulking agent bulking agents excipient filler fillers excipient CHEBI:75325 cathartic cathartics cathartic CHEBI:75358 curing agent curing agents vulcanization agent vulcanization agents vulcanizing agent vulcanizing agents curing agent CHEBI:75380 EC 1.11.1.6 (catalase) inhibitor CAT inhibitor CAT inhibitors EC 1.11.1.6 (catalase) inhibitors EC 1.11.1.6 inhibitor EC 1.11.1.6 inhibitors caperase inhibitor caperase inhibitors catalase (EC 1.11.1.6) inhibitor catalase (EC 1.11.1.6) inhibitors catalase inhibitor catalase inhibitors catalase-peroxidase inhibitor catalase-peroxidase inhibitors equilase inhibitor equilase inhibitors hydrogen-peroxide:hydrogen-peroxide oxidoreductase inhibitor hydrogen-peroxide:hydrogen-peroxide oxidoreductase inhibitors optidase inhibitor optidase inhibitors EC 1.11.1.6 (catalase) inhibitor CHEBI:75381 EC 1.11.1.* (peroxidases) inhibitor EC 1.11.1 inhibitor EC 1.11.1 inhibitors EC 1.11.1.* (peroxidase) inhibitor EC 1.11.1.* (peroxidase) inhibitors EC 1.11.1.* (peroxidases) inhibitors EC 1.11.1.* inhibitor EC 1.11.1.* inhibitors inhibitor of peroxidases inhibitors of peroxidases peroxidases inhibitors EC 1.11.1.* (peroxidases) inhibitor CHEBI:75414 platelet-activating factor receptor agonist platelet-activating factor receptor agonists platelet-activating factor receptor agonist CHEBI:75416 EC 6.1.1.* (ligases forming aminoacyl tRNA and related compounds) inhibitor EC 6.1.1.* (ligases forming aminoacyl tRNA and related compounds) inhibitors EC 6.1.1.* inhibitor EC 6.1.1.* inhibitors aminoacyl tRNA synthetase inhibitor aminoacyl tRNA synthetase inhibitors ligases forming aminoacyl tRNA and related compounds (EC 6.1.1.*) inhibitor ligases forming aminoacyl tRNA and related compounds (EC 6.1.1.*) inhibitors tRNA synthetase inhibitor tRNA synthetase inhibitors EC 6.1.1.* (ligases forming aminoacyl tRNA and related compounds) inhibitor CHEBI:75429 EC 1.4.4.2 [glycine dehydrogenase (aminomethyl-transferring)] inhibitor EC 1.4.4.2 (glycine dehydrogenase (aminomethyl-transferring)) inhibitor EC 1.4.4.2 (glycine dehydrogenase (aminomethyl-transferring)) inhibitors EC 1.4.4.2 [glycine dehydrogenase (aminomethyl-transferring)] inhibitors EC 1.4.4.2 inhibitor EC 1.4.4.2 inhibitors P-protein inhibitor P-protein inhibitors glycine cleavage system P-protein inhibitor glycine cleavage system P-protein inhibitors glycine decarboxylase inhibitor glycine decarboxylase inhibitors glycine dehydrogenase (aminomethyl-transferring) (EC 1.4.4.2) inhibitor glycine dehydrogenase (aminomethyl-transferring) (EC 1.4.4.2) inhibitors glycine dehydrogenase (aminomethyl-transferring) inhibitor glycine dehydrogenase (aminomethyl-transferring) inhibitors glycine dehydrogenase (decarboxylating) inhibitor glycine dehydrogenase (decarboxylating) inhibitors glycine-cleavage complex P-protein inhibitor glycine-cleavage complex P-protein inhibitors glycine-cleavage complex inhibitor glycine-cleavage complex inhibitors glycine:H-protein-lipoyllysine oxidoreductase (decarboxylating, acceptor-amino-methylating) glycine:H-protein-lipoyllysine oxidoreductase (decarboxylating, acceptor-amino-methylating) inhibitor glycine:lipoylprotein oxidoreductase (decarboxylating and acceptor-aminomethylating) inhibitor glycine:lipoylprotein oxidoreductase (decarboxylating and acceptor-aminomethylating) inhibitors protein P1 inhibitor protein P1 inhibitors EC 1.4.4.2 [glycine dehydrogenase (aminomethyl-transferring)] inhibitor CHEBI:75495 EC 6.1.1.11 (serine--tRNA ligase) inhibitor EC 6.1.1.11 (serine--tRNA ligase) inhibitor EC 6.1.1.11 (serine--tRNA ligase) inhibitors EC 6.1.1.11 inhibitor EC 6.1.1.11 inhibitors L-serine:tRNA(Ser) ligase (AMP-forming) inhibitor L-serine:tRNA(Ser) ligase (AMP-forming) inhibitors SerRS inhibitor SerRS inhibitors serine translase inhibitor serine translase inhibitors serine--tRNA ligase (EC 6.1.1.11) inhibitor serine--tRNA ligase (EC 6.1.1.11) inhibitors serine--tRNA ligase inhibitor serine--tRNA ligase inhibitors seryl-tRNA synthetase inhibitor seryl-tRNA synthetase inhibitors seryl-transfer RNA synthetase inhibitor seryl-transfer RNA synthetase inhibitors seryl-transfer ribonucleate synthetase inhibitor seryl-transfer ribonucleate synthetase inhibitors seryl-transfer ribonucleic acid synthetase inhibitor seryl-transfer ribonucleic acid synthetase inhibitors EC 6.1.1.11 (serine--tRNA ligase) inhibitor CHEBI:75595 EC 5.1.1.1 (alanine racemase) inhibitor EC 5.1.1.1 (alanine racemase) inhibitors EC 5.1.1.1 inhibitor EC 5.1.1.1 inhibitors L-alanine racemase inhibitor L-alanine racemase inhibitors alanine racemase (EC 5.1.1.1) inhibitor alanine racemase (EC 5.1.1.1) inhibitors alanine racemase inhibitor alanine racemase inhibitors EC 5.1.1.1 (alanine racemase) inhibitor CHEBI:75596 EC 5.* (isomerase) inhibitor EC 5.* (isomerase) inhibitors EC 5.* inhibitor EC 5.* inhibitors EC 5.*.*.* inhibitor EC 5.*.*.* inhibitors isomerase (EC 5.*) inhibitor isomerase (EC 5.*) inhibitors isomerase inhibitor isomerase inhibitors EC 5.* (isomerase) inhibitor CHEBI:75598 EC 6.3.2.4 (D-alanine--D-alanine ligase) inhibitor D-alanine--D-alanine ligase (EC 6.3.2.4) inhibitor D-alanine--D-alanine ligase (EC 6.3.2.4) inhibitors D-alanine--D-alanine ligase inhibitor D-alanine--D-alanine ligase inhibitors D-alanine:D-alanine ligase (ADP-forming) inhibitor D-alanine:D-alanine ligase (ADP-forming) inhibitors EC 6.3.2.4 (D-alanine--D-alanine ligase) inhibitors EC 6.3.2.4 inhibitor EC 6.3.2.4 inhibitors alanine:alanine ligase (ADP-forming) inhibitor alanine:alanine ligase (ADP-forming) inhibitors alanylalanine synthetase inhibitor alanylalanine synthetase inhibitors EC 6.3.2.4 (D-alanine--D-alanine ligase) inhibitor CHEBI:75599 EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor EC 6.3.2.2 (glutamate--cysteine ligase) inhibitors EC 6.3.2.2 inhibitor EC 6.3.2.2 inhibitors gamma-glutamyl-L-cysteine synthetase inhibitor gamma-glutamyl-L-cysteine synthetase inhibitors gamma-glutamylcysteine synthetase inhibitor gamma-glutamylcysteine synthetase inhibitors gamma-glutamylcysteinyl synthetase inhibitor gamma-glutamylcysteinyl synthetase inhibitors glutamate--cysteine ligase (EC 6.3.2.2) inhibitor glutamate--cysteine ligase (EC 6.3.2.2) inhibitors glutamate--cysteine ligase inhibitor glutamate--cysteine ligase inhibitors EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor CHEBI:75600 EC 6.3.* (C-N bond-forming ligase) inhibitor C--N bond-forming ligase inhibitor C--N bond-forming ligase inhibitors C-N bond-forming ligase (EC 6.3.*) inhibitor C-N bond-forming ligase (EC 6.3.*) inhibitors C-N bond-forming ligase inhibitor C-N bond-forming ligase inhibitors EC 6.3.* (C-N bond-forming ligase) inhibitorS EC 6.3.* inhibitor EC 6.3.* inhibitors EC 6.3.*.* inhibitor EC 6.3.*.* inhibitors EC 6.3.* (C-N bond-forming ligase) inhibitor CHEBI:75603 EC 6.* (ligase) inhibitor EC 6.* (ligase) inhibitors EC 6.* inhibitor EC 6.* inhibitors EC 6.*.*.* inhibitor EC 6.*.*.* inhibitors ligase inhibitor ligase inhibitors EC 6.* (ligase) inhibitor CHEBI:75604 EC 6.4.* (C-C bond-forming ligase) inhibitor C--C bond-forming ligase inhibitor C--C bond-forming ligase inhibitors C-C bond-forming ligase (EC 6.4.*) inhibitor C-C bond-forming ligase (EC 6.4.*) inhibitorS C-C bond-forming ligase inhibitor C-C bond-forming ligase inhibitors EC 6.4.* (C-C bond-forming ligase) inhibitorS EC 6.4.* inhibitor EC 6.4.* inhibitors EC 6.4.*.* inhibitor EC 6.4.*.* inhibitors EC 6.4.* (C-C bond-forming ligase) inhibitor CHEBI:75605 EC 6.5.* (phosphoric ester bond-forming ligase) inhibitor EC 6.5.* (phosphoric ester bond-forming ligase) inhibitors EC 6.5.* inhibitor EC 6.5.* inhibitors EC 6.5.*.* inhibitor EC 6.5.*.* inhibitors phosphoric ester bond-forming ligase (EC 6.5.*) inhibitor phosphoric ester bond-forming ligase (EC 6.5.*) inhibitors phosphoric ester bond-forming ligase inhibitor phosphoric ester bond-forming ligase inhibitors EC 6.5.* (phosphoric ester bond-forming ligase) inhibitor CHEBI:7565 nifedipine 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsaeuredimethylester Adalat Adapine Coracten Nifecard Nifecor Nifedipine Nifedipres Procardia dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate nifedipine nifedipino nifedipinum nifedipine CHEBI:75763 eukaryotic metabolite eukaryotic metabolites eukaryotic metabolite CHEBI:75767 animal metabolite animal metabolites animal metabolite CHEBI:75768 mammalian metabolite mammalian metabolites mammalian metabolite CHEBI:75771 mouse metabolite Mus musculus metabolite Mus musculus metabolites mouse metabolites mouse metabolite CHEBI:75772 Saccharomyces cerevisiae metabolite S. cerevisiae metabolite S. cerevisiae metabolites S. cerevisiae secondary metabolite S. cerevisiae secondary metabolites Saccharomyces cerevisiae metabolites Saccharomyces cerevisiae secondary metabolites baker's yeast metabolite baker's yeast metabolites baker's yeast secondary metabolite baker's yeast secondary metabolites Saccharomyces cerevisiae metabolite CHEBI:75787 prokaryotic metabolite prokaryotic metabolites prokaryotic metabolite CHEBI:75835 anti-anaemic agent anti-anaemic agents anti-anaemic drug anti-anaemic drugs anti-anemia agent anti-anemia agents anti-anemia drug anti-anemia drugs anti-anemic agent anti-anemic agents anti-anemic drug anti-anemic drugs antianaemia agent antianaemia agents antianaemia drug antianaemia drugs antianaemic agent antianaemic agents antianaemic drug antianaemic drugs antianemia drug antianemia drugs anti-anaemic agent CHEBI:75968 EC 6.3.2.19 (ubiquitin--protein ligase) inhibitor EC 6.3.2.19 (ubiquitin--protein ligase) inhibitors EC 6.3.2.19 inhibitor EC 6.3.2.19 inhibitors S-phase kinase-associated protein 2 inhibitor S-phase kinase-associated protein 2 inhibitors Skp2 inhibitor Skp2 inhibitors ubiquitin--protein ligase inhibitor ubiquitin--protein ligase inhibitors ubiquitin-activating enzyme inhibitor ubiquitin-activating enzyme inhibitors ubiquitin:protein-lysine N-ligase (AMP-forming) inhibitor ubiquitin:protein-lysine N-ligase (AMP-forming) inhibitors EC 6.3.2.19 (ubiquitin--protein ligase) inhibitor CHEBI:76022 soluble guanylate cyclase activator sGC activator sGC activators soluble guanylate cyclase activators soluble guanylyl cyclase activator soluble guanylyl cyclase activators soluble guanylate cyclase activator CHEBI:76206 xenobiotic metabolite xenobiotic metabolites xenobiotic metabolite CHEBI:76219 fluorogen fluorogen CHEBI:76395 EC 2.3.1.48 (histone acetyltransferase) inhibitor EC 2.3.1.48 (histone acetyltransferase) inhibitors EC 2.3.1.48 inhibitor EC 2.3.1.48 inhibitors HAT inhibitor HAT inhibitors acetyl-CoA:histone acetyltransferase inhibitor acetyl-CoA:histone acetyltransferase inhibitors histone acetokinase inhibitor histone acetokinase inhibitors histone acetylase inhibitor histone acetylase inhibitors histone acetyltransferase (EC 2.3.1.48) inhibitor histone acetyltransferase (EC 2.3.1.48) inhibitors histone acetyltransferase inhibitor histone acetyltransferase inhibitors histone transacetylase inhibitor histone transacetylase inhibitors nucleosome-histone acetyltransferase inhibitor nucleosome-histone acetyltransferase inhibitors EC 2.3.1.48 (histone acetyltransferase) inhibitor CHEBI:76413 greenhouse gas greenhouse gases greenhouse gas CHEBI:76414 propellant propellants propellant CHEBI:76498 coral metabolite coral metabolites coral metabolite CHEBI:76507 marine metabolite marine metabolites marine metabolite CHEBI:76531 odorant receptor antagonist odorant receptor antagonists odorant receptor blocker odorant receptor blockers odorant receptor antagonist CHEBI:76595 nephroprotective agent nephroprotective agents nephroprotective agent CHEBI:76617 EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor ABL inhibitor ABL inhibitors ABL1 inhibitor ABL1 inhibitors ABL2 inhibitor ABL2 inhibitors ABLL inhibitor ABLL inhibitors ACK1 inhibitor ACK1 inhibitors ACK2 inhibitor ACK2 inhibitors AGMX1 inhibitor AGMX1 inhibitors ARG inhibitor ARG inhibitors ATK inhibitor ATK inhibitors ATP:[protein]-L-tyrosine O-phosphotransferase (non-specific) inhibitor ATP:[protein]-L-tyrosine O-phosphotransferase (non-specific) inhibitors BLK inhibitor BLK inhibitors BMX inhibitor BMX inhibitors BRK inhibitor BRK inhibitors BTK inhibitor BTK inhibitors BTKL inhibitor BTKL inhibitors Bmk inhibitor Bmk inhibitors Bruton's tyrosine kinase inhibitor Bruton's tyrosine kinase inhibitors Bsk inhibitor Bsk inhibitors CAKb inhibitor CAKb inhibitors CHK inhibitor CHK inhibitors CSK inhibitor CSK inhibitors CTK inhibitor CTK inhibitors CYL inhibitor CYL inhibitors Cdgip inhibitor Cdgip inhibitors EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitors EC 2.7.10.2 inhibitor EC 2.7.10.2 inhibitors EMT inhibitor EMT inhibitors ETK inhibitor ETK inhibitors FAK inhibitor FAK inhibitors FAK2 inhibitor FAK2 inhibitors FER inhibitor FER inhibitors FES inhibitor FES inhibitors FGR inhibitor FGR inhibitors FPS inhibitor FPS inhibitors FRK inhibitor FRK inhibitors FYN inhibitor FYN inhibitors Fadk inhibitor Fadk inhibitors Fert1/2 inhibitor Fert1/2 inhibitors HCK inhibitor HCK inhibitors HCTK inhibitor HCTK inhibitors HYL inhibitor HYL inhibitors IMD1 inhibitor IMD1 inhibitors ITK inhibitor ITK inhibitors IYK inhibitor IYK inhibitors JAK1 inhibitor JAK1 inhibitors JAK2 inhibitor JAK2 inhibitors JAK3 inhibitor JAK3 inhibitors JTK1 inhibitor JTK1 inhibitors JTK9 inhibitor JTK9 inhibitors Janus kinase 1 inhibitor Janus kinase 1 inhibitors Janus kinase 2 inhibitor Janus kinase 2 inhibitors Janus kinase 3 inhibitor Janus kinase 3 inhibitors Janus kinase inhibitor L-JAK inhibitor L-JAK inhibitors LCK inhibitor LCK inhibitors LSK inhibitor LSK inhibitors LYN inhibitor LYN inhibitors MATK inhibitor MATK inhibitors Ntk inhibitor Ntk inhibitors PKB inhibitor PKB inhibitors PSCTK inhibitor PSCTK inhibitors PSCTK1 inhibitor PSCTK1 inhibitors PSCTK2 inhibitor PSCTK2 inhibitors PSCTK4 inhibitor PSCTK4 inhibitors PSCTK5 inhibitor PSCTK5 inhibitors PTK2 inhibitor PTK2 inhibitors PTK2B inhibitor PTK2B inhibitors PTK6 inhibitor PTK6 inhibitors PYK2 inhibitor PYK2 inhibitors RAFTK inhibitor RAFTK inhibitors RAK inhibitor RAK inhibitors Rlk inhibitor Rlk inhibitors SLK inhibitor SLK inhibitors SRC inhibitor SRC inhibitors SRC2 inhibitor SRC2 inhibitors SRK inhibitor SRK inhibitors SRM inhibitor SRM inhibitors SRMS inhibitor SRMS inhibitors STD inhibitor STD inhibitors SYK inhibitor SYK inhibitors SYN inhibitor SYN inhibitors Sik inhibitor Sik inhibitors TEC inhibitor TEC inhibitors TNK1 inhibitor TNK1 inhibitors TXK inhibitor TXK inhibitors TYK2 inhibitor TYK2 inhibitors TYK3 inhibitor TYK3 inhibitors Tck inhibitor Tck inhibitors Tsk inhibitor Tsk inhibitors YES1 inhibitor YES1 inhibitors YK2 inhibitor YK2 inhibitors ZAP70 inhibitor ZAP70 inhibitors cytoplasmic protein tyrosine kinase inhibitor cytoplasmic protein tyrosine kinase inhibitors focal adhesion kinase inhibitor focal adhesion kinase inhibitors non-specific protein-tyrosine kinase (EC 2.7.10.2) inhibitor non-specific protein-tyrosine kinase (EC 2.7.10.2) inhibitors p60c-src protein tyrosine kinase inhibitor p60c-src protein tyrosine kinase inhibitors EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor CHEBI:76648 fluorescence quencher fluorescence quenchers fluorescence quencher CHEBI:76655 EC 2.1.* (C1-transferase) inhibitor C1-transferase (EC 2.1.*) inhibitor C1-transferase (EC 2.1.*) inhibitors C1-transferase inhibitor C1-transferase inhibitors EC 2.1.* (C1-transferase) inhibitors EC 2.1.* inhibitor EC 2.1.* inhibitors one-carbon-containing group transferase inhibitor one-carbon-containing group transferase inhibitors EC 2.1.* (C1-transferase) inhibitor CHEBI:76660 EC 2.2.* (aldehyde or ketone transferase) inhibitor EC 2.2.* (aldehyde or ketone transferase) inhibitors EC 2.2.* inhibitor EC 2.2.* inhibitors aldehyde or ketone transferase inhibitor aldehyde or ketone transferase inhibitors aldehyde/ketone transferase (EC 2.2.*) inhibitor aldehyde/ketone transferase (EC 2.2.*) inhibitors aldehyde/ketone transferase inhibitor aldehyde/ketone transferase inhibitors EC 2.2.* (aldehyde or ketone transferase) inhibitor CHEBI:76661 EC 2.3.* (acyltransferase) inhibitor EC 2.3.* (acyltransferase) inhibitors EC 2.3.* inhibitor EC 2.3.* inhibitors acyltransferase inhibitor acyltransferase inhibitors EC 2.3.* (acyltransferase) inhibitor CHEBI:76662 EC 2.4.* (glycosyltransferase) inhibitor EC 2.4.* (glycosyltransferase) inhibitors EC 2.4.* inhibitor EC 2.4.* inhibitors glycosyltransferase (EC 2.4.*) inhibitor glycosyltransferase (EC 2.4.*) inhibitors glycosyltransferase inhibitor glycosyltransferase inhibitors EC 2.4.* (glycosyltransferase) inhibitor CHEBI:76663 EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitors EC 2.5.1.* inhibitor EC 2.5.1.* inhibitors alkyl/aryl (non-methyl) transferase inhibitor alkyl/aryl (non-methyl) transferase inhibitors non-methyl alkyl/aryl transferase (EC 2.5.1.*) inhibitor non-methyl alkyl/aryl transferase (EC 2.5.1.*) inhibitors non-methyl alkyl/aryl transferase inhibitor non-methyl alkyl/aryl transferase inhibitors non-methyl-alkyl or aryl transferase inhibitor non-methyl-alkyl or aryl transferase inhibitors EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor CHEBI:76665 EC 2.6.* (nitrogenous group transferase) inhibitor EC 2.6.* inhibitor EC 2.6.* inhibitors nitrogenous group transferase (EC 2.6.*) inhibitor nitrogenous group transferase (EC 2.6.*) inhibitors nitrogenous group transferase inhibitor nitrogenous group transferase inhibitors EC 2.6.* (nitrogenous group transferase) inhibitor CHEBI:76668 EC 2.7.* (P-containing group transferase) inhibitor EC 2.7.* (P-containing group transferase) inhibitors EC 2.7.* (phosphorus-containing group transferase) inhibitor EC 2.7.* (phosphorus-containing group transferase) inhibitors EC 2.7.* inhibitor EC 2.7.* inhibitors phosphorus-containing group transferase (EC 2.7.*) inhibitor phosphorus-containing group transferase (EC 2.7.*) inhibitors phosphorus-containing group transferase inhibitor phosphorus-containing group transferase inhibitors EC 2.7.* (P-containing group transferase) inhibitor CHEBI:76676 EC 2.8.* (S-containing group transferase) inhibitor EC 2.8.* (S-containing group transferase) inhibitor EC 2.8.* (S-containing group transferase) inhibitors EC 2.8.* inhibitor EC 2.8.* inhibitors S-containing group transferase inhibitor S-containing group transferase inhibitors sulfur-containing group transferase (EC 2.8.*) inhibitor sulfur-containing group transferase (EC 2.8.*) inhibitors sulfur-containing group transferase inhibitor sulfur-containing group transferase inhibitors EC 2.8.* (S-containing group transferase) inhibitor CHEBI:76677 EC 2.9.* (Se-containing group transferase) inhibitor EC 2.9.* (Se-containing group transferase) inhibitors EC 2.9.* inhibitor EC 2.9.* inhibitors Se-containing group transferase inhibitor Se-containing group transferase inhibitors selenium-containing group transferase (EC 2.9.*) inhibitor selenium-containing group transferase (EC 2.9.*) inhibitors selenium-containing group transferase inhibitor selenium-containing group transferase inhibitors EC 2.9.* (Se-containing group transferase) inhibitor CHEBI:76681 EC 2.10.* (Mo- or W-containing group transferase) inhibitor EC 2.10.* (Mo- or W-containing group transferase) inhibitors EC 2.10.* inhibitor EC 2.10.* inhibitors Mo- or W-containing group transferase (EC 2.10.*) inhibitor Mo- or W-containing group transferase (EC 2.10.*) inhibitors Mo- or W-containing group transferase inhibitor Mo- or W-containing group transferase inhibitors EC 2.10.* (Mo- or W-containing group transferase) inhibitor CHEBI:76692 EC 5.1.* (racemase/epimerase) inhibitor EC 5.1.* (racemase/epimerase) inhibitors EC 5.1.* inhibitor EC 5.1.* inhibitors racemase and epimerase (EC 5.1*) inhibitor racemase and epimerase (EC 5.1*) inhibitors racemase and epimerase inhibitor racemase and epimerase inhibitors racemase/epimerase inhibitor racemase/epimerase inhibitors EC 5.1.* (racemase/epimerase) inhibitor CHEBI:76693 EC 5.2.* (cis-trans-isomerase) inhibitor EC 5.2.* (cis-trans-isomerase) inhibitors EC 5.2.* inhibitor EC 5.2.* inhibitors cis-trans-isomerase (EC5.2.*) inhibitor cis-trans-isomerase (EC5.2.*) inhibitors cis-trans-isomerase inhibitor cis-trans-isomerase inhibitors EC 5.2.* (cis-trans-isomerase) inhibitor CHEBI:76694 EC 5.3.* (intramolecular oxidoreductase) inhibitor EC 5.3.* (intramolecular oxidoreductase) inhibitors intramolecular oxidoreductase (EC 5.3.*) inhibitor intramolecular oxidoreductase (EC 5.3.*) inhibitors intramolecular oxidoreductase inhibitor intramolecular oxidoreductase inhibitors EC 5.3.* (intramolecular oxidoreductase) inhibitor CHEBI:76695 EC 5.4.* (intramolecular transferase) inhibitor EC 5.4.* (intramolecular transferase) inhibitors intramolecular transferase (EC 5.4.*) inhibitor intramolecular transferase (EC 5.4.*) inhibitors intramolecular transferase inhibitor intramolecular transferase inhibitors EC 5.4.* (intramolecular transferase) inhibitor CHEBI:76696 EC 5.5.* (intramolecular lyase) inhibitor EC 5.5.* (intramolecular lyase) inhibitors EC 5.5.* inhibitor EC 5.5.* inhibitors intramolecular lyase inhibitor intramolecular lyase inhibitors EC 5.5.* (intramolecular lyase) inhibitor CHEBI:76697 EC 5.99.* (other isomerases) inhibitor EC 5.99.* (miscellaneous isomerases) inhibitor EC 5.99.* (miscellaneous isomerases) inhibitors EC 5.99.* (other isomerase) inhibitor EC 5.99.* (other isomerase) inhibitors EC 5.99.* (other isomerases) inhibitors EC 5.99.* inhibitor EC 5.99.* inhibitors EC 5.99.* (other isomerases) inhibitor CHEBI:76706 EC 6.1.* (C-O bond-forming ligase) inhibitor C-O bond-forming ligase (EC 6.1.*) inhibitor C-O bond-forming ligase (EC 6.1.*) inhibitors C-O bond-forming ligase inhibitor C-O bond-forming ligase inhibitors EC 6.1.* (C-O bond-forming ligase) inhibitors EC 6.1.* inhibitor EC 6.1.* inhibitors EC 6.1.* (C-O bond-forming ligase) inhibitor CHEBI:76707 EC 6.2.* (C-S bond-forming ligase) inhibitor C-S bond-forming ligase (EC 6.2.*) inhibitor C-S bond-forming ligase (EC 6.2.*) inhibitors C-S bond-forming ligase inhibitor C-S bond-forming ligase inhibitors EC 6.2.* (C-S bond-forming ligase) inhibitors EC 6.2.* inhibitor EC 6.2.* inhibitors EC 6.2.* (C-S bond-forming ligase) inhibitor CHEBI:76708 EC 6.6.* (N-metal bond-forming ligase) inhibitor EC 6.6.* (N-metal bond-forming ligase) inhibitors EC 6.6.* inhibitor EC 6.6.* inhibitors N-metal bond-forming ligase (EC 6.6.*) inhibitor N-metal bond-forming ligase (EC 6.6.*) inhibitors N-metal bond-forming ligase inhibitor N-metal bond-forming ligase inhibitors EC 6.6.* (N-metal bond-forming ligase) inhibitor CHEBI:76710 EC 4.* (lyase) inhibitor EC 4.* (lyase) inhibitors EC 4.* inhibitor EC 4.* inhibitors EC 4.*.*.* inhibitor EC 4.*.*.* inhibitors lyase (EC 4.*) inhibitor lyase (EC 4.*) inhibitorS lyase inhibitor lyase inhibitors EC 4.* (lyase) inhibitor CHEBI:76711 EC 4.1.* (C-C lyase) inhibitor C-C lyase (EC 4.1.*) inhibitor C-C lyase (EC 4.1.*) inhibitors C-C lyase inhibitor C-C lyase inhibitors EC 4.1.* (C-C lyase) inhibitors EC 4.1.* inhibitor EC 4.1.* inhibitors EC 4.1.* (C-C lyase) inhibitor CHEBI:76712 EC 4.2.* (C-O lyase) inhibitor C-O lyase (EC 4.2.*) inhibitor C-O lyase (EC 4.2.*) inhibitors C-O lyase inhibitor C-O lyase inhibitors EC 4.2.* (C-O lyase) inhibitors EC 4.2.* inhibitor EC 4.2.* inhibitors EC 4.2.* (C-O lyase) inhibitor CHEBI:76713 EC 4.3.* (C-N lyase) inhibitor C-N lyase (EC 4.3.*) inhibitor C-N lyase (EC 4.3.*) inhibitors C-N lyase inhibitor C-N lyase inhibitors EC 4.3.* (C-N lyase) inhibitors EC 4.3.* inhibitor EC 4.3.* inhibitors EC 4.3.* (C-N lyase) inhibitor CHEBI:76714 EC 4.4.* (C-S lyase) inhibitor C-S lyase (EC 4.4.*) inhibitor C-S lyase (EC 4.4.*) inhibitors C-S lyase inhibitor C-S lyase inhibitors EC 4.4.* (C-S lyase) inhibitors EC 4.4.* inhibitor EC 4.4.* inhibitors EC 4.4.* (C-S lyase) inhibitor CHEBI:76715 EC 4.5.* (C-halide lyase) inhibitor C-halide lyase (EC 4.5.*) inhibitor C-halide lyase (EC 4.5.*) inhibitors C-halide lyase inhibitor C-halide lyase inhibitors EC 4.5.* (C-halide lyase) inhibitors EC 4.5.* inhibitor EC 4.5.* inhibitors EC 4.5.* (C-halide lyase) inhibitor CHEBI:76716 EC 4.6.* (P-O lyase) inhibitor EC 4.6.* (P-O lyase) inhibitors EC 4.6.* inhibitor EC 4.6.* inhibitors P-O lyase (EC 4.6.*) inhibitor P-O lyase (EC 4.6.*) inhibitors P-O lyase inhibitor P-O lyase inhibitors EC 4.6.* (P-O lyase) inhibitor CHEBI:76717 EC 4.7.* (C-P lyase) inhibitor C-P lyase (EC 4.7.*) inhibitor C-P lyase (EC 4.7.*) inhibitors C-P lyase inhibitor C-P lyase inhibitors EC 4.7.* (C-P lyase) inhibitors EC 4.7.* inhibitor EC 4.7.* inhibitors EC 4.7.* (C-P lyase) inhibitor CHEBI:76718 EC 4.99.* (miscellaneous lyase) inhibitor EC 4.99.* (miscellaneous lyase) inhibitors EC 4.99.* (other lyase) inhibitor EC 4.99.* (other lyase) inhibitors EC 4.99.* inhibitor EC 4.99.* inhibitors miscellaneous lyase (EC 4.99.*) inhibitor miscellaneous lyase (EC 4.99.*) inhibitors miscellaneous lyase inhibitor miscellaneous lyase inhibitors other lyase (EC 4.99.*) inhibitor other lyase (EC 4.99.*) inhibitors EC 4.99.* (miscellaneous lyase) inhibitor CHEBI:76720 antisense oligonucleotide antisense oligonucleotide CHEBI:76725 EC 1.* (oxidoreductase) inhibitor EC 1.* (oxidoreductase) inhibitors EC 1.* inhibitor EC 1.* inhibitors oxidoreductase (EC 1.*) inhibitor oxidoreductase (EC 1.*) inhibitors oxidoreductase inhibitor oxidoreductase inhibitors EC 1.* (oxidoreductase) inhibitor CHEBI:76726 EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitor EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitors EC 1.1.* inhibitor EC 1.1.* inhibitors inhibitor of oxidoreductase acting on CH-OH group of donor inhibitor of oxidoreductase acting on CH-OH group of donors inhibitors of oxidoreductase acting on CH-OH group of donor inhibitors of oxidoreductase acting on CH-OH group of donors oxidoreductase acting on donor CH-OH group (EC 1.1.*) inhibitor oxidoreductase acting on donor CH-OH group (EC 1.1.*) inhibitors oxidoreductase acting on donor CH-OH group inhibitor oxidoreductase acting on donor CH-OH group inhibitors EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitor CHEBI:76727 EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitor EC 1.2.* (oxidoreductase acting on donor aldehyde or oxo group) inhibitor EC 1.2.* (oxidoreductase acting on donor aldehyde or oxo group) inhibitors EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitors EC 1.2.* inhibitor EC 1.2.* inhibitors inhibitor of oxidoreductase acting on aldehyde or oxo group of donor inhibitor of oxidoreductase acting on aldehyde or oxo group of donors inhibitor of oxidoreductase acting on aldehyde/oxo group of donor inhibitor of oxidoreductase acting on aldehyde/oxo group of donors inhibitors of oxidoreductase acting on aldehyde or oxo group of donor inhibitors of oxidoreductase acting on aldehyde or oxo group of donors inhibitors of oxidoreductase acting on aldehyde/oxo group of donor inhibitors of oxidoreductase acting on aldehyde/oxo group of donors oxidoreductase acting on donor aldehyde or oxo group (EC 1.2.*) inhibitor oxidoreductase acting on donor aldehyde or oxo group (EC 1.2.*) inhibitors oxidoreductase acting on donor aldehyde or oxo group inhibitor oxidoreductase acting on donor aldehyde or oxo group inhibitors oxidoreductase acting on donor aldehyde/oxo group (EC 1.2.*) inhibitor oxidoreductase acting on donor aldehyde/oxo group (EC 1.2.*) inhibitors oxidoreductase acting on donor aldehyde/oxo group inhibitor oxidoreductase acting on donor aldehyde/oxo group inhibitors EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitor CHEBI:76729 EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitor EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitors EC 1.3.* inhibitor EC 1.3.* inhibitors inhibitor of oxidoreductase acting on CH-CH group of donor inhibitor of oxidoreductase acting on CH-CH group of donors inhibitors of oxidoreductase acting on CH-CH group of donor inhibitors of oxidoreductase acting on CH-CH group of donors oxidoreductase acting on donor CH-CH group (EC 1.3.*) inhibitor oxidoreductase acting on donor CH-CH group (EC 1.3.*) inhibitors oxidoreductase acting on donor CH-CH group inhibitor oxidoreductase acting on donor CH-CH group inhibitors EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitor CHEBI:76730 EC 1.4.* (oxidoreductase acting on donor CH-NH2 group) inhibitor EC 1.4.* (oxidoreductase acting on donor CH-NH2 group) inhibitor EC 1.4.* (oxidoreductase acting on donor CH-NH2 group) inhibitors EC 1.4.* inhibitor EC 1.4.* inhibitors inhibitor of oxidoreductase acting on CH-NH2 group of donor inhibitor of oxidoreductase acting on CH-NH2 group of donors inhibitors of oxidoreductase acting on CH-NH2 group of donor inhibitors of oxidoreductase acting on CH-NH2 group of donors oxidoreductase acting on CH-NH2 group of donor inhibitor oxidoreductase acting on CH-NH2 group of donor inhibitors oxidoreductase acting on CH-NH2 group of donors (EC 1.4.*) inhibitor oxidoreductase acting on CH-NH2 group of donors (EC 1.4.*) inhibitors EC 1.4.* (oxidoreductase acting on donor CH-NH2 group) inhibitor CHEBI:76731 EC 1.5.* (oxidoreductase acting on donor CH-NH group) inhibitor EC 1.5.* (oxidoreductase acting on donor CH-NH group) inhibitors EC 1.5.* inhibitor EC 1.5.* inhibitors inhibitor of oxidoreductase acting on CH-NH group of donor inhibitor of oxidoreductase acting on CH-NH group of donors inhibitors of oxidoreductase acting on CH-NH group of donor inhibitors of oxidoreductase acting on CH-NH group of donors oxidoreductase acting on donor CH-NH group (EC 1.5.*) inhibitor oxidoreductase acting on donor CH-NH group (EC 1.5.*) inhibitors EC 1.5.* (oxidoreductase acting on donor CH-NH group) inhibitor CHEBI:76733 EC 1.6.* (oxidoreductase acting on NADH or NADPH) inhibitor EC 1.6.* (oxidoreductase acting on NADH or NADPH) inhibitors inhibitor of oxidoreductase acting on NADH or NADPH inhibitor of oxidoreductase acting on NADH or NADPH (EC 1.6.*) inhibitors of oxidoreductase acting on NADH or NADPH inhibitors of oxidoreductase acting on NADH or NADPH (EC 1.6.*) oxidoreductase acting on NADH or NADPH (EC 1.6.*) inhibitor oxidoreductase acting on NADH or NADPH (EC 1.6.*) inhibitors oxidoreductase acting on NADH or NADPH inhibitor oxidoreductase acting on NADH or NADPH inhibitors EC 1.6.* (oxidoreductase acting on NADH or NADPH) inhibitor CHEBI:76734 EC 1.7.* (oxidoreductase acting on other nitrogenous compounds as donors) inhibitor EC 1.7.* (oxidoreductase acting on other nitrogenous compounds as donors) inhibitors EC 1.7.* inhibitor EC 1.7.* inhibitors inhibitor of oxidoreductase acting on other nitrogenous compounds as donors inhibitor of oxidoreductase acting on other nitrogenous compounds as donors (EC 1.7.*) inhibitors of oxidoreductase acting on other nitrogenous compounds as donors inhibitors of oxidoreductase acting on other nitrogenous compounds as donors (EC 1.7.*) EC 1.7.* (oxidoreductase acting on other nitrogenous compounds as donors) inhibitor CHEBI:76735 EC 1.8.* (oxidoreductase acting on sulfur group of donors) inhibitor EC 1.8.* (oxidoreductase acting on sulfur group of donors) inhibitors EC 1.8.* inhibitor EC 1.8.* inhibitors oxidoreductase acting on a sulfur group of donors (EC 1.8.*) inhibitor oxidoreductase acting on a sulfur group of donors (EC 1.8.*) inhibitors EC 1.8.* (oxidoreductase acting on sulfur group of donors) inhibitor CHEBI:76736 EC 1.9.* (oxidoreductase acting on donor heme group) inhibitor EC 1.9.* (oxidoreductase acting on a heme group of donors) inhibitor EC 1.9.* (oxidoreductase acting on a heme group of donors) inhibitors EC 1.9.* (oxidoreductase acting on donor heme group) inhibitors EC 1.9.* inhibitor EC 1.9.* inhibitors oxidoreductase acting on a heme group of donors (EC 1.9.*) inhibitor oxidoreductase acting on a heme group of donors (EC 1.9.*) inhibitors EC 1.9.* (oxidoreductase acting on donor heme group) inhibitor CHEBI:76737 EC 1.10.* (oxidoreductase acting on diphenols and related substances as donors) inhibitor EC 1.10.* (oxidoreductase acting on diphenols and related substances as donors) inhibitors EC 1.10.* (oxidoreductases acting on diphenols and related substances as donors) inhibitor EC 1.10.* (oxidoreductases acting on diphenols and related substances as donors) inhibitors EC 1.10.* inhibitor EC 1.10.* inhibitors inhibitor of an oxidoreductase acting on diphenols and related substances as donor inhibitor of an oxidoreductase acting on diphenols and related substances as donor (EC 1.10.*) inhibitor of an oxidoreductase acting on diphenols and related substances as donors inhibitors of an oxidoreductase acting on diphenols and related substances as donor inhibitors of an oxidoreductase acting on diphenols and related substances as donor (EC 1.10.*) inhibitors of an oxidoreductase acting on diphenols and related substances as donors EC 1.10.* (oxidoreductase acting on diphenols and related substances as donors) inhibitor CHEBI:76738 EC 1.11.* (oxidoreductase acting on peroxide as donors) inhibitor EC 1.11.* (oxidoreductase acting on peroxide as donors) inhibitors EC 1.11.* (oxidoreductases acting on peroxide as donors) inhibitor EC 1.11.* (oxidoreductases acting on peroxide as donors) inhibitors EC 1.11.* inhibitor EC 1.11.* inhibitors oxidoreductase acting on peroxide as donors (EC 1.11.*) inhibitor oxidoreductase acting on peroxide as donors (EC 1.11.*) inhibitors oxidoreductases acting on peroxide as donors (EC 1.11.*) inhibitor oxidoreductases acting on peroxide as donors (EC 1.11.*) inhibitors EC 1.11.* (oxidoreductase acting on peroxide as donors) inhibitor CHEBI:76739 EC 1.12.* (oxidoreductase acting on hydrogen as donors) inhibitor EC 1.12.* (oxidoreductase acting on hydrogen as donors) inhibitors EC 1.12.* (oxidoreductases acting on hydrogen as donors) inhibitor EC 1.12.* (oxidoreductases acting on hydrogen as donors) inhibitors EC 1.12.* inhibitor EC 1.12.* inhibitors inhibitor of oxidoreductase acting on hydrogen as donors inhibitor of oxidoreductase acting on hydrogen as donors (EC 1.12.*) inhibitors of oxidoreductase acting on hydrogen as donors inhibitors of oxidoreductase acting on hydrogen as donors (EC 1.12.*) oxidoreductase acting on hydrogen as donors inhibitor oxidoreductase acting on hydrogen as donors inhibitors EC 1.12.* (oxidoreductase acting on hydrogen as donors) inhibitor CHEBI:76740 EC 1.13.* [oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases)] inhibitor EC 1.13.* [oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases)] inhibitors EC 1.13.* inhibitor EC 1.13.* inhibitors oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases) (EC 1.13.*) inhibitor oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases) (EC 1.13.*) inhibitors oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases) inhibitor oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases) inhibitors EC 1.13.* [oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases)] inhibitor CHEBI:76741 EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitors EC 1.14.* inhibitor EC 1.14.* inhibitors inhibitor of oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*) inhibitor of oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*) inhibitors of oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*) inhibitors of oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*) oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*) inhibitor oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*) inhibitors oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen inhibitor oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen inhibitors EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor CHEBI:76742 EC 1.15.* (oxidoreductase acting on superoxide as acceptor) inhibitor EC 1.15.* (oxidoreductase acting on superoxide as acceptor) inhibitors EC 1.15.* inhibitor EC 1.15.* inhibitors inhibitor of oxidoreductase acting on superoxide as acceptor inhibitor of oxidoreductase acting on superoxide as acceptor (EC 1.15.*) inhibitors of oxidoreductase acting on superoxide as acceptor inhibitors of oxidoreductase acting on superoxide as acceptor (EC 1.15.*) oxidoreductase acting on superoxide as acceptor (EC 1.15.*) inhibitor oxidoreductase acting on superoxide as acceptor (EC 1.15.*) inhibitors oxidoreductase acting on superoxide as acceptor inhibitor oxidoreductase acting on superoxide as acceptor inhibitors EC 1.15.* (oxidoreductase acting on superoxide as acceptor) inhibitor CHEBI:76743 EC 1.16.* (oxidoreductase oxidising metal ions) inhibitor EC 1.16.* (oxidoreductase oxidising metal ions) inhibitors EC 1.16.* (oxidoreductase oxidizing metal ions) inhibitor EC 1.16.* (oxidoreductase oxidizing metal ions) inhibitors EC 1.16.* inhibitor EC 1.16.* inhibitors oxidoreductase oxidising metal ions (EC 1.16.*) inhibitor oxidoreductase oxidising metal ions (EC 1.16.*) inhibitors oxidoreductase oxidising metal ions inhibitor oxidoreductase oxidising metal ions inhibitors oxidoreductase oxidizing metal ions (EC 1.16.*) inhibitor oxidoreductase oxidizing metal ions (EC 1.16.*) inhibitors oxidoreductase oxidizing metal ions inhibitor oxidoreductase oxidizing metal ions inhibitors EC 1.16.* (oxidoreductase oxidising metal ions) inhibitor CHEBI:76744 EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitors EC 1.17.* inhibitor EC 1.17.* inhibitors oxidoreductase acting on CH or CH2 (EC 1.17.*) inhibitor oxidoreductase acting on CH or CH2 (EC 1.17.*) inhibitors oxidoreductase acting on CH or CH2 inhibitor oxidoreductase acting on CH or CH2 inhibitors EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor CHEBI:76745 EC 1.18.* (oxidoreductase acting on Fe-S proteins as donors) inhibitor EC 1.18.* (oxidoreductase acting on Fe-S proteins as donors) inhibitors EC 1.18.* (oxidoreductase acting on iron-sulfur proteins as donors) inhibitor EC 1.18.* (oxidoreductase acting on iron-sulfur proteins as donors) inhibitors EC 1.18.* inhibitor EC 1.18.* inhibitors inhibitor of oxidoreductase acting on Fe-S proteins as donors inhibitor of oxidoreductase acting on iron-sulfur proteins as donors inhibitors of oxidoreductase acting on Fe-S proteins as donors inhibitors of oxidoreductase acting on iron-sulfur proteins as donors inhibitors of oxidoreductases acting on iron-sulfur proteins as donors oxidoreductase acting on Fe-S proteins as donors (EC 1.18.*) inhibitor oxidoreductase acting on Fe-S proteins as donors (EC 1.18.*) inhibitors oxidoreductase acting on iron-sulfur proteins as donors (EC 1.18.*) inhibitor oxidoreductase acting on iron-sulfur proteins as donors (EC 1.18.*) inhibitors EC 1.18.* (oxidoreductase acting on Fe-S proteins as donors) inhibitor CHEBI:76746 EC 1.19.* (oxidoreductase acting on reduced flavodoxin as donor) inhibitor EC 1.19.* (oxidoreductase acting on reduced flavodoxin as donor) inhibitors EC 1.19.* inhibitor EC 1.19.* inhibitors inhibitor of oxidoreductase acting on reduced flavodoxin as donor inhibitor of oxidoreductase acting on reduced flavodoxin as donor (EC 1.19.*) inhibitors of oxidoreductase acting on reduced flavodoxin as donor inhibitors of oxidoreductase acting on reduced flavodoxin as donor (EC 1.19.*) oxidoreductase acting on reduced flavodoxin as donor (EC 1.19.*) inhibitor oxidoreductase acting on reduced flavodoxin as donor (EC 1.19.*) inhibitors EC 1.19.* (oxidoreductase acting on reduced flavodoxin as donor) inhibitor CHEBI:76747 EC 1.20.* (oxidoreductase acting on P or As in donors) inhibitor EC 1.20.* (oxidoreductase acting on P or As in donors) inhibitors EC 1.20.* (oxidoreductase acting on phosphorus or arsenic in donors) inhibitor EC 1.20.* (oxidoreductase acting on phosphorus or arsenic in donors) inhibitors EC 1.20.* inhibitor EC 1.20.* inhibitors oxidoreductase acting on P or As in donors (EC 1.20.*) inhibitor oxidoreductase acting on P or As in donors (EC 1.20.*) inhibitors oxidoreductase acting on phosphorus or arsenic in donors (EC 1.20.*) inhibitor oxidoreductase acting on phosphorus or arsenic in donors (EC 1.20.*) inhibitors EC 1.20.* (oxidoreductase acting on P or As in donors) inhibitor CHEBI:76748 EC 1.21.* (oxidoreductase acting on X-H and Y-H to form an X-Y bond) inhibitor EC 1.21.* (oxidoreductase acting on X-H and Y-H to form an X-Y bond) inhibitors EC 1.21.* inhibitor EC 1.21.* inhibitors oxidoreductase acting on X-H and Y-H to form an X-Y bond (EC 1.21.*) inhibitor oxidoreductase acting on X-H and Y-H to form an X-Y bond (EC 1.21.*) inhibitors oxidoreductase acting on X-H and Y-H to form an X-Y bond inhibitor oxidoreductase acting on X-H and Y-H to form an X-Y bond inhibitors EC 1.21.* (oxidoreductase acting on X-H and Y-H to form an X-Y bond) inhibitor CHEBI:76750 EC 1.22.* (oxidoreductase acting on halogen in donors) inhibitor EC 1.22.* (oxidoreductase acting on halogen in donors) inhibitors EC 1.22.* inhibitor EC 1.22.* inhibitors inhibitor of oxidoreductase acting on halogen in donors inhibitor of oxidoreductase acting on halogen in donors (EC 1.22.*) inhibitors of oxidoreductase acting on halogen in donors inhibitors of oxidoreductase acting on halogen in donors (EC 1.22.*) oxidoreductase acting on halogen in donors (EC 1.22.*) inhibitor oxidoreductase acting on halogen in donors (EC 1.22.*) inhibitors EC 1.22.* (oxidoreductase acting on halogen in donors) inhibitor CHEBI:76752 EC 1.23.* (oxidoreductase acting on C-O-C group as acceptor) inhibitor EC 1.23.* (oxidoreductase acting on C-O-C group as acceptor) inhibitors EC 1.23.* inhibitor EC 1.23.* inhibitors inhibitor of oxidoreductase acting on C-O-C group as acceptor inhibitor of oxidoreductase acting on C-O-C group as acceptor (EC 1.23.*) inhibitors of oxidoreductase acting on C-O-C group as acceptor inhibitors of oxidoreductase acting on C-O-C group as acceptor (EC 1.23.*) oxidoreductase acting on C-O-C group as acceptor (EC 1.23.*) inhibitor oxidoreductase acting on C-O-C group as acceptor (EC 1.23.*) inhibitors oxidoreductase acting on C-O-C group as acceptor inhibitor oxidoreductase acting on C-O-C group as acceptor inhibitors EC 1.23.* (oxidoreductase acting on C-O-C group as acceptor) inhibitor CHEBI:76753 EC 1.97.* (other oxidoreductase) inhibitor EC 1.97.* (miscellaneous oxidoreductase) inhibitor EC 1.97.* (miscellaneous oxidoreductase) inhibitors EC 1.97.* (other oxidoreductase) inhibitors EC 1.97.* inhibitor EC 1.97.* inhibitors inhibitor of 'other' oxidoreductase (EC 1.97.*) inhibitor of miscellaneous oxidoreductase (EC 1.97.*) inhibitors of 'other' oxidoreductase (EC 1.97.*) inhibitors of miscellaneous oxidoreductase (EC 1.97.*) EC 1.97.* (other oxidoreductase) inhibitor CHEBI:76755 EC 1.98.* (enzymes using H2 as reductant) inhibitor EC 1.98.* (enzymes using H2 as reductant) inhibitors EC 1.98.* inhibitor EC 1.98.* inhibitors inhibitor of enzymes using H2 as reductant (EC 1.98.*) inhibitors of enzymes using H2 as reductant (EC 1.98.*) EC 1.98.* (enzymes using H2 as reductant) inhibitor CHEBI:76757 EC 1.99.* (other oxidoreductases using O2 as oxidant) inhibitor EC 1.99.* (other oxidoreductases using O2 as oxidant) inhibitors EC 1.99.* inhibitor EC 1.99.* inhibitors EC 1.99.* (other oxidoreductases using O2 as oxidant) inhibitor CHEBI:76759 EC 3.* (hydrolase) inhibitor EC 3.* (hydrolase) inhibitors EC 3.* inhibitor EC 3.* inhibitors EC 3.*.*.* inhibitor EC 3.*.*.* inhibitors hydrolase (EC 3.*) inhibitor hydrolase (EC 3.*) inhibitors hydrolase inhibitor hydrolase inhibitors EC 3.* (hydrolase) inhibitor CHEBI:76760 EC 3.1.* (ester hydrolase) inhibitor EC 3.1.* (ester hydrolase) inhibitors EC 3.1.* inhibitor EC 3.1.* inhibitors ester hydrolase (EC 3.1.*) inhibitor ester hydrolase (EC 3.1.*) inhibitors ester hydrolase inhibitor ester hydrolase inhibitors EC 3.1.* (ester hydrolase) inhibitor CHEBI:76761 EC 3.2.* (glycosylase) inhibitor EC 3.2.* (glycosylase) inhibitors EC 3.2.* inhibitor EC 3.2.* inhibitors glycosylase (EC 3.2.*) inhibitor glycosylase (EC 3.2.*) inhibitors glycosylase inhibitor glycosylase inhibitors EC 3.2.* (glycosylase) inhibitor CHEBI:76762 EC 3.3.* (ether hydrolase) inhibitor EC 3.3.* (ether hydrolase) inhibitors EC 3.3.* (hydrolase acting on ether bond) inhibitor EC 3.3.* (hydrolase acting on ether bond) inhibitors EC 3.3.* inhibitor EC 3.3.* inhibitors ether hydrolase (EC 3.3.*) inhibitor ether hydrolase (EC 3.3.*) inhibitors ether hydrolase inhibitor ether hydrolase inhibitors EC 3.3.* (ether hydrolase) inhibitor CHEBI:76764 EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitor EC 3.5.* (hydrolase acting on non-peptide C-N bond) inhibitor EC 3.5.* (hydrolase acting on non-peptide C-N bond) inhibitors EC 3.5.* (hydrolases acting on C-N bonds, other than peptide bonds) inhibitor EC 3.5.* (hydrolases acting on C-N bonds, other than peptide bonds) inhibitors EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitors EC 3.5.* inhibitor EC 3.5.* inhibitors EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitor CHEBI:76766 EC 3.7.* (hydrolases acting on C-C bonds) inhibitor EC 3.7.* (hydrolases acting on C-C bonds) inhibitors EC 3.7.* (hydrolases acting on carbon-carbon bonds) inhibitor EC 3.7.* (hydrolases acting on carbon-carbon bonds) inhibitors EC 3.7.* inhibitor EC 3.7.* inhibitors EC 3.7.* (hydrolases acting on C-C bonds) inhibitor CHEBI:76767 EC 3.8.* (hydrolases acting on halide bonds) inhibitor EC 3.8.* (hydrolases acting on halide bonds) inhibitors EC 3.8.* inhibitor EC 3.8.* inhibitors hydrolases acting on halide bonds (EC 3.8.*) inhibitor hydrolases acting on halide bonds (EC 3.8.*) inhibitors inhibitor of hydrolases acting on halide bonds (EC 3.8.*) inhibitors of hydrolases acting on halide bonds (EC 3.8.*) EC 3.8.* (hydrolases acting on halide bonds) inhibitor CHEBI:76768 EC 3.9.* (hydrolases acting on P-N bonds) inhibitor EC 3.9.* (hydrolases acting on P-N bonds) inhibitors EC 3.9.* (hydrolases acting on phosphorus-nitrogen bonds) inhibitor EC 3.9.* (hydrolases acting on phosphorus-nitrogen bonds) inhibitors EC 3.9.* inhibitor EC 3.9.* inhibitors hydrolases acting on P-N bonds (EC 3.9.*) inhibitor hydrolases acting on P-N bonds (EC 3.9.*) inhibitors hydrolases acting on phosphorus-nitrogen bonds (EC 3.9.*) inhibitor hydrolases acting on phosphorus-nitrogen bonds (EC 3.9.*) inhibitors inhibitor of hydrolases acting on P-N bonds inhibitor of hydrolases acting on P-N bonds (EC 3.9.*) inhibitor of hydrolases acting on phosphorus-nitrogen bonds inhibitor of hydrolases acting on phosphorus-nitrogen bonds (EC 3.9.*) inhibitors of hydrolases acting on P-N bonds inhibitors of hydrolases acting on P-N bonds (EC 3.9.*) inhibitors of hydrolases acting on phosphorus-nitrogen bonds inhibitors of hydrolases acting on phosphorus-nitrogen bonds (EC 3.9.*) EC 3.9.* (hydrolases acting on P-N bonds) inhibitor CHEBI:76769 EC 3.10.* (hydrolases acting on S-N bonds) inhibitor EC 3.10.* (hydrolases acting on S-N bonds) inhibitors EC 3.10.* (hydrolases acting on sulfur-nitrogen bonds) inhibitor EC 3.10.* (hydrolases acting on sulfur-nitrogen bonds) inhibitors EC 3.10.* inhibitor EC 3.10.* inhibitors hydrolases acting on S-N bonds (EC 3.10.*) inhibitor hydrolases acting on S-N bonds (EC 3.10.*) inhibitors hydrolases acting on sulfur-nitrogen bonds (EC 3.10.*) inhibitor hydrolases acting on sulfur-nitrogen bonds (EC 3.10.*) inhibitors inhibitor of hydrolases acting on S-N bonds inhibitor of hydrolases acting on S-N bonds (EC 3.10.*) inhibitor of hydrolases acting on sulfur-nitrogen bonds inhibitor of hydrolases acting on sulfur-nitrogen bonds (EC 3.10.*) inhibitors of hydrolases acting on S-N bonds inhibitors of hydrolases acting on S-N bonds (EC 3.10.*) inhibitors of hydrolases acting on sulfur-nitrogen bonds inhibitors of hydrolases acting on sulfur-nitrogen bonds (EC 3.10.*) EC 3.10.* (hydrolases acting on S-N bonds) inhibitor CHEBI:76770 EC 3.11.* (hydrolases acting on C-P bonds) inhibitor EC 3.11.* (hydrolases acting on C-P bonds) inhibitors EC 3.11.* (hydrolases acting on carbon-phosphorus bonds) inhibitor EC 3.11.* (hydrolases acting on carbon-phosphorus bonds) inhibitors EC 3.11.* inhibitor EC 3.11.* inhibitors hydrolases acting on C-P bonds (EC 3.11.*) inhibitor hydrolases acting on C-P bonds (EC 3.11.*) inhibitors hydrolases acting on carbon-phosphorus bonds (EC 3.11.*) inhibitor hydrolases acting on carbon-phosphorus bonds (EC 3.11.*) inhibitors inhibitor of hydrolases acting on C-P bonds inhibitor of hydrolases acting on C-P bonds (EC 3.11.*) inhibitor of hydrolases acting on carbon-phosphorus bonds inhibitor of hydrolases acting on carbon-phosphorus bonds (EC 3.11.*) inhibitors of hydrolases acting on C-P bonds inhibitors of hydrolases acting on C-P bonds (EC 3.11.*) inhibitors of hydrolases acting on carbon-phosphorus bonds inhibitors of hydrolases acting on carbon-phosphorus bonds (EC 3.11.*) EC 3.11.* (hydrolases acting on C-P bonds) inhibitor CHEBI:76771 EC 3.12.* (hydrolases acting on S-S bonds) inhibitor EC 3.12.* (hydrolases acting on S-S bonds) inhibitors EC 3.12.* (hydrolases acting on sulfur-sulfur bonds) inhibitor EC 3.12.* (hydrolases acting on sulfur-sulfur bonds) inhibitors EC 3.12.* inhibitor EC 3.12.* inhibitors hydrolases acting on S-S bonds (EC 3.12.*) inhibitor hydrolases acting on S-S bonds (EC 3.12.*) inhibitors hydrolases acting on S-S bonds inhibitor hydrolases acting on S-S bonds inhibitors hydrolases acting on sulfur-sulfur bonds (EC 3.12.*) inhibitor hydrolases acting on sulfur-sulfur bonds (EC 3.12.*) inhibitors hydrolases acting on sulfur-sulfur bonds inhibitor hydrolases acting on sulfur-sulfur bonds inhibitors EC 3.12.* (hydrolases acting on S-S bonds) inhibitor CHEBI:76772 EC 3.13.* (hydrolases acting on C-S bonds) inhibitor EC 3.13.* (hydrolases acting on C-S bonds) inhibitors EC 3.13.* (hydrolases acting on carbon-sulfur bonds) inhibitor EC 3.13.* (hydrolases acting on carbon-sulfur bonds) inhibitors EC 3.13.* inhibitor EC 3.13.* inhibitors hydrolases acting on C-S bonds (EC 3.13.*) inhibitor hydrolases acting on C-S bonds (EC 3.13.*) inhibitors hydrolases acting on C-S bonds inhibitor hydrolases acting on C-S bonds inhibitors hydrolases acting on carbon-sulfur bonds (EC 3.13.*) inhibitor hydrolases acting on carbon-sulfur bonds (EC 3.13.*) inhibitors hydrolases acting on carbon-sulfur bonds inhibitor hydrolases acting on carbon-sulfur bonds inhibitors EC 3.13.* (hydrolases acting on C-S bonds) inhibitor CHEBI:76773 EC 3.1.1.* (carboxylic ester hydrolase) inhibitor EC 3.1.1.* (carboxylic ester hydrolase) inhibitors EC 3.1.1.* inhibitor EC 3.1.1.* inhibitors carboxylic ester hydrolase (EC 3.1.1.*) inhibitor carboxylic ester hydrolase (EC 3.1.1.*) inhibitors EC 3.1.1.* (carboxylic ester hydrolase) inhibitor CHEBI:76775 EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor EC 3.1.3.* (phosphoric monoester hydrolase) inhibitors EC 3.1.3.* inhibitor EC 3.1.3.* inhibitors inhibitor of phosphoric monoester hydrolase inhibitor of phosphoric monoester hydrolase (EC 3.1.3.*) inhibitors of phosphoric monoester hydrolase inhibitors of phosphoric monoester hydrolase (EC 3.1.3.*) phosphoric monoester hydrolase (EC 3.1.3.*) inhibitor phosphoric monoester hydrolase (EC 3.1.3.*) inhibitors phosphoric monoester hydrolase inhibitor phosphoric monoester hydrolase inhibitors EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor CHEBI:76779 EC 3.4.21.26 (prolyl oligopeptidase) inhibitor EC 3.4.21.26 (prolyl oligopeptidase) inhibitors EC 3.4.21.26 inhibitor EC 3.4.21.26 inhibitors endoprolylpeptidase inhibitor endoprolylpeptidase inhibitors post-proline cleaving enzyme inhibitor post-proline cleaving enzyme inhibitors post-proline endopeptidase inhibitor post-proline endopeptidase inhibitors proline endopeptidase inhibitor proline endopeptidase inhibitors proline-specific endopeptidase inhibitor proline-specific endopeptidase inhibitors prolyl endopeptidase inhibitor prolyl endopeptidase inhibitors prolyl oligopeptidase (EC 3.4.21.26) inhibitor prolyl oligopeptidase (EC 3.4.21.26) inhibitors prolyl oligopeptidase inhibitor EC 3.4.21.26 (prolyl oligopeptidase) inhibitor CHEBI:76782 EC 3.4.15.* (peptidyl-dipeptidase) inhibitor EC 3.4.15.* (peptidyl-dipeptidase) inhibitors EC 3.4.15.* inhibitor EC 3.4.15.* inhibitors inhibitor of peptidyl-dipeptidases inhibitor of peptidyl-dipeptidases (EC 3.4.15.*) inhibitors of peptidyl-dipeptidases inhibitors of peptidyl-dipeptidases (EC 3.4.15.*) peptidyl-dipeptidase (EC 3.4.15.*) inhibitor peptidyl-dipeptidase (EC 3.4.15.*) inhibitors peptidyl-dipeptidase inhibitor peptidyl-dipeptidase inhibitors EC 3.4.15.* (peptidyl-dipeptidase) inhibitor CHEBI:76785 EC 3.1.26.* (endoribonucleases producing 5'-phosphomonoesters) inhibitor EC 3.1.26.* (endoribonucleases producing 5'-phosphomonoesters) inhibitors EC 3.1.26.* inhibitor EC 3.1.26.* inhibitors endoribonuclease producing 5'-phosphomonoesters (EC 3.1.26.*) inhibitor endoribonuclease producing 5'-phosphomonoesters (EC 3.1.26.*) inhibitors endoribonuclease producing 5'-phosphomonoesters inhibitor endoribonuclease producing 5'-phosphomonoesters inhibitors EC 3.1.26.* (endoribonucleases producing 5'-phosphomonoesters) inhibitor CHEBI:76787 EC 3.4.11.* (aminopeptidase) inhibitor EC 3.4.11.* (aminopeptidase) inhibitors EC 3.4.11.* inhibitor EC 3.4.11.* inhibitors aminopeptidase (EC 3.4.11.*) inhibitor aminopeptidase (EC 3.4.11.*) inhibitors EC 3.4.11.* (aminopeptidase) inhibitor CHEBI:76788 EC 3.4.14.* (dipeptidyl- and tripeptidyl-peptidases) inhibitor EC 3.4.14.* (dipeptidyl- and tripeptidyl-peptidases) inhibitors EC 3.4.14.* inhibitor EC 3.4.14.* inhibitors EC 3.4.14.*(dipeptidyl-peptidases and tripeptidyl-peptidases) inhibitor EC 3.4.14.*(dipeptidyl-peptidases and tripeptidyl-peptidases) inhibitors dipeptidyl- and tripeptidyl-peptidase (EC 3.4.14.*) inhibitor dipeptidyl- and tripeptidyl-peptidase (EC 3.4.14.*) inhibitors dipeptidyl- and tripeptidyl-peptidase inhibitor dipeptidyl- and tripeptidyl-peptidase inhibitors dipeptidyl- and tripeptidyl-peptidases (EC 3.4.14.*) inhibitor dipeptidyl- and tripeptidyl-peptidases (EC 3.4.14.*) inhibitors dipeptidyl- and tripeptidyl-peptidases inhibitor dipeptidyl- and tripeptidyl-peptidases inhibitors dipeptidyl-peptidases and tripeptidyl-peptidases (EC 3.4.14.*) inhibitor dipeptidyl-peptidases and tripeptidyl-peptidases (EC 3.4.14.*) inhibitors EC 3.4.14.* (dipeptidyl- and tripeptidyl-peptidases) inhibitor CHEBI:76789 EC 2.4.1.* (hexosyltransferase) inhibitor EC 2.4.1.* (hexosyltransferase) inhibitors EC 2.4.1.* inhibitor EC 2.4.1.* inhibitors hexosyltransferase (EC 2.4.1.*) inhibitor hexosyltransferase (EC 2.4.1.*) inhibitors hexosyltransferase inhibitor hexosyltransferase inhibitors EC 2.4.1.* (hexosyltransferase) inhibitor CHEBI:76790 EC 2.4.2.* (pentosyltransferase) inhibitor EC 2.4.2.* (pentosyltransferase) inhibitors EC 2.4.2.* inhibitor EC 2.4.2.* inhibitors pentosyltransferase (EC 2.4.2.*) inhibitor pentosyltransferase (EC 2.4.2.*) inhibitors pentosyltransferase inhibitor pentosyltransferase inhibitors EC 2.4.2.* (pentosyltransferase) inhibitor CHEBI:76791 EC 3.1.27.* (endoribonucleases producing other than 5'-phosphomonoesters) inhibitor EC 3.1.27.* (endoribonucleases producing other than 5'-phosphomonoesters) inhibitors EC 3.1.27.* inhibitor EC 3.1.27.* inhibitors inhibitor of endoribonucleases producing other than 5'-phosphomonoesters inhibitor of endoribonucleases producing other than 5'-phosphomonoesters (EC 3.1.27.*) inhibitors of endoribonucleases producing other than 5'-phosphomonoesters inhibitors of endoribonucleases producing other than 5'-phosphomonoesters (EC 3.1.27.*) EC 3.1.27.* (endoribonucleases producing other than 5'-phosphomonoesters) inhibitor CHEBI:76795 EC 3.4.22.36 (caspase-1) inhibitor EC 3.4.22.36 (caspase-1) inhibitors EC 3.4.22.36 inhibitor EC 3.4.22.36 inhibitors ICE inhibitor ICE inhibitors caspase-1 (EC 3.4.22.36) inhibitor caspase-1 (EC 3.4.22.36) inhibitors caspase-1 inhibitor caspase-1 inhibitors interleukin 1 converting enzyme inhibitor interleukin 1 converting enzyme inhibitors interleukin 1beta converting enzyme inhibitor interleukin 1beta converting enzyme inhibitors interleukin 1beta precursor proteinase inhibitor interleukin 1beta precursor proteinase inhibitors interleukin 1beta-converting endopeptidase inhibitor interleukin 1beta-converting endopeptidase inhibitors interleukin 1beta-converting enzyme inhibitor interleukin 1beta-converting enzyme inhibitors interleukin-1 beta convertase precursor inhibitor interleukin-1 beta convertase precursor inhibitors interleukin-1beta convertase inhibitor interleukin-1beta convertase inhibitors interleukin-1beta converting enzyme inhibitor interleukin-1beta converting enzyme inhibitors interleukin-1beta precursor proteinase inhibitor interleukin-1beta precursor proteinase inhibitors precursor interleukin-1beta converting enzyme inhibitor precursor interleukin-1beta converting enzyme inhibitors pro-interleukin 1beta proteinase inhibitor pro-interleukin 1beta proteinase inhibitors prointerleukin 1beta protease inhibitor prointerleukin 1beta protease inhibitors protease A inhibitor protease A inhibitors protease VII inhibitor protease VII inhibitors EC 3.4.22.36 (caspase-1) inhibitor CHEBI:76796 EC 3.4.22.* (cysteine endopeptidase) inhibitor EC 3.4.22.* (cysteine endopeptidase) inhibitors EC 3.4.22.* inhibitor EC 3.4.22.* inhibitors cysteine endopeptidase (EC 3.4.22.*) inhibitor cysteine endopeptidase (EC 3.4.22.*) inhibitors cysteine endopeptidase inhibitor cysteine endopeptidase inhibitors EC 3.4.22.* (cysteine endopeptidase) inhibitor CHEBI:76797 EC 2.5.1.18 (glutathione transferase) inhibitor EC 2.5.1.18 (glutathione transferase) inhibitors EC 2.5.1.18 inhibitor EC 2.5.1.18 inhibitors RX:glutathione R-transferase inhibitor RX:glutathione R-transferase inhibitors S-(hydroxyalkyl)glutathione lyase inhibitor S-(hydroxyalkyl)glutathione lyase inhibitors glutathione S-alkyl transferase inhibitor glutathione S-alkyl transferase inhibitors glutathione S-alkyltransferase inhibitor glutathione S-alkyltransferase inhibitors glutathione S-aralkyltransferase inhibitor glutathione S-aralkyltransferase inhibitors glutathione S-aryltransferase inhibitor glutathione S-aryltransferase inhibitors glutathione S-transferase inhibitor glutathione S-transferase inhibitors glutathione transferase (EC 2.5.1.18) inhibitor glutathione transferase (EC 2.5.1.18) inhibitors glutathione transferase inhibitor glutathione transferase inhibitors EC 2.5.1.18 (glutathione transferase) inhibitor CHEBI:76798 EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitors EC 1.14.15.4 inhibitor EC 1.14.15.4 inhibitors cytochrome p450 XIB1 inhibitor cytochrome p450 XIB1 inhibitors steroid 11beta-hydroxylase inhibitor steroid 11beta-hydroxylase inhibitors steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitors steroid 11beta-monooxygenase inhibitors steroid 11beta/18-hydroxylase inhibitor steroid 11beta/18-hydroxylase inhibitors steroid,reduced-adrenodoxin:oxygen oxidoreductase (11beta-hydroxylating) inhibitor steroid,reduced-adrenodoxin:oxygen oxidoreductase (11beta-hydroxylating) inhibitors EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor CHEBI:76807 EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitors EC 3.5.1.* inhibitor EC 3.5.1.* inhibitors non-peptide linear amide C-N hydrolase (EC 3.5.1.*) inhibitor non-peptide linear amide C-N hydrolase (EC 3.5.1.*) inhibitors EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor CHEBI:76808 EC 3.5.2.* (non-peptide cyclic amide C-N hydrolase) inhibitor EC 3.5.2.* (non-peptide cyclic amide C-N hydrolase) inhibitors EC 3.5.2.* inhibitor EC 3.5.2.* inhibitors non-peptide cyclic amide C-N hydrolase (EC 3.5.2.*) inhibitor non-peptide cyclic amide C-N hydrolase (EC 3.5.2.*) inhibitors non-peptide cyclic amide C-N hydrolase inhibitor non-peptide cyclic amide C-N hydrolase inhibitors EC 3.5.2.* (non-peptide cyclic amide C-N hydrolase) inhibitor CHEBI:76809 EC 3.5.4.* (non-peptide cyclic amidine C-N hydrolase) inhibitor EC 3.5.4.* (non-peptide cyclic amidine C-N hydrolase) inhibitors non-peptide cyclic amidine C-N hydrolase (EC 3.5.4.*) inhibitor non-peptide cyclic amidine C-N hydrolase (EC 3.5.4.*) inhibitors non-peptide cyclic amidine C-N hydrolase inhibitor non-peptide cyclic amidine C-N hydrolase inhibitors EC 3.5.4.* (non-peptide cyclic amidine C-N hydrolase) inhibitor CHEBI:76811 EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitors EC 3.1.4.12 inhibitor EC 3.1.4.12 inhibitors SMase inhibitor SMase inhibitors acid sphingomyelinase inhibitor acid sphingomyelinase inhibitors neutral sphingomyelinase inhibitor neutral sphingomyelinase inhibitors sphingomyelin cholinephosphohydrolase inhibitor sphingomyelin cholinephosphohydrolase inhibitors sphingomyelin phosphodiesterase (EC 3.1.4.12) inhibitor sphingomyelin phosphodiesterase (EC 3.1.4.12) inhibitors sphingomyelin phosphodiesterase inhibitor sphingomyelin phosphodiesterase inhibitors EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor CHEBI:76812 EC 2.7.11.* (protein-serine/threonine kinase) inhibitor EC 2.7.11.* (protein-serine/threonine kinase) inhibitors EC 2.7.11.* inhibitor EC 2.7.11.* inhibitors protein-serine/threonine kinase (EC 2.7.11.*) inhibitor protein-serine/threonine kinase (EC 2.7.11.*) inhibitors protein-serine/threonine kinase inhibitor protein-serine/threonine kinase inhibitors EC 2.7.11.* (protein-serine/threonine kinase) inhibitor CHEBI:76815 EC 2.7.7.* (nucleotidyltransferase) inhibitor EC 2.7.7.* (nucleotidyltransferase) inhibitors inhibitor of nucleotidyltransferases inhibitor of nucleotidyltransferases (EC 2.7.7.*) inhibitors of nucleotidyltransferases inhibitors of nucleotidyltransferases (EC 2.7.7.*) nucleotidyltransferase (EC 2.7.7.*) inhibitor nucleotidyltransferase (EC 2.7.7.*) inhibitors nucleotidyltransferase inhibitor nucleotidyltransferase inhibitors EC 2.7.7.* (nucleotidyltransferase) inhibitor CHEBI:76816 EC 2.7.8.* (transferases for other substituted phosphate groups) inhibitor EC 2.7.8.* (transferases for other substituted phosphate groups) inhibitors EC 2.7.8.* inhibitor EC 2.7.8.* inhibitors EC 2.7.8.* (transferases for other substituted phosphate groups) inhibitor CHEBI:76817 EC 2.7.10.* (protein-tyrosine kinase) inhibitor EC 2.7.10.* (protein-tyrosine kinase) inhibitors EC 2.7.10.* inhibitor EC 2.7.10.* inhibitors protein-tyrosine kinase (EC 2.7.10.*) inhibitor protein-tyrosine kinase (EC 2.7.10.*) inhibitors protein-tyrosine kinase inhibitor protein-tyrosine kinase inhibitors EC 2.7.10.* (protein-tyrosine kinase) inhibitor CHEBI:76818 EC 2.7.3.* (phosphotransferases with a nitrogenous group as acceptor) inhibitor EC 2.7.3.* (phosphotransferases with a nitrogenous group as acceptor) inhibitors EC 2.7.3.* inhibitor EC 2.7.3.* inhibitors phosphotransferases with a nitrogenous group as acceptor (EC 2.7.3.*) inhibitor phosphotransferases with a nitrogenous group as acceptor (EC 2.7.3.*) inhibitors EC 2.7.3.* (phosphotransferases with a nitrogenous group as acceptor) inhibitor CHEBI:76822 EC 3.2.1.31 (beta-glucuronidase) inhibitor EC 3.2.1.31 (beta-glucuronidase) inhibitors EC 3.2.1.31 inhibitor EC 3.2.1.31 inhibitors beta-D-glucuronoside glucuronosohydrolase inhibitor beta-D-glucuronoside glucuronosohydrolase inhibitors beta-glucuronidase (EC 3.2.1.31) inhibitor beta-glucuronidase (EC 3.2.1.31) inhibitors beta-glucuronidase inhibitor beta-glucuronidase inhibitors beta-glucuronide glucuronohydrolase inhibitor beta-glucuronide glucuronohydrolase inhibitors exo-beta-D-glucuronidase inhibitor exo-beta-D-glucuronidase inhibitors glucuronidase inhibitor glucuronidase inhibitors ketodase inhibitor ketodase inhibitors EC 3.2.1.31 (beta-glucuronidase) inhibitor CHEBI:76823 EC 6.3.1.* (acid-ammonia/amine ligase) inhibitor EC 6.3.1.* (acid-ammonia/amine ligase) inhibitors EC 6.3.1.* inhibitor EC 6.3.1.* inhibitors acid-ammonia (or amine) ligase inhibitor acid-ammonia (or amine) ligase inhibitors EC 6.3.1.* (acid-ammonia/amine ligase) inhibitor CHEBI:76824 EC 6.4.1.* (carboxylase) inhibitor EC 6.4.1.* (C-C bond forming ligase) inhibitor EC 6.4.1.* (C-C bond forming ligase) inhibitors EC 6.4.1.* (C-C bond-forming ligase) inhibitors EC 6.4.1.* (carboxylase) inhibitors EC 6.4.1.* inhibitor EC 6.4.1.* inhibitors inhibitor of ligases forming C-C bonds inhibitor of ligases forming C-C bonds (EC 6.4.1.*) inhibitors of ligases forming C-C bonds inhibitors of ligases forming C-C bonds (EC 6.4.1.*) EC 6.4.1.* (carboxylase) inhibitor CHEBI:76827 EC 6.5.1.* (DNA/RNA repair enzymes) inhibitor EC 6.5.1.* (DNA/RNA repair enzymes) inhibitors EC 6.5.1.* inhibitor EC 6.5.1.* inhibitors EC 6.5.1.* (DNA/RNA repair enzymes) inhibitor CHEBI:76828 EC 5.1.1.* (racemases acting on amino acids and derivatives) inhibitor EC 5.1.1.* (racemases acting on amino acids and derivatives) inhibitors EC 5.1.1.* inhibitor EC 5.1.1.* inhibitors inhibitor of racemases acting on amino acids and derivatives inhibitor of racemases acting on amino acids and derivatives (EC 5.1.1.*) inhibitors of racemases acting on amino acids and derivatives inhibitors of racemases acting on amino acids and derivatives (EC 5.1.1.*) EC 5.1.1.* (racemases acting on amino acids and derivatives) inhibitor CHEBI:76829 EC 5.4.3.* (intramolecular transferase transferring amino groups) inhibitor EC 5.4.3.* (intramolecular transferase transferring amino groups) inhibitors EC 5.4.3.* inhibitor EC 5.4.3.* inhibitors inhibitor of intramolecular transferase transferring amino groups inhibitor of intramolecular transferase transferring amino groups (EC 5.4.3.*) inhibitors of intramolecular transferase transferring amino groups inhibitors of intramolecular transferase transferring amino groups (EC 5.4.3.*) EC 5.4.3.* (intramolecular transferase transferring amino groups) inhibitor CHEBI:76830 EC 5.99.1.* (miscellaneous isomerase) inhibitor EC 5.99.1.* (miscellaneous isomerase) inhibitors EC 5.99.1.* inhibitor EC 5.99.1.* inhibitors EC 5.99.1.* (miscellaneous isomerase) inhibitor CHEBI:76831 EC 4.4.1.* (C-S lyase) inhibitor C-S lyase (EC 4.4.1.*) inhibitor C-S lyase (EC 4.4.1.*) inhibitors EC 4.4.1.* (C-S lyase) inhibitors EC 4.4.1.* inhibitor EC 4.4.1.* inhibitors EC 4.4.1.* (C-S lyase) inhibitor CHEBI:76832 EC 4.3.1.* (ammonia-lyase) inhibitor EC 4.3.1.* (ammonia-lyase) inhibitors EC 4.3.1.* (ammonia-lyases) inhibitor EC 4.3.1.* (ammonia-lyases) inhibitors EC 4.3.1.* inhibitor EC 4.3.1.* inhibitors ammonia-lyase (EC 4.3.1.*) inhibitor ammonia-lyase (EC 4.3.1.*) inhibitors ammonia-lyase inhibitor ammonia-lyase inhibitors EC 4.3.1.* (ammonia-lyase) inhibitor CHEBI:76834 EC 2.5.* (non-methyl-alkyl or aryl transferase) inhibitor EC 2.5.* (non-methyl-alkyl or aryl transferase) inhibitors EC 2.5.* inhibitor EC 2.5.* inhibitors non-methyl-alkyl or aryl transferase (EC 2.5.*) inhibitor non-methyl-alkyl or aryl transferase (EC 2.5.*) inhibitors EC 2.5.* (non-methyl-alkyl or aryl transferase) inhibitor CHEBI:76835 EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+)acceptor) inhibitors EC 1.1.1.* inhibitor EC 1.1.1.* inhibitors oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor (EC 1.1.1.*) inhibitor oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor (EC 1.1.1.*) inhibitors EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor CHEBI:76836 EC 1.1.3.* (oxidoreductase acting on donor CH-OH group, oxygen as acceptor) inhibitor EC 1.1.3.* (oxidoreductase acting on donor CH-OH group, oxygen as acceptor) inhibitors EC 1.1.3.* inhibitor EC 1.1.3.* inhibitors oxidoreductase acting on donor CH-OH group, oxygen as acceptor (EC 1.1.3.*) inhibitor oxidoreductase acting on donor CH-OH group, oxygen as acceptor (EC 1.1.3.*) inhibitors EC 1.1.3.* (oxidoreductase acting on donor CH-OH group, oxygen as acceptor) inhibitor CHEBI:76837 EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 O atoms) inhibitor EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 O atoms) inhibitors EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 atoms of oxygen) inhibitor EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 atoms of oxygen) inhibitors EC 1.13.11.* inhibitor EC 1.13.11.* inhibitors oxidoreductase acting on single donors and incorporating 2 atoms of oxygen (EC 1.13.11.*) inhibitor oxidoreductase acting on single donors and incorporating 2 atoms of oxygen (EC 1.13.11.*) inhibitors EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 O atoms) inhibitor CHEBI:76838 EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitors EC 1.14.14.* (oxidoreductase acting on paired donors, with incorporation of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor EC 1.14.14.* (oxidoreductase acting on paired donors, with incorporation of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitors EC 1.14.14.* inhibitor EC 1.14.14.* inhibitors oxidoreductase acting on paired donors, with incorporation of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor (EC 1.14.14.*) inhibitor oxidoreductase acting on paired donors, with incorporation of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor (EC 1.14.14.*) inhibitors EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor CHEBI:76840 EC 1.14.99.* (miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor EC 1.14.99.* (miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitors EC 1.14.99.* inhibitor EC 1.14.99.* inhibitors miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.99.*) inhibitor miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.99.*) inhibitors EC 1.14.99.* (miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor CHEBI:76841 EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitors EC 1.14.13.* inhibitor EC 1.14.13.* inhibitors oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor (EC 1.14.13.*) inhibitor oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor (EC 1.14.13.*) inhibitors EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor CHEBI:76843 EC 1.14.15.* (oxidoreductase acting on paired donors, with reduced Fe-S protein as one donor, incorporating 1 O atom) inhibitor EC 1.14.15.* (oxidoreductase acting on paired donors, with reduced Fe-S protein as one donor, incorporating 1 O atom) inhibitors EC 1.14.15.* (oxidoreductase acting on paired donors, with reduced iron-sulfur protein as one donor, incorporating 1 atom of oxygen) inhibitor EC 1.14.15.* (oxidoreductase acting on paired donors, with reduced iron-sulfur protein as one donor, incorporating 1 atom of oxygen) inhibitors EC 1.14.15.* inhibitor EC 1.14.15.* inhibitors oxidoreductase acting on paired donors, with reduced iron-sulfur protein as one donor, incorporating 1 atom of oxygen (EC 1.14.15.*) inhibitor oxidoreductase acting on paired donors, with reduced iron-sulfur protein as one donor, incorporating 1 atom of oxygen (EC 1.14.15.*) inhibitors EC 1.14.15.* (oxidoreductase acting on paired donors, with reduced Fe-S protein as one donor, incorporating 1 O atom) inhibitor CHEBI:76845 EC 1.14.18.* (oxidoreductase acting on paired donors, miscellaneous compound as one donor, incorporating 1 atom of oxygen) inhibitor EC 1.14.18.* (oxidoreductase acting on paired donors, miscellaneous compound as one donor, incorporating 1 atom of oxygen) inhibitors EC 1.14.18.* inhibitor EC 1.14.18.* inhibitors oxidoreductase acting on paired donors, miscellaneous compound as one donor, incorporating 1 atom of oxygen (EC 1.14.18.*) inhibitor oxidoreductase acting on paired donors, miscellaneous compound as one donor, incorporating 1 atom of oxygen (EC 1.14.18.*) inhibitors EC 1.14.18.* (oxidoreductase acting on paired donors, miscellaneous compound as one donor, incorporating 1 atom of oxygen) inhibitor CHEBI:76847 EC 1.14.16.* (oxidoreductase acting on paired donors, reduced pteridine as one donor, incorporating 1 atom of oxygen) inhibitor EC 1.14.16.* (oxidoreductase acting on paired donors, reduced pteridine as one donor, incorporating 1 atom of oxygen) inhibitors EC 1.14.16.* inhibitor EC 1.14.16.* inhibitors oxidoreductase acting on paired donors, reduced pteridine as one donor, incorporating 1 atom of oxygen (EC 1.14.16.*) inhibitor oxidoreductase acting on paired donors, reduced pteridine as one donor, incorporating 1 atom of oxygen (EC 1.14.16.*) inhibitors EC 1.14.16.* (oxidoreductase acting on paired donors, reduced pteridine as one donor, incorporating 1 atom of oxygen) inhibitor CHEBI:76848 EC 1.17.4.* (oxidoreductase acting on CH or CH2 with a disulfide as acceptor) inhibitor EC 1.17.4.* (oxidoreductase acting on CH or CH2 with a disulfide as acceptor) inhibitors EC 1.17.4.* inhibitor EC 1.17.4.* inhibitors oxidoreductase acting on CH or CH2 with a disulfide as acceptor (EC 1.17.4.*) inhibitor oxidoreductase acting on CH or CH2 with a disulfide as acceptor (EC 1.17.4.*) inhibitors EC 1.17.4.* (oxidoreductase acting on CH or CH2 with a disulfide as acceptor) inhibitor CHEBI:76850 EC 1.17.3.* (oxidoreductase acting on CH or CH2 with oxygen as acceptor) inhibitor EC 1.17.3.* (oxidoreductase acting on CH or CH2 with oxygen as acceptor) inhibitors EC 1.17.3.* inhibitor EC 1.17.3.* inhibitors oxidoreductase acting on CH or CH2 with oxygen as acceptor (EC 1.17.3.*) inhibitor oxidoreductase acting on CH or CH2 with oxygen as acceptor (EC 1.17.3.*) inhibitors EC 1.17.3.* (oxidoreductase acting on CH or CH2 with oxygen as acceptor) inhibitor CHEBI:76852 EC 1.2.1.* (oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor) inhibitor EC 1.2.1.* (oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor) inhibitors EC 1.2.1.* inhibitor EC 1.2.1.* inhibitors oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor (EC 1.2.1.*) inhibitor oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor (EC 1.2.1.*) inhibitors EC 1.2.1.* (oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor) inhibitor CHEBI:76853 EC 1.2.3.* (oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor) inhibitor EC 1.2.3.* (oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor) inhibitors EC 1.2.3.* inhibitor EC 1.2.3.* inhibitors oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor (EC 1.2.3.*) inhibitor oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor (EC 1.2.3.*) inhibitors EC 1.2.3.* (oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor) inhibitor CHEBI:76857 EC 1.3.1.* (oxidoreductase acting on donor CH-CH group, NAD(+) or NADP(+) as acceptor) inhibitor EC 1.3.1.* (oxidoreductase acting on CH-CH group of donor with NAD(+) or NADP(+) as acceptor) inhibitor EC 1.3.1.* (oxidoreductase acting on CH-CH group of donor with NAD(+) or NADP(+) as acceptor) inhibitors EC 1.3.1.* (oxidoreductase acting on CH-CH group of donor, NAD(+) or NADP(+) as acceptor) inhibitor EC 1.3.1.* (oxidoreductase acting on CH-CH group of donor, NAD(+) or NADP(+) as acceptor) inhibitors EC 1.3.1.* (oxidoreductase acting on donor CH-CH group, NAD(+) or NADP(+) as acceptor) inhibitors EC 1.3.1.* inhibitor EC 1.3.1.* inhibitors oxidoreductase acting on CH-CH group of donor with NAD(+) or NADP(+) as acceptor (EC 1.3.1.*) inhibitor oxidoreductase acting on CH-CH group of donor with NAD(+) or NADP(+) as acceptor (EC 1.3.1.*) inhibitors EC 1.3.1.* (oxidoreductase acting on donor CH-CH group, NAD(+) or NADP(+) as acceptor) inhibitor CHEBI:76858 EC 1.3.98.* (oxidoreductase acting on donor CH-CH group, with other, known, acceptors) inhibitor EC 1.3.98.* (oxidoreductase acting on CH-CH group of donors, with other, known, acceptors) inhibitor EC 1.3.98.* (oxidoreductase acting on CH-CH group of donors, with other, known, acceptors) inhibitors EC 1.3.98.* (oxidoreductase acting on donor CH-CH group, with other, known, acceptors) inhibitors EC 1.3.98.* inhibitor EC 1.3.98.* inhibitors oxidoreductase acting on CH-CH group of donors, with other, known, acceptors (EC 1.3.98.*) inhibitor oxidoreductase acting on CH-CH group of donors, with other, known, acceptors (EC 1.3.98.*) inhibitors EC 1.3.98.* (oxidoreductase acting on donor CH-CH group, with other, known, acceptors) inhibitor CHEBI:76859 EC 1.3.99.* (oxidoreductase acting on donor CH-CH group, with other acceptors) inhibitor EC 1.3.99.* (oxidoreductase acting on donor CH-CH group with other acceptors) inhibitors EC 1.3.99.* (oxidoreductase acting on donor CH-CH group, with other acceptors) inhibitors EC 1.3.99.* inhibitor EC 1.3.99.* inhibitors oxidoreductase acting on donor CH-CH group with other acceptors (EC 1.3.99.*) inhibitor oxidoreductase acting on donor CH-CH group with other acceptors (EC 1.3.99.*) inhibitors EC 1.3.99.* (oxidoreductase acting on donor CH-CH group, with other acceptors) inhibitor CHEBI:76860 EC 1.3.3.* (oxidoreductase acting on donor CH-CH group, oxygen as acceptor) inhibitor EC 1.3.3.* (oxidoreductase acting on donor CH-CH group with oxygen as acceptor) inhibitor EC 1.3.3.* (oxidoreductase acting on donor CH-CH group with oxygen as acceptor) inhibitors EC 1.3.3.* (oxidoreductase acting on donor CH-CH group, oxygen as acceptor) inhibitors EC 1.3.3.* inhibitor EC 1.3.3.* inhibitors oxidoreductase acting on donor CH-CH group with oxygen as acceptor (EC 1.3.3.*) inhibitor oxidoreductase acting on donor CH-CH group with oxygen as acceptor (EC 1.3.3.*) inhibitors EC 1.3.3.* (oxidoreductase acting on donor CH-CH group, oxygen as acceptor) inhibitor CHEBI:76861 EC 1.4.3.* (oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor) inhibitor EC 1.4.3.* (oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor) inhibitors EC 1.4.3.* inhibitor EC 1.4.3.* inhibitors oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor (EC 1.4.3.*) inhibitor oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor (EC 1.4.3.*) inhibitors EC 1.4.3.* (oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor) inhibitor CHEBI:76862 EC 1.4.4.* (oxidoreductase acting on donor CH-NH2 group, a disulfide as acceptor) inhibitor EC 1.4.4.* (oxidoreductase acting on donor CH-NH2 group, a disulfide as acceptor) inhibitors EC 1.4.4.* inhibitor EC 1.4.4.* inhibitors oxidoreductase acting on donor CH-NH2 group, a disulfide as acceptor (EC 1.4.4.*) inhibitor oxidoreductase acting on donor CH-NH2 group, a disulfide as acceptor (EC 1.4.4.*) inhibitors EC 1.4.4.* (oxidoreductase acting on donor CH-NH2 group, a disulfide as acceptor) inhibitor CHEBI:76863 EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitor EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitors EC 1.5.1.* inhibitor EC 1.5.1.* inhibitors oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor (EC 1.5.1.*) inhibitor oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor (EC 1.5.1.*) inhibitors EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitor CHEBI:76866 EC 1.6.5.* (oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor) inhibitor EC 1.6.5.* (oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor) inhibitors EC 1.6.5.* inhibitor EC 1.6.5.* inhibitors oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor (EC 1.6.5.*) inhibitor oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor (EC 1.6.5.*) inhibitors EC 1.6.5.* (oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor) inhibitor CHEBI:76867 EC 1.6.3.* (oxidoreductase acting on NADH or NADPH with oxygen as acceptor) inhibitor EC 1.6.3.* (oxidoreductase acting on NADH or NADPH with oxygen as acceptor) inhibitors EC 1.6.3.* inhibitor EC 1.6.3.* inhibitors oxidoreductase acting on NADH or NADPH with oxygen as acceptor (EC 1.6.3.*) inhibitor oxidoreductase acting on NADH or NADPH with oxygen as acceptor (EC 1.6.3.*) inhibitors EC 1.6.3.* (oxidoreductase acting on NADH or NADPH with oxygen as acceptor) inhibitor CHEBI:76869 EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor) inhibitor EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor) inhibitors EC 1.8.1.* inhibitor EC 1.8.1.* inhibitors oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor (EC 1.8.1.*) inhibitor oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor (EC 1.8.1.*) inhibitors EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor) inhibitor CHEBI:76870 EC 1.9.3.* (oxidoreductase acting on donor heme group, oxygen as acceptor) inhibitor EC 1.9.3.* (oxidoreductase acting on donor heme group, oxygen as acceptor) inhibitors EC 1.9.3.* inhibitor EC 1.9.3.* inhibitors oxidoreductase acting on donor heme group, oxygen as acceptor (EC 1.9.3.*) inhibitor oxidoreductase acting on donor heme group, oxygen as acceptor (EC 1.9.3.*) inhibitors EC 1.9.3.* (oxidoreductase acting on donor heme group, oxygen as acceptor) inhibitor CHEBI:76871 EC 2.1.1.* (methyltransferases) inhibitor EC 2.1.1.* (methyltransferase) inhibitor EC 2.1.1.* (methyltransferase) inhibitors EC 2.1.1.* (methyltransferases) inhibitors EC 2.1.1.* inhibitor EC 2.1.1.* inhibitors methyltransferase (EC 2.1.1.*) inhibitor methyltransferase (EC 2.1.1.*) inhibitors EC 2.1.1.* (methyltransferases) inhibitor CHEBI:76874 EC 2.1.2.* (hydroxymethyl-, formyl- and related transferases) inhibitor EC 2.1.2.* (hydroxymethyl-, formyl- and related transferases) inhibitors EC 2.1.2.* inhibitor EC 2.1.2.* inhibitors hydroxymethyl-, formyl- and related transferases (EC 2.1.2.*) inhibitor hydroxymethyl-, formyl- and related transferases (EC 2.1.2.*) inhibitors EC 2.1.2.* (hydroxymethyl-, formyl- and related transferases) inhibitor CHEBI:76876 EC 2.2.1.* (transketolase/transaldolase) inhibitor EC 2.2.1.* (transketolase/transaldolase) inhibitors EC 2.2.1.* (transketolases and transaldolases) inhibitor EC 2.2.1.* (transketolases and transaldolases) inhibitors EC 2.2.1.* inhibitor EC 2.2.1.* inhibitors transketolase/transaldolase (EC 2.2.1.*) inhibitor transketolase/transaldolase (EC 2.2.1.*) inhibitors EC 2.2.1.* (transketolase/transaldolase) inhibitor CHEBI:76877 EC 2.3.2.* (aminoacyltransferase) inhibitor EC 2.3.2.* (aminoacyltransferase) inhibitors EC 2.3.2.* inhibitor EC 2.3.2.* inhibitors aminoacyltransferase (EC 2.3.2.*) inhibitor aminoacyltransferase (EC 2.3.2.*) inhibitors EC 2.3.2.* (aminoacyltransferase) inhibitor CHEBI:76878 EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitors EC 2.3.1.* inhibitor EC 2.3.1.* inhibitors acyltransferase transferring other than amino-acyl group EC 2.3.1.* inhibitor acyltransferase transferring other than amino-acyl group EC 2.3.1.* inhibitors EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor CHEBI:76879 EC 2.6.1.* (transaminase) inhibitor EC 2.6.1.* (transaminase) inhibitors EC 2.6.1.* inhibitor EC 2.6.1.* inhibitors transaminase (EC 2.6.1.*) inhibitor transaminase (EC 2.6.1.*) inhibitors EC 2.6.1.* (transaminase) inhibitor CHEBI:76881 EC 2.7.1.* (phosphotransferases with an alcohol group as acceptor) inhibitor EC 2.7.1.* (phosphotransferases with an alcohol group as acceptor) inhibitors EC 2.7.1.* inhibitor EC 2.7.1.* inhibitors phosphotransferases with an alcohol group as acceptor (EC 2.7.1.*) inhibitor phosphotransferases with an alcohol group as acceptor (EC 2.7.1.*) inhibitors EC 2.7.1.* (phosphotransferases with an alcohol group as acceptor) inhibitor CHEBI:76882 EC 2.4.99.* (glycosyltransferases transferring other glycosyl groups) inhibitor EC 2.4.99.* (glycosyltransferases transferring other glycosyl groups) inhibitors EC 2.4.99.* inhibitor EC 2.4.99.* inhibitors glycosyltransferases transferring other glycosyl groups (EC 2.4.99.*) inhibitor glycosyltransferases transferring other glycosyl groups (EC 2.4.99.*) inhibitors EC 2.4.99.* (glycosyltransferases transferring other glycosyl groups) inhibitor CHEBI:76883 EC 3.11.1.* (hydrolases acting on C-P bonds of phosphono-acetaldehyde, -acetate, or -pyruvate) inhibitor EC 3.11.1.* (hydrolases acting on C-P bonds of phosphono-acetaldehyde, -acetate, or -pyruvate) inhibitors EC 3.11.1.* inhibitor EC 3.11.1.* inhibitors hydrolases acting on C-P bonds of phosphono-acetaldehyde, -acetate, or -pyruvate (EC 3.11.1.*) inhibitor hydrolases acting on C-P bonds of phosphono-acetaldehyde, -acetate, or -pyruvate (EC 3.11.1.*) inhibitors EC 3.11.1.* (hydrolases acting on C-P bonds of phosphono-acetaldehyde, -acetate, or -pyruvate) inhibitor CHEBI:76885 EC 3.4.23.* (aspartic endopeptidase) inhibitor EC 3.4.23.* (aspartic endopeptidase) inhibitors EC 3.4.23.* (aspartic endopeptidases) inhibitor EC 3.4.23.* (aspartic endopeptidases) inhibitors EC 3.4.23.* inhibitor EC 3.4.23.* inhibitors aspartic endopeptidase (EC 3.4.23.*) inhibitor aspartic endopeptidase (EC 3.4.23.*) inhibitors aspartic endopeptidases (EC 3.4.23.*) inhibitor aspartic endopeptidases (EC 3.4.23.*) inhibitors EC 3.4.23.* (aspartic endopeptidase) inhibitor CHEBI:76891 EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitors EC 3.4.11.14 inhibitor EC 3.4.11.14 inhibitors alanine aminopeptidase inhibitor alanine aminopeptidase inhibitors aminopolypeptidase inhibitor aminopolypeptidase inhibitors arylamidase inhibitor arylamidase inhibitors cytosol alanyl aminopeptidase (EC 3.4.11.14) inhibitor cytosol alanyl aminopeptidase (EC 3.4.11.14) inhibitors cytosol alanyl aminopeptidase inhibitor cytosol alanyl aminopeptidase inhibitors cytosol aminopeptidase III inhibitor cytosol aminopeptidase III inhibitors human liver aminopeptidase inhibitor human liver aminopeptidase inhibitors puromycin-sensitive aminopeptidase inhibitor puromycin-sensitive aminopeptidase inhibitors soluble alanyl aminopeptidase inhibitor soluble alanyl aminopeptidase inhibitors thiol-activated aminopeptidase inhibitor thiol-activated aminopeptidase inhibitors EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor CHEBI:76893 EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor DAP II inhibitor DAP II inhibitors EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitors EC 3.4.14.2 inhibitor EC 3.4.14.2 inhibitors carboxytripeptidase inhibitor carboxytripeptidase inhibitors dipeptidyl aminopeptidase II inhibitor dipeptidyl aminopeptidase II inhibitors dipeptidyl arylamidase II inhibitor dipeptidyl arylamidase II inhibitors dipeptidyl peptidase II inhibitor dipeptidyl peptidase II inhibitors dipeptidyl(amino)peptidase II inhibitor dipeptidyl(amino)peptidase II inhibitors dipeptidyl-peptidase II (EC 3.4.14.2) inhibitor dipeptidyl-peptidase II (EC 3.4.14.2) inhibitors dipeptidyl-peptidase II inhibitor dipeptidyl-peptidase II inhibitors dipeptidylarylamidase inhibitor dipeptidylarylamidase inhibitors EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor CHEBI:76895 EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitors EC 3.6.3.* inhibitor EC 3.6.3.* inhibitors acid anhydride hydrolase catalysing transmembrane movement of substances (EC 3.6.3.*) inhibitor acid anhydride hydrolase catalysing transmembrane movement of substances (EC 3.6.3.*) inhibitors EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor CHEBI:76898 EC 1.14.14.1 (unspecific monooxygenase) inhibitor EC 1.14.14.1 (unspecific monooxygenase) inhibitors EC 1.14.14.1 inhibitor EC 1.14.14.1 inhibitors aryl hydrocarbon hydroxylase inhibitor aryl hydrocarbon hydroxylase inhibitors aryl-4-monooxygenase inhibitor aryl-4-monooxygenase inhibitors flavoprotein monooxygenase inhibitor flavoprotein monooxygenase inhibitors flavoprotein-linked monooxygenase inhibitor flavoprotein-linked monooxygenase inhibitors microsomal P-450 inhibitor microsomal P-450 inhibitors microsomal monooxygenase inhibitor microsomal monooxygenase inhibitors substrate,reduced-flavoprotein:oxygen oxidoreductase (RH-hydroxylating or -epoxidising) inhibitor substrate,reduced-flavoprotein:oxygen oxidoreductase (RH-hydroxylating or -epoxidising) inhibitors unspecific monooxygenase (EC 1.14.14.1) inhibitor unspecific monooxygenase (EC 1.14.14.1) inhibitors unspecific monooxygenase inhibitor unspecific monooxygenase inhibitors xenobiotic monooxygenase inhibitor xenobiotic monooxygenase inhibitors EC 1.14.14.1 (unspecific monooxygenase) inhibitor CHEBI:76902 EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitors EC 1.14.11.* (oxidoreductase acting on paired donors, with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors) inhibitor EC 1.14.11.* (oxidoreductase acting on paired donors, with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors) inhibitors EC 1.14.11.* inhibitor EC 1.14.11.* inhibitors oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors (EC 1.14.11.*) inhibitor oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors (EC 1.14.11.*) inhibitors oxidoreductase acting on paired donors, with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (EC 1.14.11.*) inhibitor oxidoreductase acting on paired donors, with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (EC 1.14.11.*) inhibitors EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor CHEBI:76906 EC 4.1.1.* (carboxy-lyase) inhibitor EC 4.1.1.* (carboxy-lyase) inhibitors EC 4.1.1.* inhibitor EC 4.1.1.* inhibitors carboxy-lyase (EC 4.1.1.*) inhibitor carboxy-lyase (EC 4.1.1.*) inhibitors carboxy-lyases (EC 4.1.1.*) inhibitor carboxy-lyases (EC 4.1.1.*) inhibitors EC 4.1.1.* (carboxy-lyase) inhibitor CHEBI:76907 EC 4.2.1.* (hydro-lyases) inhibitor EC 4.2.1.* (hydro-lyase) inhibitor EC 4.2.1.* (hydro-lyase) inhibitors EC 4.2.1.* (hydro-lyases) inhibitors EC 4.2.1.* inhibitor EC 4.2.1.* inhibitors hydro-lyase (EC 4.2.1.*) inhibitor hydro-lyase (EC 4.2.1.*) inhibitors EC 4.2.1.* (hydro-lyases) inhibitor CHEBI:76916 hyperglycemic agent diabetes inducer hyperglycemic agents hyperglycemic agent CHEBI:76920 EC 1.1.3.9 (galactose oxidase) inhibitor D-galactose oxidase inhibitor D-galactose oxidase inhibitors D-galactose:oxygen 6-oxidoreductase inhibitor D-galactose:oxygen 6-oxidoreductase inhibitors EC 1.1.3.9 (galactose oxidase) inhibitors EC 1.1.3.9 inhibitor EC 1.1.3.9 inhibitors beta-galactose oxidase inhibitor beta-galactose oxidase inhibitors galactose oxidase inhibitor galactose oxidase inhibitors EC 1.1.3.9 (galactose oxidase) inhibitor CHEBI:76924 plant metabolite plant metabolites plant secondary metabolites plant metabolite CHEBI:76926 EC 3.4.13.19 (membrane dipeptidase) inhibitor DPH I inhibitors EC 3.4.13.19 (membrane dipeptidase) inhibitors EC 3.4.13.19 inhibitor EC 3.4.13.19 inhibitors MDP inhibitors aminodipeptidase inhibitors dehydropeptidase I (DPH I) inhibitors dehydropeptidase I inhibitors dipeptidase inhibitors dipeptide hydrolase inhibitors dipeptidyl hydrolase inhibitors glycosyl-phosphatidylinositol-anchored renal dipeptidase inhibitors membrane dipeptidase (EC 3.4.13.19) inhibitor membrane dipeptidase (EC 3.4.13.19) inhibitors membrane dipeptidase inhibitor membrane dipeptidase inhibitors microsomal dipeptidase inhibitors nonspecific dipeptidase inhibitors renal dipeptidase inhibitors EC 3.4.13.19 (membrane dipeptidase) inhibitor CHEBI:76932 pathway inhibitor metabolic pathway inhibitor metabolic pathway inhibitors pathway inhibitors pathway inhibitor CHEBI:76938 EC 3.6.4.* (hydrolases acting on ATP; involved in cellular and subcellular movement) inhibitor EC 3.6.4.* (hydrolase acting on ATP; involved in cellular and subcellular movement) inhibitor EC 3.6.4.* (hydrolase acting on ATP; involved in cellular and subcellular movement) inhibitors EC 3.6.4.* (hydrolases acting on ATP; involved in cellular and subcellular movement) inhibitors EC 3.6.4.* inhibitor EC 3.6.4.* inhibitors hydrolases acting on ATP; involved in cellular and subcellular movement (EC 3.6.4.*) inhibitor hydrolases acting on ATP; involved in cellular and subcellular movement (EC 3.6.4.*) inhibitors EC 3.6.4.* (hydrolases acting on ATP; involved in cellular and subcellular movement) inhibitor CHEBI:76939 EC 3.6.4.10 (non-chaperonin molecular chaperone ATPase) inhibitor ATP phosphohydrolase (polypeptide-polymerising) inhibitor ATP phosphohydrolase (polypeptide-polymerising) inhibitors ATP phosphohydrolase (polypeptide-polymerizing) inhibitor ATP phosphohydrolase (polypeptide-polymerizing) inhibitors EC 3.6.4.10 (non-chaperonin molecular chaperone ATPase) inhibitors EC 3.6.4.10 inhibitor EC 3.6.4.10 inhibitors molecular chaperone Hsc70 ATPase inhibitor molecular chaperone Hsc70 ATPase inhibitors non-chaperonin molecular chaperone ATPase (EC 3.6.4.10) inhibitor non-chaperonin molecular chaperone ATPase (EC 3.6.4.10) inhibitors EC 3.6.4.10 (non-chaperonin molecular chaperone ATPase) inhibitor CHEBI:76940 EC 3.4.21.4 (trypsin) inhibitor EC 3.4.21.4 (trypsin) inhibitors EC 3.4.21.4 inhibitor EC 3.4.21.4 inhibitors alpha-trypsin inhibitor alpha-trypsin inhibitors beta-trypsin inhibitor beta-trypsin inhibitors cocoonase inhibitor cocoonase inhibitors parenzyme inhibitor parenzyme inhibitors parenzymol inhibitor parenzymol inhibitors pseudotrypsin inhibitor pseudotrypsin inhibitors sperm receptor hydrolase inhibitor sperm receptor hydrolase inhibitors tripcellim inhibitor tripcellim inhibitors trypsin (EC 3.4.21.4) inhibitor trypsin (EC 3.4.21.4) inhibitors trypsin inhibitor trypsin inhibitors tryptar inhibitor tryptar inhibitors tryptase inhibitor tryptase inhibitors trypure inhibitor trypure inhibitors EC 3.4.21.4 (trypsin) inhibitor CHEBI:76946 fungal metabolite fungal metabolites fungal metabolite CHEBI:76956 Aspergillus metabolite Aspergillus metabolites Aspergillus metabolite CHEBI:76960 Chaetomium metabolite Chaetomium metabolites Chaetomium metabolite CHEBI:76964 Penicillium metabolite Penicillium metabolites Penicillium metabolite CHEBI:76967 human xenobiotic metabolite human xenobiotic metabolites human xenobiotic metabolite CHEBI:76968 fungal xenobiotic metabolite fungal xenobiotic metabolites fungal xenobiotic metabolite CHEBI:76969 bacterial metabolite bacterial metabolite CHEBI:76971 Escherichia coli metabolite E.coli metabolite E.coli metabolites Escherichia coli metabolites Escherichia coli metabolite CHEBI:76973 Streptococcus pneumoniae metabolite S. pneumoniae metabolite S. pneumoniae metabolites S. pneumoniae secondary metabolite S. pneumoniae secondary metabolites Streptococcus pneumoniae metabolites Streptococcus pneumoniae secondary metabolites Streptococcus pneumoniae metabolite CHEBI:76976 bacterial xenobiotic metabolite bacterial xenobiotic metabolites bacterial xenobiotic metabolite CHEBI:76977 corticotropin-releasing factor receptor antagonist CRF antagonist CRF antagonists corticotropin-releasing factor receptor antagonists corticotropin-releasing factor receptor antagonist CHEBI:76988 xenoestrogen xenoestrogens xenoestrogen CHEBI:76989 phytoestrogen phytoestrogens phytoestrogen CHEBI:76990 mycoestrogen mycoestrogens mycoestrogen CHEBI:76998 aryl hydrocarbon receptor antagonist AhR antagonist AhR antagonists AhR receptor antagonist AhR receptor antagonists aryl hydrocarbon receptor antagonists aryl hydrocarbon receptor antagonist CHEBI:77019 EC 1.10.99.* (oxidoreductases acting on diphenols and related substances as donors, other acceptors) inhibitor EC 1.10.99.* (oxidoreductases acting on diphenols and related substances as donors, other acceptors) inhibitors EC 1.10.99.* inhibitor EC 1.10.99.* inhibitors oxidoreductases acting on diphenols and related substances as donors, other acceptors (EC 1.10.99.*) inhibitor oxidoreductases acting on diphenols and related substances as donors, other acceptors (EC 1.10.99.*) inhibitors EC 1.10.99.* (oxidoreductases acting on diphenols and related substances as donors, other acceptors) inhibitor CHEBI:77020 EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor 1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide:quinone oxidoreductase inhibitor 1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide:quinone oxidoreductase inhibitors EC 1.10.99.2 (ribosyldihydronicotinamide dehydrogenase (quinone)) inhibitor EC 1.10.99.2 (ribosyldihydronicotinamide dehydrogenase (quinone)) inhibitors EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitors EC 1.10.99.2 inhibitor EC 1.10.99.2 inhibitors N-ribosyldihydronicotinamide dehydrogenase (quinone) inhibitor N-ribosyldihydronicotinamide dehydrogenase (quinone) inhibitors NAD(P)H:quinone oxidoreductase-2 inhibitor NAD(P)H:quinone oxidoreductase-2 inhibitors NAD(P)H:quinone oxidoreductase2 inhibitor NAD(P)H:quinone oxidoreductase2 inhibitors NQO2 inhibitor NQO2 inhibitors NRH:quinone oxidoreductase 2 inhibitor NRH:quinone oxidoreductase 2 inhibitors QR2 inhibitor QR2 inhibitors quinone reductase 2 inhibitor quinone reductase 2 inhibitors ribosyldihydronicotinamide dehydrogenase (quinone) (EC 1.10.99.2) inhibitor ribosyldihydronicotinamide dehydrogenase (quinone) (EC 1.10.99.2) inhibitors EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor CHEBI:77022 EC 2.3.3.* (acyltransferase converting acyl to alkyl group on transfer) inhibitor EC 2.3.3.* (acyltransferase converting acyl to alkyl group on transfer) inhibitors EC 2.3.3.* inhibitor EC 2.3.3.* inhibitors acyltransferase converting acyl to alkyl group on transfer (EC 2.3.3.*) inhibitor acyltransferase converting acyl to alkyl group on transfer (EC 2.3.3.*) inhibitors EC 2.3.3.* (acyltransferase converting acyl to alkyl group on transfer) inhibitor CHEBI:77023 EC 2.3.3.1 [citrate (Si)-synthase] inhibitor (R)-citrate synthase inhibitor (R)-citrate synthase inhibitors EC 2.3.3.1 (citrate (Si)-synthase) inhibitor EC 2.3.3.1 (citrate (Si)-synthase) inhibitors EC 2.3.3.1 [citrate (Si)-synthase] inhibitors EC 2.3.3.1 inhibitor EC 2.3.3.1 inhibitors acetyl-CoA:oxaloacetate C-acetyltransferase [thioester-hydrolysing, (pro-S)-carboxymethyl forming] inhibitor acetyl-CoA:oxaloacetate C-acetyltransferase [thioester-hydrolysing, (pro-S)-carboxymethyl forming] inhibitors citrate (Si)-synthase (EC 2.3.3.1) inhibitor citrate (Si)-synthase (EC 2.3.3.1) inhibitors citrate condensing enzyme inhibitor citrate condensing enzyme inhibitors citrate oxaloacetate-lyase [(pro-3S)-CH2COO->acetyl-CoA] inhibitor citrate oxaloacetate-lyase [(pro-3S)-CH2COO->acetyl-CoA] inhibitors citrate oxaloacetate-lyase, CoA-acetylating inhibitor citrate oxaloacetate-lyase, CoA-acetylating inhibitors citrate synthase inhibitor citrate synthase inhibitors citrate synthetase inhibitor citrate synthetase inhibitors citric synthase inhibitor citric synthase inhibitors citric-condensing enzyme inhibitor citric-condensing enzyme inhibitors citrogenase inhibitor citrogenase inhibitors condensing enzyme inhibitor condensing enzyme inhibitors oxalacetic transacetase inhibitor oxalacetic transacetase inhibitors oxaloacetate transacetase inhibitor oxaloacetate transacetase inhibitors EC 2.3.3.1 [citrate (Si)-synthase] inhibitor CHEBI:77024 EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor 4-nitrophenylphosphatase (EC 3.1.3.41) inhibitor 4-nitrophenylphosphatase (EC 3.1.3.41) inhibitors 4-nitrophenylphosphate phosphohydrolase inhibitor 4-nitrophenylphosphate phosphohydrolase inhibitors EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitors EC 3.1.3.41 inhibitor EC 3.1.3.41 inhibitors Ecto-p-nitrophenyl phosphatase inhibitor Ecto-p-nitrophenyl phosphatase inhibitors K-pNPPase inhibitor K-pNPPase inhibitors NPPase inhibitor NPPase inhibitors PNPPase inhibitor PNPPase inhibitors nitrophenyl phosphatase inhibitor nitrophenyl phosphatase inhibitors p-nitrophenylphosphatase inhibitor p-nitrophenylphosphatase inhibitors p-nitrophenylphosphate phosphohydrolase inhibitor p-nitrophenylphosphate phosphohydrolase inhibitors para-nitrophenyl phosphatase inhibitor para-nitrophenyl phosphatase inhibitors xK-pNPPase inhibitors EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor CHEBI:77034 mucolytic mucolytics mucolytic CHEBI:77035 expectorant expectorants expectorant CHEBI:77088 EC 1.4.7.* (oxidoreductase acting on donor CH-NH2 group, Fe-S protein as acceptor) inhibitor EC 1.4.7.* (oxidoreductase acting on donor CH-NH2 group, Fe-S protein as acceptor) inhibitors EC 1.4.7.* inhibitor EC 1.4.7.* inhibitors inhibitor of oxidoreductase acting on donor CH-NH2 group, Fe-S protein as acceptor inhibitors of oxidoreductase acting on donor CH-NH2 group, Fe-S protein as acceptor oxidoreductase acting on donor CH-NH2 group, Fe-S protein as acceptor (EC 1.4.7.*) inhibitor oxidoreductase acting on donor CH-NH2 group, Fe-S protein as acceptor (EC 1.4.7.*) inhibitors EC 1.4.7.* (oxidoreductase acting on donor CH-NH2 group, Fe-S protein as acceptor) inhibitor CHEBI:77089 EC 2.5.1.49 (O-acetylhomoserine aminocarboxypropyltransferase) inhibitor EC 2.5.1.49 (O-acetylhomoserine aminocarboxypropyltransferase) inhibitors EC 2.5.1.49 inhibitor EC 2.5.1.49 inhibitors O-acetyl-L-homoserine acetate-lyase (adding methanethiol) inhibitor O-acetyl-L-homoserine acetate-lyase (adding methanethiol) inhibitors O-acetyl-L-homoserine sulfhydrolase inhibitor O-acetyl-L-homoserine sulfhydrolase inhibitors O-acetyl-L-homoserine:methanethiol 3-amino-3-carboxypropyltransferase inhibitor O-acetyl-L-homoserine:methanethiol 3-amino-3-carboxypropyltransferase inhibitors O-acetylhomoserine (thiol)-lyase inhibitor O-acetylhomoserine (thiol)-lyase inhibitors O-acetylhomoserine aminocarboxypropyltransferase (EC 2.5.1.49) inhibitor O-acetylhomoserine aminocarboxypropyltransferase (EC 2.5.1.49) inhibitors O-acetylhomoserine aminocarboxypropyltransferase inhibitor O-acetylhomoserine aminocarboxypropyltransferase inhibitors O-acetylhomoserine sulfhydrolase inhibitor O-acetylhomoserine sulfhydrolase inhibitors methionine synthase inhibitor methionine synthase inhibitors EC 2.5.1.49 (O-acetylhomoserine aminocarboxypropyltransferase) inhibitor CHEBI:77090 EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor (L-SOS)lyase inhibitor (L-SOS)lyase inhibitors EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitors EC 4.3.1.10 inhibitor EC 4.3.1.10 inhibitors L-serine-O-sulfate ammonia-lyase (pyruvate-forming) inhibitor L-serine-O-sulfate ammonia-lyase (pyruvate-forming) inhibitors serine-sulfate ammonia-lyase (EC 4.3.1.10) inhibitor serine-sulfate ammonia-lyase (EC 4.3.1.10) inhibitors serine-sulfate ammonia-lyase inhibitor serine-sulfate ammonia-lyase inhibitors EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor CHEBI:77102 EC 1.3.5.* (oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor) inhibitor EC 1.3.5.* (oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor) inhibitors EC 1.3.5.* inhibitor EC 1.3.5.* inhibitors inhibitor of oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor inhibitor of oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor (EC 1.3.5.*) inhibitors of oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor inhibitors of oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor (EC 1.3.5.*) oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor (EC 1.3.5.*) inhibitor oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor (EC 1.3.5.*) inhibitors EC 1.3.5.* (oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor) inhibitor CHEBI:77103 EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor (S)-dihydroorotate:(acceptor) oxidoreductase inhibitor (S)-dihydroorotate:(acceptor) oxidoreductase inhibitors (S)-dihydroorotate:acceptor oxidoreductase inhibitor (S)-dihydroorotate:acceptor oxidoreductase inhibitors (S)-dihydroorotate:quinone oxidoreductase inhibitor (S)-dihydroorotate:quinone oxidoreductase inhibitors DHOD inhibitor DHOD inhibitors DHODH inhibitor DHODH inhibitors DHOdehase inhibitor DHOdehase inhibitors EC 1.3.5.2 (dihydroorotate dehydrogenase (quinone)) inhibitor EC 1.3.5.2 (dihydroorotate dehydrogenase (quinone)) inhibitors EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitors EC 1.3.5.2 inhibitor EC 1.3.5.2 inhibitors dihydroorotate:ubiquinone oxidoreductase inhibitor dihydroorotate:ubiquinone oxidoreductase inhibitors EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor CHEBI:77105 EC 1.10.2.* (oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor) inhibitor EC 1.10.2.* (oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor) inhibitors EC 1.10.2.* inhibitor EC 1.10.2.* inhibitors inhibitor of an oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor (EC 1.10.2.*) inhibitors of an oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor (EC 1.10.2.*) oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor (EC 1.10.2.*) inhibitor oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor (EC 1.10.2.*) inhibitors EC 1.10.2.* (oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor) inhibitor CHEBI:77106 EC 1.10.2.2 (quinol--cytochrome-c reductase) inhibitor EC 1.10.2.2 (quinol--cytochrome-c reductase) inhibitors EC 1.10.2.2 inhibitor EC 1.10.2.2 inhibitors inhibitor of quinol--cytochrome-c reductase (EC 1.10.2.2) inhibitors of quinol--cytochrome-c reductase (EC 1.10.2.2) quinol--cytochrome-c reductase (EC 1.10.2.2) inhibitor quinol--cytochrome-c reductase (EC 1.10.2.2) inhibitors EC 1.10.2.2 (quinol--cytochrome-c reductase) inhibitor CHEBI:77108 EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-13-enoate:NAD(+) 15-oxidoreductase inhibitor (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-13-enoate:NAD(+) 15-oxidoreductase inhibitors (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate:NAD(+) 15-oxidoreductase inhibitor (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate:NAD(+) 15-oxidoreductase inhibitors 11alpha,15-dihydroxy-9-oxoprost-13-enoate:NAD(+) 15-oxidoreductase inhibitor 11alpha,15-dihydroxy-9-oxoprost-13-enoate:NAD(+) 15-oxidoreductase inhibitors 15-OH-PGDH inhibitor 15-OH-PGDH inhibitors 15-hydroxyprostaglandin dehydrogenase (NAD(+)) (EC 1.1.1.141) inhibitor 15-hydroxyprostaglandin dehydrogenase (NAD(+)) (EC 1.1.1.141) inhibitors 15-hydroxyprostaglandin dehydrogenase (NAD(+)) inhibitor 15-hydroxyprostaglandin dehydrogenase (NAD(+)) inhibitors 15-hydroxyprostaglandin dehydrogenase inhibitor 15-hydroxyprostaglandin dehydrogenase inhibitors 15-hydroxyprostanoic dehydrogenase inhibitor 15-hydroxyprostanoic dehydrogenase inhibitors EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitors EC 1.1.1.141 inhibitor EC 1.1.1.141 inhibitors NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase (type I) inhibitor NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase (type I) inhibitors NAD-specific 15-hydroxyprostaglandin dehydrogenase inhibitor NAD-specific 15-hydroxyprostaglandin dehydrogenase inhibitors PGDH inhibitor PGDH inhibitors prostaglandin dehydrogenase inhibitor prostaglandin dehydrogenase inhibitors EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor CHEBI:77109 EC 1.21.3.* (oxidoreductase acting on X-H and Y-H to form an X-Y bond, with oxygen as acceptor) inhibitor EC 1.21.3.* (oxidoreductase acting on X-H and Y-H to form an X-Y bond, with oxygen as acceptor) inhibitors EC 1.21.3.* inhibitor EC 1.21.3.* inhibitors inhibitor of oxidoreductase acting on X-H and Y-H to form an X-Y bond, with oxygen as acceptor inhibitor of oxidoreductase acting on X-H and Y-H to form an X-Y bond, with oxygen as acceptor (EC 1.21.3.*) inhibitors of oxidoreductase acting on X-H and Y-H to form an X-Y bond, with oxygen as acceptor inhibitors of oxidoreductase acting on X-H and Y-H to form an X-Y bond, with oxygen as acceptor (EC 1.21.3.*) oxidoreductase acting on X-H and Y-H to form an X-Y bond, with oxygen as acceptor (EC 1.21.3.*) inhibitor oxidoreductase acting on X-H and Y-H to form an X-Y bond, with oxygen as acceptor (EC 1.21.3.*) inhibitors EC 1.21.3.* (oxidoreductase acting on X-H and Y-H to form an X-Y bond, with oxygen as acceptor) inhibitor CHEBI:77110 EC 1.21.3.3 (reticuline oxidase) inhibitor (S)-reticuline:oxygen oxidoreductase (methylene-bridge-forming) inhibitor (S)-reticuline:oxygen oxidoreductase (methylene-bridge-forming) inhibitors BBE inhibitor BBE inhibitors EC 1.21.3.3 (reticuline oxidase) inhibitors EC 1.21.3.3 inhibitor EC 1.21.3.3 inhibitors EC 1.5.3.9 inhibitor EC 1.5.3.9 inhibitors berberine bridge enzyme inhibitor berberine bridge enzyme inhibitors berberine-bridge-forming enzyme inhibitor berberine-bridge-forming enzyme inhibitors reticuline oxidase (EC 1.21.3.3) inhibitor reticuline oxidase (EC 1.21.3.3) inhibitors reticuline oxidase inhibitor reticuline oxidase inhibitors tetrahydroprotoberberine synthase inhibitor tetrahydroprotoberberine synthase inhibitors EC 1.21.3.3 (reticuline oxidase) inhibitor CHEBI:77111 EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor 3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase (EC 2.1.1.116) inhibitor 3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase (EC 2.1.1.116) inhibitors EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitors EC 2.1.1.116 inhibitor EC 2.1.1.116 inhibitors S-adenosyl-L-methionine:3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase inhibitor S-adenosyl-L-methionine:3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase inhibitors EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor CHEBI:77113 EC 2.7.11.10 (IkappaB kinase) inhibitor ATP:[IkappaB protein] phosphotransferase ATP:[IkappaB protein] phosphotransferase inhibitor CHUK inhibitor CHUK inhibitors EC 2.7.11.10 (IkappaB kinase) inhibitors EC 2.7.11.10 inhibitor EC 2.7.11.10 inhibitors IKBKA inhibitor IKBKA inhibitors IKBKB inhibitor IKBKB inhibitors IKK inhibitor IKK inhibitors IKK-1 inhibitor IKK-1 inhibitors IKK-2 inhibitor IKK-2 inhibitors IkappaB kinase (EC 2.7.11.10) inhibitor IkappaB kinase (EC 2.7.11.10) inhibitors IkappaB kinase inhibitor IkappaB kinase inhibitors STK12 inhibitor STK12 inhibitors TANK-binding kinase 1 inhibitor TANK-binding kinase 1 inhibitors TBK1 inhibitor TBK1 inhibitors EC 2.7.11.10 (IkappaB kinase) inhibitor CHEBI:77115 EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor (S)-tetrahydroprotoberberine N-methyltransferase (EC 2.1.1.122) inhibitor (S)-tetrahydroprotoberberine N-methyltransferase (EC 2.1.1.122) inhibitors (S)-tetrahydroprotoberberine N-methyltransferase inhibitor (S)-tetrahydroprotoberberine N-methyltransferase inhibitors EC 2.1.1.122 ((S)-tetrahydroprotoberberine N-methyltransferase) inhibitor EC 2.1.1.122 ((S)-tetrahydroprotoberberine N-methyltransferase) inhibitors EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitors EC 2.1.1.122 inhibitor EC 2.1.1.122 inhibitors S-adenosyl-L-methionine:(S)-7,8,13,14-tetrahydroprotoberberine cis-N-methyltransferase inhibitor S-adenosyl-L-methionine:(S)-7,8,13,14-tetrahydroprotoberberine cis-N-methyltransferase inhibitors tetrahydroprotoberberine cis-N-methyltransferase inhibitor tetrahydroprotoberberine cis-N-methyltransferase inhibitors EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor CHEBI:77117 EC 3.5.5.* (hydrolase acting on C-N bonds in nitriles) inhibitor EC 3.5.5.* (hydrolase acting on C-N bonds in nitriles) inhibitors EC 3.5.5.* inhibitor EC 3.5.5.* inhibitors hydrolase acting on C-N bonds in nitriles (EC 3.5.5.*) inhibitor hydrolase acting on C-N bonds in nitriles (EC 3.5.5.*) inhibitors inhibitor of hydrolases acting on C-N bonds in nitriles inhibitors of hydrolases acting on C-N bonds in nitriles EC 3.5.5.* (hydrolase acting on C-N bonds in nitriles) inhibitor CHEBI:77118 EC 3.5.5.1 (nitrilase) inhibitor EC 3.5.5.1 (nitrilase) inhibitors EC 3.5.5.1 inhibitor EC 3.5.5.1 inhibitors acetonitrilase inhibitor acetonitrilase inhibitors benzonitrilase inhibitor benzonitrilase inhibitors nitrilase (EC 3.5.5.1) inhibitor nitrilase (EC 3.5.5.1) inhibitors nitrile aminohydrolase inhibitor nitrile aminohydrolase inhibitors EC 3.5.5.1 (nitrilase) inhibitor CHEBI:77119 EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor (5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate:NADP(+) 9-oxidoreductase inhibitor (5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate:NADP(+) 9-oxidoreductase inhibitors 9-keto-prostaglandin E2 reductase inhibitor 9-keto-prostaglandin E2 reductase inhibitors 9-ketoprostaglandin reductase inhibitor 9-ketoprostaglandin reductase inhibitors EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitors EC 1.1.1.189 inhibitor EC 1.1.1.189 inhibitors PGE-9-ketoreductase inhibitor PGE-9-ketoreductase inhibitors PGE2 9-oxoreductase inhibitor PGE2 9-oxoreductase inhibitors PGE2-9-OR inhibitor PGE2-9-OR inhibitors PGE2-9-ketoreductase inhibitor PGE2-9-ketoreductase inhibitors prostaglandin 9-ketoreductase inhibitor prostaglandin 9-ketoreductase inhibitors prostaglandin E 9-ketoreductase inhibitor prostaglandin E 9-ketoreductase inhibitors prostaglandin E2-9-oxoreductase inhibitor prostaglandin E2-9-oxoreductase inhibitors prostaglandin-E2 9-reductase (EC 1.1.1.189) inhibitor prostaglandin-E2 9-reductase (EC 1.1.1.189) inhibitors reductase, 15-hydroxy-9-oxoprostaglandin inhibitor reductase, 15-hydroxy-9-oxoprostaglandin inhibitors EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor CHEBI:77161 Toll-like receptor 2 agonist TLR 2 agonist TLR 2 agonists TLR-2 agonist TLR-2 agonists Toll-like receptor 2 agonists Toll-like receptor-2 agonist Toll-like receptor-2 agonists Toll-like receptor 2 agonist CHEBI:77178 histological dye biological stain biological stains histological dyes histological stain histological stains histological dye CHEBI:77182 food colouring food coloring food colorings food colourings food colouring CHEBI:77194 EC 2.7.1.33 (pantothenate kinase) inhibitor ATP:(R)-pantothenate 4'-phosphotransferase inhibitor ATP:(R)-pantothenate 4'-phosphotransferase inhibitors ATP:pantothenate 4'-phosphotransferase inhibitor ATP:pantothenate 4'-phosphotransferase inhibitors D-pantothenate kinase inhibitor D-pantothenate kinase inhibitors EC 2.7.1.33 (pantothenate kinase) inhibitors EC 2.7.1.33 inhibitor EC 2.7.1.33 inhibitors pantothenate kinase (EC 2.7.1.33) inhibitor pantothenate kinase (EC 2.7.1.33) inhibitors pantothenate kinase (phosphorylating) inhibitor pantothenate kinase (phosphorylating) inhibitors pantothenic acid kinase inhibitor pantothenic acid kinase inhibitors EC 2.7.1.33 (pantothenate kinase) inhibitor CHEBI:77255 EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitors EC 3.4.24.83 inhibitor EC 3.4.24.83 inhibitors anthrax lethal factor endopeptidase (EC 3.4.24.83) inhibitor anthrax lethal factor endopeptidase (EC 3.4.24.83) inhibitors lethal toxin inhibitor lethal toxin inhibitors EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor CHEBI:77307 cardioprotective agent cardioprotective agents cardioprotective agent CHEBI:77318 pregnane X receptor agonist PXR agonist PXR agonists pregnane X receptor agonists pregnane X receptor agonist CHEBI:77324 UDP-glucuronosyltransferase activator UDP-glucuronosyltransferase activators UDP-glucuronosyltransferase activator CHEBI:77326 androstane receptor agonist CAR agonist CAR agonists androstane receptor agonists constitutive androstane receptor agonist constitutive androstane receptor agonists androstane receptor agonist CHEBI:77402 EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitors EC 1.8.1.12 inhibitor EC 1.8.1.12 inhibitors N(1),N(8)-bis(glutathionyl)spermidine reductase inhibitor N(1),N(8)-bis(glutathionyl)spermidine reductase inhibitors NADPH2:trypanothione oxidoreductase inhibitor NADPH2:trypanothione oxidoreductase inhibitors NADPH:trypanothione oxidoreductase inhibitor NADPH:trypanothione oxidoreductase inhibitors trypanothione reductase inhibitor trypanothione reductase inhibitors trypanothione-disulfide reductase (EC 1.8.1.12) inhibitor trypanothione-disulfide reductase (EC 1.8.1.12) inhibitors trypanothione:NADP(+) oxidoreductase inhibitor trypanothione:NADP(+) oxidoreductase inhibitors EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor CHEBI:77425 EC 1.1.1.188 (prostaglandin-F synthase) inhibitor (5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate:NADP(+) 11-oxidoreductase inhibitor (5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate:NADP(+) 11-oxidoreductase inhibitors EC 1.1.1.188 (prostaglandin-F synthase) inhibitors EC 1.1.1.188 inhibitor EC 1.1.1.188 inhibitors NADPH-dependent prostaglandin D2 11-keto reductase inhibitor NADPH-dependent prostaglandin D2 11-keto reductase inhibitors PGD2 11-ketoreductase inhibitor PGD2 11-ketoreductase inhibitors PGF synthetase inhibitor PGF synthetase inhibitors PGF2alpha synthetase inhibitor PGF2alpha synthetase inhibitors prostaglandin 11-keto reductase inhibitor prostaglandin 11-keto reductase inhibitors prostaglandin 11-ketoreductase inhibitor prostaglandin 11-ketoreductase inhibitors prostaglandin D2-ketoreductase inhibitor prostaglandin D2-ketoreductase inhibitors prostaglandin F synthase inhibitor prostaglandin F synthase inhibitors prostaglandin F synthetase inhibitor prostaglandin F synthetase inhibitors prostaglandin-D2 11-reductase inhibitor prostaglandin-D2 11-reductase inhibitors reductase, 15-hydroxy-11-oxoprostaglandin inhibitor reductase, 15-hydroxy-11-oxoprostaglandin inhibitors synthetase, prostaglandin F2alpha inhibitor synthetase, prostaglandin F2alpha inhibitors EC 1.1.1.188 (prostaglandin-F synthase) inhibitor CHEBI:77484 EC 1.1.1.25 (shikimate dehydrogenase) inhibitor 5-dehydroshikimate reductase inhibitor 5-dehydroshikimate reductase inhibitors 5-dehydroshikimic reductase inhibitor 5-dehydroshikimic reductase inhibitors AroE inhibitor AroE inhibitors DHS reductase inhibitor DHS reductase inhibitors EC 1.1.1.25 (shikimate dehydrogenase) inhibitors EC 1.1.1.25 inhibitor EC 1.1.1.25 inhibitors dehydroshikimic reductase inhibitor dehydroshikimic reductase inhibitors shikimate 5-dehydrogenase inhibitor shikimate 5-dehydrogenase inhibitors shikimate dehydrogenase (EC 1.1.1.25) inhibitor shikimate dehydrogenase (EC 1.1.1.25) inhibitors shikimate dehydrogenase inhibitor shikimate dehydrogenase inhibitors shikimate oxidoreductase inhibitor shikimate oxidoreductase inhibitors shikimate:NADP(+) 3-oxidoreductase inhibitor shikimate:NADP(+) 3-oxidoreductase inhibitors shikimate:NADP(+) 5-oxidoreductase inhibitor shikimate:NADP(+) 5-oxidoreductase inhibitors shikimate:NADP(+) oxidoreductase inhibitor shikimate:NADP(+) oxidoreductase inhibitors EC 1.1.1.25 (shikimate dehydrogenase) inhibitor CHEBI:77495 bradykinin receptor agonist bradykinin receptor agonists bradykinin receptor agonist CHEBI:77496 bradykinin receptor B2 agonist B2 receptor agonist B2 receptor agonists B2R agonist B2R agonists bradykinin receptor B2 agonists bradykinin receptor B2 agonist CHEBI:77521 thermal degradation product thermal artefact thermal artefacts thermal degradation products thermal degradation product CHEBI:77523 Maillard reaction product Maillard product Maillard products maillard reaction products Maillard reaction product CHEBI:77567 eugeroic eugeroics vigilance promoting agent vigilance promoting agents vigilance promoting drug vigilance promoting drugs vigilance-promoting agent vigilance-promoting agents vigilance-promoting drug vigilance-promoting drugs wake-promoting agent wake-promoting agents wake-promoting drug wake-promoting drugs wakefulness-promoting agent wakefulness-promoting agents wakefulness-promoting drug wakefulness-promoting drugs eugeroic CHEBI:77608 loop diuretic loop diuretics loop diuretic CHEBI:77654 EC 1.1.1.267 (1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibitor 1-deoxy-D-xylulose-5-phosphate isomeroreductase inhibitor 1-deoxy-D-xylulose-5-phosphate isomeroreductase inhibitors 1-deoxy-D-xylulose-5-phosphate reductoisomerase (EC 1.1.1.267) inhibitor 1-deoxy-D-xylulose-5-phosphate reductoisomerase (EC 1.1.1.267) inhibitors 1-deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor 1-deoxy-D-xylulose-5-phosphate reductoisomerase inhibitors 1-deoxyxylulose-5-phosphate reductoisomerase inhibitor 1-deoxyxylulose-5-phosphate reductoisomerase inhibitors 2-C-methyl-D-erythritol-4-phosphate:NADP(+) oxidoreductase (isomerising) inhibitor 2-C-methyl-D-erythritol-4-phosphate:NADP(+) oxidoreductase (isomerising) inhibitors 2-C-methyl-D-erythritol-4-phosphate:NADP(+) oxidoreductase (isomerizing) inhibitor 2-C-methyl-D-erythritol-4-phosphate:NADP(+) oxidoreductase (isomerizing) inhibitors 2C-methyl-D-erythritol-4-phosphate (MEP) synthase inhibitor 2C-methyl-D-erythritol-4-phosphate (MEP) synthase inhibitors DXP-reductoisomerase inhibitor DXP-reductoisomerase inhibitors EC 1.1.1.267 (1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibitors EC 1.1.1.267 inhibitor EC 1.1.1.267 inhibitors EC 1.1.1.267 (1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibitor CHEBI:77703 EC 4.3.1.3 (histidine ammonia-lyase) inhibitor EC 4.3.1.3 (histidine ammonia-lyase) inhibitors EC 4.3.1.3 inhibitor EC 4.3.1.3 inhibitors L-histidine ammonia-lyase (urocanate-forming) inhibitor L-histidine ammonia-lyase (urocanate-forming) inhibitors L-histidine ammonia-lyase inhibitor L-histidine ammonia-lyase inhibitors histidase inhibitor histidase inhibitors histidinase inhibitor histidinase inhibitors histidine alpha-deaminase inhibitor histidine alpha-deaminase inhibitors histidine ammonia-lyase (EC 4.3.1.3) inhibitor histidine ammonia-lyase (EC 4.3.1.3) inhibitors histidine ammonia-lyase inhibitor histidine ammonia-lyase inhibitors EC 4.3.1.3 (histidine ammonia-lyase) inhibitor CHEBI:77705 EC 3.4.19.* (omega-peptidase) inhibitor EC 3.4.19.* (omega-peptidase) inhibitors EC 3.4.19.* inhibitor EC 3.4.19.* inhibitors omega-peptidase (EC 3.4.19.*) inhibitor omega-peptidase (EC 3.4.19.*) inhibitors omega-peptidase inhibitor omega-peptidase inhibitors EC 3.4.19.* (omega-peptidase) inhibitor CHEBI:77706 EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor 5-oxoprolyl-peptidase inhibitors EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitors EC 3.4.19.3 inhibitor EC 3.4.19.3 inhibitors L-pyroglutamyl peptide hydrolase inhibitor L-pyroglutamyl peptide hydrolase inhibitors L-pyrrolidonecarboxylate peptidase inhibitor L-pyrrolidonecarboxylate peptidase inhibitors pyrase inhibitor pyrase inhibitors pyroglutamate aminopeptidase inhibitor pyroglutamate aminopeptidase inhibitors pyroglutamidase inhibitor pyroglutamidase inhibitors pyroglutamyl aminopeptidase inhibitor pyroglutamyl aminopeptidase inhibitors pyroglutamyl-peptidase I (EC 3.4.19.3) inhibitor pyroglutamyl-peptidase I (EC 3.4.19.3) inhibitors pyroglutamyl-peptidase I inhibitor pyroglutamyl-peptidase I inhibitors pyrrolidone-carboxyl peptidase inhibitor pyrrolidone-carboxyl peptidase inhibitors pyrrolidonecarboxylyl peptidase inhibitor pyrrolidonecarboxylyl peptidase inhibitors pyrrolidonyl peptidase inhibitor pyrrolidonyl peptidase inhibitors5-oxoprolyl-peptidase inhibitor EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor CHEBI:77715 nasal decongestant decongestant decongestants nasal decongestants nasal decongestant CHEBI:77731 p53 activator cellular tumor antigen p53 activator cellular tumor antigen p53 activators p53 activators phosphoprotein p53 activator phosphoprotein p53 activators tumor protein p53 activator tumor protein p53 activators tumour protein p53 activator tumour protein p53 activators tumour suppressor p53 activator tumour suppressor p53 activators p53 activator CHEBI:77745 EC 3.4.24.18 (meprin A) inhibitor EC 3.4.24.18 (meprin A) inhibitors EC 3.4.24.18 inhibitor EC 3.4.24.18 inhibitors N-benzoyl-L-tyrosyl-p-aminobenzoic acid hydrolase inhibitor N-benzoyl-L-tyrosyl-p-aminobenzoic acid hydrolase inhibitors PABA-peptide hydrolase inhibitor PABA-peptide hydrolase inhibitors PPH inhibitor PPH inhibitors endopeptidase-2 inhibitor endopeptidase-2 inhibitors meprin A (EC 3.4.24.18) inhibitor meprin A (EC 3.4.24.18) inhibitors meprin A inhibitor meprin A inhibitors meprin inhibitor meprin inhibitors meprin-a inhibitor meprin-a inhibitors EC 3.4.24.18 (meprin A) inhibitor CHEBI:77746 human metabolite H. sapiens metabolite H. sapiens metabolites Homo sapiens metabolite Homo sapiens metabolites human metabolite CHEBI:77747 EC 3.6.3.1 (phospholipid-translocating ATPase) inhibitor ATP phosphohydrolase (phospholipid-flipping) inhibitor ATP phosphohydrolase (phospholipid-flipping) inhibitors EC 3.6.3.1 (phospholipid-translocating ATPase) inhibitors EC 3.6.3.1 inhibitor EC 3.6.3.1 inhibitors Mg(2)(+)-ATPase inhibitor Mg(2)(+)-ATPase inhibitors aminophospholipid-transporting ATPase inhibitor aminophospholipid-transporting ATPase inhibitors flippase inhibitor flippase inhibitors magnesium-ATPase inhibitor magnesium-ATPase inhibitors phospholipid-translocating ATPase (EC 3.6.3.1) inhibitor phospholipid-translocating ATPase (EC 3.6.3.1) inhibitors phospholipid-translocating ATPase inhibitor phospholipid-translocating ATPase inhibitors phospholipid-transporting ATPase inhibitor phospholipid-transporting ATPase inhibitors EC 3.6.3.1 (phospholipid-translocating ATPase) inhibitor CHEBI:77748 EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor ATP phosphohydrolase (steroid-exporting) inhibitor ATP phosphohydrolase (steroid-exporting) inhibitors ATP phosphohydrolase (xenobiotic-exporting) inhibitor ATP phosphohydrolase (xenobiotic-exporting) inhibitors EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitors EC 3.6.3.44 inhibitor EC 3.6.3.44 inhibitors MDR protein inhibitor MDR protein inhibitors P-glycoprotein inhibitor P-glycoprotein inhibitors PDR protein inhibitor PDR protein inhibitors multidrug-resistance protein inhibitor multidrug-resistance protein inhibitors pleiotropic-drug-resistance protein inhibitor pleiotropic-drug-resistance protein inhibitors steroid-transporting ATPase inhibitor steroid-transporting ATPase inhibitors xenobiotic-transporting ATPase (EC 3.6.3.44) inhibitor xenobiotic-transporting ATPase (EC 3.6.3.44) inhibitors xenobiotic-transporting ATPase inhibitor xenobiotic-transporting ATPase inhibitors EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor CHEBI:77750 ATP/ADP translocase inhibitor ATP-ADP translocase inhibitor ATP-ADP translocase inhibitors ATP/ADP translocase inhibitors ATP/ADP translocase inhibitor CHEBI:77758 EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor 3',5'-cyclic-AMP 5'-nucleotidohydrolase inhibitor 3',5'-cyclic-AMP 5'-nucleotidohydrolase inhibitors 3',5'-cyclic-AMP phosphodiesterase (EC 3.1.4.53) inhibitor 3',5'-cyclic-AMP phosphodiesterase (EC 3.1.4.53) inhibitors 3',5'-cyclic-AMP phosphodiesterase inhibitor 3',5'-cyclic-AMP phosphodiesterase inhibitors EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitors EC 3.1.4.53 inhibitor EC 3.1.4.53 inhibitors cAMP-specific PDE inhibitor cAMP-specific PDE inhibitors cAMP-specific phosphodiesterase inhibitor cAMP-specific phosphodiesterase inhibitors EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor CHEBI:77763 EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor 1-pyrroline dehydrogenase inhibitor 1-pyrroline dehydrogenase inhibitors 1-pyrroline-5-carboxylate dehydrogenase inhibitor 1-pyrroline-5-carboxylate dehydrogenase inhibitors 1-pyrroline-5-carboxylate:NAD(+) oxidoreductase inhibitor 1-pyrroline-5-carboxylate:NAD(+) oxidoreductase inhibitors Delta(1)-pyrroline-5-carboxylate dehydrogenase inhibitor Delta(1)-pyrroline-5-carboxylate dehydrogenase inhibitors Delta(1)-pyrroline-5-carboxylic acid dehydrogenase inhibitor Delta(1)-pyrroline-5-carboxylic acid dehydrogenase inhibitors EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitors EC 1.2.1.88 inhibitor EC 1.2.1.88 inhibitors L-glutamate gamma-semialdehyde dehydrogenase (EC 1.2.1.88) inhibitor L-glutamate gamma-semialdehyde dehydrogenase (EC 1.2.1.88) inhibitors L-glutamate gamma-semialdehyde dehydrogenase inhibitor L-glutamate gamma-semialdehyde dehydrogenase inhibitors L-glutamate gamma-semialdehyde:NAD(+) oxidoreductase inhibitor L-glutamate gamma-semialdehyde:NAD(+) oxidoreductase inhibitors L-pyrroline-5-carboxylate-NAD(+) oxidoreductase inhibitor L-pyrroline-5-carboxylate-NAD(+) oxidoreductase inhibitors pyrroline-5-carboxylate dehydrogenase inhibitor pyrroline-5-carboxylate dehydrogenase inhibitors pyrroline-5-carboxylic acid dehydrogenase inhibitor pyrroline-5-carboxylic acid dehydrogenase inhibitors EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor CHEBI:77780 sulfaphenazole 1-phenyl-5-sulfanilamidopyrazole 3-(p-aminobenzenesulfonamido)-2-phenylpyrazole 4-amino-N-(1-phenyl-1H-pyrazol-5-yl)benzenesulfonamide 5-sulfanilamido-1-phenylpyrazole N'-(1-phenylpyrazol-5-yl)sulfanilamide N(1)-(1-phenylpyrazol-5-yl)sulfanilamide Sulfabid sulfafenazol sulfaphenazol sulfaphenazole sulfaphenazolum sulphaphenazole sulfaphenazole CHEBI:77781 EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor 13-deoxydaunorubicin hydroxylase (EC 1.14.13.181) inhibitor 13-deoxydaunorubicin hydroxylase (EC 1.14.13.181) inhibitors 13-deoxydaunorubicin hydroxylase inhibitor 13-deoxydaunorubicin hydroxylase inhibitors 13-deoxydaunorubicin,NADPH:oxygen oxidoreductase (13-hydroxylating) inhibitor 13-deoxydaunorubicin,NADPH:oxygen oxidoreductase (13-hydroxylating) inhibitors DoxA inhibitor DoxA inhibitors EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitors EC 1.14.13.181 inhibitor EC 1.14.13.181 inhibitors EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor CHEBI:77783 EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor EC 1.14.13.67 (quinine 3-monooxygenase) inhibitors EC 1.14.13.67 inhibitor EC 1.14.13.67 inhibitors quinine 3-hydroxylase inhibitor quinine 3-hydroxylase inhibitors quinine 3-monooxygenase (EC 1.14.13.67) inhibitor quinine 3-monooxygenase (EC 1.14.13.67) inhibitors quinine 3-monooxygenase inhibitor quinine 3-monooxygenase inhibitors quinine,NADPH:oxygen oxidoreductase inhibitor quinine,NADPH:oxygen oxidoreductase inhibitors EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor CHEBI:77853 persistent organic pollutant POP POPs persistent organic pollutants persistent organic pollutant CHEBI:77881 EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor 2,3-diaminopropanoate ammonia-lyase (adding H2O; pyruvate-forming) inhibitor 2,3-diaminopropanoate ammonia-lyase (adding H2O; pyruvate-forming) inhibitors 2,3-diaminopropanoate ammonia-lyase (adding water; pyruvate-forming) inhibitor 2,3-diaminopropanoate ammonia-lyase (adding water; pyruvate-forming) inhibitors 2,3-diaminopropanoate ammonia-lyase inhibitor 2,3-diaminopropanoate ammonia-lyase inhibitors 2,3-diaminopropionate ammonia-lyase inhibitor 2,3-diaminopropionate ammonia-lyase inhibitors EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitors EC 4.3.1.15 inhibitor EC 4.3.1.15 inhibitors alpha,beta-diaminopropionate ammonia-lyase inhibitor alpha,beta-diaminopropionate ammonia-lyase inhibitors diaminopropionatase inhibitor diaminopropionatase inhibitors diaminopropionate ammonia-lyase (EC 4.3.1.15) inhibitor diaminopropionate ammonia-lyase (EC 4.3.1.15) inhibitors diaminopropionate ammonia-lyase inhibitor diaminopropionate ammonia-lyase inhibitors EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor CHEBI:77884 EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitors EC 1.14.13.70 inhibitor EC 1.14.13.70 inhibitors cytochrome P450 51 inhibitor cytochrome P450 51 inhibitors lanosterol 14-demethylase inhibitor lanosterol 14-demethylase inhibitors lanosterol 14alpha-demethylase inhibitor lanosterol 14alpha-demethylase inhibitors obtusufoliol 14-demethylase inhibitor obtusufoliol 14-demethylase inhibitors sterol 14-demethylase inhibitor sterol 14-demethylase inhibitors sterol 14alpha-demethylase inhibitor sterol 14alpha-demethylase inhibitors sterol,NADPH:oxygen oxidoreductase (14-methyl cleaving) inhibitor sterol,NADPH:oxygen oxidoreductase (14-methyl cleaving) inhibitors EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor CHEBI:77941 EC 3.5.1.4 (amidase) inhibitor EC 3.5.1.4 (amidase) inhibitors EC 3.5.1.4 inhibitor EC 3.5.1.4 inhibitors N-acetylaminohydrolase inhibitor N-acetylaminohydrolase inhibitors acylamidase inhibitor acylamidase inhibitors acylamide amidohydrolase inhibitor acylamide amidohydrolase inhibitors amidase (EC 3.5.1.4) inhibitor amidase (EC 3.5.1.4) inhibitors amidase inhibitor amidase inhibitors amidohydrolase inhibitor amidohydrolase inhibitors deaminase inhibitor deaminase inhibitors fatty acylamidase inhibitor fatty acylamidase inhibitors EC 3.5.1.4 (amidase) inhibitor CHEBI:77953 EC 6.1.1.4 (leucine--tRNA ligase) inhibitor EC 6.1.1.4 (leucine--tRNA ligase) inhibitors EC 6.1.1.4 inhibitor EC 6.1.1.4 inhibitors L-leucine:tRNA(Leu) ligase (AMP-forming) inhibitor L-leucine:tRNA(Leu) ligase (AMP-forming) inhibitors leucine translase inhibitor leucine translase inhibitors leucine--tRNA ligase inhibitor leucine--tRNA ligase inhibitors leucine--tRNA synthetase inhibitor leucine--tRNA synthetase inhibitors leucyl--tRNA synthetase inhibitor leucyl--tRNA synthetase inhibitors leucyl-transfer RNA synthetase inhibitor leucyl-transfer RNA synthetase inhibitors leucyl-transfer ribonucleate synthetase inhibitor leucyl-transfer ribonucleate synthetase inhibitors leucyl-transfer ribonucleic acid synthetase inhibitor leucyl-transfer ribonucleic acid synthetase inhibitors EC 6.1.1.4 (leucine--tRNA ligase) inhibitor CHEBI:77960 food firming agent firming agent firming agents food firming agents food firming agent CHEBI:77962 food antioxidant food antioxidants food antioxidant CHEBI:77963 sequestrant sequestrants sequestrant CHEBI:77964 anticaking agent anti-caking agent anti-caking agents anticaking agents anticaking agent CHEBI:77965 food anticaking agent food anti-caking agent food anti-caking agents food anticaking agent food anticaking agent CHEBI:77966 food stabiliser food stabilisers food stabilizer food stabilizers stabiliser stabilisers stabilizer stabilizers food stabiliser CHEBI:77968 humectant humectants humectant CHEBI:77969 food humectant food humectants food humectant CHEBI:77970 food thickening agent food thickening agents thickening agent thickening agents food thickening agent CHEBI:77971 raising agent food raising agent food raising agents leavening agent leavening agents raising agents raising agent CHEBI:77972 food glazing agent food glazing agents glazing agent glazing agents food glazing agent CHEBI:77973 antifoaming agent antifoaming agents defoamer defoamers antifoaming agent CHEBI:77974 food packaging gas food packaging gases food packaging gas CHEBI:78003 food bleaching agent food bleaching agents food bleaching agent CHEBI:78004 food bulking agent filler fillers food bulking agents food bulking agent CHEBI:78006 food colour retention agent color retention agent color retention agents colour retention agent colour retention agents food color retention agent food color retention agents food colour retention agents food colour retention agent CHEBI:78007 foaming agent foaming agents foaming agent CHEBI:78009 Wiskott-Aldrich syndrome protein inhibitor N-WASP inhibitor N-WASP inhibitors WASP inhibitor WASP inhibitors Wiskott-Aldrich syndrome protein inhibitors Wiskott-Aldrich syndrome protein inhibitor CHEBI:78016 food gelling agent food gelling agents food gelling agent CHEBI:78017 food propellant food propellants food propellant CHEBI:78024 EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitors EC 4.1.1.50 inhibitor EC 4.1.1.50 inhibitors S-adenosyl-L-methionine carboxy-lyase [(5-deoxy-5-adenosyl)(3-aminopropyl)methylsulfonium-salt-forming] inhibitor S-adenosyl-L-methionine carboxy-lyase [(5-deoxy-5-adenosyl)(3-aminopropyl)methylsulfonium-salt-forming] inhibitors S-adenosyl-L-methionine carboxy-lyase [S-adenosyl 3-(methylthio)propylamine-forming] inhibitor S-adenosyl-L-methionine carboxy-lyase [S-adenosyl 3-(methylthio)propylamine-forming] inhibitors S-adenosyl-L-methionine carboxy-lyase inhibitor S-adenosyl-L-methionine carboxy-lyase inhibitors S-adenosyl-L-methionine decarboxylase inhibitor S-adenosyl-L-methionine decarboxylase inhibitors S-adenosylmethionine decarboxylase inhibitor S-adenosylmethionine decarboxylase inhibitors EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor CHEBI:78031 Wnt signalling inhibitor Wnt signaling inhibitor Wnt signaling inhibitors Wnt signalling inhibitors Wnt-signaling inhibitor Wnt-signaling inhibitors Wnt-signalling inhibitor Wnt-signalling inhibitors Wnt signalling inhibitor CHEBI:78058 food antifoaming agent food antifoaming agents food defoamer food defoamers food antifoaming agent CHEBI:78059 food additive carrier carrier carriers food additive carriers food additive carrier CHEBI:78152 enzyme mimic enzyme mimetic enzyme mimetics enzyme mimics enzyme mimic CHEBI:7823 oxazepam (+-)-Oxazepam (RS)-Oxazepam 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one Oxazepam Serax Tazepam oxazepam CHEBI:78248 vitamin B1 antagonist vitamin B1 antagonists vitamin B1 antagonist CHEBI:78295 food component dietary component dietary components food components food component CHEBI:78298 environmental contaminant environmental contaminants environmental contaminant CHEBI:78299 environmental food contaminant environmental food contaminants environmental food contaminant CHEBI:78361 lichen metabolite lichen metabolites lichen metabolite CHEBI:78366 EC 2.7.1.1 (hexokinase) inhibitor ATP-dependent hexokinase inhibitor ATP-dependent hexokinase inhibitors ATP:D-hexose 6-phosphotransferase inhibitor ATP:D-hexose 6-phosphotransferase inhibitors EC 2.7.1.1 (hexokinase) inhibitors EC 2.7.1.1 inhibitor EC 2.7.1.1 inhibitors glucose ATP phosphotransferase inhibitor glucose ATP phosphotransferase inhibitors hexokinase (phosphorylating) inhibitor hexokinase (phosphorylating) inhibitors hexokinase D inhibitor hexokinase D inhibitors hexokinase inhibitor hexokinase inhibitors hexokinase type I inhibitor hexokinase type I inhibitors hexokinase type II inhibitor hexokinase type II inhibitors hexokinase type III inhibitor hexokinase type III inhibitors hexokinase type IV glucokinase inhibitor hexokinase type IV glucokinase inhibitors hexokinase type IV inhibitor hexokinase type IV inhibitors EC 2.7.1.1 (hexokinase) inhibitor CHEBI:78372 EC 3.1.1.5 (lysophospholipase) inhibitor 2-lysophosphatidylcholine acylhydrolase inhibitor 2-lysophosphatidylcholine acylhydrolase inhibitors EC 3.1.1.5 (lysophospholipase) inhibitors EC 3.1.1.5 inhibitor EC 3.1.1.5 inhibitors NTE inhibitor NTE inhibitors NTE-LysoPLA inhibitor NTE-LysoPLA inhibitors NTE-lysophospholipase inhibitor NTE-lysophospholipase inhibitors lecithinase B inhibitor lecithinase B inhibitors lecitholipase inhibitor lecitholipase inhibitors lysolecithinase inhibitor lysolecithinase inhibitors lysophopholipase L2 inhibitor lysophopholipase L2 inhibitors lysophosphatidase inhibitor lysophosphatidase inhibitors lysophosphatidylcholine hydrolase inhibitor lysophosphatidylcholine hydrolase inhibitors lysophospholipase (EC 3.1.1.5) inhibitor lysophospholipase (EC 3.1.1.5) inhibitors lysophospholipase A1 inhibitor lysophospholipase A1 inhibitors lysophospholipase inhibitor lysophospholipase inhibitors lysophospholipase transacylase inhibitor lysophospholipase transacylase inhibitors neuropathy target esterase inhibitor neuropathy target esterase inhibitors phosphatidase B inhibitor phosphatidase B inhibitors phospholipase B inhibitor phospholipase B inhibitors EC 3.1.1.5 (lysophospholipase) inhibitor CHEBI:78377 EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor 2-enoyl-CoA reductase inhibitor 2-enoyl-CoA reductase inhibitors EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitors EC 1.3.1.8 inhibitor EC 1.3.1.8 inhibitors acyl-CoA dehydrogenase (NADP(+)) (EC 1.3.1.8) inhibitor acyl-CoA dehydrogenase (NADP(+)) (EC 1.3.1.8) inhibitors acyl-CoA dehydrogenase (NADP(+)) inhibitor acyl-CoA dehydrogenase (NADP(+)) inhibitors acyl-CoA:NADP(+) 2-oxidoreductase inhibitor acyl-CoA:NADP(+) 2-oxidoreductase inhibitors crotonyl coenzyme A reductase inhibitor crotonyl coenzyme A reductase inhibitors crotonyl-CoA reductase inhibitor crotonyl-CoA reductase inhibitors dehydrogenase, acyl coenzyme A (nicotinamide adenine dinucleotide phosphate) inhibitor dehydrogenase, acyl coenzyme A (nicotinamide adenine dinucleotide phosphate) inhibitors enoyl coenzyme A reductase inhibitor enoyl coenzyme A reductase inhibitors EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor CHEBI:78379 EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitors EC 2.5.1.7 inhibitor EC 2.5.1.7 inhibitors MurA transferase inhibitor MurA transferase inhibitors UDP-N-acetylglucosamine 1-carboxyvinyl-transferase inhibitor UDP-N-acetylglucosamine 1-carboxyvinyl-transferase inhibitors UDP-N-acetylglucosamine 1-carboxyvinyltransferase (EC 2.5.1.7) inhibitor UDP-N-acetylglucosamine 1-carboxyvinyltransferase (EC 2.5.1.7) inhibitors UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitors UDP-N-acetylglucosamine enoylpyruvyltransferase inhibitor UDP-N-acetylglucosamine enoylpyruvyltransferase inhibitors enoylpyruvate transferase inhibitor enoylpyruvate transferase inhibitors phosphoenolpyruvate-UDP-acetylglucosamine-3-enolpyruvyltransferase inhibitor phosphoenolpyruvate-UDP-acetylglucosamine-3-enolpyruvyltransferase inhibitors phosphoenolpyruvate:UDP-2-acetamido-2-deoxy-D-glucose 2-enoyl-1-carboxyethyltransferase inhibitor phosphoenolpyruvate:UDP-2-acetamido-2-deoxy-D-glucose 2-enoyl-1-carboxyethyltransferase inhibitors phosphoenolpyruvate:UDP-N-acetyl-D-glucosamine 1-carboxyvinyltransferase inhibitor phosphoenolpyruvate:UDP-N-acetyl-D-glucosamine 1-carboxyvinyltransferase inhibitors phosphoenolpyruvate:UDP-N-acetyl-alpha-D-glucosamine 1-carboxyvinyltransferase inhibitor phosphoenolpyruvate:UDP-N-acetyl-alpha-D-glucosamine 1-carboxyvinyltransferase inhibitors phosphoenolpyruvate:uridine diphosphate N-acetylglucosamine enolpyruvyltransferase inhibitor phosphoenolpyruvate:uridine diphosphate N-acetylglucosamine enolpyruvyltransferase inhibitors phosphoenolpyruvate:uridine-5'-diphospho-N-acetyl-2-amino-2-deoxyglucose 3-enolpyruvyltransferase inhibitor phosphoenolpyruvate:uridine-5'-diphospho-N-acetyl-2-amino-2-deoxyglucose 3-enolpyruvyltransferase inhibitors phosphopyruvate-uridine diphosphoacetylglucosamine pyruvatetransferase inhibitor phosphopyruvate-uridine diphosphoacetylglucosamine pyruvatetransferase inhibitors pyruvate-UDP-acetylglucosamine transferase inhibitor pyruvate-UDP-acetylglucosamine transferase inhibitors pyruvate-uridine diphospho-N-acetyl-glucosamine transferase inhibitor pyruvate-uridine diphospho-N-acetyl-glucosamine transferase inhibitors pyruvate-uridine diphospho-N-acetylglucosamine transferase inhibitor pyruvate-uridine diphospho-N-acetylglucosamine transferase inhibitors pyruvic-uridine diphospho-N-acetylglucosaminyltransferase inhibitor pyruvic-uridine diphospho-N-acetylglucosaminyltransferase inhibitors EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor CHEBI:78380 EC 3.5.4.1 (cytosine deaminase) inhibitor EC 3.5.4.1 (cytosine deaminase) inhibitors EC 3.5.4.1 inhibitor EC 3.5.4.1 inhibitors cytosine aminohydrolase inhibitor cytosine aminohydrolase inhibitors cytosine deaminase (EC 3.5.4.1) inhibitor cytosine deaminase (EC 3.5.4.1) inhibitors cytosine deaminase inhibitor cytosine deaminase inhibitors isocytosine deaminase inhibitor isocytosine deaminase inhibitors EC 3.5.4.1 (cytosine deaminase) inhibitor CHEBI:78381 EC 5.1.2.* (racemases acting on hydroxy acids and derivatives) inhibitor EC 5.1.2.* (racemases acting on hydroxy acids and derivatives) inhibitors EC 5.1.2.* inhibitor EC 5.1.2.* inhibitors inhibitor of racemases acting on hydroxy acids and derivatives inhibitor of racemases acting on hydroxy acids and derivatives (EC 5.1.2.*) inhibitors of racemases acting on hydroxy acids and derivatives inhibitors of racemases acting on hydroxy acids and derivatives (EC 5.1.2.*) EC 5.1.2.* (racemases acting on hydroxy acids and derivatives) inhibitor CHEBI:78382 EC 5.1.3.* (racemases acting on carbohydrates and derivatives) inhibitor EC 5.1.3.* (racemases acting on carbohydrates and derivatives) inhibitors EC 5.1.3.* inhibitor EC 5.1.3.* inhibitors inhibitor of racemases acting on carbohydrates and derivatives inhibitor of racemases acting on carbohydrates and derivatives (EC 5.1.3.*) inhibitors of racemases acting on carbohydrates and derivatives inhibitors of racemases acting on carbohydrates and derivatives (EC 5.1.3.*) EC 5.1.3.* (racemases acting on carbohydrates and derivatives) inhibitor CHEBI:78383 EC 5.1.99.* (racemases acting on other compounds) inhibitor EC 5.1.99.* (racemases acting on other compounds) inhibitors EC 5.1.99.* inhibitor EC 5.1.99.* inhibitors inhibitor of racemases acting on other compounds (EC 5.1.99.*) inhibitors of racemases acting on other compounds (EC 5.1.99.*) EC 5.1.99.* (racemases acting on other compounds) inhibitor CHEBI:78384 EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor 4-epimerase inhibitor 4-epimerase inhibitors EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitors EC 5.1.3.2 inhibitor EC 5.1.3.2 inhibitors UDP-D-galactose 4-epimerase inhibitor UDP-D-galactose 4-epimerase inhibitors UDP-alpha-D-glucose 4-epimerase inhibitor UDP-alpha-D-glucose 4-epimerase inhibitors UDP-galactose 4-epimerase inhibitor UDP-galactose 4-epimerase inhibitors UDP-glucose 4-epimerase (EC 5.1.3.2) inhibitor UDP-glucose 4-epimerase (EC 5.1.3.2) inhibitors UDP-glucose 4-epimerase inhibitor UDP-glucose 4-epimerase inhibitors UDP-glucose epimerase inhibitor UDP-glucose epimerase inhibitors UDPG-4-epimerase inhibitor UDPG-4-epimerase inhibitors UDPgalactose 4-epimerase inhibitor UDPgalactose 4-epimerase inhibitors UDPglucose 4-epimerase inhibitor UDPglucose 4-epimerase inhibitors galactowaldenase inhibitor galactowaldenase inhibitors uridine diphosphate galactose 4-epimerase inhibitor uridine diphosphate galactose 4-epimerase inhibitors uridine diphosphate glucose 4-epimerase inhibitor uridine diphosphate glucose 4-epimerase inhibitors uridine diphospho-galactose-4-epimerase inhibitor uridine diphospho-galactose-4-epimerase inhibitors uridine diphosphoglucose 4-epimerase inhibitor uridine diphosphoglucose 4-epimerase inhibitors uridine diphosphoglucose epimerase inhibitor uridine diphosphoglucose epimerase inhibitors EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor CHEBI:78433 refrigerant refrigerants refrigerant CHEBI:78444 EC 3.1.1.1 (carboxylesterase) inhibitor Alpha-carboxylesterase inhibitor Alpha-carboxylesterase inhibitors Beta-esterase inhibitor Beta-esterase inhibitors EC 3.1.1.1 (carboxylesterase) inhibitors ali-esterase inhibitor ali-esterase inhibitors butyrate esterase inhibitor butyrate esterase inhibitors butyryl esterase inhibitor butyryl esterase inhibitors carboxyl ester hydrolase inhibitor carboxyl ester hydrolase inhibitors carboxylate esterase inhibitor carboxylate esterase inhibitors carboxylesterase inhibitor carboxylesterase inhibitors carboxylic acid esterase inhibitor carboxylic acid esterase inhibitors carboxylic esterase inhibitor carboxylic esterase inhibitors carboxylic-ester hydrolase inhibitor carboxylic-ester hydrolase inhibitors cocaine esterase inhibitor cocaine esterase inhibitors esterase A inhibitor esterase A inhibitors esterase B inhibitor esterase B inhibitors esterase D inhibitor esterase D inhibitors methylbutyrase inhibitor methylbutyrase inhibitors methylbutyrate esterase inhibitor methylbutyrate esterase inhibitors monobutyrase inhibitor monobutyrase inhibitors nonspecific carboxylesterase inhibitor nonspecific carboxylesterase inhibitors procaine esterase inhibitor procaine esterase inhibitors propionyl esterase inhibitor propionyl esterase inhibitors serine esterase inhibitor serine esterase inhibitors triacetin esterase inhibitor triacetin esterase inhibitors vitamin A esterase inhibitor vitamin A esterase inhibitors EC 3.1.1.1 (carboxylesterase) inhibitor CHEBI:78505 venom venoms venom CHEBI:78547 protein kinase A agonist protein kinase A agonists protein kinase A agonist CHEBI:78548 adenylate cyclase agonist adenylate cyclase agonists adenylyl cyclase agonist adenylyl cyclase agonists adenylate cyclase agonist CHEBI:78592 vesicant blister agent blister agents vesicants vesicant CHEBI:78606 Hsp70 inducer Hsp70 activator Hsp70 activators Hsp70 inducers heat shock protein 70 activator heat shock protein 70 activators heat shock protein 70 inducer heat shock protein 70 inducers Hsp70 inducer CHEBI:78622 EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor 3-hydroxy-3-methylglutaryl coenzyme A reductase kinase inhibitor 3-hydroxy-3-methylglutaryl coenzyme A reductase kinase inhibitors 3-hydroxy-3-methylglutaryl-CoA reductase kinase inhibitor 3-hydroxy-3-methylglutaryl-CoA reductase kinase inhibitors AMP-activated protein kinase inhibitor AMP-activated protein kinase inhibitors AMPK inhibitor AMPK inhibitors ATP:[hydroxymethylglutaryl-CoA reductase (NADPH)] phosphotransferase inhibitor ATP:[hydroxymethylglutaryl-CoA reductase (NADPH)] phosphotransferase inhibitors EC 2.7.11.31 ([hydroxymethylglutaryl-CoA reductase (NADPH)] kinase) inhibitor EC 2.7.11.31 ([hydroxymethylglutaryl-CoA reductase (NADPH)] kinase) inhibitors EC 2.7.11.31 inhibitor EC 2.7.11.31 inhibitors EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitors HMG-CoA reductase kinase inhibitor HMG-CoA reductase kinase inhibitors STK29 inhibitor STK29 inhibitors [hydroxymethylglutaryl-CoA reductase (NADPH)] kinase inhibitor [hydroxymethylglutaryl-CoA reductase (NADPH)] kinase inhibitors [hydroxymethylglutaryl-CoA reductase (NADPH2)] kinase inhibitor [hydroxymethylglutaryl-CoA reductase (NADPH2)] kinase inhibitors beta-hydroxy-beta-methylglutaryl-CoA reductase kinase inhibitor beta-hydroxy-beta-methylglutaryl-CoA reductase kinase inhibitors hydroxymethylglutaryl coenzyme A reductase kinase (phosphorylating) inhibitor hydroxymethylglutaryl coenzyme A reductase kinase (phosphorylating) inhibitors hydroxymethylglutaryl coenzyme A reductase kinase inhibitor hydroxymethylglutaryl coenzyme A reductase kinase inhibitors hydroxymethylglutaryl-CoA reductase kinase inhibitor hydroxymethylglutaryl-CoA reductase kinase inhibitors reductase kinase inhibitor reductase kinase inhibitors EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor CHEBI:78623 bone morphogenetic protein receptor antagonist BMP antagonist BMP antagonists BMP receptor inhibitor BMP receptor inhibitors bone morphogenetic protein antagonists bone morphogenetic protein inhibitor bone morphogenetic protein receptor inhibitors bone morphogenetic protein receptor antagonist CHEBI:78675 fundamental metabolite essential metabolite essential metabolites fundamental metabolites fundamental metabolite CHEBI:78678 EC 4.6.1.2 (guanylate cyclase) inhibitor EC 4.6.1.2 (guanylate cyclase) inhibitors EC 4.6.1.2 inhibitor EC 4.6.1.2 inhibitors GTP diphosphate-lyase (cyclizing) inhibitor GTP diphosphate-lyase (cyclizing) inhibitors GTP diphosphate-lyase (cyclizing; 3',5'-cyclic-GMP-forming) inhibitor GTP diphosphate-lyase (cyclizing; 3',5'-cyclic-GMP-forming) inhibitors guanyl cyclase inhibitor guanyl cyclase inhibitors guanylyl cyclase inhibitor guanylyl cyclase inhibitors EC 4.6.1.2 (guanylate cyclase) inhibitor CHEBI:78681 tropomyosin-related kinase B receptor antagonist TrkB receptor antagonist TrkB receptor antagonists tropomyosin-related kinase B receptor antagonists tropomyosin-related kinase B receptor antagonist CHEBI:78691 EC 2.3.1.97 (glycylpeptide N-tetradecanoyltransferase) inhibitor EC 2.3.1.97 (glycylpeptide N-tetradecanoyltransferase) inhibitors myristoyl-CoA-protein N-myristoyltransferase inhibitor myristoyl-CoA-protein N-myristoyltransferase inhibitors myristoyl-coenzyme A:protein N-myristoyl transferase inhibitor myristoyl-coenzyme A:protein N-myristoyl transferase inhibitors peptide N-myristoyltransferase inhibitor peptide N-myristoyltransferase inhibitors protein N-myristoyltransferase inhibitor protein N-myristoyltransferase inhibitors tetradecanoyl-CoA:glycylpeptide N-tetradecanoyltransferase inhibitor tetradecanoyl-CoA:glycylpeptide N-tetradecanoyltransferase inhibitors EC 2.3.1.97 (glycylpeptide N-tetradecanoyltransferase) inhibitor CHEBI:78728 EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor Delta(24)-sterol reductase (EC 1.3.1.72) inhibitor Delta(24)-sterol reductase (EC 1.3.1.72) inhibitors Delta(24)-sterol reductase inhibitor Delta(24)-sterol reductase inhibitors EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitors EC 1.3.1.72 inhibitor EC 1.3.1.72 inhibitors lanosterol Delta (24)-reductase sterol:NADP(+) Delta(24)-oxidoreductase EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor CHEBI:78756 EC 2.5.1.6 (methionine adenosyltransferase) inhibitor ATP-methionine adenosyltransferase inhibitor ATP-methionine adenosyltransferase inhibitors ATP:L-methionine S-adenosyltransferase inhibitor ATP:L-methionine S-adenosyltransferase inhibitors AdoMet synthetase inhibitor AdoMet synthetase inhibitors EC 2.5.1.6 (methionine adenosyltransferase) inhibitors EC 2.5.1.6 inhibitor EC 2.5.1.6 inhibitors S-adenosyl-L-methionine synthetase inhibitor S-adenosyl-L-methionine synthetase inhibitors S-adenosylmethionine synthase inhibitor S-adenosylmethionine synthase inhibitors S-adenosylmethionine synthetase inhibitor S-adenosylmethionine synthetase inhibitors adenosylmethionine synthetase inhibitor adenosylmethionine synthetase inhibitors methionine S-adenosyltransferase inhibitor methionine S-adenosyltransferase inhibitors methionine-activating enzyme inhibitor methionine-activating enzyme inhibitors EC 2.5.1.6 (methionine adenosyltransferase) inhibitor CHEBI:78760 EC 2.7.1.91 (sphingosine kinase) inhibitor ATP:sphinganine 1-phosphotransferase inhibitor ATP:sphinganine 1-phosphotransferase inhibitors EC 2.7.1.91 (sphinganine kinase) inhibitor EC 2.7.1.91 (sphinganine kinase) inhibitors EC 2.7.1.91 (sphingosine kinase) inhibitors EC 2.7.1.91 inhibitor EC 2.7.1.91 inhibitors SGK inhibitor SGK inhibitors SK inhibitor SK inhibitors dihydrosphingosine kinase (phosphorylating) inhibitor dihydrosphingosine kinase (phosphorylating) inhibitors dihydrosphingosine kinase inhibitor dihydrosphingosine kinase inhibitors sphinganine kinase inhibitor sphinganine kinase inhibitors sphingoid base kinase inhibitor sphingoid base kinase inhibitors sphingosine kinase (phosphorylating) inhibitor sphingosine kinase (phosphorylating) inhibitors EC 2.7.1.91 (sphingosine kinase) inhibitor CHEBI:78763 EC 2.7.11.18 (myosin-light-chain kinase) inhibitor ATP:[myosin-light-chain] O-phosphotransferase inhibitor ATP:[myosin-light-chain] O-phosphotransferase inhibitors ATP:myosin-light-chain O-phosphotransferase inhibitor ATP:myosin-light-chain O-phosphotransferase inhibitors EC 2.7.11.18 (myosin-light-chain kinase) inhibitors EC 2.7.11.18 inhibitor EC 2.7.11.18 inhibitors MLCK inhibitor MLCK inhibitors MLCkase inhibitor MLCkase inhibitors [myosin-light-chain] kinase inhibitor [myosin-light-chain] kinase inhibitors calcium/calmodulin-dependent myosin light chain kinase inhibitor calcium/calmodulin-dependent myosin light chain kinase inhibitors myosin kinase inhibitor myosin kinase inhibitors myosin light chain kinase inhibitor myosin light chain kinase inhibitors myosin light chain protein kinase inhibitor myosin light chain protein kinase inhibitors myosin light-chain kinase (phosphorylating) inhibitor myosin light-chain kinase (phosphorylating) inhibitors myosin light-chain kinase inhibitor myosin light-chain kinase inhibitors myosin-light-chain kinase (EC 2.7.11.18) inhibitor myosin-light-chain kinase (EC 2.7.11.18) inhibitors myosin-light-chain kinase inhibitor myosin-light-chain kinase inhibitors smooth-muscle-myosin-light-chain kinase inhibitor smooth-muscle-myosin-light-chain kinase inhibitors EC 2.7.11.18 (myosin-light-chain kinase) inhibitor CHEBI:78803 nematode metabolite nematode metabolites nematode metabolite CHEBI:78804 Caenorhabditis elegans metabolite C. elegans metabolite C. elegans metabolites Caenorhabditis elegans metabolites Caenorhabditis elegans metabolite CHEBI:78926 survivin dimerisation modulator survivin dimerisation modulators survivin modulator survivin modulators survivin dimerisation modulator CHEBI:78927 EC 3.6.1.* (hydrolases acting on acid anhydrides in P-containing anhydrides) inhibitor EC 3.6.1.* (hydrolases acting on acid anhydrides in P-containing anhydrides) inhibitors EC 3.6.1.* (hydrolases acting on acid anhydrides in phosphorus-containing anhydrides) inhibitor EC 3.6.1.* (hydrolases acting on acid anhydrides in phosphorus-containing anhydrides) inhibitors EC 3.6.1.* inhibitor EC 3.6.1.* inhibitors hydrolases acting on acid anhydrides in P-containing anhydrides (EC 3.6.1.*) inhibitor hydrolases acting on acid anhydrides in P-containing anhydrides (EC 3.6.1.*) inhibitors hydrolases acting on acid anhydrides in phosphorus-containing anhydrides (EC 3.6.1.*) inhibitor hydrolases acting on acid anhydrides in phosphorus-containing anhydrides (EC 3.6.1.*) inhibitors EC 3.6.1.* (hydrolases acting on acid anhydrides in P-containing anhydrides) inhibitor CHEBI:78928 EC 3.6.1.3 (adenosinetriphosphatase) inhibitor (Ca(2+) + Mg(2+))-ATPase inhibitor (Ca(2+) + Mg(2+))-ATPase inhibitors ATP hydrolase inhibitor ATP hydrolase inhibitors ATP monophosphatase inhibitor ATP monophosphatase inhibitors ATP phosphohydrolase inhibitor ATP phosphohydrolase inhibitors ATPase inhibitor ATPase inhibitors EC 3.6.1.3 (adenosinetriphosphatase) inhibitors EC 3.6.1.3 inhibitor EC 3.6.1.3 inhibitors HCO3(-)-ATPase inhibitor HCO3(-)-ATPase inhibitors SV40 T-antigen inhibitor SV40 T-antigen inhibitors adenosine 5'-triphosphatase inhibitor adenosine 5'-triphosphatase inhibitors adenosine triphosphatase inhibitor adenosine triphosphatase inhibitors adenosinetriphosphatase (EC 3.6.1.3) inhibitor adenosinetriphosphatase (EC 3.6.1.3) inhibitors adenosinetriphosphatase inhibitor adenosinetriphosphatase inhibitors adenylpyrophosphatase inhibitor adenylpyrophosphatase inhibitors complex V (mitochondrial electron transport) inhibitor complex V (mitochondrial electron transport) inhibitors triphosphatase inhibitor triphosphatase inhibitors EC 3.6.1.3 (adenosinetriphosphatase) inhibitor CHEBI:78947 archaeal metabolite archaeal metabolites archaeal metabolite CHEBI:79046 melatonin receptor agonist melatonin receptor agonists melatonin receptor agonist CHEBI:79050 EC 3.4.22.52 (calpain-1) inhibitor EC 3.4.22.52 (calpain-1) inhibitors EC 3.4.22.52 inhibitor EC 3.4.22.52 inhibitors calcium-activated neutral protease I inhibitor calcium-activated neutral protease I inhibitors calpain-1 (EC 3.4.22.52) inhibitor calpain-1 (EC 3.4.22.52) inhibitors calpain-1 inhibitor calpain-1 inhibitors mu-calpain inhibitor mu-calpain inhibitors EC 3.4.22.52 (calpain-1) inhibitor CHEBI:79056 plasticiser plasticisers plasticizer plasticizers plasticiser CHEBI:79085 potassium channel opener potassium channel activator potassium channel activators potassium channel agonist potassium channel agonists potassium channel openers potassium channel opener CHEBI:79088 EC 3.4.24.35 (gelatinase B) inhibitor 92-kDa gelatinase inhibitor 92-kDa gelatinase inhibitors 92-kDa type IV collagenase inhibitor 92-kDa type IV collagenase inhibitors 95 kDa type IV collagenase/gelatinase inhibitor 95 kDa type IV collagenase/gelatinase inhibitors EC 3.4.24.35 (gelatinase B) inhibitors EC 3.4.24.35 inhibitor EC 3.4.24.35 inhibitors MMP 9 inhibitor MMP 9 inhibitors collagenase IV inhibitor collagenase IV inhibitors collagenase type IV inhibitor collagenase type IV inhibitors gelatinase B (EC 3.4.24.35) inhibitor gelatinase B (EC 3.4.24.35) inhibitors gelatinase B inhibitor gelatinase B inhibitors gelatinase MMP 9 inhibitor gelatinase MMP 9 inhibitors macrophage gelatinase inhibitor macrophage gelatinase inhibitors matrix metalloproteinase 9 inhibitor matrix metalloproteinase 9 inhibitors type IV collagen metalloproteinase inhibitor type IV collagen metalloproteinase inhibitors type V collagenase inhibitor type V collagenase inhibitors EC 3.4.24.35 (gelatinase B) inhibitor CHEBI:79091 EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor ATP:protein phosphotransferase (MAPKK-activated) inhibitor ATP:protein phosphotransferase (MAPKK-activated) inhibitors Dp38 inhibitor Dp38 inhibitors EC 2.7.11.24 (mitogen-activated protein kinase) inhibitors EC 2.7.11.24 inhibitor EC 2.7.11.24 inhibitors ERK inhibitor ERK inhibitors ERK1 inhibitor ERK1 inhibitors ERK2 inhibitor ERK2 inhibitors JNK inhibitor JNK inhibitors JNK3alpha1 inhibitor JNK3alpha1 inhibitors LeMPK3 inhibitor LeMPK3 inhibitors MAP kinase inhibitor MAP kinase inhibitors MAP-2 kinase inhibitor MAP-2 kinase inhibitors MAPK inhibitor MAPK inhibitors MBP kinase I inhibitor MBP kinase I inhibitors MBP kinase II inhibitor MBP kinase II inhibitors MEK inhibitor MEK inhibitors PMK-1 inhibitor PMK-1 inhibitors PMK-2 inhibitor PMK-2 inhibitors PMK-3 inhibitor PMK-3 inhibitors SAPK inhibitor SAPK inhibitors STK26 inhibitor STK26 inhibitors c-Jun N-terminal kinase inhibitor c-Jun N-terminal kinase inhibitors extracellular signal-regulated kinase inhibitor extracellular signal-regulated kinase inhibitors microtubule-associated protein 2 kinase inhibitor microtubule-associated protein 2 kinase inhibitors microtubule-associated protein kinase inhibitor microtubule-associated protein kinase inhibitors mitogen-activated protein kinase (EC 2.7.11.24) inhibitor mitogen-activated protein kinase (EC 2.7.11.24) inhibitors mitogen-activated protein kinase inhibitor mitogen-activated protein kinase inhibitors myelin basic protein kinase inhibitor myelin basic protein kinase inhibitors p38-2 inhibitor p38-2 inhibitors p38delta inhibitor p38delta inhibitors p42 mitogen-activated protein kinase inhibitor p42 mitogen-activated protein kinase inhibitors p42(mapk) inhibitor p42(mapk) inhibitors p44mpk inhibitor p44mpk inhibitors pp42 inhibitor pp42 inhibitors pp44(mapk) inhibitor pp44(mapk) inhibitors stress-activated protein kinase inhibitor stress-activated protein kinase inhibitors EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor CHEBI:79092 EC 1.11.2.* (oxidoreductase with H2O2 as acceptor, incorporating 1 O atom into product) inhibitor EC 1.11.2.* (oxidoreductase with H2O2 as acceptor, incorporating 1 O atom into product) inhibitors EC 1.11.2.* inhibitor EC 1.11.2.* inhibitors EC 1.11.2.* (oxidoreductase with H2O2 as acceptor, incorporating 1 O atom into product) inhibitor CHEBI:79093 EC 1.11.2.2 (myeloperoxidase) inhibitor EC 1.11.2.2 (myeloperoxidase) inhibitors EC 1.11.2.2 inhibitor EC 1.11.2.2 inhibitors MPO inhibitor MPO inhibitors chloride:hydrogen-peroxide oxidoreductase (hypochlorite-forming) inhibitor chloride:hydrogen-peroxide oxidoreductase (hypochlorite-forming) inhibitors myeloperoxidase (EC 1.11.2.2) inhibitor myeloperoxidase (EC 1.11.2.2) inhibitors myeloperoxidase inhibitor myeloperoxidase inhibitors verdoperoxidase inhibitor verdoperoxidase inhibitors EC 1.11.2.2 (myeloperoxidase) inhibitor CHEBI:79314 flame retardant flame retardants flame retardant CHEBI:7936 paroxetine (-)-(3S,4R)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine Paroxetine paroxetina paroxetinum paroxetine CHEBI:79386 glycerophosphoinositol synthesis inhibitor GPI synthesis inhibitor GPI synthesis inhibitors glycerophosphoinositol synthesis inhibitors glycerophosphoinositol synthesis inhibitor CHEBI:79392 EC 6.1.1.2 (tryptophan--tRNA ligase) inhibitor EC 6.1.1.2 (tryptophan--tRNA ligase) inhibitors EC 6.1.1.2 inhibitor EC 6.1.1.2 inhibitors L-tryptophan-tRNA(Trp) ligase (AMP-forming) inhibitor L-tryptophan-tRNA(Trp) ligase (AMP-forming) inhibitors L-tryptophan:tRNA(Trp) ligase (AMP-forming) inhibitor L-tryptophan:tRNA(Trp) ligase (AMP-forming) inhibitors TrpRS inhibitor TrpRS inhibitors tryptophan translase inhibitor tryptophan translase inhibitors tryptophan--tRNA ligase (EC 6.1.1.2) inhibitor tryptophan--tRNA ligase (EC 6.1.1.2) inhibitors tryptophanyl ribonucleic synthetase inhibitor tryptophanyl ribonucleic synthetase inhibitors tryptophanyl-tRNA synthase inhibitor tryptophanyl-tRNA synthase inhibitors tryptophanyl-tRNA synthetase inhibitor tryptophanyl-tRNA synthetase inhibitors tryptophanyl-transfer RNA synthetase inhibitor tryptophanyl-transfer RNA synthetase inhibitors tryptophanyl-transfer ribonucleate synthetase inhibitor tryptophanyl-transfer ribonucleate synthetase inhibitors tryptophanyl-transfer ribonucleic acid synthetase inhibitor tryptophanyl-transfer ribonucleic acid synthetase inhibitors tryptophanyl-transfer ribonucleic synthetase inhibitor tryptophanyl-transfer ribonucleic synthetase inhibitors EC 6.1.1.2 (tryptophan--tRNA ligase) inhibitor CHEBI:8050 phenacetin 1-Acetamido-4-ethoxybenzene 4-Ethoxyacetanilide Acetophenetidin Acetophenetidine Acetophenetin Acetphenetidin Achrocidin Codempiral Commotional Contradol Contradouleur Fenacetina N-(4-ethoxyphenyl)acetamide Phenacetin Phenacetine Phenacetinum phenacetin phenacetin CHEBI:82632 phytochrome chromophore phytochrome chromophores phytochrome chromophore CHEBI:82655 animal growth promotant animal growth promotants animal growth promoter animal growth promoters animal growth promotant CHEBI:82665 EC 2.7.11.22 (cyclin-dependent kinase) inhibitor ATP:cyclin phosphotransferase inhibitor ATP:cyclin phosphotransferase inhibitors Bur1 Cdk inhibitor Bur1 Cdk inhibitors Bur1 inhibitor Bur1 inhibitors CDK inhibitor CDK inhibitors Cak1 inhibitor Cak1 inhibitors Cak1p inhibitor Cak1p inhibitors Cdc28p inhibitor Cdc28p inhibitors Cdk-activating protein kinase inhibitors Cdk1 inhibitor Cdk1 inhibitors Cdk19 inhibitor Cdk19 inhibitors Cdk2 inhibitor Cdk2 inhibitors Cdk3 inhibitor Cdk3 inhibitors Cdk4 inhibitor Cdk4 inhibitors Cdk5 inhibitor Cdk5 inhibitors Cdk6 inhibitor Cdk6 inhibitors Cdk7 inhibitor Cdk7 inhibitors Cdk8 inhibitor Cdk8 inhibitors Cdk9 inhibitor Cdk9 inhibitors D-type cyclin kinase inhibitor D-type cyclin kinase inhibitors EC 2.7.11.22 (cyclin-dependent kinase) inhibitors EC 2.7.11.22 inhibitor EC 2.7.11.22 inhibitors PCTAIRE-1 inhibitor PCTAIRE-1 inhibitors STK25 inhibitor STK25 inhibitors cdc2 inhibitor cdc2 inhibitors cdc2 kinase inhibitor cdc2 kinase inhibitors cdk-activating kinase inhibitor cdk-activating kinase inhibitors cyclin A-activated cdc2 inhibitor cyclin A-activated cdc2 inhibitors cyclin A-activated cdk2 inhibitor cyclin A-activated cdk2 inhibitors cyclin D-cdk6 kinase inhibitor cyclin D-cdk6 kinase inhibitors cyclin D-dependent kinase inhibitor cyclin D-dependent kinase inhibitors cyclin E kinase inhibitor cyclin E kinase inhibitors cyclin-A associated kinase inhibitor cyclin-A associated kinase inhibitors cyclin-dependent kinase 6 inhibitor cyclin-dependent kinase 6 inhibitors cyclin-dependent kinase inhibitor cyclin-dependent kinase inhibitors cyclin-dependent kinase-2 inhibitor cyclin-dependent kinase-2 inhibitors cyclin-dependent kinase-4 inhibitor cyclin-dependent kinase-4 inhibitors cyclin-dependent protein kinase activating kinase inhibitor cyclin-dependent protein kinase activating kinase inhibitors cyk inhibitor cyk inhibitors ndk inhibitor ndk inhibitors neuronal cdc2-like kinase inhibitor neuronal cdc2-like kinase inhibitors EC 2.7.11.22 (cyclin-dependent kinase) inhibitor CHEBI:82756 EC 6.1.1.12 (aspartate--tRNA ligase) inhibitor EC 6.1.1.12 (aspartate--tRNA ligase) inhibitors EC 6.1.1.12 inhibitor EC 6.1.1.12 inhibitors L-aspartate:tRNA(Asp) ligase (AMP-forming) inhibitor L-aspartate:tRNA(Asp) ligase (AMP-forming) inhibitors aspartic acid translase inhibitor aspartic acid translase inhibitors aspartyl ribonucleate synthetase inhibitor aspartyl ribonucleate synthetase inhibitors aspartyl ribonucleic synthetase inhibitor aspartyl ribonucleic synthetase inhibitors aspartyl-tRNA synthetase inhibitors aspartyl-transfer RNA synthetase inhibitor aspartyl-transfer RNA synthetase inhibitors aspartyl-transfer ribonucleic acid synthetase inhibitor aspartyl-transfer ribonucleic acid synthetase inhibitors EC 6.1.1.12 (aspartate--tRNA ligase) inhibitor CHEBI:82821 EC 3.4.22.53 (calpain-2) inhibitor EC 3.4.22.53 (calpain-2) inhibitors EC 3.4.22.53 inhibitor EC 3.4.22.53 inhibitors calcium-activated neutral protease II inhibitor calcium-activated neutral protease II inhibitors calpain-2 (EC 3.4.22.53) inhibitor calpain-2 (EC 3.4.22.53) inhibitors m-calpain inhibitor m-calpain inhibitors milli-calpain inhibitor milli-calpain inhibitors EC 3.4.22.53 (calpain-2) inhibitor CHEBI:82823 EC 3.4.22.54 (calpain-3) inhibitor CANP 3 inhibitor CANP 3 inhibitors CAPN3 inhibitor CAPN3 inhibitors EC 3.4.22.54 (calpain-3) inhibitors EC 3.4.22.54 inhibitor EC 3.4.22.54 inhibitors calcium-activated neutral proteinase 3 inhibitor calcium-activated neutral proteinase 3 inhibitors calpain 3 inhibitor calpain 3 inhibitors calpain L3 inhibitor calpain L3 inhibitors calpain p94 inhibitor calpain p94 inhibitors calpain-3 (EC 3.4.22.54) inhibitor calpain-3 (EC 3.4.22.54) inhibitors muscle calpain inhibitor muscle calpain inhibitors muscle-specific calcium-activated neutral protease 3 inhibitor muscle-specific calcium-activated neutral protease 3 inhibitors p94 inhibitor p94 inhibitors EC 3.4.22.54 (calpain-3) inhibitor CHEBI:82824 calpain inhibitor calpain inhibitors calpain inhibitor CHEBI:82891 glucocorticoid receptor antagonist glucocorticoid receptor antagonists glucocorticoid receptor antagonist CHEBI:82933 gut flora metabolite gut flora metabolites gut flora metabolite CHEBI:82973 EC 3.4.24.11 (neprilysin) inhibitor CALLA (common acute lymphoblastic leukemia-associated) antigens inhibitor CALLA (common acute lymphoblastic leukemia-associated) antigens inhibitors CALLA antigen inhibitor CALLA antigen inhibitors CALLA glycoprotein inhibitor CALLA glycoprotein inhibitors CALLA glycoproteins inhibitor CALLA glycoproteins inhibitors CALLA inhibitor CALLA inhibitors CD10 inhibitor CD10 inhibitors EC 3.4.24.11 (neprilysin) inhibitors EC 3.4.24.11 inhibitor EC 3.4.24.11 inhibitors NEP inhibitor NEP inhibitors acute lymphoblastic leukemia antigen inhibitor acute lymphoblastic leukemia antigen inhibitors common acute lymphoblastic leukemia antigen inhibitor common acute lymphoblastic leukemia antigen inhibitors common acute lymphoblastic leukemia-associated antigens inhibitor common acute lymphoblastic leukemia-associated antigens inhibitors endopeptidase 24.11 inhibitor endopeptidase 24.11 inhibitors endopeptidase inhibitor endopeptidase inhibitors endopeptidase-2 inhibitor endopeptidase-2 inhibitors enkephalinase inhibitor enkephalinase inhibitors kidney-brush-border neutral endopeptidase inhibitor kidney-brush-border neutral endopeptidase inhibitors kidney-brush-border neutral peptidase inhibitor kidney-brush-border neutral peptidase inhibitors kidney-brush-border neutral proteinase inhibitor kidney-brush-border neutral proteinase inhibitors membrane metalloendopeptidase inhibitor membrane metalloendopeptidase inhibitors neprilysin (EC 3.4.24.11) inhibitor neprilysin (EC 3.4.24.11) inhibitors neprilysin inhibitor neprilysin inhibitors neutral endopeptidase 24.11 inhibitor neutral endopeptidase 24.11 inhibitors neutral endopeptidase inhibitor neutral endopeptidase inhibitors neutral metallendopeptidase inhibitor neutral metallendopeptidase inhibitors EC 3.4.24.11 (neprilysin) inhibitor CHEBI:82974 EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitors EC 3.4.24.71 inhibitor EC 3.4.24.71 inhibitors ECE-1 inhibitor ECE-1 inhibitors endothelin-converting enzyme 1 (EC 3.4.24.71) inhibitor endothelin-converting enzyme 1 (EC 3.4.24.71) inhibitors endothelin-converting enzyme 1 inhibitor endothelin-converting enzyme 1 inhibitors endothelin-converting enzyme inhibitor endothelin-converting enzyme inhibitors EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor CHEBI:83034 EC 4.1.2.27 (sphinganine-1-phosphate aldolase) inhibitor EC 4.1.2.27 (sphinganine-1-phosphate aldolase) inhibitors EC 4.1.2.27 inhibitor EC 4.1.2.27 inhibitors S1P lyase inhibitor S1P lyase inhibitors dihydrosphingosine 1-phosphate aldolase inhibitor dihydrosphingosine 1-phosphate aldolase inhibitors sphinganine-1-phosphate alkanal-lyase inhibitor sphinganine-1-phosphate alkanal-lyase inhibitors sphinganine-1-phosphate lyase inhibitor sphinganine-1-phosphate lyase inhibitors sphinganine-1-phosphate palmitaldehyde-lyase (phosphoethanolamine-forming) inhibitor sphinganine-1-phosphate palmitaldehyde-lyase (phosphoethanolamine-forming) inhibitors sphinganine-1-phosphate palmitaldehyde-lyase inhibitor sphinganine-1-phosphate palmitaldehyde-lyase inhibitors sphingosine-1-phosphate aldolase inhibitor sphingosine-1-phosphate aldolase inhibitors sphingosine-1-phosphate lyase inhibitor sphingosine-1-phosphate lyase inhibitors EC 4.1.2.27 (sphinganine-1-phosphate aldolase) inhibitor CHEBI:83035 EC 4.1.2.* (aldehyde-lyase) inhibitor EC 4.1.2.* (aldehyde-lyase) inhibitors EC 4.1.2.* (aldehyde-lyases) inhibitor EC 4.1.2.* (aldehyde-lyases) inhibitors EC 4.1.2.* inhibitor EC 4.1.2.* inhibitors EC 4.1.2.* (aldehyde-lyase) inhibitor CHEBI:83038 Daphnia galeata metabolite Daphnia galeata metabolites Daphnia galeata metabolite CHEBI:83039 crustacean metabolite crustacean metabolites crustacean metabolite CHEBI:83056 Daphnia magna metabolite Daphnia magna metabolites Daphnia magna metabolite CHEBI:83057 Daphnia metabolite Daphnia metabolites Daphnia metabolite CHEBI:83072 EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitors EC 1.3.5.1 inhibitor EC 1.3.5.1 inhibitors SDH inhibitor SDH inhibitors complex II inhibitor complex II inhibitors succinate dehydrogenase (ubiquinone) inhibitor succinate dehydrogenase (ubiquinone) inhibitors succinate dehydrogenase complex inhibitor succinate dehydrogenase complex inhibitors succinate dehydrogenase inhibitor succinate dehydrogenase inhibitors succinate:quinone oxidoreductase inhibitor succinate:quinone oxidoreductase inhibitors succinate:ubiquinone oxidoreductase inhibitor succinate:ubiquinone oxidoreductase inhibitors succinic dehydrogenase inhibitor succinic dehydrogenase inhibitors EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor CHEBI:83074 kairomone kairomones kairomone CHEBI:83075 Daphnia pulex metabolite Daphnia pulex metabolites Daphnia pulex metabolite CHEBI:83146 Daphnia tenebrosa metabolite Daphnia tenebrosa metabolites Daphnia tenebrosa metabolite CHEBI:83156 EC 6.2.1.* (acid-thiol ligase) inhibitor EC 6.2.1.* (acid-thiol ligase) inhibitors EC 6.2.1.* (acid-thiol ligases) inhibitor EC 6.2.1.* (acid-thiol ligases) inhibitors EC 6.2.1.* inhibitor EC 6.2.1.* inhibitors EC 6.2.1.* (acid-thiol ligase) inhibitor CHEBI:83157 EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor ACS3 inhibitor ACS3 inhibitors EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitors EC 6.2.1.3 inhibitor EC 6.2.1.3 inhibitors FAA1 inhibitor FAA1 inhibitors LCFA synthetase inhibitor LCFA synthetase inhibitors acyl coenzyme A synthetase inhibitor acyl coenzyme A synthetase inhibitors acyl-CoA ligase inhibitor acyl-CoA ligase inhibitors acyl-CoA synthetase inhibitor acyl-CoA synthetase inhibitors acyl-activating enzyme inhibitor acyl-activating enzyme inhibitors acyl-coenzyme A ligase inhibitor acyl-coenzyme A ligase inhibitors arachidonyl-CoA synthetase inhibitor arachidonyl-CoA synthetase inhibitors fatty acid CoA ligase inhibitor fatty acid CoA ligase inhibitors fatty acid elongase inhibitor fatty acid elongase inhibitors fatty acid thiokinase (long chain) inhibitor fatty acid thiokinase (long chain) inhibitors fatty acyl-coenzyme A synthetase inhibitor fatty acyl-coenzyme A synthetase inhibitors lignoceroyl-CoA synthase inhibitor lignoceroyl-CoA synthase inhibitors long chain fatty acyl-CoA synthetase inhibitor long chain fatty acyl-CoA synthetase inhibitors long-chain acyl CoA synthetase inhibitor long-chain acyl CoA synthetase inhibitors long-chain acyl-CoA synthetase I inhibitor long-chain acyl-CoA synthetase I inhibitors long-chain acyl-CoA synthetase II inhibitor long-chain acyl-CoA synthetase II inhibitors long-chain acyl-coenzyme A synthetase inhibitor long-chain acyl-coenzyme A synthetase inhibitors long-chain fatty acid:CoA ligase (AMP-forming) inhibitor long-chain fatty acid:CoA ligase (AMP-forming) inhibitors long-chain fatty acyl coenzyme A synthetase inhibitor long-chain fatty acyl coenzyme A synthetase inhibitors oleoyl-CoA synthetase inhibitor oleoyl-CoA synthetase inhibitors palmitoyl coenzyme A synthetase inhibitor palmitoyl coenzyme A synthetase inhibitors palmitoyl-CoA ligase inhibitor palmitoyl-CoA ligase inhibitors palmitoyl-CoA synthase inhibitor palmitoyl-CoA synthase inhibitors pristanoyl-CoA synthetase inhibitor pristanoyl-CoA synthetase inhibitors stearoyl-CoA synthetase inhibitor stearoyl-CoA synthetase inhibitors thiokinase inhibitor thiokinase inhibitors EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor CHEBI:83296 orexin receptor antagonist orexin receptor antagonists orexin receptor antagonist CHEBI:83313 protease-activated receptor-1 antagonist PAR-1 antagonist PAR-1 antagonists PAR-1 receptor antagonist PAR-1 receptor antagonists PAR1 antagonist PAR1 antagonists coagulation factor II (thrombin) receptor antagonist coagulation factor II (thrombin) receptor antagonists coagulation factor II receptor antagonist coagulation factor II receptor antagonists coagulation factor II thrombin receptor antagonist coagulation factor II thrombin receptor antagonists protease activated receptor 1 antagonist protease activated receptor 1 antagonists protease-activated receptor 1 antagonist protease-activated receptor 1 antagonists protease-activated receptor-1 antagonists proteinase-activated receptor 1 antagonist proteinase-activated receptor 1 antagonists protease-activated receptor-1 antagonist CHEBI:83316 EC 1.14.13.72 (methylsterol monooxygenase) inhibitor 4,4-dimethyl-5alpha-cholest-7-en-3beta-ol,NAD(P)H:oxygen oxidoreductase (hydroxylating) inhibitor 4,4-dimethyl-5alpha-cholest-7-en-3beta-ol,NAD(P)H:oxygen oxidoreductase (hydroxylating) inhibitors 4,4-dimethyl-5alpha-cholest-7-en-3beta-ol,hydrogen-donor:oxygen oxidoreductase (hydroxylating) inhibitor 4,4-dimethyl-5alpha-cholest-7-en-3beta-ol,hydrogen-donor:oxygen oxidoreductase (hydroxylating) inhibitors 4-methylsterol oxidase inhibitor 4-methylsterol oxidase inhibitors EC 1.14.13.72 (ethylsterol monooxygenase) inhibitors EC 1.14.13.72 inhibitor EC 1.14.13.72 inhibitors methylsterol hydroxylase inhibitor methylsterol hydroxylase inhibitors methylsterol monooxygenase (EC 1.14.13.72) inhibitor methylsterol monooxygenase (EC 1.14.13.72) inhibitors methylsterol monooxygenase inhibitor methylsterol monooxygenase inhibitors EC 1.14.13.72 (methylsterol monooxygenase) inhibitor CHEBI:83317 sterol biosynthesis inhibitor sterol biosynthesis inhibitors sterol biosynthesis inhibitor CHEBI:83319 EC 1.3.1.70 (Delta(14)-sterol reductase) inhibitor 4,4-dimethyl-5alpha-cholesta-8,24-dien-3beta-ol:NADP(+) Delta(14)-oxidoreductase inhibitor 4,4-dimethyl-5alpha-cholesta-8,24-dien-3beta-ol:NADP(+) Delta(14)-oxidoreductase inhibitors C-14 sterol reductase inhibitor C-14 sterol reductase inhibitors Delta(14)-sterol reductase (EC 1.3.1.70) inhibitor Delta(14)-sterol reductase (EC 1.3.1.70) inhibitors Delta(14)-sterol reductase inhibitor Delta(14)-sterol reductase inhibitors EC 1.3.1.70 (Delta(14)-sterol reductase) inhibitors EC 1.3.1.70 inhibitor EC 1.3.1.70 inhibitors sterol C14-reductase inhibitor sterol C14-reductase inhibitors EC 1.3.1.70 (Delta(14)-sterol reductase) inhibitor CHEBI:83399 marine xenobiotic metabolite marine xenobiotic metabolites marine xenobiotic metabolite CHEBI:83609 steatosis inducing agent steatosis inducing agents steatosis inducing drug steatosis inducing drugs steatosis inducing agent CHEBI:83612 hepatic steatosis inducing agent hepatic steatosis inducing agents hepatic steatosis inducing drug hepatic steatosis inducing drugs hepatic steatosis inducing agent CHEBI:83734 sterol demethylation inhibitor sterol demethylation inhibitors sterol demethylation inhibitor CHEBI:83741 phospholipid biosynthesis inhibitor phospholipid biosynthesis inhibitors phospholipid biosynthesis inhibitor CHEBI:83757 EC 2.4.1.231 [alpha,alpha-trehalose phosphorylase (configuration-retaining)] inhibitor EC 2.4.1.231 [alpha,alpha-trehalose phosphorylase (configuration-retaining)] inhibitors EC 2.4.1.231 inhibitor EC 2.4.1.231 inhibitors alpha,alpha-trehalose phosphorylase (configuration-retaining) (EC 2.4.1.231) inhibitor alpha,alpha-trehalose phosphorylase (configuration-retaining) (EC 2.4.1.231) inhibitors alpha,alpha-trehalose phosphorylase (configuration-retaining) inhibitor alpha,alpha-trehalose phosphorylase (configuration-retaining) inhibitors alpha,alpha-trehalose:phosphate alpha-D-glucosyltransferase inhibitor alpha,alpha-trehalose:phosphate alpha-D-glucosyltransferase inhibitors trehalose phosphorylase inhibitor trehalose phosphorylase inhibitors EC 2.4.1.231 [alpha,alpha-trehalose phosphorylase (configuration-retaining)] inhibitor CHEBI:83760 EC 2.4.1.64 (alpha,alpha-trehalose phosphorylase) inhibitor EC 2.4.1.64 (alpha,alpha-trehalose phosphorylase) inhibitors EC 2.4.1.64 inhibitor EC 2.4.1.64 inhibitors alpha,alpha-trehalose phosphorylase (EC 2.4.1.64) inhibitor alpha,alpha-trehalose phosphorylase (EC 2.4.1.64) inhibitors alpha,alpha-trehalose phosphorylase inhibitor alpha,alpha-trehalose phosphorylase inhibitors alpha,alpha-trehalose:phosphate beta-D-glucosyltransferase inhibitor alpha,alpha-trehalose:phosphate beta-D-glucosyltransferase inhibitors trehalose phosphorylase inhibitor trehalose phosphorylase inhibitors EC 2.4.1.64 (alpha,alpha-trehalose phosphorylase) inhibitor CHEBI:83762 EC 3.2.1.28 (alpha,alpha-trehalase) inhibitor EC 3.2.1.28 (alpha,alpha-trehalase) inhibitors EC 3.2.1.28 inhibitor EC 3.2.1.28 inhibitors alpha,alpha-trehalase (EC 3.2.1.28) inhibitor alpha,alpha-trehalase (EC 3.2.1.28) inhibitors alpha,alpha-trehalase inhibitor alpha,alpha-trehalase inhibitors EC 3.2.1.28 (alpha,alpha-trehalase) inhibitor CHEBI:83799 nonstructural protein 5A inhibitor HCV non-structural protein 5A inhibitor HCV non-structural protein 5A inhibitors NS5A inhibitor NS5A inhibitors NS5A replication complex inhibitor NS5A replication complex inhibitors nonstructural protein 5A inhibitors nonstructural protein 5A inhibitor CHEBI:84012 EC 4.2.1.94 (scytalone dehydratase) inhibitor EC 4.2.1.94 (scytalone dehydratase) inhibitors EC 4.2.1.94 inhibitor EC 4.2.1.94 inhibitors scytalone 7,8-hydro-lyase (1,3,8-trihydroxynaphthalene-forming) inhibitor scytalone 7,8-hydro-lyase (1,3,8-trihydroxynaphthalene-forming) inhibitors scytalone 7,8-hydro-lyase inhibitor scytalone 7,8-hydro-lyase inhibitors EC 4.2.1.94 (scytalone dehydratase) inhibitor CHEBI:84036 EC 3.4.24.24 (gelatinase A) inhibitor 72 kDa gelatinase inhibitor 72 kDa gelatinase inhibitors 72 kDa gelatinase type A inhibitor 72 kDa gelatinase type A inhibitors EC 3.4.24.35 (gelatinase B) inhibitors EC 3.4.24.35 inhibitor EC 3.4.24.35 inhibitors MMP 2 inhibitor MMP 2 inhibitors collagenase IV inhibitor collagenase IV inhibitors collagenase type IV inhibitor collagenase type IV inhibitors matrix metalloproteinase 2 inhibitor matrix metalloproteinase 2 inhibitors type IV collagen metalloproteinase inhibitor type IV collagen metalloproteinase inhibitors type IV collagenase inhibitor type IV collagenase inhibitors type IV collagenase/gelatinase inhibitor type IV collagenase/gelatinase inhibitors EC 3.4.24.24 (gelatinase A) inhibitor CHEBI:84087 human urinary metabolite human urinary metabolites human urinary metabolite CHEBI:84264 EC 3.5.1.19 (nicotinamidase) inhibitor EC 3.5.1.19 (nicotinamidase) inhibitors EC 3.5.1.19 inhibitor EC 3.5.1.19 inhibitors YNDase inhibitor YNDase inhibitors nicotinamidase (EC 3.5.1.19) inhibitor nicotinamidase (EC 3.5.1.19) inhibitors nicotinamidase inhibitor nicotinamidase inhibitors nicotinamide amidase inhibitor nicotinamide amidase inhibitors nicotinamide amidohydrolase inhibitor nicotinamide amidohydrolase inhibitors nicotinamide deaminase inhibitor nicotinamide deaminase inhibitors EC 3.5.1.19 (nicotinamidase) inhibitor CHEBI:84297 EC 3.4.21.64 (peptidase K) inhibitor EC 3.4.21.64 (peptidase K) inhibitors EC 3.4.21.64 inhibitor EC 3.4.21.64 inhibitors Tritirachium album proteinase K inhibitor Tritirachium album proteinase K inhibitors Tritirachium album serine proteinase inhibitor Tritirachium album serine proteinase inhibitors endopeptidase K inhibitor endopeptidase K inhibitors peptidase K inhibitor peptidase K inhibitors proteinase K inhibitor proteinase K inhibitors EC 3.4.21.64 (peptidase K) inhibitor CHEBI:84735 algal metabolite algal metabolites algal metabolite CHEBI:84799 EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor 2-naphthylamine N-acetyltransferase inhibitor 2-naphthylamine N-acetyltransferase inhibitors 4-aminobiphenyl N-acetyltransferase inhibitor 4-aminobiphenyl N-acetyltransferase inhibitors EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitors EC 2.3.1.5 inhibitor EC 2.3.1.5 inhibitora N-acetyltransferase inhibitor N-acetyltransferase inhibitors acetyl CoA-arylamine N-acetyltransferase inhibitor acetyl CoA-arylamine N-acetyltransferase inhibitors acetyl-CoA:arylamine N-acetyltransferase inhibitor acetyl-CoA:arylamine N-acetyltransferase inhibitors arylamine N-acetyltransferase (EC 2.3.1.5) inhibitor arylamine N-acetyltransferase (EC 2.3.1.5) inhibitors arylamine N-acetyltransferase inhibitor arylamine N-acetyltransferase inhibitors arylamine acetylase inhibitor arylamine acetylase inhibitors arylamine acetyltransferase inhibitor arylamine acetyltransferase inhibitors beta-naphthylamine N-acetyltransferase inhibitor beta-naphthylamine N-acetyltransferase inhibitors indoleamine N-acetyltransferase inhibitor indoleamine N-acetyltransferase inhibitors p-aminosalicylate N-acetyltransferase inhibitor p-aminosalicylate N-acetyltransferase inhibitors serotonin N-acetyltransferase inhibitor serotonin N-acetyltransferase inhibitors serotonin acetyltransferase inhibitor serotonin acetyltransferase inhibitors EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor CHEBI:84800 EC 2.4.1.1 (glycogen phosphorylase) inhibitor (1->4)-alpha-D-glucan:phosphate alpha-D-glucosyltransferase inhibitor (1->4)-alpha-D-glucan:phosphate alpha-D-glucosyltransferase inhibitors 1,4-alpha-D-glucan:phosphate alpha-D-glucosyltransferase inhibitor 1,4-alpha-D-glucan:phosphate alpha-D-glucosyltransferase inhibitors 1,4-alpha-glucan phosphorylase inhibitor 1,4-alpha-glucan phosphorylase inhibitors EC 2.4.1.1 (glycogen phosphorylase) inhibitors EC 2.4.1.1 inhibitor EC 2.4.1.1 inhibitors alpha-glucan phosphorylase inhibitor alpha-glucan phosphorylase inhibitors amylopectin phosphorylase inhibitor amylopectin phosphorylase inhibitors amylophosphorylase inhibitor amylophosphorylase inhibitors glucan phosphorylase inhibitor glucan phosphorylase inhibitors glucosan phosphorylase inhibitor glucosan phosphorylase inhibitors glycogen phosphorylase (EC 2.4.1.1) inhibitor glycogen phosphorylase (EC 2.4.1.1) inhibitors glycogen phosphorylase inhibitor glycogen phosphorylase inhibitors granulose phosphorylase inhibitor granulose phosphorylase inhibitors maltodextrin phosphorylase inhibitor maltodextrin phosphorylase inhibitors muscle phosphorylase a and b inhibitor muscle phosphorylase a and b inhibitors muscle phosphorylase inhibitor muscle phosphorylase inhibitors myophosphorylase inhibitor myophosphorylase inhibitors phosphorylase inhibitor phosphorylase inhibitors polyphosphorylase inhibitor polyphosphorylase inhibitors potato phosphorylase inhibitor potato phosphorylase inhibitors starch phosphorylase inhibitor starch phosphorylase inhibitors EC 2.4.1.1 (glycogen phosphorylase) inhibitor CHEBI:84801 EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor 1D-myo-inositol-trisphosphate 3-kinase inhibitor 1D-myo-inositol-trisphosphate 3-kinase inhibitors ATP:1D-myo-inositol-1,4,5-trisphosphate 3-phosphotransferase inhibitor ATP:1D-myo-inositol-1,4,5-trisphosphate 3-phosphotransferase inhibitors EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitors EC 2.7.1.127 inhibitor EC 2.7.1.127 inhibitors IP3 3-kinase inhibitor IP3 3-kinase inhibitors IP3K inhibitor IP3K inhibitors Ins(1,4,5)P3 3-kinase inhibitor Ins(1,4,5)P3 3-kinase inhibitors inositol 1,4,5-trisphosphate 3-kinase inhibitor inositol 1,4,5-trisphosphate 3-kinase inhibitors inositol-trisphosphate 3-kinase (EC 2.7.1.127) inhibitor inositol-trisphosphate 3-kinase (EC 2.7.1.127) inhibitors inositol-trisphosphate 3-kinase inhibitor inositol-trisphosphate 3-kinase inhibitors EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor CHEBI:84802 EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor ATP:1D-myo-inositol-1,4,5-trisphosphate 6-phosphotransferase inhibitor ATP:1D-myo-inositol-1,4,5-trisphosphate 6-phosphotransferase inhibitors ArgRIII inhibitor ArgRIII inhibitors AtIpk2alpha inhibitor AtIpk2alpha inhibitors AtIpk2beta inhibitor AtIpk2beta inhibitors EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitors EC 2.7.1.151 inhibitor EC 2.7.1.151 inhibitors IP3/IP4 6-/3-kinase inhibitor IP3/IP4 6-/3-kinase inhibitors IP3/IP4 dual-specificity 6-/3-kinase inhibitor IP3/IP4 dual-specificity 6-/3-kinase inhibitors IpK2 inhibitor IpK2 inhibitors IpmK inhibitor IpmK inhibitors inositol polyphosphate 6-/3-/5-kinase inhibitor inositol polyphosphate 6-/3-/5-kinase inhibitors inositol-polyphosphate multikinase (EC 2.7.1.151) inhibitor inositol-polyphosphate multikinase (EC 2.7.1.151) inhibitors inositol-polyphosphate multikinase inhibitor inositol-polyphosphate multikinase inhibitors EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor CHEBI:84803 EC 2.7.4.* (phosphotransferases with a phosphate group as acceptor) inhibitor EC 2.7.4.* (phosphotransferases with a phosphate group as acceptor) inhibitors EC 2.7.4.* inhibitor EC 2.7.4.* inhibitors phosphotransferases with a phosphate group as acceptor (EC 2.7.4.*) inhibitor phosphotransferases with a phosphate group as acceptor (EC 2.7.4.*) inhibitors EC 2.7.4.* (phosphotransferases with a phosphate group as acceptor) inhibitor CHEBI:84804 EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor ATP:nucleoside-diphosphate phosphotransferase inhibitor ATP:nucleoside-diphosphate phosphotransferase inhibitors EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitors EC 2.7.4.6 inhibitor EC 2.7.4.6 inhibitors UDP kinase inhibitor UDP kinase inhibitors nucleoside 5'-diphosphate kinase inhibitor nucleoside 5'-diphosphate kinase inhibitors nucleoside diphosphate (UDP) kinase inhibitor nucleoside diphosphate (UDP) kinase inhibitors nucleoside diphosphokinase inhibitor nucleoside diphosphokinase inhibitors nucleoside-diphosphate kinase (EC 2.7.4.6) inhibitor nucleoside-diphosphate kinase (EC 2.7.4.6) inhibitors nucleoside-diphosphate kinase inhibitor nucleoside-diphosphate kinase inhibitors nucleotide phosphate kinase inhibitor nucleotide phosphate kinase inhibitors uridine diphosphate kinase inhibitor uridine diphosphate kinase inhibitors EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor CHEBI:85011 EC 2.6.1.16 (glutamine--fructose-6-phosphate transaminase (isomerizing)) inhibitor D-fructose-6-phosphate amidotransferase inhibitor D-fructose-6-phosphate amidotransferase inhibitors EC 2.6.1.16 (glutamine--fructose-6-phosphate transaminase (isomerizing)) inhibitors EC 2.6.1.16 inhibitor EC 2.6.1.16 inhibitors GlcN6P synthase inhibitor GlcN6P synthase inhibitors L-glutamine-D-fructose-6-phosphate amidotransferase inhibitor L-glutamine-D-fructose-6-phosphate amidotransferase inhibitors L-glutamine:D-fructose-6-phosphate isomerase (deaminating) inhibitor L-glutamine:D-fructose-6-phosphate isomerase (deaminating) inhibitors glucosamine 6-phosphate synthase inhibitor glucosamine 6-phosphate synthase inhibitors glucosamine-6-phosphate isomerase (glutamine-forming) inhibitor glucosamine-6-phosphate isomerase (glutamine-forming) inhibitors glucosamine-6-phosphate synthase inhibitor glucosamine-6-phosphate synthase inhibitors glucosaminephosphate isomerase inhibitor glucosaminephosphate isomerase inhibitors hexosephosphate aminotransferase inhibitor hexosephosphate aminotransferase inhibitors EC 2.6.1.16 (glutamine--fructose-6-phosphate transaminase (isomerizing)) inhibitor CHEBI:85012 thrombopoietin receptor agonist TPO receptor agonist TPO receptor agonists thrombopoietin receptor agonists thrombopoietin receptor agonist CHEBI:85046 skin lightening agent melanogenesis inhibitor melanogenesis inhibitors skin bleaching agent skin bleaching agents skin depigmenting agent skin depigmenting agents skin lightening agents skin whitening agent skin whitening agents skin lightening agent CHEBI:85048 EC 1.10.3.* (oxidoreductase acting on diphenols and related substances as donors with oxygen as acceptor) inhibitor EC 1.10.3.* (oxidoreductase acting on diphenols and related substances as donors with oxygen as acceptor) inhibitors EC 1.10.3.* inhibitor EC 1.10.3.* inhibitors EC 1.10.3.* (oxidoreductase acting on diphenols and related substances as donors with oxygen as acceptor) inhibitor CHEBI:85049 EC 1.10.3.1 (catechol oxidase) inhibitor 1,2-benzenediol:oxygen oxidoreductase inhibitor 1,2-benzenediol:oxygen oxidoreductase inhibitors Dopa oxidase inhibitor Dopa oxidase inhibitors EC 1.10.3.1 (catechol oxidase) inhibitors EC 1.10.3.1 inhibitor EC 1.10.3.1 inhibitors catechol oxidase (EC 1.10.3.1) inhibitor catechol oxidase (EC 1.10.3.1) inhibitors catechol oxidase inhibitor catechol oxidase inhibitors catecholase inhibitor catecholase inhibitors diphenol oxidase inhibitor diphenol oxidase inhibitors o-diphenol oxidoreductase inhibitor o-diphenol oxidoreductase inhibitors o-diphenol:oxygen oxidoreductase inhibitor o-diphenol:oxygen oxidoreductase inhibitors o-diphenolase inhibitor o-diphenolase inhibitors phenolase inhibitor phenolase inhibitors polyphenol oxidase inhibitor polyphenol oxidase inhibitors pyrocatechol oxidase inhibitor pyrocatechol oxidase inhibitors tyrosinase inhibitor tyrosinase inhibitors EC 1.10.3.1 (catechol oxidase) inhibitor CHEBI:85050 EC 1.10.3.2 (laccase) inhibitor EC 1.10.3.2 (laccase) inhibitors EC 1.10.3.2 inhibitor EC 1.10.3.2 inhibitors benzenediol:oxygen oxidoreductase inhibitor benzenediol:oxygen oxidoreductase inhibitors laccase (EC 1.10.3.2) inhibitor laccase (EC 1.10.3.2) inhibitors laccase inhibitor laccase inhibitors p-diphenol oxidase inhibitor p-diphenol oxidase inhibitors urishiol oxidase inhibitor urishiol oxidase inhibitors urushiol oxidase inhibitor urushiol oxidase inhibitors EC 1.10.3.2 (laccase) inhibitor CHEBI:85051 EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitors EC 1.13.11.24 inhibitor EC 1.13.11.24 inhibitors flavonol 2,4-oxygenase inhibitor flavonol 2,4-oxygenase inhibitors quercetin 2,3-dioxygenase (EC 1.13.11.24) inhibitor quercetin 2,3-dioxygenase (EC 1.13.11.24) inhibitors quercetin 2,3-dioxygenase inhibitor quercetin 2,3-dioxygenase inhibitors quercetin:oxygen 2,3-oxidoreductase (decyclising) inhibitor quercetin:oxygen 2,3-oxidoreductase (decyclising) inhibitors quercetin:oxygen 2,3-oxidoreductase (decyclizing) inhibitor quercetin:oxygen 2,3-oxidoreductase (decyclizing) inhibitors quercetin:oxygen 2,3-oxidoreductase (ring-opening) inhibitor quercetin:oxygen 2,3-oxidoreductase (ring-opening) inhibitors quercetinase inhibitor quercetinase inhibitors EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor CHEBI:85052 EC 1.4.3.3 (D-amino-acid oxidase) inhibitor D-amino-acid oxidase (EC 1.4.3.3) inhibitor D-amino-acid oxidase (EC 1.4.3.3) inhibitors D-amino-acid oxidase inhibitor D-amino-acid oxidase inhibitors D-amino-acid:oxygen oxidoreductase (deaminating) inhibitor D-amino-acid:oxygen oxidoreductase (deaminating) inhibitors EC 1.4.3.3 (D-amino-acid oxidase) inhibitors EC 1.4.3.3 inhibitor EC 1.4.3.3 inhibitors L-amino acid:O2 oxidoreductase inhibitor L-amino acid:O2 oxidoreductase inhibitors new yellow enzyme inhibitor new yellow enzyme inhibitors ophio-amino-acid oxidase inhibitor ophio-amino-acid oxidase inhibitors EC 1.4.3.3 (D-amino-acid oxidase) inhibitor CHEBI:85053 EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} activator 3-hydroxy-3-methylglutaryl coenzyme A reductase kinase activator 3-hydroxy-3-methylglutaryl coenzyme A reductase kinase activators 3-hydroxy-3-methylglutaryl-CoA reductase kinase activator 3-hydroxy-3-methylglutaryl-CoA reductase kinase activators AMP-activated protein kinase activator AMP-activated protein kinase activators AMPK activator AMPK activators ATP:[hydroxymethylglutaryl-CoA reductase (NADPH)] phosphotransferase activator ATP:[hydroxymethylglutaryl-CoA reductase (NADPH)] phosphotransferase activators EC 2.7.11.31 ([hydroxymethylglutaryl-CoA reductase (NADPH)] kinase) activator EC 2.7.11.31 ([hydroxymethylglutaryl-CoA reductase (NADPH)] kinase) activators EC 2.7.11.31 activator EC 2.7.11.31 activators EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} activators HMG-CoA reductase kinase activator HMG-CoA reductase kinase activators STK29 activator STK29 activators [hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activator [hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activators [hydroxymethylglutaryl-CoA reductase (NADPH2)] kinase activator [hydroxymethylglutaryl-CoA reductase (NADPH2)] kinase activators beta-hydroxy-beta-methylglutaryl-CoA reductase kinase activator beta-hydroxy-beta-methylglutaryl-CoA reductase kinase activators hydroxymethylglutaryl coenzyme A reductase kinase (phosphorylating) activator hydroxymethylglutaryl coenzyme A reductase kinase (phosphorylating) activators hydroxymethylglutaryl coenzyme A reductase kinase activator hydroxymethylglutaryl coenzyme A reductase kinase activators hydroxymethylglutaryl-CoA reductase kinase activator hydroxymethylglutaryl-CoA reductase kinase activators reductase kinase activator reductase kinase activators EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} activator CHEBI:85094 EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor ATP:protein phosphotransferase (cAMP-dependent) inhibitor ATP:protein phosphotransferase (cAMP-dependent) inhibitors EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitors EC 2.7.11.11 inhibitor EC 2.7.11.11 inhibitors PKA C inhibitor PKA C inhibitors PKA inhibitor PKA inhibitors STK22 inhibitor inhibitor STK22 inhibitors inhibitors cAMP-dependent protein kinase (EC 2.7.11.11) inhibitor cAMP-dependent protein kinase (EC 2.7.11.11) inhibitors cAMP-dependent protein kinase inhibitor cAMP-dependent protein kinase inhibitors protein kinase A inhibitor protein kinase A inhibitors EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor CHEBI:85113 EC 2.7.11.12 (cGMP-dependent protein kinase) inhibitor 3':5'-cyclic GMP-dependent protein kinase inhibitor 3':5'-cyclic GMP-dependent protein kinase inhibitors ATP:protein phosphotransferase (cGMP-dependent) inhibitor ATP:protein phosphotransferase (cGMP-dependent) inhibitors EC 2.7.11.12 (cGMP-dependent protein kinase) inhibitors EC 2.7.11.12 inhibitor EC 2.7.11.12 inhibitors PKG 1alpha inhibitor PKG 1alpha inhibitors PKG 1beta inhibitor PKG 1beta inhibitors PKG II inhibitor PKG II inhibitors PKG inhibitor PKG inhibitors STK23 inhibitor STK23 inhibitors cGMP-dependent protein kinase (EC 2.7.11.12) inhibitor cGMP-dependent protein kinase (EC 2.7.11.12) inhibitors cGMP-dependent protein kinase Ibeta inhibitor cGMP-dependent protein kinase Ibeta inhibitors cGMP-dependent protein kinase inhibitor cGMP-dependent protein kinase inhibitors guanosine 3':5'-cyclic monophosphate-dependent protein kinase inhibitor guanosine 3':5'-cyclic monophosphate-dependent protein kinase inhibitors EC 2.7.11.12 (cGMP-dependent protein kinase) inhibitor CHEBI:85180 nonnucleoside hepatitis C virus polymerase inhibitor NS5B inhibitor NS5B inhibitors nonnucleoside hepatitis C virus polymerase inhibitors nonstructural protein 5B inhibitor nonstructural protein 5B inhibitors nonnucleoside hepatitis C virus polymerase inhibitor CHEBI:85185 hepatitis C virus nonstructural protein 5A inhibitor NS5A inhibitor NS5A inhibitors hepatitis C virus nonstructural protein 5A inhibitors nonstructural protein 5A inhibitor nonstructural protein 5A inhibitors hepatitis C virus nonstructural protein 5A inhibitor CHEBI:85234 human blood serum metabolite human blood serum metabolites human blood serum metabolite CHEBI:85384 GABA reuptake inhibitor GABA re-uptake inhibitor GABA re-uptake inhibitors GABA reuptake inhibitors gamma-aminobutyric acid re-uptake inhibitor gamma-aminobutyric acid re-uptake inhibitors gamma-aminobutyric acid reuptake inhibitor gamma-aminobutyric acid reuptake inhibitors GABA reuptake inhibitor CHEBI:85424 glycine transporter 2 inhibitor GlyT2 inhibitor GlyT2 inhibitors glycine transporter 2 inhibitors glycine transporter 2 inhibitor CHEBI:85425 glycine transporter inhibitor glycine transporter inhibitors glycine transporter inhibitor CHEBI:85540 thromboxane A2 antagonist TXA2/PGH2 antagonist TXA2/PGH2 antagonists TXA2/PGH2 receptor antagonist TXA2/PGH2 receptor antagonists thromboxane A2 antagonists thromboxane A2 receptor antagonist thromboxane A2 receptor antagonists thromboxane A2 antagonist CHEBI:85618 EC 2.5.1.31 {ditrans,polycis-undecaprenyl-diphosphate synthase [(2E,6E)-farnesyl-diphosphate specific]} inhibitor (2E,6E)-farnesyl-diphosphate:isopentenyl-diphosphate cistransferase (adding 8 isopentenyl units) inhibitor (2E,6E)-farnesyl-diphosphate:isopentenyl-diphosphate cistransferase (adding 8 isopentenyl units) inhibitors EC 2.5.1.31 inhibitor EC 2.5.1.31 inhibitors EC 2.5.1.31 {ditrans,polycis-undecaprenyl-diphosphate synthase [(2E,6E)-farnesyl-diphosphate specific]} inhibitors UPP synthetase inhibitor UPP synthetase inhibitors bactoprenyl-diphosphate synthase inhibitor bactoprenyl-diphosphate synthase inhibitors ditrans,polycis-undecaprenyl-diphosphate synthase inhibitor ditrans,polycis-undecaprenyl-diphosphate synthase inhibitors ditrans,polycis-undecaprenylcistransferase inhibitor ditrans,polycis-undecaprenylcistransferase inhibitors undecaprenyl diphosphate synthetase inhibitor undecaprenyl diphosphate synthetase inhibitors undecaprenyl pyrophosphate synthase inhibitor undecaprenyl pyrophosphate synthase inhibitors undecaprenyl pyrophosphate synthetase inhibitor undecaprenyl pyrophosphate synthetase inhibitors undecaprenyl-diphosphate synthase inhibitor undecaprenyl-diphosphate synthase inhibitors EC 2.5.1.31 {ditrans,polycis-undecaprenyl-diphosphate synthase [(2E,6E)-farnesyl-diphosphate specific]} inhibitor CHEBI:86009 EC 1.4.1.* (oxidoreductase acting on donor CH-NH2 group; NAD(+) or NADP(+) as acceptor) inhibitor EC 1.4.1.* (oxidoreductase acting on donor CH-NH2 group with NAD(+) or NADP(+) as acceptor) inhibitor EC 1.4.1.* (oxidoreductase acting on donor CH-NH2 group with NAD(+) or NADP(+) as acceptor) inhibitors EC 1.4.1.* (oxidoreductase acting on donor CH-NH2 group; NAD(+) or NADP(+) as acceptor) inhibitors EC 1.4.1.* inhibitor EC 1.4.1.* inhibitors EC 1.4.1.* (oxidoreductase acting on donor CH-NH2 group; NAD(+) or NADP(+) as acceptor) inhibitor CHEBI:86010 EC 1.4.1.3 {glutamate dehydrogenase [NAD(P)(+)]} inhibitor EC 1.4.1.3 inhibitor EC 1.4.1.3 inhibitors EC 1.4.1.3 {glutamate dehydrogenase [NAD(P)(+)]} inhibitors L-glutamate:NAD(P)(+) oxidoreductase (deaminating) inhibitor L-glutamate:NAD(P)(+) oxidoreductase (deaminating) inhibitors glutamate dehydrogenase [NAD(P)(+)] (EC 1.4.1.3) inhibitor glutamate dehydrogenase [NAD(P)(+)] (EC 1.4.1.3) inhibitors glutamate dehydrogenase [NAD(P)(+)] inhibitor glutamate dehydrogenase [NAD(P)(+)] inhibitors glutamic dehydrogenase inhibitor glutamic dehydrogenase inhibitors EC 1.4.1.3 {glutamate dehydrogenase [NAD(P)(+)]} inhibitor CHEBI:86029 liver X receptor agonist LXR agonist LXR agonists liver X receptor agonists liver X receptor agonist CHEBI:86264 rat metabolite Rattus norvegicus metabolite Rattus norvegicus metabolites rat metabolites rat metabolite CHEBI:86327 antifungal drug anti-fungal drug anti-fungal drugs anti-fungal medication anti-fungal medications antifungal drugs antifungal medication antifungal medications pharmaceutical fungicide pharmaceutical fungicides antifungal drug CHEBI:86328 antifungal agrochemical agrichemical fungicide agrichemical fungicides agrochemical fungicide agrochemical fungicides anti-fungal agrichemical anti-fungal agrichemicals anti-fungal agrochemical anti-fungal agrochemicals antifungal agrichemical antifungal agrichemicals antifungal agrochemicals antifungal agrochemical CHEBI:86383 EC 5.3.3.* (intramolecular oxidase transposing C=C bonds) inhibitor EC 5.3.3.* (intramolecular oxidase transposing C=C bonds) inhibitors EC 5.3.3.* inhibitor EC 5.3.3.* inhibitors intramolecular oxidase transposing C=C bonds inhibitor (EC 5.3.3.*) inhibitor intramolecular oxidase transposing C=C bonds inhibitor (EC 5.3.3.*) inhibitors EC 5.3.3.* (intramolecular oxidase transposing C=C bonds) inhibitor CHEBI:86385 EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor Delta(7)-cholestenol Delta(7)-Delta(8)-isomerase inhibitor Delta(7)-cholestenol Delta(7)-Delta(8)-isomerase inhibitors EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitors EC 5.3.3.5 inhibitor EC 5.3.3.5 inhibitors cholestenol Delta-isomerase (EC 5.3.3.5) inhibitor cholestenol Delta-isomerase (EC 5.3.3.5) inhibitors EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor CHEBI:86430 EC 1.14.13.78 (ent-kaurene oxidase) inhibitor EC 1.14.13.78 (ent-kaurene oxidase) inhibitors EC 1.14.13.78 inhibitor EC 1.14.13.78 inhibitors ent-kaurene oxidase (EC 1.14.13.78) inhibitor ent-kaurene oxidase (EC 1.14.13.78) inhibitors EC 1.14.13.78 (ent-kaurene oxidase) inhibitor CHEBI:86501 EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor CYP3A4 inhibitor CYP3A4 inhibitors CYP4A21 inhibitor CYP4A21 inhibitors EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitors EC 1.14.13.97 inhibitor EC 1.14.13.97 inhibitors cytochrome P450 3A4 inhibitor cytochrome P450 3A4 inhibitors taurochenodeoxycholate 6alpha-hydroxylase inhibitor taurochenodeoxycholate 6alpha-hydroxylase inhibitors taurochenodeoxycholate 6alpha-monooxygenase inhibitor taurochenodeoxycholate 6alpha-monooxygenase inhibitors taurochenodeoxycholate,NADPH:oxygen oxidoreductase (6alpha-hydroxylating) inhibitor taurochenodeoxycholate,NADPH:oxygen oxidoreductase (6alpha-hydroxylating) inhibitors EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor CHEBI:86966 EC 3.4.21.92 (endopeptidase Clp) inhibitor ATP-dependent Clp protease inhibitor ATP-dependent Clp protease inhibitors Clp protease inhibitor Clp protease inhibitors ClpP inhibitor ClpP inhibitors EC 3.4.21.92 (endopeptidase Clp) inhibitors EC 3.4.21.92 inhibitor EC 3.4.21.92 inhibitors caseinolytic protease inhibitor caseinolytic protease inhibitors endopeptidase Ti inhibitor endopeptidase Ti inhibitors protease Ti inhibitor protease Ti inhibitors EC 3.4.21.92 (endopeptidase Clp) inhibitor CHEBI:87183 STAT3 inhibitor STAT3 inhibitors signal transducer and activator of transcription 3 inhibitor signal transducer and activator of transcription 3 inhibitors STAT3 inhibitor CHEBI:87588 Smad3 inhibitor Mothers against decapentaplegic homolog 3 inhibitors Mothers against decapentaplegic homologue 3 inhibitor Mothers against decapentaplegic homologue 3 inhibitors SMAD family member 3 inhibitor SMAD family member 3 inhibitors SMAD3 inhibitors Smad3 inhibitor Smad3 inhibitors mothers against decapentaplegic homolog 3 inhibitor Smad3 inhibitor CHEBI:87786 signal transducer and activator of transcription 5 protein inhibitor STAT5 inhibitor STAT5 inhibitors signal transducer and activator of transcription 5 protein inhibitors signal transducer and activator of transcription 5 protein inhibitor CHEBI:88048 cyanotoxin cyanotoxins cyanotoxin CHEBI:88188 drug allergen allergenic drug drug allergen CHEBI:88227 potassium ionophore potassium ionophores potassium ionophore CHEBI:88230 autophagy inhibitor autophagocytosis inhibitor autophagocytosis inhibitors autophagy inhibitors autophagy inhibitor CHEBI:88285 EC 2.7.12.* [dual-specificity kinases (those acting on Ser/Thr and Tyr residues)] inhibitor EC 2.7.12.* [dual-specificity kinases (those acting on Ser/Thr and Tyr residues)] inhibitors EC 2.7.12.* inhibitor EC 2.7.12.* inhibitors inhibitor of dual-specificity kinases (those acting on Ser/Thr and Tyr residues) (EC 2.7.12.*) inhibitors of dual-specificity kinases (those acting on Ser/Thr and Tyr residues) (EC 2.7.12.*) EC 2.7.12.* [dual-specificity kinases (those acting on Ser/Thr and Tyr residues)] inhibitor CHEBI:88286 EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor ATP:protein phosphotransferase (MAPKKK-activated) inhibitor ATP:protein phosphotransferase (MAPKKK-activated) inhibitors EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitors EC 2.7.12.2 inhibitor EC 2.7.12.2 inhibitors MAP kinase kinase 4 inhibitor MAP kinase kinase 4 inhibitors MAP kinase kinase 7 inhibitor MAP kinase kinase 7 inhibitors MAP kinase kinase inhibitor MAP kinase kinase inhibitors MAP kinase or ERK kinase inhibitor MAP kinase or ERK kinase inhibitors MAP2K inhibitor MAP2K inhibitors MAPKK inhibitor MAPKK inhibitors MAPKK1 inhibitor MAPKK1 inhibitors MEK inhibitor MEK inhibitors MEK1 inhibitor MEK1 inhibitors MEK2 inhibitor MEK2 inhibitors MKK inhibitor MKK inhibitors MKK2 inhibitor MKK2 inhibitors MKK4 inhibitor MKK4 inhibitors MKK6 inhibitor MKK6 inhibitors MKK7 inhibitor MKK7 inhibitors STK27 inhibitor STK27 inhibitors mitogen-activated protein kinase kinase (EC 2.7.12.2) inhibitor mitogen-activated protein kinase kinase (EC 2.7.12.2) inhibitors mitogen-activated protein kinase kinase inhibitor mitogen-activated protein kinase kinase inhibitors EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor CHEBI:88295 G-protein-coupled receptor antagonist G-protein-coupled receptor antagonists GPCR antagonist GPCR antagonists G-protein-coupled receptor antagonist CHEBI:88336 retinoic acid receptor gamma agonist NR1B3 agonist NR1B3 agonists RARgamma agonist RARgamma agonists nuclear receptor subfamily 1, group B, member 3 agonist nuclear receptor subfamily 1, group B, member 3 agonists retinoic acid receptor gamma agonists retinoic acid receptor gamma agonist CHEBI:88355 alpha-secretase activator alpha-secretase activators alpha-secretase activator CHEBI:90113 EC 1.1.1.170 [3beta-hydroxysteroid-4alpha-carboxylate 3-dehydrogenase (decarboxylating)] inhibitor 3beta-hydroxy-4alpha-methylcholestenecarboxylate 3-dehydrogenase (decarboxylating) inhibitor 3beta-hydroxy-4alpha-methylcholestenecarboxylate 3-dehydrogenase (decarboxylating) inhibitors 3beta-hydroxy-4beta-methylcholestenecarboxylate 3-dehydrogenase (decarboxylating) inhibitor 3beta-hydroxy-4beta-methylcholestenecarboxylate 3-dehydrogenase (decarboxylating) inhibitors 3beta-hydroxy-4beta-methylcholestenoate dehydrogenase inhibitor 3beta-hydroxy-4beta-methylcholestenoate dehydrogenase inhibitors 3beta-hydroxysteroid-4alpha-carboxylate 3-dehydrogenase (decarboxylating) (EC 1.1.1.170) inhibitor 3beta-hydroxysteroid-4alpha-carboxylate 3-dehydrogenase (decarboxylating) (EC 1.1.1.170) inhibitors 3beta-hydroxysteroid-4alpha-carboxylate 3-dehydrogenase (decarboxylating) inhibitor 3beta-hydroxysteroid-4alpha-carboxylate 3-dehydrogenase (decarboxylating) inhibitors 3beta-hydroxysteroid-4alpha-carboxylate:NAD(P)(+) 3-oxidoreductase (decarboxylating) inhibitor 3beta-hydroxysteroid-4alpha-carboxylate:NAD(P)(+) 3-oxidoreductase (decarboxylating) inhibitors EC 1.1.1.170 [3beta-hydroxysteroid-4alpha-carboxylate 3-dehydrogenase (decarboxylating)] inhibitors EC 1.1.1.170 inhibitor EC 1.1.1.170 inhibitors sterol 4alpha-carboxylic decarboxylase inhibitor sterol 4alpha-carboxylic decarboxylase inhibitors sterol-4alpha-carboxylate 3-dehydrogenase (decarboxylating) inhibitor sterol-4alpha-carboxylate 3-dehydrogenase (decarboxylating) inhibitors EC 1.1.1.170 [3beta-hydroxysteroid-4alpha-carboxylate 3-dehydrogenase (decarboxylating)] inhibitor CHEBI:90172 c-Jun N-terminal kinase inhibitor JNK inhibitor JNK inhibitors c-Jun N-terminal kinase inhibitors c-Jun N-terminal kinase inhibitor CHEBI:90190 EC 2.1.1.37 [DNA (cytosine-5-)-methyltransferase] inhibitor DNA 5-cytosine methylase inhibitor DNA 5-cytosine methylase inhibitors DNA cytosine c(5) methylase inhibitor DNA cytosine c(5) methylase inhibitors DNA cytosine methylase inhibitor DNA cytosine methylase inhibitors DNA methylase inhibitor DNA methylase inhibitors DNA methyltransferase inhibitor DNA methyltransferase inhibitors DNA transmethylase inhibitor DNA transmethylase inhibitors DNA-cytosine 5-methylase inhibitor DNA-cytosine 5-methylase inhibitors DNA-cytosine methyltransferase inhibitor DNA-cytosine methyltransferase inhibitors EC 2.1.1.37 [DNA (cytosine-5-)-methyltransferase] inhibitors EC 2.1.1.37 inhibitor EC 2.1.1.37 inhibitors EcoRI methylase inhibitor EcoRI methylase inhibitors HpaII methylase inhibitor HpaII methylase inhibitors HpaII' methylase inhibitor HpaII' methylase inhibitors M.BsuRIa inhibitor M.BsuRIa inhibitors M.BsuRIb inhibitor M.BsuRIb inhibitors S-adenosyl-L-methionine:DNA (cytosine-5-)-methyltransferase inhibitor S-adenosyl-L-methionine:DNA (cytosine-5-)-methyltransferase inhibitors Typ II DNA methylase inhibitor Typ II DNA methylase inhibitors cytosine 5-methyltransferase inhibitor cytosine 5-methyltransferase inhibitors cytosine DNA methylase inhibitors cytosine DNA methyltransferase inhibitor cytosine DNA methyltransferase inhibitors cytosine-specific DNA methyltransferase inhibitor cytosine-specific DNA methyltransferase inhibitors deoxyribonucleate methylase inhibitor deoxyribonucleate methylase inhibitors deoxyribonucleate methyltransferase inhibitor deoxyribonucleate methyltransferase inhibitors deoxyribonucleic (cytosine-5-)-methyltransferase inhibitor deoxyribonucleic (cytosine-5-)-methyltransferase inhibitors deoxyribonucleic acid (cytosine-5-)-methyltransferase inhibitor deoxyribonucleic acid (cytosine-5-)-methyltransferase inhibitors deoxyribonucleic acid methylase inhibitor deoxyribonucleic acid methylase inhibitors deoxyribonucleic acid methyltransferase inhibitor deoxyribonucleic acid methyltransferase inhibitors deoxyribonucleic acid modification methylase inhibitor deoxyribonucleic acid modification methylase inhibitors deoxyribonucleic methylase inhibitor deoxyribonucleic methylase inhibitors methylphosphotriester-DNA methyltransferase inhibitor methylphosphotriester-DNA methyltransferase inhibitors modification methylase inhibitor modification methylase inhibitors restriction-modification system inhibitor restriction-modification system inhibitors site-specific DNA-methyltransferase (cytosine-specific) inhibitor site-specific DNA-methyltransferase (cytosine-specific) inhibitors EC 2.1.1.37 [DNA (cytosine-5-)-methyltransferase] inhibitor CHEBI:90199 c-Met tyrosine kinase inhibitor MET inhibitor MET inhibitors MET proto-oncogene, receptor tyrosine kinase inhibitor MET proto-oncogene, receptor tyrosine kinase inhibitors c-Met inhibitor c-Met inhibitors c-Met tyrosine kinase inhibitors c-Met tyrosine kinase inhibitor CHEBI:90285 EC 4.1.1.23 (orotidine-5'-phosphate decarboxylase) inhibitor EC 4.1.1.23 (orotidine-5'-phosphate decarboxylase) inhibitors EC 4.1.1.23 inhibitor EC 4.1.1.23 inhibitors ODCase inhibitor ODCase inhibitors OMP decarboxylase inhibitor OMP decarboxylase inhibitors OMP-DC inhibitor OMP-DC inhibitors OMPdcase inhibitor OMPdcase inhibitors UMP synthase inhibitor UMP synthase inhibitors orotate decarboxylase inhibitor orotate decarboxylase inhibitors orotate monophosphate decarboxylase inhibitor orotate monophosphate decarboxylase inhibitors orotic decarboxylase inhibitor orotic decarboxylase inhibitors orotidine 5'-phosphate decarboxylase inhibitor orotidine 5'-phosphate decarboxylase inhibitors orotidine monophosphate decarboxylase inhibitor orotidine monophosphate decarboxylase inhibitors orotidine phosphate decarboxylase inhibitor orotidine phosphate decarboxylase inhibitors orotidine-5'-monophosphate decarboxylase inhibitor orotidine-5'-monophosphate decarboxylase inhibitors orotidine-5'-phosphate carboxy-lyase (UMP-forming) inhibitor orotidine-5'-phosphate carboxy-lyase (UMP-forming) inhibitors orotidine-5'-phosphate carboxy-lyase inhibitor orotidine-5'-phosphate carboxy-lyase inhibitors orotidine-5'-phosphate decarboxylase (EC 4.1.1.23) inhibitor orotidine-5'-phosphate decarboxylase (EC 4.1.1.23) inhibitors orotidylic acid decarboxylase inhibitor orotidylic acid decarboxylase inhibitors orotidylic decarboxylase inhibitor orotidylic decarboxylase inhibitors orotodylate decarboxylase inhibitor orotodylate decarboxylase inhibitors uridine 5'-monophosphate synthase inhibitor uridine 5'-monophosphate synthase inhibitors EC 4.1.1.23 (orotidine-5'-phosphate decarboxylase) inhibitor CHEBI:90318 EC 6.4.1.1 (pyruvate carboxylase) inhibitor EC 6.4.1.1 (pyruvate carboxylase) inhibitors EC 6.4.1.1 inhibitor EC 6.4.1.1 inhibitors pyruvate carboxylase (EC 6.4.1.1) inhibitor pyruvate carboxylase (EC 6.4.1.1) inhibitors pyruvate carboxylase inhibitor pyruvate carboxylase inhibitors pyruvate:carbon-dioxide ligase (ADP-forming) inhibitor pyruvate:carbon-dioxide ligase (ADP-forming) inhibitors pyruvic carboxylase inhibitor pyruvic carboxylase inhibitors EC 6.4.1.1 (pyruvate carboxylase) inhibitor CHEBI:90365 EC 4.6.1.1 (adenylate cyclase) inhibitor 3',5'-cyclic AMP synthetase inhibitor 3',5'-cyclic AMP synthetase inhibitors ATP diphosphate-lyase (cyclising) inhibitor ATP diphosphate-lyase (cyclising) inhibitors ATP diphosphate-lyase (cyclising; 3',5'-cyclic-AMP-forming) inhibitor ATP diphosphate-lyase (cyclising; 3',5'-cyclic-AMP-forming) inhibitors ATP diphosphate-lyase (cyclizing) inhibitor ATP diphosphate-lyase (cyclizing) inhibitors ATP diphosphate-lyase (cyclizing; 3',5'-cyclic-AMP-forming) inhibitor ATP diphosphate-lyase (cyclizing; 3',5'-cyclic-AMP-forming) inhibitors ATP pyrophosphate-lyase inhibitor ATP pyrophosphate-lyase inhibitors EC 4.6.1.1 (adenylate cyclase) inhibitors EC 4.6.1.1 inhibitor EC 4.6.1.1 inhibitors adenyl cyclase inhibitor adenylate cyclase (EC 4.6.1.1) inhibitor adenylate cyclase (EC 4.6.1.1) inhibitors adenylate cyclase inhibitor adenylate cyclase inhibitors adenylyl cyclase inhibitor adenylyl cyclase inhibitors adenylylcyclase inhibitor adenylylcyclase inhibitors EC 4.6.1.1 (adenylate cyclase) inhibitor CHEBI:90374 histone acetyltransferase activator HAT activator HAT activators histone acetyltransferase activators histone acetyltransferase activator CHEBI:90375 Sir1 inhibitor SIRT1 inhibitor SIRT1 inhibitors Sir1 inhibitors sirtuin 1 inhibitor sirtuin 1 inhibitors Sir1 inhibitor CHEBI:90414 secretagogue secretagogues secretagogue CHEBI:90415 insulin secretagogue insulin secretagogues insulin secretagogue CHEBI:90689 EC 5.3.1.* (intramolecular oxidoreductase interconverting aldoses and ketoses) inhibitor EC 5.3.1.* (intramolecular oxidoreductase interconverting aldoses and ketoses) inhibitor CHEBI:90691 EC 5.3.1.1 (triose-phosphate isomerase) inhibitor D-glyceraldehyde-3-phosphate ketol-isomerase inhibitor D-glyceraldehyde-3-phosphate ketol-isomerase inhibitors EC 5.3.1.1 (triose-phosphate isomerase) inhibitors EC 5.3.1.1 inhibitor EC 5.3.1.1 inhibitors phosphotriose isomerase inhibitor phosphotriose isomerase inhibitors triose phosphate mutase inhibitor triose phosphate mutase inhibitors triose phosphoisomerase inhibitor triose phosphoisomerase inhibitors triose-phosphate isomerase (EC 5.3.1.1) inhibitor triose-phosphate isomerase (EC 5.3.1.1) inhibitors triose-phosphate isomerase inhibitor triose-phosphate isomerase inhibitors triosephosphate isomerase inhibitor triosephosphate isomerase inhibitors triosephosphate mutase inhibitor triosephosphate mutase inhibitors EC 5.3.1.1 (triose-phosphate isomerase) inhibitor CHEBI:90708 retinoic acid receptor modulator retinoic acid receptor modulators retinoic acid receptor modulator CHEBI:90709 nuclear receptor modulator nuclear receptor modulators nuclear receptor modulator CHEBI:90710 receptor modulator receptor modulators receptor modulator CHEBI:90713 retinoic acid receptor alpha antagonist RAR alpha antagonist RAR alpha antagonists RARalpha antagonist RARalpha antagonists retinoic acid receptor alpha antagonists retinoic acid receptor alpha antagonist CHEBI:90714 retinoic acid receptor antagonist RAR antagonist RAR antagonists retinoic acid receptor antagonists retinoic acid receptor antagonist CHEBI:90742 retinoic acid receptor beta agonist RAR beta agonist RAR beta agonists RARbeta agonist RARbeta agonists retinoic acid receptor beta agonists retinoic acid receptor beta agonist CHEBI:90744 retinoic acid receptor gamma antagonist RAR gamma antagonist RAR gamma antagonists RARgamma antagonist RARgamma antagonists retinoic acid receptor gamma antagonists retinoic acid receptor gamma antagonist CHEBI:90749 antidote to cyanide poisoning antidote to cyanide poisoning CHEBI:90753 antidote to organophosphate poisoning antidote to acetylcholinesterase inhibitor poisoning antidote to nerve agents antidote to organophosphate poisoning CHEBI:90755 antidote to opioid poisoning antidote to opioid overdose antidote to opioid poisoning CHEBI:90757 antidote to benzodiazepine poisoning antidote to benzodiazepine overdose antidote to benzodiazepine poisoning CHEBI:90767 eukaryotic translation elongation factor 1alpha 1 inhibitor EEF1A1 inhibitor EEF1A1 inhibitors eEF1A inhibitor eEF1A inhibitors eukaryotic translation elongation factor 1alpha 1 inhibitors eukaryotic translation elongation factor 1alpha 1 inhibitor CHEBI:90780 AKT1 kinase inhibitor AKT1 kinase inhibitors RAC-alpha serine/threonine-protein kinase inhibitor RAC-alpha serine/threonine-protein kinase inhibitors AKT1 kinase inhibitor CHEBI:90845 prostacyclin receptor agonist IP receptor agonist IP receptor agonists IP1 agonist IP1 agonists prostacyclin receptor I2 agonist prostacyclin receptor I2 agonists prostacyclin receptor agonists prostacyclin receptor agonist CHEBI:90846 liver X receptor inverse agonist LXR inverse agonist LXR inverse agonists liver X receptor inverse agonists liver X receptor inverse agonist CHEBI:90847 inverse agonist inverse agonists inverse agonist CHEBI:90878 EC 2.4.2.4 (thymidine phosphorylase) inhibitor EC 2.4.2.4 (thymidine phosphorylase) inhibitors EC 2.4.2.4 inhibitor EC 2.4.2.4 inhibitors deoxythymidine phosphorylase inhibitor deoxythymidine phosphorylase inhibitors pyrimidine deoxynucleoside phosphorylase inhibitor pyrimidine deoxynucleoside phosphorylase inhibitors pyrimidine phosphorylase inhibitor pyrimidine phosphorylase inhibitors thymidine phosphorylase inhibitor thymidine phosphorylase inhibitors thymidine-orthophosphate deoxyribosyltransferase inhibitor thymidine-orthophosphate deoxyribosyltransferase inhibitors thymidine:phosphate deoxy-D-ribosyltransferase inhibitor thymidine:phosphate deoxy-D-ribosyltransferase inhibitors thymidine:phosphate deoxy-alpha-D-ribosyltransferase inhibitor thymidine:phosphate deoxy-alpha-D-ribosyltransferase inhibitors EC 2.4.2.4 (thymidine phosphorylase) inhibitor CHEBI:90920 EC 1.8.5.* (oxidoreductase acting on sulfur group donors, quinone or similar as acceptor) inhibitor EC 1.8.5.* (oxidoreductase acting on sulfur group donors, quinone or similar as acceptor) inhibitors EC 1.8.5.* inhibitor EC 1.8.5.* inhibitors oxidoreductase acting on sulfur group donors, quinone or similar as acceptor (EC 1.8.5.*) inhibitor oxidoreductase acting on sulfur group donors, quinone or similar as acceptor (EC 1.8.5.*) inhibitors EC 1.8.5.* (oxidoreductase acting on sulfur group donors, quinone or similar as acceptor) inhibitor CHEBI:90921 EC 1.8.5.4 (sulfide:quinone reductase) inhibitor EC 1.8.5.4 (sulfide:quinone reductase) inhibitors EC 1.8.5.4 inhibitor EC 1.8.5.4 inhibitors sulfide:quinone oxidoreductase inhibitor sulfide:quinone oxidoreductase inhibitors sulfide:quinone reductase (EC 1.8.5.4) inhibitor sulfide:quinone reductase (EC 1.8.5.4) inhibitors sulfide:quinone reductase inhibitor sulfide:quinone reductase inhibitors EC 1.8.5.4 (sulfide:quinone reductase) inhibitor CHEBI:90961 ERK dimerisation inhibitor ERK dimerisation inhibitors extracellular signal-regulated kinase dimerisation inhibitor extracellular signal-regulated kinase dimerisation inhibitors ERK dimerisation inhibitor CHEBI:90991 steroid receptor coactivator stimulator SRC stimulator SRC stimulators steroid receptor coactivator small molecule stimulator steroid receptor coactivator small molecule stimulators steroid receptor coactivator stimulators steroid receptor coactivator stimulator CHEBI:91015 corrosion inhibitor corrosion inhibitors corrosion inhibitor CHEBI:91016 GABAA receptor agonist GABAA receptor agonists GABAA receptor agonist CHEBI:91025 erythropoietin inhibitor EPO inhibitor EPO inhibitors erythropoietin inhibitors erythropoietin inhibitor CHEBI:91079 purinergic receptor P2 antagonist P2 antagonist P2 antagonists non-selective P2 purinergic antagonist non-selective P2 purinergic antagonists purinergic receptor P2 antagonists purinergic receptor P2 antagonist CHEBI:91081 purinergic receptor P2X antagonist P2X antagonist P2X antagonists purinergic receptor P2X antagonists purinergic receptor P2X antagonist CHEBI:91085 collagen cross-linking inhibitor collagen cross-linking inhibitors collagen cross-linking inhibitor CHEBI:91092 EC 2.7.11.26 (tau-protein kinase) inhibitor ATP:[tau-protein] O-phosphotransferase inhibitor ATP:[tau-protein] O-phosphotransferase inhibitors ATP:tau-protein O-phosphotransferase inhibitor ATP:tau-protein O-phosphotransferase inhibitors CDK5/p23 inhibitor CDK5/p23 inhibitors EC 2.7.11.26 (tau-protein kinase) inhibitors EC 2.7.11.26 inhibitor EC 2.7.11.26 inhibitors GSK inhibitor GSK inhibitors GSK-3 inhibitor GSK-3 inhibitors STK31 inhibitor STK31 inhibitors TPK I inhibitor TPK I inhibitors TPK II inhibitor TPK II inhibitors TPK inhibitor TPK inhibitors TTK inhibitor TTK inhibitors [tau-protein] kinase inhibitor [tau-protein] kinase inhibitors brain protein kinase PK40erk inhibitor brain protein kinase PK40erk inhibitors cdk5/p20 inhibitor cdk5/p20 inhibitors glycogen synthase kinase-3beta inhibitor glycogen synthase kinase-3beta inhibitors protein tau kinase inhibitor protein tau kinase inhibitors tau kinase inhibitor tau kinase inhibitors tau-protein kinase I inhibitor tau-protein kinase I inhibitors tau-protein kinase II inhibitor tau-protein kinase II inhibitors tau-tubulin inhibitor tau-tubulin inhibitors EC 2.7.11.26 (tau-protein kinase) inhibitor CHEBI:91139 elastin-laminin receptor agonist ELR agonist ELR agonists elastin-laminin receptor agonists elastin-laminin receptor agonist CHEBI:91141 EC 1.1.5.3 (glycerol-3-phosphate dehydrogenase) inhibitor EC 1.1.5.3 (glycerol-3-phosphate dehydrogenase) inhibitors EC 1.1.5.3 inhibitor EC 1.1.5.3 inhibitors glycerol-3-phosphate dehydrogenase inhibitor glycerol-3-phosphate dehydrogenase inhibitors EC 1.1.5.3 (glycerol-3-phosphate dehydrogenase) inhibitor CHEBI:91142 EC 1.1.5.* (oxidoreductase acting on donor CH-OH group, quinone or similar compound as acceptor) inhibitor EC 1.1.5.* (oxidoreductase acting on donor CH-OH group, quinone or simliar compound as acceptor) inhibitors EC 1.1.5.* inhibitor EC 1.1.5.* inhibitors oxidoreductase acting on donor CH-OH group, quinone or simliar compound as acceptor (EC 1.1.5.*) inhibitor oxidoreductase acting on donor CH-OH group, quinone or simliar compound as acceptor (EC 1.1.5.*) inhibitors EC 1.1.5.* (oxidoreductase acting on donor CH-OH group, quinone or similar compound as acceptor) inhibitor CHEBI:91189 VEGF activator VEGF activators VEGF inducer VEGF inducers vascular endothelial growth factor activator vascular endothelial growth factor activators vascular endothelial growth factor inducer vascular endothelial growth factor inducers VEGF activator CHEBI:91193 lysophosphatidic acid receptor antagonist LPA receptor antagonist LPA receptor antagonists LPAR antagonist LPAR antagonists lysophosphatidic acid receptor antagonists lysophosphatidic acid receptor antagonist CHEBI:91202 TGFbeta receptor antagonist TGFR antagonist TGFR antagonists TGFbeta receptor antagonists transforming growth factor receptor antagonist transforming growth factor receptor antagonists TGFbeta receptor antagonist CHEBI:91214 macrophage migration inhibitory factor inhibitor MIF inhibitor MIF inhibitors macrophage migration inhibitory factor inhibitors macrophage migration inhibitory factor inhibitor CHEBI:9590 tienilic acid (2,3-Dichloro-4-(2-thenoyl)phenoxy)acetic acid (2,3-Dichloro-4-(2-thiophenecarbonyl)phenoxy)acetic acid 4-(2-Theonyl)-2,3-dichlorphenoxyessigsaeure 4-(2-Thienylketo)-2,3-dichlorophenoxyacetic acid Thienylic acid Ticrynafen [2,3-dichloro-4-(2-thienylcarbonyl)phenoxy]acetic acid acide tienilique acido tienilico acidum tienilicum tienilic acid tienilic acid CLO:0000001 cell line cell A cultured cell that is part of a cell line - a stable and homogeneous population of cells with a common biological origin and propagation history in culture A cultured cell that is part of a cell line - a stable and homogeneous population of cells with a common biological origin and propagation history in culture Yongqun He, Matthew Brush, Sirarat Sarntivijai, Alexander Diehl, Jie Zheng, Yu Lin, Bjoern Peters A 'cell line cell' is a part of a cell line established through the passaging/selection of a primary cultured cells or the experimental modification of an existing cell line. New types of cell line cells are established after sufficient passaging of a primary culture to establish a stable and homogenous population that qualifies as a line (typically 1-20 passages), or following some spontaneous or experimental modification that confers novel characteristics to an existing line. A cell line cell typically has mutations of five or more genes compared to the original cell that derives the cell line cell. Some gene mutations may turn on some oncogenes. Cell line cells can be in active culture, stored in a quiescent state for future use (e.g. frozen in liquid nitrogen), or applied in experimental procedures. cell line cell CLO:0000019 immortal cell line cell A cell line cell that is expected to be capable of an unlimited number of divisions, and is thus able to support indefinite propagation in vitro as part of an immortal cell line. Yongqun He, Matthew Brush, Allen Xiang, Asiyah Yu Lin, Sirarat Sarntivijai, James Malone, Jie Zheng, Tomasz Adamusiak continuous cell line cell permanent cell line cell immortal cell line cell CLO:0000031 cell line He, Tong-Chuan, et al., Identification of c-MYC as a target of the APC pathway. Science 281.5382 (1998): 1509-1512.: "To evaluate the transcriptional effects of APC, we studied a human colorectal cancer cell line (HT29-APC) containing a zinc-inducible APC gene and a control cell line (HT29–β-Gal) containing an analogous inducible lacZ gene". Note that common usage in the literature is often of the form "a human colorectal cancer cell line", as seen above. But such references to studies in "a line" refer to the fact that discrete populations of cells that are input into culturing or experiments, not an entire lineage of cells. It is these discrete populations that we refer to as 'cell lines'. A cultured cell population that represents a genetically stable and homogenous population of cultured cells that shares a common propagation history (i.e. has been successively passaged together in culture). A cultured cell population that represents a genetically stable and homogenous population of cultured cells that shares a common propagation history (i.e. has been successively passaged together in culture). In the spring of 2013, a working group comprised of domain experts and representatives from CLO, OBI, CL, and ReO worked to establish a consensus model and definitions of cultured cells across these efforts. This included a careful characterization of how the term 'cell line' should be defined and applied. Notes about this work and its outcomes can be found on the CLO wiki here: http://code.google.com/p/clo-ontology/wiki/Cell_Lines MB, SS, JZ, MAH, BP, CS, YH The term 'line' is used when a culture has undergone an intentional experimental process to establish a more uniform and stable population of cells (see 'establishing cell line'). This will require one or more passages, but may involve additional selection processes. Through such passaging and/or selection processes, the resulting 'line' attains some level of genetic stability and compositional homogeneity which is typically absent in primary cultures. Because of their relative homogeneity, ‘lines’ are capable of being characterized and stably propagated over a period of time. A new *type* of cell line can be established not only through the passaging/selection of a primary culture, but also through experimental modifications of existing lines (e.g. immortalization, stable genetic modifications, drug selection for a resistant subset, etc.). The definition provided here establishes the 'scale' of cell populations that qualify as cell lines - specifically those with a shared propagation history in culture. In this way, the 'cell line' class demarcates populations that represent what researchers actually use in the practice of science - e.g. as inputs to culturing, experimentation, and sharing. The definition is such that cell lines will exhibit important attributes. For example, they will have a relatively homogenous cell type composition as they have experienced similar selective pressures due to their continuous co-propagation. In addition, these populations can also be characterized by a passage number, again owing to their common passaging history.  As defined here, 'cell line' can refer to a population of cells in active culture, applied experimentally, or stored in a quiescent state for future use. cell line CLO:0001008 LCL-1042 697 697 cell CHEMBL: CHEMBL3308147 CVCL: CVCL_0079 HyperCLDB: cl117 Sanger: COSMIC ID:906800 CLO:0001230 293 293 HEK 293 cell HEK 293 HEK-293 Human Embryonic Kidney 293 WEB: http://hek293.com/ WEB: http://web.expasy.org/cellosaurus/CVCL_0045 WEB: https://www.atcc.org/Products/All/CRL-1573.aspx HEK293 ATCC: CRL-1573 BTO: BTO_0000007 EFO: EFO_0001182) RRID: CVCL_0045 CLO:0001235 293T/17 WEB: https://www.atcc.org/Products/All/CRL-11268.aspx 293T/17 cell ATCC: CRL-11268 CLO:0001601 LCL-1601 A549 A549 cell ATCC: CCL-185 CHEMBL: CHEMBL3307651 CVCL: CVCL_0023 EFO: EFO_0001086 HyperCLDB: cl207 CLO:0001654 LCL-1756 ACHN ACHN cell ATCC: CRL-1611 CHEMBL: CHEMBL3307633 CVCL: CVCL_1067 EFO: EFO_0002108 CLO:0001716 AML12 AML12 cell ATCC: CRL-2254 CLO:0001842 BA/F3 BA/F3 cell HyperCLDB: cl5028 CLO:0002044 LCL-1310 BT-549 disease: ductal carcinoma BT-549 cell ATCC: HTB-122 CHEMBL: CHEMBL3308490 CVCL: CVCL_1092 EFO: EFO_0001096 CLO:0002115 LCL-1300 C-33 A C-33 A cell ATCC: HTB-31 CLO:0002172 LCL-1170 Caco-2 disease: colorectal adenocarcinoma Caco-2 cell ATCC: HTB-37 CHEMBL: CHEMBL3307519 CVCL: CVCL_0025 EFO: EFO_0001099 HyperCLDB: cl618 MeSH: D018938 CLO:0002175 CAKI-1 CAKI-1 cell HyperCLDB: cl623 CLO:0002176 LCL-1774 Caki-1 disease: clear cell carcinoma (kidney primary) Caki-1 cell ATCC: HTB-46 CHEMBL: CHEMBL3307522 CVCL: CVCL_0234 EFO: EFO_0002149 CLO:0002191 LCL-1580 ZN Calu-1 disease: epidermoid carcinoma (lung primary) Calu-1 cell ATCC: HTB-54 CHEMBL: CHEMBL3308031 CVCL: CVCL_0608 EFO: EFO_0002151 HyperCLDB: cl631 HyperCLDB: cl632 CLO:0002334 LCL-1012 CCRF-CEM CCRF-CEM cell ATCC: CCL-119 CHEMBL: CHEMBL3307641 CVCL: CVCL_0207 EFO: EFO_0002128 CLO:0002420 CHL-1 CHL-1 cell ATCC: CRL-9446 CLO:0002421 CHO Chinese Hamster Ovary cell CHO cell HyperCLDB: cl721 MeSH: D016466 CLO:0002462 CHO-K1 CHO-K1 cell ATCC: CCL-61 CLO:0002544 LCL-1173 COLO 205 disease: colorectal adenocarcinoma (colon primary) COLO 205 cell ATCC: CCL-222 CHEMBL: CHEMBL3308348 CVCL: CVCL_0218 ECACC: 87061208 EFO: EFO_0003082 CLO:0002597 COS-7 COS-7 cell ATCC: CRL-1651 MeSH: D019556 CLO:0002785 LCL-1175 DLD-1 disease: colorectal adenocarcinoma DLD-1 cell ATCC: CCL-221 CHEMBL: CHEMBL3307580 CVCL: CVCL_0248 CLO:0002840 LCL-1146 DU 145 disease: carcinoma (prostate primary) DU 145 cell ATCC: HTB-81 CLO:0003603 H-4-II-E disease: hepatoma H-4-II-E cell ATCC: CRL-1548 CLO:0003610 H69AR disease: carcinoma; small cell lung cancer; multidrug resistant H69AR cell ATCC: CRL-11351 CLO:0003665 LCL-1161 immortal human epithelial cell line cell that was derived from some colon epithelial cell from a human patient with the disease colon carcinoma HCT 116 HCT-116 HCT116 WEB: http://web.expasy.org/cellosaurus/CVCL_0291 WEB: https://www.atcc.org/products/all/CCL-247.aspx disease: colorectal carcinoma HCT 116 cell ATCC: CCL-247 ECACC: 91091005 HyperCLDB: cl1575 MeSH: D045325 RRID:CVCL_0291 CLO:0003679 LCL-1053 HEL HEL cell CHEMBL: CHEMBL3308090 CVCL: CVCL_0001 DSMZ: ACC 11 HyperCLDB: cl1585 CLO:0003684 LCL-1512 an immortal human uterine cervix-derived epithelial cell line that was derived from cervical adenocarcinoma cancer cells taken on February 8, 1951 from Henrietta Lacks, a patient who died of her cancer on October 4, 1951. HeLa WEB: http://en.wikipedia.org/wiki/HeLa WEB: http://www.atcc.org/products/all/CCL-2.aspx WEB: https://www.ncbi.nlm.nih.gov/pubmed/12001993 HeLa cell ATCC: CCL-2 CHEMBL: CHEMBL3308376 EFO: EFO_0001185 HyperCLDB: cl1601 MeSH: D006367 RRID:CVCL_0030 CLO:0003704 LCL-1925 HEP G2 HEP-G2 HEPG2 Hep G2 HepG2 WEB: http://web.expasy.org/cellosaurus/CVCL_0027 WEB: https://en.wikipedia.org/wiki/Hep_G2 WEB: https://www.atcc.org/products/all/HB-8065.aspx Hep G2 cell ATCC: HB-8065 HyperCLDB: cl1644 RRID:CVCL_0027 CLO:0003775 LCL-1054 HL-60 disease: promyeloblast; acute promyelocytic leukemia HL-60 cell ATCC: CCL-240 CHEMBL: CHEMBL3307654 CVCL: CVCL_0002 EFO: EFO_0002793 HyperCLDB: cl1684 HyperCLDB: cl1689 MeSH: D018922 CLO:0004009 LCL-1315 HS578T Hs 578T disease: ductal carcinoma Hs 578T cell ATCC: HTB-126 CLO:0004276 HT-1080 disease: fibrosarcoma HT-1080 cell ATCC: CCL-121 CLO:0004283 LCL-1180 HT-29 HT29 disease: colorectal adenocarcinoma HT-29 cell ATCC: HTB-38 CHEMBL: CHEMBL3307768 CVCL: CVCL_0320 EFO: EFO_0001193 HyperCLDB: cl1752 MeSH: D019073 CLO:0004307 HUV-EC-C HUVEC WEB: https://www.atcc.org/Products/All/CRL-1730.aspx HUV-EC-C cell ATCC: CRL-1730 CLO:0004342 IEC-6 disease: epithelium IEC-6 cell ATCC: CRL-1592 HyperCLDB: cl1802 CLO:0007043 an immortalized human T lymphocyte cell that was derived in the late 1970s from the peripheral blood of a 14-year-old boy with T cell leukemia JURKAT WEB: https://en.wikipedia.org/wiki/Jurkat_cells disease: leukemia, T cell JURKAT cell HyperCLDB: cl5296 MeSH: D019169 RRID: CVCL_0065 CLO:0007203 L6 L6 cell ATCC: CRL-1458 CLO:0007606 LCL-1460 an immortal breast cancer cell line cell isolated in 1970 from a 69-year-old Caucasian woman. ZN MCF 7 cell MCF-7 cell MCF7 WEB: http://web.expasy.org/cellosaurus/CVCL_0031 WEB: https://en.wikipedia.org/wiki/MCF-7 disease: adenocarcinoma (mammary gland primary) MCF7 cell ATCC: HTB-22 CHEMBL: CHEMBL3308403 EFO: EFO_0002082 HyperCLDB: cl3366 HyperCLDB: cl3372 RRID: CVCL_0031 CLO:0007634 LCL-1461 an immortal breast cancer cell line cell derived from a human patient with breast adenocarcinoma ZN, YH MDA-MB-231 MDA-MB-231 cell ATCC: HTB-26 CHEMBL: CHEMBL3307960 EFO: EFO_0001209 RRID: CVCL_0062 CLO:0007646 MDCK MDCK cell HyperCLDB: cl5078 CLO:0007657 LCL-1305 ME-180 disease: epidermoid carcinoma (cervix primary) ME-180 cell ATCC: HTB-33 CHEMBL: CHEMBL3308114 CVCL: CVCL_1401 CLO:0007865 MRC-5 MRC-5 cell ATCC: CCL-171 HyperCLDB: cl3564 CLO:0007904 Mv 1 Lu Mv 1 Lu cell HyperCLDB: cl3604 HyperCLDB: cl3608 HyperCLDB: cl3609 CLO:0008172 NIH-3T3 NIH-3T3 cell ATCC: CRL-1658 HyperCLDB: cl3710 HyperCLDB: cl3711 MeSH: D041681 CLO:0009015 LCL-2000 SH-SY5Y SHSY5Y https://www.atcc.org/en/Products/Cells_and_Microorganisms/By_Tissue/Bone_Marrow/CRL-2266.aspx SH-SY5Y cell ATCC: CRL-2266 CLO:0009047 LCL-1282 A melanoma cell line cell. This cell line was established in 1974 from a metastatic site (axillary lymph node) in a 24-year-old Caucasian female with malignant melanoma, expresses mutant B-Raf (V600E) and wildtype N-Ras. SK-MEL-5 WEB: http://web.expasy.org/cellosaurus/CVCL_1706 WEB: http://www.ncbi.nlm.nih.gov/pubmed/3121170 WEB: https://strap.nci.nih.gov/celline_detail.php?sample_id=56 SK-MEL-5 cell ATCC: HTB-70 CHEMBL: CHEMBL3307744 CVCL: CVCL_0527 EFO: EFO_0002080 PubChem AID: 488899 Sanger: COSMIC ID:905956 CLO:0009059 LCL-1971 SK-N-SH SK-N-SH cell ATCC: HTB-11 CHEMBL: CHEMBL3307745 CVCL: CVCL_0531 EFO: EFO_0003072 CLO:0009215 LCL-1195 SW403 SW403 cell ATCC: CCL-230 PubChem AID: 504653 RRID: CVCL_0545 Sanger: COSMIC ID:910908 CLO:0009348 LCL-1072 THP-1 THP1 THP-1 cell ATCC: TIB-202 CHEMBL: CHEMBL3307574 CVCL: CVCL_0006 EFO: EFO_0001253 HyperCLDB: cl4514 CLO:0009454 LCL-1431 U-2 OS U2OS WEB: https://www.atcc.org/Products/All/HTB-96.aspx U-2 OS cell ATCC: HTB-96 CHEMBL: CHEMBL3307757 CVCL: CVCL_0042 EFO: EFO_0002869 CLO:0009463 U87 MG There is a CLO term for the cell line already: http://purl.obolibrary.org/obo/CLO_0009464 obsolete: U87 MG cell HyperCLDB: cl5280 CLO:0009524 Vero Vero cell ATCC: CCL-81 HyperCLDB: cl4644 MeSH: D014709 CLO:0009526 VERO 76 VERO 76 cell ATCC: CRL-1587 HyperCLDB: cl4655 CLO:0009527 VERO C1008 VERO C1008 cell ATCC: CRL-1586 HyperCLDB: cl4656 HyperCLDB: cl4657 CLO:0009905 LCL-1346 A human glioblastoma cell line cell. The cell line is part of the NCI-60 screening panel. Oliver He, Jiangan Xie SNB-75 SNB75 WEB: http://web.expasy.org/cellosaurus/CVCL_1706 WEB: http://www.ncbi.nlm.nih.gov/pubmed/3121170 WEB: https://strap.nci.nih.gov/celline_detail.php?sample_id=56 SNB75 cell PubChem AID: 652144 Sanger: COSMIC ID:905982 CLO:0037059 LCL-1134 Oliver He, Jiangan Xie SU-DHL-10 SU-DHL-10 cell DSMZ: ACC 576 CLO:0037063 LCL-1138 Oliver He, Jiangan Xie SU-DHL-6 SU-DHL-6 cell DSMZ: ACC 572 CLO:0037212 BJeLR cell is BJ fibroblast cell line cell transformed with hTERT, genomic SV40 LT and ST oncoproteins, and oncogenic HRASV12. YH, JX BJeLR PubChem probe report: http://www.ncbi.nlm.nih.gov/books/NBK98919/ PubMed: http://www.ncbi.nlm.nih.gov/pubmed/18355723 BJeLR cell PubChem AID: 2635 CLO:0037213 BJeH=BJ derivative transformed only with hTERT (BJ fibroblasts were derived from primary human cells by transformation with hTERT, genomic SV40 Large T (LT) and Ssmall T (ST)) YH, JX BJeLR PubChem probe report: http://www.ncbi.nlm.nih.gov/books/NBK98919/ PubMed: http://www.ncbi.nlm.nih.gov/pubmed/18355723 BJeH cell PUbChem AID: 493051 CLO:0037214 A human follicular lymphoms cell line Oliver He, Jiangan Xie RS11846 WEB: http://cellfinder.org/ontology?id=CELDA_00012667 RS-11846 cell PubChem AID: 743410 RRID: CVCL_E048 CLO:0037216 A derivative of the CHO cell line that is adapted to high-density, serum-free suspension culture YH, JX WEB: https://www.thermofisher.com/order/catalog/product/R80007 CHO-S cell PubChem AID: 624379 CLO:0037217 DRD=BJ fibroblasts expressing hTERT, SV40 small T oncoprotein, dominant negative p53, cyclin D1, a mutant form of CDK4, along with the oncogene HRASV12 JX, YH WEB: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683762/ DRD cell PubChem AID: 2633 CLO:0037218 HL2/3 is a derivative of HeLa cells and contains a stably integrated copies of the HIV-1 molecular clone HXB2/3gpt. JX, YH WEB: https://www.aidsreagent.org/reagentdetail.cfm?t=cell_lines&id=83 WEB: https://www.ncbi.nlm.nih.gov/pubmed/?term=2078409 HL2/3 PubChem AID: 504574 CLO:0037219 HeLa-MAGI-CCR5 cells are derived from HeLa cells and express human CD4, CXCR4 and CCR5, and an integrated gene encoding the b-galactosidase gene expressed from the HIV long terminal repeat. JX, YH WEB: http://web.expasy.org/cellosaurus/CVCL_D260 MAGI-CCR5 cells; HeLa-R5-16, engineered to express the Envelope protein (Env) from the CCR5-tropic HIV-1 clinical isolate 92US715, and also to express the Tat protein from HIV-1 NL4 3 HeLa-MAGI-CCR5 PubChem AID: 504341 RRID: CVCL_D260 CLO:0037220 HeLa-R5-16 (gift from Roche Palo Alto, LLC) is a derivative of HeLa cells, engineered to express the Envelope protein (Env) from the CCR5-tropic HIV-1 clinical isolate 92US715, and also to express the Tat protein from HIV-1 NL43 JX, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/?term=16314403 HeLa-R5-16 PubChem AID: 504341 CLO:0037221 RD-HGA16 is derivative of CHO cells stably transfected with the promiscuous G-protein Gα16 gene and hygromycin-resistant. RD-HGA16 is from FLIPR LiveWare Cells (Molecular Devices, Sunnyvale CA), a series of cells and expression vectors successfully used in drug discovery, based on G-protein chimeras developed by Bruce Conklin and colleagues at the Gladstone Institute, UCSF. YH, JX WEB: http://go.pardot.com/l/83942/2015-06-17/njr/83942/4464/Data_Sheet__FLIPR_LiveWare_G_protein_Cells_and_Plasmids.pdf RD-HGA16 PubChem AID: 624467 CLO:0037222 Sufu-KO-LIGHT cells were derived from Sufu knockout mouse embryonic fibroblasts according to the method of Chen et al. [Genes Dev. 2009;23(16): 1910-28.] The cells were co-transfected with the zeocin resistance vector (pVgRXR, Invitrogen) and a firefly luciferase reporter driven by eight Gli binding sites and a γ-crystallin basal promoter (8XGHBS-FL). Sufu-KO-LIGHT lacks Sufu and exhibits constitutive Hh target gene expression in response to endogenous Gli activators. JX, YH WEB: https://www.google.com/patents/WO2013192301A1?cl=en Sufu-KO-LIGHT cell PubChem AID: 588413 CLO:0037223 A Hela-derived cell line cell that expresses ubiquitinated GFP (Green Fluroescent Protein) JX, YH Ub-G76V-GFP/HeLa PubChem AID: 463185 CLO:0037228 602478 The GripTite™ 293 MSR Cell Line is a genetically engineered Human Embryonic Kidney (HEK 293) cell line that expresses the human macrophage scavenger receptor and strongly adheres to standard tissue culture plates for dependable results. BAO, YH GripTite™ 293 MSR https://pubchem.ncbi.nlm.nih.gov/bioassay/602478 https://www.thermofisher.com/order/catalog/product/R79507 GripTite 293 MSR cell BAO: BAO_0030043 ThermoFisher: R79507 CLO:0037243 493062 A mouse T-cell hybridoma cell line cell that is derived from the murine hybridoma cell line 2B4, stably transfected to overexpress the human protein BCL-2. BAO, YH http://www.ncbi.nlm.nih.gov/pubmed/16697956 https://www.google.com/patents/WO2007123791A2?cl=en https://www.ncbi.nlm.nih.gov/books/NBK143557 2B4/BCL-2 cell BAO: BAO_0030042 CLO:0037246 493059 A mouse T-cell hybridoma cell line cell that is derived from the murine hybridoma cell line 2B4, stably transfected to overexpress the human protein MCL-1. BAO, YH http://www.ncbi.nlm.nih.gov/pubmed/16697956 https://www.google.com/patents/WO2007123791A2?cl=en https://www.ncbi.nlm.nih.gov/books/NBK143557 2B4/MCL-1 cell BAO: BAO_0030044 CLO:0037247 463235 AVA5 cells are derived from the Huh-7 human hepatoma cell line, stably-expressing the HCV replicon (sub-genomic [CON1], genotype 1b); http://www.apath.com/index.html. See also PMID: 27013634, 1110665, 10390360 BAO, YH https://www.ncbi.nlm.nih.gov/pubmed/10390360 https://www.ncbi.nlm.nih.gov/pubmed/1110665 https://www.ncbi.nlm.nih.gov/pubmed/27013634 AVA5 cell BAO: BAO_0030045 CLO:0037249 624396 A murine leukemia cell line driven by the overexpression of Myc and BCL-2. BAO, YH http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919900/ BCL-2 1863 cell BAO: BAO_0030052 CLO:0037251 1353 An immortalised mouse neural progenitor cell line cell that is capable of differentiation in vitro and is established by retorviral-mediated transduction of the avian myc oncogene into mitotic progenitor cells of neonatal mouse cerrebellum. Mouse strain CD1 x C57BL/6. BAO, YH http://web.expasy.org/cellosaurus/CVCL_4511 http://www.sigmaaldrich.com/catalog/product/sigma/07062902 C17.2 cell BAO: BAO_0030046 CLO:0037253 651610 CEM21 (aka CEM#21 or CEM-R5Luc1#21) is derived from CEM.NKR-CCR5 by stable transfecttion of a Tet-activator responsive Luciferase reporter Oliver He CEM#21 CEM-R5Luc1#21 https://www.ncbi.nlm.nih.gov/pubmed/10516002 CEM21 cell BAO: BAO_0030049 CLO:0037254 434939 DPX2 (aka DPX-2) is a HepG2-derived cell line stably integrated with a PXR (pregnane X receptor) expression vector plus a luciferase reporter, used to detect PXR activation/ CYP3A induction BAO, YH DPX-2 http://www.ncbi.nlm.nih.gov/pubmed/15548381 http://www.ncbi.nlm.nih.gov/pubmed/22912432 DPX2 cell BAO: BAO_0030035 CLO:0037255 623928 FA2N-4 is a human hepatocyte cell line. Reference: http://web.expasy.org/cellosaurus/CVCL_0267 BAO, YH http://cellfinder.org/ontology?id=CF_194407 http://purl.bioontology.org/ontology/MCCL/MCC_0000158 http://web.expasy.org/cellosaurus/CVCL_0267 FA2N-4 cell BAO: BAO_0030036 CLO:0037256 651646 HBL-1 (aka human is an EBV-negative B-cell lymphoma cell line established from the pleural effusion of a patient with malignant lymphoma, diffuse, large cell. BAO, YH http://purl.obolibrary.org/obo/BTO_0002522 http://web.expasy.org/cellosaurus/CVCL_4213 HBL-1 cell BAO: BAO_0030037 BTO: BTO_0002522 RRID:CVCL_4213 CLO:0037257 449755 HMC-1-8 is a human breast cancer cell line BAO, YH http://portals.broadinstitute.org/ccle/cell%20lines/HMC18_BREAST http://web.expasy.org/cellosaurus/CVCL_2949 HMC-1-8 cell BAO: BAO_0030037 RRID:CVCL_2949 CLO:0037258 2717 HMLE_sh_ECAD is a stable cell line mimicking a cancer stem cell (CSC), derived by knocking down E-Cadherin (via shRNA) in human breast epithelial cells to induce epithelial to mesenchymal transition (EMT) BAO, YH http://www.ncbi.nlm.nih.gov/pubmed/19682730 http://www.ncbi.nlm.nih.gov/pubmed/22941295 HMLE_sh_ECAD cell BAO: BAO_0030038 CLO:0037259 463074 HMLE_sh_eGFP is a human breast epithelial cell line containing shRNA to GFP (green fluorescent reporter); used as an isogenic control line for HMLE_sh_ECAD BAO, YH http://www.ncbi.nlm.nih.gov/pubmed/19682730 http://www.ncbi.nlm.nih.gov/pubmed/22941295 HMLE_sh_eGFP cell BAO: BAO_0030039 CLO:0037260 588703 HMLE_sh_TWIST is a stable cell line mimicking a cancer stem cell (CSC), derived by knocking down TWIST (via shRNA) in human breast epithelial cells to induce epithelial to mesenchymal transition (EMT); isogenic with another CSC line, HMLE_sh_ECAD BAO, YH http://www.ncbi.nlm.nih.gov/pubmed/19682730 http://www.ncbi.nlm.nih.gov/pubmed/22941295 HMLE_sh_TWIST cell BAO: BAO_0030040 CLO:0037262 651570 An engineered 3T3 mouse fibroblast cell line, which expresses the firefly luciferase reporter gene under the control of Wnt-responsive promoters (TCF/LEF). http://www.enzolifesciences.com/ENZ-61001/leading-light-wnt-reporter-assay-starter-kit/ LEADING LIGHT Wnt Reporter cell line cell BAO: BAO_0030031 CLO:0037263 624396 MCL-1 1780 is a murine leukemia cell line driven by the overexpression of Myc and MCL-1. BAO, YH http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919900/ Source: Anthony Letai (Dana Farber) MCL-1 1780 cell BAO: BAO_0030053 CLO:0037264 652260 MG213 is a subline of the BRG1/BRM-deficient cell line SW13 (http://purl.obolibrary.org/obo/CLO_0009185) that contains a stably integrated glucocorticoid-responsive MMTV-luciferase reporter. BAO, YH http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615482/ MG213 cell BAO: BAO_0030048 CLO:0037265 624495 A PathHunter Beta-Arrestin GPCR cell line (DiscoverX), engineered to co-express the ProLink (PK) tagged GPCR (DRD2L, long form of human DRD2) and the Enzyme Acceptor (EA) tagged Beta-Arrestin. Activation of DRD2L-PK induces Beta-Arrestin-EA recruitment, forcing complementation of the two Beta-galactosidase enzyme fragments (EA and PK). The resulting functional enzyme hydrolyzes substrate to generate a chemiluminescent signal. BAO, YH https://www.discoverx.com/products/cell-line/cho-k1-drd2l-beta-arrestin-cell-line-93-0579c2 PathHunter CHO-K1 DRD2L Beta-Arrestin cell BAO: BAO_0030056 CLO:0037266 624500 A PathHunter Beta-Arrestin GPCR cell line (DiscoverX), engineered to co-express the ProLink (PK) tagged GPCR (human DRD3) and the Enzyme Acceptor (EA) tagged Beta-Arrestin. Activation of DRD3-PK induces Beta-Arrestin-EA recruitment, forcing complementation of the two Beta-galactosidase enzyme fragments (EA and PK). The resulting functional enzyme hydrolyzes substrate to generate a chemiluminescent signal. BAO, YH https://www.discoverx.com/products/cell-line/cho-k1-drd3-beta-arrestin-cell-line-93-0591c2 PathHunter CHO-K1 DRD3 Beta-Arrestin cell BAO: BAO_0030057 CLO:0037268 652166 RAW-Blue cells are derived from the murine RAW 264.7 macrophages with chromosomal integration of a secreted embryonic alkaline phosphatase (SEAP) reporter construct inducible by NF-κB and AP-1. BAO, YH http://web.expasy.org/cellosaurus/CVCL_X594 http://www.invivogen.com/raw-blue RAW-Blue cell BAO: BAO_0030060 RRID:CVCL_X594 CLO:0037269 624032 A rat immortilized Schwann cell line. S-16 cell http://purl.obolibrary.org/obo/BTO_0002937 http://web.expasy.org/cellosaurus/CVCL_B072 S16 cell BAO: BAO_0030061 BTO: BTO_0002937 RRID:CVCL_B072 CLO:0037270 1355 A mouse melanoma cell line (which harbors N-Ras mutation), isolated from a small amelanotic lung metastasis in a mouse with a s.c. K-1735 tumor. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3158838/ http://www.ncbi.nlm.nih.gov/pubmed/2832058/ SW1 cell BAO: BAO_0030062 CLO:0037271 485366 'Tango cell' refers to one of many stable cell lines, all based on the parental line HEK293T, designed to work in a 'Tango beta-arrestin' recruitiment assay to measure receptor activation for more than 300 GPCRs. See PMID25895059 and https://pdspdb.unc.edu/prestotango/ BAO, YH http://www.ncbi.nlm.nih.gov/pubmed/25895059 https://pdspdb.unc.edu/prestotango/ https://www.ncbi.nlm.nih.gov/pubmed/18165312 Tango cell BTO: BAO_0030063 CLO:0037272 651712 Human diffuse large B cell lymphoma cell line derived from a 62-year-old male patient BAO, YH http://web.expasy.org/cellosaurus/CVCL_A442 TMD8 cell BAO: BAO_0030064 RRID:CVCL_A442 CLO:0037276 504935 U87-EGFRvIII (aka U87/vIII) is a stable cell line derived from U87MG (a human glioblastoma) to overexpress the most common mutation of epidermal growth factor receptor (EGFR) found in human glioblastomas--an in-frame deletion of an 801-bp sequence in the extracellular domain of EGFR termed EGFRvIII. (descr. in PMID 15548697). BAO, YH U87/vIII http://www.ncbi.nlm.nih.gov/pubmed/15548697/ U87-EGFRvIII cell BAO: BAO_0030059 A disease that involving errors in metabolic processes of building or degradation of molecules. ICD10CM:E88.9 ICD9CM:277.9 MESH:D008659 NCI:C3235 SNOMEDCT_US_2020_03_01:75934005 UMLS_CUI:C0025517 metabolic disease disease_ontology DOID:0014667 disease of metabolism DOID:0014667 A viral infectious disease that results_in infection located_in joint, has_material_basis_in Chikungunya virus, which is transmitted_by Aedes mosquito bite. The infection has_symptom fever, has_symptom arthralgia, and has_symptom maculopapular rash. GARD:6038 Chikungunya fever disease_ontology DOID:0050012 chikungunya DOID:0050012 An acquired metabolic disease that is characterized by abnormal carbohydrate metabolism. disease_ontology DOID:0050013 carbohydrate metabolism disease DOID:0050013 An ehrlichiosis that results in infection located in granular leukocyte, has_material_basis_in Anaplasma phagocytophilum, which is transmitted by lone start tick (Amblyomma americanum ). The infection has symptom headache, has symptom muscle aches, has symptom fatigue, has symptom fever and has symptom rash. DOID:0050021 DOID:0050022 human granulocytic ehrlichiosis disease_ontology HGE DOID:0050025 human granulocytic anaplasmosis DOID:0050025 An ehrlichiosis that results in infection located in monocyte or located in macrophage, has_material_basis_in Ehrlichia chaffeensis, which is transmitted by black-legged tick (Ixodes scapularis), transmitted by western black-legged tick (Ixodes pacificus) or transmitted by castor bean tick (Ixodes ricinus). The infection has symptom headache, has symptom muscle aches, has symptom fatigue, has symptom fever and has symptom rash. DOID:14091 GARD:72 disease_ontology Ehrlichiosis chafeensis DOID:0050026 human monocytic ehrlichiosis DOID:0050026 An acquired metabolic disease that is characterized by abnormal mineral metabolism. disease_ontology DOID:0050032 mineral metabolism disease DOID:0050032 A spotted fever that has_material_basis_in Rickettsia africae, which is transmitted_by ticks (Amblyomma hebraeum and Amblyomma variegatum). The infection has_symptom fever, has_symptom eschar and has_symptom maculopapular rash. DOID:0050034 DOID:0050036 Rickettsia africae spotted fever south african tick-bite fever disease_ontology DOID:0050035 African tick-bite fever DOID:0050035 A spotted fever that has_material_basis_in Rickettsia heilongjiangensis, which is transmitted_by ticks (Haemaphysalis concinna). The infection has_symptom fever, has_symptom eschar, has_symptom maculopapular rash, and has_symptom regional adenopathy. Rickettsia heilongjiangensis spotted fever disease_ontology DOID:0050046 Far Eastern spotted fever DOID:0050046 A spotted fever that has_material_basis_in Rickettsia japonica, which is transmitted_by ticks (Dermacentor taiwanensis and Haemaphysalis flava). The infection has_symptom fever, has_symptom eschars, has_symptom regional adenopathy, and has_symptom rash on extremities. DOID:0050049 Rickettsia japonica spotted fever oriental spotted fever disease_ontology DOID:0050050 Japanese spotted fever DOID:0050050 A primary bacterial infectious disease that results_in infection located_in skin, has_material_basis_in Erysipelothrix rhusiopathiae, which is transmitted_by contact with infected animals. The infection has_symptom redness of skin, has_symptom tenderness of skin and has_symptom warmth of skin. MESH:D004887 disease_ontology DOID:0050061 erysipeloid DOID:0050061 A primary systemic mycosis that is a fungal infection located_in lungs, or located_in skin, which results_in disseminated granulomatous pulmonary process and cutaneous infection in rodents, small wild mammals and humans, has_material_basis_in Chrysosporium parvum or Emmonsia crescens. disease_ontology DOID:0050072 adiaspiromycosis DOID:0050072 An aspergillosis that is a serious fungal infection of the lung with pneumonia caused by Aspergillus, which spreads to other parts of the body through bloodstream in patients with acute leukemia and recipients of tissue transplants. Clinical symptoms include pulmonary nodules and hemorrhage. disease_ontology DOID:0050073 invasive aspergillosis DOID:0050073 A nutritional deficiency that is disease characterized by a cardiomyopathy secondary to selenium deficiency. GARD:8761 disease_ontology DOID:0050083 Keshan disease DOID:0050083 A disease that is the consequence of the presence of pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, and aberrant proteins known as prions. infectious disease DOID:10115 DOID:11078 DOID:1304 DOID:1321 DOID:2040 DOID:2288 DOID:3099 DOID:4120 DOID:4620 DOID:5256 DOID:945 DOID:95 DOID:9532 DOID:9696 ICD9CM:079.0 UMLS_CUI:C0001485 infectious disease disease_ontology DOID:0050117 DO:wk disease by infectious agent DOID:0050117 A viral infectious disease that results_in inflammation located_in brain, has_material_basis_in La Crosse virus, which is transmitted_by treehole mosquito, Ochlerotatus triseriatus. The infection has_symptom seizures, has_symptom headache, has_symptom fever, has_symptom coma, and has_symptom paralysis. DOID:10840 ICD10CM:A83.5 ICD9CM:062.5 MESH:D004670 SNOMEDCT_US_2020_03_01:69627004 UMLS_CUI:C0014053 California Encephalitis California virus encephalitis Neuroinvasive California encephalitis virus infection disease_ontology DOID:0050118 La Crosse encephalitis DOID:0050118 A lymphatic system disease that is characterized by an expansion of the monocyte-macrophage population and intense hemophagocytosis. It can occur de novo, but more often occurs in the setting of another disorder, usually an infection or a malignancy. A clinical picture of fever, hepatosplenomegaly, lymphadenopathy and peripheral pancytopenia. The morphologic hallmark of this syndrome is the phagocytosis of hematopoietic elements by morphologically normal macrophages. DOID:6453 GARD:6589 ICD10CM:D76.1 MESH:D051359 NCI:C34792 OMIM:PS267700 ORDO:540 SNOMEDCT_US_2020_03_01:190958003 UMLS_CUI:C0024291 haemophagocytic syndrome disease_ontology DOID:0050120 Xref MGI. MESH:C537250 added from NeuroDevNet [WAK]. hemophagocytic lymphohistiocytosis DOID:0050120 A paranasal sinus disease involving inflammation of the paranasal sinuses resulting from bacterial, fungal, viral infection, allergic or autoimmune issues. Symptoms can include fever, weakness, fatigue, cough and congestion. There may also be mucus drainage in the back of the throat, called postnasal drip. DOID:2052 DOID:9564 ICD10CM:J01 ICD9CM:461 NCI:C128411 SNOMEDCT_US_2020_03_01:195649005 UMLS_CUI:C0149512 disease_ontology DOID:0050127 sinusitis DOID:0050127 Secretory diarrhea is a diarrhea where there is an increase in the active secretion, or there is an inhibition of absorption causing little to no structural damage. The most common cause of this type of diarrhea is a cholera toxin that stimulates the secretion of anions, especially chloride ions. disease_ontology DOID:0050129 secretory diarrhea DOID:0050129 A fungal infectious disease that results_in infection of the outermost layer located_in skin or located_in hair shaft, has_material_basis_in Fungi. No living tissue is invaded and there is no cellular response from the host. DOID:13370 ICD10CM:B36.9 MESH:D010854 SNOMEDCT_US_2020_03_01:266218008 SNOMEDCT_US_2020_03_01:47382004 UMLS_CUI:C0031898 UMLS_CUI:C2980104 Steroid-modified tinea infection piedra disease_ontology DOID:0050133 Adding a UMLS CUI for piedra C2980104. superficial mycosis DOID:0050133 A fungal infectious disease that results_in infection of the keratinized layers located_in skin, located_in hair or located_in nail, which extends deeper into the epidermis, has_material_basis_in Fungi and results_in_formation_of skin lesions. disease_ontology DOID:0050134 cutaneous mycosis DOID:0050134 A fungal infectious disease that results_in infection located_in skin or located_in subcutaneous tissue, has_material_basis_in Fungi, which penetrate the dermis or even deeper during or after a skin trauma. disease_ontology DOID:0050135 subcutaneous mycosis DOID:0050135 A fungal infectious disease that results_in infection of internal organs and tissues located_in human body, has_material_basis_in Fungi, which enter the body via the respiratory tract, through the gut, paranasal sinuses or skin and spread through the bloodstream to multiple organs. disease_ontology DOID:0050136 systemic mycosis DOID:0050136 A diarrhea that is of rapid onset and course characterized by frequent loose or liquid bowel movements. Acute diarrhea is a common cause of death in developing countries and the second most common cause of infant deaths worldwide. disease_ontology DOID:0050140 acute diarrhea DOID:0050140 A botulism that involves intoxication caused by botulinum neurotoxins (BoNTA, B, E and F) in adults, has_material_basis_in Clostridium botulinum A, has_material_basis_in Clostridium botulinum B, has_material_basis_in Clostridium botulinum E and has_material_basis_in Clostridium botulinum F, which are transmitted by ingestion of bacterial spores, which then grow in the intestine and release toxins. disease_ontology DOID:0050141 intestinal botulism DOID:0050141 An upper respiratory tract disease which involves inflammation, pain, and swelling of the adenoid tissue due to the infection by bacteria and viruses. It occurs primarily in children and may be secondary to an allergy, infection of nose or throat and an obstruction of the eustachian tube. The infection has symptom pain, has symptom redness, has symptom swelling, and has symptom difficulty swallowing. DOID:13750 ICD10CM:J35.02 ICD9CM:474.01 SNOMEDCT_US_2020_03_01:195794009 UMLS_CUI:C0396023 chronic adenoiditis disease_ontology DOID:0050145 adenoiditis DOID:0050145 An otitis externa which is a disease of the ear produced by the growth of fungi in the external auditory canal. It is characterized by inflammation, pruritus, scaling and severe discomfort. The most common fungi are Aspergillus niger and Candida albicans. MESH:D059249 Singapore ear disease_ontology DOID:0050147 otomycosis DOID:0050147 An upper respiratory tract disease involving inflammation of both larynx and trachea often caused by viral infection. The infection can close off the windpipe. DOID:11795 DOID:9390 ICD10CM:J04 ICD10CM:J37.1 ICD9CM:464 ICD9CM:476.1 SNOMEDCT_US_2020_03_01:276443001 SNOMEDCT_US_2020_03_01:83271005 UMLS_CUI:C0155811 UMLS_CUI:C0155837 disease_ontology DOID:0050148 laryngotracheitis DOID:0050148 A legionellosis that involves a milder respiratory illness without pneumonia. Symptoms include fever, headache and muscle aches which last for 2 to 5 days. disease_ontology DOID:0050150 Pontiac fever DOID:0050150 A bacterial pneumonia which is an acute pulmonary inflammatory response that develops after the inhalation of colonized oropharyngeal material containing bacteria. It is seen in individuals with dysphagia and gastric dysmotility. The disease has_symptom tachypnea and has_symptom cough. ICD10CM:J69.0 MESH:D011015 SNOMEDCT_US_2020_03_01:47839005 UMLS_CUI:C0032290 disease_ontology DOID:0050152 aspiration pneumonia DOID:0050152 An aspergillosis that presents as a clump of tangled mass of Aspergillus fungus fibres, blood clots, and white blood cells, which exists in the cavities of the lungs that develop in an area of previous lung disease or lung scarring. disease_ontology DOID:0050153 pulmonary aspergilloma DOID:0050153 A nervous system disease which is located in a part of the nervous system responsible for processing sensory information that consists of sensory receptors, neural pathways, and parts of the brain involved in sensory perception. Commonly recognized sensory systems are those for vision, hearing, somatic sensation (touch), taste and olfaction (smell). disease_ontology DOID:0050155 sensory system disease DOID:0050155 A pulmonary fibrosis that is characterized by scarring of the lung. EFO:0000768 GARD:8609 ICD10CM:J84.112 ICD9CM:516.31 MESH:D054990 NCI:C35716 OMIM:178500 SNOMEDCT_US_2020_03_01:28168000 UMLS_CUI:C1800706 FIBROCYSTIC PULMONARY DYSPLASIA IDIOPATHIC PULMONARY FIBROSIS, FAMILIAL cryptogenic fibrosing alveolitis disease_ontology DOID:0050156 OMIM mapping confirmed by DO. [SN]. idiopathic pulmonary fibrosis DOID:0050156 An idiopathic interstitial pneumonia characterized by lung inflammation and scarring that obstructs the small airways and air sacs of the lungs (alveoli). A flu-like illness, with a cough, fever, a feeling of illness (malaise), fatigue, and weight loss, heralds the onset in about 50% of people. Frequent presence of crackling sounds (called Velcro crackles) when the doctor listens with a stethoscope. DOID:2798 GARD:1620 ICD10CM:J84.116 ICD9CM:516.36 MESH:D018549 NCI:C62586 SNOMEDCT_US_2020_03_01:129458007 UMLS_CUI:C0242770 BOOP Cryptogenic organising pneumonitis Cryptogenic organizing pneumonitis bronchiolitis obliterans organising pneumonia bronchiolitis obliterans organizing pneumonia cryptogenic organising pneumonia idiopathic bronchiolitis obliterans with organising pneumonia idiopathic bronchiolitis obliterans with organizing pneumonia disease_ontology DOID:0050157 cryptogenic organizing pneumonia DOID:0050157 An anthrax disease that results in infection located in lung lymph nodes brought on by breathing in the spores of the bacteria Bacillus anthracis. The first symptoms of inhalation anthrax are like cold or flu symptoms and can include a sore throat, mild fever and muscle aches. Later symptoms include cough, chest discomfort, shortness of breath, tiredness and muscle aches. pulmonary anthrax respiratory anthrax wool-sorters' disease woolsorters' disease disease_ontology DOID:0050160 inhalation anthrax DOID:0050160 A respiratory system disease which involves the lower respiratory tract. ICD9CM:478.19 SNOMEDCT_US_2020_03_01:195823002 UMLS_CUI:C0029581 disease_ontology DOID:0050161 lower respiratory tract disease DOID:0050161 An autoimmune polyendocrine syndrome that is inherited in an autosomal recessive fashion, which is characterized by abnormal functioning of the immune system that causes auto-reactivity against endocrine organs. GARD:8466 OMIM:240300 Autoimmune Polyglandular Syndrome I Whitaker syndrome autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy disease_ontology DOID:0050167 autoimmune polyendocrine syndrome type 1 DOID:0050167 An autoimmune polyendocrine syndrome that is characterized by abnormal functioning of the immune system that causes auto-reactivity against endocrine organs. It is more heterogeneous and has not been linked to one gene. GARD:7611 OMIM:269200 Schmidt syndrome disease_ontology DOID:0050168 autoimmune polyendocrine syndrome type 2 DOID:0050168 A lupus erythematosus that causes skin lesions on parts of the body that are exposed to sunlight. GARD:6225 disease_ontology DOID:0050169 cutaneous lupus erythematosus DOID:0050169 A viral infectious disease that results_in inflammation located_in brain, has_material_basis_in Tick-borne encephalitis virus, which is transmitted_by Ixodes ticks. The infection has_symptom drowsiness, has_symptom confusion, has_symptom sensory disturbances, and has_symptom paralysis. DOID:0050176 DOID:10251 DOID:10252 GARD:5216 ICD10CM:A84.1 ICD9CM:063.2 MESH:D004675 SNOMEDCT_US_2020_03_01:16901001 UMLS_CUI:C0014054 Central European encephalitis Far Eastern TBE Russian spring-summer encephalitis Siberian tick-borne encephalitis Taiga encephalitis Western European tick-borne encephalitis west-Siberian encephalitis disease_ontology DOID:0050175 tick-borne encephalitis DOID:0050175 A genetic disease that is the result of one or more abnormal alleles and may be dominant, semi-dominant, or recessive. disease_ontology DOID:0050177 monogenic disease DOID:0050177 A skin disease that is a type of allergic reaction located_in skin, which occurs in response to medications, infections, or illness. GARD:6372 MESH:D004892 disease_ontology DOID:0050185 erythema multiforme DOID:0050185 A viral infectious disease that is a hemorrhagic fever, has_material_basis_in Junin virus, which is transmitted_by rodent, Calomys musculinus. The infection has_symptom fever, has_symptom fatigue, has_symptom malaise, has_symptom leukopenia, has_symptom thrombocytopenia, and has_symptom hemorrhagic manifestations. disease_ontology DOID:0050194 Argentine hemorrhagic fever DOID:0050194 A viral infectious disease that is a hemorrhagic fever, has_material_basis_in Guanarito virus, which is transmitted_by cotton rat, Sigmodon alstoni and transmitted_by cane mouse, Zygodontomys brevicauda. The infection has_symptom fever, has_symptom headache, has_symptom myalgia, has_symptom sore throat, has_symptom weakness, has_symptom anorexia, has_symptom nausea, has_symptom vomiting, has_symptom convulsions, has_symptom epistaxis, has_symptom bleeding gums, has_symptom hematemesis, has_symptom melena, and has_symptom menorrhagia. disease_ontology DOID:0050196 Venezuelan hemorrhagic fever DOID:0050196 A hemorrhagic fever with renal syndrome that results_in infection located_in kidney, has_material_basis_in Hantaan virus, which is transmitted_by the eurasian field mouse, Apodemus agrarius, or has_material_basis_in Seoul virus, which is transmitted_by norwegian rat, Rattus norvegicus. The infection has_symptom headache, has_symptom back pain, has_symptom abdominal pain, has_symptom fever, has_symptom chills, has_symptom nausea, has_symptom blurred vision, has_symptom flushing of the face, has_symptom redness of the eyes, has_symptom rash, has_symptom low blood pressure, has_symptom acute shock, has_symptom vascular leakage, and has_symptom acute kidney failure, which can cause severe fluid overload. disease_ontology DOID:0050200 Korean hemorrhagic fever DOID:0050200 A neuromuscular junction disease that is characterized by an abnormality of acetylcholine (ACh) release at the neuromuscular junction which results from an autoimmune attack against voltage-gated calcium channels (VGCC) on the presynaptic motor nerve terminal. ICD10CM:G70.80 ICD9CM:358.3 MESH:D015624 NCI:C3155 SNOMEDCT_US_2020_03_01:230688006 UMLS_CUI:C0022972 Eaton-Lambert syndrome LEMS Lambert-Eaton syndrome disease_ontology DOID:0050214 Lambert-Eaton myasthenic syndrome DOID:0050214 A parasitic protozoa infectious disease that involves infection of the central nervous system caused by Naegleria fowleri. The symptoms include headache, nausea, rigidity of the neck muscles, vomiting, delirium, seizures and coma. GARD:9554 Naegleria fowleri infection disease_ontology DOID:0050242 primary amebic meningoencephalitis DOID:0050242 A parasitic protozoa infectious disease that results in infection of the brain caused by Acanthamoeba or Balamuthia mandrillaris. The symptoms include headaches, altered mental status, and focal neurologic deficit, which progresses over several weeks to death. GARD:12651 Acanthamoeba encephalitis Acanthamoeba granulomatous encephalitis Granulomatous Amebic Encephalitis due to Acanthamoeba granulomatous amoebic encephalitis disease_ontology DOID:0050246 granulomatous amebic encephalitis DOID:0050246 A parasitic helminthiasis infectious disease that involves parasitic infection of the intestine, central nervous system and eyes by Angiostrongylus cantonensis or Angiostrongylus costaricensis. GARD:683 disease_ontology DOID:0050256 angiostrongyliasis DOID:0050256 A parasitic ectoparasitic infectious disease that is an inflammatory skin disease caused by the parasitic infestation of the female chigoe flea, Tunga penetrans in animals and humans. The symptoms include skin inflammation, severe pain, itching, and a lesion at the site of infection that is characterized by a black dot at the center of a swollen red lesion, surrounded a white halo. GARD:393 MESH:D058285 disease_ontology DOID:0050266 tungiasis DOID:0050266 A myiasis that involves parasitic infestation of Oestrus ovis larvae in the eye causing severe irritation, edema, and pain. disease_ontology DOID:0050268 ophthalmomyiasis DOID:0050268 An subcutaneous mycosis that is a chronic inflammatory or granulomatous fungal infection caused by Conidiobolus species, which is restricted to the nasal submucosa and characterized by polyps or palpable restricted subcutaneous masses. Symptoms include nasal obstruction, drainage and sinus pain. Subcutaneous nodules develop in the nasal and perinasal regions. disease_ontology DOID:0050279 conidiobolomycosis DOID:0050279 An opportunistic mycosis that involves localized or hematogenously disseminated fungal infection by Fusarium solani or Fusarium oxysporum. Skin lesions are seen in neutropenic patients, and indolent cellulitis or soft-tissue necrosis occur in immunocompromised patients at the site of trauma. MESH:D060585 disease_ontology DOID:0050289 fusariosis DOID:0050289 An opportunistic mycosis that results_in disseminated infection, has_material_basis_in Trichosporon and results_in_formation_of nontender erythematous nodules anywhere on the body. MESH:D060586 disease_ontology DOID:0050290 trichosporonosis DOID:0050290 A systemic mycosis that results_in infection located_in human body, has_material_basis_in Fungi, which can overcome the physiological and cellular defences of the normal human host. The primary deep pathogens usually gain access to the host via the respiratory tract. disease_ontology DOID:0050292 primary systemic mycosis DOID:0050292 A refractive error that is characterized by the significant difference in perceived sizes of an object between the two eyes. MESH:D000839 disease_ontology DOID:0050304 aniseikonia DOID:0050304 A hypothyroidism that is present at birth. DOID:11631 DOID:11632 GARD:1487 ICD10CM:E00.1 ICD10CM:E03.1 ICD9CM:243 MESH:D003409 NCI:C26734 NCI:C98921 OMIM:PS275200 SNOMEDCT_US_2020_03_01:217710005 SNOMEDCT_US_2020_03_01:75065003 UMLS_CUI:C0010308 UMLS_CUI:C0342200 disease_ontology DOID:0050328 Xref MGI. OMIM mapping confirmed by DO. [SN]. congenital hypothyroidism DOID:0050328 A syndrome that is characterized by autosomal dominant inheritance of abnormalities affecting the lacrimal and salivary glands and ducts, ears, teeth and fingers and toes. OMIM:149730 LEVY-HOLLISTER SYNDROME lacrimoauriculodentodigital syndrome disease_ontology DOID:0050331 OMIM mapping confirmed by DO. [SN]. LADD syndrome DOID:0050331 A vestibular disease that is characterized by progressive hearing loss resulting from congenital enlargement of the vestibular aqueducts. GARD:8651 disease_ontology DOID:0050332 OMIM mapping confirmed by DO. [SN]. enlarged vestibular aqueduct DOID:0050332 A phosphorus metabolism disease that is characterized by hypophosphatemia and the symptoms of osteomalacia including bone pain, skeletal deformities and osteoarthritis. MESH:D017674 disease_ontology DOID:0050336 hypophosphatemia DOID:0050336 A bacterial infectious disease that results_in infection by bacteria as a result of their presence or activity within the normal, healthy host, and their intrinsic virulence is, in part, a necessary consequence of their need to reproduce and spread. disease_ontology DOID:0050338 primary bacterial infectious disease DOID:0050338 A bacterial infectious disease that results_in infection by bacteria which are part of the normal human flora when one or more of the defense mechanisms designed to restrict them from the usually sterile internal tissues are breached by accident, by intent (surgery), or by an underlying metabolic or an infectious disorder. disease_ontology DOID:0050339 commensal bacterial infectious disease DOID:0050339 A bacterial infectious disease that results_in infection by bacteria in individuals whose host defense mechanisms have been compromised. disease_ontology DOID:0050340 opportunistic bacterial infectious disease DOID:0050340 A botulism that involves intoxication caused by botulinum neurotoxins (BoNTA, B, E and F), which are transmitted by ingestion of food contaminated with preformed toxins, has_material_basis_in Clostridium botulinum A, has_material_basis_in Clostridium botulinum B, has_material_basis_in Clostridium botulinum E and has_material_basis_in Clostridium botulinum F. The infection has symptom blurred vision, has symptom diplopia, has symptom dysarthria, has symptom dysphonia, has symptom dysphagia and has symptom descending muscle paralysis. disease_ontology DOID:0050352 foodborne botulism DOID:0050352 A botulism that involves intoxication caused by botulinum neurotoxins (BoNTA, B, E and F), has_material_basis_in Clostridium botulinum A, has_material_basis_in Clostridium botulinum B, has_material_basis_in Clostridium botulinum E and has_material_basis_in Clostridium botulinum F, which are transmitted by contact of spores with the open wounds, which then reproduce in an anaerobic environment to produce toxins. disease_ontology DOID:0050353 wound botulism DOID:0050353 A botulism that involves intoxication caused by botulinum neurotoxins (BoNTA or B) in infants, has_material_basis_in Clostridium botulinum A or has_material_basis_in Clostridium botulinum B, which are transmitted_by ingestion of bacterial spores, which then grow in the intestine and release toxins. The infection has_symptom constipation, has_symptom lethargy, has_symptom difficulty feeding, has_symptom swallowing, has_symptom ptosis, has_symptom loss of head control, and has_symptom muscle weakness. disease_ontology DOID:0050354 infant botulism DOID:0050354 A bartonellosis that results_in infection located_in endothelial cells or located_in red blood cells, has_material_basis_in Bartonella bacilliformis, which is transmitted_by sandflies of genus Lutzomyia. The infection has acute and chronic phases. The acute phase is characterized by severe hemolytic anemia and transient immunosuppression. The chronic phase is characterized by verruga peruana lesions which may ulcerate and bleed. Carrion disease Oroya fever disease_ontology DOID:0050398 Carrion's disease DOID:0050398 An intestinal disease that has_material_basis_in mutations in the APC gene and involves formation of numerous polyps in the epithelium of the large intestine which are initially benign and later transform into colon cancer. GARD:6408 MESH:D011125 NCI:C3339 OMIM:PS175100 ORDO:733 SNOMEDCT_US_2020_03_01:72900001 UMLS_CUI:C0032580 adenomatous polyposis of the colon disease_ontology DOID:0050424 OMIM mapping confirmed by DO. [SN]. familial adenomatous polyposis DOID:0050424 A skin disease that is characterized by ulceration of less than 10 percent of the surface area of the body. The disease is often precipitated by the use of medications, such as antibiotics or antiepileptics, or onset of infection. EFO:0004276 GARD:7700 ICD10CM:L51.1 ICD9CM:695.13 NCI:C79484 NCI:C79777 SNOMEDCT_US_2020_03_01:73442001 UMLS_CUI:C0038325 disease_ontology DOID:0050426 Stevens-Johnson syndrome MESH:D013262 DOID:0050426 A syndrome that is characterized by a deficiency in the ability to repair ultraviolet damage that has_material_basis_in autosomal recessive inheritance of DNA repair. GARD:7910 ICD10CM:Q82.1 MESH:D014983 NCI:C3452 ORDO:910 SNOMEDCT_US_2020_03_01:44600005 UMLS_CUI:C0043346 disease_ontology DOID:0050427 OMIM mapping confirmed by DO. [SN]. xeroderma pigmentosum DOID:0050427 A palmoplantar keratosis characterized by a well-demarcated, symmetric keratoderma located_in palms and located_in soles. MESH:D015776 NCI:C3147 OMIM:600962 OMIM:613000 OMIM:615735 ORDO:2337 SNOMEDCT_US_2020_03_01:81206005 UMLS_CUI:C0022584 UMLS_CUI:C3489771 Thost-Unna Syndrome Unna-Thost Syndrome diffuse nonepidermolytic palmomplantar keratoderma tylosis disease_ontology DOID:0050428 Xref MGI. OMIM mapping confirmed by DO. [SN]. nonepidermolytic palmoplantar keratoderma DOID:0050428 A pemphigus that is characterized by recurring blistering most commonly occurring in the folds of the skin and has_material_basis_in mutations in the ATP2C1 gene that result in loss of adhesion within the skin. GARD:6559 ICD10CM:Q82.8 MESH:D016506 NCI:C82865 OMIM:169600 SNOMEDCT_US_2020_03_01:79468000 UMLS_CUI:C0085106 BENIGN CHRONIC PEMPHIGUS Pemphigus, Benign Familial disease_ontology DOID:0050429 OMIM mapping confirmed by DO. [SN]. Hailey-Hailey disease DOID:0050429 A multiple endocrine neoplasia characterized by medullary carcinoma of the thyroid, pheochromocytoma, hyperparathyroidism, and occasionally cutaneous lichen amyloidosis. ICD10CM:E31.22 ICD9CM:258.02 MESH:D018813 NCI:C3226 OMIM:171400 ORDO:247698 SNOMEDCT_US_2020_03_01:721188000 UMLS_CUI:C0025268 MEN2A Sipple syndrome multiple endocrine neoplasia II disease_ontology DOID:0050430 OMIM mapping confirmed by DO. [SN]. multiple endocrine neoplasia type 2A DOID:0050430 An intrinsic cardiomyopathy that is characterized by hypokinetic areas involving the free wall of the right ventricle, with fibrofatty replacement of the right ventricular myocardium, with associated arrhythmias originating in the right ventricle. MESH:D019571 NCI:C84571 OMIM:PS107970 ORDO:217656 ORDO:247 SNOMEDCT_US_2020_03_01:281170005 UMLS_CUI:C0349788 ARVC ARVC cardiomyopathy ARVD arrhythmogenic right ventricular dysplasia arrhythmogenic right ventricular dysplasia/cardiomyopathy disease_ontology DOID:0050431 Xref MGI. OMIM mapping confirmed by DO. [SN]. arrhythmogenic right ventricular cardiomyopathy DOID:0050431 An autism spectrum disorder that is characterized by significant difficulties in social interaction, along with restricted and repetitive patterns of behavior and interests. It differs from other autism spectrum disorders by its relative preservation of linguistic and cognitive development. GARD:5855 ICD10CM:F84.5 MESH:D020817 NCI:C97159 OMIM:608631 OMIM:608638 OMIM:608781 OMIM:609954 ORDO:1162 SNOMEDCT_US_2020_03_01:154879004 UMLS_CUI:C0236792 disease_ontology DOID:0050432 Xref MGI. OMIM mapping confirmed by DO. [SN]. Asperger syndrome DOID:0050432 A prion disease that is characterized by insomnia, hallucinations, dementia and death, located_in the brain. GARD:6429 ICD10CM:A81.83 ICD9CM:046.72 MESH:D034062 NCI:C84711 OMIM:600072 SNOMEDCT_US_2020_03_01:83157008 UMLS_CUI:C0206042 disease_ontology DOID:0050433 OMIM mapping confirmed by DO. [SN]. fatal familial insomnia DOID:0050433 A syndrome that is characterized by global growth retardation of the muscle, liver, brain and eyes as well as constrictive pericarditis and has_material_basis_in mutations in the TRIM37 gene. GARD:95 MESH:D050336 NCI:C84906 OMIM:253250 ORDO:2576 SNOMEDCT_US_2020_03_01:81604003 UMLS_CUI:C0524582 MUL Mulibrey growth disorder Muscle-Liver-Brain-Eye Nanism PERICARDIAL CONSTRICTION AND GROWTH FAILURE Perheentupa Syndrome disease_ontology DOID:0050436 OMIM mapping confirmed by DO. [SN]. mulibrey nanism DOID:0050436 A lysosomal storage disease that is characterized by cardiomyopathy, skeletal myopathy and intellectual disability and has_material_basis_in mutations in the LAMP2 gene. GARD:9730 MESH:D052120 NCI:C84735 OMIM:300257 SNOMEDCT_US_2020_03_01:419097006 UMLS_CUI:C0878677 ANTOPOL DISEASE PSEUDOGLYCOGENOSIS II disease_ontology DOID:0050437 OMIM mapping confirmed by DO. [SN]. Danon disease DOID:0050437 A syndrome that is characterized by gonadal dysgenesis, streak gonads, progressive focal segmental glomerulonephropathy and the development of urogenital cancers that is the result of mutation in the WT1 gene. GARD:2375 MESH:D052159 NCI:C122805 OMIM:136680 SNOMEDCT_US_2020_03_01:445431000 UMLS_CUI:C0950122 disease_ontology DOID:0050438 OMIM mapping confirmed by DO. [SN]. Frasier syndrome DOID:0050438 A syndrome characterized by a combination of hearing loss and visual impairment. GARD:7843 MESH:D052245 NCI:C85217 OMIM:PS276900 ORDO:886 SNOMEDCT_US_2020_03_01:57838006 UMLS_CUI:C0271097 disease_ontology DOID:0050439 Xref MGI. OMIM mapping confirmed by DO. [LS]. Usher syndrome DOID:0050439 A sphingolipidosis that is characterized by leukodystrophy, ichthyosis, skeletal abnormalities and shortened life expectancy and has_material_basis_in mutation in the SUMF1 gene that results in deficiency in multiple sulfatase enzymes. ICD10CM:E75.26 MESH:D052517 NCI:C84908 OMIM:272200 SNOMEDCT_US_2020_03_01:254076009 SNOMEDCT_US_2020_03_01:54898003 UMLS_CUI:C0268263 UMLS_CUI:C1720864 Sulfatidosis, Juvenile, Austin Type multiple sulfatase deficiency disease disease_ontology DOID:0050441 OMIM mapping confirmed by DO. [SN]. mucosulfatidosis DOID:0050441 A peroxisomal disease that is characterized by neurological impairment, intellectual disability, hepatosplenomegaly and ichthyosis and results from the accumulation of very long chain fatty acids and phytanic acid, secondary to mutation in the PEX genes. ICD10CM:G60.1 MESH:D052919 NCI:C84789 OMIM:266510 SNOMEDCT_US_2020_03_01:238062008 UMLS_CUI:C0282527 infantile phytanic acid storage disease disease_ontology DOID:0050444 OMIM mapping confirmed by DO. [SN]. infantile Refsum disease DOID:0050444 A rickets has_material_basis in X-linked mutations in the PHEX gene that lead to increased circulating levels of FGF-23, a phosphate-regulating hormone (phosphatonin), that leads to reduced renal phosphate reabsorption and consequently abnormal bone mineralization. MESH:D053098 NCI:C123265 NCI:C85234 OMIM:307800 UMLS_CUI:C0733682 UMLS_CUI:C1845168 UMLS_CUI:C3540852 Hypophosphatemia, Vitamin D-Resistant Rickets Vitamin D-Resistant Rickets, X-Linked X-linked hypophosphatemia hypophosphatemic rickets X-linked dominant disease_ontology DOID:0050445 OMIM mapping confirmed by DO. [SN]. X-linked dominant hypophosphatemic rickets DOID:0050445 A skin disease characterized by a defect in the normal process of keratinization of the mucosa. MESH:D053529 NCI:C84760 OMIM:193900 OMIM:615785 ORDO:171723 SNOMEDCT_US_2020_03_01:85388002 UMLS_CUI:C1721005 white sponge nevus white sponge nevus of Cannon disease_ontology DOID:0050448 Xref MGI. OMIM mapping confirmed by DO. [SN]. hereditary mucosal leukokeratosis DOID:0050448 A syndrome that is characterized by hypertrophic nails and hyperkeratosis of the hands and feet and has_material_basis in gene mutations that result in changes in keratin. GARD:10753 MESH:D053549 NCI:C84986 OMIM:PS167200 ORDO:2309 SNOMEDCT_US_2020_03_01:39427000 UMLS_CUI:C0265334 UMLS_CUI:C1706595 UMLS_CUI:C1721007 Jackson-Lawler Type Pachyonychia Congenita Jadassohn-Lewandowsky Syndrome PACHYONYCHIA CONGENITA, JADASSOHN-LEWANDOWSKY TYPE Pachyonychia Congenita Type 1 disease_ontology DOID:0050449 OMIM mapping confirmed by DO. [SN]. pachyonychia congenita DOID:0050449 A renal tubular transport disease that is has_material_basis_in mutations in genes that produce proteins involved in the kidneys' reabsorption of salt (sodium chloride or NaCl) from urine back into the bloodstream, thus impairing the kidneys' ability to reabsorb salt, leading to the loss of excess salt in the urine (salt wasting). GARD:8547 MESH:D053579 NCI:C84730 OMIM:263800 SNOMEDCT_US_2020_03_01:3188003 UMLS_CUI:C0268450 HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA disease_ontology DOID:0050450 OMIM mapping confirmed by DO. [SN]. Gitelman syndrome DOID:0050450 A heart conduction disease that is characterized by abnormal electrocardiogram (ECG) findings and an increased risk of sudden cardiac death. GARD:1030 ICD10CM:I49.8 MESH:D053840 NCI:C142891 OMIM:PS601144 ORDO:130 SNOMEDCT_US_2020_03_01:418818005 UMLS_CUI:C1142166 UMLS_CUI:C1721096 Bangungut Brugada type idiopathic ventricular fibrillation Dream disease Pokkuri death syndrome SUNDS sudden unexplained nocturnal death syndrome disease_ontology DOID:0050451 OMIM mapping confirmed by DO. [SN]. Brugada syndrome DOID:0050451 A peroxisomal disease that is characterized by cortical atrophy, microcephaly, dysmorphic facies, muscular hypotonia and intellectual disability and has_material_basis_in mutation in the MVK gene that results in deficiency of mevalonate kinase and impaired cholesterol. biosynthesis. GARD:3588 ICD10CM:M04.1 MESH:D054078 NCI:C84890 OMIM:610377 ORDO:29 SNOMEDCT_US_2020_03_01:124327008 SNOMEDCT_US_2020_03_01:234538002 UMLS_CUI:C0342731 UMLS_CUI:C0398691 UMLS_CUI:C1959626 Mevalonate Kinase Deficiency disease_ontology DOID:0050452 OMIM mapping confirmed by DO. [SN]. mevalonic aciduria DOID:0050452 A congenital nervous system abnormality characterized by the absence of folds in the cerebral cortex and caused_by defective neuronal migration during the 12th to 24th weeks of gestation. GARD:12291 ICD10CM:Q04.3 MESH:D054082 NCI:C103921 OMIM:300067 OMIM:300215 OMIM:607432 OMIM:611603 OMIM:614019 OMIM:615191 ORDO:102009 SNOMEDCT_US_2020_03_01:204036008 SNOMEDCT_US_2020_03_01:23024003 UMLS_CUI:C0266463 UMLS_CUI:C0266483 disease_ontology DOID:0050453 Xref MGI. OMIM mapping confirmed by DO. [SN]. lissencephaly DOID:0050453 A congenital nervous system abnormality characterized by non proper migration of neurons during the early development of the fetal brain. MESH:D054091 OMIM:300049 OMIM:608097 OMIM:608098 OMIM:612881 OMIM:615544 ORDO:98892 SNOMEDCT_US_2020_03_01:448227009 SNOMEDCT_US_2020_03_01:816068000 UMLS_CUI:C1848213 UMLS_CUI:C1868720 periventricular heterotopia disease_ontology DOID:0050454 Xref MGI. OMIM mapping confirmed by DO. [SN]. periventricular nodular heterotopia DOID:0050454 A primary bacterial infectious disease that results_in infection located_in skin or located_in subcutaneous tissue, has_material_basis_in Mycobacterium ulcerans, which could be transmitted_by insects. The bacterium produces a toxin, named mycolactone, which causes subcutaneous fat necrosis and inhibits an immune response. The infection has_symptom nodule, which is a painless, mobile swelling in the skin. GARD:9520 ICD10CM:A31.1 MESH:D054312 NCI:C84604 SNOMEDCT_US_2020_03_01:186343005 UMLS_CUI:C0085568 Bairnsdale ulcer Daintree ulcer Mossman ulcer Searl ulcer Searle's ulcer disease_ontology DOID:0050456 Buruli ulcer disease DOID:0050456 A male infertility disease characterized by male sterility, has_material_basis_in azospermia without abnormal sexual development. GARD:8406 MESH:D054331 SNOMEDCT_US_2020_03_01:73465006 UMLS_CUI:C1384583 DEL CASTILLO SYNDROME Germinal Cell Aplasia disease_ontology DOID:0050457 OMIM mapping confirmed by DO. [SN]. Sertoli cell-only syndrome DOID:0050457 A myelodysplastic/myeloproliferative neoplasm that is characterized by the uncontrolled growth of monocytes. GARD:9884 ICD10CM:C93.3 MESH:D054429 NCI:C9233 OMIM:607785 SNOMEDCT_US_2020_03_01:445227008 UMLS_CUI:C0349639 disease_ontology DOID:0050458 OMIM mapping confirmed by DO. [SN]. juvenile myelomonocytic leukemia DOID:0050458 A phosphorus metabolism disease characterized by hyperphosphatemia and abnormal deposits of phosphate and calcium in joints and soft tissues, results from abnomral phosphorus metabolism and has_material_basis_in mutations in the FGF23, GALNT3 or KL gene. MESH:D054559 NCI:C113750 SNOMEDCT_US_2020_03_01:20165001 UMLS_CUI:C0085681 disease_ontology DOID:0050459 hyperphosphatemia DOID:0050459 A chromosomal deletion syndrome that is characterized by distinct craniofacial features, hypotonia and intellectual disability and has_material_basis_in a microdeletion of the short arm of chromosome 4. DOID:6684 GARD:7896 ICD10CM:Q93.3 MESH:D054877 NCI:C35528 OMIM:194190 ORDO:280 SNOMEDCT_US_2020_03_01:17122004 UMLS_CUI:C0796117 UMLS_CUI:C1956097 4p deletion syndrome PITT SYNDROME Pitt-Rogers-Danks Syndrome chromosome 4p16.3 deletion syndrome disease_ontology DOID:0050460 OMIM mapping confirmed by DO. [LS]. Wolf-Hirschhorn syndrome DOID:0050460 A lysosomal storage disease that is characterized by delayed speech at 2-3 years of age, has_material_basis_in mutations in the AGA gene that result in the absence or shortage of the aspartylglucosaminidase enzyme in lysosomes, preventing the normal breakdown of glycoproteins. GARD:5854 ICD10CM:E77.1 MESH:D054880 NCI:C61273 OMIM:208400 SNOMEDCT_US_2020_03_01:54954004 UMLS_CUI:C0268225 aspartylglucosaminidase deficiency aspartylglycosaminuria glycosylasparaginase deficiency disease_ontology DOID:0050461 OMIM mapping confirmed by DO. [SN]. aspartylglucosaminuria MESH:D054880 DOID:0050461 A syndrome that is characterized at birth or prenatally by malformations and deformities affecting the majority of the skeleton and other areas of the body with autosomal recessive inheritance of the FGFR2 gene. OMIM:201750 OMIM:207410 SNOMEDCT_US_2020_03_01:62964007 trapezoidocephaly-synostosis syndrome disease_ontology DOID:0050462 OMIM mapping confirmed by DO. [SN]. Antley-Bixler syndrome MESH:D054882 DOID:0050462 An osteochondrodysplasia that has_material_basis_in a mutation in chromosome 17 which results_in bowing in the located_in tibia or located_in femur. GARD:10027 MESH:D055036 NCI:C120205 NCI:C84609 OMIM:114290 ORDO:140 SNOMEDCT_US_2020_03_01:74928006 UMLS_CUI:C1861922 UMLS_CUI:C1861923 Acampomelic Campomelic Dysplasia disease_ontology DOID:0050463 OMIM mapping confirmed by DO. [SN]. campomelic dysplasia DOID:0050463 A lipid storage disease that is characterized by abnormalities in swallowing, cognition, joint function, and central nervous system due to a deficiency in the enzyme ceramidase that results in sphingolipids deposition. GARD:6426 MESH:D055577 NCI:C84710 OMIM:228000 SNOMEDCT_US_2020_03_01:79935000 UMLS_CUI:C0268255 Farber disease N-laurylsphingosine deacylase deficiency acid ceramidase deficiency disease_ontology DOID:0050464 OMIM mapping confirmed by DO. [SN]. Farber lipogranulomatosis DOID:0050464 A Lynch syndrome that is characterized by a propensity to develop cancers of the gastrointestinal tract, genitourinary tract, and skin that has_material_basis_in mutations in DNA mismatch repair genes. GARD:6821 MESH:D055653 NCI:C84905 OMIM:158320 SNOMEDCT_US_2020_03_01:403824007 UMLS_CUI:C1321489 disease_ontology DOID:0050465 OMIM mapping confirmed by DO. [SN]. Muir-Torre syndrome DOID:0050465 A syndrome that is characterized by increased risk of aortic aneurysm and dissection, elongated limbs, hypertelorism, bifid uvula and easy skin bruising due to mutations in TGFB3 that results in connective tissue defects. GARD:10788 MESH:D055947 NCI:C75006 ORDO:60030 SNOMEDCT_US_2020_03_01:446263001 UMLS_CUI:C1836635 UMLS_CUI:C2697932 disease_ontology DOID:0050466 Xref MGI. OMIM mapping confirmed by DO. [SN]. Loeys-Dietz syndrome DOID:0050466 A skin disease that is characterized by areas of sharply demarcated, brown hyperkeratosis and has_material_basis_in mutations in genes encoding for connexin channels proteins in the epidermis. MESH:D056266 NCI:C84696 OMIM:PS133200 ORDO:317 SNOMEDCT_US_2020_03_01:70041004 UMLS_CUI:C0265961 UMLS_CUI:C1851480 Erythrokeratodermia Figurata Variabilis Greither Disease disease_ontology DOID:0050467 OMIM mapping confirmed by DO. [SN]. erythrokeratodermia variabilis MESH:D056266 DOID:0050467 A syndrome that is characterized by an accumulation of protein-rich fluid (lymph) in the soft layers of tissue under the skin resulting in pleural effusions, lymphedema (due to lymphatic hypoplasia) and yellow dystrophic nails hat lack a cuticle, grow slowly, and are loose or detached. GARD:184 ICD10CM:L60.5 MESH:D056684 NCI:C85238 OMIM:153300 SNOMEDCT_US_2020_03_01:400211001 UMLS_CUI:C0221348 disease_ontology DOID:0050468 OMIM mapping confirmed by DO. [SN]. yellow nail syndrome DOID:0050468 A RASopathy characterized by craniofacial dysmorphology, cardiac defects, mild mental retardation, and high birth weight followed by a failure to thrive and developmental delays. GARD:1550 MESH:D056685 NCI:C84652 OMIM:218040 SNOMEDCT_US_2020_03_01:205803001 UMLS_CUI:C0587248 FCS SYNDROME Faciocutaneoskeletal Syndrome disease_ontology DOID:0050469 OMIM mapping confirmed by DO. [SN]. Costello syndrome DOID:0050469 A syndrome that is characterized by protuberant and low-set ears, flaring nostrils, thick lips, enlarged secondary sex organs and overwhelming insulin resistance and has_material_basis_in mutation within the INSR gene causing abnormalities in the insulin receptor. MESH:D056731 NCI:C131000 NCI:C84676 OMIM:246200 ORDO:508 SNOMEDCT_US_2020_03_01:111307005 SNOMEDCT_US_2020_03_01:33559001 UMLS_CUI:C0265344 UMLS_CUI:C0271695 Leprechaunism disease_ontology DOID:0050470 OMIM mapping confirmed by DO. [SN]. Donohue syndrome DOID:0050470 A syndrome characterized by myxomas, spotty pigmentation of the skin and endocrine overactivity. GARD:1119 MESH:D056733 NCI:C4705 OMIM:160980 OMIM:605244 OMIM:608837 ORDO:1359 SNOMEDCT_US_2020_03_01:733491005 UMLS_CUI:C0406810 UMLS_CUI:C1854540 UMLS_CUI:C2607929 Carney Complex, Type 1 Carney Complex, Type 2 Carney Syndrome Carney complex variant LAMB Syndrome NAME Syndrome disease_ontology DOID:0050471 Xref MGI. OMIM mapping confirmed by DO. [SN]. Carney complex DOID:0050471 A hair disease that is characterized by short, easily broken hair that results in alopecia and has_material_basis_in mutations in genes for type II hair cortex keratins. GARD:93 ICD10CM:Q84.1 MESH:D056734 NCI:C84894 OMIM:158000 SNOMEDCT_US_2020_03_01:69488000 UMLS_CUI:C0546966 disease_ontology DOID:0050472 OMIM mapping confirmed by DO. [SN]. monilethrix DOID:0050472 A syndrome that is characterized by multiorgan dysfunction. The key features are childhood obesity, blindness due to congenital retinal dystrophy, and sensorineural hearing loss with autosomal recessive inheritance and has_material_basis_in mutations in the ALMS1 gene. MESH:D056769 NCI:C84549 OMIM:203800 SNOMEDCT_US_2020_03_01:63702009 UMLS_CUI:C0268425 disease_ontology DOID:0050473 OMIM mapping confirmed by DO. [SN]. Alstrom syndrome MESH:D056769 DOID:0050473 A skin disease that is characterized by chronic skin inflammation, trichorrhexis invaginata, atopic dermatitis and has_material_basis_in mutations in the SPINK5 gene resulting in reduced capacity to inhibit serine proteases expressed in the skin. GARD:7182 MESH:D056770 NCI:C84922 OMIM:256500 ORDO:634 SNOMEDCT_US_2020_03_01:312514006 UMLS_CUI:C0265962 disease_ontology DOID:0050474 OMIM mapping confirmed by DO. [SN]. Netherton syndrome DOID:0050474 A syndrome characterized by short stature, bachycephaly and other facial abnormalities, brachydactyly, joint stiffness and distinctive ocular abnormalities. GARD:4936 MESH:D056846 NCI:C85226 OMIM:277600 OMIM:608328 OMIM:613195 OMIM:614819 ORDO:3449 SNOMEDCT_US_2020_03_01:205801004 UMLS_CUI:C0265313 UMLS_CUI:C1869114 UMLS_CUI:C1869115 GEMSS syndrome Marchesani-Weill Syndrome Mesodermal Dysmorphodystrophy, Congenital Spherophakia Brachymorphia Syndrome congenital mesodermal dystrophy disease_ontology DOID:0050475 Xref MGI. OMIM mapping confirmed by DO. [LS]. Weill-Marchesani syndrome DOID:0050475 A lipid metabolism disorder that has_material_basis_in X-linked inheritance of the tafazzin gene and is characterized by decreased production of an enzyme required to produce cardiolipin. GARD:5890 ICD10CM:E78.71 MESH:D056889 NCI:C84585 OMIM:302060 SNOMEDCT_US_2020_03_01:297231002 UMLS_CUI:C0574083 3-methylglutaconicaciduria type 2 3-methylglutaconicaciduria type II MGA Type 2 MGA type II disease_ontology DOID:0050476 OMIM mapping confirmed by DO. [SN]. Barth syndrome MESH:D056889 DOID:0050476 A renal tubular transport disease that is characterized by hypertension and hypokalemia caused by dysregulation of epithelial sodium channels causing over expression of the channel. GARD:7381 MESH:D056929 NCI:C84827 OMIM:177200 SNOMEDCT_US_2020_03_01:707749005 UMLS_CUI:C0221043 Liddle's syndrome Pseudoaldosteronism disease_ontology DOID:0050477 OMIM mapping confirmed by DO. [SN]. Liddle syndrome DOID:0050477 A typhus that has_material_basis_in Rickettsia typhi or has_material_basis_in Rickettsia felis, which are transmitted by fleas (Xenopsylla cheopis). The infection has symptom headache, has symptom fever, has symptom chills, has symptom myalgia, has symptom nausea, has symptom vomiting, has symptom cough and has symptom rash. DOID:0050028 DOID:0050029 DOID:0050030 DOID:0050057 DOID:0050058 Rat-Flea Typhus Rickettsia felis spotted fever Urban Typhus of Malaya cat flea rickettsiosis fleaborne typhus murine typhus toulon typhus urban typhus disease_ontology Shop typhus DOID:0050481 endemic typhus DOID:0050481 A primary bacterial infectious disease that results_in infection, has_material_basis_in Neorickettsia sennetsu, which is transmitted_by ingestion of raw or under-cooked gray mullet fish infected with the trematodes. The infection has_symptom fever, has_symptom malaise, has_symptom anorexia, has_symptom lymphadenopathy, has_symptom hepatosplenomegaly, has_symptom fatigue, has_symptom chills, has_symptom headache, has_symptom backache and has_symptom myalgia. GARD:120 Sennetsu ehrlichiosis disease_ontology DOID:0050485 sennetsu fever DOID:0050485 A skin disease that is characterized by a rash that results from a variety of causes including bacteria, viruses, toxins, drugs and autoimmune disorders. ICD10CM:R21 ICD9CM:782.1 MESH:D005076 NCI:C111884 SNOMEDCT_US_2020_03_01:112625008 UMLS_CUI:C0015230 Rash exanthema disease_ontology DOID:0050486 exanthem DOID:0050486 A viral infectious disease that results_in infection in infants and children, located_in skin, has_material_basis_in Human herpesvirus 6 or has_material_basis_in Human herpesvirus 7 and has_symptom sudden high fever, and has_symptom red rash that occurs first on the trunk then spreading to legs and neck. ICD10CM:B08.2 ICD9CM:058.1 MESH:D005077 SNOMEDCT_US_2020_03_01:54385001 UMLS_CUI:C0015231 Roseola Infantum Sixth Disease disease_ontology DOID:0050495 exanthema subitum DOID:0050495 A T-cell leukemia that results_in abnormal increase of lymphocytes, derives_from T-cells, has_material_basis_in Human T-lymphotropic virus 1, which is transmitted_by sexual contact, transmitted_by contaminated needles used by intravenous-drug users, and transmitted_by breast feeding. The infection results_in_formation_of skin lesions. GARD:13103 ICD10CM:C91.5 MESH:D015459 NCI:C3184 SNOMEDCT_US_2020_03_01:77430005 UMLS_CUI:C0023493 Adult T-cell leukemia/lymphoma disease_ontology DOID:0050523 adult T-cell leukemia DOID:0050523 A diabetes mellitus that has_material_basis_in autosomal dominant inheritance of mutations in the MODY genes impacting beta-cell function, typically occurring before 25 years of age and caused by primary insulin secretion defects. GARD:3697 ICD10CM:E11.8 KEGG:04950 OMIM:606391 ORDO:552 MODY Mason-type diabetes disease_ontology DOID:0050524 Xref MGI. OMIM mapping confirmed by DO. [SN]. maturity-onset diabetes of the young DOID:0050524 A syndrome that is characterized by brittle hair, short stature, decreased fertility and cognitive impairment without photosensitivity has_material_basis_in mutations in the TTDN1 gene. OMIM:234050 AMISH BRITTLE HAIR BRAIN SYNDROME BIDS syndrome HAIR-BRAIN SYNDROME TTD4 disease_ontology DOID:0050528 OMIM mapping confirmed by DO. [SN]. nonphotosensitive trichothiodystrophy 4 DOID:0050528 A spinal muscular atrophy that is characterized by progressive muscular weakness and motor disability that typically presents in the third decade of life and has_material_basis_in mutations in the SMN1 or SMN2 genes that are required for the survival of motor neurons. ICD10CM:G12.1 MESH:C563948 OMIM:271150 ORDO:83420 UMLS_CUI:C1838230 SMA4 SPINAL MUSCULAR ATROPHY, ADULT FORM SPINAL MUSCULAR ATROPHY, TYPE IV spinal muscular atrophy 4 disease_ontology DOID:0050529 OMIM mapping confirmed by DO. [SN]. adult spinal muscular atrophy DOID:0050529 A hereditary night blindness that is characterized by hemeralopia with a moderate loss of visual acuity and caused by defective photoreceptor-to-bipolar cell signaling with common ERG findings of reduced or absent b-waves and generally normal a-waves. ICD10CM:H53.63 ICD9CM:368.61 MESH:C537743 OMIM:PS310500 ORDO:215 SNOMEDCT_US_2020_03_01:193687000 UMLS_CUI:C1306122 congenital essential nyctalopia disease_ontology DOID:0050534 Xref MGI. OMIM mapping confirmed by DO. [SN]. congenital stationary night blindness DOID:0050534 A retinal vascular disease characterized by the prevention of blood vessel formation at the edges of the retina and the hemorrhage of the blood vessels in the retina. GARD:1613 ICD10CM:H35.00 ICD9CM:362.10 OMIM:PS133780 ORDO:891 SNOMEDCT_US_2020_03_01:193355009 UMLS_CUI:C0004608 FEVR familial exudative vitreoretinopathy disease_ontology DOID:0050535 Xref MGI. OMIM mapping confirmed by DO. [SN]. exudative vitreoretinopathy DOID:0050535 A cataract that is characterized by a distinctive discoid lens opacity situated posteriorly and adjacent to the posterior capsule. CATARACT, POSTERIOR POLAR disease_ontology DOID:0050537 OMIM mapping confirmed by DO. [SN]. posterior polar cataract DOID:0050537 A Charcot-Marie-Tooth disease characterized by demyelination of the peripheral nerve axons. GARD:12433 hereditary motor and sensory neuropathy type 1 disease_ontology DOID:0050538 OMIM mapping confirmed by DO. [SN]. Charcot-Marie-Tooth disease type 1 DOID:0050538 A Charcot-Marie-Tooth disease that is characterized by motor and sensory peripheral neuropathies caused by demyelination. OMIM:145900 DEJERINE-SOTTAS NEUROPATHY DEJERINE-SOTTAS SYNDROME disease_ontology DOID:0050540 OMIM mapping confirmed by DO. [SN]. Charcot-Marie-Tooth disease type 3 DOID:0050540 An amino acid metabolic disorder that involves an excess of the amino acid methionine, in the blood. This condition can occur when methionine is not broken down properly in the body. disease_ontology DOID:0050544 Xref MGI. OMIM mapping confirmed by DO. [SN]. hypermethioninemia DOID:0050544 A physical disorder characterized by the abnormal distribution of the major visceral organs within the chest and abdomen. GARD:10875 OMIM:306955 OMIM:605376 OMIM:606325 OMIM:613751 OMIM:614779 ORDO:450 heterotaxia situs ambiguus disease_ontology DOID:0050545 Xref MGI. OMIM mapping confirmed by DO. [SN]. visceral heterotaxy DOID:0050545 An adrenal gland disease that is characterized by cortisol deficiency, hypoaldosteronism and excessive or insufficient sex hormones, has_material_basis_in the mutation in the gene for 21-hydroxylase, 11beta-hydroxylase, 3beta-hydroxysteroid, 17alpha-hydroxylase or 20,22-desmolase. OMIM:613743 ADRENAL INSUFFICIENCY, CONGENITAL, WITH 46,XY SEX REVERSAL, PARTIAL OR COMPLETE P450scc DEFICIENCY disease_ontology DOID:0050546 OMIM mapping confirmed by DO. [SN]. congenital adrenal insufficiency DOID:0050546 A thyroid gland medullary carcinoma that has_material_basis_in autosomal dominant inheritance. OMIM:155240 THYROID CARCINOMA, FAMILIAL MEDULLARY disease_ontology DOID:0050547 OMIM mapping confirmed by DO. [SN]. familial medullary thyroid carcinoma DOID:0050547 A neuropathy characterized by congenital insensitivity to pain resulting in ulceration to the fingers, tongue, lips, and other distal appendages. OMIM:PS162400 familial dysautonomia, type II hereditary sensory and autonomic neuropathy disease_ontology DOID:0050548 Xref MGI. OMIM mapping confirmed by DO. [SN]. hereditary sensory neuropathy DOID:0050548 A syndrome that is characterized by childhood onset of joint stiffness and severe contractures of the hands and feet, erythematous skin lesions with subsequent development of severe lipodystrophy that has_material_basis_in homozygous or compound heterozygous mutation in PSMB8 on chromosome 6p21.32. GARD:10988 OMIM:256040 ORDO:324999 JOINT CONTRACTURES, MUSCULAR ATROPHY, MICROCYTIC ANEMIA, AND PANNICULITIS-INDUCED LIPODYSTROPHY disease_ontology DOID:0050553 JMP syndrome DOID:0050553 A sideroblastic anemia that is characterized by decreased production of hemoglobin and ataxia and has_material_basis_in the mutation in the ABCB7 gene. DOID:0060064 OMIM:301310 Anemia sideroblastic and spinocerebellar ataxia X-linked sideroblastic anaemia and ataxia X-linked sideroblastic anaemia with ataxia X-linked sideroblastic anemia and ataxia disease_ontology DOID:0050554 OMIM mapping confirmed by DO. [SN]. X-linked sideroblastic anemia with ataxia DOID:0050554 A muscular dystrophy that is characterized by diminished muscle tone (hypotonia), progressive muscle weakness and degeneration (atrophy), abnormally fixed joints, spinal rigidity, and delays in reaching motor milestones such as sitting or standing unassisted. GARD:9138 ICD9CM:359.0 OMIM:254100 ORDO:97242 SNOMEDCT_US_2020_03_01:193221009 UMLS_CUI:C2937300 disease_ontology DOID:0050557 Xref MGI. OMIM mapping confirmed by DO. [SN]. congenital muscular dystrophy DOID:0050557 A congenital muscular dystrophy that is characterized by muscle weakness and respiratory depression and has_material_basis_in mutation in the COL6A1, COL6A2 and COL6A3 that produce components of type VI collagen. GARD:4769 OMIM:254090 ULLRICH DISEASE Ullrich scleroatonic muscular dystrophy disease_ontology DOID:0050558 OMIM mapping confirmed by DO. [SN]. Ullrich congenital muscular dystrophy DOID:0050558 A congenital muscular dystrophy-dystroglycanopathy type A that is characterized by muscle weakness, failure to thrive, severe intellectual and developmental disability, impaired vision and cardiac abnormalities and has_material_basis_in mutation in the FKTN gene that produces the fukutin protein. GARD:6475 OMIM:253800 ORDO:272 disease_ontology DOID:0050559 OMIM mapping confirmed by DO. [SN]. Fukuyama congenital muscular dystrophy DOID:0050559 A congenital muscular dystrophy that is characterized by hypotonia, seizures, severe intellectual and developmental disability, eye abnormalities and early death and has_material_basis_in mutations in multiple genes including POMT1, POMT2, ISPD, FKTN, FKRP, and LARGE1. GARD:2599 MESH:D058494 HARD syndrome cerebroocular dysplasia-muscular dystrophy syndrome disease_ontology DOID:0050560 OMIM mapping confirmed by DO. [SN]. Walker-Warburg syndrome DOID:0050560 A childhood electroclinical syndrome that is characterized by frequent seizures and intellectual disability that present in early childhood. GARD:9912 OMIM:606369 ORDO:2382 Lennox syndrome disease_ontology DOID:0050561 Lennox-Gastaut syndrome DOID:0050561 An auditory system disease that is associated with permanent hearing loss caused by damage to structures in the inner ear and/or the middle ear, which is not associated with other signs and symptoms. nonsyndromic hearing loss nonsyndromic hereditary hearing loss disease_ontology DOID:0050563 nonsyndromic deafness DOID:0050563 A nonsyndromic deafness characterized by an X-linked inheritance mode. ICD10CM:H90.3 OMIM:PS304500 ORDO:90625 X-linked deafness disease_ontology DOID:0050566 OMIM mapping confirmed by DO. [SN]. X-linked nonsyndromic deafness DOID:0050566 A physical disorder that is characterized by cleft lip and/or cleft palate that result in feeding, speech and hearing problems caused by failures during development. OMIM:PS119530 disease_ontology DOID:0050567 Xref MGI. OMIM mapping confirmed by DO. [SN]. orofacial cleft DOID:0050567 A dysostosis that results_in abnormal development located_in vertebrae or located_in ribs. The bones of the spine do not develop properly, which causes them to be misshapen and abnormally joined together. GARD:12174 GARD:6798 OMIM:122600 OMIM:277300 OMIM:608681 OMIM:609813 OMIM:613686 ORDO:1797 ORDO:2311 Jarcho-Levin syndrome spondylocostal dysostosis, autosomal recessive 3 spondylothoracic dysostosis spondylothoracic dysplasia disease_ontology DOID:0050568 Xref MGI. OMIM mapping confirmed by DO. [SN]. spondylocostal dysostosis DOID:0050568 A syndrome characterized by intrauterine growth retardation and postnatal dwarfism with microcephaly and intellectual disability. GARD:8562 ICD10CM:Q87.1 OMIM:PS210600 ORDO:808 Harper's syndrome Virchow-Seckel dwarfism bird-headed dwarfism microcephalic primordial dwarfism disease_ontology DOID:0050569 Xref MGI. OMIM mapping confirmed by DO. [SN]. Seckel syndrome DOID:0050569 A retinal degeneration that characterized by progressive deterioration of the cone and rod photoreceptor cells. GARD:10790 ICD10CM:H35.5 ORDO:1872 cone-rod retinal dystrophy disease_ontology DOID:0050572 Xref MGI. OMIM mapping confirmed by DO. [SN]. cone-rod dystrophy DOID:0050572 An amino acid metabolic disorder that is an autosomal recessive neurometabolic disorder characterized by the significant elevation of urinary levels of hydroxyglutaric acid causing progressive brain damage. GARD:10761 disease_ontology DOID:0050573 2-hydroxyglutaric aciduria DOID:0050573 An 2-hydroxyglutaric aciduria that involves damage to cerebellum affecting movement coordination resulting in problems with balance and muscle coordination (ataxia). GARD:10472 OMIM:236792 ORDO:79314 L-2-HYDROXYGLUTARIC ACIDEMIA disease_ontology DOID:0050574 L-2-hydroxyglutaric aciduria DOID:0050574 An 2-hydroxyglutaric aciduria that involves developmental delay, seizures, weak muscle tone (hypotonia), and abnormalities in the largest part of the brain (the cerebrum), which controls many important functions such as muscle movement, speech, vision, thinking, emotion, and memory. GARD:5661 OMIM:PS600721 disease_ontology DOID:0050575 D-2-hydroxyglutaric aciduria DOID:0050575 A syndrome that is characterized by characterized by sagittal craniosynostosis and facial, ectodermal, and skeletal anomalies. OMIM:PS218330 Levin syndrome Sensenbrenner syndrome disease_ontology DOID:0050577 OMIM mapping confirmed by DO. [SN]. cranioectodermal dysplasia DOID:0050577 A macular degeneration that is characterized by a central cone dysfunction leading to a loss of vision with a normal fundus and normal fluorescein angiography findings. OMIM:613587 disease_ontology DOID:0050578 OMIM mapping confirmed by DO. [SN]. occult macular dystrophy DOID:0050578 A dysostosis characterized by short fingers and toes. GARD:11913 ORDO:294937 disease_ontology DOID:0050581 Xref MGI. OMIM mapping confirmed by DO. [SN]. brachydactyly MESH:D059327 DOID:0050581 An impulse control disorder that involves the uncontrollable plucking of ones hair. GARD:7803 MESH:D014256 OMIM:613229 disease_ontology DOID:0050587 OMIM mapping confirmed by DO. [SN]. trichotillomania DOID:0050587 A congenital muscular dystrophy characterized by muscle weakness, cognitive impairment and brain abnormalities and has_material_basis_in mutation to the POMT1 gene that encodes O-mannosyltransferase. ICD10CM:G71.2 OMIM:613151 OMIM:613152 OMIM:613155 OMIM:613156 OMIM:615351 OMIM:616094 OMIM:PS613155 ORDO:370953 CMD due to dystroglycanopathy disease_ontology DOID:0050588 Xref MGI. muscular dystrophy-dystroglycanopathy DOID:0050588 An intestinal disease characterized by inflammation located in all parts of digestive tract. EFO:0003767 KEGG:05321 MESH:D015212 NCI:C3138 OMIM:PS266600 SNOMEDCT_US_2020_03_01:155759008 UMLS_CUI:C0021390 disease_ontology DOID:0050589 Xref MGI. OMIM mapping confirmed by DO. [SN]. inflammatory bowel disease DOID:0050589 A neutropenia characterized by a maturation arrest of granulopoiesis at the level or promyelocytes and early onset of severe bacterial infections. GARD:13592 ICD10CM:D70 OMIM:PS202700 ORDO:42738 disease_ontology DOID:0050590 Xref MGI. OMIM mapping confirmed by DO. [SN]. severe congenital neutropenia DOID:0050590 A tooth disease characterized by failure to develop on or more missing teeth. ICD10CM:K00.0 ICD9CM:520.0 MESH:D000848 OMIM:106600 OMIM:150400 OMIM:313500 OMIM:602639 OMIM:604625 OMIM:610926 ORDO:2227 ORDO:99798 SNOMEDCT_US_2020_03_01:234951001 UMLS_CUI:C0399352 familial tooth agenesis hypodontia oligodontia selective tooth agenesis disease_ontology DOID:0050591 Xref MGI. tooth agenesis DOID:0050591 A bone development disease characterized by skeletal abnormalities and resulting in difficulty in breathing caused by mutations that result in ciliopathy. ICD10CM:Q77.2 OMIM:PS208500 ORDO:474 Jeune syndrome short-rib thoracic dysplasia with or without polydactyly thoracic pelvic phalangeal dystrophy disease_ontology DOID:0050592 OMIM mapping confirmed by DO. [SN]. asphyxiating thoracic dystrophy DOID:0050592 A parasitic helminthiasis infectious disease that has_material_basis_in Taenia solium or has_material_basis_in Taenia saginata, which are transmitted by ingestion of undercooked contaminated meat. DOID:10076 ICD10CM:B68.1 ICD9CM:123.2 SNOMEDCT_US_2020_03_01:69163003 UMLS_CUI:C0152073 disease_ontology Beef tapeworm infection Infection by Taeniarhynchus saginatus Taenia saginata infectious disease DOID:0050596 taeniasis DOID:0050596 A schistosomiasis that involves parasitic infection of the intestine caused by Schistosoma mansoni, Schistosoma intercalatum or Schistosomiasis japonicum. The symptoms include fever, cough, abdominal pain, diarrhea, hepatosplenomegaly, colonic polyposis with bloody diarrhea and eosinophilia. DOID:13692 DOID:13721 DOID:3468 ICD10CM:B65.1 ICD10CM:B65.2 ICD9CM:120.1 ICD9CM:120.2 MESH:D012554 MESH:D012555 NCI:C35001 NCI:C35002 NCI:C35364 OMIM:181460 ORDO:1247 SNOMEDCT_US_2020_03_01:187114003 SNOMEDCT_US_2020_03_01:52179003 SNOMEDCT_US_2020_03_01:750009 UMLS_CUI:C0036329 UMLS_CUI:C0036330 UMLS_CUI:C0276932 Katayama fever Schistosoma japonicum infection Schistosoma mansoni infectious disease schistosomiasis japonica disease_ontology DOID:0050597 Xref MGI. intestinal schistosomiasis DOID:0050597 A tuberculosis that occurs at body sites other than the lung. disease_ontology DOID:0050598 extrapulmonary tuberculosis DOID:0050598 An extrapulmonary tuberculosis that is located_in gastrointestinal tract, located_in peritoneum, located_in omentum, located_in mesentery, located_in liver, located_in spleen or located_in pancreas. disease_ontology DOID:0050599 abdominal tuberculosis DOID:0050599 A syndrome that is characterized by albinism, black lock, cell migration disorder of the neurocytes of the gut and sensorineural deafness and has_material_basis_in a mutation in the endothelin B receptor gene (EDNRB). OMIM:600501 ABCDS albinism, black lock, cell migration disorder of the neurocytes of the gut, and deafness disease_ontology DOID:0050600 OMIM mapping confirmed by DO. [SN]. ABCD syndrome DOID:0050600 A syndrome that is characterized by light pigmentation with excessive freckling, sparse hair involving the scalp and axilla, lacrimal duct stenosis or atresia, onychodysplasia, hypodontia or early loss of permanent teeth, athelia or hypoplastic nipples, and breast hypoplasia, has_material_basis_in a mutation in TP63. GARD:384 OMIM:103285 acro-dermato-ungual-lacrimal-tooth syndrome disease_ontology DOID:0050601 OMIM mapping confirmed by DO. [SN]. ADULT syndrome DOID:0050601 A syndrome characterized by achalasia, adrenal insufficiency and alacrima and has_material_basis_in mutations in the AAAS gene that encodes ALADIN within the nuclear envelope and results in dysfunction of the autonomic nervous system. GARD:457 OMIM:231550 AAAS Achalasia-Addisonianism-Alacrimia syndrome Allgrove Syndrome disease_ontology DOID:0050602 OMIM mapping confirmed by DO. [SN]. triple-A syndrome DOID:0050602 An osteochondrodysplasia characterized by a lack of formation of the distal extremities has_material_basis_in mutation in the LMBR1 gene. GARD:376 OMIM:200500 Acheiropodia Horn-Kolb Syndrome disease_ontology DOID:0050603 OMIM mapping confirmed by DO. [SN]. acheiropody DOID:0050603 A metal metabolism disorder characterized by dermatitis around bodily openings and the tips of fingers and toes, alopecia and diarrhea and has_material_basis_in mutation in the SLC39A4 gene that encodes a zinc uptake protein and results in zinc deficiency. GARD:5723 OMIM:201100 disease_ontology DOID:0050605 acrodermatitis enteropathica DOID:0050605 A keratosis that has_material_basis_in mutations in the ATP2A2 gene. OMIM:101900 Acrokeratosis verruciformis of Hopf Hopf disease disease_ontology DOID:0050606 OMIM mapping confirmed by DO. [SN]. acrokeratosis verruciformis DOID:0050606 An organ system cancer located_in the respiratory system that is characterized by uncontrolled cellular proliferation in the respiratory tract. disease_ontology DOID:0050615 respiratory system cancer DOID:0050615 A respiratory system cancer that is located_in the paranasal sinuses. DOID:1354 DOID:2442 DOID:2765 DOID:2767 DOID:4689 MESH:D010255 NCI:C6014 NCI:C6017 NCI:C6018 NCI:C6019 NCI:C8193 UMLS_CUI:C0280334 UMLS_CUI:C0854995 UMLS_CUI:C1335336 UMLS_CUI:C1335337 UMLS_CUI:C1335340 Epidermoid carcinoma of the paranasal sinus Mucoepidermoid carcinoma of Accessory sinus adenoid cystic carcinoma of Accessory sinus paranasal sinus adenocarcinoma paranasal sinus adenoid cystic carcinoma paranasal sinus mucoepidermoid carcinoma paranasal sinus squamous cell carcinoma disease_ontology adenoid cystic carcinoma of paranasal sinus squamous cell carcinoma of paranasal sinus DOID:0050619 paranasal sinus cancer DOID:0050619 An organ system benign neoplasm that is located in the respiratory system which extends from the nasal sinuses to the diaphragm. disease_ontology DOID:0050621 respiratory system benign neoplasm DOID:0050621 An organ system benign neoplasm that is located_in reproductive system organs. disease_ontology DOID:0050622 reproductive organ benign neoplasm DOID:0050622 A urinary system benign neoplasm located_in the bladder including papillomas, leiomyomas, fibromas, hemangiomas, neurofibromas and lipomas. disease_ontology DOID:0050623 bladder benign neoplasm DOID:0050623 An organ system benign neoplasm located_in gastrointestinal tract organs. disease_ontology DOID:0050624 gastrointestinal system benign neoplasm DOID:0050624 A hepatobiliary benign neoplasm located_in the biliary tract. DOID:4609 NCI:C4441 SNOMEDCT_US_2020_03_01:126855001 UMLS_CUI:C0345913 extrahepatic bile duct neoplasm neoplasm of extrahepatic bile ducts tumor of the extrahepatic bile duct disease_ontology DOID:0050625 biliary tract benign neoplasm DOID:0050625 A syndrome that is a genetically heterogeneous encephalopathy characterized in its most severe form by cerebral atrophy, leukodystrophy, intracranial calcifications, chronic cerebrospinal fluid lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infections. GARD:575 ICD10CM:G31.8 OMIM:225750 OMIM:610181 OMIM:610329 OMIM:610333 OMIM:612952 OMIM:615010 OMIM:615846 ORDO:51 Cree encephalitis disease_ontology DOID:0050629 Xref MGI. OMIM mapping confirmed by DO. [SN]. Aicardi-Goutieres syndrome DOID:0050629 An eye disease characterized by fundus hypopigmentation, decreased visual acuity, nystagmus, astigmatism, myopia and defective darkness adaptation and has_material_basis_in mutation in the CACNA1F gene. GARD:10574 MESH:C562664 OMIM:300600 FORSIUS-ERIKSSON TYPE OCULAR ALBINISM Forsius-Eriksson syndrome disease_ontology DOID:0050630 Aland Island eye disease DOID:0050630 A syndrome that has_material_basis_in mutation at is in the gene encoding the monocarboxylate transporter-8 which alters the structure and function of the SLC16A2 protein which is then unable to transport the thyroid triiodothyronine (T3) hormone into nerve cells of the developing brain affecting normal brain development resulting in intellectual disability and problems with movement. GARD:5617 MESH:C537047 OMIM:300523 ORDO:59 AHDS ALLAN-HERNDON SYNDROME disease_ontology DOID:0050631 OMIM mapping confirmed by DO. [SN]. Allan-Herndon-Dudley syndrome DOID:0050631 A syndrome characterized by abnormal pigmentation of the skin, hair and eyes. GARD:10958 ICD10CM:E70.3 MESH:D016115 OMIM:PS203100 ORDO:55 disease_ontology DOID:0050632 Xref MGI. OMIM mapping confirmed by DO. [SN]. oculocutaneous albinism DOID:0050632 An eye disease that is characterized by reduced pigmentation of the iris and the resulting impairment of visual acuity without significantly affecting the color of skin or hair and has_material_basis in mutation in the GPR143 gene that encodes segments of the melanosomes that stores melanin. MESH:D016117 OMIM:300500 disease_ontology DOID:0050633 ocular albinism DOID:0050633 An amyloidosis characterized by pruritus, skin scratching and by deposits of amyloid in the dermis. GARD:132 OMIM:105250 OMIM:613955 ORDO:137807 PCA familial primary localized cutaneous amyloidosis disease_ontology DOID:0050639 Xref MGI. OMIM mapping confirmed by DO. [SN]. primary cutaneous amyloidosis DOID:0050639 A vascular disease that is characterized by generalized calcification of the arterial internal elastic lamina, leading to rupture of the lamina and occlusive changes in the tunica intima with stenosis and decreased elasticity of the vessel wall. GARD:8380 MESH:C537440 OMIM:208000 OMIM:614473 ORDO:51608 generalized arterial calcification of infancy idiopathic infantile arterial calcification infantile arteriosclerosis disease_ontology DOID:0050644 Xref MGI. OMIM mapping confirmed by DO. [SN]. arterial calcification of infancy DOID:0050644 A connective tissue disease that is characterized by elongation and generalized tortuosity of the major arteries including the aorta. GARD:774 MESH:C565942 OMIM:208050 disease_ontology DOID:0050645 OMIM mapping confirmed by DO. [SN]. arterial tortuosity syndrome DOID:0050645 A muscle tissue disease characterized by congenital joint contractures of hand and feet. GARD:786 OMIM:108120 OMIM:108145 OMIM:108200 OMIM:114300 OMIM:121050 OMIM:121070 OMIM:158300 OMIM:187370 OMIM:193700 OMIM:601680 OMIM:609128 OMIM:614335 OMIM:615065 ORDO:1147 ORDO:97120 Arthrogryposis Multiplex Congenita Freeman-Sheldon syndrome disease_ontology DOID:0050646 Xref MGI. OMIM mapping confirmed by DO. [SN]. distal arthrogryposis DOID:0050646 An X-linked disease that is characterized by profound congenital sensorineural hearing impairment, early-onset hypotonia, delayed motor development, mild to moderate intellectual disability, ataxia, and increased risk of infection and has_material_basis_in mutations of the PRPS1 gene. GARD:8756 MESH:C535388 OMIM:301835 ORDO:1187 SNOMEDCT_US_2020_03_01:702441001 UMLS_CUI:C0796028 ARTS Lethal ataxia with deafness and optic atrophy MRXS18 MRXSARTS fatal X-linked ataxia with deafness and loss of vision syndromic X-linked mental retardation 18 syndromic X-linked mental retardation Arts type disease_ontology DOID:0050647 OMIM mapping confirmed by DO. [SN]. Arts syndrome DOID:0050647 An osteochondrodysplasia that is characterized by specific patterns of aplasia/hypoplasia of humeri, femora, spine in newborns. OMIM:108720 OMIM:108721 OMIM:256050 disease_ontology DOID:0050648 OMIM mapping confirmed by DO. [SN]. atelosteogenesis DOID:0050648 A metal metabolism disorder that is characterized by transferrin deficiency, microcytic anemia, and iron loading, and has_material_basis_in autosomal recessive inheritance of homozygous or compound heterozygous mutation in the structural gene for transferrin on chromosome 3q22. GARD:9595 NCI:C125693 OMIM:209300 ORDO:1195 familial hypotransferrinemia disease_ontology DOID:0050649 OMIM mapping confirmed by DO. [SN]. atransferrinemia DOID:0050649 An atrial fibrillation that has_material_basis_in autosomal dominant inheritance of the familial atrial fibrillation (ATFB) genes. GARD:9740 OMIM:607554 OMIM:608583 OMIM:608988 OMIM:611493 OMIM:611494 OMIM:612201 OMIM:612240 OMIM:613055 OMIM:613980 OMIM:614022 OMIM:614049 OMIM:614050 OMIM:615377 OMIM:615378 OMIM:615770 OMIM:PS608583 ORDO:334 ATFB disease_ontology DOID:0050650 Xref MGI. familial atrial fibrillation DOID:0050650 A congenital heart septal defect characterized by an abnormal or inadequate fusion of the superior and inferior endocardial cushions with the mid portion of the atrial septum and the muscular portion of the ventricular septum, thus allowing extra blood to circulate the lungs. GARD:802 ICD10CM:Q21.2 ICD9CM:745.6 MESH:D004694 OMIM:600309 OMIM:606215 OMIM:614430 OMIM:614474 ORDO:98722 SNOMEDCT_US_2020_03_01:204322008 UMLS_CUI:C0014116 AVCD AVSD ECD atrioventricular canal defect endocardial cushion defect disease_ontology DOID:0050651 Xref MGI. OMIM mapping confirmed by DO. [SN]. atrioventricular septal defect DOID:0050651 A synostosis characterized by coronal craniosynostosis, short stature, and aplasia or hypoplasia of the radial bone. GARD:1602 MESH:C536788 OMIM:218600 ORDO:1223 SNOMEDCT_US_2020_03_01:77608001 UMLS_CUI:C0265308 disease_ontology DOID:0050654 OMIM mapping confirmed by DO. [SN]. Baller-Gerold syndrome DOID:0050654 A hypothyroidism that is characterized by thyroid dysgenesis, cleft palate, spiky hair and bifid epiglottis, has_material_basis_in homozygous mutation in the FKHL15 gene on chromosome 9q22. OMIM:241850 HYPOTHYROIDISM, ATHYROIDAL, WITH SPIKY HAIR AND CLEFT PALATE disease_ontology DOID:0050655 OMIM mapping confirmed by DO. [SN]. Bamforth-Lazarus syndrome DOID:0050655 A syndrome that is characterized by congenital microcephaly, intracranial calcifications, severe developmental delay, simplified gyration and polymicrogyria that has_material_basis_in homozygous or compound heterozygous mutation in OCLN on chromosome 5q13.2. GARD:12426 OMIM:251290 ORDO:1229 BLC-PMG BLCPMG Baraitser-Brett-Piesowicz syndrome Baraitser-Reardon syndrome PTORCH1 band-like calcification with simplified gyration and polymicrogyria bilateral band-like calcification with polymicrogyria microcephaly-intracranial calcification-intellectual disability syndrome disease_ontology DOID:0050656 pseudo-TORCH syndrome 1 DOID:0050656 A syndrome that is characterized by macrocephaly, multiple noncancerous tumors and hamartomas, and dark freckles on the penis, and has_material_basis_in heterozygous germline mutation in the PTEN gene on chromosome 10q23. GARD:5887 ICD10CM:Q87.89 MESH:D006223 NCI:C3939 OMIM:158350 ORDO:109 Bannayan-Zonana syndrome Riley-Smith syndrome Ruvalcaba-Myhre-Smith syndrome disease_ontology DOID:0050657 OMIM mapping confirmed by DO. [SN]. Bannayan-Riley-Ruvalcaba syndrome DOID:0050657 A syndrome that is characterized by leukonychia, wart-like skin growths, palmoplantar keratoderma and hearing loss, has_material_basis_in heterozygous mutation in the GJB2 gene on chromosome 13q12. OMIM:149200 KNUCKLE PADS, LEUKONYCHIA, AND SENSORINEURAL DEAFNESS disease_ontology DOID:0050658 OMIM mapping confirmed by DO. [SN]. Bart-Pumphrey syndrome DOID:0050658 A basal ganglia disease that is characterized by recurrent subacute encephalopathy, has_symptom confusion, has_symptom seizure, has_symptom ataxia, has_symptom dystonia, has_symptom supranuclear facial palsy, has_symptom external ophthalmoplegia, and has_symptom dysphagia. MESH:C537658 OMIM:607483 disease_ontology DOID:0050659 OMIM mapping confirmed by DO. [SN]. biotin-responsive basal ganglia disease DOID:0050659 A syndrome that is characterized by cutis gyrata, acanthosis nigricans and craniosynostosis, has_material_basis_in heterozygous mutation in the FGFR2 gene on chromosome 10q26. GARD:332 OMIM:123790 disease_ontology DOID:0050660 OMIM mapping confirmed by DO. [SN]. Beare-Stevenson cutis gyrata syndrome DOID:0050660 A macular degeneration that it is characterized by the disruption of cells in a small area near the center of the retina, the macula and may cause progressive vision loss. GARD:10120 GARD:182 ICD10CM:H35.5 MESH:D057826 OMIM:153700 OMIM:153840 OMIM:608161 OMIM:616151 OMIM:616152 ORDO:1243 ORDO:99000 Best disease Best macular dystrophy juvenile-onset vitelliform macular dystrophy disease_ontology DOID:0050661 Xref MGI. OMIM mapping confirmed by DO. [SN]. vitelliform macular dystrophy DOID:0050661 A macular degeneration that is characterized by central vision loss, an absent electrooculogram light rise and a reduced electroretinogram, has_material_basis_in autosomal recessive inheritance of homozygous or compound heterozygous mutation in the BEST1 gene on chromosome 11q12. MESH:C567518 OMIM:611809 autosomal recessive bestrophinopathy disease_ontology DOID:0050662 OMIM mapping confirmed by DO. [SN]. bestrophinopathy DOID:0050662 A congenital muscular dystrophy that is characterized by myopathy and joint contractures that progresses slowly, has_material_basis_in autosomal dominant inheritance of heterozygous mutation in the COL6A1 gene, the COL6A2 gene, or the COL6A3 gene. GARD:873 OMIM:158810 benign congenital muscular dystrophy disease_ontology DOID:0050663 OMIM mapping confirmed by DO. [SN]. Bethlem myopathy DOID:0050663 A fetal alcohol spectrum disorder that results in severe mental and physical defects which can develop in a child when the mother drinks alcohol during pregnancy. The presenting features include craniofacial dysmorphology (microcephaly, smooth philtrum, thin upper lip, small eye openings), pre- and postnatal growth deficiency, and central nervous system dysfunction. disease_ontology DOID:0050665 fetal alcohol syndrome DOID:0050665 A fetal alcohol spectrum disorder that results in most, but not all, of the growth deficiency and/or craniofacial features of fetal alcohol syndrome including central nervous system dysfunction due to prenatal alcohol exposure. disease_ontology DOID:0050666 partial fetal alcohol syndrome DOID:0050666 A fetal alcohol spectrum disorder that results in central nervous system dysfunction and behavioral and/or cognitive deficits due to prenatal alcohol exposure. ARND static encephalopathy disease_ontology DOID:0050667 alcohol-related neurodevelopmental disorder DOID:0050667 A cerebral palsy that is caused by damage in the outer layer of the brain, the cerebral cortex, which results in increased tone, or tension, in a muscle causing abnormal movements. disease_ontology DOID:0050669 spastic cerebral palsy DOID:0050669 A cerebral palsy that is caused by damage to the cerebellum, which affects muscle coordination, particularly in the limb. Some individuals suffer from hypotonia, tremors, difficulty with visual and/or auditory processing. GARD:10451 OMIM:605388 hypotonic cerebral palsy disease_ontology DOID:0050670 ataxic cerebral palsy DOID:0050670 A steroid inherited metabolic disorder characterized by abnormal conversion of cholesterol into bile acids which occurs predominantly in the liver. ICD10CM:K76.8 3-beta-hydroxy-delta-5-C27-steroid oxidoreductase deficiency CBA cholestasis with delta(4)-3-oxosteroid-5-beta-reductase deficiency disease_ontology DOID:0050674 Xref MGI. OMIM mapping confirmed by DO. [SN]. congenital bile acid synthesis defect DOID:0050674 A syndrome that is characterized by intellectual disability, hypotonia, hyperactivity and facies, has_material_basis_in heterozygous mutation in the KCNK9 gene on chromosome 8q24. GARD:10358 MESH:C567357 OMIM:612292 Birk-Barel mental retardation dysmorphism syndrome disease_ontology DOID:0050675 OMIM mapping confirmed by DO. [SN]. Birk-Barel syndrome DOID:0050675 A skin disease that is characterized by the development of skin papules on the head, face and upper torso, has_material_basis_in heterozygous mutation in the gene encoding folliculin on chromosome 17p11. GARD:2322 MESH:D058249 OMIM:135150 disease_ontology DOID:0050676 OMIM mapping confirmed by DO. [SN]. Birt-Hogg-Dube syndrome DOID:0050676 A syndrome characterized by familial granulomatous arthritis, uveitis and skin granulomas. It has_material_basis_in heterozygous mutations in the NOD2 gene. GARD:304 NCI:C116794 OMIM:186580 ARTHROCUTANEOUVEAL GRANULOMATOSIS BLAUS Jabs syndrome disease_ontology DOID:0050678 OMIM mapping confirmed by DO. [SN]. Blau syndrome DOID:0050678 An achromatopsia that is characterized by severely impaired color discrimination, low visual acuity, nystagmus, photophobia due to the absence of functional long wavelength-sensitive and medium wavelength-sensitive cones in the retina and has_material_basis_in recessive X-linked inheritance. GARD:917 OMIM:303700 disease_ontology DOID:0050679 OMIM mapping confirmed by DO. [SN]. blue cone monochromacy DOID:0050679 An osteochondrodysplasia that is characterized by severe dwarfism, dislocated joints, club feet, distinctive facies and dysplastic tubular bones with boomerang-like bowing, has_material_basis_in heterozygous mutation in the FLNB gene on chromosome 3p14. GARD:933 OMIM:112310 disease_ontology DOID:0050680 OMIM mapping confirmed by DO. [SN]. Boomerang dysplasia DOID:0050680 An X-linked disease that is characterized by intellectual disability, truncal obesity, seizures, hypogonadism, developmental delay, distinctive facial features, tapered fingers and short toes and has_material_basis_in X-linked recessive inheritance of mutations in the PHF6 gene. GARD:936 MESH:C536575 NCI:C157122 OMIM:301900 ORDO:127 SNOMEDCT_US_2020_03_01:21634003 UMLS_CUI:C0265339 BFLS BORJ Borjeson syndrome MRXSBFL intellectual deficiency-epilepsy-endocrine disorders syndrome mental retardation, epilepsy, and endocrine disorder syndromic X-linked mental retardation Borjeson-Forssman-Lehmann type disease_ontology DOID:0050681 OMIM mapping confirmed by DO. [SN]. Borjeson-Forssman-Lehmann syndrome DOID:0050681 A syndrome that is characterized by growth delays, failure to thrive and malformations of the head and face that results in infantile death, has_material_basis_in homozygous mutation in the EMG1 gene on chromosome 12p13. GARD:5950 MESH:C537081 OMIM:211180 ORDO:1270 SNOMEDCT_US_2020_03_01:711153001 UMLS_CUI:C1859405 BWCNS Bowen Hutterite syndrome Bowen-Conradi Hutterite syndrome disease_ontology DOID:0050684 OMIM mapping confirmed by DO. [SN]. Bowen-Conradi syndrome DOID:0050684 A carcinoma that is an undifferentiated neoplasm composed of primitive-appearing cells. snadendla 2011-06-13T01:25:14Z DOID:7137 NCI:C4099 SNOMEDCT_US_2020_03_01:5958006 UMLS_CUI:C0334239 Small cell carcinoma - intermediate cell Small cell carcinoma, intermediate cell intermediate cell small cell carcinoma disease_ontology DOID:0050685 small cell carcinoma DOID:0050685 A cancer that is classified based on the organ it starts in. snadendla 2011-06-13T03:28:33Z MESH:D009371 disease_ontology DOID:0050686 organ system cancer DOID:0050686 A cancer that is classified by the type of cell from which it is derived. snadendla 2011-06-13T03:28:50Z disease_ontology DOID:0050687 cell type cancer DOID:0050687 A large intestine cancer that is located_in the terminal part of the large intestine. snadendla 2011-06-14T01:34:36Z disease_ontology DOID:0050688 anal canal cancer DOID:0050688 A syndrome that is characterized by brachydactyly and syndactyly, has_material_basis_in heterozygous mutation in the HOXD13 gene on chromosome 2q31. snadendla 2011-06-17T03:55:47Z MESH:C565193 OMIM:610713 disease_ontology DOID:0050689 OMIM mapping confirmed by DO. [SN]. brachydactyly-syndactyly syndrome DOID:0050689 An osteochondrodysplasia characterized by generalized platyspondyly without significant long bone abnormalities and short stature. snadendla 2011-06-17T04:00:27Z GARD:10903 OMIM:113500 OMIM:271530 OMIM:271630 OMIM:613678 ORDO:1293 brachyrachia disease_ontology DOID:0050690 Xref MGI. OMIM mapping confirmed by DO. [SN]. brachyolmia DOID:0050690 A syndrome that is characterized by low birth weight and growth retardation, bilateral branchial clefts. snadendla 2011-06-17T04:10:18Z GARD:3212 OMIM:113620 disease_ontology DOID:0050691 OMIM mapping confirmed by DO. [SN]. branchiooculofacial syndrome DOID:0050691 A skin disease that is characterized by the development of several types of tumors from the skin, has_material_basis_in heterozygous mutation in the CYLD gene on chromosome 16q12. snadendla 2011-06-17T04:34:10Z GARD:10179 OMIM:605041 ORDO:79493 SNOMEDCT_US_2020_03_01:703531009 UMLS_CUI:C1857941 BRSS BSS CYLD cutaneous syndrome SBS Spiegler-Brooke Syndrome disease_ontology DOID:0050693 OMIM mapping confirmed by DO. [SN]. Brooke-Spiegler syndrome DOID:0050693 A syndrome that is characterized by sensorineural hearing loss and a variety of cranial nerve palsies, usually involving the motor components of the seventh and ninth to twelfth cranial nerves. snadendla 2011-06-17T04:38:07Z MESH:C537111 OMIM:PS211530 disease_ontology DOID:0050694 OMIM mapping confirmed by DO. [SN]. Brown-Vialetto-Van Laere syndrome MESH:C537111 DOID:0050694 A specific developmental disorder and physical disorder that is characterized by physical, behavioral and learning birth defects resulting from maternal ingestion of alcohol during pregnancy. lschriml 2011-12-01T01:01:25Z disease_ontology DOID:0050696 fetal alcohol spectrum disorder DOID:0050696 A placenta disease that is an inflammation of the fetal membranes (amnion and chorion) due to a bacterial infection. lschriml 2012-01-03T01:13:08Z MESH:D002821 disease_ontology DOID:0050697 chorioamnionitis DOID:0050697 A connective tissue disease that is an inflammation of the connective tissue of the umbilical cord. lschriml 2012-01-03T01:18:35Z disease_ontology DOID:0050698 funisitis DOID:0050698 A heart disease and a myopathy that is characterized by deterioration of the function of the heart muscle. lschriml 2012-01-03T02:54:11Z ICD10CM:I42 ICD9CM:425 ICD9CM:425.9 MESH:D009202 NCI:C34830 NCI:C53654 SNOMEDCT_US_2020_03_01:266301006 SNOMEDCT_US_2020_03_01:89461002 SNOMEDCT_US_2020_03_01:89600009 UMLS_CUI:C0033141 UMLS_CUI:C0036529 UMLS_CUI:C0878544 Cardiomyopathies disease_ontology DOID:0050700 MESH:D009202 added from NeuroDevNet [WAK]. cardiomyopathy DOID:0050700 An epilepsy syndrome that is a group of clinical entities showing a cluster of electro-clinical characteristics, classified according to age at onset, cognitive and developmental antecedents and consequences, motor and sensory examinations, EEG features, provoking or triggering factors, and patterns of seizure occurrence with respect to sleep. lschriml 2012-04-11T11:42:46Z electro-clinical syndrome disease_ontology DOID:0050701 electroclinical syndrome DOID:0050701 An electroclinical syndrome with onset in the neonatal period less than 44 weeks of gestational age. lschriml 2012-04-11T11:48:18Z disease_ontology DOID:0050702 JA:Epilepsy Genetics Kiel neonatal period electroclinical syndrome DOID:0050702 An electroclinical syndrome with onset in infancy occurring between birth and one year of age. lschriml 2012-04-11T11:48:18Z disease_ontology DOID:0050703 JA:Epilepsy Genetics Kiel infancy electroclinical syndrome DOID:0050703 An electroclinical syndrome with onset in childhood between one and 12 years of age. lschriml 2012-04-11T11:48:18Z disease_ontology DOID:0050704 JA:Epilepsy Genetics Kiel childhood electroclinical syndrome DOID:0050704 An electroclinical syndrome with onset in adolescence and adulthood. lschriml 2012-04-11T11:48:18Z disease_ontology DOID:0050705 adolescence-adult electroclinical syndrome DOID:0050705 An electroclinial syndrome that is characterized by development of seizures later in life with a variable age of onset and duration. lschriml 2012-04-11T11:48:18Z disease_ontology DOID:0050706 variable age at onset electroclinical syndrome DOID:0050706 A childhood electroclinical syndrome characterized by the occurrence of typical absence seizures starting between the age of four and ten years. lschriml 2012-04-11T02:29:04Z disease_ontology DOID:0050708 JA:Epilepsy Genetics Kiel early onset absence epilepsy DOID:0050708 A neonatal period electroclinical syndrome that is characterized by tonic spasms and partial seizures. lschriml 2012-05-10T10:02:58Z DOID:2481 GARD:9255 OMIM:PS308350 ORDO:1934 Early Infantile Epileptic Encephalopathy with Burst-Suppression disease_ontology DOID:0050709 early infantile epileptic encephalopathy DOID:0050709 An amino acid metabolic disorder that is classified by inadequate levels of the enzyme 3-methylcrotonyl-CoA carboxylase that helps break down proteins containing the amino acid leucine. This disease has_symptom muscular hypotonia (weak muscle tone), has_symptom muscular atrophy, has_symptom feeding difficulties, has_symptom recurrent episodes of vomiting and diarrhea, and has_symptom lethargy. lschriml 2012-05-22T10:32:44Z GARD:10954 OMIM:PS210200 ORDO:6 3-Methylcrotonylglycinuria 3MCC deficiency BMCC deficiency disease_ontology DOID:0050710 3-Methylcrotonyl-CoA carboxylase deficiency DOID:0050710 An iron metabolism disease that has_material_basis_in a mutation in the ceruloplasmin gene characterized by progressive neurodegeneration of the retina and basal ganglia and diabetes mellitus. lschriml 2012-05-22T11:47:25Z GARD:9499 OMIM:604290 disease_ontology DOID:0050711 aceruloplasminemia DOID:0050711 An amino acid metabolic disorder that has_material_basis_in a mutation in the GATM gene resulting in deficiency of arginine:glycine amidinotransferase which then limits creatine synthesis. lschriml 2012-05-22T11:53:57Z OMIM:612718 CEREBRAL CREATINE DEFICIENCY SYNDROME 3 arginine:glycine amidinotransferase deficiency disease_ontology DOID:0050712 AGAT deficiency DOID:0050712 An inherited metabolic disorder resulting from a deficiency in vitamin or vitamin cofactor transport or metabolism. lschriml 2012-06-11T02:44:53Z disease_ontology DOID:0050718 vitamin metabolic disorder DOID:0050718 An amino acid metabolic disorder that has_material_basis in deficiency of ornithine translocase resulting in the accumulation of ammonia in the blood. lschriml 2012-06-13T03:09:31Z OMIM:238970 HHH syndrome Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) syndrome disease_ontology DOID:0050720 ornithine translocase deficiency DOID:0050720 An amino acid metabolic disorder that has_material_basis_in defects in the biosynthesis of the amino acid L-serine. lschriml 2012-06-13T03:09:31Z disease_ontology DOID:0050721 serine deficiency DOID:0050721 A tyrosinemia that has_material_basis_in deficiency of 4-hydroxyphenylpyruvate dioxygenase disrupting the break down of tyrosine. lschriml 2012-07-06T02:55:45Z OMIM:276710 disease_ontology DOID:0050727 tyrosinemia type III DOID:0050727 A carbohydrate metabolism disorder that is characterized by abnormal accumulation or depletion of liver glycogen. lschriml 2012-07-13T10:42:54Z disease_ontology DOID:0050728 glycogen metabolism disorder DOID:0050728 A lipid storage disease that is characterized by accumulation of triglycerides in the cytoplasm of leukocytes, muscle, liver, fibroblasts, and other tissues. lschriml 2012-07-17T12:31:48Z OMIM:275630 Chanarin-Dorfman syndrome disease_ontology DOID:0050729 neutral lipid storage disease DOID:0050729 A mitochondrial metabolism disease that is characterized by a deficiency of CoQ10 resulting from reduced biosynthesis. lschriml 2012-07-17T12:58:37Z GARD:10423 OMIM:PS607426 COENZYME Q10 DEFICIENCY, PRIMARY disease_ontology DOID:0050730 coenzyme Q10 deficiency disease DOID:0050730 A vitamin metabolic disorder that results from low blood levels of vitamin B12. lschriml 2012-07-17T01:01:29Z cobalamin deficiency hypocobalaminemia disease_ontology DOID:0050731 vitamin B12 deficiency DOID:0050731 A monogenic disease that has_material_basis_in muations in genes on the X chromosome. lschriml 2012-07-24T12:47:31Z disease_ontology DOID:0050735 X-linked monogenic disease DOID:0050735 An autosomal genetic disease that is characterized by the presence of one disease-associated mutation of a gene which is sufficient to cause the disease. lschriml 2012-07-24T12:51:47Z disease_ontology DOID:0050736 autosomal dominant disease DOID:0050736 An autosomal genetic disease that is characterized by the presence of two mutated copies of the gene, both of which must be present in order for the disease or trait to develop. lschriml 2012-07-24T12:51:47Z disease_ontology DOID:0050737 autosomal recessive disease DOID:0050737 A monogenic disease that has_material_basis_in a mutation in a single gene on one of the non-sex chromosomes. lschriml 2012-07-24T04:45:53Z disease_ontology DOID:0050739 autosomal genetic disease DOID:0050739 A substance dependence that is characterized by tolerance, withdrawal symptoms, increasing use, persistent desire to decrease consumption, time spent obtaining or recovering from alcohol caused by a physical and psychological dependence on alcohol. lschriml 2012-09-05T11:48:42Z EFO:0003829 KEGG:05034 OMIM:103780 SNOMEDCT_US_2020_03_01:66590003 alcoholism disease_ontology DOID:0050741 alcohol dependence DOID:0050741 A substance dependence that is characterized by a physical dependence on nicotine. lschriml 2012-09-05T11:48:42Z EFO:0003768 ICD10CM:F17 MESH:D014029 NCI:C54203 SNOMEDCT_US_2020_03_01:56294008 UMLS_CUI:C0028043 tobacco use disorder disease_ontology DOID:0050742 nicotine dependence DOID:0050742 A non-Hodgkin lymphoma that has_material_basis_in mature T lymphocytes and natural killer cells. lschriml 2012-09-18T01:56:52Z NK-T cell lymphoma mature T-cell and natural killer cell lymphoma disease_ontology DOID:0050743 mature T-cell and NK-cell lymphoma DOID:0050743 A non-Hodgkin lymphoma involving aberrant T-cells. lschriml 2012-09-18T01:57:40Z disease_ontology DOID:0050744 anaplastic large cell lymphoma DOID:0050744 A B-cell lymphoma that is a cancer of B cells presenting as an aggressive tumour which can arise in virtually any part of the body. lschriml 2012-09-18T01:58:25Z GARD:3178 disease_ontology DOID:0050745 diffuse large B-cell lymphoma DOID:0050745 A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles. lschriml 2012-09-18T02:00:45Z GARD:6969 MESH:D020522 disease_ontology DOID:0050746 mantle cell lymphoma DOID:0050746 A B-cell lymphoma that is characterized by initial formation in the marginal zones of lymph tissue. lschriml 2012-09-18T02:00:45Z marginal zone lymphoma disease_ontology DOID:0050748 marginal zone B-cell lymphoma DOID:0050748 A mature T-cell and NK-cell lymphoma includes a group of T-cell lymphomas that develop away from the thymus. lschriml 2012-09-18T02:01:49Z GARD:7368 disease_ontology DOID:0050749 peripheral T-cell lymphoma DOID:0050749 A marginal zone B-cell lymphocyte located_in the spleen comprised of B-cells in place of white pulp. lschriml 2012-09-18T02:03:06Z disease_ontology DOID:0050750 splenic marginal zone lymphoma DOID:0050750 A hereditary ataxia that is characterized by ataxia originating in the cerebellum. lschriml 2013-01-16T01:07:02Z MESH:D002524 disease_ontology DOID:0050753 cerebellar ataxia DOID:0050753 An autosomal recessive cerebellar ataxia that is characterized by the onset of ataxia between age three and thirty including axonal sensorimotor neuropathy, oculomotor apraxia, cerebellar atrophy and elevated alpha-fetoprotein, has_material_basis_in homozygous or compound heterozygous mutation in the SETX gene on chromosome 9q34. lschriml 2013-01-16T01:07:02Z OMIM:606002 disease_ontology DOID:0050755 ataxia with oculomotor apraxia type 2 DOID:0050755 A mitochondrial metabolism disease that is characterized by hearing loss that begins early in life, problems with movement, impaired vision, and behavior problems, and has_material_basis_in mutations in the TIMM8A gene resulting in abnormal protein transport within the mitochondria. lschriml 2013-01-16T01:20:50Z DOID:0050867 MESH:C535808 OMIM:304700 ORDO:3213 Deafness Dystonia Optic Atrophy Syndrome Deafness Dystonia Optic Neuronopathy Syndrome Dystonia Deafness Syndrome Jensen syndrome Mohr-Tranebjaerg Syndrome Mohr-Tranebjaerg syndrome deafness dystonia syndrome disease_ontology DOID:0050757 deafness-dystonia-optic neuronopathy syndrome DOID:0050757 An acquired metabolic disease that characterized by excessive production of acid. lschriml 2013-01-16T01:23:37Z disease_ontology DOID:0050758 metabolic acidosis DOID:0050758 A myotonic disease that is characterized by myotonia and progressive, proximal muscle wasting and weakness affecting the skeletal and smooth muscles of the neck, shoulders, elbows and hips and has_material_basis_in the autosomal dominant inheritance of the CNBP (ZNF9) gene containing an expansion of a CCTG repeat in intron one. lschriml 2013-01-16T01:27:31Z GARD:9728 ICD10CM:G71.1 ICD10CM:G71.19 ICD9CM:359.2 MESH:D020967 NCI:C122789 NCI:C122790 NCI:C84913 OMIM:602668 SNOMEDCT_US_2020_03_01:155096007 SNOMEDCT_US_2020_03_01:41574007 SNOMEDCT_US_2020_03_01:715788001 UMLS_CUI:C0221055 UMLS_CUI:C0553604 UMLS_CUI:C0752355 proximal myotonic myopathy disease_ontology DOID:0050759 myotonic dystrophy type 2 MESH:C535686 DOID:0050759 A syndrome that is characterized by congenital joint contractures, renal tubular dysfunction, cholestasis, severe failure to thrive, ichthyosis and a defect in platelet alpha-granule biogenesis and that has_material_basis_in homozygous or compound heterozygous mutation in the VPS33B gene or homozygous or compound heterozygous mutation in the VIPAR gene on chromosome 14q24.3. lschriml 2013-01-17T12:46:38Z OMIM:PS208085 ORDO:2697 ARTHROGRYPOSIS, RENAL DYSFUNCTION, AND CHOLESTASIS Arthrogryposis, renal dysfunction and cholestasis (ARC) syndrome Arthrogryposis-renal dysfunction-cholestasis disease_ontology DOID:0050763 ARC syndrome DOID:0050763 A neurodegenerative disease that is characterized by characterized by misshapen, spiny red blood cells (acanthocytosis) and neurological abnormalities, especially movement disorders. lschriml 2013-01-17T12:54:19Z GARD:10902 MESH:D054546 ORDO:263440 disease_ontology DOID:0050765 neuroacanthocytosis DOID:0050765 A neuroacanthocytosis characterized by progressive neurodegeneration and red cell acanthocytosis, with onset in the third to fifth decade of life and has_material_basis_in homozygous or compound heterozygous mutation in the VPS13A gene, which encodes chorein, on chromosome 9q21. lschriml 2013-01-17T12:54:19Z GARD:3956 MESH:D054546 NCI:C84926 OMIM:200150 ORDO:2388 SNOMEDCT_US_2020_03_01:26848004 UMLS_CUI:C0393576 Levine-Critchley syndrome choreo-acanthocytosis disease_ontology DOID:0050766 choreaacanthocytosis DOID:0050766 A syndrome that is characterized by intellectual disability, deafness, ocular abnormalities, T-cell leukemia, cryptorchidism, hypospadias and spasticity. lschriml 2013-02-21T11:32:26Z GARD:3902 OMIM:310465 ORDO:2608 NSX disease_ontology DOID:0050769 N syndrome DOID:0050769 A liver disease that is characterized by the presence of multiple cysts located_in the liver. lschriml 2013-02-21T11:36:13Z DOID:1173 GARD:9457 OMIM:174050 congenital cystic liver disease congenital hepatic cyst fibrocystic liver disease disease_ontology DOID:0050770 polycystic liver disease DOID:0050770 An endocrine organ benign neoplasm that arises within the adrenal medulla, releasing epinephrines and norepinephrines hormones that cause either episodic or persistent high blood pressure. lschriml 2013-02-21T11:40:58Z GARD:7385 MESH:D010673 OMIM:171300 phaeochromocytoma disease_ontology DOID:0050771 pheochromocytoma DOID:0050771 A pheochromocytoma that arises in extraadrenal sympathetic ganglia. lschriml 2013-02-21T11:51:57Z MESH:D010235 NCI:C3308 OMIM:115310 OMIM:168000 OMIM:601650 OMIM:605373 OMIM:614165 OMIM:PS168000 SNOMEDCT_US_2020_03_01:302833002 UMLS_CUI:C0030421 chemodectoma glomus body tumor disease_ontology DOID:0050773 Xref MGI. paraganglioma DOID:0050773 A syndrome that is characterized by radial ray defect, patellae hypoplasia, cleft palate, diarrhea, dislocated joints, limb malformations, long nose and normal intelligence, has_material_basis_in homozygous or compound heterozygous mutation in the DNA helicase gene RECQL4 on chromosome 8q24. lschriml 2013-02-21T11:56:15Z GARD:4637 MESH:C535288 OMIM:266280 ORDO:3021 SNOMEDCT_US_2020_03_01:702413000 UMLS_CUI:C1849453 disease_ontology DOID:0050774 rapadilino syndrome DOID:0050774 An osteochondrodysplasia that is characterized by hypoplastic iliac bones, hypoplastic vertebral bodies, short ribs and broad long bones, prenatally lethal, has_material_basis_in homozygous or compound heterozygous mutation in the SLC35D1 gene on chromosome 1p31. lschriml 2013-02-21T12:00:39Z GARD:169 MESH:C536637 OMIM:269250 disease_ontology DOID:0050775 schneckenbecken dysplasia DOID:0050775 A non-syndromic intellectual disability characterized by a X-linked inheritance pattern. lschriml 2013-02-21T12:06:40Z OMIM:300716 OMIM:PS309530 ORDO:777 non-specific X-linked mental retardation disease_ontology DOID:0050776 Xref MGI. non-syndromic X-linked intellectual disability DOID:0050776 An amino acid metabolic disorder that is characterized by mental retardation, severe speech delay, behavioral abnormalities and seizures, has_material_basis_in mutation in the creatine transporter gene on chromosome Xq28. lschriml 2013-11-21T12:10:58Z disease_ontology DOID:0050798 cerebral creatine deficiency syndrome DOID:0050798 A heart conduction disease that is characterized by the impairment of the conduction between the atria and ventricles of the heart. lschriml 2014-02-12T01:35:05Z ICD10CM:I44.3 ICD9CM:426.10 MESH:D054537 NCI:C26703 SNOMEDCT_US_2020_03_01:58547007 UMLS_CUI:C0004245 AV block disease_ontology DOID:0050820 atrioventricular block MESH:D054537 DOID:0050820 A heart conduction disease that is characterized by dysfunction of the impulse-generating (pacemaker) tissue located in the right atrium of the heart which generates normal sinus rhythm. lschriml 2014-02-12T01:47:54Z SA node sinuatrial node disease_ontology DOID:0050824 sinoatrial node disease DOID:0050824 A heart disease that is located_in the innermost layer of tissue that lines the chambers of the heart. lschriml 2014-02-12T01:53:42Z disease_ontology DOID:0050825 endocardium disease DOID:0050825 A heart valve disease that is characterized by valvular insufficiency or valvular stenosis, located_in tricuspid valve between the right atrium and right ventricle. lschriml 2014-02-12T02:55:24Z DOID:13834 ICD10CM:I07 ICD9CM:397.0 SNOMEDCT_US_2020_03_01:49699002 UMLS_CUI:C0264776 RH. tricuspid valve disease Rheumatic disease of tricuspid valve Rheumatic tricuspid valve disease Tricuspid disease disease of tricuspid valve rheumatic tricuspid valve disease disease_ontology DOID:0050826 tricuspid valve disease DOID:0050826 A vascular disease that is located_in an artery. lschriml 2014-02-12T03:08:35Z disease_ontology DOID:0050828 artery disease DOID:0050828 A cardiovascular system disease that is located_in the fibrous sac surrounding the heart. lschriml 2014-02-18T12:20:15Z disease_ontology DOID:0050829 pericardium disease DOID:0050829 A dystonia that is localized to a specific part of the body. lschriml 2014-03-18T01:13:36Z GARD:6458 disease_ontology DOID:0050836 focal dystonia DOID:0050836 A focal dystonia that is characterized as dystonia that affects the muscles of the head, face, and neck. lschriml 2014-03-18T01:33:33Z disease_ontology DOID:0050845 cranio-facial dystonia DOID:0050845 A sleep disorder characterized by repeated cessation and commencing of breathing that repeatedly disrupts sleep. lschriml 2014-03-20T03:57:22Z ICD10CM:G47.3 ICD9CM:780.57 MESH:D012891 NCI:C26884 SNOMEDCT_US_2020_03_01:206750008 UMLS_CUI:C0037315 disease_ontology DOID:0050847 sleep apnea DOID:0050847 A glomerulonephritis that is characterized by hardening of the glomerulus in the kidney. lschriml 2014-04-15T03:40:31Z disease_ontology DOID:0050851 glomerulosclerosis DOID:0050851 An intellectual disability that is characterized by the presence of associated medical and behavioral sign and symptoms. lschriml 2014-08-14T10:55:32Z disease_ontology DOID:0050888 syndromic intellectual disability DOID:0050888 An intellectual disability that is characterized by the absence of associated medical and behavioral signs and symptoms. lschriml 2014-08-14T10:57:36Z OMIM:613192 OMIM:614202 disease_ontology DOID:0050889 non-syndromic intellectual disability DOID:0050889 A neurodegenerative disease that is characterized by the abnormal accumulation of aggregates of alpha-synuclein protein in neurons, nerve fibres or glial cells. lschriml 2014-08-14T03:29:17Z Synucleinopathies alpha Synucleinopathies disease_ontology DOID:0050890 synucleinopathy DOID:0050890 An infratentorial cancer that is located_in the lower part of the brain and is a type of primitive neuroectodermal tumor. lschriml 2014-10-06T14:36:37Z DOID:0060105 DOID:168 DOID:3858 DOID:4981 GARD:7005 MESH:D008527 MESH:D018242 NCI:C27294 NCI:C3222 NCI:C3716 OMIM:155255 SNOMEDCT_US_2020_03_01:189925001 SNOMEDCT_US_2020_03_01:443333004 UMLS_CUI:C0025149 UMLS_CUI:C0206663 UMLS_CUI:C1334410 CNS PNET CPNET brain medulloblastoma infratentorial primitive neuroectodermal tumor localized primitive neuroectodermal tumor disease_ontology DOID:0050902 OMIM mapping confirmed by DO. [SN]. medulloblastoma DOID:0050902 A salivary gland cancer that has_material_basis_in epithelial cells. lschriml 2014-10-08T16:52:58Z disease_ontology DOID:0050904 salivary gland carcinoma DOID:0050904 A breast carcinoma that derives_from breast lobules (milk glands). lschriml 2014-10-22T13:05:34Z disease_ontology DOID:0050938 breast lobular carcinoma DOID:0050938 A cerebellar ataxia that has_material_basis_in autosomal recessive inheritance. lschriml 2015-10-05T14:21:08Z OMIM:PS213200 ORDO:1172 disease_ontology DOID:0050950 autosomal recessive cerebellar ataxia DOID:0050950 A neurodegenerative disease that is characterized by slowly progressive incoordination of gait and often associated with poor coordination of hands, speech, and eye movements. lschriml 2015-10-05T14:38:17Z GARD:6614 disease_ontology DOID:0050951 hereditary ataxia DOID:0050951 An endocarditis that is characterized by inflammation of the endocardium caused by infectious agents. GARD:6337 disease_ontology DOID:0060000 infective endocarditis DOID:0060000 A substance-related disorder that occurs upon the abrupt discontinuation/separation or a decrease in dosage of the intake of medications, recreational drugs, and alcohol. disease_ontology DOID:0060001 withdrawal disorder DOID:0060001 A complement deficiency that is a functional deficiency in the complement component C1 inhibitor leading to hereditary angioedema (HAE) involving swelling due to leakage of fluid from blood vessels into connective tissue. Quincke edema disease_ontology DOID:0060002 C1 inhibitor deficiency DOID:0060002 An autoimmune hypersensitivity disease located_in the central nervous system. disease_ontology DOID:0060004 autoimmune disease of central nervous system DOID:0060004 An autoimmune disease that is the abnormal functioning of the immune system resulting in production of antibodies or T cells against cells and/or tissues in the endocrine system. disease_ontology DOID:0060005 autoimmune disease of endocrine system DOID:0060005 A severe combined immunodeficiency that is characterized by recurrent bacterial, viral, and fungal infections, especially of the lung, and sterile necrotizing granulomas of the skin, develops_from deficiency or decreased surface expression of MHC Class I, has_material_basis_in autosomal recessive inheritance of mutation affecting MHC Class I production or expression and frequently involves TAP1 and TAP2 subunits, and is typically asymptomatic in infancy. OMIM:604571 BLS, TYPE I BLSI HLA CLASS I DEFICIENCY bare lymphocyte syndrome type I disease_ontology DOID:0060009 OMIM mapping confirmed by DO. [SN]. MHC class I deficiency DOID:0060009 A severe combined immunodeficiency that has_material_basis in the RAG1 and RAG2 genes on chromosome 11p and the Artemis gene on chromosome 10p. It is characterized by erythroderma, desquamation, alopecia, chronic diarrhea, failure to thrive, lymphadenopathy, and hepatosplenomegaly. GARD:8198 ICD10CM:D81.8 OMIM:603554 combined immunodeficiency with hypereosinophilia disease_ontology DOID:0060010 Omenn syndrome DOID:0060010 A severe combined immunodeficiency that is a X-linked SCID that has_material_basis_in mutations in genes encoding common gamma chain proteins shared by the interleukin (IL-2,4,7,9,16 and21) receptors resulting in a non-functional gamma chain, defective interleukin signalling, minimal or ascent T- and NK cells and non-functional B-cells. DOID:5811 GARD:5618 MESH:D053632 NCI:C4682 OMIM:300400 SNOMEDCT_US_2020_03_01:203592006 UMLS_CUI:C1279481 SCID-X1 X-Linked Severe Combined Immunodeficiency XSCID gamma chain deficiency thymic epithelial hypoplasia disease_ontology DOID:0060013 OMIM mapping confirmed by DO. [LS]. X-linked severe combined immunodeficiency DOID:0060013 A severe combined immunodeficiency that is an actin regulator when mutated results in SCID through inhibition of thymic egress of mature thymocytes into peripheral lymphoid organs. OMIM:615401 disease_ontology DOID:0060019 coronin-1A deficiency DOID:0060019 A severe combined immunodeficiency that is the most severe form of SCID and has_material_basis_in mutations in the gene encoding mitochondrial adenylate kinase 2. It is characterized by congenital agranulocytosis, lymphopenia, and lymphoid and thymic hypoplasia with absent cellular and humoral immunity functions. DOID:1226 GARD:8625 MESH:C538361 NCI:C27070 OMIM:267500 SNOMEDCT_US_2020_03_01:111584000 UMLS_CUI:C0272167 De Vaal disease disease_ontology aleukocytosis DOID:0060020 OMIM mapping confirmed by DO. [SN]. reticular dysgenesis DOID:0060020 A combined T cell and B cell immunodeficiency that has_material_basis_in a mutation in the LIG4 gene, a DNA ligase, encoding a protein essential for V(D)J recombination and DNA double-strand break (DSB) repair through nonhomologous end joining (NHEJ). Patients present with immunodeficiency and developmental and growth delay. OMIM:606593 LIG4 Syndrome disease_ontology DOID:0060021 OMIM mapping confirmed by DO. [SN]. DNA ligase IV deficiency DOID:0060021 A combined T cell and B cell immunodeficiency that is a X-linked immunodeficiency with hyperimmunoglobulin M (XHIM) affecting isotype switching and is caused by the absence of CD40 ligand which is normally expressed on activated CD4+ T cells. Individuals with this mutation are unable to switch from IgM to IgG, IgA and IgE. OMIM:308230 HIGMX-1 X-linked hyper-IgM syndrome disease_ontology DOID:0060022 CD40 ligand deficiency DOID:0060022 A B cell deficiency that is an autosomal recessive disorder that has_material_basis_in mutation in the IgA (CD79 alpha) antigen receptor. GARD:10197 MESH:D017098 OMIM:137100 OMIM:269650 OMIM:609529 ORDO:69127 SNOMEDCT_US_2020_03_01:29260007 UMLS_CUI:C0162538 IgA deficiency gamma-A-globulin deficiency disease_ontology DOID:0060025 Xref MGI. immunoglobulin alpha deficiency DOID:0060025 A combined T cell and B cell immunodeficiency that is a condition where there is co-occurrence of deficient cell-mediated immunity and benign thymoma. thymoma with hypogammaglobulinemia disease_ontology DOID:0060028 Good syndrome DOID:0060028 An autoimmune disease that is the abnormal functioning of the immune system that causes your immune system to produce antibodies or T cells against cells and/or tissues in the exocrine system. disease_ontology DOID:0060029 autoimmune disease of exocrine system DOID:0060029 An autoimmune disease that is the abnormal functioning of the immune system that causes your immune system to produce antibodies or T cells against cells and/or tissues in the gastrointestinal tract. disease_ontology DOID:0060031 autoimmune disease of gastrointestinal tract DOID:0060031 An autoimmune disease that is the abnormal functioning of the immune system that causes your immune system to produce antibodies or T cells against cells and/or tissues in the musculoskeletal system. disease_ontology DOID:0060032 autoimmune disease of musculoskeletal system DOID:0060032 An autoimmune disease of the nervous system that is the abnormal functioning of the immune system that causes your immune system to produce antibodies or T cells against cells and/or tissues in the peripheral nervous system. disease_ontology DOID:0060033 autoimmune disease of peripheral nervous system DOID:0060033 A cardiomyopathy that is characterized as weakness in the muscle of the heart that is not due to an identifiable external cause. disease_ontology DOID:0060036 intrinsic cardiomyopathy DOID:0060036 A disease of mental health that occur during a child's developmental period between birth and age 18 resulting in retarding of the child's psychological or physical development. disease_ontology DOID:0060037 developmental disorder of mental health DOID:0060037 A developmental disorder of mental health that categorizes specific learning disabilities and developmental disorders affecting coordination. disease_ontology DOID:0060038 specific developmental disorder DOID:0060038 An autoimmune disease that is the abnormal functioning of the immune system that causes your immune system to produce antibodies or T cells against cells and/or tissues in the skin and connective tissue. disease_ontology DOID:0060039 autoimmune disease of skin and connective tissue DOID:0060039 A developmental disorder of mental health that refers to a group of five disorders characterized by impairments in socialization and communication, as well as restricted interests and repetitive behaviors. DOID:1208 ICD9CM:299.80 UMLS_CUI:C0154451 pervasive development disorder disease_ontology DOID:0060040 pervasive developmental disorder DOID:0060040 A pervasive developmental disorder that is a spectrum of psychological conditions. The disease has_symptom widespread abnormalities of social interactions and communication, has_symptom severely restricted interests and has_symptom highly repetitive behavior. GARD:10248 MESH:D000067877 disease_ontology DOID:0060041 autism spectrum disorder DOID:0060041 An autism spectrum disorder that involves some autistic symptoms occuring after age 3 with an abscence of all the traits necessary for a diagnosis of autism. PDD disease_ontology DOID:0060042 atypical autism DOID:0060042 A disease of mental health that involves the impairment in normal sexual functioning. disease_ontology DOID:0060043 sexual disorder DOID:0060043 A sexual disorder that is characterized recurrent, intense sexually arousing fantasies, sexual urges or behaviors generally involving nonhuman objects. disease_ontology DOID:0060044 paraphilia disorder DOID:0060044 A language disorder that involves an acquired impairment of any laguage modality such as producting or comprehending spoken or written language. disease_ontology DOID:0060046 aphasia MESH:D001037 DOID:0060046 A learning disability that involves impaired written language ability such as impairments in handwriting, spelling, organization of ideas, and composition. disease_ontology DOID:0060047 writing disorder DOID:0060047 An autoimmune disease that is the abnormal functioning of the immune system that causes your immune system to produce antibodies or T cells against cells and/or tissues in the urogenital tract. disease_ontology DOID:0060049 autoimmune disease of urogenital tract DOID:0060049 An autoimmune disease that is the abnormal functioning of the immune system that causes your immune system to produce antibodies or T cells against cells and/or tissues in the blood. disease_ontology DOID:0060050 autoimmune disease of blood DOID:0060050 An autoimmune disease that is the abnormal functioning of the immune system that causes your immune system to produce antibodies or T cells against cells and/or tissues in the cardiovascular system. disease_ontology DOID:0060051 autoimmune disease of cardiovascular system DOID:0060051 An immune system disease that has_material_basis_in abnormal immune responses. disease_ontology DOID:0060056 hypersensitivity reaction disease DOID:0060056 A hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs. DOID:1033 DOID:353 ICD10CM:C85.9 MESH:D008223 NCI:C3208 NCI:C7065 SNOMEDCT_US_2020_03_01:118600007 SNOMEDCT_US_2020_03_01:414628006 UMLS_CUI:C0024299 UMLS_CUI:C0598798 lymphoid cancer disease_ontology DOID:0060058 lymphoma DOID:0060058 A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma. MESH:D008228 OMIM:605027 ORDO:547 disease_ontology DOID:0060060 OMIM mapping confirmed by DO. [LS]. non-Hodgkin lymphoma DOID:0060060 A non-Hodgkin's lymphoma that has_material_basis_in a mutation of T cells. GARD:6226 MESH:D016410 cutaneous T-cell lymphoma disease_ontology DOID:0060061 cutaneous T cell lymphoma DOID:0060061 A kidney disease that is characterized by hyperuricemia with renal uric acid under-excretion, gout and chronic kidney disease. OMIM:162000 OMIM:613092 OMIM:614227 ORDO:209886 ORDO:217330 disease_ontology DOID:0060062 Xref MGI. OMIM mapping confirmed by DO. [LS]. familial juvenile hyperuricemic nephropathy DOID:0060062 A sideoblastic anemia that is characterized by the presence of microcytic hypochromic anemia and iron overload, and has_material_basis_in X-linked inheritance. OMIM:206000 disease_ontology DOID:0060066 OMIM mapping confirmed by DO. [LS]. pyridoxine-responsive sideroblastic anemia DOID:0060066 A mitochondrial metabolism disease that is characterized by sideroblastic anemia and exocrine pancreas dysfunction. GARD:7343 OMIM:557000 Pearson Marrow-Pancreas Syndrome disease_ontology DOID:0060067 OMIM mapping confirmed by DO. [LS]. Pearson syndrome DOID:0060067 A disease of cellular proliferation that results in abnormal growths in the body, which do not invade or destroy the surrounding tissue but, given enough time, will transform into a cancer. lschriml 2011-05-11T12:18:41Z disease_ontology DOID:0060071 pre-malignant neoplasm DOID:0060071 A disease of cellular proliferation that results in abnormal growths in the body which lack the ability to metastasize. lschriml 2011-05-11T12:18:41Z disease_ontology DOID:0060072 benign neoplasm DOID:0060072 An immune system cancer that is located_in the lymphatic system and is characterized by uncontrolled cellular proliferation of lymphoid tissue. lschriml 2011-05-11T01:05:14Z disease_ontology DOID:0060073 lymphatic system cancer DOID:0060073 A breast carcinoma in situ that is characterized by being non-invasive, not having spread outside of the duct into the surrounding breast tissue, has_material_basis_in abnormally proliferating cells, derives_from epithelial cells. lschriml 2011-06-08T12:19:28Z disease_ontology DOID:0060074 ductal carcinoma in situ DOID:0060074 A breast cancer that is characterized by the presence of estrogen receptors. lschriml 2011-06-08T12:23:02Z disease_ontology DOID:0060075 estrogen-receptor positive breast cancer DOID:0060075 A thoracic benign neoplasm that is characterized by lack of malignancy. lschriml 2011-06-08T01:02:29Z disease_ontology DOID:0060082 breast benign neoplasm DOID:0060082 An organ system cancer located_in the immune system that is characterized by uncontrolled cellular proliferation in organs of the immune system. lschriml 2011-06-08T01:11:18Z disease_ontology DOID:0060083 immune system cancer DOID:0060083 A benign neoplasm that is classified by the type of cell or tissue from which it is derived. lschriml 2011-07-14T11:59:48Z disease_ontology DOID:0060084 cell type benign neoplasm DOID:0060084 A benign neoplasm that is classified by the organ system from which it is arising from. lschriml 2011-07-14T12:12:23Z disease_ontology DOID:0060085 organ system benign neoplasm DOID:0060085 A reproductive organ benign neoplasm that is characterized by a lack of malignancy located_in the female reproductive system. lschriml 2011-07-14T12:20:52Z disease_ontology DOID:0060086 female reproductive organ benign neoplasm DOID:0060086 A reproductive organ benign neoplasm that is characterized by a lack of malignancy located_in the male reproductive system. lschriml 2011-07-14T12:20:52Z disease_ontology DOID:0060087 male reproductive organ benign neoplasm DOID:0060087 An organ system benign neoplasm that is located_in endocrine glands which secretes a type of hormone directly into the bloodstream to regulate the body. lschriml 2011-07-14T01:45:15Z disease_ontology DOID:0060089 endocrine organ benign neoplasm DOID:0060089 A nervous system benign neoplasm that is characterized by lack of malignancy. lschriml 2011-07-14T01:45:15Z disease_ontology DOID:0060090 central nervous system benign neoplasm DOID:0060090 An organ system benign neoplasm disease located_in the blood, heart, blood vessels or the lymphatic system. lschriml 2011-07-14T01:45:15Z disease_ontology DOID:0060091 cardiovascular organ benign neoplasm DOID:0060091 A connective tissue benign neoplasm that is located_in bone. lschriml 2011-07-15T01:34:59Z disease_ontology DOID:0060094 bone benign neoplasm DOID:0060094 A female reproductive organ benign neoplasm that is located_in the uterus. lschriml 2011-07-15T01:42:11Z DOID:0060113 disease_ontology DOID:0060095 uterine benign neoplasm DOID:0060095 A nervous system benign neoplasm that is located_in a sensory organ. lschriml 2011-07-15T01:45:26Z disease_ontology DOID:0060096 sensory organ benign neoplasm DOID:0060096 An organ system benign neoplam that is located_in the thoracic cavity. lschriml 2011-07-15T01:55:57Z disease_ontology DOID:0060097 thoracic benign neoplasm DOID:0060097 A bone benign neoplasm of the bone that is characterized by clinical and histological similarity to osteoid osteomas. lschriml 2011-07-15T02:14:40Z MESH:D018215 disease_ontology DOID:0060098 osteoblastoma DOID:0060098 An organ system benign neoplasm that is located_in the muscular and skeletal organs. lschriml 2011-07-15T02:28:52Z disease_ontology DOID:0060099 musculoskeletal system benign neoplasm DOID:0060099 An organ system cancer located_in the muscular and skeletal organs and characterized by uncontrolled cellular proliferation of the musculoskeletal organs. lschriml 2011-07-15T02:30:51Z DOID:0060124 skeletal system cancer disease_ontology DOID:0060100 musculoskeletal system cancer DOID:0060100 A cell type benign neoplasm that has_material_basis_in glial cells. lschriml 2011-07-19T01:27:04Z disease_ontology DOID:0060101 benign glioma DOID:0060101 A central nervous system cancer of children and young adults that develops from neural crest cells located_in cerebrum, has_material_basis_in abnormally proliferating cells derives_from neuroectoderm. lschriml 2011-07-21T02:24:10Z disease_ontology DOID:0060103 central nervous system primitive neuroectodermal neoplasm DOID:0060103 A brain cancer that has_material_basis_in glial cells. lschriml 2011-07-22T12:42:50Z lower grade glioma disease_ontology DOID:0060108 brain glioma DOID:0060108 A female reproductive organ benign neoplasm that is located_in the vulva. lschriml 2011-07-25T11:50:50Z disease_ontology DOID:0060109 vulvar benign neoplasm DOID:0060109 A female reproductive organ benign neoplasm that is located_in the ovary. lschriml 2011-07-25T11:50:50Z disease_ontology DOID:0060112 ovarian benign neoplasm DOID:0060112 An organ system benign neoplasm that is located_in the central nervous system or located_in the peripheral nervous system. lschriml 2011-07-25T12:47:43Z disease_ontology DOID:0060115 nervous system benign neoplasm DOID:0060115 A nervous system cancer that is located in the sensory system. lschriml 2011-07-25T01:51:56Z disease_ontology DOID:0060116 sensory system cancer DOID:0060116 A disease of anatomical entity that is located_in the thoracic cavity. lschriml 2011-07-25T02:23:47Z disease_ontology DOID:0060118 thoracic disease DOID:0060118 A gastrointestinal system cancer that is located_in the pharynx. lschriml 2011-07-27T01:26:34Z MESH:D010610 NCI:C3325 SNOMEDCT_US_2020_03_01:126685009 UMLS_CUI:C0031347 pharyngeal neoplasm pharynx neoplasm disease_ontology pharyngeal cancer DOID:0060119 pharynx cancer DOID:0060119 An organ system benign neoplasm located_in the integumentary system organs. lschriml 2011-07-27T01:49:44Z disease_ontology DOID:0060121 integumentary system benign neoplasm DOID:0060121 An organ system cancer that is located_in the skin, hair and nails. lschriml 2011-07-27T02:31:34Z disease_ontology DOID:0060122 integumentary system cancer DOID:0060122 A musculoskeletal system benign neoplasm that is located_in connective tissue. lschriml 2011-07-27T02:35:57Z DOID:177 MESH:D012983 NCI:C3377 SNOMEDCT_US_2020_03_01:126600002 UMLS_CUI:C0037579 neoplasm of soft tissue neoplasm of soft tissues soft tissue benign neoplasm tumor of the soft tissue disease_ontology DOID:0060123 connective tissue benign neoplasm DOID:0060123 A hypersensitivity reaction type IV disease that results from a proliferation of cells producing immunoglobulin heavy chains. lschriml 2011-08-22T11:23:09Z ICD10CM:C88.2 MESH:D006362 NCI:C3082 NCI:C3083 NCI:C3892 SNOMEDCT_US_2020_03_01:61493004 SNOMEDCT_US_2020_03_01:6381009 SNOMEDCT_US_2020_03_01:68979007 UMLS_CUI:C0018852 UMLS_CUI:C0018854 UMLS_CUI:C0242310 disease_ontology DOID:0060125 heavy chain disease MESH:D006362 DOID:0060125 A heavy chain disease that results from an overproduction of alpha antibodies (IgA). lschriml 2011-08-22T11:23:09Z Seligmann's disease disease_ontology DOID:0060126 alpha chain disease DOID:0060126 A heavy chain disease that results from an overproduction of gamma antibody (IgG). lschriml 2011-08-22T11:23:09Z GARD:10346 Franklin's disease disease_ontology DOID:0060127 gamma heavy chain disease DOID:0060127 A heavy chain disease that results from an overproduction of mu antibody (IgM). lschriml 2011-08-22T11:23:09Z disease_ontology DOID:0060128 mu chain disease DOID:0060128 An agnosia that is a deficiency in understanding, processing, or describing emotions. lschriml 2011-08-22T12:04:56Z disease_ontology DOID:0060131 alexithymia DOID:0060131 An agnosia that is a loss of the ability to recognize musical notes, rhythms, and intervals. lschriml 2011-08-22T12:04:56Z receptive amusia disease_ontology DOID:0060132 amusia DOID:0060132 An agnosia that is a loss of the ability to gain feedback about one's own condition or impairments. lschriml 2011-08-22T12:04:56Z disease_ontology DOID:0060133 anosognosia DOID:0060133 An agnosia that is a loss of the ability to distinguish visual shapes. lschriml 2011-08-22T12:04:56Z disease_ontology DOID:0060134 apperceptive agnosia DOID:0060134 An agnosia that is a loss of the ability to map out physical actions in order to repeat them in functional activities. lschriml 2011-08-22T12:04:56Z GARD:5838 ICD10CM:R48.2 SNOMEDCT_US_2019_09_01:68345001 disease_ontology DOID:0060135 apraxia MESH:D001072 DOID:0060135 An agnosia that is a loss of the ability to recognize visual scenes or classes of objects but retain the abilty to describe them. lschriml 2011-08-22T12:04:56Z disease_ontology DOID:0060136 associative agnosia DOID:0060136 An agnosia that is a loss of the ability to distinguishing environmental and non-verbal auditory cues including difficulty distinguishing speech from non-speech sounds even though hearing is usually normal. lschriml 2011-08-22T12:04:56Z disease_ontology DOID:0060137 auditory agnosia DOID:0060137 An agnosia that is a loss of the ability to perceive any auditory information but whose hearing is intact. lschriml 2011-08-22T12:04:56Z disease_ontology DOID:0060140 cortical deafness DOID:0060140 An agnosia that is a loss of the ability to distinguish the fingers on the hand. lschriml 2011-08-22T12:04:56Z disease_ontology DOID:0060141 finger agnosia DOID:0060141 An agnosia that is a loss of the ability to perceive a whole object while perceiving only parts of details. lschriml 2011-08-22T12:04:56Z disease_ontology DOID:0060142 form agnosia DOID:0060142 An agnosia that is a loss of the ability to perceive and process pain. lschriml 2011-08-22T12:04:56Z analgesia disease_ontology DOID:0060145 pain agnosia DOID:0060145 An agnosia that is a loss of the ability to recgonize a whole image or scene while retianing the ability to recognize objects or details in their visual field one at a time. lschriml 2011-08-22T12:04:56Z GARD:11943 disease_ontology DOID:0060148 simultanagnosia DOID:0060148 An agnosia that is the loss of the ability to recognize objects by touch based on its texture, size and weight. lschriml 2011-08-22T12:04:56Z somatosensory agnosia disease_ontology DOID:0060150 astereognosia DOID:0060150 An agnosia that is a loss of the ability to recognize or identify objects by touch alone. lschriml 2011-08-22T12:04:56Z disease_ontology DOID:0060151 tactile agnosia DOID:0060151 An agnosia that is a loss of the ability to recognising spoken words as semantically meaningful. lschriml 2011-08-22T12:04:56Z disease_ontology DOID:0060154 verbal auditory agnosia DOID:0060154 An agnosia that is a loss of the ability to visually recognize objects. lschriml 2011-08-22T12:04:56Z MESH:C531604 UMLS_CUI:C2930796 disease_ontology DOID:0060155 visual agnosia DOID:0060155 A disease of metabolism that has _material_basis_in enzyme deficiency or accumulation of enzymes or toxins which interfere with normal function due to an endocrine organ disease, organ malfunction, inadequate intake, dietary deficiency, or malabsorption. lschriml 2011-08-24T02:53:03Z disease_ontology DOID:0060158 acquired metabolic disease DOID:0060158 An amino acid metabolic disorder that disrupts normal amino acid metabolism causing a building up of branched-chain amino acids. lschriml 2011-08-26T11:17:14Z GARD:9433 organic acid metabolism disorder organic aciduria disease_ontology DOID:0060159 organic acidemia DOID:0060159 A spinal muscular atrophy that is associated with the survival of motor neuron protein in childhood. lschriml 2011-08-29T01:15:14Z GARD:7674 MESH:D014897 NCI:C85076 ORDO:70 UMLS_CUI:C0700595 spinal muscular atrophies of childhood survival motor neuron spinal muscular atrophy disease_ontology DOID:0060160 childhood spinal muscular atrophy DOID:0060160 A spinal muscular dystrophy that has_material_basis_in an X-linked recessive expansion of CAG triplet repeats (glutamine) in exon 1 of AR gene encoding the androgen receptor. lschriml 2011-08-29T01:31:03Z GARD:6818 MESH:D055534 NCI:C85233 OMIM:313200 SNOMEDCT_US_2020_03_01:230253001 UMLS_CUI:C1839259 Kennedy disease SBMA Spinobulbar Muscular Atrophy X-Linked Bulbo-Spinal Atrophy X-linked Spinal and Bulbar Muscular Atrophy spinal bulbar muscular atrophy disease_ontology DOID:0060161 Kennedy's disease DOID:0060161 An autosomal dominant cerebellar ataxia that has_material_basis_in expansion of CAG triplet repeats (glutamine) encoding a polyglutamine tract in the atrophin-1 protein. lschriml 2011-08-29T01:41:48Z GARD:5643 MESH:D020191 NCI:C122653 OMIM:125370 SNOMEDCT_US_2020_03_01:702422004 UMLS_CUI:C0751781 DRPLA Haw River Syndrome Naito-Oyanagi disease disease_ontology DOID:0060162 dentatorubral-pallidoluysian atrophy MESH:D020191 NCI:C122653 UMLS_CUI:C0751781 DOID:0060162 A somatoform disorder that involves an excessive concern about and preoccupation with a perceived defect in his or her physical features (body image). lschriml 2011-09-07T01:38:34Z body dysmorphia dysmorphic syndrome dysmorphophobia disease_ontology DOID:0060163 body dysmorphic disorder DOID:0060163 A somatoform disorder that involves chronic pain in one or more areas, and is thought to be caused by psychological stress. lschriml 2011-09-07T01:42:46Z disease_ontology DOID:0060164 pain disorder DOID:0060164 A recurrent hypersomnia that is characterized by recurring periods of excessive amounts of sleep and altered behavior. lschriml 2011-09-07T02:46:02Z MESH:D017593 OMIM:148840 disease_ontology DOID:0060165 Kleine-Levin syndrome DOID:0060165 A histidine metabolism disease characterized by a deficiency of the enzyme histidase. lschriml 2011-09-20T12:47:05Z GARD:6661 MESH:C538320 OMIM:235800 histidinuria disease_ontology DOID:0060168 histidinemia DOID:0060168 An infancy electroclinical syndrome that is characterized by convulsions, with onset at age 3 to 12 months. lschriml 2011-10-28T02:55:02Z GARD:1518 GARD:857 OMIM:601764 OMIM:605751 OMIM:607745 OMIM:612627 ORDO:306 BFIC BFIE benign familial infantile convulsion benign familial infantile seizures disease_ontology DOID:0060169 Xref MGI. benign familial infantile epilepsy DOID:0060169 An adolescence-adult electroclinical syndrome statring between the age of ten to 17 years characterized by the occurrence of typical absence seizures. lschriml 2011-11-08T10:42:18Z disease_ontology DOID:0060172 JA:Epilepsy Genetics Kiel juvenile absence epilepsy DOID:0060172 A syndrome that is characterized by cardiac, hand/foot, facial, and neurodevelopmental features. The two forms are type 1 (classic) and type 2, a rare form that has_material_basis_in mutations in a transcript variant of CACNA1C on chromosome 12p13.33. lschriml 2011-11-08T12:52:33Z DOID:0110649 ICD10CM:G72.3 MESH:C536962 OMIM:601005 ORDO:65283 ORDO:768 disease_ontology DOID:0060173 Timothy syndrome DOID:0060173 A gamma-amino butyric acid metabolism disorder that is characterized by a deficiency of succinic semialdehyde dehydrogenase resulting in elevated levels of gamma-hydroxybutyric acid. lschriml 2011-11-08T02:02:12Z MESH:C535803 OMIM:271980 4-hydroxybutyric aciduria SSADH gamma-hydroxybutyric aciduria disease_ontology DOID:0060175 succinic semialdehyde dehydrogenase deficiency DOID:0060175 An amino acid metabolic disorder characterized by impairment of the GABA catabolic pathway. lschriml 2011-11-08T02:02:12Z disease_ontology DOID:0060176 gamma-amino butyric acid metabolism disorder DOID:0060176 A gamma-amino butyric acid metabolism disorder that is characterized by an excess of homocarnosine in the brain and has_material_basis_in a deficiency of serum carnosinase in its ability to hydrolyze homocarnosine. lschriml 2011-11-08T02:02:12Z GARD:2730 MESH:C535328 disease_ontology DOID:0060177 homocarnosinosis DOID:0060177 An inflammatory bowel disease that involves inflammation located_in colon. emitraka 2014-09-12T14:31:45Z EFO:0003872 ICD10CM:K52.9 MESH:D003092 NCI:C26723 SNOMEDCT_US_2020_03_01:64226004 UMLS_CUI:C0009319 disease_ontology DOID:0060180 colitis DOID:0060180 An urticaria induced by external physical influences. emitraka 2014-11-21T15:51:38Z disease_ontology DOID:0060220 WD correction. physical urticaria DOID:0060220 A heart conduction disease that is characterized by uncoordinated electrical activity in the heart's upper chambers (the atria), which causes the heartbeat to become fast and irregular and has symptoms palpitations, weakness, fatigue, lightheadedness, dizziness, confusion, shortness of breath and chest pain. emitraka 2015-01-16T14:55:21Z ICD9CM:427.31 MESH:D001281 NCI:C50466 SNOMEDCT_US_2020_03_01:266306001 UMLS_CUI:C0004238 A-fib disease_ontology DOID:0060224 atrial fibrillation MESH:D001281 DOID:0060224 A gastrointestinal system disease that is located_in the gallbladder. emitraka 2015-02-02T15:48:08Z DOID:0000000 ICD10CM:K82.9 ICD9CM:575.9 MESH:D005705 NCI:C34631 OMIM:609918 OMIM:609919 OMIM:611465 SNOMEDCT_US_2020_03_01:155807008 UMLS_CUI:C0016977 disease_ontology DOID:0060262 Xref MGI. gallbladder disease DOID:0060262 A non-syndromic intellectual disability characterized by an autosomal dominant inheritance pattern. emitraka 2015-02-10T16:47:55Z GARD:12107 OMIM:PS156200 ORDO:178469 autosomal dominant mental retardation autosomal dominant non-syndromic mental retardation disease_ontology DOID:0060307 NT MGI. autosomal dominant non-syndromic intellectual disability DOID:0060307 A syndromic intellectual characterized by an X-linked inheritance pattern. emitraka 2015-02-11T16:14:46Z OMIM:PS309510 syndromic X-linked mental retardation disease_ontology DOID:0060309 NT MGI. syndromic X-linked intellectual disability DOID:0060309 A syndrome associated with mutations encoding defective proteins, which result in either abnormal function formation or function of cilia. emitraka 2015-05-21T10:41:29Z disease_ontology DOID:0060340 ciliopathy DOID:0060340 A chromosomal disease that has_material_basis_in partial deletion of chromosomes. elvira 2015-09-28T15:48:41Z disease_ontology DOID:0060388 chromosomal deletion syndrome DOID:0060388 A chromosomal disease that has_material_basis_in extra copies of a chromosomal region. elvira 2015-10-02T15:19:23Z disease_ontology DOID:0060429 chromosomal duplication syndrome DOID:0060429 A corneal dystrophy that is characterized by abnormal deposition of proteins in the cornea and is caused by mutations in TGFBI gene of chromosome 5q. elvira 2015-10-16T16:39:25Z disease_ontology DOID:0060441 epithelial-stromal TGFBI dystrophy DOID:0060441 A corneal dystrophy that affects the corneal stroma. elvira 2015-10-16T16:39:25Z disease_ontology DOID:0060442 stromal dystrophy DOID:0060442 A corneal dystrophy that affects the corneal endothelium and/or the descemet membrane. elvira 2015-10-16T16:39:25Z endothelial dystrophy disease_ontology DOID:0060443 corneal endothelial dystrophy DOID:0060443 An allergic disease that is located_in the respiratory tract. airway allergy disease_ontology DOID:0060496 respiratory allergy DOID:0060496 An allergic disease that is located_in the gastrointestinal tract. disease_ontology DOID:0060502 gastrointestinal allergy DOID:0060502 A food allergy triggered by a plant fruit product. disease_ontology DOID:0060503 fruit allergy DOID:0060503 A bone disease that is located_in the spine. disease_ontology DOID:0060564 spinal disease DOID:0060564 A syndrome that is characterized by abdominal obesity, blood lipid disorders, inflammation, insulin resistance or full-blown diabetes, and increased risk of developing cardiovascular disease. GARD:9226 OMIM:PS605552 disease_ontology DOID:0060611 abdominal obesity-metabolic syndrome DOID:0060611 An ichthyosis that is characterized by autosomal recessive inheritance and abnormal skin scaling over the whole body due to a defect in keratinization. DOID:1699 ICD10CM:Q80.2 MESH:D017490 NCI:C84805 OMIM:PS242300 ORDO:281097 SNOMEDCT_US_2020_03_01:12215009 UMLS_CUI:C0079154 ARCI lamellar ichthyosis non bullous congenital ichthyosiform erythroderma disease_ontology DOID:0060655 autosomal recessive congenital ichthyosis DOID:0060655 A congenital nervous system abnormality characterized by failure of the anterior neuropore to close resulting in partial or complete absence of the cranial vault accompanied by absence of overlying tissues, including the brain and cerebral hemispheres, skull and scalp. GARD:5808 ICD10CM:Q00.0 OMIM:206500 ORDO:1048 disease_ontology DOID:0060668 anencephaly MESH:D000757 DOID:0060668 A leukodystrophy characterized by T2 hyperintensity and T1 iso- or hyperintensity of affected white matter in the central nervous system. OMIM:PS312080 HLD disease_ontology DOID:0060786 hypomyelinating leukodystrophy DOID:0060786 A syndrome that has_material_basis_in homozygous deletion on chromosome 2p21 that disrupts the SLC3A1 and PREPL genes. The deletion ranges in size from 23.8 to 75.5 kb. Itis characterized_by neonatal and infantile hypotonia and failure to thrive, cystinuria type 1 and nephrolithiasis, growth retardation due to growth hormone deficiency, and minor facial dysmorphism. ICD10CM:E72.0 OMIM:606407 ORDO:163690 cystinuria with mitochondrial disease disease_ontology DOID:0060858 hypotonia-cystinuria syndrome DOID:0060858 A primary bacterial infectious disease caused by the bacteria of the genus Salmonella. It has sypmtoms diarrhea, fever, vomiting, and abdominal cramps 12 to 72 hours after infection. In most cases, the illness lasts four to seven days, and most people recover without treatment. ICD10CM:A02.0 ICD9CM:003.0 Salmonella infection disease_ontology DOID:0060859 salmonellosis DOID:0060859 A vascular disease caused by the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. MESH:D013927 disease_ontology DOID:0060903 thrombosis DOID:0060903 A fruit allergy triggered by Fabaceae (legume) plant fruit or seed food product. Fabaceae allergy disease_ontology DOID:0060904 legume allergy DOID:0060904 A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from precursor cells called blast cells. disease_ontology DOID:0070003 blastoma DOID:0070003 A bone marrow cancer that is formed of any one of the bone marrow cells belonging to the granulocytic (neutrophil, eosinophil, basophil), monocytic/macrophage, erythroid, megakaryocytic and mast cell lineages. myeloma disease_ontology DOID:0070004 myeloid neoplasm DOID:0070004 An electroclinical syndrome characterized by the occurrence of generalized onset seizures that cause lapses in awareness, begin and end abruptly, typically last only a few seconds and are associated with abnormal spike-wave discharges as seen by electroencephalogram. MESH:D004832 disease_ontology DOID:0070309 absence epilepsy DOID:0070309 A nutritional deficiency disease that is characterized by low levels of thiamine. NCI:C34418 SNOMEDCT_US_2020_03_01:399357009 disease_ontology DOID:0070313 thiamine deficiency disease DOID:0070313 A mitochondrial metabolism disease that is characterized by significant reduction in mitochondrial DNA in affected tissues, resulting in impaired mtDNA-encoded protein synthesis and energy production in the affected tissues and organs. GARD:13643 OMIM:PS603041 ORDO:35698 mtDNA depletion syndrome disease_ontology DOID:0070329 mitochondrial DNA depletion syndrome DOID:0070329 A musculoskeletal system disease that affects the muscles. disease_ontology DOID:0080000 muscular disease DOID:0080000 A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. DOID:1290 ICD10CM:M89.9 MESH:D001847 SNOMEDCT_US_2020_03_01:76069003 UMLS_CUI:C0005940 disease_ontology skeletal disease DOID:0080001 bone disease DOID:0080001 A bone disease that results_in formation or resorption abnormalities located_in bone. disease_ontology DOID:0080005 bone remodeling disease DOID:0080005 A bone disease that results_in abnormal growth and development located_in bone or located_in cartilage. disease_ontology DOID:0080006 bone development disease DOID:0080006 A bone structure disease that results_in change or damage of structure located_in bone. disease_ontology DOID:0080007 bone deterioration disease DOID:0080007 A bone disease that results_in an interruption of blood supply located_in bone. disease_ontology DOID:0080008 ischemic bone disease DOID:0080008 A X-linked monogenic disease that has_material_basis_in dominant inheritance. disease_ontology DOID:0080009 X-linked dominant disease DOID:0080009 A bone disease that has_material_basis_in an abnormality in the location or function of the skeletal structure. disease_ontology DOID:0080010 bone structure disease DOID:0080010 A bone remodeling disease that results in an abnormal decrease of bone density or mass. MESH:D001862 disease_ontology DOID:0080011 bone resorption disease DOID:0080011 A X-linked monogenic disease that has_material_basis_in recessive inheritance. disease_ontology DOID:0080012 X-linked recessive disease DOID:0080012 A genetic disease that has_material_basis_in extra, missing, or re-arranged chromosomes. disease_ontology DOID:0080014 chromosomal disease DOID:0080014 A disease that has_material_basis_in a genetic abnormality, error with embryonic development, infection or compromised intrauterine environment. congenital disorder disease_ontology DOID:0080015 physical disorder DOID:0080015 A neural tube defect that is characterized by incomplete closing of the spine and membranes around the spinal cord during early development. GARD:7673 ICD10CM:Q05 ICD9CM:741 MESH:D016135 NCI:C101214 SNOMEDCT_US_2020_03_01:156888006 UMLS_CUI:C0080178 disease_ontology DOID:0080016 spina bifida MESH:D016135 NCI:C101214 DOID:0080016 An osteochondrodysplasia that is characterized by abnormally broad ends of the arm and leg long bones resembling a boat oar or paddle due to enlargement of the spongy inner layer of bone. OMIM:215050 Bakwin-Krida syndrome Pyle's disease Pyle-Cohn syndrome disease_ontology DOID:0080019 metaphyseal dysplasia DOID:0080019 An osteochondrodysplasia that results_in abnormalities of bone growth located_in vertebral column, located_in epiphysis, located_in metaphysis. disease_ontology DOID:0080027 spondyloepimetaphyseal dysplasia DOID:0080027 A bone remodeling disease that results_in the destruction of normal bone and replacing it with fibrous bone tissue. GARD:6444 disease_ontology DOID:0080031 fibrous dysplasia DOID:0080031 An osteosclerosis that is characterized by hyperostosis and sclerosis of the craniofacial bones associated with abnormal modeling of the metaphyses. OMIM:PS123000 ORDO:1522 disease_ontology DOID:0080033 Xref MGI. craniometaphyseal dysplasia DOID:0080033 A hyperostosis that has_material_basis_in a mutation in the SOST gene which results_in overgrowth of endosteal bone producing dense and wide bones throughout the body especially located_in skull. DOID:0080035 OMIM:239100 ORDO:3152 van Buchem disease disease_ontology DOID:0080036 SOST-related sclerosing bone dysplasia DOID:0080036 An osteochondrodysplasia that has_material_basis_in a mutation in the CTSK gene which results_in dwarfism, brittle bones, osteopetrosis, shortening of the distal phalanges. GARD:4611 MESH:D058631 OMIM:265800 ORDO:763 disease_ontology DOID:0080038 pycnodysostosis DOID:0080038 An osteochondrodysplasia that has_material_basis_in mutation in the FGFR3 gene which affects ossification of cartilage and results_in short limb dwarfism. GARD:6724 ICD10CM:Q77.4 MESH:C562937 NCI:C118697 OMIM:146000 ORDO:429 SNOMEDCT_US_2020_03_01:205468002 UMLS_CUI:C0410529 disease_ontology DOID:0080041 hypochondroplasia DOID:0080041 An osteochondrodysplasia that has_material_basis_in deficient endochondral ossification which results_in dwarfism, short-trunk, short-limbed, anascara, disaprportionately large cranium, and a narrow chest which leads to death in utero or during early neonatal period. GARD:2882 OMIM:PS200600 disease_ontology DOID:0080043 achondrogenesis DOID:0080043 An osteochondrodysplasia that has_material_basis_in a mutation in the COL2A1 gene which results_in dwarfism with a short trunk and limbs as well as vision and hearing problems. The disease has_symptom large joints, has_symptom wide set eyes, has_symptom round flat face. GARD:6841 MESH:C537207 OMIM:156550 disease_ontology DOID:0080045 Kniest dysplasia DOID:0080045 A syndrome that is characterized by a distinctive facial appearance, eye abnormalities, hearing loss, and joint problems. GARD:10782 OMIM:PS108300 ORDO:828 disease_ontology DOID:0080046 OMIM mapping confirmed by DO. [SN]. Stickler syndrome DOID:0080046 An osteochondrodysplasia that has_material_basis_in mutations in the COMP gene which results_in short limb dwarfism. DOID:14800 GARD:4540 MESH:C535819 OMIM:177170 PSEUDOACHONDROPLASIA SPONDYLOEPIPHYSEAL DYSPLASIA, PSEUDOACHONDROPLASTIC pseudoachondroplastic dysplasia disease_ontology DOID:0080047 OMIM mapping confirmed by DO. [SN]. pseudoachondroplasia DOID:0080047 An osteochondrodysplasia that has_material_basis_in mesomelia and acromelia, which results_in short limb dwarfism. GARD:6 ORDO:93437 disease_ontology DOID:0080049 acromesomelic dysplasia DOID:0080049 A colonic disease that is characterized by bowel obstruction resulting from impairment of the muscle contractions that move food through the digestive tract. lschriml 2015-10-19T14:28:30Z DOID:3878 GARD:12744 GARD:6789 MESH:D007418 NCI:C34733 ORDO:2978 SNOMEDCT_US_2020_03_01:715201005 UMLS_CUI:C0021847 Chronic intestinal pseudo-obstruction neuronal intestinal dysplasia disease_ontology DOID:0080072 intestinal pseudo-obstruction DOID:0080072 A physical disorder characterized by incomplete closure of the neural tube. lschriml 2015-10-19T14:41:42Z GARD:4016 OMIM:301410 OMIM:601634 disease_ontology DOID:0080074 neural tube defect DOID:0080074 A mitochondrial DNA depletion syndrome that is characterized by a clinical triad of psychomotor retardation, intractable epilepsy, and liver failure in infants and young children, and has_material_basis_in autosomal recessive inheritance of homozygous or compound heterozygous mutation in the nuclear gene encoding mitochondrial DNA polymerase gamma on chromosome 15q26. DOID:1442 GARD:5783 ICD10CM:G31.81 MESH:D002549 NCI:C35257 OMIM:203700 ORDO:726 SNOMEDCT_US_2020_03_01:20415001 UMLS_CUI:C0205710 Alper's syndrome Alpers disease Alpers progressive infantile poliodystrophy Alpers syndrome Alpers' disease or gray-matter degeneration Diffuse Cerebral Sclerosis of Schilder mitochondrial DNA depletion syndrome 4a progressive sclerosing poliodystrophy disease_ontology DOID:0080122 Alpers-Huttenlocher syndrome MESH:D002549 DOID:0080122 A mitochondrial DNA depletion syndrome that is characterized by progressive ataxia, hypotonia, hyporeflexia, athetosis and sensory impairment and has_material_basis_in autosomal recessive homozygous or compound heterozygous mutation in the C10ORF2 gene, which encodes the twinkle and twinky proteins, on chromosome 10q24. DOID:0050556 GARD:4062 MESH:C535523 OMIM:271245 OHAHA SYNDROME infantile onset spinocerebellar ataxia disease_ontology DOID:0080126 mitochondrial DNA depletion syndrome 7 DOID:0080126 A lipid storage disease characterized by lysosomal and lipase deficiency. OMIM:278000 disease_ontology DOID:0080217 lysosomal and lipase deficiency DOID:0080217 A central nervous system benign neoplasm the is located_in the peripheral nervous system. disease_ontology DOID:0080320 peripheral nervous system benign neoplasm DOID:0080320 A peripheral nervous system benign neoplasm that is located_in the autonomic nervous system. disease_ontology DOID:0080321 autonomic nervous system benign neoplasm DOID:0080321 A cystic kidney disease that is characterized by the growth of fluid-filled cysts in the kidneys that reduces kidney function and may lead to kidney failure. OMIM:PS173900 disease_ontology DOID:0080322 polycystic kidney disease DOID:0080322 A gastrointestinal system cancer that is located_in the hepatobiliary system. disease_ontology DOID:0080355 hepatobiliary system cancer DOID:0080355 A cell type cancer that is composed_of epithelial tissue in which tumor cells form glands or glandlike structures, representing an early form of colorectal cancer. disease_ontology DOID:0080364 malignant adenoma DOID:0080364 A male reproductive system disease that is located_in the epididymis. disease_ontology DOID:0080373 epididymis disease DOID:0080373 A peroxisomal biogenesis disorder that has_material_basis_in defects in PEX genes. DOID:0080378 OMIM:PS214100 disease_ontology DOID:0080377 peroxisomal biogenesis disorder DOID:0080377 An early infantile epileptic encephalopathy that has_material_basis_in heterozygous mutation in the SCN1A gene on chromosome 2q24. DOID:0060171 GARD:10430 OMIM:607208 ORDO:33069 early infantile epileptic encephalopathy 6 disease_ontology DOID:0080422 Dravet syndrome DOID:0080422 A lipid storage disease that is characterized by increased storage of carbohydrates and lipids. disease_ontology DOID:0080488 mucolipidosis DOID:0080488 A thyroid gland carcinoma that derives_from epithelial cells of glandular origin. NCI:C27380 disease_ontology DOID:0080524 thyroid gland adenocarcinoma DOID:0080524 A thyroid gland adenocarcinoma characterized by extensive evidence of follicular cell differentiation. NCI:C7153 disease_ontology DOID:0080525 differentiated thyroid gland carcinoma DOID:0080525 A hyperimmunoglobin syndrome that is characterized by an immune system that fails to produce normal levels of the antibodies IgA, IgG and IgE but can produce normal or elevated levels of IgM. NCI:C3990 OMIM:PS308230 immunodeficiency with hyper-IgM disease_ontology DOID:0080544 hyper IgM syndrome DOID:0080544 A hyperimmunoglobulin syndrome that is characterized by eczema, distinct facial features, a tendency to experience bone fractures and recurrent bacterial infections of the skin and lungs. GARD:10956 OMIM:PS147060 hyper immunoglobulin E syndrome disease_ontology DOID:0080545 hyper IgE syndrome DOID:0080545 A viral infectious disease that has_material_basis_in Coronavirus. disease_ontology DOID:0080599 Coronavirus infectious disease DOID:0080599 A benign neoplasm that derives_from germ cells. disease_ontology DOID:0080601 germ cell benign neoplasm DOID:0080601 A germ cell benign neoplasm that derives_from mature tissue elements or a limited amount of immature tissue elements. NCI:C67107 disease_ontology DOID:0080602 benign teratoma DOID:0080602 A kidney benign neoplasm that is located_in the kidney cortex. benign nephroma disease_ontology DOID:0080615 nephroma DOID:0080615 A kidney disease that is located_in the kidney cortex. disease_ontology DOID:0080616 kidney cortex disease DOID:0080616 A sensory system benign neoplasm that is located in the auditory system. NCI:C8417 disease_ontology DOID:0080619 auditory system benign neoplasm DOID:0080619 A B-cell acute lymphoblastic leukemia that is characterized by the presence of too many B-cell lymphoblasts in the blood and bone marrow. DOID:7061 NCI:C8936 UMLS_CUI:C0862030 B-ALL precursor B lymphoblastic lymphoma/leukemia disease_ontology DOID:0080630 B-lymphoblastic leukemia/lymphoma DOID:0080630 An acute lymphocytic leukemia characterized by too many B-cell lymphoblasts (immature white blood cells) in the bone marrow and blood. NCI:C8644 B acute lymphoblastic leukemia B-cell acute lymphocytic leukemia disease_ontology DOID:0080638 B-cell acute lymphoblastic leukemia DOID:0080638 A bone cancer that has_material_basis_in abnormally proliferating cells derives from embryonic mesoderm. disease_ontology DOID:0080639 bone sarcoma DOID:0080639 A syndrome that has_material_basis_in mutations in genes that alter the Ras subfamily and mitogen-activated protein kinases that control signal transduction. RAS/mitogen-activated protein kinase syndrome disease_ontology DOID:0080690 RASopathy DOID:0080690 An asthma that is characterized by severe and sudden onset of increasing wheezing, airways closing, smooth muscle contraction, mucus plugging and lower airway edema that may be reversible upon treatment. disease_ontology DOID:0080810 acute asthma DOID:0080810 A malignant glioma that originate from two types of glial cells, astrocytes and oligodendrocytes. NCI:C132067 disease_ontology DOID:0080829 low-grade glioma DOID:0080829 A low-grade glioma that occurs in children and encompasses tumors of astrocytic, oligodendroglial, and mixed glial-neuronal histology. disease_ontology DOID:0080830 pediatric low-grade glioma DOID:0080830 A hypogonadism characterized by a impaired signalling by gonadotrpin relasing hormone. DOID:7455 ICD10CM:E23.0 OMIM:PS147950 ORDO:432 ORDO:478 congenital idiopathic hypogonadotropic hypogonadism hypogonadotropism isolated congenital gonadotropin deficiency disease_ontology DOID:0090070 hypogonadotropic hypogonadism DOID:0090070 A neuronal ceroid lipofuscinosis that is characterized by juvenile-onset of progressive dementia, seizures, and progressive visual failure and an ultrastructural pattern of lipopigment with a 'fingerprint' profile and has_material_basis_in homozygous or compound heterozygous mutation in the CLN3 gene on chromosome 16p11. DOID:0050756 GARD:5897 ICD10CM:E75.4 OMIM:204200 ORDO:228346 Batten disease CLN3 juvenile neuronal ceroid lipofuscinosis disease_ontology DOID:0110731 neuronal ceroid lipofuscinosis 3 DOID:0110731 A neurodegenerative disease characterized by progressive iron accumulation in the basal ganglia and other regions of the brain, resulting in extrapyramidal movements, such as parkinsonism and dystonia. GARD:11899 MESH:C538421 OMIM:PS234200 ORDO:385 UMLS_CUI:C2931845 NBIA disease_ontology DOID:0110734 neurodegeneration with brain iron accumulation DOID:0110734 A congenital muscular dystrophy-dystroglycanopathy type A characterized by cobblestone lissencephaly, muscle weakness, and brain and eye anomalies that has_material_basis_in autosomal recessive inheritance a defect in alpha-dystroglycan post-translational processing. OMIM:PS236670 ORDO:352687 MDDGA congenital muscular alpha-dystroglycanopathy with brain and eye anomalies klissencephaly type 2 with muscular and ocular involvement disease_ontology DOID:0111229 congenital muscular dystrophy-dystroglycanopathy type A DOID:0111229 A familial hyperlipidemia characterized by hypertriglyceridemia and fasting chylomicronemia. ORDO:444490 disease_ontology DOID:0111417 familial chylomicronemia syndrome DOID:0111417 A syndrome characterized by facial, limbs and genital anomalies, and a disproportionate acromelic short stature. ORDO:915 Aarskog-Scott syndrome faciodigitogenital syndrome faciogenital dysplasia disease_ontology DOID:0111824 Aarskog syndrome DOID:0111824 A syndrome characterized by sparse, brittle, sulfur-deficient hair that is easily broken and in more severe cases delayed development, significant intellectual disability, and recurrent infections. MESH:D054463 NCI:C4924 ORDO:33364 SNOMEDCT_US_2020_03_01:723551003 UMLS_CUI:C1955934 TTD disease_ontology DOID:0111866 trichothiodystrophy DOID:0111866 A trichothiodystrophy characterized by absence of extreme sensitivity to UV radiation. disease_ontology DOID:0111867 nonphotosensitive trichothiodystrophy DOID:0111867 A primary immunodeficiency disease that involves multiple components of the immune system. disease_ontology DOID:0111962 combined immunodeficiency DOID:0111962 An intestinal disease that involves intestinal infection that has_material_basis_in viruses, bacteria, fungi and parasites. DOID:10960 DOID:12509 DOID:5270 ICD10CM:A00-A09 ICD9CM:001-009.99 SNOMEDCT_US_2020_03_01:187266003 UMLS_CUI:C0178238 bacterial enteritis disease_ontology DOID:100 Updating outdated UMLS CUI. intestinal infectious disease DOID:100 DOID:11053 DOID:12112 DOID:12114 ICD9CM:389.1 MESH:D006319 NCI:C26739 SNOMEDCT_US_2020_03_01:60700002 UMLS_CUI:C0018784 High Frequency Hearing Loss High frequency deafness Perceptive deafness Perceptive hearing loss Perceptive hearing loss or deafness Sensorineural Deafness Sensory hearing loss central hearing loss high-frequency hearing loss disease_ontology DOID:10003 sensorineural hearing loss MESH:D006319 DOID:10003 NCI:C5265 UMLS_CUI:C1336753 disease_ontology DOID:10011 thyroid lymphoma DOID:10011 A multiple endocrine neoplasia that has_material_basis_in a mutation in the MEN1 tumor suppressor gene and is characterized by over active endocrine glands frequently involving tumors of the parathyroid glands, the pituitary gland, and the pancreas. GARD:3829 ICD10CM:E31.21 ICD9CM:258.01 MESH:D018761 NCI:C3225 OMIM:131100 ORDO:652 SNOMEDCT_US_2020_03_01:30664006 UMLS_CUI:C0025267 MEN type I Wermer syndrome Wermer's syndrome disease_ontology DOID:10017 OMIM mapping confirmed by DO. [SN]. multiple endocrine neoplasia type 1 DOID:10017 An endometrial disease that is characterized by inflammation of the endometrium. MESH:D004716 NCI:C26764 SNOMEDCT_US_2020_03_01:155975003 UMLS_CUI:C0014179 disease_ontology DOID:1002 endometritis DOID:1002 ICD10CM:C24.1 ICD9CM:156.2 NCI:C3536 SNOMEDCT_US_2020_03_01:93668007 UMLS_CUI:C0153454 malignant tumour of ampulla of vater disease_ontology DOID:10020 ampulla of Vater cancer DOID:10020 A small intestine cancer that is located_in the beginning section of the small intestine. DOID:6072 ICD10CM:C17.0 ICD9CM:152.0 MESH:D004379 NCI:C4803 NCI:C9328 SNOMEDCT_US_2020_03_01:254570009 SNOMEDCT_US_2020_03_01:363403002 UMLS_CUI:C0153426 UMLS_CUI:C0541912 Duodenal cancer cancer of duodenum duodenal neoplasm disease_ontology DOID:10021 duodenum cancer DOID:10021 A migraine characterized by migraine headache which is preceded or accompanied by a transient focal neurological phenomenon. DOID:10025 ICD10CM:G43.1 ICD9CM:346.0 MESH:D020325 NCI:C117005 OMIM:609179 OMIM:609670 SNOMEDCT_US_2020_03_01:155047002 UMLS_CUI:C0154723 classic migraine disease_ontology DOID:10024 Xref MGI. migraine with aura DOID:10024 A tertiary neurosyphilis that results in slow degeneration of the nerve cells and nerve fibers that carry sensory information to the brain. The infection has symptom intense, stabbing pain in the back and legs that recurs irregularly, has symptom gait ataxia, has symptom hyperesthesia, has symptom paresthesia, has symptom loss of bladder sensation leading to urine retention, has symptom erectile dysfunction. GARD:8730 ICD10CM:A52.11 ICD9CM:094.0 MESH:D013606 NCI:C35057 SNOMEDCT_US_2020_03_01:266134000 UMLS_CUI:C0039223 Posterior spinal sclerosis Tabes dorsalis - neurosyphilis disease_ontology DOID:10027 tabes dorsalis DOID:10027 A female reproductive system disease that is characterized by an infection of the female reproductive organs. ICD10CM:N73.9 ICD9CM:614.9 MESH:D000292 NCI:C3889 SNOMEDCT_US_2020_03_01:266648001 UMLS_CUI:C0242172 PID disease_ontology DOID:1003 pelvic inflammatory disease DOID:1003 ICD10CM:H52.52 ICD9CM:367.51 SNOMEDCT_US_2020_03_01:68158006 UMLS_CUI:C0235238 Ciliary muscle paresis Cycloplegic paralysis of accommodation Paresis of accommodation disease_ontology DOID:10033 cycloplegia DOID:10033 An eye disease that is characterized by decreased ability to change the optical power of the eye to maintain a clear image. ICD10CM:H52.5 ICD9CM:367.5 SNOMEDCT_US_2020_03_01:155137002 UMLS_CUI:C0152198 disease_ontology DOID:10034 eye accommodation disease DOID:10034 MESH:D004416 UMLS_CUI:C0205747 FAMM syndrome familial atypical multiple mole-melanoma disease_ontology DOID:10041 OMIM mapping confirmed by DO. [SN]. dysplastic nevus syndrome DOID:10041 A melanoma that is characterized as highly aggressive and manifests as a uniform blue-black, blue-red, or amelanotic nodule. GARD:9961 NCI:C4225 SNOMEDCT_US_2020_03_01:2142002 UMLS_CUI:C0334424 nodular melanoma disease_ontology DOID:10047 nodular malignant melanoma DOID:10047 A uterine disease that is located_in the endometrium. NCI:C3504 SNOMEDCT_US_2020_03_01:418632009 UMLS_CUI:C0151622 disease_ontology DOID:1005 endometrial disease DOID:1005 NCI:C4426 SNOMEDCT_US_2020_03_01:126696001 UMLS_CUI:C0345746 Subglottic tumor disease_ontology DOID:10069 subglottis neoplasm DOID:10069 A parasitic helminthiasis infectious disease that involves infection of the bowel by Hymenolepis nana or Hymenolepis diminuta. The symptoms include diarrhea, gastrointestinal discomfort, itchy anus, poor appetite and weakness. GARD:2787 ICD10CM:B71.0 ICD9CM:123.6 MESH:D006925 NCI:C84768 SNOMEDCT_US_2020_03_01:187153007 UMLS_CUI:C0020413 Hymenolepis infectious disease dwarf tapeworm infection disease_ontology DOID:10074 hymenolepiasis DOID:10074 A parasitic helminthiasis infectious disease that involves parasitic infection caused by Diphyllobothrium latum through the consumption of raw or undercooked fish. The symptoms include abdominal discomfort, diarrhea, vomiting, weight loss and vitamin B12 deficiency with pernicious anemia. GARD:942 ICD10CM:B70.0 ICD9CM:123.4 MESH:D004169 NCI:C128391 SNOMEDCT_US_2020_03_01:187151009 UMLS_CUI:C0012561 DiphylloboInOwlthrium infection fish tapeworm disease_ontology DOID:10075 diphyllobothriasis MESH:D004169 DOID:10075 A taeniasis that results from ingestion of eggs or larvae of the Taenia solium tapeworm in undercooked pork or fecally contaminated food or water, which subsequently infect the central nervous system, heart, muscles, subcutaneous tissues, and eyes. Neurocysticercosis causes seizures, mental disturbances, focal neurologic deficits and intracerebral lesions. DOID:10078 DOID:14424 GARD:8194 ICD10CM:B69 ICD9CM:123.1 MESH:D003551 NCI:C34520 SNOMEDCT_US_2020_03_01:59051007 UMLS_CUI:C0010678 Pork tapeworm infection Tapeworm infection: intestinal taenia solum Tapeworm infection: pork intestinal taenia solium infection neurocysticercosis tenia solium infectious disease disease_ontology DOID:10079 cysticercosis DOID:10079 A parasitic helminthiasis infectious disease that involves parasitic infection by the genus Spirometra. A painful nodule develops after the plerocercoid larvae migrate to the brain causing cerebral sparganosis. Subcutaneous tissue, breast, orbit, urinary tract, pleural cavity, lungs, abdominal viscera and inner ear can be infected. ICD10CM:B70.1 ICD9CM:123.5 MESH:D013031 NCI:C35030 SNOMEDCT_US_2020_03_01:187152002 UMLS_CUI:C0037753 Infection by Sparganum Sparganosis disease_ontology DOID:10080 sparganosis MESH:D013031 DOID:10080 A central nervous system disease that is located_in the skull and is characterized by a collection of pus (infected material) inside the skull. ICD9CM:324.0 NCI:C34734 SNOMEDCT_US_2020_03_01:192738001 UMLS_CUI:C0021874 disease_ontology DOID:10095 intracranial abscess DOID:10095 A trypanosomiasis that results from infection by Trypanosoma brucei and gambiense, which is transmitted by the bite of an infected tsetse fly (Glossina spp). The symptoms include fever, headache, joint pain, itching, confusion, sensory disturbances, poor coordination and sleep disturbances. ICD10CM:B56 ICD9CM:086.5 KEGG:05143 MESH:D014353 NCI:C84541 SNOMEDCT_US_2020_03_01:27031003 UMLS_CUI:C0041228 African sleeping sickness African trypanosomiasis disease_ontology DOID:10112 sleeping sickness DOID:10112 A parasitic protozoa infectious disease that involves infection caused by parasitic protozoan of the genus Trypanosoma in animals and humans. ICD10CM:B57.2 ICD9CM:086 MESH:D014352 SNOMEDCT_US_2020_03_01:266205000 UMLS_CUI:C0041227 disease_ontology DOID:10113 trypanosomiasis DOID:10113 A skin disease that is characterized by discoloration of the skin. ICD9CM:709.09 UMLS_CUI:C0375489 disease_ontology DOID:10123 pigmentation disease DOID:10123 An eye disease that affects the cornea, which is the transparent surface of the eye that assists in light refraction. DOID:2284 ICD10CM:H18.9 ICD9CM:371.9 MESH:D003316 NCI:C26731 SNOMEDCT_US_2020_03_01:15250008 UMLS_CUI:C0010034 disease_ontology DOID:10124 corneal disease DOID:10124 A corneal disease characterized by structural changes within the cornea causing it to thin and change, leading to a protruding conical shape. GARD:6824 ICD10CM:H18.6 ICD9CM:371.6 MESH:D007640 NCI:C26806 OMIM:148300 OMIM:608586 OMIM:608932 OMIM:609271 OMIM:614622 OMIM:614623 OMIM:614628 OMIM:614629 ORDO:156071 SNOMEDCT_US_2020_03_01:267733008 UMLS_CUI:C0022578 conical cornea disease_ontology DOID:10126 Xref MGI. keratoconus DOID:10126 A vein disease that is characterized by impaired flow of blood through the veins. ICD9CM:459.81 MESH:D014689 NCI:C127822 SNOMEDCT_US_2020_03_01:20696009 UMLS_CUI:C0042485 peripheral venous insufficiency disease_ontology DOID:10128 venous insufficiency DOID:10128 ICD9CM:302.79 UMLS_CUI:C0033951 disease_ontology DOID:10132 psychosexual disorder DOID:10132 ICD10CM:E50.7 ICD9CM:375.15 MESH:D014985 NCI:C34503 SNOMEDCT_US_2020_03_01:193887002 UMLS_CUI:C0043349 Conjunctival xerosis disease_ontology DOID:10138 xerophthalmia DOID:10138 ICD10CM:H11.10 ICD9CM:372.50 SNOMEDCT_US_2020_03_01:40787005 UMLS_CUI:C0155160 disease_ontology DOID:10139 conjunctival degeneration DOID:10139 A lacrimal apparatus disease that is characterized by persistent irritation or burning of the coreneal surface. ICD10CM:H04.12 MESH:D015352 NCI:C34553 SNOMEDCT_US_2020_03_01:193980001 UMLS_CUI:C0013238 Tear film insufficiency dry eye disease disease_ontology DOID:10140 dry eye syndrome MESH:D015352 DOID:10140 An intestinal cancer that is located_in the small intestine. GARD:9385 ICD10CM:C17 ICD9CM:152.9 NCI:C7523 SNOMEDCT_US_2020_03_01:363509000 UMLS_CUI:C0153425 disease_ontology DOID:10154 small intestine cancer DOID:10154 A gastrointestinal system cancer that is located_in the intestine. ICD10CM:C26.0 ICD9CM:159.0 MESH:D007414 NCI:C4572 SNOMEDCT_US_2020_03_01:93838000 UMLS_CUI:C0346627 malignant intestinal tumors malignant neoplasm of intestine disease_ontology DOID:10155 intestinal cancer DOID:10155 An ischemic bone disease that results_in necrosis located_in bone. DOID:10160 DOID:10161 DOID:10162 DOID:10163 DOID:10164 DOID:4128 DOID:8380 DOID:86 ICD10CM:M87 ICD10CM:M87.9 ICD9CM:732.3 ICD9CM:733.41 ICD9CM:733.42 ICD9CM:733.43 ICD9CM:733.44 MESH:D010020 NCI:C34404 NCI:C34841 NCI:C34880 NCI:C35226 NCI:C35517 SNOMEDCT_US_2020_03_01:156837008 SNOMEDCT_US_2020_03_01:17926002 SNOMEDCT_US_2020_03_01:240196003 SNOMEDCT_US_2020_03_01:29281007 SNOMEDCT_US_2020_03_01:43453000 SNOMEDCT_US_2020_03_01:62100001 SNOMEDCT_US_2020_03_01:83453001 UMLS_CUI:C0003977 UMLS_CUI:C0027543 UMLS_CUI:C0029445 UMLS_CUI:C0158442 UMLS_CUI:C0158449 UMLS_CUI:C0158450 UMLS_CUI:C0158451 UMLS_CUI:C0745048 Avascular necrosis of bone aseptic necrosis bone necrosis disease_ontology DOID:10159 osteonecrosis DOID:10159 A skin benign neoplasm that derives_from fat cells. DOID:10198 DOID:3943 ICD9CM:214.0 NCI:C4616 NCI:C5566 SNOMEDCT_US_2020_03_01:255187008 SNOMEDCT_US_2020_03_01:93159009 UMLS_CUI:C0153968 UMLS_CUI:C0347394 UMLS_CUI:C1333174 Cutaneous Lipoma Lipoma of skin cutaneous lipomatous tumor lipoma of face disease_ontology DOID:10188 skin lipoma DOID:10188 A bone inflammation disease that has_material_basis_in infection located_in bone or located_in bone marrow. DOID:1018 DOID:1020 DOID:10281 DOID:10282 DOID:10692 DOID:10860 DOID:1164 DOID:11788 DOID:11959 DOID:12011 DOID:13673 DOID:13674 DOID:13675 DOID:13678 DOID:13684 DOID:13737 DOID:14003 DOID:14100 DOID:14166 DOID:2249 DOID:2250 DOID:5858 DOID:9456 GARD:7286 ICD9CM:730.1 SNOMEDCT_US_2020_03_01:203181001 UMLS_CUI:C0008707 disease_ontology DOID:1019 osteomyelitis DOID:1019 A breast benign neoplasm that is composed of lipocytes. NCI:C4647 SNOMEDCT_US_2020_03_01:276891009 UMLS_CUI:C0349565 Lipoma of breast disease_ontology DOID:10199 breast lipoma DOID:10199 EFO:0004799 ICD9CM:574.5 SNOMEDCT_US_2020_03_01:197397004 UMLS_CUI:C0006739 disease_ontology DOID:10211 cholelithiasis DOID:10211 A myositis that results_in inflammation located_in muscle or located_in skin where a skin rash is often seen prior to the onset of muscle weakness. The disease may result from either a viral infection or an autoimmune reaction. GARD:6263 ICD10CM:M33 ICD9CM:710.3 MESH:D003882 NCI:C26744 SNOMEDCT_US_2020_03_01:38826005 UMLS_CUI:C0011633 Polymyositis with skin involvement dermatopolymyositis disease_ontology Amyopathic dermatomyositis Amyopathic dermatomyositis DOID:10223 MESH:C538250 added from NeuroDevNet [WAK]. dermatomyositis DOID:10223 ICD10CM:I70.0 ICD9CM:440.0 SNOMEDCT_US_2020_03_01:81817003 UMLS_CUI:C0155733 Aortic atherosclerosis Atherosclerosis of aorta disease_ontology DOID:10230 aortic atherosclerosis DOID:10230 ICD10CM:F65.2 ICD9CM:302.4 MESH:D005084 NCI:C94352 SNOMEDCT_US_2020_03_01:192514003 UMLS_CUI:C0015269 disease_ontology DOID:10236 exhibitionism DOID:10236 A primary bacterial infectious disease that results_in infection located_in superficial peripheral nerves, located_in skin, located_in mucous membranes of the upper respiratory tract, located_in anterior chamber of the eyes, or located_in testes, has_material_basis_in Mycobacterium leprae, which is transmitted_by aerosol spread from infected nasal secretions to exposed nasal and oral mucosa. The infection has_symptom skin lesions, has_symptom sensory loss, has_symptom motor loss and has_symptom eye damage. EFO:0001054 GARD:6886 ICD10CM:A30 ICD9CM:030 MESH:D007918 NCI:C84824 OMIM:607572 OMIM:609888 OMIM:613407 ORDO:548 SNOMEDCT_US_2020_03_01:154298007 UMLS_CUI:C0023343 disease_ontology DOID:1024 Xref MGI. leprosy DOID:1024 A hemolytic anemia characterized by decreased synthesis of one or more hemoglobin polypeptide chains. DOID:12242 DOID:12243 GARD:7756 ICD10CM:D56 ICD9CM:282.4 MESH:D013789 NCI:C35069 SNOMEDCT_US_2020_03_01:191192008 UMLS_CUI:C0039730 Sickle-cell thalassemia with crisis Sickle-cell thalassemia without crisis thalassemia Hb-S disease with crisis thalassemia Hb-S disease without crisis disease_ontology DOID:10241 OMIM mapping confirmed by DO. [LS]. thalassemia DOID:10241 A primary bacterial infectious disease that results in infection located_in leukocyte, has_material_basis_in Ehrlichia chaffeensis or Anaplasma phagocytophilum, which are transmitted_by lone start stick and transmitted_by black-legged tick respectively. The infection has_symptom headache, has_symptom muscle aches, has_symptom fatigue and has_symptom rash. DOID:0050023 GARD:2092 ICD10CM:A77.4 ICD9CM:082.4 MESH:D016873 SNOMEDCT_US_2020_03_01:77361002 UMLS_CUI:C0085399 human ehrlichiosis disease_ontology DOID:10242 ehrlichiosis MESH:D016873 DOID:10242 A pleural disease that is characterized by inflammation of the pleura, the lining of the pleural cavity surrounding the lungs. ICD9CM:511.8 UMLS_CUI:C0029799 disease_ontology DOID:10247 pleurisy DOID:10247 A viral infectious disease that results in infection in sheep and rarely humans, has_material_basis_in Louping ill virus, which is transmitted by sheep tick, Ixodes ricinus. The infection has symptom lethargy, has symptom muscle pains, has symptom fever, and has symptom focal neurological signs. ICD10CM:A84.8 ICD9CM:063.1 MESH:D008146 SNOMEDCT_US_2020_03_01:59350003 UMLS_CUI:C0024025 Louping ill disease_ontology DOID:10250 louping ill DOID:10250 A viral infectious disease that results in inflammation located in salivary gland, has_material_basis_in Mumps rubulavirus, which is transmitted by droplet spread of saliva or mucus from the mouth, nose, or throat of an infected person, or transmitted by contaminated fomites. The infection has symptom fever, has symptom headache, has symptom muscle aches, has symptom tiredness, has symptom loss of appetite, has symptom swollen and tender salivary glands under the ears or jaw on one or both sides of the face. GARD:7116 ICD10CM:B26 ICD9CM:072 MESH:D009107 NCI:C29888 SNOMEDCT_US_2020_03_01:154352008 UMLS_CUI:C0026780 disease_ontology DOID:10264 mumps DOID:10264 A cardiovascular system disease that involves the heart's electrical conduction system. ICD9CM:426.6 SNOMEDCT_US_2020_03_01:195053008 UMLS_CUI:C0029630 heart rhythm disease disease_ontology DOID:10273 heart conduction disease DOID:10273 A male reproductive organ cancer that is located_in the prostate. DOID:514 ICD10CM:C61 ICD9CM:185 KEGG:05215 MESH:D011471 NCI:C3343 NCI:C7378 OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959 ORDO:1331 SNOMEDCT_US_2020_03_01:126906006 SNOMEDCT_US_2020_03_01:93974005 UMLS_CUI:C0033578 UMLS_CUI:C0376358 NGP - new growth of prostate hereditary prostate cancer malignant tumor of the prostate prostate cancer, familial prostate neoplasm prostatic cancer prostatic neoplasm tumor of the prostate disease_ontology DOID:10283 Xref MGI. OMIM mapping confirmed by DO. [SN]. prostate cancer DOID:10283 GARD:6422 ICD10CM:G72.3 MESH:D010245 NCI:C84709 SNOMEDCT_US_2020_03_01:193241004 UMLS_CUI:C0030443 disease_ontology DOID:1029 familial periodic paralysis DOID:1029 ICD10CM:I73.0 MESH:D011928 OMIM:179600 SNOMEDCT_US_2020_03_01:195295006 UMLS_CUI:C0034734 Raynaud's disease Raynaud's syndrome disease_ontology DOID:10300 OMIM mapping confirmed by DO. [SN]. Raynaud disease MESH:D011928 DOID:10300 A parotid disease characterized by the inflammation of one or both parotid glands. ICD10CM:K11.2 MESH:D010309 NCI:C114281 SNOMEDCT_US_2020_03_01:196481002 UMLS_CUI:C0030583 disease_ontology DOID:10301 parotitis MESH:D010309 DOID:10301 MESH:D010305 UMLS_CUI:C0030579 disease_ontology DOID:10302 parotid disease DOID:10302 GARD:7638 ICD10CM:K11.2 ICD9CM:527.2 MESH:D012793 NCI:C26882 SNOMEDCT_US_2020_03_01:42982001 UMLS_CUI:C0037023 Sialoadenitis disease_ontology DOID:10303 sialadenitis DOID:10303 A endocardium disease characterized by inflammation of the endocardium of the heart chambers and valves. DOID:14058 ICD10CM:I33.9 ICD9CM:421.9 MESH:D004696 NCI:C34582 NCI:C35432 SNOMEDCT_US_2020_03_01:56819008 SNOMEDCT_US_2020_03_01:91357005 UMLS_CUI:C0014118 UMLS_CUI:C0375268 disease_ontology DOID:10314 endocarditis DOID:10314 An interstitial lung disease that is caused by the inhalation of dust. ICD10CM:J64 ICD9CM:505 MESH:D011009 NCI:C26861 SNOMEDCT_US_2020_03_01:196004000 UMLS_CUI:C0032273 disease_ontology DOID:10316 pneumoconiosis DOID:10316 A pneumoconiosis caused by inhalation and retention of asbestos fibers. GARD:5852 ICD10CM:J61 ICD9CM:501 MESH:D001195 NCI:C84573 SNOMEDCT_US_2020_03_01:266400008 UMLS_CUI:C0003949 disease_ontology DOID:10320 asbestosis DOID:10320 GARD:5976 ICD10CM:J66.0 MESH:D002095 NCI:C84605 SNOMEDCT_US_2020_03_01:155589004 UMLS_CUI:C0006542 Flax-dressers' disease Stripper's asthma cotton mill fever disease_ontology DOID:10323 byssinosis DOID:10323 A pneumoconiosis that is an inflammation and scarring of the uper lobes of the lungs causing nodular lesions resulting from inhalation of silica, quartz or slate particles. DOID:14007 GARD:7647 ICD10CM:J62.8 ICD9CM:502 MESH:D012829 NCI:C3369 SNOMEDCT_US_2020_03_01:155590008 UMLS_CUI:C0037116 Pneumoconiosis due to silicates Silica pneumoconiosis Silicotic fibrosis of lung silicotuberculosis disease_ontology DOID:10325 silicosis DOID:10325 ICD10CM:J60 ICD9CM:500 MESH:D055008 NCI:C34390 SNOMEDCT_US_2020_03_01:29422001 UMLS_CUI:C0003165 Coal Miner's Pneumoconiosis Coal workers' lung Coal workers' pneumoconiosis Melanoedema black lung disease_ontology DOID:10327 anthracosis DOID:10327 GARD:7645 ICD10CM:J63.4 MESH:D012806 SNOMEDCT_US_2020_03_01:155591007 UMLS_CUI:C0037061 pulmonary siderosis disease_ontology DOID:10328 siderosis DOID:10328 GARD:5932 ICD10CM:H02.52 ICD9CM:374.46 MESH:D016569 UMLS_CUI:C0005744 disease_ontology DOID:10348 blepharophimosis MESH:D016569 DOID:10348 A breast benign neoplasm that is characterized by a fluid-filled sac. ICD10CM:N60.0 MESH:D047688 NCI:C5315 SNOMEDCT_US_2020_03_01:56726003 UMLS_CUI:C0006144 Cyst of the breast disease_ontology DOID:10350 breast cyst DOID:10350 A leukemia that has_material_basis_in a B-cell or T-cell lineage involving primarily the bone marrow and the peripheral blood. DOID:10747 ICD10CM:C91 ICD9CM:204 MESH:D007945 NCI:C7539 SNOMEDCT_US_2020_03_01:93170002 UMLS_CUI:C0023448 lymphoblastic leukaemia lymphoblastic leukemia lymphocytic leukaemia lymphoid leukemia disease_ontology DOID:1037 lymphoid leukemia DOID:1037 A primary bacterial infectious disease that results in infection located in skin, located in joint or located in bone, has_material_basis_in Treponema pallidum subsp pertenue, which is transmitted by direct skin contact with an infected person. The infection has symptom skin lesions. GARD:7913 ICD10CM:A66 ICD9CM:102 MESH:D015001 NCI:C41353 SNOMEDCT_US_2020_03_01:266213004 UMLS_CUI:C0043388 Bouba frambesia frambesia tropica frambosie polypapilloma tropicum thymosis disease_ontology DOID:10371 yaws DOID:10371 ICD10CM:H53.03 ICD9CM:368.01 MESH:D000550 SNOMEDCT_US_2020_03_01:35600002 UMLS_CUI:C0750903 Strabismic amblyopia disease_ontology DOID:10375 suppression amblyopia DOID:10375 An eye disease that is characterized by poor vision in one eye resulting from the brain failing to process inputs from one eye and over time favors the other eye. ICD10CM:H53.00 ICD9CM:368.00 MESH:D000550 NCI:C118764 SNOMEDCT_US_2020_03_01:155145007 UMLS_CUI:C0002418 disease_ontology DOID:10376 amblyopia MESH:D000550 DOID:10376 ICD10CM:H53.01 ICD9CM:368.02 SNOMEDCT_US_2020_03_01:193638002 UMLS_CUI:C0152189 Deprivation amblyopia disease_ontology DOID:10378 disuse amblyopia DOID:10378 MESH:D015463 NCI:C3181 SNOMEDCT_US_2020_03_01:110006004 UMLS_CUI:C0023486 disease_ontology DOID:1039 prolymphocytic leukemia DOID:1039 ICD10CM:M89.4 ICD9CM:731.2 MESH:D010005 SNOMEDCT_US_2020_03_01:46922002 UMLS_CUI:C0029412 Bamberger-Marie disease HPOA - hypertrophic pulmonary osteoarthropathy Marie Bamberger disease hypertrophic pulmonary osteoarthropathy disease_ontology DOID:10393 secondary hypertrophic osteoarthropathy DOID:10393 A plague that results_in infection located_in lung, which results from direct inhalation of the bacillus and has_symptom fever, has_symptom chills, has_symptom cough and has_symptom difficulty breathing. DOID:10401 DOID:10402 ICD10CM:A20.2 ICD9CM:020.3 ICD9CM:020.4 ICD9CM:020.5 MESH:D010930 SNOMEDCT_US_2020_03_01:35339003 SNOMEDCT_US_2020_03_01:38976008 SNOMEDCT_US_2020_03_01:67525007 UMLS_CUI:C0152937 UMLS_CUI:C0152938 UMLS_CUI:C0524688 primary pneumonic plague secondary pneumonic plague disease_ontology DOID:10398 pneumonic plague DOID:10398 A disease by infectious agent that results_in infection, has_material_basis_in Bacteria. ICD10CM:A49.9 MESH:D001424 NCI:C2890 SNOMEDCT_US_2020_03_01:87628006 UMLS_CUI:C0004623 disease_ontology DOID:104 bacterial infectious disease DOID:104 A lymphocytic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood. EFO:0000095 GARD:6104 ICD10CM:C91.10 ICD9CM:204.1 MESH:D015451 NCI:C3163 OMIM:109543 OMIM:151400 OMIM:609630 OMIM:612557 OMIM:612558 OMIM:612559 ORDO:67038 SNOMEDCT_US_2020_03_01:51092000 UMLS_CUI:C0023434 B-cell chronic lymphocytic leukaemia B-cell chronic lymphocytic leukemia CLL chronic lymphatic leukaemia chronic lymphatic leukemia chronic lymphocytic leukaemia lymphoplasmacytic leukaemia lymphoplasmacytic leukemia disease_ontology B-cell chronic lymphoid leukemia DOID:1040 Xref MGI. chronic lymphocytic leukemia DOID:1040 A physical disorder that is characterized by abnormal segmentation of the vertebra during fetal development which results in fusion located in cervical vertebra. DOID:14747 GARD:10280 ICD10CM:Q76.1 ICD9CM:756.16 MESH:D007714 NCI:C98967 OMIM:PS118100 ORDO:2345 SNOMEDCT_US_2020_03_01:268349005 UMLS_CUI:C0022738 Klippel-Feil and Turner syndrome Klippel-Feil deformity, deafness and facial asymmetry autosomal dominant Klippel-Feil syndrome congenital dystrophia brevicollis congenital synostosis of cervical vertebrae disease_ontology DOID:10426 Xref MGI. OMIM mapping confirmed by DO. [SN]. Klippel-Feil syndrome DOID:10426 A corneal ulcer that is characterized by painful peripheral corneal ulceration, sterile limbal inflammation, and episcleral and conjunctival edema. ICD10CM:H16.05 ICD9CM:370.07 SNOMEDCT_US_2020_03_01:22440001 UMLS_CUI:C0155072 Mooren ulcer disease_ontology DOID:10439 Mooren's ulcer DOID:10439 An upper respiratory tract disease which is characterized by inflammation of the tonsils resulting from bacterial (Group A streptococcus) and viral (Epstein-Barr virus, adenovirus) infections. Symptoms include a severe sore throat, painful or difficult swallowing, coughing, headache, myalgia, fever and chills. DOID:10454 DOID:13751 ICD10CM:J35.01 ICD9CM:474.00 MESH:D014069 NCI:C116006 SNOMEDCT_US_2020_03_01:195665006 SNOMEDCT_US_2020_03_01:195794009 UMLS_CUI:C0040425 UMLS_CUI:C0149517 Throat infection - tonsillitis chronic tonsillitis disease_ontology DOID:10456 tonsillitis DOID:10456 A legionellosis that is characterized by severe form of infection producing pneumonia. Symptoms include fever, chills, and cough. ICD10CM:A48.1 ICD9CM:482.84 MESH:D007877 NCI:C128339 SNOMEDCT_US_2020_03_01:195889001 UMLS_CUI:C0023241 Infection by Legionella pneumophilia Legionella Legionella pneumonia Legionnaire's disease disease_ontology DOID:10457 Legionnaires' disease DOID:10457 A primary bacterial infectious disease that results_in infection located_in respiratory tract, has_material_basis_in Legionella pneumophila, which is transmitted_by inhalation of droplets containing bacteria. The symptoms include dry cough, fever, headache and diarrhea. MESH:D007876 NCI:C128334 SNOMEDCT_US_2020_03_01:26726000 UMLS_CUI:C0023240 Legionella infection disease_ontology DOID:10458 legionellosis DOID:10458 An upper respiratory tract disease which involves inflammation of the mucous membranes of the nose, throat, eyes, and eustachian tubes with watery then purulent discharge. This is an acute contagious disease caused by rhinoviruses, human parainfluenza viruses, human respiratory syncytial virus, influenza viruses, adenoviruses, enteroviruses, or metapneumovirus. ICD10CM:J00 ICD9CM:460 MESH:D003139 NCI:C34500 SNOMEDCT_US_2020_03_01:195648002 UMLS_CUI:C0009443 Acute viral rhinopharyngitis Nasopharyngitis - acute Nasopharyngitis, acute acute Nasopharyngitis acute coryza acute nasopharyngitis acute rhinitis rhino-sinusitis disease_ontology DOID:10459 common cold DOID:10459 A nasopharyngeal disease which involves inflammation of the nasal passages and upper part of the pharynx. DOID:11587 ICD10CM:J00 ICD10CM:J31.1 ICD9CM:472.2 MESH:D009304 NCI:C34837 SNOMEDCT_US_2020_03_01:155524006 SNOMEDCT_US_2020_03_01:51476001 UMLS_CUI:C0027441 UMLS_CUI:C0155826 chronic nasopharyngitis disease_ontology DOID:10460 nasopharyngitis DOID:10460 ICD10CM:K02 ICD9CM:521.02 SNOMEDCT_US_2020_03_01:442551007 UMLS_CUI:C0266846 Compound dental caries Dental caries extending into dentine Dentin caries disease_ontology DOID:10461 dentin caries DOID:10461 ICD10CM:M76.5 ICD9CM:726.64 SNOMEDCT_US_2020_03_01:156662006 UMLS_CUI:C0158317 Patellar tendonitis disease_ontology DOID:10471 patellar tendinitis DOID:10471 ICD10CM:Q79.1 MESH:D003965 NCI:C98912 SNOMEDCT_US_2020_03_01:34168003 UMLS_CUI:C0011981 disease_ontology DOID:10480 diaphragmatic eventration DOID:10480 A muscular disease that is located_in the diaphragm. ICD10CM:J98.6 ICD9CM:519.4 SNOMEDCT_US_2020_03_01:48475001 UMLS_CUI:C0152097 disease_ontology DOID:10481 diaphragm disease DOID:10481 GARD:6381 ICD10CM:Q39.0 MESH:D004933 NCI:C87072 SNOMEDCT_US_2020_03_01:156947007 UMLS_CUI:C0014850 Congenital atresia of esophagus Congenital imperforate esophagus Imperforate esophagus Oesophageal atresia disease_ontology DOID:10485 esophageal atresia DOID:10485 ICD10CM:Q41.1 MESH:D007409 NCI:C84790 UMLS_CUI:C0021828 disease_ontology DOID:10486 intestinal atresia DOID:10486 A megacolon that is characterized by a blockage of the large intestine due to improper muscle movement in the bowel. GARD:6660 ICD10CM:Q43.1 MESH:D006627 NCI:C34700 OMIM:600156 OMIM:606874 OMIM:606875 OMIM:608462 OMIM:611644 ORDO:388 SNOMEDCT_US_2020_03_01:204739008 UMLS_CUI:C0019569 Hirschsprung disease aganglionic megacolon congenital megacolon macrocolon pelvirectal achalasia total intestinal aganglionosis disease_ontology DOID:10487 Xref MGI. OMIM mapping confirmed by DO. [SN]. Hirschsprung's disease DOID:10487 GARD:6769 ICD10CM:Q42.3 MESH:D001006 NCI:C84784 OMIM:207500 OMIM:301800 SNOMEDCT_US_2020_03_01:156956004 UMLS_CUI:C0003466 Congenital atresia of anus Congenital or infantile occlusion of anus Imperforate anus anal atresia disease_ontology DOID:10488 OMIM mapping confirmed by DO. [SN]. imperforate anus DOID:10488 ICD9CM:255.4 NCI:C26691 SNOMEDCT_US_2020_03_01:68588005 UMLS_CUI:C0405580 Adrenal Cortical Insufficiency Corticoadrenal insufficiency disease_ontology DOID:10493 adrenal cortical hypofunction DOID:10493 A pneumonia described as an inflammatory illness of the lung commonly caused by viruses such as influenza virus, parainfluenza, adenovirus, rhinovirus, herpes simplex virus, respiratory syncytial virus, hantavirus, and cytomegalovirus. DOID:13167 ICD10CM:J12.9 ICD9CM:480 MESH:D011024 SNOMEDCT_US_2020_03_01:195880002 UMLS_CUI:C0032310 disease_ontology DOID:10533 viral pneumonia DOID:10533 A gastrointestinal system cancer that is located_in the stomach. DOID:10539 DOID:10542 DOID:10543 DOID:4713 GARD:7704 ICD10CM:C16 ICD10CM:C16.2 ICD10CM:C16.5 ICD10CM:C16.6 ICD9CM:151 ICD9CM:151.4 ICD9CM:151.5 ICD9CM:151.6 MESH:D013274 NCI:C3387 NCI:C9331 OMIM:613659 SNOMEDCT_US_2020_03_01:126824007 SNOMEDCT_US_2020_03_01:269459004 SNOMEDCT_US_2020_03_01:269460009 SNOMEDCT_US_2020_03_01:93717002 SNOMEDCT_US_2020_03_01:94074003 UMLS_CUI:C0024623 UMLS_CUI:C0038356 UMLS_CUI:C0153421 UMLS_CUI:C0153422 UMLS_CUI:C0153423 gastric cancer gastric neoplasm disease_ontology DOID:10534 OMIM mapping confirmed by DO. [SN]. stomach cancer DOID:10534 GARD:6485 NCI:C4636 SNOMEDCT_US_2020_03_01:276811008 UMLS_CUI:C0349532 Lymphoma of the stomach disease_ontology DOID:10540 gastric lymphoma DOID:10540 ICD10CM:C16.0 ICD9CM:151.0 SNOMEDCT_US_2020_03_01:93738008 UMLS_CUI:C0153417 Ca cardia - stomach malignant neoplasm of cardia of stomach disease_ontology DOID:10548 cardia cancer DOID:10548 A central nervous system disease that involves encephalitis which occurs along with meningitis. ICD10CM:A69.22 MESH:D008590 NCI:C34813 SNOMEDCT_US_2020_03_01:7125002 UMLS_CUI:C0025309 Meningoencephalitis disease_ontology DOID:10554 meningoencephalitis DOID:10554 A syndrome that has_material_basis_in mutation in the OCRL gene on chromosome Xq26 and that is characterized by hydrophthalmia, cataract, mental retardation, vitamin D-resistant rickets, amino aciduria, and reduced ammonia production by the kidney. GARD:3295 ICD10CM:E72.03 MEDDRA:10051707 MESH:D009800 NCI:C84940 OMIM:309000 ORDO:534 SNOMEDCT_US_2020_03_01:79385002 UMLS_CUI:C0028860 Lowe syndrome lowe oculocerebrorenal syndrome oculocerebrorenal syndrome of Lowe disease_ontology DOID:1056 OMIM mapping confirmed by DO. [SN]. oculocerebrorenal syndrome DOID:1056 A bone remodeling disease that has_material_basis_in a vitamin D deficiency which results_in softening located_in bone. GARD:7285 ICD9CM:268.2 NCI:C26838 SNOMEDCT_US_2020_03_01:190639009 UMLS_CUI:C0029442 disease_ontology DOID:10573 osteomalacia MESH:D010018 DOID:10573 ICD10CM:E83.5 ICD9CM:275.4 MESH:D002128 SNOMEDCT_US_2020_03_01:267442002 UMLS_CUI:C0006705 disease_ontology DOID:10575 calcium metabolism disease DOID:10575 A cerebral degeneration characterized by dysfunction of the white matter of the brain. GARD:6895 ICD9CM:330.0 NCI:C61253 SNOMEDCT_US_2020_03_01:5101009 UMLS_CUI:C0023520 disease_ontology DOID:10579 leukodystrophy DOID:10579 A sphingolipidosis characterized by the accumulation of sulfatides in cells, especially the myelin producing cells of the nervous system. GARD:3230 ICD10CM:E75.25 MESH:D007966 NCI:C61251 OMIM:249900 OMIM:250100 ORDO:512 SNOMEDCT_US_2020_03_01:3621006 UMLS_CUI:C0023522 MLD Scholz cerebral sclerosis arylsulfatase A deficiency deficiency of cerebroside-sulfatase sulfatide lipoidosis disease_ontology DOID:10581 Xref MGI. OMIM mapping confirmed by DO. [SN]. metachromatic leukodystrophy DOID:10581 GARD:5691 ICD10CM:G60.1 ICD9CM:356.3 MESH:D012035 NCI:C85043 OMIM:266500 OMIM:266510 SNOMEDCT_US_2020_03_01:25362006 UMLS_CUI:C0034960 HMSN type IV HSMN IV Heredopathia atactica polyneuritiformis Refsum's disease disease_ontology DOID:10582 OMIM mapping confirmed by DO. [SN]. Refsum disease DOID:10582 A retinal degeneration characterized by the gradual deterioration of the photoreceptors or the retinal pigment epithelium of the retina leading to progressive sight loss. DOID:14742 GARD:5694 ICD10CM:H35.52 MESH:C538365 MESH:D012174 NCI:C85045 OMIM:PS268000 ORDO:791 SNOMEDCT_US_2020_03_01:155113002 UMLS_CUI:C0035334 UMLS_CUI:C0220701 pericentral pigmentary retinopathy disease_ontology DOID:10584 Xref MGI. OMIM mapping confirmed by DO. [LS]. retinitis pigmentosa DOID:10584 GARD:6844 ICD10CM:E75.23 MESH:D007965 NCI:C61254 OMIM:245200 SNOMEDCT_US_2020_03_01:192782005 UMLS_CUI:C0023521 Diffuse globoInOwlid body sclerosis GLOBOID CELL LEUKOENCEPHALOPATHY Galactosylceramide beta-galactosidase deficiency Krabbe's disease Krabbe's leukodystrophy beta galactocerebrosidase deficiency globoInOwlid cell leukodystrophy disease_ontology DOID:10587 OMIM mapping confirmed by DO. [SN]. Krabbe disease DOID:10587 A leukodystrophy that disrupts the breakdown of very-long-chain fatty acids resulting in progressive brain damage, failure of the adrenal glands and eventually death. DOID:13451 ICD10CM:E71.52 MESH:D000326 NCI:C61252 OMIM:300100 SNOMEDCT_US_2020_03_01:65389002 UMLS_CUI:C0162309 ALD Bronze Schilder disease Encephalitis periaxialis concentrica Encephalitis periaxialis, Schilder's Siemerling-Creutzfeldt Disease X-linked adrenoleukodystrophy diffuse sclerosis sudanophilic cerebral sclerosis disease_ontology DOID:10588 MESH:D000326w added from NeuroDevNet [WAK]. adrenoleukodystrophy MESH:D000326 DOID:10588 A specific developmental disorder that involves significant limitations both in mental functioning and in adaptive behavior such as communicating, taking care of him or herself, and social skills. NCI:C84392 SNOMEDCT_US_2020_03_01:1855002 UMLS_CUI:C0025362 MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15 disease_ontology mental retardation DOID:1059 OMIM mapping submitted by NeuroDevNet. [LS]. intellectual disability DOID:1059 A hypertension occurring during pregnancy characterized by large amounts of protein in the urine (proteinuria) and edema, usually by the last trimester of pregnancy. DOID:12684 ICD10CM:O14 MESH:D011225 NCI:C85021 OMIM:189800 OMIM:609402 OMIM:609403 OMIM:609404 OMIM:614592 ORDO:275555 SNOMEDCT_US_2020_03_01:6758009 UMLS_CUI:C0032914 gestational hypertension hypertension induced by pregnancy pre-eclamptic toxaemia preeclampsia preeclampsia/eclampsia pregnancy associated hypertension pregnancy toxemia proteinuric hypertension of pregnancy toxaemia of pregnancy disease_ontology DOID:10591 Xref MGI. OMIM mapping confirmed by DO. [SN]. pre-eclampsia DOID:10591 A neuromuscular disease that is characterized by a slowly progressive degeneration of the muscles of the foot, lower leg, hand and forearm. GARD:6034 ICD10CM:G60.0 ICD9CM:356.1 MESH:D002607 NCI:C75467 OMIM:PS118220 SNOMEDCT_US_2020_03_01:193158000 UMLS_CUI:C0007959 CMT - Charcot-Marie-Tooth disease disease_ontology DOID:10595 Charcot-Marie-Tooth disease DOID:10595 An amino acid metabolic disorder that is caused by abnormalities of the renal tubules and is characterized especially by aminoaciduria involving only monocarboxylic monoamines, a dry red scaly rash, and episodic muscular incoordination due to the effects of the disease on the cerebellum. GARD:6569 ICD10CM:E72.02 MESH:D006250 NCI:C84748 OMIM:234500 SNOMEDCT_US_2020_03_01:80902009 UMLS_CUI:C0018609 Neutral 1 amino acid transport defect deficiency of tryptophan oxygenase neutral amino acid transport defect disease_ontology DOID:1060 OMIM mapping confirmed by DO. [SN]. Hartnup disease DOID:1060 A tic disorder that is characterized by single or multiple motor or phonic tics, but not both, which are present for more than a year. ICD10CM:F95.1 ICD9CM:307.22 MESH:D013981 NCI:C116768 SNOMEDCT_US_2020_03_01:192623005 UMLS_CUI:C0008701 chronic motor or vocal tic disorder disease_ontology DOID:10600 chronic tic disorder DOID:10600 ICD10CM:R73.03 MESH:D018149 NCI:C34646 SNOMEDCT_US_2020_03_01:267426009 UMLS_CUI:C0271650 Glucose: intolerance Glucose: malabsorption Malabsorption of glucose disease_ontology DOID:10603 glucose intolerance DOID:10603 ICD10CM:E73 MESH:D007787 NCI:C3154 OMIM:223100 SNOMEDCT_US_2020_03_01:267497007 UMLS_CUI:C0022951 LM - Lactose malabsorption disease_ontology DOID:10604 OMIM mapping confirmed by DO. [SN]. lactose intolerance MESH:D007787 DOID:10604 An intestinal disease that is characterized by a reduced ability to absorb nutrients due to the physical loss or the loss of function of a portion of the small and/or large intestine. MESH:D012778 NCI:C99059 SNOMEDCT_US_2020_03_01:204768009 UMLS_CUI:C0036992 acquired short bowel syndrome short gut syndrome disease_ontology DOID:10605 short bowel syndrome DOID:10605 An intestinal disease characterized by a dysbalance of the bacterial flora of the small intestine, causing derangement to the normal physiological processes of digestion and absorption. ICD10CM:K90.2 ICD9CM:579.2 MESH:D001765 NCI:C34431 SNOMEDCT_US_2020_03_01:77225009 UMLS_CUI:C0005750 Bacterial overgrowth syndrome Blind loop syndrome disease_ontology DOID:10606 blind loop syndrome DOID:10606 GARD:7824 ICD10CM:K90.1 ICD9CM:579.1 MESH:D013182 NCI:C45428 SNOMEDCT_US_2020_03_01:155846005 UMLS_CUI:C0038054 Sprue - tropical Tropical steatorrhea disease_ontology DOID:10607 tropical sprue DOID:10607 An autoimmune disease of gastrointestinal tract that is caused by a reaction located_in small intestine to gliadin, a prolamin (gluten protein) found in wheat, and similar proteins found in the crops of the tribe Triticeae. The disease is associated with HLA-DQ gene. It has_symptom abdominal pain, has_symptom constipation, has_symptom diarrhea, has_symptom nausea and vomiting, and has_symptom loss of appetite. EFO:0001060 GARD:11998 ICD10CM:K90.0 ICD9CM:579.0 MESH:D002446 NCI:C26714 OMIM:607202 OMIM:609754 OMIM:611598 OMIM:612005 OMIM:612006 OMIM:612007 OMIM:612008 OMIM:612009 OMIM:612011 ORDO:555 SNOMEDCT_US_2020_03_01:197477005 UMLS_CUI:C0007570 celiac sprue coeliac disease idiopathic steatorrhea disease_ontology DOID:10608 Xref MGI. OMIM mapping confirmed by DO. [SN]. celiac disease DOID:10608 A bone remodeling disease that has_material_basis_in impaired mineralization or calcification of bones before epiphyseal closure due to deficiency or impaired metabolism of vitamin D, phosphorus or calcium which results_in softening and deformity located_in bone. DOID:11672 GARD:5700 ICD10CM:E55.0 ICD9CM:268.0 MESH:D012279 NCI:C26878 OMIM:264700 OMIM:277440 OMIM:600081 OMIM:600785 ORDO:289157 SNOMEDCT_US_2020_03_01:190639009 SNOMEDCT_US_2020_03_01:68295002 UMLS_CUI:C0035579 UMLS_CUI:C0221468 active rickets vitamin D hydroxylation-deficient rickets vitamin D-dependent rickets disease_ontology DOID:10609 Xref MGI. rickets MESH:D012279 DOID:10609 ICD10CM:K90.3 ICD9CM:579.4 SNOMEDCT_US_2020_03_01:155845009 UMLS_CUI:C0152166 pancreatic steatorrhoea disease_ontology DOID:10610 pancreatic steatorrhea DOID:10610 MESH:D011504 OMIM:226300 SNOMEDCT_US_2020_03_01:66972006 UMLS_CUI:C0033680 Enteropathy, exudative Exudative enteropathy Protein-losing enteropathy disease_ontology DOID:10611 OMIM mapping confirmed by DO. [SN]. protein-losing enteropathy DOID:10611 An urticaria that is characterized by erythematous papules and plaques, has_symptom pruritis, and has_material_basis_in allergic reaction. ICD10CM:L50.0 ICD9CM:708.0 SNOMEDCT_US_2020_03_01:201260002 UMLS_CUI:C0149526 Allergic urticaria disease_ontology DOID:10612 allergic urticaria DOID:10612 A renal tubular transport disease of the proximal renal tubes characterized by glucosuria, phosphaturia, generalized aminoaciduria and HCO3 wasting. DOID:5956 GARD:9118 MESH:D005198 NCI:C3034 NCI:C4377 OMIM:PS134600 ORDO:3337 SNOMEDCT_US_2020_03_01:236468006 SNOMEDCT_US_2020_03_01:40488004 UMLS_CUI:C0015624 UMLS_CUI:C0341703 Congenital Fanconi syndrome De Toni-Fanconi syndrome Fanconi-de Toni syndrome Fanconi-de-Toni syndrome Infantile nephropathic cystinosis Lignac-Fanconi syndrome adult Fanconi Anemia adult Fanconi syndrome deToni Fanconi syndrome disease_ontology DOID:1062 Xref MGI. OMIM mapping confirmed by DO. [SN]. Fanconi syndrome MESH:D005198 DOID:1062 An eye disease where one or both eyeballs are abnormally small. DOID:10650 GARD:12085 ICD10CM:Q11.2 ICD9CM:743.1 MESH:D008850 NCI:C98989 SNOMEDCT_US_2020_03_01:156902006 UMLS_CUI:C0026010 microphthalmos simple microphthalmos disease_ontology DOID:10629 Xref MGI. OMIM mapping confirmed by DO. [SN]. microphthalmia DOID:10629 ICD10CM:N12 MESH:D009395 NCI:C26834 SNOMEDCT_US_2020_03_01:28689008 UMLS_CUI:C0027707 renal tubulo-interstitial disease disease_ontology DOID:1063 interstitial nephritis DOID:1063 A syndrome that is characterized by diabetes mellitus, optic atrophy, and deafness. GARD:7898 MESH:D014929 NCI:C35133 ORDO:3463 SNOMEDCT_US_2020_03_01:70694009 UMLS_CUI:C0043207 disease_ontology DOID:10632 OMIM mapping confirmed by DO. [LS]. Wolfram syndrome DOID:10632 A lysosomal storage disease characterized by the abnormal accumulation of cystine in the lysosomes. It follows an autosomal recessive inheritance pattern and that has_material_basis_in mutations in the CTNS gene, located on chromosome 17. GARD:6236 MESH:D003554 NCI:C129932 OMIM:219750 OMIM:219800 OMIM:219900 ORDO:213 SNOMEDCT_US_2020_03_01:62332007 UMLS_CUI:C2931187 cystine storage disease disease_ontology DOID:1064 cystinosis DOID:1064 A personality disorder that involves a need for social isolation, anxiety in social situations, odd behavior and thinking, and often unconventional beliefs. ICD10CM:F21 ICD9CM:301.22 MESH:D012569 NCI:C92632 SNOMEDCT_US_2020_03_01:231486008 UMLS_CUI:C0036363 disease_ontology DOID:10646 schizotypal personality disorder DOID:10646 A tauopathy that is characterized by memory lapses, confusion, emotional instability and progressive loss of mental ability and results in progressive memory loss, impaired thinking, disorientation, and changes in personality and mood starting and leads in advanced cases to a profound decline in cognitive and physical functioning and is marked histologically by the degeneration of brain neurons especially in the cerebral cortex and by the presence of neurofibrillary tangles and plaques containing beta-amyloid. EFO:0000249 GARD:10254 ICD10CM:G30 ICD9CM:331.0 KEGG:05010 MESH:D000544 NCI:C2866 SNOMEDCT_US_2020_03_01:73768007 UMLS_CUI:C0002395 Alzheimer disease Alzheimers dementia disease_ontology DOID:10652 Xref MGI. OMIM mapping confirmed by DO. [SN]. Alzheimer's disease DOID:10652 NCI:C5493 UMLS_CUI:C0940607 Colonic Lipoma disease_ontology DOID:10655 lipoma of colon DOID:10655 A glaucoma characterized by optic nerve damage resulting in progressive loss of visual field and increased pressure in the eye due to trabecular blockage. EFO:0004190 ICD10CM:H40.1 ICD9CM:365.1 MESH:D005902 NCI:C34641 OMIM:137750 OMIM:177700 OMIM:602429 OMIM:603383 OMIM:606689 OMIM:608695 OMIM:608696 OMIM:609745 OMIM:609887 OMIM:610535 OMIM:611274 OMIM:611276 OMIM:613100 SNOMEDCT_US_2020_03_01:84494001 UMLS_CUI:C0017612 Wide-angle glaucoma glaucoma simplex open angle glaucoma pigmentary glaucoma disease_ontology DOID:1067 Xref MGI. open-angle glaucoma DOID:1067 A breast disease characterized by painful infection of the breast tissue. MESH:D008413 NCI:C53662 SNOMEDCT_US_2020_03_01:155952005 UMLS_CUI:C0024894 Inflammatory breast disease Inflammatory disease of breast breast inflammation disease_ontology DOID:10690 mastitis DOID:10690 ICD9CM:360.03 SNOMEDCT_US_2020_03_01:193269007 UMLS_CUI:C0154774 disease_ontology DOID:10697 chronic endophthalmitis DOID:10697 A parasitic helminthiasis infectious disease that involves parasitic infection by flukes of the genus Paragonimus. In the acute phase, the symptoms are diarrhea, abdominal pain, fever, cough, urticaria, hepatosplenomegaly, pulmonary abnormalities, and eosinophilia. Pulmonary manifestations include cough, expectoration of discolored sputum, hemoptysis, and chest radiographic abnormalities. Various organs like brain, spleen and liver can be infected. GARD:9815 ICD10CM:B66.4 ICD9CM:121.2 MESH:D010237 NCI:C84995 SNOMEDCT_US_2020_03_01:30369007 UMLS_CUI:C0030424 Infection by Paragonimus lung fluke disease lung fluke infection pulmonary paragonimiasis disease_ontology DOID:10699 paragonimiasis DOID:10699 An open-angle glaucoma that is characterized by the absence of any apparent obstruction of aqueous outflow through the trabecular meshwork with gonioscopy, but often with elevated intraocular pressure. ICD10CM:H40.11 ICD9CM:365.11 MESH:D005902 NCI:C35394 OMIM:137760 SNOMEDCT_US_2020_03_01:77075001 UMLS_CUI:C0339573 chronic simple glaucoma disease_ontology DOID:1070 OMIM mapping confirmed by DO. [SN]. primary open angle glaucoma DOID:1070 A parasitic protozoa infectious disease that involves infection of the small intestine by a single-celled enteric protozoan parasite Giardia intestinalis. The symptoms include greasy and malodorous stools, diarrhea, abdominal pain, bloating, nausea, and vomiting. ICD10CM:A07.1 ICD9CM:007.1 MESH:D005873 SNOMEDCT_US_2020_03_01:266176008 UMLS_CUI:C0017536 Infection by Giardia lamblia beaver feaver disease_ontology DOID:10718 giardiasis DOID:10718 GARD:6549 ICD9CM:242.00 UMLS_CUI:C0154138 disease_ontology DOID:10719 toxic diffuse goiter DOID:10719 A kidney disease characterized by the failure of the kidneys to adequately filter waste products from the blood. ICD10CM:N19 ICD9CM:586 MESH:D051437 NCI:C4376 SNOMEDCT_US_2020_03_01:42399005 UMLS_CUI:C0035078 renal failure disease_ontology DOID:1074 PRISM. kidney failure DOID:1074 ICD9CM:330.1 SNOMEDCT_US_2020_03_01:16517004 UMLS_CUI:C0007788 disease_ontology DOID:10742 cerebral lipidosis DOID:10742 A otitis which involves inflammation of the middle ear. ICD10CM:H66.9 ICD9CM:382.9 MESH:D010033 NCI:C34885 SNOMEDCT_US_2020_03_01:65363002 UMLS_CUI:C0029882 disease_ontology DOID:10754 otitis media DOID:10754 ICD10CM:N11 ICD9CM:590.0 NCI:C123216 SNOMEDCT_US_2020_03_01:123293005 UMLS_CUI:C0085697 disease_ontology DOID:1076 chronic pyelonephritis DOID:1076 GARD:8229 ICD10CM:K76.6 ICD9CM:572.3 MESH:D006975 NCI:C3119 SNOMEDCT_US_2020_03_01:155821005 UMLS_CUI:C0020541 disease_ontology DOID:10762 portal hypertension DOID:10762 An artery disease characterized by chronic elevated blood pressure in the arteries. EFO:0000537 ICD10CM:I10 ICD9CM:401-405.99 MESH:D006973 NCI:C3117 SNOMEDCT_US_2020_03_01:38341003 UMLS_CUI:C0020538 HTN High blood pressure hyperpiesia vascular hypertensive disorder disease_ontology hypertensive disease DOID:10763 hypertension DOID:10763 GARD:9430 ICD10CM:M31.1 MESH:D011697 NCI:C78797 OMIM:274150 SNOMEDCT_US_2020_03_01:360402008 UMLS_CUI:C0034155 Moschcowitz's syndrome disease_ontology DOID:10772 thrombotic thrombocytopenic purpura DOID:10772 ICD10CM:I40.1 ICD9CM:422.91 SNOMEDCT_US_2020_03_01:194954007 UMLS_CUI:C0155689 Idiopathic myocarditis Isolated (Fiedler's) myocarditis fiedler myocarditis disease_ontology DOID:10778 fiedler's myocarditis DOID:10778 ICD10CM:D74 ICD9CM:289.7 MESH:D008708 NCI:C34817 SNOMEDCT_US_2020_03_01:191386007 UMLS_CUI:C0025637 disease_ontology DOID:10783 methemoglobinemia DOID:10783 A spotted fever that has_material_basis_in Rickettsia australis, which is transmitted_by ticks (Ixodes holocyclus). The infection has_symptom fever, has_symptom headache, has_symptom myalgia, has_symptom maculopapular rash, and has_symptom lymphadenopathy. DOID:0050038 Australian tick typhus Rickettsia australis spotted fever disease_ontology North Queensland tick typhus DOID:10784 Queensland tick typhus DOID:10784 A sinusitis which involves infection of the frontal sinuses over the eyes in the brow area. This causes pain or pressure in the frontal sinus cavity and headache over the forehead. ICD10CM:J32.1 MESH:D015522 NCI:C34626 SNOMEDCT_US_2020_03_01:275485006 UMLS_CUI:C0016735 disease_ontology DOID:10791 frontal sinusitis DOID:10791 A maxillary sinusitis which lasts for 12 weeks or more. ICD10CM:J32.0 ICD9CM:473.0 NCI:C34477 SNOMEDCT_US_2020_03_01:195785003 UMLS_CUI:C0008698 chronic antritis disease_ontology DOID:10792 chronic maxillary sinusitis DOID:10792 A sinusitis which involves infection of sphenoid sinuses that causes pain or pressure behind the eyes, but often refers to the vertex of the head. ICD10CM:J32.3 MESH:D015524 NCI:C35031 SNOMEDCT_US_2020_03_01:13266007 UMLS_CUI:C0037886 Sphenoidal sinusitis disease_ontology DOID:10794 sphenoid sinusitis DOID:10794 A parasitic helminthiasis infectious disease that involves parasitic infection of the lymphatics and subcutaneous tissue by nematodes of the superfamily Filarioidea. ICD10CM:B74 ICD9CM:125.9 MESH:D005368 NCI:C34611 SNOMEDCT_US_2020_03_01:50342004 UMLS_CUI:C0016085 disease due to superfamily Filarioidea disease_ontology DOID:1080 filariasis MESH:D005368 DOID:1080 A respiratory system cancer that is located_in the nasal cavity. ICD10CM:C30.0 ICD9CM:160.0 NCI:C4918 SNOMEDCT_US_2020_03_01:93917007 UMLS_CUI:C0728864 malignant neoplasm of nasal cavities malignant tumor of the nasal cavity disease_ontology DOID:10811 nasal cavity cancer DOID:10811 NCI:C6074 UMLS_CUI:C1334921 Lymphoma of the nasal cavity lymphoma of nasal cavity disease_ontology DOID:10813 nasal cavity lymphoma DOID:10813 A duodenum cancer that derives_from epithelial cells of glandular origin. NCI:C7889 SNOMEDCT_US_2020_03_01:408644002 UMLS_CUI:C0278804 Duodenal adenocarcinoma disease_ontology DOID:10816 duodenum adenocarcinoma DOID:10816 A filariasis that is a zoonotic infection caused by nematodes Dirofilaria immitis or Dirofilaria repens, which are transmitted to humans from dogs, cats, wolves and coyotes by infected mosquitoes. The disease manifests as either subcutaneous nodules or pulmonary lesions. GARD:11908 ICD10CM:B74.8 MESH:D004184 SNOMEDCT_US_2020_03_01:73328005 UMLS_CUI:C0012602 Dirofilaria infectious disease Infection by Dirofilaria disease_ontology DOID:1082 dirofilariasis DOID:1082 ICD10CM:F65.3 ICD9CM:302.82 MESH:D014843 NCI:C94360 SNOMEDCT_US_2020_03_01:192515002 UMLS_CUI:C0042979 disease_ontology DOID:10834 voyeurism DOID:10834 A viral infectious disease that results in inflammation located in brain of horses and humans, has_material_basis_in Eastern equine encephalitis virus, which is transmitted by Aedes, transmitted by Coquillettidia, and transmitted by Culex species of mosquitoes. The infection has symptom sudden onset of headache, has symptom high fever, has symptom chills, has symptom vomiting, has symptom disorientation, has symptom seizures, and has symptom coma. GARD:10821 ICD10CM:A83.2 ICD9CM:062.2 MESH:D020242 SNOMEDCT_US_2020_03_01:40177004 UMLS_CUI:C0153065 Neuroinvasive Eastern equine encephalitis virus infection disease_ontology EEE DOID:10841 Eastern equine encephalitis DOID:10841 A viral infectious disease that results_in inflammation located_in brain, has_material_basis_in Murray Valley encephalitis virus, which is transmitted_by Culex annulirostris mosquitoes. The infection has_symptom fever, has_symptom headache, has_symptom nausea, has_symptom vomiting, has_symptom drowsiness, has_symptom confusion, has_symptom fitting, and has_symptom weakness. ICD10CM:A83.4 ICD9CM:062.4 SNOMEDCT_US_2020_03_01:66454007 UMLS_CUI:C0153066 Australian X disease Australian encephalitis disease_ontology DOID:10842 Murray Valley encephalitis DOID:10842 A viral infectious disease that results_in inflammation located_in brain of horses and humans, has_material_basis_in Western equine encephalomyelitis virus, which is transmitted_by Culex and transmitted_by Aedes species of mosquitoes. The infection has_symptom fever, has_symptom headache, has_symptom nausea, has_symptom vomiting, has_symptom anorexia, has_symptom malaise, has_symptom altered mental status, and has_symptom weakness. GARD:7888 ICD10CM:A83.1 ICD9CM:062.1 MESH:D020241 NCI:C85227 SNOMEDCT_US_2020_03_01:47523006 UMLS_CUI:C0153064 disease_ontology WEE DOID:10843 Western equine encephalitis DOID:10843 A viral infectious disease that results_in infection located_in brain, has_material_basis_in Japanese encephalitis virus, which is transmitted_by Culex tritaeniorhynchus mosquito bite. The infection has_symptom headache, has_symptom high fever, has_symptom neck stiffness, has_symptom stupor, has_symptom disorientation, has_symptom coma, has_symptom tremors, has_symptom convulsions, and has_symptom spastic paralysis. GARD:6797 ICD10CM:A83.0 ICD9CM:062.0 MESH:D004672 NCI:C34577 SNOMEDCT_US_2020_03_01:266194002 UMLS_CUI:C0014057 Japanese B encephalitis disease_ontology DOID:10844 Japanese encephalitis DOID:10844 A viral infectious disease that results_in inflammation located_in brain, has_material_basis_in St. Louis encephalitis virus, which is transmitted_by Culex mosquitoes. The infection has_symptom headache, has_symptom high fever, has_symptom neck stiffness, has_symptom stupor, has_symptom disorientation, has_symptom coma, has_symptom tremors, has_symptom convulsions and has_symptom spastic paralysis. ICD10CM:A83.3 ICD9CM:062.3 MESH:D004674 SNOMEDCT_US_2020_03_01:10429004 UMLS_CUI:C0014060 Neuroinvasive St. Louis encephalitis virus infection disease_ontology DOID:10845 St. Louis encephalitis DOID:10845 A chromosomal duplciation syndrome that is characterized by slow growth before birth and a low birth weight and that has_material_basis_in three copies of chromosome 18. ICD9CM:758.2 MESH:D000073842 NCI:C101362 SNOMEDCT_US_2020_03_01:51500006 UMLS_CUI:C0152096 Complete trisomy 18 syndrome E3 Trisomy trisomy 18 disease_ontology DOID:1085 OMIM mapping confirmed by DO. [LS]. Edwards syndrome DOID:1085 A mouth disease located_in the salivary gland. DOID:12898 ICD9CM:527.8 UMLS_CUI:C0029773 Non-neoplastic Salivary gland disease Salivary gland disease disease_ontology DOID:10854 salivary gland disease DOID:10854 ICD10CM:H49 ICD9CM:378.5 SNOMEDCT_US_2020_03_01:12942001 UMLS_CUI:C0152221 Incomitant dissociation Paralytic strabismus disease_ontology DOID:10863 paralytic squint DOID:10863 A degeneration of macula and posterior pole that is characterized by a loss of vision in the center of the visual field (the macula) resulting from damage to the retina and resulting in blurring of the sharp central vision. EFO:0001365 ICD10CM:H35.30 ICD9CM:362.50 MESH:D008268 NCI:C84391 OMIM:PS603075 SNOMEDCT_US_2020_03_01:18222007 UMLS_CUI:C0242383 Age Related Maculopathies Age Related Maculopathy Senile macular degeneration Senile macular retinal degeneration age-related macular degeneration disease_ontology DOID:10871 OMIM mapping confirmed by DO. [SN]. age related macular degeneration DOID:10871 ICD10CM:H35.32 ICD9CM:362.52 SNOMEDCT_US_2020_03_01:11290001 UMLS_CUI:C0271084 Exudative senile macular degeneration of retina Neovascular age-related macular degeneration Senile macular degeneration, wet Wet senile macular retinal degeneration disease_ontology DOID:10873 Kuhnt-Junius degeneration DOID:10873 A spina bifida that is characterized by herniation of the meninges between the vertebrae. SNOMEDCT_US_2020_03_01:268308005 UMLS_CUI:C0025299 disease_ontology DOID:1088 meningocele MESH:D008588 DOID:1088 A viral infectious disease that results_in infection located_in skin, has_material_basis_in Human coxsackievirus A16 or has_material_basis_in Human enterovirus 71, which are transmitted_by contaminated fomites, and transmitted_by contact with nose and throat secretions, saliva, blister fluid and stool of infected persons. The infection has_symptom fever, has_symptom poor appetite, has_symptom malaise, has_symptom sore throat, has_symptom painful sores in the mouth, and has_symptom skin rash on the palms of the hands and soles of the feet. ICD10CM:B08.4 ICD9CM:074.3 MESH:D006232 NCI:C128439 SNOMEDCT_US_2020_03_01:175497008 UMLS_CUI:C0018572 Vesicular stomatitis and exanthem disease_ontology DOID:10881 hand, foot and mouth disease DOID:10881 A viral infectious disease that results in necrosis located in intercostal muscle, has_material_basis_in Human enterovirus B. The infection has symptom severe chest pain, has symptom fever, has symptom malaise, has symptom pleuritis, and has symptom headache. ICD10CM:B33.0 ICD9CM:074.1 MESH:D011000 SNOMEDCT_US_2020_03_01:83264000 UMLS_CUI:C0032238 Bamble disease Bornholm disease Epidemic pleurisy Epidemic, myositis devil's grip epidemic myalgia disease_ontology DOID:10882 epidemic pleurodynia DOID:10882 A viral infectious disease that results in infection located in mouth, has_material_basis_in Human coxsackievirus A16, has_material_basis_in Human enterovirus 71, has_material_basis_in group B coxsackievirus, or has_material_basis_in echoviruses, which are transmitted by ingestion of food contaminated with feces, transmitted by contact with pharyngeal secretions, or transmitted by droplet spread of oronasal secretions. The infection has symptom fever, has symptom sore throat, and has symptom lesions in the back area of the mouth, particularly the soft palate or tonsillar pillars. ICD10CM:B08.5 ICD9CM:074.0 MESH:D006557 SNOMEDCT_US_2020_03_01:154358007 UMLS_CUI:C0019338 Vesicular pharyngitis disease_ontology DOID:10883 herpangina DOID:10883 GARD:4018 SNOMEDCT_US_2020_03_01:282784007 UMLS_CUI:C0560648 spinal dysraphism disease_ontology DOID:1089 OMIM mapping confirmed by DO. [LS]. tethered spinal cord syndrome NCI:C99080 DOID:1089 A physical disorder characterized by an abnormally placed urethral opening on the underside of the penis or on the perineum. ICD10CM:Q54 MESH:D007021 NCI:C40341 OMIM:146450 OMIM:300633 OMIM:300758 OMIM:300856 ORDO:440 SNOMEDCT_US_2020_03_01:156968008 UMLS_CUI:C0848558 familial hypospadias disease_ontology DOID:10892 Xref MGI. OMIM mapping confirmed by DO. [SN]. hypospadias DOID:10892 A congenital nervous system abnormality that is characterized by a significantly smaller than normal head in infants. GARD:3603 GARD:7038 ICD10CM:Q02 ICD9CM:742.1 MESH:D008831 NCI:C85874 SNOMEDCT_US_2020_03_01:156893009 UMLS_CUI:C0025958 Microcephalus microencephaly disease_ontology DOID:10907 OMIM mapping confirmed by DO. [SN]. microcephaly MESH:D008831 DOID:10907 A cerebral degeneration characterized by an abnormal accumulation of cerebrospinal fluid in the ventricles of the brain, leading to progressive enlargement of the head. GARD:6682 ICD10CM:G91 MESH:D006849 NCI:C3111 OMIM:123155 OMIM:236600 OMIM:236635 OMIM:307000 OMIM:615219 ORDO:2182 ORDO:2185 SNOMEDCT_US_2020_03_01:267687006 UMLS_CUI:C0020255 hydrocephalus, X-linked hydrocephalus, nonsyndromic, autosomal recessive disease_ontology DOID:10908 Xref MGI. OMIM mapping confirmed by DO. [SN]. hydrocephalus DOID:10908 A mouth disease located_in the teeth. MESH:D014076 SNOMEDCT_US_2020_03_01:72722003 UMLS_CUI:C0040435 teeth disease disease_ontology DOID:1091 tooth disease DOID:1091 A cognitive disorder where the memory is disturbed or lost and involves the loss of memories previously established, loss of the ability to create new memories, or loss of the ability to learn new information. DOID:4544 ICD10CM:R41.3 ICD9CM:294.0 MESH:D000647 NCI:C2867 SNOMEDCT_US_2020_03_01:247606008 SNOMEDCT_US_2020_03_01:3298001 UMLS_CUI:C0002622 UMLS_CUI:C0002625 Amnestic syndrome Korsakoff's psychosis or syndrome amnesia disease_ontology DOID:10914 amnestic disorder DOID:10914 A nutritional deficiency disease that is characterized by ophthalmoplegia, ataxia, change in mental status and acute onset of severe memory impairment without any dysfunction in intellectual abilities, and has_material_basis_in thiamine deficiency. MESH:D020915 NCI:C35764 OMIM:277730 SNOMEDCT_US_2020_03_01:69482004 UMLS_CUI:C0349464 Korsakoff Syndrome Korsakoff's psychosis Korsakoff's syndrome Korsakov psychosis Korsakov's psychosis disease_ontology DOID:10915 OMIM mapping confirmed by DO. [LS]. Wernicke-Korsakoff syndrome DOID:10915 A gender identity disorder that is characterized by an individual's identification with a gender inconsistent or not culturally associated with their biological sex. ICD9CM:302.50 SNOMEDCT_US_2020_03_01:191782007 UMLS_CUI:C0040630 disease_ontology DOID:10919 transsexualism DOID:10919 A blood protein disease that is characterized by low number of red blood cells, repeated infections, and periodic episodes of pain, resulting from atypical hemoglobin molecules called hemoglobin S, which can distort red blood cells into a sickle, or crescent, shape. DOID:12924 DOID:13024 GARD:8614 ICD10CM:D57.1 ICD10CM:D57.2 ICD9CM:282.6 ICD9CM:282.63 MESH:D000755 MESH:D006450 NCI:C34383 NCI:C34676 OMIM:603903 ORDO:232 SNOMEDCT_US_2020_03_01:154798006 SNOMEDCT_US_2020_03_01:35434009 UMLS_CUI:C0002895 UMLS_CUI:C0019034 Hb SC disease Hb-S/Hb-C disease Hb-SS disease without crisis Hemoglobin S disease without crisis Sickle-cell/Hb-C disease without crisis drepanocytosis haemoglobin SC disease hemoglobin SC disease sickle cell anaemia disease_ontology DOID:10923 OMIM mapping confirmed by DO. [LS]. sickle cell anemia DOID:10923 A personality disorder that involves a prolonged disturbance of personality function characterized by depth and variability of moods. ICD10CM:F60.3 ICD9CM:301.83 MESH:D001883 NCI:C92633 SNOMEDCT_US_2020_03_01:20010003 UMLS_CUI:C0006012 disease_ontology DOID:10930 borderline personality disorder DOID:10930 A personality disorder that is characterized by a pervasive psychological dependence on other people. ICD10CM:F60.7 ICD9CM:301.6 MESH:D003859 NCI:C92637 SNOMEDCT_US_2020_03_01:192492003 UMLS_CUI:C0011548 disease_ontology DOID:10931 dependent personality disorder DOID:10931 A personality disorder that is characterized by a pervasive pattern of preoccupation with orderliness, perfectionism, and mental and interpersonal control at the expense of flexibility, openness, and efficiency. ICD10CM:F60.5 ICD9CM:301.4 MESH:D003193 NCI:C92638 SNOMEDCT_US_2020_03_01:191761001 UMLS_CUI:C0009595 OCPD disease_ontology Anankastic personality disorder DOID:10932 obsessive-compulsive personality disorder DOID:10932 A dissociative disorder that involves the simultaneous display of multiple distinct identities or personalities. ICD10CM:F44.81 ICD9CM:300.14 MESH:D009105 NCI:C94330 SNOMEDCT_US_2020_03_01:31611000 UMLS_CUI:C0026773 Dissociative identity disorder disease_ontology DOID:10934 multiple personality disorder DOID:10934 A disease of mental health in which the normally well-integrated functions of memory, identity, perception, or consciousness are separated (dissociated). DOID:4963 ICD10CM:F44.9 ICD10CM:F48.9 ICD9CM:300.15 ICD9CM:300.9 MESH:D004213 NCI:C92197 SNOMEDCT_US_2020_03_01:154883004 UMLS_CUI:C0012746 UMLS_CUI:C0041857 dissociative disease dissociative reaction disease_ontology DOID:10935 dissociative disorder DOID:10935 A personality disorder that is characterized by a lack of interest in social relationships, a tendency towards a solitary lifestyle, secretiveness, emotional coldness and sometimes sexual apathy, with a simultaneous rich, elaborate and exclusively internal fantasy world. ICD10CM:F60.1 ICD9CM:301.2 MESH:D012557 NCI:C92631 SNOMEDCT_US_2020_03_01:192486009 UMLS_CUI:C0036339 disease_ontology DOID:10936 schizoid personality disorder DOID:10936 A disease of mental health that involves a failure to resist an impulsive act or behaviour that may be harmful to self or others. ICD10CM:F63.9 ICD9CM:312.30 MESH:D007174 NCI:C34723 SNOMEDCT_US_2020_03_01:192098008 UMLS_CUI:C0021122 disease_ontology DOID:10937 impulse control disorder DOID:10937 A personality disorder that is characterized by paranoia and a pervasive, long-standing suspiciousness and generalized mistrust of others. ICD10CM:F60.0 ICD9CM:301.0 MESH:D010260 NCI:C92630 SNOMEDCT_US_2020_03_01:270529002 UMLS_CUI:C0030477 disease_ontology DOID:10938 paranoid personality disorder DOID:10938 A personality disorder that involves a pervasive pattern of disregard for, and violation of, the rights of others that begins in childhood or early adolescence and continues into adulthood. ICD10CM:F60.2 ICD9CM:301.7 MESH:D000987 NCI:C88413 SNOMEDCT_US_2020_03_01:191769004 UMLS_CUI:C0003431 Asocial personality Dissocial personality disorder Psychopath.personality Psychopathic personality Psychopathic personality disorder sociopathic personality disease_ontology DOID:10939 antisocial personality disorder DOID:10939 A specific developmental disorder that is characterized by co-existence of attentional problems and hyperactivity, with each behavior occurring infrequently alone and symptoms starting before seven years of age. DOID:1093 EFO:0003888 MESH:D001289 NCI:C35092 OMIM:143465 OMIM:608903 OMIM:608904 OMIM:608905 OMIM:608906 OMIM:612311 OMIM:612312 SNOMEDCT_US_2020_03_01:229713001 UMLS_CUI:C0041671 ADHD attention deficit disorder hyperkinetic disorder disease_ontology DOID:1094 Xref MGI. attention deficit hyperactivity disorder DOID:1094 EFO:0003870 MESH:D002532 NCI:C34458 SNOMEDCT_US_2020_03_01:128609009 UMLS_CUI:C0007766 brain aneurysm disease_ontology DOID:10941 intracranial aneurysm DOID:10941 A mouth disease located_in the tongue. ICD10CM:K14 ICD9CM:529.9 MESH:D014060 SNOMEDCT_US_2020_03_01:69244009 UMLS_CUI:C0040409 disease_ontology DOID:10944 tongue disease DOID:10944 A kidney disease that is characterized by an inflammation of the kidneys. ICD10CM:N08 MESH:D009393 NCI:C26833 SNOMEDCT_US_2020_03_01:52845002 UMLS_CUI:C0027697 disease_ontology DOID:10952 nephritis DOID:10952 A parasitic helminthiasis infectious disease that involves infection of the intestine, lungs, skin and central nervous system with nematode Strongyloides stercoralis. DOID:0050008 GARD:8195 ICD10CM:B78 ICD9CM:127.2 MESH:D013322 NCI:C128398 SNOMEDCT_US_2020_03_01:1214006 UMLS_CUI:C0038463 Infection by Strongyloides disseminated strongyloidiasis disease_ontology DOID:10955 strongyloidiasis DOID:10955 A spastic cerebral palsy that affects lower extremities resulting in tight leg and hip muscles. The legs cross at the knees, making it difficult to walk. DOID:3778 ICD10CM:G80.1 ICD9CM:343.0 MESH:D002547 NCI:C34781 SNOMEDCT_US_2020_03_01:1178005 SNOMEDCT_US_2020_03_01:275469001 UMLS_CUI:C0023882 UMLS_CUI:C0154695 Diplegic infantile cerebral palsy Infantile spastic cerebral palsy Little's disease Littles disease cerebral spastic infantile paralysis infantile diplegic cerebral palsy disease_ontology DOID:10965 spastic diplegia DOID:10965 A spastic cerebral palsy that affects one side of the body resulting in stiff arm, hand and leg. On the affected side,the arm and leg may not develop normally. GARD:10448 ICD9CM:343.1 SNOMEDCT_US_2020_03_01:258714003 UMLS_CUI:C0270805 Congenital hemiplegia Hemiplegic cerebral palsy Hemiplegic infantile cerebral palsy hemiplegic cerebral palsy spastic hemiplegic cerebral palsy disease_ontology DOID:10967 spastic hemiplegia DOID:10967 A central nervous system disease that is characterized by the complete paralysis of half of the body. GARD:6583 ICD9CM:343.4 MESH:D006429 SNOMEDCT_US_2020_03_01:155024003 UMLS_CUI:C0392550 Infantile hemiplegia Postnatal infantile hemiplegia disease_ontology DOID:10969 hemiplegia DOID:10969 A spastic cerebral palsy that affects all four limbs. The individuals have difficulty with walking and talking. ICD9CM:343.2 MESH:D002547 OMIM:603513 OMIM:612900 ORDO:210141 SNOMEDCT_US_2020_03_01:192953000 UMLS_CUI:C0154697 quadriplegic infantile cerebral palsy spastic quadriplegic cerebral palsy tetraplegic infantile cerebral palsy disease_ontology DOID:10970 Xref MGI. spastic quadriplegia DOID:10970 ICD10CM:N70 ICD9CM:614.2 SNOMEDCT_US_2020_03_01:46536000 UMLS_CUI:C0036133 Salpingitis/oophoritis Tubo-ovarian inflammatory disease disease_ontology DOID:10972 salpingo-oophoritis DOID:10972 ICD10CM:N70.01 NCI:C40120 SNOMEDCT_US_2020_03_01:8912009 UMLS_CUI:C0269038 disease_ontology DOID:10973 acute salpingitis DOID:10973 An ovarian disease that is characterized by inflammation of the ovary. ICD10CM:N70.92 MESH:D009869 SNOMEDCT_US_2020_03_01:266648001 UMLS_CUI:C0029051 disease_ontology DOID:10974 oophoritis DOID:10974 EFO:0004254 ICD10CM:N03.2 MESH:D015433 NCI:C34645 SNOMEDCT_US_2020_03_01:197710000 UMLS_CUI:C0017665 membranous nephropathy disease_ontology DOID:10976 membranous glomerulonephritis DOID:10976 A syndrome disease that is characterized by glomerulonephritis, endstage kidney disease, and hearing loss. GARD:5785 MESH:D009394 ORDO:63 SNOMEDCT_US_2020_03_01:57333009 UMLS_CUI:C0027706 Hereditary Nephritis disease_ontology DOID:10983 OMIM mapping confirmed by DO. [SN]. Alport syndrome DOID:10983 Alpha thalassemia is a thalassemia involving the genes HBA1and HBA2 hemoglobin genes. GARD:621 ICD10CM:D56.0 ICD9CM:282.43 MESH:D017085 NCI:C34368 OMIM:604131 SNOMEDCT_US_2020_03_01:191186002 UMLS_CUI:C0002312 Alpha thalassaemia alpha-Thalassemia disease_ontology DOID:1099 OMIM mapping confirmed by DO. [SN]. alpha thalassemia DOID:1099 A very rare form of acute disseminated encephalomyelitis, characterized by a brief but intense attack of inflammation and necrotizing vasculitis of venules and hemorrhage, and edema. GARD:8629 MESH:D004684 NCI:C84535 OMIM:606752 SNOMEDCT_US_2020_03_01:72986009 UMLS_CUI:C0014077 AHL Weston-Hurst syndrome acute haemorrhagic leucoencephalitis of Weston Hurst acute hemorrhagic encephalomyelitis acute necrotizing hemorrhagic leukoencephalitis disease_ontology DOID:10992 OMIM mapping confirmed by DO. [SN]. acute hemorrhagic leukoencephalitis DOID:10992 An eye disease that affects the lens of the eye, which is the transparent disc that focuses light to the photosensors in the back of the eye. ICD10CM:H27.9 MESH:D007905 NCI:C26812 SNOMEDCT_US_2020_03_01:194613002 UMLS_CUI:C0023308 disease_ontology DOID:110 lens disease DOID:110 A female reproductive system disease that is located_in the ovary. MESH:D010049 NCI:C26841 SNOMEDCT_US_2020_03_01:5552004 UMLS_CUI:C0029928 disease_ontology DOID:1100 ovarian disease DOID:1100 ICD9CM:372.52 SNOMEDCT_US_2020_03_01:66139007 UMLS_CUI:C0155161 disease_ontology DOID:11028 pseudopterygium DOID:11028 ICD10CM:H11.15 ICD9CM:372.51 MESH:D059407 NCI:C129468 SNOMEDCT_US_2020_03_01:267735001 UMLS_CUI:C0152255 disease_ontology DOID:11029 pinguecula DOID:11029 ICD10CM:H18.20 ICD9CM:371.2 MESH:D015715 NCI:C50508 SNOMEDCT_US_2020_03_01:193811006 UMLS_CUI:C0010037 Corneal oedema disease_ontology DOID:11030 corneal edema DOID:11030 ICD10CM:H18.1 ICD9CM:371.23 NCI:C26970 SNOMEDCT_US_2020_03_01:193815002 UMLS_CUI:C0155111 disease_ontology DOID:11031 bullous keratopathy DOID:11031 ICD10CM:H18.22 ICD9CM:371.21 SNOMEDCT_US_2020_03_01:193813009 UMLS_CUI:C0155109 disease_ontology DOID:11033 idiopathic corneal edema DOID:11033 A dissociative disorder where he continuity of the patient's memory is disrupted. Patients with dissociative amnesia have recurrent episodes in which they forget important personal information or events, usually connected with trauma or severe stress. ICD10CM:F44.0 ICD9CM:300.12 MESH:D000647 NCI:C94328 SNOMEDCT_US_2020_03_01:192420000 UMLS_CUI:C0236795 psychogenic amnesia disease_ontology DOID:11037 dissociative amnesia DOID:11037 A dissociative disorder in which the sufferer is affected by persistent or recurrent feelings of depersonalization and/or derealization. GARD:6260 ICD9CM:300.6 MESH:D003861 NCI:C94331 SNOMEDCT_US_2020_03_01:70764005 UMLS_CUI:C0683416 Neurotic derealization disease_ontology DOID:11038 depersonalization disorder DOID:11038 A syndrome that results_in rheumatoid arthritis, splenomegaly and neutropenia. GARD:8234 ICD10CM:M05.0 ICD9CM:714.1 MESH:D005258 NCI:C84712 OMIM:134750 SNOMEDCT_US_2020_03_01:57160007 UMLS_CUI:C0015773 Felty syndrome Rheumatoid arthritis with splenoadenomegaly and leukopenia disease_ontology DOID:11042 OMIM mapping confirmed by DO. [SN]. Felty's syndrome DOID:11042 GARD:8661 ICD10CM:Q79.3 ICD9CM:756.73 MESH:D020139 NCI:C84725 OMIM:230750 SNOMEDCT_US_2020_03_01:72951007 UMLS_CUI:C0265706 disease_ontology DOID:11044 OMIM mapping confirmed by DO. [SN]. gastroschisis DOID:11044 A lung disease that is characterized by a newborn breathing in a mixture of meconium and amniotic fluid into the lungs around the time of delivery. GARD:10494 ICD10CM:P24.01 MESH:D008471 NCI:C87093 SNOMEDCT_US_2020_03_01:85779008 UMLS_CUI:C0025048 Neonatal aspiration of meconium meconium aspiration disease_ontology DOID:11049 meconium aspiration syndrome DOID:11049 An urinary system cancer that results_in malignant growth located_in the urinary bladder. DOID:5428 GARD:12210 ICD10CM:C67 ICD9CM:188 KEGG:05219 MESH:D001749 NCI:C2901 NCI:C9334 OMIM:109800 SNOMEDCT_US_2020_03_01:126885006 SNOMEDCT_US_2020_03_01:363455001 UMLS_CUI:C0005684 UMLS_CUI:C0005695 bladder cancer tumor of the bladder disease_ontology DOID:11054 OMIM mapping confirmed by DO. [SN]. urinary bladder cancer DOID:11054 A primary bacterial infectious disease that results_in systemic infection, has_material_basis_in Pasteurella multocida, which is transmitted_by animal bite, scratch, or lick. The infection has_symptom joint pain has_symptom fever, has_symptom rigors, has_symptom pneumonia, has_symptom meningeal irritation, and has_symptom tachycardia. ICD10CM:A28.0 ICD9CM:027.2 MESH:D010326 SNOMEDCT_US_2020_03_01:276199008 UMLS_CUI:C0030636 Pasteurella infection Pasteurella infectious disease disease_ontology DOID:11055 pasteurellosis DOID:11055 A placenta disease that is characterized by placenta attachment to the uterine wall close to or covering the cervix. ICD10CM:O44 MESH:D010923 NCI:C26858 SNOMEDCT_US_2020_03_01:157059004 UMLS_CUI:C0032046 disease_ontology DOID:11060 placenta praevia DOID:11060 A esophageal cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. EFO:0002916 NCI:C3513 SNOMEDCT_US_2020_03_01:255079005 UMLS_CUI:C0152018 cancer of esophagus cancer of oesophagus carcinoma OF ESOPHAGUS carcinoma of esophagus carcinoma of oesophagus disease_ontology DOID:1107 esophageal carcinoma DOID:1107 A primary bacterial infectious disease that is caused by the bacteria of the genus Brucella, when humans come in contact with contaminated animals or animal products or ingestion of infected food products. The disease has_symptom fever, has_symptom sweat, has_symptom headache, has_symptom back pain, has_symptom physical weakness, has_symptom joint pain and has_symptom fatigue. DOID:0050060 GARD:5966 ICD10CM:A23 ICD9CM:023 MESH:D002006 NCI:C84602 SNOMEDCT_US_2020_03_01:154296006 UMLS_CUI:C0006309 Maltese fever undulant fever disease_ontology Bang's disease Gibraltar fever Malta fever Mediterranean fever DOID:11077 brucellosis DOID:11077 A parasitic ectoparasitic infectious disease that is caused by parasitic dipterous fly larvae (maggots) feeding on the host's necrotic or living tissue. ICD10CM:B87 ICD9CM:134.0 MESH:D009198 NCI:C128400 SNOMEDCT_US_2020_03_01:266225001 UMLS_CUI:C0027030 Infestation by fly larvae Infestation by maggots Maggot infestation disease_ontology DOID:11080 myiasis DOID:11080 ICD10CM:H31.0 ICD9CM:363.3 SNOMEDCT_US_2020_03_01:53854005 UMLS_CUI:C0008512 disease_ontology DOID:11086 chorioretinal scar DOID:11086 A respiratory system disease that is characterized by deprivation of oxygen to a newborn infant that lasts long enough during the birth process to cause physical harm, usually to the brain. GARD:5857 ICD10CM:P84 ICD9CM:768.9 MESH:D001238 SNOMEDCT_US_2020_03_01:413654009 UMLS_CUI:C0004045 Asphyxia - birth Asphyxia, in liveborn infant Birth asphyxia postnatal asphyxia disease_ontology DOID:11088 asphyxia neonatorum MESH:D001238 DOID:11088 A primary bacterial infectious disease that is a zoonotic infectious disease affecting multiple organs, has_material_basis_in Coxiella burnetii, which is transmitted_by inhalation of air contaminated by barnyard dust containing dried placental material, birth fluids, or excreta of infected herd animals, transmitted_by ingestion of contaminated milk, transmitted_by tick bites and transmitted_by contact with infected person. The infection has_symptom fever, has_symptom headache, has_symptom cough, has_symptom pleuritic chest pain, has_symptom myalgia and has_symptom arthralgia. GARD:7515 ICD10CM:A78 ICD9CM:083.0 MESH:D011778 NCI:C34970 SNOMEDCT_US_2020_03_01:266205000 UMLS_CUI:C0034362 Infection due to Coxiella burnetii disease_ontology DOID:11100 Q fever DOID:11100 A primary bacterial infectious disease that results in systemic infection, has_material_basis_in Bartonella quintana, which is transmitted by body lice (Pediculus humanus corporis). The infection has symptom relapsing fever, has symptom headache, has symptom shin pain, and has symptom soreness of the muscles of the legs and back. ICD10CM:A79.0 ICD9CM:083.1 MESH:D014205 SNOMEDCT_US_2020_03_01:82214002 UMLS_CUI:C0040830 His-Werner disease Quintan fever Wolhynian fever shin bone fever tibialgic fever disease_ontology DOID:11101 trench fever MESH:D014205 DOID:11101 A primary bacterial infectious disease that is caused by the bacteria of the genus Bartonella. ICD10CM:A44 ICD9CM:088.0 MESH:D001474 NCI:C84586 SNOMEDCT_US_2020_03_01:17116008 UMLS_CUI:C0004771 Bartonella infectious disease Rochalimaea infection bartonelliasis disease_ontology DOID:11102 bartonellosis DOID:11102 A primary bacterial infectious disease that results in infection, located in endothelial cell of artery or located in endothelial cell of vein, has_material_basis_in Rickettsia, which is transmitted by ticks and mites. The infection has symptom fever, has symptom headache, has symptom fatigue, has symptom muscle aches, and has symptom maculopapular or petechial rash. A distinctive eschar (blackened or crusted skin) may develop at the site of a tick bite. GARD:4998 ICD10CM:A77.9 ICD9CM:082.0 MESH:D000073605 SNOMEDCT_US_2020_03_01:186771002 UMLS_CUI:C0038041 Spotted fever group rickettsial disease disease_ontology DOID:11104 spotted fever DOID:11104 A fundus dystrophy that is characterized by discrete uniform white dots over the entire fundus with greatest density in the midperiphery and no macular involvement. MESH:C562733 OMIM:136880 SNOMEDCT_US_2020_03_01:68222009 UMLS_CUI:C0311338 Pigmentary retinal dystrophy retinitis punctata albescens disease_ontology DOID:11105 OMIM mapping confirmed by DO. [SN]. fundus albipunctatus DOID:11105 ICD10CM:N13.30 ICD9CM:591 MESH:D006869 NCI:C26796 SNOMEDCT_US_2020_03_01:155866001 UMLS_CUI:C0020295 disease_ontology DOID:11111 hydronephrosis DOID:11111 A tic disorder that is characterized by multiple physical (motor) tics and at least one vocal (phonic) tic present for more than a year. EFO:0004895 GARD:7783 ICD10CM:F95.2 ICD9CM:307.23 MESH:D005879 NCI:C35078 OMIM:137580 SNOMEDCT_US_2020_03_01:5158005 UMLS_CUI:C0040517 Guinon's disease Psychogenic tics Tourette syndrome motor-verbal tic disorder disease_ontology DOID:11119 OMIM mapping confirmed by DO. [SN]. Gilles de la Tourette syndrome DOID:11119 ICD10CM:K04.0 ICD9CM:522.0 MESH:D011671 NCI:C52595 SNOMEDCT_US_2020_03_01:155638006 UMLS_CUI:C0034103 disease_ontology DOID:11121 pulpitis DOID:11121 A hypersensitivity vasculitis that is characterized by purpura (purplish plaques), arthralgia, gastrointestinal upset, and/or glomerulonephritis, and may be related to increased immune response following an infection. GARD:8204 ICD10CM:D69.0 ICD9CM:287.0 MESH:D011695 NCI:C34963 SNOMEDCT_US_2020_03_01:191306005 UMLS_CUI:C0034152 Allergic purpura Autoimmune purpura Henoch-Sch?nlein purpura Henoch-Sch@nlein purpura Henoch-Scholein purpura Henoch-Schonlein Purpura Purpura, autoimmune disease_ontology DOID:11123 Henoch-Schoenlein purpura DOID:11123 disease_ontology DOID:11132 prostatic hypertrophy DOID:11132 A cell type cancer that has_material_basis_in abnormally proliferating cells derives from embryonic mesoderm. DOID:3936 ICD10CM:C49 ICD9CM:171.9 SNOMEDCT_US_2020_03_01:93765001 UMLS_CUI:C0153519 connective and soft tissue neoplasm tumor of soft tissue and skeleton disease_ontology DOID:1115 sarcoma DOID:1115 MESH:D041761 NCI:C34443 SNOMEDCT_US_2020_03_01:235919008 UMLS_CUI:C0947622 disease_ontology DOID:11151 cholecystolithiasis DOID:11151 A miliaria that is characterized by erythematous papules resulting in leakage of sweat into the deeper, subcorneal layers of the epidermis provoking a local inflammatory reaction. ICD10CM:L74.0 ICD9CM:705.1 MESH:D008883 SNOMEDCT_US_2020_03_01:44279002 UMLS_CUI:C0162423 prickly heat disease_ontology DOID:11153 miliaria rubra DOID:11153 A sweat gland disease that is characterized by reduced ability to sweat, has_symptom hyperthermia and dry skin of affected areas, and has_material_basis_in trauma to the sweat glands. ICD10CM:L74.4 MESH:D007007 NCI:C34718 SNOMEDCT_US_2020_03_01:201189007 UMLS_CUI:C0020620 Hypohidrosis Oligohidrosis disease_ontology DOID:11155 hypohidrosis MESH:D007007 DOID:11155 A hypohidrosis that is characterized by the inability to sweat and has_symptom hyperthermia and dry skin. ICD10CM:L74.4 ICD9CM:705.0 MESH:D007007 NCI:C34385 OMIM:206600 SNOMEDCT_US_2020_03_01:201189007 UMLS_CUI:C0003028 Adiaphoresis absence of sweating disease_ontology DOID:11156 OMIM mapping confirmed by DO. [SN]. anhidrosis DOID:11156 A commensal bacterial infectious disease that results_in inflammation located_in respiratory tract, has_material_basis_in Bordetella pertussis, or has_material_basis_in Bordetella parapertussis, which produce toxins that paralyze the cilia of the respiratory epithelial cells. The infection is characterized by a prolonged, high-pitched, deeply indrawn breath (whoop). DOID:11333 DOID:11751 KEGG:05133 MESH:D001885 SNOMEDCT_US_2020_03_01:26484003 UMLS_CUI:C0006015 WC - Whooping cough bordetella infection whooping cough disease_ontology DOID:1116 pertussis DOID:1116 A lung disease characterized by inadequate gas exchange by the respiratory system. DOID:11391 DOID:11392 DOID:11393 ICD10CM:J96.0 ICD9CM:518.81 NCI:C27043 SNOMEDCT_US_2020_03_01:65710008 UMLS_CUI:C0264490 acute and chronic respiratory failure acute respiratory Failure acute-on-chronic respiratory failure chronic respiratory failure respiratory insufficiency/failure disease_ontology DOID:11162 respiratory failure DOID:11162 ICD10CM:H18.42 ICD9CM:371.43 MESH:C562399 NCI:C118765 OMIM:217500 SNOMEDCT_US_2020_03_01:35055000 UMLS_CUI:C0155120 Band-shaped keratopathy disease_ontology DOID:11164 OMIM mapping confirmed by DO. [SN]. band keratopathy DOID:11164 A viral infectious disease that results_in infection located_in skin, has_material_basis_in human papillomavirus (types 2 and 4). This infection has_symptom raised wart with roughened surface, most common on hands, but can grow anywhere on the body. ICD10CM:B07.8 ICD9CM:078.1 NCI:C27087 SNOMEDCT_US_2020_03_01:57019003 UMLS_CUI:C0043037 disease_ontology DOID:11165 common wart DOID:11165 A viral infectious disease that results_in infection located_in skin of vagina, cervix, uterus, anus, penis, scrotum, mouth, and throat, has_material_basis_in human papillomaviruses (types 6 and 11), which are transmitted_by direct contact with the skin during oral, genital, or anal sex with an infected partner. The infection has_symptom anogenital warts. DOID:7877 ICD10CM:A63.0 ICD9CM:078.11 MESH:D003218 NCI:C2960 NCI:C4820 SNOMEDCT_US_2020_03_01:240542006 SNOMEDCT_US_2020_03_01:302812006 UMLS_CUI:C0009663 UMLS_CUI:C0554632 Anogenital Human papilloma Virus Infectious Disease Anogenital warts Genital warts genital wart virus infectious disease venereal wart disease_ontology Condyloma acuminatum DOID:11168 anogenital venereal wart DOID:11168 ICD10CM:H05.4 ICD9CM:376.5 MESH:D015841 NCI:C79552 SNOMEDCT_US_2020_03_01:267746003 UMLS_CUI:C0014306 disease_ontology DOID:11175 enophthalmos DOID:11175 A otitis media which involves transudation of fluid in the middle ear without pus formation. ICD10CM:H65 ICD9CM:381.4 SNOMEDCT_US_2020_03_01:275481002 UMLS_CUI:C0271446 Nonsuppurative otitis media disease_ontology DOID:11180 non-suppurative otitis media DOID:11180 ICD10CM:H10.02 ICD9CM:372.03 UMLS_CUI:C0029668 disease_ontology DOID:11184 acute conjunctivitis DOID:11184 A synostosis that results_in the fusion of two or more digits. GARD:13181 ICD10CM:Q70 ICD9CM:755.1 MESH:D013576 NCI:C87125 ORDO:295012 ORDO:90025 ORDO:93403 SNOMEDCT_US_2020_03_01:156989004 UMLS_CUI:C0039075 chromosome 2q35 duplication syndrome symphalangism symphalangy webbing of digits disease_ontology DOID:11193 Xref MGI. syndactyly MESH:D013576 DOID:11193 A syndrome that has_material_basis_in a large deletion of the chromosome 22q11.2 region which includes the DGS gene needed for development of the thymus and related glands with subsequent lack of T-cell production. GARD:10299 ICD10CM:D82.1 ICD9CM:279.11 MESH:D004062 NCI:C2989 OMIM:188400 SNOMEDCT_US_2020_03_01:77128003 UMLS_CUI:C0012236 22q11.2 deletion syndrome DiGeorge sequence DiGeorge's syndrome Pharyngeal pouch syndrome disease_ontology DOID:11198 OMIM mapping confirmed by DO. [SN]. DiGeorge syndrome DOID:11198 A parathyroid gland disease characterized by decreased function of parathyroid glands with underproduction of parathyroid hormone (PTH), leading to abnormally low ionized calcium levels in the blood. GARD:6733 ICD10CM:E20 ICD9CM:252.1 MESH:D007011 NCI:C78350 OMIM:146200 OMIM:307700 ORDO:2238 SNOMEDCT_US_2020_03_01:154697005 UMLS_CUI:C0020626 disease_ontology DOID:11199 Xref MGI. hypoparathyroidism MESH:D007011 DOID:11199 DOID:111 DOID:13536 DOID:14031 GARD:6384 ICD10CM:I85.01 ICD9CM:456.0 ICD9CM:456.2 ICD9CM:456.20 NCI:C78282 SNOMEDCT_US_2020_03_01:195475003 SNOMEDCT_US_2020_03_01:195643006 SNOMEDCT_US_2020_03_01:236067006 UMLS_CUI:C0155789 UMLS_CUI:C0155791 UMLS_CUI:C0155792 Bleeding esophageal varices Bleeding oesophageal varices esophageal varices esophageal varices in disease classified elsewhere, with bleeding esophageal varices with bleeding esophageal varices with bleeding in disease EC esophageal varices without bleeding esophageal varices without mention of bleeding disease_ontology DOID:112 esophageal varix DOID:112 A primary immunodeficiency disease that is characterized by decreased numbers of circulating or functioning T cells. DOID:613 NCI:C27145 NCI:C27872 SNOMEDCT_US_2020_03_01:402792003 UMLS_CUI:C1274233 UMLS_CUI:C1333147 T cell immunodeficiency T lymphocyte deficiency T lymphocyte immunodeficiency disease_ontology DOID:11200 T cell deficiency DOID:11200 An endocrine system disease that is located_in the parathyroid gland. ICD10CM:E21.5 ICD9CM:252.9 MESH:D010279 NCI:C26844 SNOMEDCT_US_2020_03_01:73132005 UMLS_CUI:C0030517 disease of parathyroid glands disease_ontology DOID:11201 parathyroid gland disease DOID:11201 A chronic conjunctivitis that is an inflammation of the conjunctiva involing red, itchy, and watery eyes a resulting from an exposure to an allergen or an irritant. MESH:D003233 NCI:C34506 SNOMEDCT_US_2020_03_01:231854006 UMLS_CUI:C0009766 disease_ontology DOID:11204 allergic conjunctivitis DOID:11204 A substance abuse that involves the recurring use of opioid drugs despite negative consequences. ICD10CM:F11.1 ICD9CM:305.5 MESH:D009293 SNOMEDCT_US_2020_03_01:5602001 UMLS_CUI:C0029095 disease_ontology DOID:11206 opioid abuse DOID:11206 A viral infectious disease that results in inflammation located in conjunctiva, has_material_basis_in Human coxsackievirus A24 or has_material_basis_in Human enterovirus 70, which are transmitted by contaminated fomites or transmitted by contact with contaminated hands. The infection has symptom vascular dilation, has symptom eyelid edema, has symptom photophobia, has symptom redness of the eyes, has symptom watering of the eye, has symptom conjunctival congestion, and has symptom superficial punctate epithelial keratitis. ICD9CM:077.4 MESH:D003232 NCI:C34505 SNOMEDCT_US_2020_03_01:186677009 UMLS_CUI:C0009765 Apollo disease Epidemic hemorrhagic conjunctivitis disease_ontology viral conjunctivitis DOID:11227 acute hemorrhagic conjunctivitis DOID:11227 ICD10CM:H05.0 ICD9CM:376.0 SNOMEDCT_US_2020_03_01:20551005 UMLS_CUI:C0155256 acute inflammation of orbit disease_ontology DOID:11230 acute orbital inflammation DOID:11230 An acute orbital inflammation that is characterized by painful orbital mass and has_symptom eyelid edema, has_symptom erythema, has_symptom chemiosis, has_symptom proptosis, has_symptom blurred vision, has_symptom headache, has_symptom fever and has_symptom double vision. ICD10CM:H05.01 ICD9CM:376.01 MESH:D054517 NCI:C99000 SNOMEDCT_US_2020_03_01:194005002 UMLS_CUI:C0149507 disease_ontology DOID:11234 orbital cellulitis DOID:11234 A intestinal cancer that is located_in the appendix. ICD10CM:C18.1 ICD9CM:153.5 MESH:D001063 NCI:C9333 SNOMEDCT_US_2020_03_01:93679002 UMLS_CUI:C0496779 cancer of the appendix malignant neoplasm of appendix vermiformis malignant tumor of appendix malignant tumor of the appendix disease_ontology DOID:11239 appendix cancer DOID:11239 MESH:D001063 NCI:C4434 SNOMEDCT_US_2020_03_01:126846004 UMLS_CUI:C0003614 appendix neoplasm neoplasm of appendix disease_ontology DOID:11240 appendiceal neoplasm DOID:11240 MESH:D000751 SNOMEDCT_US_2020_03_01:111468003 UMLS_CUI:C0002891 anaemia neonatal anemia neonatal neonatal anaemia disease_ontology DOID:11244 neonatal anemia DOID:11244 ICD10CM:D65 ICD9CM:286.6 MESH:D004211 NCI:C2992 SNOMEDCT_US_2020_03_01:67406007 UMLS_CUI:C0012739 DIC Defibrination syndrome Diffuse or disseminated intravascular coagulation disease_ontology DOID:11247 disseminated intravascular coagulation DOID:11247 A nutritional deficiency disease that is characterized by easy bleeding due to an inability to form blood clots caused by vitamin K deficiency, occurs most commonly in newborns, and has_material_basis_in deficiency of vitamin K secondary to liver prematurity, lack of vitamin K in a breastmillk diet, largely sterile gut, malabsorption, diarrhea, chronic illness, menorrhagia, chronic kidney disease, and some medications. ICD10CM:E56.1 ICD9CM:269.0 MESH:D014813 NCI:C99108 SNOMEDCT_US_2020_03_01:52675005 UMLS_CUI:C0042880 deficiency of vitamin K vitamin K deficiency vitamin K deficiency hemorrhagic disease disease_ontology DOID:11249 vitamin K deficiency bleeding DOID:11249 A primary bacterial infectious disease that refers to a group of diseases, located in endothelial cells of the small venous, arterial, and capillary vessels, has_material_basis_in Rickettsia bacteria, which are transmitted by lice, transmitted by fleas, and transmitted by mites. DOID:11255 DOID:12353 GARD:7833 ICD10CM:A75.0 ICD10CM:A75.2 ICD10CM:A75.9 ICD9CM:080 ICD9CM:081.0 ICD9CM:081.9 MESH:D014437 MESH:D014438 NCI:C84688 NCI:C84689 SNOMEDCT_US_2020_03_01:154375001 SNOMEDCT_US_2020_03_01:25668000 SNOMEDCT_US_2020_03_01:39111003 UMLS_CUI:C0041471 UMLS_CUI:C0041472 UMLS_CUI:C0041473 Endemic Typhus fever Exanthematic Typhus fever Flea typhus Louse-borne [epidemic] typhus Moscow typhus Murine [endemic] typhus Typhus fever endemic flea-borne typhus epidemic louse-borne typhus disease_ontology Classical typhus Epidemic (louse-borne) typhus Epidemic louse-borne typhus fever due to Rickettsia prowazekii European typhus Exanthematous typhus Famine fever Flea-borne rickettsiosis Flea-borne typhus Hospital fever Jail fever Louse-borne rickettsiosis Louse-borne typhus Mexican typhus Murine typhus Petechial fever Prison fever Rat flea typhus Ship fever Shop typhus Typhus exanthematique Urban typhus DOID:11256 typhus DOID:11256 A bartonellosis that results_in infection located_in lymph node, has_material_basis_in Bartonella henselae or has_material_basis_in Bartonella clarridgeiae, which are transmitted_by scratch or bite of a kitten, or transmitted_by contact of animal's saliva with an eye or through broken skin. The infection has_symptom regional lymphadenopathy, has_symptom headache, has_symptom chills, has_symptom backache, and has_symptom abdominal pain. ICD10CM:A28.1 ICD9CM:078.3 MESH:D002372 NCI:C84620 SNOMEDCT_US_2020_03_01:123319006 UMLS_CUI:C0007361 Debre's Syndrome Debre-Mollaret Syndrome Foshay-Mollaret Cat Scratch Fever benign lymphoreticulosis cat scratch fever disease_ontology DOID:11258 cat-scratch disease DOID:11258 A viral infectious disease that results in inflammation located in brain or located in spinal cord, has_material_basis_in Rabies virus, which is transmitted by bite of an infected animal, or transmitted by contact of mucous membranes with saliva of an infected animal. The infection has symptom fever, has symptom headache, has symptom prickling or itching sensation at the site of bite, has symptom anxiety, has symptom confusion, has symptom agitation, has symptom delirium, has symptom difficulty swallowing, has symptom hydrophobia, and has symptom paralysis. GARD:7516 ICD10CM:A82 ICD9CM:071 MESH:D011818 NCI:C28182 SNOMEDCT_US_2020_03_01:14168008 UMLS_CUI:C0034494 Lyssa disease_ontology DOID:11260 rabies DOID:11260 A primary bacterial infectious disease that results_in systemic infection, has_material_basis_in Chlamydia psittaci, which is transmitted_by inhaling aerosolized dried droppings or transmitted_by contact with infected birds. The infection has_symptom fever, has_symptom headache, has_symptom rash, has_symptom chills, and has_symptom pneumonia. ICD10CM:A70 ICD9CM:073 MESH:D009956 NCI:C34873 SNOMEDCT_US_2020_03_01:154369005 UMLS_CUI:C0029291 psittacosis disease_ontology DOID:11262 ornithosis DOID:11262 A commensal bacterial infectious disease that results_in infection located_in eye, has_material_basis_in Chlamydia trachomatis (A, B, Ba and C serovars), which is transmitted_by contact with eye discharge from the infected person and transmitted_by congenital method. The infection causes eyelid to turn inward which makes eyelashes to scratch the cornea. DOID:13013 DOID:13264 GARD:10374 ICD10CM:A71 ICD10CM:A71.0 ICD10CM:A71.1 ICD9CM:076 ICD9CM:076.0 ICD9CM:076.1 MESH:D014141 SNOMEDCT_US_2020_03_01:154367007 SNOMEDCT_US_2020_03_01:29976007 SNOMEDCT_US_2020_03_01:52812002 UMLS_CUI:C0040592 UMLS_CUI:C0153107 UMLS_CUI:C0153108 active stage trachoma trachoma dubium disease_ontology DOID:11265 trachoma DOID:11265 A viral infectious disease that is a hemorrhagic fever, located in kidney, has_material_basis_in Hantaan virus, has_material_basis_in Dobrava-Belgrade orthohantavirus has_material_basis_in Seoul virus, or has_material_basis_in Puumala virus, which are carried and transmitted by rodents. The infection has symptom headache, has symptom fever, has symptom muscle pains, has symptom facial flush, has symptom petechiae, has symptom hemorrhagic features, has symptom proteinuria, and has symptom renal failure. ICD10CM:A98.5 ICD9CM:078.6 MESH:D006480 NCI:C84753 SNOMEDCT_US_2020_03_01:186701001 UMLS_CUI:C0019101 HFRS Hemorrhagic fever, Russian Hemorrhagic nephrosonephritis Puumala virus nephropathy disease_ontology DOID:11266 Hantavirus hemorrhagic fever with renal syndrome DOID:11266 GARD:6825 ICD10CM:H18.44 ICD9CM:371.45 MESH:C536156 SNOMEDCT_US_2020_03_01:85149007 UMLS_CUI:C0152455 disease_ontology DOID:11267 keratomalacia DOID:11267 ICD10CM:K04.5 ICD9CM:522.6 SNOMEDCT_US_2020_03_01:718052004 UMLS_CUI:C0392492 disease_ontology DOID:11269 chronic apical periodontitis DOID:11269 ICD10CM:E05.2 ICD9CM:242.3 NCI:C35171 SNOMEDCT_US_2020_03_01:57777000 UMLS_CUI:C0342127 Plummer disease Toxic nodular Goiter Toxic nodular goiter disease_ontology DOID:11277 Plummer's disease DOID:11277 MESH:D010899 NCI:C26853 SNOMEDCT_US_2020_03_01:237701005 UMLS_CUI:C0032001 Pituitary apoplexy disease_ontology DOID:1129 pituitary apoplexy DOID:1129 A hemangioma that is characterized by a configuration of blood vessels that shunts arterial blood directly into veins by bypassing the capillary system. ICD10CM:I77.0 NCI:C2882 SNOMEDCT_US_2020_03_01:403966009 UMLS_CUI:C0334533 Arteriovenous hemangioma Cirsoid aneurysm Racemose Angioma Racemose aneurysm Racemose hemangioma disease_ontology DOID:11294 arteriovenous malformation DOID:11294 NCI:C27117 SNOMEDCT_US_2020_03_01:95830009 UMLS_CUI:C0342405 Pituitary infarction disease_ontology DOID:1130 pituitary infarct DOID:1130 A schistosomiasis that is a short-term, cutaneous inflammatory response associated with penetration of the skin by cercariae of bird schistosome, Austrobilharzia variglandis. The disease has symptom skin reddening, has symptom skin itching, in the water or immediately after emerging and has symptom itchy, raised papules, occur within hours of infection. GARD:9747 ICD10CM:B65.3 ICD9CM:120.3 NCI:C34457 SNOMEDCT_US_2020_03_01:187115002 UMLS_CUI:C0546996 Cutaneous schistosomiasis Sea bather's eruption disease_ontology DOID:11302 cercarial dermatitis DOID:11302 A viral infectious disease that is a hemorrhagic fever, has_material_basis_in Kyasanur forest disease virus, which is transmitted by Haemaphysalis spinigera tick bite. The infection has symptom fever, has symptom headache, has symptom stiffness of the neck, has symptom severe muscle pain, has symptom cough, has symptom dehydration, and has symptom bleeding problems. GARD:8257 ICD10CM:A98.2 ICD9CM:065.2 MESH:D007733 SNOMEDCT_US_2020_03_01:23097003 UMLS_CUI:C0022810 disease_ontology DOID:11320 Kyasanur forest disease DOID:11320 GARD:6370 ICD10CM:A46 ICD9CM:035 MESH:D004886 SNOMEDCT_US_2020_03_01:266005008 UMLS_CUI:C0014733 disease_ontology DOID:11330 erysipelas DOID:11330 A hypersensitivity reaction type IV disease characterized by the growth of collections of inflammatory cells (granulomas) in multiple organs. GARD:7607 ICD10CM:D86 ICD9CM:135 MESH:D012507 NCI:C34995 ORDO:797 SNOMEDCT_US_2020_03_01:154425004 UMLS_CUI:C0036202 Boeck sarcoid lymphogranulomatosis disease_ontology DOID:11335 sarcoidosis MESH:D012507 DOID:11335 A primary bacterial infectious disease that involves the inflammation of mucosa lining the nasal cavity, pharynx, larynx, trachea and bronchi that is characterized by the formation of granulomas, dense induration of the tissues and nodular deformity caused by Klebsiella rhinoscleromatis. ICD9CM:040.1 MESH:D012226 SNOMEDCT_US_2020_03_01:72409005 UMLS_CUI:C0035468 disease_ontology DOID:11336 rhinoscleroma DOID:11336 A primary bacterial infectious disease that results in prolonged contraction of skeletal muscle fibers, has_material_basis_in Clostridium tetani, which produces tetanospasmin, a neurotoxin, which is carried to the brain and spinal cord, where it binds irreversibly to receptors inhibiting neurotransmission. Damaged upper motor neurons cannot control reflex responses to afferent sensory stimuli. GARD:5144 ICD10CM:A35 ICD9CM:037 MESH:D013742 NCI:C85185 SNOMEDCT_US_2020_03_01:154312006 UMLS_CUI:C0039614 Infection due to Clostridium tetani clostridial tetanus disease_ontology DOID:11338 tetanus DOID:11338 An opportunistic mycosis that is located in lungs, but can also occur in eyes, ears, skin, thyroid, pituitary, palate, parathyroid, esophagus, pleura, heart, liver, spleen, small intestine, adrenals, kidneys, bone marrow, and lymph nodes, has_material_basis_in Pneumocystis jirovecii that effects interstitial and alveolar tissues and has symptom nonproductive cough, has symptom shortness of breath, and has symptom fever. GARD:4386 ICD10CM:B59 ICD9CM:136.3 MESH:D011020 NCI:C3334 SNOMEDCT_US_2020_03_01:57541005 UMLS_CUI:C1535939 Pneumocystis carinii pneumonia Pneumocystis jirovecii pneumonia Pneumocystis pneumonia Pneumocystosis Pneumocystosis pneumonia pulmonary pneumocystosis disease_ontology DOID:11339 pneumocystosis DOID:11339 DOID:1133 DOID:13280 DOID:13901 DOID:2405 ICD10CM:K06.0 ICD10CM:K06.01 ICD9CM:523.2 ICD9CM:523.24 MESH:D005889 NCI:C82068 SNOMEDCT_US_2020_03_01:155645006 SNOMEDCT_US_2020_03_01:59898000 UMLS_CUI:C0017572 UMLS_CUI:C0266916 Gingival recession Gingival recession, localized localized gingival recession minimal gingival recession moderate gingival recession severe gingival recession disease_ontology DOID:1134 gingival recession DOID:1134 An eye disease that affects the sclera, which is the white fibrous outer layer of the eyeball. ICD10CM:H15 MESH:D015422 NCI:C79717 SNOMEDCT_US_2020_03_01:33064008 UMLS_CUI:C0036412 disease_ontology DOID:11343 scleral disease DOID:11343 ICD10CM:N32.3 ICD9CM:596.3 MESH:C562406 NCI:C160155 OMIM:109820 SNOMEDCT_US_2020_03_01:268335001 UMLS_CUI:C0156273 Diverticulum - bladder Diverticulum of bladder disease_ontology DOID:11353 OMIM mapping confirmed by DO. [SN]. bladder diverticulum DOID:11353 A viral infectious disease that results in infection, has_material_basis_in Sandfly fever Naples virus, or has_material_basis_in Sandfly fever sicilian virus, which are transmitted by Phlebotomus papatasi sandfly. The infection has symptom fever, has symptom severe frontal headaches, has symptom muscle ache, has symptom joint aches, has symptom flushing of the face, and has symptom tachycardia. ICD10CM:A93.1 ICD9CM:066.0 MESH:D010217 SNOMEDCT_US_2020_03_01:33670001 UMLS_CUI:C0030372 Sandfly fever Sandfly-borne arboviral fever Sandfly-borne bunyavirus fever Sandfly-borne phleboviral disease pappataci fever disease_ontology DOID:11360 Phlebotomus fever DOID:11360 ICD10CM:H27.11 ICD9CM:379.32 MESH:D007906 NCI:C34772 SNOMEDCT_US_2020_03_01:155203002 UMLS_CUI:C0023316 Subluxation of lens disease_ontology DOID:11364 lens subluxation MESH:D007906 DOID:11364 ICD10CM:Q12.3 ICD9CM:743.35 NCI:C35172 OMIM:610256 SNOMEDCT_US_2020_03_01:35387008 UMLS_CUI:C0152422 APHAKIA, CONGENITAL PRIMARY Congenital absence of lens disease_ontology DOID:11367 OMIM mapping confirmed by DO. [SN]. congenital aphakia DOID:11367 A colonic disease that is characterized by an abnormal dilation of the colon. DOID:1771 ICD10CM:K59.39 MESH:D008531 NCI:C34810 SNOMEDCT_US_2020_03_01:33995003 UMLS_CUI:C0025160 Dilatation of colon disease_ontology DOID:11372 megacolon DOID:11372 A parasitic helminthiasis infectious disease that involves parasitic infection due to migrating immature worms of Gnathostoma spinigerum or Gnathostoma hispidum, which occurs by eating undercooked fish or poultry containing third-stage larvae, or by drinking water containing infective second-stage larvae in Cyclops. Migration in the subcutaneous tissues causes intermittent, migratory, painful, pruritic swellings (cutaneous larva migrans). Migration to other tissues (visceral larva migrans), result in cough, hematuria, and ocular involvement, with the most serious manifestations eosinophilic meningitis with myeloencephalitis. GARD:9286 ICD10CM:B83.1 ICD9CM:128.1 MESH:D058429 NCI:C128395 SNOMEDCT_US_2020_03_01:44086001 UMLS_CUI:C0018013 Gnathostomiasis Infectious Disease by Gnathostoma disease_ontology DOID:11379 gnathomiasis DOID:11379 GARD:10264 MESH:D008579 NCI:C6935 SNOMEDCT_US_2020_03_01:189167009 UMLS_CUI:C0347515 Spinal Cord meningioma Spinal meningioma disease_ontology DOID:1138 spinal meningioma DOID:1138 ICD10CM:Q53.9 ICD9CM:752.51 MESH:D003456 NCI:C12326 OMIM:219050 SNOMEDCT_US_2020_03_01:204879009 UMLS_CUI:C0010417 Cryptorchism Undescended testicle Undescended testis undescended testicles disease_ontology DOID:11383 OMIM mapping confirmed by DO. [SN]. cryptorchidism DOID:11383 A language disorder that involves difficulties with verbal and written expression characterized by an ability to use expressive spoken language that is markedly below the appropriate level for the mental age, but with a language comprehension that is within normal limits. ICD10CM:F80.1 ICD9CM:315.31 NCI:C92562 SNOMEDCT_US_2020_03_01:80360005 UMLS_CUI:C0236826 Developmental expressive language disorder disease_ontology DOID:11385 expressive language disorder DOID:11385 A central nervous system disease that is characterized by a collection of pus (infected material) between the outer covering of the brain and spinal cord and the bones of the skull or spine and is caused by infection in the area between the bones of the skull or spine, and the membranes covering the brain and spinal cord (meninges). MESH:D020802 SNOMEDCT_US_2020_03_01:310671007 UMLS_CUI:C0270629 abscess epidural disease_ontology DOID:11387 epidural abscess DOID:11387 ICD9CM:437.4 SNOMEDCT_US_2020_03_01:28366008 UMLS_CUI:C0007773 Cerebral arteritis disease_ontology DOID:11390 cerebral arteritis DOID:11390 A respiratory failure that results from diffuse injury to the endothelium of the lung (as in sepsis, chest trauma, massive blood transfusion, aspiration of the gastric contents, or pneumonia) and is characterized by pulmonary edema with an abnormally high amount of protein in the edematous fluid and by difficult rapid breathing and hypoxemia. GARD:5698 ICD10CM:J80 MESH:D012128 NCI:C3353 SNOMEDCT_US_2020_03_01:155627006 UMLS_CUI:C0035222 ARDS Non-cardiogenic pulmonary edema Shock lung acute respiratory distress syndrome adult RDS disease_ontology DOID:11394 PRISM. adult respiratory distress syndrome DOID:11394 A cardiovascular system disease that involves the heart. ICD10CM:I51.9 ICD9CM:429.9 MESH:D006331 NCI:C3079 SNOMEDCT_US_2020_03_01:194707003 UMLS_CUI:C0018799 disease_ontology DOID:114 heart disease DOID:114 NCI:C5134 UMLS_CUI:C1334264 disease_ontology DOID:1140 spinal canal and spinal cord meningioma DOID:1140 ICD10CM:N16 ICD9CM:590.80 MESH:D011704 NCI:C34965 SNOMEDCT_US_2020_03_01:45816000 UMLS_CUI:C0034186 disease_ontology DOID:11400 pyelonephritis DOID:11400 MESH:D011705 NCI:C123038 SNOMEDCT_US_2020_03_01:197777006 UMLS_CUI:C0034188 Xanthogranulomatous pyelonephritis disease_ontology DOID:11401 xanthogranulomatous pyelonephritis DOID:11401 A primary bacterial infectious disease that is characterized by sore throat, low fever, and an adherent membrane (a pseudomembrane) on the tonsils, pharynx, and/or nasal cavity. A milder form of diphtheria can be restricted to the skin. It is caused by Corynebacterium diphtheriae, an aerobic Gram-positive bacterium. Diphtheria toxin spreads through the bloodstream and can lead to potentially life-threatening complications that affect other organs of the body, such as the heart and kidneys. DOID:4132 GARD:1875 MESH:D003354 SNOMEDCT_US_2020_03_01:397434007 UMLS_CUI:C0010153 corynebacterium infection disease_ontology DOID:11405 diphtheria DOID:11405 A female reproductive system disease characterized by the growth of fallopian tube-like epithelium outside the fallopian tube. NCI:C40121 SNOMEDCT_US_2020_03_01:55850004 UMLS_CUI:C0269106 disease_ontology DOID:11427 endosalpingiosis DOID:11427 ICD10CM:H50.1 ICD9CM:378.1 MESH:D005099 NCI:C34601 SNOMEDCT_US_2020_03_01:155194007 UMLS_CUI:C0015310 Divergent Strabismus Divergent concomitant strabismus disease_ontology DOID:1143 exotropia DOID:1143 A brain disease that is characterized by pressure on the intracranial tissues by an effusion of blood or cerebrospinal fluid, an abscess, a neoplasm, a depressed fracture of the skull, or edema of the brain. ICD10CM:G93.5 ICD9CM:348.4 SNOMEDCT_US_2020_03_01:46963008 UMLS_CUI:C0009592 disease_ontology DOID:11457 brain compression DOID:11457 GARD:4561 ICD10CM:G93.2 ICD9CM:348.2 MESH:D011559 NCI:C85035 OMIM:243200 SNOMEDCT_US_2020_03_01:68267002 UMLS_CUI:C0033845 Pseudotumor cerebri benign intracran. hypt. benign intracranial hypertension idiopathic intracranial hypertension disease_ontology DOID:11459 OMIM mapping confirmed by DO. [SN]. pseudotumor cerebri DOID:11459 ICD9CM:337.1 UMLS_CUI:C0154691 autonomic nervous system disorder disease_ontology DOID:11465 autonomic nervous system disease DOID:11465 A bone resorption disease characterized by decreased density of normally mineralized bone which results_in the thinning of bone tissue and decreased mechanical strength. EFO:0003882 ICD10CM:M81.0 ICD9CM:733.0 MESH:D010024 NCI:C3298 OMIM:166710 SNOMEDCT_US_2020_03_01:156825006 UMLS_CUI:C0029456 disease_ontology DOID:11476 Xref MGI. osteoporosis DOID:11476 A physical disorder that is characterized by the presence of more than five fingers per hand or five toes per foot. DOID:14779 GARD:4410 ICD10CM:Q69 ICD9CM:755.0 MESH:C562429 MESH:D017689 NCI:C87110 OMIM:174200 OMIM:174500 OMIM:174700 OMIM:603596 SNOMEDCT_US_2020_03_01:205119005 UMLS_CUI:C0152427 UMLS_CUI:C0220697 postaxial polydactyly disease_ontology Supernumerary digit DOID:1148 polydactyly DOID:1148 ICD9CM:423.2 MESH:D010494 NCI:C78246 SNOMEDCT_US_2020_03_01:155340008 UMLS_CUI:C0031048 Constrictive pericarditis disease_ontology DOID:11481 constrictive pericarditis DOID:11481 A pericardial effusion that results from blood in the pericardial sac. ICD9CM:423.0 MESH:D010490 NCI:C111644 SNOMEDCT_US_2020_03_01:155339006 UMLS_CUI:C0019064 Haemopericardium disease_ontology DOID:11482 hemopericardium DOID:11482 GARD:6670 ICD10CM:G90.2 MESH:D006732 NCI:C28155 OMIM:143000 SNOMEDCT_US_2020_03_01:192922002 UMLS_CUI:C0019937 Bernard Horner syndrome Horner syndrome cervical sympathetic paralysis disease_ontology DOID:11486 Horner's syndrome DOID:11486 A pericardial effusion in which fluid accumulates in the pericardium (the sac in which the heart is enclosed) and the pericardial spaces fills up faster than the pericardial sac can stretch. ICD10CM:I31.4 ICD9CM:423.3 MESH:D002305 NCI:C50481 SNOMEDCT_US_2020_03_01:266295005 UMLS_CUI:C0007177 Rose's tamponade pericardial tamponade disease_ontology DOID:115 cardiac tamponade DOID:115 DOID:11737 DOID:13947 ICD10CM:Q23.3 ICD9CM:396.3 ICD9CM:746.6 MESH:D008944 NCI:C50888 SNOMEDCT_US_2020_03_01:194736003 SNOMEDCT_US_2020_03_01:194977007 SNOMEDCT_US_2020_03_01:29928006 UMLS_CUI:C0026266 UMLS_CUI:C0158619 UMLS_CUI:C0264774 Congenital insufficiency of mitral valve Mitral valve incompetence congenital mitral insufficiency congenital mitral regurgitation mitral regurgitation disease_ontology DOID:11502 mitral valve insufficiency DOID:11502 NCI:C27033 SNOMEDCT_US_2020_03_01:277879009 UMLS_CUI:C0259749 disease_ontology DOID:11504 autonomic neuropathy DOID:11504 A otitis media which involves inflammation of the middle ear with infected effusion containing pus. ICD10CM:H66.4 ICD9CM:382.4 MESH:D010035 SNOMEDCT_US_2020_03_01:267758003 UMLS_CUI:C0029888 Otitis media with effusion - purulent Purulent otitis media disease_ontology DOID:11506 suppurative otitis media DOID:11506 ICD10CM:I82.0 MESH:D006502 OMIM:600880 SNOMEDCT_US_2020_03_01:195436007 UMLS_CUI:C0019154 hepatic vein thrombosis disease_ontology DOID:11512 Budd-Chiari syndrome DOID:11512 ICD10CM:K14.5 ICD9CM:529.5 MESH:D014063 OMIM:137400 SNOMEDCT_US_2020_03_01:52368004 UMLS_CUI:C0040412 Congenital fissure of tongue Congenital plicated tongue Fissure of tongue Fissure of tongue, congenital Furrowed tongue Plicated tongue Tongue, Fissured geographic tongue and fissured tongue lingua plicata scrotal tongue disease_ontology DOID:11514 OMIM mapping confirmed by DO. [SN]. fissured tongue DOID:11514 A heart disease that is caused by high blood pressure. ICD10CM:I11 ICD9CM:402 NCI:C157879 SNOMEDCT_US_2020_03_01:155297007 UMLS_CUI:C0152105 disease_ontology DOID:11516 hypertensive heart disease DOID:11516 ICD10CM:J38.6 ICD9CM:478.74 MESH:D007829 NCI:C79608 SNOMEDCT_US_2020_03_01:195864007 UMLS_CUI:C0023075 Stenosis of larynx disease_ontology DOID:11527 laryngostenosis DOID:11527 ICD10CM:H18.83 ICD9CM:371.42 SNOMEDCT_US_2020_03_01:2055003 UMLS_CUI:C0155119 recurrent erosion of cornea recurrent erosion syndrome disease_ontology DOID:11541 recurrent corneal erosion DOID:11541 ICD10CM:H16.31 ICD9CM:370.55 NCI:C26969 SNOMEDCT_US_2020_03_01:64366002 UMLS_CUI:C0155091 disease_ontology DOID:11543 corneal abscess DOID:11543 A corneal dystrophy characterized by accumulation of focal outgrowths (guttae) and thickening of Descemet's membrane, leading to corneal edema and loss of vision. EFO:0003946 GARD:10018 ICD10CM:H18.51 MESH:D005642 NCI:C84721 OMIM:136800 OMIM:610158 OMIM:613267 OMIM:613268 OMIM:613269 OMIM:613270 OMIM:613271 OMIM:615523 ORDO:98974 SNOMEDCT_US_2020_03_01:16949007 UMLS_CUI:C0016781 FCED Fuchs' corneal dystrophy Fuchs' endothelial corneal dystrophy disease_ontology DOID:11555 Xref MGI. Fuchs' endothelial dystrophy DOID:11555 An arthritis that has_material_basis_in the accumulation of salt crystals located_in joint. DOID:11303 DOID:1155 DOID:12090 DOID:12102 DOID:12945 DOID:13298 DOID:13299 DOID:13301 DOID:13302 DOID:13303 DOID:13304 DOID:14143 DOID:14220 DOID:14513 DOID:1834 DOID:1945 DOID:2486 ICD9CM:712.1 NCI:C34955 OMIM:118600 OMIM:118610 OMIM:600668 ORDO:1416 SNOMEDCT_US_2020_03_01:201624004 SNOMEDCT_US_2020_03_01:201625003 UMLS_CUI:C0033802 UMLS_CUI:C0157852 calcium pyrophosphate deposition disease pseudogout disease_ontology DOID:1156 Xref MGI. chondrocalcinosis DOID:1156 ICD10CM:H35.03 ICD9CM:362.11 MESH:D058437 NCI:C3514 SNOMEDCT_US_2020_03_01:422001004 UMLS_CUI:C0152132 disease_ontology DOID:11561 hypertensive retinopathy DOID:11561 A somatoform disorder that involves heart disease symptoms without any identifiable physiological abnormatlities. ICD9CM:306.2 MESH:D009449 SNOMEDCT_US_2020_03_01:46219009 UMLS_CUI:C0027821 Cardiovascular malfunction arising from mental factors Cardiovascular neurosis Da Costa's syndrome Krishaber's disease disease_ontology DOID:11569 neurocirculatory asthenia DOID:11569 A primary bacterial infectious disease that results_in infection, has_material_basis_in Listeria monocytogenes, which is transmitted_by ingestion of contaminated food or raw milk or transmitted_by congenital method. Ingestion of Listeria by pregnant women has_symptom nausea, has_symptom vomiting, has_symptom diarrhea, has_symptom fever, has_symptom malaise, has_symptom back pain, and has_symptom headache. Maternal infection with Listeria can result in chorioamnionitis, premature labor, spontaneous abortion, or stillbirth. ICD10CM:A32 ICD9CM:027.0 MESH:D008088 NCI:C82994 SNOMEDCT_US_2020_03_01:186315001 UMLS_CUI:C0023860 Infection by Listeria monocytogenes Listeria infection disease_ontology DOID:11573 listeriosis DOID:11573 A peripheral nervous system disease that involves an acute loss of function of the lumbar plexus, neurologic elements (nerve roots) of the spinal canal below the termination (conus) of the spinal cord. GARD:10987 ICD10CM:G83.4 ICD9CM:344.6 MESH:D000077684 NCI:C35436 SNOMEDCT_US_2020_03_01:89356000 UMLS_CUI:C0392548 disease_ontology DOID:11577 Cauda equina syndrome DOID:11577 ICD10CM:H16.25 ICD9CM:370.31 SNOMEDCT_US_2020_03_01:193773009 UMLS_CUI:C0155080 Phlyctenular keratoconjunctivitis Strumous ophthalmia disease_ontology DOID:11581 phlyctenulosis DOID:11581 ICD10CM:G90.1 MESH:D004402 NCI:C84706 OMIM:223900 SNOMEDCT_US_2020_03_01:204087006 UMLS_CUI:C0013364 HSAN III familial autonomic nervous dysfunction familial dysautonomia disease_ontology DOID:11589 OMIM mapping confirmed by DO. [SN]. Riley-Day syndrome DOID:11589 ICD9CM:536.8 UMLS_CUI:C0013396 disease_ontology DOID:1159 functional gastric disease DOID:1159 ICD10CM:H15.84 ICD9CM:379.11 SNOMEDCT_US_2020_03_01:111534007 UMLS_CUI:C0155359 Scleral ectasia disease_ontology DOID:11595 scleral staphyloma DOID:11595 GARD:6467 MESH:D013547 OMIM:144100 SNOMEDCT_US_2020_03_01:56046002 UMLS_CUI:C0038994 Baillarger syndrome gustatory hyperhidrosis gustatory sweating disease_ontology DOID:11599 OMIM mapping confirmed by DO. [SN]. Frey syndrome DOID:11599 DOID:5780 ICD10CM:C38.0 NCI:C4567 NCI:C4651 SNOMEDCT_US_2020_03_01:126734005 SNOMEDCT_US_2020_03_01:93957005 UMLS_CUI:C0346609 UMLS_CUI:C0349574 Pericardial tumor malignant neoplasm of pericardium malignant tumor of Pericardium disease_ontology DOID:116 pericardium cancer DOID:116 A meningitis that has_material_basis_in a fungal infection. MESH:D016921 SNOMEDCT_US_2020_03_01:24321005 UMLS_CUI:C0085438 disease_ontology DOID:11608 fungal meningitis DOID:11608 An ovarian dysfunction that is characterized by hyperandrogenism, polycystic ovaries, hirsutism, oligomenorrhea or amenorrhea, anovulation and excessive body weight. EFO:0000660 ICD10CM:E28.2 ICD9CM:256.4 MESH:D011085 NCI:C26862 OMIM:184700 SNOMEDCT_US_2020_03_01:69878008 UMLS_CUI:C0032460 Multicystic ovaries PCOS Polycystic Ovarian disease Polycystic ovaries Polycystic ovary syndrome Stein-Leventhal synd. Stein-Leventhal syndrome polycystic ovary disease_ontology DOID:11612 OMIM mapping confirmed by DO. [SN]. polycystic ovary syndrome DOID:11612 MESH:D017588 SNOMEDCT_US_2020_03_01:237793004 UMLS_CUI:C0206081 hyperandrogenization syndrome disease_ontology DOID:11613 hyperandrogenism DOID:11613 DOID:11614 ICD10CM:C60 ICD10CM:C60.2 ICD9CM:187.3 ICD9CM:187.4 MESH:D010412 NCI:C7547 SNOMEDCT_US_2020_03_01:93716006 SNOMEDCT_US_2020_03_01:93954003 UMLS_CUI:C0153600 UMLS_CUI:C0153601 Ca penis Penile Ca malignant Penile tumor malignant neoplasm of body of penis penile neoplasm disease_ontology DOID:11615 penile cancer DOID:11615 ICD10CM:K04.1 ICD9CM:522.1 MESH:D003790 SNOMEDCT_US_2020_03_01:196332000 UMLS_CUI:C0011407 necrosis of the pulp necrotic pulp pulp necrosis disease_ontology DOID:11623 dental pulp necrosis DOID:11623 MESH:D010412 NCI:C3317 SNOMEDCT_US_2020_03_01:126896003 UMLS_CUI:C0030849 Penile tumor neoplasm of penis disease_ontology DOID:11624 penile benign neoplasm DOID:11624 MESH:D018382 NCI:C85191 OMIM:188570 OMIM:274300 SNOMEDCT_US_2020_03_01:50375007 UMLS_CUI:C2940786 Generalized thyroid hormone resistance Refetoff syndrome Thyroid hormone resistance syndrome Thyroid hormone responsiveness defect thyroid hormone resistance disease_ontology DOID:11633 OMIM mapping confirmed by DO. [LS]. thyroid hormone resistance syndrome DOID:11633 ICD10CM:H52.4 ICD9CM:367.4 MESH:D011305 SNOMEDCT_US_2020_03_01:155135005 UMLS_CUI:C0033075 disease_ontology DOID:11638 presbyopia DOID:11638 A bullous skin disease characterized by skin lesions and scaring and located_in mucous membranes and located_in skin. DOID:11655 GARD:5913 ICD10CM:L12.1 ICD9CM:694.6 ICD9CM:694.61 MESH:D010390 NCI:C34907 OMIM:164185 SNOMEDCT_US_2020_03_01:34250006 SNOMEDCT_US_2020_03_01:76092003 UMLS_CUI:C0030804 UMLS_CUI:C0157721 Cicatricial pemphigoid with ocular involvement Ocular pemphigoid benign mucous membrane pemphigoid benign mucous membrane pemphigoid with ocular involvement ocular pemphigus disease_ontology DOID:11656 cicatricial pemphigoid DOID:11656 An arthritis that involves sudden and rapidly developing attacks of arthritis with a remission period that results_in no joint damage or symptoms. DOID:1165 DOID:1177 DOID:1178 DOID:1179 DOID:12951 DOID:13354 DOID:13355 DOID:13771 GARD:7304 ICD10CM:M12.3 ICD9CM:719.3 ICD9CM:719.31 MESH:C538103 SNOMEDCT_US_2020_03_01:202455001 SNOMEDCT_US_2020_03_01:202457009 UMLS_CUI:C0085574 UMLS_CUI:C0158178 Hench's syndrome Hench-Rosenberg syndrome disease_ontology DOID:1166 palindromic rheumatism DOID:1166 A color blindness that is characterised by a selective deficiency of blue vision, has_material_basis_in autosomal dominant inheritance of a mutation in the OPN1SW gene and is associated with a deficiency or absence of blue-sensitive cone photoreceptor function. ICD10CM:H53.55 ICD9CM:368.53 MESH:D003117 OMIM:190900 SNOMEDCT_US_2020_03_01:51886007 UMLS_CUI:C0155017 Tritan defect Tritanopia disease_ontology DOID:11661 OMIM mapping confirmed by DO. [SN]. blue color blindness DOID:11661 ICD10CM:Q91.7 ICD9CM:758.1 MESH:D000073839 NCI:C101223 SNOMEDCT_US_2020_03_01:21111006 UMLS_CUI:C0152095 D1 Trisomy trisomy 13 disease_ontology Patau's syndrome DOID:11665 OMIM mapping confirmed by DO. [LS]. Patau syndrome DOID:11665 A filariasis that involves parasitic infection caused by the nematode Onchocerca volvulus, which is transmitted to humans through the bite of a blackfly of the genus Simulium. The worms spread throughout the body and, when they die, cause intense itching and a strong immune system response that can destroy nearby tissue. The symptoms include pruritus, dermatitis, blindness, onchocercomata (subcutaneous nodules), and lymphadenopathy. GARD:7252 ICD10CM:B73 ICD9CM:125.3 MESH:D009855 NCI:C34861 SNOMEDCT_US_2020_03_01:38539003 UMLS_CUI:C0029001 Infection by Onchocerca volvulus Onchocerca volvulus infection volvulosis disease_ontology DOID:11678 onchocerciasis DOID:11678 DOID:3147 ICD10CM:E78.5 MESH:D006949 MESH:D006951 NCI:C34707 NCI:C34709 SNOMEDCT_US_2020_03_01:154739000 SNOMEDCT_US_2020_03_01:3744001 UMLS_CUI:C0020473 UMLS_CUI:C0020476 familial hyperlipoproteinemia hyperlipemia disease_ontology hyperlipidaemia DOID:1168 familial hyperlipidemia DOID:1168 NCI:C27548 SNOMEDCT_US_2020_03_01:201096007 UMLS_CUI:C1321683 disease_ontology DOID:11684 melanoacanthoma DOID:11684 ICD10CM:K04.4 ICD9CM:522.4 SNOMEDCT_US_2020_03_01:88071000 UMLS_CUI:C0155934 acute apical periodontitis of pulpal origin disease_ontology DOID:11693 acute apical periodontitis DOID:11693 A hepatic vascular disease that is characterized by a blood clot that forms within the hepatic portal vein. ICD10CM:I81 ICD9CM:452 NCI:C78565 SNOMEDCT_US_2020_03_01:155455003 UMLS_CUI:C0155773 disease_ontology DOID:11695 portal vein thrombosis DOID:11695 A cardiovascular cancer located_in the heart. DOID:9918 GARD:2619 ICD10CM:C38.0 ICD9CM:164.1 MESH:D006338 NCI:C3081 NCI:C3548 SNOMEDCT_US_2020_03_01:126730001 SNOMEDCT_US_2020_03_01:93825008 UMLS_CUI:C0018809 UMLS_CUI:C0153500 Cardiac tumor Tumour of heart malignant Cardiac tumor malignant neoplasm of heart disease_ontology DOID:117 heart cancer DOID:117 A selective immunoglobulin deficiency disease that is caused by a reduction in some types of gamma globulins. MESH:D004406 SNOMEDCT_US_2020_03_01:127389001 UMLS_CUI:C0013374 Dysgammaglobulinemia disease_ontology DOID:11702 dysgammaglobulinemia MESH:D004406 DOID:11702 A peripheral vascular disease that is characterized by narrowing of the arteries as a complication arising from chronic diabetes. DOID:10182 ICD9CM:250.7 MESH:D003925 NCI:C35610 SNOMEDCT_US_2020_03_01:127014009 UMLS_CUI:C0011871 UMLS_CUI:C0011875 Diabetic vascular disorder diabetic peripheral angiopathy disease_ontology DOID:11713 diabetic angiopathy DOID:11713 A diabetes mellitus that manifests during pregnancy. EFO:0004593 ICD10CM:O24.4 MESH:D016640 NCI:C34942 SNOMEDCT_US_2020_03_01:11687002 UMLS_CUI:C0085207 GDM Gestational diabetes mellitus Maternal gestational diabetes mellitus disease_ontology DOID:11714 gestational diabetes DOID:11714 A glucose metabolism disease that is characterized by blood glucose levels are high, but not high enough to be classified as type 2 diabetes. ICD10CM:R73.03 MESH:D011236 NCI:C122685 SNOMEDCT_US_2020_03_01:15777000 UMLS_CUI:C0362046 Prediabetes impaired glucose tolerance prediabetic state disease_ontology DOID:11716 prediabetes syndrome DOID:11716 A diabetes mellitus that is characterized by hyperglycemia occuring within the first 6 months of life. ICD10CM:P70.2 ICD9CM:775.1 NCI:C99248 SNOMEDCT_US_2020_03_01:49817004 UMLS_CUI:C0158981 diabetes mellitus syndrome in newborn infant neonatal diabetes mellitus disease_ontology DOID:11717 neonatal diabetes DOID:11717 DOID:0050527 ICD10CM:E78.1 ICD9CM:272.1 MESH:D006953 NCI:C34711 OMIM:144600 OMIM:145750 SNOMEDCT_US_2020_03_01:154741004 UMLS_CUI:C0020480 Endogenous hyperlipidaemia Fredrickson type IV Lipidemia Fredrickson type IV hyperlipoproteinemia Fredrickson type IV lipidaemia VLDL hyperlipoproteinemia familial hypertriglyceridemia disease_ontology DOID:1172 OMIM mapping confirmed by DO. [SN]. hyperlipoproteinemia type IV DOID:1172 A muscular dystrophy that is characterized by predominant weakness and atrophy beginning in the feet and/or hands. ICD10CM:G71.09 MESH:D049310 NCI:C84675 ORDO:399096 ORDO:5448 ORDO:59135 SNOMEDCT_US_2020_03_01:58795000 UMLS_CUI:C0751336 Miyoshi muscular dystrophy distal muscular dystrophy disease_ontology DOID:11720 Xref MGI. OMIM mapping confirmed by DO. [SN]. distal myopathy DOID:11720 A myotonic disease that is characterized by progressive muscle wasting and weakness affecting the distal skeletal and smooth muscles of lower legs, hands, neck, and face along with myotonia and cataracts and has_material_basis_in the autosomal dominant inheritance of the DMPK gene containing an expansion of a CTG trinucleotide repeat in the non-coding region. GARD:8310 ICD10CM:G71.11 ICD9CM:359.21 MESH:D009223 NCI:C84914 OMIM:160900 SNOMEDCT_US_2020_03_01:77956009 UMLS_CUI:C0027126 Dystrophia myotonica Steinert disease congenital myotonic dystrophy myotonic dystrophy of Steinert disease_ontology DOID:11722 OMIM mapping confirmed by DO. [SN]. myotonic dystrophy type 1 MESH:C535686 DOID:11722 A muscular dystrophy that has_material_basis_in X-linked mutations in the DMD gene found on the X chromosome. It is characterized by rapidly progressing muscle weakness and muscle atrophy initially involving the lower extremities and eventually affecting the whole body. It affects males whereas females can be carriers. The symptoms start before the age of six and may appear at infancy. GARD:6291 MESH:D020388 NCI:C75482 OMIM:310200 SNOMEDCT_US_2020_03_01:155095006 UMLS_CUI:C0013264 Muscular dystrophy, Duchenne disease_ontology DOID:11723 OMIM mapping confirmed by DO. [SN]. Duchenne muscular dystrophy DOID:11723 A muscular dystrophy that is characterized by weakening of the muscles of the hip and shoulders which comprise the limb girdle muscles. GARD:6907 ICD10CM:G71.09 MESH:D049288 NCI:C84828 ORDO:263 SNOMEDCT_US_2020_03_01:56096001 UMLS_CUI:C0686353 Erb's muscular dystrophy Leyden-Mbius muscular dystrophy limb girdle muscular dystrophy disease_ontology DOID:11724 Xref MGI. OMIM mapping confirmed by DO. [SN]. limb-girdle muscular dystrophy DOID:11724 A syndrome that is characterized by slow growth before and after birth, intellectual disability that is usually severe to profound, skeletal abnormalities involving the arms and hands, and distinctive facial features. GARD:10109 ICD10CM:Q87.19 MESH:D003635 NCI:C75016 OMIM:PS122470 ORDO:199 SNOMEDCT_US_2020_03_01:40354009 UMLS_CUI:C0270972 Brachmann de Lange syndrome De Lange syndrome disease_ontology DOID:11725 Xref MGI. OMIM mapping confirmed by DO. [SN]. Cornelia de Lange syndrome DOID:11725 A muscular dystrophy that chiefly affects muscles used for movement (skeletal) and heart (cardiac) muscle. GARD:6329 MESH:D020389 NCI:C84685 OMIM:PS310300 ORDO:261 SNOMEDCT_US_2020_03_01:129620000 UMLS_CUI:C0410189 EDMD disease_ontology DOID:11726 Xref MGI. OMIM mapping confirmed by DO. [SN]. Emery-Dreifuss muscular dystrophy DOID:11726 GARD:9941 ICD10CM:G71.02 MESH:D020391 NCI:C84704 SNOMEDCT_US_2020_03_01:56096001 UMLS_CUI:C0238288 Landouzy Dejerine muscular dystrophy Landouzy-Dejerine muscular dystrophy Muscular dystrophy, Landouzy-Dejerine disease_ontology DOID:11727 OMIM mapping confirmed by DO. [SN]. facioscapulohumeral muscular dystrophy DOID:11727 A primary bacterial infectious disease that results_in infection, has_material_basis_in Borrelia burgdorferi, which is transmitted_by blacklegged tick (Ixodes scapularis) or transmitted_by western blacklegged tick (Ixodes pacificus). The infection has_symptom fever, has_symptom headache, has_symptom fatigue, and has_symptom skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system. DOID:12233 GARD:12073 ICD10CM:A69.2 ICD9CM:088.81 MESH:D008193 MESH:D020852 NCI:C45161 SNOMEDCT_US_2020_03_01:154376000 SNOMEDCT_US_2020_03_01:715507005 UMLS_CUI:C0024198 UMLS_CUI:C0752235 Bannwarth syndrome Bannworth's syndrome Lyme borreliosis Neurological Lyme disease lyme neuroboInOwlrreliosis neuroboInOwlrreliosis disease_ontology DOID:11729 Lyme disease DOID:11729 MESH:D042883 SNOMEDCT_US_2020_03_01:197397004 UMLS_CUI:C0701818 disease_ontology DOID:11755 choledocholithiasis DOID:11755 ICD10CM:D50 MESH:D000747 NCI:C34380 SNOMEDCT_US_2020_03_01:44452003 UMLS_CUI:C0002884 ANEMIA HYPOCHROMIC disease_ontology DOID:11759 hypochromic anemia DOID:11759 A lower respiratory tract disease that affects the airways leading into the lungs, which is caused due to inflammation of the bronchi and bronchioles, infection, or blockage. DOID:1175 DOID:12322 MESH:D001982 SNOMEDCT_US_2020_03_01:41427001 UMLS_CUI:C0006261 Bronchospasm disease_ontology DOID:1176 bronchial disease DOID:1176 ICD10CM:H55.03 ICD9CM:379.53 MESH:D009759 SNOMEDCT_US_2020_03_01:39771000 UMLS_CUI:C0271384 Ocular nystagmus Searching eye movements visual deprivation nystagmus disease_ontology DOID:11771 spontaneous ocular nystagmus DOID:11771 ICD10CM:H44.53 ICD9CM:360.44 SNOMEDCT_US_2020_03_01:193288000 UMLS_CUI:C0152458 Leucocoria disease_ontology DOID:11772 leukocoria DOID:11772 ICD10CM:H52.22 ICD9CM:367.21 SNOMEDCT_US_2020_03_01:68905002 UMLS_CUI:C0152193 disease_ontology DOID:11781 regular astigmatism DOID:11781 A refractive error characterized by the optics of the eye to focus a point object into a sharp focused image on the retina, has_symptom blurred vision. EFO:0004222 ICD10CM:H52.2 ICD9CM:367.2 MESH:D001251 OMIM:603047 SNOMEDCT_US_2020_03_01:155134009 UMLS_CUI:C0004106 disease_ontology DOID:11782 OMIM mapping confirmed by DO. [SN]. astigmatism DOID:11782 ICD9CM:289.52 UMLS_CUI:C1260402 disease_ontology DOID:11786 splenic sequestration DOID:11786 A pericardium disease that is characterized by an abnormal accumulation of fluid in the pericardial cavity. MESH:D010490 NCI:C3319 SNOMEDCT_US_2020_03_01:70370001 UMLS_CUI:C0031039 disease_ontology DOID:118 pericardial effusion DOID:118 A nutritional deficiency disease that is characterized by inadequate dietary protein and calories, which can have profound systemic effects including decreased metabolism, altered tissue distribution, compromised immunity, and impaired growth, and has_material_basis_in dietary deprivation. ICD10CM:E46 ICD9CM:263.9 MESH:D011502 NCI:C34952 SNOMEDCT_US_2020_03_01:72608005 UMLS_CUI:C0033677 disease_ontology DOID:11801 protein-energy malnutrition DOID:11801 ICD10CM:H43.81 ICD9CM:379.21 SNOMEDCT_US_2020_03_01:60189009 UMLS_CUI:C0155366 Vitreous degeneration disease_ontology DOID:11816 vitreous syneresis DOID:11816 A urinary system cancer that is located_in the ureter. ICD10CM:C66 ICD9CM:189.2 MESH:D014516 NCI:C7543 OMIM:191600 SNOMEDCT_US_2020_03_01:94121005 UMLS_CUI:C0153619 malignant tumour of ureter malignant ureteral tumor disease_ontology DOID:11819 OMIM mapping confirmed by DO. [SN]. ureter cancer DOID:11819 A syndrome that is characterized by papulonodular skin lesions containing a proliferation of true macrophages associated with arthritis. GARD:7103 ICD10CM:E78.81 NCI:C27896 ORDO:139436 SNOMEDCT_US_2020_03_01:84241008 UMLS_CUI:C0311284 Lipoid dermatoarthritis Multicentric reticulohistiocytosis disease_ontology DOID:11824 multicentric reticulohistiocytosis DOID:11824 A refractive error characterized by the inability to see farther objects clearly. EFO:0003927 ICD10CM:H52.1 ICD9CM:367.1 MESH:D009216 NCI:C102533 OMIM:160700 OMIM:255500 OMIM:300613 OMIM:310460 OMIM:603221 OMIM:608367 OMIM:608474 OMIM:608908 OMIM:609256 OMIM:609257 OMIM:609258 OMIM:609259 OMIM:609994 OMIM:609995 OMIM:610320 OMIM:612554 OMIM:612717 OMIM:613959 OMIM:613969 OMIM:614166 OMIM:614167 OMIM:615420 OMIM:615431 OMIM:615946 SNOMEDCT_US_2020_03_01:155133003 UMLS_CUI:C0027092 near vision near-sightedness short-sightedness disease_ontology DOID:11830 Xref MGI. myopia MESH:D009216 DOID:11830 ICD10CM:H47.61 ICD9CM:377.75 MESH:D019575 NCI:C118707 SNOMEDCT_US_2020_03_01:68574006 UMLS_CUI:C0155320 disease_ontology DOID:11831 cortical blindness DOID:11831 MESH:D012640 NCI:C3980 SNOMEDCT_US_2020_03_01:39194005 UMLS_CUI:C0270824 epilepsy, visual disease_ontology DOID:11832 visual epilepsy DOID:11832 A bone development disease where one or both are inclined inwards, axially rotated outwards, and pointing downwards with concomitant soft tissue abnormalities. DOID:0001874 ICD10CM:Q66.89 ICD9CM:754.51 MESH:D003025 NCI:C84641 OMIM:119800 SNOMEDCT_US_2020_03_01:33163000 UMLS_CUI:C0009081 Congenital equinovarus Equinovarus deformity of foot congenital clubfoot congenital talipes equinovarus disease_ontology DOID:11836 OMIM mapping confirmed by DO. [SN]. clubfoot DOID:11836 A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability. ICD10CM:N04 ICD9CM:581 MESH:D009404 NCI:C34845 SNOMEDCT_US_2020_03_01:155851004 UMLS_CUI:C0027726 disease_ontology DOID:1184 Xref MGI. nephrotic syndrome DOID:1184 MESH:D003329 NCI:C34515 SNOMEDCT_US_2020_03_01:23687008 UMLS_CUI:C0010073 Coronary Vasospasm Coronary artery spasm disease_ontology DOID:11840 coronary artery vasospasm DOID:11840 MESH:D020429 SNOMEDCT_US_2020_03_01:359842002 UMLS_CUI:C0751932 Posterior tibial neuropathy Tibial neuropathy disease_ontology DOID:1187 tibial neuropathy DOID:1187 GARD:7392 ICD10CM:G31.01 ICD9CM:331.11 MESH:D020774 NCI:C85008 OMIM:172700 SNOMEDCT_US_2020_03_01:154998003 UMLS_CUI:C0236642 Dementia in Pick's disease LOBAR ATROPHY OF BRAIN PICK DISEASE OF BRAIN Pick disease disease_ontology DOID:11870 OMIM mapping confirmed by DO. [SN]. Pick's disease MESH:D020774 DOID:11870 ICD10CM:K12.1 MESH:D013282 SNOMEDCT_US_2020_03_01:196576008 UMLS_CUI:C0038364 Denture sore mouth disease_ontology DOID:11875 denture stomatitis DOID:11875 A neuropathy that is characterized by damage to a single nerve, which results in loss of movement, sensation, or other function of that nerve. ICD10CM:G58.9 MESH:D020422 SNOMEDCT_US_2020_03_01:304595001 UMLS_CUI:C0494491 disease_ontology DOID:1188 mononeuropathy DOID:1188 MESH:D014516 NCI:C3427 SNOMEDCT_US_2020_03_01:126882009 UMLS_CUI:C0041955 neoplasm of ureter ureteral tumor disease_ontology DOID:11885 ureteral benign neoplasm DOID:11885 A female reproductive system cancer that is located_in the vagina. DOID:1902 GARD:9348 ICD10CM:C52 ICD9CM:184.0 MESH:D014625 NCI:C3437 NCI:C7410 SNOMEDCT_US_2020_03_01:126921000 SNOMEDCT_US_2020_03_01:188210000 UMLS_CUI:C0042237 UMLS_CUI:C0042258 malignant neoplasm of vagina malignant tumor of vagina malignant vaginal tumor neoplasm of vagina vagina neoplasm vaginal tumor disease_ontology DOID:119 vaginal cancer DOID:119 ICD10CM:K31.84 ICD9CM:536.3 MESH:D018589 NCI:C80512 SNOMEDCT_US_2020_03_01:235675006 UMLS_CUI:C0152020 Gastroparalysis Gastroparesis syndrome gastric atonia disease_ontology DOID:11914 gastroparesis DOID:11914 A dermatophytosis that results_in fungal skin infection located_in groin, located_in perineum, or located_in perianal region, has_material_basis_in Ascomycota fungi that belong to a group called dermatophytes and has_symptom itching in groin, thigh skin folds, or anus and results_in_formation_of rash which appears as raised red plaques (platelike areas) and scaly patches with sharply defined borders that may blister and ooze. ICD9CM:110.3 NCI:C34535 SNOMEDCT_US_2020_03_01:59089002 UMLS_CUI:C0011638 Dermatophytosis of Groin and Perianal Area Dermatophytosis of groin & perianal area Dermatophytosis of groin and perianal area Dhobie itch disease_ontology DOID:11917 tinea cruris DOID:11917 A nervous system cancer that is located in the peripheral nervous system. DOID:3194 MESH:D010524 MESH:D018317 NCI:C3321 NCI:C4972 SNOMEDCT_US_2020_03_01:126980002 SNOMEDCT_US_2020_03_01:189946005 UMLS_CUI:C0031118 UMLS_CUI:C0206727 neoplasm of peripheral nerve nerve sheath neoplasm tumor of PNS disease_ontology DOID:1192 peripheral nervous system neoplasm DOID:1192 A respiratory system cancer that is located_in the trachea. ICD10CM:C33 ICD9CM:162.0 NCI:C9346 SNOMEDCT_US_2020_03_01:187855003 UMLS_CUI:C0153489 disease_ontology DOID:11920 tracheal cancer DOID:11920 DOID:11934 An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx. GARD:12425 MESH:D006258 NCI:C3077 SNOMEDCT_US_2020_03_01:255055008 UMLS_CUI:C0018671 head and neck neoplasm head and neck tumours head/neck neoplasm tumor of head and neck disease_ontology DOID:11934 head and neck cancer DOID:11934 EFO:0004226 GARD:6956 ICD10CM:A81.0 ICD9CM:046.1 MESH:D007562 NCI:C26802 OMIM:123400 SNOMEDCT_US_2020_03_01:155061007 UMLS_CUI:C0022336 CJD Creutzfeldt Jacob syndrome Creutzfeldt Jakob disease Creutzfeldt-Jacob disease Jakob-Creutzfeldt disease Subacute spongiform encephalopathy Transmissible virus dementia disease_ontology DOID:11949 OMIM mapping confirmed by DO. [SN]. Creutzfeldt-Jakob disease DOID:11949 NCI:C27025 SNOMEDCT_US_2020_03_01:129611009 UMLS_CUI:C0238309 Ischemic peripheral neuropathy disease_ontology DOID:1195 ischemic neuropathy DOID:1195 DOID:11962 ICD10CM:K20 ICD9CM:530.1 MESH:D004941 NCI:C9224 SNOMEDCT_US_2020_03_01:155673008 UMLS_CUI:C0014868 acute esophagitis disease_ontology DOID:11963 esophagitis DOID:11963 A dysostosis that results_in abnormal fusing of adjacent bones. MESH:D013580 UMLS_CUI:C0039093 disease_ontology DOID:11971 synostosis DOID:11971 A primary bacterial infectious disease that involves intoxication caused by botulinum neurotoxins (BoNTA, B, E and F) located in neuromuscular junction resulting in descending muscle paralysis, has_material_basis_in Clostridium botulinum A, has_material_basis_in Clostridium botulinum B, has_material_basis_in Clostridium botulinum E and has_material_basis_in Clostridium botulinum F. GARD:943 ICD10CM:A05.1 MESH:D001906 NCI:C84599 SNOMEDCT_US_2020_03_01:154276003 UMLS_CUI:C0006057 Botulism poisoning Food poisoning due to Clostridium botulinum Foodborne botulism Infection due to clostridium botulinum Intoxication with Clostridium botulinum toxin disease_ontology DOID:11976 botulism DOID:11976 ICD9CM:278.01 MESH:D009767 NCI:C34858 SNOMEDCT_US_2020_03_01:389986000 UMLS_CUI:C0028756 Severe obesity disease_ontology DOID:11981 morbid obesity DOID:11981 A chromosomal disease that is characterized by weak muscle tone, feeding difficulties, poor growth, and delayed development. Beginning in childhood, affected individuals develop an insatiable appetite, which leads to chronic overeating and obesity. GARD:5575 ICD10CM:Q87.11 ICD9CM:759.81 MESH:D011218 NCI:C75463 OMIM:176270 ORDO:739 SNOMEDCT_US_2020_03_01:205794007 UMLS_CUI:C0032897 Prader Willi syndrome disease_ontology DOID:11983 OMIM mapping confirmed by DO. [SN]. Prader-Willi syndrome DOID:11983 An intrinsic cardiomyopathy that is characterized by abnormal thickening (hypertrophy) of the heart without any obvious cause. DOID:11986 ICD9CM:425.1 KEGG:05410 MESH:D002312 MESH:D024741 NCI:C34449 NCI:C84773 ORDO:217568 SNOMEDCT_US_2020_03_01:389998005 SNOMEDCT_US_2020_03_01:83978005 UMLS_CUI:C0007194 UMLS_CUI:C0949658 familial hypertrophic cardiomyopathy hypertrophic obstructive cardiomyopathy disease_ontology DOID:11984 Xref MGI. OMIM mapping confirmed by DO. [SN]. hypertrophic cardiomyopathy DOID:11984 An osteosclerosis that results_in numerous bone islands located_in skeleton. GARD:4158 ICD10CM:Q78.8 ICD9CM:756.53 MESH:D010023 NCI:C84985 SNOMEDCT_US_2020_03_01:9147009 UMLS_CUI:C0029455 disease_ontology DOID:11991 osteopoikilosis DOID:11991 ICD10CM:N50.0 ICD9CM:608.3 NCI:C123259 SNOMEDCT_US_2020_03_01:155938008 UMLS_CUI:C0156312 disease_ontology DOID:11994 atrophy of testis DOID:11994 ICD10CM:N44.02 ICD9CM:608.2 MESH:D013086 NCI:C26885 OMIM:187400 SNOMEDCT_US_2020_03_01:198046000 UMLS_CUI:C0037856 Torsion of testicle Torsion of testis testicular Torsion disease_ontology DOID:11996 spermatic cord torsion DOID:11996 ICD10CM:N43.4 ICD9CM:608.1 MESH:D013088 NCI:C120909 SNOMEDCT_US_2020_03_01:155936007 UMLS_CUI:C0037859 disease_ontology DOID:11997 spermatocele DOID:11997 A reproductive organ cancer that is manifested in the female genitals. This includes organs such as the ovaries, fallopian tubes, uterus, cervix, vagina and vulva. DOID:1244 DOID:1281 ICD10CM:C57 ICD9CM:184 MESH:D005833 NCI:C3053 NCI:C4913 SNOMEDCT_US_2020_03_01:126907002 SNOMEDCT_US_2020_03_01:188207007 UMLS_CUI:C0017416 UMLS_CUI:C0153585 UMLS_CUI:C0699889 female reproductive cancer malignant Gynecologic tumor malignant neoplasm of female genital organ disease_ontology DOID:120 female reproductive organ cancer DOID:120 GARD:9790 ICD10CM:H47.01 ICD9CM:377.41 MESH:D018917 SNOMEDCT_US_2020_03_01:14357004 UMLS_CUI:C0155305 Ischemic optic neuropathy disease_ontology DOID:12010 anterior ischemic optic neuropathy DOID:12010 An adrenal adenoma characterized by the over production of aldosterone. GARD:7456 ICD10CM:E26.01 ICD9CM:255.12 MESH:D006929 NCI:C34510 SNOMEDCT_US_2020_03_01:13536004 UMLS_CUI:C1384514 Conn syndrome primary aldosteronism primary hyperaldosteronism disease_ontology DOID:12028 Conn's syndrome DOID:12028 ICD9CM:292.8 UMLS_CUI:C0154325 disease_ontology DOID:1203 drug-induced mental disorder DOID:1203 An uveitis that is characterized by inflammation of all layers of the uvea (middle layer) of the eye, which includes the iris, ciliary body, and choroid. GARD:8577 ICD10CM:H44.11 ICD9CM:360.12 MESH:D015864 NCI:C84989 SNOMEDCT_US_2020_03_01:75614007 UMLS_CUI:C0030343 Diffuse uveitis disease_ontology DOID:12030 panuveitis DOID:12030 An immune system disease that is an exaggerated immune response to allergens, such as insect venom, dust mites, pollen, pet dander, drugs or some foods. allergic disease ICD10CM:T78.40 MESH:D006967 NCI:C3114 SNOMEDCT_US_2020_03_01:257550005 UMLS_CUI:C0020517 allergic hypersensitivity disease hypersensitivity hypersensitivity reaction type I disease disease_ontology DOID:1205 allergic disease DOID:1205 An opportunistic mycosis that results_in fungal infection and has_material_basis_in Cryptococcus neoformans or Cryptococcus gattii. GARD:6218 ICD10CM:B45 ICD9CM:117.5 MESH:D003453 NCI:C2967 SNOMEDCT_US_2020_03_01:42386007 UMLS_CUI:C0010414 Busse-Buschke's disease European cryptococcosis cryptococcal infection torula torulosis disease_ontology cryptococcus neoformans infection DOID:12053 cryptococcosis MESH:D003453 DOID:12053 A pervasive developmental disease that is characterized by normal early growth and development followed by a slowing of development, loss of purposeful use of the hands, distinctive hand movements, slowed brain and head growth, problems with walking, seizures, and intellectual disability. GARD:5696 ICD10CM:F84.2 MESH:D015518 NCI:C75488 OMIM:312750 OMIM:613454 SNOMEDCT_US_2020_03_01:192583003 UMLS_CUI:C0035372 Rett's disorder cerebroatrophic hyperammonemia disease_ontology DOID:1206 OMIM mapping confirmed by DO. [SN]. Rett syndrome DOID:1206 GARD:7805 ICD10CM:G50.0 ICD9CM:350.1 MESH:D014277 OMIM:190400 SNOMEDCT_US_2020_03_01:155066002 UMLS_CUI:C0040997 Trifacial neuralgia Trigeminal neuralgia trifocal neuralgia disease_ontology DOID:12098 OMIM mapping confirmed by DO. [LS]. trigeminal neuralgia DOID:12098 A female reproductive system disease that is located_in the vagina. MESH:D014623 NCI:C26910 SNOMEDCT_US_2020_03_01:25658005 UMLS_CUI:C0042251 disease_ontology DOID:121 vaginal disease DOID:121 An optic nerve disease that results_in inflammation located_in optic nerve which may cause a complete or partial loss of vision. GARD:7320 ICD10CM:H46 ICD9CM:377.3 MESH:D009902 NCI:C84950 SNOMEDCT_US_2020_03_01:194051001 UMLS_CUI:C0029134 disease_ontology DOID:1210 optic neuritis DOID:1210 A lung disease that is characterized the accumulation of tiny fragments of calcium phosphate gradually accumulate in the alveoli of the lungs. GARD:11894 ICD10CM:J84.02 ICD9CM:516.2 MESH:C562405 OMIM:265100 SNOMEDCT_US_2020_03_01:196160008 UMLS_CUI:C0155912 disease_ontology DOID:12117 OMIM mapping confirmed by DO. [SN]. pulmonary alveolar microlithiasis DOID:12117 An iron metabolism disease that has_material_basis_in an accumulation of hemosiderin, an iron-storage complex, resulting in iron overload. GARD:6595 MESH:D006486 NCI:C82892 SNOMEDCT_US_2020_03_01:39011001 UMLS_CUI:C0019114 haemosiderosis disease_ontology DOID:12119 hemosiderosis DOID:12119 A lung disease that is characterized by abnormal accumulation of surfactant occurs within the alveoli, interfering with gas exchange. ICD10CM:J84.01 ICD9CM:516.0 MESH:D011649 NCI:C85037 OMIM:265120 OMIM:300770 OMIM:610913 OMIM:610921 OMIM:614370 ORDO:264675 SNOMEDCT_US_2020_03_01:10501004 UMLS_CUI:C0034050 disease_ontology DOID:12120 Xref MGI. pulmonary alveolar proteinosis DOID:12120 An autoimmune disease that is characterized by necrotizing granulomatous inflammation of the upper and lower respiratory tract, glomerulonephritis, vasculitis, and the presence of antineutrophil cytoplasmatic autoantibodies (ANCAs) in patient sera, and is located_in lung, located_in kidney, located_in skin resulting from an autoimmune attack by antineutrophil cytoplasmic antibodies against small and medium-size blood vessels. GARD:7880 ICD10CM:M31.3 ICD9CM:446.4 MESH:D014890 NCI:C3444 OMIM:608710 SNOMEDCT_US_2020_03_01:195353004 UMLS_CUI:C3495801 Necrotizing respiratory granulomatosis Wegener granulomatosis, formerly disease_ontology DOID:12132 granulomatosis with polyangiitis DOID:12132 A blood coagulation disease that has_material_basis_in Factor VIII deficiency, which results in the formation of fibrin deficient clots which makes coagulation much more prolonged. GARD:6591 ICD10CM:D66 ICD9CM:286.0 MESH:D006467 NCI:C27146 OMIM:306700 ORDO:98878 SNOMEDCT_US_2020_03_01:28293008 UMLS_CUI:C0019069 Congenital factor VIII disorder Hemophilia A Subhemophilia classic hemophilia A disease_ontology DOID:12134 OMIM mapping confirmed by DO. [SN]. factor VIII deficiency MESH:D006467 DOID:12134 A mood disorder that involves the presence of a low mood almost daily over a span of at least two years. ICD10CM:F34.1 ICD9CM:300.4 MESH:D019263 NCI:C34562 SNOMEDCT_US_2020_03_01:192384008 UMLS_CUI:C0013415 dysthymia disease_ontology DOID:12139 dysthymic disorder DOID:12139 A trypanosomiasis that is a tropical parasitic disease caused by the flagellate protozoan Trypanosoma cruzi, which is transmitted to humans and other mammals by an insect vector, the blood-sucking assassin bugs of the subfamily Triatominae (family Reduviidae), most commonly species belonging to the Triatoma, Rhodnius, and Panstrongylus genera. The symptoms include fever, fatigue, body aches, headache, rash, loss of appetite, diarrhea, vomiting, swelling of the eyelids and myocarditis. DOID:0050016 DOID:0050019 DOID:0050020 GARD:6030 ICD9CM:086.2 KEGG:05142 SNOMEDCT_US_2020_03_01:186817003 UMLS_CUI:C0007932 Chagas' disease chagas' disease with digestive system involvement chagas' disease with nervous system involvement chagas' disease with other organ involvement disease_ontology American trypanosomiasis DOID:12140 Chagas disease DOID:12140 ICD9CM:596.54 MESH:D001750 NCI:C79696 SNOMEDCT_US_2020_03_01:192972000 UMLS_CUI:C0005697 Neuropathic bladder neurogenic dysfunction of the urinary bladder neurogenic urinary bladder disorder disease_ontology DOID:12143 neurogenic bladder DOID:12143 ICD9CM:596.52 SNOMEDCT_US_2020_03_01:9009001 UMLS_CUI:C0489967 Low bladder compliance hyperactivity of bladder hypertonic bladder hypertonicity of bladder disease_ontology DOID:12144 low compliance bladder DOID:12144 ICD9CM:596.55 SNOMEDCT_US_2020_03_01:236655005 UMLS_CUI:C0341747 disease_ontology DOID:12145 detrusor sphincter dyssynergia DOID:12145 A viral infectious disease that results in infection located in brain, or located in meninges, or located in brain and meninges, has_material_basis_in Lymphocytic choriomeningitis virus, which is transmitted by common house mouse, Mus musculus. The infection has symptom fever, has symptom lack of appetite, has symptom headache, has symptom muscle aches, has symptom malaise, has symptom nausea, and has symptom vomiting. DOID:10662 ICD10CM:A87.2 MESH:D008216 SNOMEDCT_US_2020_03_01:192668002 UMLS_CUI:C0024266 LCM Lymphocytic choriomeningitis virus encephalomyelitis Lymphocytic meningitis Lymphocytic meningoencephalitis disease_ontology DOID:12155 lymphocytic choriomeningitis DOID:12155 ICD10CM:H35.4 ICD9CM:362.6 NCI:C34919 SNOMEDCT_US_2020_03_01:193393004 UMLS_CUI:C1320640 peripheral degeneration of retina disease_ontology DOID:12161 peripheral retinal degeneration DOID:12161 ICD10CM:G56.2 ICD9CM:354.2 SNOMEDCT_US_2020_03_01:55802003 UMLS_CUI:C1288279 Lesion of ulnar nerve disease_ontology DOID:12168 ulnar nerve lesion DOID:12168 ICD10CM:G56.0 ICD9CM:354.0 MESH:D002349 NCI:C34450 OMIM:115430 SNOMEDCT_US_2020_03_01:193126005 UMLS_CUI:C0007286 CTS - Carpal tunnel syndrome Carpal tunnel syndrome Median nerve entrapment carpal tunnel median neuropathy disease_ontology DOID:12169 OMIM mapping confirmed by DO. [SN]. carpal tunnel syndrome DOID:12169 ICD10CM:E07.1 ICD9CM:246.1 SNOMEDCT_US_2020_03_01:190304001 UMLS_CUI:C0152077 Dyshormonogenic goiter Dyshormonogenic goitre dyshormonogenic goitre disease_ontology DOID:12175 dyshormonogenic goiter DOID:12175 A thyroid gland disease that involves an abnormal enlargement of the thyroid gland. ICD10CM:E04.9 ICD9CM:240.9 MESH:D006042 NCI:C26785 SNOMEDCT_US_2020_03_01:237568003 UMLS_CUI:C0018021 goitre disease_ontology DOID:12176 goiter MESH:D006042 DOID:12176 An agammaglobulinemia that is results in insufficient production of antibodies needed to respond to exposure of pathogens and is characterized by low Ig levels with phenotypically normal B cells that can proliferate but do not develop into Ig-producing cells. GARD:6140 ICD10CM:D83 ICD9CM:279.06 MESH:D017074 OMIM:240500 OMIM:607594 OMIM:613493 OMIM:613494 OMIM:613495 OMIM:613496 OMIM:614699 OMIM:614700 OMIM:615577 OMIM:615767 ORDO:1572 SNOMEDCT_US_2020_03_01:191010004 UMLS_CUI:C0009447 CVID acquired agammaglobulinemia acquired hypogammaglobulinemia common variable agammaglobulinemia sporadic hypogammaglobulinemia disease_ontology DOID:12177 Xref MGI. OMIM mapping confirmed by DO. [SN]. common variable immunodeficiency DOID:12177 An otitis interna characterized by an abnormal bone growth in the middle ear. EFO:0004213 ICD10CM:H80.80 ICD9CM:387.8 OMIM:166800 OMIM:605727 OMIM:608244 OMIM:608484 OMIM:611571 OMIM:611572 OMIM:612096 OMIM:615589 ORDO:2794 SNOMEDCT_US_2020_03_01:194382008 UMLS_CUI:C0029696 disease_ontology DOID:12185 Xref MGI. otosclerosis MESH:D010040 DOID:12185 ICD10CM:C18.7 ICD9CM:153.3 MESH:D012811 SNOMEDCT_US_2020_03_01:94006002 UMLS_CUI:C0153436 Ca sigmoid colon malignant tumor of sigmoid colon disease_ontology DOID:12192 sigmoid colon cancer DOID:12192 ICD10CM:H16.14 ICD9CM:370.21 SNOMEDCT_US_2020_03_01:193767008 UMLS_CUI:C0259799 Punctate keratitis Thygeson superficial punctate keratitis Thygeson's superficial punctate keratitis disease_ontology DOID:12197 punctate epithelial keratoconjunctivitis DOID:12197 A viral infectious disease that results in infection, has_material_basis_in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted by Aedes mosquito bite. The infection has symptom fever, has symptom severe headache, has symptom severe pain behind the eyes, has symptom joint pain, has symptom muscle and bone pain, has symptom rash, and has symptom mild bleeding. DOID:0050142 GARD:6254 ICD10CM:A90 ICD9CM:061 MESH:D003715 NCI:C34528 SNOMEDCT_US_2020_03_01:38362002 UMLS_CUI:C0011311 Dengue Fever breakbone fever classic dengue disease_ontology classical dengue DOID:12205 dengue disease DOID:12205 A placenta disease that is characterized by a deficiency of amniotic fluid sometimes resulting in an embryonic defect through adherence between embryo and amnion. DOID:12595 DOID:12596 ICD10CM:O41.0 ICD9CM:658.0 MESH:D016104 NCI:C92839 SNOMEDCT_US_2020_03_01:157051001 UMLS_CUI:C0079924 Oligohydramnios - delivered antepartum oligohydramnios delivered oligohydramnios disease_ontology DOID:12215 oligohydramnios DOID:12215 A dementia that is characterized by the development of abnormal proteinaceous (alpha-synuclein) cytoplasmic inclusions, called Lewy bodies, throughout the brain that results in progressive decline in mental abilities. GARD:3243 ICD10CM:G31.83 ICD9CM:331.82 MESH:D020961 NCI:C84826 OMIM:127750 SNOMEDCT_US_2020_03_01:192808003 UMLS_CUI:C0752347 Dementia with Lewy bodies Diffuse Lewy body disease Lewy body disease Senile dementia of the Lewy body type disease_ontology DOID:12217 OMIM mapping confirmed by DO. [SN]. Lewy body dementia DOID:12217 A connective tissue disease that is located_in cartilage. ICD10CM:M94.9 MESH:D002357 SNOMEDCT_US_2020_03_01:50927007 UMLS_CUI:C0007302 Cartilage disorder Chondropathy disease_ontology DOID:1222 cartilage disease DOID:1222 ICD10CM:K31.2 ICD9CM:537.6 SNOMEDCT_US_2020_03_01:54051005 UMLS_CUI:C0267183 Hourglass stricture or stenosis of stomach disease_ontology DOID:12234 cascade stomach DOID:12234 A liver cirrhosis characterized by chronic and slow progressive destruction of intrahepatic bile ducts. DOID:1851 EFO:0004267 GARD:7459 ICD10CM:K74.3 ICD10CM:K74.5 ICD9CM:571.6 MESH:D008105 NCI:C27167 NCI:C51225 OMIM:109720 OMIM:613007 OMIM:613008 OMIM:614220 OMIM:614221 ORDO:186 SNOMEDCT_US_2020_03_01:1761006 SNOMEDCT_US_2020_03_01:31712002 UMLS_CUI:C0008312 UMLS_CUI:C0023892 biliary liver cirrhosis cholestatic cirrhosis chronic nonsuppurative destructive cholangitis primary biliary cirrhosis disease_ontology DOID:12236 Xref MGI. OMIM mapping confirmed by DO. [SN]. primary biliary cholangitis DOID:12236 MESH:D001655 UMLS_CUI:C0005403 disease_ontology DOID:12237 bile reflux DOID:12237 NCI:C6810 SNOMEDCT_US_2020_03_01:277664004 UMLS_CUI:C0349644 lymphoma of the testis malignant lymphoma of testis testicular Lymphoma disease_ontology DOID:12253 testicular lymphoma DOID:12253 A blood coagulation disease that has_material_basis_in Factor IX deficiency, which makes coagulation much more prolonged. The disease is inherited as an X-linked recessive trait. GARD:8732 ICD10CM:D67 ICD9CM:286.1 MESH:D002836 NCI:C26721 OMIM:306900 SNOMEDCT_US_2020_03_01:41788008 UMLS_CUI:C0008533 Congenital factor IX deficiency Congenital factor IX disorder deficiency, functional factor IX factor IX deficiency disease_ontology DOID:12259 OMIM mapping confirmed by DO. [SN]. hemophilia B DOID:12259 ICD10CM:D70 ICD9CM:288.0 MESH:D009503 SNOMEDCT_US_2020_03_01:191336001 UMLS_CUI:C0027947 disease_ontology DOID:1227 neutropenia DOID:1227 An eye disease characterized by missing pieces of tissue in structures that form the eye, such as the iris, retina, choroid or optic disc. GARD:1433 ICD10CM:Q13.0 MESH:D003103 NCI:C98877 OMIM:120200 OMIM:120300 OMIM:216820 ORDO:194 ORDO:98945 SNOMEDCT_US_2020_03_01:93390002 UMLS_CUI:C0009363 coloboInOwlma of eye coloboInOwlma of macula congenital ocular coloboInOwlma disease_ontology DOID:12270 Xref MGI. OMIM mapping confirmed by DO. [SN]. coloboma DOID:12270 An iris disease that is characterized by a complete or partial absence of the colored part of the eye. GARD:5816 ICD10CM:Q13.1 ICD9CM:743.45 MESH:D015783 NCI:C84563 OMIM:106210 SNOMEDCT_US_2020_03_01:69278003 UMLS_CUI:C0003076 Aplasia of iris disease_ontology DOID:12271 OMIM mapping confirmed by DO. [SN]. aniridia DOID:12271 ICD10CM:H52.31 ICD9CM:367.31 MESH:D015858 SNOMEDCT_US_2020_03_01:3289004 UMLS_CUI:C0003081 disease_ontology DOID:12273 anisometropia MESH:D015858 DOID:12273 NCI:C9277 UMLS_CUI:C1336711 disease_ontology DOID:12286 testicular leukemia DOID:12286 A viral infectious disease that is a hemorrhagic fever, has_material_basis_in Crimean-Congo hemorrhagic fever virus, which is transmitted_by Hyalomma ticks. The infection has_symptom headache, has_symptom high fever, has_symptom back pain, has_symptom joint pain, has_symptom stomach pain, has_symptom vomiting, has_symptom red eyes, has_symptom flushed face, has_symptom red throat, has_symptom petechiae (red spots) on the palate, has_symptom jaundice, has_symptom nosebleeds, and has_symptom blood in the feces and urine. ICD10CM:A98.0 ICD9CM:065.0 MESH:D006479 NCI:C34682 SNOMEDCT_US_2020_03_01:43489008 UMLS_CUI:C0019099 CHF Congo virus Congo-Crimean Hemorrhagic Fever Crimean hemorrhagic fever disease_ontology DOID:12287 Crimean-Congo hemorrhagic fever DOID:12287 An autoimmune disease that is caused by T helper cell mediated autoimmune attack of melanocytes resulting in inflammation of the inside of the eye, whitening of hair, skin pigment loss, and meningitis. GARD:7862 ICD10CM:H20.82 ICD9CM:364.24 MESH:D014607 NCI:C85218 SNOMEDCT_US_2020_03_01:44923005 UMLS_CUI:C0042170 Harada's disease Vogt-Koyanagi syndrome uveomeningoencephalitic syndrome disease_ontology DOID:12297 Vogt-Koyanagi-Harada disease DOID:12297 An autoimmune disease that causes depigmentation of patches of skin resulting from loss of function or death of melanoctyes. EFO:0004208 GARD:10751 ICD10CM:L80 ICD9CM:709.01 MESH:D014820 NCI:C26915 OMIM:193200 SNOMEDCT_US_2020_03_01:156437000 UMLS_CUI:C0042900 disease_ontology DOID:12306 OMIM mapping confirmed by DO. [LS]. vitiligo DOID:12306 A bilirubin metabolic disorder that involves elevated levels of unconjugated bilirubin without elevation of liver alanine transaminase and aspartate transaminase enzymes as a result of the deficient ability of hepatocytes to secrete conjugated bilirubin into the bile. GARD:6289 ICD10CM:E80.6 MESH:D007566 NCI:C34741 OMIM:237500 SNOMEDCT_US_2020_03_01:44553005 UMLS_CUI:C0022350 Dubin Johnson syndrome chronic idiopathic jaundice disease_ontology DOID:12308 OMIM mapping confirmed by DO. [SN]. Dubin-Johnson syndrome DOID:12308 An epithelial-stromal TGFBI dystrophy that is characterized by progressive accumulation of deposits within the layers of the cornea. ICD10CM:H18.53 ICD9CM:371.53 MESH:D003317 NCI:C34651 SNOMEDCT_US_2020_03_01:45283008 UMLS_CUI:C0018179 granular corneal dystrophy disease_ontology DOID:12318 granular corneal dystrophy DOID:12318 ICD9CM:416.8 SNOMEDCT_US_2020_03_01:194887007 UMLS_CUI:C0155673 disease_ontology DOID:12326 chronic pulmonary heart disease DOID:12326 ICD10CM:F64.1 ICD9CM:302.3 MESH:D014190 NCI:C94359 SNOMEDCT_US_2020_03_01:472948001 UMLS_CUI:C0040774 Dual-role transvestism Fetishistic transvestism Transvestic fetishism cross dresser disease_ontology DOID:1233 transvestism DOID:1233 ICD10CM:N46 ICD9CM:606 MESH:D007248 SNOMEDCT_US_2020_03_01:155924001 UMLS_CUI:C0021364 disease_ontology DOID:12336 male infertility DOID:12336 ICD10CM:I86.1 ICD9CM:456.4 MESH:D014646 SNOMEDCT_US_2020_03_01:195480007 UMLS_CUI:C0042341 Scrotal varices disease_ontology DOID:12337 varicocele DOID:12337 A disease of mental health that involves a conflict between a person's actual physical gender and the gender that person identifies himself or herself as. ICD10CM:F64.2 ICD9CM:302.6 SNOMEDCT_US_2020_03_01:5095008 UMLS_CUI:C0236802 disease_ontology DOID:1234 gender identity disorder DOID:1234 A malignant retroperitoneal cancer and sarcoma that is located_in the retroperitoneal space. NCI:C4832 SNOMEDCT_US_2020_03_01:307219002 UMLS_CUI:C0585129 disease_ontology DOID:12341 retroperitoneal sarcoma DOID:12341 An osteochondrodysplasia that has_material_basis_in a deficiency in type-I collagen which results_in brittle bones and defective connective tissue. DOID:14708 GARD:1017 ICD10CM:Q78.0 ICD9CM:756.51 MESH:D010013 NCI:C26837 OMIM:PS166200 ORDO:666 SNOMEDCT_US_2020_03_01:78314001 UMLS_CUI:C0029434 Lobstein's syndrome Osteopsathyrosis Vrolik's disease brittle bone disease disease_ontology Fragilitas ossium DOID:12347 Xref MGI. OMIM mapping confirmed by DO. [SN]. osteogenesis imperfecta DOID:12347 ICD10CM:F65.0 ICD9CM:302.81 MESH:D005329 NCI:C94353 SNOMEDCT_US_2020_03_01:192513009 UMLS_CUI:C0015957 disease_ontology DOID:1235 fetishism DOID:1235 DOID:12350 ICD9CM:571.1 NCI:C34352 SNOMEDCT_US_2020_03_01:9953008 UMLS_CUI:C0001306 Alcoholic Hepatitis Alcoholic hepatitis acute Alcoholic Hepatitis acute alcoholic hepatitis acute alcoholic liver disease disease_ontology DOID:12351 alcoholic hepatitis DOID:12351 A eustachian tube disorder with a wider eustachian tube which allows a larger bolus of bacteria-laden material from the nasopharynx during an infection to enter the middle ear, causing a more fulminant infection. GARD:10812 ICD10CM:H69.0 ICD9CM:381.7 SNOMEDCT_US_2020_03_01:30280005 UMLS_CUI:C0155434 disease_ontology DOID:12358 patulous eustachian tube DOID:12358 An autoimmune disease of endocrine system that involves production of excessive amount of thyroid hormones, located_in thyroid gland. EFO:0004237 ICD10CM:E05.0 MESH:D006111 NCI:C3071 SNOMEDCT_US_2020_03_01:154655004 UMLS_CUI:C0018213 Grave's disease Graves disease exophthalmic goiter disease_ontology Basedow's disease DOID:12361 Xref MGI. OMIM mapping confirmed by DO. [SN]. Graves' disease DOID:12361 A parasitic protozoa infectious disease characterized as a vector-borne infectious disease caused by the presence of protozoan parasites of the genus Plasmodium in the red blood cells, transmitted from an infected to an uninfected individual by the bite of anopheline mosquitoes, and characterized by periodic attacks of chills and fever that coincide with mass destruction of blood cells and the release of toxic substances by the parasite at the end of each reproductive cycle. DOID:12552 EFO:0001068 GARD:6961 ICD10CM:B54 ICD9CM:084 MESH:D008288 NCI:C34797 SNOMEDCT_US_2020_03_01:154374002 UMLS_CUI:C0024530 induced malaria disease_ontology DOID:12365 Xref MGI. malaria DOID:12365 ICD10CM:H18.4 ICD9CM:371.4 SNOMEDCT_US_2020_03_01:111521006 UMLS_CUI:C0155118 disease_ontology DOID:1237 corneal degeneration DOID:1237 A pneumonia involving inflammation of lungs that begins in the terminal bronchioles, which become clogged with thick mucus that forms consolidated patches in adjacent lobules. It is caused by bacteria and viruses. ICD10CM:J18.0 ICD9CM:485 MESH:D001996 NCI:C26710 SNOMEDCT_US_2020_03_01:155551009 UMLS_CUI:C0006285 Chest infection - bronchopneumonia bronchial pneumonia lobular pneumonia disease_ontology DOID:12375 bronchopneumonia DOID:12375 A motor neuron disease that is a degenerative neuromuscular disease characterized by lower motor neuron degeneration associated with progressive muscle weakness and atrophy. GARD:7674 ICD10CM:G12.9 ICD9CM:335.1 MESH:D009134 NCI:C85075 SNOMEDCT_US_2020_03_01:5262007 UMLS_CUI:C0026847 disease_ontology DOID:12377 spinal muscular atrophy DOID:12377 MESH:D017029 SNOMEDCT_US_2020_03_01:307358009 UMLS_CUI:C0085417 Complex partial epileptic seizure Psychomotor epilepsy epilepsy, psychomotor psychomotor epilepsy disease_ontology DOID:12382 complex partial epilepsy DOID:12382 An intestinal infectious disease that involves inflammation of the intestines, especially colon, due to chemical irritants, bacteria, protozoa, or parasitic worms, which results in severe diarrhea with passage of mucus and blood. ICD9CM:009.2 MESH:D004403 SNOMEDCT_US_2020_03_01:154268000 UMLS_CUI:C0013369 Infectious diarrhea disease_ontology DOID:12384 dysentery DOID:12384 A primary bacterial infectious disease that results_in infection located_in epithelium of colon, has_material_basis_in Shigella boydii, has_material_basis_in Shigella dysenteriae, has_material_basis_in Shigella flexneri, or has_material_basis_in Shigella sonnei, which produce toxins that can attack the lining of the large intestine, causing swelling, ulcers on the intestinal wall, and bloody diarrhea. The bacteria are transmitted_by ingestion of food and water contaminated with feces. DOID:11378 DOID:12950 DOID:2041 DOID:924 DOID:925 GARD:4818 ICD10CM:A03 ICD10CM:A03.0 ICD10CM:A03.1 ICD10CM:A03.2 ICD9CM:004 ICD9CM:004.0 ICD9CM:004.1 ICD9CM:004.2 KEGG:05131 MESH:D004405 NCI:C157978 SNOMEDCT_US_2020_03_01:111817006 SNOMEDCT_US_2020_03_01:34335000 SNOMEDCT_US_2020_03_01:55760004 SNOMEDCT_US_2020_03_01:66301008 UMLS_CUI:C0013371 UMLS_CUI:C0302358 UMLS_CUI:C0302359 UMLS_CUI:C0302360 Shigella boydii infectious disease Shigella flexneri infectious disease Shigella gastroenteritis Shigella sonnei infectious disease bacillary dysentery disease_ontology DOID:12385 shigellosis DOID:12385 A kidney disease characterized by a complete or partial resistance of the kidneys to vasopressin (ADH). GARD:7178 ICD10CM:N25.1 ICD9CM:588.1 MESH:D018500 NCI:C84919 OMIM:125800 OMIM:304800 ORDO:223 SNOMEDCT_US_2020_03_01:123294004 UMLS_CUI:C0162283 disease_ontology vasopressin-resistant diabetes insipidus DOID:12387 Xref MGI. OMIM mapping submitted by NeuroDevNet. [LS]. nephrogenic diabetes insipidus DOID:12387 MESH:D020790 NCI:C84933 OMIM:125700 OMIM:304900 SNOMEDCT_US_2020_03_01:267393007 UMLS_CUI:C0687720 Pituitary diabetes insipidus Vasopressin deficiency central diabetes insipidus vasopressin defective diabetes insipidus disease_ontology DOID:12388 OMIM mapping confirmed by DO. [SN]. neurohypophyseal diabetes insipidus DOID:12388 DOID:14446 ICD9CM:374.00 MESH:D004774 SNOMEDCT_US_2020_03_01:246821008 UMLS_CUI:C0014390 disease_ontology DOID:12397 entropion DOID:12397 An impulse control disorder that involves the uncontrollable impulse to gamble, irrespective of the interference the behaviour has on the individual's life. ICD10CM:F63.0 ICD9CM:312.31 MESH:D005715 NCI:C94335 OMIM:606349 SNOMEDCT_US_2020_03_01:18085000 UMLS_CUI:C0030662 Compulsive gambling Pathological gambling disease_ontology DOID:12399 OMIM mapping confirmed by DO. [SN]. pathological gambling DOID:12399 A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells. DOID:9145 ICD10CM:C95.90 ICD9CM:208 MESH:D007938 NCI:C3161 SNOMEDCT_US_2020_03_01:255049003 UMLS_CUI:C0023418 disease_ontology DOID:1240 leukemia DOID:1240 An impulse control disorder that involves the repeated impulse to steal for no great gain, when he or she has sufficient money to pay for the item and no need for what is stolen. ICD10CM:F63.2 ICD9CM:312.32 MESH:D007174 NCI:C94333 SNOMEDCT_US_2020_03_01:69361009 UMLS_CUI:C0022734 Pathological stealing disease_ontology DOID:12400 kleptomania DOID:12400 An impulse control disorder that involves the episodic inability to control violent impulses with a disproportionate degree of aggressiveness. DOID:9404 ICD10CM:F60.3 ICD10CM:F63.81 ICD9CM:301.3 ICD9CM:312.34 MESH:D007174 NCI:C94332 SNOMEDCT_US_2020_03_01:192096007 SNOMEDCT_US_2020_03_01:268757006 UMLS_CUI:C0021776 UMLS_CUI:C0152183 explosive personality disorder disease_ontology DOID:12401 intermittent explosive disorder DOID:12401 An impulse control disorder that involves the uncontrollable impulse to repeatedly set fires with no obvious motive. ICD10CM:F63.1 ICD9CM:312.33 MESH:D005391 NCI:C94334 SNOMEDCT_US_2020_03_01:600009 UMLS_CUI:C0016142 Pathological firesetting firesetting behavior disease_ontology DOID:12402 pyromania DOID:12402 A dermatophytosis that results_in fungal infection located_in skin of foot, especially between the toes, has_material_basis_in Trichophyton or has_material_basis_in Epidermophyton and has_symptom fissures, has_symptom scaling, has_symptom maceration, and eroded areas between the toes and on the plantar surface of the foot. ICD10CM:B35.3 ICD9CM:110.4 MESH:D014008 SNOMEDCT_US_2020_03_01:186993002 UMLS_CUI:C0040259 Athlete's foot Dermatophytosis of foot disease_ontology ringworm of foot DOID:12403 tinea pedis DOID:12403 An eye disease that involves the globe of the eye. ICD10CM:H44.39 ICD9CM:360.29 SNOMEDCT_US_2020_03_01:194638007 UMLS_CUI:C0154780 disease_ontology DOID:1242 globe disease DOID:1242 ICD9CM:378.81 SNOMEDCT_US_2020_03_01:1534008 UMLS_CUI:C0702143 Palsy of conjugate gaze disease_ontology DOID:12445 conjugate gaze palsy DOID:12445 An anemia that is characterized by a deficiency of red blood cells, white blood cells and platelets produced by bone marrow. GARD:5836 ICD10CM:D61.9 ICD9CM:284.9 MESH:D000741 NCI:C2870 OMIM:609135 SNOMEDCT_US_2020_03_01:154807001 UMLS_CUI:C0002874 disease_ontology DOID:12449 OMIM mapping confirmed by DO. [SN]. aplastic anemia DOID:12449 A female reproductive organ cancer that is located_in the vulva. DOID:1282 GARD:9349 ICD10CM:C51 ICD9CM:184.4 MESH:D014846 NCI:C3443 NCI:C7502 SNOMEDCT_US_2020_03_01:126922007 SNOMEDCT_US_2020_03_01:94143002 UMLS_CUI:C0042995 UMLS_CUI:C0375071 Ca vulva Vulvar tumor malignant Vulvar tumor malignant neoplasm of vulva malignant tumor of vulva neoplasm of vulva vulval cancer vulval neoplasm vulvar neoplasm disease_ontology DOID:1245 vulva cancer DOID:1245 An anemia that is characterized by a reduction in the number of red blood cells, white blood cells, and platelets. ICD10CM:D61.81 ICD9CM:284.1 MESH:D010198 NCI:C34889 SNOMEDCT_US_2020_03_01:127034005 UMLS_CUI:C0030312 disease_ontology DOID:12450 pancytopenia MESH:D010198 DOID:12450 MESH:D013436 SNOMEDCT_US_2020_03_01:32117000 UMLS_CUI:C0038732 Sulfemoglobinemia Sulfhemoglobinemia disease_ontology DOID:12451 sulfhemoglobinemia DOID:12451 A hematopoietic system disease that is characterized by abnormal blood clotting or bleeding. DOID:13997 DOID:2212 DOID:9474 ICD10CM:D68.9 ICD9CM:286 MESH:D001778 NCI:C2902 SNOMEDCT_US_2020_03_01:64779008 UMLS_CUI:C0005779 coagulation protein disease postpartum coagulation defect postpartum coagulation defect with delivery inherited blood coagulation disease disease_ontology DOID:1247 blood coagulation disease DOID:1247 A parasitic helminthiasis infectious disease that involves infection of the intestine, liver and lungs caused by Capillaria species. ICD10CM:B81.1 ICD9CM:127.5 MESH:D017189 SNOMEDCT_US_2020_03_01:52979002 UMLS_CUI:C0006897 Capillaria infection disease_ontology DOID:12474 capillariasis DOID:12474 A facial paralysis resulting from dysfunction in the cranial nerve VII (facial nerve). GARD:5906 ICD10CM:G51.0 ICD9CM:351.0 MESH:D020330 SNOMEDCT_US_2020_03_01:193093009 UMLS_CUI:C0376175 Bell palsy Bell's (facial) palsy disease_ontology DOID:12506 Bell's palsy DOID:12506 An urogenital tuberculosis that is located_in epididymis, has_symptom pain and has_symptom scrotal swelling. ICD9CM:016.4 SNOMEDCT_US_2020_03_01:83652003 UMLS_CUI:C0152814 disease_ontology DOID:1251 tuberculous epididymitis DOID:1251 MESH:D012167 NCI:C50732 SNOMEDCT_US_2020_03_01:40024006 UMLS_CUI:C0035321 Retinal break Retinal dialysis Retinal tear disease_ontology DOID:12514 retinal perforation DOID:12514 A parasitic helminthiasis infectious disease that involves parasitic infection located_in intestine in humans, has_material_basis_in Trichuris trichiura, which is transmitted_by ingestion of food contaminated with egg-carrying soil. The infection has_symptom abdominal pain, has_symptom diarrhea, has_symptom rectal prolapse and has_symptom growth retardation. GARD:10720 ICD10CM:B79 ICD9CM:127.3 MESH:D014257 NCI:C128399 SNOMEDCT_US_2020_03_01:60570001 UMLS_CUI:C0040954 Infection by Trichuris trichura Trichuriasis infection Whipworm disease trichuris trichiura infection disease_ontology DOID:1252 trichuriasis DOID:1252 GARD:7733 ICD10CM:G57.5 ICD9CM:355.5 MESH:D013641 NCI:C85183 SNOMEDCT_US_2020_03_01:155077008 UMLS_CUI:C0039319 disease_ontology DOID:12526 tarsal tunnel syndrome DOID:12526 A blood coagulation disease that is a hereditary abnormality which slows the blood clotting process. It arises from a qualitative or quantitative deficiency of von Willebrand factor (vWF), a multimeric protein that is required for platelet adhesion. GARD:7867 ICD10CM:D68.0 ICD9CM:286.4 MESH:D014842 NCI:C68677 SNOMEDCT_US_2020_03_01:11093006 UMLS_CUI:C0042974 vascular hemophilia vascular pseudohemophilia von Willebrand disease von Willebrand disorder von Willebrand's-Jurgens' disease von Willebrand-Jrgens disease disease_ontology DOID:12531 OMIM mapping confirmed by DO. [SN]. von Willebrand's disease DOID:12531 A trichostrongyloidiasis that involves infection of the small intestine with Trichostrongylus colubriformis or Trichostrongylus axei, which results in abdominal pain, diarrhea, anorexia, headache, fatigue, anemia and eosinophilia. ICD10CM:B81.2 ICD9CM:127.6 MESH:D014253 SNOMEDCT_US_2020_03_01:33710003 UMLS_CUI:C0040948 Infection by Trichostrongylus Infection by Trichostrongylus species Trichostrongyliasis disease_ontology DOID:1254 trichostrongylosis MESH:D014253 DOID:1254 A viral infectious disease that results_in inflammation located_in liver, has_material_basis_in Hepatitis A virus, which is transmitted_by ingestion of contaminated food or water, or transmitted_by direct contact with an infected person. The infection has_symptom fever, has_symptom fatigue, has_symptom loss of appetite, has_symptom nausea, has_symptom vomiting, has_symptom abdominal pain, has_symptom clay-colored bowel movements, has_symptom joint pain, and has_symptom jaundice. DOID:12547 MESH:D006506 NCI:C3096 SNOMEDCT_US_2020_03_01:40468003 UMLS_CUI:C0019159 Viral hepatitis, type A disease_ontology Viral hepatitis A DOID:12549 hepatitis A DOID:12549 A parasitic helminthiasis infectious disease that involves parasitic infection of animals and humans by nematodes of the superfamily Trichostrongyloidea. MESH:D014252 UMLS_CUI:C0040947 disease_ontology DOID:1255 trichostrongyloidiasis DOID:1255 A kidney disease that is characterized by hemolytic anemia, thrombocytopenia, and renal failure caused by platelet thrombi in the microcirculation of the kidney and other organs. GARD:6588 ICD10CM:D59.3 ICD9CM:283.11 MESH:D006463 NCI:C75545 ORDO:2134 SNOMEDCT_US_2020_03_01:123308008 UMLS_CUI:C0019061 haemolytic-uraemic syndrome hemolytic uremic syndrome disease_ontology DOID:12554 Xref MGI. hemolytic-uremic syndrome DOID:12554 ICD10CM:H50.81 ICD9CM:378.71 MESH:D004370 NCI:C84678 OMIM:126800 OMIM:604356 ORDO:233 SNOMEDCT_US_2020_03_01:60318001 UMLS_CUI:C0013261 Duane's syndrome Stilling-Turk-Duane syndrome disease_ontology DOID:12557 OMIM mapping confirmed by DO. [SN]. Duane retraction syndrome DOID:12557 GARD:4503 ICD10CM:H49.4 ICD9CM:378.72 MESH:D017246 OMIM:PS157640 SNOMEDCT_US_2020_03_01:194126004 UMLS_CUI:C0162674 progressive external ophthalmoplegia disease_ontology DOID:12558 chronic progressive external ophthalmoplegia DOID:12558 An osteoporosis with no known cause that is characterized by pain in the back and extremities, walking difficulties, multiple fractures, and radiological evidence of osteoporosis. ICD9CM:733.02 OMIM:259750 SNOMEDCT_US_2020_03_01:3345002 UMLS_CUI:C0158447 Idiopathic osteoporosis juvenile osteoporosis disease_ontology DOID:12559 idiopathic juvenile osteoporosis DOID:12559 A learning disability involving a math disability can cause such difficulties as learning math concepts (such as quantity, place value, and time), difficulty memorizing math facts, difficulty organizing numbers, and understanding how problems are organized on the page. MESH:D060705 Mathematics disorder disorder of arithmetical skills disease_ontology DOID:12568 dyscalculia DOID:12568 A glaucoma characterized by glaucomatous optic atrophy secondary to a lens abnormality and has_symptom progressive decreased vision, especially decreased peripheral vision. Phacogenic glaucoma can be caused by cataracts, trauma to the eye, or age-related damage that obstructs aqueous outflow, leading to inappropriately increased intraocular pressure and eventual optic nerve atrophy with associated vision loss. ICD9CM:365.59 SNOMEDCT_US_2020_03_01:84333006 UMLS_CUI:C0154959 disease_ontology DOID:12571 phacogenic glaucoma DOID:12571 ICD10CM:P72.1 ICD9CM:775.3 NCI:C114906 SNOMEDCT_US_2020_03_01:13795004 UMLS_CUI:C0158983 Neonatal thyrotoxicosis disease_ontology DOID:12573 neonatal thyrotoxicosis DOID:12573 MESH:D014524 NCI:C79804 SNOMEDCT_US_2020_03_01:95588004 UMLS_CUI:C0041972 Obstruction of urethra disease_ontology DOID:12577 urethral obstruction DOID:12577 A syndrome that has_material_basis_in deletion of the end of the chromosome 5 p arm and that is characterized by intellectual disability, delayed development, small head size, low birth weight, weak muscle tone widely set eyes, low-set ears, a small jaw, a rounded face and a high-pitched cry that sounds like that of a cat. GARD:6213 ICD10CM:Q93.4 ICD9CM:758.31 MESH:D003410 NCI:C34518 OMIM:123450 SNOMEDCT_US_2020_03_01:70173007 UMLS_CUI:C0010314 5p deletion syndrome 5p partial monosomy syndrome Cri-du-chat syndrome chromosome 5 short arm deletion syndrome chromosome 5p deletion syndrome disease_ontology DOID:12580 OMIM mapping confirmed by DO. [SN]. Cri-Du-Chat syndrome DOID:12580 A chromosomal deletion disease that has_material_basis_in deletion polymorphisms at chromosome location 22q11 and that is characterized by variable developmental problems and schizoid features. ICD10CM:Q93.81 ICD9CM:758.32 MESH:D004062 OMIM:192430 SNOMEDCT_US_2020_03_01:205642004 UMLS_CUI:C0220704 22q11 Deletion Syndrome Shprintzen syndrome VCF-Velocardiofacial syndrome deletion 22q11.2 syndrome disease_ontology DOID:12583 OMIM mapping confirmed by DO. [LS]. velocardiofacial syndrome DOID:12583 A renal agenesis characterized by the typical physical appearance and associated pulmonary hypoplasia of a newborn as a direct result of kidney failure, oligohydramnios and compression while in the uterus. GARD:4462 ICD10CM:Q60.6 NCI:C40435 SNOMEDCT_US_2020_03_01:41962002 UMLS_CUI:C0178426 Potter sequence Potter syndrome disease_ontology DOID:12594 Potter's syndrome DOID:12594 MESH:D010249 SNOMEDCT_US_2020_03_01:280483007 UMLS_CUI:C0030455 pelvic cellulitis disease_ontology DOID:1260 parametritis DOID:1260 A lymphoid leukemia that occurs when a hematopoietic stem cell undergoes malignant transformation into a primitive, undifferentiated cell with abnormal longevity producing large numbers of white blood cells to be produced and enter the blood stream. DOID:12621 ICD10CM:C95.00 ICD9CM:208.0 NCI:C9300 OMIM:308960 SNOMEDCT_US_2020_03_01:24072005 UMLS_CUI:C0085669 UMLS_CUI:C1378511 Stem cell Leukemia Stem cell leukaemia disease_ontology DOID:12603 acute leukemia DOID:12603 ICD10CM:K31.1 MESH:D011707 NCI:C34966 SNOMEDCT_US_2020_03_01:367403001 UMLS_CUI:C0034194 disease_ontology DOID:12639 pyloric stenosis DOID:12639 ICD10CM:K44 MESH:D006551 NCI:C98945 OMIM:142400 SNOMEDCT_US_2020_03_01:236053002 SNOMEDCT_US_2020_03_01:3662000 SNOMEDCT_US_2020_03_01:84089009 UMLS_CUI:C0267725 UMLS_CUI:C0376710 UMLS_CUI:C3489393 Diaphragmatic - hiatus -hernia hiatal hernia disease_ontology DOID:12642 OMIM mapping confirmed by DO. [SN]. hiatus hernia DOID:12642 ICD10CM:H93.3 ICD9CM:388.5 MESH:D000160 NCI:C27207 SNOMEDCT_US_2020_03_01:77949003 UMLS_CUI:C0001163 acoustic nerve disease disease_ontology DOID:12657 vestibulocochlear nerve disease DOID:12657 A primary systemic mycosis that results_in systemic fungal infection located_in mucosa, located_in lymph nodes, located_in bone, located_in skin or located_in lungs, has_material_basis_in Paracoccidioides brasiliensis. GARD:7323 ICD10CM:B41 ICD9CM:116.1 MESH:D010229 NCI:C34891 SNOMEDCT_US_2020_03_01:59925007 UMLS_CUI:C0030409 Mucocutaneous-lymphangitic paracoccidioidomycosis Paracoccidioidomycosis paracoccidioidal mycosis disease_ontology DOID:12662 paracoccidioidomycosis DOID:12662 A primary systemic mycosis that results_in a systemic fungal infection, has_material_basis_in Blastomyces dermatitidis, transmitted_by airborne spores and has_symptom skin lesions, has_symptom lung lesions and has_symptom pleural thickening. DOID:13067 GARD:5931 ICD10CM:B40 ICD9CM:116.0 MESH:D001759 NCI:C34428 SNOMEDCT_US_2020_03_01:266217003 UMLS_CUI:C0005716 Blastomyces Dermatitidis Infection Blastomycotic infection Chicago disease Gilchrist's disease Infection by Blastomyces dermatitidis North American blastomycosis disease_ontology DOID:12663 blastomycosis DOID:12663 DOID:12671 ICD10CM:H53.30 ICD9CM:368.30 NCI:C34422 SNOMEDCT_US_2020_03_01:83275001 UMLS_CUI:C0005461 simultaneous visual perception without fusion disease_ontology DOID:12667 binocular vision disease DOID:12667 ICD10CM:H53.31 ICD9CM:368.34 SNOMEDCT_US_2020_03_01:79195003 UMLS_CUI:C0155010 disease_ontology DOID:12668 abnormal retinal correspondence DOID:12668 ICD10CM:E83.52 ICD9CM:275.42 MESH:D006934 NCI:C3112 SNOMEDCT_US_2020_03_01:154752005 UMLS_CUI:C0020437 disease_ontology DOID:12678 hypercalcemia DOID:12678 GARD:7177 MESH:D009397 NCI:C84918 SNOMEDCT_US_2020_03_01:154752005 UMLS_CUI:C0027709 disease_ontology DOID:12679 nephrocalcinosis DOID:12679 A brain disease that is characterized by damage to neurons of the corticobulbar tract, has_symptom dysarthria, has_symptom dysphagia, has_symptom spasticity located_in tongue, has_symptom abnormal bulbar reflexes, and has_symptom emotional outbursts. ICD9CM:335.23 MESH:D020828 NCI:C129934 SNOMEDCT_US_2020_03_01:7379000 UMLS_CUI:C0033790 Pseudobulbar palsy pseudobulbar paralysis disease_ontology DOID:12680 pseudobulbar palsy DOID:12680 A inner ear infectious disease caused by a viral infection which involves inflammation of the vestibular nerve. It usually results as a complication of an upper respiratory infection. This causes sudden and severe vertigo, nausea and vomiting. Auditory symptoms are usually absent. ICD10CM:H81.2 ICD9CM:386.12 MESH:D020338 SNOMEDCT_US_2020_03_01:232293008 UMLS_CUI:C0751908 Epidemic neurolabyrinthitis Vestibular neuritis disease_ontology DOID:12683 vestibular neuronitis DOID:12683 GARD:223 MESH:D009464 NCI:C3276 SNOMEDCT_US_2020_03_01:269643009 UMLS_CUI:C0027859 Vestibular Neurilemmoma Vestibular schwannoma disease_ontology DOID:12689 acoustic neuroma DOID:12689 A nervous system disease that is characterized by complete paralysis of all voluntary muscles except for the ones that control the movements of the eyes. GARD:6919 ICD10CM:G83.5 ICD9CM:344.81 MESH:D000080422 SNOMEDCT_US_2020_03_01:38023001 UMLS_CUI:C0023944 Locked in syndrome Locked-in state disease_ontology DOID:12697 locked-in syndrome DOID:12697 A disorder of sexual development that is characterized by enlargement or swelling of male breast tissue resulting from elevated male estrogen levels or imbalanced estrogen and testosterone levels. ICD10CM:N62 MESH:D006177 NCI:C3073 SNOMEDCT_US_2020_03_01:155963008 UMLS_CUI:C0018418 disease_ontology DOID:12698 gynecomastia DOID:12698 A cell type benign neoplasm that is a benign tumor of smooth muscle cells. MESH:D007889 NCI:C3157 SNOMEDCT_US_2020_03_01:702978006 UMLS_CUI:C0023267 leiomyomatous neoplasm leiomyomatous tumor disease_ontology DOID:127 leiomyoma DOID:127 A vascular disease characterized by the presence of multiple arteriovenous malformations that lack intervening capillaries and result in direct connections between arteries and veins. GARD:6626 ICD10CM:I78.0 ICD9CM:448.0 MESH:D013683 NCI:C35064 OMIM:187300 OMIM:600376 OMIM:601101 OMIM:615506 ORDO:774 SNOMEDCT_US_2020_03_01:266324004 UMLS_CUI:C0039445 Osler hemorrhagic telangiectasia syndrome Osler-Weber-Rendu disease Rendu-Osler-Weber disease disease_ontology DOID:1270 Xref MGI. OMIM mapping confirmed by DO. [SN]. hereditary hemorrhagic telangiectasia DOID:1270 An acquired metabolic disease that has_material_basis_in the presence of abnormally-high levels of prolactin in the blood. DOID:12699 ICD10CM:E22.1 MESH:D002640 MESH:D006966 SNOMEDCT_US_2020_03_01:190468001 SNOMEDCT_US_2020_03_01:85039006 UMLS_CUI:C0008043 UMLS_CUI:C0020514 Chiari-Frommel syndrome Pregnancy-related A-G syndrome hyperprolactinaemia disease_ontology DOID:12700 hyperprolactinemia DOID:12700 An autosomal recessive cerebellar ataxia that is characterized by cerebellar ataxia, telangiectases, immune defects, and a predisposition to malignancy and that has_material_basis_in homozygous or compound heterozygous mutation in the ATM gene on chromosome 11q22. GARD:5862 MESH:D001260 NCI:C2887 OMIM:208900 SNOMEDCT_US_2020_03_01:68504005 UMLS_CUI:C0004135 Boder-Sedgwick syndrome Louis Bar syndrome disease_ontology DOID:12704 OMIM mapping confirmed by DO. [SN]. ataxia telangiectasia MESH:D001260 DOID:12704 DOID:0050555 GARD:6468 ICD9CM:334.0 MESH:D005621 NCI:C84718 SNOMEDCT_US_2020_03_01:155011003 UMLS_CUI:C0016719 Friedreich ataxia 1 Friedreich's ataxia Friedreich's tabes disease_ontology DOID:12705 Xref MGI. Friedreich ataxia MESH:D005621 DOID:12705 A vascular disease that is located_in the capillaries. ICD10CM:I78 ICD9CM:448 SNOMEDCT_US_2020_03_01:58729003 UMLS_CUI:C0155765 disease of capillaries disease_ontology DOID:1271 capillary disease DOID:1271 A kidney disease that is characterized by a chronic tubulointerstitial nephritis that progress to terminal renal failure during the second decade (juvenile form) or before the age of 5 years (infantile form) resulting from dysfunction of ciliary proteins (ciliopathy). GARD:206 ICD10CM:Q61.5 NCI:C123200 OMIM:PS256100 ORDO:655 SNOMEDCT_US_2020_03_01:204958008 UMLS_CUI:C0687120 medullary cystic disease medullary cystic kidney disease_ontology DOID:12712 Xref MGI. OMIM mapping confirmed by DO. [SN]. nephronophthisis DOID:12712 A syndrome characterized by short limbs, short ribs, postaxial polydactyly, dysplastic nails and teeth, and in many patients congenital cardiac defects that has_material_basis_in homozygous or compound heterozygous mutation in either EVC or EVC2 on chromosome 4p16.2. GARD:1301 ICD10CM:Q77.6 ICD9CM:756.55 MESH:D004613 NCI:C84684 OMIM:225500 SNOMEDCT_US_2020_03_01:62501005 UMLS_CUI:C0013903 Chondroectodermal dysplasia Ellis-van Creveld syndrome mesoectodermal dysplasia disease_ontology DOID:12714 OMIM mapping confirmed by DO. [SN]. Ellis-Van Creveld syndrome DOID:12714 A respiratory failure that is characterized by deficiency of the surfactant coating the inner surface of the lungs, by failure of the lungs to expand and contract properly during breathing with resulting collapse, and by the accumulation of a protein-containing film lining the alveoli and their ducts. DOID:11395 DOID:13859 ICD10CM:P22.0 MESH:D006819 OMIM:267450 SNOMEDCT_US_2020_03_01:26168007 UMLS_CUI:C0020192 HMD - Hyaline membrane disease Neonatal respiratory Distress syndrome hyaline membrane disease pulmonary hyaline membrane disease pulmonary hypoperfusion syndrome of newborn respiratory distress syndrome of newborn disease_ontology DOID:12716 newborn respiratory distress syndrome DOID:12716 MESH:D013684 NCI:C28194 SNOMEDCT_US_2020_03_01:112641009 UMLS_CUI:C0039446 telangiectasia disease_ontology DOID:1272 telangiectasis DOID:1272 ICD10CM:I67.2 ICD9CM:437.0 MESH:D002537 NCI:C34459 SNOMEDCT_US_2020_03_01:266258005 UMLS_CUI:C0007775 Cerebral atherosclerosis disease_ontology DOID:12720 cerebral atherosclerosis DOID:12720 An osteochondrodysplasia that has_material_basis_in defective cartilage mineralization into bone which results in irregular ossification centers of the located in hip or located in knee. The disease has symptom fatigue, has symptom joint pain. GARD:10756 ICD9CM:756.56 MESH:D010009 ORDO:251 SNOMEDCT_US_2020_03_01:59708000 UMLS_CUI:C0026760 polyepiphyseal dysplasia disease_ontology DOID:12721 Xref MGI. multiple epiphyseal dysplasia DOID:12721 A viral infectious disease that results_in infection located_in upper respiratory tract or located_in lower respiratory tract, has_material_basis_in Human respiratory syncytial virus, which is transmitted_by droplet spread of nasal secretions from an infected person while coughing or sneezing, or transmitted_by contaminated fomites. The infection has_symptom runny nose, has_symptom fever, has_symptom cough, has_symptom wheezing, and has_symptom respiratory distress. MESH:D018357 NCI:C3354 SNOMEDCT_US_2020_03_01:186750007 UMLS_CUI:C0035235 disease_ontology DOID:1273 respiratory syncytial virus infectious disease DOID:1273 ICD10CM:K03.4 ICD9CM:521.5 MESH:D006936 SNOMEDCT_US_2020_03_01:78537008 UMLS_CUI:C0020441 Cementation hyperplasia disease_ontology DOID:12733 hypercementosis DOID:12733 ICD10CM:H18.72 ICD9CM:371.73 SNOMEDCT_US_2020_03_01:193849005 UMLS_CUI:C0152440 disease_ontology DOID:12753 corneal staphyloma DOID:12753 DOID:12760 ICD10CM:C69.3 ICD9CM:190.6 MESH:D002830 NCI:C2949 NCI:C3566 SNOMEDCT_US_2020_03_01:127001008 SNOMEDCT_US_2020_03_01:93755007 UMLS_CUI:C0008523 UMLS_CUI:C0153630 Choroidal tumor choroid neoplasm malignant tumor of choroid malignant tumor of the Choroid neoplasm of choroid disease_ontology DOID:12759 choroid cancer DOID:12759 GARD:7777 MESH:D020333 NCI:C85193 SNOMEDCT_US_2020_03_01:75111000 UMLS_CUI:C0040381 Tolosa-Hunt syndrome disease_ontology DOID:1278 tolosa-hunt syndrome DOID:1278 ICD9CM:374.14 SNOMEDCT_US_2020_03_01:28914006 UMLS_CUI:C0155196 disease_ontology DOID:12782 cicatricial ectropion DOID:12782 A migraine that is characterized by migraine headaches that are not accompanied by an aura. ICD10CM:G43.0 ICD9CM:346.1 MESH:D020326 NCI:C117004 OMIM:607501 SNOMEDCT_US_2020_03_01:56097005 UMLS_CUI:C0338480 common migraine disease_ontology DOID:12783 Xref MGI. migraine without aura DOID:12783 GARD:7061 GARD:7237 ICD9CM:378.9 MESH:D015835 SNOMEDCT_US_2020_03_01:45030009 UMLS_CUI:C0028850 disorder of eye movements eye movement disorder disease_ontology DOID:1279 ocular motility disease DOID:1279 A lysosomal storage disease that involves the accumulation of glycosaminoglycans in the tissues and their excretion in the urine. DOID:14716 GARD:7065 ICD10CM:E76.3 ICD9CM:277.5 MESH:D009083 NCI:C61259 OMIM:252700 OMIM:PS607014 ORDO:79213 SNOMEDCT_US_2020_03_01:267452003 UMLS_CUI:C0026703 disease_ontology DOID:12798 Xref MGI. OMIM mapping submitted by NeuroDevNet. [LS]. mucopolysaccharidosis DOID:12798 A mucopolysaccharidosis characterized by a deficiency of the lysosomal enzyme N-acetylgalactosamine 4-sulfatase. GARD:7095 MESH:D009087 NCI:C61264 OMIM:253200 SNOMEDCT_US_2020_03_01:69463008 UMLS_CUI:C0026709 MPS VI - Maroteaux-Lamy syndrome Maroteaux - Lamy syndrome Maroteaux-Lamy syndrome arylsulfatase B deficiency deficiency of N-acetylgalactosamine-4-sulfatase disease_ontology DOID:12800 OMIM mapping confirmed by DO. [SN]. mucopolysaccharidosis VI DOID:12800 A mucopolysaccharidosis characterized by a deficiency of the lysosomal enzyme resulting in incomplete breakdown of the heparan sulfate sugar chain. DOID:14729 DOID:14788 MESH:D009084 NCI:C61262 OMIM:252940 ORDO:581 SNOMEDCT_US_2020_03_01:190936000 UMLS_CUI:C0026706 Mucopolysaccharidosis, MPS-III N-sulphoglucosamine sulphohydrolase deficiency Sanfilippo's syndrome heparan sulfate sulfatase deficiency naglu deficiency disease_ontology DOID:12801 OMIM mapping confirmed by DO. [SN]. mucopolysaccharidosis III DOID:12801 A mucopolysaccharidosis characterized by a deficiency of the lysosomal enzymes galactose 6-sulfate sulfatase (Type A) or beta-galactosidase (Type B) needed to break down the keratan sulfate sugar chain. DOID:0050808 DOID:14767 ICD10CM:E76.219 MESH:D009085 NCI:C61263 SNOMEDCT_US_2020_03_01:378007 UMLS_CUI:C0026707 Mucopolysaccharidosis, MPS-IV deficiency of N-acetylgalactosamine-6-sulphatase deficiency of chondroitinsulphatase galactosamine-6-sulfatase deficiency Osteochondrodystrophy chondroosteodystrophy disease_ontology DOID:12804 OMIM mapping confirmed by DO. [SN]. mucopolysaccharidosis IV DOID:12804 ICD10CM:G82.5 ICD9CM:344.00 MESH:D011782 NCI:C50721 SNOMEDCT_US_2020_03_01:11538006 UMLS_CUI:C0034372 tetraplegia disease_ontology DOID:12835 quadriplegia DOID:12835 MESH:D013958 NCI:C112836 SNOMEDCT_US_2020_03_01:190262002 UMLS_CUI:C0040127 Thyroid crisis Thyrotoxic crisis disease_ontology DOID:12837 thyroid crisis DOID:12837 A female reproductive system disease that is characteried by the descent of one or more of the pelvic structures (bladder, uterus, vagina) from the normal anatomic location toward or through the vaginal opening. ICD9CM:618.8 UMLS_CUI:C0029801 disease_ontology DOID:1284 prolapse of female genital organ DOID:1284 A parasitic helminthiasis infectious disease that involves infection of skin, eyes, and viscera in humans by the parasitic nematodes Ancylostoma braziliense, Ancylostoma ceylanicum, Ancylostoma duodenale or Ancylostoma caninum. The larvae cause lesions on the skin at the site of penetration. The infection has_symptom intestinal bleeding, has_symptom abdominal pain, has_symptom anemia, has_symptom severe diarrhea and has_symptom malnutrition. GARD:9742 ICD10CM:B76.0 MESH:D000724 NCI:C35805 SNOMEDCT_US_2020_03_01:85807000 UMLS_CUI:C0002831 disease_ontology DOID:12841 ancylostomiasis MESH:D000724 DOID:12841 An autoimmune disease of peripheral nervous system that causes body's immune system to attack part of the peripheral nervous system. GARD:6554 ICD10CM:G61.0 MESH:D020275 NCI:C116345 OMIM:139393 SNOMEDCT_US_2020_03_01:155082001 UMLS_CUI:C0018378 Infectious neuronitis Post-infectious polyneuritis Postinfectious polyneuritis acute infective polyneuritis acute inflammatory demyelinating polyradiculopathy acute postinfectious polyneuropathy disease_ontology DOID:12842 OMIM mapping confirmed by DO. [SN]. Guillain-Barre syndrome DOID:12842 An autism spectrum disorder that is characterized by symptoms across all three symptom domains (communication, social, restricted repetitive interests and behaviors), delayed language development, and symptom onset prior to age 3 years. EFO:0003758 ICD10CM:F84.0 ICD9CM:299.0 MESH:D001321 NCI:C97161 OMIM:209850 ORDO:106 SNOMEDCT_US_2020_03_01:38763009 UMLS_CUI:C0004352 Kanner's syndrome autism autistic disorder of childhood onset childhood autism infantile autism disease_ontology DOID:12849 Xref MGI. OMIM mapping confirmed by DO. [SN]. autistic disorder DOID:12849 MESH:D012002 SNOMEDCT_US_2020_03_01:5964004 UMLS_CUI:C0034882 disease_ontology DOID:1285 rectal disease DOID:1285 A neurodegenerative disease that has_material_basis_in autosomal dominant inheritance and is characterized by unwanted choreatic movements, behavioral and psychiatric disturbances and dementia and has_material_basis_in expansion of CAG triplet repeats (glutamine) resulting in neuron degeneration affecting muscle coordination, cognitive abilities. GARD:6677 ICD10CM:G10 ICD9CM:333.4 KEGG:05016 MESH:D006816 NCI:C82342 OMIM:143100 SNOMEDCT_US_2020_03_01:155006000 UMLS_CUI:C0020179 HD Huntington disease Huntington's chorea disease_ontology DOID:12858 Huntington's disease DOID:12858 A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis. DOID:73 ICD9CM:429.2 MESH:D002318 NCI:C2931 SNOMEDCT_US_2020_03_01:266275004 UMLS_CUI:C0007222 disease of subdivision of hemolymphoid system disease_ontology DOID:1287 cardiovascular system disease DOID:1287 A Guillain-Barre syndrome that manifests as a descending paralysis. It usually affects the eye muscles first and presents with the triad of ophthalmoplegia, ataxia, and areflexia. GARD:3668 ICD10CM:G61.0 MESH:D019846 NCI:C116958 SNOMEDCT_US_2020_03_01:1767005 UMLS_CUI:C0393799 Fisher's syndrome Miller-Fisher variant of Guillain-Barre syndrome disease_ontology DOID:12889 Miller Fisher syndrome DOID:12889 A central nervous system disease that results in the progressive deterioration of function or structure of neurons. DOID:4874 ICD10CM:G31.9 MESH:D019636 NCI:C27090 SNOMEDCT_US_2020_03_01:362975008 UMLS_CUI:C0524851 UMLS_CUI:C1285162 Neurodegenerative disease degenerative disease disease_ontology DOID:1289 neurodegenerative disease DOID:1289 An autoimmune disease that involves attack of immune cells which destroy the exocrine glands that produce tears and saliva. DOID:416 GARD:10252 ICD10CM:M35.0 ICD10CM:M35.00 ICD9CM:710.2 MESH:D012859 NCI:C26883 NCI:C70647 OMIM:270150 SNOMEDCT_US_2020_03_01:267875002 SNOMEDCT_US_2020_03_01:83901003 UMLS_CUI:C0086981 UMLS_CUI:C1527336 Sicca syndrome Sjogren syndrome xerodermosteosis disease_ontology DOID:12894 OMIM mapping confirmed by DO. [LS]. Sjogren's syndrome DOID:12894 GARD:8444 MESH:D007638 SNOMEDCT_US_2020_03_01:78946008 UMLS_CUI:C0022575 KCS disease_ontology DOID:12895 keratoconjunctivitis sicca DOID:12895 An autoimmune disease that is characterized by chronic enlargement of the glands of the head and neck, has_symptom lumps of the face and neck, dry eyes, dry mouth, and intermittent fever, and is often associated with an underlying autoimmune disorder, hematologic malignancy, tuberculosis infection, or syphilis infection. GARD:7043 ICD10CM:K11.8 MESH:D008882 NCI:C34819 SNOMEDCT_US_2020_03_01:7826003 UMLS_CUI:C0026103 IgG4-related dacryoadenitis and sialadenitis Mikulicz's disease disease_ontology DOID:12900 Mikulicz disease DOID:12900 ICD10CM:K11.8 MESH:D012797 SNOMEDCT_US_2020_03_01:109769000 UMLS_CUI:C0037033 Necrotizing sialometaplasia disease_ontology DOID:12901 necrotizing sialometaplasia DOID:12901 ICD10CM:K11.6 ICD9CM:527.6 NCI:C27649 SNOMEDCT_US_2020_03_01:196508008 UMLS_CUI:C0026686 Mucous retention cyst of salivary gland Ranula Salivary Cyst Salivary gland mucocele disease_ontology DOID:12904 mucocele of salivary gland DOID:12904 An endocardium disease that is characterized by a thickening of the inmost lining of the heart chambers due to an increase in the amount of supporting connective tissue and elastic fibers. GARD:2121 GARD:6336 ICD10CM:I42.4 ICD9CM:425.3 MESH:D004695 NCI:C98922 OMIM:226000 SNOMEDCT_US_2020_03_01:65457005 UMLS_CUI:C0014117 Elastomyofibrosis disease_ontology DOID:12929 OMIM mapping confirmed by DO. [SN]. endocardial fibroelastosis MESH:D004695 DOID:12929 An intrinsic cardiomyopathy that is characterized by an an enlarged heart and damage to the myocardium causing the heart to pump blood inefficiently. EFO:0000407 GARD:221 ICD10CM:I42.0 KEGG:05414 MESH:D002311 NCI:C84673 OMIM:PS115200 ORDO:217604 SNOMEDCT_US_2020_03_01:74368002 UMLS_CUI:C0007193 primary dilated cardiomyopathy disease_ontology Congestive cardiomyopathy Familial dilated cardiomyopathy Familial dilated cardiomyopathy Idiopathic dilation cardiomyopathy Idiopathic dilation cardiomyopathy DOID:12930 Xref MGI. OMIM mapping confirmed by DO. [LS]. dilated cardiomyopathy DOID:12930 GARD:6340 ICD9CM:425.0 MESH:D004719 NCI:C34585 SNOMEDCT_US_2020_03_01:111507009 UMLS_CUI:C0553980 African endomyocardial fibrosis Becker's disease Endomyocardial sclerosis Obscure African cardiomyopathy obscure African cardiomyopathy disease_ontology DOID:12932 endomyocardial fibrosis DOID:12932 GARD:6817 ICD10CM:H49.81 MESH:D007625 NCI:C84798 OMIM:530000 SNOMEDCT_US_2020_03_01:25792000 UMLS_CUI:C0022541 disease_ontology DOID:12934 OMIM mapping confirmed by DO. [SN]. Kearns-Sayre syndrome DOID:12934 A vulva cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. NCI:C4866 UMLS_CUI:C0677055 Vulvar carcinoma disease_ontology carcinoma of vulva DOID:1294 vulva carcinoma DOID:1294 ICD10CM:H02.2 ICD9CM:374.2 SNOMEDCT_US_2020_03_01:193936001 UMLS_CUI:C0152226 disease_ontology DOID:12959 lagophthalmos DOID:12959 A synostosis that results_in craniosynostosis and syndactyly. DOID:0080004 ICD9CM:755.55 MESH:D000168 NCI:C34348 OMIM:101200 SNOMEDCT_US_2020_03_01:63661009 UMLS_CUI:C1510455 Apert syndrome disease_ontology DOID:12960 OMIM mapping confirmed by DO. [SN]. acrocephalosyndactylia MESH:D000168 DOID:12960 A hematologic cancer located_in the central nervous system. NCI:C5440 UMLS_CUI:C1332884 Leukemia of the CNS disease_ontology DOID:12969 central nervous system leukemia DOID:12969 A congenital hemolytic anemia characterized by the production of red blood cells with a sphere shape, rather than the normal biconcave disk shape. GARD:6639 ICD10CM:D58.0 ICD9CM:282.0 MESH:D013103 NCI:C97074 ORDO:822 SNOMEDCT_US_2020_03_01:154795009 UMLS_CUI:C0037889 Congenital spherocytic hemolytic anemia Minkowski Chauffard syndrome spherocytic anemia disease_ontology DOID:12971 Xref MGI. hereditary spherocytosis DOID:12971 MESH:D018921 NCI:C4062 SNOMEDCT_US_2020_03_01:30419000 UMLS_CUI:C0282548 Leukostasis disease_ontology DOID:12986 leukostasis DOID:12986 A leukopenia that is characterized by a severe lack of of granulocytes with a drop in granulocyte concentration below 200 cells/mm³ of blood. ICD10CM:D70 MESH:D000380 SNOMEDCT_US_2020_03_01:154830007 UMLS_CUI:C0001824 Granulocytopenic disorder Granulopenia granulocytopenia disease_ontology DOID:12987 agranulocytosis MESH:D000380 DOID:12987 A specific developmental disorder marked by a pattern of repetitive behavior wherein the rights of others or social norms are violated. EFO:0004216 ICD10CM:F91 ICD9CM:312.9 MESH:D019955 NCI:C89329 SNOMEDCT_US_2020_03_01:430909002 UMLS_CUI:C0149654 disease_ontology DOID:12995 conduct disorder DOID:12995 MESH:D016893 NCI:C95804 SNOMEDCT_US_2020_03_01:195181000 UMLS_CUI:C0007282 Carotid artery stenosis Stenosis, carotid artery disease_ontology DOID:13001 carotid stenosis DOID:13001 ICD9CM:435.2 MESH:D013349 NCI:C35044 SNOMEDCT_US_2020_03_01:15258001 UMLS_CUI:C0038531 Subclavian artery stenosis subclavian steal phenomenon subclavian steal steno-occlusive disease disease_ontology DOID:13002 subclavian steal syndrome DOID:13002 ICD10CM:G45.0 ICD9CM:435.3 MESH:D014715 SNOMEDCT_US_2020_03_01:195196001 UMLS_CUI:C0042568 Vertebro-basilar insufficiency Vertebrobasilar arterial insufficiency Vertebrobasilar artery syndrome Vertebrobasilar insufficiency disease_ontology DOID:13003 vertebrobasilar insufficiency MESH:D014715 DOID:13003 ICD10CM:B30.0 ICD9CM:077.1 NCI:C34590 SNOMEDCT_US_2020_03_01:60548004 UMLS_CUI:C0014493 EKC Epidemic keratoconjunctivitis disease_ontology DOID:13014 shipyard eye DOID:13014 GARD:5695 ICD10CM:H35.1 ICD9CM:362.21 MESH:D012178 NCI:C34982 SNOMEDCT_US_2020_03_01:155110004 UMLS_CUI:C0035344 Retrolental fibroplasia premature retinopathy disease_ontology DOID:13025 retinopathy of prematurity DOID:13025 An amnestic disorder that is characterized by temporary but almost total disruption of short-term memory with a range of problems accessing older memories. GARD:8172 ICD10CM:G45.4 ICD9CM:437.7 MESH:D020236 NCI:C85198 SNOMEDCT_US_2020_03_01:366963000 UMLS_CUI:C0338591 disease_ontology DOID:13027 transient global amnesia DOID:13027 ICD10CM:N48.1 MESH:D001446 NCI:C26705 SNOMEDCT_US_2020_03_01:155928003 UMLS_CUI:C0004690 disease_ontology DOID:13033 balanitis DOID:13033 A primary bacterial infectious disease that results_in infection, has_material_basis_in Borrelia, which is transmitted_by tick or transmitted_by body louse. ICD10CM:A68 ICD9CM:087 MESH:D012061 SNOMEDCT_US_2020_03_01:186820006 UMLS_CUI:C0035021 disease_ontology DOID:13034 relapsing fever DOID:13034 A relapsing fever that is characterized by relapsing or recurring episodes of fever, has_material basis_in Borrelia hermsii, has_material basis_in Borrelia parkeri or has_material basis_in Borrelia duttoni, which are transmitted_by soft ticks (Ornithodoros parkeri and Ornithodoros hermsii). The infection has_symptom tachypnea, has_symptom tachycardia, has_symptom hepatosplenomegaly and has_symptom lymphadenopathy. ICD10CM:A68.1 ICD9CM:087.1 NCI:C34976 SNOMEDCT_US_2020_03_01:10301003 UMLS_CUI:C0035022 Relapsing fever, tick-borne Tick-borne relapsing fever disease_ontology DOID:13036 tick-borne relapsing fever DOID:13036 ICD10CM:P29.3 ICD9CM:747.83 MESH:D010547 NCI:C85006 OMIM:265380 SNOMEDCT_US_2020_03_01:35604006 UMLS_CUI:C0031190 Fetal circulation Persistent fetal circulation Persistent fetal circulation syndrome Persistent foetal circulation Persistent foetal circulation syndrome Persistent pulmonary hypertension of the newborn congenital alveolar capillary dysplasia with misalignment of pulmonary veins persistent foetal circulation syndrome persistent pulmonary hypertension of the newborn disease_ontology DOID:13042 OMIM mapping confirmed by DO. [SN]. persistent fetal circulation syndrome DOID:13042 ICD10CM:N25.0 ICD9CM:588.0 MESH:D012080 NCI:C114827 SNOMEDCT_US_2020_03_01:266617009 UMLS_CUI:C0035086 renal rickets disease_ontology DOID:13068 renal osteodystrophy DOID:13068 A cognitive disorder resulting from a loss of brain function affecting memory, thinking, language, judgement and behavior. ICD9CM:290.8 UMLS_CUI:C0154319 disease_ontology DOID:1307 dementia DOID:1307 A dermatophytosis that results_in fungal infection located_in nail, has_material_basis_in Ascomycota fungi that belong to a group called dermatophytes, which cause separation of the nail plate from the nail bed and has_symptom thickening of subungueal area. Sometimes, white islands are seen on the external nail plates. These gradually coalesce until the entire nail plate is involved. DOID:10462 DOID:11399 DOID:11761 DOID:12844 DOID:12845 DOID:12846 DOID:12847 DOID:12848 DOID:13119 DOID:9412 DOID:9690 DOID:9691 ICD9CM:681.9 UMLS_CUI:C0007644 Dermatophytic onychia Dermatophytosis of nail Onychomycosis due to dermatophyte cellulitis and abscess of buttock cellulitis and abscess of face cellulitis and abscess of finger cellulitis and abscess of finger and toe cellulitis and abscess of gluteal region cellulitis and abscess of trunk cellulitis and abscess of upper arm and forearm dermatophytic onychomycosis disease_ontology Tinea unguium cellulitis and abscess DOID:13074 tinea unguium DOID:13074 A dermatomycosis that effects skin and subcutaneous tissue located in foot, located in trunk, located in buttocks, located in eyelids, located in lacrimal glands, located in paranasal sinuses, located in mandible, located in scalp, located in neck, located in perineum, or located in testes and has symptom sinus discharge and results in formation of nodules. ICD10CM:B47 MESH:D008271 NCI:C85505 SNOMEDCT_US_2020_03_01:410039003 UMLS_CUI:C0024449 Madura foot Maduromycosis, mycotic Mycotic mycetoma eumycetoma maduromycosis disease_ontology DOID:13078 eumycotic mycetoma DOID:13078 GARD:10285 ICD10CM:P91.2 ICD9CM:779.7 MESH:D007969 NCI:C99013 SNOMEDCT_US_2020_03_01:230769007 UMLS_CUI:C0023529 disease_ontology DOID:13088 periventricular leukomalacia DOID:13088 MESH:D020765 UMLS_CUI:C0752138 disease_ontology DOID:13089 intracranial arterial disease DOID:13089 ICD10CM:H34.23 ICD9CM:362.32 MESH:D015356 NCI:C34436 SNOMEDCT_US_2020_03_01:50821009 UMLS_CUI:C0006123 Arterial retinal branch occlusion Retinal Arterial Branch Occlusion Retinal arterial branch occlusion disease_ontology DOID:13094 branch retinal artery occlusion DOID:13094 MESH:D014715 UMLS_CUI:C0042560 Vertebral artery syndrome disease_ontology DOID:13095 vertebral artery insufficiency DOID:13095 A retinal artery occlusion characterized by blockage of blood flow through the central retinal artery. ICD10CM:H34.1 ICD9CM:362.31 MESH:D015356 NCI:C34456 SNOMEDCT_US_2020_03_01:38742007 UMLS_CUI:C0007688 disease_ontology DOID:13098 central retinal artery occlusion DOID:13098 A cerebral arterial disease characterized by constriction of certain arteries at the base of the brain. Blood flow is blocked by the constriction and also by blood clots. GARD:7064 ICD10CM:I67.5 ICD9CM:437.5 MESH:D009072 NCI:C84895 OMIM:252350 OMIM:300845 OMIM:607151 OMIM:608796 OMIM:614042 OMIM:615750 ORDO:2573 ORDO:280679 ORDO:401945 SNOMEDCT_US_2020_03_01:69116000 UMLS_CUI:C0026654 progressive intracranial arterial occlusion disease_ontology DOID:13099 Xref MGI. OMIM mapping confirmed by DO. [SN]. Moyamoya disease MESH:D009072 DOID:13099 MESH:D020301 UMLS_CUI:C0751895 disease_ontology DOID:13100 intracranial vasospasm DOID:13100 A bladder benign neoplasm that derives_from smooth muscle cells. NCI:C6178 UMLS_CUI:C1332560 leiomyoma of the urinary bladder disease_ontology DOID:13109 bladder leiomyoma DOID:13109 ICD9CM:374.04 SNOMEDCT_US_2020_03_01:67383002 UMLS_CUI:C0155191 disease_ontology DOID:13113 cicatricial entropion DOID:13113 DOID:3945 EFO:0004236 GARD:6517 MESH:D005923 NCI:C37308 OMIM:PS603278 SNOMEDCT_US_2020_03_01:25821008 UMLS_CUI:C0017668 FGS FSGS focal glomerular sclerosis focal glomerulosclerosis disease_ontology DOID:1312 Xref MGI. OMIM mapping confirmed by DO. [SN]. focal segmental glomerulosclerosis DOID:1312 ICD10CM:D53.0 ICD9CM:281.4 SNOMEDCT_US_2020_03_01:85746008 UMLS_CUI:C0154290 Anemia due to protein deficiency Protein-deficiency anaemia Protein-deficiency anemia protein-deficiency anaemia disease_ontology DOID:13120 protein-deficiency anemia DOID:13120 ICD9CM:281.9 SNOMEDCT_US_2020_03_01:191125001 UMLS_CUI:C0041782 deficiency anemias disease_ontology DOID:13121 deficiency anemia DOID:13121 A childhood spinal muscular atrophy that is a severe form and is characterized by muscle weakness onset from birth to six months of age, the inability to sit unassisted. GARD:7883 ICD10CM:G12.0 ICD9CM:335.0 MESH:D014897 NCI:C98670 OMIM:253300 SNOMEDCT_US_2020_03_01:64383006 UMLS_CUI:C0043116 HMN (Hereditary motor Neuropathy) Proximal type I SMA1 Spinal muscular atrophy 1 hereditary motor neuropathy proximal type I infantile muscular atrophy progressive muscular atrophy of infancy disease_ontology DOID:13137 OMIM mapping confirmed by DO. [SN]. Werdnig-Hoffmann disease DOID:13137 ICD9CM:580.0 SNOMEDCT_US_2020_03_01:197579006 UMLS_CUI:C0341692 acute glomerulonephritis with lesion of proliferative glomerulonephritis disease_ontology DOID:13138 acute proliferative glomerulonephritis DOID:13138 NCI:C128143 SNOMEDCT_US_2020_03_01:45406000 UMLS_CUI:C0403416 disease_ontology DOID:13139 crescentic glomerulonephritis DOID:13139 An uveal disease is characterized by inflammation of any of the layers of the uvea of the eye, which includes the iris, ciliary body, and choroid. ICD10CM:H20.9 MESH:D014605 NCI:C26909 SNOMEDCT_US_2020_03_01:267719008 UMLS_CUI:C0042164 disease_ontology DOID:13141 uveitis DOID:13141 ICD10CM:H55.04 ICD9CM:379.55 MESH:D009759 SNOMEDCT_US_2020_03_01:9520006 UMLS_CUI:C0155380 Dissociated nystagmus disease_ontology DOID:13174 dissociated nystagmus DOID:13174 An arthritis that has_material_basis_in uric acid crystal deposits located_in joint. DOID:14144 EFO:0004274 ICD10CM:M10 ICD9CM:274 ICD9CM:274.0 MESH:D006073 MESH:D015210 NCI:C34650 SNOMEDCT_US_2020_03_01:201661008 SNOMEDCT_US_2020_03_01:90560007 UMLS_CUI:C0003868 UMLS_CUI:C0018099 Articular gout Gouty arthropathy gouty arthritis disease_ontology DOID:13189 gout DOID:13189 A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain. DOID:2125 DOID:2126 DOID:3543 DOID:6649 DOID:911 ICD10CM:C71 ICD9CM:191 ICD9CM:239.6 MESH:D001932 NCI:C2907 NCI:C3568 NCI:C5115 NCI:C7710 SNOMEDCT_US_2020_03_01:126952004 SNOMEDCT_US_2020_03_01:428061005 SNOMEDCT_US_2020_03_01:93727008 UMLS_CUI:C0006118 UMLS_CUI:C0153633 UMLS_CUI:C0220624 UMLS_CUI:C0750974 UMLS_CUI:C0750979 UMLS_CUI:C1334557 BT - Brain tumour adult brain tumor adult malignant brain neoplasm brain neoplasm brain neoplasm, adult malignant brain tumour malignant primary brain neoplasm malignant primary brain tumor malignant tumor of Brain malignant tumor of adult brain neoplasm of brain primary brain neoplasm primary brain tumor primary malignant neoplasm of brain tumor of the Brain disease_ontology DOID:1319 brain cancer DOID:1319 MESH:D006045 SNOMEDCT_US_2020_03_01:66392007 UMLS_CUI:C0018024 Retrosternal thyroid goiter Retrosternal thyroid goitre Substernal goiter Substernal goitre substernal goitre disease_ontology DOID:13200 substernal goiter DOID:13200 ICD9CM:362.02 NCI:C84457 SNOMEDCT_US_2020_03_01:154679002 UMLS_CUI:C0154830 PDR disease_ontology DOID:13207 proliferative diabetic retinopathy DOID:13207 ICD9CM:426.51 SNOMEDCT_US_2020_03_01:46319007 UMLS_CUI:C0155704 Right bundle branch block with left posterior fascicular block disease_ontology DOID:13209 right bundle branch block DOID:13209 An uterine benign neoplasm derived from the smooth muscle layer of the uterus. EFO:0000731 ICD10CM:D25 ICD9CM:218 MESH:D007889 NCI:C3434 OMIM:150699 SNOMEDCT_US_2020_03_01:95315005 UMLS_CUI:C0042133 Plexiform leiomyoma UTERUS FIBROMA leiomyoma of Corpus Uteri uterine leiomyoma disease_ontology DOID:13223 OMIM mapping confirmed by DO. [LS]. uterine fibroid DOID:13223 A respiratory system cancer that is located_in the lung. DOID:13075 DOID:1322 DOID:9881 ICD10CM:C34.1 ICD10CM:C34.2 ICD10CM:C34.3 ICD9CM:162.3 ICD9CM:162.4 ICD9CM:162.5 ICD9CM:162.8 OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210 SNOMEDCT_US_2020_03_01:187860004 SNOMEDCT_US_2020_03_01:187864008 SNOMEDCT_US_2020_03_01:187868006 SNOMEDCT_US_2020_03_01:187874006 UMLS_CUI:C0024624 UMLS_CUI:C0153491 UMLS_CUI:C0153492 UMLS_CUI:C0153493 disease_ontology lung neoplasm DOID:1324 lung cancer DOID:1324 ICD10CM:K03.3 ICD9CM:521.4 MESH:D014091 SNOMEDCT_US_2020_03_01:70931000 UMLS_CUI:C0040451 disease_ontology DOID:13240 tooth resorption MESH:D014091 DOID:13240 A respiratory system cancer that is located_in the bronchus. ICD10CM:C34 ICD9CM:162.9 SNOMEDCT_US_2020_03_01:187875007 UMLS_CUI:C0348343 malignant neoplasm of bronchus and lung malignant neoplasm of bronchus or lung disease_ontology DOID:1325 bronchus cancer DOID:1325 A gastrointestinal system disease described as the condition of having frequent loose or liquid bowel movements. Acute diarrhea is a common cause of death in developing countries and the second most common cause of infant deaths worldwide. The loss of fluids through diarrhea can cause severe dehydration which is one cause of death in diarrhea sufferers. Along with water, sufferers also lose dangerous amounts of important salts, electrolytes, and other nutrients. There are at least four types of diarrhea: secretory diarrhea, osmotic diarrhea, motility-related diarrhea, and inflammatory diarrhea. DOID:0050006 ICD9CM:009.2 MESH:D004403 SNOMEDCT_US_2020_03_01:154268000 UMLS_CUI:C0013369 disease_ontology diarrhea of presumed infectious origin diarrhoea DOID:13250 diarrhea is both a disease and a symptom [ms] diarrhea DOID:13250 A primary bacterial infectious disease that is a communicable systemic illness, has_material_basis_in Salmonella enterica subsp enterica serovar Typhi, which is transmitted_by ingestion of food or water contaminated with the feces of an infected person. The infection has_symptom fever, has_symptom diarrhea, has_symptom prostration, has_symptom headache, has_symptom splenomegaly, has_symptom liver enlargement, has_symptom eruption of rose-colored spots, and has_symptom leukopenia. DOID:3054 GARD:9564 ICD10CM:A01.0 ICD9CM:002.0 MESH:D014435 NCI:C35089 SNOMEDCT_US_2020_03_01:186091002 UMLS_CUI:C0041466 Typhoid disease_ontology DOID:13258 typhoid fever DOID:13258 An inherited metabolic disorder that involves certain enzymes in the heme bio-synthetic pathway resulting in the overproduction and accumulation of the porphyrins. GARD:10353 ICD10CM:E80.20 ICD9CM:277.1 MESH:D011164 NCI:C97096 SNOMEDCT_US_2020_03_01:190912004 UMLS_CUI:C0032708 Hematoporphyria Porphyrinopathy disorder of porphyrin and hem metabolism disorder of porphyrin metabolism disease_ontology DOID:13268 porphyria DOID:13268 GARD:6619 ICD10CM:E80.29 MESH:D046349 NCI:C84759 OMIM:121300 SNOMEDCT_US_2020_03_01:7425008 UMLS_CUI:C0162531 Coproporphyrinogen oxidase deficiency Hereditary coproporphyria hereditary coproporphyria porphyria disease_ontology DOID:13269 OMIM mapping confirmed by DO. [SN]. hereditary coproporphyria DOID:13269 An acute porphyria characterized by a deficiency in the enzyme ferrochelatase, leading to abnormally high levels of protoporphyrin in the tissue. GARD:4527 ICD10CM:E80.0 MESH:D046351 NCI:C84698 OMIM:177000 OMIM:300752 ORDO:79278 SNOMEDCT_US_2020_03_01:51022005 UMLS_CUI:C0162568 EPP Erythropoietic protoporphyria Protoporphyria disease_ontology DOID:13270 Xref MGI. OMIM mapping confirmed by DO. [SN]. erythropoietic protoporphyria DOID:13270 GARD:4446 ICD10CM:E80.0 MESH:D017092 NCI:C84697 OMIM:263700 SNOMEDCT_US_2020_03_01:67312003 UMLS_CUI:C0162530 Erythropoietic porphyria disease_ontology DOID:13271 OMIM mapping confirmed by DO. [SN]. cutaneous porphyria DOID:13271 A viral infectious disease that results_in infection, has_material_basis_in Rift Valley fever virus, which is transmitted_by Aedes mosquitoes. The virus affects domestic animals (cattle, buffalo, sheep, goats, and camels) and humans. The infection has_symptom jaundice, has_symptom vomiting blood, has_symptom passing blood in the feces, has_symptom ecchymoses (caused by bleeding in the skin), has_symptom bleeding from the nose or gums, has_symptom menorrhagia and has_symptom bleeding from venepuncture sites. ICD10CM:A92.4 MESH:D012295 NCI:C128419 SNOMEDCT_US_2020_03_01:7077006 UMLS_CUI:C0035613 disease_ontology DOID:1328 Rift Valley fever DOID:1328 A gastrointestinal tuberculosis that involves diffuse mucosal fold thickening, formation of ulcers and fistulae located_in intestine. The infection has_symptom abdominal pain, has_symptom gastrointestinal bleeding, has_symptom nausea and has_symptom vomiting. ICD9CM:014.8 UMLS_CUI:C0152724 tuberculosis of intestine disease_ontology DOID:13282 intestinal tuberculosis DOID:13282 An osteochondrosis that results_in abnormal bone growth and curvature located_in thoracic vertebral column. GARD:7610 ICD10CM:M42.0 ICD9CM:732.0 MESH:D012544 NCI:C34999 OMIM:181440 SNOMEDCT_US_2020_03_01:53406005 UMLS_CUI:C0036310 Juvenile osteochondritis of the spine Juvenile osteochondrosis of Scheurermann Juvenile osteochondrosis of spine Scheuermann's kyphosis Sherman's Disease Scheuermann disease disease_ontology DOID:13300 OMIM mapping confirmed by DO. [SN]. Scheuermann's disease DOID:13300 ICD10CM:K86.81 MESH:D010188 NCI:C84316 SNOMEDCT_US_2020_03_01:47367009 UMLS_CUI:C0267963 Exocrine pancreatic insufficiency disease_ontology DOID:13316 exocrine pancreatic insufficiency DOID:13316 A carbohydrate metabolic disorder that involves low blood glucose resulting from an excess of insulin. DOID:9996 ICD10CM:E16.9 MESH:D046768 NCI:C4375 SNOMEDCT_US_2020_03_01:42681006 UMLS_CUI:C0027773 Islet cell hyperplasia nesidioblastosis persistent hyperinsulinemia hypoglycemia of infancy disease_ontology DOID:13317 OMIM mapping confirmed by DO. [SN]. hyperinsulinemic hypoglycemia DOID:13317 A cataract that is characterized by loss of lens transparency secondary to hyperglycemia related to diabetes mellitus. ICD9CM:366.41 SNOMEDCT_US_2020_03_01:43959009 UMLS_CUI:C0011876 Cataract - diabetic disease_ontology DOID:13328 diabetic cataract DOID:13328 A toxoplasmosis that involves a reactivated infection of the mother transmitted to the fetus during pregnancy. Spontaneous abortion and stillbirth may occur. GARD:10326 ICD10CM:P37.1 MESH:D014125 NCI:C50503 SNOMEDCT_US_2020_03_01:268875000 UMLS_CUI:C0040560 Congenital toxoplasmosis Toxoplasmosis - congen. disease_ontology DOID:13336 congenital toxoplasmosis DOID:13336 ICD10CM:F65.4 ICD9CM:302.2 MESH:D010378 NCI:C94355 SNOMEDCT_US_2020_03_01:192516001 UMLS_CUI:C0030764 Paedophilia disease_ontology DOID:13351 pedophilia DOID:13351 ICD10CM:M22.4 ICD9CM:717.7 MESH:D046789 OMIM:168900 SNOMEDCT_US_2020_03_01:156521009 UMLS_CUI:C0008475 Chondromalacia of patella Chondromalacia patellae softening of articular cartilage of patella disease_ontology DOID:13357 OMIM mapping confirmed by DO. [SN]. chondromalacia patellae DOID:13357 A collagen disease that is characterized by extremely flexible joints, elastic skin, and excessive bruising caused by a heritable defect in collagen synthesis, which leads to marked healing difficulties. EDS has five cardinal signs, which may be present to some degree in all of the subtypes. These five cardinal signs are skin fragility, blood vessel fragility, skin hyperelasticity, joint hypermobility, and characteristic subcutaneous nodules. DOID:14696 GARD:6322 ICD10CM:Q79.6 ICD9CM:756.83 MESH:D004535 NCI:C34568 OMIM:PS130000 SNOMEDCT_US_2020_03_01:268352002 UMLS_CUI:C0013720 Cutis hyperelastica elastic skin disease_ontology DOID:13359 OMIM mapping confirmed by DO. [LS]. OMIM mapping by NeuroDevNet. [LS]. Ehlers-Danlos syndrome DOID:13359 A learning disability involing difficulty reading resulting primarily from neurological factors which affect any part of the reading process. ICD9CM:315.09 UMLS_CUI:C0154631 disease_ontology DOID:13365 reading disorder DOID:13365 A movement disease that is of unknown etiology characterized by progressive rigidity. GARD:5023 ICD10CM:G25.82 ICD9CM:333.91 MESH:D016750 NCI:C85170 OMIM:184850 SNOMEDCT_US_2020_03_01:5217008 UMLS_CUI:C0085292 Stiff-man syndrome stiff man syndrome disease_ontology DOID:13366 Stiff-Person syndrome DOID:13366 A dermatophytosis that results_in fungal skin infection located_in hand, has_material_basis_in Ascomycota fungi that belong to a group called dermatophytes and has_symptom itching, has_symptom burning, has_symptom cracking, and has_symptom scaling. ICD10CM:B35.2 ICD9CM:110.2 SNOMEDCT_US_2020_03_01:48971001 UMLS_CUI:C0153246 Dermatophytosis of hand Tinea manus disease_ontology DOID:13369 tinea manuum DOID:13369 A typhus that has_material_basis_in Orientia tsutsugamushi, which is transmitted by trombiculid mites (Leptotrombidium deliense). The infection has symptom fever, has symptom headache, has symptom muscle pain, has symptom cough, has symptom maculopapular rash, has symptom eschar, has symptom splenomegaly and has symptom lymphadenopathy. ICD10CM:A75.3 ICD9CM:081.2 MESH:D012612 SNOMEDCT_US_2020_03_01:73911003 UMLS_CUI:C0036472 Japanese river fever Kedani fever Scrub mite-borne typhus Tsutsugamushi Tsutsugamushi disease disease_ontology Chigger-borne rickettsiosis Chigger-borne typhus Mite-borne rickettsiosis Mite-borne typhus Scrub (mite-borne) typhus Tropical typhus Tsutsugamushi fever Typhus fever due to Rickettsia tsutsugamushi DOID:13371 scrub typhus DOID:13371 A plasma protein metabolism disease that has_material_basis_in defective production of the protease inhibitor alpha 1-antitrypsin (A1AT), leading to decreased A1AT activity in the blood and lungs, and deposition of excessive abnormal A1AT protein in liver cells. GARD:5784 ICD10CM:E88.01 ICD9CM:273.4 MESH:D019896 NCI:C84397 OMIM:613490 SNOMEDCT_US_2020_03_01:30188007 UMLS_CUI:C0221757 AAT deficiency disease_ontology DOID:13372 OMIM mapping confirmed by DO. [SN]. alpha 1-antitrypsin deficiency MESH:D019896 DOID:13372 A connective tissue disease that is characterized by progressive ossification of skeletal muscle, fascia, tendons, and ligaments and has_material_basis_in heterozygous mutation in the ACVR1 gene. GARD:6445 ICD10CM:M61.1 ICD9CM:728.11 MESH:D009221 NCI:C3040 OMIM:135100 ORDO:337 SNOMEDCT_US_2020_03_01:82725007 UMLS_CUI:C0016037 Stone Man Syndrome myositis ossificans progressiva progressive myositis ossificans progressive ossifying myositis disease_ontology DOID:13374 OMIM mapping confirmed by DO. [SN]. fibrodysplasia ossificans progressiva DOID:13374 A lymphadenitis characterized by swelling of cervical lymph nodes in infants and young children and inflammation of medium-sized blood vessels located_in body, has_symptom fever, has_symptom congestion of ocular conjunctivae, has_symptom reddening of lips, has_symptom reddening of oral cavity, has_symptom protuberance of tongue papillae and has_symptom edema of extremities. EFO:0004246 GARD:6816 ICD10CM:M30.3 ICD9CM:446.1 MESH:D009080 NCI:C34825 OMIM:611775 SNOMEDCT_US_2020_03_01:75053002 UMLS_CUI:C0026691 Kawasaki's disease MLNS acute febrile MCLS acute febrile mucocutaneous lymph node syndrome mucocutaneous lymph node syndrome disease_ontology DOID:13378 OMIM mapping confirmed by DO. [SN]. Kawasaki disease DOID:13378 A congenital hemolytic anemia characterized by ineffective erythropoiesis, and resulting from a decrease in the number of red blood cells (RBCs) in the body and a less than normal quantity of hemoglobin in the blood. GARD:1999 ICD10CM:D64.4 MESH:D000742 NCI:C84646 OMIM:PS224120 ORDO:85 SNOMEDCT_US_2020_03_01:191272005 UMLS_CUI:C0002876 congenital dyshaematopoietic anaemia disease_ontology DOID:1338 Xref MGI. OMIM mapping confirmed by DO. [SN]. congenital dyserythropoietic anemia DOID:1338 A nutritional deficiency disease that is characterized by a decrease in red blood cells due to malabsorption of vitamin B12, has_symptom fatigue, pallor, shortness of breath, glossitis, ataxia, and/or paresthesia, has_material_basis_in atrophic gastritis, autoimmune disorder affecting the production or function of intrinsic factor, and/or genetic factors. GARD:12671 ICD10CM:D51.0 ICD9CM:281.0 MESH:D000752 NCI:C2871 OMIM:170900 SNOMEDCT_US_2020_03_01:191139001 UMLS_CUI:C0002892 ANEMIA PERNICIOUS Addison's anaemia Biermer's anaemia Biermer's anemia pernicious anaemia disease_ontology DOID:13381 OMIM mapping confirmed by DO. [SN]. pernicious anemia DOID:13381 A macrocytic anemia that is characterized by inhibition of DNA synthesis during red blood cell production. ICD10CM:D53.1 MESH:D000749 NCI:C34382 OMIM:261100 OMIM:613839 SNOMEDCT_US_2020_03_01:191138009 UMLS_CUI:C0002888 Grasbeck-Imerslund syndrome Imerslund-Grasbeck syndrome MGA1 Norwegian type RH-MGA1 megaloblastic anaemia recessive hereditary megaloblastic anaemia 1 recessive hereditary megaloblastic anemia 1 disease_ontology IGS DOID:13382 Xref MGI. megaloblastic anemia DOID:13382 A congenital hypoplastic anemia that is characterized by anemia (low red blood cell counts) with decreased erythroid progenitors in the bone marrow and has_material_basis_insufficient levels of red blood cells due to bone marrow dysfunction. GARD:6274 ICD10CM:D61.01 MESH:D029503 NCI:C61236 OMIM:PS105650 ORDO:124 SNOMEDCT_US_2020_03_01:188588001 Blackfan - Diamond syndrome chronic constitutional pure red cell anaemia disease_ontology DOID:1339 Xref MGI. OMIM mapping confirmed by DO. [SN]. Diamond-Blackfan anemia DOID:1339 A blindness that is characterized by the inability or decreased ability to see color, or perceive color differences, under normal lighting conditions. ICD10CM:H53.5 ICD9CM:368.5 MESH:D003117 NCI:C3891 SNOMEDCT_US_2020_03_01:193683001 UMLS_CUI:C0242225 BLINDNESS COLOR Colour blindness Colour vision deficiency disease_ontology DOID:13399 color blindness DOID:13399 GARD:7504 MESH:D012010 NCI:C34974 SNOMEDCT_US_2020_03_01:191252000 UMLS_CUI:C0034902 Pure Red cell Aplasia Pure red cell aplasia Red cell hypoplasia primary red cell aplasia disease_ontology DOID:1340 pure red-cell aplasia DOID:1340 MESH:D000793 OMIM:607140 UMLS_CUI:C0002982 disease_ontology DOID:13401 OMIM mapping confirmed by DO. [SN]. angioid streaks DOID:13401 ICD10CM:D86.3 NCI:C34996 SNOMEDCT_US_2020_03_01:55941000 UMLS_CUI:C0036203 Cutaneous Sarcoidosis Cutaneous sarcoid Cutaneous sarcoidosis disease_ontology DOID:13402 skin sarcoidosis DOID:13402 A sarcoidosis that is characterized by conduction abnormalities, arrhythmias, and congestive heart failure with noncaseating granulomas present on endomyocardial biopsy, and develops_from a type IV hypersensitivity reaction with noncaseating granulomas infiltrating the myocardial tissue, especially that of the left ventricle. NCI:C35589 SNOMEDCT_US_2020_03_01:75403004 UMLS_CUI:C0392077 Cardiac sarcoidosis disease_ontology DOID:13405 cardiac sarcoidosis DOID:13405 A brain disease that is characterized by loss of brain function, the occurrence of confusion, altered level of consciousness, and coma that results when the liver is unable to remove toxins from the blood. GARD:10452 ICD10CM:K72 ICD9CM:572.2 MESH:D006501 NCI:C79596 SNOMEDCT_US_2020_03_01:197332007 UMLS_CUI:C0019151 Portal-systemic encephalopathy disease_ontology DOID:13413 hepatic encephalopathy DOID:13413 DOID:13639 ICD10CM:D61.0 ICD10CM:D61.01 ICD9CM:284.0 MESH:D029502 SNOMEDCT_US_2020_03_01:191236003 SNOMEDCT_US_2020_03_01:267523003 UMLS_CUI:C0702159 UMLS_CUI:C0949116 congenital aplastic anaemia congenital aplastic anemia congenital hypoplastic anaemia disease_ontology Constitutional aplastic anaemia DOID:1342 congenital hypoplastic anemia DOID:1342 DOID:2863 ICD10CM:N34.2 ICD9CM:597.80 MESH:D014526 NCI:C26904 SNOMEDCT_US_2020_03_01:154388003 SNOMEDCT_US_2020_03_01:31822004 UMLS_CUI:C0041976 UMLS_CUI:C0311389 Non-Gonococcal Urethritis Nongonococcal urethritis disease_ontology DOID:1343 urethritis DOID:1343 A primary bacterial infectious disease that results in septicemic infection, has_material_basis_in Burkholderia mallei, which is transmitted by contact with tissues or body fluids of infected animals, or through mucosal surfaces such as the eyes and nose. The infection has symptom fever, has symptom chills, has symptom sweating, has symptom muscle aches, has symptom chest pain, has symptom muscle tightness, has symptom headache, has symptom mucopurulent nasal discharge, and has symptom nodular lesions in the lungs. GARD:9536 ICD10CM:A24.0 ICD9CM:024 MESH:D005896 NCI:C34638 SNOMEDCT_US_2020_03_01:4639008 UMLS_CUI:C0017589 Farcy pipes Infection due to Pseudomonas mallei disease_ontology DOID:13444 glanders DOID:13444 ICD10CM:I65.1 ICD9CM:433.0 SNOMEDCT_US_2020_03_01:78658006 UMLS_CUI:C0265098 disease_ontology DOID:13446 basilar artery occlusion DOID:13446 A primary systemic mycosis that results_in systemic fungal infection, has_material_basis_in Coccidioides immitis, transmitted_by airborne spores and has_symptom conjunctivitis, has_symptom arthritis, has_symptom chest pain and results_in_formation_of skin nodules. DOID:13981 GARD:9525 ICD10CM:B38 ICD9CM:114 MESH:D003047 NCI:C84642 SNOMEDCT_US_2020_03_01:266218008 UMLS_CUI:C0009186 primary extrapulmonary coccidioidomycosis disease_ontology DOID:13450 coccidioidomycosis DOID:13450 GARD:12911 ICD10CM:H15.0 ICD9CM:379.00 MESH:D015423 NCI:C119046 SNOMEDCT_US_2020_03_01:155201000 UMLS_CUI:C0036416 disease_ontology DOID:13452 scleritis DOID:13452 ICD10CM:N36.42 ICD9CM:599.82 SNOMEDCT_US_2020_03_01:16031000119101 UMLS_CUI:C0375381 Intrinsic (urethral) sphincter deficiency [ISD] disease_ontology DOID:13461 urethral intrinsic sphincter deficiency DOID:13461 A balantitis characterized by white plaques or patches on genitals. ICD9CM:607.81 NCI:C3523 SNOMEDCT_US_2020_03_01:198028006 UMLS_CUI:C0152460 Penile Lichen Sclerosus disease_ontology DOID:13477 balanitis xerotica obliterans MESH:D052798 DOID:13477 An osteochondrodysplasia that results_in short arms and legs with excess folds of skin. GARD:85 ICD10CM:Q77.1 MESH:D013796 NCI:C85187 OMIM:187600 OMIM:187601 OMIM:273680 ORDO:1860 ORDO:2655 ORDO:93274 ORDO:93275 SNOMEDCT_US_2020_03_01:29352008 UMLS_CUI:C0039743 disease_ontology DOID:13481 Xref MGI. OMIM mapping confirmed by DO. [LS]. thanatophoric dysplasia MESH:D013796 DOID:13481 A syndrome that is characterized by overgrowth of the bones, skin, and other tissues. GARD:7475 MESH:D016715 NCI:C85032 OMIM:176920 SNOMEDCT_US_2020_03_01:394527003 UMLS_CUI:C0085261 Wiedemann's syndrome disease_ontology DOID:13482 OMIM mapping confirmed by DO. [SN]. Proteus syndrome DOID:13482 A pervasive developmental disorder that is a rare condition characterized by late onset (greater than 3 years of age) of developmental delays in language, social function, and motor skills where children who have had previously normal development who then appear to regress. GARD:6040 ICD10CM:F84.3 ICD9CM:299.1 NCI:C97164 SNOMEDCT_US_2020_03_01:71961003 UMLS_CUI:C0236791 Disintegrative psychosis Heller's syndrome Symbiotic psychosis disease_ontology DOID:13487 childhood disintegrative disease DOID:13487 ICD10CM:N34.3 ICD9CM:597.81 SNOMEDCT_US_2020_03_01:31273004 UMLS_CUI:C0156279 disease_ontology DOID:13498 urethral syndrome DOID:13498 MESH:D010255 NCI:C7488 SNOMEDCT_US_2020_03_01:126675008 UMLS_CUI:C0030470 neoplasm of accessory sinus tumor of Accessory sinus disease_ontology DOID:1350 paranasal sinus benign neoplasm DOID:1350 A facial nerve disease characterized by congenital, uni- or bilateral, non-progressive facial weakness and limited abduction of the eye(s). GARD:8549 ICD10CM:Q87.0 MESH:D020331 NCI:C84893 OMIM:157900 SNOMEDCT_US_2020_03_01:89444000 UMLS_CUI:C0221060 Moebius congenital oculofacial paralysis Oromandibular-limb hypogenesis spectrum disease_ontology DOID:13501 OMIM mapping confirmed by DO. [SN]. Mobius syndrome DOID:13501 ICD10CM:N30.3 ICD9CM:595.3 NCI:C123175 SNOMEDCT_US_2020_03_01:155885003 UMLS_CUI:C1261278 disease_ontology DOID:13507 trigonitis DOID:13507 A syndrome that is characterized by the growth of numerous noncancerous tumors in many parts of the body. GARD:7830 ICD10CM:Q85.1 ICD9CM:759.5 MESH:D014402 NCI:C3424 OMIM:PS191100 SNOMEDCT_US_2020_03_01:157033002 UMLS_CUI:C0041341 Bourneville's disease Epiloia Tuberose sclerosis Tuberous sclerosis syndrome cerebral sclerosis disease_ontology DOID:13515 OMIM mapping confirmed by DO. [LS]. tuberous sclerosis DOID:13515 MESH:D010254 NCI:C26843 SNOMEDCT_US_2020_03_01:7393007 UMLS_CUI:C0030469 disorder of nasal sinus disease_ontology DOID:1352 paranasal sinus disease DOID:1352 A tetanus that occurs in newborn babies when the birth cord stump gets dirty through cutting it with an unclean blade or applying substances containing bacteria to it. The infection has symptom stiff body, has symptom muscle spasms, has symptom difficulty in breathing, and has symptom exhaustion. ICD10CM:A33 ICD9CM:771.3 NCI:C116814 SNOMEDCT_US_2020_03_01:43424001 UMLS_CUI:C0343312 Tetanus neonatorum neonatal tetanus disease_ontology DOID:13521 tetanus neonatorum DOID:13521 A filariasis that involves parasitic infection of the skin and eyes caused by the nematode Loa loa, which is transmitted through the bite of a deer fly or mango fly. The disease is characterized by episodic angioedema in the arms and legs, and cyst-like enlargements of the connective tissue around the sheaths of muscle tendons. Dead worms may cause chronic abscesses, which may lead to the formation of granulomatous reactions and fibrosis. GARD:3283 ICD10CM:B74.3 ICD9CM:125.2 MESH:D008118 NCI:C34784 SNOMEDCT_US_2020_03_01:44250009 UMLS_CUI:C0023968 disease_ontology DOID:13523 loiasis DOID:13523 An osteosclerosis that has_material_basis_in lack of bone resorption which results_in abnormally hard and brittle bones. GARD:4155 ICD10CM:Q78.2 ICD9CM:756.52 MESH:D010022 NCI:C26840 OMIM:PS259700 OMIM:PS607634 ORDO:667 SNOMEDCT_US_2020_03_01:205500005 UMLS_CUI:C0029454 Albers-Schonberg disease marble bone disease_ontology DOID:13533 Xref MGI. OMIM mapping submitted by NeuroDevNet. [LS]. osteopetrosis DOID:13533 A parathyroid gland disease characterized by an overactivity of the parathyroid glands, leading to an excess of parathyroid hormone in the body. ICD10CM:E21.3 ICD9CM:252.0 MESH:D006961 NCI:C48259 OMIM:145000 OMIM:145001 OMIM:610071 ORDO:99879 SNOMEDCT_US_2020_03_01:190451000 UMLS_CUI:C0020502 disease_ontology DOID:13543 Xref MGI. hyperparathyroidism DOID:13543 An open-angle glaucoma characterized by increased intrinsic resistance to aqueous outflow without known secondary causes, an anatomically narrow anterior chamber angle, or elevated intraocular pressure compared to the average population. Normal tension glaucoma has_symptom progressive decreased vision and progressive loss of peripheral vision. ICD10CM:H40.12 ICD9CM:365.12 MESH:D057066 SNOMEDCT_US_2020_03_01:155124000 UMLS_CUI:C0152136 Normal tension glaucoma disease_ontology DOID:13544 low tension glaucoma DOID:13544 A primary angle-closure glaucoma characterized by acute closure of the anterior chamber angle by an intrinsic defect such that aqueous outflow is blocked and the intraocular pressure becomes suddenly inappropriately elevated threatening optic nerve damage and visual field loss; but that typically resolves spontaneously after several hours, even though it may recur. Interval angle-closure glaucoma has_symptom sudden pain, redness, headache, and blurry vision with haloes around lights that resolves spontaneously. Interval angle-closure glaucoma can be caused by exacerbation of chronic primary angle-closure glaucoma, typically by a medication or state that dilates the eyes and thus narrows the anterior chamber angle, blocking any aqueous outflow. ICD10CM:H40.23 ICD9CM:365.21 SNOMEDCT_US_2020_03_01:65460003 UMLS_CUI:C0154945 Angle-closure glaucoma, subacute Intermittent angle-closure glaucoma Prodromal angle closure glaucoma disease_ontology DOID:13549 interval angle-closure glaucoma DOID:13549 A glaucoma characterized by closure of the anterior chamber angle such that aqueous outflow is blocked and the intraocular pressure becomes inappropriately elevated leading to optic nerve damage and visual field loss. Angle-closure glaucoma has_symptom progressive peripheral vision loss, decreased vision, and pain, redness, and headache in acute cases. Angle closure glaucoma can be caused by anatomically narrow angle, injury to the trabecular meshwork, and injuries to the anterior chamber, such as neovascularization and uveitis. MESH:D015812 NCI:C34639 SNOMEDCT_US_2020_03_01:270882001 UMLS_CUI:C0017605 ACG - Angle-closure glaucoma Angle Closure Glaucoma Angle-closure glaucoma Closed angle glaucoma Narrow cleft glaucoma primary open-angle glaucoma with narrow angles disease_ontology DOID:13550 angle-closure glaucoma DOID:13550 ICD10CM:H47.32 ICD9CM:377.21 MESH:D015594 SNOMEDCT_US_2020_03_01:33629003 UMLS_CUI:C0029128 Drusen of optic disc optic nerve head drusen disease_ontology DOID:13561 optic disk drusen DOID:13561 An opportunistic mycosis that involves a spectrum of diseases of humans and animals caused by members of the genus Aspergillus infecting lungs, brain, kidney, heart, bone, eyes, sinuses, skin and gastrointestinal tract. It is a serious illnesses in people with a weakened immune system. GARD:5856 ICD10CM:B44 ICD9CM:117.3 MESH:D001228 NCI:C2886 SNOMEDCT_US_2020_03_01:266218008 UMLS_CUI:C0004030 Infection due to Aspergillus disease_ontology DOID:13564 aspergillosis MESH:D001228 DOID:13564 ICD10CM:O43.02 MESH:D005330 NCI:C113824 SNOMEDCT_US_2020_03_01:13404009 UMLS_CUI:C2909036 Fetal blood loss from fetal hemorrhage into co-twin Fetal hemorrhage into co-twin Twin to twin transfusion Twin-to-twin blood transfer disease_ontology DOID:13576 twin-to-twin transfusion syndrome DOID:13576 A bile duct disease that is characterized by where bile cannot flow from the liver to the duodenum. ICD10CM:K83.1 ICD9CM:576.2 MESH:D002779 NCI:C83006 SNOMEDCT_US_2020_03_01:33688009 UMLS_CUI:C0008370 Obstruction of bile duct bile occlusion disease_ontology DOID:13580 cholestasis DOID:13580 A pre-eclampsia characterized by the presence of seizures. DOID:13592 GARD:6316 ICD10CM:O15 MESH:D004461 NCI:C87167 SNOMEDCT_US_2020_03_01:156111007 UMLS_CUI:C0013537 Eclampsia in puerperium Eclampsia, postpartum Postpartum eclampsia disease_ontology DOID:13593 eclampsia DOID:13593 A cholestasis characterized by blockage of the ducts that carry bile from the liver to the gallbladder. GARD:12010 ICD10CM:Q44.2 ICD9CM:751.61 MESH:D001656 NCI:C34421 OMIM:210500 ORDO:30391 SNOMEDCT_US_2020_03_01:77480004 UMLS_CUI:C0005411 Atresia of bile duct Congenital biliary atresia biliary atresia, congenital disease_ontology DOID:13608 biliary atresia DOID:13608 NCI:C4419 SNOMEDCT_US_2020_03_01:126678005 UMLS_CUI:C0345672 neoplasm of frontal sinus tumor of the Frontal sinus disease_ontology DOID:1361 frontal sinus benign neoplasm DOID:1361 ICD10CM:Q21.1 MESH:D054092 NCI:C34619 SNOMEDCT_US_2020_03_01:268316001 UMLS_CUI:C0016522 Atrial septal defect within oval fossa Defect, Patent or persistent, ostium secundum Ostium secundum type atrial septal defect Persistent ostium secundum foramen ovale patent disease_ontology DOID:13620 patent foramen ovale DOID:13620 A primary bacterial infectious disease that results_in infection located_in intestine, has_material_basis_in Campylobacter jejuni, which is transmitted_by ingestion of contaminated food or water or transmitted_by contact with infected people or animals. The infection has_symptom diarrhea or has_symptom dysentery, has_symptom abdominal cramps and pain, and has_symptom fever. DOID:13621 MESH:D002169 SNOMEDCT_US_2020_03_01:86500004 UMLS_CUI:C0006818 Campylobacteriosis disease_ontology DOID:13622 campylobacteriosis DOID:13622 ICD10CM:H16.13 ICD9CM:370.24 NCI:C118750 SNOMEDCT_US_2020_03_01:1714005 UMLS_CUI:C0155078 disease_ontology DOID:13626 photokeratitis DOID:13626 A glucosephosphate dehydrogenase deficiency characterized by a hemolytic reaction to consumption of broad beans. ICD10CM:D55.0 MESH:D005236 NCI:C34607 SNOMEDCT_US_2020_03_01:154801000 UMLS_CUI:C0015702 disease_ontology DOID:13628 favism DOID:13628 ICD9CM:521.32 UMLS_CUI:C1456162 disease_ontology DOID:13629 dentine erosion DOID:13629 A congenital hypoplastic anemia characterized by progressive pancytopenia with bone marrow failure, variable congenital malformations and predisposition to develop hematological or solid tumors. It is a result of a genetic defect in a cluster of proteins responsible for DNA repair. GARD:6425 ICD10CM:D61.09 MESH:D005199 NCI:C62505 OMIM:PS227650 ORDO:84 SNOMEDCT_US_2020_03_01:30575002 UMLS_CUI:C0015625 Fanconi anaemia Fanconi pancytopenia Fanconi panmyelopathy Fanconi's anaemia Fanconi's anemia disease_ontology DOID:13636 Xref MGI. OMIM mapping confirmed by DO. [SN]. OMIM mapping by NeuroDevNet. [LS]. Fanconi anemia DOID:13636 A phacogenic glaucoma that is characterized by open-angle glaucoma related to deposition of extracellular fibrillar material in anterior segment structures, which blocks aqueous fluid outflow, raises intraocular pressure, and leads to eventual optic nerve atrophy and visual field loss. Exfoliation syndrome has_symptom progressive decreased vision, especially peripheral vision. Exfoliation syndrome is caused by age-related deposition of fibrillar material in anterior segment structures. EFO:0004235 ICD9CM:365.52 MESH:D017889 NCI:C129025 OMIM:177650 SNOMEDCT_US_2020_03_01:111514006 UMLS_CUI:C0206368 Pseudoexfoliation glaucoma Pseudoexfoliation syndrome disease_ontology DOID:13641 OMIM mapping confirmed by DO. [SN]. exfoliation syndrome MESH:D017889 DOID:13641 GARD:7606 MESH:D020083 NCI:C119049 SNOMEDCT_US_2020_03_01:60684003 UMLS_CUI:C0263859 Synovitis, acne, pustulosis palmaris, hyperostosis, osteomyelitis syndrome disease_ontology DOID:13677 SAPHO syndrome DOID:13677 ICD10CM:F52.4 ICD9CM:302.75 MESH:D061686 NCI:C94349 SNOMEDCT_US_2020_03_01:123302009 UMLS_CUI:C0033038 disease_ontology DOID:13709 premature ejaculation DOID:13709 ICD10CM:K00.3 ICD9CM:520.3 MESH:D009050 NCI:C85059 SNOMEDCT_US_2020_03_01:30265004 UMLS_CUI:C0026618 Intrinsic enamel discolouration of fluorosis Mottled teeth Mottling of enamel disease_ontology DOID:13711 dental fluorosis DOID:13711 A senile cataract that is characterized by full white or brunescent opacification of the lens of the eye such that the red reflex is obscured. It is a later stage of senile cataracts and is caused by a multifactorial etiology related to aging. SNOMEDCT_US_2020_03_01:193590000 UMLS_CUI:C0152257 Total or mature cataract Total, mature senile cataract disease_ontology DOID:13717 mature cataract DOID:13717 A schistosomiasis that involves parasitic infection of the brain and spinal cord by Schistosoma haematobium, Schistosoma mansoni or Schistosoma japonicum causing acute or subacute myelopathy, focal central nervous system impairment, seizures and increased intracranial pressure. MESH:D020818 UMLS_CUI:C0752191 disease_ontology DOID:13722 neuroschistosomiasis DOID:13722 A nutritional deficiency disease that is characterized by vitamin C (ascorbic acid) deficiency and has_symptom fatigue, weakness, anemia, petechiae, corkscrew hair, gingivitis, and poor wound healing. GARD:10406 ICD10CM:E54 MESH:D012614 NCI:C35010 OMIM:240400 SNOMEDCT_US_2020_03_01:267493006 UMLS_CUI:C0036474 disease_ontology DOID:13724 OMIM mapping confirmed by DO. [SN]. scurvy DOID:13724 A thiamine deficiency disease that is characterized by being severe and chronic. GARD:9948 ICD10CM:E51.1 ICD9CM:265.0 MESH:D001602 NCI:C34418 SNOMEDCT_US_2020_03_01:267491008 UMLS_CUI:C0005122 disease_ontology DOID:13725 beriberi MESH:D001602 DOID:13725 An uterine benign neoplasm that has_material_basis_in cells reminiscent of proliferative phase endometrial stroma. NCI:C4262 SNOMEDCT_US_2020_03_01:189810002 UMLS_CUI:C0334485 disease_ontology DOID:1373 endometrial stromal nodule DOID:1373 ICD9CM:360.02 MESH:D010202 SNOMEDCT_US_2020_03_01:33382000 UMLS_CUI:C0030332 disease_ontology DOID:13732 panophthalmitis DOID:13732 ICD10CM:H04.2 ICD9CM:375.2 MESH:D007766 NCI:C50552 SNOMEDCT_US_2020_03_01:49393005 UMLS_CUI:C0152227 Epiphora Excessive tear production Watering eye disease_ontology DOID:13757 excessive tearing DOID:13757 A lice infestation that involves parasitic infestation by pubic lice Pthirus pubis, which are found in the pubic hair, less commonly in eyebrows, eyelashes, beard, mustache, armpit, perianal area, groin, trunk and scalp. The symptoms include itching in the pubic and groin area. Intense itching leads to scratching which can cause sores and secondary bacterial infection of the skin. ICD10CM:B85.3 ICD9CM:132.2 NCI:C35777 SNOMEDCT_US_2020_03_01:71011005 UMLS_CUI:C0030759 Infestation by Phthirus pubis Pediculosis Pubis Pediculus pubis Phthiriasis pubis Phthirus pubis Phthirus/pediculus pubis - pubic lice - crabs crabs disease_ontology DOID:13760 Pthirus pubis infestation DOID:13760 A parasitic helminthiasis infectious disease that involves parasitic infection of the bile ducts of the liver by Clonorchis sinensis. The symptoms include abdominal pain, nausea, diarrhea, and eosinophilia. In long-standing infections, cholangitis, cholelithiasis, pancreatitis, and cholangiocarcinoma can develop. ICD10CM:B66.1 ICD9CM:121.1 MESH:D003003 SNOMEDCT_US_2020_03_01:11938002 UMLS_CUI:C0009021 Oriental liver fluke disease disease_ontology DOID:13767 clonorchiasis DOID:13767 A parasitic helminthiasis infectious disease that involves parasitic infection of the liver, pancreas and gall bladder by Opisthorchis viverrini or Opisthorchis felineus. The symptoms include dyspepsia, abdominal pain, diarrhea, constipation, hepatomegaly, cholangitis, cholecystitis, and chlolangiocarcinoma. GARD:9746 ICD10CM:B66.0 ICD9CM:121.0 MESH:D009889 SNOMEDCT_US_2020_03_01:187124006 UMLS_CUI:C0029106 Infection by Opisthorchis disease_ontology DOID:13768 opisthorchiasis DOID:13768 An adrenal cortical hypofunction that is characterized by insufficient steroid hormone production by the adrenal glands. GARD:5740 ICD10CM:E27.1 MESH:D000224 NCI:C26689 OMIM:103230 OMIM:240200 SNOMEDCT_US_2020_03_01:363732003 UMLS_CUI:C0001403 Addison disease Addison disease, chronic adrenal insufficiency HYPOADRENOCORTICISM, FAMILIAL primary adrenocortical insufficiency primary hypoadrenalism disease_ontology DOID:13774 Addison's disease DOID:13774 A primary immunodeficiency disease that results_in skin squamous cell carcinoma located_in skin, associated with a high risk of carcinoma. It is characterized by abnormal susceptibility to human papillomaviruses of the skin and has_symptom lesions on the body. GARD:6357 MESH:D004819 NCI:C126877 OMIM:PS226400 ORDO:302 SNOMEDCT_US_2020_03_01:19138001 UMLS_CUI:C0014522 disease_ontology DOID:13777 OMIM mapping confirmed by DO. [SN]. epidermodysplasia verruciformis MESH:D004819 DOID:13777 A primary bacterial infectious disease that is a sexually transmitted infection located in skin of the genitals, has_material_basis_in Haemophilus ducreyi, which is transmitted by sexual contact. The infection has symptom painful and soft ulcers. GARD:9522 ICD10CM:A57 ICD9CM:099.0 MESH:D002602 SNOMEDCT_US_2020_03_01:154391003 UMLS_CUI:C0007947 Ulcus molle, skin disease_ontology DOID:13778 chancroid DOID:13778 ICD10CM:M35.7 ICD9CM:728.5 SNOMEDCT_US_2020_03_01:85551004 UMLS_CUI:C0152093 benign joint hypermobility disease_ontology DOID:13781 hypermobility syndrome DOID:13781 ICD10CM:H73.0 ICD9CM:384.00 SNOMEDCT_US_2020_03_01:297009 UMLS_CUI:C0155460 acute myringitis disease_ontology DOID:13790 acute tympanitis DOID:13790 A uterine cancer that is located_in tissues lining the uterus. DOID:5654 EFO:0004230 GARD:11981 ICD10CM:C54.1 KEGG:05213 MESH:D016889 NCI:C27815 NCI:C3012 OMIM:608089 SNOMEDCT_US_2020_03_01:123844007 UMLS_CUI:C0007103 UMLS_CUI:C0014170 endometrial Ca endometrial neoplasm malignant endometrial neoplasm malignant neoplasm of endometrium neoplasm of endometrium primary malignant neoplasm of endometrium tumor of Endometrium disease_ontology DOID:1380 endometrial cancer DOID:1380 A commensal bacterial infectious disease that results_in inflammation, located_in conjunctiva of the eye, has_material_basis_in Chlamydia trachomatis, which is transmitted_by sexual contact. The infection has_symptom swollen conjunctiva and eyelids and has_symptom discharge of pus and mucus. GARD:6777 ICD10CM:A74.0 ICD9CM:077.0 MESH:D003235 SNOMEDCT_US_2020_03_01:111840005 UMLS_CUI:C0009770 Chlamydial conjunctivitis Inclusion blennorrhoea adult inclusion conjunctivitis inclusion blenorrhea disease_ontology Paratrachoma DOID:13800 inclusion conjunctivitis DOID:13800 ICD10CM:E78.49 MESH:D006950 NCI:C35637 OMIM:144250 SNOMEDCT_US_2020_03_01:48190005 UMLS_CUI:C0020474 familial multiple lipoprotein-type hyperlipidemia hyperbetalipoproteinemia with prebetalipoproteinemia mixed hyperlipidaemia type IIb hyperlipoproteinemia disease_ontology DOID:13809 OMIM mapping confirmed by DO. [SN]. familial combined hyperlipidemia DOID:13809 A sweat gland disease that is characterized by dilatation of the follicular infundibulum with hyperkeratosis, acanthosis, and spongiosis with perifollicular inflammation leading to hair loss and has_symptom flesh colored papules with hair loss and pruritis, especially of the axilla. GARD:6462 ICD10CM:L75.2 ICD9CM:705.82 MESH:D005588 NCI:C84716 SNOMEDCT_US_2020_03_01:254682006 UMLS_CUI:C0016632 Fox Fordyce disease disease_ontology DOID:1381 Fox-Fordyce disease DOID:1381 A commensal bacterial infectious disease that results_in infection located_in lymph nodes, has_material_basis_in Chlamydia trachomatis, which is transmitted_by sexual contact, and transmitted_by fomites. The infection has_symptom inguinal lymphadenitis, has_symptom abscesses in the groin area, and has_symptom lymphangitis. GARD:9545 ICD10CM:A55 ICD9CM:099.1 MESH:D008219 NCI:C26822 SNOMEDCT_US_2020_03_01:266213004 UMLS_CUI:C0024286 Climatic or tropical bubo Durand-Nicolas-Favre disease Lymphogranuloma inguinale Poradenitis inguinale Strumous bubo disease_ontology DOID:13819 lymphogranuloma venereum DOID:13819 A sweat gland disease that is characterized by blocked eccrine sweat glands and ducts. ICD10CM:L74.3 MESH:D008883 NCI:C34820 SNOMEDCT_US_2020_03_01:63951004 UMLS_CUI:C0026113 eccrine miliaria heat rash sweat rash disease_ontology DOID:1382 miliaria DOID:1382 A skin disease located_in the sweat glands. ICD10CM:L74.9 ICD9CM:705.9 MESH:D013543 SNOMEDCT_US_2020_03_01:88232005 UMLS_CUI:C0038986 disease_ontology DOID:1383 sweat gland disease DOID:1383 GARD:7342 ICD10CM:Q25.0 ICD9CM:747.0 MESH:D004374 NCI:C84492 OMIM:607411 SNOMEDCT_US_2020_03_01:156928009 UMLS_CUI:C0013274 Patent ductus Botalli disease_ontology ductus arteriosus, Patent DOID:13832 OMIM mapping confirmed by DO. [SN]. patent ductus arteriosus DOID:13832 A hypolipoproteinemia that is characterized by an inablility to fully absorb dietary fats, cholesterol and fat-soluble vitamins, has_material_basis_in an autosomal recessive disorder of lipid metabolism that has_material_basis_in mutation in the microsomal triglyceride transfer protein that catalyzes the transport of lipids and is required in the secretion of BETA-LIPOPROTEINS. GARD:5 ICD10CM:E78.6 MESH:D000012 NCI:C84525 OMIM:200100 SNOMEDCT_US_2020_03_01:83123000 UMLS_CUI:C0000744 familial hypobetalipoproteinemia microsomal triglyceride transfer protein deficiency disease disease_ontology DOID:1386 OMIM mapping confirmed by DO. [SN]. abetalipoproteinemia MESH:D000012 DOID:1386 A primary angle-closure glaucoma characterized by acute closure of the anterior chamber angle by an intrinsic defect such that aqueous outflow is blocked and the intraocular pressure becomes suddenly inappropriately elevated threatening futher optic nerve damage and visual field loss. Acute closed-angle glaucoma has_symptom sudden pain, redness, headache, and blurry vision with haloes around lights. Acute closed-angle glaucoma can be caused by exacerbation of chronic primary angle-closure glaucoma, typically by a medication or state that dilates the eyes and thus narrows the anterior chamber angle, blocking any aqueous outflow. ICD10CM:H40.21 ICD9CM:365.22 SNOMEDCT_US_2020_03_01:30041005 UMLS_CUI:C0154946 acute angle-closure glaucoma disease_ontology DOID:13862 acute closed-angle glaucoma DOID:13862 ICD10CM:G52.7 ICD9CM:352.6 SNOMEDCT_US_2020_03_01:78152008 UMLS_CUI:C0154733 Multiple cranial nerve palsies Multiple cranial nerve palsy disease_ontology DOID:13866 multiple cranial nerve palsy DOID:13866 ICD10CM:F52.0 ICD9CM:302.71 MESH:D020018 NCI:C94337 SNOMEDCT_US_2020_03_01:78889008 UMLS_CUI:C0020594 Lack or loss of sexual desire disease_ontology DOID:13868 hypoactive sexual desire disorder DOID:13868 GARD:8394 ICD10CM:E78.6 ICD9CM:272.5 MESH:D007009 SNOMEDCT_US_2020_03_01:363140000 UMLS_CUI:C0020623 Hypolipoproteinaemia disease_ontology Lipoprotein deficiencies DOID:1387 hypolipoproteinemia DOID:1387 GARD:7731 ICD10CM:E78.6 MESH:D013631 NCI:C85182 OMIM:205400 SNOMEDCT_US_2020_03_01:190783007 UMLS_CUI:C0039292 familial alpha-lipoprotein deficiency familial high density lipoprotein deficiency familial hypoalphalipoproteinemia disease_ontology DOID:1388 OMIM mapping confirmed by DO. [LS]. Tangier disease MESH:D013631 DOID:1388 ICD10CM:I49.5 MESH:D012804 NCI:C62244 OMIM:163800 OMIM:608567 ORDO:166282 SNOMEDCT_US_2020_03_01:266307005 UMLS_CUI:C0037052 sinus node infection disease_ontology DOID:13884 Xref MGI. sick sinus syndrome MESH:D012804 DOID:13884 A peripheral system disease that is characterized by damage affecting peripheral nerves (peripheral neuropathy) in roughly the same areas on both sides of the body, featuring weakness, numbness, pins-and-needles, and burning pain. ICD10CM:A69.22 MESH:D011115 NCI:C26951 SNOMEDCT_US_2020_03_01:193166009 UMLS_CUI:C0152025 disease_ontology DOID:1389 polyneuropathy DOID:1389 MESH:D010212 NCI:C3712 SNOMEDCT_US_2020_03_01:63451008 UMLS_CUI:C0205874 Epidermoid papilloma disease_ontology DOID:139 squamous cell papilloma DOID:139 A hypolipoproteinemia characterized by permanently low levels of apolipoprotein B and LDL cholesterol resulting from an impaired ability to absorb and transport fats. MESH:D006995 SNOMEDCT_US_2020_03_01:190786004 UMLS_CUI:C0020597 Hypo-beta-lipoproteinemia disease_ontology DOID:1390 hypobetalipoproteinemia DOID:1390 ICD10CM:E78.6 MESH:D007863 NCI:C84813 OMIM:245900 SNOMEDCT_US_2020_03_01:238091006 UMLS_CUI:C0023195 LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY lecithin acyltransferase deficiency disease_ontology DOID:1391 OMIM mapping confirmed by DO. [SN]. Norum disease DOID:1391 ICD9CM:368.51 MESH:D003117 OMIM:303900 SNOMEDCT_US_2020_03_01:51445007 UMLS_CUI:C0155015 Protan defect Protanopia disease_ontology DOID:13910 red color blindness DOID:13910 A color blindness that is characterized by a congenital cone color vision disorder, the inability to perceive color and to achieve satisfactory visual acuity at high light levels has_material_basis_in autosomal recessive inheritance. ICD10CM:H53.51 ICD9CM:368.54 MESH:D003117 NCI:C84528 ORDO:49382 SNOMEDCT_US_2020_03_01:56852002 UMLS_CUI:C0152200 ACHM Monochromatism disease_ontology DOID:13911 achromatopsia DOID:13911 ICD10CM:H52.21 ICD9CM:367.22 SNOMEDCT_US_2020_03_01:47099006 UMLS_CUI:C0152194 disease_ontology DOID:13919 irregular astigmatism DOID:13919 ICD9CM:377.24 MESH:C562401 OMIM:177800 SNOMEDCT_US_2020_03_01:57138009 UMLS_CUI:C0155300 disease_ontology DOID:1392 OMIM mapping confirmed by DO. [SN]. pseudopapilledema DOID:1392 An esophagitis characterized by inflammation involving eosinophils located_in esophagus. EFO:0004232 ICD10CM:K20.0 ICD9CM:530.13 MESH:D057765 NCI:C27105 OMIM:610247 OMIM:613412 ORDO:73247 SNOMEDCT_US_2020_03_01:235599003 UMLS_CUI:C0341106 disease_ontology DOID:13922 Xref MGI. OMIM mapping confirmed by DO. [SN]. eosinophilic esophagitis DOID:13922 MESH:D007767 NCI:C34757 SNOMEDCT_US_2020_03_01:95769009 UMLS_CUI:C0022906 Blocked lacrimal canaliculus Obstruction of lacrimal canaliculus Obstruction of lacrimal ducts disease_ontology DOID:13929 lacrimal duct obstruction DOID:13929 An eye disease that affects the neural pathway from the optic nerve to the visual cortex, through which light is interpreted as an image. ICD10CM:H47.9 NCI:C35342 SNOMEDCT_US_2020_03_01:54767005 UMLS_CUI:C0155287 disease_ontology DOID:1393 visual pathway disease DOID:1393 ICD10CM:G51.0 MESH:D005158 NCI:C26769 SNOMEDCT_US_2020_03_01:90039006 UMLS_CUI:C0015469 Facial Palsy disease_ontology DOID:13934 facial paralysis DOID:13934 A female reproductive system disease that is characterized by the absence of menstruation. ICD10CM:N91.2 ICD9CM:626.0 MESH:D000568 NCI:C61443 SNOMEDCT_US_2020_03_01:156034000 UMLS_CUI:C0002453 absence of menstruation amenia disease_ontology DOID:13938 amenorrhea MESH:D000568 DOID:13938 A schistosomiasis that involves parasitic infection of the urinary tract caused by a digenetic trematode Schistosoma haematobium causing cystitis, ureteritis, fibrosis of the bladder and haematuria, which can progress to bladder cancer. ICD9CM:120.0 MESH:D012553 NCI:C39294 SNOMEDCT_US_2020_03_01:60979006 UMLS_CUI:C0276926 Schistosoma Hematobium Infection Schistosoma haematobium Schistosoma hematobium infectious disease Schistosomiasis due to schistosoma haematobium Schistosomiasis of bladder Vesical schistosomiasis bladder Schistosomiasis cystitis with bilharziasis disease_ontology Schistosoma haematobium infection DOID:1394 urinary schistosomiasis DOID:1394 ICD9CM:386.11 MESH:D065635 OMIM:193007 OMIM:613106 SNOMEDCT_US_2020_03_01:111541001 UMLS_CUI:C0155502 benign paroxysmal positional vertigo disease_ontology DOID:13941 Xref MGI. OMIM mapping confirmed by DO. [SN]. benign paroxysmal positional nystagmus DOID:13941 A leukodystrophy characterized by recurrent subcortical ischemic stroke and cognitive impairment. GARD:1049 ICD10CM:I67.850 MESH:D046589 NCI:C84606 OMIM:600142 OMIM:PS125310 ORDO:136 SNOMEDCT_US_2020_03_01:390723008 UMLS_CUI:C0751587 cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy hereditary multi-infarct dementia disease_ontology DOID:13945 CADASIL DOID:13945 ICD10CM:N32.0 ICD9CM:596.0 MESH:D001748 NCI:C79541 SNOMEDCT_US_2020_03_01:197859007 UMLS_CUI:C0005694 Obstruction of bladder neck or vesicourethral orifice disease_ontology DOID:13948 bladder neck obstruction DOID:13948 GARD:6787 MESH:D018856 NCI:C27189 SNOMEDCT_US_2020_03_01:197834003 UMLS_CUI:C0282488 ulcerative cystitis disease_ontology DOID:13949 interstitial cystitis DOID:13949 A parasitic helminthiasis infectious disease that involves infection of the intestine, urinary tract, skin, liver and spleen caused by multiple species of the trematode fluke of the genus Schistosoma. The symptoms include fever, chills, nausea, abdominal pain, diarrhea, malaise, myalgia, liver and spleen enlargement, rash and hematuria. GARD:9687 ICD9CM:120.8 SNOMEDCT_US_2020_03_01:187116001 UMLS_CUI:C0029827 disease_ontology DOID:1395 schistosomiasis DOID:1395 A senile cataract that is characterized by dense white opacification of the lens and milky fluid in the lens capsule such that the dense nucleus of the lens sinks in the surrounding fluid. It is the late stage of senile cataracts and is caused by a multifactorial etiology related to aging. ICD9CM:366.18 SNOMEDCT_US_2020_03_01:247065006 UMLS_CUI:C0152258 hypermature cataract disease_ontology DOID:13964 Morgagni cataract DOID:13964 A disease by infectious agent that is carried out by a parasite which by definition is a pathogen that simultaneously injures and derives sustenance from its host. DOID:11681 DOID:13509 DOID:1396 DOID:1494 DOID:2114 DOID:2293 DOID:2922 DOID:3564 DOID:4191 DOID:886 DOID:948 DOID:9639 DOID:9644 ICD10CM:H44.12 ICD9CM:360.13 NCI:C34587 SNOMEDCT_US_2020_03_01:57100005 UMLS_CUI:C0014238 Ectoparasitic disease parasitemia disease_ontology DOID:1398 parasitic infectious disease DOID:1398 An osteochondrodysplasia that has_material_basis_in mutations in the RUNX2 gene which results_in undeveloped or absent located_in clavicle along with delayed closing of fontanels in the located_in skull. GARD:6118 ICD10CM:Q74.0 MESH:D002973 NCI:C75020 OMIM:119600 OMIM:216330 ORDO:1452 SNOMEDCT_US_2020_03_01:65976001 UMLS_CUI:C0008928 Marie-Sainton Disease cleidocranial dysostosis disease_ontology DOID:13994 Xref MGI. OMIM mapping confirmed by DO. [SN]. cleidocranial dysplasia DOID:13994 NCI:C4007 SNOMEDCT_US_2020_03_01:449074003 UMLS_CUI:C0278805 small intestinal Lymphoma disease_ontology DOID:13996 small intestine lymphoma DOID:13996 An eye disease that affects the lacrimal apparatus (the lacrimal gland and its related structures) which moisten and drain the eye. ICD10CM:H04 ICD9CM:375 MESH:D007766 NCI:C26809 SNOMEDCT_US_2020_03_01:267740009 UMLS_CUI:C0022904 disease_ontology DOID:1400 lacrimal apparatus disease DOID:1400 ICD9CM:442.83 SNOMEDCT_US_2020_03_01:70405009 UMLS_CUI:C0155747 disease_ontology DOID:14006 splenic artery aneurysm DOID:14006 ICD10CM:K70.3 ICD9CM:571.2 MESH:D008104 NCI:C34782 SNOMEDCT_US_2020_03_01:420054005 UMLS_CUI:C0023891 Alcoholic Cirrhosis Alcoholic cirrhosis of liver Laennec's cirrhosis Laennec's cirrhosis, alcoholic Portal cirrhosis disease_ontology DOID:14018 alcoholic liver cirrhosis DOID:14018 A nutritional deficiency disease that is characterized by a decrease in red blood cells due to lack of folate, has_material_basis in insufficient folic acid in diet, hemolytic anemia, alcoholism, and/or certain medicines. ICD10CM:D52 ICD9CM:281.2 SNOMEDCT_US_2020_03_01:85649008 UMLS_CUI:C0151482 Folate deficiency anaemia Folate deficiency anemia Folate-deficiency anaemia Folate-deficiency anemia Folate-deficient megaloblastic anaemia folic acid deficiency anaemia disease_ontology DOID:14026 folic acid deficiency anemia DOID:14026 A blood protein disease that is characterized by polyneuropathy, oranomegaly, endocrinopathy, monoclonal gammopathy, and skin changes, especially hyperpigmentation. GARD:7411 MESH:D016878 NCI:C80303 SNOMEDCT_US_2020_03_01:79268002 UMLS_CUI:C0085404 disease_ontology DOID:14039 POEMS syndrome DOID:14039 An autoimmune disease of endocrine system characterized by abnormal functioning of the immune system that causes auto-reactivity against endocrine organs. ICD10CM:E31.0 MESH:D016884 NCI:C84576 SNOMEDCT_US_2020_03_01:41864002 UMLS_CUI:C0085409 Autoimmune polyglandular failure Lloyd's syndrome autoimmune polyendocrinopathy disease_ontology DOID:14040 autoimmune polyendocrine syndrome DOID:14040 A bipolar disorder that is characterized by at least one manic or mixed episode. ICD9CM:296.50 SNOMEDCT_US_2020_03_01:49468007 UMLS_CUI:C0236773 disease_ontology DOID:14042 bipolar I disorder DOID:14042 A primary systemic mycosis located_in subcutaneous tissues, located_in brain, located_in sinuses, located_in lungs, or located_in peritoneal cavity, has_material_basis_in Exophiala dermatitidis, has_material_basis_in Phialophora, has_material_basis_in Bipolaris hawaiiensis, has_material_basis_in Exserohilum, has_material_basis_in Cladophialophora bantiana, has_material_basis_in Phaeoannellomyces, has_material_basis_in Aureobasidium, has_material_basis_in Cladosporium cladosporoides, has_material_basis_in Alternaria or has_material_basis_in Rhinocladiella mackenziei and results_in_formation_of subcutaneous abscesses arising at the site of minor trauma, and occur in both immunosuppressed and immunocompetent individuals. GARD:12803 MESH:D060446 Infection by dematiacious fungi phaehyphomycosis disease_ontology DOID:14049 phaeohyphomycosis DOID:14049 An angle-closure glaucoma characterized by closure of the anterior chamber angle by an intrinsic defect such that aqueous outflow is blocked and the intraocular pressure becomes inappropriately elevated leading to optic nerve damage and visual field loss. Primary angle-closure glaucoma has_symptom progressive peripheral vision loss, decreased vision, and pain, redness, and headache in acute cases. Primary angle closure glaucoma can be caused by anatomically narrow angle, defects in the trabecular meshwork, and iris abnormalities. Primary angle-closure glaucoma has a strong genetic component. ICD10CM:H40.2 ICD9CM:365.2 SNOMEDCT_US_2020_03_01:193544008 UMLS_CUI:C0017606 primary Angle Closure Glaucoma disease_ontology DOID:1405 primary angle-closure glaucoma DOID:1405 MESH:D007500 NCI:C50621 SNOMEDCT_US_2020_03_01:65074000 UMLS_CUI:C0022081 disease_ontology DOID:1406 iritis DOID:1406 NCI:C35443 SNOMEDCT_US_2020_03_01:68544003 UMLS_CUI:C0403414 Post-Streptococcal Glomerulonephritis disease_ontology DOID:14064 acute poststreptococcal glomerulonephritis DOID:14064 NCI:C35587 SNOMEDCT_US_2020_03_01:197585004 UMLS_CUI:C0341689 acute Diffuse Glomerulonephritis disease_ontology DOID:14066 acute diffuse nephritis DOID:14066 A malaria that presents as a rare febrile complication of repeated malarial attacks characterized by intravascular haemolysis, haemoglobinuria and kidney failure, resulting from destruction of red blood cells caused by heavy parasitization with Plasmodium falciparum or Plasmodium vivax. ICD9CM:084.8 MESH:D001742 NCI:C34426 SNOMEDCT_US_2020_03_01:56625005 UMLS_CUI:C0005681 Black water fever Blackwater fever Hemoglobinuric, malaria Malarial Hemoglobinuria disease_ontology DOID:14068 blackwater fever DOID:14068 GARD:10941 MESH:D014606 NCI:C35109 SNOMEDCT_US_2020_03_01:193500005 UMLS_CUI:C0042165 disease_ontology DOID:1407 anterior uveitis DOID:1407 ICD9CM:379.54 SNOMEDCT_US_2020_03_01:46888001 UMLS_CUI:C0155379 Nystagmus associated with disorder of the vestibular system disease_ontology DOID:14070 vestibular nystagmus DOID:14070 A bone inflammation disease that results_in inflammation located_in epicondyle. DOID:14162 ICD10CM:M77.1 ICD9CM:726.32 MESH:D013716 NCI:C34589 NCI:C35067 SNOMEDCT_US_2020_03_01:156659008 SNOMEDCT_US_2020_03_01:268088003 UMLS_CUI:C0014488 UMLS_CUI:C0039516 Lateral epicondylitis andrel epicondylitis archer's elbow golfer's elbow hockey elbow medial epicondylitis disease_ontology shooter's elbow tennis elbow DOID:14087 epicondylitis DOID:14087 ICD9CM:521.08 MESH:D017213 SNOMEDCT_US_2020_03_01:30512007 UMLS_CUI:C0162644 Cementum caries Dental caries of root surface Root caries disease_ontology DOID:14089 root caries DOID:14089 A spotted fever that has_material_basis_in Rickettsia conorii subsp conorii, which is transmitted_by dog tick (Rhipicephalus sanguineus). The infection has_symptom fever, has_symptom eschar (usually single), has_symptom regional adenopathy, has_symptom maculopapular rash on extremities. DOID:0050039 DOID:0050040 DOID:0050044 DOID:0050045 ICD10CM:A77.1 ICD9CM:082.1 MESH:D001907 SNOMEDCT_US_2020_03_01:186779000 UMLS_CUI:C0006060 African tick typhus Rickettsia conorii spotted fever South African tick-bite fever african tick typhus kenya tick typhus marseilles fever disease_ontology Boutonneuse disease Conor and Bruch's disease Kenya fever Kenyan tick typhus Mediterranean spotted fever Mediterranean tick fever DOID:14095 boutonneuse fever DOID:14095 A large intestine cancer that is located_in the anus. DOID:12240 GARD:9300 ICD10CM:C21.0 ICD10CM:C21.1 ICD9CM:154.2 ICD9CM:154.3 NCI:C7379 SNOMEDCT_US_2020_03_01:93669004 SNOMEDCT_US_2020_03_01:93676009 UMLS_CUI:C0153445 UMLS_CUI:C0153446 anal cancer malignant anal tumor disease_ontology DOID:14110 anus cancer DOID:14110 ICD10CM:K14.2 ICD9CM:529.2 SNOMEDCT_US_2020_03_01:7522008 UMLS_CUI:C0155963 Persistent tuberculum impar disease_ontology DOID:14111 median rhomboid glossitis DOID:14111 A commensal bacterial infectious disease that results_in infection, has_material_basis_in Streptococcus pyogenes or has_material_basis_in Staphylococcus aureus , which produce toxins that are absorbed systemically and produce the systemic manifestations. The infection has_symptom fever, has_symptom rash, has_symptom hypotension, has_symptom multiorgan failure, has_symptom desquamation, has_symptom vomiting, has_symptom diarrhea, has_symptom headache, and has_symptom nonfocal neurologic abnormalities. ICD10CM:A48.3 ICD9CM:040.82 MESH:D012772 NCI:C35498 SNOMEDCT_US_2020_03_01:18504008 UMLS_CUI:C0600327 TSS Toxic Shock syndrome Toxic shock syndrome toxic shock disease_ontology DOID:14115 toxic shock syndrome DOID:14115 A familial hyperlipemia characterized by a deficiency of the enzyme lipoprotein lipase and the subsequent build up of chylomicrons and increased plasma concentration of triglycerides. GARD:12241 ICD10CM:E78.3 ICD9CM:272.3 MESH:D008072 NCI:C84771 OMIM:238600 ORDO:309015 SNOMEDCT_US_2020_03_01:34171006 UMLS_CUI:C0023817 Fredrickson type I hyperlipoproteinemia Fredrickson type I lipaemia familial LPL deficiency familial chylomicronemia syndrome familial hyperlipoproteinemia type I hypercholesterinaemic xanthomatosis hyperchylomicronemia mixed hyperglyceridemia disease_ontology DOID:14118 OMIM mapping confirmed by DO. [SN]. familial lipoprotein lipase deficiency DOID:14118 A urinary system disease which consists of the presence of bacteria in urine. ICD10CM:R82.71 MEDDRA:10004056 MESH:D001437 SNOMEDCT_US_2020_03_01:61373006 UMLS_CUI:C0004659 disease_ontology DOID:1412 bacteriuria DOID:1412 A prolapse of the female genital organ that is characterized by the descent of the bladder causing a bulge in the anterolateral vaginal walls. ICD10CM:N81.12 ICD9CM:618.02 SNOMEDCT_US_2020_03_01:441891001 UMLS_CUI:C2711750 disease_ontology DOID:14130 lateral cystocele DOID:14130 A female reproductive system disease that is characterized by an excessively mobile uterus secondary to lacerations of the broad and cardinal ligaments, specific tenderness with movement of the cervix and previous untoward obstetrics events, such as premature maternal voluntary efforts, precipate delivery, and forceps delivery. ICD9CM:620.6 SNOMEDCT_US_2020_03_01:69186005 UMLS_CUI:C0152079 Broad ligament laceration syndrome disease_ontology DOID:14133 Masters-Allen syndrome DOID:14133 An ovarian disease that is characterized by irregular or absent ovulation. ICD9CM:256.3 SNOMEDCT_US_2020_03_01:267399006 UMLS_CUI:C0029697 disease_ontology DOID:1414 ovarian dysfunction DOID:1414 An ureteral disease this is characterized by the formation of stoney concentrations in the ureter. ICD10CM:N20.1 ICD9CM:592.1 MESH:D053039 NCI:C114696 SNOMEDCT_US_2020_03_01:31054009 UMLS_CUI:C0041952 Ureteric calculus Ureteric stone calculus of ureter disease_ontology DOID:14146 ureterolithiasis DOID:14146 GARD:6556 MESH:D015799 NCI:C84744 OMIM:258870 SNOMEDCT_US_2020_03_01:314467007 UMLS_CUI:C0018425 Gyrate atrophy of the choroid and/or retina Ornithinemia with gyrate atrophy gyrate atrophy of the retina disease_ontology DOID:1415 OMIM mapping by NeuroDevNet. [LS]. gyrate atrophy DOID:1415 ICD10CM:H31.9 ICD9CM:363.9 MESH:D015862 NCI:C34468 SNOMEDCT_US_2020_03_01:193480005 UMLS_CUI:C0008521 disease_ontology DOID:1417 choroid disease DOID:1417 MESH:D018306 NCI:C3791 SNOMEDCT_US_2020_03_01:302832007 UMLS_CUI:C0206719 Neurolipocytoma disease_ontology DOID:14174 central neurocytoma DOID:14174 GARD:7855 ICD10CM:Q85.8 MESH:D006623 NCI:C3105 OMIM:193300 SNOMEDCT_US_2020_03_01:46659004 UMLS_CUI:C0019562 Hippel Lindau syndrome Von Hippel-Lindau syndrome von Hippel-Lindau syndrome disease_ontology DOID:14175 OMIM mapping confirmed by DO. [LS]. von Hippel-Lindau disease DOID:14175 ICD9CM:279.04 SNOMEDCT_US_2020_03_01:190983003 UMLS_CUI:C1457897 Congenital hypogammaglobulinaemia Congenital hypogammaglobulinemia disease_ontology DOID:14177 congenital hypogammaglobulinemia DOID:14177 An agammaglobulinemia that is that has_material_basis_in a mutation in the Bruton's tyrosine kinase (BTK) gene on the X chromosome resulting in X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement. MESH:C537409 NCI:C3822 OMIM:300755 ORDO:47 SNOMEDCT_US_2020_03_01:65880007 UMLS_CUI:C0221026 BTK deficiency Bruton agammaglobulinemia tyrosine kinase deficiency Bruton's Sex-Linked Agammaglobulinemia Bruton's agammaglobulinaemia Bruton's type agammaglobulinemia Bruton-type agammaglobulinemia disease_ontology DOID:14179 OMIM mapping confirmed by DO. [SN]. X-linked agammaglobulinemia DOID:14179 ICD10CM:M75.3 ICD9CM:726.11 SNOMEDCT_US_2020_03_01:239957000 UMLS_CUI:C0158303 disease_ontology DOID:14181 calcific tendinitis DOID:14181 ICD10CM:G62.1 ICD9CM:357.5 MESH:D020269 NCI:C26926 SNOMEDCT_US_2020_03_01:7916009 UMLS_CUI:C0085677 Alcohol-related polyneuropathy Alcoholic polyneuropathy disease_ontology DOID:14183 alcoholic neuropathy MESH:D020269 DOID:14183 A connective tissue disease characterized by restriction of both active and passive range of motion located_in the scapulohumeral joint and has_symptom pain and has_symptom restricted range of motion. ICD10CM:M75.0 ICD9CM:726.0 MESH:D002062 SNOMEDCT_US_2020_03_01:156664007 UMLS_CUI:C0311223 Adhesive capsulitis of shoulder adhesions-capsulitis,shoulder disease_ontology DOID:14188 frozen shoulder DOID:14188 adult onset dermatomyositis disease_ontology DOID:14202 adult dermatomyositis DOID:14202 A syndrome characterized by disruption of mineralization of bones and teeth that has_material_basis_in mutation in ALPL on chromosome 1p36.12. DOID:14763 GARD:6734 ICD10CM:E83.39 MESH:C562440 MESH:D007014 NCI:C26798 ORDO:436 SNOMEDCT_US_2020_03_01:30174008 SNOMEDCT_US_2020_03_01:70848009 UMLS_CUI:C0020630 UMLS_CUI:C0220743 childhood hypophosphatasia deficiency of alkaline phosphatase hypophospatasia, childhood disease_ontology DOID:14213 OMIM mapping confirmed by DO. [SN]. hypophosphatasia DOID:14213 A purine-pyrimidine metabolic disorder that is an autosomal recessive metabolic disorder in which there is absent or significantly decreased activity of dihydropyrimidine dehydrogenase, an enzyme involved in the metabolism of uracil and thymine. GARD:19 MESH:D054067 NCI:C84672 OMIM:274270 SNOMEDCT_US_2020_03_01:238016000 UMLS_CUI:C1959620 UMLS_CUI:C3495551 Dihydropyrimidine dehydrogenase deficiency Dihydrouracil Dehydrogenase deficiency familial pyrimidinaemia thymine-uracilurea disease_ontology DOID:14218 dihydropyrimidine dehydrogenase deficiency DOID:14218 A renal tubular transport disease characterized by excess levels of acid in the blood, due to a failure of the kidneys to appropriately acidify the urine. GARD:7552 ICD10CM:N25.89 MESH:D000141 NCI:C28129 OMIM:179830 OMIM:267200 OMIM:602722 SNOMEDCT_US_2020_03_01:1776003 UMLS_CUI:C0001126 disease_ontology DOID:14219 Xref MGI. renal tubular acidosis DOID:14219 An abdominal obesity-metabolic syndrome characterized by insulin resistance and hyperinsulinemia, dyslipidemia, essential hypertension, abdominal obesity, glucose intolerance or noninsulin-dependent diabetes mellitus and an increased risk of cardiovascular events. EFO:0000195 GARD:9226 ICD10CM:E88.81 ICD9CM:277.7 MESH:D024821 NCI:C84442 OMIM:605552 SNOMEDCT_US_2020_03_01:190394009 UMLS_CUI:C0524620 abdominal obesity-metabolic syndrome 1 dysmetabolic syndrome X metabolic syndrome X disease_ontology DOID:14221 OMIM mapping confirmed by DO. [SN]. abdominal obesity-metabolic syndrome 1 DOID:14221 A connective tissue disease characterized by bluish-brown discoloration of connective tissues that develops from the deposition of homogentisic acid and subsequent oxidation and polymerization reactions. GARD:7231 ICD10CM:E70.29 MESH:D009794 NCI:C84938 SNOMEDCT_US_2020_03_01:21924005 UMLS_CUI:C0028817 disease_ontology DOID:14223 ochronosis DOID:14223 A frontal sinusitis which lasts for less than 4 weeks. ICD10CM:J01.1 ICD9CM:461.1 SNOMEDCT_US_2020_03_01:155500003 UMLS_CUI:C0155805 disease_ontology DOID:14225 acute frontal sinusitis DOID:14225 A male infertility disease characterized by the absence of any measurable level of sperm in semen. EFO:0000279 ICD10CM:N46.0 ICD9CM:606.0 MESH:D053713 NCI:C80076 ORDO:217034 SNOMEDCT_US_2020_03_01:425558002 UMLS_CUI:C0004509 spermatogenic failure disease_ontology DOID:14227 Xref MGI. azoospermia MESH:D053713 DOID:14227 A male fertility issue defined as a low sperm concentration in the ejaculate. ICD10CM:N46.1 ICD9CM:606.1 MESH:D009845 NCI:C34860 UMLS_CUI:C0028960 disease_ontology DOID:14228 oligospermia DOID:14228 A scleral disease that is characterized by a painless severe necrotizing scleritis where the sclera is white, avascular, and thin. The choroid can become exposed leading to infarction and necrosis of related areas; the sclera can also thin such that the dark uvea protrudes through the front of the eye, forming a staphyloma which has_symptom loss of vision and appearance of a dark bulge. Scleromalacia perforans is usually caused by a rare complication of autoimmune disease like rheumatoid arthritis. ICD10CM:H15.05 ICD9CM:379.04 SNOMEDCT_US_2020_03_01:26664005 UMLS_CUI:C0155354 disease_ontology DOID:14230 scleromalacia perforans DOID:14230 A suppurative otitis media which is persistent and long-lasting. ICD10CM:H66.3 ICD9CM:382.3 NCI:C128386 SNOMEDCT_US_2020_03_01:38394007 UMLS_CUI:C0271454 chronic suppurative otitis media disease_ontology DOID:14247 chronic purulent otitis media DOID:14247 A chromosomal disease that is characterized by flat-looking facial features and weak muscle tone (hypotonia) in infancy and is caused by trisomy of all or a critical portion of chromosome 21 and is associated with intellectual disability. GARD:10247 ICD10CM:Q90 ICD9CM:758.0 MESH:D004314 NCI:C2993 OMIM:190685 ORDO:870 SNOMEDCT_US_2020_03_01:41040004 UMLS_CUI:C0013080 Complete trisomy 21 syndrome Down's syndrome Down's syndrome - trisomy 21 Downs syndrome G Trisomy trisomy 21 syndrome disease_ontology DOID:14250 OMIM mapping confirmed by DO. [SN]. Down syndrome DOID:14250 ICD10CM:H35.51 ICD9CM:362.73 SNOMEDCT_US_2020_03_01:79556007 UMLS_CUI:C0154863 Vitreoretinal dystrophies disease_ontology DOID:14251 vitreoretinal dystrophy DOID:14251 A rheumatoid arthritis that is characterized by high fevers, rash, sore throat and joint pain. GARD:436 ICD10CM:M06.1 MESH:D016706 SNOMEDCT_US_2020_03_01:239920006 UMLS_CUI:C0085253 adult onset Still's disease adult-onset Still disease disease_ontology DOID:14256 adult-onset Still's disease DOID:14256 A urinary system disease that is located_in the ureter. MESH:D014515 UMLS_CUI:C0041954 disease_ontology DOID:1426 ureteral disease DOID:1426 A syndrome that is characterized by moderate to severe mental retardation, macroorchidism, and distinct facial features, including long face, large ears, and prominent jaw, and has_material_basis_in X-linked inheritance and a loss of FMR1 function. GARD:6464 ICD10CM:Q99.2 ICD9CM:759.83 MESH:D005600 NCI:C84717 OMIM:300624 ORDO:908 SNOMEDCT_US_2020_03_01:390007001 UMLS_CUI:C0016667 FRAGILE X MENTAL RETARDATION SYNDROME MARKER X SYNDROME MARTIN-BELL SYNDROME disease_ontology DOID:14261 OMIM mapping confirmed by DO. [SN]. fragile X syndrome DOID:14261 A neonatal period electroclinical syndrome that is characterized by tonic-clonic seizures in newborns occurring within the first seven days of life and ceasing within the first 15 weeks of life and has_material_basis_in autosomal dominant inheritance of voltage-gated potassium channels or a chromosomal inversion. MESH:D020936 NCI:C84593 OMIM:121200 OMIM:121201 OMIM:269720 ORDO:1949 SNOMEDCT_US_2020_03_01:38281008 UMLS_CUI:C0270851 benign familial neonatal seizures benign neonatal convulsions disease_ontology DOID:14264 Xref MGI. benign neonatal seizures DOID:14264 A pulmonary valve disease that occurs when the pulmonary valve is not strong enough to prevent backflow into the right ventricle. If it is secondary to pulmonary hypertension it is referred to as a Graham Steell murmur. DOID:11210 MESH:D011665 NCI:C51447 SNOMEDCT_US_2020_03_01:91434003 UMLS_CUI:C0034088 Pulmonic insufficiency Pulmonic valve regurgitation pulmonary incompetence pulmonary incompetence, non-rheumatic pulmonary insufficiency following trauma and surgery pulmonary regurg. pulmonary regurgitation disease_ontology DOID:14265 Replacing outdated UMLS CUI. pulmonary valve insufficiency MESH:D011665 DOID:14265 EFO:0004268 ICD10CM:K83.09 MESH:D015209 SNOMEDCT_US_2020_03_01:4032000 UMLS_CUI:C0008313 fibrosing cholangitis disease_ontology DOID:14268 sclerosing cholangitis DOID:14268 ICD10CM:K83.09 NCI:C35372 SNOMEDCT_US_2020_03_01:26918003 UMLS_CUI:C0311273 Ascending Cholangitis Ascending cholangitis disease_ontology DOID:14270 ascending cholangitis DOID:14270 ICD10CM:E16 ICD9CM:251 SNOMEDCT_US_2020_03_01:190427005 UMLS_CUI:C0154189 disease_ontology DOID:1428 endocrine pancreas disease DOID:1428 ICD10CM:M89.4 MESH:D010004 NCI:C85023 OMIM:259100 SNOMEDCT_US_2020_03_01:88220006 UMLS_CUI:C0029411 Pachydermoperiostosis of nail Pachydermoperiostosis syndrome disease_ontology DOID:14283 OMIM mapping confirmed by DO. [SN]. primary hypertrophic osteoarthropathy DOID:14283 MESH:D046788 UMLS_CUI:C0877149 disease_ontology DOID:14284 patellofemoral pain syndrome DOID:14284 A tricuspid valve disease that is a congenital heart defect in which the septal leaflet of the tricuspid valve is displaced towards the apex of the right ventricle of the heart. GARD:6313 ICD10CM:Q22.5 ICD9CM:746.2 MESH:D004437 NCI:C84681 OMIM:224700 SNOMEDCT_US_2020_03_01:1796006 UMLS_CUI:C0013481 Ebstein's anomaly Ebstein's anomaly of common atrioventricular valve Ebstein's anomaly of right atrioventricular valve Ebstein's anomaly of tricuspid valve disease_ontology DOID:14289 OMIM mapping confirmed by DO. [SN]. Ebstein anomaly DOID:14289 A RASopathy that is characterized by autosomal dominant inheritance of brown skin spots called lentigines that are similar to freckles, heart defects, widely spaced eyes a sunken chest or protruding chest and short stature. GARD:1100 MESH:D044542 NCI:C84820 OMIM:PS151100 ORDO:500 SNOMEDCT_US_2020_03_01:111306001 UMLS_CUI:C0175704 Capute-Rimoin-Konigsmark-Esterly-Richardson syndrome Generalized lentiginosis Gorlin syndrome II LEOPARD syndrome Lentiginosis profusa syndrome Moynahan syndrome Multiple lentigines syndrome Progressive cardiomyopathic lentiginosis disease_ontology DOID:14291 OMIM mapping confirmed by DO. [SN]. Noonan syndrome with multiple lentigines DOID:14291 A pleural empyema which involves presence of pus in the pleural cavity and calcified visceral pleura. It results from a large number of mycobacteria spilling into the pleural space, usually from rupture of a cavity or an adjacent paranchymal focus via a bronchopleural fistula. MESH:D004654 NCI:C34575 SNOMEDCT_US_2020_03_01:186184002 UMLS_CUI:C0014014 Tuberculous empyema disease_ontology DOID:14305 tuberculous empyema DOID:14305 An eye disease characterized by a lack or loss of vision. ICD10CM:H54 ICD9CM:369 SNOMEDCT_US_2020_03_01:193698004 UMLS_CUI:C0155020 vision impairment vision loss visual impairment disease_ontology DOID:1432 blindness DOID:1432 An anxiety disorder that is characterized by long-lasting anxiety that is not focused on any one object or situation. ICD10CM:F41.1 ICD9CM:300.02 NCI:C92622 SNOMEDCT_US_2020_03_01:192401002 UMLS_CUI:C0270549 disease_ontology DOID:14320 generalized anxiety disorder DOID:14320 A connective tissue disease that is characterized by tall stature, elongated extremities, mitral valve prolapse, aortic dilatation, aortic dissection, and subluxation of the lens. GARD:6975 ICD10CM:Q87.4 ICD9CM:759.82 MESH:D008382 NCI:C34807 OMIM:154700 SNOMEDCT_US_2020_03_01:19346006 UMLS_CUI:C0024796 Marfan's syndrome disease_ontology DOID:14323 OMIM mapping confirmed by DO. [SN]. Marfan syndrome MESH:D008382 DOID:14323 A malaria that involves infection with more than one species of Plasmodium at the same time. ICD9CM:084.5 SNOMEDCT_US_2020_03_01:21070001 UMLS_CUI:C0153121 Malaria fever by more than one parasite malaria by more than one parasite disease_ontology DOID:14325 mixed malaria DOID:14325 A synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions. EFO:0002508 GARD:10251 ICD10CM:G20 ICD9CM:332 KEGG:05012 MESH:D010300 NCI:C26845 OMIM:PS168600 ORDO:2828 SNOMEDCT_US_2020_03_01:49049000 UMLS_CUI:C0030567 Parkinson disease paralysis agitans disease_ontology DOID:14330 Xref MGI. OMIM mapping confirmed by DO. [SN]. Parkinson's disease DOID:14330 ICD10CM:E06.0 MESH:D013969 NCI:C129724 SNOMEDCT_US_2020_03_01:3511005 UMLS_CUI:C0040150 Infectious thyroiditis Suppurative thyroiditis acute suppurative thyroiditis disease_ontology DOID:14350 suppurative thyroiditis DOID:14350 ICD10CM:H18.71 ICD9CM:371.71 SNOMEDCT_US_2020_03_01:14748007 UMLS_CUI:C0155135 disease_ontology DOID:1436 corneal ectasia DOID:1436 An amino acid metabolic disorder that involves defective proteins called carnitine transporters, which bring carnitine into cells and prevent its escape from the body preventing the body cannot utilize fats for energy. DOID:1668 ICD10CM:E71.41 ICD9CM:277.81 MESH:C536778 NCI:C98864 OMIM:212140 SNOMEDCT_US_2020_03_01:21764004 UMLS_CUI:C0342788 carnitine transporter deficiency carnitine uptake defect deficiency of plasma-membrane carnitine transporter primary carnitine deficiency renal carnitine transport defect disease_ontology DOID:14365 OMIM mapping confirmed by DO. [SN]. systemic primary carnitine deficiency disease DOID:14365 A scabies that involves infestation of human itch mite Sarcoptes scabiei type hominis in immunocompromised and elderly persons, which is characterized by vesicles and formation of thick crusts over the skin, accompanied by abundant mites but only slight itching. NCI:C34855 SNOMEDCT_US_2020_03_01:128870005 UMLS_CUI:C0028425 Crusted scabies disease_ontology DOID:14374 norwegian scabies DOID:14374 ICD10CM:R82.81 MESH:D011776 NCI:C119028 SNOMEDCT_US_2020_03_01:4800001 UMLS_CUI:C0034359 Pus cells in urine disease_ontology DOID:1439 pyuria DOID:1439 An autosomal dominant cerebellar ataxia that is characterized by slow degeneration of the hindbrain and has_material_basis_in expansion of CAG triplet repeats (glutamine) in the ATXN3 gene. MESH:D017827 NCI:C84830 OMIM:109150 SNOMEDCT_US_2020_03_01:91952008 UMLS_CUI:C0024408 Azorean disease MJD SCA3 spinocerebellar ataxia 3 spinocerebellar ataxia type 3 disease_ontology DOID:1440 OMIM mapping confirmed by DO. [SN]. Machado-Joseph disease MESH:D017827 DOID:1440 MESH:D019559 NCI:C62578 SNOMEDCT_US_2020_03_01:87730004 UMLS_CUI:C0343084 Capillary leak syndrome disease_ontology DOID:14400 capillary leak syndrome MESH:D019559 DOID:14400 A cerebellar ataxia that has_material_basis_in autosomal dominant inheritance. DOID:2478 MESH:D020754 NCI:C82341 OMIM:PS164400 ORDO:94 SNOMEDCT_US_2020_03_01:129609000 UMLS_CUI:C0087012 spinocerebellar ataxia disease_ontology DOID:1441 autosomal dominant cerebellar ataxia DOID:1441 An osteochondrosis that results_in death and fracture located_in hip joint. DOID:14561 GARD:6874 ICD10CM:M91.2 MESH:D007873 NCI:C34766 OMIM:150600 SNOMEDCT_US_2020_03_01:15739006 SNOMEDCT_US_2020_03_01:270545000 UMLS_CUI:C0022441 UMLS_CUI:C0023234 Calve - Perthes' disease Coxa plana Juvenile osteochond-hip/pelvis Juvenile osteochondrosis of hip and/or pelvis Perthe's disease Perthes disease Pseudocoxalgia juvenile osteochondrosis of hip and pelvis osteochondrosis of Legg-Calve-Perthes pseudocoxalgia disease_ontology Legg-Calve-Perthes symptom DOID:14415 OMIM mapping confirmed by DO. [SN]. Legg-Calve-Perthes disease DOID:14415 A parasitic helminthiasis infectious disease that involves parasitic infection by the larvae of the nematode Dracunculus medinensis, which are transmitted to humans by drinking water containing copepods infected with the larvae. The female, which contains larvae, burrows into the deeper connective tissues or adjacent to long bones or joints of the extremities. The worm emerges as a whitish filament in the center of a painful ulcer, accompanied by inflammation and frequently by secondary bacterial infection. GARD:6286 ICD10CM:B72 ICD9CM:125.7 MESH:D004320 NCI:C84677 SNOMEDCT_US_2020_03_01:48874008 UMLS_CUI:C0013100 Dracontiasis Infection by Dracunculus medinensis disease_ontology DOID:14418 dracunculiasis DOID:14418 GARD:6519 ICD10CM:G52.1 ICD9CM:352.1 MESH:D020435 SNOMEDCT_US_2020_03_01:43763009 UMLS_CUI:C0154731 Glossopharyngeal neuralgia disease_ontology DOID:14423 glossopharyngeal neuralgia DOID:14423 A brain disease that is characterized by loss of structure or function of neurons, including death of neurons and loss of brain tissue. GARD:6019 ICD9CM:331.9 SNOMEDCT_US_2020_03_01:52522001 UMLS_CUI:C0154671 Brain degeneration disease_ontology DOID:1443 cerebral degeneration DOID:1443 A physical urticaria induced by sweating. ICD10CM:L50.5 ICD9CM:708.5 SNOMEDCT_US_2020_03_01:73098005 UMLS_CUI:C0152230 disease_ontology DOID:14443 cholinergic urticaria DOID:14443 A deep keratitis that is characterized by inflammation of the anterior sclera and subsequent inflammation of the adjacent cornea with opacification of the corneal stroma and has_symptom pain, red eyes, photophobia, tearing, and blurry vision. Sclerosing keratitis is caused by severe anterior scleritis that causes inflammation and injury to the adjacent corneal layer. Anterior scleritis can be caused by autoimmune diseases, connective tissue diseases, and infection. ICD10CM:H16.33 ICD9CM:370.54 SNOMEDCT_US_2020_03_01:27886001 UMLS_CUI:C0155090 Sclerokeratitis disease_ontology DOID:14444 sclerosing keratitis DOID:14444 A disorder of sexual development that is characterized by a progressive loss of germ cells on the developing gonads of an embryo. GARD:2538 ICD9CM:758.6 MESH:D006059 NCI:C61420 SNOMEDCT_US_2020_03_01:268356004 UMLS_CUI:C0018051 Gonadal dysgenesis syndrome disease_ontology DOID:14447 gonadal dysgenesis DOID:14447 A gonadal dysgenesis that is characterized by progressive loss of primordial cells on the developing glands of an embryo, leading to extremely hypoplastic and dysfuctioning gonads resulting in one differentiated gonad and either a streak gonad or streak testis. MESH:D006060 NCI:C120199 SNOMEDCT_US_2020_03_01:205682006 UMLS_CUI:C0018055 disease_ontology DOID:14449 mixed gonadal dysgenesis DOID:14449 GARD:195 ICD10CM:G72.3 MESH:D020513 NCI:C123429 OMIM:170500 ORDO:682 SNOMEDCT_US_2020_03_01:304737009 UMLS_CUI:C0238357 familial hyperkalemic periodic paralysis disease_ontology DOID:14451 OMIM mapping confirmed by DO. [SN]. hyperkalemic periodic paralysis DOID:14451 GARD:5557 GARD:6729 ICD10CM:G72.3 MESH:D020514 NCI:C84775 OMIM:170400 OMIM:613345 ORDO:681 SNOMEDCT_US_2020_03_01:240093008 UMLS_CUI:C0238358 Hypokalemic familial periodic paralysis Hypokalemic periodic paralysis Periodic paralysis I Westphal disease familial hypokalemic periodic paralysis familial periodic paralysis periodic hypokalemic paralysis disease_ontology DOID:14452 OMIM mapping confirmed by DO. [SN]. hypokalemic periodic paralysis DOID:14452 An extrinsic allergic alveolitis which is induced by the inhalation of spores (Aspergillus sp and thermophilic actinomycetes) in dust from moldy hay or straw. It is characterized by sudden onset, fever, cough, expectoration, and breathlessness. GARD:6427 ICD10CM:J67.0 ICD9CM:495.0 MESH:D005203 NCI:C34605 SNOMEDCT_US_2020_03_01:155581001 UMLS_CUI:C0015634 Farmers lung farmer lung disease_ontology DOID:14453 farmer's lung DOID:14453 A nervous system disease that is characterized by hyperthermia, muscular rigidity, autonomic dysfunction and altered consciousness and is associated with administration of antipsychotic and other central dopaminergic blockers. GARD:7195 ICD10CM:G21.0 ICD9CM:333.92 MESH:D009459 NCI:C94829 ORDO:94093 SNOMEDCT_US_2020_03_01:15244003 UMLS_CUI:C0027849 disease_ontology DOID:14464 neuroleptic malignant syndrome DOID:14464 A viral infectious disease that results in infection located in lung, has_material_basis_in Sin Nombre virus, transmitted by deer mouse (Myodes glareolus), has_material_basis_in Black Creek Canal virus, transmitted by cotton rat (Sigmodon hispidus), has_material_basis_in Bayou virus, transmitted by marsh rice rat (Oryzomys palustris), has_material_basis_in Laguna Negra virus, transmitted by small vesper mouse (Calomys laucha), or has_material_basis_in Andes virus, transmitted by rice rat (Oligoryzomys longicaudatus). The infection has _ymptom fever, has_symptom muscle pain, has_symptom headache, has_symptom cough, has_symptom vomiting, has_symptom chills which rapidly progress to bilateral interstitial pulmonary infiltrates occurrence, pulmonary edema and hypoxia often resulting in death from shock or cardiac complications. GARD:69 MESH:D018804 NCI:C84747 SNOMEDCT_US_2020_03_01:120639003 UMLS_CUI:C0243025 disease_ontology DOID:14472 hantavirus pulmonary syndrome DOID:14472 A vesiculobullous skin disease that is characterized by erythematous papules, vesicles, and plaques around the trunk and extremities that develop during pregnancy, particularly during the second and third trimesters, has_symptom pruritis, and has_material_basis_in autoantibodies to the basement membrane, which triggers a complement cascade and attracts eosinophils to the subepidermis. ICD10CM:O26.4 MESH:D006559 NCI:C85003 SNOMEDCT_US_2020_03_01:86081009 UMLS_CUI:C0019343 Gestational herpes herpes gestationis disease_ontology DOID:14482 pemphigoid gestationis DOID:14482 A primary systemic mycosis that results_in a systemic fungal infection, has_material_basis_in Sporothrix schenckii in animals and humans and results_in_formation_of red papule at the site of inoculation. GARD:7692 ICD10CM:B42 ICD9CM:117.1 MESH:D013174 SNOMEDCT_US_2020_03_01:266218008 UMLS_CUI:C0038034 disease_ontology DOID:14484 sporotrichosis DOID:14484 ICD10CM:K91.1 MESH:D004377 NCI:C2994 SNOMEDCT_US_2020_03_01:155785007 UMLS_CUI:C0013288 Dumping (jejunal) syndrome Jejunal syndrome disease_ontology DOID:14495 dumping syndrome DOID:14495 GARD:7899 ICD10CM:E75.5 MESH:D015223 NCI:C61271 SNOMEDCT_US_2020_03_01:82500001 UMLS_CUI:C0043208 Acid esterase deficiency Acid lipase deficiency Wolman xanthomatosis Wolman's disease Wolman's or triglyceride storage type III disease Xanthomatosis, familial disease_ontology DOID:14497 Wolman disease DOID:14497 GARD:3268 MESH:D008065 NCI:C84829 OMIM:247100 SNOMEDCT_US_2020_03_01:38692000 UMLS_CUI:C0023795 Lipid proteinosis Lipoid proteinosis URBACH-WIETHE DISEASE disease_ontology DOID:14498 OMIM mapping confirmed by DO. [SN]. lipoid proteinosis DOID:14498 A sphingolipidosis that is characterized by the buildup of globotriaosylceramide in the body's cells and has_material_basis_in X-linked inherited mutations in the GLA gene, encoding alpha-galactosidase A, on chromosome Xq22. GARD:6400 ICD10CM:E75.21 MESH:D000795 NCI:C84701 OMIM:301500 SNOMEDCT_US_2020_03_01:16652001 UMLS_CUI:C0002986 Alpha-galactosidase A deficiency Angiokeratoma Corporis Diffusum Fabry's disease alpha galactosidase deficiency deficiency of melibiase disease_ontology DOID:14499 OMIM mapping confirmed by DO. [SN]. Fabry disease DOID:14499 GARD:6473 ICD10CM:E77.1 MESH:D005645 NCI:C61274 OMIM:230000 SNOMEDCT_US_2020_03_01:64716005 UMLS_CUI:C0016788 A-fucosidase deficiency alpha fucosidase deficiency disease_ontology DOID:14500 OMIM mapping confirmed by DO. [SN]. fucosidosis DOID:14500 MESH:D015217 SNOMEDCT_US_2020_03_01:57218003 UMLS_CUI:C0008384 disease_ontology DOID:14502 cholesterol ester storage disease MESH:D015217 DOID:14502 GARD:10739 ICD10CM:E75.4 MESH:D009472 NCI:C61257 OMIM:PS256730 ORDO:216 ORDO:79262 SNOMEDCT_US_2020_03_01:42012007 UMLS_CUI:C0027877 hereditary ceroid lipofuscinosis disease_ontology DOID:14503 Xref MGI. OMIM mapping submitted by NeuroDevNet. [LS]. neuronal ceroid lipofuscinosis DOID:14503 A sphingoliidosis characterized by the accumulation of the lipid sphingomyelin in lysosomes in cells. DOID:0050442 DOID:0050443 DOID:14770 GARD:13334 ICD10CM:E75.24 MESH:D009542 NCI:C61269 SNOMEDCT_US_2020_03_01:58459009 UMLS_CUI:C0028064 Sphingomyelinase Deficiency Disease lipoid histiocytosis sphingomyelin lipidosis disease_ontology DOID:14504 OMIM mapping confirmed by DO. [SN]. Niemann-Pick disease DOID:14504 A chromosomal deletion syndrome that is a nephroblastoma that results_in a rare genetic syndrome in which affected children are predisposed to develop Wilms tumor, Aniridia (absence of the colored part of the eye, the iris), genitourinary anomalies, and mental retardation. The condition results from a deletion on chromosome 11 resulting in the loss of several genes. As such, it is one of the best studied examples of a condition caused by loss of neighbouring (contiguous) genes. GARD:5528 MESH:D017624 NCI:C3718 OMIM:194072 SNOMEDCT_US_2020_03_01:715215007 UMLS_CUI:C0206115 11p partial monosomy syndrome Wilms tumor-Aniridia-Genitourinary Anomalies-Mental Retardation syndrome chromosome 11p13 deletion syndrome disease_ontology DOID:14515 OMIM mapping confirmed by DO. [LS]. WAGR syndrome DOID:14515 A syndrome characterized by acute brain damage and liver function problems. It has been associated with aspirin consumption by children with viral illness, although it also occurs in the absence of aspirin use. GARD:7570 ICD10CM:G93.7 ICD9CM:331.81 MESH:D012202 NCI:C34983 SNOMEDCT_US_2020_03_01:74351001 UMLS_CUI:C0035400 Reye's syndrome disease_ontology DOID:14525 Reye syndrome DOID:14525 MESH:D012391 UMLS_CUI:C0035851 disease_ontology DOID:14550 root resorption DOID:14550 A chronic pulmonary heart disease characterized by an increase of blood pressure in the pulmonary artery, pulmonary vein, or pulmonary capillaries, among others, has symptoms shortness of breath, dizziness, fainting, leg swelling. ICD10CM:I27.0 ICD9CM:416.0 NCI:C97119 OMIM:178600 OMIM:265400 OMIM:615342 OMIM:615343 OMIM:615344 ORDO:422 SNOMEDCT_US_2020_03_01:26174007 UMLS_CUI:C0152171 disease_ontology DOID:14557 Xref MGI. OMIM mapping confirmed by DO. [SN]. primary pulmonary hypertension DOID:14557 ICD10CM:K14.0 ICD9CM:529.0 MESH:D005928 NCI:C112199 SNOMEDCT_US_2020_03_01:155666003 UMLS_CUI:C0017675 disease_ontology DOID:1456 glossitis DOID:1456 A disease that is characterized by abnormally rapid cell division. neoplasm DOID:0000818 cell process disease neoplasm disease_ontology DOID:14566 disease of cellular proliferation DOID:14566 A thyroid gland disease which involves an underproduction of thyroid hormone. DOID:11630 EFO:0004705 ICD10CM:E03.9 ICD9CM:244.9 MESH:D007037 NCI:C26800 SNOMEDCT_US_2020_03_01:267465007 UMLS_CUI:C0020676 Thyroid deficiency Thyroid insufficiency disease_ontology DOID:1459 hypothyroidism DOID:1459 GARD:7318 ICD10CM:H47.1 ICD9CM:377.0 MESH:D010211 NCI:C3307 SNOMEDCT_US_2020_03_01:423341008 UMLS_CUI:C0030353 disease_ontology DOID:146 papilledema DOID:146 ICD10CM:N41.9 ICD9CM:601.9 MESH:D011472 NCI:C26866 SNOMEDCT_US_2020_03_01:155907007 UMLS_CUI:C0033581 disease_ontology DOID:14654 prostatitis DOID:14654 A dysostosis that results_in shortening of interphalangeal joints located_in hand or located_in foot along with mental deficiency. GARD:2015 GARD:5724 MESH:C538179 OMIM:101800 OMIM:614613 ORDO:950 SNOMEDCT_US_2020_03_01:66758006 UMLS_CUI:C0220659 disease_ontology DOID:14669 OMIM mapping confirmed by DO. [SN]. acrodysostosis DOID:14669 An intestinal disease characterized by the presence of numerous atresic segments in the small and large intestines that has_material_basis_in homozygous or compound heterozygous mutation in TTC7A on chromosome 2p21. GARD:3013 MESH:C562441 OMIM:243150 ORDO:2300 SNOMEDCT_US_2020_03_01:95472001 UMLS_CUI:C0220744 GIDID MEDDRA:10028210 Multiple gastrointestinal atresias familial intestinal polyatresia syndrome gastrointestinal defects and immunodeficiency syndrome disease_ontology DOID:14671 OMIM mapping confirmed by DO. [SN]. multiple intestinal atresia DOID:14671 A syndrome that is characterized by the presence of at least three of the following: vertebral defects, anal atresia, cardiac defects, tracheo-esophageal fistula, renal anomalies, and limb abnormalities. GARD:5443 ICD10CM:Q87.2 MESH:C536534 OMIM:192350 OMIM:276950 SNOMEDCT_US_2020_03_01:205830006 UMLS_CUI:C0220708 disease_ontology VATER syndrome DOID:14679 OMIM mapping confirmed by DO. [LS]. VACTERL association DOID:14679 An otitis interna which involves inflammation of the labyrinths. ICD10CM:H83.0 ICD9CM:386.3 MESH:D007762 SNOMEDCT_US_2020_03_01:155239008 UMLS_CUI:C0022893 disease_ontology DOID:1468 labyrinthitis DOID:1468 A physical disorder that is characterized by severe intrauterine growth retardation, poor postnatal growth, craniofacial features such as a triangular shaped face and a broad forehead, body asymmetry, and a variety of minor malformations. GARD:4870 ICD10CM:Q87.19 MESH:D056730 NCI:C85068 OMIM:180860 SNOMEDCT_US_2020_03_01:15069006 UMLS_CUI:C0175693 Silver Russell Dwarfism disease_ontology DOID:14681 OMIM mapping confirmed by DO. [LS]. Silver-Russell syndrome DOID:14681 An eye disease characterized by abnormalities of the front part of the eye, the anterior segment. GARD:5701 ICD10CM:Q13.81 NCI:C131001 ORDO:782 SNOMEDCT_US_2020_03_01:47507006 UMLS_CUI:C0265341 Anomaly, Rieger's Axenfeld syndrome RGS - Rieger syndrome Rieger's anomaly disease_ontology Hagedoom syndrome DOID:14686 Xref MGI. OMIM mapping confirmed by DO. [SN]. Axenfeld-Rieger syndrome DOID:14686 An osteochondrodysplasia that has_material_basis_in abnormal cartilage development due to mutations in the SLC26A2 gene which results_in short limb dwarfism. GARD:6275 ICD10CM:Q77.5 MESH:C536170 NCI:C156311 OMIM:222600 SNOMEDCT_US_2020_03_01:58561002 UMLS_CUI:C0220726 disease_ontology DOID:14687 OMIM mapping confirmed by DO. [SN]. diastrophic dysplasia DOID:14687 DOID:4366 GARD:5683 ICD10CM:E78.72 MESH:D019082 NCI:C85071 OMIM:270400 SNOMEDCT_US_2020_03_01:43929004 UMLS_CUI:C0175694 Rutledge lethal multiple congenital anomaly syndrome Smith-Opitz-Inborn syndrome disease_ontology DOID:14692 OMIM mapping confirmed by DO. [LS]. Smith-Lemli-Opitz syndrome DOID:14692 GARD:2056 MESH:D004476 OMIM:129500 SNOMEDCT_US_2020_03_01:54209007 UMLS_CUI:C0162361 Clouston's hidrotic ectodermal dysplasia Clouston's syndrome Hidrotic ectodermal dysplasia syndrome ectodermal dysplasia 2, Clouston type hidrotic ectodermal dysplasia disease_ontology DOID:14693 OMIM mapping confirmed by DO. [SN]. Clouston syndrome DOID:14693 A syndrome that involves abnormal development of the pancreas, nose and scalp, with mental retardation, hearing loss and growth failure. It is inherited in an autosomal recessive manner. GARD:80 MESH:C535880 OMIM:243800 ORDO:2315 SNOMEDCT_US_2020_03_01:75979009 UMLS_CUI:C0175692 JBS disease_ontology DOID:14694 OMIM mapping confirmed by DO. [SN]. Johanson-Blizzard syndrome DOID:14694 A galactosemia that involves an accumulation of galactose and galactitol secondary to the decreased conversion of galactose to galactose-1-phosphate by galactokinase. GARD:2422 ICD10CM:E74.29 MESH:D005693 NCI:C114767 OMIM:230200 SNOMEDCT_US_2020_03_01:124302001 UMLS_CUI:C0268155 Galactosemia II disease_ontology DOID:14695 OMIM mapping confirmed by DO. [SN]. galactokinase deficiency DOID:14695 A chromosomal deletion syndrome that is characterized by absence of the radius bone and platelet deficiency and bilateral absence of the radii with the presence of both thumbs and generally transient thrombocytopenia (less than 50 platelets/nL) and that has_material_basis_in compound heterozygosity for a rare null mutation involving the RBM8A gene on chromosome 1q12 on 1 allele and 1 of 2 low-frequency noncoding single-nucleotide polymorphisms in RBM8A on the other. ICD10CM:Q87.2 MESH:C536940 NCI:C99038 OMIM:274000 ORDO:3320 SNOMEDCT_US_2020_03_01:85589009 UMLS_CUI:C0175703 Radial aplasia-thrombocytopenia syndrome Thrombocytopenia with absent radii (TAR) syndrome chromosome 1q21.1 deletion syndrome disease_ontology DOID:14699 OMIM mapping confirmed by DO. [LS]. thrombocytopenia-absent radius syndrome DOID:14699 An endogenous depression that is characterized by an all-encompassing low mood accompanied by low self-esteem, and by loss of interest or pleasure in normally enjoyable activities. DOID:10614 DOID:2240 DOID:2241 DOID:7580 ICD10CM:F32 ICD10CM:F33.9 ICD9CM:296.2 ICD9CM:296.3 NCI:C34796 OMIM:608520 OMIM:608691 SNOMEDCT_US_2020_03_01:268621008 SNOMEDCT_US_2020_03_01:36923009 UMLS_CUI:C0024517 UMLS_CUI:C0154409 recurrent major depression single major depressive episode disease_ontology DOID:1470 Xref MGI. major depressive disorder DOID:1470 An organic acidemia that involes a nonfunctional propionyl CoA carboxylase affecting conversion of aminio acids and fats into sugar for energy. DOID:14706 GARD:467 ICD10CM:E71.121 MESH:D056693 NCI:C85030 OMIM:606054 SNOMEDCT_US_2020_03_01:69080001 UMLS_CUI:C0268579 UMLS_CUI:C2717876 GLYCINEMIA, KETOTIC KETOTIC HYPERGLYCINEMIA ketotic II glycinemia ketotic glycinemia propionic aciduria propionyl-CoA carboxylase deficiency disease_ontology DOID:14701 OMIM mapping confirmed by DO. [SN]. propionic acidemia DOID:14701 A syndrome characterized by branchial arch anomalies (branchial fistulas, clefts, or cysts), hearing impairment, structural defects of the outer, middle, and inner ear, and renal abnormalities. GARD:10147 MEDDRA:10071135 MESH:D019280 NCI:C98983 SNOMEDCT_US_2020_03_01:290006 UMLS_CUI:C0265234 Branchio-Oto-renal syndrome Branchio-otorenal dysplasia Melnick-Fraser syndrome branchiootorenal dysplasia disease_ontology DOID:14702 OMIM mapping confirmed by DO. [SN]. branchiootorenal syndrome DOID:14702 A syndrome characterized by retardation, hyperactivity, hypotonia, broad thumbs, big first toes and a characteristic facial appearance including macrocephaly and has an X-linked recessive inheritance pattern. GARD:2317 MESH:C537923 OMIM:300321 OMIM:300406 OMIM:300422 OMIM:300581 OMIM:305450 ORDO:323 ORDO:93932 SNOMEDCT_US_2020_03_01:49984004 UMLS_CUI:C0220769 Keller syndrome Opitz-Kaveggia syndrome disease_ontology DOID:14711 Xref MGI. OMIM mapping confirmed by DO. [SN]. FG syndrome DOID:14711 A myopathy characterized by abnormally located nuclei in skeletal muscle cells. The nuclei are located in the center of the cell, instead of their normal location at the periphery. GARD:101 MESH:D020914 NCI:C84648 ORDO:595 ORDO:596 ORDO:69186 ORDO:69189 SNOMEDCT_US_2020_03_01:193223007 UMLS_CUI:C0175709 myotubular myopathy disease_ontology DOID:14717 Xref MGI. centronuclear myopathy DOID:14717 An amino acid metabolic disorder characterized by inability to process isoleucine and ketones, has_symptom recurrent ketoacidotic attacks in infancy marked by vomitting, lethargy, dehydration, and seizures, and has_material_basis_in mutation in the ACAT1 gene of chromosome 11q22.3 responsible for producing the ACAT1 enzyme in mitochondria, which processes isoleucine and ketones. GARD:872 MESH:C535818 OMIM:203750 ORDO:134 SNOMEDCT_US_2020_03_01:238067002 UMLS_CUI:C1533628 2-methyl-3-hydroxybutyricacidemia 3-ketothiolase deficiency 3-oxothiolase deficiency Mitochondrial acetoacetyl-CoA Thiolase deficiency alpha-methylacetoaceticaciduria peroxisomal thiolase deficiency disease_ontology DOID:14723 OMIM mapping confirmed by DO. [SN]. beta-ketothiolase deficiency DOID:14723 A microcephaly that has_material_basis_in heterozygous mutation in an autosomal gene. MESH:C537323 OMIM:156580 UMLS_CUI:C0220693 disease_ontology DOID:14725 OMIM mapping confirmed by DO. [SN]. autosomal dominant microcephaly DOID:14725 A syndrome that is characterized by prenatal and postnatal overgrowth, accelerated osseous maturation, characteristic craniofacial appearance, and developmental delay and has_material_basis_in heterozygous mutation in the EZH2 gene on chromosome 7q36. GARD:5545 GARD:7878 MESH:C562443 OMIM:277590 UMLS_CUI:C0220765 WEAVER-LIKE SYNDROME Weaver-Williams syndrome disease_ontology DOID:14731 OMIM mapping confirmed by DO. [LS]. Weaver syndrome DOID:14731 A syndrome that has_material_basis_in mutation in the EFNB1 gene on chromosome Xq13 and is characterized in hemizygous males by hypertelorism and with greater severity in females by frontonasal dysplasia, craniofacial asymmetry, craniosynostosis, bifid nasal tip, grooved nails, wiry hair, and abnormalities of the thoracic skeleton. GARD:1578 MESH:C536456 OMIM:304110 ORDO:1520 SNOMEDCT_US_2020_03_01:715421009 UMLS_CUI:C0220767 CFND CFNS craniofrontonasal dysostosis craniofrontonasal dysplasia disease_ontology DOID:14737 OMIM mapping confirmed by DO. [SN]. craniofrontonasal syndrome DOID:14737 A periodontitis that is characterized by rapid attachment loss and bone destruction in the presence of little local factors such as dental plaque and dental calculus resulting in inflammation and a loss of periodontium. ICD10CM:K05.2 MESH:D010520 OMIM:170650 OMIM:608526 SNOMEDCT_US_2020_03_01:449908004 UMLS_CUI:C0031106 juvenile periodontitis disease_ontology DOID:1474 OMIM mapping confirmed by DO. [SN]. aggressive periodontitis MESH:D010520 DOID:1474 A syndrome that is characterized by short stature, sparse hair, a bulbous nasal tip and cone-shaped epiphyses (the growing ends of bones), as well as severe generalized shortening of all finger and toe bones (brachydactyly). DOID:0050552 MESH:C536820 NCI:C75109 OMIM:190350 SNOMEDCT_US_2020_03_01:239016009 UMLS_CUI:C0432233 trichorhinophalangeal syndrome type 1 type I trichorhinophalangeal syndrome disease_ontology Trichorhinophalangeal dysplasia type I DOID:14743 OMIM mapping confirmed by DO. [LS]. trichorhinophalangeal syndrome type I DOID:14743 A syndrome characterized by intellectual disability, focal dystonia of the hands and dysarthria. GARD:4235 MESH:C562446 OMIM:309510 ORDO:94083 UMLS_CUI:C0220775 X-linked Russell-Silver syndrome disease_ontology DOID:14744 OMIM mapping confirmed by DO. [SN]. OMIM mapping submitted by NeuroDevNet. [LS]. Partington syndrome DOID:14744 A syndrome that occurs rarely and is characterized by excessive physical growth during the first 2 to 3 years of life. GARD:10091 ICD10CM:Q87.3 MESH:D058495 NCI:C75019 OMIM:PS117550 ORDO:821 SNOMEDCT_US_2020_03_01:75968004 UMLS_CUI:C0175695 cerebral gigantism disease_ontology DOID:14748 Xref MGI. Sotos syndrome DOID:14748 An organic acidemia that involves an accumulation of methylmalonic acid in the blood. DOID:14782 DOID:14802 GARD:7033 methylmalonic aciduria disease_ontology DOID:14749 OMIM mapping confirmed by DO. [SN]. methylmalonic acidemia DOID:14749 A benign vascular tumor that is composed of dilated lymphatic channels. GARD:9789 ICD10CM:D18.1 ICD9CM:228.1 MESH:D008202 NCI:C8965 SNOMEDCT_US_2020_03_01:154625006 UMLS_CUI:C0024221 Congenital lymphangioma benign lymphangioma disease_ontology DOID:1475 lymphangioma DOID:1475 An organic acidemia that disrupts or prevents normal metabolism of the branched-chain amino acid leucine. GARD:465 ICD10CM:E71.110 MESH:C538167 NCI:C98964 OMIM:243500 SNOMEDCT_US_2020_03_01:87827003 UMLS_CUI:C0268575 Isovaleryl-CoA dehydrogenase deficiency isovaleric acid CoA dehydrogenase deficiency isovaleric aciduria disease_ontology DOID:14753 OMIM mapping confirmed by DO. [SN]. isovaleric acidemia DOID:14753 An amino acid metabolic disorder that involves the accumulation of argininosuccinic acid (ASA) in the blood and urine. GARD:5843 MESH:D056807 NCI:C84569 OMIM:207900 SNOMEDCT_US_2020_03_01:41013004 UMLS_CUI:C0268547 Argininosuccinate lyase deficiency argininosuccinic acidemia arginosuccinase deficiency deficiency of argininosuccinate lyase disease_ontology DOID:14755 OMIM mapping confirmed by DO. [SN]. argininosuccinic aciduria DOID:14755 A synostosis characterized by the fusion of carpal and tarsal bones, which causes stiffness and immobility of the hands and the feet. OMIM:186400 SNOMEDCT_US_2020_03_01:62628008 UMLS_CUI:C0175700 Multiple synostosis syndrome SYNOSTOSES, TARSAL, CARPAL AND DIGITAL disease_ontology DOID:14762 OMIM mapping confirmed by DO. [LS]. calcaneonavicular coalition DOID:14762 Asyndrome that is characterized by autosomal dominant inheritance of large-joint dislocations and characteristic craniofacial abnormalities. GARD:6860 OMIM:150250 dominant larsen syndrome disease_ontology DOID:14764 OMIM mapping confirmed by DO. [SN]. Larsen syndrome DOID:14764 A renal disease that is characterized by the failure of one or both kidneys to develop. GARD:9228 OMIM:191830 ORDO:93108 hereditary renal aplasia hereditary urogenital adysplasia renal adysplasia renal aplasia disease_ontology DOID:14766 renal agenesis DOID:14766 An ectodermal dysplasia characterized by short-limbed short stature and fine, sparse hair that has_material_basis_in homozygous or compound heterozygous mutation in RMRP on chromosome 9p13.3. DOID:0080022 MESH:C535916 NCI:C61245 OMIM:250250 SNOMEDCT_US_2020_03_01:234421004 UMLS_CUI:C0220748 CHH McKusick type metaphyseal chondrodysplasia Metaphyseal chondrodysplasia, McKusick type disease_ontology DOID:14773 OMIM mapping confirmed by DO. [SN]. cartilage-hair hypoplasia DOID:14773 A syndrome characterized by blepharophimosis, ptosis, epicanthus inversus, and telecanthus with (type I) or without (premature ovarian failure) that has_material_basis_in heterozygous or rarely homozygous mutation in FOXL2 on chromosome 3q22.3. MESH:C562419 OMIM:110100 SNOMEDCT_US_2020_03_01:79833006 UMLS_CUI:C0220663 disease_ontology Blepharophimosis, ptosis, epicanthus inversus syndrome DOID:14778 OMIM mapping confirmed by DO. [SN]. blepharophimosis, ptosis, and epicanthus inversus syndrome DOID:14778 A syndrome that is characterized by short stature, moderate to severe degrees of mental retardation, developmental abnormalities of the limbs, bones of the spine (vertebrae), extremities, and/or underdevelopment of the bones of the skeleton. GARD:82 MESH:C537015 OMIM:148050 ORDO:2332 SNOMEDCT_US_2020_03_01:711156009 UMLS_CUI:C0220687 disease_ontology DOID:14780 OMIM mapping confirmed by DO. [SN]. KBG syndrome DOID:14780 DOID:0080025 GARD:4987 OMIM:183900 Late Spondyloepiphyseal Dysplasia disease_ontology DOID:14789 OMIM mapping confirmed by DO. [SN]. spondyloepiphyseal dysplasia congenita DOID:14789 A retinal disease that is characterized by nystagmus, sluggish or no pupillary responses, and severe vision loss or blindness. GARD:634 MESH:D057130 NCI:C129075 OMIM:PS204000 ORDO:65 SNOMEDCT_US_2020_03_01:193413001 UMLS_CUI:C0339527 LCA Leber's amaurosis Leber's congenital amaurosis Leber's disease disease_ontology DOID:14791 Xref MGI. OMIM mapping confirmed by DO. [SN]. Leber congenital amaurosis DOID:14791 An ectodermal dysplasia that is characterized by malformation of ectodermal (skin, hair, teeth and sweat glands) structures including hypotrichosis (sparseness of scalp and body hair), hypohidrosis (reduced ability to sweat), and hypodontia (congenital absence of teeth). DOID:0050446 DOID:0050447 GARD:76 MESH:D053358 NCI:C84562 OMIM:129490 OMIM:224900 OMIM:300291 OMIM:305100 ORDO:238468 SNOMEDCT_US_2020_03_01:239007005 UMLS_CUI:C0162359 Christ-Siemens-Touraine Syndrome Ectodermal Dysplasia 1, Anhydrotic Hypohidrotic X-linked ectodermal dysplasia anhidrotic ectodermal dysplasia 3 disease_ontology DOID:14793 OMIM mapping confirmed by DO. [SN]. hypohidrotic ectodermal dysplasia DOID:14793 A syndrome that is characterized by microcephaly, growth retardation and a characteristic facial appearance including but not limited to narrow or triangular shaped head, micrognathia, ptosis, a broad, wide-tipped nose, and wide-set eyes with drooping eyelids. GARD:6290 ICD10CM:Q87.19 MEDDRA:10059589 MESH:C535718 NCI:C125591 OMIM:223370 SNOMEDCT_US_2020_03_01:2593002 UMLS_CUI:C0175691 Dubowitz's syndrome disease_ontology DOID:14796 OMIM mapping confirmed by DO. [SN]. Dubowitz syndrome DOID:14796 A periodontal disease that is located_in the gums. MESH:D005882 SNOMEDCT_US_2020_03_01:18718003 UMLS_CUI:C0017563 gum disease disease_ontology DOID:1483 gingival disease DOID:1483 A syndrome that is characterized by the buildup of thick, sticky mucus that can damage many organs. DOID:12447 DOID:13383 DOID:14395 DOID:1484 GARD:6233 ICD10CM:E84 ICD9CM:277.0 MESH:D003550 NCI:C2975 OMIM:219700 ORDO:586 SNOMEDCT_US_2020_03_01:85809002 UMLS_CUI:C0010674 CF mucoviscidosis disease_ontology DOID:1485 OMIM mapping confirmed by DO. [SN]. cystic fibrosis MESH:D003550 DOID:1485 A parasitic helminthiasis infectious disease that involves parasitic infection of humans and domestic animals caused by the larval stages of tapeworms of the genus Echinococcus in the liver, lungs, spleen, brain, heart and kidneys. DOID:12149 DOID:2783 ICD10CM:B67 ICD9CM:122 MESH:D004443 NCI:C84682 SNOMEDCT_US_2020_03_01:154414008 UMLS_CUI:C0013502 Echinococcosis of liver echinococcal disease hepatic echinococcosis hydatid disease hydatidosis liver echinococcus pulmonary echinococcosis disease_ontology DOID:1496 echinococcosis DOID:1496 A primary bacterial infectious disease that is described as an acute, diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae, which is characterized by profuse watery diarrhea, vomiting, leg cramps, circulatory collapse and shock. GARD:6043 ICD10CM:A00 ICD9CM:001 MESH:D002771 SNOMEDCT_US_2020_03_01:186087007 UMLS_CUI:C0008354 Cholera Cholera - Vibrio cholerae Cholera due to Vibrio cholerae Vibrio cholerae disease_ontology DOID:1498 cholera MESH:D002771 DOID:1498 A disease of anatomical entity that is located_in reproductive system organs. DOID:6309 NCI:C27613 UMLS_CUI:C1335037 genital system disease disease_ontology DOID:15 reproductive system disease DOID:15 A disease that involves a psychological or behavioral pattern generally associated with subjective distress or disability that occurs in an individual, and which are not a part of normal development or culture. ICD10CM:F99 MESH:D001523 NCI:C2893 SNOMEDCT_US_2020_03_01:74732009 UMLS_CUI:C0004936 disease_ontology DOID:150 disease of mental health DOID:150 An opportunistic mycosis that involves fungal infection of the mouth, throat, skin, scalp, vagina, fingers, nails, bronchi, lungs, heart and brain by Candida species, of which Candida albicans is the most common. Systemic Candida infections are usually confined to severely immunocompromised persons. DOID:1507 ICD10CM:B37 ICD9CM:112 MESH:D002177 NCI:C26711 SNOMEDCT_US_2020_03_01:154403005 UMLS_CUI:C0006840 Disseminated candidiasis systemic candidiasis disease_ontology DOID:1508 candidiasis DOID:1508 A personality disorder that is characterized by a pervasive pattern of social inhibition, feelings of inadequacy, extreme sensitivity to negative evaluation, and avoidance of social interaction. ICD10CM:F60.6 ICD9CM:301.82 MESH:D010554 NCI:C92636 SNOMEDCT_US_2020_03_01:191771004 UMLS_CUI:C0004444 anxious personality disorder disease_ontology DOID:1509 avoidant personality disorder DOID:1509 A disease of mental health that involve long-term patterns of thoughts and behaviors that cause serious problems with relationships and work. ICD9CM:301.8 SNOMEDCT_US_2020_03_01:191770003 UMLS_CUI:C0029707 character disorder disease_ontology DOID:1510 personality disorder DOID:1510 An intestinal disease located_in the cecum. MESH:D002429 SNOMEDCT_US_2020_03_01:128525008 UMLS_CUI:C0007527 disorder of cecum disease_ontology DOID:1518 cecal disease DOID:1518 A cecum cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. NCI:C3491 SNOMEDCT_US_2020_03_01:269538009 UMLS_CUI:C0149640 Caecum carcinoma Cecal cancer carcinoma of cecum disease_ontology DOID:1519 cecum carcinoma DOID:1519 A large intestine cancer that is located_in the cecum. ICD10CM:C18.0 ICD9CM:153.4 MESH:D002430 NCI:C9329 SNOMEDCT_US_2020_03_01:93736007 UMLS_CUI:C0153437 malignant neoplasm of caecum malignant tumor of the cecum disease_ontology DOID:1521 cecum cancer DOID:1521 A skin disease that is characterized by inflammation of subcutaneous adipose tissue. ICD10CM:M79.3 ICD9CM:729.30 MESH:D015434 NCI:C112112 SNOMEDCT_US_2020_03_01:268122002 UMLS_CUI:C0030326 disease_ontology DOID:1526 panniculitis DOID:1526 ICD10CM:N48.8 ICD9CM:607.8 SNOMEDCT_US_2020_03_01:198558008 UMLS_CUI:C0029785 disease_ontology DOID:1529 penile disease DOID:1529 A thoracic disease which may involve inflammation of pleura, collection of air within the pleural cavity, abnormal collection of pleural fluid, abnormal growths on the pleura (pleural tumor) and pleural plaques. The main causes of pleural diseases including pleural effusions are congestive heart failure, malignancy, parapneumonic infections and pulmonary embolism. DOID:1531 MESH:D010995 NCI:C26859 SNOMEDCT_US_2020_03_01:88075009 UMLS_CUI:C0032226 disorder of pleura non-neoplastic pleural disease disease_ontology DOID:1532 pleural disease DOID:1532 A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from two germinal layers of tissue. DOID:1905 MESH:D018198 NCI:C3729 NCI:C6930 SNOMEDCT_US_2020_03_01:8145008 UMLS_CUI:C0206625 UMLS_CUI:C1368354 malignant mixed cancer malignant mixed neoplasm mixed tumor mixed tumor, malignant disease_ontology malignant mixed tumor mixed neoplasm DOID:154 mixed cell type cancer DOID:154 An endocrine gland cancer located_in the parathyroid glands located in the neck. DOID:11006 DOID:1541 GARD:7329 ICD10CM:C75.0 ICD9CM:194.1 MESH:D010282 NCI:C3313 NCI:C4906 NCI:C9322 OMIM:608266 SNOMEDCT_US_2020_03_01:127020005 SNOMEDCT_US_2020_03_01:363481002 UMLS_CUI:C0030521 UMLS_CUI:C0153653 UMLS_CUI:C0687150 Parathyroid gland neoplasm carcinoma of Parathyroid gland malignant neoplasm of parathyroid gland malignant neoplasm of the Parathyroid malignant tumor of parathyroid gland neoplasm of parathyroid gland parathyroid gland cancer parathyroid neoplasm disease_ontology parathyroid gland adenocarcinoma DOID:1540 OMIM mapping confirmed by DO. [SN]. parathyroid carcinoma DOID:1540 A skin disease characterized by skin rash notable for pale red, raised and itchy bumps, located_in the upper dermis. ICD9CM:708.8 SNOMEDCT_US_2020_03_01:267817001 UMLS_CUI:C0029839 disease_ontology DOID:1555 urticaria DOID:1555 A hypersensitivity reaction disease that is characterized by the accumulation of antigen-antibody immune complexes, causing an inflammatory response and injury. MESH:D007105 UMLS_CUI:C0020951 immune complex disease disease_ontology DOID:1557 hypersensitivity reaction type III disease DOID:1557 A skin disease characterized by the rapid swelling of the dermis, subcutaneous tissue, mucosa and submucosal tissues. ICD10CM:T78.3 MESH:D000799 NCI:C112175 SNOMEDCT_US_2020_03_01:41291007 UMLS_CUI:C0002994 Angioneurotic oedema Quincke's edema angioneurotic edema giant urticaria disease_ontology DOID:1558 angioedema DOID:1558 A disease of mental health that affects cognitive functions including memory processing, perception and problem solving. ICD10CM:F09 MESH:D019965 NCI:C34870 SNOMEDCT_US_2020_03_01:111479008 UMLS_CUI:C0029227 cognitive disease disease_ontology Organic Mental disorder DOID:1561 cognitive disorder DOID:1561 A subcutaneous mycosis that is a chronic subcutaneous fungal infection, which presents as nodular or verrucoid, ulcerated, or crusted skin lesions on exposed areas of skin caused by Fonsecaea pedrosoi, Fonsecaea compacta, Cladophialophora carrionii or Phialophora verrucosa. Histological examination reveals muriform cells (with perpendicular septations) or thick walled, dark-colored, rounded forms (copper pennies) that are characteristic of this infection. GARD:1319 ICD10CM:B43.9 ICD9CM:117.2 MESH:D002862 SNOMEDCT_US_2020_03_01:187079000 UMLS_CUI:C0008582 Chromomycosis Mossy foot disease disease_ontology DOID:1562 chromoblastomycosis DOID:1562 A cutaneous mycosis that results in fungal infection located in skin or of its appendages, has_material_basis_in Ascomycota fungi other than the dermatophytes. ICD9CM:111.9 MESH:D003881 SNOMEDCT_US_2020_03_01:47382004 UMLS_CUI:C0011630 disease_ontology DOID:1563 dermatomycosis DOID:1563 A disease by infectious agent that results_in infection, has_material_basis_in Fungi, which pass the resistance barriers of the human or animal body. ICD10CM:B49 ICD9CM:110-118.99 MESH:D009181 NCI:C3245 SNOMEDCT_US_2020_03_01:154393000 UMLS_CUI:C0026946 mycosis disease_ontology mycoses DOID:1564 fungal infectious disease DOID:1564 ICD10CM:H02.1 ICD9CM:374.1 MESH:D004483 SNOMEDCT_US_2020_03_01:155178000 UMLS_CUI:C0013592 Ectropion of eyelid Everted margin disease_ontology DOID:1570 ectropion DOID:1570 ICD10CM:G91.2 MESH:D006850 OMIM:236690 SNOMEDCT_US_2020_03_01:30753002 UMLS_CUI:C0020258 Low pressure hydrocephalus disease_ontology DOID:1572 OMIM mapping confirmed by DO. [SN]. normal pressure hydrocephalus DOID:1572 ICD10CM:G91.0 ICD9CM:331.3 MESH:D006849 NCI:C34501 SNOMEDCT_US_2020_03_01:59013007 UMLS_CUI:C0009451 disease_ontology DOID:1573 communicating hydrocephalus DOID:1573 A musculoskeletal system disease that involves inflammation or pain in the muscles, joints, or fibrous tissue. disease_ontology DOID:1575 rheumatic disease DOID:1575 A disease of anatomical entity that located_in the respiratory system which extends from the nasal sinuses to the diaphragm. DOID:3226 ICD10CM:J98 ICD9CM:519 SNOMEDCT_US_2020_03_01:155603009 UMLS_CUI:C0029582 disease_ontology DOID:1579 respiratory system disease DOID:1579 A pulmonary tuberculosis causing granulomatous leisons in the larynx resulting from an inflammation caused by mycobacteria leading to hoarseness, dysphagia and odynophagia. ICD10CM:A15.5 ICD9CM:012.3 MESH:D014387 NCI:C26895 SNOMEDCT_US_2020_03_01:70341005 UMLS_CUI:C0041315 disease_ontology DOID:1583 laryngeal tuberculosis DOID:1583 A lung disease that involves a vasoocclusive crisis of the pulmonary vasculature seen in patients with sickle cell anemia. The crisis is initiated by a lung infection, and the resulting inflammation and loss of oxygen tension leads to sickling of red cells and further vasoocclusion. The disease has_symptom fever, has_symptom pleuritic chest pain, has_symptom tachypnea, has_symptom cough, has_symptom hypoxemia, has_symptom marked leukocytosis, and has_symptom diffuse infiltrates on chest radiograph. ICD9CM:517.3 MESH:D056586 NCI:C138179 SNOMEDCT_US_2020_03_01:372146004 UMLS_CUI:C0742343 acute chest syndrome in sickle cell disease disease_ontology DOID:1584 acute chest syndrome MESH:D056586 DOID:1584 A connective tissue disease that develops from an antecedent Group A Streptococcal pharyngeal infection and has_symptom carditis, has_symptom polyarthritis, has_symptom chorea, has_symptom erythema marginatum, has_symptom subcutaneous nodules, has_symptom arthralgia, has_symptom prolonged PR interval, and/or has_symptom fever. DOID:1006 DOID:1007 GARD:5699 ICD10CM:I00 ICD10CM:I00-I02 ICD9CM:390 ICD9CM:390-392.99 MESH:D012213 NCI:C34984 SNOMEDCT_US_2020_03_01:155265007 SNOMEDCT_US_2020_03_01:274095001 UMLS_CUI:C0035436 UMLS_CUI:C0264743 ACUTE RHEUMATIC FEVER RhF - Rheumatic fever disease_ontology DOID:1586 rheumatic fever MESH:D012213 DOID:1586 NCI:C3991 SNOMEDCT_US_2020_03_01:2897005 UMLS_CUI:C0272286 Auto-immune thrombocytopenia Immune thrombocytopenia Thrombocytopenia Due to Immune Destruction disease_ontology DOID:1587 thrombocytopenia due to platelet alloimmunization DOID:1587 A blood platelet disease that is characterized by low a platelet count in the blood. ICD10CM:D69.6 ICD9CM:287.5 MESH:D013921 OMIM:188000 OMIM:273900 OMIM:300367 OMIM:313900 OMIM:612004 ORDO:852 SNOMEDCT_US_2020_03_01:165556002 UMLS_CUI:C0040034 disease_ontology DOID:1588 Xref MGI. thrombocytopenia DOID:1588 A mental depression that is characterized by a dysregulation of the endogenous opioid system and not of the monaminergic system. DOID:6340 EFO:0003761 MESH:D003866 NCI:C34532 NCI:C35094 OMIM:608516 SNOMEDCT_US_2020_03_01:191599006 UMLS_CUI:C0011573 UMLS_CUI:C0041696 clinical depression unipolar depression disease_ontology DOID:1595 OMIM mapping confirmed by DO. [LS]. endogenous depression DOID:1595 DOID:14672 ICD10CM:F32.9 MESH:D003863 NCI:C2982 SNOMEDCT_US_2020_03_01:41006004 UMLS_CUI:C0011570 disease_ontology DOID:1596 mental depression DOID:1596 A disease of anatomical entity that is located_in the integumentary system comprising the skin and its appendages. disease_ontology DOID:16 integumentary system disease DOID:16 DOID:1600 DOID:9941 ICD10CM:I88.1 ICD10CM:L04 ICD9CM:289.1 ICD9CM:683 MESH:D008199 NCI:C26821 NCI:C26966 NCI:C26978 SNOMEDCT_US_2020_03_01:154836001 SNOMEDCT_US_2020_03_01:156318008 SNOMEDCT_US_2020_03_01:19471005 UMLS_CUI:C0024205 UMLS_CUI:C0154304 UMLS_CUI:C0157705 Adenitis Inflammation of lymph node acute adenitis acute lymphadenitis chronic Lymphadenitis chronic adenitis disease_ontology DOID:1602 lymphadenitis DOID:1602 A brain disease that is characterized by coma or unconsciousness, develops from a prolonged insufficient supply of glucose to the brain, has_symptom decreased cognition, has_symptom aberrant behavior, has_symptom seizure, and has_symptom coma. ICD10CM:E15 ICD9CM:251.0 SNOMEDCT_US_2020_03_01:267476006 UMLS_CUI:C0020617 disease_ontology DOID:1607 hypoglycemic coma DOID:1607 A skin disease characterized_by growth of keratin on the skin or mucous membranes. MESH:D007642 NCI:C34747 SNOMEDCT_US_2020_03_01:254666005 UMLS_CUI:C0022593 disease_ontology DOID:161 keratosis DOID:161 A thoracic cancer that originates in the mammary gland. DOID:1648 DOID:4241 ICD10CM:C50 MESH:D001943 NCI:C9335 OMIM:114480 SNOMEDCT_US_2020_03_01:254837009 UMLS_CUI:C0006142 breast tumor malignant neoplasm of breast malignant tumor of the breast mammary cancer mammary tumor primary breast cancer disease_ontology mammary neoplasm DOID:1612 Xref MGI. OMIM mapping confirmed by DO. [SN]. breast cancer DOID:1612 A breast benign neoplasm comprised of fibrous and glandoular tissues located_in breast. DOID:2684 DOID:2693 DOID:7226 ICD10CM:D24 MESH:D018226 NCI:C3744 NCI:C4276 NCI:C5194 SNOMEDCT_US_2020_03_01:254847007 SNOMEDCT_US_2020_03_01:269640007 SNOMEDCT_US_2020_03_01:65877006 UMLS_CUI:C0178421 UMLS_CUI:C0206650 UMLS_CUI:C0346158 UMLS_CUI:C1333137 Complex Fibroadenoma of breast Fibroadenoma Fibroadenoma of breast Juvenile fibroadenoma cellular Fibroadenoma fibroadenoma juvenile fibroadenoma of breast disease_ontology DOID:1618 breast fibroadenoma DOID:1618 DOID:162 A disease of cellular proliferation that is malignant and primary, characterized by uncontrolled cellular proliferation, local cell invasion and metastasis. ICD10CM:C80.1 ICD9CM:199 ICDO:M8000/3 MESH:D009369 NCI:C9305 SNOMEDCT_US_2020_03_01:269513004 UMLS_CUI:C0006826 malignant neoplasm malignant tumor primary cancer disease_ontology DOID:162 Updating out dated UMLS CUI. cancer DOID:162 A breast benign neoplasm that is has_material_basis_in epithelial tissue in which tumor cells form glands or glandlike structures. NCI:C40382 SNOMEDCT_US_2020_03_01:269640007 UMLS_CUI:C1328385 Ademoma - breast disease_ontology DOID:1625 breast adenoma DOID:1625 MESH:D018300 NCI:C3785 SNOMEDCT_US_2020_03_01:5244003 UMLS_CUI:C0206713 ductal papilloma disease_ontology DOID:1627 intraductal papilloma DOID:1627 A breast myoepithelial neoplasm that affects the breast and is characterized by biphasic proliferation of both epithelial and myoepithelial cells. DOID:6640 NCI:C5143 NCI:C6899 UMLS_CUI:C1334564 UMLS_CUI:C1510795 breast Adenomyoepithelioma with malignant Change malignant adenomyoepithelioma of breast disease_ontology adenomyoepithelioma of the breast DOID:1642 breast adenomyoepithelioma DOID:1642 A heart septal defect characterized by an opening in the interventricular septum, causing a shunt between ventricles. GARD:7853 ICD10CM:Q21.0 ICD9CM:745.4 MESH:D006345 NCI:C84506 OMIM:614429 OMIM:614431 OMIM:614432 ORDO:1480 SNOMEDCT_US_2020_03_01:156914003 UMLS_CUI:C0018818 Interventricular septal defect Ventricular septal abnormality disease_ontology DOID:1657 Xref MGI. ventricular septal defect DOID:1657 A brain cancer that is located in the supratentorial region. DOID:1658 ICD10CM:C71.0 MESH:D015173 NCI:C3397 NCI:C4964 UMLS_CUI:C0038874 UMLS_CUI:C0751589 Brain neoplasm, Supratentorial malignant Supratentorial tumor disease_ontology DOID:1659 supratentorial cancer DOID:1659 MESH:D017600 NCI:C3717 SNOMEDCT_US_2020_03_01:1513001 UMLS_CUI:C0206094 Infantile Melanotic neuroectodermal neoplasm Melanotic neuroectodermal tumor Melanotic neuroectodermal tumor of infancy Melanotic neuroectodermal tumour Melanotic neuroectodermal tumour of infancy Pigmented neuroectodermal tumour of infancy melanotic neuroectodermal tumour disease_ontology DOID:166 melanotic neuroectodermal tumor DOID:166 A pineal gland neoplasm located_in the brain. GARD:9369 MESH:D010871 NCI:C9344 SNOMEDCT_US_2020_03_01:31671006 UMLS_CUI:C0205898 Pineal PNET disease_ontology DOID:1664 pineoblastoma DOID:1664 A pleural disease that is characterized as an abnormal collection of air in the pleural space between the lung and the chest wall. ICD10CM:J93.1 SNOMEDCT_US_2020_03_01:196103008 UMLS_CUI:C0029850 disease_ontology DOID:1673 pneumothorax MESH:D011030 DOID:1673 A bladder disease that is characterized by inflammation of the bladder. ICD10CM:N30 ICD9CM:595 MESH:D003556 NCI:C26738 SNOMEDCT_US_2020_03_01:38822007 UMLS_CUI:C0010692 disease_ontology DOID:1679 cystitis DOID:1679 ICD10CM:Q21.9 MESH:D006343 NCI:C84482 SNOMEDCT_US_2020_03_01:204290008 UMLS_CUI:C0018816 Cardiac septal defects Congenital septal defect of heart Septal defect septal defect disease_ontology DOID:1681 heart septal defect DOID:1681 ICD10CM:Q24.9 ICD9CM:746.9 MESH:D006330 NCI:C34666 SNOMEDCT_US_2020_03_01:268315002 UMLS_CUI:C0018798 Congenital Heart Defects Congenital anomaly of heart Heart Malformation congenital heart defect heart defect disease_ontology Heart-congenital defect DOID:1682 OMIM mapping confirmed by DO. [SN]. congenital heart disease DOID:1682 An eye disease that is characterized by an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. EFO:0000516 ICD10CM:H40 ICD9CM:365 MESH:D005901 NCI:C26782 SNOMEDCT_US_2020_03_01:155120009 UMLS_CUI:C0017601 disease_ontology DOID:1686 glaucoma DOID:1686 A glaucoma characterized by narrowing of the anterior chamber angle secondary to neovascularization along the iris and iridocorneal angle such that the aqueous fluid outflow is blocked and intraocular pressure becomes inappropriately elevated leading to optic nerve damage and visual field loss. Neovascular glaucoma has_symptom progressive peripheral vision loss, decreased vision, and pain, redness, and headache in acute cases. Neovascular glaucoma can be related to abnormal angiogenesis with ischemic retinal diseases, inflammation, diabetes mellitus, intraocular malignancy, and autoinmmune diseases. MESH:D015355 SNOMEDCT_US_2020_03_01:193564003 UMLS_CUI:C0017609 secondary angle-closure glaucoma with rubeosis disease_ontology DOID:1687 neovascular glaucoma DOID:1687 An endocrine gland cancer that has_material_basis_in neuroendocrine cells. ICD10CM:D3A.8 ICD9CM:209-209.99 MESH:D018358 NCI:C3809 SNOMEDCT_US_2020_03_01:55937004 UMLS_CUI:C0206754 neuroendocrine neoplasm disease_ontology DOID:169 neuroendocrine tumor DOID:169 A skin disease characterized by drying and scaling of skin with the accumulation of thick scales and cracks that may be painful or bleed. MESH:D007057 ORDO:79354 ichthyoses non-syndromic ichthyosis disease_ontology DOID:1697 ichthyosis DOID:1697 A disease of anatomical entity that occurs in the muscular and/or skeletal system. MESH:D009140 NCI:C107377 SNOMEDCT_US_2020_03_01:268047003 UMLS_CUI:C0026857 disease_ontology DOID:17 musculoskeletal system disease DOID:17 An organ system cancer located_in endocrine system that is characterized by uncontrolled cellular proliferation of the hormone producing glands of the endocrine system. DOID:10009 ICD10CM:C75.9 ICD9CM:194.9 MESH:D004701 NCI:C3010 NCI:C3575 SNOMEDCT_US_2020_03_01:127015005 SNOMEDCT_US_2020_03_01:93780007 UMLS_CUI:C0014132 UMLS_CUI:C0153658 Endocrine tumor endocrine neoplasm malignant Endocrine tumor malignant neoplasm of endocrine gland malignant tumour of endocrine gland neoplasm of endocrine gland neoplasm of endocrine system disease_ontology DOID:170 endocrine gland cancer DOID:170 An ichthyosis that is characterized by a build-up of scales on the skin, typically on the back of the neck and trunk resulting from skin cells that do not properly separate from the outermost surface of the skin, and has_material_basis_in X-linked recessive mutation or deletion of the STS gene on chromosome Xp22. GARD:7904 ICD10CM:Q80.1 MESH:D016114 NCI:C84779 OMIM:308100 SNOMEDCT_US_2020_03_01:72523005 UMLS_CUI:C0079588 X-linked ichthyosis with steryl-sulphatase deficiency X-linked placental steryl-sulphatase deficiency X-linked recessive ichthyosis disease_ontology DOID:1700 OMIM mapping confirmed by DO. [LS]. X-linked ichthyosis DOID:1700 A lipid metabolism disorder that involves defects in steroid metabolism. MESH:D043202 UMLS_CUI:C1257809 disease_ontology DOID:1701 steroid inherited metabolic disorder DOID:1701 An ichthyosis that has_material_basis_in heterozygous mutation in the filaggrin gene on chromosome 1q21 and is characterized by dead skin cells accumulate in thick, dry scales on your skin's surface. GARD:6752 ICD10CM:Q80.0 MESH:D016112 NCI:C84778 OMIM:146700 SNOMEDCT_US_2020_03_01:205551004 UMLS_CUI:C0079584 Dominant congenital ichthyosiform erythroderma disease_ontology DOID:1702 OMIM mapping confirmed by DO. [SN]. ichthyosis vulgaris DOID:1702 MESH:D017599 SNOMEDCT_US_2020_03_01:73676002 UMLS_CUI:C0206093 primitive Neuroectodermal neoplasm disease_ontology DOID:171 neuroectodermal tumor DOID:171 An aortic valve disease that is characterized by narrowing of the heart's aortic valve opening. DOID:12034 DOID:1711 GARD:5830 ICD10CM:I06.0 ICD10CM:Q23.0 ICD10CM:Q25.1 ICD9CM:395.0 ICD9CM:746.3 MESH:D001024 NCI:C50462 SNOMEDCT_US_2020_03_01:155282009 SNOMEDCT_US_2020_03_01:18546004 SNOMEDCT_US_2020_03_01:60573004 UMLS_CUI:C0003507 UMLS_CUI:C0152417 UMLS_CUI:C0155567 Aortic stenosis Rheumatic aortic stenosis rheumatic aortic valve stenosis disease_ontology DOID:1712 Xref MGI. OMIM mapping confirmed by DO. [SN]. aortic valve stenosis MESH:D001024 DOID:1712 MESH:D049309 NCI:C97041 SNOMEDCT_US_2020_03_01:65540008 UMLS_CUI:C0333992 Clear cell acanthoma Pale (Clear cell) acanthoma disease_ontology DOID:172 clear cell acanthoma DOID:172 DOID:10297 DOID:11480 DOID:12880 DOID:13836 DOID:1723 DOID:9780 DOID:9781 DOID:9782 DOID:9783 ICD10CM:K26 ICD9CM:532 MESH:D004381 NCI:C26755 SNOMEDCT_US_2020_03_01:155691003 SNOMEDCT_US_2020_03_01:39755000 UMLS_CUI:C0010474 UMLS_CUI:C0013295 Curling Ulcer Curling's ulcers Stress Ulcer disease_ontology DOID:1724 Adding UMLS CUI for Curling Ulcer C0013295. duodenal ulcer DOID:1724 An organ system cancer that is located in the peritoneum. ICD10CM:C48.1 ICD9CM:158.8 SNOMEDCT_US_2020_03_01:187808008 UMLS_CUI:C0153466 disease_ontology cancer of peritoneum peritoneal neoplasm DOID:1725 peritoneum cancer DOID:1725 MESH:D012170 NCI:C34981 SNOMEDCT_US_2020_03_01:46085004 UMLS_CUI:C0035328 Occlusion, of retinal vein Retinal vein occlusion disease_ontology DOID:1727 retinal vein occlusion DOID:1727 ICD10CM:H34 ICD9CM:362.3 NCI:C34980 SNOMEDCT_US_2020_03_01:267717005 UMLS_CUI:C0035326 Retinal vasc. occlusion disease_ontology DOID:1729 retinal vascular occlusion DOID:1729 NCI:C6796 UMLS_CUI:C1333371 Eccrine tumor eccrine skin neoplasm disease_ontology DOID:173 eccrine sweat gland neoplasm DOID:173 A primary systemic mycosis that results in systemic fungal infection, has_material_basis_in Histoplasma capsulatum var capsulatum or has_material_basis_in Histoplasma capsulatum var duboisii, transmitted_by airborne spores and has_symptom nonproductive cough, has_symptom headache, has_symptom loss of appetite and has_symptom muscle pains. DOID:351 ICD10CM:B39 ICD9CM:115 MESH:C538362 MESH:D006660 NCI:C34977 NCI:C77201 SNOMEDCT_US_2020_03_01:266218008 UMLS_CUI:C0019655 UMLS_CUI:C0035288 disease_ontology DOID:1731 histoplasmosis DOID:1731 A coccidiosis that involves a parasitic protozoan infection of the intestine of humans and a wide range of animals caused by Cryptosporidium species, through contaminated water and food, The symptoms include watery diarrhea, dehydration, weight loss, abdominal pain, fever, nausea and vomiting. Cryptosporidium infections have also been found in other digestive tract organs, the lungs, and conjunctiva. Immunocompromised persons are at greater risk of developing the infection. DOID:1732 GARD:6219 ICD10CM:A07.2 ICD9CM:007.4 MESH:D003457 NCI:C128408 SNOMEDCT_US_2020_03_01:186126003 UMLS_CUI:C0010418 Cryptosporidial gastroenteritis Infection by Cryptosporidium intestinal cryptosporidiosis disease_ontology DOID:1733 cryptosporidiosis DOID:1733 GARD:8604 MESH:D049309 NCI:C7419 UMLS_CUI:C0846967 disease_ontology DOID:174 acanthoma MESH:D049309 DOID:174 ICD9CM:292.1 MESH:D011605 SNOMEDCT_US_2020_03_01:191498001 UMLS_CUI:C0033937 Drug-induced psychosis Drug-induced psychotic disorder disease_ontology DOID:1742 drug psychosis DOID:1742 A carcinoma that derives_from squamous epithelial cells. DOID:5512 EFO:0000707 GARD:1091 MESH:D002294 MESH:D018307 NCI:C2929 SNOMEDCT_US_2020_03_01:154605007 UMLS_CUI:C0007137 UMLS_CUI:C0751688 epidermoid carcinoma malignant squamous cell tumor squamous carcinoma squamous cell Epithelioma squamous cell cancer disease_ontology DOID:1749 squamous cell carcinoma DOID:1749 A cardiovascular cancer that is located_in blood vessels. DOID:3339 DOID:5454 DOID:5548 DOID:7019 DOID:7020 DOID:7392 MESH:D019043 NCI:C5348 NCI:C5380 NCI:C5383 NCI:C5388 NCI:C7390 SNOMEDCT_US_2020_03_01:126737003 SNOMEDCT_US_2020_03_01:93817006 UMLS_CUI:C0282607 UMLS_CUI:C0346845 UMLS_CUI:C1290407 UMLS_CUI:C1334616 UMLS_CUI:C1334617 UMLS_CUI:C1334630 UMLS_CUI:C1335753 Blood Vessel neoplasm Blood vessel tumor Blood vessel tumors Blood vessel tumour disorder Haemangiomatous tumour blood vessel neoplasm leiomyosarcoma of the renal Vein malignant great vessel tumor malignant tumor of pulmonary Vein malignant tumor of pulmonary artery malignant vascular neoplasm malignant vascular tumor neoplasm of great vessel pulmonary artery malignant neoplasm pulmonary vein malignant neoplasm renal vein leiomyosarcoma vascular tissue neoplasm vascular tumors disease_ontology DOID:175 vascular cancer DOID:175 A mitral valve disease that is characterized by the narrowing of the orifice of the mitral valve of the heart. MESH:D008946 NCI:C50654 SNOMEDCT_US_2020_03_01:79619009 UMLS_CUI:C0026269 Mitral stenosis disease_ontology DOID:1754 mitral valve stenosis DOID:1754 ICD10CM:G51 ICD9CM:351 MESH:D005155 NCI:C27594 SNOMEDCT_US_2020_03_01:90039006 UMLS_CUI:C0015464 disease_ontology DOID:1756 facial nerve disease DOID:1756 MESH:D005150 NCI:C84703 OMIM:141300 SNOMEDCT_US_2020_03_01:29868009 UMLS_CUI:C0015458 PARRY-ROMBERG SYNDROME disease_ontology DOID:1757 OMIM mapping confirmed by DO. [SN]. facial hemiatrophy DOID:1757 An organ system cancer that located_in the heart and blood vessels. NCI:C4784 SNOMEDCT_US_2020_03_01:721573003 UMLS_CUI:C0497243 Cardiovascular tumors cardiovascular neoplasm disease_ontology DOID:176 cardiovascular cancer DOID:176 GARD:7010 ICD10CM:G51.2 MESH:D008556 NCI:C84886 OMIM:155900 SNOMEDCT_US_2020_03_01:2511001 UMLS_CUI:C0025235 Cheilitis granulomatosa of Mescher-Melkersson-Rosenthal Melkersson's syndrome disease_ontology DOID:1761 OMIM mapping confirmed by DO. [SN]. Melkersson-Rosenthal syndrome DOID:1761 ICD10CM:K59.31 MESH:D008532 SNOMEDCT_US_2020_03_01:28536002 UMLS_CUI:C0025162 disease_ontology DOID:1770 toxic megacolon DOID:1770 A cardiovascular system disease that primarily affects the blood vessels which includes the arteries, veins and capillaries that carry blood to and from the heart. DOID:0000405 DOID:2403 DOID:2869 DOID:324 DOID:325 DOID:45 ICD10CM:I72.9 ICD9CM:442.9 MESH:D000783 MESH:D014652 MESH:D020758 MESH:D020760 NCI:C26693 NCI:C35117 SNOMEDCT_US_2020_03_01:27550009 SNOMEDCT_US_2020_03_01:371029002 SNOMEDCT_US_2020_03_01:432119003 UMLS_CUI:C0002940 UMLS_CUI:C0042373 UMLS_CUI:C0752127 UMLS_CUI:C0752130 vascular tissue disease disease_ontology DOID:178 vascular disease DOID:178 An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage. DOID:10008 ICD10CM:C73 ICD9CM:193 KEGG:05216 MESH:D013964 NCI:C3414 NCI:C7510 SNOMEDCT_US_2020_03_01:127018007 SNOMEDCT_US_2020_03_01:94098005 UMLS_CUI:C0007115 UMLS_CUI:C0040136 Thyroid gland neoplasm malignant neoplasm of thyroid gland malignant tumour of thyroid gland neoplasm of thyroid gland thyroid neoplasm disease_ontology DOID:1781 thyroid gland cancer DOID:1781 An endocrine gland cancer located_in the pituitary gland located at the base of the brain. DOID:5671 GARD:9371 ICD10CM:C75.1 MESH:D010911 NCI:C3330 NCI:C4769 SNOMEDCT_US_2020_03_01:127024001 SNOMEDCT_US_2020_03_01:93964007 UMLS_CUI:C0032019 UMLS_CUI:C0496842 Pituitary gland neoplasm malignant Pituitary neoplasm malignant tumor of pituitary gland neoplasm of pituitary gland pituitary gland cancer pituitary neoplasm disease_ontology DOID:1785 pituitary cancer DOID:1785 MESH:D000314 NCI:C2860 SNOMEDCT_US_2020_03_01:54292009 UMLS_CUI:C0001630 Adrenal Rest neoplasm disease_ontology DOID:1786 adrenal rest tumor MESH:D000314 DOID:1786 A pericardium disease that is characterized by an inflammation of the pericardium and has_symptom chest pain. MESH:D010493 NCI:C34915 SNOMEDCT_US_2020_03_01:3238004 UMLS_CUI:C0031046 disease_ontology DOID:1787 pericarditis DOID:1787 A peritoneum cancer that develops from cells of the mesothelium and is located_in the peritoneum. DOID:0050874 DOID:7954 ICD10CM:C45.1 NCI:C8704 NCI:C9350 SNOMEDCT_US_2020_03_01:187806007 UMLS_CUI:C0346109 UMLS_CUI:C0854886 Advanced malignant Mesothelioma of Peritoneum advanced malignant peritoneal mesothelioma malignant mesothelioma of peritoneum disease_ontology DOID:1788 peritoneal mesothelioma DOID:1788 A cell type cancer that has_material_basis_in mesothelial tissue that develops from the thin layer of tissue that covers many of the internal organs. DOID:4487 DOID:6965 DOID:7434 MESH:C562839 NCI:C27926 NCI:C4456 NCI:C7865 NCI:C8420 OMIM:156240 SNOMEDCT_US_2020_03_01:109378008 UMLS_CUI:C0278752 UMLS_CUI:C0345967 UMLS_CUI:C0392400 UMLS_CUI:C1332338 Diffuse malignant Mesothelioma advanced malignant mesothelioma asbestos-related malignant mesothelioma malignant tumor of Mesothelium disease_ontology DOID:1790 OMIM mapping confirmed by DO. [SN]. malignant mesothelioma DOID:1790 A carcinoma that is located_in the inside of the abdomen. NCI:C40022 UMLS_CUI:C1514428 primary peritoneal carcinoma disease_ontology DOID:1791 peritoneal carcinoma DOID:1791 An endocrine gland cancer located_in the pancreas. DOID:14356 DOID:1797 DOID:3588 DOID:9859 GARD:9364 ICD10CM:C25.0 ICD10CM:C25.1 ICD10CM:C25.2 ICD9CM:157.0 ICD9CM:157.1 ICD9CM:157.2 ICD9CM:157.8 KEGG:05212 MESH:D010190 NCI:C3305 ORDO:1333 ORDO:217074 SNOMEDCT_US_2020_03_01:126859007 SNOMEDCT_US_2020_03_01:187796007 SNOMEDCT_US_2020_03_01:93715005 SNOMEDCT_US_2020_03_01:93823001 SNOMEDCT_US_2020_03_01:94082003 UMLS_CUI:C0030297 UMLS_CUI:C0153458 UMLS_CUI:C0153459 UMLS_CUI:C0153460 UMLS_CUI:C0153463 Ca body of pancreas Ca head of pancreas Ca tail of pancreas malignant neoplasm of body of pancreas malignant neoplasm of head of pancreas malignant neoplasm of tail of pancreas pancreas neoplasm pancreatic neoplasm pancreatic tumor disease_ontology DOID:1793 Xref MGI. pancreatic cancer DOID:1793 A pancreatic cancer that arises from the epithelial cells of the exocrine pancreatic tissue. DOID:1794 NCI:C7430 SNOMEDCT_US_2020_03_01:255088001 UMLS_CUI:C0346648 malignant neoplasm of the Exocrine pancreas malignant tumor of exocrine pancreas malignant tumour of exocrine pancreas disease_ontology DOID:1795 malignant exocrine pancreas neoplasm DOID:1795 An islet cell tumor that has_material_basis_in epithelial cells. GARD:13034 ICD10CM:C25.4 ICD9CM:157.4 MESH:D018273 NCI:C3770 SNOMEDCT_US_2020_03_01:254612002 UMLS_CUI:C1328479 Islet cell carcinoma carcinoma of endocrine pancreas malignant neoplasm of islets of Langerhans pancreatic neuroendocrine carcinoma disease_ontology DOID:1798 pancreatic endocrine carcinoma DOID:1798 A pancreatic cancer that is located_in the pancreatic islet cells. DOID:10165 ICD10CM:C25.4 ICD10CM:D13.7 MESH:D007516 NCI:C27031 SNOMEDCT_US_2020_03_01:254611009 SNOMEDCT_US_2020_03_01:261713004 UMLS_CUI:C0242363 UMLS_CUI:C0496784 Islet cell neoplasm Islet cell tumor Islet cell tumour endocrine pancreas cancer islet cell tumour malignant pancreatic Endocrine tumor malignant pancreatic Endocrine tumour malignant tumor of endocrine pancreas malignant tumour of endocrine pancreas pancreatic Endocrine neoplasm disease_ontology DOID:1799 islet cell tumor DOID:1799 A disease of anatomical entity that is located_in kidney, ureter, bladder and urethra. DOID:579 NCI:C27599 UMLS_CUI:C1335051 Non-neoplastic urinary tract disease urinary tract disease disease_ontology DOID:18 urinary system disease DOID:18 A bone benign neoplasm that is located_in the mouth and results_in an overgrowth of gingival tissue due to irritation or trauma. MESH:D018214 NCI:C8422 SNOMEDCT_US_2020_03_01:189896007 UMLS_CUI:C0206640 Fibro-osteoma disease_ontology peripheral ossifying fibroma DOID:180 ossifying fibroma DOID:180 A carcinoma that derives_from neuroendocrine cells. MESH:D018278 NCI:C3773 SNOMEDCT_US_2020_03_01:55937004 UMLS_CUI:C0206695 disease_ontology DOID:1800 neuroendocrine carcinoma DOID:1800 ICD9CM:355.9 MESH:D020422 SNOMEDCT_US_2020_03_01:32595002 UMLS_CUI:C0235880 disease_ontology DOID:1802 mononeuritis DOID:1802 MESH:D009443 NCI:C116381 SNOMEDCT_US_2020_03_01:247378004 UMLS_CUI:C0027813 peripheral neuritis disease_ontology DOID:1803 neuritis DOID:1803 ICD10CM:G90.5 ICD9CM:337.2 MESH:D012019 NCI:C85042 OMIM:604335 SNOMEDCT_US_2020_03_01:203492008 UMLS_CUI:C0034931 disease_ontology DOID:1811 OMIM mapping confirmed by DO. [SN]. reflex sympathetic dystrophy DOID:1811 A calcium metabolism disease that is the result of the formation of calcium deposits in any soft tissue. MESH:D002114 NCI:C3672 SNOMEDCT_US_2020_03_01:237881004 UMLS_CUI:C0006663 Pathologically calcified structure pathologic calcification disease_ontology DOID:182 calcinosis DOID:182 A childhood electroclinical syndrome that is characterized by brief and frequent absence seizures in children with age of onset between four and ten years. MESH:D004832 NCI:C3023 SNOMEDCT_US_2020_03_01:163596002 UMLS_CUI:C0014553 petit mal seizure pyknolepsy disease_ontology absence seizure DOID:1825 childhood absence epilepsy DOID:1825 A brain disease that is characterized by the occurrance of at least two unprovoked seizures resulting from a persistent epileptogenic abnormality of the brain that is able to spontaneously generate paroxysmal activity and typically manifested by sudden brief episodes of altered or diminished consciousness, involuntary movements, or convulsions. EFO:0000474 ICD10CM:G40.909 ICD9CM:345.9 MESH:D004827 NCI:C3020 SNOMEDCT_US_2020_03_01:267698007 UMLS_CUI:C0014544 epilepsy syndrome epileptic syndrome disease_ontology DOID:1826 epilepsy DOID:1826 An epilepsy syndrome that is characterised by generalised seizures with no apparent cause which arise from many independent foci (multifocal epilepsies) or from epileptic circuits that involve the whole brain. MESH:D004829 NCI:C3021 OMIM:600669 SNOMEDCT_US_2020_03_01:155043003 UMLS_CUI:C0014548 Generalised epilepsy disease_ontology DOID:1827 Xref MGI. idiopathic generalized epilepsy DOID:1827 ICD9CM:598.8 UMLS_CUI:C0029752 disease_ontology DOID:1829 urethral stricture MESH:D14525 DOID:1829 GARD:1521 MESH:D007706 NCI:C75486 OMIM:309400 SNOMEDCT_US_2020_03_01:59178007 UMLS_CUI:C0022716 COPPER TRANSPORT DISEASE Menkes kinky-hair syndrome steely hair syndrome disease_ontology DOID:1838 OMIM mapping confirmed by DO. [SN]. Menkes disease DOID:1838 A connective tissue cancer that is located_in bone and is characterized by uncontrolled cellular proliferation that destroys normal bone tissue. DOID:3348 MESH:D001859 NCI:C9343 SNOMEDCT_US_2020_03_01:126537000 UMLS_CUI:C0005967 CA - bone cancer bone neoplasm bone tumour malignant bone neoplasm malignant bone tumour malignant neoplasm of bone malignant osseous tumor neoplasm of bone osseous tumor disease_ontology DOID:184 bone cancer DOID:184 A drug dependence that involves the continued use of cannabis despite problems related to use of the substance. ICD10CM:F12.2 ICD9CM:304.3 MESH:D002189 NCI:C34445 SNOMEDCT_US_2020_03_01:268766005 UMLS_CUI:C0006870 disease_ontology DOID:1849 cannabis dependence DOID:1849 A cholestasis characterized by impairment of the bile flow caused by obstruction located_in liver. GARD:10214 MESH:D002780 NCI:C84400 ORDO:284385 SNOMEDCT_US_2020_03_01:4637005 UMLS_CUI:C0008372 neonatal intrahepatic cholestasis disease_ontology DOID:1852 Xref MGI. intrahepatic cholestasis DOID:1852 A bone disease characterized by replacement of bone in the jaws with fibrous tissue leding to facial swelling that has_material_basis_in heterozygous mutation in SH3BP2 on chromosome 4p16.3. GARD:6036 ICD10CM:M27.8 MESH:D002636 NCI:C84630 OMIM:118400 SNOMEDCT_US_2020_03_01:76098004 UMLS_CUI:C0008029 disease_ontology DOID:1856 OMIM mapping confirmed by DO. [SN]. cherubism DOID:1856 A syndrome that is characterized by polyostotic fibrous dysplasia, precocious puberty, and café-au-lait spots and has_material_basis_in spontaneous post zygotic missense mutation at ARG201 or Gln227 of the GNAS gene during embryogenesis. DOID:11345 GARD:6995 ICD10CM:Q78.1 ICD9CM:756.54 NCI:C34610 OMIM:174800 SNOMEDCT_US_2020_03_01:726029005 UMLS_CUI:C0016065 fibrous dysplasia of bone osteitis fibrosa disseminata polyostotic fibrous dysplasia disease_ontology DOID:1858 OMIM mapping confirmed by DO. [SN]. McCune Albright syndrome MESH:D005359 DOID:1858 A bone cancer and jaw disease that is located in the jaw and results in a swollen jaw, results in numbness or a tingling sensation in jaw, and results in an abnormal growth of the jaw bone. MESH:D007573 SNOMEDCT_US_2020_03_01:126634001 UMLS_CUI:C0022364 neoplasm of jaw disease_ontology jaw neoplasm DOID:1862 jaw cancer DOID:1862 MESH:D012888 NCI:C3375 SNOMEDCT_US_2020_03_01:126538005 UMLS_CUI:C0037305 disease_ontology DOID:1863 skull cancer DOID:1863 ICD10CM:M27.1 ICD9CM:526.3 MESH:D006101 SNOMEDCT_US_2020_03_01:15350006 UMLS_CUI:C0162375 central giant cell (reparative) granuloma central giant cell granuloma central giant cell reparative granuloma of jaw disease_ontology DOID:1866 giant cell reparative granuloma DOID:1866 EFO:0004234 Sexual impotence erectile dysfunction disease_ontology DOID:1875 impotence DOID:1875 ICD10CM:F52.9 NCI:C3347 SNOMEDCT_US_2020_03_01:39894007 UMLS_CUI:C0549622 disease_ontology DOID:1876 sexual dysfunction DOID:1876 A heart septal defect located_in in the septum that separates the two atria of the heart. ICD10CM:Q21.1 MESH:D006344 NCI:C84473 OMIM:PS108800 ORDO:1478 SNOMEDCT_US_2020_03_01:156915002 UMLS_CUI:C0018817 atrial septal defect atrioseptal defect auricular septal defect congenital atrial septal defect interatrial septal defect interauricular septal defect disease_ontology DOID:1882 Xref MGI. atrial heart septal defect DOID:1882 A viral infectious disease that results_in inflammation located_in liver, has_material_basis_in Hepatitis C virus, which is transmitted_by blood from an infected person enters the body of an uninfected person. The infection has_symptom fever, has_symptom fatigue, has_symptom loss of appetite, has_symptom nausea, has_symptom vomiting, has_symptom abdominal pain, has_symptom clay-colored bowel movements, has_symptom joint pain, and has_symptom jaundice. DOID:12430 DOID:12432 DOID:2049 EFO:0003047 ICD10CM:B19.20 ICD9CM:070.7 MESH:D006526 NCI:C3098 SNOMEDCT_US_2020_03_01:154349000 UMLS_CUI:C0019196 NANBH Viral hepatitis C chronic hepatitis C hepatitis C infection hepatitis nonA nonB disease_ontology DOID:1883 hepatitis C DOID:1883 A hepatitis that involves viral infection causing inflammation of the liver. DOID:12548 DOID:1331 DOID:1885 MESH:D006524 UMLS_CUI:C0019194 Viral hepatitis with hepatic coma animal viral hepatitis human viral hepatitis disease_ontology DOID:1884 viral hepatitis DOID:1884 A cranial nerve disease that is located_in the optic nerve. MESH:D009901 NCI:C79698 SNOMEDCT_US_2020_03_01:77157004 UMLS_CUI:C0029132 disorder of the second nerve optic nerve disorder optic neuropathy disease_ontology DOID:1891 optic nerve disease DOID:1891 MESH:D051677 NCI:C4247 SNOMEDCT_US_2020_03_01:34360000 UMLS_CUI:C0334463 Fibroxanthosarcoma MFH disease_ontology DOID:1907 malignant fibrous histiocytoma DOID:1907 A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from melanocytes which are found in skin, the bowel and the eye. EFO:0000756 KEGG:05218 MESH:D008545 NCI:C3224 SNOMEDCT_US_2020_03_01:2092003 UMLS_CUI:C0025202 Naevocarcinoma malignant melanoma disease_ontology DOID:1909 melanoma MESH:D008545 DOID:1909 A germ cell cancer that has_material_basis_in cells that line the yolk sac of the embryo. MESH:D018240 NCI:C3011 SNOMEDCT_US_2020_03_01:74409009 UMLS_CUI:C0014145 Hepatoid yolk sac tumour Yolk Sac neoplasm Yolk sac tumor Yolk sac tumour endodermal sinus tumour infantile embryonal carcinoma disease_ontology DOID:1911 endodermal sinus tumor DOID:1911 ICD10CM:E79.1 MESH:D007926 NCI:C61255 OMIM:300322 SNOMEDCT_US_2020_03_01:190918000 UMLS_CUI:C0023374 Complete hypoxanthine-guanine phosphoribosyltransferase deficiency HG-PRT deficiency Hypoxanthine-guanine phosphoribosyltransferase deficiency Hypoxanthine-guanine-phosphoribosyltransferase deficiency Lesch - Nyhan syndrome X-linked hyperuricemia deficiency of IMP pyrophosphorylase hypoxanthine guanine phosphoribosyltransferase deficiency disease_ontology DOID:1919 OMIM mapping confirmed by DO. [SN]. Lesch-Nyhan syndrome DOID:1919 A reproductive organ cancer that is located_in the sex cord-derived tissues of the ovary or testis and derives_from granulosa cells, Leydig cells, Sertoli cells, and fibroblasts. DOID:12293 MESH:D018312 NCI:C3794 SNOMEDCT_US_2020_03_01:253028001 UMLS_CUI:C0206724 Sex Cord-Stromal neoplasm Sex cord stromal tumour Specialized gonadal neoplasm Specialized gonadal tumor Specialized gonadal tumour sex cord-gonadal stromal tumour disease_ontology DOID:192 sex cord-gonadal stromal tumor DOID:192 An acquired metabolic disease that has_material_basis_in an abnormally high level of uric acid in the blood. MESH:D033461 NCI:C3961 SNOMEDCT_US_2020_03_01:271198001 UMLS_CUI:C0740394 Blood urate raized uricacidemia disease_ontology DOID:1920 hyperuricemia DOID:1920 A chromosomal duplication syndrome that is characterized by infertility and that has_material_basis_in an extra X chromosome in cells in men. GARD:8705 ICD10CM:Q98.0 ICD9CM:758.7 MESH:D007713 NCI:C34752 SNOMEDCT_US_2020_03_01:405770005 UMLS_CUI:C0022735 47, XXY Hypogonadotropic Hypogonadism Klinefelter's syndrome XXY syndrome XXY trisomy disease_ontology DOID:1921 No OMIM mapping, confirmed by DO. [LS]. Klinefelter syndrome DOID:1921 A gonadal disease that is characterized by atypical development of chromosomal, gonadal, or anatomic sex. MESH:D012734 UMLS_CUI:C0036875 sex development disorder sex differentiation disease disease_ontology DOID:1923 disorder of sexual development DOID:1923 A gonadal disease that is characterized by diminished functional activity of the gonads. MESH:D007006 NCI:C9227 OMIM:241100 OMIM:312300 SNOMEDCT_US_2020_03_01:48130008 UMLS_CUI:C0020619 disease_ontology DOID:1924 hypogonadism DOID:1924 An autosomal dominant non-syndromic intellectual disability that is characterized by mental retardation associated with coarse facial features, hypertrichosis, sparse scalp hair, and hypoplastic or absent fifth fingernails or toenails. GARD:6124 MESH:C536436 NCI:C35321 OMIM:PS135900 ORDO:1465 SNOMEDCT_US_2020_03_01:10007009 UMLS_CUI:C0265338 Dwarfism-Onychodysplasia Fifth Digit Syndrome Short Stature-Onychodysplasia. disease_ontology DOID:1925 OMIM mapping confirmed by DO. [SN]. Coffin-Siris syndrome DOID:1925 A sphingolipidosis characterized by deficiency of the enzyme glucocerebrosidase which results in the accumulation of harmful quantities of the glycolipid glucocerebroside throughout the body, especially within the bone marrow, spleen and liver. GARD:8233 ICD10CM:E75.22 MESH:D005776 NCI:C61268 ORDO:355 SNOMEDCT_US_2020_03_01:190794006 UMLS_CUI:C0017205 Gaucher disease acid beta-glucosidase deficiency glocucerebrosidase deficiency glucosylceramide beta-glucosidase deficiency kerasin thesaurismosis disease_ontology DOID:1926 Xref MGI. OMIM mapping confirmed by DO. [SN]. Gaucher's disease DOID:1926 A lipid storage disease characterized by functional deficiencies in the enzymes needed for lysosomal degradation of sphingolipid substrates. GARD:7672 ICD10CM:E75.3 MESH:D013106 NCI:C117254 SNOMEDCT_US_2020_03_01:58459009 UMLS_CUI:C0037899 Sphingolipidosis sphingolipidoses disease_ontology DOID:1927 sphingolipidosis DOID:1927 A syndrome that is characterized by mild to moderate intellectual disability, a broad forehead, a short nose with a broad tip, full cheeks, and a wide mouth with full lips and difficulty with visual-spatial tasks and has_material_basis_in hemizygous deletion of 1.5 to 1.8 Mb on chromosome 7q11.23. ICD10CM:Q93.82 MESH:D018980 NCI:C85232 OMIM:194050 SNOMEDCT_US_2020_03_01:63247009 UMLS_CUI:C0175702 Fanconi Schlesinger syndrome disease_ontology DOID:1928 OMIM mapping confirmed by DO. [LS]. Williams-Beuren syndrome DOID:1928 An aortic valve stenosis that is characterized by a narrowing of the section of the aorta just above the valve that connects the aorta to the heart. GARD:743 ICD10CM:Q25.3 MESH:D021921 NCI:C85176 OMIM:185500 SNOMEDCT_US_2020_03_01:204436002 UMLS_CUI:C0003499 Supra-valvular aortic stenosis disease_ontology DOID:1929 supravalvular aortic stenosis DOID:1929 An organ system cancer that is manifested in the reproductive organs. DOID:1900 NCI:C3674 UMLS_CUI:C0178830 Reproductive tumor malignant reproductive system neoplasm disease_ontology cancer of reproductive system DOID:193 reproductive organ cancer DOID:193 A syndrome characterized by pituitary dysfunction, childhood onset ataxia, peripheral neuropathy, spastic paraplegia, and chorioretinopathy that has_material_basis_in homozygous or compound heterozygous mutation in PNPLA6 on chromosome 19p13.2. GARD:12635 MEDDRA:10056710 MESH:D007849 NCI:C34760 OMIM:245800 ORDO:2377 SNOMEDCT_US_2020_03_01:232059000 UMLS_CUI:C0023138 LNMS disease_ontology Laurence-Moon-Biedl syndrome DOID:1930 OMIM mapping confirmed by DO. [SN]. Laurence-Moon syndrome DOID:1930 A syndrome that is characterized by delayed development, intellectual disability, severe speech impairment, and problems with movement and balance. GARD:5810 ICD10CM:Q93.51 MESH:D017204 NCI:C75462 OMIM:105830 SNOMEDCT_US_2020_03_01:76880004 UMLS_CUI:C0162635 happy puppet syndrome puppetlike syndrome disease_ontology DOID:1932 OMIM mapping confirmed by DO. [SN]. Angelman syndrome MESH:D017204 DOID:1932 A syndrome characterized by short stature, moderate to sever intellectual disability, distinctive facial features and broad thumbs and first toes. GARD:7593 ICD10CM:Q87.2 MESH:D012415 NCI:C75466 OMIM:180849 OMIM:610543 OMIM:613684 ORDO:783 SNOMEDCT_US_2020_03_01:157032007 UMLS_CUI:C0035934 Broad Thumb-Hallux syndrome Rubinstein syndrome proximal chromosome 16p13.3 deletion syndrome disease_ontology DOID:1933 Xref MGI. OMIM mapping confirmed by DO. [SN]. Rubinstein-Taybi syndrome DOID:1933 A bone development disease that results in defective ossification of located in bone. MESH:D004413 NCI:C34560 SNOMEDCT_US_2020_03_01:109420003 UMLS_CUI:C0013393 disease_ontology DOID:1934 dysostosis DOID:1934 A syndrome that results from mutations in multiple BBS genes affecting cellular cilia structure or function (ciliopathy) resulting in variable presentation and characterized principally by obesity, retinitis pigmentosa,vision loss, polydactyly, mental retardation, hypogonadism, and renal failure in some cases. GARD:6866 ICD10CM:Q87.89 MESH:D020788 NCI:C118632 OMIM:PS209900 ORDO:110 SNOMEDCT_US_2020_03_01:5619004 UMLS_CUI:C0752166 disease_ontology DOID:1935 OMIM mapping confirmed by DO. [SN]. Bardet-Biedl syndrome DOID:1935 EFO:0003914 ICD10CM:I70 ICD9CM:440 MESH:D050197 NCI:C35768 SNOMEDCT_US_2020_03_01:155414001 UMLS_CUI:C0004153 disease_ontology DOID:1936 atherosclerosis MESH:D050197 DOID:1936 A parasitic protozoa infectious disease that is caused by singled-celled protozoan parasites Trichomonas vaginalis or Trichomonas tenax, which infect the urogenital tract and mouth respectively. DOID:10996 ICD10CM:A59 ICD9CM:131 MESH:D014245 NCI:C35720 SNOMEDCT_US_2020_03_01:56335008 UMLS_CUI:C0040921 disease_ontology trichomonas infection DOID:1947 trichomoniasis DOID:1947 A cholangitis that is characterized by an inflammation that is located in the gallbladder. DOID:1948 DOID:2829 DOID:9438 GARD:30 ICD10CM:K81 ICD9CM:575.10 MESH:D002764 NCI:C34465 OMIM:600803 SNOMEDCT_US_2020_03_01:76581006 UMLS_CUI:C0008325 acute and chronic cholecystitis acute cholecystitis acute on chronic cholecystitis chronic cholecystitis disease_ontology DOID:1949 OMIM mapping confirmed by DO. [SN]. cholecystitis DOID:1949 A female reproductive system disease that is located_in the fallopian tube. MESH:D005184 NCI:C26771 SNOMEDCT_US_2020_03_01:128134005 UMLS_CUI:C0015556 disease_ontology DOID:1962 fallopian tube disease DOID:1962 A fallopian tube cancer that is located_in the fallopian tube. MESH:D005185 NCI:C3867 SNOMEDCT_US_2020_03_01:276870001 UMLS_CUI:C0238122 cancer of the fallopian tube carcinoma of fallopian tube fallopian tube Ca disease_ontology DOID:1963 fallopian tube carcinoma DOID:1963 A female reproductive organ cancer that is located_in fallopian tube. DOID:1961 GARD:9162 ICD10CM:C57.0 ICD9CM:183.2 MESH:D005185 NCI:C3032 NCI:C7480 SNOMEDCT_US_2020_03_01:126916003 SNOMEDCT_US_2020_03_01:93794008 UMLS_CUI:C0015558 UMLS_CUI:C0153579 fallopian tube neoplasm malignant neoplasm of uterine tube malignant tumor of fallopian tube malignant tumour of fallopian tube neoplasm of fallopian tube tumor of the fallopian tube tumor, fallopian tube, malignant disease_ontology DOID:1964 fallopian tube cancer DOID:1964 A smooth muscle cancer that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis. GARD:6880 MESH:D007890 NCI:C3158 SNOMEDCT_US_2020_03_01:443719001 UMLS_CUI:C0023269 Leiomyosarcomas disease_ontology DOID:1967 leiomyosarcoma DOID:1967 A brain disease that is caused by damage to the motor control centers of the developing brain during pregnancy, during childbirth or after birth, which affects muscle movement and balance. DOID:1968 ICD10CM:G80 MESH:D002547 NCI:C34460 SNOMEDCT_US_2020_03_01:155024003 UMLS_CUI:C0007789 infantile cerebral palsy disease_ontology DOID:1969 cerebral palsy DOID:1969 A carcinosarcoma that derives_from simultaneously or consecutively in mesodermal tissue and glandular epithelium. MESH:D018195 NCI:C9474 SNOMEDCT_US_2020_03_01:189804002 UMLS_CUI:C0001442 Adenosarcoma mullerian Adenosarcoma disease_ontology DOID:1974 adenosarcoma MESH:D018195 DOID:1974 MESH:D012004 NCI:C3350 SNOMEDCT_US_2020_03_01:126847008 UMLS_CUI:C0034885 Rectal tumor neoplasm of rectum rectum neoplasm disease_ontology DOID:1984 rectal benign neoplasm DOID:1984 A colorectal cancer that is located_in the rectum. DOID:1989 ICD10CM:C20 ICD9CM:154.1 MESH:D012004 NCI:C7418 NCI:C9382 SNOMEDCT_US_2020_03_01:254582000 SNOMEDCT_US_2020_03_01:93984006 UMLS_CUI:C0007113 UMLS_CUI:C0949022 carcinoma of rectum carcinoma of the rectum malignant Rectal tumor malignant neoplasm of rectum malignant rectum tumor malignant tumor of rectum rectal cancer disease_ontology cancer of rectum DOID:1993 rectum cancer DOID:1993 A rectum cancer that derives_from epithelial cells of glandular origin. NCI:C9383 SNOMEDCT_US_2020_03_01:254582000 UMLS_CUI:C0149978 Rectal adenocarcinoma disease_ontology DOID:1996 rectum adenocarcinoma DOID:1996 MESH:D005870 NCI:C3055 SNOMEDCT_US_2020_03_01:443790001 UMLS_CUI:C0017525 disease_ontology DOID:200 benign giant cell tumor DOID:200 A nervous system benign neoplasm that is characterized as a nerve tissue tumor. MESH:D009463 NCI:C3275 SNOMEDCT_US_2020_03_01:25169009 UMLS_CUI:C0027858 disease_ontology DOID:2001 neuroma DOID:2001 ICD9CM:362.56 MESH:D019773 SNOMEDCT_US_2020_03_01:193391002 UMLS_CUI:C0339543 Macular puckering of retina Macular retinal puckering cellophane maculopathy disease_ontology DOID:2006 preretinal fibrosis DOID:2006 ICD10CM:H35.3 ICD9CM:362.5 SNOMEDCT_US_2020_03_01:193384000 UMLS_CUI:C0339436 degeneration of macula and posterior pole of retina degeneration of macula or posterior pole disease_ontology DOID:2007 degeneration of macula and posterior pole DOID:2007 A musculoskeletal system cancer that is located_in connective tissue. MESH:D009372 SNOMEDCT_US_2020_03_01:126598008 UMLS_CUI:C0027656 Tumour of connective tissue connective tissue neoplasm neoplasm of connective tissues disease_ontology DOID:201 connective tissue cancer DOID:201 A T cell deficiency that results from the disfunction or underdevelopment of the thymus. ICD10CM:D81.4 ICD9CM:279.13 OMIM:242700 ORDO:83471 SNOMEDCT_US_2020_03_01:55602000 UMLS_CUI:C0152094 Nezelof's syndrome T-cell immunodeficiency with thymic aplasia TIDTA thymic aplasia thymic dysplasia with normal immunoglobulins disease_ontology DOID:2012 OMIM mapping confirmed by DO. [SN]. Nezelof syndrome DOID:2012 ICD10CM:E16.1 MESH:D006946 SNOMEDCT_US_2020_03_01:154694003 UMLS_CUI:C0020459 hyperinsulinemia disease_ontology DOID:2018 hyperinsulinism DOID:2018 A female reproductive organ cancer that is located_in the placenta. DOID:2023 ICD10CM:C58 ICD9CM:181 NCI:C3555 SNOMEDCT_US_2020_03_01:188187004 UMLS_CUI:C0153572 Placental tumors malignant Placental tumor malignant neoplasm of placenta neoplasm of placenta placental cancer primary malignant neoplasm of placenta disease_ontology DOID:2021 placenta cancer DOID:2021 A choriocarcicoma that develops in the presence of a preceding gestational event. NCI:C4646 SNOMEDCT_US_2020_03_01:1884006 UMLS_CUI:C0349557 Gestational choriocarcinoma Gestational chorionepithelioma Molar pregnancy with choriocarcinoma disease_ontology DOID:2025 gestational choriocarcinoma DOID:2025 A hyperostosis that involves formation of new bone on the surface of preexisting bone. ICD10CM:M27.8 ICD9CM:726.91 MESH:D005096 NCI:C3029 SNOMEDCT_US_2020_03_01:80400009 UMLS_CUI:C1442903 bone spur bony outgrowth orbital exostosis osteophyte swimmer's exostosis disease_ontology DOID:203 exostosis DOID:203 A cognitive disorder that involves an excessive, irrational dread of everyday situations. DOID:12884 ICD10CM:F41.9 MESH:D001008 NCI:C2878 OMIM:607834 SNOMEDCT_US_2020_03_01:65673007 UMLS_CUI:C0003469 anxiety anxiety state disease_ontology DOID:2030 anxiety disorder DOID:2030 A specific developmental disorder that involves specific developmental disorders of speech and language. ICD10CM:F80.9 MESH:D003147 NCI:C2958 SNOMEDCT_US_2020_03_01:74825008 UMLS_CUI:C0009460 disease_ontology DOID:2033 communication disorder DOID:2033 A brain disease that is characterized by cerebral softening located_in cerebrum has_material_basis_in injured or dead cells of the central nervous system. MESH:D004678 NCI:C98920 SNOMEDCT_US_2020_03_01:58762006 UMLS_CUI:C0014068 disease_ontology DOID:2034 encephalomalacia DOID:2034 A connective tissue disease characterized by damage of tissues located_in the entheses, the site of insertion of tendons or ligaments into bones or joint capsules, with symptoms of pain, swelling and inflammation. ICD10CM:M77.9 ICD9CM:726.90 MESH:D000070676 SNOMEDCT_US_2020_03_01:278525009 UMLS_CUI:C0242490 disease_ontology DOID:204 enthesopathy MESH:D000070676 DOID:204 A viral infectious disease that results_in inflammation located_in liver, has_material_basis_in Hepatitis B virus, which is transmitted_by sexual contact, transmitted_by blood transfusions, and transmitted_by fomites like needles or syringes. The infection has_symptom fever, has_symptom fatigue, has_symptom loss of appetite, has_symptom nausea, has_symptom vomiting, has_symptom abdominal pain, has_symptom clay-colored bowel movements, has_symptom joint pain, and has_symptom jaundice. DOID:12591 DOID:12592 DOID:2042 EFO:0004197 MESH:D006509 NCI:C3097 SNOMEDCT_US_2020_03_01:66071002 UMLS_CUI:C0019163 chronic hepatitis B hepatitis B infection disease_ontology Serum hepatitis DOID:2043 hepatitis B DOID:2043 A viral infectious disease that results_in inflammation located_in liver, has_material_basis_in Hepatitis delta virus, which is an incomplete virus that requires the helper function of Hepatitis B virus to replicate and only occurs among people who are infected with the Hepatitis B virus. The infection has_symptom fatigue, has_symptom lethargy, has_symptom anorexia, has_symptom nausea, has_symptom jaundice, has_symptom clay-colored stools, has_symptom dark urine, has_symptom changes in personality, has_symptom disturbances in sleep, has_symptom confusion, has_symptom abnormal behavior, has_symptom somnolence, and has_symptom coma. DOID:2046 MESH:D003699 SNOMEDCT_US_2020_03_01:424460009 UMLS_CUI:C0011226 delta hepatitis disease_ontology DOID:2047 hepatitis D DOID:2047 An autoimmune disease of gastrointestinal tract that results_in inflammation located_in liver caused by the body's immune system attacking the liver cells. DOID:4745 GARD:5871 ICD9CM:571.42 MESH:D019693 NCI:C27778 SNOMEDCT_US_2020_03_01:16098491000119109 UMLS_CUI:C0241910 UMLS_CUI:C1332355 Autoimmune Hepatitis Autoimmune chronic active hepatitis Autoimmune hepatitis autoimmune hepatitis with centrilobular necrosis disease_ontology DOID:2048 autoimmune hepatitis DOID:2048 A bone remodeling disease that results in an abnormal growth of located in bone. ICD10CM:M89.3 MESH:D015576 NCI:C34712 SNOMEDCT_US_2020_03_01:13814009 UMLS_CUI:C0020492 bone hypertrophy hypertrophy of bone disease_ontology DOID:205 hyperostosis DOID:205 A maxillary sinusitis which lasts for less than 4 weeks. ICD10CM:J01.0 ICD9CM:461.0 SNOMEDCT_US_2020_03_01:155499007 UMLS_CUI:C0155804 acute antritis disease_ontology DOID:2050 acute maxillary sinusitis DOID:2050 A sinusitis which involves infection of maxillary sinuses that causes pain or pressure over the cheeks just below the eyes, tooth ache, and headache. ICD10CM:J32.0 MESH:D015523 NCI:C34809 SNOMEDCT_US_2020_03_01:275484005 UMLS_CUI:C0024959 disease_ontology DOID:2051 maxillary sinusitis DOID:2051 An anxiety disorder which results from a traumatic experience that results in psychological trauma. ICD10CM:F43.1 ICD9CM:309.81 MESH:D013313 NCI:C3389 SNOMEDCT_US_2020_03_01:192415000 UMLS_CUI:C0038436 PTSD traumatic neurosis disease_ontology post-traumatic stress disorder DOID:2055 post-traumatic stress disorder DOID:2055 A candidiasis that refers to a heterogeneous group of disorders characterized by recurrent or persistent superficial fungal infections located_in skin, located_in mucous membrane, or located_in nail due to T-cell defects, has-agent Candida species and has_symptom scaling of skin lesions, has_symptom thickening of nails, has_symptom swollen periungal tissue, and has_symptom scarring of the scalp. DOID:2056 GARD:12313 MESH:D002178 NCI:C34444 OMIM:114580 OMIM:212050 OMIM:607644 OMIM:613108 OMIM:613956 OMIM:614162 OMIM:615527 OMIM:616445 ORDO:1334 SNOMEDCT_US_2020_03_01:234568006 UMLS_CUI:C0006845 chronic Mucocutaneous Candidiasis disease_ontology DOID:2058 chronic mucocutaneous candidiasis DOID:2058 A female reproductive system disease that is located_in the vulva. MESH:D014845 NCI:C27631 SNOMEDCT_US_2020_03_01:5089007 UMLS_CUI:C0042994 disease_ontology DOID:2059 vulvar disease DOID:2059 disease_ontology Eccrine nodular hidradenoma nodular hidradenoma DOID:2061 nodular hidradenoma DOID:2061 GARD:10547 MESH:D018252 NCI:C3761 OMIM:186600 SNOMEDCT_US_2020_03_01:189051001 UMLS_CUI:C0206673 disease_ontology DOID:2065 syringoma DOID:2065 ICD9CM:569.83 MESH:D007416 NCI:C39611 SNOMEDCT_US_2020_03_01:56905009 UMLS_CUI:C0021845 Perforation of intestine disease_ontology DOID:2074 intestinal perforation DOID:2074 A bowel dysfunction that is characterized by infrequent or difficult evacuation of feces. ICD10CM:K59.0 ICD9CM:564.0 MESH:D003248 NCI:C37930 SNOMEDCT_US_2020_03_01:363693003 UMLS_CUI:C0009806 disease_ontology DOID:2089 constipation DOID:2089 ICD10CM:M12.8 ICD9CM:716.4 NCI:C35761 SNOMEDCT_US_2020_03_01:66191007 UMLS_CUI:C0152083 disease_ontology DOID:2092 transient arthritis DOID:2092 A vulva cancer that has_material_basis in melanocytes. NCI:C40329 SNOMEDCT_US_2020_03_01:254896002 UMLS_CUI:C0241989 malignant melanoma of vulva disease_ontology DOID:2093 vulvar melanoma DOID:2093 ICD10CM:C44 NCI:C4810 SNOMEDCT_US_2020_03_01:255095005 UMLS_CUI:C1321904 malignant neoplasm of sweat gland malignant tumor of the Sweat gland disease_ontology DOID:2095 sweat gland cancer DOID:2095 A vulva adenocarcinoma that is characterized by distinctive large cells with prominent cytoplasm, referred to as Paget cells and is an intraepithelial neoplasm of epithelial origin expressing apocrine or eccrine glandular-like features. NCI:C4027 SNOMEDCT_US_2020_03_01:254898001 UMLS_CUI:C1275217 Paget's disease of vulva Vulval Paget's disease Vulvar Paget's disease vulval Paget disease disease_ontology DOID:2097 vulval Paget's disease DOID:2097 A vulva carcinoma that derives_from epithelial cells of glandular origin. NCI:C6380 UMLS_CUI:C1336975 adenocarcinoma of Vulva disease_ontology adenocarcinoma of the vulva DOID:2098 vulva adenocarcinoma DOID:2098 A muscle tissue disease that is characterised by slow muscle relaxation associated with hyperexcitation of the muscle fibres. GARD:12301 ICD9CM:359.22 MESH:D009224 NCI:C84912 OMIM:160800 OMIM:255700 ORDO:614 UMLS_CUI:C0027127 Congenital myotonia, autosomal dominant form Thomsen disease Thomsen's disease disease_ontology DOID:2106 OMIM mapping confirmed by DO. [SN]. myotonia congenita DOID:2106 A coccidiosis that involves infection of the epithelial cells of the small intestine with Cystoisospora belli, which results in nonbloody diarrhea with crampy abdominal pain, malabsorption and weight loss. DOID:4891 ICD10CM:A07.3 MESH:D021865 NCI:C4076 SNOMEDCT_US_2020_03_01:73034009 UMLS_CUI:C0311386 Infection by Isospora belli and Isospora hominis Isosporosis isosporiasis disease_ontology DOID:2112 cystoisosporiasis DOID:2112 A parasitic protozoa infectious disease that occurs in the intestinal tract of animals and humans caused by Coccidia protozoa. Immunocompromised persons are at greater risk of developing the infection. MESH:D003048 NCI:C34493 SNOMEDCT_US_2020_03_01:186125004 UMLS_CUI:C0009187 Coccidiosis disease_ontology intestinal coccidiosis DOID:2113 coccidiosis DOID:2113 A primary immunnodeficiency disease that is caused by a lack of infection-fighting antibody producing B cells (immunoglobulins) or B cells that are not functioning properly. DOID:6026 ICD9CM:279.03 SNOMEDCT_US_2020_03_01:190982008 UMLS_CUI:C0154276 B cell (antibody) deficiencies Immunoglobulin heavy chain deficiency immunoglobulin heavy chain deletion disease_ontology DOID:2115 B cell deficiency DOID:2115 A syndrome characterized at birth by streaks of very thin skin (dermal hypoplasia), cutis aplasia, and telangiectases, and has_material_basis_in heterozygous mutation in the PORCN gene on chromosome Xp11.23. GARD:6457 MESH:D005489 NCI:C84715 OMIM:305600 ORDO:2092 SNOMEDCT_US_2020_03_01:205573006 UMLS_CUI:C0016395 FDH FODH Goltz syndrome Goltz-Gorlin syndrome disease_ontology DOID:2120 OMIM mapping confirmed by DO. [SN]. focal dermal hypoplasia DOID:2120 A syndrome characterized by abnormal development in 2 or more ectodermal structures (hair, nails, teeth, and sweat glands) without other systemic findings. GARD:6317 ICD9CM:757.31 MESH:D004476 NCI:C84683 OMIM:PS305100 ORDO:79373 SNOMEDCT_US_2020_03_01:8654005 UMLS_CUI:C0013575 Congenital ectodermal defect Congenital ectodermal dysplasia disease_ontology DOID:2121 ectodermal dysplasia DOID:2121 A primary bacterial infectious disease that has_material_basis_in Francisella tularensis, which is transmitted by dog tick bite (Dermacentor variabilis), transmitted by deer flies (Chrysops sp) or transmitted by contact with infected animal tissues. GARD:396 ICD9CM:021.8 SNOMEDCT_US_2020_03_01:186298002 UMLS_CUI:C0029835 disease_ontology DOID:2123 tularemia DOID:2123 A brain cancer that is usually located in the brain, but can occur anywhere in the central nervous system. NCI:C6906 OMIM:609322 ORDO:99966 SNOMEDCT_US_2020_03_01:128792003 UMLS_CUI:C1266184 Atypical teratoid/rhabdoid tumor Atypical teratoid/rhabdoid tumour Rhabdoid tumor of the CNS Rhabdoid tumour of the CNS atypical teratoid rhabdoid tumour disease_ontology AT/RT rhabdoid tumor predisposition syndrome DOID:2129 OMIM mapping confirmed by DO. [SN]. atypical teratoid rhabdoid tumor DOID:2129 ICD10CM:K03.8 ICD9CM:521.8 SNOMEDCT_US_2020_03_01:197505001 UMLS_CUI:C0029770 disease_ontology DOID:214 teeth hard tissue disease DOID:214 An extrapulmonary tuberculosis that is located_in urogenital system. ICD10CM:A18.1 ICD9CM:016 MESH:D014401 SNOMEDCT_US_2020_03_01:4445009 UMLS_CUI:C0041333 disease_ontology Genitourinary tuberculosis DOID:2149 urogenital tuberculosis DOID:2149 An ovary epithelial cancer that has_material_basis_in epithelial and stromal tissue and arises from the surface epithelium of the ovary. NCI:C40026 UMLS_CUI:C1518236 disease_ontology DOID:2151 malignant ovarian surface epithelial-stromal neoplasm DOID:2151 An ovarian cancer that is derives_from ovarian surface epithelium. NCI:C4381 SNOMEDCT_US_2020_03_01:237057005 UMLS_CUI:C0341823 Ovarian Surface epithelial-Stromal tumor disease_ontology DOID:2152 ovary epithelial cancer DOID:2152 A kidney cancer that affects the kidneys and typically located_in children. DOID:5177 DOID:5180 ICDO:M8960/3 MESH:D009396 NCI:C27730 NCI:C3267 NCI:C6180 OMIM:194070 SNOMEDCT_US_2020_03_01:25081006 UMLS_CUI:C0027708 UMLS_CUI:C1332219 UMLS_CUI:C1333015 adult nephroblastoma disease_ontology Wilms' tumor DOID:2154 OMIM mapping confirmed by DO. [SN]. nephroblastoma DOID:2154 An ovarian cancer that originates in the germ (egg) cells of the ovary. GARD:9330 NCI:C3873 OMIM:603737 SNOMEDCT_US_2020_03_01:237059008 UMLS_CUI:C0238324 germ cell neoplasm of Ovary germ cell tumor of ovary disease_ontology ovarian germ cell tumor DOID:2156 OMIM mapping confirmed by DO. [SN]. ovarian germ cell cancer DOID:2156 A teeth hard tissue disease that is characterized by damage to a tooth that can happen when decay-causing bacteria in your mouth make acids that attack the tooth’s surface, or enamel. DOID:10785 DOID:10870 DOID:11913 EFO:0003819 ICD10CM:K02 ICD10CM:K02.6 ICD9CM:521.0 ICD9CM:521.07 MESH:D003731 NCI:C52593 SNOMEDCT_US_2020_03_01:155632007 UMLS_CUI:C0011334 UMLS_CUI:C1456145 Dental caries extending into pulp Dental caries of smooth surface Dental caries pit and fissure disease_ontology DOID:216 dental caries DOID:216 DOID:4728 NCI:C27102 SNOMEDCT_US_2020_03_01:232340005 UMLS_CUI:C0339820 disease_ontology DOID:2163 nasal cavity disease DOID:2163 ICD9CM:521.01 SNOMEDCT_US_2020_03_01:80353004 UMLS_CUI:C0266853 Dental caries limited to enamel primary dental caries simple dental cavity disease_ontology DOID:217 enamel caries DOID:217 A vaginal disease that is characterized by inflammation of the vagina. DOID:10769 ICD9CM:616.1 MESH:D014627 NCI:C26911 SNOMEDCT_US_2020_03_01:198212006 SNOMEDCT_US_2020_03_01:393596009 UMLS_CUI:C0042267 UMLS_CUI:C0042268 disease_ontology DOID:2170 vaginitis DOID:2170 A sensory system cancer located_in the eye that is characterized by uncontrolled cellular proliferation in the eye. DOID:9985 ICD9CM:190.8 MESH:D005134 NCI:C3030 SNOMEDCT_US_2020_03_01:126995000 SNOMEDCT_US_2020_03_01:188277006 UMLS_CUI:C0015414 UMLS_CUI:C0153632 Ocular tumor eye neoplasm malignant eye neoplasm neoplasm of eye neoplasm of eye proper disease_ontology DOID:2174 ocular cancer DOID:2174 ICD10CM:C18.2 ICD9CM:153.6 SNOMEDCT_US_2020_03_01:93683002 UMLS_CUI:C0153439 Ca ascending colon malignant neoplasm of right colon malignant tumor of ascending colon disease_ontology DOID:218 ascending colon cancer DOID:218 A dental enamel hypoplasia characterized by abnormal enamel formation. GARD:5791 ICD10CM:K00.5 MESH:D000567 OMIM:PS104500 ORDO:88661 SNOMEDCT_US_2020_03_01:78494001 UMLS_CUI:C0002452 disease_ontology DOID:2187 Xref MGI. amelogenesis imperfecta DOID:2187 A colorectal cancer that is located_in the colon. ICD10CM:C18 ICD9CM:153 MESH:D003110 NCI:C9242 SNOMEDCT_US_2020_03_01:363406005 UMLS_CUI:C0007102 disease_ontology DOID:219 colon cancer DOID:219 A blood coagulation disease that is characterized by easy bleeding, has_symptom prolonged umbilical cord bleeding, epistaxis, bleeding of the gums, menorrhagia, recurrent miscarriages, abnormal scar formation and wound healing, and hemarthrosis, and has_material_basis_in autosomal recessive inheritance of mutation of the F13A1 or F13B gene, which encodes Factor XIII, formally known as fibrin stabilizing factor. GARD:10766 MESH:D005177 NCI:C98941 OMIM:613225 OMIM:613235 SNOMEDCT_US_2020_03_01:50189006 UMLS_CUI:C0015530 Factor XIII deficiency disease Hereditary factor XIII deficiency disease deficiency, Laki-Lorand factor disease_ontology DOID:2211 OMIM mapping confirmed by DO. [SN]. factor XIII deficiency DOID:2211 ICD10CM:D69.9 ICD9CM:287.9 MESH:D006474 SNOMEDCT_US_2020_03_01:268884000 UMLS_CUI:C0019087 Hemorrhagic diathesis Hemorrhagic disease disease_ontology DOID:2213 hemorrhagic disease DOID:2213 A blood coagulation disease that is characterized by easy bleeding, has_symptom epistaxis, bleeding of the gums, menorrhagia, and occasionally hemarthrosis, and has_material_basis_in autosomal recessive inheritance of mutation in the F7 gene, which encodes coagulation factor VII, an important factor in the clotting cascade. GARD:2238 ICD10CM:D68.2 MESH:D005168 NCI:C131631 SNOMEDCT_US_2020_03_01:154820003 UMLS_CUI:C0015503 Factor VII deficiency deficiency, stable disease_ontology DOID:2215 factor VII deficiency DOID:2215 GARD:2237 ICD10CM:D68.2 MESH:D005166 NCI:C98938 OMIM:227400 SNOMEDCT_US_2020_03_01:191284007 UMLS_CUI:C0015499 Hereditary hypoproaccelerinaemia Labile factor deficiency Proaccelerin deficiency deficiency, labile disease_ontology DOID:2216 OMIM mapping confirmed by DO. [SN]. factor V deficiency DOID:2216 A blood coagulation disease characterized by autosomal recessive inheritance of mucosal bleeding, purpuric skin bleeding, epistaxis, and menorrhagia with prolonged bleeding times, enlarged platelets and absence of platelet aggregation in response to von Willebrand factor that has material_basis_in mutation in the GP1BA gene, the GP1BB gene, or the GP9 gene which are subunits of the platelet membrane von Willebrand factor receptor complex, glycoprotein Ib. MESH:D001606 NCI:C84595 OMIM:231200 ORDO:274 SNOMEDCT_US_2020_03_01:54569005 UMLS_CUI:C0005129 Bernard - Soulier thrombopathy Bernard Soulier syndrome Giant platelet syndrome Hemorrhagic dystrophic thrombocytopenia Thrombopathy, Bernard-Soulier disease_ontology DOID:2217 OMIM mapping confirmed by DO. [SN]. Bernard-Soulier syndrome DOID:2217 A blood coagulation disease that is characterized by an abnormal increase or decrease in platelets or platelet dysfunction. MESH:D001791 NCI:C131634 SNOMEDCT_US_2020_03_01:22716005 UMLS_CUI:C0005818 Thrombocytopathy platelet disorder disease_ontology DOID:2218 blood platelet disease DOID:2218 A blood coagulation disease characterized by autosomal recessive inheritance of failure of platelet aggregation and absent or diminished clot retraction that has material_basis_in mutation in the ITGA2B or ITGB3 genes on chromosome 17q21.32. GARD:2478 ICD10CM:D69.1 MESH:D013915 NCI:C61249 OMIM:273800 ORDO:849 SNOMEDCT_US_2020_03_01:32942005 UMLS_CUI:C0040015 BDPLT2 Glanzmann thrombasthenia Glycoprotein IIb/IIIa defect Thrombocytasthenia deficiency of GP IIb-IIIa complex deficiency of glycoprotein complex IIb-IIIa deficiency of platelet fibrinogen receptor platelet glycoprotein IIb-IIIa deficiency platelet-type bleeding disorder 2 thrombasthenia of Glanzmann and Naegeli disease_ontology DOID:2219 OMIM mapping confirmed by DO. [LS]. Glanzmann's thrombasthenia DOID:2219 A blood coagulation disease that is characterized by the partial or complete absence of factor X activity in the blood. GARD:6404 MESH:D005171 NCI:C131632 SNOMEDCT_US_2020_03_01:76642003 UMLS_CUI:C0015519 Factor X deficiency disease, Stuart-Prower disease_ontology DOID:2222 factor X deficiency DOID:2222 GARD:5034 MESH:D010981 OMIM:185050 SNOMEDCT_US_2020_03_01:234474009 UMLS_CUI:C0032197 Dense body defect Platelet dense granule deficiency Platelet storage pool defect disease_ontology DOID:2223 platelet storage pool deficiency DOID:2223 A myeloproliferative neoplasm that is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage and that results_in the overproduction of platelets. GARD:6594 ICD10CM:D47.3 ICD9CM:238.71 MESH:D013920 NCI:C3407 OMIM:187950 OMIM:601977 OMIM:614521 ORDO:3318 ORDO:71493 SNOMEDCT_US_2020_03_01:234499005 UMLS_CUI:C0040028 Essential thrombocythaemia familial thrombocytosis hemorrhagic thrombocythemia hereditary thrombocythemia primary Thrombocytosis disease_ontology DOID:2224 Xref MGI. OMIM mapping confirmed by DO. [SN]. essential thrombocythemia DOID:2224 A myeloid neoplasm that is characterized by a group of slow growing blood cancers in which large numbers of abnormal red blood cells, white blood cells, or platelets grow and spread in the bone marrow and the peripheral blood. DOID:6002 ICD10CM:D47.1 NCI:C4345 SNOMEDCT_US_2020_03_01:115248004 UMLS_CUI:C1292778 CMPD CMPD, U chronic myeloproliferative disease disease_ontology DOID:2226 myeloproliferative neoplasm DOID:2226 A blood platelet disease that is characterized by the presence of high platelet counts in the blood. MESH:D013922 NCI:C35530 SNOMEDCT_US_2020_03_01:165557006 UMLS_CUI:C0836924 Thrombocythaemia disease_ontology DOID:2228 thrombocytosis DOID:2228 A blood coagulation disease that is characterized by deficiency of factor XI clotting factor and mild prolonged bleeding, especially of mucosal sites following trauma, and has_material_basis_in homozygous, compound heterozygous, or heterozygous mutation of the coagulation factor XI gene of chromosome 4q35.2. GARD:9670 ICD10CM:D68.1 ICD9CM:286.2 MESH:D005173 NCI:C84705 OMIM:612416 SNOMEDCT_US_2020_03_01:49762007 UMLS_CUI:C0015523 Congenital factor XI deficiency Hereditary factor XI deficiency disease Rosenthal's disease hemophilia C plasma thromboplastin antecedent deficiency disease_ontology DOID:2229 OMIM mapping confirmed by DO. [SN]. factor XI deficiency DOID:2229 A blood coagulation disease that is characterized by prolonged PTT time without clinical symptoms, and has_material_basis_in a mutation in the F12 gene on chromosome 5q33. GARD:6558 MESH:D005175 NCI:C131740 OMIM:234000 ORDO:330 SNOMEDCT_US_2020_03_01:46981006 UMLS_CUI:C0015526 Factor XII deficiency disease Hageman Factor deficiency deficiency, Hageman disease_ontology DOID:2231 OMIM mapping confirmed by DO. [SN]. factor XII deficiency DOID:2231 An epilepsy syndrome that is characterised by seizures that are preceded by an isolated disturbance of a cerebral function and arise from an epileptic focus, a small portion of the brain that serves as the irritant driving the epileptic response. MESH:D004828 NCI:C122812 SNOMEDCT_US_2020_03_01:230381009 UMLS_CUI:C0014547 localisation-related epilepsy partial epilepsy disease_ontology DOID:2234 focal epilepsy DOID:2234 A blood coagulation disease that is characterized by an impaired blood clotting resulting from a lack deficiency of a the fibrinogen protein (coagulation factor I). GARD:5761 MESH:D000347 NCI:C98130 OMIM:202400 SNOMEDCT_US_2020_03_01:278504009 UMLS_CUI:C0001733 Factor I deficiency Fibrinogen deficiency disease_ontology DOID:2236 OMIM mapping confirmed by DO. [SN]. congenital afibrinogenemia DOID:2236 DOID:12352 DOID:14551 DOID:1706 DOID:1707 DOID:2238 ICD10CM:K73.9 ICD9CM:570 ICD9CM:571.4 ICD9CM:571.41 MESH:D006521 NCI:C82978 SNOMEDCT_US_2020_03_01:155813004 SNOMEDCT_US_2020_03_01:197268000 SNOMEDCT_US_2020_03_01:266539002 UMLS_CUI:C0001308 UMLS_CUI:C0019189 UMLS_CUI:C0149519 acute and subacute liver necrosis acute hepatitis acute/subac. necrosis of liver animal hepatitis chronic hepatitis chronic persistent hepatitis disease_ontology DOID:2237 hepatitis DOID:2237 A brain ischemia that is characterized by ischemia of brief duration and without resultant tissue death. DOID:2315 ICD10CM:G45.9 MESH:D002546 NCI:C50781 SNOMEDCT_US_2020_03_01:195196001 UMLS_CUI:C0007787 TIA TIA - Transient ischaemic attack TRANSIENT ISCHEMIC ATTACK Transient cerebral ischaemia Transient cerebral ischemia Transient ischemic attacks transient ischemic attack disease_ontology DOID:224 transient cerebral ischemia DOID:224 An bone structure disease that involves degeneration between vertebra located_in vertebral column. DOID:8708 DOID:8709 DOID:8888 DOID:8905 DOID:9949 ICD10CM:M47 ICD9CM:721.9 MESH:D055009 OMIM:184300 SNOMEDCT_US_2020_03_01:8847002 UMLS_CUI:C0038019 Lumbar spondylosis with myelopathy Spondylogenic compression of lumbar spinal cord Spondylogenic compression of thoracic spinal cord Spondylosis with myelopathy Thoracic or lumbar spondylosis with myelopathy lumbosacral spondylosis without myelopathy spondylosis with myelopathy disease_ontology DOID:2247 spondylosis DOID:2247 A disease characterized by a group of signs and symptoms that occur together and characterize a particular abnormality. MESH:D013577 NCI:C28193 SNOMEDCT_US_2020_03_01:64572001 UMLS_CUI:C0039082 disease_ontology DOID:225 syndrome DOID:225 A uterine disease that is located_in the cervix. MESH:D002577 NCI:C40241 SNOMEDCT_US_2020_03_01:63339007 UMLS_CUI:C0007867 disease_ontology DOID:2253 cervix disease DOID:2253 A bone development disease that results_in defective development of cartilage or bone. DOID:1764 ICD10CM:Q78.9 ICD9CM:756.4 MESH:D010009 NCI:C34466 NCI:C84978 SNOMEDCT_US_2020_03_01:205510001 SNOMEDCT_US_2020_03_01:67988000 UMLS_CUI:C0008449 UMLS_CUI:C0029422 Cartilage Development disorder Congenital anomaly of cartilage Osteochondrodysplasia syndrome chondrodystrophy skeletal dysplasia disease_ontology DOID:2256 osteochondrodysplasia DOID:2256 Ankylosis is a arthropathy where there is a stiffness of a joint, the result of injury or disease. The rigidity may be complete or partial and may be due to inflammation of the tendinous or muscular structures outside the joint or of the tissues of the joint itself. ICD10CM:M24.6 ICD9CM:718.5 MESH:D000844 SNOMEDCT_US_2020_03_01:36504009 UMLS_CUI:C0003090 disease_ontology DOID:227 ankylosis MESH:D000844 DOID:227 A candidiasis that involves fungal infection of the vaginal mucous membranes in women caused by Candida albicans. The symptoms include intense vulval pruritus, burning, erythema and dyspareunia associated with a creamy white, curd-like discharge. ICD10CM:B37.3 ICD9CM:112.1 MESH:D002181 NCI:C2914 SNOMEDCT_US_2020_03_01:154404004 UMLS_CUI:C0700345 Candidal vulvovaginitis Candidal: cervix Candidiasis of vulva and vagina Monilial vulvovaginitis Vulvovaginal Candidiasis disease_ontology DOID:2272 vulvovaginal candidiasis DOID:2272 An upper respiratory tract disease involving inflammation of the throat or pharynx resulting from bacterial, viral, fungal infections or irritants like pollutants or chemical substances and smoking. The infection is often referred to as sore throat. The symptoms include pain during swallowing, enlarged tonsils coated with a white discharge, runny nose, cough and slight fever. DOID:10455 DOID:11586 DOID:11588 DOID:938 DOID:939 ICD10CM:J02 ICD9CM:462 ICD9CM:472 ICD9CM:478.20 MESH:D010608 MESH:D010612 NCI:C26850 NCI:C26851 NCI:C34355 SNOMEDCT_US_2020_03_01:195654001 SNOMEDCT_US_2020_03_01:195763009 SNOMEDCT_US_2020_03_01:37616004 SNOMEDCT_US_2020_03_01:75860007 UMLS_CUI:C0001344 UMLS_CUI:C0031345 UMLS_CUI:C0031350 UMLS_CUI:C0155824 Inflamed throat Persistent sore throat Pharyngeal disorder Pharyngitis - acute Sore throat - chronic acute pharyngitis acute sore throat chronic pharyn/nasopharyngitis chronic pharyngitis chronic pharyngitis and nasopharyngitis chronic sore throat disease_ontology pharyngeal disease DOID:2275 pharyngitis DOID:2275 An endocrine system disease that is located_in the gonads. MESH:D006058 NCI:C26786 UMLS_CUI:C0018050 disease_ontology DOID:2277 gonadal disease DOID:2277 A hidradenitis that is characterized by chronic inflammation of the apocrine sweat glands, has_symptom painful nodules, abscesses, sinus tract formation, scarring, erythema, pruritis, and pain, and has_material_basis_in chronic inflammation of the apocrine sweat glands leading to recurrent folliculitis and an accompanying immune response that worsens inflammation. GARD:6658 ICD10CM:L73.2 MESH:D017497 NCI:C128429 OMIM:142690 OMIM:613736 OMIM:613737 SNOMEDCT_US_2020_03_01:201204008 UMLS_CUI:C0162836 Acne inversa, familial Hidradenitis suppurativa disease_ontology DOID:2280 OMIM mapping confirmed by DO. [SN]. hidradenitis suppurativa DOID:2280 A sweat gland disease that is characterized by inflammation of the apocrine sweat glands and has_symptom erythema, edema, papules, plaques, pruritis, and pain. ICD9CM:705.83 MESH:D016575 NCI:C112190 SNOMEDCT_US_2020_03_01:267866004 UMLS_CUI:C0085160 Hidradenitis Hydradenitis disease_ontology DOID:2282 hidradenitis DOID:2282 NCI:C27012 UMLS_CUI:C0235270 disease_ontology DOID:2283 keratopathy DOID:2283 A reproductive system disease that impairs the ability to reproduce and is located in the uterus, vagina, cervix, ovaries or fallopian tubes. ICD9CM:629.9 MESH:D005831 SNOMEDCT_US_2020_03_01:38233001 UMLS_CUI:C0017411 disease_ontology DOID:229 female reproductive system disease DOID:229 A primary bacterial infectious disease that involves systemic infection, has_material_basis_in Leptospira, which is transmitted by contact with water, food, or soil containing urine from the infected animals. The infection has symptom jaundice, has symptom chills, has symptom fever, has symptom muscle pain, and has symptom hepatomegaly. DOID:11348 GARD:7881 ICD10CM:A27 ICD10CM:A27.0 ICD9CM:100 ICD9CM:100.0 MESH:D007922 MESH:D014895 NCI:C84825 SNOMEDCT_US_2020_03_01:154391003 SNOMEDCT_US_2020_03_01:398067003 UMLS_CUI:C0023364 UMLS_CUI:C0043102 Fort Bragg fever Leptospirosis icterohaemorrhagica Rat Catcher's Yellows Weil's disease nanukayami fever spirochetal jaundice disease_ontology DOID:2297 leptospirosis DOID:2297 A motor neuron disease characterized by painless but progressive weakness and stiffness of the muscles of the legs. ICD10CM:G12.23 ICD9CM:335.24 MESH:D016472 NCI:C129933 OMIM:611637 ORDO:35689 SNOMEDCT_US_2020_03_01:81211007 UMLS_CUI:C0154682 adult-onset primary lateral sclerosis primary lateral sclerosis disease_ontology DOID:230 Xref MGI. lateral sclerosis DOID:230 A bone structure disease that involves a defect located_in lumbar vertebral column. ICD10CM:M43.0 MESH:D013169 NCI:C35034 SNOMEDCT_US_2020_03_01:203688008 UMLS_CUI:C0038018 disease_ontology DOID:2300 spondylolysis DOID:2300 A specific developmental disorder that is characterized by repeated, rhythmic, purposeless movements or activities such as head banging, nail biting, or body rocking. ICD10CM:F98.4 ICD9CM:307.3 MESH:D019956 SNOMEDCT_US_2020_03_01:5507002 UMLS_CUI:C0038273 Stereotyped repetitive movements Stereotypy habit disorder disease_ontology DOID:2303 stereotypic movement disorder DOID:2303 A neurodegenerative disease that is located_in the motor neurones. ICD10CM:G12.2 ICD9CM:335.2 MESH:D016472 SNOMEDCT_US_2020_03_01:37340000 UMLS_CUI:C0085084 disease_ontology DOID:231 motor neuron disease DOID:231 An opportunistic bacterial infectious disease that results_in disseminated infection in immunocompromised hosts, has_material_basis_in Nocardia asteroides. The infection has_symptom pneumonia, has_symptom cellulitis, has_symptom lesions in the brain or meninges, and has_symptom ascending regional lymphadenopathy. GARD:7210 ICD10CM:A43 MESH:D009617 SNOMEDCT_US_2020_03_01:29227009 UMLS_CUI:C0028242 Nocardia infectious disease disease_ontology DOID:2312 nocardiosis DOID:2312 An ischemia that is characterized by insufficient blood flow to the brain to meet metabolic demand. MESH:D002545 SNOMEDCT_US_2020_03_01:193049009 UMLS_CUI:C0007786 Ischaemic encephalopathy Ischemic encephalopathy cerebral ischemia disease_ontology DOID:2316 brain ischemia DOID:2316 A lung disease that is characterized by narrowing of pulmonary airways. MESH:D008173 UMLS_CUI:C0600260 respiratory airway obstruction disease_ontology DOID:2320 obstructive lung disease DOID:2320 A gastrointestinal system infectious disease that involves inflammation of the lining of the stomach and small and large intestines, which is caused by viruses, bacteria, or parasites. Chemicals and drugs also cause gastroenteritis. The symptoms include diarrhea, loss of appetite, nausea, vomiting, cramps, and discomfort in the abdomen. DOID:4094 DOID:5269 ICD10CM:K52.9 MESH:D005759 NCI:C34632 SNOMEDCT_US_2020_03_01:154278002 UMLS_CUI:C0017160 cholera morbus infectious colitis, enteritis and gastroenteritis disease_ontology DOID:2326 gastroenteritis MESH:D005759 DOID:2326 A jaw cancer and mandibular disease that affects your lower jawbone. DOID:12408 ICD10CM:C41.1 ICD9CM:170.1 MESH:D008339 NCI:C35178 SNOMEDCT_US_2020_03_01:126551000 SNOMEDCT_US_2020_03_01:448668007 UMLS_CUI:C0024694 UMLS_CUI:C0153511 malignant neoplasm of inferior maxilla malignant neoplasm of lower Jaw bone mandible cancer neoplasm of mandible disease_ontology malignant neoplasm of mandible mandibular neoplasm DOID:2338 mandibular cancer DOID:2338 A synostosis that results_in premature fusion located_in skull. GARD:6209 ICD10CM:Q75.0 MESH:D003398 NCI:C84655 OMIM:123100 OMIM:182212 OMIM:600593 OMIM:600775 OMIM:604757 OMIM:615314 ORDO:1531 SNOMEDCT_US_2020_03_01:205414007 UMLS_CUI:C0010278 Premature closure of cranial sutures disease_ontology DOID:2340 Xref MGI. OMIM mapping confirmed by DO. [SN]. OMIM mapping by NeuroDevNet. [LS]. craniosynostosis DOID:2340 ICD10CM:D89.0 ICD9CM:273.0 NCI:C35885 SNOMEDCT_US_2020_03_01:190808009 UMLS_CUI:C0154254 Polyclonal hypergammaglobulinemia disease_ontology DOID:2344 polyclonal hypergammaglobulinemia DOID:2344 An inherited metabolic disorder that involves plasma protein metabolism malfunction. ICD9CM:273.8 SNOMEDCT_US_2020_03_01:190822009 UMLS_CUI:C0029594 disease_ontology DOID:2345 plasma protein metabolism disease DOID:2345 ICD10CM:I70 ICD9CM:440 MESH:D050197 NCI:C34403 NCI:C35768 SNOMEDCT_US_2020_03_01:155414001 SNOMEDCT_US_2020_03_01:39468009 UMLS_CUI:C0004153 UMLS_CUI:C3665365 Cardiovascular arteriosclerosis disease_ontology DOID:2348 arteriosclerotic cardiovascular disease DOID:2348 An artery disease that is characterized by a thickening and hardening of arterial walls in the arteries. ICD10CM:I70 MESH:D001161 NCI:C34398 SNOMEDCT_US_2020_03_01:195251000 UMLS_CUI:C0003850 Arteriosclerosis Arteriosclerotic vascular disease disease_ontology DOID:2349 arteriosclerosis DOID:2349 An intestinal benign neoplasm that is located_in the colon. MESH:D003110 NCI:C2953 SNOMEDCT_US_2020_03_01:126838000 UMLS_CUI:C0009375 Colonic Mass Colonic tumor colon neoplasm neoplasm of colon disease_ontology DOID:235 colonic benign neoplasm DOID:235 ICD10CM:E83.1 ICD9CM:275.0 MESH:D019189 SNOMEDCT_US_2020_03_01:30913008 UMLS_CUI:C0012715 Iron disorder disorder of iron metabolism iron disorder disease_ontology DOID:2351 iron metabolism disease DOID:2351 A metal metabolism disorder characterized by the accumulation of iron in various organs of the body. ICD10CM:E83.11 MESH:D006432 NCI:C84481 OMIM:231100 OMIM:PS235200 ORDO:139498 SNOMEDCT_US_2020_03_01:86781004 UMLS_CUI:C0018995 Haemochromatosis diabetes bronze iron storage disorder disease_ontology DOID:2352 Xref MGI. hemochromatosis DOID:2352 An aplastic anemia that is characterized by displacement of hemopoietic bone-marrow tissue either by fibrosis, tumors or granulomas. ICD10CM:D61.82 MESH:D000750 SNOMEDCT_US_2020_03_01:2694001 UMLS_CUI:C0002890 ANEMIA LEUKOERYTHROBLASTIC Anemia, leukoerythroblastic Leukoerythroblastosis disease_ontology myelophthisis DOID:2354 myelophthisic anemia DOID:2354 A hematopoietic system disease that is characterized by a decrease in the normal number of red blood cells. EFO:0004272 ICD10CM:D64.9 ICD9CM:285.9 MESH:D000740 NCI:C2869 SNOMEDCT_US_2020_03_01:64593003 UMLS_CUI:C0002871 anaemia disease_ontology DOID:2355 PRISM. anemia MESH:D000740 DOID:2355 MESH:D000748 NCI:C34381 SNOMEDCT_US_2020_03_01:83414005 UMLS_CUI:C0002886 ANEMIA MACROCYTIC Macrocytic anaemia disease_ontology DOID:2361 macrocytic anemia DOID:2361 A viral infectious disease that results in inflammation located in brain, has_material_basis_in West Nile virus, which is transmitted_by Culex, transmitted by Aedes, and transmitted_by Anopheles species of mosquitoes. The infection has_symptom high fever, has_symptom headache, has_symptom neck stiffness, has_symptom stupor, has_symptom disorientation, has_symptom coma, has_symptom tremors, has_symptom convulsions, has_symptom muscle weakness, has_symptom vision loss, has_symptom numbness, and has_symptom paralysis. GARD:9959 ICD10CM:A92.31 ICD9CM:066.41 MESH:D014901 SNOMEDCT_US_2020_03_01:392662004 UMLS_CUI:C0751583 West Nile Fever with encephalitis West Nile fever encephalitis disease_ontology DOID:2365 West Nile encephalitis DOID:2365 A viral infectious disease that results_in infection, has_material_basis_in West Nile virus, which is transmitted_by Culex and transmitted_by Aedes mosquitoes. The infection has_symptom fever, has_symptom sore throat, has_symptom headache, has_symptom body ache, has_symptom nausea, has_symptom maculopapular rash and has_symptom vomiting. ICD10CM:A92.3 ICD9CM:066.4 MESH:D014901 SNOMEDCT_US_2020_03_01:12381007 UMLS_CUI:C0043124 disease_ontology DOID:2366 West Nile fever DOID:2366 MESH:D019150 NCI:C161542 SNOMEDCT_US_2020_03_01:230365004 UMLS_CUI:C0338473 disease_ontology DOID:2367 neuroaxonal dystrophy DOID:2367 A sphingolipidosis that is characterized by the accumulation of lipids known as gangliosides. GARD:12510 ICD10CM:E75.10 MESH:D005733 ORDO:309144 SNOMEDCT_US_2020_03_01:50967008 UMLS_CUI:C0017083 disease_ontology DOID:2368 gangliosidosis DOID:2368 A hematopoietic system disease characterized by oval or elliptical red blood cells, slight or absent hemolysis with little or no anemia; splenomegaly is often present. GARD:6621 ICD10CM:D58.1 ICD9CM:282.1 MESH:D004612 NCI:C35882 OMIM:130600 OMIM:611804 ORDO:288 SNOMEDCT_US_2020_03_01:154801000 UMLS_CUI:C0013902 Congenital elliptocytosis ovalocytosis disease_ontology DOID:2373 Xref MGI. OMIM mapping confirmed by DO. [SN]. hereditary elliptocytosis DOID:2373 A demyelinating disease that involves damage to the fatty myelin sheaths around the axons of the brain and spinal cord resulting in demyelination and scarring. EFO:0003885 GARD:10255 ICD10CM:G35 ICD9CM:340 MESH:D009103 NCI:C3243 OMIM:612594 OMIM:612595 OMIM:612596 SNOMEDCT_US_2020_03_01:155023009 UMLS_CUI:C0026769 Generalized multiple sclerosis insular sclerosis disease_ontology DOID:2377 OMIM mapping confirmed by DO. [LS]. multiple sclerosis MESH:D009103 DOID:2377 A brain disease that is characterized by hyperbilirubinemia-induced brain dysfunction. GARD:6830 ICD10CM:P57 MESH:D007647 NCI:C84799 SNOMEDCT_US_2020_03_01:157135006 UMLS_CUI:C0022610 bilirubin encephalopathy disease_ontology DOID:2382 kernicterus DOID:2382 A pigmentation disease characterized by a high level of bilirubin in the blood, causing a yellowing of the skin and other tissues of a newborn infant. ICD10CM:P59.9 MESH:D007567 NCI:C99246 SNOMEDCT_US_2020_03_01:299968002 UMLS_CUI:C0022353 neonatal hyperbilirubinemia neonatal icterus disease_ontology DOID:2383 neonatal jaundice DOID:2383 A brain disease that is characterised by the presence of neurological symptoms of ophthalmoplegia, ataxia, and confusion caused by biochemical lesions of the central nervous system after exhaustion of B-vitamin reserves, in particular thiamine (vitamin B1). ICD10CM:E51.2 MESH:D014899 SNOMEDCT_US_2020_03_01:190627001 UMLS_CUI:C0043121 Wernicke's disease Wernicke's encephalopathy disease_ontology DOID:2384 Wernicke encephalopathy DOID:2384 ICD9CM:593.81 NCI:C35338 SNOMEDCT_US_2020_03_01:16934004 UMLS_CUI:C0268790 renal vascular disease vascular disorder of kidney disease_ontology DOID:2388 renal artery disease DOID:2388 A female reproductive organ cancer that is located_in the ovary. DOID:0060070 DOID:2144 DOID:9595 GARD:7295 ICD10CM:C56 ICD9CM:183.0 MESH:D010051 NCI:C4984 NCI:C7431 OMIM:167000 OMIM:607893 ORDO:213500 ORDO:213517 SNOMEDCT_US_2020_03_01:123843001 SNOMEDCT_US_2020_03_01:372117006 SNOMEDCT_US_2020_03_01:93934004 UMLS_CUI:C0919267 UMLS_CUI:C1140680 UMLS_CUI:C1299247 malignant Ovarian tumor malignant tumour of ovary ovarian neoplasm ovary neoplasm primary ovarian cancer tumor of the Ovary disease_ontology DOID:2394 Xref MGI. OMIM mapping confirmed by DO. [SN]. ovarian cancer DOID:2394 MESH:D007499 NCI:C34737 SNOMEDCT_US_2020_03_01:85478004 UMLS_CUI:C0022078 disease_ontology DOID:240 iris disease DOID:240 GARD:9618 MESH:D016586 NCI:C3474 SNOMEDCT_US_2020_03_01:12169001 UMLS_CUI:C0085167 neoplasm of granular cell disease_ontology DOID:2411 granular cell tumor DOID:2411 NCI:C4481 SNOMEDCT_US_2020_03_01:254766004 UMLS_CUI:C0346063 Cutaneous Ganglioneuroma Ganglioneuroma of skin disease_ontology DOID:2425 cutaneous ganglioneuroma DOID:2425 A central nervous system benign neoplasm that has_material_basis_in mature neurons, and is classified by the absence of neoplastic glial cells. GARD:10638 MESH:D005729 NCI:C6934 SNOMEDCT_US_2020_03_01:78268004 gangliocytoma of central nervous system disease_ontology DOID:2426 gangliocytoma DOID:2426 NCI:C4463 SNOMEDCT_US_2020_03_01:126489007 UMLS_CUI:C0345988 neoplasm of skin with adnexal differentiation neoplasm of the skin Appendage skin appendage tumour disease_ontology DOID:2433 epidermal appendage tumor DOID:2433 MESH:D005918 NCI:C4222 SNOMEDCT_US_2020_03_01:7429002 UMLS_CUI:C0334421 disease_ontology DOID:2436 glomangioma DOID:2436 NCI:C4475 SNOMEDCT_US_2020_03_01:254735005 UMLS_CUI:C0346041 dermis tumour neoplasm of Dermis tumor of dermis tumour of dermis disease_ontology DOID:2438 dermis tumor DOID:2438 MESH:D006964 SNOMEDCT_US_2020_03_01:10649000 UMLS_CUI:C0020506 disease_ontology DOID:2444 hyperpituitarism MESH:D006964 DOID:2444 A disease of metabolism that has_material_basis_in excessive growth hormone production which results_in enlargement located_in limb. GARD:5725 MESH:D000172 NCI:C84533 SNOMEDCT_US_2020_03_01:154698000 UMLS_CUI:C0001206 disease_ontology DOID:2449 acromegaly DOID:2449 ICD10CM:H34.81 ICD9CM:362.35 MESH:D012170 NCI:C118859 SNOMEDCT_US_2020_03_01:193378003 UMLS_CUI:C0154841 disease_ontology DOID:2450 central retinal vein occlusion DOID:2450 GARD:4524 ICD10CM:D68.59 MESH:D018455 NCI:C99026 SNOMEDCT_US_2020_03_01:1563006 UMLS_CUI:C0242666 Protein S deficiency Protein S deficiency disease disease_ontology DOID:2451 protein S deficiency DOID:2451 A blood coagulation disease that is characterized by an increased tendency to form clots. ICD10CM:D68.59 MESH:D019851 NCI:C84479 OMIM:PS188050 SNOMEDCT_US_2020_03_01:191302007 UMLS_CUI:C0398623 hypercoagulability state disease_ontology DOID:2452 OMIM mapping confirmed by DO. [LS]. thrombophilia MESH:D019851 DOID:2452 NCI:C35170 SNOMEDCT_US_2020_03_01:57534004 UMLS_CUI:C0154833 retina circulation disorder disease_ontology DOID:2462 retinal vascular disease DOID:2462 A cognitive disorder that involves abnormal thinking and perceptions resulting in a disconnection with reality. EFO:0000677 ICD9CM:298.8 UMLS_CUI:C0029516 mental or behavioural disorder disease_ontology DOID:2468 psychotic disorder DOID:2468 A systemic mycosis that results_in fungal infection located_in human body of immunocompromised individuals, has_material_basis_in Fungi. The organisms invade via the respiratory tract, alimentary tract, or intravascular devices. DOID:0050137 ICD9CM:118 SNOMEDCT_US_2020_03_01:78999002 UMLS_CUI:C0029119 Opportunistic mycoses Opportunistic mycosis opportunistic systemic mycoses disease_ontology DOID:2473 opportunistic mycosis DOID:2473 ICD10CM:H10.4 ICD9CM:372.1 NCI:C35197 SNOMEDCT_US_2020_03_01:155163007 UMLS_CUI:C0155145 chronic Conjunctivitis disease_ontology DOID:2475 chronic conjunctivitis DOID:2475 ICD10CM:G60.0 MESH:D015417 NCI:C75467 SNOMEDCT_US_2020_03_01:128202008 UMLS_CUI:C0027888 HSMN HSMN - Hereditary sensory and motor neuropathy Hereditary motor and sensory neuropathy neuropathic muscular atrophy disease_ontology DOID:2477 motor peripheral neuropathy DOID:2477 A brain disease that is characterized by vertigo caused by hemorrhagic insult, ischemic insult or mass lesion of the cerebellum, the vestibular nuclei, and the brainstem, has_symptom dizziness, has_symptom nausea, has_symptom vomiting and has_symptom difficulty walking. ICD10CM:H81.4 ICD9CM:386.2 MESH:D014717 SNOMEDCT_US_2020_03_01:20425006 UMLS_CUI:C0155503 Vertigo of central origin central vestibular vertigo disease_ontology DOID:2479 central nervous system origin vertigo DOID:2479 A respiratory system benign neoplasm that derives_from smooth muscle cells and is located_in the trachea. DOID:246 MESH:D014134 NCI:C3419 NCI:C6049 SNOMEDCT_US_2020_03_01:126703006 UMLS_CUI:C0040582 UMLS_CUI:C1336772 leiomyoma of the Trachea disease_ontology DOID:248 trachea leiomyoma DOID:248 ICD9CM:275.3 MESH:D010760 NCI:C97095 SNOMEDCT_US_2020_03_01:190858002 UMLS_CUI:C0031707 Phosphorus disorder disorder of phosphorus metabolism phosphorus metabolism disorder disease_ontology DOID:2485 phosphorus metabolism disease DOID:2485 ICD9CM:742 SNOMEDCT_US_2020_03_01:204018008 UMLS_CUI:C0158538 congenital neurologic anomaly disease_ontology DOID:2490 congenital nervous system abnormality DOID:2490 A neuropathy that involves damage to nerves of the peripheral nervous system. DOID:10596 ICD9CM:356.2 MESH:D009477 NCI:C3501 SNOMEDCT_US_2020_03_01:193163001 SNOMEDCT_US_2020_03_01:95662005 UMLS_CUI:C0151313 UMLS_CUI:C0699739 Sensory neuropathy peripheral Sensory Neuropathy sensory neuropathy disease_ontology DOID:2491 sensory peripheral neuropathy DOID:2491 MESH:D020252 NCI:C84724 SNOMEDCT_US_2020_03_01:412795008 UMLS_CUI:C0267211 Watermelon stomach disease_ontology DOID:2493 gastric antral vascular ectasia DOID:2493 A vascular disease that is characterized as a small vascular malformation of the gut. DOID:12071 MESH:D016888 SNOMEDCT_US_2020_03_01:71072006 UMLS_CUI:C0085411 angiodysplasia of stomach and duodenum with hemorrhage disease_ontology DOID:2494 angiodysplasia MESH:D016888 DOID:2494 NCI:C4390 SNOMEDCT_US_2020_03_01:5050001 UMLS_CUI:C0343082 Senile hemangioma Senile naevus of skin disease_ontology DOID:2495 senile angioma DOID:2495 ICD9CM:521.31 UMLS_CUI:C1456161 disease_ontology DOID:2497 enamel erosion DOID:2497 DOID:11509 DOID:12687 ICD10CM:K03.2 ICD9CM:521.3 MESH:D014077 SNOMEDCT_US_2020_03_01:82212003 UMLS_CUI:C0040436 generalized erosion localized erosion disease_ontology DOID:2498 tooth erosion DOID:2498 A vasculitis that involves inflammation of the aorta that carries blood from the heart to the rest of the body. DOID:13377 GARD:7730 ICD10CM:M31.4 ICD9CM:446.7 MESH:D001015 MESH:D013625 NCI:C34391 NCI:C35062 OMIM:207600 SNOMEDCT_US_2020_03_01:359789008 SNOMEDCT_US_2020_03_01:42153001 UMLS_CUI:C0003490 UMLS_CUI:C0039263 Aortic Arch syndrome Aortic arch arteritis Aortic arch syndrome Idiopathic aortitis Takayasu arteritis Takayasu's disease disease_ontology DOID:2508 OMIM mapping confirmed by DO. [SN]. Takayasu's arteritis DOID:2508 ICD9CM:291.89 UMLS_CUI:C1456283 disease_ontology DOID:251 alcohol-induced mental disorder DOID:251 A syndrome characterized by multiple early-onset basal cell carcinoma, multiple jaw keratocysts and skeletal abnormalities that has_material_basis_in heterozygous mutation in either PTCH1, PTCH2, or SUFU on chromosome 9q22, 1p32, or 10q24-q25, respectively. GARD:7166 MEDDRA:10062804 MESH:D001478 NCI:C2892 OMIM:109400 ORDO:377 SNOMEDCT_US_2020_03_01:69408002 UMLS_CUI:C0004779 Gorlin syndrome NBCCS basal cell nevus syndrome disease_ontology DOID:2512 OMIM mapping confirmed by DO. [SN]. nevoid basal cell carcinoma syndrome DOID:2512 A skin carcinoma affecting basal cells. DOID:4275 DOID:4276 EFO:0004193 KEGG:05217 MESH:D018295 NCI:C156767 NCI:C3784 NCI:C7586 SNOMEDCT_US_2020_03_01:127570002 SNOMEDCT_US_2020_03_01:154507009 SNOMEDCT_US_2020_03_01:252995000 UMLS_CUI:C0007117 UMLS_CUI:C0206710 UMLS_CUI:C1368295 Basal cell cancer Basal cell carcinoma of skin Basal cell neoplasm Basal cell tumor Epithelioma basal cell Rodent ulcer malignant Basal cell neoplasm malignant basal cell tumor disease_ontology DOID:2513 Xref MGI. basal cell carcinoma DOID:2513 ICD10CM:N45.2 MESH:D009920 NCI:C97145 SNOMEDCT_US_2020_03_01:367112009 UMLS_CUI:C0029191 Inflammation of testis Orchititis disease_ontology DOID:2518 orchitis DOID:2518 MESH:D013733 NCI:C26890 SNOMEDCT_US_2020_03_01:236763001 UMLS_CUI:C0039584 disorder of testis testis disorder disease_ontology DOID:2519 testicular disease DOID:2519 An alcohol-induced mental disorder involving prominent hallucinations and delusions occurring during or shortly after acute alcohol intoxication or withdrawal. ICD9CM:291.9 MESH:D011604 SNOMEDCT_US_2020_03_01:154852003 UMLS_CUI:C0033936 Alcoholic psychoses disease_ontology DOID:252 alcoholic psychosis DOID:252 A proteinuria that is characterized by the leaking of blood protein into the urine, swelling or edema, and degenerative lesions without inflammation. MESH:D009401 SNOMEDCT_US_2020_03_01:90708001 UMLS_CUI:C0027720 disease_ontology DOID:2527 nephrosis DOID:2527 DOID:0000815 ICD10CM:D73 ICD9CM:289.50 MESH:D013158 NCI:C35823 SNOMEDCT_US_2020_03_01:51244008 UMLS_CUI:C0037997 Dyssplenism Spleen disease disease_ontology DOID:2529 splenic disease DOID:2529 ICD10CM:D73.3 NCI:C35347 SNOMEDCT_US_2020_03_01:82053000 UMLS_CUI:C0272412 disease_ontology DOID:2530 splenic abscess DOID:2530 An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes. DOID:1034 DOID:2532 MESH:D019337 NCI:C27134 SNOMEDCT_US_2020_03_01:414388001 UMLS_CUI:C0376544 Hematologic malignancy Hematologic neoplasm Hematological tumors blood cancer hematopoietic and lymphoid system tumor hematopoietic cancer hematopoietic neoplasm hematopoietic tumors malignant hematopoietic neoplasm disease_ontology DOID:2531 hematologic cancer DOID:2531 GARD:9973 ICD10CM:D73.5 MESH:D013159 SNOMEDCT_US_2020_03_01:22996003 UMLS_CUI:C0037998 Splenic infarct Splenic infarction disease_ontology DOID:2533 splenic infarction DOID:2533 ICD10CM:G61.81 ICD9CM:357.81 MESH:D020277 NCI:C84636 SNOMEDCT_US_2020_03_01:128209004 UMLS_CUI:C0393819 disease_ontology DOID:2536 chronic inflammatory demyelinating polyneuritis DOID:2536 ICD9CM:357 SNOMEDCT_US_2020_03_01:193172009 UMLS_CUI:C0154758 disease_ontology DOID:2537 inflammatory and toxic neuropathy DOID:2537 GARD:6855 ICD10CM:G40.8 MESH:D018887 NCI:C84806 OMIM:245570 ORDO:98818 SNOMEDCT_US_2020_03_01:230438007 UMLS_CUI:C0282512 acquired epileptic aphasia disease_ontology DOID:2538 OMIM mapping confirmed by DO. [SN]. Landau-Kleffner syndrome DOID:2538 An epilepsy syndrome that is located_in an area of the brain other than the temporal lobe. NCI:C7760 SNOMEDCT_US_2020_03_01:111498005 UMLS_CUI:C0270849 Extratemporal epilepsy disease_ontology DOID:2544 extratemporal epilepsy DOID:2544 A cardiovascular organ benign neoplasm that has_material_basis_in endothelial cells that line blood vessels and is characterised by increased number of normal or abnormal vessels filled with blood. ICD10CM:D18.0 ICD9CM:228.00 MESH:D006391 NCI:C3085 SNOMEDCT_US_2020_03_01:154625006 UMLS_CUI:C0018916 disease_ontology DOID:255 hemangioma DOID:255 A chondromalacia that is characterized by recurrent inflammation of cartilage and other tissues throughout the body. GARD:7417 ICD10CM:M94.1 MESH:D011081 NCI:C157268 SNOMEDCT_US_2020_03_01:72275000 UMLS_CUI:C0032453 Chondromalacia, systemic disease_ontology DOID:2556 relapsing polychondritis DOID:2556 A cartilage disease that is characterized by softening and breakdown of cartilage inside a joint. ICD10CM:M94.2 ICD9CM:733.92 MESH:D002357 SNOMEDCT_US_2020_03_01:63198006 UMLS_CUI:C0085700 disease_ontology DOID:2557 chondromalacia DOID:2557 A drug dependence that involves the continued use of opiate drugs despite despite problems related to use of the substance. ICD10CM:F11.2 ICD9CM:304.00 MESH:D009293 SNOMEDCT_US_2020_03_01:75544000 UMLS_CUI:C0524662 Opioid type dependence disease_ontology DOID:2559 opiate dependence DOID:2559 An opiate dependence that involves the continued use of morphine despite despite problems related to use of the substance. MESH:D009021 SNOMEDCT_US_2020_03_01:286934009 UMLS_CUI:C0026552 disease_ontology DOID:2560 morphine dependence DOID:2560 A corneal dystrophy that is characterized by corneal haze, bilateral loss of vision, eventually necessitating corneal transplantation resulting from progressive punctate opacities in the cornea. ICD10CM:H18.55 ICD9CM:371.55 MESH:D003317 NCI:C34793 OMIM:217800 SNOMEDCT_US_2020_03_01:60258001 UMLS_CUI:C0024439 Fehr corneal dystrophy MACULAR DYSTROPHY, CORNEAL, 1 disease_ontology DOID:2565 macular corneal dystrophy DOID:2565 DOID:8944 ICD10CM:H18.5 ICD9CM:371.5 MESH:D003317 NCI:C34512 NCI:C34513 SNOMEDCT_US_2020_03_01:5587004 SNOMEDCT_US_2020_03_01:77797009 UMLS_CUI:C0010035 UMLS_CUI:C0010036 disease_ontology DOID:2566 corneal dystrophy DOID:2566 A cervix disease that is characterized by inflammation of the cervix. DOID:10110 ICD10CM:N72 ICD9CM:616.0 MESH:D002575 NCI:C26716 SNOMEDCT_US_2020_03_01:198199009 SNOMEDCT_US_2020_03_01:237081003 UMLS_CUI:C0007860 UMLS_CUI:C0007861 disease_ontology DOID:2568 cervicitis DOID:2568 ICD9CM:362.57 MESH:D015593 SNOMEDCT_US_2020_03_01:141199000 UMLS_CUI:C0035312 disease_ontology DOID:2569 OMIM mapping confirmed by DO. [SN]. retinal drusen DOID:2569 A histiocytosis that is characterized by clonal proliferation of Langerhans cells. DOID:10617 DOID:10618 DOID:10620 DOID:10623 DOID:10624 DOID:10625 DOID:2553 DOID:2554 DOID:9582 ICD10CM:C96.0 ICD10CM:C96.6 ICD9CM:202.5 MESH:C538636 MESH:D006646 NCI:C3107 NCI:C3160 OMIM:246400 OMIM:604856 SNOMEDCT_US_2020_03_01:154583006 SNOMEDCT_US_2020_03_01:234439008 UMLS_CUI:C0019621 UMLS_CUI:C0023381 Histiocytosis X Langerhan's cell histiocytosis Langerhans cell granulomatosis Letterer-Siwe disease Letterer-Siwe disease involving intra-abdominal lymph nodes Letterer-Siwe disease involving intrapelvic lymph nodes Letterer-Siwe disease involving intrathoracic lymph nodes Letterer-Siwe disease involving lymph nodes of axilla and upper limb Letterer-Siwe disease involving lymph nodes of head, face and neck Letterer-Siwe disease involving lymph nodes of head, face, and neck Letterer-Siwe disease involving lymph nodes of inguinal region and lower limb Letterer-Siwe disease involving lymph nodes of multiple sites Letterer-Siwe disease involving spleen Letterer-Siwe disease of intra-abdominal lymph nodes Letterer-Siwe disease of intrapelvic lymph nodes Letterer-Siwe disease of intrathoracic lymph nodes Letterer-Siwe disease of lymph nodes of axilla and upper limb Letterer-Siwe disease of lymph nodes of axilla and/or upper limb Letterer-Siwe disease of lymph nodes of head, face and neck Letterer-Siwe disease of lymph nodes of head, face and/or neck Letterer-Siwe disease of lymph nodes of inguinal region amd/or lower limb Letterer-Siwe disease of lymph nodes of inguinal region and lower limb Letterer-Siwe disease of lymph nodes of inguinal region and/or lower limb Letterer-Siwe disease of lymph nodes of multiple sites Letterer-Siwe disease of spleen disease_ontology DOID:2571 OMIM mapping confirmed by DO. [SN]. Langerhans-cell histiocytosis DOID:2571 A drug dependence that involves the continued use of barbiturates despite problems related to use of the substance. ICD9CM:304.11 UMLS_CUI:C0154482 disease_ontology DOID:2575 barbiturate dependence DOID:2575 A chondrodysplasia punctata that is characterized by disproportionately short stature primarily affecting the proximal parts of the extremities, a typical facial appearance including a broad nasal bridge, epicanthus, high-arched palate, dysplastic external ears, and micrognathia, congenital contractures, characteristic ocular involvement, dwarfism, and severe mental retardation with spasticity. GARD:13160 ICD10CM:E71.540 MESH:D018902 NCI:C85047 OMIM:PS215100 ORDO:177 SNOMEDCT_US_2020_03_01:56692003 UMLS_CUI:C0282529 Chondrodysplasia Punctata, Rhizomelic Form disease_ontology DOID:2580 OMIM mapping confirmed by DO. [SN]. rhizomelic chondrodysplasia punctata DOID:2580 A syndrome that is characterized by abnormal calcification of the epiphyses, causing stippling in radiography. GARD:8542 ICD10CM:Q77.3 MESH:D002806 NCI:C84632 OMIM:215105 ORDO:93442 SNOMEDCT_US_2020_03_01:205486004 UMLS_CUI:C0008445 Chondrodysplasia punctata congenita disease_ontology DOID:2581 DeObs MGI. chondrodysplasia punctata MESH:D002806 DOID:2581 GARD:363 MESH:D020642 NCI:C84526 OMIM:614097 SNOMEDCT_US_2020_03_01:190954001 UMLS_CUI:C0268419 deficiency of catalase disease_ontology DOID:2582 acatalasia DOID:2582 A B cell deficiency that is caused by a reduction in all types of gamma globulins. DOID:618 ICD10CM:D80.1 ICD9CM:279.00 MESH:D000361 NCI:C26931 OMIM:601495 OMIM:612692 OMIM:613500 OMIM:613501 OMIM:615214 OMIM:PS601495 SNOMEDCT_US_2020_03_01:119250001 SNOMEDCT_US_2020_03_01:267512002 UMLS_CUI:C0001768 UMLS_CUI:C0086438 IGHM hypogammaglobulinemia mu heavy chain deficiency disease_ontology DOID:2583 OMIM mapping confirmed by DO. [SN]. agammaglobulinemia MESH:D000361 DOID:2583 ICD10CM:C32.0 ICD9CM:161.0 NCI:C3544 SNOMEDCT_US_2020_03_01:187841006 UMLS_CUI:C0153483 Ca larynx - glottis malignant tumor of glottis malignant tumor of the Glottis disease_ontology DOID:2595 glottis cancer DOID:2595 A respiratory system cancer that is located_in the larynx. GARD:6862 ICD10CM:C32 ICD9CM:161 MESH:D007822 NCI:C7484 SNOMEDCT_US_2020_03_01:93859007 UMLS_CUI:C0007107 disease_ontology DOID:2596 larynx cancer DOID:2596 MESH:D007822 NCI:C3156 SNOMEDCT_US_2020_03_01:126692004 UMLS_CUI:C0023055 laryngeal tumor larynx neoplasm neoplasm of larynx disease_ontology DOID:2598 laryngeal benign neoplasm DOID:2598 NCI:C4923 SNOMEDCT_US_2020_03_01:372103002 UMLS_CUI:C0740083 Glottic carcinoma carcinoma of glottis disease_ontology DOID:2599 glottis carcinoma DOID:2599 An endocrine system disease that is located_in the pancreas. ICD10CM:K86.8 ICD9CM:577.8 SNOMEDCT_US_2020_03_01:197566002 UMLS_CUI:C0029771 disease_ontology DOID:26 pancreas disease DOID:26 A larynx cancer that has_material_basis_in epithelial cells. NCI:C4855 SNOMEDCT_US_2020_03_01:154480006 UMLS_CUI:C0595989 cancer of Larynx cancer of larynx carcinoma of larynx disease_ontology DOID:2600 laryngeal carcinoma DOID:2600 A cell type benign neoplasm that is a cartilaginous tumor encapsulated with a lobular growing pattern. GARD:6052 MESH:D002812 NCI:C53459 SNOMEDCT_US_2020_03_01:269638002 UMLS_CUI:C0936248 central Chondroma disease_ontology DOID:2602 chondroma DOID:2602 A cell type benign neoplam that is composed of epithelial tissue on papillae of vascularized connective tissue. DOID:1635 MESH:D010212 NCI:C3713 NCI:C7440 SNOMEDCT_US_2020_03_01:711329002 SNOMEDCT_US_2020_03_01:82049002 UMLS_CUI:C0030354 UMLS_CUI:C0205875 papillomatosis disease_ontology DOID:2615 papilloma DOID:2615 A kidney cancer which is manifested in the kidney. NCI:C4527 SNOMEDCT_US_2020_03_01:254923001 UMLS_CUI:C0346256 hemangiopericytoma of kidney renal hemangiopericytoma disease_ontology DOID:262 kidney hemangiopericytoma DOID:262 A peripheral nervous system neoplasm that is located_in the autonomic nervous system. NCI:C5112 UMLS_CUI:C1332356 tumor of Autonomic nervous system disease_ontology DOID:2621 autonomic nervous system neoplasm DOID:2621 DOID:3661 GARD:4214 MESH:D020288 NCI:C3698 NCI:C5800 OMIM:260500 SNOMEDCT_US_2020_03_01:18021007 UMLS_CUI:C0205770 UMLS_CUI:C1332963 childhood choroid plexus papilloma disease_ontology DOID:2626 OMIM mapping confirmed by DO. [SN]. choroid plexus papilloma DOID:2626 A urinary system cancer that is located_in the kidney. DOID:11834 DOID:3676 ICD10CM:C64 ICD9CM:189.0 MESH:D007680 NCI:C120456 NCI:C3150 NCI:C7548 SNOMEDCT_US_2020_03_01:126880001 SNOMEDCT_US_2020_03_01:93849006 UMLS_CUI:C0022665 UMLS_CUI:C0494158 UMLS_CUI:C0740457 malignant neoplasm of kidney except pelvis malignant tumour of kidney renal cancer disease_ontology DOID:263 kidney cancer DOID:263 An adenoma that forms a cyst. MESH:D003537 NCI:C2972 SNOMEDCT_US_2020_03_01:189680006 UMLS_CUI:C0010633 Cystadenoma Cystoma disease_ontology DOID:2634 cystadenoma DOID:2634 An ovarian benign neoplasm that has_material_basis_in the surface epithelium of the ovary. GARD:9397 MESH:D001948 NCI:C39954 SNOMEDCT_US_2020_03_01:74739000 UMLS_CUI:C0006160 benign ovarian Brenner tumor benign ovarian Brenner tumour ovarian Brenner tumour disease_ontology DOID:2636 ovarian Brenner tumor DOID:2636 A breast fibroadenoma that is characterized by stromal proliferation around epithelial structures. NCI:C4272 SNOMEDCT_US_2020_03_01:41382006 UMLS_CUI:C0334497 Pericanalicular Fibroadenoma of breast Pericanalicular fibroadenoma disease_ontology DOID:2639 breast pericanalicular fibroadenoma DOID:2639 A soft tissue cancer that is a soft tissue sarcoma and originates in the pericytes in the walls of capillaries. DOID:5372 GARD:2627 MESH:D006393 NCI:C3087 SNOMEDCT_US_2020_03_01:134335004 UMLS_CUI:C0018922 Haemangiopericytic meningioma hemangiopericytoma, malignant malignant hemangiopericytoma disease_ontology DOID:264 hemangiopericytoma DOID:264 An ovarian germ cell monodermal and highly specialized teratoma that is composed either exclusively or predominantly of thyroid tissue. MESH:D013330 NCI:C7468 SNOMEDCT_US_2020_03_01:24327009 UMLS_CUI:C0038478 Struma ovarii disease_ontology DOID:2640 struma ovarii DOID:2640 A monodermal teratoma that has_material_basis in germ cells that are highly specialized and is located_in the ovary. NCI:C8113 UMLS_CUI:C0280134 Ovarian Monodermal and Highly Specialized teratoma disease_ontology DOID:2641 ovarian germ cell monodermal and highly specialized teratoma DOID:2641 MESH:D054973 NCI:C38150 SNOMEDCT_US_2020_03_01:388601000 UMLS_CUI:C1300127 PEComa neoplasm with Perivascular epithelioid cell differentiation disease_ontology DOID:2643 perivascular epithelioid cell tumor DOID:2643 A cell type benign neoplasm that has_material_basis_in mesothelium. DOID:2644 ICD10CM:C45 MESH:D008654 NCI:C3234 SNOMEDCT_US_2020_03_01:154491004 UMLS_CUI:C0025500 benign tumor of Mesothelium disease_ontology DOID:2645 benign mesothelioma DOID:2645 NCI:C6581 SNOMEDCT_US_2020_03_01:404086000 UMLS_CUI:C1266175 disease_ontology DOID:2647 parachordoma DOID:2647 DOID:7387 NCI:C4174 SNOMEDCT_US_2020_03_01:78424008 UMLS_CUI:C1368816 Sebaceous adenoma adenoma of the Sebaceous gland skin appendage sebaceous adenoma disease_ontology DOID:2648 sebaceous adenoma DOID:2648 A connective tissue benign neoplasm that derives_from chondroblasts and begins in cartilage at the ends of long bones (thighbone, shinbone, humerus) close to the joints. GARD:6047 MESH:D002804 NCI:C2945 SNOMEDCT_US_2020_03_01:9001003 UMLS_CUI:C0008441 Chondroblastoma of bone disease_ontology DOID:2649 chondroblastoma DOID:2649 A cystic teratoma that is composed exclusively of mature tissues derived from two or three germ layers (ectoderm, mesoderm and endoderm). ICD10CM:K09.8 MESH:D003884 NCI:C9011 SNOMEDCT_US_2020_03_01:189117002 UMLS_CUI:C0011649 Dermoid choristoma Dermoid tumour Mature cystic teratoma cystic dermoid choristoma teratoma, benign disease_ontology DOID:2658 dermoid cyst DOID:2658 A benign teratoma that is characterized by the presence of cysts or cystic spaces. NCI:C9014 SNOMEDCT_US_2020_03_01:42717009 UMLS_CUI:C1368903 disease_ontology DOID:2660 cystic teratoma DOID:2660 A sweat gland benign neoplasm that is composed_of outgrowths of myoepithelial cells from a sweat gland. MESH:D009208 NCI:C40392 SNOMEDCT_US_2020_03_01:69291002 UMLS_CUI:C0027070 Myoepithelial adenoma Myoepithelial neoplasm benign myoepithelioma disease_ontology DOID:2661 myoepithelioma DOID:2661 MESH:D013544 NCI:C3398 SNOMEDCT_US_2020_03_01:126490003 UMLS_CUI:C0038987 Sweat gland tumor neoplasm of sweat gland tumor of the Sweat gland disease_ontology DOID:2664 sweat gland benign neoplasm DOID:2664 MESH:D008637 NCI:C3233 SNOMEDCT_US_2020_03_01:44524009 UMLS_CUI:C0025464 disease_ontology DOID:2668 mesenchymoma DOID:2668 A carcinoma that derives_from transitional epithelial cells. DOID:3995 GARD:7794 MESH:D002295 NCI:C2930 NCI:C6783 SNOMEDCT_US_2020_03_01:118287003 SNOMEDCT_US_2020_03_01:27090000 UMLS_CUI:C0007138 UMLS_CUI:C0334265 transitional carcinoma transitional cell tumor urothelial cell carcinoma disease_ontology transitional cell neoplasm DOID:2671 transitional cell carcinoma DOID:2671 A nephroma that is characterized as a localized, well-circumscribed multilocular tumor lined by hobnail epithelium. NCI:C7504 multilocular cystic nephroma, mixed epithelial stromal tumour and renal epithelial stromal tumour disease_ontology DOID:2673 adult cystic nephroma DOID:2673 GARD:10640 NCI:C9505 SNOMEDCT_US_2020_03_01:87211000119104 UMLS_CUI:C1266177 Dysembryoplastic Neuroepithelial neoplasm Dysembryoplastic neuroepithelial tumor Dysembryoplastic neuroepithelial tumour dysembryoplastic neuroepithelial tumour disease_ontology DOID:2679 dysembryoplastic neuroepithelial tumor DOID:2679 A cell type benign neoplasm that is composed_of glandular and fibrous tissues, with a relatively large proportion of glands. MESH:D000232 SNOMEDCT_US_2020_03_01:189823009 UMLS_CUI:C0001422 disease_ontology DOID:2683 adenofibroma MESH:D000232 DOID:2683 NCI:C6582 SNOMEDCT_US_2020_03_01:404076001 UMLS_CUI:C1266128 Ossifying Fibromyxoma Ossifying fibromyxoid tumor Ossifying fibromyxoid tumour ossifying fibromyxoid tumour disease_ontology DOID:2685 ossifying fibromyxoid tumor DOID:2685 A lymphatic system cancer that has_material_basis_in endothelial cells located_in lymphatic vessels. DOID:2686 MESH:C537491 MESH:D008204 NCI:C3205 NCI:C4490 SNOMEDCT_US_2020_03_01:403986008 SNOMEDCT_US_2020_03_01:62497000 UMLS_CUI:C0024224 UMLS_CUI:C0346082 Lymphangiosarcoma of Stewart and Treves Stewart-Treves syndrome malignant Lymphangioendothelioma skin lymphangiosarcoma disease_ontology DOID:2689 lymphangiosarcoma DOID:2689 A muscle benign neoplasm that is characterized as benign hyperplastic lesions of uterine smooth muscle cells. ICD10CM:D21 MESH:D009214 NCI:C4882 SNOMEDCT_US_2020_03_01:66357004 UMLS_CUI:C0027086 benign neoplasm of the Muscle disease_ontology DOID:2691 myoma DOID:2691 A sex cord-gonadal stromal tumor that secretes testosterone characterized by excessive proliferation of Leydig cells located_in ovary or testicle. DOID:0050616 MESH:D007984 NCI:C3188 NCI:C4213 SNOMEDCT_US_2020_03_01:45002009 SNOMEDCT_US_2020_03_01:77870005 UMLS_CUI:C0023601 UMLS_CUI:C0334410 Leydig cell neoplasm disease_ontology DOID:2696 Leydig cell tumor DOID:2696 NCI:C8383 SNOMEDCT_US_2020_03_01:41627005 UMLS_CUI:C0334684 renal cell adenoma disease_ontology DOID:2697 renal adenoma DOID:2697 NCI:C39812 SNOMEDCT_US_2020_03_01:128760004 UMLS_CUI:C1266141 Metanephric adenofibroma disease_ontology DOID:2698 nephrogenic adenofibroma DOID:2698 A sarcoma and malignant non-epithelial hepatic and intrahepatic bile duct neoplasm sthat is located_in the liver. NCI:C4437 SNOMEDCT_US_2020_03_01:254601002 UMLS_CUI:C0345906 hepatic sarcoma disease_ontology DOID:270 liver sarcoma DOID:270 DOID:2665 MESH:D000070779 NCI:C3829 NCI:C6532 SNOMEDCT_US_2020_03_01:5178002 SNOMEDCT_US_2020_03_01:71508003 UMLS_CUI:C0221289 UMLS_CUI:C0588125 Synovioma, benign benign synovioma benign tumor of Synovium localized Giant cell tumor of Tenosynovium disease_ontology DOID:2701 nodular tenosynovitis DOID:2701 GARD:7396 ICD10CM:M12.2 MESH:D013586 NCI:C3401 SNOMEDCT_US_2020_03_01:202903009 UMLS_CUI:C0039106 Diffuse Giant cell tumor of Tenosynovium villous tenosynovitis disease_ontology DOID:2702 pigmented villonodular synovitis DOID:2702 A connective tissue disease that results_in inflammation located_in synovial membrane that lines a synovial joint which causes pain and swelling. GARD:7722 MESH:D013585 NCI:C50766 SNOMEDCT_US_2020_03_01:268092005 UMLS_CUI:C0039103 disease_ontology DOID:2703 synovitis DOID:2703 NCI:C6531 UMLS_CUI:C1334624 malignant tumor of Synovium disease_ontology DOID:2706 synovium cancer DOID:2706 An extrinsic allergic alveolitis that is characterized by a set of symptoms such as headache, fatigue, eye irritation, and breathing difficulties that affect workers in modern airtight office buildings. The disease is caused by indoor pollutants (as formaldehyde fumes, particulate matter, or microorganisms), and the symptoms tend to disappear when affected individuals leave the building. MESH:D018877 SNOMEDCT_US_2020_03_01:19076009 UMLS_CUI:C0037050 disease_ontology DOID:2710 sick building syndrome DOID:2710 ICD10CM:N47.1 MESH:D010688 NCI:C26852 SNOMEDCT_US_2020_03_01:449826002 UMLS_CUI:C0031538 Tight foreskin Tight frenulum disease_ontology DOID:2712 phimosis DOID:2712 A syndrome characterized by sun sensitivity, short stature, predisposition to the development of cancer and genomic instability. MESH:D001816 NCI:C2903 OMIM:210900 ORDO:125 SNOMEDCT_US_2020_03_01:4434006 UMLS_CUI:C0005859 Bloom-Torre-Machacek syndrome Congenital Telangiectatic Erythema syndrome disease_ontology DOID:2717 OMIM mapping confirmed by DO. [SN]. Bloom syndrome DOID:2717 A pneumothorax that is characterized by having air in the chest cavity and blood in the chest cavity. ICD10CM:J94.2 MESH:D006468 SNOMEDCT_US_2020_03_01:16632002 UMLS_CUI:C0019077 haemopneumothorax disease_ontology DOID:2718 hemopneumothorax DOID:2718 A vascular disease that is located_in the liver. NCI:C35442 SNOMEDCT_US_2020_03_01:235878005 UMLS_CUI:C0400923 vascular disorder of liver disease_ontology DOID:272 hepatic vascular disease DOID:272 A dermatitis that selectively affects the hands and feet. GARD:5722 MESH:D000169 NCI:C84532 SNOMEDCT_US_2020_03_01:8197001 UMLS_CUI:C0001197 disease_ontology DOID:2722 acrodermatitis MESH:D000169 DOID:2722 A skin disease characterized by itchy, erythematous, vesicular, weeping and crusting patches of skin. DOID:8614 DOID:8917 ICD10CM:L30.9 MESH:D003872 NCI:C2983 SNOMEDCT_US_2020_03_01:238538009 UMLS_CUI:C0011603 eczema skin inflammation disease_ontology DOID:2723 dermatitis DOID:2723 ICD10CM:Q82.5 MESH:D018324 NCI:C7457 SNOMEDCT_US_2020_03_01:56975005 UMLS_CUI:C0206733 Capillary hemangioma Congenital vascular hamartoma Congenital vascular naevus Infantile hemangioma Juvenile hemangioma Strawberry haemangioma Strawberry nevus Strawberry nevus of skin cellular hemangioma of Infancy disease_ontology DOID:2725 capillary hemangioma DOID:2725 A skin disease characterized by cutaneous pigmentation, premature graying, dystrophy of the nails, leukoplakia of the oral mucosa, continuous lacrimation due to atresia of the lacrimal ducts, often thrombocytopenia, anemia, testicular atrophy in the male carriers and predisposition to cancer. GARD:10905 MESH:D019871 NCI:C111802 OMIM:PS127550 ORDO:1775 SNOMEDCT_US_2020_03_01:74911008 UMLS_CUI:C0265965 disease_ontology DOID:2729 Xref MGI. OMIM mapping by NeuroDevNet. [LS]. dyskeratosis congenita DOID:2729 A vesiculobullous skin disease that is characterized by formation of blisters with only minor skin trauma, which can cause widespread wounds, dehydration, electrolyte abnormalities, and severe infection, frequently develops_from mutations in connective tissue elements, including genes encoding keratin, collagen, and laminin. GARD:6359 ICD10CM:Q81 MESH:D004820 NCI:C67383 SNOMEDCT_US_2020_03_01:205580008 UMLS_CUI:C0014527 Epidermolysis bullosa acantholysis bullosa disease_ontology DOID:2730 epidermolysis bullosa DOID:2730 A skin disease that is characterized by fluid filled blisters. MESH:D012872 UMLS_CUI:C0037275 disease_ontology DOID:2731 vesiculobullous skin disease DOID:2731 GARD:4392 ICD10CM:Q82.8 MESH:D011038 NCI:C3335 OMIM:268400 SNOMEDCT_US_2020_03_01:205572001 UMLS_CUI:C0032339 Congenital poikiloderma RTS disease_ontology DOID:2732 OMIM mapping confirmed by DO. [SN]. Rothmund-Thomson syndrome MESH:D011038 DOID:2732 ICD10CM:L90 NCI:C35163 SNOMEDCT_US_2020_03_01:16343004 UMLS_CUI:C0151514 Atrophoderma Atrophy - skin atrophic condition of skin disease_ontology DOID:2733 skin atrophy DOID:2733 ICD10CM:E50.8 MESH:D007644 NCI:C84665 OMIM:124200 SNOMEDCT_US_2020_03_01:157017000 UMLS_CUI:C0022595 DARIER-WHITE DISEASE Darier's disease Keratosis follicularis disease_ontology DOID:2734 OMIM mapping confirmed by DO. [SN]. keratosis follicularis DOID:2734 A bone disease characterized by short stature, coarse and dysmorphic facies, bowing of the long bones, and vertebral anomalies that has_material_basis_in heterozygous mutation in NOTCH2 on chromosome 1p12. DOID:2735 GARD:508 MESH:D030981 MESH:D031845 NCI:C35545 NCI:C84745 OMIM:102500 SNOMEDCT_US_2020_03_01:63122002 UMLS_CUI:C0917715 UMLS_CUI:C0917990 Cheney syndrome HJCYS SFPKS acroosteolysis with osteoporosis and changes in skull and mandible arthrodentoosteodysplasia serpentine fibula-polycystic kidney syndrome disease_ontology DOID:2736 OMIM mapping confirmed by DO. [SN]. Hajdu-Cheney syndrome DOID:2736 A connective tissue disease that is characterized by the accumulation of deposits of calcium and other minerals in elastic fibers, which are a component of connective tissue, this can result in changes in the skin, eyes, cardiovascular system and gastrointestinal system. GARD:9643 MESH:D011561 NCI:C85036 OMIM:177850 OMIM:264800 ORDO:758 SNOMEDCT_US_2020_03_01:7109007 UMLS_CUI:C0033847 Gronblad-Strandberg syndrome disease_ontology DOID:2738 Xref MGI. OMIM mapping confirmed by DO. [SN]. pseudoxanthoma elasticum DOID:2738 A bilirubin metabolic disorder that involves elevated levels of unconjugated bilirubin as bilirubin is not being conjugated as a result of reduced glucuronyltransferase activity. GARD:6507 ICD10CM:E80.4 MESH:D005878 NCI:C84729 OMIM:143500 SNOMEDCT_US_2020_03_01:27503000 UMLS_CUI:C0017551 Constitutional hyperbilirubinemia Gilbert's disease Gilbert's syndrome Gilbert-Meulengracht syndrome hereditary nonhemolytic jaundice disease_ontology DOID:2739 OMIM mapping confirmed by DO. [SN]. Gilbert syndrome DOID:2739 An inherited metabolic disorder that involves elevated levels of bilirubin resulting from disruption of bilirubin metabolism. DOID:2740 MESH:D006932 MESH:D006933 NCI:C84761 SNOMEDCT_US_2020_03_01:154770008 UMLS_CUI:C0020433 UMLS_CUI:C0020435 hereditary hyperbilirubinemia hyperbilirubinemia disease_ontology hyperbilirubinaemia DOID:2741 bilirubin metabolic disorder DOID:2741 A sensory system disease that is characterized by auditory dysfunction located_in the auditory system. DOID:1490 DOID:2011 ICD10CM:H93.9 ICD9CM:388.9 MESH:D004427 NCI:C26757 SNOMEDCT_US_2020_03_01:194193002 UMLS_CUI:C0013447 ear and mastoid disease disease_ontology DOID:2742 auditory system disease DOID:2742 ICD10CM:N12 MESH:D011702 NCI:C34964 SNOMEDCT_US_2020_03_01:27174002 UMLS_CUI:C0034183 disease_ontology DOID:2744 pyelitis DOID:2744 A personality disorder that involves an excessive preoccupation with issues of personal adequacy, power, prestige and vanity. ICD10CM:F60.81 ICD9CM:301.81 MESH:D010554 NCI:C92635 SNOMEDCT_US_2020_03_01:80711002 UMLS_CUI:C0027402 disease_ontology DOID:2745 narcissistic personality disorder DOID:2745 GARD:6528 ICD10CM:E74.04 MESH:D006012 NCI:C84738 OMIM:232600 SNOMEDCT_US_2020_03_01:55912009 UMLS_CUI:C0017924 Glycogen storage disease, type V McArdle's disease glycogen storage disease type V myophosphorylase deficiency disease_ontology DOID:2746 OMIM mapping confirmed by DO. [SN]. glycogen storage disease V DOID:2746 A glycogen metabolism disorder that has_material_basis_in enzymes deficiencies necessary in the processing of glycogen synthesis or breakdown within muscles, liver, and other cell types. ICD10CM:E74.0 ICD9CM:271.0 MESH:D006008 NCI:C61272 SNOMEDCT_US_2020_03_01:267498002 UMLS_CUI:C0017919 glycogenosis glycogenoses disease_ontology DOID:2747 glycogen storage disease DOID:2747 GARD:2520 ICD10CM:E74.09 MESH:D006011 NCI:C84737 OMIM:232500 SNOMEDCT_US_2020_03_01:11179002 UMLS_CUI:C0017923 Amylopectinosis Branching-transferase deficiency glycogenosis Glycogen storage disease, type IV brancher deficiency glycogenosis deficiency of 1,4-alpha-glucan branching enzyme disease_ontology DOID:2750 OMIM mapping confirmed by DO. [SN]. glycogen storage disease IV DOID:2750 A glycogen storage disease that has_material_basis_in deficiency of the lysosomal acid alpha-glucosidase enzyme resulting in damage to muscle and nerve cells due to an accumulation of glycogen in the lysosome. GARD:5714 ICD10CM:E74.02 MESH:D006009 NCI:C84734 OMIM:232300 SNOMEDCT_US_2020_03_01:237967002 UMLS_CUI:C0017921 Generalized glycogenosis Glycogen storage disease, type II Glycogenosis, type 2 Lysosomal alpha-1,4-glucosidase deficiency Pompe's disease acid maltase deficiency deficiency of glucoamylase deficiency of maltase glycogen storage disease type II disease_ontology DOID:2752 OMIM mapping confirmed by DO. [SN]. glycogen storage disease II DOID:2752 A primary bacterial infectious disease that results_in infection, has_material_basis_in Mycobacterium avium complex (MAC), which is transmitted_by inhalation or transmitted_by ingestion of via the respiratory or gastrointestinal tract respectively. The bacteria cause disseminated infection in HIV infected people, while pulmonary disease in immunocompetent persons. GARD:7123 MESH:D015270 NCI:C36197 SNOMEDCT_US_2020_03_01:14009004 UMLS_CUI:C0026916 Infection due to Mycobacterium intracellulare MAC disease Mycobacterium Avium Infection Mycobacterium avium Complex disease_ontology DOID:2755 Mycobacterium avium complex disease MESH:D015270 DOID:2755 A specific developmental disorder that is characterized by the persistent presence of involuntary brief movements or sounds occuring intermittently and unpredictably out of a background of normal motor activity. ICD10CM:F95 ICD9CM:307.20 MESH:D013981 SNOMEDCT_US_2020_03_01:155005001 UMLS_CUI:C0040188 disease_ontology DOID:2769 tic disorder DOID:2769 A contact dermatitis that is characterized by a cutaneous inflammatory reaction to repeated contact with an irritant substance, friction, liquid, or adverse temperature that interacts with the skin and often has_symptom erythema, edema, scaling, pain, pruritis, or burning sensation. ICD10CM:L24.9 MESH:D017453 NCI:C27151 SNOMEDCT_US_2020_03_01:110979008 UMLS_CUI:C0162823 Irritant Contact Dermatitis Irritant contact dermatitis primary irritant dermatitis disease_ontology DOID:2772 irritant dermatitis DOID:2772 ICD10CM:L25.9 MESH:D003877 NCI:C26743 SNOMEDCT_US_2020_03_01:156338009 UMLS_CUI:C0011616 Contact dermatitis Contact dermatitis/eczema Contact eczema Dermatitis, venenata dermatitis venenata disease_ontology DOID:2773 contact dermatitis DOID:2773 A bone cancer that is located_in almost exclusively in the long bones. MESH:D050398 NCI:C7644 ORDO:55881 UMLS_CUI:C1367554 disease_ontology DOID:2776 adamantinoma MESH:D050398 DOID:2776 A lung cancer that is located_in the lung and that arises from transformed cells of mesenchymal origin. NCI:C4860 UMLS_CUI:C0598790 pulmonary sarcoma disease_ontology DOID:2784 lung sarcoma DOID:2784 A cerebellar disease that is characterized by hypoplasia and upward rotation of the cerebellar vermis and cystic dilation of the fourth ventricle. GARD:6242 ICD10CM:Q03.1 MESH:D003616 NCI:C75012 OMIM:220200 SNOMEDCT_US_2020_03_01:14447001 UMLS_CUI:C0010964 Atresia of foramina of Magendie and Luschka disease_ontology DOID:2785 OMIM mapping confirmed by DO. [SN]. Dandy-Walker syndrome DOID:2785 A brain disease that is characterized by damage to brain substance located_in cerebellum; has_symptom ataxia, has_symptom dysarthria, and has_symptom cerebellar cognitive affective syndrome. MESH:D002526 SNOMEDCT_US_2020_03_01:267691001 UMLS_CUI:C0007760 disease_ontology DOID:2786 cerebellar disease DOID:2786 A parasitic infectious disease that is caused by parasitic protozoa which are microorganisms classified as unicellular eukaryotes. DOID:0060003 DOID:10553 DOID:3734 DOID:3804 DOID:947 ICD10CM:B64 MESH:D011528 NCI:C34953 SNOMEDCT_US_2020_03_01:95896000 UMLS_CUI:C0033740 mastigophora infectious disease sarcomastigophora infectious disease disease_ontology DOID:2789 parasitic protozoa infectious disease DOID:2789 A parasitic helminthiasis infectious disease that involves infection of the small intestine of humans, dogs and cats by the nematode Necator americanus causing abdominal pain, diarrhea, cramps, weight loss and anemia. Cutaneous larvae migrans in humans is characterized by skin ruptures and severe itching. DOID:13048 ICD10CM:B76.1 MESH:D009332 NCI:C34838 SNOMEDCT_US_2020_03_01:36667009 UMLS_CUI:C0027528 disease_ontology DOID:2790 necatoriasis DOID:2790 A pneumonia located_in the lung parenchyma of unknown cause. ICD10CM:J84.114 MESH:D000080203 SNOMEDCT_US_2020_03_01:129459004 UMLS_CUI:C0085786 Diffuse idiopathic pulmonary fibrosis Idiopathic fibrosing alveolitis disease_ontology IPF DOID:2797 idiopathic interstitial pneumonia DOID:2797 A obstructive lung disease involving obstruction of the bronchioles due to inflammation and fibrosis which occurs as a complication of various lung conditions or physiological insults. GARD:9551 MESH:D001989 NCI:C62580 SNOMEDCT_US_2020_03_01:40100001 UMLS_CUI:C0006272 Bronchiolitis exudativa Bronchiolitis fibrosa obliterans Obliterative bronchiolitis disease_ontology DOID:2799 bronchiolitis obliterans DOID:2799 A disease of anatomical entity that is located_in endocrine glands which secretes a type of hormone directly into the bloodstream to regulate the body. ICD10CM:E34.9 ICD9CM:259.9 MESH:D004700 NCI:C3009 SNOMEDCT_US_2020_03_01:67432001 UMLS_CUI:C0014130 disease_ontology DOID:28 endocrine system disease DOID:28 ICD10CM:C72.50 ICD9CM:192.0 MESH:D003390 NCI:C3571 SNOMEDCT_US_2020_03_01:188311003 UMLS_CUI:C0153644 malignant neoplasm of cranial nerve malignant neoplasm of cranial nerves malignant tumor of cranial nerve malignant tumor of the Cranial nerve disease_ontology DOID:2815 cranial nerve malignant neoplasm DOID:2815 MESH:D009668 SNOMEDCT_US_2020_03_01:89488007 UMLS_CUI:C0028432 disorder of the nose nasal disorder disease_ontology DOID:2825 nose disease DOID:2825 DOID:2827 MESH:D042101 NCI:C35578 SNOMEDCT_US_2020_03_01:19968009 UMLS_CUI:C0267841 acute acalculous cholecystitis acute cholecystitis without calculus cholecystitis without calculus disease_ontology DOID:2828 acalculous cholecystitis MESH:D042101 DOID:2828 A bronchial disease that is characterized by chronic inflammation and narrowing of the airways, which is caused by a combination of environmental and genetic factors. The disease has_symptom recurring periods of wheezing (a whistling sound while breathing), has_symptom chest tightness, has_symptom shortness of breath, has_symptom mucus production and has_symptom coughing. DOID:12703 DOID:13829 DOID:13830 DOID:2840 DOID:5783 EFO:0000270 GARD:10246 ICD10CM:J45 ICD9CM:493 KEGG:05310 MESH:D001249 NCI:C28397 OMIM:600807 SNOMEDCT_US_2020_03_01:187687003 UMLS_CUI:C0004096 Exercise induced asthma bronchial hyperreactivity chronic obstructive asthma chronic obstructive asthma with acute exacerbation chronic obstructive asthma with status asthmaticus exercise-induced asthma disease_ontology DOID:2841 Xref MGI. asthma MESH:D001249 DOID:2841 An autosomal genetic disease that is characterized by delayed repolarization of the heart following a heartbeat increases the risk of episodes of torsade de pointes (TDP, a form of irregular heartbeat that originates from the ventricles). DOID:4069 GARD:6922 ICD10CM:I45.81 ICD9CM:426.82 MESH:D008133 NCI:C34786 OMIM:PS192500 ORDO:101016 ORDO:768 SNOMEDCT_US_2020_03_01:20852007 SNOMEDCT_US_2020_03_01:9651007 UMLS_CUI:C0023976 UMLS_CUI:C0035828 LQT Romano-Ward syndrome long Q-T syndrome disease_ontology DOID:2843 OMIM mapping confirmed by DO. [SN]. long QT syndrome DOID:2843 MESH:D003866 NCI:C34812 SNOMEDCT_US_2020_03_01:35489007 UMLS_CUI:C0025193 disease_ontology DOID:2848 melancholia DOID:2848 A chronic lymphocytic leukemia that is characterized by over production of B cells (lymphocytes) by the bone marrow where the B cells appear hairy under a microscope. GARD:6560 ICD10CM:C91.4 ICD9CM:202.4 MESH:D007943 NCI:C7402 SNOMEDCT_US_2020_03_01:118613001 UMLS_CUI:C0023443 disease_ontology DOID:285 hairy cell leukemia DOID:285 A thyroid gland disease that is characterized by elevated thyroxine levels in the blood. MESH:D006981 NCI:C131850 UMLS_CUI:C0020551 disease_ontology DOID:2855 hyperthyroxinemia MESH:D006981 DOID:2855 ICD10CM:E07.81 ICD9CM:790.94 MESH:D005067 NCI:C113170 SNOMEDCT_US_2020_03_01:237542005 UMLS_CUI:C0015190 Euthyroid sick syndrome Sick-euthyroid syndrome disease_ontology DOID:2856 euthyroid sick syndrome DOID:2856 GARD:12455 ICD10CM:D58.2 MESH:D006453 NCI:C3092 SNOMEDCT_US_2020_03_01:154794008 UMLS_CUI:C0019045 hemoglobinopathies disease_ontology DOID:2860 hemoglobinopathy DOID:2860 A carbohydrate metabolic disorder that is characterised by abnormally low levels of glucose-6-phosphate dehydrogenase (abbreviated G6PD or G6PDH). GARD:6520 MESH:D005955 NCI:C98933 SNOMEDCT_US_2020_03_01:124134002 UMLS_CUI:C2939465 Glucose-6-phosphate dehydrogenase deficiency deficiency of G-6PD disease_ontology DOID:2862 glucosephosphate dehydrogenase deficiency DOID:2862 An endometrial carcinoma that derives_from epithelial cells of glandular origin. DOID:5827 DOID:6650 NCI:C6287 NCI:C6290 NCI:C7359 SNOMEDCT_US_2020_03_01:123845008 SNOMEDCT_US_2020_03_01:762458004 UMLS_CUI:C0279763 UMLS_CUI:C1153706 UMLS_CUI:C1336905 adenocarcinoma of endometrium adenocarcinoma of the Endometrium adenocarcinoma of uterus endometrial adenoacanthoma endometrial endometrioid adenocarcinoma endometrial endometrioid adenocarcinoma with squamous differentiation endometrioid adenoma or carcinoma endometrioid adenomas and carcinomas endometrioid carcinoma of Endometrium disease_ontology DOID:2870 endometrial adenocarcinoma DOID:2870 A endometrial cancer that is located_in the tissue lining the uterus. DOID:3000 MESH:D016889 MESH:D018269 NCI:C3769 NCI:C7558 SNOMEDCT_US_2020_03_01:30289006 SNOMEDCT_US_2020_03_01:93781006 UMLS_CUI:C0206687 UMLS_CUI:C0476089 carcinoma of the Endometrium endometrioid carcinoma endometrioid carcinoma of female Reproductive system disease_ontology DOID:2871 OMIM mapping confirmed by DO. [SN]. endometrial carcinoma DOID:2871 A laryngeal carcinoma that has_material_basis_in squamous cells. NCI:C4044 SNOMEDCT_US_2020_03_01:707358000 UMLS_CUI:C0280324 Epidermoid carcinoma of the Larynx squamous cell carcinoma of larynx disease_ontology DOID:2876 laryngeal squamous cell carcinoma DOID:2876 A uterine disease that is characterized by the presence of endometrial tissue grows outside of the endometrium, such as into the myometrium. ICD10CM:N80.0 ICD9CM:617.0 MESH:D062788 NCI:C6996 OMIM:600458 SNOMEDCT_US_2020_03_01:76376003 UMLS_CUI:C0341858 Endometriosis interna Endometriosis of myometrium Endometriosis, myometrium adenomyosis uterine Adenomyosis disease_ontology DOID:288 OMIM mapping confirmed by DO. [SN]. endometriosis of uterus DOID:288 A male reproductive organ benign neoplasm that derives_from glandular epithelial cells and that is located_in the prostate. MESH:D011470 NCI:C4795 SNOMEDCT_US_2020_03_01:21173002 UMLS_CUI:C0520477 adenoma - prostate adenoma of prostate benign adenoma of prostate prostate adenoma disease_ontology DOID:2883 prostatic adenoma DOID:2883 MESH:D012181 UMLS_CUI:C0035352 disease_ontology DOID:2889 retrocochlear disease DOID:2889 A female reproductive system disease characterized by the growth of endometrial tissue outside the uterine body. EFO:0001065 ICD10CM:N80 ICD9CM:617 MESH:D004715 NCI:C3014 SNOMEDCT_US_2020_03_01:11871002 UMLS_CUI:C0014175 disease_ontology DOID:289 endometriosis DOID:289 An endocrine organ benign neoplasm that is located_in the thyroid and derives_from glandular epithelial cells. MESH:D013964 NCI:C3502 SNOMEDCT_US_2020_03_01:189174004 UMLS_CUI:C0151468 adenoma of thyroid gland disease_ontology DOID:2891 thyroid adenoma DOID:2891 A cervical cancer that is located_in the cervix uteri or located_in the cervical area and that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. NCI:C9039 SNOMEDCT_US_2020_03_01:285432005 UMLS_CUI:C0302592 cancer of cervix carcinoma cervix uteri carcinoma of cervix carcinoma of the Cervix Uteri disease_ontology DOID:2893 OMIM mapping confirmed by DO. [SN]. cervix carcinoma DOID:2893 A syndrome that is characterized by incomplete development of the ear, nose, soft palate, lip, and mandible. It is associated with anomalous development of the first branchial arch and second branchial arch. GARD:6540 ICD10CM:Q87.0 MESH:D006053 NCI:C84740 OMIM:164210 ORDO:374 SNOMEDCT_US_2020_03_01:46567003 UMLS_CUI:C0265240 Facio-auriculo-vertebral spectrum First AND second branchial arch syndrome First arch syndrome HEMIFACIAL MICROSOMIA OAV (oculoauriculovertebral) dysplasia Otomandibular dysostosis disease_ontology DOID:2907 OMIM mapping confirmed by DO. [SN]. Goldenhar syndrome DOID:2907 A syndrome that is characterized by bilateral and symmetric downslanting palpebral fissures, malar hypoplasia, micrognathia, and external ear abnormalities. GARD:9124 ICD10CM:Q75.4 MESH:D008342 NCI:C75018 OMIM:PS154500 SNOMEDCT_US_2020_03_01:205416009 UMLS_CUI:C0242387 Franceschetti syndrome Mandibulofacial dysostosis mandibulofacial dysostosis disease_ontology DOID:2908 OMIM mapping confirmed by DO. [SN]. Treacher Collins syndrome MESH:D008342 DOID:2908 DOID:2912 ICD10CM:K85 ICD9CM:577.0 MESH:D010195 NCI:C95437 SNOMEDCT_US_2020_03_01:39726008 UMLS_CUI:C0001339 PANCREATITIS NECROTIZING acute necrotizing pancreatitis disease_ontology DOID:2913 acute pancreatitis DOID:2913 A disease of anatomical entity that is located_in the immune system. EFO:0000540 ICD10CM:D89.9 ICD9CM:279.9 SNOMEDCT_US_2020_03_01:154782004 UMLS_CUI:C0041806 disease_ontology DOID:2914 immune system disease DOID:2914 A hypersensitivity reaction disease that is characterized by a cell-mediated response to antigens, where Th1 helper T cells react with antigens on antigen-presenting cells and cause a delayed type immune response. ICD10CM:C88.9 MESH:D007160 SNOMEDCT_US_2020_03_01:127071007 UMLS_CUI:C0021070 disease_ontology immunoproliferative disease DOID:2916 hypersensitivity reaction type IV disease DOID:2916 A hypersensitivity reaction type IV disease that involves large amounts of cryoglobulins in the blood which become thick or gel-like in cold temperatures. GARD:6217 ICD10CM:D89.1 MESH:D003449 NCI:C26736 SNOMEDCT_US_2020_03_01:30911005 UMLS_CUI:C0010403 CRYOGLOBULINEMIA Cryoimmunoglobulinaemia disease_ontology DOID:2917 cryoglobulinemia DOID:2917 NCI:C5102 SNOMEDCT_US_2020_03_01:416510003 UMLS_CUI:C1334361 lacrimal system neoplasm neoplasm of lacrimal system tumor of the lacrimal system disease_ontology DOID:292 lacrimal system cancer DOID:292 GARD:11982 MESH:D015432 NCI:C34644 OMIM:305800 SNOMEDCT_US_2020_03_01:80321008 UMLS_CUI:C0017662 Lobular glomerulonephritis chronic glomerulonephritis, lobular disease_ontology DOID:2920 membranoproliferative glomerulonephritis DOID:2920 A nephritis that causes inflammation of the glomeruli located_in kidney. GARD:6516 ICD10CM:N08 MESH:D005921 NCI:C26784 SNOMEDCT_US_2020_03_01:36171008 UMLS_CUI:C0017658 disease_ontology DOID:2921 glomerulonephritis DOID:2921 A syndrome that is characterized by large cutaneous hemangiomata with hypertrophy of the related bones and soft tissues. ICD10CM:Q87.2 MESH:D007715 NCI:C84801 OMIM:149000 SNOMEDCT_US_2020_03_01:59078009 UMLS_CUI:C0022739 Haemangiectatic hypertrophy Klippel-Trenaunay-Weber syndrome angioosteohypertrophy syndrome disease_ontology DOID:2926 OMIM mapping confirmed by DO. [SN]. Klippel-Trenaunay syndrome DOID:2926 A viral infectious disease that results_in infection in birds and humans, has_material_basis_in Newcastle disease virus, which is transmitted_by contact with feces and urine of an infected bird, or transmitted_by fomites. The infection has_symptom conjunctivitis, has_symptom headache, and has_symptom lacrimation in humans, and has_symptom gasping, has_symptom coughing, has_symptom twisting of head and neck, has_symptom circling, has_symptom complete paralysis, has_symptom watery diarrhea, and has_symptom reduced egg production in birds. MESH:D009521 NCI:C34849 SNOMEDCT_US_2020_03_01:258300000 UMLS_CUI:C0027983 Newcastle's disease Pseudo-fowlpest disease_ontology DOID:2929 Newcastle disease DOID:2929 A syndrome characterized by oculocutaneous albinism, immune deficiency, coagulation deficiency and neuropathy; it is that has_material_basis_in mutations in the CHS1 gene. GARD:6035 ICD10CM:E70.330 MESH:D002609 NCI:C2941 OMIM:214500 ORDO:167 SNOMEDCT_US_2020_03_01:111396008 UMLS_CUI:C0007965 CHS Chediak - Steinbrinck anomaly disease_ontology DOID:2935 OMIM mapping confirmed by DO. [SN]. Chediak-Higashi syndrome DOID:2935 DOID:291 ICD9CM:190.2 NCI:C3563 NCI:C4360 SNOMEDCT_US_2020_03_01:127004000 SNOMEDCT_US_2020_03_01:188271007 UMLS_CUI:C0153627 UMLS_CUI:C0339124 malignant neoplasm of lacrimal gland malignant tumour of lacrimal gland neoplasm of lacrimal gland tumor of the lacrimal gland disease_ontology DOID:294 lacrimal gland cancer DOID:294 A lung disease that is an inflammation of the bronchioles, the smallest air passages of the lungs. It is caused by viruses and bacteria. The disease has_symptom cough, has_symptom wheezing, has_symptom shortness of breath, has_symptom fever, has_symptom nasal flaring in infants and has_symptom bluish skin due to lack of oxygen. MESH:D001988 NCI:C39658 SNOMEDCT_US_2020_03_01:4120002 UMLS_CUI:C0006271 disease_ontology DOID:2942 bronchiolitis DOID:2942 A Coronavirus infection that results_in infection located_in respiratory tract, has_material_basis_in SARS coronavirus (SARS-CoV), which is transmitted_by droplet spread of respiratory secretions, transmitted_by ingestion of contaminated food, or transmitted_by fomites. The infection has_symptom fever, has_symptom headache, has_symptom body aches, has_symptom dry cough, and has_symptom hypoxia. GARD:9237 ICD10CM:J12.81 ICD9CM:079.82 MESH:D045169 NCI:C85064 SNOMEDCT_US_2020_03_01:398447004 UMLS_CUI:C1175175 SARS SARS-CoV infection disease_ontology DOID:2945 severe acute respiratory syndrome DOID:2945 ICD10CM:T75.3 ICD9CM:994.6 MESH:D009041 NCI:C34824 OMIM:158280 SNOMEDCT_US_2020_03_01:37031009 UMLS_CUI:C0026603 Travel Sickness disease_ontology DOID:2951 OMIM mapping confirmed by DO. [SN]. motion sickness DOID:2951 ICD10CM:H83.9 MESH:D007759 NCI:C128369 NCI:C27166 SNOMEDCT_US_2020_03_01:194690003 SNOMEDCT_US_2020_03_01:20425006 UMLS_CUI:C0022890 UMLS_CUI:C0494559 labyrinthine disease disease_ontology DOID:2952 inner ear disease DOID:2952 A B cell deficiency that is characterized by relative predominance of certain immunoglobulin subtypes and deficiencies of others. NCI:C27579 UMLS_CUI:C1334069 disease_ontology DOID:2959 hyperimmunoglobulin syndrome DOID:2959 A trichothiodystrophy characterized by skin that is extremely sensitive to ultraviolet (UV) rays from sunlight. MESH:D054463 NCI:C4924 OMIM:PS601675 SNOMEDCT_US_2020_03_01:723551003 IBIDS syndrome TTD-P Tay syndrome sulfur-deficient brittle hair syndrome trichothiodystrophy with congenital ichthyosis disease_ontology DOID:2960 OMIM mapping confirmed by DO. [SN]. photosensitive trichothiodystrophy DOID:2960 A syndrome that has_material_basis_in rare mutations in two DNA excision repair proteins, ERCC-8 and ERCC-6, and characterized by growth failure, impaired development of the nervous system, abnormal sensitivity to sunlight (photosensitivity), and premature aging. GARD:6122 ICD10CM:Q87.19 MESH:D003057 NCI:C9460 OMIM:133540 OMIM:216400 ORDO:191 ORDO:90321 ORDO:90322 ORDO:90324 SNOMEDCT_US_2020_03_01:205832003 UMLS_CUI:C0009207 Neill-Dingwall syndrome disease_ontology Cockayne's syndrome DOID:2962 Xref MGI. OMIM mapping confirmed by DO. [SN]. Cockayne syndrome DOID:2962 ICD10CM:M71.9 MESH:D002062 NCI:C94407 SNOMEDCT_US_2020_03_01:156677003 UMLS_CUI:C0006444 disease_ontology DOID:2965 bursitis DOID:2965 NCI:C4397 SNOMEDCT_US_2020_03_01:17264009 UMLS_CUI:C0344460 carcinoma ex pleomorphic adenoma carcinoma in pleomorphic adenoma disease_ontology DOID:297 pleomorphic adenoma carcinoma DOID:297 MESH:D052177 UMLS_CUI:C0022679 renal Cyst disease_ontology DOID:2975 cystic kidney disease DOID:2975 A carbohydrate metabolic disorder characterized by impaired glyoxylate metabolism resulting in accumulation of oxalate throughout the body typically manifesting as kidney and bladder stones. DOID:2979 ICD10CM:E72.53 ICD10CM:R82.992 MESH:D006959 MESH:D006960 NCI:C123158 OMIM:PS259900 ORDO:416 SNOMEDCT_US_2020_03_01:190766003 SNOMEDCT_US_2020_03_01:367621000119107 UMLS_CUI:C0020500 UMLS_CUI:C0020501 disease_ontology DOID:2977 OMIM mapping confirmed by DO. [SN]. primary hyperoxaluria DOID:2977 An inherited metabolic disorder that affect the catabolism and anabolism of carbohydrates. DOID:9434 MESH:D002239 UMLS_CUI:C0007001 disorder of carbohydrate transport and metabolism inborn carbohydrate metabolism disorder inborn errors of carbohydrate metabolism disease_ontology DOID:2978 carbohydrate metabolic disorder DOID:2978 MESH:D010501 SNOMEDCT_US_2020_03_01:111404004 UMLS_CUI:C0031065 disease_ontology DOID:2982 perinephritis DOID:2982 MESH:D001002 NCI:C114699 SNOMEDCT_US_2020_03_01:139460001 UMLS_CUI:C0003460 Suppression of urinary secretion disease_ontology DOID:2983 anuria DOID:2983 A glomerulonephritis characterized by build up of IgA antibody in the glomerulus. EFO:0004194 GARD:863 MESH:D005922 NCI:C34643 OMIM:161950 SNOMEDCT_US_2020_03_01:236407003 UMLS_CUI:C0017661 Berger's IgA or IgG nephropathy Focal Glomerulonephritis IGA glomerulonephritis IgA nephropathy primary IgA nephropathy segmental glomerulonephritis disease_ontology DOID:2986 OMIM mapping confirmed by DO. [SN]. IgA glomerulonephritis DOID:2986 An autoimmune disease characterized by recurrent episodes of fever and acute inflammation of the membranes lining the abdomen, joints and lungs; that has_material_basis_in mutations in the MEFV gene, which encodes the protein pyrin. GARD:6421 ICD10CM:M04.1 ICD9CM:277.31 MESH:D010505 NCI:C84707 OMIM:134610 OMIM:249100 ORDO:342 SNOMEDCT_US_2020_03_01:12579009 UMLS_CUI:C0031069 benign paroxysmal peritonitis disease_ontology DOID:2987 Xref MGI. OMIM mapping confirmed by DO. [SN]. familial Mediterranean fever DOID:2987 An autoimmune disease that is characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with characteristic elevated levels of antibodies directed against membrane anionic phospholipids (anticardiolipin). GARD:5824 ICD10CM:D68.61 MESH:D016736 NCI:C61283 OMIM:107320 SNOMEDCT_US_2020_03_01:201450008 UMLS_CUI:C0085278 Antiphospholipid syndrome antiphospholipid antibody syndrome disease_ontology DOID:2988 OMIM mapping confirmed by DO. [SN]. antiphospholipid syndrome MESH:D016736 DOID:2988 A carcinoma that has_material_basis_in abnormally proliferating cells, derives_from epithelial cells, which originate in glandular tissue. MESH:D000230 NCI:C2852 SNOMEDCT_US_2020_03_01:443961001 UMLS_CUI:C0001418 disease_ontology DOID:299 adenocarcinoma MESH:D000230 DOID:299 A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from germ cells. DOID:2157 MESH:D009373 NCI:C3708 SNOMEDCT_US_2020_03_01:302853003 UMLS_CUI:C0205851 malignant tumor of the germ cell disease_ontology germ cell neoplasm germ cell tumour DOID:2994 germ cell cancer DOID:2994 A sex cord-gonadal stromal tumor characterized by variable proportions of Sertoli cells, Leydig cells, primitive gonadal stroma and/or heterologous elements located_in the ovaries and testicles. DOID:0050618 GARD:9967 MESH:D018310 SNOMEDCT_US_2020_03_01:34110004 UMLS_CUI:C0206723 disease_ontology DOID:2997 Sertoli-Leydig cell tumor DOID:2997 A male reproductive system cancer that is located_in the testicles. DOID:12231 DOID:5554 GARD:7746 ICD10CM:C62 ICD9CM:186 MESH:D013736 NCI:C3404 NCI:C5053 NCI:C7251 SNOMEDCT_US_2020_03_01:126900000 SNOMEDCT_US_2020_03_01:94087009 UMLS_CUI:C0039590 UMLS_CUI:C0153594 UMLS_CUI:C1333010 childhood neoplasm of the testis neoplasm of testis pediatric testicular neoplasm testicular tumor testis cancer testis neoplasm disease_ontology DOID:2998 OMIM mapping confirmed by DO. [SN]. testicular cancer DOID:2998 A sex cord-gonadal stromal tumor that has_material_basis_in granulosa cells and arises from the sex cord stroma. DOID:5333 MESH:D006106 NCI:C3070 NCI:C4205 SNOMEDCT_US_2020_03_01:18861007 SNOMEDCT_US_2020_03_01:46585005 UMLS_CUI:C0018206 UMLS_CUI:C0334401 Granulosa cell neoplasm Granulosa cell tumor, adult type Granulosa cell tumour, sarcomatoid malignant granulosa cell neoplasm disease_ontology DOID:2999 granulosa cell tumor DOID:2999 A breast cancer that arises from myoepithelial cells, which are a normal constituent of the salivary acini and ducts and are found between the epithelial cells and the basement membrane. NCI:C40389 UMLS_CUI:C1511319 disease_ontology DOID:3004 breast myoepithelial neoplasm DOID:3004 A breast carcinoma in situ that is characterized by abnormal cells are found in the lobules (glands that make milk) of the breast. NCI:C27939 UMLS_CUI:C0861352 Lobular Intraepithelial Neoplasia lobular carcinoma in situ disease_ontology DOID:3010 lobular neoplasia DOID:3010 A syndrome characterized by autosomal dominant inheritance of increased risk of developing several types of cancer, including breast cancer, osteosarcomata and soft tissue sarcomata. GARD:6902 MESH:D016864 NCI:C3476 OMIM:PS151623 ORDO:524 SNOMEDCT_US_2020_03_01:428850001 UMLS_CUI:C0085390 Li-Fraumeni Familiar cancer Susceptibility syndrome SBLA syndrome sarcoma, breast, leukaemia and adrenal gland syndrome disease_ontology DOID:3012 Xref MGI. OMIM mapping confirmed by DO. [SN]. Li-Fraumeni syndrome DOID:3012 A breast benign neoplasm that is located_in the breast ducts. NCI:C36083 UMLS_CUI:C0948967 disease_ontology DOID:3013 intraductal breast benign neoplasm DOID:3013 A breast cancer that is characterized by a prominent infiltrative border, unequivocal sarcomatous areas, and stromal overgrowth and arises_from the stroma, lined by an epithelial and myoepithelial bilayer, forming a leaflike structure. They tend to grow rapidly and present in middle-aged women (40s-50s). DOID:1632 DOID:3018 MESH:D003557 NCI:C4275 NCI:C4504 NCI:C7575 SNOMEDCT_US_2020_03_01:254844000 SNOMEDCT_US_2020_03_01:712989008 SNOMEDCT_US_2020_03_01:87913009 UMLS_CUI:C0238031 UMLS_CUI:C0346154 UMLS_CUI:C0600066 Phyllodes breast neoplasm Phyllodes tumor, malignant breast malignant phyllodes tumour malignant Mammary Phyllodes tumor malignant Mammary Phyllodes tumour malignant Phyllodes neoplasm malignant cystosarcoma phyllodes malignant phyllodes tumor malignant phyllodes tumor of breast malignant phyllodes tumour malignant phyllodes tumour of breast phyllodes breast tumor phyllodes breast tumour disease_ontology DOID:3016 breast malignant phyllodes tumor DOID:3016 A breast cancer that has_material_basis_in abnormally proliferating cells derives_from mesenchymal cells. NCI:C4670 SNOMEDCT_US_2020_03_01:278050001 UMLS_CUI:C0349667 sarcoma of breast disease_ontology DOID:3017 breast sarcoma DOID:3017 A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning. MESH:D019966 NCI:C16522 SNOMEDCT_US_2020_03_01:26416006 UMLS_CUI:C0013146 disease_ontology DOID:302 substance abuse DOID:302 A carcinoma that has_material_basis_in abnormally proliferating cells, derives_from spindle cells and/or derives_from giant cells. GARD:8568 MESH:D018267 NCI:C3768 SNOMEDCT_US_2020_03_01:45410002 UMLS_CUI:C0206685 acinic cell carcinoma disease_ontology DOID:3025 acinar cell carcinoma DOID:3025 A disease of mental health involving the abuse or dependence on a substance that is ingested in order to produce a high, alter one's senses, or otherwise affect functioning. MESH:D019966 NCI:C92203 UMLS_CUI:C0236969 disease_ontology DOID:303 substance-related disorder DOID:303 An adenocarcinoma that derives_from epithelial cells originating in glandular tissue, which produce mucin. DOID:4532 MESH:D002288 NCI:C26712 NCI:C27379 SNOMEDCT_US_2020_03_01:72495009 SNOMEDCT_US_2020_03_01:900006 UMLS_CUI:C0007130 UMLS_CUI:C0334368 Mucin-Secreting adenocarcinoma Mucin-Secreting carcinoma Mucin-producing adenocarcinoma Mucous carcinoma Pseudomyxoma peritonei with unknown primary site mucin-producing adenocarcinoma disease_ontology DOID:3030 mucinous adenocarcinoma DOID:3030 A contact dermatitis that is an allergic skin reaction to foreign chemical or substances leading to red, itchy, weepy reaction where the skin has come into contact with a substance that the immune system recognizes as foreign. ICD10CM:L23 MESH:D017449 NCI:C26998 SNOMEDCT_US_2020_03_01:200841005 UMLS_CUI:C0162820 disease_ontology DOID:3042 allergic contact dermatitis DOID:3042 A hypersensitivity reaction type I disease that is an abnormal response to a food, triggered by the body's immune system. MESH:D005512 SNOMEDCT_US_2020_03_01:213018006 UMLS_CUI:C0016470 food hypersensitivity disease_ontology DOID:3044 food allergy DOID:3044 A vasculitits that is systemic vasculitis realized as blood vessel inflammation and has_symptom asthma along with hay fever, rash and gastrointestinal bleeding. ICD10CM:M30.1 MESH:D015267 NCI:C34481 SNOMEDCT_US_2020_03_01:82275008 UMLS_CUI:C0008728 Allergic Granulomatous Angiitis Allergic granulomatosis angiitis Churg-Strauss vasculitis disease_ontology DOID:3049 Churg-Strauss syndrome DOID:3049 A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. DOID:2428 DOID:6570 MESH:D002277 MESH:D009375 NCI:C2916 NCI:C3709 SNOMEDCT_US_2020_03_01:188083002 SNOMEDCT_US_2020_03_01:269513004 SNOMEDCT_US_2020_03_01:71298006 UMLS_CUI:C0007097 UMLS_CUI:C0553707 UMLS_CUI:C1368683 epithelial cancer epithelioma malignant Epithelioma disease_ontology DOID:305 carcinoma DOID:305 A primary bacterial infectious disease that results_in infection located_in intestine, has_material_basis_in Salmonella enterica subsp enterica serovar Paratyphi A, B or C, which are transmitted_by ingestion of contaminated food. The infection has_symptom fever, has_symptom headache, has_symptom abdominal pain, has_symptom malaise, has_symptom anorexia, has_symptom constipation, has_symptom rosy spots on the central body, has_symptom non productive cough (in early stage of illness), has_symptom bradycardia, and has_symptom hepatosplenomegaly. DOID:13324 DOID:13325 DOID:3053 ICD10CM:A01.1 ICD10CM:A01.2 ICD10CM:A01.3 ICD10CM:A01.4 ICD9CM:002.1 ICD9CM:002.2 ICD9CM:002.3 ICD9CM:002.9 MESH:D010284 NCI:C34894 NCI:C34895 NCI:C34896 NCI:C34897 SNOMEDCT_US_2020_03_01:51254007 SNOMEDCT_US_2020_03_01:71085009 SNOMEDCT_US_2020_03_01:76623002 SNOMEDCT_US_2020_03_01:85904008 UMLS_CUI:C0030528 UMLS_CUI:C0343375 UMLS_CUI:C0343376 UMLS_CUI:C0343377 Paratyphoid Paratyphoid A fever Paratyphoid B fever Paratyphoid C fever Paratyphoid Fever A Paratyphoid Fever B Paratyphoid Fever C Paratyphoid fever A Paratyphoid fever B Paratyphoid fever C paratyphoid a paratyphoid b paratyphoid c disease_ontology DOID:3055 paratyphoid fever DOID:3055 An astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has_material_basis_in abnormally proliferating cells derives_from multiple cell types including astrocytes and oligondroctyes. DOID:3075 DOID:3080 GARD:2491 MESH:D005909 NCI:C3058 NCI:C39750 NCI:C9094 SNOMEDCT_US_2020_03_01:63634009 UMLS_CUI:C0017636 UMLS_CUI:C0278878 UMLS_CUI:C1514422 GBM adult glioblastoma multiforme glioblastoma multiforme grade IV adult Astrocytic tumor primary glioblastoma multiforme spongioblastoma multiforme disease_ontology DOID:3068 glioblastoma DOID:3068 A malignant glioma that is has_material_basis_in astrocyte cells, a type of star-shaped glial cell, located in the brain and spinal cord. DOID:4861 ICDO:M9400/3 MESH:D001254 NCI:C4951 NCI:C60781 SNOMEDCT_US_2020_03_01:189914005 SNOMEDCT_US_2020_03_01:99131000119108 UMLS_CUI:C0004114 UMLS_CUI:C0750935 Astrocytic tumor Astrocytoma, NOS astrocytoma of Cerebrum astrocytoma of brain astroglioma cerebral astrocytoma disease_ontology DOID:3069 astrocytoma MESH:D001254 DOID:3069 A cell type cancer that has_material_basis_in glial cells and is located in brain or located in spine. DOID:2627 ICDO:M9380/3 KEGG:05214 MESH:D005910 NCI:C4822 OMIM:PS137800 ORDO:182067 SNOMEDCT_US_2020_03_01:393564001 SNOMEDCT_US_2020_03_01:74532006 UMLS_CUI:C0017638 UMLS_CUI:C0555198 Neuroglial tumor glial cell tumor glioma, malignant malignant Neuroglial tumor disease_ontology DOID:3070 Xref MGI. OMIM mapping confirmed by DO. [SN]. malignant glioma DOID:3070 A gliomablastoma that is characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation. GARD:5653 MESH:D018316 NCI:C3796 SNOMEDCT_US_2020_03_01:35262004 UMLS_CUI:C0206726 Glioblastoma with sarcomatous component disease_ontology DOID:3071 gliosarcoma DOID:3071 MESH:D004831 UMLS_CUI:C0014550 Epileptic seizures - myoclonic Epileptic seizures, myoclonic Myoclonic seizure Myoclonic seizure disorder myoclonia epileptica myoclonic epilepsy disease_ontology DOID:308 early myoclonic encephalopathy DOID:308 GARD:6234 MESH:D018191 NCI:C3724 OMIM:257350 SNOMEDCT_US_2020_03_01:40225001 UMLS_CUI:C0206620 cystic Hygroma disease_ontology DOID:3081 cystic lymphangioma DOID:3081 A lung disease that is characterized by inflammation and altered lung interstitium compromising pulmonary function and often has_symptom shortness of breath, dyspnea, and/or cough. GARD:13336 ICD10CM:J84.9 MESH:D017563 SNOMEDCT_US_2020_03_01:64667001 UMLS_CUI:C0206062 ILD disease_ontology DOID:3082 interstitial lung disease DOID:3082 An obstructive lung disease that is characterized by irreversible airflow obstruction due to chronic bronchitis, emphysema, and/or small airways disease. DOID:11500 DOID:6144 EFO:0000341 ICD10CM:J44.9 MESH:D029424 NCI:C3199 OMIM:606963 SNOMEDCT_US_2020_03_01:13645005 UMLS_CUI:C0024117 COLD COPD chronic obstructive airway disease chronic obstructive lung disease disease_ontology DOID:3083 chronic obstructive pulmonary disease DOID:3083 ICD10CM:K06.1 MESH:D019214 SNOMEDCT_US_2020_03_01:54711002 UMLS_CUI:C0376480 Gingival enlargement disease_ontology DOID:3086 gingival overgrowth DOID:3086 DOID:10422 DOID:10424 ICD10CM:K05.0 ICD10CM:K05.1 ICD10CM:K05.10 ICD9CM:523.0 ICD9CM:523.1 MESH:D005891 NCI:C34474 NCI:C34636 SNOMEDCT_US_2020_03_01:155643004 SNOMEDCT_US_2020_03_01:196355002 SNOMEDCT_US_2020_03_01:266490003 UMLS_CUI:C0008684 UMLS_CUI:C0017574 UMLS_CUI:C0155937 acute gingivitis chronic gingivitis disease_ontology DOID:3087 gingivitis DOID:3087 An organ system cancer located_in the nervous system that affects the central or peripheral nervous system. DOID:1193 DOID:3195 DOID:4695 ICD9CM:192.9 MESH:D009380 NCI:C35562 SNOMEDCT_US_2020_03_01:188306000 UMLS_CUI:C0027665 UMLS_CUI:C0153643 UMLS_CUI:C1334956 malignant neoplasm of nervous system neoplasm of nervous system nervous system neoplasm neural neoplasm neural tumor tumor of the nervous system disease_ontology DOID:3093 nervous system cancer DOID:3093 A germ cell cancer that is derives_from a mixture of germs cells and embryonal cells. MESH:D009373 UMLS_CUI:C0027658 disease_ontology germ cell and embryonal neoplasm DOID:3095 germ cell and embryonal cancer DOID:3095 A vascular disease that is characterized by compression at the superior thoracic outlet[1] resulting from excess pressure placed on a neurovascular bundle passing between the anterior scalene and middle scalene muscles. GARD:7759 ICD10CM:G54.0 MESH:D013901 NCI:C85188 SNOMEDCT_US_2020_03_01:2040007 UMLS_CUI:C0039984 TOS - Thoracic outlet syndrome disease_ontology DOID:3103 thoracic outlet syndrome DOID:3103 A parasitic helminthiasis infectious disease that involves infection of the intestine of humans and birds with nematodes of the genus Ascaridia. MESH:D001198 SNOMEDCT_US_2020_03_01:2435008 UMLS_CUI:C0003952 disease_ontology DOID:3108 ascaridiasis DOID:3108 An adenocarcinoma that derives_from epithelial cells originating in glandular tissue, in which cystic accumulations of retained secretions are formed. MESH:D003536 NCI:C2971 SNOMEDCT_US_2020_03_01:21008007 UMLS_CUI:C0010631 disease_ontology DOID:3111 cystadenocarcinoma DOID:3111 An adenocarcinoma that derives_from epithelial cells originating in glandular tissue, which form complex papillary structures and exhibit compressive, destructive growth that replaces the normal tissue. DOID:5596 MESH:D000231 NCI:C2853 SNOMEDCT_US_2020_03_01:4797003 UMLS_CUI:C0001420 Infiltrating and papillary adenocarcinoma Papillary adenocarcinoma infiltrating papillary adenocarcinoma disease_ontology DOID:3112 papillary adenocarcinoma DOID:3112 A cystadenocarcinoma that derives_from epithelial cells originating in glandular tissue forming serous lesions. MESH:D018284 NCI:C3778 SNOMEDCT_US_2020_03_01:90725004 UMLS_CUI:C0206701 serous adenocarcinoma serous carcinoma disease_ontology DOID:3114 serous cystadenocarcinoma DOID:3114 NCI:C7514 UMLS_CUI:C1334323 renal and ureteral tumor disease_ontology DOID:3116 kidney benign neoplasm DOID:3116 A gastrointestinal system benign neoplasm located_in the hepatobiliary system. NCI:C8614 UMLS_CUI:C0854196 hepatobiliary tumors disease_ontology DOID:3117 hepatobiliary benign neoplasm DOID:3117 A gastrointestinal system disease that is located_in the liver and/or biliary tract. MESH:D004066 NCI:C3959 UMLS_CUI:C0267792 liver and biliary tract disease disease_ontology DOID:3118 hepatobiliary disease DOID:3118 An organ system cancer located_in gastrointestinal tract that is manifested in organs of the gastrointestinal system. DOID:4945 DOID:8377 ICD10CM:C26.9 ICD9CM:239.0 MESH:D004067 MESH:D005770 NCI:C3052 NCI:C4890 SNOMEDCT_US_2020_03_01:128348002 SNOMEDCT_US_2020_03_01:276806006 SNOMEDCT_US_2020_03_01:428905002 UMLS_CUI:C0012243 UMLS_CUI:C0017185 UMLS_CUI:C0685938 GI tumor digestive system cancer gastrointestinal tract cancer disease_ontology DOID:3119 gastrointestinal system cancer DOID:3119 A biliary tract cancer that is located_in the gallbladder. DOID:8090 DOID:8157 GARD:9328 ICD10CM:C23 ICD9CM:156.0 MESH:D005706 NCI:C3048 NCI:C35676 NCI:C7481 SNOMEDCT_US_2020_03_01:126854002 SNOMEDCT_US_2020_03_01:93810008 UMLS_CUI:C0016978 UMLS_CUI:C0153452 UMLS_CUI:C0278806 gallbladder Ca gallbladder neoplasm localized malignant gallbladder neoplasm malignant neoplasm of gallbladder malignant tumor of the gallbladder malignant tumour of gallbladder tumor of the gallbladder disease_ontology DOID:3121 gallbladder cancer DOID:3121 MESH:D017219 SNOMEDCT_US_2020_03_01:196759006 UMLS_CUI:C0162651 gastric outflow obstruction disease_ontology DOID:3122 gastric outlet obstruction DOID:3122 A syndrome that is characterized by tumors in at least two endocrine glands. Multiple endocrine adenomatosis disease_ontology DOID:3125 multiple endocrine neoplasia DOID:3125 A rectal disease that involves inflammation of the rectal mucosa, which results from infection, inflammatory bowel disease, or radiation. Sexually transmitted pathogens (Neisseria gonorrhoeae, Chlamydia trachomatis, herpes simplex virus 1 and 2, Treponema pallidum) and enteric pathogens (Campylobacter, Shigella, Salmonella) are involved in the disease. Symptoms are rectal discomfort and bleeding. ICD10CM:K62.89 MESH:D011349 NCI:C38011 SNOMEDCT_US_2020_03_01:266534007 UMLS_CUI:C0033246 ulcerative proctitis disease_ontology DOID:3127 proctitis DOID:3127 DOID:11479 DOID:11993 MESH:D001004 NCI:C26695 SNOMEDCT_US_2020_03_01:32110003 UMLS_CUI:C0003462 Nontraumatic tear of anus Solitary anal ulcer Ulcer of anus anal disease anal fissure anal fissure and fistula anal ulcer fissure in ano disease_ontology DOID:3128 anus disease DOID:3128 An acute porphyria characterized by painful, blistering skin lesions that develop on sun-exposed skin. GARD:7433 ICD10CM:E80.1 MESH:D017119 NCI:C27725 OMIM:176090 OMIM:176100 ORDO:101330 SNOMEDCT_US_2020_03_01:61860000 UMLS_CUI:C0162566 disease_ontology DOID:3132 Xref MGI. OMIM mapping confirmed by DO. [SN]. porphyria cutanea tarda DOID:3132 A porphyria that has_symptom abdominal pain, has_symptom neuropathy, has_symptom autonomic instability and has_symptom psychosis. MESH:D017094 OMIM:612740 ORDO:100924 SNOMEDCT_US_2020_03_01:55056006 UMLS_CUI:C0162533 hepatic porphyria disease_ontology DOID:3133 Xref MGI. acute porphyria DOID:3133 MESH:D005148 UMLS_CUI:C0015456 disease_ontology DOID:3134 facial dermatosis DOID:3134 MESH:D012536 SNOMEDCT_US_2020_03_01:402694007 UMLS_CUI:C0036271 Dermatosis of scalp disease_ontology DOID:3136 scalp dermatosis DOID:3136 GARD:8603 ICD10CM:L83 MESH:D000052 NCI:C26687 OMIM:100600 OMIM:200170 SNOMEDCT_US_2020_03_01:72129000 UMLS_CUI:C0000889 AN - Acanthosis nigricans Acanthosis nigricans Keratosis nigricans keratosis nigricans disease_ontology DOID:3138 OMIM mapping confirmed by DO. [SN]. acanthosis nigricans MESH:D000052 DOID:3138 A connective tissue disease characterized by accumulation of glycosaminoglycan located_in the dermal tissue. MESH:D017520 SNOMEDCT_US_2020_03_01:11528001 UMLS_CUI:C0162855 disease_ontology DOID:3141 mucinoses DOID:3141 A skin disease characterized by loose, hanging, wrinkled skin lacking in elasticity. GARD:6227 ICD10CM:Q82.8 MESH:D003483 NCI:C84663 OMIM:PS123700 ORDO:209 SNOMEDCT_US_2020_03_01:238825007 UMLS_CUI:C0010495 Cutis laxa loose skin disease_ontology DOID:3144 Xref MGI. cutis laxa DOID:3144 An inherited metabolic disorder that involves the creation and degradation of lipids. MESH:D008052 UMLS_CUI:C0023772 dyslipidemia fatty acid metabolism disorder disease_ontology DOID:3146 lipid metabolism disorder DOID:3146 ICD10CM:E88.2 MESH:D008068 SNOMEDCT_US_2020_03_01:37095002 UMLS_CUI:C0023801 disease_ontology DOID:3153 lipomatosis DOID:3153 MESH:D006229 UMLS_CUI:C0018567 disease_ontology DOID:3158 hand dermatosis DOID:3158 MESH:D012878 NCI:C3372 SNOMEDCT_US_2020_03_01:126488004 UMLS_CUI:C0037286 neoplasm of skin neoplasm of skin by site skin neoplasm tumor of the skin disease_ontology DOID:3165 skin benign neoplasm DOID:3165 A cell type benign neoplasm composed_of epithelial cells located_in the ectodermal or endodermal cells linking body cavities. MESH:D018307 NCI:C3792 SNOMEDCT_US_2020_03_01:118286007 UMLS_CUI:C0206720 Epidermoid cell tumor squamous cell tumor disease_ontology DOID:3168 squamous cell neoplasm DOID:3168 MESH:D000236 NCI:C79951 SNOMEDCT_US_2020_03_01:86143001 UMLS_CUI:C0205650 Papillary adenoma glandular papilloma disease_ontology DOID:3172 papillary adenoma DOID:3172 NCI:C4101 SNOMEDCT_US_2020_03_01:48218007 UMLS_CUI:C0334243 disease_ontology DOID:3177 verrucous papilloma DOID:3177 NCI:C4614 SNOMEDCT_US_2020_03_01:189051001 UMLS_CUI:C0347390 Cutaneous papilloma cutaneous papilloma papilloma of skin disease_ontology DOID:3178 skin papilloma DOID:3178 MESH:D018308 NCI:C3793 SNOMEDCT_US_2020_03_01:104081000119103 UMLS_CUI:C0206721 Inverted papilloma Inverted papilloma, squamous cell disease_ontology DOID:3179 inverted papilloma DOID:3179 ICD9CM:335.21 MESH:D009134 NCI:C85027 SNOMEDCT_US_2020_03_01:88923002 UMLS_CUI:C0917981 Pure progressive muscular atrophy progressive spinal muscular atrophy disease_ontology DOID:318 progressive muscular atrophy DOID:318 DOID:3182 GARD:9953 MESH:D009837 NCI:C129319 NCI:C6960 SNOMEDCT_US_2020_03_01:73348003 UMLS_CUI:C0028945 UMLS_CUI:C1335110 oligodendroglial neoplasm oligodendroglial tumor disease_ontology DOID:3181 oligodendroglioma DOID:3181 A spinal cancer that is located in the spinal cord and has_material_basis_in glial cells. NCI:C4534 SNOMEDCT_US_2020_03_01:254946004 UMLS_CUI:C2937245 Glial neoplasm Spinal Cord Glial tumor of spinal cord glioma of spinal cord disease_ontology DOID:3185 spinal cord glioma DOID:3185 ICD10CM:G95.9 ICD9CM:336.9 MESH:D013118 NCI:C97110 SNOMEDCT_US_2020_03_01:48522003 UMLS_CUI:C0037928 disease_ontology myelopathy DOID:319 spinal cord disease DOID:319 A congenital structural myopathy characterized by generally non-progressive muscle weakness of varying severity; certain muscle fibers show the presence of rod-like structures called nemaline bodies. GARD:12033 ICD10CM:G71.2 MESH:D017696 OMIM:PS161800 ORDO:607 SNOMEDCT_US_2020_03_01:75072002 UMLS_CUI:C0206157 Nemaline body disease nemaline rod myopathy rod myopathy disease_ontology DOID:3191 Xref MGI. nemaline myopathy DOID:3191 MESH:D009442 NCI:C3269 SNOMEDCT_US_2020_03_01:985004 UMLS_CUI:C0027809 Psammomatous schwannoma schwannoma disease_ontology DOID:3192 A neuroma that is characterized as a benign nerve sheath tumor that is composed of Schwann cells. neurilemmoma DOID:3192 A peripheral nervous system neoplasm that is located in the connective tissue surrounding nerves. MESH:D018317 UMLS_CUI:C0751689 neoplasm of the nerve Sheath nerve sheath tumour disease_ontology DOID:3193 peripheral nerve sheath neoplasm DOID:3193 A brain stem cancer that is characterized by neoplasms in the fossa located_in cerebellopotine angle. NCI:C5414 Cerebellopontine angle tumor Cerebellopontine angle tumour cerebellopontine angle tumour neoplasm of the Cerebellopontine Angle disease_ontology DOID:3200 cerebellopontine angle tumor DOID:3200 NCI:C6970 SNOMEDCT_US_2020_03_01:253088003 UMLS_CUI:C1306247 Melanotic Schwannoma Melanotic neurilemmoma Pigmented Neurilemmoma Pigmented schwannoma disease_ontology DOID:3205 melanotic neurilemmoma DOID:3205 An epidermolysis bullosa that is characterized by recurrent blistering located in the lamina lucida of the basement membrane secondary to minor trauma, which can cause limited wounds, dehydration, electrolyte abnormalities, severe infection, among other issues, and has_material_basis_in mutation in genes related to laminin 332, which strengthens the skin. GARD:2152 MESH:D016109 NCI:C90598 SNOMEDCT_US_2020_03_01:76905008 UMLS_CUI:C0079301 congenital junctional epidermolysis bullosa disease_ontology DOID:3209 Xref MGI. junctional epidermolysis bullosa DOID:3209 A viral infectious disease that results in inflammation located in spinal cord, has_material_basis_in Human T-lymphotropic virus 1, which is transmitted by sexual contact, and transmitted by breast feeding. The infection has symptom spastic weakness of both legs, has symptom muscle stiffness, has symptom sensory disturbance, and has symptom spasms. ICD10CM:G04.1 MESH:D015493 OMIM:159580 SNOMEDCT_US_2020_03_01:45129002 UMLS_CUI:C0030481 HTLV-associated myelopathy Tropical spastic paralysis Tropical spastic paraplegia disease_ontology DOID:321 OMIM mapping confirmed by DO. [LS]. tropical spastic paraparesis DOID:321 A hypomyelinating leukodystrophy characterized by impaired myelin formation, nystagmus, spastic quadriplegia, ataxia, and developmental delay that has_material_basis_in mutation in the PLP1 gene on chromosome Xq22. GARD:4265 MESH:D020371 NCI:C75487 OMIM:312080 ORDO:702 SNOMEDCT_US_2020_03_01:64855000 UMLS_CUI:C0205711 HLD1 Leukodystrophy, sudanophilic PMD Pelizaeus Merzbacher brain sclerosis Pelizaeus-Merzbacher brain sclerosis diffuse familial brain sclerosis hypomyelinating leukodystrophy 1 sudanophilic leukodystrophy, Paelizeus-Merzbacher type disease_ontology DOID:3210 Pelizaeus-Merzbacher disease DOID:3210 An inherited metabolic disorder that involve an abnormal accumulation of substances inside the lysosome resulting from defects in lysosomal function. MESH:D016464 NCI:C61250 SNOMEDCT_US_2020_03_01:23585005 UMLS_CUI:C0085078 disorder of lysosomal enzyme inborn lysosomal enzyme disorder lysosomal storage metabolism disorder disease_ontology DOID:3211 lysosomal storage disease DOID:3211 A neurodegenerative disease that is characterized by damage to the myelin sheath present around nerve axons. MESH:D003711 NCI:C34527 UMLS_CUI:C0011303 demyelinating disorder disease_ontology DOID:3213 demyelinating disease DOID:3213 A spinal cord disease that is characterized by inflammation of the white matter or gray matter of the spinal cord. GARD:7130 MESH:D009187 NCI:C26832 SNOMEDCT_US_2020_03_01:192682002 UMLS_CUI:C0026975 disease_ontology DOID:322 myelitis DOID:322 GARD:4647 MESH:D020918 SNOMEDCT_US_2020_03_01:128200000 UMLS_CUI:C0458219 Complex regional pain syndromes disease_ontology DOID:3223 complex regional pain syndrome DOID:3223 ICD10CM:S12.8 MESH:D014133 NCI:C35079 SNOMEDCT_US_2020_03_01:47125007 UMLS_CUI:C0040580 disease_ontology DOID:3225 tracheal disease DOID:3225 MESH:D014135 NCI:C78646 SNOMEDCT_US_2020_03_01:11296007 UMLS_CUI:C0040583 Stenosis of trachea disease_ontology DOID:3227 tracheal stenosis MESH:D014135 DOID:3227 MESH:D013271 UMLS_CUI:C0038353 stomach dilatation disease_ontology DOID:3229 gastric dilatation DOID:3229 MESH:D006610 UMLS_CUI:C0019537 disease_ontology DOID:3230 high pressure neurological syndrome DOID:3230 A hematologic cancer that has_material_basis_in lymphoma located_in central nervous system. DOID:3233 ICD9CM:200.5 NCI:C9301 SNOMEDCT_US_2020_03_01:307649006 UMLS_CUI:C0280803 Microglioma primary CNS lymphoma disease_ontology DOID:3234 central nervous system lymphoma DOID:3234 A pneumonia that is defined as an acute lung injury after the inhalation of foreign material such as regurgitated acidic gastric contents, petroleum products and laxative oils. This syndrome occurs in patients who have a marked disturbance of consciousness such as that resulting from a drug overdose, seizures, a massive cerebrovascular accident, or the use of anesthesia. Aspiration of gastric contents results in a chemical burn of the tracheobronchial tree and pulmonary parenchyma, causing an intense parenchymal inflammatory reaction. The disease has_symptom non-productive cough, has_symptom tachypnea, has_symptom bronchospasm, has_symptom bloody sputum, has_symptom frothy sputum, or has_symptom respiratory distress, 2-5 hrs after aspiration. DOID:13016 DOID:13506 ICD10CM:J69.0 MESH:D011015 SNOMEDCT_US_2020_03_01:47839005 UMLS_CUI:C0032290 Chemical pneumonitis Mendelson's Syndrome disease_ontology DOID:3240 aspiration pneumonitis DOID:3240 An aspiration pneumonitis resulting from the aspiration of lipids. It is the result of a foreign body-type reaction to the presence of lipid material within the lung parenchyma. It is caused by inhalation of nasal drops with oil base or cosmetic oil and aspiration of mineral oil when used as a laxative agent. DOID:13015 ICD10CM:J69.1 MESH:D011017 SNOMEDCT_US_2020_03_01:196038008 UMLS_CUI:C0032298 Exogenous lipoid pneumonia Lipoid pneumonitis disease_ontology DOID:3241 lipid pneumonia DOID:3241 A rhabdomyosarcoma wherein the mesenchymally-derived malignant cells resemble the primitive developing skeletal muscle of the embryo; it occurs most often in the head and neck area or in the genital or urinary organs. GARD:4702 MESH:D018233 NCI:C8971 OMIM:268210 ORDO:99757 SNOMEDCT_US_2020_03_01:404051002 UMLS_CUI:C0206656 disease_ontology DOID:3246 Xref MGI. embryonal rhabdomyosarcoma DOID:3246 A skeletal muscle cancer that arise from skeletal muscle progenitors. MESH:D012208 NCI:C3359 SNOMEDCT_US_2020_03_01:302847003 UMLS_CUI:C0035412 disease_ontology DOID:3247 rhabdomyosarcoma DOID:3247 A rhabdomyosarcoma and sarcoma of prostate that is located_in the prostate. NCI:C5522 UMLS_CUI:C1335518 Rhabdomyosarcoma of the prostate disease_ontology DOID:3252 prostate rhabdomyosarcoma DOID:3252 A vascular disease that is characterized by a restriction in blood supply to tissues. MESH:D007511 NCI:C34738 SNOMEDCT_US_2020_03_01:52674009 UMLS_CUI:C0022116 disease_ontology DOID:326 ischemia DOID:326 A hyper IgE syndrome that has_material_basis_in heterozygous mutation in the STAT3 gene on chromosome 17q21. GARD:6800 MESH:D007589 NCI:C126342 OMIM:147060 ORDO:2314 UMLS_CUI:C1968689 UMLS_CUI:C2936739 Job syndrome Job's syndrome hyperimmunoglobulin E syndrome disease_ontology DOID:3261 OMIM mapping confirmed by DO. [SN]. hyper IgE recurrent infection syndrome 1 DOID:3261 A primary immunodeficiency disease where phagocytes have a diminished ability to fight bacterial infection. MESH:D010585 UMLS_CUI:C0031306 phagocytic dysfunction disease_ontology DOID:3262 phagocyte bactericidal dysfunction MESH:D010585 DOID:3262 An integumentary system disease characterized by congenital absence of melanocytes in areas of the skin and hair that has_material_basis_in heterozygous mutation in either KIT or SNAI2 on chromosome 4q12 or 8q11.21, respectively. GARD:4344 ICD10CM:E70.39 MESH:D016116 NCI:C85009 OMIM:172800 ORDO:2884 SNOMEDCT_US_2020_03_01:718122005 UMLS_CUI:C0080024 PIEBALD TRAIT Partial albinism disease_ontology DOID:3263 OMIM mapping confirmed by DO. [SN]. piebaldism DOID:3263 A phagocyte bactericidal dysfunction characterized by an inability to resist repeated infectious diseases and a tendency to develop chronic inflammation. Life-threatening recurrent fungal and bacterial infections affecting the skin, lungs, and bones may occur along with swollen areas of inflamed tissues known as granulomas that can be widely distributed. GARD:6100 ICD10CM:D71 MESH:D006105 NCI:C26788 ORDO:379 SNOMEDCT_US_2020_03_01:11210002 UMLS_CUI:C0018203 Bridges-Good syndrome CGD Congenital dysphagocytosis Quie syndrome disease_ontology DOID:3265 Xref MGI. OMIM mapping confirmed by DO. [SN]. chronic granulomatous disease DOID:3265 An ovarian benign neoplasm that has_material_basis_in glandular epithelial tissue in which cystic accumulations of retained secretions are formed. NCI:C4060 SNOMEDCT_US_2020_03_01:198297004 UMLS_CUI:C0346169 Cystoma Serosum simplex simple cystoma of ovary simple cystoma of the ovary disease_ontology DOID:3269 ovarian cystadenoma DOID:3269 GARD:7725 MESH:D013595 NCI:C85179 OMIM:186700 ORDO:3280 SNOMEDCT_US_2020_03_01:155020007 UMLS_CUI:C0039144 disease_ontology DOID:327 syringomyelia DOID:327 A thymus cancer that derives_from epithelial cells located_in the thymus. The tumor cells in a thymoma look similar to the normal cells of the thymus, grow slowly, and rarely spread beyond the thymus. MESH:D013945 NCI:C3411 SNOMEDCT_US_2020_03_01:444231005 UMLS_CUI:C0040100 disease_ontology DOID:3275 thymoma DOID:3275 An immune system cancer located_in the thymus. DOID:10143 ICD10CM:C37 ICD9CM:164.0 MESH:D013953 NCI:C4962 SNOMEDCT_US_2020_03_01:94096009 UMLS_CUI:C0751552 Thymic tumor neoplasm of thymus thymic neoplasm disease_ontology DOID:3277 thymus cancer DOID:3277 NCI:C7114 UMLS_CUI:C1328042 epithelioid Thymoma disease_ontology DOID:3282 dendritic cell thymoma DOID:3282 A thymus cancer that derives_from epithelial cells. The tumor cells in a thymic carcinoma look very different from the normal cells of the thymus, grow more quickly, and have usually spread to other parts of the body when the cancer is found. MESH:D013945 NCI:C7569 SNOMEDCT_US_2020_03_01:128717008 UMLS_CUI:C0205969 Thymic carcinoma Thymoma, malignant malignant Thymoma disease_ontology DOID:3284 thymic carcinoma DOID:3284 A viral infectious disease that results in infection of primates, rodents and humans, located in skin, has_material_basis_in Monkeypox virus, which is transmitted by contact with the animal's blood, body fluids, rash, or with the body fluids of a sick person, transmitted by fomites, and transmitted by respiratory droplets. The infection has symptom fever, has symptom muscle ache, has symptom headache, and has symptom lymphadenopathy. GARD:10722 ICD10CM:B04 ICD9CM:059.01 MESH:D045908 NCI:C128421 SNOMEDCT_US_2020_03_01:240466002 UMLS_CUI:C0276180 disease_ontology DOID:3292 monkeypox DOID:3292 A viral infectious disease that results_in infection, located_in skin, has_material_basis_in Vaccinia virus, which is used as a live vaccine against smallpox. The virus is transmitted_by contact with the vaccination site before it has healed, or transmitted_by fomites that have been contaminated with live virus from the vaccination site. The infection has_symptom rash, has_symptom fever, and has_symptom body aches. MESH:D014615 SNOMEDCT_US_2020_03_01:111852003 UMLS_CUI:C0042214 disease_ontology DOID:3298 vaccinia DOID:3298 A cell type benign neoplasm that is composed_of a mixture of gonadal elements, such as large primordial germ cells, immature Sertoli cells or granulosa cells of the sex cord, and gonadal stromal cells (which comprises the granulosa, theca, and fibrocyte cells). MESH:D018238 NCI:C3754 OMIM:424500 SNOMEDCT_US_2020_03_01:74751003 UMLS_CUI:C0206661 disease_ontology DOID:3301 OMIM mapping confirmed by DO. [SN]. gonadoblastoma DOID:3301 A notochordal cancer that derives_from cellular remnants of the notochord. GARD:1303 MESH:D002817 NCI:C2947 SNOMEDCT_US_2020_03_01:50007008 UMLS_CUI:C0008487 notochordoma disease_ontology DOID:3302 OMIM mapping confirmed by DO. [SN]. chordoma DOID:3302 An embryonal cancer and bone cancer and mesenchymal cell neoplasm that is located_in the notochord. NCI:C7063 UMLS_CUI:C1335069 disease_ontology notochordal tumor DOID:3303 notochordal cancer DOID:3303 A germ cell cancer that lacks histologic differentiation. It usually refers to a tumor in the brain. MESH:D018237 NCI:C3753 SNOMEDCT_US_2020_03_01:154603000 UMLS_CUI:C0206660 disease_ontology DOID:3304 germinoma DOID:3304 A mixed germ cell tumor that is a mixture of teratoma with embryonal carcinoma, or with choriocarcinoma, or with both. MESH:D018243 NCI:C3756 SNOMEDCT_US_2020_03_01:67830002 UMLS_CUI:C0206664 Teratocarcinoma mixed Embryonal carcinoma and teratoma disease_ontology DOID:3305 teratocarcinoma DOID:3305 A germ cell and embryonal cancer that is an encapsulated tumor with tissue or organ components resembling normal derivatives of all three germ layers. MESH:D013724 NCI:C3403 SNOMEDCT_US_2020_03_01:36591000119102 UMLS_CUI:C0039538 disease_ontology DOID:3307 teratoma DOID:3307 An embryonal cancer that is a type of germ cell tumour that is located_in the ovaries or located_in the testes. DOID:5676 GARD:5140 MESH:D018236 NCI:C3752 NCI:C8880 SNOMEDCT_US_2020_03_01:28047004 UMLS_CUI:C0206659 UMLS_CUI:C0855159 primary extragonadal embryonal carcinoma disease_ontology DOID:3308 embryonal carcinoma DOID:3308 A nervous system disease that affects either the spinal cord (myelopathy) or brain (encephalopathy) of the central nervous system. ICD10CM:G96.9 MESH:D002493 NCI:C2934 SNOMEDCT_US_2020_03_01:267144009 UMLS_CUI:C0007682 disease_ontology DOID:331 central nervous system disease DOID:331 An allergic contact dermatitis that is a chronically relapsing inflammatory allergic response located_in the skin that causes itching and flaking. EFO:0000274 ICD10CM:L20 MESH:D003876 OMIM:603165 OMIM:PS603165 SNOMEDCT_US_2020_03_01:156331003 UMLS_CUI:C0011615 Atopic dermatitis Atopic neurodermatitis Besnier's prurigo allergic dermatitis atopic eczema disease_ontology DOID:3310 Xref MGI. OMIM mapping confirmed by DO. [SN]. atopic dermatitis DOID:3310 A mood disorder that involves alternating periods of mania and depression. DOID:3311 DOID:9554 DOID:9555 EFO:0000289 GARD:10249 ICD10CM:F31 ICD9CM:296.40 ICD9CM:296.60 ICD9CM:296.80 MESH:D001714 NCI:C34423 NCI:C34424 NCI:C34805 SNOMEDCT_US_2020_03_01:16506000 SNOMEDCT_US_2020_03_01:191627008 SNOMEDCT_US_2020_03_01:192355004 SNOMEDCT_US_2020_03_01:68569003 UMLS_CUI:C0005586 UMLS_CUI:C0005587 UMLS_CUI:C0024713 UMLS_CUI:C0236780 Manic Bipolar Affective disorder Manic Depressive disorder Manic bipolar I disorder bipolar depression bipolar disorder manic phase manic depression manic disorder mixed bipolar disorder disease_ontology Depressive-manic psych. DOID:3312 bipolar disorder DOID:3312 A cell type benign neoplasm that is primarily located in the kidneys but may be found in the lungs, liver or other organs and is derived from perivascular epithelioid cells. MESH:D018207 NCI:C3734 SNOMEDCT_US_2020_03_01:19929002 UMLS_CUI:C0206633 Angiomyolipoma disease_ontology DOID:3314 angiomyolipoma MESH:D018207 DOID:3314 A cell type benign neoplasm that is composed of lipocytes. DOID:3154 DOID:9291 ICD10CM:D17 ICD10CM:D17.9 ICD9CM:214 MESH:D008067 MESH:D018205 NCI:C3192 NCI:C4248 NCI:C4502 OMIM:151900 SNOMEDCT_US_2020_03_01:115227001 SNOMEDCT_US_2020_03_01:154612003 SNOMEDCT_US_2020_03_01:254830006 UMLS_CUI:C0023798 UMLS_CUI:C0206631 UMLS_CUI:C0346118 LIPOMATOSIS, FAMILIAL MULTIPLE Lipomatous neoplasm Lipomatous tumor benign lipomatous tumor benign tumor of Adipose tissue multiple lipomatosis tumor of adipose tissue disease_ontology DOID:3315 OMIM mapping confirmed by DO. [SN]. lipoma DOID:3315 DOID:5234 NCI:C6528 NCI:C6530 UMLS_CUI:C1334611 UMLS_CUI:C1335392 malignant perivascular cancer disease_ontology DOID:3316 perivascular tumor DOID:3316 A lung disease that is characterized by progressive cystic destruction of the lung and lymphatic abnormalities, frequently associated with renal angiomyolipomas. DOID:3682 GARD:3319 NCI:C38153 OMIM:606690 ORDO:538 SNOMEDCT_US_2020_03_01:277844007 UMLS_CUI:C0349649 lung lymphangioleiomyomatosis lymphangiomyomatosis pulmonary lymphangioleiomyomatosis disease_ontology DOID:3319 lymphangioleiomyomatosis MESH:D018192 DOID:3319 A motor neuron disease that is characterized by muscle spasticity, rapidly progressive weakness due to muscle atrophy, difficulty in speaking, swallowing, and breathing. EFO:0000253 GARD:5786 ICD10CM:G12.21 ICD9CM:335.20 KEGG:05014 MESH:D000690 NCI:C34373 OMIM:PS105400 ORDO:803 SNOMEDCT_US_2020_03_01:86044005 UMLS_CUI:C0002736 ALS Lou Gehrig's disease motor neuron disease, bulbar disease_ontology DOID:332 amyotrophic lateral sclerosis MESH:D000690 DOID:332 GARD:7737 ICD10CM:E75.02 MESH:D013661 NCI:C85184 OMIM:272800 SNOMEDCT_US_2020_03_01:111385000 UMLS_CUI:C0039373 A GM2 gangliosidosis that is characterized the onset in infancy of developmental retardation, followed by paralysis, dementia and blindness, with death in the second or third year of life and has_material_basis_in homozygous or compound heterozygous mutation in the alpha subunit of the hexosaminidase A gene (HEXA) on chromosome 15q23. GM2 gangliosidosis, type 1 hexosaminidase A deficiency disease_ontology DOID:3320 OMIM mapping confirmed by DO. [SN]. Tay-Sachs disease DOID:3320 A gangliosidosis that is characterized by excessive accumulation of ganglioside GM2 and related glycolipids in the lysosomes. ICD10CM:E75.0 MESH:D020143 SNOMEDCT_US_2020_03_01:33316007 UMLS_CUI:C0268274 gangliosidosis GM2 disease_ontology DOID:3321 GM2 gangliosidosis DOID:3321 A GM2 gangliosidosis that is characterized by an accumulation of GM2 gangliosides, particularly in neurons, and that has_material_basis_in mutation in the beta subunit of hexosaminidase (HEXB) on chromosome 5q13. GARD:7604 ICD10CM:E75.01 MESH:D012497 NCI:C85052 OMIM:268800 SNOMEDCT_US_2020_03_01:23849003 UMLS_CUI:C0036161 Sandhoff Jatzkewitz disease disease_ontology DOID:3323 OMIM mapping confirmed by DO. [SN]. Sandhoff disease MESH:D012497 DOID:3323 A cognitive disorder that involves a disturbance in mood as the predominant underlying feature. EFO:0004247 ICD10CM:F39 MESH:D019964 NCI:C92200 SNOMEDCT_US_2020_03_01:46206005 UMLS_CUI:C0525045 episodic mood disorder disease_ontology DOID:3324 Updating outdated UMLS CUI. mood disorder DOID:3324 MESH:D011694 SNOMEDCT_US_2020_03_01:402852007 UMLS_CUI:C0034151 disease_ontology DOID:3325 hyperglobulinemic purpura DOID:3325 ICD10CM:D69.2 MESH:D011693 NCI:C78787 SNOMEDCT_US_2020_03_01:423902002 UMLS_CUI:C0034150 Purpuric disorder disease_ontology DOID:3326 purpura MESH:D011693 DOID:3326 MESH:D019305 OMIM:117100 UMLS_CUI:C0376532 BCECTS benign Rolandic epilepsy benign childhood epilepsy with centrotemporal spike rolandic epilepsy sylvan seizures disease_ontology DOID:3329 benign epilepsy with centrotemporal spikes DOID:3329 A personality disorder that is characterized by a pattern of excessive emotionality and attention-seeking, including an excessive need for approval and inappropriately seductive behavior, usually beginning in early adulthood. ICD10CM:F60.4 ICD9CM:301.5 MESH:D006677 NCI:C92634 SNOMEDCT_US_2020_03_01:192489002 UMLS_CUI:C0019681 disease_ontology DOID:334 histrionic personality disorder DOID:334 A bone resorption disease that has_material_basis_in hyperparathyroidism which results_in hyperactivity in osteoclasts, deformity, and loss of mass located_in bone. MESH:D010002 NCI:C34875 SNOMEDCT_US_2020_03_01:190451000 UMLS_CUI:C0029405 Osteitis fibrosa cystica generalisata Von Recklinghausen's bone disease hyperparathyroid bone disease disease_ontology DOID:3341 osteitis fibrosa DOID:3341 A bone disease that results_in inflammation of the located_in bone. MESH:D010000 SNOMEDCT_US_2020_03_01:274144001 UMLS_CUI:C0029400 Inflammatory disorder of bone bone inflammatory disease osteitis disease_ontology DOID:3342 bone inflammation disease DOID:3342 A mucolipidosis that is characterized by a deficiency of the enzyme alpha-N -acetyl neuraminidase (sialidase). GARD:10670 MESH:D009081 NCI:C61267 OMIM:256550 SNOMEDCT_US_2020_03_01:70528007 UMLS_CUI:C0026697 Mucolipidosis type I sialidosis disease_ontology DOID:3343 OMIM mapping submitted by NeuroDevNet. [LS]. glycoproteinosis DOID:3343 A lipid storage disease that is characterized by the desposition of yellowish cholesterol-rich material in tendons or other body parts. MESH:D014973 SNOMEDCT_US_2020_03_01:63103006 UMLS_CUI:C0043325 xanthelasmatosis disease_ontology DOID:3345 xanthomatosis DOID:3345 A bone sarcoma that is located_in bone that has_material_basis_in cells of mesenchymal origin. DOID:183 GARD:7284 MESH:D012516 MESH:D018213 NCI:C9145 OMIM:259500 ORDO:668 SNOMEDCT_US_2020_03_01:189878003 UMLS_CUI:C0029463 UMLS_CUI:C0206639 Osteogenic sarcoma Skeletal sarcoma bone tissue neoplasm osteoid sarcoma disease_ontology DOID:3347 OMIM mapping confirmed by DO. [SN]. osteosarcoma DOID:3347 A cell type cancer that has_material_basis_in abnormally proliferating cells derives from embryonic connective tissue that is capable of developing into connective tissue, such as bone, and cartilage, the lymphatic system, and the circulatory system. DOID:1630 NCI:C6587 NCI:C7059 UMLS_CUI:C1332517 UMLS_CUI:C1334699 benign miscellaneous mesenchymal tumor mesenchymal tumor disease_ontology DOID:3350 mesenchymal cell neoplasm DOID:3350 A connective tissue cancer that has_material_basis_in fibrous connective tissue and characterized by the presence of immature proliferating fibroblasts or undifferentiated anaplastic spindle cells in a storiform pattern. DOID:156 DOID:3509 GARD:2327 MESH:D005354 MESH:D018218 NCI:C3043 NCI:C6605 NCI:C7075 SNOMEDCT_US_2020_03_01:443250000 UMLS_CUI:C0016057 UMLS_CUI:C0206643 UMLS_CUI:C1336021 Fibrocytic tumor fibrosarcoma of soft tissue fibrous tissue neoplasm disease_ontology DOID:3355 fibrosarcoma DOID:3355 NCI:C7780 UMLS_CUI:C0278511 localised Osteogenic sarcoma localised osteosarcoma localized Osteogenic sarcoma disease_ontology DOID:3356 localized osteosarcoma DOID:3356 GARD:6200 ICD10CM:I25.41 ICD9CM:414.11 MESH:D003323 SNOMEDCT_US_2020_03_01:50570003 UMLS_CUI:C0010051 Aneurysm of coronary vessels Aneurysmal lesion of coronary artery Arteriovenous aneurysm of coronary vessels disease_ontology DOID:3362 coronary aneurysm DOID:3362 A connective tissue cancer that has_material_basis in neural crest cells derives_from undeveloped, undifferentiated neuroectoderm. DOID:0050607 DOID:4158 DOID:4390 DOID:4391 DOID:4392 DOID:4980 GARD:6390 MESH:C563168 MESH:D012512 MESH:D018241 NCI:C27901 NCI:C27903 NCI:C4817 NCI:C7542 NCI:C7806 NCI:C9341 OMIM:612219 SNOMEDCT_US_2020_03_01:134210007 SNOMEDCT_US_2020_03_01:73676002 SNOMEDCT_US_2020_03_01:76909002 UMLS_CUI:C0553580 UMLS_CUI:C0684337 UMLS_CUI:C0796547 UMLS_CUI:C0863029 UMLS_CUI:C0877849 UMLS_CUI:C1334408 Ewing's family localized tumor Ewing's sarcoma/peripheral primitive neuroectodermal tumor Ewing's tumor Ewings sarcoma Ewings sarcoma-primitive neuroectodermal tumor PNET of Thoracopulmonary Region localized Ewing sarcoma localized Ewing's sarcoma localized Ewing's sarcoma/peripheral primitive neuroectodermal tumor localized Ewing's tumor localized peripheral primitive neuroectodermal tumor peripheral primitive neuroectodermal tumor disease_ontology DOID:3369 OMIM mapping confirmed by DO. [SN]. Ewing sarcoma DOID:3369 A bone sarcoma that has_material_basis_in cells derived from transformed cells that produce cartilage. DOID:3370 GARD:6004 GARD:6055 MESH:D002813 NCI:C2946 NCI:C7155 OMIM:215300 SNOMEDCT_US_2020_03_01:443520009 SNOMEDCT_US_2020_03_01:735679005 UMLS_CUI:C0008479 UMLS_CUI:C1335473 Cartilaginous cancer chondrosarcoma of bone primary chondrosarcoma of the bone disease_ontology DOID:3371 OMIM mapping confirmed by DO. [SN]. chondrosarcoma DOID:3371 MESH:D018217 NCI:C8969 SNOMEDCT_US_2020_03_01:91242000 UMLS_CUI:C0206642 Parosteal Osteogenic sarcoma Parosteal Osteosarcoma disease_ontology DOID:3373 juxtacortical osteosarcoma DOID:3373 NCI:C7134 UMLS_CUI:C1332591 Surface Osteosarcoma disease_ontology DOID:3374 peripheral osteosarcoma DOID:3374 DOID:8580 NCI:C53707 SNOMEDCT_US_2020_03_01:307576001 UMLS_CUI:C0585442 Osteosarcoma of bone primary Osteosarcoma of bone disease_ontology DOID:3376 bone osteosarcoma DOID:3376 NCI:C4023 SNOMEDCT_US_2020_03_01:12302002 UMLS_CUI:C0279622 Round cell osteosarcoma small cell Osteosarcoma disease_ontology DOID:3377 small cell osteogenic sarcoma DOID:3377 Medullary Osteosarcoma Medullary osteosarcoma conventional Osteosarcoma disease_ontology DOID:3378 conventional central osteosarcoma DOID:3378 A central nervous system cancer develops from schwann cells located_in cranial nerves, has_material_basis_in abnormally proliferating cells. MESH:D003390 NCI:C2963 SNOMEDCT_US_2020_03_01:126966009 UMLS_CUI:C0010267 neoplasm of cranial nerve disease_ontology DOID:338 cranial nerve neoplasm DOID:338 A lipomatous cancer that arises in fat cells in deep soft tissue retroperitoneum and the extremities. GARD:6913 MESH:D008080 NCI:C3194 SNOMEDCT_US_2020_03_01:254829001 UMLS_CUI:C0023827 disease_ontology DOID:3382 liposarcoma DOID:3382 A vaginitis that is characterized by a grayish vaginal discharge usually of foul odor and the presence of Gardnerella vaginalis. MESH:D016585 NCI:C116973 SNOMEDCT_US_2020_03_01:237092002 UMLS_CUI:C0085166 disease_ontology DOID:3385 bacterial vaginosis DOID:3385 A mouth disease that is relating to or affecting the structures surrounding and supporting the teeth. ICD10CM:K05.6 MESH:D010510 NCI:C63743 SNOMEDCT_US_2020_03_01:196354003 UMLS_CUI:C0031090 Periodontal disease disease of supporting structures of teeth periodontium disorder disease_ontology DOID:3388 periodontal disease DOID:3388 An ectodermal dysplasia that is characterized by palmoplantar keratoderma associated with early-onset periodontitis and has_material_basis_in homozygous or compound heterozygous mutation in the cathepsin C gene on chromosome 11q14. GARD:3100 MESH:D010214 NCI:C84992 OMIM:245000 ORDO:678 SNOMEDCT_US_2020_03_01:40158001 UMLS_CUI:C0030360 Papillon Lefevre syndrome Papillon-Lefvre syndrome disease_ontology DOID:3389 OMIM mapping confirmed by DO. [SN]. Papillon-Lefevre disease DOID:3389 A keratosis characterized by abnormal thickening of the palms and the soles. GARD:8167 ICD10CM:L85.2 SNOMEDCT_US_2020_03_01:28596004 UMLS_CUI:C0022596 Keratosis palmaris et plantaris Palmoplantar Keratoderma palmo-plantar keratodermas disease_ontology DOID:3390 palmoplantar keratosis DOID:3390 An artery disease that is characterized by plaque building up along the inner walls of the arteries of the heart resulting in a narrowing of the arteries and a reduced blood supply to the cardiac muscles. DOID:10506 DOID:3363 DOID:3394 DOID:9420 EFO:0001645 ICD10CM:I20-I25 ICD10CM:I25 ICD10CM:I25.1 ICD10CM:I25.10 ICD9CM:410-414.99 ICD9CM:414.0 ICD9CM:414.9 MESH:D003324 MESH:D003327 MESH:D017202 NCI:C35505 NCI:C50625 OMIM:300464 OMIM:607339 OMIM:608316 OMIM:608318 OMIM:608320 OMIM:610947 OMIM:611139 OMIM:612030 OMIM:614293 SNOMEDCT_US_2020_03_01:194852007 SNOMEDCT_US_2020_03_01:233822007 SNOMEDCT_US_2020_03_01:41702007 SNOMEDCT_US_2020_03_01:53741008 UMLS_CUI:C0010054 UMLS_CUI:C0010068 UMLS_CUI:C0151744 UMLS_CUI:C0264694 CHD Coronary disease coronary arteriosclerosis coronary heart disease disease_ontology DOID:3393 Xref MGI. coronary artery disease DOID:3393 ICD10CM:E22.2 MESH:D007177 NCI:C3988 SNOMEDCT_US_2020_03_01:55004003 UMLS_CUI:C0021141 syndrome of Inappropriate Antidiuretic Hormone Secretion syndrome of inappropriate secretion of ADH syndrome of inappropriate secretion of antidiuretic hormone syndrome of inappropriate vasopressin secretion disease_ontology DOID:3401 inappropriate ADH syndrome MESH:D007177 DOID:3401 A lymphatic system disease that is characterized by an excessive number of histiocytes. DOID:3344 MESH:D015614 NCI:C3106 SNOMEDCT_US_2020_03_01:60657004 UMLS_CUI:C0019618 Hand Schuller Christian disease chronic Histiocytosis X disease_ontology DOID:3405 histiocytosis DOID:3405 MESH:D002340 NCI:C84476 SNOMEDCT_US_2020_03_01:371160000 UMLS_CUI:C0007273 disorder of carotid artery disease_ontology DOID:3407 carotid artery disease DOID:3407 A vascular disease that is characterized by obstruction of larger arteries not within the coronary, aortic arch vasculature, or brain. DOID:2868 ICD9CM:443.81 MESH:D001157 SNOMEDCT_US_2020_03_01:195624006 SNOMEDCT_US_2020_03_01:2929001 UMLS_CUI:C0003838 UMLS_CUI:C0031115 arterial occlusive disease disease_ontology DOID:341 peripheral vascular disease DOID:341 A lysosomal storage disease that has_material_basis_in deficiency of the alpha-D-manosidase enzyme resulting in the impairment of cell function from a build up of complex sugars derived from glycoproteins in the lysosome. GARD:6968 MESH:D008363 NCI:C84548 OMIM:248500 SNOMEDCT_US_2020_03_01:65524005 UMLS_CUI:C0024748 Alpha-D-mannosidosis alpha-mannosidase deficiency deficiency of alpha-mannosidase disease_ontology DOID:3413 OMIM mapping confirmed by DO. [SN]. alpha-mannosidosis MESH:D008363 DOID:3413 A cranial nerve disease that is located_in the ninth cranial nerve or its nuclei in the medulla. ICD10CM:G52 ICD9CM:352 SNOMEDCT_US_2020_03_01:193098000 UMLS_CUI:C0154730 ninth cranial nerve disease disease_ontology DOID:3418 glossopharyngeal nerve disease DOID:3418 MESH:D019574 NCI:C4801 SNOMEDCT_US_2020_03_01:126968005 UMLS_CUI:C0524802 Tumour of optic nerve neoplasm of optic nerve tumor of Second Cranial nerve disease_ontology DOID:3419 optic nerve neoplasm DOID:3419 ICD9CM:442.82 SNOMEDCT_US_2020_03_01:40136003 UMLS_CUI:C0155746 disease_ontology DOID:342 subclavian artery aneurysm DOID:342 ICD10CM:H81.9 MESH:D015837 SNOMEDCT_US_2020_03_01:20425006 UMLS_CUI:C0042594 Vertigo, vestibular disorder disease_ontology DOID:3426 vestibular disease DOID:3426 A myositis that is characterized by late onset of skeletal muscle inflammation, weakness, and atrophy with cytoplasmic granules and vacuoles in the muscle. GARD:3896 ICD10CM:G72.41 ICD9CM:359.71 MESH:D018979 NCI:C84786 OMIM:147421 ORDO:611 SNOMEDCT_US_2020_03_01:72315009 UMLS_CUI:C0238190 disease_ontology DOID:3429 OMIM mapping confirmed by DO. [SN]. inclusion body myositis MESH:D018979 DOID:3429 A laryngeal disease involving an inflammation of the larynx leading to hoarse voice or a complete loss of voice due to irritation of the vocal cords caused by viral, bacterial or fungal infection, inflammation due to overuse of the vocal cords and excessive coughing, smoking, or alcohol consumption. MESH:D007827 NCI:C26811 SNOMEDCT_US_2020_03_01:45913009 UMLS_CUI:C0023067 disease_ontology DOID:3437 laryngitis DOID:3437 A breast adenocarcinoma that has_material_basis_in epidermal Paget cells, which are malignant glandular epithelial cells with abundant and clear cytoplasm, usually containing mucin, and pleomorphic and hyperchromatic nucleus. NCI:C7073 UMLS_CUI:C1368019 Paget cell neoplasm Paget's disease Paget's disease of the breast mammary Paget disease disease_ontology DOID:3443 mammary Paget's disease DOID:3443 NCI:C5598 UMLS_CUI:C1332274 Paget's disease of anus anal Paget disease disease_ontology Paget's disease of the anus DOID:3446 anal Paget's disease DOID:3446 An anal carcinoma that originating in the cortex of the adrenal gland and derives_from epithelial cells of glandular origin. NCI:C5600 SNOMEDCT_US_2020_03_01:423607006 UMLS_CUI:C1332257 adenocarcinoma of anus disease_ontology adenocarcinoma of the anus DOID:3447 anus adenocarcinoma DOID:3447 A penile cancer that is located_in the skin or tissues of the penis. NCI:C9061 SNOMEDCT_US_2020_03_01:372106005 UMLS_CUI:C0853105 Penile carcinoma carcinoma of penis disease_ontology DOID:3449 penis carcinoma DOID:3449 A female reproductive system disease that is located_in the uterus. ICD10CM:N85.9 ICD9CM:621.9 MESH:D014591 NCI:C26907 SNOMEDCT_US_2020_03_01:237068005 UMLS_CUI:C0042131 disease_ontology DOID:345 uterine disease DOID:345 A skin cancer that is located_in tissues of the skin and develops from epithelial cells. NCI:C4914 UMLS_CUI:C0699893 carcinoma of skin disease_ontology DOID:3451 skin carcinoma DOID:3451 A cerebrovascular disease that is characterized by tissue necrosis located_in the brain, resulting from inadequate blood flow through the brain. MESH:D020520 UMLS_CUI:C0751955 disease_ontology DOID:3454 brain infarction DOID:3454 A breast lobular carcinoma that is characterized by infiltration into the tissue of the breast outside of the lobule where it originated. MESH:D018275 NCI:C3771 SNOMEDCT_US_2020_03_01:89740008 UMLS_CUI:C0206692 Lobular carcinoma Lobular carcinoma of breast Lobular carcinoma of the breast disease_ontology DOID:3457 invasive lobular carcinoma DOID:3457 A breast carcinoma that originates in the milk ducts and/or lobules (glandular tissue) of the breast. NCI:C5214 UMLS_CUI:C0858252 Mammary adenocarcinoma disease_ontology adenocarcinoma of breast DOID:3458 breast adenocarcinoma DOID:3458 A breast cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. EFO:0000305 MESH:D001943 NCI:C4872 SNOMEDCT_US_2020_03_01:154513000 UMLS_CUI:C0678222 Mammary carcinoma carcinoma of breast disease_ontology DOID:3459 breast carcinoma DOID:3459 A thoracic disease that is located_in the breast. ICD10CM:N64.9 ICD9CM:610-612.99 MESH:D001941 NCI:C26709 SNOMEDCT_US_2020_03_01:79604008 UMLS_CUI:C0006145 disease_ontology DOID:3463 breast disease DOID:3463 An ocular cancer that is located_in the uvea, which are the pigmented layers of the eye consisting of the iris, ciliary body, and choroid. The uvea is the most common location of intraocular malignancy in adults and may commonly be caused by a subtype of cancer that arises from melanocytes. DOID:12754 MESH:D014604 NCI:C3436 NCI:C6105 UMLS_CUI:C0042162 UMLS_CUI:C1334629 Uveal tumor malignant Uveal tumor malignant uvea neoplasm disease_ontology DOID:3479 uveal cancer DOID:3479 An eyelid disease that is characterized by exacerbations and remissions of eyelid edema, which results in a stretching and subsequent atrophy of the eyelid tissue, leading to the formation of redundant folds over the lid margins. ICD10CM:H02.3 ICD9CM:374.34 SNOMEDCT_US_2020_03_01:193944001 UMLS_CUI:C0005742 disease_ontology DOID:348 blepharochalasis DOID:348 An eye disease affecting the uvea, which are the pigmented layers of the eye consisting of the iris, ciliary body, and choroid. GARD:8192 MESH:D014603 NCI:C26908 SNOMEDCT_US_2020_03_01:95678007 UMLS_CUI:C0042161 disease_ontology DOID:3480 uveal disease DOID:3480 A primary bacterial infectious disease that results_in infection, located_in lymph node, located_in vasculature or located_in lungs, has_material_basis_in Yersinia pestis, which is transmitted_by oriental rat flea (Xenopsylla cheopis) infected by feeding on rodents and other mammals, transmitted_by air, transmitted_by direct contact or transmitted_by ingestion of contaminated undercooked food. ICD10CM:A20 ICD9CM:020 MESH:D010930 NCI:C85015 SNOMEDCT_US_2020_03_01:58750007 UMLS_CUI:C0032064 disease_ontology DOID:3482 plague DOID:3482 GARD:8616 ICD10CM:D47.02 MESH:D034721 NCI:C9235 SNOMEDCT_US_2020_03_01:123310005 UMLS_CUI:C0221013 SMCD - systemic mast cell disease systemic tissue mast cell disease disease_ontology DOID:349 systemic mastocytosis DOID:349 A RASopathy that is characterized by mildly unusual facial features, short stature, heart defects, bleeding problems, skeletal malformations, and many other signs and symptoms. GARD:10955 ICD10CM:Q87.19 MESH:D009634 NCI:C34854 OMIM:PS163950 ORDO:648 SNOMEDCT_US_2020_03_01:88327006 UMLS_CUI:C0028326 Turner's phenotype, karyotype normal disease_ontology DOID:3490 OMIM mapping confirmed by DO. [SN]. Noonan syndrome DOID:3490 A gonadal dysgenesis that is characterized by short stature and early loss of ovarian function resulting from ovarian hypofunction or premature ovarian failure and has_material_basis_in one missing or structurally altered X chromosome. DOID:5448 GARD:2540 GARD:7831 ICD10CM:Q96 MESH:D014424 NCI:C26900 NCI:C34434 SNOMEDCT_US_2020_03_01:38804009 UMLS_CUI:C0041408 UMLS_CUI:C1527168 Bonnevie-Ullrich syndrome Gonadal dysgenesis - Turner Karyotype 45, X Monosomy X XO syndrome monosomy X syndrome disease_ontology DOID:3491 No OMIM mapping, confirmed by DO. [LS]. Turner syndrome DOID:3491 A collagen disease that is considered an overlap of three diseases, systemic lupus erythematosus, scleroderma, and polymyositis with very high titers of circulating antinuclear antibody to a ribonucleoprotein antigen. GARD:7051 ICD10CM:M35.1 MESH:D008947 NCI:C84892 SNOMEDCT_US_2020_03_01:33110008 UMLS_CUI:C0026272 Connective tissue disease overlap syndrome mixed collagen vascular disease disease_ontology DOID:3492 mixed connective tissue disease DOID:3492 An adenocarcinoma that derives_from epithelial cells originating in glandular tissue, which have signet ring appearance. MESH:D018279 NCI:C3774 SNOMEDCT_US_2020_03_01:189701002 UMLS_CUI:C0206696 Signet Ring cell adenocarcinoma Signet ring carcinoma Signet ring cell carcinoma disease_ontology DOID:3493 signet ring cell adenocarcinoma DOID:3493 A pancreatic adenocarcinoma that derives_from pancreatic duct cells. NCI:C9120 SNOMEDCT_US_2020_03_01:792907004 UMLS_CUI:C1335302 ductal adenocarcinoma of the pancreas disease_ontology DOID:3498 pancreatic ductal adenocarcinoma DOID:3498 GARD:6987 ICD10CM:D47.09 MESH:D008415 NCI:C84269 OMIM:154800 SNOMEDCT_US_2020_03_01:78745000 UMLS_CUI:C0024899 mast cell hyperplasia disease_ontology DOID:350 OMIM mapping confirmed by DO. [LS]. mastocytosis DOID:350 A fibrosarcoma that is located_in the dermis laryer of the skin and that begins as a hard nodule and grows slowly. GARD:9569 MESH:D018223 OMIM:607907 SNOMEDCT_US_2020_03_01:302844005 UMLS_CUI:C0206647 disease_ontology DOID:3507 MESH:C538219 added from NeuroDevNet [WAK]. dermatofibrosarcoma protuberans DOID:3507 GARD:8211 MESH:D018319 SNOMEDCT_US_2020_03_01:19897006 UMLS_CUI:C0206729 Neurosarcoma disease_ontology DOID:3512 neurofibrosarcoma DOID:3512 NCI:C8088 UMLS_CUI:C0279981 disease_ontology DOID:3520 pediatric fibrosarcoma DOID:3520 MESH:D020244 UMLS_CUI:C0740392 disease_ontology DOID:3525 middle cerebral artery infarction DOID:3525 A cerebrovascular disease that is characterized by an area of necrotic tissue in the brain resulting from a blockage or narrowing in the arteries supplying blood and oxygen to the brain. ICD10CM:I63 MESH:D002544 NCI:C50486 OMIM:601367 SNOMEDCT_US_2020_03_01:195188006 UMLS_CUI:C0007785 CVA - Cerebral infarction Cerebral infarct Cerebral infarction disease_ontology DOID:3526 cerebral infarction DOID:3526 MESH:D002539 UMLS_CUI:C0007774 disease_ontology DOID:3527 cerebral arterial disease DOID:3527 ICD10CM:G71.2 MESH:D020512 NCI:C83010 OMIM:117000 SNOMEDCT_US_2020_03_01:43152001 UMLS_CUI:C0751951 central core disease disease_ontology DOID:3529 OMIM mapping confirmed by DO. [SN]. central core myopathy DOID:3529 MESH:D034081 UMLS_CUI:C1135993 disease_ontology DOID:3530 chronic wasting disease DOID:3530 A progressive myoclonus epilepsy characterized by onset between 6 and 13 years of age of action- and stimulus-sensitive myoclonus, tonic-clonic seizures with ataxia, and a mild cognitive decline. GARD:3876 MESH:D020194 SNOMEDCT_US_2020_03_01:192847001 UMLS_CUI:C0751785 Unverricht - Lundborg disease Unverricht's disease Unverricht-Lundborg disease disease_ontology DOID:3535 OMIM mapping confirmed by DO. [LS]. Unverricht-Lundborg syndrome DOID:3535 A cerebral ventricle cancer that is located_in the plexus located_in the ventricles of the brain. MESH:D016545 NCI:C3473 SNOMEDCT_US_2020_03_01:254942002 UMLS_CUI:C0085138 tumor of choroid plexus tumor of the Choroid Plexus disease_ontology choroid plexus neoplasm DOID:3540 choroid plexus cancer DOID:3540 A cerebrum cancer that is located_in the cerebral ventricles. DOID:10856 GARD:6025 ICD10CM:C71.5 ICD9CM:191.5 MESH:D002551 NCI:C2937 SNOMEDCT_US_2020_03_01:126958000 SNOMEDCT_US_2020_03_01:363471001 UMLS_CUI:C0007798 UMLS_CUI:C0346906 Intraventricular tumor of brain cerebral ventricle neoplasm disease_ontology DOID:3541 cerebral ventricle cancer DOID:3541 A sarcoma that has_material_basis in mast cells. ICD10CM:C96.22 ICD9CM:202.6 MESH:D012515 NCI:C9348 SNOMEDCT_US_2020_03_01:118615008 UMLS_CUI:C0036221 disease_ontology DOID:355 mast-cell sarcoma DOID:355 GARD:7712 MESH:D013478 NCI:C85175 SNOMEDCT_US_2020_03_01:24988007 UMLS_CUI:C0038828 Superior mesenteric artery syndrome disease_ontology DOID:3557 superior mesenteric artery syndrome DOID:3557 ICD10CM:K31.5 MESH:D004380 NCI:C79548 SNOMEDCT_US_2020_03_01:95532008 UMLS_CUI:C0013292 disease_ontology DOID:3558 duodenal obstruction DOID:3558 An appendix cancer that is characterized by progressive accumulation of mucus-secreting tumor cells within the abdomen and pelvis. GARD:7488 MESH:D011553 NCI:C3345 SNOMEDCT_US_2020_03_01:307601000 UMLS_CUI:C0033822 Pseudomyxoma peritonei mucinous Ascites disease_ontology DOID:3559 pseudomyxoma peritonei DOID:3559 A central nervous system cancer that are manifested in the central nervous system and arise from the arachnoid cap cells of the arachnoid villi in the meninges. DOID:1137 DOID:3554 DOID:3567 DOID:4750 GARD:7015 ICD10CM:D32.9 ICDO:M9530/3 MESH:D008577 MESH:D008579 NCI:C3229 NCI:C3230 NCI:C4656 NCI:C6971 NCI:C7048 SNOMEDCT_US_2020_03_01:127579001 SNOMEDCT_US_2020_03_01:269643009 SNOMEDCT_US_2020_03_01:302820008 UMLS_CUI:C0025284 UMLS_CUI:C0025286 UMLS_CUI:C0349604 UMLS_CUI:C1334698 UMLS_CUI:C1336537 intracranial meningioma meningeal neoplasm meningothelial cell tumor neoplasm of the meninges primary Meningeal tumor supratentorial meningioma disease_ontology DOID:3565 meningioma DOID:3565 A hepatobiliary system cancer that is located_in the liver. DOID:12300 DOID:269 DOID:7330 DOID:915 DOID:919 ICD10CM:C22.0 ICD10CM:C22.9 ICD9CM:155.0 ICD9CM:155.2 MESH:D008113 NCI:C34803 NCI:C7692 SNOMEDCT_US_2020_03_01:126851005 SNOMEDCT_US_2020_03_01:187771009 SNOMEDCT_US_2020_03_01:93870000 UMLS_CUI:C0023903 UMLS_CUI:C0024620 UMLS_CUI:C0345904 UMLS_CUI:C0854795 Ca liver - primary Resectable malignant neoplasm of Liver ca liver - primary hepatic cancer hepatic neoplasm malignant hepato-biliary neoplasm malignant neoplasm of liver malignant neoplasm of liver, not specified as primary or secondary malignant neoplasm of liver, primary malignant tumor of liver neoplasm of liver non-resectable primary hepatic malignant neoplasm primary liver cancer primary malignant neoplasm of Liver primary malignant neoplasm of liver resectable malignant neoplasm of the liver disease_ontology DOID:3571 liver cancer DOID:3571 MESH:D012851 UMLS_CUI:C0037198 disease_ontology DOID:3572 intracranial sinus thrombosis DOID:3572 MESH:D020227 SNOMEDCT_US_2020_03_01:21258007 UMLS_CUI:C0270639 Thrombosis of lateral venous sinus Thrombosis transverse sinus disease_ontology DOID:3574 lateral sinus thrombosis DOID:3574 MESH:D020225 SNOMEDCT_US_2020_03_01:70607008 UMLS_CUI:C0338575 Thrombosis of superior longitudinal sinus Thrombosis of superior sagittal sinus disease_ontology DOID:3576 sagittal sinus thrombosis DOID:3576 A sex cord-gonadal stromal tumor characterized by excessive proliferation of Sertoli cells. DOID:0050617 MESH:D012707 NCI:C39976 SNOMEDCT_US_2020_03_01:89089007 UMLS_CUI:C0036769 tubular androblastoma disease_ontology DOID:3577 Sertoli cell tumor DOID:3577 NCI:C39911 UMLS_CUI:C1515283 disease_ontology DOID:3579 testicular gonadoblastoma DOID:3579 DOID:14071 DOID:3598 ICD10CM:O01 ICD9CM:630 MESH:D006828 MESH:D031901 NCI:C3110 NCI:C4699 NCI:C7887 OMIM:231090 SNOMEDCT_US_2020_03_01:156085008 SNOMEDCT_US_2020_03_01:417475006 UMLS_CUI:C0020217 UMLS_CUI:C0278796 UMLS_CUI:C1135868 gestational trophoblastic neoplasia hydatidiform mole molar pregnancy disease_ontology DOID:3590 OMIM mapping confirmed by DO. [SN]. gestational trophoblastic neoplasm DOID:3590 NCI:C6900 SNOMEDCT_US_2020_03_01:128767001 UMLS_CUI:C1266159 disease_ontology DOID:3593 epithelioid trophoblastic tumor DOID:3593 A placenta cancer that has_material_basis_in trophoblastic cells. GARD:6059 ICD10CM:C58 MESH:D002822 NCI:C2948 SNOMEDCT_US_2020_03_01:189444004 UMLS_CUI:C0008497 Chorioepithelioma disease_ontology DOID:3594 choriocarcinoma DOID:3594 A choriocarcinoma that is characterized by low beta-hCG levels and arises from neoplastic transformation of intermediate trophoblastic cells. MESH:D018245 NCI:C3757 SNOMEDCT_US_2020_03_01:75320001 UMLS_CUI:C0206666 Placental site trophoblastic tumor Placental site trophoblastic tumour Placental-Site Gestational Trophoblastic neoplasm placental site trophoblastic tumour disease_ontology DOID:3596 placental site trophoblastic tumor DOID:3596 A nervous system disease that results from exposure to neurotoxicants and is characterized by an altered mental status, memory loss, and visual problems. MESH:D020258 NCI:C27961 SNOMEDCT_US_2020_03_01:19466003 UMLS_CUI:C0235032 neurotoxicity neurotoxicity syndrome disease_ontology DOID:3602 toxic encephalopathy DOID:3602 A cystadenocarcinoma that derives_from epithelial cells originating in glandular tissue, with a capsulated structure and mucus-producing cells. MESH:D018282 NCI:C3776 SNOMEDCT_US_2020_03_01:79143006 UMLS_CUI:C0206699 Pseudomucinous cystadenocarcinoma disease_ontology DOID:3603 mucinous cystadenocarcinoma DOID:3603 An ovarian cystadenocarcinoma that is characterized by the presence of mucin. NCI:C4026 SNOMEDCT_US_2020_03_01:254851009 UMLS_CUI:C0279665 Ovarian mucinous cystadenocarcinoma mucinous cystadenocarcinoma of ovary disease_ontology DOID:3604 ovarian mucinous cystadenocarcinoma DOID:3604 An ovary adenocarcinoma that is characterized by the presence of cysts or cystic spaces. NCI:C5228 SNOMEDCT_US_2020_03_01:314191009 UMLS_CUI:C1096638 cystadenocarcinoma of ovary cystadenocarcinoma of the Ovary disease_ontology DOID:3605 ovarian cystadenocarcinoma DOID:3605 An ovary adenocarcinoma that is characterized by the presence of mucin. NCI:C5243 UMLS_CUI:C1335167 mucinous carcinoma of Ovary disease_ontology DOID:3606 ovarian mucinous adenocarcinoma DOID:3606 An appendix carcinoma that derives_from epithelial cells of glandular origin. NCI:C7718 SNOMEDCT_US_2020_03_01:413445002 UMLS_CUI:C0238003 Appendiceal adenocarcinoma disease_ontology DOID:3608 appendix adenocarcinoma DOID:3608 A cervix disease that is characterized by the growth endometrial tissue that is located on the cervix. NCI:C27623 SNOMEDCT_US_2020_03_01:61640006 UMLS_CUI:C0269107 Endometriosis of cervix cervical Endometriosis disease_ontology DOID:361 cervix endometriosis DOID:361 ICD10CM:H30.9 MESH:D012173 NCI:C115993 SNOMEDCT_US_2020_03_01:35426003 UMLS_CUI:C0035333 disease_ontology DOID:3612 retinitis DOID:3612 GARD:5984 MESH:D017825 NCI:C84611 OMIM:271900 SNOMEDCT_US_2020_03_01:80544005 UMLS_CUI:C0206307 CANAVAN-VAN BOGAERT-BERTRAND DISEASE Spongy degeneration of central nervous system disease_ontology DOID:3613 OMIM mapping confirmed by DO. [SN]. Canavan disease DOID:3613 A hypogonadotropic hypogonadism with a defective sense of smell (anosmia or hyposmia). GARD:10771 ICD10CM:E23.0 MESH:D017436 NCI:C75479 ORDO:478 SNOMEDCT_US_2020_03_01:190559001 UMLS_CUI:C0162809 Hypogonadism with anosmia Kallman syndrome Kallman's syndrome familial hypogonadism with anosmia disease_ontology DOID:3614 Kallmann syndrome DOID:3614 A lipoma that is a painful subcutaneous nodule, having all other features of a typical lipoma. MESH:D018206 NCI:C3733 SNOMEDCT_US_2020_03_01:404057003 UMLS_CUI:C0206632 disease_ontology DOID:3616 angiolipoma MESH:D018206 DOID:3616 A nervous system cancer that is located_in the central nervous system. DOID:0060093 DOID:1318 EFO:0000326 ICD10CM:C72.9 MESH:D016543 NCI:C4627 NCI:C9293 SNOMEDCT_US_2020_03_01:126951006 SNOMEDCT_US_2020_03_01:93744007 UMLS_CUI:C0085136 UMLS_CUI:C0348374 CNS neoplasm central nervous system tumor central nervous system tumors malignant neoplasm of central nervous system malignant tumor of CNS neoplasm of central nervous system disease_ontology DOID:3620 central nervous system cancer DOID:3620 An aortic disease that is characterized by an enlargement (dilation) of the aorta to greater than 1.5 times normal size. DOID:11138 DOID:7682 DOID:7692 DOID:7703 ICD10CM:I71.1 ICD10CM:I71.3 ICD10CM:I71.5 ICD10CM:I71.8 ICD10CM:I71.9 ICD9CM:441.1 ICD9CM:441.3 ICD9CM:441.5 ICD9CM:441.6 MESH:D001014 MESH:D001019 NCI:C26697 NCI:C27046 NCI:C27198 NCI:C27299 SNOMEDCT_US_2020_03_01:14336007 SNOMEDCT_US_2020_03_01:155419006 SNOMEDCT_US_2020_03_01:195265003 SNOMEDCT_US_2020_03_01:34365005 SNOMEDCT_US_2020_03_01:73067008 UMLS_CUI:C0003486 UMLS_CUI:C0265010 UMLS_CUI:C0265012 UMLS_CUI:C0741160 UMLS_CUI:C1305122 ruptured aortic aneurysm disease_ontology DOID:3627 aortic aneurysm MESH:D001014 MESH:D001019 DOID:3627 A female reproductive organ cancer that is located_in the uterus. DOID:4363 ICD10CM:C55 ICD9CM:179 MESH:D014594 NCI:C3435 NCI:C3552 SNOMEDCT_US_2020_03_01:126908007 SNOMEDCT_US_2020_03_01:371973000 UMLS_CUI:C0042138 UMLS_CUI:C0153567 CA - cancer of uterus Tumour of uterus malignant neoplasm of uterus malignant uterine tumor neoplasm of uterus uterine tumor uterus neoplasm disease_ontology DOID:363 uterine cancer DOID:363 A lysosomal storage disease that has_material_basis_in deficiency of the beta-A-manosidase enzyme resulting in the disruption of N-linked glycoprotein oligosaccharide catabolism. MESH:D044905 NCI:C84596 OMIM:248510 SNOMEDCT_US_2020_03_01:238047006 UMLS_CUI:C4048196 Beta-D-mannosidosis beta-mannosidase deficiency lysosomal beta-mannosidase deficiency disease_ontology DOID:3633 OMIM mapping confirmed by DO. [SN]. beta-mannosidosis DOID:3633 A neuromuscular junction disease that is characterized by weakness and easy fatiguability resulting from a genetic defect at the junction where the nerve stimulates muscle activity that result in muscle weakness and may affect nerve cells (presynaptic), muscle cells (postsynaptic) or the space between nerve and muscle cells (synaptic). GARD:11902 MESH:D020294 NCI:C84647 OMIM:PS601462 ORDO:590 SNOMEDCT_US_2020_03_01:230672006 UMLS_CUI:C0751882 disease_ontology DOID:3635 Xref MGI. congenital myasthenic syndrome DOID:3635 A teratoma that is located_in the central nervous system. NCI:C5441 UMLS_CUI:C1332895 CNS teratoma disease_ontology DOID:3640 central nervous system teratoma DOID:3640 GARD:6331 MESH:D004652 NCI:C84686 SNOMEDCT_US_2020_03_01:393569006 UMLS_CUI:C0014008 Empty sella syndrome disease_ontology DOID:3642 empty sella syndrome MESH:D004652 DOID:3642 NCI:C27066 SNOMEDCT_US_2020_03_01:59572000 UMLS_CUI:C0271558 Pituitary necrosis disease_ontology DOID:3646 necrosis of pituitary DOID:3646 A carbohydrate metabolic disorder characterized by the buildup of lactic acid in the body and a variety of neurological problems and caused by a deficiency of one of the three enzymes in the pyruvate dehydrogenase complex. GARD:4620 GARD:7513 ICD10CM:E74.4 MESH:D015325 NCI:C103968 OMIM:245348 OMIM:245349 OMIM:312170 OMIM:608782 OMIM:614111 ORDO:79243 SNOMEDCT_US_2020_03_01:46683007 UMLS_CUI:C0034345 deficiency of pyruvic dehydrogenase pyruvate dehydrogenase complex deficiency disease pyruvate dehydrogenase deficiency disease_ontology DOID:3649 Xref MGI. OMIM mapping confirmed by DO. [SN]. pyruvate decarboxylase deficiency DOID:3649 A urinary system disease that is located_in the bladder. ICD10CM:N32.9 ICD9CM:596.9 MESH:D001745 NCI:C2900 SNOMEDCT_US_2020_03_01:42643001 UMLS_CUI:C0005686 Urinary Bladder Disease disease_ontology DOID:365 bladder disease DOID:365 A metabolic acidosis characterized by buildup of lactate. ICD10CM:E87.2 MESH:D000140 NCI:C98969 SNOMEDCT_US_2020_03_01:91273001 UMLS_CUI:C0001125 disease_ontology DOID:3650 lactic acidosis DOID:3650 A mitochondrial metabolism disease characterized by progressive loss of mental and movement abilities. Symptoms usually begin between ages of three months and two years and include loss of appetite, vomiting, irritability and seizure activity. GARD:6877 ICD10CM:G31.82 MESH:D007888 NCI:C84814 OMIM:256000 ORDO:506 SNOMEDCT_US_2020_03_01:29570005 UMLS_CUI:C0023264 Infantile necrotizing encephalomyelopathy Leigh syndrome juvenile subacute necrotizing encephalomyelopathy disease_ontology subacute necrotizing encephalomyelopathy DOID:3652 Xref MGI. OMIM mapping confirmed by DO. [SN]. Leigh disease DOID:3652 A lysosomal storage disease characterized by increased sialic acid in the urine. MESH:D029461 NCI:C85067 OMIM:269921 OMIM:604369 SNOMEDCT_US_2020_03_01:238051008 UMLS_CUI:C0342853 disease_ontology DOID:3659 OMIM mapping confirmed by DO. [LS]. OMIM mapping submitted by NeuroDevNet. [LS]. sialuria DOID:3659 NCI:C5121 SNOMEDCT_US_2020_03_01:126967000 UMLS_CUI:C0346319 neoplasm of olfactory nerve tumor of Olfactory nerve disease_ontology DOID:366 olfactory nerve neoplasm DOID:366 A hematologic cancer that has_material_basis_in mast cells. ICD10CM:D47.09 NCI:C9295 SNOMEDCT_US_2020_03_01:127581004 UMLS_CUI:C0334664 Mast cell Proliferative disease mast cell tumor mastocytoma disease_ontology DOID:3664 mast cell neoplasm DOID:3664 ICD10CM:I73.9 MESH:D007383 SNOMEDCT_US_2020_03_01:195312007 UMLS_CUI:C0021775 Charcot's syndrome Intermittent claudication disease_ontology DOID:3669 intermittent claudication DOID:3669 A childhood kidney neoplasm that is located_in the kidney, liver, muscle, heart, lung, soft tissues, skin and central nervous system. GARD:7572 MESH:D018335 NCI:C3808 SNOMEDCT_US_2020_03_01:83118000 UMLS_CUI:C0206743 Rhabdoid sarcoma malignant rhabdoid tumour disease_ontology rhabdoid tumor DOID:3672 rhabdoid cancer MESH:D018335 DOID:3672 NCI:C6563 UMLS_CUI:C1333003 pediatric renal tumor disease_ontology DOID:3675 childhood kidney cancer DOID:3675 A supratentorial cancer that is located_in the cerebrum. DOID:912 ICD9CM:191.8 NCI:C4874 SNOMEDCT_US_2020_03_01:126953009 SNOMEDCT_US_2020_03_01:188300006 UMLS_CUI:C0153642 UMLS_CUI:C1263885 cerebral cancer neoplasm of cerebrum tumor of Cerebrum disease_ontology DOID:368 cerebrum cancer DOID:368 MESH:D008175 NCI:C3200 SNOMEDCT_US_2020_03_01:126713003 UMLS_CUI:C0024121 tumor of the lung disease_ontology DOID:3683 lung benign neoplasm DOID:3683 A mitochondrial encephalomyopathy that is characterized by mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes, has_symptom myalgia, motor weakness, headaches, seizures, and stroke-like episodes with acute hemiparesis and severe headaches, and develops_from mutation in mitochondrial genes including MT-TL1, which encodes tRNA proteins. ICD10CM:E88.41 MESH:D017241 NCI:C84885 OMIM:540000 SNOMEDCT_US_2020_03_01:39925003 UMLS_CUI:C0162671 MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES disease_ontology DOID:3687 OMIM mapping confirmed by DO. [SN]. MELAS syndrome DOID:3687 ICD10CM:G54.5 MESH:D020968 NCI:C84600 SNOMEDCT_US_2020_03_01:26609002 UMLS_CUI:C0221759 Brachial neuritis Parsonage-Aldren-Turner syndrome disease_ontology DOID:3689 brachial plexus neuritis DOID:3689 GARD:2197 MESH:D018304 NCI:C3789 SNOMEDCT_US_2020_03_01:76060004 UMLS_CUI:C0206717 Asthesioneuroblastoma Esthesioneuroblastoma Esthesioneuroepithelioma Olfactory Esthesioneuroblastoma paranasal sinus Olfactory neuroblastoma disease_ontology DOID:369 olfactory neuroblastoma DOID:369 ICD10CM:G54.0 MESH:D020516 NCI:C27194 SNOMEDCT_US_2020_03_01:3548001 UMLS_CUI:C0700251 Brachial plexus disorder brachial plexopathy disease_ontology DOID:3690 brachial plexus neuropathy DOID:3690 An integumentary system disease that is located_in skin. DOID:1576 DOID:1698 DOID:187 DOID:6486 DOID:8948 ICD9CM:702 MESH:D012871 MESH:D012873 NCI:C156032 NCI:C3371 SNOMEDCT_US_2020_03_01:201095006 SNOMEDCT_US_2020_03_01:5613003 SNOMEDCT_US_2020_03_01:95320005 UMLS_CUI:C0029574 UMLS_CUI:C0037274 UMLS_CUI:C0037277 Genodermatosis skin and subcutaneous tissue disease disease_ontology DOID:37 skin disease DOID:37 A fallopian tube carcinoma that derives_from epithelial cells of glandular origin. NCI:C6265 UMLS_CUI:C1333590 adenocarcinoma of the fallopian tube disease_ontology DOID:3706 fallopian tube adenocarcinoma DOID:3706 A bladder carcinoma that derives_from epithelial cells of glandular origin. NCI:C4032 SNOMEDCT_US_2020_03_01:255110003 UMLS_CUI:C0279682 adenocarcinoma of bladder adenocarcinoma of the urinary bladder bladder adenocarcinoma, Not Otherwise Specified disease_ontology DOID:3711 bladder adenocarcinoma DOID:3711 An ovarian carcinoma that derives_from epithelial cells of glandular origin. DOID:7816 NCI:C7700 UMLS_CUI:C0948216 Ovarian adenocarcinoma ovarian adenoacanthoma disease_ontology adenocarcinoma of the ovary DOID:3713 ovary adenocarcinoma DOID:3713 A stomach carcinoma that derives_from epithelial cells of glandular origin. NCI:C4004 SNOMEDCT_US_2020_03_01:408647009 UMLS_CUI:C0278701 adenocarcinoma of stomach stomach adenocarcinoma disease_ontology DOID:3717 gastric adenocarcinoma DOID:3717 ICD10CM:C90.3 MESH:D010954 NCI:C9349 SNOMEDCT_US_2020_03_01:302852008 UMLS_CUI:C0032131 Myeloma - solitary Myeloma, solitary Solitary myeloma Solitary plasmacytoma disease_ontology DOID:3721 plasmacytoma DOID:3721 A parasitic protozoa infectious disease that involves infection of humans and cattle caused by a genus of parasitic protozoa Theileria, which is transmitted by ixodid ticks. MESH:D013801 SNOMEDCT_US_2020_03_01:68771000 UMLS_CUI:C0039753 Infection by Theileria theileriosis disease_ontology DOID:3733 theileriasis DOID:3733 A squamous cell carcinoma that is a diffuse, papillary, non metastasizing, well differentiated, malignant neoplasm of epidermis or oral epithelium. MESH:D018289 NCI:C3781 SNOMEDCT_US_2020_03_01:89906000 UMLS_CUI:C0206706 Warty carcinoma verrucous squamous carcinoma verrucous squamous cell carcinoma disease_ontology DOID:3737 verrucous carcinoma DOID:3737 An acquired metabolic disease that is characterized by an insufficient intake of food or of certain nutrients, by an inability of the body to absorb and use nutrients, or by overconsumption of certain foods. MESH:D009748 NCI:C26836 SNOMEDCT_US_2020_03_01:191077005 UMLS_CUI:C3714509 Nutritional disorder disease_ontology DOID:374 nutrition disease DOID:374 A cervix carcinoma that has_material_basis_in squamous cells of the cervix. NCI:C4028 SNOMEDCT_US_2020_03_01:254886006 UMLS_CUI:C0279671 squamous cell carcinoma of cervix squamous cell carcinoma of the Cervix Uteri disease_ontology DOID:3744 cervical squamous cell carcinoma DOID:3744 An esophageal carcinoma that derives_from epithelial squamous cells located_in the esophagus. MESH:D000077277 NCI:C4024 SNOMEDCT_US_2020_03_01:276804009 UMLS_CUI:C0279626 SCC of esophagus SCC of oesophagus oesophagus squamous cell carcinoma disease_ontology DOID:3748 OMIM mapping confirmed by DO. [SN]. esophagus squamous cell carcinoma DOID:3748 NCI:C8188 UMLS_CUI:C0280328 verrucous carcinoma of the Larynx disease_ontology DOID:3752 larynx verrucous carcinoma DOID:3752 A syndrome characterized by oculocutaneous albinism, bleeding problems due to platelet storage pool defect, visual impairment and lysosomal accumulation of ceroid lipofuscin. GARD:6643 ICD10CM:E70.331 MESH:D022861 NCI:C37261 OMIM:PS203300 ORDO:231531 ORDO:231537 ORDO:280663 ORDO:79430 SNOMEDCT_US_2020_03_01:60255003 UMLS_CUI:C0079504 disease_ontology DOID:3753 Xref MGI. OMIM mapping confirmed by DO. [SN]. Hermansky-Pudlak syndrome DOID:3753 A thrombophilia that is characterized by the tendency to form clots in the veins. ICD10CM:D68.59 MESH:D020152 NCI:C98815 OMIM:613118 SNOMEDCT_US_2020_03_01:36351005 UMLS_CUI:C0272375 AT III deficiency hereditary thrombophilia due to congenital antithrombin deficiency disease_ontology DOID:3755 Xref MGI. antithrombin III deficiency DOID:3755 A thrombophilia that is characterized by recurrent venous thrombosis and that has_material_basis_in heterozygous mutation in the PROC gene on chromosome 2q14. GARD:4521 ICD10CM:D68.59 MESH:D020151 NCI:C99025 ORDO:745 SNOMEDCT_US_2020_03_01:76407009 UMLS_CUI:C0398625 disease_ontology DOID:3756 protein C deficiency DOID:3756 MESH:D012734 NCI:C45909 SNOMEDCT_US_2020_03_01:52572004 UMLS_CUI:C0019269 disease_ontology DOID:3763 hermaphroditism DOID:3763 A syndrome that is characterized by the association of diffuse mesangial sclerosis (DMS), male pseudohermaphroditism with a 46,XY karyotype, and nephroblastoma that derives_from an abnormality in the WT1 gene (Wilms' tumor suppressor gene). GARD:5576 MESH:D030321 NCI:C84668 OMIM:194080 SNOMEDCT_US_2020_03_01:236385009 UMLS_CUI:C0950121 disease_ontology DOID:3764 OMIM mapping confirmed by DO. [SN]. Denys-Drash syndrome DOID:3764 DOID:11226 ICD10CM:Q56 ICD10CM:Q56.3 ICD9CM:752.7 MESH:D012734 NCI:C124575 SNOMEDCT_US_2020_03_01:204895009 SNOMEDCT_US_2020_03_01:268328009 UMLS_CUI:C0021193 UMLS_CUI:C0033804 Indeterminate sex and pseudohermaphroditism disease_ontology DOID:3765 pseudohermaphroditism DOID:3765 A vaginal discharge that is characterized by a whitish or yellow color. ICD10CM:N89.8 MESH:D007973 NCI:C34775 SNOMEDCT_US_2020_03_01:156017008 UMLS_CUI:C0023533 Leukorrhea of vagina discharge - leukorrhea disease_ontology DOID:3766 leukorrhea DOID:3766 A vaginal disease that is characterized by the presence of discharge. MESH:D019522 NCI:C50795 SNOMEDCT_US_2020_03_01:70856007 UMLS_CUI:C0227791 disease_ontology DOID:3767 vaginal discharge DOID:3767 An interstitial lung disease that is characterized by destruction, scarring, and thickening of the interstitial lung tissues and progressive pulmonary function loss in a restrictive pattern, has_symptom progressive shortness of breath, fatigue, and chronic cough, possibly has_material_basis_in exposure to certain chemicals, autoimmune conditions, and radiation. MESH:D011658 NCI:C26869 SNOMEDCT_US_2020_03_01:155613001 UMLS_CUI:C0034069 Fibrosis of lung disease_ontology DOID:3770 pulmonary fibrosis DOID:3770 NCI:C5592 SNOMEDCT_US_2020_03_01:128789002 UMLS_CUI:C1322252 Chordoid glioma disease_ontology DOID:3774 chordoid glioma DOID:3774 An ovarian disease that is characterized by the absence of ovulation. MESH:D000858 NCI:C34388 SNOMEDCT_US_2020_03_01:34571000 UMLS_CUI:C0003128 disease_ontology DOID:3781 anovulation DOID:3781 A syndrome that is characterized by skeletal malformations, growth retardation, hearing deficit, paroxysmal movement disorders, and cognitive impairment in affected males and some carrier females, and has_material_basis_in mutation in the RSK2 gene on chromosome Xp22. GARD:6123 MESH:D038921 NCI:C84643 OMIM:303600 SNOMEDCT_US_2020_03_01:15182000 UMLS_CUI:C0265252 disease_ontology DOID:3783 OMIM mapping confirmed by DO. [SN]. Coffin-Lowry syndrome DOID:3783 DOID:13122 DOID:835 ICD10CM:H61.9 ICD9CM:380 NCI:C26972 SNOMEDCT_US_2020_03_01:49130001 UMLS_CUI:C0155388 Preauricular cyst Preauricular sinus and fistula Preauricular sinus or fistula disease_ontology DOID:379 external ear disease DOID:379 A soft tissue infectious disease that involves accumulation of pus in the pleural cavity as a result of infection within the lung (pneumonia) or a lung abscess spreading into the space. The symptoms include cough, fever, chest pain, sweating and shortness of breath. DOID:11023 DOID:13630 DOID:14304 ICD10CM:J86 MESH:D016724 NCI:C45692 SNOMEDCT_US_2020_03_01:196069007 UMLS_CUI:C0014013 Empyema Empyema of pleura Empyema of pleura without fistula Empyema with fistula Empyema with no fistula Empyema with pleural fistula Empyema without mention of fistula Empyema, chest Pleural empyema with fistula Purulent pleurisy Thorax abscess abscess of pleural cavity abscess of thorax empyema empyema with fistula lung empyema pleural empyema with no fistula purulent pleuritis pyothorax disease_ontology DOID:3798 Updating outdated UMLS CUI. pleural empyema DOID:3798 A bone disease that is located_in the joint. DOID:13871 DOID:13960 DOID:1843 DOID:1903 DOID:226 DOID:2317 DOID:2318 DOID:546 DOID:9489 ICD10CM:M00-M02 ICD10CM:M12.9 ICD9CM:711 ICD9CM:719.90 MESH:D007592 NCI:C35760 NCI:C78402 SNOMEDCT_US_2020_03_01:48548006 SNOMEDCT_US_2020_03_01:8316001 UMLS_CUI:C0022408 UMLS_CUI:C0157749 Ankylosis of joint of ankle and/or foot Ankylosis of joint of forearm Ankylosis of joint of hand Ankylosis of joint of lower leg Ankylosis of joint of multiple sites Ankylosis of joint of shoulder region Ankylosis of joint of upper arm Ankylosis of multiple joints Infectious arthropathy Joint ankylosis of the ankle and foot Joint ankylosis of the ankle and/or foot Joint ankylosis of the forearm Joint ankylosis of the hand Joint ankylosis of the lower leg Joint ankylosis of the pelvic region and thigh Joint ankylosis of the shoulder region Joint ankylosis of the upper arm ankylosis of ankle and foot joint ankylosis of forearm joint ankylosis of hand joint ankylosis of joint of multiple sites ankylosis of joint of pelvic region and thigh ankylosis of joint of shoulder region ankylosis of lower leg joint ankylosis of upper arm joint disease_ontology DOID:381 arthropathy DOID:381 An allergic contact dermatitis that is characterized by a delayed-type hypersensitivity cutaneous reaction in response to a photoantigen applied to the skin in individuals previously sensitized to the same substance, and has_symptom erythematous papules, vesicles, or eczema. MESH:D017454 SNOMEDCT_US_2020_03_01:111209006 UMLS_CUI:C0162824 Photoallergic contact dermatitis Photoallergic dermatitis Photoallergic eczema disease_ontology DOID:3818 photoallergic dermatitis DOID:3818 A diaphragm disease characterized by the lack of development of all or part of the diaphragm, which results in an abnormal opening that allows the stomach and intestines to move into the chest cavity and crowd the heart and lungs. GARD:1481 ICD10CM:K44 MESH:D006548 NCI:C34687 OMIM:142340 OMIM:222400 OMIM:610187 ORDO:2140 SNOMEDCT_US_2020_03_01:155748004 UMLS_CUI:C0019284 Diaphragmatic Hernia disease_ontology DOID:3827 Xref MGI. OMIM mapping confirmed by DO. [SN]. congenital diaphragmatic hernia ICD10CM:Q79.0 DOID:3827 A pituitary gland benign neoplasm that derives_from glandular epithelial cells. MESH:D010911 NCI:C3329 OMIM:PS102200 SNOMEDCT_US_2020_03_01:154621002 UMLS_CUI:C0032000 adenoma of the Pituitary gland disease_ontology DOID:3829 pituitary adenoma DOID:3829 DOID:10392 GARD:7897 ICD10CM:I45.6 ICD9CM:426.7 MESH:D014927 NCI:C35132 OMIM:194200 SNOMEDCT_US_2020_03_01:195057009 SNOMEDCT_US_2020_03_01:74390002 UMLS_CUI:C0043202 UMLS_CUI:C0392470 Anomalous A-V excitation Wolff-Parkinson-White pattern anomalous atrioventricular excitation disease_ontology DOID:384 OMIM mapping confirmed by DO. [LS]. OMIM mapping confirmed by DO. [SN]. Wolff-Parkinson-White syndrome DOID:384 GARD:10486 MESH:D003397 NCI:C2964 SNOMEDCT_US_2020_03_01:189179009 UMLS_CUI:C0010276 neoplasm of Rathke's Pouch disease_ontology DOID:3840 craniopharyngioma DOID:3840 MESH:D019292 NCI:C4676 UMLS_CUI:C0376527 tumors of Skull Base disease_ontology DOID:3842 skull base cancer DOID:3842 DOID:6097 NCI:C5125 NCI:C5126 UMLS_CUI:C1333286 UMLS_CUI:C1334576 malignant Diencephalic tumor malignant diencephalic neoplasm tumor of Diencephalon disease_ontology DOID:3843 diencephalic neoplasm DOID:3843 DOID:4133 DOID:4134 DOID:6252 DOID:6253 GARD:7378 ICD10CM:Q85.8 MESH:D010580 NCI:C3324 NCI:C4733 NCI:C7755 OMIM:175200 ORDO:2869 SNOMEDCT_US_2020_03_01:157029009 SNOMEDCT_US_2020_03_01:277161008 SNOMEDCT_US_2020_03_01:53633000 UMLS_CUI:C0031269 UMLS_CUI:C0265323 UMLS_CUI:C0456487 Colonic hamartomatous polyp Peutz Jeghers colon polyp Peutz Jeghers polyp Peutz-Jeghers polyp of small Intestine gastric Peutz-Jeghers polyp peutz-jeghers small bowel hamartoma disease_ontology DOID:3852 OMIM mapping confirmed by DO. [SN]. Peutz-Jeghers syndrome DOID:3852 NCI:C39908 SNOMEDCT_US_2020_03_01:236740006 UMLS_CUI:C0341767 Seminal Vesicle neoplasm seminal vesicle tumour tumor of seminal vesicle tumour of seminal vesicle disease_ontology DOID:3855 seminal vesicle tumor DOID:3855 A reproductive organ cancer that is manifested in the male genital system. This includes organs such as the penis and scrotum. DOID:10284 ICD10CM:C63.9 ICD9CM:187.9 MESH:D005834 NCI:C3054 NCI:C8561 SNOMEDCT_US_2020_03_01:126895004 SNOMEDCT_US_2020_03_01:363515000 UMLS_CUI:C0017417 UMLS_CUI:C0153606 male genital cancer male reproductive system neoplasm malignant neoplasm of male genital organ malignant neoplasm of male genital organ or tract malignant neoplasm of male genital organs malignant tumor of male Reproductive system malignant tumor of male genital organ neoplasm of male genital organ tumor of male Reproductive system disease_ontology male genital neoplasm DOID:3856 male reproductive organ cancer DOID:3856 A medulloblastoma that is characterized by cells that are larger than would be normally expected. NCI:C6904 SNOMEDCT_US_2020_03_01:128790006 UMLS_CUI:C1266180 large cell Medulloblastoma disease_ontology DOID:3857 large cell medulloblastoma DOID:3857 MESH:D008527 NCI:C3706 SNOMEDCT_US_2020_03_01:24604009 UMLS_CUI:C0205833 Medullomyoblastoma disease_ontology DOID:3861 medullomyoblastoma DOID:3861 DOID:6380 MESH:D008527 NCI:C4011 NCI:C9373 UMLS_CUI:C0278876 UMLS_CUI:C1332188 adult brain medulloblastoma disease_ontology DOID:3864 adult medulloblastoma DOID:3864 MESH:D008527 NCI:C3997 UMLS_CUI:C0278510 pediatric Medulloblastoma disease_ontology DOID:3869 childhood medulloblastoma DOID:3869 MESH:D003109 UMLS_CUI:C0009374 disease_ontology DOID:3877 functional colonic disease DOID:3877 A syndrome that is characterized by an increased risk for colon cancer and cancers of the endometrium, ovary, stomach, small intestine, hepatobiliary tract, urinary tract, brain, and skin and has_material_basis_in mutation of mismatch repair genes that increases the risk of many types of cancers. DOID:0050586 DOID:3040 GARD:9905 MESH:D003123 NCI:C120083 OMIM:PS120435 ORDO:144 SNOMEDCT_US_2020_03_01:315058005 UMLS_CUI:C0009405 UMLS_CUI:C1333990 COCA 1 HNPCC - hereditary nonpolyposis colon cancer Hereditary Defective Mismatch Repair syndrome hereditary nonpolyposis colorectal cancer hereditary nonpolyposis colorectal neoplasm disease_ontology DOID:3883 OMIM mapping confirmed by DO. [SN]. Lynch syndrome DOID:3883 GARD:5732 MESH:D017118 NCI:C84536 OMIM:176000 SNOMEDCT_US_2020_03_01:190914003 UMLS_CUI:C0162565 AIP - acute intermittent porphyria Pyrroloporphyria porphyria intermittent acute disease_ontology DOID:3890 acute intermittent porphyria DOID:3890 A placenta disease that is characterized by insufficient blood flow to the placenta during pregnancy. MESH:D010927 SNOMEDCT_US_2020_03_01:156185006 UMLS_CUI:C0032051 disease_ontology DOID:3891 placental insufficiency DOID:3891 A pancreatic cystadenoma that is characterized by the overproduction of insulin. DOID:3903 GARD:3010 MESH:D007340 MESH:D007516 NCI:C65184 NCI:C95598 SNOMEDCT_US_2020_03_01:189586007 SNOMEDCT_US_2020_03_01:25324008 UMLS_CUI:C0021670 UMLS_CUI:C0022134 Insulin-Producing tumor of Islet cells Islet cell adenoma disease_ontology DOID:3892 insulinoma DOID:3892 MESH:D018251 NCI:C3760 SNOMEDCT_US_2020_03_01:80549000 UMLS_CUI:C0206672 Apocrine Cystadenoma Apocrine cystadenoma Eccrine Cystadenoma Eccrine hidrocystoma of skin Hidrocystoma disease_ontology DOID:3893 hidrocystoma MESH:D018251 DOID:3893 NCI:C4168 SNOMEDCT_US_2020_03_01:307596009 UMLS_CUI:C0334345 tubular Apocrine adenoma disease_ontology DOID:3895 apocrine adenoma DOID:3895 A sweat gland benign neoplasm that is located_in an apical sweat gland. MESH:D006607 NCI:C7560 SNOMEDCT_US_2020_03_01:81393009 UMLS_CUI:C0019522 Hidradenoma of skin Sweat gland adenoma Syringoadenoma disease_ontology DOID:3896 hidradenoma DOID:3896 A vulvar disease that is characterized by inflammation of the vulva. ICD10CM:N76.2 MESH:D014847 SNOMEDCT_US_2020_03_01:63144007 UMLS_CUI:C0042996 disease_ontology DOID:3901 vulvitis DOID:3901 A bronchus cancer that has_material_basis_in epithelial cells. MESH:D002283 NCI:C35875 SNOMEDCT_US_2020_03_01:254622008 UMLS_CUI:C0007121 BC - Bronchogenic carcinoma disease_ontology DOID:3904 bronchus carcinoma DOID:3904 A lung cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells and is located_in the lungs and has_symptom cough and has_symptom chest discomfort or pain and has_symptom weight loss and has_symptom hemoptysis. EFO:0001071 NCI:C4878 SNOMEDCT_US_2020_03_01:154485001 UMLS_CUI:C0684249 cancer of lung disease_ontology carcinoma of lung DOID:3905 OMIM mapping confirmed by DO. [SN]. lung carcinoma DOID:3905 MESH:D001984 SNOMEDCT_US_2020_03_01:126705004 UMLS_CUI:C0006264 bronchus neoplasm neoplasm of bronchus disease_ontology DOID:3906 bronchial benign neoplasm DOID:3906 A non-small cell lung carcinoma that has_material_basis_in the squamous cell. NCI:C3493 SNOMEDCT_US_2020_03_01:254634000 UMLS_CUI:C0149782 Epidermoid cell carcinoma of the lung disease_ontology squamous cell carcinoma of lung DOID:3907 lung squamous cell carcinoma DOID:3907 A lung carcinoma that is characterized as any type of epithelial lung cancer other than small cell lung carcinoma. EFO:0003060 KEGG:05223 MESH:D002289 NCI:C2926 SNOMEDCT_US_2020_03_01:254637007 UMLS_CUI:C0007131 NSCLC Non-small cell lung cancer non-small cell lung carcinoma disease_ontology DOID:3908 lung non-small cell carcinoma DOID:3908 A syndrome characterized by extreme short stature, low body weight, early loss of hair, lipodystrophy, scleroderma, decreased joint mobility, osteolysis, and facial features that resemble aged persons that has_material_basis_in mutation in LMNA on chromosome 1q22. GARD:7467 ICD10CM:E34.8 MEDDRA:10036794 MESH:D011371 NCI:C34951 OMIM:176670 ORDO:740 SNOMEDCT_US_2020_03_01:190590004 UMLS_CUI:C0033300 HGPS Hutchinson Gilford syndrome Hutchinson-Gilford Progeria syndrome Hutchinson-Gilford disease disease_ontology DOID:3911 OMIM mapping confirmed by DO. [SN]. progeria DOID:3911 NCI:C4374 SNOMEDCT_US_2020_03_01:235967003 UMLS_CUI:C0341486 disease_ontology DOID:3918 pancreatic cystadenoma DOID:3918 NCI:C6504 UMLS_CUI:C1333298 disease_ontology DOID:3923 diffuse lipomatosis DOID:3923 GARD:7350 MESH:C535549 NCI:C27486 SNOMEDCT_US_2020_03_01:190802005 UMLS_CUI:C0406608 disease_ontology DOID:3927 pelvic lipomatosis DOID:3927 An inner ear disease which involves inflammation of the inner ear. NCI:C27339 UMLS_CUI:C1168225 inner ear infection disease_ontology DOID:3930 otitis interna DOID:3930 NCI:C4501 SNOMEDCT_US_2020_03_01:254828009 UMLS_CUI:C0346117 malignant lipomatous tumor malignant tumor of Adipose tissue disease_ontology DOID:3939 lipomatous cancer DOID:3939 ICD10CM:E24.0 MESH:D047748 NCI:C113210 SNOMEDCT_US_2020_03_01:190502001 UMLS_CUI:C0221406 Overproduction of ACTH pituitary-dependent Cushing disease disease_ontology DOID:3946 pituitary-dependent Cushing's disease DOID:3946 MESH:D000308 NCI:C113208 SNOMEDCT_US_2020_03_01:47270006 UMLS_CUI:C0001622 Adrenocortical hyperfunction hyperadrenalism hypercortisolism disease_ontology DOID:3947 adrenal gland hyperfunction DOID:3947 An adrenal cortex cancer that forms in the outer layer of tissue of the adrenal gland and that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. GARD:558 MESH:D018268 NCI:C9325 OMIM:202300 SNOMEDCT_US_2020_03_01:255035007 UMLS_CUI:C0206686 Adrenal cortical carcinoma carcinoma of the Adrenal cortex disease_ontology DOID:3948 adrenocortical carcinoma MESH:D018268 DOID:3948 An adrenal cancer that is located_in the cortex (steroid hormone-producing tissue) of the adrenal gland and that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. carcinoma of the Adrenal gland disease_ontology DOID:3950 adrenal carcinoma DOID:3950 ICD10CM:I40 ICD9CM:422 NCI:C35206 SNOMEDCT_US_2020_03_01:155336004 UMLS_CUI:C0155686 disease_ontology DOID:3951 acute myocarditis DOID:3951 MESH:D000303 SNOMEDCT_US_2020_03_01:129636003 UMLS_CUI:C0001614 disease_ontology DOID:3952 adrenal cortex disease DOID:3952 An endocrine gland cancer located_in the adrenal glands which are located above the kidneys. DOID:11007 GARD:5751 ICD10CM:C74 ICD9CM:194.0 MESH:D000310 NCI:C2859 NCI:C9338 SNOMEDCT_US_2020_03_01:127021009 SNOMEDCT_US_2020_03_01:93665005 UMLS_CUI:C0001624 UMLS_CUI:C0750887 adrenal cancer adrenal neoplasm malignant Adrenal tumor malignant neoplasm of adrenal gland neoplasm of adrenal gland tumor of the Adrenal gland disease_ontology DOID:3953 adrenal gland cancer DOID:3953 A thyroid gland cancer that has_material_basis_in epithelial cells. EFO:0002892 MESH:D013964 NCI:C4815 UMLS_CUI:C0549473 head and neck cancer, Thyroid thyroid gland carcinoma disease_ontology DOID:3963 thyroid gland carcinoma DOID:3963 GARD:9266 NCI:C4068 SNOMEDCT_US_2020_03_01:29792007 UMLS_CUI:C0302182 Trabecular adenocarcinoma trabecular carcinoma disease_ontology DOID:3965 Merkel cell carcinoma DOID:3965 A differentiated thyroid gland carcinoma that is characterized by the small mushroom shape of the tumor which has a stem attached to the epithelial layer abd arises from the follicular cells of the thyroid gland. GARD:12027 MESH:D000077273 NCI:C4035 OMIM:188550 SNOMEDCT_US_2020_03_01:255029007 UMLS_CUI:C0238463 Papillary carcinoma of the Thyroid gland disease_ontology DOID:3969 OMIM mapping confirmed by DO. [SN]. thyroid gland papillary carcinoma DOID:3969 An intrinsic cardiomyopathy characterized by impaired ventricular filling, with normal or decreased diastolic volume of either or both ventricles typically resulting from increased stiffness of the myocardium. ICD10CM:I42.5 MESH:D002313 NCI:C62798 OMIM:115210 OMIM:PS115210 ORDO:75249 SNOMEDCT_US_2020_03_01:389996009 UMLS_CUI:C0007196 Cardiomyopathy, constrictive Restrictive cardiomyopathy primary restrictive cardiomyopathy disease_ontology Familial restrictive cardiomyopathy Familial restrictive cardiomyopathy DOID:397 Xref MGI. OMIM mappings 115210, 612422 added from NeuroDevNet [WAK]. restrictive cardiomyopathy DOID:397 A thyroid gland carcinoma that has_material_basis_in parafollicular cells. MESH:C536914 NCI:C3879 SNOMEDCT_US_2020_03_01:255032005 UMLS_CUI:C0238462 Medullary carcinoma of the Thyroid gland Medullary thyroid carcinoma Ultimobranchial thyroid tumor Ultimobranchial thyroid tumour medullary thyroid carcinoma disease_ontology DOID:3973 thyroid gland medullary carcinoma DOID:3973 A cardiomyopathy that is characterized by the pathology occuring outside of the myocardium. ICD9CM:425.8 SNOMEDCT_US_2020_03_01:195580005 UMLS_CUI:C0155699 disease_ontology DOID:3978 extrinsic cardiomyopathy DOID:3978 A neurodegeneration with brain iron accumulation that has_material_basis_in autosomal recessive inheritance of mutation in the PANK2 gene on chromosome 20p13. GARD:6564 ICD10CM:G23.0 MESH:D006211 NCI:C8967 OMIM:234200 ORDO:157850 SNOMEDCT_US_2020_03_01:2992000 UMLS_CUI:C0018523 Hallervorden-Spatz disease Hallervorden-Spatz syndrome NBIA1 Pigmentary pallidal degeneration brain Iron Accumulation type I syndrome neurodegeneration with brain iron accumulation 1 disease_ontology DOID:3981 OMIM mapping confirmed by DO. [SN]. pantothenate kinase-associated neurodegeneration DOID:3981 A cranio-facial dystonia that is accompanied by blepharospasm. GARD:7008 MESH:D008538 SNOMEDCT_US_2020_03_01:230325003 UMLS_CUI:C0025183 disease_ontology DOID:3982 Meige syndrome DOID:3982 A trichostrongyloidiasis that involves parasitic infection of the ruminant gastrointestinal tract by nematodes of the genus Ostertagia. MESH:D010029 UMLS_CUI:C0029471 disease_ontology DOID:3985 ostertagiasis DOID:3985 A primary bacterial infectious disease that is located_in lungs, located_in lymph nodes, located_in pericardium, located_in brain, located_in pleura or located_in gastrointestinal tract, has_material_basis_in Mycobacterium tuberculosis, which is transmitted_by droplets released into the air when an infected person coughs or sneezes. DOID:10096 DOID:12688 DOID:12691 DOID:415 DOID:9901 DOID:9902 GARD:7827 MESH:D014375 SNOMEDCT_US_2020_03_01:15202009 UMLS_CUI:C0041295 disease_ontology DOID:399 tuberculosis MESH:D014376 DOID:399 An organ system cancer that is located_in the kidneys, ureteres, bladder or urethra. ICD10CM:C68.9 ICD9CM:189.9 SNOMEDCT_US_2020_03_01:448233000 UMLS_CUI:C0348371 disease_ontology DOID:3996 urinary system cancer DOID:3996 A disease is a disposition (i) to undergo pathological processes that (ii) exists in an organism because of one or more disorders in that organism. MESH:D004194 NCI:C2991 SNOMEDCT_US_2020_03_01:64572001 UMLS_CUI:C0012634 disease_ontology DOID:4 disease DOID:4 An ovarian cancer that has_material_basis_in epithelial tissue and is located_in the ovary. EFO:0001075 UMLS_CUI:C0677886 Ovarian carcinoma disease_ontology DOID:4001 OMIM mapping confirmed by DO. [SN]. ovarian carcinoma DOID:4001 A bladder carcinoma that has_material_basis_in transitional cells located_in the lining of the bladder. NCI:C39851 SNOMEDCT_US_2020_03_01:393562002 UMLS_CUI:C0279680 bladder transitional cell carcinoma transitional cell carcinoma of bladder urinary bladder urothelial carcinoma urothelial bladder carcinoma disease_ontology DOID:4006 bladder urothelial carcinoma DOID:4006 A urinary bladder cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. EFO:0000292 NCI:C4912 SNOMEDCT_US_2020_03_01:269607003 UMLS_CUI:C0699885 carcinoma of urinary bladder disease_ontology DOID:4007 bladder carcinoma DOID:4007 A tuberculosis that is resistant to isoniazid and rifampicin, the two most powerful first-line anti-TB drugs. MESH:D018088 NCI:C128415 SNOMEDCT_US_2020_03_01:423092005 UMLS_CUI:C0206526 disease_ontology DOID:401 multidrug-resistant tuberculosis DOID:401 A transitional cell carcinoma that has several papillary fronds with central fibrovascular core lined by transitional type epithelium. NCI:C4122 SNOMEDCT_US_2020_03_01:12400006 UMLS_CUI:C0334274 Papillary transitional cell carcinoma disease_ontology DOID:4012 papillary transitional carcinoma DOID:4012 A ureteral disease that is characterized_as a congenital anomaly in which the distal end of the ureter swells as it enters the bladder. MESH:D014518 NCI:C123159 OMIM:191650 SNOMEDCT_US_2020_03_01:12818004 UMLS_CUI:C0041960 disease_ontology DOID:4022 OMIM mapping confirmed by DO. [LS]. ureterocele DOID:4022 A skin hemangioma that is characterized by the presence of small red dots that cluster together to form a linear or snake-like array or ring-shaped pattern located_in the blood vessels of the skin. ICD10CM:L81.7 NCI:C3926 OMIM:106050 OMIM:300652 ORDO:95429 SNOMEDCT_US_2020_03_01:49465005 UMLS_CUI:C0263637 Angioma serpiginosum of skin disease_ontology DOID:4028 Xref MGI. angioma serpiginosum DOID:4028 A stomach disease that is an inflammation of the lining of the stomach. DOID:4032 DOID:8697 DOID:8845 DOID:9190 ICD10CM:K29.7 MESH:D005756 NCI:C26780 SNOMEDCT_US_2020_03_01:155711008 UMLS_CUI:C0017152 Erosive Gastritis Erosive gastropathy acute gastric mucosal erosion disease_ontology DOID:4029 gastritis DOID:4029 A gastrointestinal system disease that is located_in the mouth. MESH:D009059 NCI:C27641 SNOMEDCT_US_2020_03_01:118938008 UMLS_CUI:C0026636 disease_ontology DOID:403 mouth disease DOID:403 ICD9CM:558.41 NCI:C35330 SNOMEDCT_US_2020_03_01:359804008 UMLS_CUI:C1262481 Eosinophilic Gastroenteritis Eosinophilic gastroenteritis disease_ontology DOID:4031 eosinophilic gastroenteritis DOID:4031 NCI:C27051 SNOMEDCT_US_2020_03_01:235658000 UMLS_CUI:C1283271 disease_ontology DOID:4035 lymphocytic gastritis DOID:4035 An abdominal tuberculosis that results_in infection located_in gastrointestinal tract. The infection has_symptom abdominal pain, has_symptom weight loss, has_symptom fever, has_symptom anorexia, has_symptom change in bowel habits, has_symptom nausea, and has_symptom vomiting. DOID:9802 MESH:D014385 SNOMEDCT_US_2020_03_01:154286002 UMLS_CUI:C0041312 Tuberculosis of gastrointestinal tract Tuberculosis of intestines, peritoneum and mesenteric glands Tuberculosis of intestines, peritoneum, and mesenteric glands tuberculosis of intestines, peritoneum and mesenteric glands disease_ontology DOID:404 gastrointestinal tuberculosis DOID:404 NCI:C6516 UMLS_CUI:C1334619 malignant tumor of Skeletal Muscle disease_ontology DOID:4043 skeletal muscle cancer DOID:4043 NCI:C6514 SNOMEDCT_US_2020_03_01:699955004 UMLS_CUI:C1335971 tumor of Skeletal Muscle disease_ontology DOID:4044 skeletal muscle neoplasm DOID:4044 A musculoskeletal system cancer that is located_in muscle. DOID:4046 ICD10CM:C49 MESH:D009217 MESH:D019042 NCI:C4883 SNOMEDCT_US_2020_03_01:20667008 SNOMEDCT_US_2020_03_01:93913006 UMLS_CUI:C0027095 UMLS_CUI:C0684743 malignant neoplasm of muscle malignant tumor of muscle malignant tumor of the Muscle myosarcoma disease_ontology DOID:4045 muscle cancer DOID:4045 DOID:4382 GARD:4701 MESH:D018232 NCI:C3749 NCI:C7958 OMIM:268220 SNOMEDCT_US_2020_03_01:404053004 UMLS_CUI:C0206655 UMLS_CUI:C0279613 Alveolar rhabdomyosarcoma alveolar childhood rhabdomyosarcoma disease_ontology DOID:4051 OMIM mapping confirmed by DO. [SN]. alveolar rhabdomyosarcoma DOID:4051 A prostate cancer that is located_in the prostate. NCI:C7731 UMLS_CUI:C0238393 sarcoma of the prostate disease_ontology DOID:4054 prostate sarcoma DOID:4054 NCI:C4716 SNOMEDCT_US_2020_03_01:128750008 UMLS_CUI:C0431111 Rhabdomyosarcoma with ganglionic differentiation disease_ontology DOID:4055 ectomesenchymoma DOID:4055 MESH:D004383 SNOMEDCT_US_2020_03_01:9733003 UMLS_CUI:C0013299 Duodenogastric reflux disease_ontology DOID:4071 duodenogastric reflux DOID:4071 MESH:D004378 SNOMEDCT_US_2020_03_01:196598004 UMLS_CUI:C0013289 duodenal disease duodenum disorder disease_ontology DOID:4072 duodenum disease DOID:4072 NCI:C3874 SNOMEDCT_US_2020_03_01:235966007 UMLS_CUI:C0238337 cystadenocarcinoma of pancreas disease_ontology DOID:4073 pancreatic cystadenocarcinoma DOID:4073 A pancreatic carcinoma that derives_from epithelial cells of glandular origin. NCI:C8294 SNOMEDCT_US_2020_03_01:700423003 UMLS_CUI:C0281361 pancreas adenocarcinoma disease_ontology adenocarcinoma of the pancreas DOID:4074 pancreatic adenocarcinoma DOID:4074 A tricuspid valve disease that is characterized by the narrowing of the orifice of the tricuspid valve of the heart. This causes increased resistance to blood flow through the valve. MESH:D014264 NCI:C50783 SNOMEDCT_US_2020_03_01:49915006 UMLS_CUI:C0040963 Tricuspid stenosis disease_ontology DOID:4078 tricuspid valve stenosis DOID:4078 A heart disease involving one or more of the four valves of the heart (the aortic and mitral valves on the left and the pulmonary and tricuspid valves on the right). DOID:989 MESH:D006349 MESH:D016127 NCI:C45525 SNOMEDCT_US_2020_03_01:368009 SNOMEDCT_US_2020_03_01:398995000 UMLS_CUI:C0018824 UMLS_CUI:C0079485 Valvular heart disease disease_ontology DOID:4079 heart valve disease DOID:4079 A tricuspid valve disease that is characterized by failure of the heart's tricuspid valve to close properly during systole. As a result, with each heart beat, blood is pumped out from the right side of the heart in the opposite direction to normal. MESH:D014262 NCI:C50842 SNOMEDCT_US_2020_03_01:111287006 UMLS_CUI:C0040961 Tricuspid incompetence Tricuspid regurgitation Tricuspid valve regurgitation disease_ontology DOID:4080 tricuspid valve insufficiency DOID:4080 A germ cell and embryonal cancer that derives_from trophoblastic tissue. MESH:D014328 NCI:C3422 SNOMEDCT_US_2020_03_01:115234004 UMLS_CUI:C0041182 Trophoblastic neoplasm Trophoblastic tumor disease_ontology DOID:4085 trophoblastic neoplasm DOID:4085 DOID:2164 DOID:2165 DOID:46 ICD10CM:K76.9 ICD9CM:573.9 MESH:D008107 NCI:C3196 SNOMEDCT_US_2020_03_01:62857009 UMLS_CUI:C0023895 disorder of liver hepatic disorder disease_ontology DOID:409 liver disease DOID:409 A communication disorder that is a loss of ability to recognize objects, persons, sounds, shapes, or smells while the specific sense is not defective nor is there any significant memory loss. DOID:4019 GARD:8 ICD10CM:R48.1 MESH:D000377 NCI:C84542 SNOMEDCT_US_2020_03_01:42341009 UMLS_CUI:C0001816 Dyspraxia Dyspraxia syndrome disease_ontology DOID:4090 agnosia MESH:D000377 DOID:4090 A parasitic ectoparasitic infectious disease that involves parasitic infestation of blood feeding ticks of the families Ixodidae and Argasidae on animals and humans. Ticks are vectors of a number diseases, including Lyme disease, Q fever, Colorado tick fever, tularemia, tick-borne relapsing fever, babesiosis, ehrlichiosis and tick-borne meningoencephalitis, as well as anaplasmosis in cattle and canine jaundice. MESH:D013984 UMLS_CUI:C0040196 disease_ontology DOID:4109 tick infestation DOID:4109 A parasitic infectious disease that is caused by organisms that live primarily on the surface of the host. MESH:D004478 UMLS_CUI:C0013578 ectoparasitism disease_ontology DOID:4110 parasitic ectoparasitic infectious disease DOID:4110 An integumentary system disease that is located_in nail. ICD10CM:L60 ICD9CM:703 MESH:D009260 SNOMEDCT_US_2020_03_01:17790008 UMLS_CUI:C0027339 disease_ontology DOID:4123 nail disease DOID:4123 MESH:D003137 UMLS_CUI:C0009440 disease_ontology DOID:4137 common bile duct disease DOID:4137 MESH:D001649 NCI:C96716 SNOMEDCT_US_2020_03_01:118926004 UMLS_CUI:C0005395 bile duct disorder disorder of bile duct disease_ontology DOID:4138 bile duct disease DOID:4138 A gallbladder disease characterized by altered tonus of the sphincter of Oddi, disturbance in the coordination of contraction of the biliary ducts, and/or reduction in the speed of emptying of the biliary tree. DOID:4139 MESH:D001657 SNOMEDCT_US_2020_03_01:43469007 UMLS_CUI:C0005416 sphincter of oddi dysfunction disease_ontology DOID:4140 biliary dyskinesia DOID:4140 A bone cancer that is located_in the area behind the eye and derives_from the orbit or secondarily derives_from an adjacent source (eyelid, paranasal sinus, or intracranial compartment). It results_in the eye pushing forward causing a bulging of the eye called proptosis. DOID:9984 ICD10CM:C69.6 ICD9CM:190.1 MESH:D009918 NCI:C3290 NCI:C3562 SNOMEDCT_US_2020_03_01:127003006 SNOMEDCT_US_2020_03_01:363462005 UMLS_CUI:C0029185 UMLS_CUI:C0153626 malignant neoplasm of orbit neoplasm of orbit proper orbit cancer orbital tumor disease_ontology DOID:4143 orbital cancer DOID:4143 GARD:6258 ICD10CM:K00.5 MESH:D003811 NCI:C84667 OMIM:125490 OMIM:125500 ORDO:49042 SNOMEDCT_US_2020_03_01:367461002 UMLS_CUI:C0011436 disease_ontology DOID:4154 OMIM mapping confirmed by DO. [SN]. dentinogenesis imperfecta DOID:4154 A syphilis that is the first stage of syphilis, marked by the development of a chancre, which is characterized by mononuclear leukocytic infiltration, macrophages, and lymphocytes. ICD9CM:091 SNOMEDCT_US_2020_03_01:186846005 UMLS_CUI:C0153139 Symptomatic early syphilis early symptomatic syphilis early syphilis, symptomatic disease_ontology DOID:4156 primary syphilis DOID:4156 An integumentary system cancer located_in the skin that is the uncontrolled growth of abnormal skin cells. GARD:10421 MESH:D012878 NCI:C2920 SNOMEDCT_US_2020_03_01:94047004 UMLS_CUI:C0007114 CA - skin cancer malignant neoplasm of skin melanoma and Non-melanoma skin cancer disease_ontology cancer of skin DOID:4159 skin cancer DOID:4159 NCI:C42048 UMLS_CUI:C1511934 disease_ontology DOID:4160 differentiating neuroblastoma DOID:4160 MESH:D018305 NCI:C3790 SNOMEDCT_US_2020_03_01:116381000119105 UMLS_CUI:C0206718 Ganglioneuroblastoma disease_ontology DOID:4163 ganglioneuroblastoma DOID:4163 A primary bacterial infectious disease that is a sexually transmitted systemic disease, has_material_basis_in Treponema pallidum subsp pallidum, which is transmitted_by sexual contact, transmitted_by blood product transfusion, transmitted_by congenital method from mother to fetus or transmitted_by contact with infectious lesions. If left untreated, produces chancres, rashes, and systemic lesions in a clinical course with three stages continued over many years. DOID:11095 ICD10CM:A51.0 MESH:D002601 SNOMEDCT_US_2020_03_01:736686006 UMLS_CUI:C0007939 syphilitic chancre disease_ontology DOID:4166 syphilis DOID:4166 An immune system disease that is an overactive immune response of the body against substances and tissues normally present in the body resulting from an abnormal functioning of the immune system that results in the production of antibodies or T cell directed against the host tissues. autoimmune disease ICD9CM:720 OMIM:109100 UMLS_CUI:C0003089 autoimmune hypersensitivity disease hypersensitivity reaction type II disease disease_ontology DOID:417 Xref MGI. autoimmune disease DOID:417 MESH:D012203 NCI:C113150 SNOMEDCT_US_2020_03_01:199580004 UMLS_CUI:C0035404 Rh incompatibility affecting management of mother disease_ontology DOID:4175 Rh isoimmunization DOID:4175 MESH:D001787 UMLS_CUI:C0005806 disease_ontology DOID:4176 blood group incompatibility DOID:4176 A scleroderma that is characterized by fibrosis (or hardening) of the skin and major organs, as well as vascular alterations, and autoantibodies. EFO:0000717 GARD:9748 ICD10CM:M34.0 ICD9CM:710.1 MESH:D012595 NCI:C72070 OMIM:181750 SNOMEDCT_US_2020_03_01:89155008 UMLS_CUI:C0036421 Scleroderma Scleroderma syndrome progressive systemic sclerosis systemic sclerosis disease_ontology DOID:418 systemic scleroderma DOID:418 GARD:7860 MESH:D011556 NCI:C129722 OMIM:612463 SNOMEDCT_US_2020_03_01:190867002 UMLS_CUI:C0033835 Normocalcemic pseudohypoparathyroidism Pseudopseudohypoparathyroidism disease_ontology DOID:4183 OMIM mapping confirmed by DO. [SN]. pseudopseudohypoparathyroidism DOID:4183 GARD:10758 ICD10CM:E20.1 MESH:D011547 NCI:C99027 OMIM:612462 SNOMEDCT_US_2020_03_01:190867002 UMLS_CUI:C0033806 disease_ontology DOID:4184 OMIM mapping confirmed by DO. [SN]. pseudohypoparathyroidism MESH:D011547 DOID:4184 A speech disorder that involves mispronouncing speech sounds by omitting, distorting, substituting, or adding sounds which can make speech difficult to understand. MESH:D001184 SNOMEDCT_US_2020_03_01:8187005 UMLS_CUI:C0003910 Articulation impairment Phonological disorder disease_ontology DOID:4186 articulation disorder DOID:4186 A speech disorder that involves a complete inability to speak. MESH:D009155 SNOMEDCT_US_2020_03_01:267771000 UMLS_CUI:C0026884 disease_ontology DOID:4189 mutism DOID:4189 A rheumatic disease that involves the abnormal growth of connective tissue, which supports the skin and internal organs. MESH:D012594 NCI:C26746 SNOMEDCT_US_2020_03_01:201440007 UMLS_CUI:C0011644 dermatosclerosis disease_ontology DOID:419 scleroderma DOID:419 DOID:12751 ICD9CM:434.0 MESH:D020767 SNOMEDCT_US_2020_03_01:155401002 UMLS_CUI:C0079102 UMLS_CUI:C0752143 cerebral thrombosis disease_ontology DOID:4193 intracranial thrombosis DOID:4193 MESH:D044882 NCI:C53655 SNOMEDCT_US_2020_03_01:126877002 UMLS_CUI:C1257958 disorder of glucose metabolism disease_ontology DOID:4194 glucose metabolism disease DOID:4194 ICD10CM:R73.9 MESH:D006943 NCI:C26797 SNOMEDCT_US_2020_03_01:144187006 UMLS_CUI:C0020456 disease_ontology DOID:4195 hyperglycemia DOID:4195 A hair disease characterized by hair growth that is abnormal in quantity or location. ICD10CM:L68 MESH:D006983 NCI:C79597 ORDO:79365 SNOMEDCT_US_2020_03_01:201164001 UMLS_CUI:C0020555 disease_ontology DOID:420 hypertrichosis DOID:420 MESH:D020427 NCI:C27596 UMLS_CUI:C0747533 Peroneal Neuropathy disease_ontology DOID:4201 peroneal neuropathy DOID:4201 A brain stem cancer that is characterized by mass lesion of the brainstem, associated cranial nerve nuclei and long tracts, has_material_basis_in abnormally proliferating cells, derives_from glial cells. NCI:C8501 SNOMEDCT_US_2020_03_01:444545003 UMLS_CUI:C0677865 Brainstem Neuroglial tumor disease_ontology DOID:4202 brain stem glioma DOID:4202 DOID:13974 DOID:4204 DOID:4208 GARD:8244 ICD10CM:C71.7 ICD9CM:191.7 MESH:D020295 NCI:C3570 NCI:C4869 NCI:C4975 NCI:C5967 SNOMEDCT_US_2020_03_01:126961004 SNOMEDCT_US_2020_03_01:93726004 UMLS_CUI:C0153641 UMLS_CUI:C0677866 UMLS_CUI:C0751886 UMLS_CUI:C1332192 malignant neoplasm of brain stem malignant neoplasm of brainstem neoplasm of adult brain stem neoplasm of brain stem primary brain Stem tumor primary brain stem neoplasm disease_ontology DOID:4203 brain stem cancer DOID:4203 DOID:12786 ICD10CM:C71.6 ICD9CM:191.6 MESH:D002528 NCI:C2935 NCI:C3569 SNOMEDCT_US_2020_03_01:126960003 SNOMEDCT_US_2020_03_01:449420002 UMLS_CUI:C0007762 UMLS_CUI:C0153640 cerebellar cancer malignant tumor of Cerebellum disease_ontology DOID:4205 cerebellum cancer DOID:4205 An integumentary system disease that is located_in hair. MESH:D006201 NCI:C34656 SNOMEDCT_US_2020_03_01:267862002 UMLS_CUI:C0018500 disease_ontology DOID:421 hair disease DOID:421 A malignant ovarian surface epithelial-stromal neoplasm that has_material_basis_in the surface epithelium of the ovary. MESH:D001948 NCI:C4270 SNOMEDCT_US_2020_03_01:42194009 UMLS_CUI:C0334495 disease_ontology DOID:4217 malignant ovarian Brenner tumor DOID:4217 MESH:D020914 NCI:C84648 UMLS_CUI:C0752282 disease_ontology DOID:422 congenital structural myopathy DOID:422 A dermatitis that is characterized by a pyogenic infection causing the formation of pus. ICD10CM:L08.0 ICD9CM:686.0 MESH:D011711 SNOMEDCT_US_2020_03_01:267838007 UMLS_CUI:C0034212 disease_ontology DOID:4223 pyoderma DOID:4223 An endometrial stromal tumor that has_material_basis in connective tissue. GARD:6339 MESH:D018203 NCI:C8973 SNOMEDCT_US_2020_03_01:70555003 UMLS_CUI:C0206630 ESS Undifferentiated endometrial sarcoma endometrial stromal sarcoma, high grade disease_ontology DOID:4226 endometrial stromal sarcoma DOID:4226 A muscular disease in which the muscle fibers do not function resulting in muscular weakness. ICD10CM:G72.9 ICD9CM:359.9 MESH:D009135 NCI:C101216 SNOMEDCT_US_2020_03_01:155094005 UMLS_CUI:C0026848 disease_ontology DOID:423 myopathy DOID:423 NCI:C6511 UMLS_CUI:C1334620 malignant tumor of Smooth Muscle disease_ontology DOID:4230 smooth muscle cancer DOID:4230 MESH:D051642 NCI:C35765 SNOMEDCT_US_2020_03_01:154614002 UMLS_CUI:C1509147 disease_ontology DOID:4231 histiocytoma DOID:4231 A Ewing sarcoma that is morphologically indistinguishable from skeletal Ewing sarcoma but is located in extraosseous locations. NCI:C27293 ORDO:370334 UMLS_CUI:C1333514 extraosseous Ewing's sarcoma extraosseous Ewing's sarcoma/peripheral primitive neuroectodermal tumor extraskeletal Ewing sarcom disease_ontology DOID:4232 extraosseous Ewing sarcoma DOID:4232 A sarcoma that is characterized by solid nests and fascicles of tumor cells with clear cytoplasm and prominent nucleoli. It presents as a slow growing mass that especially affects tendons and aponeuroses and it is deeply situated. DOID:4881 MESH:D018227 NCI:C27370 NCI:C3745 SNOMEDCT_US_2020_03_01:12622007 UMLS_CUI:C0206651 UMLS_CUI:C1332198 Clear cell sarcoma Clear cell sarcoma of soft Parts adult soft part clear cell sarcoma malignant melanoma of soft tissues melanoma, malignant, of soft parts disease_ontology malignant melanoma of soft parts DOID:4233 clear cell sarcoma DOID:4233 A sarcoma that results_in cells that are spindle-shaped. They are usually resistant to radiation therapy. MESH:D012509 NCI:C27005 SNOMEDCT_US_2020_03_01:9801004 UMLS_CUI:C0205945 disease_ontology DOID:4235 spindle cell sarcoma DOID:4235 A mixed cell type cancer that has_material_basis_in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components. DOID:1971 DOID:2610 DOID:4234 MESH:D002296 MESH:D018199 MESH:D018200 NCI:C34448 NCI:C3730 NCI:C8975 SNOMEDCT_US_2020_03_01:112684005 SNOMEDCT_US_2020_03_01:63264007 SNOMEDCT_US_2020_03_01:84427001 UMLS_CUI:C0007140 UMLS_CUI:C0206627 UMLS_CUI:C1334603 MMMT Mesodermal mixed tumor malignant mixed Mullerian tumor malignant mixed mesodermal (mullerian) tumor mesodermal mixed tumor mixed Mesodermal (mullerian) tumor mullerian mixed tumor disease_ontology DOID:4236 carcinosarcoma DOID:4236 A soft tissue cancer that is a slow growing tumor of an unknown origin that effects children and effects young adults. DOID:5315 DOID:5318 GARD:5654 MESH:D018234 NCI:C3750 NCI:C7943 NCI:C8092 OMIM:606243 ORDO:163699 SNOMEDCT_US_2020_03_01:88195001 UMLS_CUI:C0206657 UMLS_CUI:C0279544 UMLS_CUI:C0279985 Alveolar Soft Part sarcoma disease_ontology DOID:4239 OMIM mapping confirmed by DO. [SN]. alveolar soft part sarcoma DOID:4239 A lung disease that is characterized by pulmonary collapse, accompanied by hypoventilation which can affect a lobe, segment, or all of the lung, resulting in a decrease in the ventilation/perfusion ratio. ICD10CM:P28.0 ICD9CM:770.4 SNOMEDCT_US_2020_03_01:42908004 UMLS_CUI:C0270163 primary atelectasis of newborn primary atelectasis, in perinatal period disease_ontology DOID:424 pulmonary immaturity DOID:424 A kidney cancer that is located in the kidney's connective tissue. NCI:C4525 SNOMEDCT_US_2020_03_01:254918001 UMLS_CUI:C0346251 renal sarcoma sarcoma of kidney disease_ontology DOID:4242 kidney sarcoma DOID:4242 MESH:D023903 UMLS_CUI:C0948480 disease_ontology DOID:4247 coronary restenosis DOID:4247 MESH:D023921 NCI:C80427 SNOMEDCT_US_2020_03_01:233970002 UMLS_CUI:C0242231 Coronary artery stenosis disease_ontology DOID:4248 coronary stenosis DOID:4248 A prion disease characterized by adult onset of memory loss, dementia, ataxia, and pathologic deposition of amyloid-like plaques in the brain. GARD:7690 ICD10CM:A81.82 ICD9CM:046.71 MESH:D016098 NCI:C84727 OMIM:137440 SNOMEDCT_US_2020_03_01:67155006 UMLS_CUI:C0017495 Gerstmann-Straussler-Scheinker disease PRION DEMENTIA disease_ontology DOID:4249 OMIM mapping confirmed by DO. [SN]. Gerstmann-Straussler-Scheinker syndrome DOID:4249 ICD10CM:H11.82 ICD9CM:372.81 SNOMEDCT_US_2020_03_01:408663001 UMLS_CUI:C0878693 disease_ontology DOID:4250 conjunctivochalasis DOID:4250 An eye disease affecting the conjunctiva, which is the mucous membrane surrounding the eye and interior of the eyelids. ICD10CM:H11.9 ICD9CM:372.9 MESH:D003229 NCI:C27605 SNOMEDCT_US_2020_03_01:194583004 UMLS_CUI:C0009759 disease_ontology DOID:4251 conjunctival disease DOID:4251 A leukodystrophy that is characterized by the destruction of white matter and the formation of Rosenthal fibers consisting of abnormal clumps of protein that accumulate in astrocytes. GARD:5774 MESH:D038261 NCI:C84545 OMIM:203450 SNOMEDCT_US_2020_03_01:81854007 UMLS_CUI:C0270726 Alexander's disease disease_ontology DOID:4252 OMIM mapping confirmed by DO. [SN]. Alexander disease MESH:D038261 DOID:4252 An osteosclerosis that has_material_basis_in a mutation of the LEMD3 gene which results_in a hyperdense bony cortex. GARD:9474 MESH:D008557 NCI:C84887 OMIM:155950 SNOMEDCT_US_2020_03_01:240173003 UMLS_CUI:C0025239 disease_ontology DOID:4253 OMIM mapping confirmed by DO. [SN]. melorheostosis MESH:D008557 DOID:4253 A bone remodeling disease that results_in abnormal elevated bone density or mass. ICD10CM:Q78.2 MESH:D010026 NCI:C41236 SNOMEDCT_US_2020_03_01:49347007 UMLS_CUI:C0029464 disease_ontology DOID:4254 osteosclerosis DOID:4254 A bone inflammation disease that causes bone changes, soft tissue swelling and irritability in infants. The disease has been associated with COL1A1 gene. It has symptom soft-tissue swelling, has symptom bone lesions, and has symptom irritability. GARD:1051 ICD10CM:M89.8 MESH:D006958 NCI:C84645 OMIM:114000 SNOMEDCT_US_2020_03_01:24752008 UMLS_CUI:C0020497 cortical congenital hyperostosis infantile cortical hyperostosis disease_ontology DOID:4257 OMIM mapping confirmed by DO. [SN]. Caffey disease DOID:4257 MESH:D020235 SNOMEDCT_US_2020_03_01:30767006 UMLS_CUI:C1510417 disease_ontology DOID:4260 gait apraxia MESH:D020235 DOID:4260 A brain disease characterized by marked reduction of nearly all motor functions including facial expressions, gestures and speech output, but with some degree of alertness. MESH:D000405 SNOMEDCT_US_2020_03_01:53333005 UMLS_CUI:C0001889 Coma vigilans disease_ontology DOID:4267 akinetic mutism MESH:D000405 DOID:4267 A microsporidiosis that is a zoonotic infectious disease results_in disseminated fungal infection in dogs, cats, hamsters, guinea pigs, rats, mice and humans, has_material_basis_in Encephalitozoon cuniculi, has_material_basis_in Encephalitozoon intestinalis or has_material_basis_in Encephalitozoon hellem. MESH:D016890 SNOMEDCT_US_2020_03_01:12825006 UMLS_CUI:C0085412 Infection by Encephalitozoon disease_ontology DOID:4270 encephalitozoonosis DOID:4270 An opportunistic mycosis that results_in systemic fungal infection in immunocompromised people, has_material_basis_in Microsporidia phylum members. GARD:3655 ICD10CM:B60.8 MESH:D016881 NCI:C84891 SNOMEDCT_US_2020_03_01:61842000 UMLS_CUI:C0085407 Infection by Microspora Infection by Microsporea Infection by Microsporida disease_ontology DOID:4271 microsporidiosis DOID:4271 A basal cell carcinoma characterized by elevated, pearl shaped nodules with telengactisae on the surface and periphery. DOID:4296 NCI:C62282 SNOMEDCT_US_2020_03_01:716274007 UMLS_CUI:C1304300 Basal cell carcinoma, nodular Circumscribed solid basal cell carcinoma skin nodulo-ulcerative basal cell carcinoma skin solid (nodular) Basal cell carcinoma disease_ontology DOID:4280 nodular basal cell carcinoma DOID:4280 An external ear cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. NCI:C6081 UMLS_CUI:C1333492 carcinoma of the External ear disease_ontology carcinoma of external ear DOID:4288 external ear carcinoma DOID:4288 A congenital heart disease that is characterized by partial or entire anomalous curved venous drainage of the right lung to the inferior vena cava, association with variable right lung and pulmonary artery hypoplasia, dextraposition of the heart and an anomalous systemic blood supply to the ipsilateral lung. ICD10CM:Q26.8 MESH:D012587 NCI:C85056 OMIM:106700 ORDO:185 SNOMEDCT_US_2020_03_01:39905002 UMLS_CUI:C0036400 Halasz syndrome congenital venolobar syndrome hypogenetic lung syndrome mirror-image lung syndrome pulmonary venolobar syndrome total anomalous pulmonary venous return vena cava bronchovascular syndrome disease_ontology DOID:4297 scimitar syndrome DOID:4297 A benign giant cell tumor that results_in the presence of multinucleated giant cells. MESH:D018212 NCI:C121932 SNOMEDCT_US_2020_03_01:697970009 UMLS_CUI:C0206638 Giant cell neoplasm of bone Giant cell tumor of bone Giant cell tumour of bone bone giant cell tumour disease_ontology giant cell myeloma osteoclastoma DOID:4305 bone giant cell tumor DOID:4305 A peripheral nervous system disease that is characterized by the pinching of a nerve root in the spine and has symptoms of pain, weakness, numbness and tingling. ICD10CM:M54.1 MESH:D011843 SNOMEDCT_US_2020_03_01:394640000 UMLS_CUI:C0700594 pinched nerve disease_ontology DOID:4306 radiculopathy DOID:4306 MESH:D009209 UMLS_CUI:C0027073 disease_ontology DOID:431 myofascial pain syndrome DOID:431 MESH:D018235 NCI:C3751 SNOMEDCT_US_2020_03_01:75109009 UMLS_CUI:C0206658 disease_ontology DOID:4310 smooth muscle tumor DOID:4310 An acquired epidermolysis bullosa that is characterized by formation of recurrent blisters secondary to minor trauma in the skin and mucosa, and has_material_basis_in the development of autoantibodies to type VII collagen. ICD10CM:L12.3 MESH:D016107 NCI:C84690 SNOMEDCT_US_2020_03_01:2772003 UMLS_CUI:C0079293 acquired epidermolysis bullosa disease_ontology DOID:4313 epidermolysis bullosa acquisita DOID:4313 NCI:C27516 SNOMEDCT_US_2020_03_01:733892008 UMLS_CUI:C1333414 disease_ontology DOID:4323 epidermolytic acanthoma DOID:4323 A viral infectious disease that is a hemorrhagic fever, has_material_basis_in Zaire ebolavirus, has_material_basis_in Sudan ebolavirus, has_material_basis_in Cote d'Ivoire ebolavirus, or has_material_basis_in Bundibugyo ebolavirus, which are transmitted_by contact with the body fluids of an infected animal or person, transmitted by contaminated fomites, or transmitted by infected medical equipment. The infection has_symptom fever, has_symptom headache, has_symptom joint pain, has_symptom muscle aches, has_symptom sore throat, has_symptom weakness, has_symptom diarrhea, has_symptom vomiting, has_symptom stomach pain, has_symptom rash, has_symptom red eyes, has_symptom hiccups, and has_symptom internal and external bleeding. GARD:2035 ICD10CM:A98.4 MESH:D019142 NCI:C36171 SNOMEDCT_US_2020_03_01:123323003 UMLS_CUI:C0282687 Ebola virus disease disease_ontology DOID:4325 Ebola hemorrhagic fever DOID:4325 A viral infectious disease that is a hemorrhagic fever, has_material_basis_in Marburgvirus, which is transmitted_by contact with the body fluids of an infected person. The infection has_symptom fever, has_symptom chills, has_symptom headache, has_symptom myalgia, has_symptom maculopapular rash on the trunk, has_symptom nausea, has_symptom vomiting, has_symptom chest pain, has_symptom sore throat, has_symptom abdominal pain, has_symptom diarrhea, and has_symptom bleeding. GARD:9444 ICD10CM:A98.3 MESH:D008379 NCI:C84883 SNOMEDCT_US_2020_03_01:123322008 UMLS_CUI:C0024788 Marburg disease Marburg virus disease disease_ontology DOID:4327 Marburg hemorrhagic fever DOID:4327 GARD:8231 MESH:D015616 SNOMEDCT_US_2020_03_01:127069007 UMLS_CUI:C0019624 disease_ontology DOID:4330 non-Langerhans-cell histiocytosis DOID:4330 A female reproductive system disease that is characterized by epithelium-lined fluid-filled cysts in the adnexa adjacent to the fallopian tube and ovary. ICD10CM:Q50.5 MESH:D010310 SNOMEDCT_US_2020_03_01:204831002 UMLS_CUI:C0030584 Cyst, fimbrial Embryonic fimbrial cyst disease_ontology DOID:4333 parovarian cyst DOID:4333 A tinea capitis that results_in fungal infection located_in scalp, located_in glabrous skin or located_in nail, has_material_basis_in Ascomycota fungi that belong to a group called dermatophytes and results_in_formation_of scutula, yellowish cup-shaped crusts of dense masses of mycelium and epithelial debris, which develop at the surface of a hair follicle with the shaft in the center of the raised lesion. Removal of these crusts reveals an oozing, moist, red base. Later, atrophy of the skin occurs leaving a cicatricial alopecia and scarring. DOID:0050109 ICD10CM:B35 MESH:D014007 NCI:C35072 SNOMEDCT_US_2020_03_01:85375000 UMLS_CUI:C0040254 favus disease_ontology DOID:4336 tinea favosa DOID:4336 A dermatophytosis that results_in contagious fungal infection located_in scalp, located_in hair of head, located_in eyebrow or located_in eyelash, has_material_basis_in Ascomycota fungi that belong to a group called dermatophytes and has_symptom itching of the scalp, has_symptom pus filled lesions on the scalp, and has_symptom patches of hair loss, sometimes with a 'black dot' pattern. DOID:0050114 DOID:12319 ICD9CM:110.0 NCI:C34536 SNOMEDCT_US_2020_03_01:186985002 UMLS_CUI:C0011640 Scalp ringworm Trichophyton rubrum tinea capitis dermatophytosis of scalp or beard tinea capitis due to Trichophyton rubrum disease_ontology Dermatophytosis of scalp DOID:4337 tinea capitis DOID:4337 GARD:7848 MESH:D046350 NCI:C85219 OMIM:176200 SNOMEDCT_US_2020_03_01:58275005 UMLS_CUI:C0162532 Protocoproporphyria Protoporphyrinogen oxidase deficiency Variegate porphyria disease_ontology DOID:4346 variegate porphyria DOID:4346 MESH:D008210 NCI:C78442 SNOMEDCT_US_2020_03_01:234109007 UMLS_CUI:C0024248 Lymph cyst disease_ontology DOID:4347 lymphocele DOID:4347 A female reproductive organ cancer that is located_in the cervix. DOID:4361 ICD10CM:C53 ICD9CM:180 MESH:D002583 NCI:C2940 NCI:C9311 OMIM:603956 SNOMEDCT_US_2020_03_01:123841004 SNOMEDCT_US_2020_03_01:254885005 UMLS_CUI:C0007847 UMLS_CUI:C0007873 cervical neoplasm cervix cancer cervix uteri cancer neoplasm of uterine cervix tumor of the Cervix Uteri uterine cervical neoplasm disease_ontology DOID:4362 cervical cancer DOID:4362 A steroid inherited metabolic disorder characterized by decreased conversion of biologically active cortisol to inactive cortisone resulting in low aldosterone levels, metabolic alkalosis, hypernatremia, hypokalemia and early-onset severe hypertension that has_material_basis_in homozygous or compound heterozygous mutation in the HSD11B2 gene on chromosome 16. DOID:0090121 GARD:433 MESH:D043204 NCI:C123231 OMIM:218030 ORDO:320 SNOMEDCT_US_2020_03_01:237770005 UMLS_CUI:C0342488 11-beta-hydroxysteroid dehydrogenase deficiency type 2 Ulick syndrome cortisol 11-beta-ketoreductase deficiency syndrome of apparent mineralocorticoid excess disease_ontology DOID:4367 apparent mineralocorticoid excess syndrome DOID:4367 An autoimmune disease of the nervous system that has_material_basis_in antibodies to acetylcholine receptors at the neuromuscular junction, has_symptom ptosis, has_symptom diplopia, has_symptom dysphagia, has_symptom dysarthria, has_symptom muscle weakness and has_symptom shortness of breath. DOID:443 DOID:444 GARD:7122 ICD10CM:G70.0 ICD10CM:G70.00 ICD9CM:358.0 ICD9CM:358.00 MESH:D009157 NCI:C60989 OMIM:254200 SNOMEDCT_US_2020_03_01:155092009 UMLS_CUI:C0026896 UMLS_CUI:C1260409 disease_ontology DOID:437 OMIM mapping confirmed by DO. [SN]. myasthenia gravis DOID:437 A hypersensitivity reaction type IV disease that is characterized by chronic urticarial rash and monoclonal IgM gammopathy, has_symptom rash, intermittent fever, arthralgia, and lymphadenopathy. GARD:12390 MESH:D019873 SNOMEDCT_US_2020_03_01:402415001 UMLS_CUI:C0524988 disease_ontology DOID:4371 Schnitzler syndrome DOID:4371 DOID:1957 DOID:1958 ICD10CM:I66 ICD9CM:434.1 MESH:D020766 SNOMEDCT_US_2020_03_01:75543006 UMLS_CUI:C0007780 UMLS_CUI:C0752140 Cerebral embolism with cerebral infarction cerebral embolism disease_ontology DOID:4372 intracranial embolism DOID:4372 A food allergy that is an allergy or hypersensitivity to dietary substances from the yolk or whites of eggs, causing an overreaction of the immune system which may lead to severe physical symptoms. MESH:D021181 SNOMEDCT_US_2020_03_01:91930004 UMLS_CUI:C0559469 Allergy to eggs disease_ontology DOID:4377 egg allergy DOID:4377 A legume allergy that is an allergy or hypersensitivity to dietary substances from peanuts causing an overreaction of the immune system which in a small percentage of people may lead to severe physical symptoms. MESH:D021183 SNOMEDCT_US_2020_03_01:91935009 UMLS_CUI:C0559470 allergy to peanuts peanut allergic reaction disease_ontology DOID:4378 peanut allergy DOID:4378 An autoimmune disease affecting the nervous system. MESH:D020274 NCI:C99383 UMLS_CUI:C0751871 disease_ontology autoimmune nervous system disorder DOID:438 autoimmune disease of the nervous system DOID:438 MESH:D047708 SNOMEDCT_US_2020_03_01:128917003 UMLS_CUI:C1266121 Lipoleiomyoma Myofibroma disease_ontology DOID:4386 myofibroma DOID:4386 A neuromuscular disease that is characterized by the disfunction of conduction through the neuromuscular junction. MESH:D020511 SNOMEDCT_US_2020_03_01:128213006 UMLS_CUI:C0751950 disease_ontology DOID:439 neuromuscular junction disease DOID:439 ICD10CM:L40.3 MESH:D011565 NCI:C34888 SNOMEDCT_US_2020_03_01:238610005 UMLS_CUI:C0030246 Acropustulosis Palmoplantar Pustulosis Pustular psoriasis of the palms and/or soles disease_ontology DOID:4398 pustulosis of palm and sole DOID:4398 NCI:C35277 UMLS_CUI:C0234894 disease_ontology DOID:4399 acneiform dermatitis DOID:4399 A neuropathy that affect the nerves that control the voluntary muscles. ICD10CM:G70.9 ICD9CM:358 MESH:D009468 SNOMEDCT_US_2020_03_01:1664005 UMLS_CUI:C0027868 disease_ontology DOID:440 neuromuscular disease DOID:440 MESH:D005499 NCI:C94408 SNOMEDCT_US_2020_03_01:156411003 UMLS_CUI:C0016436 disease_ontology DOID:4409 folliculitis DOID:4409 A viral infectious disease that results_in inflammation located_in liver, has_material_basis_in Hepatitis E virus, which is transmitted_by ingestion of contaminated food. The infection has_symptom fever, has_symptom fatigue, has_symptom loss of appetite, has_symptom nausea, has_symptom vomiting, has_symptom abdominal pain, has_symptom clay-colored bowel movements, has_symptom dark urine, has_symptom joint pain, and has_symptom jaundice. DOID:12431 GARD:9541 MESH:D016751 SNOMEDCT_US_2020_03_01:7111000119109 UMLS_CUI:C0085293 disease_ontology DOID:4411 hepatitis E DOID:4411 MESH:D018219 NCI:C3739 SNOMEDCT_US_2020_03_01:25889007 UMLS_CUI:C0206644 Fibroxanthoma benign fibrous histiocytoma fibrous Histiocytoma disease_ontology DOID:4415 fibrous histiocytoma DOID:4415 DOID:4417 GARD:9807 MESH:D018219 NCI:C6801 NCI:C8402 SNOMEDCT_US_2020_03_01:254749001 SNOMEDCT_US_2020_03_01:403999006 UMLS_CUI:C0002991 UMLS_CUI:C0346049 Dermatofibroma Fibrohistiocytic tumor Pleomorphic fibroma Sclerosing angioma Sclerosing angioma of skin benign Cutaneous fibrous Histiocytoma dermatofibroma fibrohistiocytic tumor fibrous histiocytoma of skin fibrous xanthoma of skin disease_ontology DOID:4418 cutaneous fibrous histiocytoma DOID:4418 A sphingolipidosis characterized by dysfunctional metabolism of sphingolipids. MESH:D012618 NCI:C85062 OMIM:269600 SNOMEDCT_US_2020_03_01:37821003 UMLS_CUI:C0036489 Sea-blue histiocyte syndrome disease_ontology DOID:4423 OMIM mapping confirmed by DO. [SN]. sea-blue histiocytosis DOID:4423 MESH:D014972 NCI:C3451 SNOMEDCT_US_2020_03_01:71709009 UMLS_CUI:C0043324 Multiple eruptive juvenile xanthogranuloma Naevoxanthoendothelioma Xanthoma neviforme disease_ontology DOID:4424 juvenile xanthogranuloma DOID:4424 A reading disorder resulting from a developmental reading disability involving the inability to process graphic symbols resulting in impairment of reading ability. ICD10CM:F81.0 MESH:D004410 NCI:C96410 OMIM:300509 OMIM:600202 OMIM:604254 OMIM:606616 OMIM:606896 OMIM:608995 SNOMEDCT_US_2020_03_01:154954003 UMLS_CUI:C0476254 disease_ontology DOID:4428 Xref MGI. dyslexia DOID:4428 GARD:4900 MESH:D013005 NCI:C3379 SNOMEDCT_US_2020_03_01:128642005 UMLS_CUI:C0037661 Somatostatin cell neoplasm Somatostatin cell tumour disease_ontology DOID:4430 somatostatinoma DOID:4430 NCI:C5272 UMLS_CUI:C1335976 meningioma of the Skull Base disease_ontology DOID:4437 skull base meningioma DOID:4437 A central nervous system cancer that is characterized by tumors near the pineal gland, the pituitary gland and the tissue just above it, develops from mismigrational pluripotent embryonic cells that remain in the brain after birth, has_material_basis_in abnormally proliferating cells derives_from germ cells. NCI:C5461 UMLS_CUI:C1332880 central nervous system germ cell tumour germ cell tumor of the CNS germ cell tumour of the CNS disease_ontology DOID:4439 central nervous system germ cell tumor DOID:4439 A germinoma that has_material_basis_in cells that make sperm and eggs. MESH:D018239 NCI:C9309 SNOMEDCT_US_2020_03_01:443675005 UMLS_CUI:C0036631 Seminoma, Pure disease_ontology DOID:4440 OMIM mapping confirmed by DO. [LS]. seminoma DOID:4440 A germ cell cancer that derives_from cells that give rise to egg cells. MESH:D004407 NCI:C2996 SNOMEDCT_US_2020_03_01:60718004 UMLS_CUI:C0013377 disease_ontology DOID:4441 dysgerminoma DOID:4441 MESH:D008269 NCI:C34794 OMIM:153880 SNOMEDCT_US_2020_03_01:193387007 UMLS_CUI:C0024440 disease_ontology DOID:4447 OMIM mapping confirmed by DO. [SN]. cystoid macular edema DOID:4447 A retinal degeneration characterized by gradual deterioration of light-sensing cells in the tissues at the back of the eye and has_symptom vision loss. MESH:D008268 NCI:C123330 ORDO:279 SNOMEDCT_US_2020_03_01:302891003 UMLS_CUI:C0024437 Macular degeneration of retina disease_ontology DOID:4448 Xref MGI. macular degeneration DOID:4448 MESH:D008269 NCI:C35468 SNOMEDCT_US_2020_03_01:37231002 UMLS_CUI:C0271051 macular edema macular oedema macular retinal oedema disease_ontology DOID:4449 macular retinal edema DOID:4449 GARD:5893 ICD10CM:E26.81 ICD9CM:255.13 MESH:D001477 NCI:C34412 OMIM:PS601678 SNOMEDCT_US_2020_03_01:707742001 UMLS_CUI:C0004775 Aldosteronism with hyperplasia of the adrenal cortex Bartter's syndrome disease_ontology DOID:445 Bartter disease DOID:445 A renal carcinoma that has_material_basis_in the lining of the proximal convoluted renal tubule of the kidney. EFO:0000681 GARD:13215 MESH:D002292 NCI:C9385 OMIM:300854 ORDO:217071 SNOMEDCT_US_2020_03_01:254915003 UMLS_CUI:C0007134 RCC adenocarcinoma of kidney hypernephroma disease_ontology DOID:4450 Xref MGI. renal cell carcinoma DOID:4450 A kidney cancer that derives_from the lining of the proximal convoluted tubule (the very small tubes in the kidney that filter the blood and remove waste products). NCI:C9384 SNOMEDCT_US_2020_03_01:254915003 UMLS_CUI:C1378703 carcinoma of kidney kidney carcinoma disease_ontology DOID:4451 renal carcinoma DOID:4451 GARD:9571 disease_ontology DOID:4455 hereditary renal cell carcinoma DOID:4455 An adrenal gland hyperfunction disease that results in the overproduction of aldosterone by the adrenal glands. DOID:12252 ICD10CM:E24 ICD10CM:E26 ICD9CM:255.0 ICD9CM:255.1 MESH:D003480 MESH:D006929 NCI:C113213 NCI:C2969 OMIM:605635 OMIM:613677 ORDO:235936 SNOMEDCT_US_2020_03_01:154705004 SNOMEDCT_US_2020_03_01:88213004 UMLS_CUI:C0010481 UMLS_CUI:C0020428 Cushing syndrome Cushing's syndrome hyperaldosteronism disease_ontology DOID:446 Xref MGI. primary hyperaldosteronism DOID:446 NCI:C4524 SNOMEDCT_US_2020_03_01:254916002 UMLS_CUI:C0346249 cystadenocarcinoma of kidney renal cystadenocarcinoma disease_ontology DOID:4463 multilocular clear cell renal cell carcinoma DOID:4463 A renal cell carcinoma that begins in distal collecting ducts of the kidney with a tubulopapillary morphology and intracytoplasmic mucicarminophilic material. GARD:9573 MESH:D002292 NCI:C6194 SNOMEDCT_US_2020_03_01:733470002 UMLS_CUI:C1266044 carcinoma of renal Collecting duct renal Medullary carcinoma renal carcinoma, collecting duct type disease_ontology DOID:4464 collecting duct carcinoma DOID:4464 A renal cell carcinoma that is characterized by the development of multiple, bilateral papillary renal tumors. DOID:8063 GARD:9572 MESH:C538614 MESH:D002292 NCI:C27890 NCI:C6975 OMIM:605074 SNOMEDCT_US_2020_03_01:4797003 UMLS_CUI:C1306837 UMLS_CUI:C1336078 Chromophil carcinoma of kidney Papillary renal cell carcinoma papillary kidney carcinoma sporadic papillary renal cell carcinoma disease_ontology DOID:4465 OMIM mapping confirmed by DO. [SN]. papillary renal cell carcinoma DOID:4465 A renal cell carcinoma that has_material_basis_in cells that appear very pale or clear when examined under microscope. GARD:9574 MESH:D002292 NCI:C4033 SNOMEDCT_US_2020_03_01:254915003 UMLS_CUI:C0279702 Clear cell carcinoma of kidney clear cell kidney carcinoma conventional (Clear cell) renal cell carcinoma conventional renal cell carcinoma renal clear cell carcinoma disease_ontology Clear-cell metastatic renal cell carcinoma Clear-cell metastatic renal cell carcinoma DOID:4467 MESH:C538445 added from NeuroDevNet [WAK]. clear cell renal cell carcinoma DOID:4467 An adenocarcinoma that derives_from epithelial cells which have clear cytoplasm. DOID:2617 DOID:4940 MESH:D008649 MESH:D018262 NCI:C36815 NCI:C4072 NCI:C4156 SNOMEDCT_US_2020_03_01:2221008 SNOMEDCT_US_2020_03_01:30546008 SNOMEDCT_US_2020_03_01:80727009 UMLS_CUI:C0025490 UMLS_CUI:C0206681 UMLS_CUI:C0334322 Clear cell adenocarcinoma Mesonephroid Clear cell carcinoma Mesonephroma Mesonephroma, malignant Water-Clear cell adenocarcinoma Water-clear cell adenocarcinoma Water-clear cell carcinoma Wolffian duct neoplasm malignant Mesonephroma mesonephroma disease_ontology DOID:4468 clear cell adenocarcinoma DOID:4468 MESH:D015499 UMLS_CUI:C0035091 inborn renal tubular transport disorder disease_ontology DOID:447 renal tubular transport disease DOID:447 A renal cell carcinoma that has_material_basis_in chromophobe cell that appear pale when viewed under microscope, but that are larger and display different features than clear cells. GARD:6064 MESH:D002292 NCI:C4146 SNOMEDCT_US_2020_03_01:128667008 UMLS_CUI:C1266042 Chromophobe carcinoma of kidney chromophobe adenocarcinoma kidney chromophobe renal cell carcinoma, chromophobe cell disease_ontology DOID:4471 chromophobe renal cell carcinoma DOID:4471 MESH:D011546 NCI:C85034 SNOMEDCT_US_2020_03_01:77098009 UMLS_CUI:C0033805 disease_ontology DOID:4479 pseudohypoaldosteronism DOID:4479 An osteochondrodysplasia that results_in dwarfism which has_material_basis_in abnormal ossification of cartilage in located_in long bone. GARD:8173 ICD10CM:Q77.4 MESH:D000130 NCI:C34345 OMIM:100800 SNOMEDCT_US_2020_03_01:268273004 UMLS_CUI:C0001080 Achondroplastic physique Chondrodystrophia osteosclerosis congenita disease_ontology DOID:4480 OMIM mapping confirmed by DO. [SN]. achondroplasia MESH:D000130 DOID:4480 A rhinitis that is an allergic inflammation and irritation of the nasal airways involving sneezing, runny nose, nasal congestion, itching and tearing of the eyes caused by exposure to an allergen such as pollen, dust, mold, animal dander and droppings of cockroaches or house dust mites. DOID:12089 DOID:14030 DOID:8241 DOID:8242 EFO:0003956 NCI:C34987 OMIM:607154 SNOMEDCT_US_2020_03_01:38103000 UMLS_CUI:C0002103 Non-seasonal allergic rhinitis Perenial allergic rhinitis atopic rhinitis hay fever pollenosis seasonal allergic rhinitis disease_ontology DOID:4481 allergic rhinitis MESH:D065631 DOID:4481 A upper respiratory infectious disease which involves irritation and inflammation of the mucous membrane of the nose due to viruses, bacteria or irritants. The inflammation results in generation of excessive amounts of mucus leading to runny nose, as well as nasal congestion and post-nasal drip. MESH:D012220 NCI:C34986 SNOMEDCT_US_2020_03_01:70076002 UMLS_CUI:C0035455 disease_ontology runny nose DOID:4483 rhinitis DOID:4483 An influenza that results in infection located in respiratory tract of humans, domestic and wild birds, has_material_basis_in Influenza A virus, which is transmitted by contact with infected poultry. Five strains of avian influenza A viruses (H5N1, H7N3, H7N2, H7N7 and H9N2) are known to cause human infections. The infection has_symptom fever, has_symptom cough, has_symptom sore throat, has_symptom muscle aches, has_symptom nausea, has_symptom diarrhea, has_symptom vomiting, has_symptom neurologic changes, has_symptom pneumonia, and has_symptom acute respiratory distress. ICD10CM:J09.X MESH:D005585 SNOMEDCT_US_2020_03_01:55604004 UMLS_CUI:C0016627 avian flu bird flu disease_ontology DOID:4492 avian influenza DOID:4492 A muscular dystrophy that is characterized by progressive muscle wasting and weakness. ICD10CM:G71.1 ICD9CM:359.2 MESH:D020967 NCI:C84913 SNOMEDCT_US_2020_03_01:155096007 UMLS_CUI:C0553604 disease_ontology DOID:450 myotonic disease MESH:D009223 MESH:D020967 DOID:450 NCI:C34939 UMLS_CUI:C1514284 hypopotassemia potassium deficiency disorder disease_ontology DOID:4500 hypokalemia DOID:4500 A syndrome that is characterized by malformations of the face, oral cavity, and digits. ICD10CM:Q87.0 MESH:D009958 SNOMEDCT_US_2020_03_01:52868006 UMLS_CUI:C0029294 oral-facial-digital syndrome disease_ontology DOID:4501 Xref MGI. OMIM mapping confirmed by DO. [SN]. orofaciodigital syndrome DOID:4501 A gastrointestinal system benign neoplasm that is a located_in the salivary glands. MESH:D008949 NCI:C35691 OMIM:181030 SNOMEDCT_US_2020_03_01:8360001 UMLS_CUI:C0026277 Pleomorphic adenoma mixed tumor of the Salivary gland disease_ontology DOID:452 pleomorphic adenoma DOID:452 A salivary gland carcinoma that is characterized by squamous cells, mucus-secreting cells, and intermediate cells. GARD:10671 MESH:D018277 NCI:C3772 SNOMEDCT_US_2020_03_01:4079000 UMLS_CUI:C0206694 MEC Mucoepidermoid carcinoma disease_ontology DOID:4531 mucoepidermoid carcinoma DOID:4531 A syndrome that affects growth, cranial development, hair growth and dental development. GARD:288 MESH:D006210 NCI:C84746 OMIM:234100 ORDO:2108 SNOMEDCT_US_2020_03_01:7903009 UMLS_CUI:C0018522 Francois dyscephalic syndrome Hallerman - Streiff syndrome Hallermann's syndrome disease_ontology DOID:4534 OMIM mapping confirmed by DO. [SN]. Hallermann-Streiff syndrome DOID:4534 A hair disease that is characterized by sparse hair on the scalp resulting from abnormal hair follicle development and has_material_basis in mutations in proteins involved in hair growth, division or proliferation of cells within hair follicles. MESH:D007039 OMIM:PS605389 ORDO:55654 SNOMEDCT_US_2020_03_01:53602002 UMLS_CUI:C0020678 disease_ontology DOID:4535 Xref MGI. hypotrichosis DOID:4535 A writing disorder that involves a deficiency in the ability to write where the writing is distorted or incorrect, spelling difficulty, poor handwriting or trouble putting thoughts on paper. ICD10CM:R48.8 MESH:D000381 SNOMEDCT_US_2020_03_01:27206009 UMLS_CUI:C0001825 disease_ontology DOID:4540 dysgraphia DOID:4540 An amnestic disorder that involves a loss of one's pre-existing memories to conscious recollection. ICD10CM:R41.2 MESH:D000648 NCI:C34372 SNOMEDCT_US_2020_03_01:51921000 UMLS_CUI:C0002624 disease_ontology DOID:4543 retrograde amnesia DOID:4543 MESH:D018211 NCI:C3737 SNOMEDCT_US_2020_03_01:56565002 UMLS_CUI:C0206637 disease_ontology DOID:4545 mesenchymal chondrosarcoma DOID:4545 NCI:C27481 SNOMEDCT_US_2020_03_01:404080006 UMLS_CUI:C1275279 mesenchymal extraosseous chondrosarcoma disease_ontology DOID:4548 extraskeletal mesenchymal chondrosarcoma DOID:4548 A chondrosarcoma that is located_in exclusively soft tissue. disease_ontology DOID:4549 extraosseous chondrosarcoma DOID:4549 MESH:D001005 NCI:C2877 SNOMEDCT_US_2020_03_01:126849006 UMLS_CUI:C0003463 anal neoplasm anal tumors neoplasm of anus disease_ontology DOID:4551 anus benign neoplasm DOID:4551 NCI:C4450 SNOMEDCT_US_2020_03_01:254629004 UMLS_CUI:C0345958 large cell carcinoma of lung large cell lung carcinoma disease_ontology DOID:4556 lung large cell carcinoma DOID:4556 A parasitic helminthiasis infectious disease that involves infection of the intestine with the nematode Ascaris lumbricoides. Larvae migrating through the lungs cause cough, wheezing and hemoptysis. Bowel or biliary obstruction causes cramping abdominal pain, nausea, and vomiting. Peritonitis, enlargement of the liver or spleen, toxicity and pneumonia are observed when larvae get into the portal circulation. ICD10CM:B77 ICD9CM:127.0 MESH:D001196 NCI:C128392 SNOMEDCT_US_2020_03_01:2435008 UMLS_CUI:C0003950 Ascariasis - roundworm disease_ontology Ascaris lumbricoides infection DOID:456 ascariasis DOID:456 MESH:D008579 NCI:C4055 SNOMEDCT_US_2020_03_01:724171006 UMLS_CUI:C0281784 meningioma, benign disease_ontology DOID:4587 benign meningioma DOID:4587 NCI:C4720 SNOMEDCT_US_2020_03_01:19453003 UMLS_CUI:C0431119 Lymphoplasmacyte-Rich meningioma Lymphoplasmocyte-rich meningioma disease_ontology DOID:4591 lymphoplasmacyte-rich meningioma DOID:4591 GARD:1039 ICD10CM:Q80.3 MESH:D017488 NCI:C62569 OMIM:113800 SNOMEDCT_US_2020_03_01:20512000 UMLS_CUI:C0079153 Bullous ichthyosiform erythroderma Epidermolytic palmoplantar hyperkeratosis bullous congenital ichthyosiform erythroderma disease_ontology DOID:4603 OMIM mapping confirmed by DO. [SN]. epidermolytic hyperkeratosis DOID:4603 A biliary tract cancer that is located_in the bile duct. DOID:10019 ICD10CM:C24.0 ICD9CM:156.1 MESH:D001650 NCI:C2898 NCI:C7483 SNOMEDCT_US_2020_03_01:93790004 UMLS_CUI:C0005396 UMLS_CUI:C0153453 Ca extrahepatic bile ducts bile duct tumor malignant neoplasm of the extrahepatic bile duct disease_ontology DOID:4606 bile duct cancer DOID:4606 A hepatobiliary system cancer that results_in malignant growth located_in the gallbladder or located_in the bile duct. DOID:8092 GARD:5924 GARD:9304 ICD10CM:C24.9 ICD9CM:156.9 MESH:D001661 SNOMEDCT_US_2020_03_01:126853008 SNOMEDCT_US_2020_03_01:93688006 UMLS_CUI:C0005426 UMLS_CUI:C0750952 malignant tumour of biliary tract disease_ontology DOID:4607 biliary tract cancer DOID:4607 DOID:2692 MESH:D009379 MESH:D019042 NCI:C4063 SNOMEDCT_US_2020_03_01:115228006 UMLS_CUI:C0027664 UMLS_CUI:C0282606 Myomatous neoplasm Myomatous tumor muscle neoplasm muscle tissue neoplasm neoplasm of muscle disease_ontology DOID:461 muscle benign neoplasm DOID:461 A gastrointestinal system benign neoplasm that is located_in the intestine. MESH:D007414 NCI:C3141 SNOMEDCT_US_2020_03_01:126769007 UMLS_CUI:C0021841 intestinal tumors intestine growth neoplasm of intestinal tract disease_ontology DOID:4610 intestinal benign neoplasm DOID:4610 MESH:D020424 SNOMEDCT_US_2020_03_01:55802003 UMLS_CUI:C0154743 Ulnar neuropathy disease_ontology DOID:4613 ulnar neuropathy DOID:4613 A congenital nervous system abnormality characterized by failed or incomplete separation of the forebrain early in gestation; it is accompanied by a spectrum of characteristic craniofacial anomalies. GARD:6665 ICD10CM:Q04.2 MESH:D016142 NCI:C74988 OMIM:PS236100 ORDO:2162 SNOMEDCT_US_2020_03_01:30915001 UMLS_CUI:C0079541 Holoprosencephaly sequence disease_ontology DOID:4621 Xref MGI. OMIM mapping confirmed by DO. [SN]. holoprosencephaly DOID:4621 A syndrome that is characterized by an asymmetric distribution of cartilagenous tumors, which may lead to skeletal deformities and limb-length discrepancy. This condition primarily affects the long bones and cartilage of the joints of the arms and legs, specifically the area where the shaft and head of a long bone meet. GARD:7251 ICD10CM:Q78.4 MESH:D004687 NCI:C3213 OMIM:166000 ORDO:296 SNOMEDCT_US_2020_03_01:46041001 UMLS_CUI:C0024454 DYSCHONDROPLASIA ENCHONDROMATOSIS, MULTIPLE Enchondromatosis with haemangiomata Kast's syndrome OSTEOCHONDROMATOSIS disease_ontology DOID:4624 OMIM mapping confirmed by DO. [SN]. Ollier disease DOID:4624 GARD:6681 ICD10CM:Q04.3 MESH:D006832 NCI:C98949 SNOMEDCT_US_2020_03_01:30023002 UMLS_CUI:C0020225 disease_ontology DOID:4626 hydranencephaly DOID:4626 MESH:D020240 SNOMEDCT_US_2020_03_01:39746003 UMLS_CUI:C0234523 Classic apraxia Ideomotor dyspraxia Limb-kinetic apraxia Transcortical apraxia disease_ontology DOID:4627 ideomotor apraxia DOID:4627 NCI:C26937 SNOMEDCT_US_2020_03_01:3502005 UMLS_CUI:C0149642 cervical Lymphadenitis cervical lymphadenitis disease_ontology DOID:4637 cervical adenitis DOID:4637 NCI:C27135 SNOMEDCT_US_2020_03_01:48573006 UMLS_CUI:C0392051 Suppurative lymphadenopathy disease_ontology DOID:4639 suppurative lymphadenitis DOID:4639 An epidermolysis bullosa that is characterized by recurrent blistering at the level of the epidermis secondary to minor trauma, which can cause limited wounds, dehydration, electrolyte abnormalities, severe infection, among other issues, and has_material_basis_in mutation in the KRT5, KRT14, or PLEC genes, which encode keratin and plectin proteins that provide resilience in skin. GARD:10752 ICD10CM:Q81.0 MESH:D016110 NCI:C84692 OMIM:601001 OMIM:615425 ORDO:304 SNOMEDCT_US_2020_03_01:205585003 UMLS_CUI:C0079298 Epidermolysis bullosa simplex disease_ontology DOID:4644 epidermolysis bullosa simplex DOID:4644 DOID:770 ICD10CM:C69.2 ICD9CM:190.5 MESH:D019572 NCI:C3216 NCI:C4800 SNOMEDCT_US_2020_03_01:127002001 SNOMEDCT_US_2020_03_01:93987004 UMLS_CUI:C0024622 UMLS_CUI:C0524801 Retinal tumor malignant Retinal neoplasm malignant neoplasm of retina malignant tumor of retina neoplasm of retina disease_ontology DOID:4645 retinal cancer DOID:4645 MESH:D012175 NCI:C8495 UMLS_CUI:C0751483 Hereditary Retinoblastoma disease_ontology DOID:4648 familial retinoblastoma DOID:4648 A retinoblastoma that develops in both eyes. NCI:C8713 UMLS_CUI:C0854914 disease_ontology DOID:4650 bilateral retinoblastoma DOID:4650 ICD10CM:D47.02 MESH:D034721 NCI:C9286 SNOMEDCT_US_2020_03_01:70910003 UMLS_CUI:C0272203 ISM Indolent systemic mastocytosis disease_ontology DOID:4660 indolent systemic mastocytosis DOID:4660 A syndrome that is an adverse physical reaction to low levels of many common chemicals. MESH:D018777 SNOMEDCT_US_2020_03_01:702772003 UMLS_CUI:C0242992 20th century disease chemical AIDS environmental illness idiopathic environmental illness total allergy syndrome disease_ontology DOID:4661 multiple chemical sensitivity DOID:4661 A disorder of sexual developement that is characterized by the inability of the cell to respond to androgens in individuals with a karyotype of 46,XY resulting in female physical traits but male genetic makeup. DOID:4672 GARD:5803 ICD10CM:E34.5 ICD9CM:259.51 NCI:C27226 OMIM:300068 ORDO:754 SNOMEDCT_US_2020_03_01:12313004 UMLS_CUI:C0039585 Androgen resistance syndrome Androgen-Insensitivity Syndrome Feminisation - testicular Goldberg - Maxwell syndrome Goldberg-Maxwell syndrome testicular Feminization syndrome testicular feminization disease_ontology DOID:4674 OMIM mapping confirmed by DO. [SN]. androgen insensitivity syndrome MESH:D013734 DOID:4674 A corneal disease that is characterized by inflammation of the cornea. ICD10CM:H16 ICD9CM:370 MESH:D007634 NCI:C26805 SNOMEDCT_US_2020_03_01:193757003 UMLS_CUI:C0022568 disease_ontology DOID:4677 keratitis DOID:4677 MESH:D006391 NCI:C3699 SNOMEDCT_US_2020_03_01:54249004 UMLS_CUI:C0205789 Intramuscular Angioma Intramuscular hemangioma disease_ontology DOID:468 intramuscular hemangioma DOID:468 A breast carcinoma that represents a mixed group of malignant neoplasms characterized by the histologic presence of two or more cellular types. GARD:10804 NCI:C5164 SNOMEDCT_US_2020_03_01:763479005 UMLS_CUI:C1334708 Metaplastic carcinoma of the breast disease_ontology metaplastic carcinoma of breast DOID:4680 breast metaplastic carcinoma DOID:4680 NCI:C3860 SNOMEDCT_US_2020_03_01:372101000 UMLS_CUI:C0238019 carcinoma of extrahepatic bile duct extrahepatic bile duct cancer disease_ontology DOID:4682 extrahepatic bile duct carcinoma DOID:4682 NCI:C4472 SNOMEDCT_US_2020_03_01:254713002 UMLS_CUI:C0346019 Mucoepidermoid carcinoma of skin Mucoepidermoid skin carcinoma disease_ontology DOID:4683 cutaneous mucoepidermoid carcinoma DOID:4683 A globe disease that is characterized by inflammation of the inside of the eye. MESH:D009877 NCI:C34586 SNOMEDCT_US_2020_03_01:1847009 UMLS_CUI:C0014236 disease_ontology DOID:4692 endophthalmitis DOID:4692 DOID:8371 GARD:12698 MESH:D018317 NCI:C4973 NCI:C6912 SNOMEDCT_US_2020_03_01:128795001 UMLS_CUI:C0751691 UMLS_CUI:C1370657 soft tissue Perineurioma disease_ontology DOID:4697 perineurioma DOID:4697 ICD10CM:N42.9 ICD9CM:602.9 MESH:D011469 NCI:C26865 SNOMEDCT_US_2020_03_01:30281009 UMLS_CUI:C0033575 disease_ontology DOID:47 prostate disease DOID:47 MESH:D049328 NCI:C3945 SNOMEDCT_US_2020_03_01:40467008 UMLS_CUI:C0265985 Mongolian Macula disease_ontology DOID:4702 mongolian spot DOID:4702 A brain cancer that is located_in the infratentorial region. DOID:4789 ICD10CM:C71.7 MESH:D015192 NCI:C3139 NCI:C4966 UMLS_CUI:C0021432 UMLS_CUI:C0751593 brain neoplasm, Infratentorial malignant Infratentorial tumors disease_ontology DOID:4706 infratentorial cancer DOID:4706 NCI:C5280 UMLS_CUI:C1333630 meningioma of the Foramen Magnum disease_ontology DOID:4708 foramen magnum meningioma DOID:4708 NCI:C4905 SNOMEDCT_US_2020_03_01:254773009 UMLS_CUI:C0687140 Angioma of the skin Angiomatous naevus of skin disease_ontology DOID:471 skin hemangioma DOID:471 A brain disease that is characterized by low pressure inside the skull, and thus in the brain tissue and cerebrospinal fluid; may occur as a result of an occult or iatrogenically caused leak of CSF into another body cavity; may result in the downward displacement of the cerebellar tonsils through the foramen magnum or Chiari malformation; has_symptom orthostatic headache; other symptoms are related to compression of cranial nerves due to brain sagging. MESH:D019585 SNOMEDCT_US_2020_03_01:433691000124104 UMLS_CUI:C0524812 disease_ontology DOID:4723 intracranial hypotension DOID:4723 A brain disease that is characterized by excess accumulation of fluid in the intracellular and/or extracellular spaces of the brain, has_symptom nausea, has_symptom vomiting, has_symptom blurred vision, has_symptom seizure, has_symptom coma. MESH:D001929 SNOMEDCT_US_2020_03_01:85974009 UMLS_CUI:C1527311 intracranial swelling wet brain disease_ontology DOID:4724 brain edema DOID:4724 A disease of mental health that involves physical symptoms suggesting a physical illness where the biological or medical cause of the symptoms is indeterminate. DOID:10133 DOID:144 ICD10CM:F45 ICD10CM:F45.0 ICD9CM:300.8 ICD9CM:300.81 MESH:D013001 NCI:C34956 SNOMEDCT_US_2020_03_01:192430009 SNOMEDCT_US_2020_03_01:60368009 UMLS_CUI:C0037650 UMLS_CUI:C0520482 physiological malfunction arising from mental factor psychophysiologic disorder psychosomatic disorder disease_ontology DOID:4737 somatoform disorder DOID:4737 MESH:D006391 NCI:C4298 SNOMEDCT_US_2020_03_01:253054009 UMLS_CUI:C0205788 Angiolymphoid hyperplasia with eosinophilia epithelioid haemangioma epithelioid hemangioma disease_ontology DOID:474 histiocytoid hemangioma DOID:474 A placenta disease that is characterized by an abnormally deep attachment of the placenta, through the endometrium and into the myometrium. ICD10CM:O43.21 MESH:D010921 NCI:C26856 SNOMEDCT_US_2020_03_01:70129008 UMLS_CUI:C0032044 disease_ontology DOID:4744 placenta accreta DOID:4744 ICD10CM:G23.2 MESH:D020955 NCI:C125695 OMIM:271930 OMIM:500003 OMIM:609161 SNOMEDCT_US_2020_03_01:29618004 UMLS_CUI:C0270733 disease_ontology DOID:4751 OMIM mapping confirmed by DO. [LS]. striatonigral degeneration DOID:4751 DOID:11510 GARD:7079 MESH:D012791 MESH:D019578 NCI:C84909 SNOMEDCT_US_2020_03_01:16576004 SNOMEDCT_US_2020_03_01:230297002 UMLS_CUI:C0037019 UMLS_CUI:C0393571 Multiple system atrophy Shy-Drager syndrome disease_ontology DOID:4752 OMIM mapping confirmed by DO. [LS]. multiple system atrophy DOID:4752 A lung cancer that has_material_basis_in tissues of the lung and has_material_basis_in pleural tissues. It is most commonly effects children. MESH:D018202 NCI:C3732 SNOMEDCT_US_2020_03_01:189815007 UMLS_CUI:C0206629 Blastoma of lung disease_ontology DOID:4765 pulmonary blastoma DOID:4765 A pulmonary blastoma that derives_from the lung or pleural cavity. GARD:8757 MESH:C537516 NCI:C5669 OMIM:601200 SNOMEDCT_US_2020_03_01:707670009 UMLS_CUI:C1266144 Pleuropulmonary blastoma disease_ontology DOID:4769 OMIM mapping confirmed by DO. [SN]. pleuropulmonary blastoma DOID:4769 A kidney cancer that is characterized by the presence of fibroblastic cells. DOID:4772 GARD:1493 MESH:D018201 NCI:C6569 UMLS_CUI:C1332965 disease_ontology DOID:4773 congenital mesoblastic nephroma DOID:4773 NCI:C35799 UMLS_CUI:C0859036 disease_ontology DOID:4781 diffuse glomerulonephritis DOID:4781 NCI:C5817 UMLS_CUI:C1334246 intracranial PNET disease_ontology DOID:4788 intracranial primitive neuroectodermal tumor DOID:4788 DOID:665 MESH:D000794 NCI:C2874 NCI:C4488 SNOMEDCT_US_2020_03_01:254788004 SNOMEDCT_US_2020_03_01:26810009 UMLS_CUI:C0002985 UMLS_CUI:C0346075 Angiokeratoma Angiokeratoma of skin Cutaneous Angiokeratoma skin angiokeratoma disease_ontology DOID:479 angiokeratoma DOID:479 MESH:D018242 NCI:C4327 SNOMEDCT_US_2020_03_01:715903004 UMLS_CUI:C0334596 Diktyoma, malignant Medulloepithelioma Medulloepithelioma, central nervous system disease_ontology DOID:4790 medulloepithelioma DOID:4790 GARD:7366 NCI:C6968 SNOMEDCT_US_2020_03_01:699318007 UMLS_CUI:C1336538 Supratentorial PNET disease_ontology DOID:4791 supratentorial primitive neuroectodermal tumor DOID:4791 MESH:D018242 NCI:C4915 SNOMEDCT_US_2020_03_01:253070006 UMLS_CUI:C0700367 disease_ontology DOID:4794 ependymoblastoma DOID:4794 MESH:D018489 SNOMEDCT_US_2020_03_01:21162009 UMLS_CUI:C0242700 disease_ontology DOID:4796 space motion sickness DOID:4796 NCI:C9284 SNOMEDCT_US_2020_03_01:397357000 UMLS_CUI:C1301365 systemic mastocytosis with associated clonal haematological non-mast cell lineage disease systemic mastocytosis with associated clonal, hematologic non-mast-cell lineage disease disease_ontology DOID:4797 SM-AHNMD DOID:4797 A reproductive system disease that affects male reproductive organs. ICD10CM:N50.9 ICD9CM:608.9 MESH:D005832 SNOMEDCT_US_2020_03_01:64557000 UMLS_CUI:C0017412 disease_ontology DOID:48 male reproductive system disease DOID:48 A brain disease that is characterized by a clinical syndrome of either hyperkinetic movement or hyperkinetic movement unrelated to weakness or spasticity. MESH:D009069 NCI:C116757 SNOMEDCT_US_2020_03_01:60342002 UMLS_CUI:C0026650 disease_ontology DOID:480 movement disease DOID:480 A xanthomatosis that is characterized by a deficiency in the production of the bile acid, chenodeoxycholic acid that has_material_basis_in autosomal recessive inheritance and results in cholestanol deposition in the brain and other tissues and with elevated levels of cholesterol in plasma. GARD:5622 MESH:D019294 NCI:C84628 OMIM:213700 SNOMEDCT_US_2020_03_01:63246000 UMLS_CUI:C0238052 Cholestanol storage disease disease_ontology DOID:4810 OMIM mapping confirmed by DO. [SN]. cerebrotendinous xanthomatosis DOID:4810 An autonomic nervous system benign neoplasm that is characterized by the presence of mature ganglion cells and a mature Schwannian stroma and arises from the sympathetic trunk in the mediastinum. MESH:D005729 NCI:C3049 NCI:C42065 SNOMEDCT_US_2020_03_01:189929007 UMLS_CUI:C0017075 UMLS_CUI:C1513025 disease_ontology DOID:4817 ganglioneuroma DOID:4817 ICD10CM:D18.0 MESH:D006392 NCI:C3086 SNOMEDCT_US_2020_03_01:67668002 UMLS_CUI:C0018920 Cavernoma Cavernous haemangioma Cavernous hemangioma disease_ontology DOID:483 cavernous hemangioma DOID:483 A squamous cell carcinoma that contains squamous cells and gland-like cells. MESH:D018196 NCI:C3727 SNOMEDCT_US_2020_03_01:403902008 UMLS_CUI:C0206623 Adenosquamous carcinoma Adenosquamous cell carcinoma mixed adenocarcinoma and squamous carcinoma disease_ontology DOID:4830 adenosquamous carcinoma DOID:4830 A syndrome that is characterized by bone loss (osteolysis) which is often associated with swelling or abnormal blood vessel growth (angiomatous proliferation). Bone loss can occur in just one bone or spread to soft tissue and adjacent bones. GARD:6542 MESH:D010015 SNOMEDCT_US_2020_03_01:240161003 UMLS_CUI:C0029436 Disappearing bone disease Gorham disease essential osteolysis massive osteolysis phantom bone disease disease_ontology Gorham-Stout Syndrome DOID:4837 Gorham's disease DOID:4837 A carcinoma that derives_from myoepithelial cells. GARD:10558 NCI:C7596 SNOMEDCT_US_2020_03_01:24292006 UMLS_CUI:C0334699 disease_ontology DOID:4838 myoepithelial carcinoma DOID:4838 MESH:D020141 SNOMEDCT_US_2020_03_01:21112004 UMLS_CUI:C0600502 disease_ontology DOID:484 vascular hemostatic disease DOID:484 ICD10CM:C44 NCI:C8409 SNOMEDCT_US_2020_03_01:188083002 UMLS_CUI:C1382026 malignant Sebaceous tumor malignant neoplasm of sebaceous gland disease_ontology DOID:4840 sebaceous carcinoma DOID:4840 MESH:D018315 NCI:C3795 SNOMEDCT_US_2020_03_01:4553004 UMLS_CUI:C0206725 Subependymal astrocytoma WHO grade I Ependymal tumor mixed subependymoma-ependymoma disease_ontology DOID:4843 subependymal glioma DOID:4843 MESH:D004806 NCI:C3017 SNOMEDCT_US_2020_03_01:443643007 UMLS_CUI:C0014474 WHO grade II Ependymal tumor epithelial ependymoma disease_ontology DOID:4844 benign ependymoma DOID:4844 NCI:C40315 SNOMEDCT_US_2020_03_01:388600004 UMLS_CUI:C1519086 disease_ontology DOID:4845 pilomyxoid astrocytoma DOID:4845 NCI:C9475 UMLS_CUI:C0740480 astrocytoma of Cerebellum disease_ontology DOID:4848 cerebellar astrocytoma DOID:4848 A pediatric low-grade glioma that is characterized by cells that look like fibers when viewed under a microscope and is located_in the brain. GARD:9808 MESH:D001254 NCI:C4047 SNOMEDCT_US_2020_03_01:67859002 UMLS_CUI:C0334583 Piloid astrocytoma grade I Astrocytic tumor disease_ontology DOID:4851 pilocytic astrocytoma DOID:4851 A salivary gland carcinoma that is characterized by a distinctive pattern in which abnormal nests or cords of epithelial cells surround and/or infiltrate ducts or glandular structures within the affected organ. These structures are typically filled with a mucous-like material or contain abnormal fibrous membranes. MESH:D003528 NCI:C2970 SNOMEDCT_US_2020_03_01:11671000 UMLS_CUI:C0010606 Cylindroma adenoid cystic cancer adenoid cystic carcinoma disease_ontology DOID:4866 salivary gland adenoid cystic carcinoma DOID:4866 ICD9CM:335 MESH:D016472 SNOMEDCT_US_2020_03_01:267693003 UMLS_CUI:C0154681 disease_ontology DOID:4873 anterior horn cell disease DOID:4873 A viral infectious disease that results_in infection, has_material_basis_in Colorado tick fever virus, which is transmitted_by rocky mountain wood tick, Dermacentor andersoni. The infection has_symptom fever for 2-3 days, followed by an afebrile period of similar duration and then another 2-3 days of fever, has_symptom headache, has_symptom myalgia, and has_symptom fatigue. ICD10CM:A93.2 MESH:D003121 SNOMEDCT_US_2020_03_01:186607005 UMLS_CUI:C0009400 Tick fever, American mountain disease_ontology DOID:4885 Colorado tick fever DOID:4885 An extrapulmonary tuberculosis that is located_in lymph node, and has_symptom lymphadenopathy, has_symptom fever, has_symptom weight loss, has_symptom fatigue, has_symptom night sweats and has_symptom cough. DOID:4888 ICD10CM:A18.2 MESH:D014388 MESH:D018601 NCI:C26896 SNOMEDCT_US_2020_03_01:10893003 UMLS_CUI:C0041316 UMLS_CUI:C0242830 Lymph Node Tuberculosis Tuberculous adenitis Tuberculous lymphadenopathy king's evil scrofula disease_ontology DOID:4889 lymph node tuberculosis DOID:4889 A bile duct carcinoma that derives_from epithelial cells of glandular origin. NCI:C27813 SNOMEDCT_US_2020_03_01:70179006 UMLS_CUI:C1370800 disease_ontology DOID:4896 bile duct adenocarcinoma DOID:4896 A bile duct cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. MESH:D001650 NCI:C27814 SNOMEDCT_US_2020_03_01:70179006 UMLS_CUI:C0740277 disease_ontology DOID:4897 bile duct carcinoma DOID:4897 pulmonary hemangioma disease_ontology DOID:490 hemangioma of lung DOID:490 An appendix cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. NCI:C9330 SNOMEDCT_US_2020_03_01:269541000 UMLS_CUI:C0728951 Ca appendix carcinoma of appendix disease_ontology DOID:4902 appendix carcinoma DOID:4902 A pancreas cancer that derives_from epithelial cells located_in the pancreas. EFO:0002618 MESH:C562463 NCI:C3850 OMIM:260350 SNOMEDCT_US_2020_03_01:154475002 UMLS_CUI:C0235974 Exocrine pancreas carcinoma carcinoma of pancreas disease_ontology Pancreatic carcinoma, familial Pancreatic carcinoma, familial exocrine cancer DOID:4905 OMIM mapping confirmed by DO. [SN]. pancreatic carcinoma DOID:4905 A small intestine carcinoma that derives_from epithelial cells of glandular origin. GARD:13090 NCI:C7888 SNOMEDCT_US_2020_03_01:424440001 UMLS_CUI:C0278803 small intestinal adenocarcinoma disease_ontology adenocarcinoma of small Intestine DOID:4906 small intestine adenocarcinoma DOID:4906 A small intestine cancer that develops from epithelial cells and is located_in the small intestine. NCI:C7724 UMLS_CUI:C0238196 small intestinal carcinoma disease_ontology cancer of the small bowel small bowel cancer DOID:4907 small intestine carcinoma DOID:4907 A anus cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells and is located_in the anus. MESH:D001005 NCI:C9291 SNOMEDCT_US_2020_03_01:187762000 UMLS_CUI:C0279637 Ca anus carcinoma of anus disease_ontology DOID:4908 anal carcinoma DOID:4908 MESH:D010911 NCI:C4536 SNOMEDCT_US_2020_03_01:128665000 UMLS_CUI:C0346300 carcinoma of the Pituitary gland disease_ontology DOID:4916 pituitary carcinoma DOID:4916 DOID:12343 ICD10CM:C65 ICD9CM:189.1 NCI:C6142 NCI:C7525 SNOMEDCT_US_2020_03_01:363457009 UMLS_CUI:C0153618 UMLS_CUI:C1335749 carcinoma of kidney Pelvis malignant neoplasm of renal pelvis malignant renal Pelvis neoplasm malignant tumor of renal pelvis renal pelvis cancer disease_ontology DOID:4919 renal pelvis carcinoma DOID:4919 NCI:C5559 UMLS_CUI:C1334577 malignant Eccrine tumor malignant eccrine skin neoplasm disease_ontology DOID:4921 eccrine sweat gland cancer DOID:4921 A thymic carcinoma that derives_from epithelial cells of glandular origin. NCI:C6459 UMLS_CUI:C1336743 adenocarcinoma of the Thymus disease_ontology DOID:4923 thymus adenocarcinoma DOID:4923 An intrahepatic cholangiocarcinoma arising near or at the confluence of the right and left hepatic ducts. DOID:5246 GARD:10175 MESH:D018285 NCI:C36077 SNOMEDCT_US_2020_03_01:253017000 UMLS_CUI:C0206702 Klatskin tumor Klatskin tumour Klatskin's tumour Perihilar extrahepatic bile duct carcinoma hilar cholangiocarcinoma hilar cholangiocellular carcinoma disease_ontology DOID:4927 Klatskin's tumor DOID:4927 GARD:6042 ICD10CM:C22.1 MESH:D018281 NCI:C35417 SNOMEDCT_US_2020_03_01:109842005 UMLS_CUI:C0345905 Intrahepatic bile duct carcinoma peripheral Cholangiocarcinoma disease_ontology DOID:4928 intrahepatic cholangiocarcinoma DOID:4928 An ampulla of Vater cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. NCI:C3908 SNOMEDCT_US_2020_03_01:254609000 UMLS_CUI:C0262401 ampulla of vater cancer ampullary carcinoma carcinoma of ampulla of vater disease_ontology DOID:4932 ampulla of Vater carcinoma DOID:4932 An ureter cancer that is located_in the ureter. NCI:C8993 UMLS_CUI:C0600079 ureteral carcinoma disease_ontology DOID:4939 ureter carcinoma DOID:4939 An in situ carcinoma that derives_from epithelial cells of glandular origin. MESH:D065311 NCI:C4123 SNOMEDCT_US_2020_03_01:51642000 UMLS_CUI:C0334276 disease_ontology DOID:4943 adenocarcinoma in situ MESH:D065311 DOID:4943 A bile duct adenocarcinoma that has_material_basis_in bile duct epithelial cells. DOID:5249 ICD10CM:C22.1 MESH:D018281 NCI:C4436 NCI:C8265 SNOMEDCT_US_2020_03_01:70179006 UMLS_CUI:C0206698 UMLS_CUI:C0280725 adult primary Cholangiocarcinoma adult primary cholangiocellular carcinoma cholangiosarcoma disease_ontology DOID:4947 cholangiocarcinoma DOID:4947 A gallbladder cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. NCI:C3844 SNOMEDCT_US_2020_03_01:255085003 UMLS_CUI:C0235782 cancer of the gallbladder carcinoma gallbladder carcinoma of gallbladder disease_ontology DOID:4948 gallbladder carcinoma DOID:4948 SNOMEDCT_US_2020_03_01:134302009 UMLS_CUI:C1509148 Sclerosing haemangioma Sclerosing hemangioma disease_ontology DOID:495 sclerosing hemangioma DOID:495 A viral infectious disease that results in destruction located in motor neurons, has_material_basis_in Human poliovirus 1, has_material_basis_in Human poliovirus 2, or has_material_basis_in Human poliovirus 3, which are transmitted by ingestion of food or water contaminated with feces, or transmitted by direct contact with the oral secretions. The infection has symptom fever, has symptom sore throat, has symptom headache, has symptom vomiting, has symptom fatigue, has symptom neck stiffness, has symptom muscle spasms, and has symptom acute flaccid paralysis. GARD:7413 ICD10CM:A80 ICD9CM:045 MESH:D011051 NCI:C35550 SNOMEDCT_US_2020_03_01:54839009 UMLS_CUI:C0032371 disease_ontology DOID:4953 poliomyelitis DOID:4953 NCI:C4754 SNOMEDCT_US_2020_03_01:128769003 UMLS_CUI:C1304508 SCH disease_ontology DOID:496 spindle cell hemangioma DOID:496 A hematopoietic cancer that derives_from the blood-forming stem cells of the bone marrow. DOID:2356 DOID:2761 EFO:0004251 ICD10CM:D47.1 MESH:D009196 SNOMEDCT_US_2020_03_01:128925001 UMLS_CUI:C0027022 bone Marrow tumor bone marrow neoplasm malignant bone Marrow tumor malignant neoplasm of bone marrow disease_ontology DOID:4960 bone marrow cancer DOID:4960 MESH:D001855 NCI:C34433 SNOMEDCT_US_2020_03_01:127035006 UMLS_CUI:C0005956 bone marrow disorder disease_ontology DOID:4961 bone marrow disease DOID:4961 An anxiety disorder that involves discress but neither delusions nor hallucinations. DOID:6342 DOID:9687 ICD10CM:F34.1 ICD10CM:F48.9 MESH:D000275 MESH:D003866 MESH:D009497 NCI:C34533 NCI:C34848 NCI:C35369 SNOMEDCT_US_2020_03_01:154881002 SNOMEDCT_US_2020_03_01:78667006 SNOMEDCT_US_2020_03_01:87414006 UMLS_CUI:C0011579 UMLS_CUI:C0027932 UMLS_CUI:C0282126 Neurotic depression reactive type Neurotic depressive state Psychoneurosis depressive neurosis neurosis neurotic depression reactive depression disease_ontology DOID:4964 neurotic disorder DOID:4964 GARD:7170 ICD10CM:E24.1 MESH:D009347 NCI:C84917 SNOMEDCT_US_2020_03_01:43019009 UMLS_CUI:C0027577 Nelson's syndrome disease_ontology DOID:4968 Nelson syndrome DOID:4968 An agnosia that results in the loss of the ability to consciously recognize familiar faces. ICD10CM:R48.3 MESH:D020238 NCI:C85031 SNOMEDCT_US_2020_03_01:18358003 UMLS_CUI:C0234512 disease_ontology DOID:4970 prosopagnosia DOID:4970 A myeloid neoplasm that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue. DOID:5737 GARD:8618 ICD10CM:D47.4 ICD10CM:D75.81 ICD9CM:238.76 ICD9CM:289.83 MESH:D055728 NCI:C2862 NCI:C3248 OMIM:254450 SNOMEDCT_US_2020_03_01:128843003 SNOMEDCT_US_2020_03_01:267572005 UMLS_CUI:C0001815 UMLS_CUI:C0026987 Agnogenic myeloid metaplasia Aleukemic myelosis Megakaryocytic myelosclerosis bone Marrow Fibrosis myelosclerosis primary myelofibrosis disease_ontology DOID:4971 OMIM mapping confirmed by DO. [SN]. myelofibrosis DOID:4971 A myeloid neoplasm that results_in the overproduction of white blood cells. DOID:6470 MESH:D054437 NCI:C27262 SNOMEDCT_US_2020_03_01:445738007 UMLS_CUI:C1301355 Myeloproliferative/Myelodysplastic syndromes myelodysplastic myeloproliferative cancer disease_ontology myelodysplastic myeloproliferative disease DOID:4972 myelodysplastic/myeloproliferative neoplasm DOID:4972 A commensal bacterial infectious disease that results_in infection, has_material_basis_in Actinobacillus ureae, which is a commensal of the human respiratory tract. The pathogen causes meningitis, endocarditis, bacteremia, atrophic rhinitis, bronchitis, pneumonia, conjunctivitis, peritonitis, and otitis media. MESH:D000187 SNOMEDCT_US_2020_03_01:16140007 UMLS_CUI:C0001247 disease_ontology DOID:4974 actinobacillosis MESH:D000187 DOID:4974 MESH:D004604 NCI:C34569 SNOMEDCT_US_2020_03_01:155485008 UMLS_CUI:C0013882 Elephantiasis disease_ontology DOID:4976 elephantiasis DOID:4976 MESH:D008209 NCI:C3207 SNOMEDCT_US_2020_03_01:266334008 UMLS_CUI:C0024236 Lymphatic edema Lymphoedema disease_ontology DOID:4977 lymphedema DOID:4977 MESH:D019512 SNOMEDCT_US_2020_03_01:445507008 UMLS_CUI:C0376670 disease_ontology DOID:4988 alcoholic pancreatitis DOID:4988 EFO:0000278 ICD10CM:K85.9 MESH:D010195 NCI:C3306 OMIM:167800 SNOMEDCT_US_2020_03_01:393591004 UMLS_CUI:C0030305 disease_ontology DOID:4989 pancreatitis DOID:4989 A movement disorder that causes involuntary tremors, especially in the hands. It occurs alone without other neurological signs and symptoms. GARD:5910 ICD10CM:G25.0 MESH:D020329 OMIM:PS190300 ORDO:862 SNOMEDCT_US_2020_03_01:192839001 UMLS_CUI:C0270736 benign essential tremor essential hereditary tremor shaky hand syndrome disease_ontology DOID:4990 Xref MGI. essential tremor DOID:4990 GARD:4107 MESH:D020339 NCI:C4537 SNOMEDCT_US_2020_03_01:254976006 UMLS_CUI:C0346326 glioma of the optic nerve disease_ontology DOID:4992 optic nerve glioma DOID:4992 An osteosclerosis that has_material_basis_in mutations in the TGFB1 gene which results_in increased bone density located_in long bone. GARD:1072 ICD10CM:Q78.3 MESH:D003966 NCI:C84610 OMIM:131300 OMIM:606631 SNOMEDCT_US_2020_03_01:34643004 UMLS_CUI:C0011989 Diaphyseal dysplasia Engelman's disease progressive diaphyseal dysplasia disease_ontology DOID:4997 Xref MGI. OMIM mapping confirmed by DO. [SN]. Camurati-Engelmann disease DOID:4997 An endocrine system disease that is located_in the thyroid. ICD10CM:E07.9 ICD9CM:246.9 MESH:D013959 NCI:C26893 SNOMEDCT_US_2020_03_01:14304000 UMLS_CUI:C0040128 disease_ontology DOID:50 thyroid gland disease DOID:50 A hepatocellular carcinoma characterized microscopically by laminated fibrous layers interspersed between the tumour cells. The polygonal, deeply eosinophilic tumor cells arise in non-cirrhotic livers. MESH:C537258 NCI:C4131 SNOMEDCT_US_2020_03_01:15619004 UMLS_CUI:C0334287 Fibrolamellar hepatocellular carcinoma Hepatocellular carcinoma, fibrolamellar Oncocytic Hepatocellular tumor disease_ontology DOID:5015 fibrolamellar carcinoma DOID:5015 A central nervous system cancer that is characterized by mesenchymal tumors within the CNS that develops from meninges, has_material_basis_in abnormally proliferating cells derives_from mesoderm. Non-meningothelial mesenchymal tumor Non-meningothelial mesenchymal tumour central nervous system mesenchymal non-meningothelial tumour disease_ontology DOID:502 central nervous system mesenchymal non-meningothelial tumor DOID:502 An endocrine gland located_in the pineal gland located in the brain. DOID:1662 DOID:4859 ICD10CM:C75.3 ICD9CM:194.4 MESH:D010871 NCI:C3328 NCI:C3573 NCI:C6965 SNOMEDCT_US_2020_03_01:127026004 SNOMEDCT_US_2020_03_01:93962006 UMLS_CUI:C0031941 UMLS_CUI:C0153655 UMLS_CUI:C1412004 Pinealoma Pineocytic tumor malignant Pineal Region tumor malignant tumor of pineal gland neoplasm of pineal gland neoplasm of the Pineal Region pineal body neoplasm tumor of the pineal region disease_ontology DOID:5032 pineal gland cancer DOID:5032 MESH:D009379 NCI:C3252 UMLS_CUI:C0027043 benign granular cell tumor disease_ontology DOID:5039 myoblastoma DOID:5039 A gastrointestinal system cancer that is located_in the esophagus. DOID:10291 DOID:10292 DOID:10448 DOID:1102 DOID:1104 GARD:6383 ICD10CM:C15.3 ICD10CM:C15.4 ICD10CM:C15.5 ICD9CM:150.2 ICD9CM:150.3 ICD9CM:150.4 ICD9CM:150.5 ICD9CM:150.8 MESH:D004938 NCI:C3028 NCI:C3533 NCI:C3534 NCI:C3535 NCI:C4764 OMIM:133239 SNOMEDCT_US_2020_03_01:126817006 SNOMEDCT_US_2020_03_01:187729008 SNOMEDCT_US_2020_03_01:93656003 SNOMEDCT_US_2020_03_01:93877002 SNOMEDCT_US_2020_03_01:93895004 SNOMEDCT_US_2020_03_01:94119000 UMLS_CUI:C0014859 UMLS_CUI:C0153413 UMLS_CUI:C0153414 UMLS_CUI:C0153415 UMLS_CUI:C0153416 UMLS_CUI:C0496775 Ca lower third oesophagus Ca middle third oesophagus esophagus cancer malignant neoplasm of distal third of esophagus malignant neoplasm of lower third of oesophagus malignant neoplasm of middle third of oesophagus malignant neoplasm of proximal third of esophagus malignant neoplasm of upper third esophagus malignant tumor of Distal Third of esophagus malignant tumor of Proximal Third of esophagus malignant tumor of abdominal esophagus malignant tumor of the middle Third of the esophagus disease_ontology DOID:5041 esophageal cancer DOID:5041 NCI:C4336 SNOMEDCT_US_2020_03_01:404041003 UMLS_CUI:C0334618 granular cell tumor, malignant malignant granular cell neoplasm malignant granular cell tumor disease_ontology DOID:5042 malignant granular cell myoblastoma DOID:5042 MESH:D002286 UMLS_CUI:C0007125 Ehrlich tumour carcinoma Ehrlich's tumor Ehrlich's tumour disease_ontology DOID:5050 Ehrlich tumor carcinoma DOID:5050 A primary bacterial infectious disease that results_in infection, has_material_basis_in Burkholderia pseudomallei, which is transmitted_by contact with the contaminated water or soil. The infection has_symptom fever, has_symptom respiratory distress, has_symptom chest pain, and has_symptom stomach pain. DOID:0050062 DOID:0050064 GARD:9546 ICD10CM:A24.9 ICD9CM:025 MESH:D008554 NCI:C128336 SNOMEDCT_US_2020_03_01:428111003 UMLS_CUI:C0025229 Nightcliff gardener's disease Pseudoglanders Whitmore's disease acute and fulminating melioidosis subacute and chronic melioidosis disease_ontology DOID:5052 melioidosis DOID:5052 A substance abuse that involves the recurring use of phencyclidine (PCP) drugs despite negative consequences. MESH:D010623 SNOMEDCT_US_2020_03_01:7071007 UMLS_CUI:C0031391 PCP abuse Phencyclidine abuse disease_ontology DOID:5062 phencyclidine abuse DOID:5062 A disease of mental health that is an abnormal and excessive emotional and behavioral reaction to a life stress that develops within 3 months of a life stress, and which is stronger or greater than what would be expected for the type of event that occurred. ICD9CM:309 SNOMEDCT_US_2020_03_01:17226007 UMLS_CUI:C0040701 adjustment disease adjustment reaction disease_ontology DOID:507 adjustment disorder DOID:507 A malignant glioma that is derived from ependymal cells, a type of glial cell, located_in ventricle lining within the central part of the brain. DOID:0060107 NCI:C6770 UMLS_CUI:C1333407 Ependymal neoplasm ependymal tumors disease_ontology DOID:5074 malignant ependymoma DOID:5074 MESH:D005910 NCI:C3903 SNOMEDCT_US_2020_03_01:443937008 UMLS_CUI:C0259783 mixed Neuroglial tumor mixed gliomas disease_ontology DOID:5076 mixed glioma DOID:5076 GARD:10632 MESH:D001254 NCI:C3696 SNOMEDCT_US_2020_03_01:449799008 UMLS_CUI:C0205768 SEGA Subependymal giant cell astrocytoma disease_ontology DOID:5077 subependymal giant cell astrocytoma DOID:5077 A cell type benign neoplasm that has_material_basis_in glial-type cells. DOID:5606 DOID:5607 GARD:2430 MESH:D018303 NCI:C27362 NCI:C27363 NCI:C3788 SNOMEDCT_US_2020_03_01:87191000119100 UMLS_CUI:C0206716 UMLS_CUI:C1332202 UMLS_CUI:C1332969 CNS ganglioglioma adult ganglioglioma childhood ganglioglioma disease_ontology DOID:5078 ganglioglioma DOID:5078 EFO:0001422 ICD10CM:K74.60 MESH:D008103 NCI:C2951 SNOMEDCT_US_2020_03_01:19943007 UMLS_CUI:C0023890 Cirrhosis cirrhosis of liver disease_ontology DOID:5082 liver cirrhosis DOID:5082 An organ system cancer located_in the thoracic cavity that develops in the different types of cells within the lungs, as well as less common cancers of the esophagus, the trachea, or the chest wall. DOID:3937 ICD10CM:C76.1 ICD9CM:195.1 MESH:D013899 NCI:C3406 NCI:C3576 SNOMEDCT_US_2020_03_01:188361007 SNOMEDCT_US_2020_03_01:255058005 UMLS_CUI:C0039981 UMLS_CUI:C0153661 Thoracic tumor thorax cancer thorax neoplasm tumor of thorax disease_ontology DOID:5093 thoracic cancer DOID:5093 NCI:C27065 SNOMEDCT_US_2020_03_01:155260002 UMLS_CUI:C0271428 disease_ontology DOID:5100 middle ear disease DOID:5100 MESH:D004428 UMLS_CUI:C0751094 auricular cancer malignant ear neoplasm malignant tumor of ear disease_ontology DOID:5101 ear cancer DOID:5101 A nutritional deficiency disease that is characterized by deficiency of copper, causing spastic gait and ataxia, often with anemia and neutropenia, has_symptom imbalance and jerking movements, and has_material_basis_in copper deficiency possibly due to malabsorption or excess zinc ingestion. MESH:D013540 SNOMEDCT_US_2020_03_01:78714004 UMLS_CUI:C0038981 human swayback disease_ontology DOID:5112 copper deficiency myelopathy DOID:5112 A nutrition disease that is characterized by deficiency of a nutritional element, such as a vitamin, mineral, carbohydrate, protein, fat, or general energy content. MESH:D003677 UMLS_CUI:C0011156 disease_ontology DOID:5113 nutritional deficiency disease DOID:5113 NCI:C4482 SNOMEDCT_US_2020_03_01:254767008 UMLS_CUI:C0346064 Cutaneous leiomyoma leiomyoma of the skin disease_ontology DOID:5132 leiomyoma cutis DOID:5132 A leiomyoma that is multiple and diffuse. MESH:D018231 NCI:C3748 SNOMEDCT_US_2020_03_01:75210008 UMLS_CUI:C0206654 disease_ontology DOID:5138 leiomyomatosis DOID:5138 A vulvar benign neoplasm that is located_in smooth muscle cells. NCI:C40326 UMLS_CUI:C1520087 disease_ontology DOID:5142 vulvar leiomyoma DOID:5142 A viral infectious disease that results_in infection, which affects dopaminergic neurotransmission located_in central nervous system, has_material_basis_in Borna disease virus, which is transmitted_by contact with infected oronasal secretions. The infection has_symptom mood disturbances, has_symptom behaviour disturbances, has_symptom cognitive disturbances, has_symptom neurologic disturbances, and has_symptom movement impairment. MESH:D001890 SNOMEDCT_US_2020_03_01:76851008 UMLS_CUI:C0006023 Enzootic encephalomyelitis disease_ontology DOID:5154 borna disease MESH:D001890 DOID:5154 A connective tissue cancer that located_in the pleura. DOID:9917 ICD10CM:C38.4 ICD9CM:163 MESH:D010997 NCI:C3332 NCI:C3547 SNOMEDCT_US_2020_03_01:126719004 SNOMEDCT_US_2020_03_01:363433009 UMLS_CUI:C0032229 UMLS_CUI:C0153494 Pleural tumor neoplasm of pleura disease_ontology DOID:5158 pleural cancer DOID:5158 MESH:D001162 SNOMEDCT_US_2020_03_01:60625000 UMLS_CUI:C0003851 Arteriosclerosis obliterans disease_ontology DOID:5160 arteriosclerosis obliterans DOID:5160 An arteriosclerosis that is characterized by thickening of the wall of the small arteries and arterioles, caused by deposition of hyaline material in the wall or concentric smooth muscle wall hypertrophy, and results in lumen narrowing and tissue ischemia. ICD10CM:I70 MESH:D050379 NCI:C35543 SNOMEDCT_US_2020_03_01:17941002 UMLS_CUI:C0878486 Arteriolosclerosis disease_ontology DOID:5162 arteriolosclerosis MESH:D050379 DOID:5162 MESH:D036821 SNOMEDCT_US_2020_03_01:68738004 UMLS_CUI:C0334695 endometrial Stromal neoplasm disease_ontology DOID:5166 endometrial stromal tumor DOID:5166 A nephroblastoma that results_in either bilateral disease or a family history of Wilms' tumour. NCI:C8496 UMLS_CUI:C0677779 Hereditary Wilms tumor Hereditary Wilms tumour WT1 hereditary Wilms' tumour disease_ontology hereditary Wilms' tumor DOID:5183 hereditary Wilms' tumor DOID:5183 ICD10CM:I77.6 MESH:D001025 NCI:C97085 SNOMEDCT_US_2020_03_01:195368003 UMLS_CUI:C0003509 disease_ontology DOID:519 aortitis DOID:519 ICD9CM:593.4 SNOMEDCT_US_2020_03_01:197807001 UMLS_CUI:C0029866 disease_ontology DOID:5199 ureteral obstruction DOID:5199 An artery disease that is characterized by degeneration of the cells composing the aortic wall. MESH:D001018 NCI:C101253 SNOMEDCT_US_2020_03_01:47040006 UMLS_CUI:C0003493 aortic disorder disorder of the aorta disease_ontology DOID:520 aortic disease DOID:520 ICD10CM:N13.9 ICD9CM:599.6 NCI:C79805 SNOMEDCT_US_2020_03_01:7163005 UMLS_CUI:C0178879 Obstructive Uropathy urinary obstruction disease_ontology DOID:5200 urinary tract obstruction DOID:5200 A carbohydrate metabolic disorder that has_material_basis_in a deficiency of fructose-1,6-bisphosphatase resulting in hypoglycemia and metabolic acidosis on fasting due to insufficient fructose bisphosphatase for gluconeogenesis. GARD:2400 ICD10CM:E74.19 MESH:D015319 NCI:C128119 OMIM:229700 SNOMEDCT_US_2020_03_01:28183005 UMLS_CUI:C0016756 fructose 1 phosphate aldolase deficiency fructose-1,6-diphosphatase deficiency disease_ontology DOID:5204 OMIM mapping confirmed by DO. [SN]. fructose-1,6-bisphosphatase deficiency DOID:5204 An ovarian germ cell teratoma that has_material_basis_in a tissue type from one germ cell layer (ectoderm, mesoderm or endoderm). NCI:C7286 SNOMEDCT_US_2020_03_01:399632009 UMLS_CUI:C1302569 Ovarian Monodermal teratoma disease_ontology DOID:5207 monodermal teratoma DOID:5207 A carbohydrate metabolic disorder that involves deficient or defective glycosylation of a variety of tissue proteins and/or lipids. GARD:10307 MESH:D018981 NCI:C84615 OMIM:PS212065 ORDO:137 SNOMEDCT_US_2020_03_01:238049009 UMLS_CUI:C0282577 carbohydrate-deficient glycoprotein syndrome disease_ontology DOID:5212 Xref MGI. congenital disorder of glycosylation DOID:5212 An autoimmune disease of peripheral nervous system that is characterized by inflammation of nerve roots and peripheral nerves and destruction of the fatty protective covering (myelin sheath) over the nerves. This affects how fast the nerve signals are transmitted and leads to loss of nerve fibers. GARD:6102 ICD10CM:G61.81 ICD9CM:357.81 MESH:D020277 NCI:C84636 SNOMEDCT_US_2020_03_01:128209004 UMLS_CUI:C0393819 disease_ontology DOID:5213 chronic inflammatory demyelinating polyradiculoneuropathy DOID:5213 NCI:C27062 SNOMEDCT_US_2020_03_01:23414001 UMLS_CUI:C0270922 peripheral demyelinating neuropathy disease_ontology DOID:5214 demyelinating polyneuropathy DOID:5214 NCI:C36071 UMLS_CUI:C1167650 disease_ontology DOID:5221 chronic polyneuropathy DOID:5221 MESH:D004684 NCI:C35383 SNOMEDCT_US_2020_03_01:111897007 UMLS_CUI:C0338418 disease_ontology DOID:5222 acute necrotizing encephalitis DOID:5222 MESH:D007246 NCI:C3836 SNOMEDCT_US_2020_03_01:8619003 UMLS_CUI:C0021359 disease_ontology DOID:5223 infertility DOID:5223 GARD:6169 MESH:D017121 NCI:C84754 ORDO:95159 SNOMEDCT_US_2020_03_01:111386004 UMLS_CUI:C0162569 disease_ontology DOID:5230 hepatoerythropoietic porphyria DOID:5230 NCI:C6529 UMLS_CUI:C1332532 disease_ontology DOID:5238 benign perivascular tumor DOID:5238 GARD:8232 GARD:8522 MESH:D018325 NCI:C3801 SNOMEDCT_US_2020_03_01:81201000 UMLS_CUI:C0206734 Capillary Hemangioblastoma disease_ontology DOID:5241 hemangioblastoma DOID:5241 A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands. ICD10CM:B20 ICD9CM:042-042.99 MESH:D015658 NCI:C3108 SNOMEDCT_US_2020_03_01:86406008 UMLS_CUI:C0019693 HIV infection disease_ontology DOID:526 human immunodeficiency virus infectious disease DOID:526 A sarcoma and malignant tumor of small intestine that is located_in the small intestine. NCI:C5335 UMLS_CUI:C1336007 sarcoma of the Small Intestine disease_ontology DOID:5272 small intestinal sarcoma DOID:5272 ICD9CM:719.08 SNOMEDCT_US_2020_03_01:156579009 UMLS_CUI:C0158157 disease_ontology DOID:528 hydrarthrosis DOID:528 A prostate sarcoma that is located_in the prostate. NCI:C5526 UMLS_CUI:C1335511 leiomyosarcoma of the prostate disease_ontology DOID:5282 prostate leiomyosarcoma DOID:5282 NCI:C27904 disease_ontology DOID:5284 retroperitoneal leiomyosarcoma DOID:5284 A breast sarcoma that arises from smooth muscle cells. NCI:C5186 UMLS_CUI:C1332631 leiomyosarcoma of the breast disease_ontology DOID:5285 breast leiomyosarcoma DOID:5285 A leiomyosarcoma and sarcoma of kidney that is located_in the kidney. NCI:C6183 UMLS_CUI:C1335743 leiomyosarcoma of kidney disease_ontology DOID:5287 kidney leiomyosarcoma DOID:5287 A focal dystonia that is characterized by the involuntary, forcible contraction of the muscles controlling eye blinks. GARD:5909 ICD10CM:G24.5 ICD9CM:333.81 MESH:D001764 NCI:C118723 SNOMEDCT_US_2020_03_01:155009007 UMLS_CUI:C0005747 disease_ontology DOID:529 OMIM mapping confirmed by DO. [SN]. blepharospasm MESH:D001764 DOID:529 A gastrointestinal system disease that is located_in the intestine. DOID:10759 DOID:11222 DOID:11789 DOID:8531 DOID:8558 DOID:8591 ICD10CM:K63.9 ICD9CM:569.9 MESH:D007410 NCI:C26801 SNOMEDCT_US_2020_03_01:266483008 UMLS_CUI:C0021831 disease_ontology DOID:5295 intestinal disease DOID:5295 An endocrine system disease that is located_in the pituitary gland. DOID:2445 DOID:8713 DOID:8714 ICD9CM:253.1 UMLS_CUI:C0029493 pituitary disease disease_ontology DOID:53 pituitary gland disease DOID:53 An adnexa disease that is located_in the eyelid. ICD10CM:H02.9 ICD9CM:374.9 MESH:D005141 NCI:C26768 SNOMEDCT_US_2020_03_01:60113004 UMLS_CUI:C0015423 disease_ontology DOID:530 eyelid disease DOID:530 A ovarian adenocarcinoma that derives_from epithelial cells which have clear cytoplasm. NCI:C40078 SNOMEDCT_US_2020_03_01:763131005 UMLS_CUI:C1518693 disease_ontology DOID:5304 ovarian clear cell adenocarcinoma DOID:5304 NCI:C4199 SNOMEDCT_US_2020_03_01:189722008 UMLS_CUI:C0334392 disease_ontology DOID:5309 epithelial-myoepithelial carcinoma DOID:5309 A syndrome characterized by tetraphocomelia, craniofacial anomalies, growth retardation, intellectual disability, and cardiac and renal abnormalities that has_material_basis_in homozygous or compound heterozygous mutation in ESCO2 on chromosome 8p21.1. DOID:0050536 GARD:7387 MESH:C535687 NCI:C4681 OMIM:268300 OMIM:269000 ORDO:3103 SNOMEDCT_US_2020_03_01:48718006 UMLS_CUI:C0392475 LONG BONE DEFICIENCIES ASSOCIATED WITH CLEFT LIP-PALATE RBS SC phocomelia syndrome disease_ontology DOID:5325 OMIM mapping confirmed by DO. [SN]. Roberts syndrome DOID:5325 ICD10CM:H33.2 ICD9CM:361.9 MESH:D012163 NCI:C26874 SNOMEDCT_US_2020_03_01:155103005 UMLS_CUI:C0035305 disease_ontology DOID:5327 retinal detachment DOID:5327 DOID:11024 ICD10CM:E32 ICD9CM:254 NCI:C26962 SNOMEDCT_US_2020_03_01:20673009 UMLS_CUI:C0154199 disease of thymus gland disease_ontology DOID:533 thymus gland disease DOID:533 MESH:D003788 NCI:C34530 SNOMEDCT_US_2020_03_01:57203004 UMLS_CUI:C0011405 Dental pulp disorder disorder of pulp of tooth pulp disorder disease_ontology DOID:5330 dental pulp disease DOID:5330 NCI:C6357 UMLS_CUI:C1336709 Granulosa cell tumor of testis Granulosa cell tumour of testis testicular granulosa cell tumour disease_ontology DOID:5331 testicular granulosa cell tumor DOID:5331 MESH:D005882 NCI:C3948 SNOMEDCT_US_2020_03_01:71708001 UMLS_CUI:C0266919 Gingival polyp epulides polyp of Gum disease_ontology DOID:5337 epulis DOID:5337 A disease of mental health that involves disruption of sleep patterns. DOID:9028 ICD9CM:307.4 UMLS_CUI:C0154564 Non-organic sleep disorder disease_ontology DOID:535 sleep disorder DOID:535 A intestinal disease located in the colon. DOID:10758 MESH:D003108 SNOMEDCT_US_2020_03_01:128524007 UMLS_CUI:C0009373 colon disorder disease_ontology DOID:5353 colonic disease DOID:5353 A liposarcoma that is characterized by the presence of a hypocellular spindle cell proliferation set in a myxoid background and has_material_basis_in chromosomal translocations. GARD:7157 MESH:D018208 OMIM:613488 ORDO:99967 SNOMEDCT_US_2020_03_01:404069006 UMLS_CUI:C0206634 Myxoid/round cell liposarcoma disease_ontology DOID:5363 OMIM mapping confirmed by DO. [SN]. myxoid liposarcoma DOID:5363 ICD10CM:R91.1 MESH:D003074 SNOMEDCT_US_2020_03_01:308689002 UMLS_CUI:C0009250 Coin lesion lung Coin lesion of lung disease_ontology DOID:5364 pulmonary coin lesion DOID:5364 DOID:5377 GARD:9452 MESH:D018296 NCI:C7368 OMIM:132600 SNOMEDCT_US_2020_03_01:274901004 UMLS_CUI:C0206711 Pilomatricoma benign pilomatricoma disease_ontology DOID:5374 OMIM mapping confirmed by DO. [SN]. pilomatrixoma MESH:D018296 DOID:5374 NCI:C7367 SNOMEDCT_US_2020_03_01:44155009 UMLS_CUI:C0859920 Hair Matrix neoplasm Hair matrix tumour disease_ontology DOID:5375 hair follicle neoplasm DOID:5375 NCI:C4114 SNOMEDCT_US_2020_03_01:307610008 UMLS_CUI:C0585475 Pilomatricoma, malignant Pilomatrix carcinoma of skin malignant Pilomatricoma disease_ontology pilomatrix carcinoma of skin DOID:5376 skin pilomatrix carcinoma DOID:5376 GARD:2641 ICD10CM:D58.2 NCI:C35287 SNOMEDCT_US_2020_03_01:25065001 UMLS_CUI:C0238159 Hb-E disease Hemoglobin E disease disease_ontology DOID:5379 hemoglobin E disease DOID:5379 A biliary tract benign neoplasm that results_in a small firm white nodule with multiple bile ducts that are located_in a fibrous stroma. MESH:D002759 NCI:C2942 SNOMEDCT_US_2020_03_01:39471001 UMLS_CUI:C0008309 Cholangioadenoma disease_ontology DOID:5381 bile duct adenoma DOID:5381 A lung benign neoplasm that derives_from glandular epithelial cells. NCI:C4455 SNOMEDCT_US_2020_03_01:254642004 UMLS_CUI:C0345964 adenoma of lung pulmonary adenoma disease_ontology DOID:5386 lung adenoma DOID:5386 A sensory organ benign neoplasm that is located_in the middle ear. NCI:C6834 SNOMEDCT_US_2020_03_01:734078009 UMLS_CUI:C1334759 adenoma of the middle ear disease_ontology adenoma of middle ear DOID:5387 middle ear adenoma DOID:5387 MESH:D018249 NCI:C3759 SNOMEDCT_US_2020_03_01:89439007 UMLS_CUI:C1510502 Follicular adenoma, oxyphilic cell Oncocytoma disease_ontology DOID:5389 oxyphilic adenoma DOID:5389 DOID:10868 ICD9CM:378.56 MESH:D009886 NCI:C79697 SNOMEDCT_US_2020_03_01:16110005 SNOMEDCT_US_2020_03_01:78097002 UMLS_CUI:C0029089 UMLS_CUI:C0155338 Total ophthalmoplegia oculomotor paralysis disease_ontology DOID:539 ophthalmoplegia DOID:539 NCI:C7739 UMLS_CUI:C0238814 disease_ontology DOID:5393 brain angioma DOID:5393 NCI:C8388 UMLS_CUI:C0854486 Secretory adenoma of the Pituitary gland disease_ontology DOID:5395 functioning pituitary adenoma DOID:5395 An adenoma that is composed_of epithelial cells admixed with adipose tissue cells. NCI:C4159 SNOMEDCT_US_2020_03_01:22024005 UMLS_CUI:C0334325 disease_ontology DOID:5398 lipoadenoma DOID:5398 A hyperopia that is characterized by eyes that do not properly align with each other when looking at an object. ICD10CM:H50.8 ICD9CM:378.7 SNOMEDCT_US_2020_03_01:194125000 UMLS_CUI:C0029831 disease_ontology DOID:540 strabismus MESH:D013285 DOID:540 A pancreatic cystadenoma that is characterized by innumerable small cysts lined by bland clear cells. MESH:D000236 NCI:C3685 SNOMEDCT_US_2020_03_01:189580001 UMLS_CUI:C0205648 Microcystic adenoma disease_ontology DOID:5403 microcystic adenoma DOID:5403 A bone formation disease that has_material_basis_in hyperactive osteoclast which results_in abnormal osteoblast bone formation located_in skull, located_in pelvis, located_in vertebral column, located_in set of limbs. EFO:0004261 GARD:8615 ICD10CM:M88 MESH:D010001 NCI:C3292 OMIM:167250 OMIM:602080 OMIM:606263 ORDO:280110 SNOMEDCT_US_2020_03_01:2089002 UMLS_CUI:C0029401 Paget disease of bone Paget's bone disease osseous Paget's disease osteitis deformans disease_ontology Familial Paget's disease of bone DOID:5408 Xref MGI. MESH:C538098 added from NeuroDevNet [WAK]. Paget's disease of bone DOID:5408 A lung carcinoma that has_material_basis_in primitive-appearing cells that are smaller than normal cells and is located_in the lung. DOID:0050875 KEGG:05222 MESH:D055752 NCI:C4917 OMIM:182280 SNOMEDCT_US_2020_03_01:254632001 UMLS_CUI:C0149925 disease_ontology DOID:5409 OMIM mapping confirmed by DO. [SN]. lung small cell carcinoma DOID:5409 A psychotic disorder that is characterized by recurring episodes of mood fluctuations and a loss of contact with reality. ICD10CM:F25 ICD9CM:295.7 MESH:D011618 NCI:C94378 SNOMEDCT_US_2020_03_01:231490005 UMLS_CUI:C0036337 disease_ontology DOID:5418 schizoaffective disorder DOID:5418 A psychotic disorder that is characterized by a disintegration of thought processes and of emotional responsiveness. DOID:14734 EFO:0000692 ICD10CM:F20 ICD9CM:295 MESH:D012559 NCI:C3362 OMIM:181500 SNOMEDCT_US_2020_03_01:58214004 UMLS_CUI:C0036341 schizophrenia-1 disease_ontology DOID:5419 Xref MGI. OMIM mapping confirmed by DO. [SN]. schizophrenia DOID:5419 An ovarian disease that is characterized by cystic enlargement of the ovaries and a fluid shift from the intravascular to the third space and has_symptom abdominal pain, has_symptom nausea and has_symptom vomiting. This disease is an iatrogenic complication of assisted reproduction technology. MESH:D016471 OMIM:608115 SNOMEDCT_US_2020_03_01:129635004 UMLS_CUI:C0085083 secondary Meig's syndrome disease_ontology DOID:5425 OMIM mapping confirmed by DO. [SN]. ovarian hyperstimulation syndrome DOID:5425 An ovarian disease where ovaries do not produce estrogen despite high levels of circulating gonadotropins in women under 40. ICD10CM:E28.3 MESH:D016649 NCI:C113352 OMIM:300511 OMIM:300604 OMIM:311360 OMIM:608996 OMIM:611548 OMIM:612310 OMIM:612964 OMIM:615723 OMIM:615724 ORDO:619 SNOMEDCT_US_2020_03_01:237788002 UMLS_CUI:C0085215 hypergonadotropic hypogonadism premature menopause premature ovarian insufficiency primary ovarian insufficiency disease_ontology DOID:5426 Xref MGI. OMIM mapping confirmed by DO. [SN]. premature ovarian failure DOID:5426 DOID:544 ICD10CM:G24 MESH:D004421 MESH:D020821 NCI:C34563 OMIM:PS128100 SNOMEDCT_US_2020_03_01:15802004 SNOMEDCT_US_2020_03_01:250068003 UMLS_CUI:C0013421 UMLS_CUI:C0393593 dystonic disease disease_ontology DOID:543 dystonia MESH:D004421 MESH:D020821 DOID:543 NCI:C39857 UMLS_CUI:C1511197 urinary bladder Papillary Urothelial neoplasm disease_ontology DOID:5432 bladder papillary transitional cell neoplasm DOID:5432 DOID:6120 NCI:C27883 NCI:C6192 SNOMEDCT_US_2020_03_01:733845009 UMLS_CUI:C1334282 UMLS_CUI:C1335329 Inverted papilloma of urinary tract Papillary transitional cell neoplasm of the urinary tract urinary tract inverted papilloma disease_ontology DOID:5433 urinary tract papillary transitional cell benign neoplasm DOID:5433 MESH:D012608 SNOMEDCT_US_2020_03_01:35103004 UMLS_CUI:C0036457 disease_ontology DOID:5434 scrapie DOID:5434 MESH:D016643 SNOMEDCT_US_2020_03_01:52869003 UMLS_CUI:C0085209 Bovine spongiform encephalopathy bovine spongiform encephalopathy disease_ontology DOID:5435 variant Creutzfeldt-Jakob disease DOID:5435 MESH:D018250 NCI:C7568 SNOMEDCT_US_2020_03_01:254719003 UMLS_CUI:C0206671 Eccrine acrospiroma Eccrine hidradenoma Eccrine hidradenoma of skin Poroma disease_ontology DOID:5442 eccrine acrospiroma DOID:5442 NCI:C7567 SNOMEDCT_US_2020_03_01:254719003 UMLS_CUI:C1370701 Clear cell Hidradenoma Clear cell hidradenoma Clear cell myoepithelioma disease_ontology DOID:5443 clear cell hidradenoma DOID:5443 DOID:1617 NCI:C4170 SNOMEDCT_US_2020_03_01:403938001 UMLS_CUI:C0334347 Eccrine spiradenoma Eccrine spiradenoma of skin benign eccrine spiradenoma disease_ontology DOID:5444 spiradenoma DOID:5444 GARD:5100 MESH:D000074009 NCI:C4172 SNOMEDCT_US_2020_03_01:8934006 UMLS_CUI:C0406803 Papillary Syringadenoma Papillary syringadenoma Syringocystadenoma papilliferum disease_ontology DOID:5445 syringocystadenoma papilliferum DOID:5445 GARD:10153 MESH:D011668 NCI:C85039 OMIM:265450 SNOMEDCT_US_2020_03_01:89420002 UMLS_CUI:C0034091 pulmonary veno-occlusive disease disease_ontology DOID:5453 OMIM mapping confirmed by DO. [SN]. pulmonary venoocclusive disease DOID:5453 A biliary tract benign neoplasm characterized by multiple papillary tumors in the intrahepatic and/or extrahepatic biliary tree. NCI:C65198 SNOMEDCT_US_2020_03_01:128663007 UMLS_CUI:C1266038 bile duct papillomatosis disease_ontology DOID:5468 biliary papillomatosis DOID:5468 An ovarian benign neoplasm that is composed_of epithelial ovarian tissue. MESH:D062625 NCI:C8985 SNOMEDCT_US_2020_03_01:2962009 UMLS_CUI:C0334317 Cystadenofibroma disease_ontology DOID:5482 cystadenofibroma DOID:5482 A synovium cancer which develops in the synovial membrane of the joints. GARD:7721 MESH:D013584 NCI:C3400 OMIM:300813 SNOMEDCT_US_2020_03_01:63211008 UMLS_CUI:C0039101 disease_ontology DOID:5485 Xref MGI. synovial sarcoma DOID:5485 A parasitic ectoparasitic infectious disease that involves infestation of lice, which are blood-feeding ectoparasitic insects of the order Phthiraptera. DOID:5490 DOID:5523 ICD10CM:B85.2 ICD9CM:132.9 MESH:D010373 NCI:C128401 SNOMEDCT_US_2020_03_01:74949007 UMLS_CUI:C0030756 Infestation by Pediculus Lice infestation Louse infestation Pediculosis + lice Pediculosis and phthirus infection Pediculosis and phthirus infections Pediculosis and phthirus infestation mixed pediculosis mixed pediculosis infestation pediculosis pediculosis and phthirus infection disease_ontology DOID:5502 lice infestation DOID:5502 A spinal cord glioma that has_material_basis_in cells linking the spinal cord central canal. NCI:C3875 SNOMEDCT_US_2020_03_01:254949006 UMLS_CUI:C0238432 Ependymal neoplasm of the Spinal Cord disease_ontology DOID:5503 spinal cord ependymoma DOID:5503 NCI:C6903 SNOMEDCT_US_2020_03_01:57706008 UMLS_CUI:C1370500 disease_ontology DOID:5504 tanycytic ependymoma DOID:5504 MESH:D004806 NCI:C4319 SNOMEDCT_US_2020_03_01:112686007 UMLS_CUI:C0334578 disease_ontology DOID:5505 papillary ependymoma DOID:5505 A nasal cavity carcinoma that has_material_basis_in squamous cells. NCI:C8192 UMLS_CUI:C0280333 squamous cell carcinoma of the nasal cavity disease_ontology squamous cell carcinoma of nasal cavity DOID:5515 nasal cavity squamous cell carcinoma DOID:5515 A stomach cancer that is located_in the stomach. EFO:0000178 NCI:C4911 SNOMEDCT_US_2020_03_01:154446008 UMLS_CUI:C0699791 cancer of the stomach carcinoma of stomach gastric carcinoma disease_ontology DOID:5517 stomach carcinoma DOID:5517 A lung disease that involves lung parenchyma or alveolar inflammation and abnormal alveolar filling with fluid (consolidation and exudation). It results from a variety of causes including infection with bacteria, viruses, fungi or parasites, and chemical or physical injury to the lungs. It is accompanied by fever, chills, cough, and difficulty in breathing. DOID:10509 DOID:11742 DOID:5871 MESH:D011014 NCI:C3333 SNOMEDCT_US_2020_03_01:266391003 UMLS_CUI:C0032285 acute pneumonia disease_ontology DOID:552 pneumonia DOID:552 A squamous cell carcinoma that has a solid, closely packed growth of cells with hyperchromatic nuclei, scant cytoplasm, small cystic spaces, and foci of necrosis. It has overlying squamous dysplasia, rare foci of overt keratinization, and/or coexistent keratinizing squamous cell carcinoma. NCI:C54244 SNOMEDCT_US_2020_03_01:128634009 UMLS_CUI:C1266005 Basaloid carcinoma Basaloid squamous cell carcinoma disease_ontology DOID:5522 basaloid squamous cell carcinoma DOID:5522 An anal carcinoma that arises near the squamocolumnar junction. NCI:C9161 SNOMEDCT_US_2020_03_01:255084004 UMLS_CUI:C1412036 Epidermoid anal carcinoma disease_ontology DOID:5525 anal squamous cell carcinoma DOID:5525 A squamous cell carcinoma that is located_in the gallbladder. NCI:C9170 UMLS_CUI:C0279658 Epidermoid gallbladder carcinoma disease_ontology squamous cell carcinoma of the gallbladder DOID:5535 gallbladder squamous cell carcinoma DOID:5535 A teratoma that is composed exclusively of mature tissues derived from two or three germ layers. NCI:C9015 SNOMEDCT_US_2020_03_01:55818009 UMLS_CUI:C1368910 disease_ontology DOID:5566 mature teratoma DOID:5566 NCI:C8110 SNOMEDCT_US_2020_03_01:716077006 UMLS_CUI:C0280131 germ cell teratoma of Ovary disease_ontology DOID:5567 ovarian germ cell teratoma DOID:5567 Microcystic Adnexal carcinoma Microcystic adnexal carcinoma of skin Syringomatous carcinoma disease_ontology DOID:5569 malignant syringoma DOID:5569 A urinary system disease that is located_in the kidney. DOID:11705 EFO:0003086 ICD10CM:N08 MESH:D007674 NCI:C3149 SNOMEDCT_US_2020_03_01:266612003 UMLS_CUI:C0022658 impaired renal function disease nephropathy disease_ontology DOID:557 kidney disease DOID:557 A syndrome characterized by overgrowth (macrosomia), an increased risk of childhood cancer and congenital malformations. GARD:3343 ICD10CM:Q87.3 MESH:D001506 NCI:C34415 OMIM:130650 ORDO:116 SNOMEDCT_US_2020_03_01:81780002 UMLS_CUI:C0004903 disease_ontology DOID:5572 OMIM mapping confirmed by DO. [SN]. Beckwith-Wiedemann syndrome MESH:D001506 DOID:5572 GARD:5493 MESH:D003969 NCI:C26749 SNOMEDCT_US_2020_03_01:447643008 UMLS_CUI:C0011993 VIP- Secreting tumor Vasoactive intestinal peptide-secreting tumor Vipoma, malignant malignant vasoactive intestinal peptide-secreting tumor disease_ontology DOID:5574 VIPoma DOID:5574 A neuroendocrine tumor that results_in an overproduction of gastric acid. MESH:D015408 NCI:C3050 SNOMEDCT_US_2020_03_01:16189002 UMLS_CUI:C0017150 Gastrin Secreting tumor Gastrin cell tumour malignant gastrinoma disease_ontology DOID:5577 gastrinoma DOID:5577 NCI:C9069 UMLS_CUI:C1368066 pancreatic G-cell tumor disease_ontology DOID:5580 pancreatic gastrinoma DOID:5580 A breast carcinoma that is characterized by the presence of arborescent fibrovascular stalks lined by epithelial cells, grossly forming a circumscribed mass. DOID:6800 NCI:C6870 UMLS_CUI:C1336027 Papillary carcinoma of the breast breast solid papillary carcinoma disease_ontology papillary carcinoma of breast solid papillary carcinoma of the breast DOID:5592 breast papillary carcinoma DOID:5592 An acute lymphoblastic leukemia that is characterized by too many T-cell lymphoblasts found in the bone marrow and blood. DOID:5599 ICD10CM:C91.5 MESH:D015459 NCI:C3184 SNOMEDCT_US_2020_03_01:77430005 UMLS_CUI:C0023493 Precursor T Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia T-cell acute lymphocytic leukaemia acute T cell leukaemia acute T cell leukemia precursor T-lymphoblastic lymphoma/leukemia disease_ontology DOID:5603 T-cell acute lymphoblastic leukemia DOID:5603 An acute lymphocytic leukemia occurring during adulthood. NCI:C4967 UMLS_CUI:C0751606 adult ALL adult acute lymphoid Leukemia disease_ontology DOID:5604 adult acute lymphocytic leukemia DOID:5604 ICD10CM:K04.2 MESH:D003784 SNOMEDCT_US_2020_03_01:57602001 UMLS_CUI:C0011401 pulp calcification pulp calcifications pulpal calcifications disease_ontology DOID:5608 dental pulp calcification DOID:5608 ICD9CM:350.8 UMLS_CUI:C0029834 disease_ontology DOID:561 trigeminal nerve disease DOID:561 A central nervous system cancer that is located_in the spinal cord. It is mostly formed from metastases from primary cancers elsewhere (commonly breast, prostate, and lung cancer). DOID:3638 DOID:7225 ICD10CM:C72.0 ICD9CM:192.2 MESH:D013120 MESH:D013125 NCI:C3381 NCI:C3572 SNOMEDCT_US_2020_03_01:126962006 SNOMEDCT_US_2020_03_01:709289008 SNOMEDCT_US_2020_03_01:94068003 UMLS_CUI:C0037930 UMLS_CUI:C0037939 UMLS_CUI:C0153646 Intraspinal tumor malignant tumor of the Spinal Cord spinal cord cancer spinal cord neoplasm tumor of the Spinal Cord disease_ontology spinal neoplasm DOID:5612 spinal cancer DOID:5612 An eye and adnexa disease that is located_in the eye. DOID:2933 ICD10CM:H44 ICD9CM:379.90 MESH:D005128 NCI:C26767 SNOMEDCT_US_2020_03_01:371409005 UMLS_CUI:C0015397 disease_ontology DOID:5614 eye disease DOID:5614 A sarcoma and hematologic cancer that derives_from follicular lymphoma. NCI:C9294 UMLS_CUI:C1334030 histiocytic and dendritic cell disease_ontology DOID:5621 histiocytic and dendritic cell cancer DOID:5621 NCI:C4538 SNOMEDCT_US_2020_03_01:254978007 UMLS_CUI:C0346328 meningioma of optic nerve sheath optic nerve Sheath meningioma disease_ontology DOID:5632 optic nerve sheath meningioma DOID:5632 A cervical carcinoma that derives_from squamous cells and gland-like cells. NCI:C4519 SNOMEDCT_US_2020_03_01:254888007 UMLS_CUI:C0346202 Adenosquamous carcinoma of cervix Adenosquamous cell carcinoma of the Cervix Uteri disease_ontology DOID:5636 cervical adenosquamous carcinoma DOID:5636 MESH:D014263 SNOMEDCT_US_2020_03_01:253383003 UMLS_CUI:C0040962 disease_ontology DOID:5644 tricuspid valve prolapse DOID:5644 A choroid plexus cancer that has_material_basis_in epithelial cells of the choroid plexus. DOID:5647 GARD:8238 MESH:C562943 NCI:C4533 NCI:C4715 SNOMEDCT_US_2020_03_01:188292007 SNOMEDCT_US_2020_03_01:88252006 UMLS_CUI:C0346289 UMLS_CUI:C0431109 disease_ontology DOID:5648 choroid plexus carcinoma DOID:5648 A neuropathy that is located_in one of the twelve cranial nerves. ICD10CM:G52.9 ICD9CM:352.9 MESH:D003389 NCI:C26733 SNOMEDCT_US_2020_03_01:73013002 UMLS_CUI:C0010266 Cranial nerve disorder disorder of cranial nerve disease_ontology DOID:5656 cranial nerve disease DOID:5656 A breast carcinoma characterized by the presence of malignant epithelial cells with clear cytoplasm which contains neutral lipids. NCI:C4152 SNOMEDCT_US_2020_03_01:189655006 UMLS_CUI:C0334318 disease_ontology DOID:5658 lipid-rich carcinoma DOID:5658 ICD10CM:H83.2 ICD9CM:386.5 SNOMEDCT_US_2020_03_01:5239005 UMLS_CUI:C0155514 disease_ontology DOID:566 labyrinthine dysfunction DOID:566 An ear cancer that is located_in the external ear. NCI:C4653 SNOMEDCT_US_2020_03_01:277156006 UMLS_CUI:C0349576 malignant neoplasm of the External ear malignant tumor of external ear disease_ontology DOID:5665 external ear cancer DOID:5665 An intestinal cancer that effects the long, tube-like organ that is connected to the small intestine at one end and the anus at the other. DOID:1994 DOID:1997 ICD10CM:C18.9 NCI:C4978 SNOMEDCT_US_2020_03_01:93854002 UMLS_CUI:C0346629 disease_ontology DOID:5672 large intestine cancer DOID:5672 A breast carcinoma that is characterized by an irregular cribriform growth pattern, nuclear grade I in at least 90% of cells, and absent myoepithelial cells. MESH:D000230 NCI:C3680 SNOMEDCT_US_2020_03_01:30156004 UMLS_CUI:C0205643 Cribriform carcinoma ductal carcinoma, cribriform type disease_ontology DOID:5675 cribriform carcinoma DOID:5675 An eye disease that is located_in the retina. ICD10CM:H35.9 ICD9CM:362.9 MESH:D012164 NCI:C26875 SNOMEDCT_US_2020_03_01:29555009 UMLS_CUI:C0035309 disease_ontology DOID:5679 retinal disease DOID:5679 A syndrome characterized by the higher than normal tendency associated with BRCA1 and BRCA2 to develop breast and ovarian cancers in genetically related families. MESH:D061325 NCI:C8493 SNOMEDCT_US_2020_03_01:718220008 UMLS_CUI:C0677776 BRCA1- and BRCA2-associated hereditary breast and ovarian cancer disease_ontology DOID:5683 Xref MGI. hereditary breast ovarian cancer syndrome DOID:5683 A spondyloepimetaphyseal dysplasia that is characterized by spondylar and nasal changes, with striations of the metaphyses that has_material_basis_in autosomal recessive inheritance. NCI:C92206 OMIM:271510 UMLS_CUI:C0920349 Spondylar and nasal Alterations-Striated Metaphyses syndrome sponastrime dysplasia disease_ontology DOID:5684 spondyloepimetaphyseal dysplasia, Sponastrime type DOID:5684 A syndrome characterized by premature aging and age-related phenotypes such as atherosclerosis, arteriosclerosis, cataracts, osteoporosis, soft tissue calcification, premature thinning, graying, and loss of hair, as well as a high incidence of some types of cancers and that has_material_basis_in mutations in the WRN gene, on chromosome 8. GARD:7885 MESH:D014898 NCI:C3447 OMIM:277700 ORDO:902 SNOMEDCT_US_2020_03_01:51626007 UMLS_CUI:C0043119 WS Werner's syndrome adult premature ageing syndrome adult progeria disease_ontology DOID:5688 OMIM mapping confirmed by DO. [LS]. Werner syndrome DOID:5688 ICD10CM:H47.6 ICD9CM:377.7 NCI:C35275 SNOMEDCT_US_2020_03_01:128329001 UMLS_CUI:C0234398 visual cortex dysfunction disease_ontology DOID:5691 visual cortex disease DOID:5691 An aortic valve disease that is characterized by leaking of the aortic valve of the heart causes blood to flow in the reverse direction during ventricular diastole, from the aorta into the left ventricle. DOID:54 DOID:55 ICD10CM:I06.1 ICD9CM:395.1 ICD9CM:396.3 MESH:D001022 NCI:C51223 SNOMEDCT_US_2020_03_01:155283004 SNOMEDCT_US_2020_03_01:194736003 SNOMEDCT_US_2020_03_01:60234000 UMLS_CUI:C0003504 UMLS_CUI:C0155568 UMLS_CUI:C0264774 Rheumatic aortic insufficiency Rheumatic aortic regurgitation Rheumatic aortic valve regurgitation aortic incompetence aortic insufficiency aortic regurgitation rheumatic aortic valve insufficiency disease_ontology Corrigan's disease DOID:57 aortic valve insufficiency DOID:57 ICD10CM:G56.10 ICD9CM:354.1 SNOMEDCT_US_2020_03_01:193127001 UMLS_CUI:C0154742 disease_ontology DOID:571 median neuropathy DOID:571 DOID:6254 NCI:C7047 NCI:C7911 UMLS_CUI:C0278864 UMLS_CUI:C0851693 Pituitary tumors, Hormone Producing Somatotropinoma growth hormone producing pituitary tumor disease_ontology DOID:5716 hormone producing pituitary cancer DOID:5716 An adrenal gland cancer that derives_from immature neuroblastic cells. NCI:C4827 SNOMEDCT_US_2020_03_01:281562007 UMLS_CUI:C0559460 neuroblastoma of Adrenal gland disease_ontology DOID:5718 adrenal neuroblastoma DOID:5718 ICD9CM:354 SNOMEDCT_US_2020_03_01:193125009 UMLS_CUI:C0154741 disease_ontology DOID:572 mononeuritis of upper limb and mononeuritis multiplex DOID:572 An optic nerve disease that is characterized the death of the retinal ganglion cell axons that comprise the optic nerve. ICD10CM:H47.2 ICD9CM:377.1 MESH:D009896 NCI:C34863 OMIM:PS165500 ORDO:98673 SNOMEDCT_US_2020_03_01:155188004 UMLS_CUI:C0029124 atrophy of optic disc disease_ontology DOID:5723 Xref MGI. optic atrophy DOID:5723 DOID:7318 MESH:D009408 NCI:C27221 SNOMEDCT_US_2020_03_01:45781009 UMLS_CUI:C0027743 UMLS_CUI:C1510429 Compression neuropathy Entrapment Neuropathy entrapment neuropathy peripheral nerve entrapment syndrome disease_ontology DOID:573 nerve compression syndrome DOID:573 ICD10CM:N70 NCI:C34968 SNOMEDCT_US_2020_03_01:155974004 UMLS_CUI:C0034220 Pyosalpingitis disease_ontology DOID:5732 pyosalpinx DOID:5732 A fallopian tube disease that is characterized by inflammation of the fallopian tube. ICD10CM:N70.91 MESH:D012488 NCI:C26880 SNOMEDCT_US_2020_03_01:155968004 UMLS_CUI:C0036130 disease_ontology DOID:5733 salpingitis DOID:5733 A nervous system disease that affects the peripheral nervous system. DOID:13069 NCI:C119734 NCI:C27587 UMLS_CUI:C0031117 UMLS_CUI:C1335029 disease_ontology peripheral nerve disease peripheral neuropathy DOID:574 peripheral nervous system disease DOID:574 A pancreatic adenocarcinoma that has_material_basis_in cells with morphological resemblance to acinar cells and is associated with increased serum lipase. NCI:C7977 SNOMEDCT_US_2020_03_01:783771003 UMLS_CUI:C0279661 pancreatic acinar cell carcinoma disease_ontology DOID:5742 pancreatic acinar cell adenocarcinoma DOID:5742 An ovary serous adenocarcinoma that has_material_basis_in glandular epithelium, in which cystic accumulations of retained secretions are formed. NCI:C7978 UMLS_CUI:C0279663 serous cystadenoma disease_ontology DOID:5746 ovarian serous cystadenocarcinoma DOID:5746 ICD9CM:424.3 NCI:C78579 SNOMEDCT_US_2020_03_01:76267008 UMLS_CUI:C0034087 pulmonary valve disorder disease_ontology DOID:5749 pulmonary valve disease DOID:5749 A cervicitis that is located_in the endocervix. NCI:C26762 SNOMEDCT_US_2020_03_01:155980007 UMLS_CUI:C0014127 disease_ontology DOID:5757 endocervicitis DOID:5757 GARD:3369 MESH:C535700 NCI:C4268 SNOMEDCT_US_2020_03_01:89623007 UMLS_CUI:C0334492 Mesenchymoma, malignant disease_ontology DOID:5758 malignant mesenchymoma DOID:5758 MESH:D012626 NCI:C3363 SNOMEDCT_US_2020_03_01:126491004 UMLS_CUI:C0036503 Sebaceous neoplasm disease_ontology DOID:5759 sebaceous gland neoplasm DOID:5759 A kidney disease that is characterized by the presence of excess proteins in the urine. ICD10CM:R80 ICD9CM:791.0 MESH:D011507 NCI:C38012 SNOMEDCT_US_2020_03_01:144515004 UMLS_CUI:C0033687 disease_ontology DOID:576 proteinuria DOID:576 NCI:C4478 SNOMEDCT_US_2020_03_01:254756007 UMLS_CUI:C0346054 Cutaneous Verruciform Xanthoma Verruciform xanthoma Verruciform xanthoma of skin disease_ontology DOID:5769 verruciform xanthoma of skin DOID:5769 A hematologic cancer and central nervous system neoplasm that is located_in the central nervous system. NCI:C5503 UMLS_CUI:C1332882 CNS hematopoietic tumor disease_ontology hematopoietic neoplasm of central nervous system DOID:5772 central nervous system hematologic cancer DOID:5772 A mouth disease that is characterized by juxta-epithelial inflammatory reaction and progressive fibrosis of the submucosal tissues. DOID:9679 GARD:7264 ICD10CM:K13.5 ICD9CM:528.8 MESH:D009914 NCI:C34866 SNOMEDCT_US_2020_03_01:32883009 UMLS_CUI:C0029171 UMLS_CUI:C0029172 Oral cavity Submucous Fibrosis Oral submucosal fibrosis Oral submucosal fibrosis, including of tongue disease_ontology DOID:5773 oral submucous fibrosis DOID:5773 ICD10CM:H73.9 ICD9CM:384.9 SNOMEDCT_US_2020_03_01:21426000 UMLS_CUI:C0041825 disease_ontology DOID:5782 tympanic membrane disease DOID:5782 A nephrolithiasis that is characterized by stones composed predominantly uric acid. ICD9CM:274.11 NCI:C123245 OMIM:605990 SNOMEDCT_US_2020_03_01:267441009 UMLS_CUI:C0403719 acute urate nephropathy disease_ontology DOID:580 uric acid nephrolithiasis DOID:580 MESH:D021922 UMLS_CUI:C0012628 disease_ontology DOID:5804 discrete subaortic stenosis DOID:5804 An aortic valve stenosis that is characterized by a narrowing of the section of the heart under the aortic valve resulting in left ventricular outflow obstruction. GARD:5052 MESH:D001020 NCI:C85172 SNOMEDCT_US_2020_03_01:250915007 UMLS_CUI:C0340375 disease_ontology DOID:5805 subvalvular aortic stenosis DOID:5805 A combined T cell and B cell immunodeficiency that is a rare autosomal recessive metabolic disorder that has_material_basis_in mutation in the PNP gene and characterized mainly by decreased T-cell function. GARD:4606 ICD10CM:D81.5 MESH:C562587 NCI:C3963 OMIM:613179 ORDO:760 SNOMEDCT_US_2020_03_01:60743005 UMLS_CUI:C0268125 PNP deficiency Purine nucleoside phosphorylase deficiency Purine-Nucleoside Phosphorylase deficiency deficiency of inosine phosphorylase disease_ontology DOID:5813 OMIM mapping confirmed by DO. [SN]. purine nucleoside phosphorylase deficiency DOID:5813 A lymphoma that begins in cells of the immune system in which different types of lymphoma cells occur at the same time. MESH:D058617 NCI:C38661 UMLS_CUI:C0545080 disease_ontology DOID:5820 composite lymphoma DOID:5820 A lymphoma that is characterized by having cellular features of both classic Hodgkin's lymphomas and large B-cell Lymphomas. GARD:10897 NCI:C37869 SNOMEDCT_US_2020_03_01:722954005 UMLS_CUI:C1333878 disease_ontology DOID:5822 gray zone lymphoma DOID:5822 A breast cancer that arises_from lymphocytes. SNOMEDCT_US_2020_03_01:278052009 UMLS_CUI:C0349669 Lymphoma of the breast lymphoma of breast malignant lymphoma of breast disease_ontology DOID:5826 breast lymphoma DOID:5826 An ovary adenocarcinoma that has_material_basis_in endometrial tissue. NCI:C7979 SNOMEDCT_US_2020_03_01:254852002 UMLS_CUI:C0346163 Ovarian endometrioid carcinoma endometrioid carcinoma ovary disease_ontology endometrioid carcinoma of ovary DOID:5828 endometrioid ovary carcinoma DOID:5828 ICD10CM:D55-D59 MESH:D000743 NCI:C34376 OMIM:266120 OMIM:612631 SNOMEDCT_US_2020_03_01:61261009 UMLS_CUI:C0002878 ANEMIA HEMOLYTIC disease_ontology DOID:583 OMIM mapping confirmed by DO. [SN]. OMIM mapping by NeuroDevNet. [LS]. hemolytic anemia DOID:583 NCI:C39921 SNOMEDCT_US_2020_03_01:9294008 UMLS_CUI:C0334517 Spermatocytic Seminoma Spermatocytic seminoma disease_ontology DOID:5834 spermatocytoma DOID:5834 DOID:6136 NCI:C7327 UMLS_CUI:C1333502 primary extragonadal seminoma disease_ontology DOID:5838 extragonadal seminoma DOID:5838 MESH:D018239 NCI:C9309 SNOMEDCT_US_2020_03_01:443675005 UMLS_CUI:C0036631 Seminoma of testis Seminoma testis testicular Seminoma Pure disease_ontology DOID:5842 testis seminoma DOID:5842 A coronary artery disease characterized by myocardial cell death (myocardial necrosis) due to prolonged ischaemia. EFO:0000612 ICD10CM:I21 MESH:D009203 NCI:C27996 OMIM:608557 SNOMEDCT_US_2020_03_01:66514008 UMLS_CUI:C0027051 Myocardial infarct heart attack disease_ontology DOID:5844 Xref MGI. myocardial infarction DOID:5844 SNOMEDCT_US_2020_03_01:194800006 UMLS_CUI:C0340319 Posterior myocardial infarction disease_ontology DOID:5847 posterior myocardial infarction DOID:5847 A kidney disease characterized by the formation of stoney concentrations in the kidneys. EFO:0004253 ICD10CM:N20 ICD9CM:592 SNOMEDCT_US_2020_03_01:155867005 UMLS_CUI:C0156257 Stone - kidney/ureter kidney stones disease_ontology DOID:585 OMIM mapping confirmed by DO. [SN]. nephrolithiasis MESH:D053040 DOID:585 MESH:D056989 SNOMEDCT_US_2020_03_01:194804002 UMLS_CUI:C0340305 Inferior myocardial infarction disease_ontology DOID:5850 inferior myocardial infarction DOID:5850 MESH:D056988 UMLS_CUI:C0262565 disease_ontology DOID:5855 anteroseptal myocardial infarction DOID:5855 A pneumonia in which certain type of white blood cell called an eosinophil accumulates in the lung. These cells cause disruption of the normal air spaces (alveoli) where oxygen is extracted from the atmosphere. It is caused by certain medications or environmental triggers, parasitic infections, and cancer. The most common symptoms include cough, fever, difficulty breathing, and sweating at night. GARD:107 ICD10CM:J82 MESH:D011657 NCI:C35150 SNOMEDCT_US_2020_03_01:196145005 UMLS_CUI:C1527407 Pneumonia, eosinophilic disease_ontology DOID:5870 eosinophilic pneumonia DOID:5870 An organ system cancer located_in the retroperitoneal space that is manifested in retroperitoneal space in the abdominal cavity behind the peritoneum. DOID:12340 DOID:9860 ICD10CM:C48 ICD10CM:C48.0 ICD9CM:158 ICD9CM:158.0 MESH:D012186 NCI:C3357 NCI:C3537 SNOMEDCT_US_2020_03_01:187801002 SNOMEDCT_US_2020_03_01:254617008 SNOMEDCT_US_2020_03_01:363420003 UMLS_CUI:C0035358 UMLS_CUI:C0153464 UMLS_CUI:C0153465 malignant neoplasm of retroperitoneum and peritoneum malignant tumor of peritoneum and retroperitoneum neoplasm of retroperitoneum neoplasm of the retroperitoneum retroperitoneal neoplasm tumor of retroperitoneum disease_ontology malignant neoplasm of retroperitoneum malignant retroperitoneal cancer DOID:5875 retroperitoneal cancer DOID:5875 NCI:C6798 UMLS_CUI:C1332318 Apocrine tumor disease_ontology DOID:5876 apocrine sweat gland neoplasm DOID:5876 GARD:6167 ICD10CM:D58.9 ICD9CM:282 MESH:D000745 NCI:C34379 SNOMEDCT_US_2020_03_01:42601008 UMLS_CUI:C0002881 congenital hemolytic anaemia hereditary hemolytic anaemia hereditary hemolytic anemia disease_ontology DOID:589 congenital hemolytic anemia DOID:589 An anxiety disorder where fear and anxiety are triggered by a specific stimulus or situation. ICD10CM:F40 ICD9CM:300.20 MESH:D010698 NCI:C35420 SNOMEDCT_US_2020_03_01:52039009 UMLS_CUI:C0349231 disease_ontology DOID:591 phobic disorder DOID:591 A phobic disorder involving the specific anxiety about being in a place or situation where escape is difficult or embarrassing or where help may be unavailable. ICD10CM:F40.0 MESH:D000379 NCI:C34362 SNOMEDCT_US_2020_03_01:154885006 UMLS_CUI:C0001818 Fear of open spaces disease_ontology DOID:593 agoraphobia DOID:593 An anxiety disorder that is characterized by unexpected and repeated episodes of intense fear accompanied by physical symptoms that may include chest pain, heart palpitations, shortness of breath, dizziness, or abdominal distress. EFO:0004262 ICD10CM:F41.0 MESH:D016584 NCI:C34890 OMIM:167870 OMIM:607853 OMIM:609985 SNOMEDCT_US_2020_03_01:191705007 UMLS_CUI:C0030319 panic anxiety syndrome disease_ontology DOID:594 Xref MGI. panic disorder DOID:594 GARD:10872 MESH:D018319 NCI:C3798 SNOMEDCT_US_2020_03_01:134324009 UMLS_CUI:C0751690 malignant neoplasm of the peripheral nerve Sheath disease_ontology DOID:5940 malignant peripheral nerve sheath tumor DOID:5940 DOID:10961 DOID:1547 ICD10CM:I65.9 ICD9CM:433.9 UMLS_CUI:C0155727 disease_ontology Occlusion and stenosis of multiple and bilateral precerebral arteries occlusion and stenosis of precerebral artery DOID:5976 occlusion precerebral artery DOID:5976 A phobic disorder that is characterized by an unreasonable or irrational fear related to exposure to specific objects or situations. ICD10CM:F40.2 MESH:C562465 NCI:C35284 OMIM:608251 SNOMEDCT_US_2020_03_01:54587008 UMLS_CUI:C0236801 simple phobia disease_ontology DOID:599 specific phobia DOID:599 A heart disease that is characterized by any structural or functional cardiac disorder that impairs the ability of the heart to fill with or pump a sufficient amount of blood throughout the body. DOID:395 ICD10CM:I50 ICD10CM:I50.9 ICD9CM:428 ICD9CM:428.0 MESH:D006333 NCI:C3080 NCI:C50577 SNOMEDCT_US_2020_03_01:155374007 SNOMEDCT_US_2020_03_01:195108009 UMLS_CUI:C0018801 UMLS_CUI:C0018802 CHF Cardiac Failure Congestive Congestive heart disease Weak heart disease_ontology DOID:6000 congestive heart failure DOID:6000 A gastrointestinal system disease that is located_in the appendix. disease_ontology DOID:60000 appendix disease DOID:60000 An artery disease that is located in the lungs. disease_ontology DOID:60001 pulmonary artery disease DOID:60001 disease_ontology DOID:60004 malignant cystadenoma DOID:60004 disease_ontology DOID:60006 benign vascular tumor DOID:60006 A cardiovascular organ benign neoplasm that is located_in the cerebrovascular system. disease_ontology DOID:60007 cerebrovascular benign neoplasm DOID:60007 An endocrine organ benign neoplasm that is located_in some parathyroid gland. disease_ontology DOID:60008 parathyroid gland benign neoplasm DOID:60008 A benign neoplasm located in the pituitary gland. disease_ontology DOID:60009 pituitary gland benign neoplasm DOID:60009 A B cell deficiency that is characterized by deficiency of an immunoglobulin subtype. The clinical course and prognosis is dependent upon the severity of the selective deficiency and associated morbidity. NCI:C27870 UMLS_CUI:C1335942 disease_ontology DOID:6025 selective immunoglobulin deficiency disease DOID:6025 DOID:5332 NCI:C39947 NCI:C4207 SNOMEDCT_US_2020_03_01:189735004 UMLS_CUI:C0334403 UMLS_CUI:C1515285 Juvenile granulosa cell tumor Juvenile granulosa cell tumour Juvenile type Granulosa cell tumor Juvenile type Granulosa cell tumour juvenile type granulosa cell neoplasm juvenile type testicular granulosa cell tumour disease_ontology DOID:6032 juvenile type testicular granulosa cell tumor DOID:6032 A gastrointestinal system disease that is located_in the esophagus. DOID:10117 DOID:10118 DOID:11798 ICD10CM:K22.9 ICD9CM:530.9 MESH:D004935 NCI:C3027 SNOMEDCT_US_2020_03_01:266497000 UMLS_CUI:C0014852 esophageal Ulcer disease_ontology DOID:6050 esophageal disease DOID:6050 An ovary epithelial cancer that is characterized by the presence of mucin. DOID:3712 NCI:C40033 NCI:C5242 SNOMEDCT_US_2020_03_01:189683008 UMLS_CUI:C1335168 UMLS_CUI:C1518233 Ovarian mucinous tumor malignant ovarian mucinous neoplasm mucinous tumor of Ovary disease_ontology DOID:6067 ovarian mucinous neoplasm DOID:6067 GARD:7327 ICD10CM:G82.2 ICD9CM:344.1 MESH:D010264 NCI:C50687 SNOMEDCT_US_2020_03_01:155031004 UMLS_CUI:C0030486 Paraplegia, lower disease_ontology DOID:607 paraplegia DOID:607 An anxiety disorder that has_symptom flashbacks, has_symptom bad dreams, has_symptom frightening thoughts, has_symptom avoidance or has_symptom hyperarousal of PTSD occurring within one month of a traumatic experience as Acute Stress Disorder or ASD. ICD9CM:308.3 SNOMEDCT_US_2020_03_01:192043003 UMLS_CUI:C0029488 traumatic stress disorder disease_ontology DOID:6088 acute stress disorder DOID:6088 DOID:11505 DOID:58 DOID:59 ICD10CM:I05 ICD10CM:I05.1 ICD9CM:394 ICD9CM:394.1 ICD9CM:424.0 NCI:C78446 SNOMEDCT_US_2020_03_01:11851006 SNOMEDCT_US_2020_03_01:155278007 SNOMEDCT_US_2020_03_01:83898004 UMLS_CUI:C0026265 UMLS_CUI:C0155563 UMLS_CUI:C0264765 Mitral RH valve dis. Rheumatic disease of mitral valve Rheumatic mitral insufficiency Rheumatic mitral valve changes Rheumatic mitral valve regurgitation chronic rheumatic mitral valve disease of mitral valve rheumatic disease of mitral valve rheumatic mitral valve incompetence disease_ontology DOID:61 mitral valve disease DOID:61 NCI:C5293 UMLS_CUI:C1334298 meningioma of the Jugular Foramen disease_ontology DOID:6110 jugular foramen meningioma DOID:6110 An immune system disease that results when one or more essential parts of the immune system is missing or not working properly at birth due to a genetic mutation. ICD10CM:D84.9 ICD9CM:279.3 KEGG:05340 MESH:D007153 NCI:C39725 OMIM:242850 OMIM:PS300755 SNOMEDCT_US_2020_03_01:191005003 UMLS_CUI:C0021051 hypoimmunity immune deficiency disorder immunodeficiency syndrome disease_ontology DOID:612 Xref MGI. primary immunodeficiency disease DOID:612 An anal canal cancer that derives_from epithelial cells. MESH:C563020 NCI:C7489 OMIM:105580 SNOMEDCT_US_2020_03_01:285310000 UMLS_CUI:C0563211 anal canal and Perianal gland carcinoma disease_ontology DOID:6126 OMIM mapping confirmed by DO. [SN]. anal canal carcinoma DOID:6126 A bronchial disease that is an inflammation of the bronchial tubes. It is caused by bacteria and viruses. The disease has_symptom cough with mucus, has_symptom shortness of breath, has_symptom low fever and has_symptom chest tightness. DOID:13503 DOID:13504 DOID:13707 DOID:13728 DOID:13729 DOID:5049 DOID:6130 DOID:6131 DOID:9982 DOID:9983 ICD10CM:J20 ICD10CM:J40 ICD10CM:J42 ICD9CM:466.0 ICD9CM:490 ICD9CM:491 MESH:D001991 MESH:D029481 NCI:C26722 NCI:C26932 NCI:C2911 SNOMEDCT_US_2020_03_01:155512004 SNOMEDCT_US_2020_03_01:155566007 SNOMEDCT_US_2020_03_01:32398004 UMLS_CUI:C0006277 UMLS_CUI:C0008677 UMLS_CUI:C0149514 CI - Chest infection Chest infection acute Bronchitis chest cold chronic bronchitis recurrent wheezy bronchitis disease_ontology acute bronchitis and bronchiolitis DOID:6132 bronchitis DOID:6132 A leukopenia that is the condition of having an abnormally low level of lymphocytes in the blood. ICD10CM:D72.810 ICD9CM:288.51 MESH:D008231 SNOMEDCT_US_2020_03_01:48813009 UMLS_CUI:C0024312 Lymphocytopenia disease_ontology DOID:614 lymphopenia DOID:614 A leukocyte disorder that is characterized by a decrease in the number of white blood cells (leukocytes) found in the blood, which places individuals at increased risk of infection. ICD10CM:D72.819 ICD9CM:288.50 MESH:D007970 SNOMEDCT_US_2020_03_01:142917003 UMLS_CUI:C0023530 Leucopenia disease_ontology DOID:615 leukopenia MESH:D007970 DOID:615 An ovarian carcinoma that is an undifferentiated neoplasm composed of primitive-appearing cells. GARD:10411 NCI:C27390 disease_ontology DOID:6179 ovarian small cell carcinoma DOID:6179 A connective tissue cancer that is characterized by the presence of epithelioid cells forming nodular patterns and has_material_basis_in mesenchymal tissue. GARD:10181 MESH:D012509 NCI:C3714 SNOMEDCT_US_2020_03_01:782827000 UMLS_CUI:C0205944 epithelioid cell sarcoma disease_ontology DOID:6193 epithelioid sarcoma DOID:6193 A conjunctival disease characterized by an inflammation of the conjunctiva, the outermost layer of the eye and the inner surface of the eyelids. ICD10CM:H10 ICD9CM:372.30 MESH:D003231 NCI:C34504 SNOMEDCT_US_2020_03_01:193857008 UMLS_CUI:C0009763 disease_ontology Madras eye DOID:6195 conjunctivitis DOID:6195 An arthritis that is an autoimmune disease which develops due to an infection located elsewhere in the body. DOID:10148 DOID:11891 DOID:13318 DOID:13519 DOID:13782 DOID:13783 DOID:13784 DOID:13785 DOID:6194 DOID:9760 GARD:5693 ICD10CM:M02.10 ICD10CM:M02.3 ICD9CM:099.3 ICD9CM:711.30 MESH:D016918 NCI:C34975 SNOMEDCT_US_2020_03_01:266212009 SNOMEDCT_US_2020_03_01:56528004 UMLS_CUI:C0035012 UMLS_CUI:C0152085 Fiessinger Leroy Reiter syndrome Post-bacterial arthropathy Reactive arthritis Reiter disease Reiter's disease postdysenteric arthropathy disease_ontology DOID:6196 reactive arthritis DOID:6196 DOID:12757 ICD10CM:C69.1 ICD9CM:190.4 NCI:C3565 NCI:C4361 SNOMEDCT_US_2020_03_01:126997008 SNOMEDCT_US_2020_03_01:93766000 UMLS_CUI:C0153629 UMLS_CUI:C0339304 Corneal tumor malignant Corneal tumor malignant neoplasm of cornea malignant tumor of cornea neoplasm of cornea disease_ontology DOID:6199 cornea cancer DOID:6199 DOID:56 ICD9CM:424.1 NCI:C78650 SNOMEDCT_US_2020_03_01:8722008 UMLS_CUI:C1260873 disease_ontology DOID:62 Updating out dated UMLS CUI. aortic valve disease DOID:62 MESH:D001796 UMLS_CUI:C0005830 blood protein disorder disease_ontology DOID:620 blood protein disease DOID:620 DOID:5883 DOID:7433 ICD10CM:C45.2 NCI:C7631 NCI:C7632 NCI:C8703 SNOMEDCT_US_2020_03_01:187885008 UMLS_CUI:C0346110 UMLS_CUI:C0854883 UMLS_CUI:C1335381 malignant Pericardial Mesothelioma malignant mesothelioma of pericardium disease_ontology DOID:6201 pericardial mesothelioma DOID:6201 MESH:D000236 SNOMEDCT_US_2020_03_01:55021007 UMLS_CUI:C0205647 Follicular adenoma Follicular adenoma of the Thyroid gland Thyroid follicular adenoma disease_ontology DOID:6204 follicular adenoma DOID:6204 A gastric adenocarcinoma that is characterized by the presence of a diffuse infiltrate, composed of individual adenocarcinoma cells or groups of adenocarcinoma cells in a fibrous or mucoid stroma. DOID:4946 NCI:C4127 NCI:C9159 SNOMEDCT_US_2020_03_01:24505004 UMLS_CUI:C0279635 UMLS_CUI:C0334280 disease_ontology DOID:6217 gastric diffuse adenocarcinoma DOID:6217 DOID:6226 DOID:9366 DOID:9871 DOID:9872 DOID:9873 DOID:9874 DOID:9875 ICD9CM:718.0 SNOMEDCT_US_2020_03_01:268062001 UMLS_CUI:C0158073 disease_ontology DOID:6227 articular cartilage disease DOID:6227 DOID:6238 NCI:C27884 NCI:C39831 SNOMEDCT_US_2020_03_01:128625004 UMLS_CUI:C1266010 UMLS_CUI:C1518358 Papillary urothelial neoplasm of low malignant potential bladder PUNLMP bladder papillary neoplasm of low malignant potential disease_ontology DOID:6239 non-invasive bladder papillary urothelial neoplasm DOID:6239 GARD:8477 MESH:C537750 NCI:C4526 OMIM:553000 SNOMEDCT_US_2020_03_01:254922006 UMLS_CUI:C0346255 Oncocytoma of kidney renal epithelial Oncocytic tumor disease_ontology DOID:6245 OMIM mapping confirmed by DO. [SN]. renal oncocytoma DOID:6245 NCI:C27319 UMLS_CUI:C0859960 disease_ontology DOID:625 transient hypogammaglobulinemia DOID:625 A primary immunodeficiency disease that is the result in a mutation of a gene encoding one of the thirty complement system proteins, produced predominantly in liver, which function to defend against infection and produce inflammation. ICD10CM:D84.1 MESH:D000081208 NCI:C4691 SNOMEDCT_US_2020_03_01:191014008 UMLS_CUI:C0272242 Complement deficiency Complement deficiency disease disease_ontology DOID:626 complement deficiency DOID:626 A dendritic cell sarcoma cancer that effects the follicular dendritic cells. ICD10CM:C96.4 MESH:D054740 NCI:C9281 SNOMEDCT_US_2020_03_01:128816008 UMLS_CUI:C1260325 Follicular Dendritic cell sarcoma Follicular dendritic cell tumour disease_ontology DOID:6262 follicular dendritic cell sarcoma DOID:6262 A breast adenocarcinoma that is characterized by the clinical appearance of inflammation, with edema and redness of the breast due to pathologic plugging of the dermal lymphatics of the breast with tumor emboli. MESH:D058922 NCI:C4001 SNOMEDCT_US_2020_03_01:254840009 UMLS_CUI:C0278601 Inflammatory carcinoma of breast Mastitis carcinomatosa disease_ontology DOID:6263 inflammatory breast carcinoma DOID:6263 A combined T cell and B cell immunodeficiency that is caused by a defect in infection-fighting immune cells resulting in individuals with non-functional immune systems. GARD:7628 MESH:D016511 NCI:C3472 SNOMEDCT_US_2020_03_01:190994004 UMLS_CUI:C0085110 SCID combined T and B cell inborn immunodeficiency disease_ontology DOID:627 severe combined immunodeficiency DOID:627 NCI:C6794 UMLS_CUI:C1333763 carcinoma of Cardia of stomach disease_ontology DOID:6270 gastric cardia carcinoma DOID:6270 NCI:C5247 UMLS_CUI:C1333762 adenocarcinoma of Cardia of stomach disease_ontology adenocarcinoma of gastric cardia DOID:6271 gastric cardia adenocarcinoma DOID:6271 NCI:C8011 SNOMEDCT_US_2020_03_01:254959007 UMLS_CUI:C0346303 TSH Secreting adenoma of the Pituitary TSH Secreting tumor of Pituitary TSH Secreting tumour of Pituitary TSH producing pituitary tumour Thyrotroph adenoma disease_ontology DOID:6275 TSH producing pituitary tumor DOID:6275 A primary immunodeficiency disease characterized by impaired T cell-mediated immunity and impaired B cell mediated humoral immunity. ICD10CM:D81 ICD9CM:279.2 NCI:C27871 OMIM:312863 ORDO:101972 SNOMEDCT_US_2020_03_01:191003005 UMLS_CUI:C0494261 Congenital Combined Immunodeficiency combined immunodeficiency disease_ontology DOID:628 Xref MGI. combined T cell and B cell immunodeficiency DOID:628 A disease that has_material_basis_in genetic variations in the human genome. MESH:D030342 NCI:C3101 SNOMEDCT_US_2020_03_01:32895009 UMLS_CUI:C0019247 disease_ontology DOID:630 genetic disease DOID:630 NCI:C27804 UMLS_CUI:C1333375 disease_ontology DOID:6307 ectopic thymus DOID:6307 ICD10CM:M79.7 MESH:D005356 NCI:C87497 SNOMEDCT_US_2020_03_01:1304004 UMLS_CUI:C0016053 disease_ontology DOID:631 fibromyalgia DOID:631 A myopathy characterized by muscle inflammation. ICD10CM:M60 MESH:D009220 NCI:C27578 OMIM:160750 SNOMEDCT_US_2020_03_01:26889001 UMLS_CUI:C0027121 Inflammatory disorder of muscle disease_ontology DOID:633 OMIM mapping confirmed by DO. [SN]. myositis DOID:633 A Human immunodeficiency virus infectious disease that results_in reduction in the numbers of CD4-bearing helper T cells below 200 per microliter of blood or 14% of all lymphocytes thereby rendering the subject highly vulnerable to life-threatening infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted_by sexual contact, transmitted_by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted_by congenital method, and transmitted_by contaminated needles. Opportunistic infections are common in people with AIDS. EFO:0000765 ICD10CM:B20 MESH:D000163 NCI:C2851 SNOMEDCT_US_2020_03_01:62479008 UMLS_CUI:C0001175 AIDS acquired Immune deficiency disease_ontology acquired immune deficiency syndrome DOID:635 acquired immunodeficiency syndrome MESH:D000163 DOID:635 A chronic lymphocytic leukemia that is characterized by the presence of immature lymphocytes in the blood and bone marrow and/or in the lymph nodes. NCI:C27911 SNOMEDCT_US_2020_03_01:399607007 UMLS_CUI:C1302547 chronic lymphocytic leukemia/small lymphocytic lymphoma disease_ontology DOID:6354 CLL/SLL DOID:6354 A demyelination disease that is characterized by severe damage to the myelin sheath of the pons' nerve cells and has_symptom acute paralysis, has_symptom dysphagia, and has_symptom dysarthria. GARD:8749 ICD10CM:G37.2 MESH:D017590 NCI:C84623 SNOMEDCT_US_2020_03_01:6807001 UMLS_CUI:C0206083 osmotic demyelination syndrome disease_ontology DOID:636 central pontine myelinolysis DOID:636 A brain disease that is characterized by moderate to severe headaches, nausea, extreme sensitivity to light and sound and intense unilaterial throbbing or pulsing. DOID:12437 EFO:0003821 ICD10CM:G43 ICD9CM:346 MESH:D008881 NCI:C89715 OMIM:157300 SNOMEDCT_US_2020_03_01:155046006 SNOMEDCT_US_2020_03_01:193036004 UMLS_CUI:C0042331 UMLS_CUI:C0149931 migraine disorder migraine variant migraine with or without aura disease_ontology DOID:6364 Xref MGI. OMIM mapping confirmed by DO. [SN]. migraine DOID:6364 A skin melanoma that is characterized by slow growth of a small pigmented spot on the skin with a clearly defined edge, surrounded by normal-appearing skin and occurs on occurs on non hair-bairing surfaces including hands and feet, subungual sites, and fingers or toes. GARD:9570 acral lentiginous melanoma, malignant malignant acral lentiginous melanoma disease_ontology DOID:6367 acral lentiginous melanoma DOID:6367 ICD10CM:D73.1 ICD9CM:289.4 MESH:D006971 NCI:C34714 SNOMEDCT_US_2020_03_01:154839008 UMLS_CUI:C0020532 hypersplenia disease_ontology DOID:6376 hypersplenism DOID:6376 An encephalomyelitis characterized by inflammation located in brain and located in spinal cord that damages myelin. It usually occurs after viral infection, but also following vaccination, bacterial or parasitic infection. GARD:8639 MESH:D004673 NCI:C34578 SNOMEDCT_US_2020_03_01:83942000 UMLS_CUI:C0014059 ADEM acute Disseminated Encephalomyelitis acute disseminated encephalitis disease_ontology DOID:639 acute disseminated encephalomyelitis DOID:639 MESH:D004679 NCI:C34580 SNOMEDCT_US_2020_03_01:154991009 UMLS_CUI:C0014070 Encephalitis &/or myelitis disease_ontology DOID:640 encephalomyelitis MESH:D004679 DOID:640 NCI:C27253 SNOMEDCT_US_2020_03_01:128670007 UMLS_CUI:C1266045 Metanephric adenoma disease_ontology DOID:6404 metanephric adenoma DOID:6404 GARD:1908 ICD10CM:Q20.1 ICD9CM:745.11 MESH:D004310 NCI:C98916 OMIM:217095 ORDO:3426 SNOMEDCT_US_2020_03_01:7484005 UMLS_CUI:C0013069 Dextrotransposition of aorta Double outlet right ventricle Double outlet right ventricle with subpulmonary ventricular septal defect Taussig-Bing syndrome or defect disease_ontology DOID:6406 OMIM mapping confirmed by DO. [SN]. double outlet right ventricle DOID:6406 GARD:2245 ICD10CM:Q21.3 ICD9CM:745.2 MESH:D013771 NCI:C84505 OMIM:187500 SNOMEDCT_US_2020_03_01:156913009 UMLS_CUI:C0039685 Ventricular septal defect with pulmonary stenosis or atresia, dextraposition of aorta, and hypertrophy of right ventricle disease_ontology DOID:6419 OMIM mapping confirmed by DO. [LS]. tetralogy of Fallot DOID:6419 GARD:4596 MESH:D011666 OMIM:265500 SNOMEDCT_US_2020_03_01:56786000 UMLS_CUI:C0034089 disease_ontology DOID:6420 pulmonary valve stenosis DOID:6420 NCI:C6078 UMLS_CUI:C0920196 carcinoma of the eyelid disease_ontology DOID:6425 eyelid carcinoma DOID:6425 A viral infectious disease that involves reactivation of JC polyomavirus in immune-compromised individuals which causes the loss of white matter (which is made up of myelin, a substance the surrounds and protects nerve fibers) in multiple areas of the brain. The symptoms include hemiparesis, aphasia, dysarthria, hemianopia, cognitive impairment and coma. GARD:7468 ICD10CM:A81.2 ICD9CM:046.3 MESH:D007968 NCI:C26815 SNOMEDCT_US_2020_03_01:22255007 UMLS_CUI:C0023524 disease_ontology PML DOID:643 progressive multifocal leukoencephalopathy DOID:643 A hypertension characterized by an increase of blood pressure in the pulmonary artery, pulmonary vein or pulmonary capillaries. ICD10CM:I27.20 MESH:D006976 NCI:C3120 SNOMEDCT_US_2020_03_01:155328008 UMLS_CUI:C0020542 disease_ontology DOID:6432 pulmonary hypertension DOID:6432 A syndrome characterized by multiple noncancerous, tumor-like growths (hamartomas) and an increased risk of certain forms of cancer, especially breast, thyroid and endometrium. DOID:3471 GARD:6202 MESH:D006223 NCI:C3076 NCI:C8419 OMIM:PS158350 ORDO:201 SNOMEDCT_US_2020_03_01:58037000 SNOMEDCT_US_2020_03_01:67944007 UMLS_CUI:C0018553 UMLS_CUI:C0391826 Cowden disease Lhermitte-Duclos disease dysplastic Gangliocytoma of Cerebellum disease_ontology multiple hamartoma syndrome DOID:6457 Xref MGI. OMIM mapping confirmed by DO. [SN]. Cowden syndrome DOID:6457 GARD:10642 NCI:C6905 SNOMEDCT_US_2020_03_01:734134003 UMLS_CUI:C1370507 Cerebellar liponeurocytoma Lipomatous Medulloblastoma disease_ontology DOID:6458 cerebellar liponeurocytoma DOID:6458 An encephalitis that involves inflammation of the brain caused by viral infection. DOID:10248 DOID:10249 DOID:10839 MESH:D004671 NCI:C34576 SNOMEDCT_US_2020_03_01:68197003 UMLS_CUI:C0014055 epidemic encephalitis disease_ontology DOID:646 viral encephalitis DOID:646 An intestinal benign neoplasm that derives_from fat cells and that is located_in the large intestine. NCI:C5678 UMLS_CUI:C1333114 Lipoma of large Intestine disease_ontology DOID:6460 large intestine lipoma DOID:6460 An ovarian benign neoplasm that is characterized by low beta-hCG levels and is has_material_basis_in glandular and fibrous tissues, with a relatively large proportion of glands. NCI:C40040 UMLS_CUI:C1518723 disease_ontology DOID:6469 ovarian mucinous adenofibroma DOID:6469 GARD:7617 ICD10CM:A81.81 ICD9CM:046.0 MESH:D007729 SNOMEDCT_US_2020_03_01:192684001 UMLS_CUI:C0022802 kuru encephalopathy disease_ontology DOID:648 kuru DOID:648 A brain disease that is characterized by brain damage resulting from the abnormal folding, clumping and accumulation of cellular proteins in the brain induced by prion proteins. ICD10CM:A81.9 KEGG:05020 MESH:D017096 NCI:C128346 SNOMEDCT_US_2020_03_01:20484008 UMLS_CUI:C0162534 Prion disease pathway Prion protein disease Spongiform Encephalopathy prion induced disorder transmissible spongiform encephalopathy disease_ontology DOID:649 prion disease DOID:649 An extraosseous chondrosarcoma that has_material_basis_in cells derived from transformed cells that produce cartilage and is characterized by a marked abundance of extracellular mucoid (myxoid) matrix. MESH:C563195 NCI:C27502 OMIM:612237 SNOMEDCT_US_2020_03_01:404079008 UMLS_CUI:C1275278 Myxoid extraosseous chondrosarcoma disease_ontology DOID:6496 OMIM mapping confirmed by DO. [SN]. extraskeletal myxoid chondrosarcoma DOID:6496 GARD:3108 ICD10CM:L82 ICD9CM:702.1 MESH:D017492 NCI:C9006 OMIM:182000 SNOMEDCT_US_2020_03_01:201096007 UMLS_CUI:C0022603 disease_ontology DOID:6498 OMIM mapping confirmed by DO. [SN]. seborrheic keratosis DOID:6498 A musculoskeletal system disease that affects tissues such as skin, tendons, and cartilage. MESH:D003240 NCI:C26729 SNOMEDCT_US_2020_03_01:201432001 UMLS_CUI:C0009782 connective tissue disorder disorder of connective tissue disease_ontology DOID:65 connective tissue disease DOID:65 An inherited metabolic disorder involving dysfunction of purine and pyrimidine metabolism. ICD10CM:E79.8 ICD9CM:277.2 SNOMEDCT_US_2020_03_01:190917005 UMLS_CUI:C0029595 inborn errors of purine-pyrimidine metabolism disease_ontology DOID:653 purine-pyrimidine metabolic disorder DOID:653 NCI:C6888 SNOMEDCT_US_2020_03_01:128713007 UMLS_CUI:C1266095 Polygonal cell Thymoma Thymoma, cortical disease_ontology DOID:6530 cortical thymoma DOID:6530 A mature B-cell neoplasm that is composed of plasma cells. EFO:0000200 MESH:D010265 SNOMEDCT_US_2020_03_01:71390001 UMLS_CUI:C1136084 Plasma cell dyscrasia Plasma cell tumour Plasmacytic tumor disease_ontology DOID:6536 plasma cell neoplasm DOID:6536 A nutrition disease that is characterized by an excess of a nutritional element, such as a vitamin, mineral, carbohydrate, protein, fat, or general energy content. MESH:D044343 SNOMEDCT_US_2020_03_01:302872003 UMLS_CUI:C1257763 disease_ontology DOID:654 Updated outdated UMLS CUI. overnutrition DOID:654 A sebaceous gland disease characterized by areas of blackheads, whiteheads, pimples, greasy skin, and possibly scarring. DOID:9906 ICD10CM:L70 ICD10CM:L70.2 ICD9CM:706.0 MESH:D000152 OMIM:604324 SNOMEDCT_US_2020_03_01:11381005 SNOMEDCT_US_2020_03_01:201210008 UMLS_CUI:C0152249 UMLS_CUI:C0702166 Acne varioliformis acne vulgaris frontalis acne disease_ontology DOID:6543 acne DOID:6543 NCI:C5368 UMLS_CUI:C1332850 Lymphoma of Heart disease_ontology DOID:6547 heart lymphoma DOID:6547 A disease of metabolism that is characterized by enzyme deficiency or accumulation of enzymes or toxins which interfere with normal function due to inherited enzyme abnormality. MESH:D008661 NCI:C34816 SNOMEDCT_US_2020_03_01:86095007 UMLS_CUI:C0025521 Inborn Errors of Metabolism Metabolic hereditary disorder inborn metabolism disorder disease_ontology DOID:655 inherited metabolic disorder DOID:655 An endocrine organ benign neoplasm that is a benign tumor of the glandular type (adenoma) in the adrenal gland. GARD:5745 adenoma of the Adrenal gland disease_ontology DOID:656 adrenal adenoma DOID:656 A cell type benign neoplasm that is composed_of epithelial tissue in which tumor cells form glands or glandlike structures. DOID:2655 MESH:D000236 NCI:C2855 NCI:C4196 SNOMEDCT_US_2020_03_01:443416007 SNOMEDCT_US_2020_03_01:79041005 UMLS_CUI:C0001430 UMLS_CUI:C0334389 acinar cell adenoma acinic cell adenoma adenomas disease_ontology DOID:657 adenoma MESH:D000236 DOID:657 disease_ontology DOID:66 muscle tissue disease DOID:66 DOID:3949 ICD10CM:C74.0 MESH:D000306 NCI:C2858 NCI:C9327 SNOMEDCT_US_2020_03_01:127022002 SNOMEDCT_US_2020_03_01:93664009 UMLS_CUI:C0001618 UMLS_CUI:C0346402 Adrenal cortical tumors malignant Adrenocortical tumor malignant neoplasm of adrenal cortex malignant tumour of adrenal cortex neoplasm of adrenal cortex disease_ontology DOID:660 adrenal cortex cancer DOID:660 A combined T cell and B cell immunodeficiency that is characterized by defects affecting how white blood cells respond and travel to the site of a wound or infection affecting the immune system. DOID:611 GARD:9544 MESH:D018370 ORDO:2968 UMLS_CUI:C0242597 Congenital leukocyte adherence deficiency disease_ontology DOID:6612 leukocyte adhesion deficiency DOID:6612 A hyper IgM syndrome that is characterized by neutropenia and a high rate of gastrointestinal and central nervous system infections and that has_material_basis_in a mutation in the CD40LG gene (300386) on chromosome Xq26. GARD:73 MESH:D053306 NCI:C3990 SNOMEDCT_US_2020_03_01:82286005 UMLS_CUI:C0272236 hyperimmunoglobulin M syndrome disease_ontology DOID:6620 X-linked hyper IgM syndrome DOID:6620 A brain angioma that is characterized by vascular abnormalities that develops from cranial and spinal blood vasculature, has_material_basis_in abnormally proliferating cells, derives_from endothelial cells in and about the vascular lumen. NCI:C5433 UMLS_CUI:C0877388 hemangioma of Cerebrum disease_ontology DOID:6621 cerebral angioma DOID:6621 A calcinosis that is the calcification or a bony hardening of ligaments in areas where they attach to your spine. GARD:6460 ICD10CM:M48.1 ICD9CM:721.6 MESH:D004057 NCI:C84671 OMIM:106400 SNOMEDCT_US_2020_03_01:31487001 UMLS_CUI:C0020498 Ankylosing vertebral hyperostosis DISH Disseminated idiopathic skeletal hyperostosis disease_ontology Forestier disease DOID:6652 OMIM mapping confirmed by DO. [SN]. diffuse idiopathic skeletal hyperostosis DOID:6652 DOID:5721 NCI:C5672 NCI:C6875 SNOMEDCT_US_2020_03_01:128628002 UMLS_CUI:C1265996 UMLS_CUI:C1334363 disease_ontology DOID:6658 pulmonary large cell neuroendocrine carcinoma DOID:6658 A syndrome that affects the teeth, nails, hair, and/or skin. It is characterized by absence (hypodontia) and/or malformation of certain primary (deciduous) and secondary (permanent) teeth occurring in association with improper development of the nails, particularly the toenails. MESH:C536736 NCI:C40553 OMIM:189500 SNOMEDCT_US_2020_03_01:400036004 UMLS_CUI:C0406735 Hypoplastic enamel-onycholysis-hypohidrosis syndrome Tooth and Nail syndrome Witkop's syndrome disease_ontology DOID:6678 OMIM mapping confirmed by DO. [LS]. tooth and nail syndrome DOID:6678 A myositis that is accompanied by ossification of muscle tissue or bony deposits in the muscles. MESH:D009221 NCI:C3253 SNOMEDCT_US_2020_03_01:44551007 UMLS_CUI:C0027122 Myisitis ossificans Ossification - muscle disease_ontology DOID:668 myositis ossificans DOID:668 A delusional disorder in which a person holds a delusion that a friend, spouse, parent, or other close family member has been replaced by an identical-looking impostor. MESH:D002194 NCI:C34446 SNOMEDCT_US_2020_03_01:44906001 UMLS_CUI:C0006895 Capgras delusion theory disease_ontology DOID:6680 Capgras syndrome DOID:6680 A bone structure disease that has_material_basis_in displacement located_in set of vertebrae. ICD10CM:M43.1 MESH:D013168 NCI:C35033 OMIM:184200 SNOMEDCT_US_2020_03_01:157003009 UMLS_CUI:C0038016 disease_ontology DOID:6682 spondylolisthesis DOID:6682 A syndromic X-linked intellectual disability affects a person's height, muscles, skeleton, genitals, and appearance of the face. GARD:4775 ICD10CM:Q87.19 MESH:C535331 NCI:C129720 OMIM:305400 SNOMEDCT_US_2020_03_01:205809002 UMLS_CUI:C0175701 Aarskog-Scott syndrome Greig's syndrome faciogenital dysplasia disease_ontology DOID:6683 OMIM mapping confirmed by DO. [SN]. X-linked Aarskog syndrome DOID:6683 A hypersensitivity reaction type IV disease that is an inherited disorder in which the body cannot properly regulate the number of immune system cells (lymphocytes). It is characterized by the production of an abnormally large number of lymphocytes. Accumulation of excess lymphocytes results in enlargement of the lymph nodes, the liver, and the spleen. GARD:8686 ICD10CM:D89.82 ICD9CM:279.41 MESH:D056735 NCI:C37864 OMIM:601859 ORDO:3261 SNOMEDCT_US_2020_03_01:702444009 UMLS_CUI:C1328840 ALPS Canale-Smith syndrome disease_ontology DOID:6688 Xref MGI. OMIM mapping confirmed by DO. [SN]. autoimmune lymphoproliferative syndrome MESH:D056735 DOID:6688 NCI:C4335 SNOMEDCT_US_2020_03_01:354002 UMLS_CUI:C0334616 MPNST with Rhabdomyosarcoma MPNST with rhabdomyoblastic differentiation malignant Triton tumor malignant Triton tumour malignant peripheral nerve sheath neoplasm with rhabdomyosarcoma disease_ontology DOID:6707 malignant triton tumor DOID:6707 A syndrome that is characterized by loss of function of the anterior two-thirds of the spinal cord that results from ischemia of the anterior spinal artery. GARD:9653 ICD10CM:G83.82 MESH:D020759 SNOMEDCT_US_2020_03_01:282785008 UMLS_CUI:C0221069 Anterior spinal artery occlusion syndrome disease_ontology DOID:6712 anterior spinal artery syndrome MESH:D020759 DOID:6712 An vascular disease that is characterized by dysfunction of the blood vessels supplying the brain. DOID:12214 DOID:3455 DOID:8231 EFO:0000712 ICD10CM:I67.9 ICD9CM:437.9 MESH:D002561 NCI:C2938 SNOMEDCT_US_2020_03_01:266312006 UMLS_CUI:C0007820 CVA Cerebrovascular accident cerebrovascular accident cerebrovascular disorder stroke disease_ontology DOID:6713 OMIM mapping confirmed by DO. [SN]. cerebrovascular disease DOID:6713 A lymphatic system cancer that affects white blood cells and involves tumor deposits in the spleen. DOID:671 GARD:7683 ICD10CM:C26.1 MESH:D013160 NCI:C3383 NCI:C3539 SNOMEDCT_US_2020_03_01:127230005 SNOMEDCT_US_2020_03_01:94071006 UMLS_CUI:C0037999 UMLS_CUI:C0153470 Splenic neoplasm malignant Splenic tumor malignant tumour of spleen spleen neoplasm disease_ontology DOID:672 spleen cancer DOID:672 A bone deterioration disease that has_material_basis_in bony spurs, disc degeneration, or thickened ligaments which results_in narrowing located_in spinal cord. DOID:10097 DOID:12235 ICD10CM:M48.0 ICD10CM:M48.02 ICD10CM:M48.061 ICD9CM:723.0 ICD9CM:724.00 MESH:D013130 SNOMEDCT_US_2020_03_01:18347007 SNOMEDCT_US_2020_03_01:268082002 SNOMEDCT_US_2020_03_01:83561009 UMLS_CUI:C0037944 UMLS_CUI:C0158280 UMLS_CUI:C0158288 Spinal stenosis of lumbar region cervical spinal stenosis lumbar spinal stenosis disease_ontology DOID:6725 spinal stenosis DOID:6725 An orofacial cleft characterized by a fissure of the soft and/or hard palate, due to faulty fusion of the two plates of the skull that form the hard palate. ICD10CM:Q35 ICD9CM:749.0 MESH:D002972 NCI:C87069 ORDO:99772 SNOMEDCT_US_2020_03_01:156940009 UMLS_CUI:C0008925 Palatoschisis disease_ontology DOID:674 OMIM mapping confirmed by DO. [SN]. cleft palate DOID:674 NCI:C7982 UMLS_CUI:C0279674 small cell carcinoma of the Cervix Uteri disease_ontology small cell carcinoma of the cervix DOID:6740 cervix small cell carcinoma DOID:6740 A rheumatoid arthritis that involves an autoimmune disease onset in children under 16 which attacks the healthy cells and tissue of located_in joint. DOID:10129 DOID:1264 DOID:675 GARD:3067 ICD10CM:M08.4 ICD9CM:714.3 ICD9CM:714.31 ICD9CM:714.32 ICD9CM:714.33 NCI:C26979 NCI:C61279 OMIM:604302 ORDO:92 SNOMEDCT_US_2020_03_01:201798003 SNOMEDCT_US_2020_03_01:201799006 SNOMEDCT_US_2020_03_01:74391003 SNOMEDCT_US_2020_03_01:7441009 UMLS_CUI:C0157916 UMLS_CUI:C0157917 UMLS_CUI:C0157918 UMLS_CUI:C0409667 Pauciarticular onset juvenile chronic arthritis Still's disease acute juvenile rheumatoid arthritis juvenile chronic polyarthritis juvenile idiopathic arthritis monarticular juvenile rheumatoid arthritis pauciarticular juvenile arthritis systemic juvenile rheumatoid arthritis disease_ontology DOID:676 Xref MGI. juvenile rheumatoid arthritis DOID:676 UMLS_CUI:C0519063 lymphoma of lung pulmonary Lymphoma disease_ontology DOID:6760 lung lymphoma DOID:6760 A movement disease that is characterized by serious and progressive problems with control of gait and balance, along with complex eye movement and thinking problems. It involves gradual deterioration and death of specific volumes of the brain. GARD:7471 ICD10CM:G23.1 MESH:D013494 NCI:C85028 OMIM:601104 OMIM:609454 OMIM:610898 ORDO:683 SNOMEDCT_US_2020_03_01:192975003 UMLS_CUI:C0038868 Steele-Richardson-Olszewski syndrome progressive supranuclear ophthalmoplegia disease_ontology DOID:678 Xref MGI. OMIM mapping confirmed by DO. [SN]. progressive supranuclear palsy DOID:678 A brain disease that is characterized by dysfunctional movement, located_in basal ganglia with_material_basis_in diseased components of the basal ganglia and associated neural circuits. MESH:D001480 SNOMEDCT_US_2020_03_01:70835005 UMLS_CUI:C0004782 disease_ontology DOID:679 basal ganglia disease DOID:679 A neurodegenerative disease that has_material_basis_in the pathological aggregation of tau protein in so-called neurofibrillary tangles (NFT) in the human brain. MESH:D024801 UMLS_CUI:C0949664 disease_ontology DOID:680 tauopathy DOID:680 GARD:10928 ICD10CM:G12.22 ICD9CM:335.22 MESH:D010244 NCI:C85026 SNOMEDCT_US_2020_03_01:54304004 UMLS_CUI:C0030442 disease_ontology DOID:681 progressive bulbar palsy DOID:681 A pilocytic astrocytoma that occurs during adolescence. MESH:D001254 NCI:C27081 UMLS_CUI:C0280783 disease_ontology DOID:6811 juvenile pilocytic astrocytoma DOID:6811 A liver carcinoma that has_material_basis_in undifferentiated hepatocytes and located_in the liver. DOID:5005 EFO:0000182 ICD10CM:C22.0 ICDO:M8170/3 NCI:C3099 OMIM:114550 ORDO:88673 SNOMEDCT_US_2019_09_01:109841003 Hepatoma disease_ontology DOID:684 OMIM mapping confirmed by DO. [SN]. hepatocellular carcinoma DOID:684 NCI:C8498 UMLS_CUI:C1512419 disease_ontology DOID:6846 familial melanoma DOID:6846 A liver cancer that has_material_basis_in epithelial cells. NCI:C7927 UMLS_CUI:C0279000 Liver and Intrahepatic bile duct carcinoma disease_ontology DOID:686 liver carcinoma DOID:686 GARD:2657 ICD10CM:C22.2 ICDO:M8970/3 MESH:D018197 NCI:C3728 SNOMEDCT_US_2020_03_01:109843000 UMLS_CUI:C0206624 disease_ontology DOID:687 hepatoblastoma DOID:687 A germ cell cancer that is associated with an embryo. MESH:D009373 NCI:C3264 UMLS_CUI:C0027654 embryo neoplasm embryonal neoplasm disease_ontology DOID:688 embryonal cancer DOID:688 A lymphoma by site that is manifested in immune system cells called lymphocytes. NCI:C35690 UMLS_CUI:C1333519 disease_ontology DOID:6903 eye lymphoma DOID:6903 ICD10CM:G57.3 MESH:D020427 NCI:C27061 SNOMEDCT_US_2020_03_01:34553007 UMLS_CUI:C0270810 Peroneal nerve palsy disease_ontology DOID:6925 peroneal nerve paralysis DOID:6925 ICD10CM:H35.81 ICD9CM:362.83 MESH:D010211 SNOMEDCT_US_2020_03_01:6141006 UMLS_CUI:C0242420 disease_ontology DOID:6929 retinal edema DOID:6929 MESH:D003744 NCI:C34529 SNOMEDCT_US_2020_03_01:699382004 UMLS_CUI:C0011351 Enamel Hypoplasia Enamel hypoplasia disease_ontology DOID:693 dental enamel hypoplasia DOID:693 DOID:2141 NCI:C3842 NCI:C39858 SNOMEDCT_US_2020_03_01:189459005 SNOMEDCT_US_2020_03_01:45083001 UMLS_CUI:C0235754 UMLS_CUI:C1384678 Urothelial papilloma bladder papilloma transitional cell papilloma of bladder urinary bladder Urothelial papilloma disease_ontology DOID:6933 bladder transitional cell papilloma DOID:6933 NCI:C3902 SNOMEDCT_US_2020_03_01:78453009 UMLS_CUI:C0259782 Telangiectatic osteosarcoma disease_ontology DOID:6951 telangiectatic osteogenic sarcoma DOID:6951 ICD10CM:H04.3 ICD9CM:375.3 SNOMEDCT_US_2020_03_01:302900006 UMLS_CUI:C0339129 disease_ontology DOID:6970 acute inflammation of lacrimal passage DOID:6970 MESH:D003969 NCI:C3488 SNOMEDCT_US_2020_03_01:70091000 UMLS_CUI:C0086768 Excessive vasoactive intestinal peptide secretion Verner-Morrison syndrome pancreatic WDHA syndrome disease_ontology DOID:6977 pancreatic cholera DOID:6977 MESH:D003807 NCI:C50778 SNOMEDCT_US_2020_03_01:13468005 UMLS_CUI:C0011432 Sensitive dentin disease_ontology DOID:698 dentin sensitivity DOID:698 A myopathy that is characterized by mitochondrial dysfunction. MESH:D017240 NCI:C101328 OMIM:251900 SNOMEDCT_US_2020_03_01:240096000 UMLS_CUI:C0162670 mitochondrial cytopathy disease_ontology DOID:699 OMIM mapping confirmed by DO. [SN]. mitochondrial myopathy DOID:699 A disease that manifests in a defined anatomical structure. DOID:1 DOID:2 DOID:5 DOID:71 DOID:72 DOID:8 disease_ontology DOID:7 disease of anatomical entity DOID:7 An inherited metabolic disorder that involves mitochondrial metabolism dysfunction. GARD:7048 MESH:D028361 SNOMEDCT_US_2020_03_01:240096000 UMLS_CUI:C0751651 disease_ontology DOID:700 mitochondrial metabolism disease DOID:700 A functioning pituitary adenoma that characterized by excess cortisol a primary cause of Cushing's syndrome. GARD:12867 MESH:D049913 NCI:C7462 OMIM:219090 SNOMEDCT_US_2020_03_01:254958004 UMLS_CUI:C1306214 ACTH-Producing Pituitary Adenoma Corticotroph adenoma Corticotropinoma disease_ontology DOID:7004 OMIM mapping confirmed by DO. [SN]. ACTH-secreting pituitary adenoma MESH:D049913 DOID:7004 MESH:D001254 NCI:C4321 SNOMEDCT_US_2020_03_01:73982001 UMLS_CUI:C0334581 Gemistocytic Astrocytic tumor Gemistocytic astrocytoma disease_ontology DOID:7005 gemistocytic astrocytoma DOID:7005 A teeth hard tissue disease characterized by presence of normal enamel but atypical dentin with abnormal pulpal morphology. ICD10CM:K00.5 MESH:D003805 OMIM:125400 OMIM:125420 ORDO:1635 SNOMEDCT_US_2020_03_01:109492001 UMLS_CUI:C0011430 Dentinal dysplasia disease_ontology DOID:701 Xref MGI. OMIM mapping confirmed by DO. [SN]. dentin dysplasia DOID:701 A parasitic helminthiasis infectious disease that results_in infection located_in intestinal mucosa with larvae of the nematodes transmitted_by ingestion of raw or poorly cooked saltwater fish, has_material_basis_in Anisakis simplex or has_material_basis_in Pseudoterranova decipiens and has_symptom abdominal pain, has_symptom nausea and vomiting. Invasive anisakiasis results in the infection of omentum, pancreas, liver, and lung. GARD:693 ICD10CM:B81.0 ICD9CM:127.1 MESH:D017129 NCI:C128393 SNOMEDCT_US_2020_03_01:442652006 UMLS_CUI:C0162576 Infection by Anisakis larva disease_ontology DOID:7033 anisakiasis MESH:D017129 DOID:7033 GARD:6870 ICD10CM:H47.22 MESH:D029242 NCI:C84808 OMIM:535000 SNOMEDCT_US_2020_03_01:194045006 UMLS_CUI:C0917796 Leber's hereditary optic neuropathy Leber's optic atrophy disease_ontology DOID:705 OMIM mapping confirmed by DO. [SN]. Leber hereditary optic neuropathy DOID:705 EFO:0000096 NCI:C27910 UMLS_CUI:C1334633 mature B-cell lymphocytic neoplasm disease_ontology DOID:706 mature B-cell neoplasm DOID:706 A non-Hodgkin lymphoma that has_material_basis_in B cells. GARD:5877 MESH:D016393 NCI:C3457 SNOMEDCT_US_2020_03_01:109979007 UMLS_CUI:C0079731 B-cell lymphocytic neoplasm disease_ontology DOID:707 B-cell lymphoma DOID:707 NCI:C6766 SNOMEDCT_US_2020_03_01:396198006 UMLS_CUI:C1300585 prostate Oat cell carcinoma small cell carcinoma of prostate disease_ontology DOID:7141 prostate small cell carcinoma DOID:7141 A histiocytic and dendritic cell cancer that derives from the lymph nodes, derives from the skin, derives from the liver, derives from the spleen and derives from bones. ICD10CM:C96.4 MESH:D054752 NCI:C6921 SNOMEDCT_US_2020_03_01:724649000 UMLS_CUI:C1260327 disease_ontology DOID:7146 Langerhans cell sarcoma MESH:D054752 DOID:7146 A bone inflammation disease that results_in inflammation in the joints of the spine and pelvis. The disease has_symptom pain, has_symptom stiffness in the spine, has_symptom stiffness in the neck, has_symptom stiffness in the hips, has_symptom stiffness in the jaw and has_symptom stiffness in the rib cage. EFO:0003898 GARD:9518 ICD10CM:M45 ICD9CM:720.0 MESH:D013167 NCI:C84564 OMIM:PS106300 ORDO:825 SNOMEDCT_US_2020_03_01:156619005 UMLS_CUI:C0038013 Bekhterev syndrome Bekhterev's disease Marie-Strumpell disease disease_ontology DOID:7147 ankylosing spondylitis DOID:7147 An arthritis that is an autoimmune disease which attacks healthy cells and tissue located_in joint. EFO:0000685 ICD10CM:M06.9 ICD9CM:714.0 KEGG:05323 MESH:D001172 NCI:C2884 OMIM:180300 SNOMEDCT_US_2020_03_01:156471009 UMLS_CUI:C0003873 Arthritis or polyarthritis, rheumatic atrophic Arthritis disease_ontology DOID:7148 OMIM mapping confirmed by DO. [SN]. rheumatoid arthritis DOID:7148 MESH:D015458 UMLS_CUI:C0023492 T-cell leukemia disease_ontology DOID:715 T-cell lymphoblastic leukemia/lymphoma DOID:715 ICD10CM:E06.1 ICD9CM:245.1 MESH:D013968 NCI:C35071 SNOMEDCT_US_2020_03_01:154666006 UMLS_CUI:C0040149 De Quervain's thyroiditis Giant-cell thyroiditis Granulomatous thyroiditis Subacute Granulomatous Thyroiditis Subacute Thyroiditis Subacute thyroiditis de Quervain's thyroiditis disease_ontology DOID:7165 subacute thyroiditis DOID:7165 ICD10CM:E06 ICD9CM:245 MESH:D013966 NCI:C26894 SNOMEDCT_US_2020_03_01:154664009 UMLS_CUI:C0040147 disease_ontology DOID:7166 Updating to more specific UMLS_CUI from C0029495 to C0040147. thyroiditis DOID:7166 NCI:C8255 SNOMEDCT_US_2020_03_01:84570003 UMLS_CUI:C0334273 Cloacogenic anal carcinoma Cloacogenic carcinoma disease_ontology DOID:7173 OMIM mapping confirmed by DO. [SN]. cloacogenic carcinoma DOID:7173 An autoimmune disease of blood that is characterized by deficient red blood cells caused by auto-antibodies. GARD:5870 ICD9CM:283.0 MESH:D000744 NCI:C34378 OMIM:205700 SNOMEDCT_US_2020_03_01:25121006 UMLS_CUI:C0002880 Autoimmune haemolytic anaemia Autoimmune hemolytic anaemia Autoimmune hemolytic anemia autoimmune hemolytic anaemia disease_ontology DOID:718 OMIM mapping confirmed by DO. [SN]. autoimmune hemolytic anemia DOID:718 NCI:C35829 SNOMEDCT_US_2020_03_01:361126006 UMLS_CUI:C1306804 Subacute lymphocytic thyroiditis disease_ontology DOID:7187 subacute lymphocytic thyroiditis DOID:7187 An autoimmune disease of endocrine system that involves inflammation located_in thyroid gland caused by the immune system reacting against its own tissues. DOID:0050435 ICD10CM:E06.3 MESH:D013967 NCI:C38766 SNOMEDCT_US_2020_03_01:190297000 UMLS_CUI:C0920350 Chronic Lymphocytic Thyroiditis Hashimoto thyroiditis Hashimoto's Disease Hashimoto's syndrome Hashimoto's thyroiditis Lymphocytic Thyroiditis disease_ontology DOID:7188 OMIM mapping confirmed by DO. [SN]. autoimmune thyroiditis DOID:7188 NCI:C35142 SNOMEDCT_US_2020_03_01:300980002 UMLS_CUI:C0085577 ANEMIA NORMOCYTIC disease_ontology DOID:720 normocytic anemia DOID:720 NCI:C9499 UMLS_CUI:C1334691 disease_ontology DOID:7206 melanomatosis DOID:7206 MESH:D008579 NCI:C4331 SNOMEDCT_US_2020_03_01:38431002 UMLS_CUI:C0334607 Psammomatous meningioma disease_ontology DOID:7210 psammomatous meningioma DOID:7210 MESH:D008579 NCI:C4330 SNOMEDCT_US_2020_03_01:511008 UMLS_CUI:C0334606 Fibroblastic meningioma disease_ontology DOID:7211 fibrous meningioma DOID:7211 A breast fibroadenoma that is larger than 5 cm. NCI:C4273 SNOMEDCT_US_2020_03_01:254846003 UMLS_CUI:C0346157 Giant Fibroadenoma Giant fibroadenoma of breast disease_ontology DOID:7223 breast giant fibroadenoma DOID:7223 ICD9CM:625.6 NCI:C35042 SNOMEDCT_US_2020_03_01:60241006 UMLS_CUI:C0038437 Stress incontinence - female female urinary stress incontinence disease_ontology DOID:724 female stress incontinence DOID:724 GARD:10635 MESH:D018302 NCI:C4324 SNOMEDCT_US_2020_03_01:48952003 UMLS_CUI:C0334587 Astroblastoma disease_ontology DOID:7305 astroblastoma DOID:7305 An organ system benign neoplasm that is located_in the kidneys, ureteres, bladder or urethra. MESH:D014571 NCI:C3431 SNOMEDCT_US_2020_03_01:254913005 UMLS_CUI:C0042076 neoplasm of urinary system tumor of the urinary system tumor of urinary tract urinary tract neoplasm disease_ontology DOID:731 urinary system benign neoplasm DOID:731 NCI:C27301 SNOMEDCT_US_2020_03_01:60703000 UMLS_CUI:C0270921 disease_ontology DOID:7319 axonal neuropathy DOID:7319 A urinary system disease that is located_in the urethra. ICD10CM:N36.9 MESH:D014522 NCI:C26903 SNOMEDCT_US_2020_03_01:4985009 UMLS_CUI:C0041969 urethra disease disease_ontology DOID:732 urethral disease DOID:732 ICD10CM:M72.4 NCI:C3827 SNOMEDCT_US_2020_03_01:268106003 UMLS_CUI:C0410005 Fasciitis - nodular Pseudosarcomatous Fasciitis Pseudosarcomatous fibromatosis nodular fasciitis disease_ontology DOID:7327 pseudosarcomatous fibromatosis DOID:7327 NCI:C7415 UMLS_CUI:C1336892 Nephrogenic adenoma of the urinary bladder disease_ontology DOID:7333 nephrogenic adenoma of urinary bladder DOID:7333 NCI:C97097 SNOMEDCT_US_2020_03_01:78236000 UMLS_CUI:C0334039 disease_ontology DOID:7334 nephrogenic adenoma DOID:7334 An urinary tract cancer that derives_from the tissues of the urethra. DOID:737 GARD:9390 ICD10CM:C68.0 ICD9CM:189.3 MESH:D014523 NCI:C7507 NCI:C9106 SNOMEDCT_US_2020_03_01:363459007 SNOMEDCT_US_2020_03_01:94123008 UMLS_CUI:C0153620 UMLS_CUI:C0700101 malignant tumour of urethra malignant urethral neoplasm urethral Ca disease_ontology cancer of urethra DOID:734 urethra cancer DOID:734 GARD:6835 MESH:D000796 NCI:C26867 SNOMEDCT_US_2020_03_01:399894006 UMLS_CUI:C0033838 Kimura's disease disease_ontology DOID:7365 Kimura disease DOID:7365 NCI:C27343 UMLS_CUI:C0948740 disease_ontology DOID:7378 pituitary hypoplasia DOID:7378 A disease of anatomical entity that has_material_basis_in hematopoietic cells. ICD10CM:D75.9 ICD9CM:289.9 MESH:D006402 NCI:C26323 SNOMEDCT_US_2020_03_01:154785002 UMLS_CUI:C0018939 Blood disease Blood dyscrasia DISEASE OF THE BLOOD AND BLOOD-FORMING ORGANS Hematological disease blood disorder disease of haematopoietic system disease of hematopoietic system haematopoietic system disease disease_ontology DOID:74 hematopoietic system disease DOID:74 A syndrome characterized by chromosomal instability, microcephaly, growth retardation, immunodeficiency, cellular hypersensitivity to X-rays, and predisposition to cancer that has_material_basis_in homozygous or compound heterozygous mutation in NBN on chromosome 8q21.3. GARD:3904 MESH:D049932 NCI:C4692 OMIM:251260 ORDO:647 SNOMEDCT_US_2020_03_01:234638009 UMLS_CUI:C0398791 Berlin breakage syndrome Microcephaly, normal intelligence and immunodeficiency NBS Seemanova syndrome II Seemanova syndrome type 2 ataxia-telangiectasia variant immunodeficiency-microcephaly-chromosomal instability syndrome microcephaly-immunodeficiency-lymphoreticuloma syndrome disease_ontology DOID:7400 OMIM mapping confirmed by DO. [SN]. Nijmegen breakage syndrome DOID:7400 An anthrax disease that results_in infection located_in skin, has_material_basis_in Bacillus anthracis, which is transmitted_by contact with infected animals or animal products. The infection has_symptom skin lesion that eventually forms an ulcer with a black center. GARD:8158 ICD10CM:A22.0 ICD9CM:022.0 MESH:C531621 SNOMEDCT_US_2020_03_01:84980006 UMLS_CUI:C0003177 disease_ontology DOID:7426 cutaneous anthrax DOID:7426 A primary bacterial infectious disease that results_in infection located_in skin, located_in lung lymph nodes or located_in gastrointestinal tract, has_material_basis_in Bacillus anthracis, transmitted_by contact with infected animals or animal products, transmitted_by airborne spores or transmitted_by ingestion of undercooked meat from infected animals and has_symptom skin ulcer, has_symptom nausea, has_symptom poor appetite, has_symptom bloody diarrhea, has_symptom fever or has_symptom shortness of breath. GARD:8157 ICD10CM:A22 ICD9CM:022 MESH:D000881 NCI:C84565 SNOMEDCT_US_2020_03_01:154295005 UMLS_CUI:C0003175 disease_ontology DOID:7427 anthrax disease DOID:7427 A blood protein disease that is characterized by the presence of an abnormal protein called monoclonal protein in the blood. GARD:7034 MGUS Monoclonal gammopathy of uncertain significance Monoclonal gammopathy of undetermined significance disease_ontology DOID:7442 monoclonal gammopathy of uncertain significance DOID:7442 A parasitic helminthiasis infectious disease that involves infection of the anus by the pinworm Enterobius vermicularis. The major symptom is perianal itching. Infected people experience perianal pruritus and excoriations from scratching. DOID:7458 ICD10CM:B80 MESH:D010123 SNOMEDCT_US_2020_03_01:154415009 UMLS_CUI:C0030100 Oxyuris vermicularis infection Threadworm infection disease_ontology Enterobius vermicularis infection Pinworm infection oxyuriasis DOID:7457 enterobiasis DOID:7457 A hypersensitivity reaction type IV disease that is characterized by absolute lymphocytosis of natural killer (CD3- CD16+) cells often with concurrent cytopenia and has_symptom fever, arthralgia, apthous ulcers, vasculitic skin rash, and peripheral neuropathy. NCI:C39591 SNOMEDCT_US_2020_03_01:722955006 UMLS_CUI:C1512709 NK-cell large granular Lymphocyte Lymphocytosis disease_ontology DOID:7465 chronic NK-cell lymphocytosis DOID:7465 A pleural cancer that has_material_basis_in mesothelium cells. ICD10CM:C45.0 NCI:C7376 SNOMEDCT_US_2020_03_01:254645002 UMLS_CUI:C0812413 malignant mesothelioma of pleura disease_ontology DOID:7474 malignant pleural mesothelioma DOID:7474 An intestinal disease characterized by the formation and inflammation of diverticula within the bowel wall. MESH:D004238 NCI:C26752 SNOMEDCT_US_2020_03_01:155779000 UMLS_CUI:C0012813 disease_ontology DOID:7475 diverticulitis DOID:7475 A bone inflammation disease that involves rupture of the growth plate in children located_in tibia. MESH:D055034 NCI:C34874 SNOMEDCT_US_2020_03_01:72047008 UMLS_CUI:C0029376 Osgood-Schlatter disease Osteochondritis of tibial tubercle Osteochondrosis of proximal tibia juvenile osteochondrosis of tibial tubercle disease_ontology DOID:7489 Osgood-Schlatter's disease DOID:7489 An immune system disease that is located_in the lymphatic system. MESH:D008206 SNOMEDCT_US_2020_03_01:266326002 UMLS_CUI:C0024228 Adenopathy Lymphangiopathy Lymphatic disease Lymphatic disorder disease of lympoid system disorder of lymph node and lymphatics disorder of lymphatic system disorder of lymphoid system lymphatic disorder lympoid system disease disease_ontology DOID:75 lymphatic system disease DOID:75 DOID:11466 DOID:12635 DOID:13115 ICD10CM:K27 ICD9CM:533 MESH:D010437 NCI:C3318 SNOMEDCT_US_2020_03_01:155701001 UMLS_CUI:C0030920 acute peptic ulcer with hemorrhage acute peptic ulcer with hemorrhage and perforation acute peptic ulcer without hemorrhage AND without perforation acute peptic ulcer without hemorrhage and without perforation disease_ontology DOID:750 peptic ulcer disease DOID:750 DOID:751 MESH:D010439 SNOMEDCT_US_2020_03_01:88169003 UMLS_CUI:C0030925 Peptic ulcer with perforation Perforated peptic ulcer acute peptic ulcer with perforation disease_ontology DOID:752 peptic ulcer perforation DOID:752 NCI:C9009 SNOMEDCT_US_2020_03_01:82049002 UMLS_CUI:C1378340 disease_ontology DOID:7532 squamous papillomatosis DOID:7532 A primary bacterial infectious disease that is a sexually transmitted infection, located_in uterus, located_in fallopian tube, located_in urethra, located_in mouth, located_in throat, located_in eye or located_in anus, has_material_basis_in Neisseria gonorrhoeae, which is transmitted_by contact with the penis, vagina, mouth, or anus or transmitted_by congenitally from mother to baby during delivery. The infection has_symptom burning sensation during urination, has_symptom discharge from the penis, has_symptom increased vaginal discharge, or has_symptom vaginal bleeding between periods. DOID:10409 DOID:13557 ICD10CM:A54 ICD9CM:098 MESH:D006069 NCI:C92950 SNOMEDCT_US_2020_03_01:186943001 UMLS_CUI:C0018081 chronic gonococcal infectious disease of lower genitourinary tract chronic gonococcal infectious disease of upper genitourinary tract disease_ontology DOID:7551 gonorrhea DOID:7551 GARD:4883 ICD10CM:Q89.3 ICD9CM:759.3 MESH:D012857 NCI:C87121 OMIM:270100 SNOMEDCT_US_2020_03_01:157033002 UMLS_CUI:C0037221 Complete transposition Laterality sequence situs inversus viscerum disease_ontology DOID:758 OMIM mapping confirmed by DO. [LS]. situs inversus DOID:758 A gastrointestinal system disease that is located_in the stomach. MESH:D013272 NCI:C26886 SNOMEDCT_US_2020_03_01:196598004 UMLS_CUI:C0038354 Gastropathy stomach disorder disease_ontology gastric disease DOID:76 stomach disease DOID:76 NCI:C4020 SNOMEDCT_US_2020_03_01:12690005 UMLS_CUI:C0279602 Fibroblastic osteosarcoma Fibrosarcomatous Osteogenic sarcoma disease_ontology DOID:7603 fibrosarcomatous osteosarcoma DOID:7603 A parathyroid gland benign neoplam that is located_in the parathyroid. MESH:D010282 NCI:C3916 SNOMEDCT_US_2020_03_01:128474007 UMLS_CUI:C0262587 adenoma of the Parathyroid gland disease_ontology adenoma of parathyroid DOID:7608 parathyroid adenoma DOID:7608 A sarcoma that results_in the formation of numerous sarcomas or located_in various parts of the body. NCI:C4243 SNOMEDCT_US_2020_03_01:9395006 UMLS_CUI:C0334451 disease_ontology DOID:7615 sarcomatosis DOID:7615 MESH:D012167 NCI:C34795 SNOMEDCT_US_2020_03_01:193388002 UMLS_CUI:C0024441 Macular hole disease_ontology DOID:7633 macular holes DOID:7633 NCI:C6776 UMLS_CUI:C1336535 disease_ontology DOID:7634 suprasellar meningioma DOID:7634 MESH:D009133 NCI:C94834 SNOMEDCT_US_2020_03_01:267693003 UMLS_CUI:C0026846 Amyotrophia Muscle wasting Wasting - muscle disease_ontology DOID:767 muscular atrophy DOID:767 NCI:C39951 UMLS_CUI:C1515282 disease_ontology DOID:7675 testicular fibroma DOID:7675 A retinal cell cancer and malignant neoplasm of retina and neuroblastoma and neuroendocrine tumors that derives_from the tissues of the retina. GARD:7563 MESH:D012175 NCI:C7541 OMIM:180200 SNOMEDCT_US_2020_03_01:154553002 UMLS_CUI:C0035335 RB RB - Retinoblastoma neuroblastoma of Retina disease_ontology DOID:768 OMIM mapping confirmed by DO. [LS]. retinoblastoma DOID:768 An autonomic nervous system neoplasm that derives_from immature nerve cells. EFO:0000621 GARD:7185 ICDO:M9500/3 MESH:D009447 NCI:C3270 ORDO:635 SNOMEDCT_US_2020_03_01:432328008 UMLS_CUI:C0027819 disease_ontology DOID:769 Xref MGI. OMIM mapping confirmed by DO. [SN]. neuroblastoma DOID:769 An aortic aneurysm that is located_in the abdominal aorta. EFO:0004214 GARD:9181 MESH:D017544 NCI:C27000 OMIM:100070 OMIM:609782 OMIM:611891 OMIM:614375 SNOMEDCT_US_2020_03_01:155422008 UMLS_CUI:C0162871 AORTIC ANEURYSM, FAMILIAL ABDOMINAL 1 disease_ontology DOID:7693 abdominal aortic aneurysm DOID:7693 A disease of anatomical entity that is located_in the gastrointestinal tract. DOID:27 DOID:944 ICD10CM:K92.9 ICD9CM:520-579.99 MESH:D004066 SNOMEDCT_US_2020_03_01:53619000 UMLS_CUI:C0012242 GIT disease Gastroenteropathy alimentary system disease digestive system disorder gastrointestinal disease gastrointestinal disorder disease_ontology DOID:77 gastrointestinal system disease DOID:77 A malignant neoplasm that derives_from the retina. NCI:C7061 UMLS_CUI:C1335765 disease_ontology DOID:771 retinal cell cancer DOID:771 An adolescence-adult electroclinical syndrome starting in adolescence exhibiting generalized tonic-clonic seizures as the only seizure type. MESH:D004830 NCI:C3022 SNOMEDCT_US_2020_03_01:352818000 UMLS_CUI:C0014549 Epileptic seizures, tonic-clonic Grand Mal epilepsy tonic-clonic epilepsy disease_ontology DOID:7725 JA:Epilepsy Genetics Kiel epilepsy with generalized tonic-clonic seizures DOID:7725 ICD9CM:362.15 SNOMEDCT_US_2020_03_01:84884003 UMLS_CUI:C0154835 disease_ontology DOID:7736 retinal telangiectasia DOID:7736 DOID:7746 MESH:D064090 NCI:C9184 UMLS_CUI:C0281658 primary intraocular lymphoma disease_ontology DOID:775 intraocular lymphoma DOID:775 GARD:6121 ICD10CM:H35.02 ICD9CM:362.12 MESH:D058456 OMIM:300216 SNOMEDCT_US_2020_03_01:193359003 UMLS_CUI:C0154832 Coats' disease Coats' syndrome Exudative retinopathy disease_ontology DOID:7765 OMIM mapping confirmed by DO. [SN]. Coats disease DOID:7765 A psychotic disorder that involves an uncommon psychiatric condition in which patients present with circumscribed symptoms of non-bizarre delusions, but with the absence of prominent hallucinations and no thought disorder, mood disorder, or significant flattening effect. ICD10CM:F22 ICD9CM:297.1 MESH:D012563 NCI:C94379 SNOMEDCT_US_2020_03_01:48500005 UMLS_CUI:C0011251 disease_ontology DOID:778 delusional disorder DOID:778 A uterine disease that is located_in the placenta. DOID:1815 DOID:5366 DOID:9219 GARD:7402 ICD10CM:O43 ICD9CM:646.9 MESH:D010922 MESH:D011248 NCI:C26857 NCI:C27619 NCI:C34941 NCI:C35169 SNOMEDCT_US_2020_03_01:125586008 SNOMEDCT_US_2020_03_01:172422001 SNOMEDCT_US_2020_03_01:198881004 UMLS_CUI:C0032045 UMLS_CUI:C0032962 UMLS_CUI:C0151864 UMLS_CUI:C1335423 disease_ontology DOID:780 placenta disease DOID:780 NCI:C5278 UMLS_CUI:C1335395 disease_ontology DOID:7818 petroclival meningioma DOID:7818 A chronic kidney disease is characterized by non-functioning kidneys, as the final stage in chronic kidney disease. ICD9CM:585.6 end stage renal failure end-stage kidney disease disease_ontology DOID:783 end stage renal disease DOID:783 A kidney failure that is characterized by the gradual loss of kidney function. ICD10CM:N18.9 ICD9CM:585.6 MESH:D007676 NCI:C9438 SNOMEDCT_US_2020_03_01:155856009 UMLS_CUI:C0022661 CKD CRF chronic kidney failure chronic renal disease chronic renal failure syndrome renal failure - chronic disease_ontology DOID:784 chronic kidney disease DOID:784 A breast carcinoma that is manifested in the female breast. NCI:C2918 UMLS_CUI:C0007104 Mammary carcinoma of female breast disease_ontology carcinoma of female breast DOID:7843 female breast carcinoma DOID:7843 A histiocytic and dendritic cell cancer that is mainly located_in lymph nodes. NCI:C27260 SNOMEDCT_US_2020_03_01:397355008 UMLS_CUI:C1301364 Dendritic cell sarcoma Dendritic cell sarcoma, not otherwise specified disease_ontology follicular dendritic cell sarcoma DOID:7849 dendritic cell sarcoma DOID:7849 ICD10CM:S12.8 ICD9CM:478.70 MESH:D007818 NCI:C26810 SNOMEDCT_US_2020_03_01:195863001 UMLS_CUI:C0023051 disease_ontology DOID:786 laryngeal disease DOID:786 An ovarian benign neoplasm characterized by solid proliferations of luteinized cells, resulting in a tumor-like ovarian enlargement that regresses during the puerperium. NCI:C40445 UMLS_CUI:C1517842 leuteoma of pregnancy luteoma of pregnancy disease_ontology DOID:7880 luteoma DOID:7880 A parasitic ectoparasitic infectious disease that involves infestation of mites belonging to the family Sarcoptidae, Trombiculidae and Demodicidae. ICD10CM:B88.9 ICD9CM:133 MESH:D008924 SNOMEDCT_US_2020_03_01:78166003 UMLS_CUI:C0026229 disease_ontology DOID:7894 mite infestation DOID:7894 ICD10CM:H44.4 ICD9CM:360.3 MESH:D015814 SNOMEDCT_US_2020_03_01:23670006 UMLS_CUI:C0028841 Hypotony of eye disease_ontology DOID:790 ocular hypotension DOID:790 NCI:C7997 SNOMEDCT_US_2020_03_01:128715000 UMLS_CUI:C0279705 Squamoid Thymoma Thymoma, epithelial Well differentiated thymic carcinoma disease_ontology DOID:7926 epithelial malignant thymoma DOID:7926 A vein disease that is characterized by swollen, twisted veins visible just under the surface of the skin. ICD10CM:I83.90 MESH:D014648 NCI:C35114 OMIM:192200 SNOMEDCT_US_2020_03_01:276504003 UMLS_CUI:C0042345 Varix Venous ectasia Venous varices varices disease_ontology DOID:799 varicose veins DOID:799 A thyroid gland disease that is characterized by excess thyroid hormone. ICD10CM:E05.9 ICD9CM:242 MESH:D013971 NCI:C61469 SNOMEDCT_US_2020_03_01:154655004 UMLS_CUI:C0040156 disease_ontology DOID:7997 OMIM mapping confirmed by DO. [LS]. thyrotoxicosis DOID:7997 A thyroid gland disease that involves an over production of thyroid hormone. ICD10CM:E05.9 MESH:D006980 NCI:C3123 OMIM:603373 OMIM:609152 ORDO:99819 SNOMEDCT_US_2020_03_01:190239004 UMLS_CUI:C0020550 overactive thyroid disease_ontology DOID:7998 Xref MGI. hyperthyroidism MESH:D006980 DOID:7998 NCI:C4140 SNOMEDCT_US_2020_03_01:8097004 UMLS_CUI:C0334303 Alveolar adenoma adenoma of alveoli disease_ontology adenoma of the alveoli DOID:8003 alveoli adenoma DOID:8003 DOID:12025 DOID:13059 DOID:13646 DOID:13933 DOID:14242 DOID:800 DOID:953 ICD10CM:M25.0 ICD9CM:719.1 MESH:D006395 SNOMEDCT_US_2020_03_01:156581006 UMLS_CUI:C0018924 Haemarthrosis of shoulder joint Haemarthrosis of the ankle and foot Haemarthrosis of the pelvic region and thigh Hemarthrosis involving ankle and foot Hemarthrosis involving forearm Hemarthrosis involving hand Hemarthrosis involving lower leg Hemarthrosis involving pelvic region and thigh Hemarthrosis involving shoulder region Hemarthrosis involving upper arm Hemarthrosis of ankle and/or foot Hemarthrosis of forearm Hemarthrosis of hand Hemarthrosis of lower leg Hemarthrosis of shoulder Hemarthrosis of shoulder region Hemarthrosis of the ankle and foot Hemarthrosis of the ankle and/or foot Hemarthrosis of the forearm Hemarthrosis of the hand Hemarthrosis of the lower leg Hemarthrosis of the pelvic region and thigh Hemarthrosis of the shoulder region Hemarthrosis of the upper arm Hemarthrosis of upper arm disease_ontology DOID:801 hemarthrosis DOID:801 A breast carcinoma that occurs in people who do not have a family history of that cancer or an inherited change in their DNA that would increase their risk for that cancer. NCI:C7566 UMLS_CUI:C1336076 disease_ontology DOID:8029 sporadic breast cancer DOID:8029 NCI:C6756 UMLS_CUI:C1335418 Pineal meningioma disease_ontology DOID:8031 pineal region meningioma DOID:8031 NCI:C6842 UMLS_CUI:C1333644 Inverted papilloma of the Frontal sinus disease_ontology DOID:8060 frontal sinus inverted papilloma DOID:8060 ICD9CM:433.10 UMLS_CUI:C0375275 Occlusion and stenosis of carotid artery disease_ontology DOID:807 carotid artery occlusion DOID:807 A substance abuse that involves the recurring use of cocaine despite negative consequences. ICD10CM:F14.1 ICD9CM:305.6 MESH:D019970 SNOMEDCT_US_2020_03_01:78267003 UMLS_CUI:C0009171 disease_ontology DOID:809 cocaine abuse DOID:809 A connective tissue disease that is characterized by marked reduction, absence, and/or the redistribution of adipose tissue. ICD10CM:E88.1 ICD9CM:272.6 MESH:D008060 NCI:C97093 SNOMEDCT_US_2020_03_01:190789006 UMLS_CUI:C0023787 disease_ontology DOID:811 lipodystrophy DOID:811 An ischemic bone disease that results_in necrosis followed by regrowth in children and teens located_in bone. DOID:7490 ICD10CM:M92 ICD10CM:M93.9 ICD9CM:732.6 MESH:D055034 NCI:C34879 SNOMEDCT_US_2020_03_01:203398006 SNOMEDCT_US_2020_03_01:65477003 UMLS_CUI:C0029429 UMLS_CUI:C0158445 Epiphyseal necrosis Osteochondrosis apophysitis epiphysitis osteochondritis osteochondritis juvenilis disease_ontology DOID:8125 osteochondrosis DOID:8125 An arthritis that involves infection by a pathogen located_in joint. DOID:10920 DOID:12314 DOID:14519 DOID:1683 DOID:2002 DOID:2003 DOID:812 GARD:6781 ICD10CM:M00 ICD9CM:711.90 ICD9CM:711.91 ICD9CM:711.92 ICD9CM:711.93 ICD9CM:711.94 ICD9CM:711.95 ICD9CM:711.96 ICD9CM:711.97 MESH:D001170 NCI:C26700 SNOMEDCT_US_2020_03_01:201594004 SNOMEDCT_US_2020_03_01:201595003 SNOMEDCT_US_2020_03_01:201596002 SNOMEDCT_US_2020_03_01:201597006 SNOMEDCT_US_2020_03_01:201598001 SNOMEDCT_US_2020_03_01:201599009 SNOMEDCT_US_2020_03_01:372938004 SNOMEDCT_US_2020_03_01:428437005 UMLS_CUI:C0003869 UMLS_CUI:C0157843 UMLS_CUI:C0157844 UMLS_CUI:C0157845 UMLS_CUI:C0157846 UMLS_CUI:C0157847 UMLS_CUI:C0157848 UMLS_CUI:C0157849 infectious arthritis disease_ontology DOID:813 septic arthritis DOID:813 NCI:C5734 UMLS_CUI:C1333748 Lymphoma of the gallbladder disease_ontology DOID:8135 gallbladder lymphoma DOID:8135 NCI:C6042 UMLS_CUI:C1336750 benign oncocytoma of the thyroid disease_ontology DOID:8162 thyroid Hurthle cell adenoma DOID:8162 NCI:C5735 UMLS_CUI:C1333749 malignant melanoma of gallbladder disease_ontology DOID:8167 gallbladder melanoma DOID:8167 A connective tissue disease characterized by inflammation located_in the mediastinum, which extends from the diaphragm to the thoracic inlet and between the pleural cavities. ICD10CM:J98.51 ICD9CM:519.2 MESH:D008480 NCI:C26827 SNOMEDCT_US_2020_03_01:47597000 UMLS_CUI:C0025064 disease_ontology DOID:819 mediastinitis DOID:819 An extrinsic cardiomyopathy that is characterized as an inflammation of the heart muscle. GARD:7137 ICD10CM:I51.4 ICD9CM:429.0 KEGG:05416 MESH:D009205 NCI:C34831 SNOMEDCT_US_2020_03_01:50920009 UMLS_CUI:C0027059 Myocardial inflammation disease_ontology DOID:820 myocarditis MESH:D009205 DOID:820 A syphilis that is characterized as the third stage of syphilis that develops after the disappearance of the secondary symptoms and is marked by ulcers and gummas under the skin and commonly by involvement of the skeletal, cardiovascular, and nervous systems. ICD10CM:A52 ICD9CM:097.0 MESH:C536774 NCI:C128414 SNOMEDCT_US_2020_03_01:72083004 UMLS_CUI:C0153188 late syphilis disease_ontology DOID:8200 tertiary syphilis DOID:8200 ICD10CM:K04.5 MESH:D010485 SNOMEDCT_US_2020_03_01:39273001 UMLS_CUI:C0031030 Apical periodontitis disease_ontology DOID:823 periapical periodontitis DOID:823 EFO:0000649 ICD10CM:K05.3 MESH:D010518 NCI:C34918 SNOMEDCT_US_2020_03_01:266491004 UMLS_CUI:C0031099 chronic pericementitis disease_ontology DOID:824 periodontitis DOID:824 A gastrointestinal system disease that involves inflammation of the peritoneum resulting from perforation of the gastrointestinal tract, which produces immediate chemical inflammation followed shortly by infection from intestinal organisms. Peritonitis can also result from appendicitis, diverticulitis, strangulating intestinal obstruction, pancreatitis, pelvic inflammatory disease, mesenteric ischemia, intraperitoneal blood, barium, or peritoneo-systemic shunts, drains, and dialysis catheters in the peritoneal cavity. The symptoms include abdominal pain and tenderness, fever, fluid in the abdomen, nausea, vomiting and low urine output. DOID:8694 DOID:8863 DOID:9233 ICD9CM:567.8 SNOMEDCT_US_2020_03_01:197183001 UMLS_CUI:C0029823 Retractile mesenteritis acute generalized peritonitis primary bacterial peritonitis sclerosing mesenteritis disease_ontology DOID:8283 peritonitis DOID:8283 A mite infestation that is a contagious ectoparasite skin infection caused by human itch mite Sarcoptes scabiei type hominis, which burrows into the upper layer of the skin but never below the stratum corneum causing severe itching and a rash found on the hands, folds of the wrist, elbow or knee, penis, breast, and shoulder blades. ICD10CM:B86 ICD9CM:133.0 MESH:D012532 NCI:C34998 SNOMEDCT_US_2020_03_01:266224002 UMLS_CUI:C0036262 Infestation by Sarcoptes scabiei Infestation by Sarcoptes scabiei var hominis Sarcoptic itch disease_ontology DOID:8295 scabies MESH:D012532 DOID:8295 A lens disease characterized by clouding of the lens inside the eye which leads to a decrease in vision. ICD10CM:H26 ICD9CM:366.8 OMIM:601371 OMIM:PS116200 SNOMEDCT_US_2020_03_01:193620000 UMLS_CUI:C0029531 disease_ontology DOID:83 Xref MGI. cataract MESH:D002386 DOID:83 A uterine corpus cancer that has_material_basis_in endometrial stroma and smooth muscle cells. NCI:C40178 UMLS_CUI:C1513364 Stromomyoma disease_ontology DOID:8302 mixed endometrial stromal and smooth muscle tumor DOID:8302 An organ system cancer located_in the ear and characterized by uncontrolled cellular proliferation of the auditory organs. MESH:D004428 NCI:C3000 SNOMEDCT_US_2020_03_01:363228008 UMLS_CUI:C0013449 disease_ontology DOID:833 auditory system cancer DOID:833 A gastrointestinal system infectious disease that involves inflammation and infection of the appendix caused by the blockage of the lumen with a small, hard piece of stool, a foreign body or worms. Mucus backs up in the appendiceal lumen, causing bacteria that live inside the appendix to multiply. The infection has_symptom pain, in the upper abdomen initially and later in the lower abdomen, has_symptom nausea, has_symptom vomiting and has_symptom fever. DOID:10275 DOID:10276 DOID:10947 ICD10CM:K37 ICD9CM:540-543.99 MESH:D001064 NCI:C35145 SNOMEDCT_US_2020_03_01:155729003 UMLS_CUI:C0003615 acute appendicitis acute appendicitis with generalized peritonitis acute appendicitis with peritoneal abscess disease_ontology DOID:8337 appendicitis DOID:8337 A complement deficiency that is characterized by deficiency of complement component 3 that increases susceptibility to infection and autoimmune diseases and has_material_basis_in autosomal recessive inheritance of mutation in the C3 gene on chromosome 19p13.3, has_symptom recurrent bacterial infections. NCI:C9468 OMIM:613779 ORDO:280133 SNOMEDCT_US_2020_03_01:771443008 UMLS_CUI:C1332655 C3 deficiency disease_ontology DOID:8354 Xref MGI. complement component 3 deficiency DOID:8354 An arthritis that has_material_basis_in worn out cartilage located_in joint. EFO:0002506 ICD9CM:715.3 UMLS_CUI:C0157946 Osteoarthrosis and allied disorder degenerative arthritis degenerative joint disease hypertrophic arthritis osteoarthrosis disease_ontology DOID:8398 Xref MGI. osteoarthritis MESH:D010003 DOID:8398 An ischemic bone disease that results_in necrosis located_in epiphysis. DOID:87 GARD:12703 ICD10CM:M93.2 ICD10CM:M93.9 ICD9CM:732.7 MESH:D010007 MESH:D010008 NCI:C34877 NCI:C34878 OMIM:165800 SNOMEDCT_US_2020_03_01:156821002 SNOMEDCT_US_2020_03_01:70736000 UMLS_CUI:C0029420 UMLS_CUI:C0029421 OCD disease_ontology DOID:84 OMIM mapping confirmed by DO. [SN]. osteochondritis dissecans DOID:84 An interstitial lung disease involving inflammation of alveoli and smallest airways (bronchioles) of the lung caused by an allergic reaction to inhaled organic dusts containing microorganisms or proteins, and chemicals. Symptoms include chills, cough, fever, malaise, shortness of breath, loss of appetite and weight loss. DOID:2707 GARD:12 ICD10CM:J67.9 ICD9CM:495 MESH:D000542 NCI:C34369 SNOMEDCT_US_2020_03_01:155581001 UMLS_CUI:C0002390 alveolitis hypersensitivity pneumonitis disease_ontology DOID:841 extrinsic allergic alveolitis DOID:841 NCI:C3888 SNOMEDCT_US_2020_03_01:254921004 UMLS_CUI:C0241961 Angiomyolipoma of kidney renal Angiomyolipoma disease_ontology DOID:8411 kidney angiomyolipoma DOID:8411 NCI:C4244 SNOMEDCT_US_2020_03_01:403996004 UMLS_CUI:C0334459 Infantile fibrosarcoma disease_ontology DOID:8418 congenital fibrosarcoma DOID:8418 A bone marrow disease characterized by an increased number of red blood cells in the bloodstream resulting in thicker blood and reduced blood flow. ICD10CM:D75.1 MESH:D011086 NCI:C26863 SNOMEDCT_US_2020_03_01:127062003 UMLS_CUI:C0032461 Erythrocythemia disease_ontology DOID:8432 polycythemia DOID:8432 ICD10CM:K56.609 ICD9CM:560.9 MESH:D007415 NCI:C9175 SNOMEDCT_US_2020_03_01:81060008 UMLS_CUI:C0021843 disease_ontology DOID:8437 intestinal obstruction DOID:8437 A postgastrectomy syndrome that is characterized by obstruction of the afferent loop that arises after gastric surgery with gastrojejunostomy reconstruction. MESH:D000343 SNOMEDCT_US_2020_03_01:20813000 UMLS_CUI:C0001727 Afferent limb syndrome disease_ontology DOID:8438 afferent loop syndrome MESH:D000343 DOID:8438 ICD10CM:K91.1 ICD9CM:564.2 MESH:D011178 SNOMEDCT_US_2020_03_01:266527005 UMLS_CUI:C0032763 Postgastric surgery syndrome disease_ontology DOID:8439 postgastrectomy syndrome DOID:8439 MESH:D045823 NCI:C37979 SNOMEDCT_US_2020_03_01:278524008 UMLS_CUI:C1258215 Ileus of intestine disease_ontology DOID:8440 ileus DOID:8440 A brachial plexus neuropathy characterized by an abnormality, usually caused by disease or trauma, located in the brachial plexus. ICD9CM:353.0 SNOMEDCT_US_2020_03_01:3548001 UMLS_CUI:C0006091 Brachial plexus lesions disease_ontology DOID:8443 brachial plexus lesion DOID:8443 An intestinal obstruction characterized by abnormal rotation of the intestines. ICD10CM:K56.2 ICD9CM:560.2 MESH:D045822 NCI:C98963 OMIM:193250 SNOMEDCT_US_2020_03_01:9707006 UMLS_CUI:C0042961 Twist of intestine, bowel, or colon Volvulus familial intestinal malrotation volvulus of midgut disease_ontology DOID:8445 intestinal volvulus DOID:8445 ICD10CM:K56.1 ICD9CM:560.0 MESH:D007443 NCI:C113484 OMIM:147710 SNOMEDCT_US_2020_03_01:155772009 UMLS_CUI:C0021933 Intussusception Intussusception of intestine Invagination of intestine or colon disease_ontology DOID:8446 OMIM mapping confirmed by DO. [SN]. intussusception DOID:8446 A bipolar disorder that involves recurrent hypomanic and dysthymic episodes, but no full manic episodes or full major depressive episodes. ICD10CM:F34.0 ICD9CM:301.13 MESH:D003527 SNOMEDCT_US_2020_03_01:191754000 UMLS_CUI:C0010598 Affective personality disorder Cycloid personality Cyclothymia Cyclothymic personality disease_ontology DOID:845 cyclothymic disorder DOID:845 A nutritional deficiency disease that is characterized by stomatitis, cheilosis, glossitis, conjunctivitis, and anemia, develops_from vitamin B2 (riboflavin) deficiency, has_symptom red chapped lips, painful swollen tongue, sore throat, blurred vision, and fatigue, and has_material_basis_in inadequate intake, endocrine disorder, liver disorder, alcoholism, and dialysis. ICD10CM:E53.0 ICD9CM:266.0 MESH:D012257 SNOMEDCT_US_2020_03_01:20307000 UMLS_CUI:C0035528 ariboflavinosis vitamin B2 deficiency disease_ontology DOID:8454 riboflavin deficiency DOID:8454 A nutritional deficiency disease that is characterized by deficiency of niacin (vitamin B3), has_symptom gastrointestinal disturbance, anorexia, diarrhea, dementia, hallucinations, depression, psychosis, and/or non-specific skin changes, and has_material_basis_in deficiency of niacin, often from inadequate diet, malabsorption, or medication side effects. GARD:10014 ICD9CM:265.2 MESH:D010383 SNOMEDCT_US_2020_03_01:267491008 UMLS_CUI:C0030783 Niacin deficiency Niacin-tryptophan deficiency Pellagra disease_ontology DOID:8457 pellagra DOID:8457 A syndrome that is characterized by absence or underdeveloped tissue connecting the left and right halves of the brain, infantile spasms and chorioretinal lacunae, which are defects in the light-sensitive tissue at the back of the eye. GARD:5764 MESH:D058540 NCI:C35256 OMIM:304050 ORDO:50 SNOMEDCT_US_2020_03_01:80651009 UMLS_CUI:C0175713 disease_ontology DOID:8461 OMIM mapping confirmed by DO. [SN]. Aicardi syndrome MESH:D058540 DOID:8461 ICD10CM:H16.0 ICD9CM:370.0 MESH:D003320 NCI:C50515 SNOMEDCT_US_2020_03_01:193758008 UMLS_CUI:C0010043 disease_ontology DOID:8463 corneal ulcer DOID:8463 ICD10CM:H33.10 ICD9CM:361.10 MESH:D041441 NCI:C85046 SNOMEDCT_US_2020_03_01:389992006 UMLS_CUI:C0152439 disease_ontology DOID:8465 retinoschisis DOID:8465 A retinal disease that is characterized by deterioration of the retina caused by the progressive and eventual death of the cells of the retina. MESH:D012162 NCI:C34979 SNOMEDCT_US_2020_03_01:95695004 UMLS_CUI:C0035304 degeneration of retina disease_ontology DOID:8466 retinal degeneration DOID:8466 A viral infectious disease that results in infection, located in respiratory tract, has_material_basis_in Influenzavirus A, has_material_basis_in Influenzavirus B, or has_material_basis_in Influenzavirus C, which are transmitted_by droplet spread of oronasal secretions during coughing, sneezing, or talking from an infected person. It is a highly contagious disease that affects birds and mammals and has_symptom chills, has_symptom fever, has_symptom sore throat, has_symptom runny nose, has_symptom muscle pains, has_symptom severe headache, has_symptom cough, and has_symptom weakness. DOID:8468 ICD10CM:J11.1 ICD9CM:487 MESH:D007251 NCI:C53482 SNOMEDCT_US_2020_03_01:155559006 UMLS_CUI:C0021400 Influenza with non-respiratory manifestation Influenza with other manifestations flu influenza with non-respiratory manifestation disease_ontology DOID:8469 influenza DOID:8469 GARD:7058 ICD10CM:L94.0 ICD9CM:701.0 MESH:D012594 NCI:C72069 SNOMEDCT_US_2020_03_01:90424004 UMLS_CUI:C0036420 Morphea Scleroderma, circumscribed or localised Scleroderma, circumscribed or localized circumscribed scleroderma localised morphea localised morphoea localised scleroderma localized morphea disease_ontology DOID:8472 localized scleroderma DOID:8472 GARD:7889 ICD10CM:K90.81 ICD9CM:040.2 MESH:D008061 NCI:C85228 SNOMEDCT_US_2020_03_01:41545003 UMLS_CUI:C0023788 Whipple's disease intestinal lipodystrophy disease_ontology DOID:8476 Whipple disease DOID:8476 A commensal bacterial infectious disease that results in infection, which is characterized by contiguous spread, suppurative and granulomatous inflammation, and formation of multiple abscesses and sinus tracts that may discharge sulfur granules, has_material_basis_in Actinomyces israelii, has_material_basis_in Actinomyces gerencseriae, has_material_basis_in Actinomyces naeslundii, has_material_basis_in Actinomyces odontolyticus, has_material_basis_in Actinomyces viscosus, has_material_basis_in Actinomyces meyeri, has_material_basis_in Propionibacterium propionicum, which require a break in the integrity of the mucous membranes and the presence of devitalized tissue to invade deeper body structures. DOID:0050000 DOID:13079 GARD:5728 ICD10CM:A42 ICD9CM:039.9 MESH:D000196 NCI:C34350 SNOMEDCT_US_2020_03_01:50508009 UMLS_CUI:C0001261 Actinomycotic madura foot Actinomycotic mycetema Actinomycotic mycetoma of foot Madura foot due to Actinomadura actinomycotic infection disease_ontology actinomycetoma boil DOID:8478 actinomycosis MESH:D000196 DOID:8478 A bone inflammation disease that involves a response to irritation or injury, characterized by joint pain, swelling, stiffness located_in joint. ICD10CM:M19.90 MESH:D001168 NCI:C2883 SNOMEDCT_US_2020_03_01:372091005 UMLS_CUI:C0003864 Inflammatory disorder of joint disease_ontology DOID:848 arthritis MESH:D001168 DOID:848 DOID:14025 DOID:14036 ICD10CM:I01.9 ICD10CM:M05.3 ICD9CM:391.9 ICD9CM:398.0 NCI:C34985 SNOMEDCT_US_2020_03_01:195136004 SNOMEDCT_US_2020_03_01:8805001 UMLS_CUI:C0035440 UMLS_CUI:C0489959 Rheumatic degeneration of myocardium Rheumatic fever with myocarditis Rheumatic myocarditis Rheumatoid myocarditis active rheumatic fever with myocarditis acute Rheumatic Myocarditis acute rheumatic carditis acute rheumatic myocarditis disease_ontology DOID:8481 rheumatic myocarditis DOID:8481 MESH:D015356 NCI:C34978 SNOMEDCT_US_2020_03_01:232035005 UMLS_CUI:C0035302 Retinal artery occlusion disease_ontology DOID:8483 retinal artery occlusion DOID:8483 A placenta disease that is characterized by an excess of amniotic fluid in the amniotic sac. ICD10CM:O40 ICD9CM:657.0 MESH:D006831 NCI:C92848 SNOMEDCT_US_2020_03_01:157052008 UMLS_CUI:C0020224 disease_ontology DOID:8488 polyhydramnios DOID:8488 ICD10CM:H53.63 ICD9CM:368.61 MESH:C537743 SNOMEDCT_US_2020_03_01:193687000 UMLS_CUI:C1306122 Congenital night blindness disease_ontology DOID:8498 OMIM mapping confirmed by DO. [SN]. hereditary night blindness DOID:8498 A retinal disease that is characterized by difficulty or the inability to see in relatively low light. ICD10CM:H53.6 ICD9CM:368.6 MESH:D009755 NCI:C34850 SNOMEDCT_US_2020_03_01:75390007 UMLS_CUI:C0028077 nyctalopia disease_ontology DOID:8499 night blindness DOID:8499 A lower respiratory tract disease in which the function of the lungs is adversely affected by narrowing or blockage of the airways resulting in poor air flow, a loss of elasticity in the lungs that produces a decrease in the total volume of air that the lungs are able to hold, and clotting, scarring, or inflammation of the blood vessels that affect the ability of the lungs to take up oxygen and to release carbon dioxide. DOID:11894 DOID:11895 DOID:29 DOID:766 ICD10CM:J98.4 MESH:D008171 NCI:C3198 SNOMEDCT_US_2020_03_01:266374002 UMLS_CUI:C0024115 disease_ontology DOID:850 Updating out dated CUI and removing lung abscess as a synonym. lung disease DOID:850 MESH:D058499 NCI:C35625 SNOMEDCT_US_2020_03_01:314407005 UMLS_CUI:C0854723 Retinal Dystrophy disease_ontology DOID:8501 fundus dystrophy DOID:8501 An autoimmune disease of skin and connective tissue that is characterized by blisters filled with a watery fluid, located_in skin. The disease is associated with the amount of gluten ingested. ICD9CM:694.8 SNOMEDCT_US_2020_03_01:200916004 UMLS_CUI:C0079957 disease_ontology DOID:8502 bullous skin disease DOID:8502 A pyoderma consisting of three forms of skin lesions having either a thick, adherent, recurrent, dirty yellow crust with an erythematous margin (common or superficial impetigo) or lessions which are superficial, thin-walled, and bullous as found in bullous impetigo. The lesions in bullous (staphylococcal) impetigo, which are always caused by S aureus, are superficial, thin-walled, and bullous. ICD10CM:L01.0 ICD9CM:684 MESH:D007169 NCI:C99088 SNOMEDCT_US_2020_03_01:156319000 UMLS_CUI:C0021099 disease_ontology DOID:8504 impetigo DOID:8504 GARD:1917 ICD10CM:L13.0 ICD9CM:694.0 MESH:D003874 NCI:C26742 SNOMEDCT_US_2020_03_01:200899006 UMLS_CUI:C0011608 Dermatitis herpetiformis Dermatosis herpetiformis Duhring's disease disease_ontology DOID:8505 dermatitis herpetiformis DOID:8505 An autoimmune disease of skin and connective tissue characterized by large blisters. GARD:5972 ICD10CM:L12.0 ICD9CM:694.5 MESH:D010391 NCI:C84389 SNOMEDCT_US_2020_03_01:77090002 UMLS_CUI:C0030805 Bullous pemphigoid disease_ontology DOID:8506 bullous pemphigoid DOID:8506 ICD10CM:L13.1 ICD9CM:694.1 MESH:D012872 SNOMEDCT_US_2020_03_01:25147002 UMLS_CUI:C0600336 Sneddon-Wilkinson disease or syndrome Subcorneal pustular dermatosis disease_ontology DOID:8508 subcorneal pustular dermatosis DOID:8508 ICD9CM:415 SNOMEDCT_US_2020_03_01:155324005 UMLS_CUI:C0155671 disease_ontology DOID:8514 acute pulmonary heart disease DOID:8514 A congestive heart failure that involves a failure of the right side of the heart and is characterized by an enlargement of the right ventricle of the heart as a response to increased resistance or high blood pressure in the lungs. ICD10CM:I27.81 MESH:D011660 SNOMEDCT_US_2020_03_01:83291003 UMLS_CUI:C0034072 cardiopulmonary disease pulmonary heart disease disease_ontology DOID:8515 Cor pulmonale DOID:8515 ICD10CM:I26.09 ICD9CM:415.0 SNOMEDCT_US_2020_03_01:155325006 UMLS_CUI:C0155672 disease_ontology DOID:8517 acute cor pulmonale DOID:8517 A myeloid leukemia that is characterized by a dominance of monocytes in the marrow. DOID:8526 DOID:8809 DOID:8884 DOID:8935 DOID:9151 ICD10CM:C93.Z ICD9CM:206.8 SNOMEDCT_US_2020_03_01:188747004 UMLS_CUI:C0153903 Schilling's leukaemia Schilling's leukemia monocytic leukaemia disease_ontology DOID:8527 monocytic leukemia DOID:8527 A pharynx cancer that is located_in the hypopharynx. DOID:12202 DOID:8532 DOID:9160 GARD:9334 ICD10CM:C13 ICD10CM:C13.2 ICD9CM:148 ICD9CM:148.3 MESH:D007012 NCI:C7190 SNOMEDCT_US_2020_03_01:93831006 SNOMEDCT_US_2020_03_01:93968005 UMLS_CUI:C0153398 UMLS_CUI:C0496770 Hypopharyngeal cancer malignant Hypopharyngeal tumor malignant neoplasm of hypopharynx malignant tumor of hypopharynx malignant tumour of hypopharynx disease_ontology DOID:8533 hypopharynx cancer DOID:8533 ICD10CM:K21.9 ICD9CM:530.81 MESH:D005764 NCI:C26781 OMIM:109350 SNOMEDCT_US_2020_03_01:235595009 UMLS_CUI:C0017168 Acid reflux GERD GERD - Gastro-esophageal reflux disease Gastresophageal reflux Gastro-esophageal reflux Gastroesophageal reflux Gastroesophageal reflux disease disease_ontology DOID:8534 OMIM mapping confirmed by DO. [SN]. gastroesophageal reflux disease DOID:8534 A viral infectious disease that results_in infection located_in nerve fiber, has_material_basis_in Human herpesvirus 3, which reactivates after appearing as chickenpox in childhood. The virus is transmitted_by direct contact with the rash, which can develop into chickenpox in newly-infected individuals. The infection has_symptom rash which is followed by blisters, has_symptom headache, has_symptom fever, has_symptom malaise, has_symptom itching, has_symptom burning pain, and has_symptom paresthesia. DOID:8554 DOID:8555 DOID:8772 DOID:8801 DOID:9085 ICD10CM:B02 ICD9CM:053 MESH:D006562 NCI:C71079 SNOMEDCT_US_2020_03_01:186514003 UMLS_CUI:C0019360 Shingles herpes zona disease_ontology DOID:8536 herpes zoster DOID:8536 DOID:8537 ICD9CM:200.0 MESH:D008228 NCI:C27824 OMIM:267730 SNOMEDCT_US_2020_03_01:154579006 UMLS_CUI:C0024302 histiocytic lymphoma large-cell Lymphomas disease_ontology DOID:8538 OMIM mapping confirmed by DO. [SN]. reticulosarcoma DOID:8538 A connective tissue disease that characterized by connective tissue disease that has_material_basis in inheritable defects in collagen. MESH:D003095 NCI:C27204 SNOMEDCT_US_2020_03_01:268048008 UMLS_CUI:C0009326 collagen disorder disease_ontology DOID:854 collagen disease DOID:854 DOID:8790 GARD:7629 ICD10CM:C84.1 ICD9CM:202.2 MESH:D012751 NCI:C3366 SNOMEDCT_US_2020_03_01:4950009 UMLS_CUI:C0036920 Sezary disease Sezary syndrome disease_ontology DOID:8541 Sezary's disease DOID:8541 A syndrome that involves prolonged and severe tiredness or weariness that is unrelated to exertion, is not relieved by rest and for a minimum of six months and is not directly caused by other conditions. GARD:7121 ICD10CM:R53.82 ICD9CM:780.71 MESH:D015673 NCI:C3037 SNOMEDCT_US_2020_03_01:193054000 UMLS_CUI:C0015674 CFS Myalgic encephalitis Myalgic encephalomyelitis Postviral fatigue syndrome disease_ontology DOID:8544 No OMIM mapping, confirmed by DO. [LS]. chronic fatigue syndrome DOID:8544 A muscle tissue disease that is characterized by a drastic and uncontrolled increase in skeletal muscle oxidative metabolism, which overwhelms the body's capacity to supply oxygen, remove carbon dioxide, and regulate body temperature. GARD:6964 ICD10CM:T88.3 ICD9CM:995.86 MESH:D008305 NCI:C84869 OMIM:PS145600 ORDO:423 SNOMEDCT_US_2020_03_01:111738008 UMLS_CUI:C0024591 anesthesia related hyperthermia malignant hyperpyrexia due to anesthesia disease_ontology DOID:8545 Xref MGI. OMIM mapping confirmed by DO. [SN]. malignant hyperthermia DOID:8545 DOID:8548 DOID:8733 ICD10CM:L98.4 ICD9CM:707 SNOMEDCT_US_2020_03_01:156423009 UMLS_CUI:C0157738 Callous ulcer Indolent ulcer disease_ontology DOID:8549 chronic ulcer of skin DOID:8549 A myeloid leukemia that is characterized by over production of white blood cells. DOID:8551 DOID:8606 EFO:0000339 GARD:6105 ICD9CM:205.1 KEGG:05220 MESH:D015464 NCI:C3174 OMIM:608232 ORDO:521 SNOMEDCT_US_2020_03_01:154592009 UMLS_CUI:C0023473 CML CML - chronic Myelogenous Leukemia Myeloid Leukemia, chronic chronic granulocytic leukaemia chronic granulocytic leukemia chronic myelogenous leukaemia chronic myelogenous leukemia chronic myeloid leukaemia disease_ontology DOID:8552 OMIM mapping confirmed by DO. [SN]. chronic myeloid leukemia DOID:8552 GARD:7510 ICD10CM:L88 ICD9CM:686.01 MESH:D017511 SNOMEDCT_US_2020_03_01:74578003 UMLS_CUI:C0085652 Pyoderma gangrenosum disease_ontology DOID:8553 pyoderma gangrenosum MESH:D017511 DOID:8553 A pharynx cancer that is located_in the oropharynx. DOID:8684 DOID:8851 DOID:8949 DOID:9168 ICD10CM:C10 ICD10CM:C10.2 ICD10CM:C10.3 ICD10CM:C10.8 ICD9CM:146 ICD9CM:146.5 ICD9CM:146.6 ICD9CM:146.7 NCI:C7398 SNOMEDCT_US_2020_03_01:187686007 SNOMEDCT_US_2020_03_01:93933005 SNOMEDCT_US_2020_03_01:93971002 UMLS_CUI:C0153382 UMLS_CUI:C0153388 UMLS_CUI:C0153389 UMLS_CUI:C0153390 Oropharyngeal carcinoma malignant Oropharyngeal tumor malignant tumor of oropharynx malignant tumour of mesopharynx oropharyngeal cancer disease_ontology DOID:8557 oropharynx cancer DOID:8557 A multiple carboxylase deficiency that involves a deficiency in biotinidase. GARD:894 ICD10CM:D81.810 MESH:D028921 NCI:C84598 OMIM:253260 SNOMEDCT_US_2020_03_01:8808004 UMLS_CUI:C0220754 BTD deficiency Juvenile-onset multiple carboxylase deficiency Late-onset multiple carboxylase deficiency deficiency of biotinidase disease_ontology DOID:856 OMIM mapping confirmed by DO. [SN]. biotinidase deficiency DOID:856 DOID:8563 DOID:8605 DOID:8975 DOID:9031 DOID:9135 ICD10CM:C00 ICD9CM:140 ICD9CM:140.6 ICD9CM:140.8 MESH:D008048 NCI:C7485 SNOMEDCT_US_2020_03_01:187626009 SNOMEDCT_US_2020_03_01:93762003 SNOMEDCT_US_2020_03_01:93869001 UMLS_CUI:C0153340 UMLS_CUI:C0153346 UMLS_CUI:C0153347 malignant neoplasm of commissure of lip malignant neoplasm of external Lip, not specified as upper or lower malignant neoplasm of labial commissure of lip malignant neoplasm of lip malignant neoplasm of lip, external malignant neoplasm of lip, inner aspect malignant neoplasm of lip, vermilion border malignant neoplasm of lower lip, buccal aspect malignant neoplasm of lower lip, inner aspect malignant neoplasm of lower lip, mucosa malignant neoplasm of lower lip, oral aspect malignant neoplasm of oral aspect of lip, not specified whether upper or lower malignant neoplasm of other sites of lip malignant neoplasm of vermilion border of lip malignant tumor of commissure of lip malignant tumor of labial mucosa malignant tumor of lip malignant tumor of lower labial mucosa malignant tumor of the Lip malignant tumour of labial commissure malignant tumour of lip disease_ontology DOID:8564 lip cancer DOID:8564 A viral infectious disease that results_in_formation_of lesions, located_in mouth, located_in face, located_in genitalia, or located_in hands, has_material_basis_in Human herpesvirus 1 or has_material_basis_in Human herpesvirus 2, which are transmitted_by direct contact with an active lesion or body fluid of an infected person. DOID:8763 DOID:9012 DOID:9239 ICD10CM:B00.9 ICD9CM:054 MESH:D006561 NCI:C155871 SNOMEDCT_US_2020_03_01:88594005 UMLS_CUI:C0019348 Herpesvirus hominis disease disease_ontology DOID:8566 herpes simplex DOID:8566 A lymphoma that is marked by the presence of a type of cell called the Reed-Sternberg cell. DOID:0060059 DOID:8652 DOID:8671 DOID:8685 DOID:8710 DOID:8715 DOID:8841 DOID:8953 DOID:9096 DOID:9107 EFO:0000183 GARD:2714 ICD10CM:C81 ICD9CM:201 MESH:D006689 NCI:C9357 OMIM:236000 OMIM:300221 OMIM:400021 ORDO:98293 SNOMEDCT_US_2020_03_01:118599009 UMLS_CUI:C0019829 HL Hodgkin disease Hodgkin lymphoma Hodgkin's sarcoma Hodgkins lymphoma stage I Subdiaphragmatic Hodgkin Lymphoma stage II Subdiaphragmatic Hodgkin Lymphoma disease_ontology DOID:8567 Xref MGI. OMIM mapping confirmed by DO. [SN]. Hodgkin's lymphoma MESH:D006689 NCI:C9357 DOID:8567 A viral infectious disease that results in inflammation, located in pharynx, has_material_basis_in Human herpesvirus 4 and has symptom fever, has symptom fatigue, has symptom lymphadenopathy, and has symptom splenomegaly. ICD10CM:B27 ICD9CM:075 MESH:D007244 NCI:C34726 SNOMEDCT_US_2020_03_01:154359004 UMLS_CUI:C0021345 Filatov's disease Gammaherpesviral mononucleosis Monocytic angina Pfeiffer's disease glandular fever mononucleosis disease_ontology DOID:8568 infectious mononucleosis DOID:8568 An amino acid metabolic disorder that involves failures of carboxylation enzymes. GARD:3824 ICD10CM:D81.81 MESH:D009100 SNOMEDCT_US_2020_03_01:62151000119109 UMLS_CUI:C0026755 disease_ontology DOID:857 multiple carboxylase deficiency MESH:D009100 DOID:857 ICD10CM:L44.1 ICD9CM:697.1 MESH:D017513 SNOMEDCT_US_2020_03_01:41890004 UMLS_CUI:C0162849 Pinkus' disease disease_ontology DOID:8573 lichen nitidus DOID:8573 ICD10CM:L28.0 ICD9CM:697.9 SNOMEDCT_US_2020_03_01:156376003 UMLS_CUI:C0023643 disease_ontology DOID:8574 lichen disease DOID:8574 A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. DOID:8576 DOID:9016 EFO:0000729 ICD10CM:K51 ICD9CM:556 ICD9CM:556.5 MESH:D003093 NCI:C2952 SNOMEDCT_US_2020_03_01:196988003 SNOMEDCT_US_2020_03_01:441971007 UMLS_CUI:C0009324 UMLS_CUI:C0375359 Left-sided ulcerative colitis disease_ontology DOID:8577 OMIM mapping confirmed by DO. [LS]. ulcerative colitis DOID:8577 ICD10CM:C05.1 ICD9CM:145.3 NCI:C3529 SNOMEDCT_US_2020_03_01:94049001 UMLS_CUI:C0153376 malignant tumor of soft palate malignant tumor of the soft Palate disease_ontology DOID:8578 soft palate cancer DOID:8578 A mature B-cell neoplasm of B-cells found in the germinal center. GARD:5973 ICD10CM:C83.7 ICD9CM:200.2 MESH:D002051 NCI:C2912 OMIM:113970 ORDO:543 SNOMEDCT_US_2020_03_01:118617000 UMLS_CUI:C0006413 Burkitt lymphoma/leukaemia Burkitt's Lymphoma Burkitt's tumor Burkitt's tumor or lymphoma malignant lymphoma, Burkitt's type small Non-Cleaved cell Lymphoma, Burkitt's type disease_ontology DOID:8584 OMIM mapping confirmed by DO. [SN]. Burkitt lymphoma DOID:8584 A multiple carboxylase deficiency that involves a deficiency in holocarboxylase synthetase. GARD:2721 ICD10CM:D81.818 MESH:D028922 NCI:C98842 OMIM:253270 SNOMEDCT_US_2020_03_01:15307001 UMLS_CUI:C0268581 Biotin-(propionyl-CoA-carboxylase) ligase deficiency Multiple carboxylase deficiency - neonatal onset disease_ontology DOID:859 OMIM mapping confirmed by DO. [SN]. holocarboxylase synthetase deficiency DOID:859 DOID:9194 ICD10CM:C93.1 ICD9CM:206.1 MESH:D007951 NCI:C34774 SNOMEDCT_US_2020_03_01:46236001 UMLS_CUI:C0023466 disease_ontology DOID:8593 chronic monocytic leukemia DOID:8593 An upper respiratory tract disease described as an acute contagious disease caused by Group A bacteria of the genus Streptococcus (especially various strains of S. pyogenes) and characterized by inflammation of the nose, throat, and mouth, generalized toxemia, and a red rash. DOID:8597 ICD10CM:A38 ICD9CM:034 ICD9CM:034.1 MESH:D012541 NCI:C94575 SNOMEDCT_US_2020_03_01:154301006 SNOMEDCT_US_2020_03_01:154303009 UMLS_CUI:C0036285 UMLS_CUI:C0343487 Scarlatina disease_ontology DOID:8596 scarlet fever DOID:8596 GARD:7379 ICD10CM:N48.6 ICD9CM:607.85 MESH:D010411 NCI:C3316 OMIM:171000 SNOMEDCT_US_2020_03_01:155931002 UMLS_CUI:C0030848 Induratio penis plastica Peyronie disease Peyronie's Fibromatosis disease_ontology DOID:8616 OMIM mapping confirmed by DO. [SN]. Peyronie's disease DOID:8616 A gastrointestinal system cancer that is located_in the oral cavity. DOID:0050627 DOID:8617 DOID:9049 DOID:9055 GARD:9360 ICD10CM:C04 ICD10CM:C04.0 ICD10CM:C04.1 ICD9CM:144 ICD9CM:144.0 ICD9CM:144.1 NCI:C9318 SNOMEDCT_US_2020_03_01:93672006 SNOMEDCT_US_2020_03_01:93802007 SNOMEDCT_US_2020_03_01:93860002 UMLS_CUI:C0153368 UMLS_CUI:C0153369 UMLS_CUI:C0496758 malignant neoplasm of floor of mouth disease_ontology DOID:8618 oral cavity cancer DOID:8618 A sleep disorder that involves recurring bouts of excessive amounts of sleepiness. ICD10CM:G47.13 ICD9CM:327.13 MESH:D006970 SNOMEDCT_US_2020_03_01:426451004 UMLS_CUI:C0751226 primary recurrent hypersomnia disease_ontology DOID:8619 recurrent hypersomnia DOID:8619 A viral infectious disease that results_in infection located_in skin, has_material_basis_in Measles virus, which is transmitted_by contact with oronasal secretions, or semen of an infected person. The infection has_symptom fever, has_symptom cough, has_symptom coryza, has_symptom conjunctivitis, and has_symptom maculopapular, erythematous rash. DOID:8621 DOID:8963 DOID:9112 GARD:3434 ICD10CM:B05 ICD9CM:055 MESH:D008457 NCI:C96406 SNOMEDCT_US_2020_03_01:154338006 UMLS_CUI:C0025007 morbilli disease_ontology DOID:8622 measles DOID:8622 A disease of anatomical entity that is located_in the central nervous system or located_in the peripheral nervous system. ICD10CM:G98 ICD9CM:349.9 MESH:D009422 NCI:C26835 SNOMEDCT_US_2020_03_01:155262005 UMLS_CUI:C0027765 disease_ontology DOID:863 nervous system disease DOID:863 A connective tissue cancer that derives_from lymphatic endothelium, and derives_from spindle cells, results_in_formation_of vascular channels that fill with blood cells, has_material_basis_in Human herpesvirus 8 (HHV8). DOID:12761 DOID:12762 DOID:12764 DOID:12766 DOID:12767 DOID:12768 DOID:12770 DOID:12771 DOID:12772 DOID:12774 DOID:12775 DOID:12776 DOID:12777 DOID:12778 DOID:6480 DOID:7239 DOID:8631 GARD:6814 ICD10CM:C46 ICD10CM:C46.0 ICD10CM:C46.1 ICD10CM:C46.2 ICD10CM:C46.3 ICD10CM:C46.4 ICD10CM:C46.5 ICD9CM:176 ICD9CM:176.0 ICD9CM:176.1 ICD9CM:176.2 ICD9CM:176.3 ICD9CM:176.4 ICD9CM:176.5 MESH:D012514 NCI:C27500 NCI:C3550 NCI:C3551 NCI:C4578 NCI:C4579 NCI:C5363 NCI:C5523 NCI:C5529 NCI:C5602 NCI:C5706 NCI:C5842 NCI:C6377 NCI:C6749 NCI:C7006 NCI:C9087 SNOMEDCT_US_2020_03_01:109385007 SNOMEDCT_US_2020_03_01:109388009 SNOMEDCT_US_2020_03_01:109390005 SNOMEDCT_US_2020_03_01:188029000 SNOMEDCT_US_2020_03_01:188144002 SNOMEDCT_US_2020_03_01:188775002 SNOMEDCT_US_2020_03_01:255114007 SNOMEDCT_US_2020_03_01:255115008 UMLS_CUI:C0036220 UMLS_CUI:C0153560 UMLS_CUI:C0153561 UMLS_CUI:C0153562 UMLS_CUI:C0153563 UMLS_CUI:C0153564 UMLS_CUI:C0153565 UMLS_CUI:C0346935 UMLS_CUI:C0346936 UMLS_CUI:C1332265 UMLS_CUI:C1332847 UMLS_CUI:C1333453 UMLS_CUI:C1333744 UMLS_CUI:C1333776 UMLS_CUI:C1334318 UMLS_CUI:C1334457 UMLS_CUI:C1335372 UMLS_CUI:C1335509 Conjunctival Kaposi's sarcoma Corneal Kaposi's sarcoma Cutaneous Kaposi's sarcoma Kaposi sarcoma Kaposi's sarcoma of Heart Kaposi's sarcoma of anus Kaposi's sarcoma of central nervous system Kaposi's sarcoma of conjunctiva Kaposi's sarcoma of cornea Kaposi's sarcoma of esophagus Kaposi's sarcoma of gastrointestinal sites Kaposi's sarcoma of lung Kaposi's sarcoma of lymph nodes Kaposi's sarcoma of palate Kaposi's sarcoma of penis Kaposi's sarcoma of skin Kaposi's sarcoma of soft tissue Kaposi's sarcoma of soft tissues Kaposi's sarcoma of the CNS Kaposi's sarcoma of the gallbladder Kaposi's sarcoma of the prostate Kaposi's sarcoma, lung Kaposi's sarcoma, skin Palate Kaposi's sarcoma anal Kaposi's sarcoma cardiac Kaposi's sarcoma central nervous system Kaposi's sarcoma conjunctival Kaposi's sarcoma corneal Kaposi's sarcoma cutaneous Kaposi's sarcoma esophageal Kaposi's sarcoma gallbladder Kaposi's sarcoma gastric Kaposi's sarcoma intestinal Kaposi's sarcoma lymph node Kaposi's sarcoma lymphadenopathic Kaposi's sarcoma palate Kaposi's sarcoma penis Kaposi's sarcoma prostate Kaposi's sarcoma pulmonary Kaposi's sarcoma soft tissue Kaposi's sarcoma disease_ontology African lymphadenopathic Kaposi's sarcoma Kaposi's sarcoma-associated herpesvirus (KSHV) DOID:8632 OMIM mapping confirmed by DO. [SN]. Kaposi's sarcoma DOID:8632 ICD9CM:557.1 SNOMEDCT_US_2020_03_01:266448009 UMLS_CUI:C0311262 CMI - chronic mesenteric ischaemia chronic mesenteric ischemia disease_ontology DOID:8633 chronic intestinal vascular insufficiency DOID:8633 An in situ carcinoma that is located_in the prostate. ICD10CM:D07.5 ICD9CM:233.4 SNOMEDCT_US_2020_03_01:92691004 UMLS_CUI:C0154088 PIN III carcinoma in situ of prostate grade III PIN disease_ontology DOID:8634 prostate carcinoma in situ DOID:8634 DOID:8897 DOID:8983 ICD10CM:K29.8 ICD9CM:535.6 MESH:D004382 NCI:C94409 SNOMEDCT_US_2020_03_01:155715004 UMLS_CUI:C0013298 Hemorrhagic duodenitis disease_ontology DOID:8643 duodenitis DOID:8643 DOID:8571 DOID:8572 DOID:8759 DOID:8776 DOID:8777 DOID:9223 ICD9CM:535.4 SNOMEDCT_US_2020_03_01:196737009 UMLS_CUI:C0029800 disease_ontology DOID:8644 gastroduodenitis DOID:8644 ICD9CM:293.89 UMLS_CUI:C0154334 disease_ontology DOID:8646 substance-induced psychosis DOID:8646 DOID:8648 DOID:8779 DOID:8900 DOID:8940 DOID:8999 DOID:9058 DOID:9068 DOID:9196 GARD:7779 ICD10CM:C01 ICD10CM:C02.0 ICD10CM:C02.1 ICD10CM:C02.2 ICD10CM:C02.4 ICD10CM:C02.9 ICD9CM:141 ICD9CM:141.0 ICD9CM:141.1 ICD9CM:141.2 ICD9CM:141.3 ICD9CM:141.5 ICD9CM:141.6 MESH:D014062 NCI:C3524 NCI:C9345 SNOMEDCT_US_2020_03_01:187644001 SNOMEDCT_US_2020_03_01:363376007 SNOMEDCT_US_2020_03_01:363377003 SNOMEDCT_US_2020_03_01:93773005 SNOMEDCT_US_2020_03_01:94100005 SNOMEDCT_US_2020_03_01:94101009 SNOMEDCT_US_2020_03_01:94134006 UMLS_CUI:C0153349 UMLS_CUI:C0153350 UMLS_CUI:C0153351 UMLS_CUI:C0153356 UMLS_CUI:C0474963 UMLS_CUI:C0496755 UMLS_CUI:C0684333 malignant neoplasm of tongue disease_ontology DOID:8649 tongue cancer DOID:8649 A vascular disease that is characterized by inflammation of the blood vessels. GARD:9565 MESH:D014657 NCI:C26912 SNOMEDCT_US_2020_03_01:195375002 UMLS_CUI:C0042384 Angiitis disease_ontology DOID:865 vasculitis DOID:865 A viral infectious disease that results_in infection located_in skin, has_material_basis_in Human herpesvirus 3, which is transmitted_by direct contact with secretions from the rash, or transmitted_by droplet spread of respiratory secretions. The infection has_symptom anorexia, has_symptom myalgia, has_symptom nausea, has_symptom fever, has_symptom headache, has_symptom sore throat, and has_symptom blisters. DOID:8658 DOID:8693 DOID:9243 ICD10CM:B01.9 ICD9CM:052 MESH:D002644 NCI:C97132 SNOMEDCT_US_2020_03_01:186508005 UMLS_CUI:C0008049 varicella disease_ontology DOID:8659 chickenpox MESH:D002644 DOID:8659 A vascular disease that is located_in a vein. ICD10CM:I82 ICD9CM:453 SNOMEDCT_US_2020_03_01:195435006 UMLS_CUI:C0155774 disease_ontology DOID:866 vein disease DOID:866 A specific developmental disorder that is characterized by abnormal eating habits that may involve either insufficient or excessive food intake to the detriment of an individual's physical and emotional health. ICD10CM:F50 ICD9CM:307.50 MESH:D001068 NCI:C89332 SNOMEDCT_US_2020_03_01:72366004 UMLS_CUI:C0013473 disease_ontology DOID:8670 eating disorder DOID:8670 DOID:8730 DOID:8744 DOID:9213 ICD9CM:057.8 SNOMEDCT_US_2020_03_01:186577001 UMLS_CUI:C0029841 disease_ontology DOID:8672 viral exanthem DOID:8672 ICD10CM:K55.3 MESH:D020345 UMLS_CUI:C0520459 ENTEROCOLITIS NECROTIZING Necrotizing enterocolitis in fetus OR newborn Perinatal necrotising enterocolitis Perinatal necrotizing enterocolitis Pseudomembranous enterocolitis in newborn necrotizing enterocolitis disease_ontology DOID:8677 perinatal necrotizing enterocolitis DOID:8677 DOID:8682 DOID:8848 GARD:12763 ICD10CM:C92.3 MESH:D023981 NCI:C35815 SNOMEDCT_US_2020_03_01:35287006 UMLS_CUI:C0152276 Chloroma Extramedullary Myeloid tumor Granulocytic sarcoma disease_ontology DOID:8683 myeloid sarcoma DOID:8683 A carcinoma in situ that is characterized by the spread of cancer in skin and the lack of invasion of surrounding tissues. DOID:8686 DOID:8699 DOID:8817 DOID:8831 DOID:8880 DOID:8989 DOID:9000 DOID:9185 DOID:9221 ICD10CM:D04 ICD10CM:D04.0 ICD10CM:D04.2 ICD10CM:D04.3 ICD10CM:D04.4 ICD10CM:D04.6 ICD10CM:D04.7 ICD9CM:232 ICD9CM:232.0 ICD9CM:232.2 ICD9CM:232.3 ICD9CM:232.4 ICD9CM:232.5 ICD9CM:232.6 ICD9CM:232.7 NCI:C3640 SNOMEDCT_US_2020_03_01:189276007 SNOMEDCT_US_2020_03_01:189291009 SNOMEDCT_US_2020_03_01:189295000 SNOMEDCT_US_2020_03_01:190179004 SNOMEDCT_US_2020_03_01:255144005 SNOMEDCT_US_2020_03_01:92735004 SNOMEDCT_US_2020_03_01:92747005 SNOMEDCT_US_2020_03_01:92749008 UMLS_CUI:C0154073 UMLS_CUI:C0154074 UMLS_CUI:C0154077 UMLS_CUI:C0154078 UMLS_CUI:C0154079 UMLS_CUI:C0154080 UMLS_CUI:C0154081 UMLS_CUI:C0347139 Cutaneous carcinoma in situ disease_ontology carcinoma in situ of skin DOID:8687 skin carcinoma in situ DOID:8687 A keratosis that is characterized by keratinizing squamous epithelium located in middle ear and/or mastoid, subepithelial connective tissue and by the progressive accumulation of keratin debris with or without surrounding inflammatory reaction. GARD:10422 ICD10CM:H71.9 ICD9CM:385.30 MESH:D002781 NCI:C2944 SNOMEDCT_US_2020_03_01:155244001 UMLS_CUI:C0008373 disease_ontology DOID:869 cholesteatoma DOID:869 DOID:8737 GARD:3863 ICD10CM:C84.0 ICD9CM:202.1 MESH:D009182 NCI:C3246 OMIM:254400 SNOMEDCT_US_2020_03_01:118618005 UMLS_CUI:C0026948 Mycosis fungoides mycosis fungoides lymphoma disease_ontology DOID:8691 OMIM mapping confirmed by DO. [SN]. mycosis fungoides DOID:8691 A leukemia that is located_in myeloid tissue. DOID:8878 DOID:8879 DOID:8910 DOID:9066 DOID:9126 GARD:8226 ICD10CM:C92 ICD9CM:205 MESH:D007951 NCI:C3172 SNOMEDCT_US_2020_03_01:269631008 UMLS_CUI:C0023470 Non-Lymphocytic Leukemia leukaemia myelogenous leukemia myelogenous myeloid granulocytic leukaemia myeloid granulocytic leukemia myeloid leukaemia disease_ontology DOID:8692 myeloid leukemia DOID:8692 A nervous system disease that is located_in nerves or nerve cells. ICD10CM:G62.9 NCI:C4731 SNOMEDCT_US_2020_03_01:42658009 UMLS_CUI:C0442874 peripheral neuropathy disease_ontology DOID:870 neuropathy DOID:870 A herpes simplex that results_in infection located_in genital system, or located_in rectum, has_material_basis_in Human herpesvirus 1 or has_material_basis_in Human herpesvirus 2, which is transmitted_by sexual contact. The infection has_symptom sores, has_symptom fever, and has_symptom swollen glands. DOID:8982 ICD9CM:054.1 MESH:D006558 NCI:C14364 SNOMEDCT_US_2020_03_01:154333002 UMLS_CUI:C0019342 Genital herpes simplex Herpes Genitalis Virus-Genital Herpes venereal herpes disease_ontology DOID:8704 genital herpes DOID:8704 DOID:14750 DOID:8711 DOID:9137 GARD:10420 ICD10CM:Q85.00 ICD9CM:237.7 MESH:D017253 NCI:C6727 ORDO:93921 SNOMEDCT_US_2020_03_01:154642000 UMLS_CUI:C0162678 Acoustic neurofibromatosis Recklinghausen's neurofibromatosis central Neurofibromatosis peripheral Neurofibromatosis von Reklinghausen disease disease_ontology DOID:8712 Xref MGI. OMIM mapping confirmed by DO. [SN]. neurofibromatosis DOID:8712 Decubitus ulcer is a chronic ulcer of skin where the ulcer is an ulceration of tissue deprived of adequate blood supply by prolonged pressure. DOID:8808 DOID:9002 DOID:9029 DOID:9129 ICD10CM:L89 ICD9CM:707.0 MESH:D003668 NCI:C50706 SNOMEDCT_US_2020_03_01:28103007 UMLS_CUI:C0011127 Decubitus (pressure) ulcer Decubitus ulcer any site pressure sores pressure ulcer disease_ontology bedsore DOID:8717 decubitus ulcer DOID:8717 A carcinoma that is an early development defined by the absence of invasion of surrounding tissues. DOID:8793 DOID:8821 ICD10CM:D09.9 ICD9CM:230-234.99 MESH:D002278 NCI:C2917 SNOMEDCT_US_2020_03_01:109355002 UMLS_CUI:C0007099 disease_ontology DOID:8719 in situ carcinoma DOID:8719 A dementia that involves impairments in cognitive function caused by problems in blood vessels that feed the brain. DOID:13915 ICD10CM:F01 ICD9CM:290.4 MESH:D015140 MESH:D015161 NCI:C34522 NCI:C34525 SNOMEDCT_US_2020_03_01:192165000 SNOMEDCT_US_2020_03_01:56267009 UMLS_CUI:C0011263 UMLS_CUI:C0011269 Multi Infarct Dementia multifocal dementia disease_ontology DOID:8725 vascular dementia DOID:8725 A viral infectious disease that results in infection located in skin, has_material_basis_in Variola virus, which is transmitted by droplets from oral, nasal or pharyngeal mucosa, transmitted by contact with the body fluids, or transmitted by fomites. The infection results in formation of lesions, first on the face, hands and forearms and later on the trunk. GARD:7444 ICD10CM:B03 ICD9CM:050 MESH:D012899 NCI:C35027 SNOMEDCT_US_2020_03_01:266193008 UMLS_CUI:C0037354 Ordinary smallpox disease_ontology DOID:8736 smallpox DOID:8736 A pneumonia involving inflammation of the lungs caused by bacteria. DOID:13815 ICD10CM:J15.9 ICD9CM:482.9 MESH:D018410 NCI:C26704 SNOMEDCT_US_2020_03_01:53084003 UMLS_CUI:C0004626 Pneumonia due to other gram-negative bacteria gram-negative pneumonia disease_ontology DOID:874 bacterial pneumonia DOID:874 A dermatitis that is an inflammatory skin condition resulting in flaky, white to yellowish scales on oily areas such as the scalp or inside the ear, which is caused due to a combination of an over production of skin oil and irritation from a yeast Malassezia furfur. The symptoms include itching, skin lesions and scales, redness, plaques and hair loss. DOID:8740 ICD10CM:L21 ICD9CM:690.1 MESH:D012628 NCI:C111888 SNOMEDCT_US_2020_03_01:156328004 UMLS_CUI:C0036508 SKIN SEBORRHEIC Seborrhoeic dermatitis Seborrhoeic eczema seborrhea disease_ontology DOID:8741 seborrheic dermatitis DOID:8741 ICD10CM:B08.3 ICD9CM:057.0 MESH:D016731 NCI:C84695 SNOMEDCT_US_2020_03_01:34730008 UMLS_CUI:C0085273 Erythema infectiosum Fifth disease disease_ontology DOID:8743 erythema infectiosum DOID:8743 An acute myeloid leukemia that derives from blood-forming tissue in which megakaryocytes proliferate in the bone marrow and circulate in the blood in large numbers. DOID:9009 GARD:524 ICD10CM:C94.2 ICD9CM:207.2 MESH:D007947 NCI:C3170 SNOMEDCT_US_2020_03_01:52220008 UMLS_CUI:C0023462 Megakaryocytic myelosis Thrombocytic leukaemia disease_ontology DOID:8761 acute megakaryocytic leukemia DOID:8761 A viral infectious disease that results_in infection located_in skin, has_material_basis_in Orf virus, which is transmitted_by contact with infected or recently vaccinated animals, or transmitted_by fomites carrying the virus. The infection has_symptom lesions on the finger, hand, arm, face, and penis. ICD10CM:B08.02 ICD9CM:051.2 MESH:D004474 SNOMEDCT_US_2020_03_01:74050005 UMLS_CUI:C0013570 Ecthyma contagiosum Ecthyma, Contagious Orf scabby mouth sheep pox thistle disease disease_ontology DOID:8771 contagious pustular dermatitis DOID:8771 An intestinal disease that involves inflammation located_in intestine. DOID:8784 DOID:8855 DOID:8942 EFO:0000384 GARD:10232 ICD10CM:K50.1 ICD9CM:555.1 MESH:D003424 NCI:C37262 SNOMEDCT_US_2020_03_01:7620006 UMLS_CUI:C0156147 Crohn disease Crohn's disease of colon Crohn's disease of large bowel Granulomatous Colitis Pediatric Crohn's disease disease_ontology DOID:8778 MESH:C536215 added from NeuroDevNet [WAK]. Crohn's disease DOID:8778 A viral infectious disease that results_in infection located_in skin, has_material_basis_in Rubella virus, which is transmitted_by droplet spread of oronasal secretions from the infected person through coughing and sneezing, and transmitted_by congenital method. The infection has_symptom rash on the face which spreads to the trunk and limbs, has_symptom fever, has_symptom lymphadenopathy, has_symptom joint pains, has_symptom headache, and has_symptom conjunctivitis. DOID:11765 DOID:1463 DOID:1464 DOID:8780 DOID:8816 DOID:8909 DOID:9106 DOID:9116 DOID:9162 DOID:9179 GARD:4742 ICD10CM:B06.9 ICD9CM:056 MESH:D012409 NCI:C85051 SNOMEDCT_US_2020_03_01:266192003 UMLS_CUI:C0035920 german measles disease_ontology DOID:8781 rubella DOID:8781 An in situ carcinoma that is located_in the breast. ICD10CM:D05 ICD9CM:233.0 MESH:D000071960 SNOMEDCT_US_2020_03_01:154636004 UMLS_CUI:C0154084 Non-Infiltrating carcinoma of breast carcinoma in situ of breast disease_ontology DOID:8791 breast carcinoma in situ MESH:D000071960 DOID:8791 An in situ carcinoma that is located_in the lung. ICD10CM:D02.2 ICD9CM:231.2 SNOMEDCT_US_2020_03_01:189262006 UMLS_CUI:C0154071 disease_ontology DOID:8800 lung carcinoma in situ DOID:8800 ICD10CM:I20.0 ICD9CM:411.1 MESH:D000789 NCI:C66911 SNOMEDCT_US_2020_03_01:155308009 UMLS_CUI:C0002965 Angina at rest Anginal chest pain at rest Impending infarction Preinfarction angina Unstable angina Worsening angina disease_ontology DOID:8805 intermediate coronary syndrome DOID:8805 An intestine carcinoma in situ that is located_in the colon. ICD10CM:D01.0 ICD9CM:230.3 SNOMEDCT_US_2020_03_01:92568009 UMLS_CUI:C0154061 carcinoma in situ of colon stage 0 Colonic carcinoma disease_ontology DOID:8826 colon carcinoma in situ DOID:8826 A parasitic infectious disease that occurs when part of the body is infested with parasitic worms such as cestodes, nematodes and trematodes. DOID:10693 DOID:3563 DOID:458 DOID:932 ICD10CM:B83.9 ICD9CM:120-129.99 MESH:D006373 NCI:C84751 SNOMEDCT_US_2020_03_01:187518006 UMLS_CUI:C0018889 helminth infection helminthiasis helminthosis worm infection disease_ontology DOID:883 parasitic helminthiasis infectious disease DOID:883 ICD10CM:C81.1 ICD9CM:201.5 NCI:C3518 SNOMEDCT_US_2020_03_01:52248008 UMLS_CUI:C0152268 Classical Hodgkin lymphoma, nodular sclerosis disease_ontology DOID:8838 Hodgkin's lymphoma, nodular sclerosis DOID:8838 A parasitic helminthiasis infectious disease that involves parasitic infection of the intestine by Metagonimus yokogawai. The symptoms are diarrhea and colicky abdominal pain. The heart and brain can also be infected. ICD10CM:B66.8 ICD9CM:121.5 MESH:D014201 NCI:C128390 SNOMEDCT_US_2020_03_01:37832003 UMLS_CUI:C0025530 Infection by Metagonimus yokogawai disease_ontology DOID:884 metagonimiasis DOID:884 A parasitic helminthiasis infectious disease that involves parasitic infection of the bile ducts of the liver by Fasciola hepatica or Fasciola gigantica. During the acute phase, manifestations include abdominal pain, hepatomegaly, fever, vomiting, diarrhea, urticaria and eosinophilia. Occasionally, infection occurs in intestinal wall, lungs, subcutaneous tissue, and pharyngeal mucosa. GARD:6428 ICD10CM:B66.3 ICD9CM:121.3 MESH:D005211 NCI:C128387 SNOMEDCT_US_2020_03_01:187125007 UMLS_CUI:C0015652 Fasciola hepatica infection Infection by Fasciola Liver flukes Sheep liver fluke infection disease_ontology DOID:885 fascioliasis DOID:885 An oral cavity cancer that is located_in the salivary gland. DOID:8873 DOID:9148 ICD10CM:C08 ICD9CM:142.8 SNOMEDCT_US_2020_03_01:187648003 UMLS_CUI:C0153362 malignant neoplasm of salivary gland disease_ontology DOID:8850 salivary gland cancer DOID:8850 An autoimmune disease that is characterized by a constellation of findings that include elevated antibodies to nuclear antigens, antiphospholipids, low complement levels, ulcers, non-scarring alopecia, renal or neurologic damage, and low white blood cell and platelet counts, has_symptom rashes, fatigue, arthritis, hair loss, seizures, and symptoms related to affected organs. ICD10CM:L93 ICD9CM:695.4 NCI:C27153 SNOMEDCT_US_2020_03_01:200936003 UMLS_CUI:C0409974 lupus disease_ontology DOID:8857 lupus erythematosus DOID:8857 A monocytic leukemia where the majority of monocytic cells are promonocytes. DOID:9208 GARD:525 ICD9CM:206.0 MESH:D007948 OMIM:151380 SNOMEDCT_US_2020_03_01:91859000 UMLS_CUI:C0023465 acute Monoblastic Leukemia and acute Monocytic Leukemia acute monocytic leukaemia acute monocytic leukaemia without mention of remission acute monocytic leukemia without mention of remission acute monocytic leukemia, FAB M5 acute monocytic leukemia, morphology disease_ontology DOID:8864 OMIM mapping confirmed by DO. [SN]. acute monocytic leukemia DOID:8864 ICD10CM:L57.0 ICD9CM:702.0 MESH:D055623 NCI:C3148 SNOMEDCT_US_2020_03_01:267858008 UMLS_CUI:C0022602 SK - Solar keratosis Senile hyperkeratosis Solar keratosis actinic (Solar) Keratosis disease_ontology DOID:8866 actinic keratosis DOID:8866 A viral infectious disease that results_in infection located_in skin, has_material_basis_in Molluscum contagiosum virus, which is transmitted_by contact with the skin, and transmitted_by fomites. The infection has_symptom lesions which are flesh-colored with a pit in the center. ICD10CM:B08.1 ICD9CM:078.0 MESH:D008976 NCI:C155872 SNOMEDCT_US_2020_03_01:154360009 UMLS_CUI:C0026393 disease_ontology DOID:8867 molluscum contagiosum DOID:8867 A central nervous system disease characterized by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis). EFO:0004256 GARD:6267 ICD10CM:G36.0 ICD9CM:341.0 MESH:D009471 NCI:C84934 SNOMEDCT_US_2020_03_01:25044007 UMLS_CUI:C0027873 Devic's disease Devic's syndrome disease_ontology DOID:8869 neuromyelitis optica DOID:8869 A parasitic helminthiasis infectious disease that involves parasitic infection of the intestine by Fasciolopsis buski. The symptoms include diarrhea, abdominal pain, fever, ascites, anasarca and intestinal obstruction. ICD10CM:B66.5 ICD9CM:121.4 MESH:D014201 NCI:C128388 SNOMEDCT_US_2020_03_01:54266002 UMLS_CUI:C0015656 Infection by Fasciolopsis buski Infectious Disease by Fasciolopsis disease_ontology DOID:888 fasciolopsiasis DOID:888 ICD10CM:L71 ICD9CM:695.3 MESH:D012393 NCI:C97136 SNOMEDCT_US_2020_03_01:1612004 UMLS_CUI:C0035854 Acne roscea Acne, erythematosa disease_ontology DOID:8881 rosacea DOID:8881 GARD:6060 ICD10CM:H30.9 ICD9CM:363.20 MESH:D002825 NCI:C110923 SNOMEDCT_US_2020_03_01:270531006 UMLS_CUI:C0008513 retinochoroiditis disease_ontology DOID:8886 chorioretinitis DOID:8886 A skin disease that is characterized by patches of thick red skin and silvery scales. EFO:0000676 GARD:10262 ICD10CM:L40 MESH:D011565 NCI:C3346 OMIM:PS177900 SNOMEDCT_US_2020_03_01:156369008 UMLS_CUI:C0033860 disease_ontology DOID:8893 Xref MGI. Update outdated UMLS CUI from C00295134 to C0033860. psoriasis DOID:8893 MESH:D017237 SNOMEDCT_US_2020_03_01:447292006 UMLS_CUI:C0162666 disease_ontology DOID:890 mitochondrial encephalomyopathy DOID:890 A variable age at onset electroclinical syndrome characterised by a relentlessly progressive disease course until death. GARD:7140 MESH:D020191 NCI:C7636 OMIM:310370 OMIM:PS254800 SNOMEDCT_US_2020_03_01:192844008 UMLS_CUI:C0751778 PME progressive Myoclonus epilepsy progressive myoclonic epilepsy disease_ontology DOID:891 OMIM mapping confirmed by DO. [SN]. OMIM mapping submitted by NeuroDevNet. [LS]. progressive myoclonus epilepsy NCI:C7636 DOID:891 A superficial mycosis that is a superficial fungal infection of the skin characterized by brown to black macules which usually occur on the palmar aspects of hands and occasionally the plantar and other surfaces of the skin, caused by Hortaea werneckii, which is a common saprophytic fungus believed to occur in soil, compost, humus and on wood in humid tropical and sub-tropical regions. ICD10CM:B36.1 ICD9CM:111.1 SNOMEDCT_US_2020_03_01:1022006 UMLS_CUI:C0152067 Infection by Cladosporium werneckii Keratomycosis nigricans Tinea palmaris nigra disease_ontology microsporosis nigra DOID:8912 tinea nigra DOID:8912 A cutaneous mycosis that results_in fungal infection located_in scalp, located_in glabrous skin, or located_in nail, has_material_basis_in Ascomycota fungi that belong to a group called dermatophytes, which have the ability to utilize keratin as a nutrient source. ICD10CM:B35 ICD9CM:110 NCI:C26745 SNOMEDCT_US_2020_03_01:154394006 UMLS_CUI:C0011636 disease_ontology DOID:8913 dermatophytosis DOID:8913 A skin cancer that has_material_basis_in melanocytes. DOID:0050609 DOID:10043 DOID:10046 DOID:10051 DOID:10052 DOID:10055 DOID:8922 ICD10CM:C43.9 ICD9CM:172.9 MESH:C562393 NCI:C3510 OMIM:608035 OMIM:612263 SNOMEDCT_US_2020_03_01:269577007 UMLS_CUI:C0151779 cutaneous melanoma malignant ear melanoma malignant lip melanoma malignant lower limb melanoma malignant melanoma of ear and/or external auricular canal malignant melanoma of skin of lower limb malignant melanoma of skin of trunk except scrotum malignant melanoma of skin of upper limb malignant neck melanoma malignant scalp melanoma malignant trunk melanoma malignant upper limb melanoma disease_ontology DOID:8923 Xref MGI. OMIM mapping confirmed by DO. [LS]. skin melanoma DOID:8923 A primary thrombocytopenia that involves relatively few platelets in blood as a result of autoantibodies. DOID:0050124 DOID:2220 ICD10CM:D69.3 ICD9CM:287.31 MESH:D016553 NCI:C3446 OMIM:188030 SNOMEDCT_US_2020_03_01:234490009 UMLS_CUI:C0398650 Autoimmune thrombocytopenic purpura Immune thrombocytopenic purpura idiopathic thrombocytopenic purpura primary thrombocytopenic purpura disease_ontology Ideopath thrombocytopenic pur Idiopathic purpura werlhof's disease DOID:8924 OMIM mapping confirmed by DO. [SN]. autoimmune thrombocytopenic purpura DOID:8924 DOID:8945 ICD10CM:D69.4 ICD9CM:287.39 SNOMEDCT_US_2020_03_01:191435001 UMLS_CUI:C0477317 disease_ontology DOID:8925 primary thrombocytopenia DOID:8925 A specific developmental disorder that involves difficulty in scholastic skills such as reading, writing, spelling, reasoning, recalling and/or organizing information resulting from the brain's inability to receive and process information. DOID:2847 ICD10CM:F81.9 MESH:D007859 NCI:C89334 SNOMEDCT_US_2020_03_01:1855002 SNOMEDCT_US_2020_03_01:192531005 UMLS_CUI:C0023186 UMLS_CUI:C0751265 Academic skill disorder learning disorder disease_ontology DOID:8927 learning disability DOID:8927 DOID:9048 DOID:9083 ICD10CM:K29.4 ICD9CM:535.1 MESH:D005757 NCI:C7405 SNOMEDCT_US_2020_03_01:155713006 UMLS_CUI:C0017154 gastric atrophy disease_ontology DOID:8929 atrophic gastritis DOID:8929 GARD:7893 ICD10CM:E83.01 MESH:D006527 NCI:C84756 OMIM:277900 SNOMEDCT_US_2020_03_01:88518009 UMLS_CUI:C0019202 Cerebral pseudosclerosis Westphal pseudosclerosis Westphal-Strumpell syndrome Wilson's disease hepatolenticular degeneration disease_ontology DOID:893 OMIM mapping confirmed by DO. [SN]. Wilson disease DOID:893 An epithelial-stromal TGFBI dystrophy that is characterized by recurrent erosions and lattice line refractile and fleck-like opacification located_in the cornea, amyloid deposits beginning in the anterior stroma, and progressive vision loss later in life, and has_material_basis_in autosomal dominant inheritance of mutation of transforming growth factor beta-induced gene located in chromosome 5q31.1, which encodes keratoepithelin. Abnormalities lead to increased amyloid protein deposition and disruption of the corneal surface. MESH:C537935 OMIM:122200 familial amyloid neuropathy, Finnish type disease_ontology DOID:8943 lattice corneal dystrophy DOID:8943 ICD9CM:362.06 SNOMEDCT_US_2020_03_01:312905005 UMLS_CUI:C0730278 High risk non proliferative diabetic retinopathy Severe NPDR disease_ontology DOID:8946 severe nonproliferative diabetic retinopathy DOID:8946 ICD9CM:362.0 MESH:D003930 NCI:C34538 SNOMEDCT_US_2020_03_01:154678005 UMLS_CUI:C0011884 Retinal abnormality - diabetes-related disease_ontology DOID:8947 diabetic retinopathy DOID:8947 An aplastic anemia where the bone marrow produces ringed sideroblasts rather than healthy red blood cells (erythrocytes). GARD:667 ICD10CM:D64.3 ICD9CM:285.0 MESH:D000756 NCI:C36078 OMIM:PS300751 SNOMEDCT_US_2020_03_01:154810008 UMLS_CUI:C0002896 ANEMIA SIDEROBLASTIC Anemia, hypochromic with iron loading disease_ontology DOID:8955 sideroblastic anemia DOID:8955 A viral infectious disease that results_in infection in rodents, cows, and humans, located_in skin, has_material_basis_in Cowpox virus, which is transmitted_by contact with an infected animal. The infection results_in_formation_of vesicopustular lesions on the hands or face. ICD10CM:B08.010 ICD9CM:051.01 MESH:D015605 SNOMEDCT_US_2020_03_01:154344005 UMLS_CUI:C0010232 yaba disease_ontology DOID:8956 cowpox DOID:8956 An inherited metabolic disorder that involves metabolic disturbances in the processing or distribution of dietary minerals. MESH:D008664 UMLS_CUI:C0025534 inborn metal metabolism disorder disease_ontology DOID:896 metal metabolism disorder DOID:896 A viral infectious disease that results_in infection located_in brain and that has_material_basis_in Measles virus which is immune resistant. GARD:7708 ICD10CM:A81.1 ICD9CM:046.2 MESH:D013344 NCI:C85171 OMIM:260470 SNOMEDCT_US_2020_03_01:84196008 UMLS_CUI:C0038522 Immunosuppressive measles encephalitis Subacute Sclerosing Panencephalitis Subacute sclerosing panencephalitis Van Bogaert's sclerosing leukoencephalitis subacute sclerosing leukoencephalopathy disease_ontology DOID:8970 subacute sclerosing panencephalitis DOID:8970 A polycystic kidney disease characterized by the presence of multiple cysts located_in the kidney resulting from ciliopathy that disrupts the function of primary cilium, inherited in an autosomal dominant fashion. GARD:7419 ICD10CM:Q61.3 ICD9CM:753.12 MESH:D007690 NCI:C75464 ORDO:730 SNOMEDCT_US_2020_03_01:204955006 UMLS_CUI:C0022680 Congenital biliary ectasias POLYCYSTIC KIDNEY AND HEPATIC DISEASE 1 disease_ontology DOID:898 Xref MGI. OMIM mapping confirmed by DO. [SN]. Updating outdated UMLS CUI. Removing Caroli disease as a synonym as this is a distinct disease. autosomal dominant polycystic kidney disease DOID:898 An uterus carcinoma in situ that is located_in the uterine cervix. ICD10CM:D06 ICD9CM:233.1 MESH:D018290 SNOMEDCT_US_2020_03_01:92564006 UMLS_CUI:C0851140 CIN III CIN III - carcinoma in situ of cervix CIN III - severe dyskaryosis Cervix Ca in situ Severe Dysplasia of the Cervix Uteri Severe dysplasia of cervix carcinoma in situ of cervix carcinoma in situ of uterine cervix carcinoma of cervix stage 0 cervical intraepithelial neoplasia grade III with severe dysplasia squamous intraepithelial neoplasia, grade III disease_ontology DOID:8991 cervix uteri carcinoma in situ DOID:8991 A myeloproliferative neoplasm characterized by erythroid hyperplasia, myeloid leukocytosis, thrombocytosis, and splenomegaly. DOID:11868 GARD:7422 ICD10CM:D45 ICD9CM:207.1 ICD9CM:238.4 MESH:D011087 NCI:C3336 OMIM:263300 SNOMEDCT_US_2020_03_01:154644004 SNOMEDCT_US_2020_03_01:188753004 UMLS_CUI:C0032463 UMLS_CUI:C0152272 Osler-Vaquez syndrome Polycythaemia rubra vera Proliferative polycythaemia chronic erythremia disease_ontology DOID:8997 OMIM mapping confirmed by DO. [SN]. polycythemia vera DOID:8997 A bone deterioration disease that has_material_basis_in gradual dehydration and tears located_in intervertebral disc. DOID:7943 EFO:0004994 NCI:C27156 SNOMEDCT_US_2020_03_01:156633005 UMLS_CUI:C0410606 cervical disc degenerative disease intervertebral disc degeneration lumbar disc degeneration vertebral disc disease disease_ontology DOID:90 degenerative disc disease DOID:90 ICD10CM:K76.81 ICD9CM:573.5 MESH:D020065 SNOMEDCT_US_2020_03_01:371067004 UMLS_CUI:C0600452 Hepatopulmonary syndrome disease_ontology DOID:900 hepatopulmonary syndrome DOID:900 A syndrome that is characterized by the sudden death of an infant that is not predicted by medical history and remains unexplained after a thorough forensic autopsy and detailed death scene investigation. GARD:7711 ICD9CM:798.0 MESH:D013398 NCI:C85173 OMIM:272120 SNOMEDCT_US_2020_03_01:51178009 UMLS_CUI:C0038644 Cot death Crib death SIDS Sudden death of nonspecific cause in infancy Sudden infant death syndrome disease_ontology DOID:9007 sudden infant death syndrome DOID:9007 An arthritis that is characterized by joint inflammation that usually occurs in combination with psoriasis. EFO:0003778 ICD10CM:L40.5 ICD9CM:696.0 MESH:D015535 NCI:C61277 SNOMEDCT_US_2020_03_01:33339001 UMLS_CUI:C0003872 arthritis psoriatica arthropathic psoriasis disease_ontology psoriatic arthropathy DOID:9008 psoriatic arthritis DOID:9008 An in situ carcinoma that is located_in the intestine. ICD10CM:D01.4 ICD9CM:230.7 SNOMEDCT_US_2020_03_01:190172008 UMLS_CUI:C0154065 disease_ontology DOID:9024 intestine carcinoma in situ DOID:9024 NCI:C38162 SNOMEDCT_US_2020_03_01:449072004 UMLS_CUI:C0740372 disease_ontology DOID:903 gastrointestinal lymphoma DOID:903 A salivary gland cancer that is located_in the parotid gland. ICD10CM:C07 ICD9CM:142.0 MESH:D010307 NCI:C3525 SNOMEDCT_US_2020_03_01:93949007 UMLS_CUI:C0747273 cancer of parotid gland malignant neoplasm of the Parotid malignant tumor of parotid gland parotid cancer disease_ontology DOID:9036 parotid gland cancer DOID:9036 A peroxisomal biogenesis disorder that is characterized by the reduction or absence of functional peroxisomes in the cells of an individual that has_material_basis_in autosomal recessive inheritance of a mutation in the peroxisome biogenesis factor (PEX) genes. GARD:7917 ICD10CM:E71.510 MESH:D015211 NCI:C85239 ORDO:912 SNOMEDCT_US_2020_03_01:88469006 UMLS_CUI:C0043459 cerebrohepatorenal syndrome congenital iron overload peroxisome biogenesis disorder disease_ontology DOID:905 OMIM mapping confirmed by DO. [LS]. OMIM mapping confirmed by DO. [SN]. Zellweger syndrome DOID:905 An in situ carcinoma that is located_in the bladder. ICD10CM:D09.0 ICD9CM:233.7 SNOMEDCT_US_2020_03_01:92546004 UMLS_CUI:C0154091 Flat CIS of the urinary bladder bladder Ca in situ carcinoma in situ of bladder disease_ontology DOID:9053 bladder carcinoma in situ DOID:9053 An inherited metabolic disorder that involves peroxisome malfunction. ICD10CM:E71.5 ICD9CM:277.86 MESH:D018901 NCI:C85005 SNOMEDCT_US_2020_03_01:238059005 UMLS_CUI:C0282528 peroxisomal disorder disease_ontology DOID:906 peroxisomal disease DOID:906 A superficial mycosis that is a chronic, superficial fungal infection of the skin caused by Malassezia furfur, which is characterized by well-demarcated white, pink, fawn, or brownish lesions, often coalescing, and covered with thin furfuraceous scales. ICD10CM:B36.0 ICD9CM:111.0 MESH:D014010 NCI:C112833 SNOMEDCT_US_2020_03_01:56454009 UMLS_CUI:C0040262 Infection by Pityrosporum furfur Pityriasis versicolor disease_ontology DOID:9060 pityriasis versicolor DOID:9060 A commensal bacterial infectious disease that is characterized by widespread erythema, peeling, and necrosis of the skin, that is caused by a toxin produced by a bacterium of the genus Staphylococcus (S. aureus). The infection has_symptoms redness of skin, has_symptom fluid-filled blister formation, has_symptom fever and has_symptom irritability. ICD10CM:L00 ICD9CM:695.81 MESH:D013206 NCI:C85077 SNOMEDCT_US_2020_03_01:87758007 UMLS_CUI:C0038165 Dermatitis exfoliativa neonatorum Pemphigus neonatorum Ritter disease Scalded skin syndrome Staphylococcal scalded skin syndrome Toxic epidermal necrolysis, subcorneal type disease_ontology DOID:9063 Ritter's disease DOID:9063 A parasitic protozoa infectious disease that involves infection caused by protozoan parasite of the genus Leishmania, which is transmitted by the bite of sand fly (subfamily Phlebotominae). DOID:9136 GARD:6881 ICD10CM:B55 ICD9CM:085 MESH:D007896 NCI:C34767 SNOMEDCT_US_2020_03_01:266206004 UMLS_CUI:C0023281 disease_ontology Post Kala-Azar Dermal Leishmaniasis Post-kala-azar dermal leishmaniasis post-kala-azar dermal infectious disease by leishmaniasis DOID:9065 leishmaniasis DOID:9065 GARD:9622 ICD10CM:M31.2 ICD9CM:446.3 MESH:D006103 NCI:C8196 SNOMEDCT_US_2020_03_01:58961005 UMLS_CUI:C0018197 Midfacial Necrotising Lesion malignant granuloma of face disease_ontology DOID:9072 lethal midline granuloma DOID:9072 A lupus erythematosus that is an inflammation of connective tissue marked by skin rashes, joint pain and swelling, inflammation of the kidneys and inflammation of the tissue surrounding the heart. EFO:0002690 GARD:10253 ICD10CM:M32.9 ICD9CM:710.0 KEGG:05322 MESH:D008180 NCI:C3201 OMIM:152700 OMIM:300809 OMIM:605480 OMIM:608437 OMIM:609903 OMIM:609939 OMIM:610065 OMIM:610066 OMIM:612254 OMIM:612378 OMIM:613145 OMIM:614420 ORDO:536 SNOMEDCT_US_2020_03_01:156450004 UMLS_CUI:C0024141 Lupus Erythematosus, systemic SLE - Lupus Erythematosus, systemic disseminated lupus erythematosus disease_ontology DOID:9074 Xref MGI. systemic lupus erythematosus DOID:9074 primary macroglobulinemia disease_ontology DOID:9080 macroglobulinemia DOID:9080 GARD:7328 ICD10CM:L41 ICD9CM:696.2 MESH:D010267 NCI:C3312 SNOMEDCT_US_2020_03_01:267851002 UMLS_CUI:C0030491 disease_ontology DOID:9088 parapsoriasis DOID:9088 A skin disease that is located_in the sebaceous gland. ICD10CM:L70.8 ICD9CM:706.1 SNOMEDCT_US_2020_03_01:201213005 UMLS_CUI:C0029485 disease_ontology DOID:9098 sebaceous gland disease DOID:9098 An in situ carcinoma that is located_in the uterus. ICD9CM:233.2 SNOMEDCT_US_2020_03_01:189342001 UMLS_CUI:C0154086 disease_ontology DOID:9108 uterus carcinoma in situ DOID:9108 A leishmaniasis that involves skin infection caused by Leishmania species, resulting in one or more cutaneous lesions. DOID:13553 DOID:9110 DOID:9122 DOID:9167 ICD10CM:B55.1 MESH:D016773 NCI:C34768 SNOMEDCT_US_2020_03_01:240637006 UMLS_CUI:C0023283 Asian Desert Cutaneous Leishmaniasis Leproid leishmaniasis diffuse cutaneous leishmaniasis disease_ontology DOID:9111 cutaneous leishmaniasis DOID:9111 A primary bacterial infectious disease that results_in infection located_in skin or located_in mucosa of genital tract, has_material_basis_in Klebsiella granulomatis, transmitted by sexual contact or transmitted_by contact with the open sores. The infection has_symptom painless genital ulcers. GARD:9532 ICD10CM:A58 ICD9CM:099.2 MESH:D006100 NCI:C3065 SNOMEDCT_US_2020_03_01:186947000 UMLS_CUI:C0018190 Granuloma Inguinale Granuloma inguinale Pudendal ulcer donovanosis pudendal ulcer disease_ontology DOID:9113 granuloma inguinale DOID:9113 A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. DOID:9118 DOID:9171 GARD:12757 ICD10CM:C92.0 ICD9CM:205.0 KEGG:05221 MESH:D015470 NCI:C3171 OMIM:601626 SNOMEDCT_US_2020_03_01:91861009 UMLS_CUI:C0023467 AML - acute Myeloid Leukemia Leukemia, Myelocytic, acute acute myeloblastic leukaemia acute myeloblastic leukemia acute myelogenous leukaemia acute myelogenous leukemia acute myeloid leukaemia disease_ontology DOID:9119 OMIM mapping confirmed by DO. [SN]. acute myeloid leukemia DOID:9119 An acquired metabolic disease that has_material_basis_in extracellular tissue deposition of mis-folded proteins called fibrils composed of low molecular weight subunits of a variety of proteins. These deposits may result in a wide range of clinical manifestations depending upon their type, location, and the amount of deposition. ICD10CM:E85 ICD9CM:277.3 MESH:D000686 NCI:C2868 SNOMEDCT_US_2020_03_01:154769007 UMLS_CUI:C0002726 amyloid disease disease_ontology DOID:9120 amyloidosis MESH:D000686 DOID:9120 A herpes simplex that results_in infection located_in skin, effected by preexisting dermatosis, has_material_basis_in Human herpesvirus 1 or Human herpesvirus 2. The infection has_symptom watery blisters, has_symptom fever, and has_symptom swelling of the lymph nodes. DOID:4408 DOID:9081 ICD10CM:B00.0 ICD9CM:054.0 ICD9CM:054.41 MESH:D007617 NCI:C35620 SNOMEDCT_US_2020_03_01:186544000 SNOMEDCT_US_2020_03_01:52464003 UMLS_CUI:C0153037 UMLS_CUI:C0854331 UMLS_CUI:C0936250 Eczema herpeticum Herpes simplex dermatitis of eyelid Herpes simplex eyelid dermatitis Herpes simplex virus dermatitis herpes simplex dermatitis herpes simplex virus eyelid dermatitis disease_ontology DOID:9123 eczema herpeticum DOID:9123 An in situ carcinoma that is located_in the stomach. ICD10CM:D00.2 ICD9CM:230.2 SNOMEDCT_US_2020_03_01:92756002 UMLS_CUI:C0154060 carcinoma in situ of stomach gastric carcinoma in situ disease_ontology DOID:9138 stomach carcinoma in situ DOID:9138 ICD10CM:K76.4 MESH:D010382 SNOMEDCT_US_2020_03_01:197366003 UMLS_CUI:C0030781 hepatic peliosis disease_ontology DOID:914 peliosis hepatis DOID:914 A leishmaniasis that is the most severe form of the disease caused by protozoan parasites of the Leishmania genus, resulting in the infection of the internal organs such as liver, spleen and bone marrow. The symptoms include fever, weight loss, and an enlarged spleen and liver. ICD10CM:B55.0 ICD9CM:085.0 MESH:D007898 NCI:C34771 OMIM:608207 OMIM:611381 OMIM:611382 ORDO:507 SNOMEDCT_US_2020_03_01:48115004 UMLS_CUI:C0023290 Infection by visceral leishmaniasis Kala-Azar disease_ontology DOID:9146 Xref MGI. visceral leishmaniasis DOID:9146 ICD10CM:C05.0 ICD9CM:145.2 NCI:C3528 SNOMEDCT_US_2020_03_01:93822006 UMLS_CUI:C0153375 malignant neoplasm of hard palate malignant tumor of hard palate malignant tumour of hard palate disease_ontology DOID:9149 hard palate cancer DOID:9149 A leishmaniasis that involves a chronic inflammatory process involving the nasal, pharyngeal, and laryngeal mucosa, which can lead to extensive tissue destruction, caused by protozoan parasites belonging to the genus Leishmania. The infection is characterized by granulomatous lesion which can destroy upper respiratory tract mucosa. ICD10CM:B55.2 ICD9CM:085.5 MESH:D007897 SNOMEDCT_US_2020_03_01:721813000 UMLS_CUI:C1328252 American Cutaneous Leishmaniasis American cutaneous leishmaniasis American mucocutaneous leishmaniasis Cutaneous leishmaniasis, American Mucocutaneous leishmaniasis Mucocutaneous leishmaniasis, American New World cutaneous leishmaniasis disease_ontology DOID:9155 mucocutaneous leishmaniasis DOID:9155 A commensal bacterial infectious disease that results in infection, located in muscle tissue, has_material_basis_in Clostridium perfringens, which produce gas that becomes trapped in the infected tissue. Gas gangrene usually develops after injuries or surgery. The infection has symptom large blisters, has symptom pain in the infected area, has symptom myonecrosis, has symptom gas production, and has symptom sepsis. ICD10CM:A48.0 ICD9CM:040.0 MESH:D005738 SNOMEDCT_US_2020_03_01:186413007 UMLS_CUI:C0017105 Gas bacillus infection Gas gangrene Myonecrosis disease_ontology DOID:9159 gas gangrene DOID:9159 DOID:692 NCI:C7103 NCI:C7106 UMLS_CUI:C1333419 UMLS_CUI:C1333976 epithelial hepatic and intrahepatic bile duct neoplasm disease_ontology DOID:916 liver benign neoplasm DOID:916 An esophageal disease that is characterized by an inability of the esophagus to move food toward the stomach resulting from the lower esophogeal sphincter not fully relaxing during swallowing. ICD10CM:K22.0 ICD9CM:530.0 MESH:D004931 NCI:C84699 OMIM:200400 SNOMEDCT_US_2020_03_01:17460002 UMLS_CUI:C0014848 Lack of reflex relaxation of lower oesophageal sphincter achalasia of cardia achalasia of esophagus cardiospasm esophageal achalasia hypertensive lower esophageal sphincter disease_ontology DOID:9164 achalasia DOID:9164 ICD10CM:L98.1 ICD9CM:698.4 SNOMEDCT_US_2020_03_01:402736003 UMLS_CUI:C1274184 Dermatitis artefacta Dermatitis factitia Dermatitis ficta Factitious skin disease disease_ontology DOID:9165 neurotic excoriation DOID:9165 A syndrome that is characterized by abnormal immune system function and a reduced ability to form blood clots resulting from a decrease in the number and size of blood cell fragments involved in clotting (microthrombocytopenia). ICD10CM:D82.0 ICD9CM:279.12 MESH:D014923 NCI:C3448 OMIM:301000 SNOMEDCT_US_2020_03_01:36070007 UMLS_CUI:C0043194 Wiskott syndrome disease_ontology DOID:9169 OMIM mapping confirmed by DO. [SN]. Wiskott-Aldrich syndrome DOID:9169 NCI:C5858 SNOMEDCT_US_2020_03_01:717329009 UMLS_CUI:C1333967 Inflammatory Pseudotumor of the Liver disease_ontology DOID:918 liver inflammatory pseudotumor DOID:918 A parasitic protozoa infectious disease that involves infection caused by the amoeba Entamoeba histolytica. Amebic invasion of the intestinal lining causes dysentery, colitis or diarrhea. The infection can also spread through the blood to the liver and, rarely, to the lungs, brain or other organs. DOID:11901 DOID:11904 GARD:652 ICD10CM:A06 ICD9CM:006 MESH:D000562 NCI:C84551 SNOMEDCT_US_2020_03_01:387754006 UMLS_CUI:C0002438 amoebiasis entamoebiasis disease_ontology chronic intestinal amebiasis DOID:9181 amebiasis MESH:D000562 DOID:9181 A bullous skin disease that is characterized by blistering of the skin and mucous membranes (mouth, nose, throat, eyes, and genitals). GARD:7352 ICD10CM:L10 ICD9CM:694.4 MESH:D010392 NCI:C34909 SNOMEDCT_US_2020_03_01:156355008 UMLS_CUI:C0030807 disease_ontology DOID:9182 pemphigus DOID:9182 ICD9CM:362.07 SNOMEDCT_US_2020_03_01:312912001 UMLS_CUI:C0730285 disease_ontology DOID:9191 diabetic macular edema DOID:9191 ICD10CM:K22.4 ICD9CM:530.5 MESH:D015154 SNOMEDCT_US_2020_03_01:40846004 UMLS_CUI:C0014858 Dyskinesia of oesophagus Oesophageal dysmotility Oesophageal motor disorder esophageal dysmotility esophageal motility disorder disease_ontology DOID:9192 dyskinesia of esophagus DOID:9192 A communication disorder that involves difficulty with the act of speech production. MESH:D013064 NCI:C5041 UMLS_CUI:C0037822 disease_ontology DOID:92 speech disorder DOID:92 A lichen disease that is located_in skin, located_in tongue or located_in oral mucosa, which presents itself in the form of papules, lesions or rashes. GARD:12344 ICD10CM:L43 ICD9CM:697.0 MESH:D008010 NCI:C3189 SNOMEDCT_US_2020_03_01:156377007 UMLS_CUI:C0023646 Lichen, ruber planus lichen ruber planus disease_ontology DOID:9201 lichen planus MESH:D008010 DOID:9201 EFO:0000280 GARD:20 ICD10CM:K22.7 ICD9CM:530.85 MESH:D001471 NCI:C2891 OMIM:614266 SNOMEDCT_US_2020_03_01:302914006 UMLS_CUI:C0004763 Barrett esophagus Barrett's esophagus with esophagitis Barrett's oesophagus Barrett's ulcer of esophagus Barretts syndrome ulcerative esophagitis disease_ontology DOID:9206 Barrett's esophagus DOID:9206 A viral infectious disease that results_in inflammation located_in facial nerve, which leads to paralysis of one side of the face, has_material_basis_in Human herpesvirus 3, which reactivates after appearing as chickenpox in childhood. The infection has_symptom vesicular rash of the ear or mouth, has_symptom tinnitus, has_symptom vertigo, has_symptom otalgia, and has_symptom headache. GARD:7525 ICD10CM:B02.21 ICD9CM:053.11 MESH:D016697 NCI:C84763 SNOMEDCT_US_2020_03_01:21954000 UMLS_CUI:C0017409 Geniculate herpes zoster Herpes Zoster Oticus Herpes zoster auricularis Herpetic geniculate ganglionitis Ramsay Hunt syndrome type 2 Ramsay Hunt syndrome type II Ramsey Hunt syndrome geniculate neuralgia nervus intermedius neuralgia disease_ontology DOID:9210 herpes zoster oticus DOID:9210 A skin disease that is characterized by hyperkeratotic follicular papules coalescing into orange-red scaly plaques, islands of sparing, and palmoplantar keratoderma. GARD:7401 ICD10CM:L44.0 ICD9CM:696.4 MESH:D010916 NCI:C85014 OMIM:173200 SNOMEDCT_US_2020_03_01:3755001 UMLS_CUI:C0032027 Devergie's disease Pityriasis rubra pilaris disease_ontology DOID:9212 OMIM mapping confirmed by DO. [SN]. pityriasis rubra pilaris DOID:9212 A sleep apnea that is characterized by a malfunction of the basic neurological controls for breathing rate and the failure to give the signal to inhale, causing the individual to miss one or more cycles of breathing. MESH:D020182 NCI:C116046 OMIM:107640 OMIM:207720 UMLS_CUI:C0520680 primary central sleep apnea disease_ontology central sleep apnea syndrome DOID:9220 Xref MGI. central sleep apnea DOID:9220 A sweat gland disease that is characterized by recurrent vesicles and bullae that develop particularly upon the lateral palms, soles, and fingers and has_symptom pruritis and cracked skin. ICD9CM:705.81 MESH:D011146 SNOMEDCT_US_2020_03_01:402567004 UMLS_CUI:C0032633 Cheiropompholyx DYSHYDROTIC ECZEMA Vesicular eczema of hands and/or feet dyshidrosis disease_ontology DOID:9230 pompholyx DOID:9230 A neuropathy that is characterized by intense, burning pain of affected extremities, severe redness and increased skin temperature. GARD:6377 ICD10CM:I73.81 ICD9CM:443.82 MESH:D004916 NCI:C34593 OMIM:133020 SNOMEDCT_US_2020_03_01:238777005 UMLS_CUI:C0014804 erythermalgia disease_ontology DOID:9240 erythromelalgia DOID:9240 A liver disease that is characterized by an accumulation of bile in the liver resulting from a reducted number of liver small bile ducts. GARD:804 ICD10CM:Q44.7 MESH:D016738 NCI:C35139 OMIM:118450 OMIM:610205 ORDO:52 SNOMEDCT_US_2020_03_01:31742004 UMLS_CUI:C0085280 Alagille-Watson syndrome Arteriohepatic dysplasia disease_ontology DOID:9245 OMIM mapping confirmed by DO. [SN]. Alagille syndrome MESH:D016738 DOID:9245 An amyloidosis where amyloid protein progressively deposits in cerebral blood vessel walls with subsequent degenerative vascular changes that usually result in spontaneous cerebral hemorrhage, ischemic lesions and progressive dementia. MESH:D028243 ORDO:85458 SNOMEDCT_US_2020_03_01:45639009 UMLS_CUI:C0268393 UMLS_CUI:C1510489 UMLS_CUI:C1527338 UMLS_CUI:C1956349 Cerebral Hemorrhage, Hereditary, with Amyloidosis Hereditary Cerebral Hemorrhage with Amyloidosis disease_ontology DOID:9246 Xref MGI. OMIM mapping confirmed by DO. [SN]. cerebral amyloid angiopathy DOID:9246 GARD:7305 MESH:D054975 NCI:C84987 OMIM:146510 SNOMEDCT_US_2020_03_01:56677004 UMLS_CUI:C0265220 A syndrome that is characterized by hypothalamic hamartoma, pituitary dysfunction, central polydactyly, and visceral malformations and has_material_basis_in autosomal dominant heterozygous mutation in the GLI3 gene on chromosome 7p14. disease_ontology DOID:9248 OMIM mapping confirmed by DO. [SN]. Pallister-Hall syndrome DOID:9248 A syndrome that is an autosomal recessive disorder, which is characterized by corpus callosum agenesis, polydactyly, multiple dysmorphic features, motor and mental retardation. GARD:5721 MESH:D055673 NCI:C84531 OMIM:200990 SNOMEDCT_US_2020_03_01:715951007 UMLS_CUI:C0796147 ACLS SCHINZEL ACROCALLOSAL SYNDROME Schinzel syndrome 1 disease_ontology DOID:9250 OMIM mapping confirmed by DO. [SN]. acrocallosal syndrome MESH:D055673 DOID:9250 An inherited metabolic disorder that is characterized by impaired synthesis and degradation of amino acids. GARD:5793 ICD10CM:E72.9 ICD9CM:270 MESH:D000592 NCI:C97090 SNOMEDCT_US_2020_03_01:42930003 UMLS_CUI:C0002514 inborn errors of amino acid metabolism disease_ontology DOID:9252 amino acid metabolic disorder DOID:9252 GARD:8598 ICD10CM:C49.A MESH:D046152 NCI:C3868 OMIM:606764 SNOMEDCT_US_2020_03_01:128755003 UMLS_CUI:C0238198 GANT GIST Stromal tumor of gastrointestinal tract Stromal tumour of gastrointestinal tract gastrointestinal stromal tumour disease_ontology DOID:9253 OMIM mapping confirmed by DO. [SN]. gastrointestinal stromal tumor DOID:9253 A leukemia that results_in an overwhelming number of tissue mast cells located_in peripheral blood. ICD10CM:C94.3 MESH:D007946 NCI:C3169 SNOMEDCT_US_2020_03_01:110002002 UMLS_CUI:C0023461 disease_ontology DOID:9254 mast-cell leukemia DOID:9254 A dementia characterized by progressive neuronal loss predominantly involving the frontal and/or temporal lobes of the brain resulting in a gradual and progressive decline in behavior or language. GARD:8436 MESH:C563003 OMIM:600274 ORDO:282 SNOMEDCT_US_2020_03_01:42369001 UMLS_CUI:C0520716 Wilhemsen-Lynch disease frontotemporal lobar degeneration multiple system tauopathy with presenile dementia pallidopontonigral degeneration disease_ontology DOID:9255 Xref MGI. OMIM mapping confirmed by DO. [SN]. frontotemporal dementia MESH:D057180 DOID:9255 A large intestine cancer that is located_in the colon and/or located_in the rectum. ICD10CM:C18.9 KEGG:05210 MESH:D015179 NCI:C2956 NCI:C4978 OMIM:114500 SNOMEDCT_US_2020_03_01:126837005 SNOMEDCT_US_2020_03_01:93854002 UMLS_CUI:C0009404 UMLS_CUI:C0346629 disease_ontology DOID:9256 Xref MGI. OMIM mapping confirmed by DO. [SN]. colorectal cancer DOID:9256 A syndrome characterized by varying degrees of deafness, minor defects in structures arising from the neural crest and pigmentation anomalies of the hair, the skin and/or the iris of both eyes. GARD:5525 MESH:D014849 NCI:C75008 NCI:C85222 OMIM:PS193500 ORDO:3440 ORDO:895 SNOMEDCT_US_2020_03_01:47434006 UMLS_CUI:C0079661 UMLS_CUI:C1847800 UMLS_CUI:C3266898 Waardenburg Shah syndrome Waardenburg syndrome van der Hoeve Halbertsona Waardenburg syndrome Waardenburg, types I and/or II disease_ontology DOID:9258 Xref MGI. OMIM mapping confirmed by DO. [SN]. Waardenburg's syndrome DOID:9258 A pharynx cancer that is located in the nasopharynx, the uppermost region of the pharynx or throat, where the nasal passages and auditory tubes join the remainder of the upper respiratory tract. DOID:8813 DOID:8814 DOID:9057 DOID:9144 DOID:9197 DOID:9229 GARD:7163 ICD10CM:C11 ICD10CM:C11.0 ICD10CM:C11.1 ICD10CM:C11.2 ICD10CM:C11.3 ICD9CM:147 ICD9CM:147.0 ICD9CM:147.1 ICD9CM:147.2 ICD9CM:147.3 MESH:D009303 NCI:C9321 OMIM:161550 OMIM:607107 ORDO:150 SNOMEDCT_US_2020_03_01:187692001 SNOMEDCT_US_2020_03_01:187693006 SNOMEDCT_US_2020_03_01:187700006 SNOMEDCT_US_2020_03_01:363398003 SNOMEDCT_US_2020_03_01:93919005 SNOMEDCT_US_2020_03_01:94078000 UMLS_CUI:C0153392 UMLS_CUI:C0153393 UMLS_CUI:C0153394 UMLS_CUI:C0153395 UMLS_CUI:C0153396 UMLS_CUI:C0238301 Nasopharyngeal carcinoma malignant Nasopharyngeal tumor malignant neoplasm of nasopharynx nasopharynx cancer disease_ontology carcinoma of nasopharynx DOID:9261 Xref MGI. OMIM mapping confirmed by DO. [SN]. nasopharynx carcinoma DOID:9261 An amino acid metabolic disorder that involves an accumulation of homocysteine in the serum and an increased excretion of homocysteine in the urine. GARD:10770 ICD10CM:E72.11 MESH:D006712 NCI:C84765 OMIM:236200 OMIM:236250 ORDO:394 SNOMEDCT_US_2020_03_01:190709008 UMLS_CUI:C0019880 CBS deficiency cystathionine beta synthase deficiency cystathionine synthase deficiency disease_ontology DOID:9263 Xref MGI. homocystinuria DOID:9263 An amino acid metabolic disorder that involves deficiency in histidine. ICD10CM:E70.4 ICD9CM:270.5 SNOMEDCT_US_2020_03_01:44176004 UMLS_CUI:C0268512 Disturbances of histidine metabolism disease_ontology DOID:9265 histidine metabolism disease DOID:9265 An amino acid metabolic disorder that involves the formation of cystine stones in the kidneys, ureter, and bladder. GARD:6237 ICD10CM:E72.01 MESH:D003555 NCI:C84664 OMIM:220100 ORDO:214 SNOMEDCT_US_2020_03_01:154738008 UMLS_CUI:C0010691 disease_ontology DOID:9266 OMIM mapping confirmed by DO. [SN]. cystinuria DOID:9266 An amino acid metabolic disorder that involves a deficiency of one of the enzymes in the urea cycle which is responsible for removing ammonia from the blood stream. GARD:7837 ICD10CM:E72.2 ICD9CM:270.6 MESH:D056806 NCI:C84785 SNOMEDCT_US_2020_03_01:36444000 UMLS_CUI:C0154246 disorder of metabolism of ornithine, citrulline, argininosuccinic acid, arginine and ammonia disorder of urea cycle metabolism urea cycle defect disease_ontology DOID:9267 urea cycle disorder DOID:9267 An amino acid metabolic disorder that involves abnormally high levels of the amino acid glycine in bodily fluids and tissues. GARD:7219 ICD10CM:E72.51 MESH:D020158 NCI:C84937 OMIM:605899 SNOMEDCT_US_2020_03_01:237939006 UMLS_CUI:C0751748 Non-ketotic hyperglycinemia nonketotic hyperglycinemia disease_ontology DOID:9268 OMIM mapping confirmed by DO. [SN]. glycine encephalopathy DOID:9268 An organic acidemia that is caused by a deficiency of decarboxylase leading to high concentrations of valine, leucine, isoleucine, and alloisoleucine in the blood, urine, and cerebrospinal fluid and characterized by an odor of maple syrup to the urine, vomiting, hypertonicity, severe mental retardation, seizures, and eventually death unless the condition is treated with dietary measures. GARD:3228 ICD10CM:E71.0 MESH:D008375 NCI:C34806 OMIM:246900 OMIM:248600 OMIM:615135 ORDO:511 SNOMEDCT_US_2020_03_01:27718001 UMLS_CUI:C0024776 Ketoacidaemia branched chain ketoaciduria disease_ontology dihydrolipoamide dehydrogenase deficiency dihydrolipoamide dehydrogenase deficiency DOID:9269 Xref MGI. OMIM mapping confirmed by DO. [SN]. maple syrup urine disease DOID:9269 An amino acid metabolic disorder that involves phenylalanine and tyrosine metabolism with the accumulation of homogentisic acid, a toxic tyrosine byproduct. DOID:0050714 GARD:5775 ICD10CM:E70.29 MESH:D000474 NCI:C84546 OMIM:203500 ORDO:56 SNOMEDCT_US_2020_03_01:24250001 UMLS_CUI:C0002066 Homogentisate 1,2-dioxygenase deficiency alcaptonuria disease_ontology deficiency of homogentisicase DOID:9270 OMIM mapping confirmed by DO. [SN]. alkaptonuria MESH:D000474 DOID:9270 An urea cycle disorder that involves a mutated and ineffective form of the enzyme ornithine transcarbamylase. GARD:8391 ICD10CM:E72.4 MESH:D020163 NCI:C84957 OMIM:311250 SNOMEDCT_US_2020_03_01:80908008 UMLS_CUI:C0268542 deficiency of citrulline phosphorylase ornithine transcarbamylase deficiency disease_ontology DOID:9271 OMIM mapping confirmed by DO. [SN]. ornithine carbamoyltransferase deficiency DOID:9271 An amino acid metabolic disorder that involves an abnormal increase of lysine in the blood. GARD:2828 ICD10CM:E72.3 MESH:D020167 NCI:C123433 OMIM:238700 OMIM:238710 ORDO:2203 SNOMEDCT_US_2020_03_01:58558003 UMLS_CUI:C0268553 disease_ontology DOID:9274 OMIM mapping confirmed by DO. [SN]. hyperlysinemia DOID:9274 An amino acid metabolic disorder that involves impaired break down of the amino acid tyrosine. ICD10CM:E70.21 MESH:D020176 NCI:C98640 SNOMEDCT_US_2020_03_01:190694001 UMLS_CUI:C0268483 disease_ontology DOID:9275 OMIM mapping submitted by NeuroDevNet. [LS]. tyrosinemia DOID:9275 An urea cycle disorder that involves arginase deficiency resulting in elevated levels of plasma arginine. ICD10CM:E72.21 MESH:D020162 NCI:C84568 OMIM:207800 SNOMEDCT_US_2020_03_01:23501004 UMLS_CUI:C0268548 Arginase deficiency argininemia deficiency of canavanase disease_ontology DOID:9278 OMIM mapping confirmed by DO. [SN]. hyperargininemia DOID:9278 An amino acid metabolic disorder that involves an abnormally large level of homocysteine in the blood. MESH:D020138 NCI:C84770 SNOMEDCT_US_2020_03_01:419503008 UMLS_CUI:C0598608 disease_ontology DOID:9279 hyperhomocysteinemia DOID:9279 A urea cycle disorder that involves accumulation of ammonia in the blood. GARD:7269 MESH:D020165 NCI:C84612 OMIM:237300 SNOMEDCT_US_2020_03_01:765329008 UMLS_CUI:C0751753 CPS I deficiency disease_ontology DOID:9280 OMIM mapping confirmed by DO. [SN]. carbamoyl phosphate synthetase I deficiency disease DOID:9280 An amino acid metabolic disorder that is characterized by a mutation in the gene for the hepatic enzyme phenylalanine hydroxylase (PAH), rendering it nonfunctional. DOID:14455 GARD:7383 ICD9CM:270.1 MESH:D010661 MESH:D017042 NCI:C81315 OMIM:261600 ORDO:716 SNOMEDCT_US_2020_03_01:154735006 SNOMEDCT_US_2020_03_01:297225000 UMLS_CUI:C0031485 UMLS_CUI:C0085547 Folling's disease PKU maternal phenylketonuria phenylalaninemia disease_ontology DOID:9281 OMIM mapping confirmed by DO. [SN]. phenylketonuria DOID:9281 An eye disease that is characterized by elevated intraocular pressure in the absence of optic nerve damage or visual field loss. ICD10CM:H40.05 ICD9CM:365.04 MESH:D009798 NCI:C3285 SNOMEDCT_US_2020_03_01:267721003 UMLS_CUI:C0028840 disease_ontology DOID:9282 ocular hypertension DOID:9282 A peripheral vascular disease characterized by blood trapped in the penis that is unable to drain. GARD:10016 ICD10CM:N48.3 ICD9CM:607.3 MESH:D011317 NCI:C85022 SNOMEDCT_US_2020_03_01:155930001 UMLS_CUI:C0033117 Mentulagra disease_ontology DOID:9286 priapism DOID:9286 An orofacial cleft that is characterized by a congenital defect in the upper lip where the maxillary prominence fails to merge with the merged medial nasal prominences. DOID:9333 EFO:0003959 ICD10CM:Q36 ICD9CM:749.1 ICD9CM:749.11 MESH:D002971 NCI:C87175 SNOMEDCT_US_2020_03_01:156941008 SNOMEDCT_US_2020_03_01:62696001 UMLS_CUI:C0008924 UMLS_CUI:C0158651 Labium leporinum cheiloschisis cleft lip, unilateral, complete complete unilateral cleft lip hare lip disease_ontology DOID:9296 cleft lip DOID:9296 A mouth disease located_in the lip. ICD10CM:K13.0 ICD9CM:528.5 MESH:D008047 NCI:C26818 SNOMEDCT_US_2020_03_01:90678009 UMLS_CUI:C0023760 disease of lips disease_ontology DOID:9297 lip disease DOID:9297 A communication disorder that involves the processing of linguistic information. ICD10CM:F80.9 MESH:D007806 NCI:C97155 SNOMEDCT_US_2020_03_01:62305002 UMLS_CUI:C0023015 disease_ontology DOID:93 language disorder DOID:93 An adnexa disease that is located_in the eye socket. ICD10CM:H05.9 ICD9CM:376.9 MESH:D009916 SNOMEDCT_US_2020_03_01:267746003 UMLS_CUI:C0029182 disease_ontology DOID:930 orbital disease DOID:930 ICD10CM:K62.3 ICD9CM:569.1 MESH:D012005 NCI:C34973 SNOMEDCT_US_2020_03_01:197214005 UMLS_CUI:C0034888 Procidentia, rectum disease_ontology DOID:9307 rectal prolapse DOID:9307 A lymphatic system disease that is characterized by inflammation of the lymphatic channels which occurs as a result of infection at a site distal to the channel. It is caused by Streptococcus pyogenes (Group A strep) or Staphylococcus aureus. Lymphangitis is also sometimes called blood poisoning. ICD10CM:I89.1 ICD9CM:457.2 MESH:D008205 NCI:C34790 SNOMEDCT_US_2020_03_01:1415005 UMLS_CUI:C0024225 disease_ontology DOID:9317 lymphangitis DOID:9317 DOID:10750 DOID:10751 DOID:9482 ICD10CM:H53.42 ICD10CM:H53.45 ICD9CM:368.42 ICD9CM:368.44 SNOMEDCT_US_2020_03_01:33970004 UMLS_CUI:C0029657 UMLS_CUI:C0152192 Blind spot area scotoma Enlarged angioscotoma Enlarged blind spot Enlarged paracaecal scotoma Generalized visual field contraction or constriction Scotoma of blind spot area Sector or arcuate visual field defects disease_ontology DOID:9335 scotoma DOID:9335 A disease by infectious agent that results in infection, has_material_basis_in Viruses. DOID:1329 ICD10CM:A94 ICD10CM:B34.9 ICD9CM:060-066.99 MESH:D001102 MESH:D014777 NCI:C3439 NCI:C34396 SNOMEDCT_US_2020_03_01:34014006 SNOMEDCT_US_2020_03_01:40610006 UMLS_CUI:C0003723 UMLS_CUI:C0042769 Viral Infection Viral disease virus infection disease_ontology DOID:934 viral infectious disease DOID:934 ICD9CM:625.5 SNOMEDCT_US_2020_03_01:156027002 UMLS_CUI:C0152078 Congestion-fibrosis syndrome Taylor syndrome pelvic congestion syndrome disease_ontology DOID:9346 Taylor's syndrome DOID:9346 ICD10CM:I77.71 ICD9CM:443.21 NCI:C125662 SNOMEDCT_US_2020_03_01:230729006 UMLS_CUI:C0338585 Carotid artery dissection Dissection of carotid artery disease_ontology DOID:9348 carotid artery dissection DOID:9348 A glucose metabolism disease characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. ICD10CM:E08-E13 ICD9CM:250 MESH:D003920 NCI:C2985 SNOMEDCT_US_2020_03_01:267467004 UMLS_CUI:C0011849 disease_ontology DOID:9351 diabetes mellitus DOID:9351 A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. EFO:0001360 ICD10CM:E11 KEGG:04930 MESH:D003924 NCI:C26747 OMIM:125853 OMIM:601283 OMIM:601407 OMIM:603694 OMIM:608036 SNOMEDCT_US_2020_03_01:44054006 UMLS_CUI:C0011860 NIDDM insulin resistance non-insulin-dependent diabetes mellitus type 2 diabetes type II diabetes mellitus disease_ontology DOID:9352 Xref MGI. OMIM mapping confirmed by DO. [SN]. type 2 diabetes mellitus DOID:9352 A central nervous system disease that is located_in the brain. DOID:8510 ICD10CM:G93.40 ICD10CM:G93.9 ICD9CM:348.30 ICD9CM:348.9 MESH:D001927 NCI:C26920 NCI:C96413 SNOMEDCT_US_2020_03_01:81308009 UMLS_CUI:C0006111 UMLS_CUI:C0085584 encephalopathy disease_ontology DOID:936 brain disease DOID:936 An acute asthma that is characterized by an acute episode with a progressive severity that is poorly responsive to standard therapeutic measures, regardless of disease severity or phenotypic variant. ICD9CM:493.91 MESH:D013224 NCI:C122577 SNOMEDCT_US_2020_03_01:36979006 UMLS_CUI:C0038218 Asthma with status asthmaticus Severe asthma attack disease_ontology DOID:9362 status asthmaticus DOID:9362 ICD10CM:N49.0 ICD9CM:608.0 SNOMEDCT_US_2020_03_01:155935006 UMLS_CUI:C0042588 Seminal vesiculitis disease_ontology DOID:9365 vesiculitis DOID:9365 DOID:9367 ICD10CM:H16.2 ICD9CM:370.40 MESH:D007637 NCI:C34744 SNOMEDCT_US_2020_03_01:155154005 UMLS_CUI:C0022573 disease_ontology DOID:9368 keratoconjunctivitis DOID:9368 An eye disease that is characterized by a bulging of the eye anteriorly out of the orbit. ICD10CM:H05.20 ICD9CM:376.30 MESH:D005094 NCI:C87114 SNOMEDCT_US_2020_03_01:155200004 UMLS_CUI:C0015300 proptosis disease_ontology DOID:9370 exophthalmos DOID:9370 A syndrome that is a chronic unilateral (or rarely bilateral) iridocyclitis appearing with the triad of heterochromia, predisposition to cataracts and glaucoma, and keratitic percipitates on the posterior corneal surface. GARD:6791 ICD10CM:H20.81 ICD9CM:364.21 SNOMEDCT_US_2020_03_01:11226001 UMLS_CUI:C0016782 Fuch's Heterochromic iridocyclitis Fuchs uveitis syndrome Fuchs' heterochromic cyclitis disease_ontology DOID:9375 Fuchs' heterochromic uveitis DOID:9375 DOID:9376 DOID:9380 ICD10CM:H20.01 ICD9CM:364.01 ICD9CM:364.2 SNOMEDCT_US_2020_03_01:193485000 SNOMEDCT_US_2020_03_01:193496008 UMLS_CUI:C0007832 UMLS_CUI:C0154909 primary iridocyclitis disease_ontology DOID:9383 iridocyclitis MESH:D015863 DOID:9383 A tracheal disease which involves bacterial infection of the trachea often caused by Staphylococcus aureus and streptococci that follows a recent viral upper respiratory infection. The symptoms include barking croup cough, loud squeaking noise while breathing, scratchy feeling in the throat, high fever, and production of large amounts of pus-filled secretions. DOID:0050149 DOID:9391 ICD10CM:J04.1 ICD9CM:464.1 MESH:D014136 NCI:C78643 SNOMEDCT_US_2020_03_01:155507000 SNOMEDCT_US_2020_03_01:62994001 UMLS_CUI:C0040584 UMLS_CUI:C0149513 acute tracheitis chronic tracheitis disease_ontology DOID:9392 tracheitis MESH:D014136 DOID:9392 A respiratory system infectious disease that involves inflammation, edema, and subsequent obstruction of the larynx, trachea, and bronchi. The disease is caused by viruses, bacteria, allergies and inhaled irritants. It is marked by episodes of difficult breathing and hoarse metallic cough in infants and young children. Croup is caused by parainfluenza virus (types 1 and 2), Influenza A and B viruses, Measles virus, adenovirus, respiratory syncytial virus, Staphylococcus and Streptococcus. ICD10CM:J05.0 ICD9CM:464.4 MESH:D003440 NCI:C26735 SNOMEDCT_US_2020_03_01:71186008 UMLS_CUI:C0010380 Croup syndrome Laryngotracheobronchitis acute Obstructive Laryngitis acute laryngotracheobronchitis disease_ontology DOID:9395 croup DOID:9395 An upper respiratory tract disease which involves inflammation of the epiglottis due to infection. Haemophilus influenzae type B is the most common bacterial causative agent, although some cases are attributable to Streptococcus pneumoniae or Streptococcus pyogenes. The infection can cause the epiglottis to either obstruct or completely close off the windpipe. Epiglottitis typically affects children, and is associated with fever, difficulty in swallowing, drooling, hoarseness of voice, and stridor. DOID:9397 DOID:9479 DOID:9481 ICD10CM:J05.1 ICD10CM:J05.10 ICD9CM:464.3 MESH:D004826 NCI:C116007 SNOMEDCT_US_2020_03_01:29608009 SNOMEDCT_US_2020_03_01:80384002 UMLS_CUI:C0014541 UMLS_CUI:C0155814 acute epiglottitis acute epiglottitis and supraglottitis disease_ontology DOID:9398 epiglottitis DOID:9398 ICD10CM:N45.3 ICD9CM:604 SNOMEDCT_US_2020_03_01:24084007 UMLS_CUI:C0149881 disease_ontology DOID:9401 epididymo-orchitis DOID:9401 ICD10CM:N45.1 MESH:D004823 SNOMEDCT_US_2020_03_01:155914009 UMLS_CUI:C0014534 disease_ontology DOID:9402 epididymitis DOID:9402 A pituitary gland disease characterized by the decreased secretion of one or more of the eight hormones normally produced by the pituitary gland. GARD:2917 ICD10CM:E23.0 MESH:D007018 NCI:C62591 OMIM:221750 OMIM:262600 OMIM:262700 OMIM:613038 OMIM:613986 ORDO:95494 SNOMEDCT_US_2020_03_01:74728003 UMLS_CUI:C0020635 Pituitary insufficiency pituitary hormone deficiency disease_ontology Pituitary hypofunction DOID:9406 Xref MGI. hypopituitarism DOID:9406 ICD10CM:E23.2 ICD9CM:253.5 MESH:D003919 NCI:C43263 SNOMEDCT_US_2020_03_01:190484000 UMLS_CUI:C0011848 disease_ontology DOID:9409 diabetes insipidus DOID:9409 An eyelid disease that is characterized by often chronic inflammation of the eyelid, generally the part where eyelashes grow. DOID:13824 ICD10CM:H01.0 ICD9CM:373.0 ICD9CM:373.4 MESH:D001762 NCI:C112183 SNOMEDCT_US_2020_03_01:193907001 SNOMEDCT_US_2020_03_01:193920003 UMLS_CUI:C0005741 UMLS_CUI:C0155181 disease_ontology DOID:9423 blepharitis DOID:9423 A brain disease that is characterized by high pressure inside the skull, the brain tissue and cerebrospinal fluid, has_symptom headache, has_symptom vomiting, has_symptom altered mental status, has_symptom papilledema. MESH:D019586 NCI:C84791 SNOMEDCT_US_2020_03_01:155052007 UMLS_CUI:C0151740 Raised intracranial pressure disease_ontology DOID:9428 intracranial hypertension DOID:9428 GARD:7548 ICD10CM:E74.8 ICD9CM:271.4 MESH:D006030 OMIM:233100 SNOMEDCT_US_2020_03_01:190759004 UMLS_CUI:C0017980 renal diabetes disease_ontology DOID:9432 OMIM mapping confirmed by DO. [SN]. renal glycosuria DOID:9432 NCI:C35335 SNOMEDCT_US_2020_03_01:71912000 UMLS_CUI:C0267918 disease_ontology DOID:9439 chronic cholangitis DOID:9439 A bile duct disease that is an inflammation of the bile duct. ICD10CM:K83.0 ICD9CM:576.1 MESH:D002761 NCI:C26718 SNOMEDCT_US_2020_03_01:155831003 UMLS_CUI:C0008311 disease_ontology DOID:9446 cholangitis DOID:9446 A lipid storage disease characterized by the accumulation of large vacuoles of triglyceride fat in liver cells via the process of steatosis. DOID:9451 ICD10CM:K70.0 ICD9CM:571.0 MESH:D005234 MESH:D005235 OMIM:228100 SNOMEDCT_US_2020_03_01:371330000 SNOMEDCT_US_2020_03_01:50325005 UMLS_CUI:C0015695 UMLS_CUI:C0015696 Fatty change of liver Steatosis of liver alcoholic fatty liver hepatic lipidosis disease_ontology DOID:9452 PRISM. fatty liver disease DOID:9452 A lysosomal storage disease that involves the accumulation of harmful amounts of lipids (fats) in some of the body's cells and tissues. DOID:10583 ICD10CM:E75.6 ICD9CM:272.7 ICD9CM:272.8 MESH:D008064 SNOMEDCT_US_2020_03_01:11455007 SNOMEDCT_US_2020_03_01:154744007 UMLS_CUI:C0023794 UMLS_CUI:C0029591 Lipoid storage diseas Lipoidosis inborn lipid storage disorder lipoidosis disease_ontology DOID:9455 lipid storage disease DOID:9455 A uterine cancer that is located_in the uterine corpus. ICD10CM:C54 ICD9CM:182 NCI:C3556 SNOMEDCT_US_2020_03_01:93718007 UMLS_CUI:C0153574 corpus uteri cancer disease_ontology DOID:9460 uterine corpus cancer DOID:9460 ICD10CM:H16.21 ICD9CM:370.34 SNOMEDCT_US_2020_03_01:14366000 UMLS_CUI:C0339295 Exposure keratoconjunctivitis lagophthalmic keratitis disease_ontology DOID:9461 exposure keratitis DOID:9461 An external ear disease that involves inflammation of the outer ear and ear canal. It can be caused by active bacterial or fungal infections. DOID:9785 ICD9CM:380.1 NCI:C3299 SNOMEDCT_US_2020_03_01:194198006 UMLS_CUI:C0021355 swimmer's ear disease_ontology DOID:9463 otitis externa DOID:9463 A syndrome characterized by nail dysplasia and absent or hypoplastic patellae that has_material_basis_in heterozygous mutation in LMX1B on chromosome 9q33.3. GARD:7160 ICD10CM:Q87.2 MEDDRA:10063431 MESH:D009261 NCI:C75120 OMIM:161200 ORDO:2614 SNOMEDCT_US_2020_03_01:22199006 UMLS_CUI:C0027341 Fong disease Turner-Kiser syndrome hereditary onychoostedysplasia iliac horn syndrome nail patella syndrome disease_ontology DOID:9467 OMIM mapping confirmed by DO. [SN]. nail-patella syndrome DOID:9467 A central nervous system disease that is characterized by an inflammation of the pia-arachnoid meninges. It can be caused by growth of bacteria, fungi, or parasites within the subarachnoid space or by the growth of bacteria or viruses within the meningeal or ependymal cells. DOID:9712 ICD10CM:G03 ICD9CM:322.9 MESH:D008581 NCI:C26828 SNOMEDCT_US_2020_03_01:154983000 UMLS_CUI:C0025289 disease_ontology DOID:9471 meningitis DOID:9471 An artery disease characterized by a blockage of the main artery of the lung or one of its branches by a substance that has travelled from elsewhere in the body, e.g. a blood clot. ICD10CM:I26 MESH:D011655 NCI:C50713 SNOMEDCT_US_2020_03_01:194882001 UMLS_CUI:C0034065 pulmonary artery embolism pulmonary embolus disease_ontology DOID:9477 PRISM. pulmonary embolism DOID:9477 ICD10CM:H04.0 ICD9CM:375.0 MESH:D003607 NCI:C26971 SNOMEDCT_US_2020_03_01:86927009 UMLS_CUI:C0155223 disease_ontology DOID:950 dacryoadenitis DOID:950 A hematopoietic system disease that is located_in white blood cells. ICD10CM:D72.9 ICD9CM:288 MESH:D007960 SNOMEDCT_US_2020_03_01:191369001 UMLS_CUI:C0023510 disease_ontology DOID:9500 leukocyte disease DOID:9500 A substance abuse that involves the recurring use of cannabis despite negative consequences. DOID:2525 ICD10CM:F12 ICD10CM:F12.1 ICD9CM:305.2 MESH:D002189 SNOMEDCT_US_2020_03_01:268769003 SNOMEDCT_US_2020_03_01:37344009 UMLS_CUI:C0006868 UMLS_CUI:C0024809 marijuana abuse disease_ontology DOID:9505 cannabis abuse DOID:9505 A sinusitis which involves infection of ethmoid sinuses that causes pain or pressure behind and between the eyes, tearing, and headache over the forehead. ICD10CM:J32.2 MESH:D015521 NCI:C34597 SNOMEDCT_US_2020_03_01:18643000 UMLS_CUI:C0015029 ethmoidal sinusitis ethmoiditis disease_ontology DOID:9507 ethmoid sinusitis DOID:9507 A syndrome characterized by marked short stature with normal or high serum growth hormone and low serum insulin-like growth factor-1 levels that has_material_basis_in homozygous or compound heterozygous mutation in GHR on chromosome 5p13-p12. GARD:6859 ICD10CM:E34.3 MESH:D046150 NCI:C130994 OMIM:262500 ORDO:633 SNOMEDCT_US_2020_03_01:38196001 UMLS_CUI:C0271568 Laron-type isolated somatotropin defect disease_ontology DOID:9521 OMIM mapping confirmed by DO. [SN]. Laron syndrome DOID:9521 A syphilis that is characterized as having serologic proof of infection without signs or symptoms of disease. DOID:12912 DOID:12913 DOID:9492 ICD10CM:A53.0 ICD9CM:097.1 MESH:D013592 NCI:C35056 SNOMEDCT_US_2020_03_01:444150000 UMLS_CUI:C0039133 disease_ontology DOID:9531 latent syphilis DOID:9531 A viral infectious disease that results_in infection, has_material_basis_in Lassa virus, which is transmitted_by multimammate rat of the genus Mastomys. The infection has_symptom fever, has_symptom retrosternal pain, has_symptom sore throat, has_symptom back pain, has_symptom cough, has_symptom abdominal pain, has_symptom vomiting, has_symptom diarrhea, has_symptom conjunctivitis, has_symptom facial swelling, has_symptom proteinuria (protein in the urine), and has_symptom mucosal bleeding. ICD10CM:A96.2 MESH:D007835 NCI:C128418 SNOMEDCT_US_2020_03_01:19065005 UMLS_CUI:C0023092 disease_ontology DOID:9537 Lassa fever DOID:9537 A myeloid neoplasm that is located_in the plasma cells in bone marrow. EFO:0001378 GARD:7108 ICD10CM:C90.0 ICD9CM:203.0 MESH:D009101 NCI:C3242 OMIM:254500 ORDO:29073 SNOMEDCT_US_2020_03_01:94705007 UMLS_CUI:C0026764 plasma cell myeloma disease_ontology DOID:9538 OMIM mapping confirmed by DO. [SN]. multiple myeloma DOID:9538 An endocrine system disease that is located_in the adrenal gland. ICD10CM:E27.9 ICD9CM:255.9 MESH:D000307 NCI:C26690 SNOMEDCT_US_2020_03_01:30171000 UMLS_CUI:C0001621 disease_ontology DOID:9553 adrenal gland disease DOID:9553 MESH:D009302 NCI:C35723 SNOMEDCT_US_2020_03_01:123952009 UMLS_CUI:C0027438 disease_ontology DOID:9561 nasopharyngeal disease DOID:9561 A ciliopathy that is characterized by impaired function of the cilia lining the respiratory tract (lower and upper, sinuses, Eustachian tube, middle ear) and fallopian tube. DOID:2925 GARD:4484 MESH:D002925 NCI:C84638 OMIM:PS244400 ORDO:244 SNOMEDCT_US_2020_03_01:86204009 UMLS_CUI:C0008780 ciliary motility disorder immotile ciliary syndrome disease_ontology DOID:9562 Xref MGI. OMIM mapping confirmed by DO. [SN]. primary ciliary dyskinesia DOID:9562 A bronchial disease that is a chronic inflammatory condition of one or more bronchi or bronchioles marked by dilatation and loss of elasticity of the walls resulting from damage to the airway wall leading to the formation of small sacs on the bronchial wall and impairment of cilia mobility in the lung. Inflammation of the bronchial wall increases mucus secretion which serves as a breeding ground for bacteria. Bronchiectasis is caused by repeated respiratory infections, immune deficiency disorders, hereditary disorders (cystic fibrosis or primary ciliary dyskinesia), mechanical factors (inhaled object or a lung tumor) or inhaling toxic substances. DOID:11046 DOID:11047 DOID:9571 ICD10CM:J47 ICD9CM:494 MESH:D001987 NCI:C84475 OMIM:211400 OMIM:613021 OMIM:613071 OMIM:PS211400 ORDO:60033 SNOMEDCT_US_2020_03_01:155580000 UMLS_CUI:C0006267 Polynesian bronchiectasis disease_ontology DOID:9563 Xref MGI. OMIM mapping confirmed by DO. [SN]. bronchiectasis DOID:9563 GARD:1827 ICD10CM:Q24.0 MESH:D003914 NCI:C84669 SNOMEDCT_US_2020_03_01:27637000 UMLS_CUI:C0011813 Heart predominantly in right hemithorax disease_ontology DOID:9565 dextrocardia DOID:9565 DOID:14713 ICD10CM:Q30.0 ICD9CM:748.0 MESH:C562435 MESH:D002754 OMIM:608911 SNOMEDCT_US_2020_03_01:156934002 UMLS_CUI:C0008297 UMLS_CUI:C0220723 Atresia of nares Imperforate nares posterior choanal atresia disease_ontology DOID:9574 OMIM mapping confirmed by DO. [SN]. choanal atresia DOID:9574 A candidiasis that involves fungal infection in neonates caused by Candida species. Low birthweight and age, prolonged intravascular catheterization and the use of antibiotic drugs are the principle predisposing conditions for systemic candidiasis in neonates. ICD10CM:P37.5 ICD9CM:771.7 NCI:C116810 SNOMEDCT_US_2020_03_01:3973009 UMLS_CUI:C0276682 Neonatal Candida infection Neonatal candida infection Neonatal monilia infection neonatal moniliasis disease_ontology DOID:9577 neonatal candidiasis DOID:9577 A viral infectious disease that results_in inflammation located_in brain of horses and humans, has_material_basis_in Venezuelan equine encephalitis virus, which is transmitted_by Culex mosquitoes. The infection has_symptom fever, has_symptom chills, has_symptom malaise, has_symptom severe headache, has_symptom photophobia, and has_symptom myalgia in the legs and lumbosacral region. GARD:6355 ICD10CM:A92.2 ICD9CM:066.2 MESH:D004685 NCI:C35121 SNOMEDCT_US_2020_03_01:89990001 UMLS_CUI:C0014078 disease_ontology Venezuelan equine fever DOID:9584 Venezuelan equine encephalitis DOID:9584 A brain disease that is characterized as an acute inflammation of the brain with flu-like symptoms. DOID:2160 MESH:D004660 NCI:C26760 SNOMEDCT_US_2020_03_01:267682000 UMLS_CUI:C0014038 disease_ontology DOID:9588 encephalitis DOID:9588 A connective tissue disease characterized by inflammation located in the fascia. ICD10CM:M72.9 ICD9CM:729.4 MESH:D005208 NCI:C50559 SNOMEDCT_US_2020_03_01:36948007 UMLS_CUI:C0015645 disease_ontology DOID:9598 fasciitis DOID:9598 A primary bacterial infectious disease that results_in infection located_in intestine caused by eating food contaminated with enterotoxins produced by bacteria, has_material_basis_in Staphylococcus aureus. The infection has_symptom diarrhea, has_symptom vomiting, has_symptom nausea, has_symptom cramps, and has_symptom weakness. ICD10CM:A05.0 ICD9CM:005.0 MESH:D013202 NCI:C35037 SNOMEDCT_US_2020_03_01:84622004 UMLS_CUI:C0038159 Staphylococcal food poisoning Staphylococcal toxaemia due to food staphyloenterotoxicosis disease_ontology DOID:96 staphyloenterotoxemia DOID:96 ICD10CM:M72.2 MESH:D036981 SNOMEDCT_US_2020_03_01:203056001 UMLS_CUI:C0149756 disease_ontology DOID:9600 plantar fasciitis DOID:9600 GARD:6454 ICD10CM:M72.6 ICD9CM:728.86 MESH:D019115 NCI:C84916 SNOMEDCT_US_2020_03_01:186428007 UMLS_CUI:C0238124 disease_ontology DOID:9602 necrotizing fasciitis DOID:9602 GARD:7191 MESH:D009455 NCI:C3272 SNOMEDCT_US_2020_03_01:404029005 UMLS_CUI:C0027830 disease_ontology DOID:962 neurofibroma DOID:962 A ureteral disease characterized by backward flow of urine from the urinary bladder into the ureter. ICD10CM:N13.7 ICD9CM:593.7 MESH:D014718 NCI:C84467 OMIM:193000 OMIM:314550 OMIM:610878 OMIM:613674 OMIM:614317 OMIM:614318 OMIM:614319 OMIM:614674 OMIM:615390 OMIM:615963 ORDO:289365 SNOMEDCT_US_2020_03_01:197811007 UMLS_CUI:C0042580 vesico-ureteral reflux disease_ontology DOID:9620 Xref MGI. OMIM mapping confirmed by DO. [LS]. vesicoureteral reflux DOID:9620 ICD10CM:N28.81 ICD9CM:593.1 NCI:C122991 SNOMEDCT_US_2020_03_01:197800004 UMLS_CUI:C0156259 disease_ontology DOID:9622 kidney hypertrophy DOID:9622 A hereditary ataxia characterized by sporadic bouts of ataxia with or without continuous muscle movement. GARD:9851 MESH:C580065 ORDO:211062 SNOMEDCT_US_2020_03_01:421455009 UMLS_CUI:C1720189 Isaacs syndrome disease_ontology DOID:963 Xref MGI. OMIM mapping confirmed by DO. [SN]. Updated outdated UMLS CUI. episodic ataxia DOID:963 A hematopoietic system disease characterized by white blood cells with unusually shaped nuclei that has_material_basis_in heterozygous mutation in LBR on chromosome 1q42.12. GARD:9148 MESH:D010381 NCI:C85002 OMIM:169400 SNOMEDCT_US_2020_03_01:85559002 UMLS_CUI:C0030779 disease_ontology DOID:9631 OMIM mapping confirmed by DO. [SN]. Pelger-Huet anomaly DOID:9631 A mouth disease that is characterized by inflammation of the mouth and lips. ICD10CM:K12.1 MESH:D013280 NCI:C26887 SNOMEDCT_US_2020_03_01:95361005 UMLS_CUI:C0038362 disease_ontology DOID:9637 stomatitis DOID:9637 A coccidiosis that involves infection of the intestine and muscles of humans and animals caused by an intracellular protozoan parasite of genus Sarcocystis. The symptoms include mild fever, diarrhea, chills, vomiting, muscle swelling, erythema, muscle tenderness,cough, arthralgia, transient pruritic rashes, headache, malaise and lymphadenopathy. ICD10CM:A07.8 ICD9CM:136.5 MESH:D012523 SNOMEDCT_US_2020_03_01:88905005 UMLS_CUI:C0036231 Sarcosporidiosis disease_ontology DOID:9640 sarcocystosis DOID:9640 A parasitic protozoa infectious disease that has_symptom mild fevers and has_symptom anemia described as malaria-like symptoms caused by a protozoan of genus Babesia, which reproduce in red blood cells and cause hemolytic anemia. They are transmitted by Ixodid ticks or by blood transfusion. Babesiosis is a zoonotic disease. GARD:5878 ICD10CM:B60.0 ICD9CM:088.82 MESH:D001404 NCI:C84581 SNOMEDCT_US_2020_03_01:187241002 UMLS_CUI:C0004576 Babesiasis Infection by babesia piroplasmosis disease_ontology DOID:9643 babesiosis DOID:9643 A pathologic nystagmus, present at birth, characterized by involuntary, rhythmic eye movements; oscillations are usually horizontal in direction. ICD10CM:H55.01 ICD9CM:379.51 MESH:D020417 OMIM:PS310700 ORDO:651 SNOMEDCT_US_2020_03_01:155205009 UMLS_CUI:C0700501 disease_ontology DOID:9649 Xref MGI. congenital nystagmus DOID:9649 ICD10CM:H55.0 ICD9CM:379.50 MESH:D009759 NCI:C3282 SNOMEDCT_US_2020_03_01:194171007 UMLS_CUI:C0028738 disease_ontology DOID:9650 pathologic nystagmus DOID:9650 ICD10CM:I50.20 ICD9CM:428.2 MESH:D054143 SNOMEDCT_US_2020_03_01:417996009 UMLS_CUI:C1135191 disease_ontology DOID:9651 systolic heart failure DOID:9651 A stomatitis characterized by the repeated formation of benign and non-contagious mouth ulcers. GARD:5834 ICD9CM:528.2 MESH:D013281 NCI:C62546 SNOMEDCT_US_2020_03_01:398870000 UMLS_CUI:C0038363 Aphtha Aphthous ulceration Canker sore Oral aphthae oral ulcer disease_ontology Oral aphthous ulcer DOID:9663 aphthous stomatitis DOID:9663 A placenta disease that is characterized by separation of the placental lining from the uterus of the mother. DOID:12976 DOID:12977 DOID:13233 DOID:13234 DOID:13587 DOID:13627 DOID:14406 DOID:9666 ICD10CM:O20.0 ICD9CM:640.0 MESH:D000033 NCI:C112857 SNOMEDCT_US_2020_03_01:54048003 UMLS_CUI:C0000821 abruptio placenta abruptio placentae disease_ontology DOID:9667 PRISM. placental abruption DOID:9667 A cataract that is characterized by thickening and loss of transparency of the lens with age progression, caused by a multifactorial etiology related to aging. ICD10CM:H25 ICD9CM:366.1 NCI:C35012 SNOMEDCT_US_2020_03_01:39450006 UMLS_CUI:C0036646 disease_ontology DOID:9669 senile cataract DOID:9669 ICD10CM:K12.1 MESH:D005892 NCI:C35039 SNOMEDCT_US_2020_03_01:450005 UMLS_CUI:C0038367 disease_ontology DOID:9673 ulcerative stomatitis DOID:9673 ICD10CM:J43.8 ICD9CM:492.8 OMIM:130700 SNOMEDCT_US_2020_03_01:195962007 UMLS_CUI:C0029607 disease_ontology DOID:9675 pulmonary emphysema MESH:D011656 DOID:9675 A cervix disease that is characterized by the beginning of dilation and effacement of a pregnant woman's cervix before her pregnancy has reached term. ICD10CM:N88.3 ICD9CM:622.5 MESH:D002581 NCI:C50607 SNOMEDCT_US_2020_03_01:36836005 UMLS_CUI:C0007871 disease_ontology DOID:9681 cervical incompetence DOID:9681 A viral infectious disease that results in infection, has_material_basis_in Yellow fever virus, which is transmitted by Aedes, transmitted by Haemagogus, or transmitted by Sabethes species of mosquitoes. The infection has symptom fever, has symptom muscle pain, has symptom backache, has symptom headache, has symptom shivers, has symptom loss of appetite, has symptom jaundice, and has symptom bleeding from the mouth, nose, eyes or stomach leading to vomitus containing blood. DOID:9683 DOID:9684 GARD:7914 ICD10CM:A95 ICD9CM:060 MESH:D015004 NCI:C35547 SNOMEDCT_US_2020_03_01:154345006 UMLS_CUI:C0043395 Sylvatic yellow fever Yellow fever, sylvan jungle yellow fever urban yellow fever disease_ontology DOID:9682 yellow fever DOID:9682 A bacterial conjuctivitis that is characterized by pain and tenderness in the eyeball and conjuctival discharge. DOID:10601 GARD:2546 ICD10CM:P39.1 ICD9CM:771.6 NCI:C116815 SNOMEDCT_US_2020_03_01:206345004 SNOMEDCT_US_2020_03_01:80881003 UMLS_CUI:C0027611 UMLS_CUI:C0029076 Gonococcal conjunctivitis Gonococcal ophthalmia neonatorum Neonatal conjunctivitis disease_ontology DOID:9699 ophthalmia neonatorum DOID:9699 MESH:D013717 SNOMEDCT_US_2020_03_01:240035004 UMLS_CUI:C0039520 Inflammation of tendon sheath disease_ontology DOID:970 tenosynovitis DOID:970 ICD10CM:H10.0 MESH:D003234 NCI:C53656 SNOMEDCT_US_2020_03_01:193877001 UMLS_CUI:C0009768 Purulent conjunctivitis disease_ontology DOID:9700 bacterial conjunctivitis DOID:9700 ICD10CM:M77.9 MESH:D052256 NCI:C97141 SNOMEDCT_US_2020_03_01:312785002 UMLS_CUI:C0039503 disease_ontology DOID:971 tendinitis DOID:971 ICD10CM:K82.0 ICD9CM:575.2 NCI:C78308 SNOMEDCT_US_2020_03_01:197415009 UMLS_CUI:C0156214 Obstruction of gallbladder disease_ontology DOID:9714 occlusion of gallbladder DOID:9714 A retinal and vitreous disease characterized by ocular inflammation, vascular dropout, large spots of hyperpigmentation, neovascularization of the peripheral and posterior retina, vitreous hemorrhage, and retinal detachment that has_material_basis_in heterozygous mutation in CAPN5 on chromosome 11q13.5. MESH:D018630 OMIM:193235 ORDO:329211 SNOMEDCT_US_2020_03_01:232016005 UMLS_CUI:C0242852 ADNIV Retinitis proliferans autosomal dominant neovascular inflammatory vitreoretinopathy proliferative vitreoretinopathy disease_ontology DOID:9719 neovascular inflammatory vitreoretinopathy DOID:9719 An eye and adnexa disease that is located in the vitreous of the eye. ICD10CM:H43.39 ICD9CM:379.24 SNOMEDCT_US_2020_03_01:194154006 UMLS_CUI:C0029872 disease_ontology DOID:9720 vitreous disease DOID:9720 ICD10CM:H44.0 ICD9CM:360.0 SNOMEDCT_US_2020_03_01:41720003 UMLS_CUI:C0259800 disease_ontology DOID:9724 purulent endophthalmitis DOID:9724 ICD10CM:H43.81 MESH:D020255 NCI:C50807 SNOMEDCT_US_2020_03_01:267747007 UMLS_CUI:C0042907 disease_ontology DOID:9726 vitreous detachment DOID:9726 An urogenital tuberculosis that results_in formation of granulomas located_in kidney. ICD9CM:016.0 MESH:D014398 NCI:C123020 SNOMEDCT_US_2020_03_01:44323002 UMLS_CUI:C0041328 Tuberculosis of kidney disease_ontology DOID:9733 renal tuberculosis DOID:9733 A non-suppurative otitis media and eustachian tube disorder in which the tube is either too narrow or too wide. It can also be cuased by nasal inflammation which leads to inflammatory swelling and obstruction of the eustachian tube, which, in turn, leads to increased negative pressure in the middle ear and improper ventilation. ICD9CM:381.8 SNOMEDCT_US_2020_03_01:194277003 UMLS_CUI:C0155435 disease_ontology DOID:9739 eustachian tube disease DOID:9739 A respiratory system disease which involves the upper respiratory tract. ICD9CM:478.19 SNOMEDCT_US_2020_03_01:195823002 UMLS_CUI:C0029581 disease_ontology DOID:974 upper respiratory tract disease DOID:974 ICD10CM:K91.5 ICD9CM:576.0 MESH:D017562 SNOMEDCT_US_2020_03_01:90782003 UMLS_CUI:C0152099 disease_ontology DOID:9740 postcholecystectomy syndrome DOID:9740 ICD10CM:K83.9 ICD9CM:576.9 MESH:D001660 SNOMEDCT_US_2020_03_01:5235004 UMLS_CUI:C0005424 disease_ontology DOID:9741 biliary tract disease DOID:9741 A varicose veins that is located_in the pelvis. ICD10CM:I86.2 ICD9CM:456.5 SNOMEDCT_US_2020_03_01:266271008 UMLS_CUI:C0155795 disease_ontology DOID:9742 pelvic varices DOID:9742 ICD9CM:250.6 MESH:D003929 NCI:C26748 SNOMEDCT_US_2020_03_01:193182005 UMLS_CUI:C0011882 disease_ontology DOID:9743 diabetic neuropathy DOID:9743 Emphysematous cholecystitis is a bacterial infectious disease consisting of an inflammation of the gallbladder characterized by air-filled expansions in interstitial or subcutaneous tissues. MESH:D041882 NCI:C35592 SNOMEDCT_US_2020_03_01:95558008 UMLS_CUI:C0521610 Gaseous pericholecystitis disease_ontology DOID:9765 emphysematous cholecystitis DOID:9765 GARD:9451 MESH:C536762 NCI:C35792 SNOMEDCT_US_2020_03_01:448286002 UMLS_CUI:C1337035 disease_ontology DOID:9766 xanthogranulomatous cholecystitis DOID:9766 MESH:D017682 UMLS_CUI:C0206146 disease_ontology DOID:9767 myocardial stunning DOID:9767 ICD10CM:I25.3 MESH:D006322 SNOMEDCT_US_2020_03_01:155317009 UMLS_CUI:C0018789 cardiac aneurysm disease_ontology DOID:9768 heart aneurysm DOID:9768 ICD10CM:I50.30 ICD9CM:428.3 MESH:D054144 SNOMEDCT_US_2020_03_01:418304008 UMLS_CUI:C1135196 disease_ontology DOID:9775 diastolic heart failure DOID:9775 An intestinal disease that is characterized by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits in the absence of any detectable organic cause. ICD10CM:K58 ICD9CM:564.1 KEGG:05321 MESH:D043183 NCI:C82343 SNOMEDCT_US_2020_03_01:155783000 UMLS_CUI:C0022104 IBD Irritable colon disease_ontology Psychogenic IBS DOID:9778 irritable bowel syndrome DOID:9778 ICD10CM:K59.9 ICD9CM:564.9 SNOMEDCT_US_2020_03_01:81120009 UMLS_CUI:C0016807 disease_ontology DOID:9779 bowel dysfunction DOID:9779 A parasitic helminthiasis infectious disease that involves parasitic infection of animals and humans by Trichinella spiralis, Trichinella nativa or Trichinella britovi. Intestinal invasion causes diarrhea, abdominal pain and vomiting. Larval migration into muscle tissues can cause periorbital and facial edema, conjunctivitis, fever, myalgias, splinter hemorrhages, rashes, and blood eosinophilia. Myocarditis, central nervous system involvement, and pneumonitis can also occur. ICD10CM:B75 ICD9CM:124 MESH:D014235 NCI:C85199 SNOMEDCT_US_2020_03_01:709018004 UMLS_CUI:C0040896 Trichinella spiralis infection disease_ontology DOID:9784 trichinosis DOID:9784 A parasitic helminthiasis infectious disease that involves zoonotic infection of humans by the larvae of Toxocara canis or Toxocara cati. The larvae invade multiple tissues like liver, heart, lungs, brain, muscle and eyes causing various symptoms including fever, anorexia, weight loss, cough, wheezing, rashes, hepatosplenomegaly, hypereosinophilia and ophthalmologic lesions. DOID:9791 GARD:7788 ICD10CM:B83.0 MESH:D007816 NCI:C34758 SNOMEDCT_US_2020_03_01:87121004 UMLS_CUI:C0023049 Infection by Toxascaris Toxocara infection visceral larva migrans disease_ontology DOID:9790 toxocariasis DOID:9790 ICD10CM:H31.2 ICD9CM:363.5 SNOMEDCT_US_2020_03_01:74469006 UMLS_CUI:C0154893 disease_ontology DOID:9794 hereditary choroidal atrophy DOID:9794 ICD10CM:H44.5 ICD9CM:360.4 SNOMEDCT_US_2020_03_01:62585004 UMLS_CUI:C0154777 disease_ontology DOID:9799 eye degenerative disease DOID:9799 ICD10CM:H31.10 ICD9CM:363.4 MESH:C535358 OMIM:215500 SNOMEDCT_US_2020_03_01:47638000 UMLS_CUI:C0344297 Choroidal degenerations disease_ontology DOID:980 OMIM mapping confirmed by DO. [SN]. choroidal sclerosis DOID:980 An autoimmune disease that is characterized by antibody attack of the basement membrane in lungs and kidneys, leading to bleeding from the lungs and kidney failure. DOID:9812 GARD:2551 ICD10CM:M31.0 ICD9CM:446.21 MESH:D019867 NCI:C84566 OMIM:233450 SNOMEDCT_US_2020_03_01:788613004 UMLS_CUI:C0403529 anti-GBM disease anti-glomerular basement membrane disease disease_ontology DOID:9808 OMIM mapping confirmed by DO. [SN]. Goodpasture syndrome DOID:9808 A hypersensitivity reaction type III disease that is characterized by inflammation and injury to blood vessels and has_symptom purpura, telangiectasia, blistering, urticaria, and ulcers. GARD:7851 ICD10CM:M31.0 ICD9CM:446.2 MESH:D018366 NCI:C35119 SNOMEDCT_US_2020_03_01:195350001 UMLS_CUI:C0151436 disease_ontology DOID:9809 hypersensitivity vasculitis DOID:9809 A vasculitis that is characterized by necrotizing inflammation of medium or small arteries. GARD:7360 ICD10CM:M30.0 ICD9CM:446.0 MESH:D010488 NCI:C26847 SNOMEDCT_US_2020_03_01:195347004 UMLS_CUI:C0031036 disease_ontology DOID:9810 polyarteritis nodosa DOID:9810 GARD:6061 ICD10CM:H31.21 ICD9CM:363.55 MESH:D015794 NCI:C34469 OMIM:303100 ORDO:180 SNOMEDCT_US_2020_03_01:75241009 UMLS_CUI:C0008525 progressive Choroidal Atrophy disease_ontology DOID:9821 OMIM mapping confirmed by DO. [SN]. choroideremia MESH:D015794 DOID:9821 ICD9CM:363.53 OMIM:613105 SNOMEDCT_US_2020_03_01:193468002 UMLS_CUI:C0339427 Choroidal dystrophy, central areolar disease_ontology DOID:9822 OMIM mapping confirmed by DO. [SN]. partial central choroid dystrophy DOID:9822 ICD10CM:Q74.0 ICD9CM:755.53 MESH:C562408 OMIM:179300 SNOMEDCT_US_2020_03_01:33313004 UMLS_CUI:C0158761 disease_ontology DOID:9827 OMIM mapping confirmed by DO. [SN]. radioulnar synostosis DOID:9827 A withdrawal disorder that is characterized by a group of problems that occur in a newborn who was exposed to addictive illegal or prescription drugs while in the mother's womb or postnatally following the discontinuance of drug treatment. DOID:6679 ICD10CM:P96.1 ICD9CM:779.5 MESH:D009357 NCI:C35808 NCI:C87101 SNOMEDCT_US_2020_03_01:414819007 UMLS_CUI:C0027609 UMLS_CUI:C1332133 Drug withdrawal syndrome in newborn disease_ontology DOID:9828 neonatal abstinence syndrome DOID:9828 ICD10CM:H52.0 ICD9CM:367.0 MESH:D006956 SNOMEDCT_US_2020_03_01:38101003 UMLS_CUI:C0020490 Far-sightedness hypermetropia disease_ontology DOID:9834 hyperopia DOID:9834 EFO:0003908 ICD10CM:H52.7 MESH:D012030 NCI:C87145 SNOMEDCT_US_2020_03_01:39021009 UMLS_CUI:C0034951 disease_ontology DOID:9835 refractive error DOID:9835 ICD10CM:H50.2 ICD9CM:378.31 MESH:D013285 NCI:C34716 SNOMEDCT_US_2020_03_01:40608009 UMLS_CUI:C0020575 disease_ontology DOID:9837 hypertropia DOID:9837 ICD10CM:H50.43 ICD9CM:378.35 SNOMEDCT_US_2020_03_01:194112008 UMLS_CUI:C0155336 disease_ontology DOID:9839 accommodative esotropia DOID:9839 A strabismus that is characterized the eye which turns inward toward the nose. GARD:8235 ICD10CM:H50.0 ICD9CM:378.0 MESH:D004948 NCI:C34596 SNOMEDCT_US_2020_03_01:155193001 UMLS_CUI:C0014877 Convergence in manifest squint Internal Strabismus crossed eyes disease_ontology DOID:9840 esotropia DOID:9840 ICD9CM:378.32 NCI:C42086 SNOMEDCT_US_2020_03_01:29491004 UMLS_CUI:C0152208 disease_ontology DOID:9841 hypotropia DOID:9841 ICD10CM:H81.399 ICD9CM:386.19 SNOMEDCT_US_2020_03_01:194359006 UMLS_CUI:C0029706 disease_ontology DOID:9847 peripheral vertigo DOID:9847 ICD10CM:H81.0 MESH:D018159 SNOMEDCT_US_2020_03_01:194346003 UMLS_CUI:C0206586 labyrinthine hydrops disease_ontology DOID:9848 endolymphatic hydrops DOID:9848 A vestibular disease characterized by vertigo, low-pitched tinnitus and hearing loss. GARD:10340 ICD10CM:H81.0 ICD9CM:386.0 MESH:D008575 OMIM:156000 SNOMEDCT_US_2020_03_01:194346003 UMLS_CUI:C0025281 Meniere disease Mnire's vertigo Otogenic vertigo disease_ontology DOID:9849 OMIM mapping confirmed by DO. [SN]. Meniere's disease DOID:9849 ICD10CM:H16.3 ICD9CM:370.5 SNOMEDCT_US_2020_03_01:193783008 UMLS_CUI:C0155087 disease_ontology DOID:9858 deep keratitis DOID:9858 An autoimmune disease resulting in the loss of hair on the scalp and elsewhere on the body initially causing bald spots. EFO:0004192 GARD:5782 ICD10CM:L63 ICD9CM:704.01 MESH:D000506 OMIM:104000 OMIM:610753 SNOMEDCT_US_2020_03_01:201131001 UMLS_CUI:C0002171 Circumscribed alopecia disease_ontology DOID:986 alopecia areata MESH:D000506 DOID:986 ICD9CM:271.3 NCI:C34731 UMLS_CUI:C0021830 disease_ontology DOID:9868 intestinal disaccharidase deficiency DOID:9868 ICD10CM:E74.12 ICD9CM:271.2 MESH:D005633 NCI:C84720 OMIM:229600 SNOMEDCT_US_2020_03_01:20290005 UMLS_CUI:C0016751 Fructosaemia Fructose-1,6-bisphosphate aldolase B deficiency Fructosemia disease_ontology DOID:9869 hereditary fructose intolerance syndrome DOID:9869 A hypotrichosis that is characterized by a loss of hair from the head or body. ICD10CM:L65.9 ICD9CM:704.0 MESH:D000505 NCI:C50575 OMIM:PS203655 SNOMEDCT_US_2020_03_01:270504008 UMLS_CUI:C0002170 disease_ontology DOID:987 alopecia MESH:D000505 DOID:987 A carbohydrate metabolic disorder that involves a defect in galactose metabolism resulting in toxic levels of galactose 1-phosphate in various tissues. GARD:2424 ICD10CM:E74.21 ICD9CM:271.1 MESH:D005693 NCI:C84723 SNOMEDCT_US_2020_03_01:38177000 UMLS_CUI:C0016952 Galactosaemia Galactose intolerance disease_ontology DOID:9870 OMIM mapping by NeuroDevNet. [LS]. galactosemia DOID:9870 A mitral valve disease where one or both of the cusps of the mitral valve bulge or collapse backward in the left atrium during systole. MESH:D008945 NCI:C50655 OMIM:157700 OMIM:607829 OMIM:610840 SNOMEDCT_US_2020_03_01:8074002 UMLS_CUI:C0026267 Barlow's syndrome floppy mitral valve disease_ontology mitral leaflet syndrome myxomatous mitral valve prolapse systolic click-murmur syndrome DOID:988 Xref MGI. OMIM mapping confirmed by DO. [SN]. mitral valve prolapse DOID:988 A muscular dystrophy that involves slowly worsening muscle weakness of the legs and pelvis, and has_material_basis in X-linked recessive inheritance of mutation in the dystrophin gene on chromosome Xp21. GARD:5900 OMIM:300376 ORDO:98895 SNOMEDCT_US_2020_03_01:111501005 UMLS_CUI:C0699741 Benign pseudohypertrophic muscular dystrophy benign congenital myopathy disease_ontology DOID:9883 OMIM mapping confirmed by DO. [SN]. Becker muscular dystrophy DOID:9883 A myopathy is characterized by progressive skeletal muscle weakness degeneration. GARD:7922 ICD10CM:G71.0 MESH:D009136 NCI:C84910 OMIM:158800 OMIM:159050 OMIM:309930 OMIM:309950 OMIM:310000 OMIM:310095 OMIM:600416 SNOMEDCT_US_2020_03_01:155095006 UMLS_CUI:C0026850 disease_ontology DOID:9884 muscular dystrophy DOID:9884 An atrioventricular block characterized by the presence of conduction system disease of any form, which is diagnosed on or before 28 days of life. GARD:6164 ICD10CM:Q24.6 ICD9CM:746.86 MESH:C535758 OMIM:234700 SNOMEDCT_US_2020_03_01:156924006 UMLS_CUI:C0149530 disease_ontology DOID:990 OMIM mapping confirmed by DO. [SN]. congenital heart block DOID:990 ICD10CM:L65.2 MESH:D000507 NCI:C82859 SNOMEDCT_US_2020_03_01:201150001 UMLS_CUI:C0002173 Alopecia mucinosa disease_ontology DOID:9905 follicular mucinosis DOID:9905 Hordeolum is a sequelae of infectious and parasitic disease consisting of an infection of the sebaceous glands at the base of the eyelashes. Styes are generally caused by a Staphylococcus aureus bacterial infection. ICD10CM:H00.01 MESH:D006726 NCI:C118722 SNOMEDCT_US_2020_03_01:74612003 UMLS_CUI:C0019917 Boil of eyelid Furuncle of eyelid Stye disease_ontology DOID:9909 hordeolum DOID:9909 disease_ontology DOID:9912 hydrocele DOID:9912 A specific developmental disorder that involves disordered motor skills where coordinated muscle movement is impaired. ICD10CM:F82 ICD9CM:315.4 MESH:D019957 NCI:C92561 SNOMEDCT_US_2020_03_01:27544004 UMLS_CUI:C0011757 disease_ontology DOID:9923 developmental coordination disorder DOID:9923 An adrenal gland disease that is characterized by failure of the adrenal gland due to bleeding into the gland. DOID:12613 GARD:9449 MESH:D014884 NCI:C85225 SNOMEDCT_US_2020_03_01:267484005 UMLS_CUI:C0043068 Meningococcal hemorrhagic adrenalitis disease_ontology DOID:9931 Waterhouse-Friderichsen syndrome DOID:9931 A lacrimal apparatus disease that is characterized by longstanding inflammation of the lacrimal passage, and has_symptom pain, increased or decreased tearing, and swelling between the eye and nose. ICD10CM:H04.4 ICD9CM:375.4 SNOMEDCT_US_2020_03_01:193990009 UMLS_CUI:C0155239 disease_ontology DOID:9935 chronic inflammation of lacrimal passage DOID:9935 ICD10CM:H04.41 ICD9CM:375.42 SNOMEDCT_US_2020_03_01:193990009 UMLS_CUI:C0149506 disease_ontology DOID:9937 chronic dacryocystitis DOID:9937 An acute inflammation of lacrimal passage that is characterized by inflammation of the lacrimal sac, has_symptom conjunctivitis and has_symptom purulent discharge. ICD10CM:H04.30 ICD9CM:375.30 MESH:D003607 NCI:C34521 SNOMEDCT_US_2020_03_01:267738004 UMLS_CUI:C0010930 disease_ontology DOID:9938 dacryocystitis DOID:9938 ICD9CM:375.43 NCI:C98968 SNOMEDCT_US_2020_03_01:42758002 UMLS_CUI:C0155241 lacrimal mucocele disease_ontology DOID:9939 dacryocystocele DOID:9939 NCI:C35346 SNOMEDCT_US_2020_03_01:76616003 UMLS_CUI:C0272394 disease_ontology DOID:9942 lymph node disease DOID:9942 A glaucoma characterized by elevated intraocular pressure secondary to chronic corticosteroid use, which leads to glaucomatous optic nerve atrophy and progressive vision loss and has_symptom progressive decreased vision, visual field defects, and decreased peripheral vision. Steroid-induced glaucoma is caused by chronic corticosteroid use. ICD9CM:365.3 SNOMEDCT_US_2020_03_01:1654001 UMLS_CUI:C0339578 Corticosteroid-induced glaucoma disease_ontology DOID:9946 steroid-induced glaucoma DOID:9946 A acute leukemia that is characterized by over production of lymphoblasts. DOID:5600 EFO:0000220 GARD:522 ICD10CM:C91.00 ICD9CM:204.0 NCI:C3167 NCI:C7055 OMIM:247640 OMIM:613065 ORDO:513 SNOMEDCT_US_2020_03_01:128822004 UMLS_CUI:C0023449 UMLS_CUI:C1335469 ALL acute lymphoblastic leukaemia acute lymphoblastic leukemia acute lymphocytic leukaemia precursor lymphoblastic lymphoma/leukemia disease_ontology DOID:9952 Xref MGI. acute lymphoblastic leukemia DOID:9952 A congenital heart disease characterized by abnormal development of the left-sided structures of the heart. GARD:6739 ICD10CM:Q23.4 ICD9CM:746.7 MESH:D018636 NCI:C98894 OMIM:241550 OMIM:614435 ORDO:2248 SNOMEDCT_US_2020_03_01:62067003 UMLS_CUI:C0152101 disease_ontology DOID:9955 Xref MGI. OMIM mapping confirmed by DO. [SN]. hypoplastic left heart syndrome DOID:9955 A uterine disease that is characterized by the presence of blood in the uterine cavity. ICD10CM:N85.7 ICD9CM:621.4 MESH:D006409 SNOMEDCT_US_2020_03_01:38280009 UMLS_CUI:C0018948 Hematometra disease_ontology DOID:9958 hemometra DOID:9958 A coccidiosis that has_material_basis_in protozoan Toxoplasma gondii. The parasite effects most genera of warm-blooded animals, including humans, but the primary host is the felid (cat) family. Animals are infected by eating infected meat, by ingestion of feces of a cat that has itself recently been infected, or transmission_by mother to fetus. The symptoms include bilateral, nontender cervical or axillary lymphadenopathy, fever, malaise, myalgia, hepatosplenomegaly, anemia and leukopenia. DOID:13334 DOID:13339 DOID:13344 ICD10CM:B58 ICD9CM:130 MESH:D014123 NCI:C3418 SNOMEDCT_US_2020_03_01:266225001 UMLS_CUI:C0040558 disseminated toxoplasmosis disease_ontology DOID:9965 toxoplasmosis DOID:9965 A uterine disease that is characterized by the uterine cavity turning inside out as a complication of childbirth. ICD10CM:N85.5 ICD9CM:665.2 MESH:D019687 SNOMEDCT_US_2020_03_01:156233003 UMLS_CUI:C0162482 disease_ontology DOID:997 uterine inversion MESH:D019687 DOID:997 An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. EFO:0001073 ICD10CM:E66.9 ICD9CM:278.00 MESH:D009765 NCI:C159658 OMIM:601665 SNOMEDCT_US_2020_03_01:5476005 UMLS_CUI:C0028754 disease_ontology DOID:9970 OMIM mapping confirmed by DO. [SN]. obesity DOID:9970 An overnutrition that is characterized by elevated vitamin D, which can subsequently cause high levels of calcium, has_symptom myalgia, fatigue, irritability, nausea, dehydration, polyuria, and nephrocalcinosis, and possibly has_material_basis_in excess intake of vitamin D. ICD10CM:E67.3 ICD9CM:278.4 SNOMEDCT_US_2020_03_01:190969000 UMLS_CUI:C1442839 disease_ontology DOID:9971 hypervitaminosis D DOID:9971 A substance-related disorder that involves the continued use of alcohol or other drugs despite problems related to use of the substance. NCI:C35458 SNOMEDCT_US_2020_03_01:255338002 UMLS_CUI:C0439857 disease_ontology DOID:9973 substance dependence DOID:9973 A substance dependence that involves the continued use of drugs despite problems related to use of the substance. ICD9CM:304.60 SNOMEDCT_US_2020_03_01:191860009 UMLS_CUI:C0029792 disease_ontology DOID:9974 drug dependence DOID:9974 A drug dependence that is a psychological dependency on the regular use of cocaine. ICD10CM:F14.2 ICD9CM:304.2 MESH:D019970 NCI:C34492 SNOMEDCT_US_2020_03_01:286934009 UMLS_CUI:C0600427 disease_ontology DOID:9975 cocaine dependence DOID:9975 An opiate dependence that involves the continued use of heroin despite problems related to use of the substance. MESH:D006556 NCI:C34694 SNOMEDCT_US_2020_03_01:191817000 UMLS_CUI:C0019337 disease_ontology DOID:9976 heroin dependence DOID:9976 A drug dependence that involves the continued use of hallucinogenic drugs despite problems related to use of the substance. ICD10CM:F16.2 ICD9CM:304.5 NCI:C34657 SNOMEDCT_US_2020_03_01:191847003 UMLS_CUI:C0018528 disease_ontology DOID:9977 hallucinogen dependence DOID:9977 GARD:6345 ICD9CM:710.5 MESH:D016603 SNOMEDCT_US_2020_03_01:95416007 UMLS_CUI:C0085179 Eosinophilia myalgia syndrome disease_ontology DOID:998 eosinophilia-myalgia syndrome DOID:998 A tertiary syphilis that results in infection located in brain or located in spinal cord. ICD10CM:A52.3 ICD9CM:094 MESH:D009494 NCI:C84935 SNOMEDCT_US_2020_03_01:154384001 UMLS_CUI:C0027927 late neurosyphilis disease_ontology DOID:9988 tertiary neurosyphilis DOID:9988 A leukocyte disease that is characterized by high numbers of eosinophils which over time enter various tissues, eventually damaging organs. GARD:2804 ICD10CM:D72.1 ICD9CM:288.3 MESH:D004802 ORDO:168956 SNOMEDCT_US_2020_03_01:418928000 UMLS_CUI:C0014457 Eosinophilic leukocytosis eosinophilia disease_ontology DOID:999 hypereosinophilic syndrome DOID:999 A glucose metabolism disease that is characterized by abnormally low levels of blood glucose. ICD10CM:E16.2 ICD9CM:251.2 MESH:D007003 NCI:C3126 SNOMEDCT_US_2020_03_01:154691006 UMLS_CUI:C0020615 Hypoglycaemia disease_ontology DOID:9993 hypoglycemia DOID:9993 ERO:0001500 Used to identify protein sequences. A chromatography technique in which the mobile phase is a liquid and is carried out either in a column or a plane for the purpose of separating mixtures. PERSON: Nicole Vasilevsky http://en.wikipedia.org/wiki/Chromatography#Liquid_chromatography liquid chromatography ERO:0002176 A mass spectrometry labeling technique in which peptides or proteins are labeled with various chemical groups that are isobaric, or the same in mass, but which fragment during tandem mass spectrometry to yield reporter ions of different mass. PERSON:Tenille Johnson http://en.wikipedia.org/wiki/Isobaric_labeling isobaric labeling GO:0000080 The cell cycle 'gap' phase which is the interval between the completion of DNA segregation by mitosis and the beginning of DNA synthesis. G1 phase of mitotic cell cycle biological_process GO:0000080 Note that this term should not be used for direct annotation. If you are trying to make an annotation to x phase, it is likely that the correct annotation is 'regulation of x/y phase transition' or to a process which occurs during the reported phase (i.e mitotic DNA replication for mitotic S-phase). To capture the phase when a specific location or process is observed, the phase term can be used in an annotation extension (PMID:24885854) applied to a cellular component term (with the relation exists_during) or a biological process term (with the relation happens_during). mitotic G1 phase GO:0000080 GO:0000084 The cell cycle phase, following G1, during which DNA synthesis takes place as part of a mitotic cell cycle. S phase of mitotic cell cycle S-phase of mitotic cell cycle biological_process GO:0000084 Note that this term should not be used for direct annotation. If you are trying to make an annotation to x phase, it is likely that the correct annotation is 'regulation of x/y phase transition' or to a process which occurs during the reported phase (i.e mitotic DNA replication for mitotic S-phase). To capture the phase when a specific location or process is observed, the phase term can be used in an annotation extension (PMID:24885854) applied to a cellular component term (with the relation exists_during) or a biological process term (with the relation happens_during). mitotic S phase GO:0000084 GO:0000085 The cell cycle 'gap' phase which is the interval between the completion of DNA synthesis and the beginning of DNA segregation by mitosis. G2 phase of mitotic cell cycle biological_process GO:0000085 Note that this term should not be used for direct annotation. If you are trying to make an annotation to x phase, it is likely that the correct annotation is 'regulation of x/y phase transition' or to a process which occurs during the reported phase (i.e mitotic DNA replication for mitotic S-phase). To capture the phase when a specific location or process is observed, the phase term can be used in an annotation extension (PMID:24885854) applied to a cellular component term (with the relation exists_during) or a biological process term (with the relation happens_during). mitotic G2 phase GO:0000085 GO:0000087 A cell cycle phase during which nuclear division occurs, and which is comprises the phases: prophase, metaphase, anaphase and telophase and occurs as part of a mitotic cell cycle. M phase of mitotic cell cycle M-phase of mitotic cell cycle biological_process GO:0000087 Note that this term should not be used for direct annotation. If you are trying to make an annotation to x phase, it is likely that the correct annotation is 'regulation of x/y phase transition' or to a process which occurs during the reported phase (i.e mitotic DNA replication for mitotic S-phase). To capture the phase when a specific location or process is observed, the phase term can be used in an annotation extension (PMID:24885854) applied to a cellular component term (with the relation exists_during) or a biological process term (with the relation happens_during). mitotic M phase GO:0000087 OBSOLETE. The directed movement of a MAP kinase to the nucleus upon activation. GO:0006606 nuclear translocation of MAPK biological_process GO:0000189 The reason for obsoletion is that all proteins are imported into the nucleus via the same mechanism, so the import of individual proteins should be captured with extensions or by GO-CAM models. obsolete MAPK import into nucleus true GO:0000189 Progression through the phases of the mitotic cell cycle, the most common eukaryotic cell cycle, which canonically comprises four successive phases called G1, S, G2, and M and includes replication of the genome and the subsequent segregation of chromosomes into daughter cells. In some variant cell cycles nuclear replication or nuclear division may not be followed by cell division, or G1 and G2 phases may be absent. GO:0007067 Wikipedia:Mitosis biological_process mitosis GO:0000278 Note that this term should not be confused with 'GO:0140014 ; mitotic nuclear division'. 'GO:0000278 ; mitotic cell cycle represents the entire mitotic cell cycle, while 'GO:0140014 ; mitotic nuclear division' specifically represents the actual nuclear division step of the mitotic cell cycle. mitotic cell cycle GO:0000278 GO:0000279 A cell cycle phase during which nuclear division occurs, and which is comprises the phases: prophase, metaphase, anaphase and telophase. Wikipedia:M_phase M-phase biological_process GO:0000279 Note that this term should not be used for direct annotation. If you are trying to make an annotation to x phase, it is likely that the correct annotation is 'regulation of x/y phase transition' or to a process which occurs during the reported phase (i.e mitotic DNA replication for mitotic S-phase). To capture the phase when a specific location or process is observed, the phase term can be used in an annotation extension (PMID:24885854) applied to a cellular component term (with the relation exists_during) or a biological process term (with the relation happens_during). M phase GO:0000279 GO:0000302 Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a reactive oxygen species stimulus. Reactive oxygen species include singlet oxygen, superoxide, and oxygen free radicals. response to AOS response to ROI response to ROS response to active oxygen species response to reactive oxidative species response to reactive oxygen intermediate biological_process GO:0000302 response to reactive oxygen species GO:0000302 GO:0000380 The process of generating multiple mRNA molecules from a given set of exons by differential use of exons from the primary transcript(s) to form multiple mature mRNAs that vary in their exon composition. splice site selection alternative nuclear mRNA splicing, via spliceosome biological_process GO:0000380 Note that this process most commonly occurs in cis, selecting or skipping exons from the same primary transcript, but it has also been observed to occur in trans at low frequency, at least in some mammals. alternative mRNA splicing, via spliceosome GO:0000380 GO:0000786 A complex comprised of DNA wound around a multisubunit core and associated proteins, which forms the primary packing unit of DNA into higher order structures. GO:0000787 GO:0000788 GO:0005718 Wikipedia:Nucleosome cytoplasmic nucleosome nuclear nucleosome cellular_component GO:0000786 nucleosome GO:0000786 GO:0001588 Combining with the neurotransmitter dopamine and activating adenylate cyclase via coupling to Gs to initiate a change in cell activity. GO:0001589 GO:0001590 dopamine D1 receptor activity dopamine D5 receptor activity molecular_function GO:0001588 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 GO:0001591 Combining with the neurotransmitter dopamine and activating adenylate cyclase via coupling to Gi/Go to initiate a change in cell activity. GO:0001592 GO:0001593 GO:0001670 dopamine D2 receptor activity dopamine D3 receptor activity dopamine D4 receptor activity molecular_function GO:0001591 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 GO:0001666 Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level. response to hypoxic stress response to lowered oxygen tension response to intermittent hypoxia response to sustained hypoxia biological_process GO:0001666 Note that this term should not be confused with 'response to anoxia ; GO:0034059'. Note that in laboratory studies, hypoxia is typically studied at O2 concentrations ranging from 0.1 - 5%. response to hypoxia GO:0001666 The appearance of a cytokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. https://github.com/geneontology/go-ontology/issues/19116 GO:0042032 GO:0042089 GO:0042107 GO:0050663 cytokine biosynthetic process cytokine metabolic process cytokine secretion interferon production interferon secretion interleukin production interleukin secretion biological_process GO:0001816 Note that this term is intended for use when a gene product is seen to cause apparent increases in intracellular or extracellular cytokine levels, without specific regard as to whether the increase is due to increased biosynthesis, increased secretion of preexisting cytokine molecules, or increased conversion from precursor molecules. cytokine production GO:0001816 OBSOLETE. The directed movement of a steroid hormone receptor into the nucleus. GO:0006606 GO:0042306 hjd 2009-07-09T02:34:42Z steroid hormone receptor nuclear translocation biological_process GO:0002146 The reason for obsoletion is that all proteins are imported into the nucleus via the same mechanism, so the import of individual proteins should be captured with extensions or by GO-CAM models. obsolete steroid hormone receptor import into nucleus true GO:0002146 OBSOLETE. The directed movement of a glucocorticoid receptor into the nucleus. GO:0042306 hjd 2009-07-09T02:36:09Z glucocorticoid receptor nuclear translocation biological_process GO:0002147 The reason for obsoletion is that all proteins are imported into the nucleus via the same mechanism, so the import of individual proteins should be captured with extensions or by GO-CAM models. obsolete glucocorticoid receptor import into nucleus true GO:0002147 GO:0002574 The process in which a relatively unspecialized myeloid precursor cell acquires the specialized features of a thrombocyte, a nucleated cell found in all vertebrates but mammals involved in hemostasis. biological_process GO:0002574 Note that platelets are the non-nucleated mammalian functional equivalent of the nucleated thrombocytes of non-mammalian vertebrates and are sometimes also referred to as thrombocytes. Platelet formation in mammals is covered by the biological_process term platelet formation ; GO:0030220. thrombocyte differentiation GO:0002574 GO:0002673 Any process that modulates the frequency, rate, or extent of an acute inflammatory response. biological_process GO:0002673 regulation of acute inflammatory response GO:0002673 GO:0003674 GO:0003824 Catalysis of a biochemical reaction at physiological temperatures. In biologically catalyzed reactions, the reactants are known as substrates, and the catalysts are naturally occurring macromolecular substances known as enzymes. Enzymes possess specific binding sites for substrates, and are usually composed wholly or largely of protein, but RNA that has catalytic activity (ribozyme) is often also regarded as enzymatic. Wikipedia:Enzyme enzyme activity molecular_function GO:0003824 catalytic activity GO:0003824 Catalysis of the reaction: GTP + H2O = GDP + phosphate. https://github.com/geneontology/go-ontology/issues/19078 dph 2015-11-11T12:47:56Z GO:0061745 hydrolase activity, acting on acid anhydrides, acting on GTP, involved in cellular and subcellular movement RHEA:19669 Reactome:R-HSA-1445143 Reactome:R-HSA-1458485 Reactome:R-HSA-156923 Reactome:R-HSA-164381 Reactome:R-HSA-165055 Reactome:R-HSA-167415 Reactome:R-HSA-170666 Reactome:R-HSA-170685 Reactome:R-HSA-170686 Reactome:R-HSA-177501 Reactome:R-HSA-203973 Reactome:R-HSA-2130641 Reactome:R-HSA-2130725 Reactome:R-HSA-2584246 Reactome:R-HSA-380979 Reactome:R-HSA-392133 Reactome:R-HSA-392212 Reactome:R-HSA-418574 Reactome:R-HSA-418582 Reactome:R-HSA-421835 Reactome:R-HSA-428941 Reactome:R-HSA-432707 Reactome:R-HSA-5333615 Reactome:R-HSA-5389839 Reactome:R-HSA-5389842 Reactome:R-HSA-5419273 Reactome:R-HSA-5419279 Reactome:R-HSA-555065 Reactome:R-HSA-5623513 Reactome:R-HSA-5638006 Reactome:R-HSA-5658231 Reactome:R-HSA-5665809 Reactome:R-HSA-5672017 Reactome:R-HSA-5694527 Reactome:R-HSA-6807877 Reactome:R-HSA-6814833 Reactome:R-HSA-8847534 Reactome:R-HSA-8847883 Reactome:R-HSA-8849082 Reactome:R-HSA-8854173 Reactome:R-HSA-8854255 Reactome:R-HSA-8854329 Reactome:R-HSA-8854604 Reactome:R-HSA-8854612 Reactome:R-HSA-8868661 Reactome:R-HSA-8981353 Reactome:R-HSA-8982020 Reactome:R-HSA-8982021 Reactome:R-HSA-8982025 Reactome:R-HSA-9640195 Reactome:R-HSA-9645598 Reactome:R-HSA-9649736 Reactome:R-HSA-983422 ARF small monomeric GTPase activity RHEB small monomeric GTPase activity Rab small monomeric GTPase activity Ran small monomeric GTPase activity Ras small monomeric GTPase activity Rho small monomeric GTPase activity Sar small monomeric GTPase activity dynamin GTPase activity heterotrimeric G-protein GTPase activity protein-synthesizing GTPase activity protein-synthesizing GTPase activity, elongation protein-synthesizing GTPase activity, initiation protein-synthesizing GTPase activity, termination signal-recognition-particle GTPase activity small monomeric GTPase activity tubulin GTPase activity molecular_function GTPase activity, coupled heterotrimeric G-protein GTPase, alpha-subunit heterotrimeric G-protein GTPase, beta-subunit heterotrimeric G-protein GTPase, gamma-subunit GO:0003924 GTPase activity GO:0003924 GO:0004872 true GO:0004939 Combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a G protein, with pharmacological characteristics of beta-adrenergic receptors; the activity involves transmitting the signal to the Gs alpha subunit of a heterotrimeric G protein. beta adrenoceptor molecular_function GO:0004939 beta-adrenergic receptor activity GO:0004939 Interacting selectively and non-covalently with one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. receptor binding Wikipedia:Ligand_(biochemistry) receptor ligand molecular_function receptor-associated protein activity GO:0005102 Where appropriate, also consider annotating to 'receptor agonist activity ; GO:0048018'. signaling receptor binding GO:0005102 GO:0005488 The selective, non-covalent, often stoichiometric, interaction of a molecule with one or more specific sites on another molecule. Wikipedia:Binding_(molecular) ligand molecular_function GO:0005488 Note that this term is in the subset of terms that should not be used for direct, manual gene product annotation. Please choose a more specific child term, or request a new one if no suitable term is available. For ligands that bind to signal transducing receptors, consider the molecular function term 'receptor binding ; GO:0005102' and its children. binding GO:0005488 GO:0005515 Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules). GO:0001948 GO:0045308 protein amino acid binding glycoprotein binding molecular_function GO:0005515 protein binding GO:0005515 GO:0005575 GO:0005634 A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. NIF_Subcellular:sao1702920020 Wikipedia:Cell_nucleus cell nucleus horsetail nucleus cellular_component GO:0005634 nucleus GO:0005634 GO:0005635 The double lipid bilayer enclosing the nucleus and separating its contents from the rest of the cytoplasm; includes the intermembrane space, a gap of width 20-40 nm (also called the perinuclear space). GO:0005636 Wikipedia:Nuclear_envelope cellular_component GO:0005635 nuclear envelope GO:0005635 GO:0005737 All of the contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. Wikipedia:Cytoplasm cellular_component GO:0005737 cytoplasm GO:0005737 GO:0005739 A semiautonomous, self replicating organelle that occurs in varying numbers, shapes, and sizes in the cytoplasm of virtually all eukaryotic cells. It is notably the site of tissue respiration. NIF_Subcellular:sao1860313010 Wikipedia:Mitochondrion mitochondria cellular_component GO:0005739 Some anaerobic or microaerophilic organisms (e.g. Entamoeba histolytica, Giardia intestinalis and several Microsporidia species) do not have mitochondria, and contain mitochondrion-related organelles (MROs) instead, called mitosomes or hydrogenosomes, very likely derived from mitochondria. To annotate gene products located in these mitochondrial relics in species such as Entamoeba histolytica, Giardia intestinalis or others, please use GO:0032047 'mitosome' or GO:0042566 'hydrogenosome'. (See PMID:24316280 for a list of species currently known to contain mitochondrion-related organelles.) mitochondrion GO:0005739 GO:0005764 A small lytic vacuole that has cell cycle-independent morphology and is found in most animal cells and that contains a variety of hydrolases, most of which have their maximal activities in the pH range 5-6. The contained enzymes display latency if properly isolated. About 40 different lysosomal hydrolases are known and lysosomes have a great variety of morphologies and functions. NIF_Subcellular:sao585356902 Wikipedia:Lysosome cellular_component GO:0005764 lysosome GO:0005764 GO:0005776 A double-membrane-bounded compartment that engulfs endogenous cellular material as well as invading microorganisms to target them to the lytic vacuole/lysosome for degradation as part of macroautophagy. NIF_Subcellular:sao8663416959 autophagic vacuole cellular_component initial autophagic vacuole GO:0005776 autophagosome GO:0005776 GO:0005783 The irregular network of unit membranes, visible only by electron microscopy, that occurs in the cytoplasm of many eukaryotic cells. The membranes form a complex meshwork of tubular channels, which are often expanded into slitlike cavities called cisternae. The ER takes two forms, rough (or granular), with ribosomes adhering to the outer surface, and smooth (with no ribosomes attached). NIF_Subcellular:sao1036339110 Wikipedia:Endoplasmic_reticulum ER cellular_component GO:0005783 endoplasmic reticulum GO:0005783 GO:0005794 A membrane-bound cytoplasmic organelle of the endomembrane system that further processes the core oligosaccharides (e.g. N-glycans) added to proteins in the endoplasmic reticulum and packages them into membrane-bound vesicles. The Golgi apparatus operates at the intersection of the secretory, lysosomal, and endocytic pathways. Golgi NIF_Subcellular:sao451912436 Wikipedia:Golgi_apparatus Golgi complex Golgi ribbon cellular_component GO:0005794 Note that the Golgi apparatus can be located in various places in the cytoplasm. In plants and lower animal cells, the Golgi apparatus exists as many copies of discrete stacks dispersed throughout the cytoplasm, while the Golgi apparatus of interphase mammalian cells is a juxtanuclear, often pericentriolar reticulum, where the discrete Golgi stacks are stitched together to form a compact and interconnected ribbon, sometimes called the Golgi ribbon. Golgi apparatus GO:0005794 GO:0005829 The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. NIF_Subcellular:sao101633890 Wikipedia:Cytosol cellular_component GO:0005829 cytosol GO:0005829 GO:0005886 The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. GO:0005904 juxtamembrane NIF_Subcellular:sao1663586795 Wikipedia:Cell_membrane cell membrane cellular membrane cytoplasmic membrane plasmalemma bacterial inner membrane inner endospore membrane plasma membrane lipid bilayer cellular_component GO:0005886 plasma membrane GO:0005886 GO:0006281 The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway. Wikipedia:DNA_repair biological_process GO:0006281 DNA repair GO:0006281 The cellular synthesis of RNA on a template of DNA. GO:0006350 GO:0061018 GO:0061022 cellular transcription transcription Wikipedia:Transcription_(genetics) DNA-dependent transcription cellular transcription, DNA-dependent transcription, DNA-dependent biological_process transcription regulator activity GO:0006351 transcription, DNA-templated GO:0006351 GO:0006355 Any process that modulates the frequency, rate or extent of cellular DNA-templated transcription. GO:0032583 GO:0045449 GO:0061019 transcriptional control regulation of cellular transcription, DNA-dependent regulation of transcription, DNA-dependent biological_process regulation of gene-specific transcription GO:0006355 regulation of transcription, DNA-templated GO:0006355 The cellular metabolic process in which a protein is formed, using the sequence of a mature mRNA or circRNA molecule to specify the sequence of amino acids in a polypeptide chain. Translation is mediated by the ribosome, and begins with the formation of a ternary complex between aminoacylated initiator methionine tRNA, GTP, and initiation factor 2, which subsequently associates with the small subunit of the ribosome and an mRNA or circRNA. Translation ends with the release of a polypeptide chain from the ribosome. GO:0006416 GO:0006453 GO:0043037 Wikipedia:Translation_(genetics) protein anabolism protein biosynthesis protein biosynthetic process protein formation protein synthesis protein translation biological_process GO:0006412 translation GO:0006412 GO:0006417 Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA or circRNA. GO:0006445 regulation of protein anabolism regulation of protein biosynthesis regulation of protein formation regulation of protein synthesis biological_process GO:0006417 regulation of translation GO:0006417 GO:0006468 The process of introducing a phosphate group on to a protein. protein amino acid phosphorylation biological_process GO:0006468 protein phosphorylation GO:0006468 The process of removing one or more phosphoric residues from a protein. protein amino acid dephosphorylation biological_process GO:0006470 protein dephosphorylation GO:0006470 The directed movement of a protein from the cytoplasm to the nucleus. establishment of protein localization to nucleus protein import into cell nucleus protein nucleus import protein transport from cytoplasm to nucleus biological_process GO:0006606 protein import into nucleus GO:0006606 The directed movement of chloride into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. biological_process GO:0006821 chloride transport GO:0006821 GO:0006914 The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation. GO:0016238 Wikipedia:Autophagy_(cellular) biological_process GO:0006914 autophagy GO:0006914 GO:0006915 A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. GO:0006917 GO:0008632 cell suicide cellular suicide Wikipedia:Apoptosis apoptotic cell death apoptotic programmed cell death programmed cell death by apoptosis activation of apoptosis apoptosis apoptosis signaling apoptotic program type I programmed cell death biological_process apoptosis activator activity caspase-dependent programmed cell death commitment to apoptosis induction of apoptosis induction of apoptosis by p53 signaling (initiator) caspase activity GO:0006915 apoptotic process GO:0006915 GO:0006950 Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in organismal or cellular homeostasis, usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation). biological_process response to abiotic stress response to biotic stress GO:0006950 Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC. response to stress GO:0006950 GO:0006954 The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. inflammation Wikipedia:Inflammation biological_process GO:0006954 inflammatory response GO:0006954 GO:0007049 The progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. Canonically, the cell cycle comprises the replication and segregation of genetic material followed by the division of the cell, but in endocycles or syncytial cells nuclear replication or nuclear division may not be followed by cell division. Wikipedia:Cell_cycle cell-division cycle biological_process GO:0007049 cell cycle GO:0007049 A regulatory process that halts progression through the cell cycle during one of the normal phases (G1, S, G2, M). arrest of cell cycle progression cessation of cell cycle termination of cell cycle biological_process GO:0007050 cell cycle arrest GO:0007050 The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal (e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light), or for signal transduction in the absence of ligand, signal-withdrawal or the activity of a constitutively active receptor. Signal transduction ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell. GO:0023033 Wikipedia:Signal_transduction signaling cascade signalling cascade biological_process signaling pathway signalling pathway GO:0007165 Note that signal transduction is defined broadly to include a ligand interacting with a receptor, downstream signaling steps and a response being triggered. A change in form of the signal in every step is not necessary. Note that in many cases the end of this process is regulation of the initiation of transcription. Note that specific transcription factors may be annotated to this term, but core/general transcription machinery such as RNA polymerase should not. signal transduction GO:0007165 GO:0007186 A series of molecular signals that proceeds with an activated receptor promoting the exchange of GDP for GTP on the alpha-subunit of an associated heterotrimeric G-protein complex. The GTP-bound activated alpha-G-protein then dissociates from the beta- and gamma-subunits to further transmit the signal within the cell. The pathway begins with receptor-ligand interaction, or for basal GPCR signaling the pathway begins with the receptor activating its G protein in the absence of an agonist, and ends with regulation of a downstream cellular process, e.g. transcription. The pathway can start from the plasma membrane, Golgi or nuclear membrane. GO:0038042 G protein coupled receptor protein signaling pathway G protein coupled receptor protein signalling pathway G-protein coupled receptor protein signal transduction G-protein coupled receptor protein signaling pathway G-protein coupled receptor signalling pathway G-protein-coupled receptor protein signalling pathway GPCR signaling pathway GPCR signalling pathway G-protein coupled receptor signaling pathway via GPCR dimer dimeric G-protein coupled receptor signaling pathway dimeric G-protein coupled receptor signalling pathway biological_process GO:0007186 G protein-coupled receptor signaling pathway GO:0007186 GO:0007259 Any process in which STAT proteins (Signal Transducers and Activators of Transcription) and JAK (Janus Activated Kinase) proteins convey a signal to trigger a change in the activity or state of a cell. The receptor signaling pathway via JAK-STAT begins with activation of a receptor and proceeeds through STAT protein activation by members of the JAK family of tyrosine kinases. STAT proteins dimerize and subsequently translocate to the nucleus. The pathway ends with regulation of target gene expression by STAT proteins. Wikipedia:JAK-STAT_signaling_pathway JAK-STAT signal transduction JAK-STAT cascade biological_process GO:0007259 receptor signaling pathway via JAK-STAT GO:0007259 The regulated release of neurotransmitter from the presynapse into the synaptic cleft via calcium-regulated exocytosis during synaptic transmission. GO:0010554 neurotransmitter release neurotransmitter secretory pathway biological_process GO:0007269 A neurotransmitter is any of a group of substances that are released on excitation from the axon terminal of a presynaptic neuron of the central or peripheral nervous system and travel across the synaptic cleft to either excite or inhibit the target cell. Among the many substances that have the properties of a neurotransmitter are acetylcholine, noradrenaline, adrenaline, dopamine, glycine, gamma-aminobutyrate, glutamic acid, substance P, enkephalins, endorphins and serotonin. neurotransmitter secretion GO:0007269 GO:0007623 Any biological process in an organism that recurs with a regularity of approximately 24 hours. GO:0050895 Wikipedia:Circadian_rhythm circadian process biological_process circadian response response to circadian rhythm GO:0007623 circadian rhythm GO:0007623 Interacting selectively and non-covalently with a drug, any naturally occurring or synthetic substance, other than a nutrient, that, when administered or applied to an organism, affects the structure or functioning of the organism; in particular, any such substance used in the diagnosis, prevention, or treatment of disease. molecular_function GO:0008144 drug binding GO:0008144 GO:0008150 GO:0008219 Any biological process that results in permanent cessation of all vital functions of a cell. A cell should be considered dead when any one of the following molecular or morphological criteria is met: (1) the cell has lost the integrity of its plasma membrane; (2) the cell, including its nucleus, has undergone complete fragmentation into discrete bodies (frequently referred to as apoptotic bodies). The cell corpse (or its fragments) may be engulfed by an adjacent cell in vivo, but engulfment of whole cells should not be considered a strict criteria to define cell death as, under some circumstances, live engulfed cells can be released from phagosomes (see PMID:18045538). biological_process accidental cell death necrosis GO:0008219 This term should not be used for direct annotation. The only exception should be when experimental data (e.g., staining with trypan blue or propidium iodide) show that cell death has occurred, but fail to provide details on death modality (accidental versus programmed). When information is provided on the cell death mechanism, annotations should be made to the appropriate descendant of 'cell death' (such as, but not limited to, GO:0097300 'programmed necrotic cell death' or GO:0006915 'apoptotic process'). Also, if experimental data suggest that a gene product influences cell death indirectly, rather than being involved in the death process directly, consider annotating to a 'regulation' term. cell death GO:0008219 GO:0008283 The multiplication or reproduction of cells, resulting in the expansion of a cell population. biological_process cell proliferation GO:0008283 This term was moved out from being a child of 'cellular process' because it is a cell population-level process, and cellular processes are restricted to those processes that involve individual cells. Also note that this term is intended to be used for the proliferation of cells within a multicellular organism, not for the expansion of a population of single-celled organisms. cell population proliferation GO:0008283 The chemical reactions and pathways resulting in the breakdown of a fatty acid, any of the aliphatic monocarboxylic acids that can be liberated by hydrolysis from naturally occurring fats and oils. Fatty acids are predominantly straight-chain acids of 4 to 24 carbon atoms, which may be saturated or unsaturated; branched fatty acids and hydroxy fatty acids also occur, and very long chain acids of over 30 carbons are found in waxes. Wikipedia:Fatty_acid_degradation fatty acid breakdown fatty acid catabolism fatty acid degradation biological_process GO:0009062 fatty acid catabolic process GO:0009062 GO:0009372 The cell-cell signaling process in which single-celled organisms carry out coordinated responses by monitoring their own population density, and often also that of other microbes, by producing small, diffusible, signal molecules, detecting the concentration of these molecules, and triggering a signal transduction pathway when a certain threshold is reached. Quorum sensing can occur amongst microbial communities in the environment or within host organisms. GO:0010699 GO:0060247 Wikipedia:Quorum_sensing quorum sensing system biological_process cell-cell signaling involved in quorum sensing detection of cell density by secreted molecule GO:0009372 quorum sensing GO:0009372 The external part of the cell wall and/or plasma membrane. GO:0009928 GO:0009929 cell associated cell bound cellular_component GO:0009986 Note that this term is intended to annotate gene products that are attached (integrated or loosely bound) to the plasma membrane or cell wall. cell surface GO:0009986 GO:0010467 The process in which a gene's sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form. Wikipedia:Gene_expression biological_process GO:0010467 gene expression GO:0010467 GO:0010468 Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form. Wikipedia:Regulation_of_gene_expression regulation of protein expression biological_process regulation of gene product expression GO:0010468 This class covers any process that regulates the rate of production of a mature gene product, and so includes processes that regulate that rate by regulating the level, stability or availability of intermediates in the process of gene expression. For example, it covers any process that regulates the level, stability or availability of mRNA or circRNA for translation and thereby regulates the rate of production of the encoded protein via translation. regulation of gene expression GO:0010468 A series of reactions, mediated by the intracellular serine/threonine kinase protein kinase A, which occurs as a result of a single trigger reaction or compound. protein kinase A signal transduction biological_process PKA signaling cascade protein kinase A signaling cascade protein kinase A signalling cascade GO:0010737 protein kinase A signaling GO:0010737 Any process that increases the rate, frequency or extent of lipid storage. Lipid storage is the accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development. positive regulation of lipid sequestration biological_process GO:0010884 positive regulation of lipid storage GO:0010884 Any process that decreases the rate, frequency or extent of lipid storage. Lipid storage is the accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development. biological_process GO:0010888 negative regulation of lipid storage GO:0010888 GO:0015893 The directed movement of a drug, a substance used in the diagnosis, treatment or prevention of a disease, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. biological_process GO:0015893 drug transport GO:0015893 GO:0016032 A multi-organism process in which a virus is a participant. The other participant is the host. Includes infection of a host cell, replication of the viral genome, and assembly of progeny virus particles. In some cases the viral genetic material may integrate into the host genome and only subsequently, under particular circumstances, 'complete' its life cycle. GO:0022415 Wikipedia:Viral_life_cycle virus process biological_process viral infection virulence GO:0016032 See also the biological process terms 'viral infectious cycle ; GO:0019058' and 'lysogeny ; GO:0030069'. viral process GO:0016032 GO:0016246 The process in which double-stranded RNAs silence cognate genes. Involves posttranscriptional gene inactivation ('silencing') both of transgenes or dsRNA introduced into a germline, and of the host gene(s) homologous to the transgenes or dsRNA. This silencing is triggered by the introduction of transgenes or double-stranded RNA (dsRNA), and can occur through a specific decrease in the level of mRNA, or by negative regulation of translation, of both host genes and transgenes. Wikipedia:RNA_interference RNAi posttranscriptional gene silencing by siRNA biological_process GO:0016246 Note that this term refers specifically to posttranscriptional mechanisms by which small interfering RNAs down-regulate gene expression. Also consider annotating to other descendants of 'gene silencing by RNA ; GO:0031047'. RNA interference GO:0016246 GO:0016301 Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule. Reactome:R-HSA-6788855 Reactome:R-HSA-6788867 phosphokinase activity molecular_function GO:0016301 Note that this term encompasses all activities that transfer a single phosphate group; although ATP is by far the most common phosphate donor, reactions using other phosphate donors are included in this term. kinase activity GO:0016301 The process of introducing a phosphate group into a molecule, usually with the formation of a phosphoric ester, a phosphoric anhydride or a phosphoric amide. Wikipedia:Phosphorylation biological_process GO:0016310 phosphorylation GO:0016310 GO:0019077 true GO:0019079 Any process involved directly in viral genome replication, including viral nucleotide metabolism. viral replication sigma virus replication biological_process GO:0019079 viral genome replication GO:0019079 Any intracellular signal transduction in which the signal is passed on within the cell via a second messenger; a small molecule or ion that can be quickly generated or released from intracellular stores, and can diffuse within the cell. Second-messenger signaling includes production or release of the second messenger, and effectors downstream of the second messenger that further transmit the signal within the cell. second messenger mediated signaling second messenger mediated signalling second messenger-mediated signaling second messenger-mediated signalling second-messenger-mediated signal transduction second-messenger-mediated signalling biological_process GO:0019932 second-messenger-mediated signaling GO:0019932 GO:0022403 One of the distinct periods or stages into which the cell cycle is divided. Each phase is characterized by the occurrence of specific biochemical and morphological events. biological_process GO:0022403 Note that this term should not be used for direct annotation. If you are trying to make an annotation to x phase, it is likely that the correct annotation is 'regulation of x/y phase transition' or to a process which occurs during the reported phase (i.e mitotic DNA replication for mitotic S-phase). To capture the phase when a specific location or process is observed, the phase term can be used in an annotation extension (PMID:24885854) applied to a cellular component term (with the relation exists_during) or a biological process term (with the relation happens_during). cell cycle phase GO:0022403 A process in which the transfer of one or more phosphate groups to a substrate transmits a signal to the phosphorylated substrate. 2010-02-16T09:30:50Z biological_process signal transduction via phosphorylation event signal transmission via phosphorylation event GO:0023014 signal transduction by protein phosphorylation GO:0023014 The entirety of a process in which information is transmitted within a biological system. This process begins with an active signal and ends when a cellular response has been triggered. jl 2010-02-16T09:30:50Z GO:0023046 GO:0044700 biological signaling signaling process signalling biological_process signalling process single organism signaling GO:0023052 Note that a signal is any variable property or parameter that serves to convey information, and may be a physical entity such as a gene product or small molecule, a photon, or a change in state such as movement or voltage change. signaling GO:0023052 A thin sheetlike process extended by the leading edge of a migrating cell or extending cell process; contains a dense meshwork of actin filaments. Wikipedia:Lamellipodia cellular_component GO:0030027 lamellipodium GO:0030027 GO:0030168 A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug. blood coagulation, platelet activation biological_process GO:0030168 platelet activation GO:0030168 GO:0030334 Any process that modulates the frequency, rate or extent of cell migration. biological_process GO:0030334 regulation of cell migration GO:0030334 The long process of a neuron that conducts nerve impulses, usually away from the cell body to the terminals and varicosities, which are sites of storage and release of neurotransmitter. NIF_Subcellular:sao1770195789 Wikipedia:Axon cellular_component GO:0030424 axon GO:0030424 The regrowth of a lost or destroyed body part, such as an organ or tissue. This process may occur via renewal, repair, and/or growth alone (i.e. increase in size or mass). Wikipedia:Regeneration_(biology) biological_process GO:0031099 regeneration GO:0031099 The regrowth of neuronal processes such as axons or dendrites in response to their loss or damage. neurite regeneration biological_process GO:0031102 neuron projection regeneration GO:0031102 GO:0031175 The process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites). neurite biosynthesis neurite development neurite formation neurite growth neurite outgrowth biological_process GO:0031175 neuron projection development GO:0031175 GO:0031690 Interacting selectively and non-covalently with an adrenergic receptor. adrenergic receptor ligand molecular_function GO:0031690 adrenergic receptor binding GO:0031690 GO:0031748 Interacting selectively and non-covalently with a D1 dopamine receptor. D1A dopamine receptor binding D1 dopamine receptor ligand molecular_function GO:0031748 D1 dopamine receptor binding GO:0031748 GO:0031752 Interacting selectively and non-covalently with a D5 dopamine receptor. D1B dopamine receptor binding D5 dopamine receptor ligand molecular_function GO:0031752 D5 dopamine receptor binding GO:0031752 A cell extension caused by localized decoupling of the cytoskeleton from the plasma membrane and characterized by rapid formation, rounded shape, and scarcity of organelles within the protrusion. Blebs are formed during apoptosis and other cellular processes, including cell locomotion, cell division, and as a result of physical or chemical stresses. Wikipedia:Bleb_(cell_biology) plasma membrane bleb cellular_component GO:0032059 bleb GO:0032059 GO:0035196 Cleavage of stem-loop RNA precursors into microRNAs (miRNAs), a class of small RNAs that primarily silence genes by blocking the translation of mRNA transcripts into protein, or by increasing the degradation of non-protein-coding RNA transcripts. GO:0030918 microRNA processing gene silencing by miRNA, production of miRNAs miRNA processing miRNA-mediated gene silencing, production of miRNAs microRNA-mediated gene silencing, production of microRNAs production of microRNAs involved in gene silencing by microRNA biological_process miRNA biogenesis microRNA biogenesis microRNA biosynthesis microRNA biosynthetic process microRNA metabolic process microRNA metabolism GO:0035196 production of miRNAs involved in gene silencing by miRNA GO:0035196 A reversible switch of a cell from one cell type or form to another, at a frequency above the expected frequency for somatic mutations. Phenotypic switching involves changes in cell morphology and altered gene expression patterns. For example, Candida albicans switches from white cells to opaque cells for sexual mating. Phenotypic switching also occurs in multicellular organisms; smooth muscle cells (SMCs) exhibit phenotypic transitions to allow rapid adaption to fluctuating environmental cues. bf 2012-03-27T01:31:28Z biological_process phenotypic dimorphism GO:0036166 Mating type switching is not considered a type of phenotypic switching: for mating type switching, consider instead annotating to 'mating type switching ; GO:0007533'. phenotypic switching GO:0036166 GO:0040029 Any process that modulates the frequency, rate or extent of gene expression; the process is mitotically or meiotically heritable, or is stably self-propagated in the cytoplasm of a resting cell, and does not entail a change in DNA sequence. biological_process GO:0040029 regulation of gene expression, epigenetic GO:0040029 GO:0042348 true Any process that modulates the establishment or extent of a membrane potential, the electric potential existing across any membrane arising from charges in the membrane itself and from the charges present in the media on either side of the membrane. biological_process GO:0042391 regulation of membrane potential GO:0042391 GO:0042493 Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a drug stimulus. A drug is a substance used in the diagnosis, treatment or prevention of a disease. GO:0017035 biological_process drug resistance drug susceptibility/resistance GO:0042493 response to drug GO:0042493 GO:0042710 A process in which planktonically growing microorganisms grow at a liquid-air interface or on a solid substrate under the flow of a liquid and produce extracellular polymers that facilitate matrix formation, resulting in a change in the organisms' growth rate and gene transcription. https://github.com/geneontology/go-ontology/issues/17727 biological_process GO:0042710 biofilm formation GO:0042710 OBSOLETE. The directed movement of a transcription factor from the cytoplasm to the nucleus. GO:0006606 transcription factor import into cell nucleus transcription factor transport from cytoplasm to nucleus transcription factor-nucleus import biological_process GO:0042991 The reason for obsoletion is that there is no distinct pathway to import transcription factors into the nucleus. obsolete transcription factor import into nucleus true GO:0042991 A prolongation or process extending from a nerve cell, e.g. an axon or dendrite. NIF_Subcellular:sao867568886 neuron process neuron protrusion neuronal cell projection neurite cellular_component nerve fiber GO:0043005 neuron projection GO:0043005 Any process that stops or reduces the activity of an enzyme. GO:0048553 down regulation of enzyme activity down-regulation of enzyme activity down-regulation of metalloenzyme activity downregulation of enzyme activity negative regulation of enzyme activity down regulation of metalloenzyme activity downregulation of metalloenzyme activity inhibition of enzyme activity inhibition of metalloenzyme activity negative regulation of metalloenzyme activity biological_process GO:0043086 negative regulation of catalytic activity GO:0043086 GO:0043484 Any process that modulates the frequency, rate or extent of RNA splicing, the process of removing sections of the primary RNA transcript to remove sequences not present in the mature form of the RNA and joining the remaining sections to form the mature form of the RNA. biological_process GO:0043484 regulation of RNA splicing GO:0043484 A series of reactions, mediated by the intracellular serine/threonine kinase protein kinase B (also called AKT), which occurs as a result of a single trigger reaction or compound. AKT signal transduction AKT signaling AKT signalling cascade PKB signal transduction PKB signaling protein kinase B signal transduction biological_process AKT signaling cascade PKB signaling cascade PKB signalling cascade protein kinase B signaling cascade protein kinase B signalling cascade GO:0043491 protein kinase B signaling GO:0043491 The portion of a cell bearing surface projections such as axons, dendrites, cilia, or flagella that includes the nucleus, but excludes all cell projections. jl 2010-02-05T10:37:16Z FBbt:00005107 FMA:67301 Wikipedia:Cell_body cell soma cellular_component GO:0044297 Note that 'cell body' and 'cell soma' are not used in the literature for cells that lack projections, nor for some cells (e.g. yeast with mating projections) that do have projections. cell body GO:0044297 Any of the smaller branches of an axon that emanate from the main axon cylinder. jl 2010-02-05T11:29:04Z NIF_Subcellular:sao1470140754 cellular_component GO:0044303 axon collateral GO:0044303 A dendrite arising from another dendrite. jl 2010-02-05T04:18:53Z NIF_Subcellular:sao884265541 dendrite branch secondary dendrite cellular_component GO:0044307 dendritic branch GO:0044307 GO:0045449 true Any process that stops, prevents, or reduces the frequency, rate or extent of establishment or extent of a membrane potential, the electric potential existing across any membrane arising from charges in the membrane itself and from the charges present in the media on either side of the membrane. down regulation of membrane potential down-regulation of membrane potential downregulation of membrane potential reduction of membrane potential inhibition of membrane potential biological_process GO:0045837 negative regulation of membrane potential GO:0045837 Any process that activates or increases the frequency, rate or extent of establishment or extent of a membrane potential, the electric potential existing across any membrane arising from charges in the membrane itself and from the charges present in the media on either side of the membrane. elevation of membrane potential up regulation of membrane potential up-regulation of membrane potential upregulation of membrane potential activation of membrane potential stimulation of membrane potential biological_process GO:0045838 positive regulation of membrane potential GO:0045838 GO:0046718 The process that occurs after viral attachment by which a virus, or viral nucleic acid, breaches the plasma membrane or cell envelope and enters the host cell. The process ends when the viral nucleic acid is released into the host cell cytoplasm. GO:0019063 VZ:936 entry of virus into host cell phage translocation viral penetration virion penetration virion penetration into host cell virus entry into host cell biological_process GO:0046718 Viral attachment to the host cell is not part of viral entry in GO because virus attachment does not always lead to viral entry: attachment can also result in the virion being carried by the host cell to another location. viral entry into host cell GO:0046718 The process whose specific outcome is the progression of a neuron over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. biological_process GO:0048666 neuron development GO:0048666 GO:0048812 The process in which the anatomical structures of a neuron projection are generated and organized. A neuron projection is any process extending from a neural cell, such as axons or dendrites. neurite biosynthesis neurite formation neurite growth biological_process neurite morphogenesis GO:0048812 neuron projection morphogenesis GO:0048812 GO:0050663 true Any process that modulates the activity of an enzyme. GO:0048552 regulation of enzyme activity regulation of metalloenzyme activity biological_process GO:0050790 regulation of catalytic activity GO:0050790 GO:0050821 Any process involved in maintaining the structure and integrity of a protein and preventing it from degradation or aggregation. positive regulation of protein stability protein stabilisation lysosomal protein stabilization biological_process protein sequestering protein stabilization activity GO:0050821 protein stabilization GO:0050821 GO:0051090 Any process that modulates the frequency, rate or extent of the activity of a transcription factor, any factor involved in the initiation or regulation of transcription. GO:1904167 GO:2000823 regulation of transcription factor activity regulation of DNA binding transcription factor activity regulation of sequence-specific DNA binding transcription factor activity regulation of androgen receptor activity regulation of thyroid hormone receptor activity biological_process GO:0051090 regulation of DNA-binding transcription factor activity GO:0051090 The cell cycle 'gap' phase which is the interval between the completion of DNA segregation (usually by mitosis or meiosis) and the beginning of DNA synthesis. Wikipedia:G1_phase biological_process GO:0051318 Note that this term should not be used for direct annotation. If you are trying to make an annotation to x phase, it is likely that the correct annotation is 'regulation of x/y phase transition' or to a process which occurs during the reported phase (i.e mitotic DNA replication for mitotic S-phase). To capture the phase when a specific location or process is observed, the phase term can be used in an annotation extension (PMID:24885854) applied to a cellular component term (with the relation exists_during) or a biological process term (with the relation happens_during). G1 phase GO:0051318 The cell cycle 'gap' phase which is the interval between the completion of DNA synthesis and the beginning of DNA segregation (usually by mitosis or meiosis). Wikipedia:G2_phase biological_process GO:0051319 Note that this term should not be used for direct annotation. If you are trying to make an annotation to x phase, it is likely that the correct annotation is 'regulation of x/y phase transition' or to a process which occurs during the reported phase (i.e mitotic DNA replication for mitotic S-phase). To capture the phase when a specific location or process is observed, the phase term can be used in an annotation extension (PMID:24885854) applied to a cellular component term (with the relation exists_during) or a biological process term (with the relation happens_during). G2 phase GO:0051319 GO:0051320 The cell cycle phase, following G1, during which DNA synthesis takes place. Wikipedia:S_phase S-phase biological_process GO:0051320 Note that this term should not be used for direct annotation. If you are trying to make an annotation to x phase, it is likely that the correct annotation is 'regulation of x/y phase transition' or to a process which occurs during the reported phase (i.e mitotic DNA replication for mitotic S-phase). To capture the phase when a specific location or process is observed, the phase term can be used in an annotation extension (PMID:24885854) applied to a cellular component term (with the relation exists_during) or a biological process term (with the relation happens_during). S phase GO:0051320 Progression through the phases of the meiotic cell cycle, in which canonically a cell replicates to produce four offspring with half the chromosomal content of the progenitor cell via two nuclear divisions. GO:0007126 Wikipedia:Meiosis biological_process meiosis GO:0051321 Note that this term should not be confused with 'GO:0140013 ; meiotic nuclear division'. 'GO:0051321 ; meiotic cell cycle represents the entire mitotic cell cycle, while 'GO:0140013 meiotic nuclear division' specifically represents the actual nuclear division step of the mitotic cell cycle. meiotic cell cycle GO:0051321 GO:0051327 A cell cycle phase during which nuclear division occurs, and which is comprises the phases: prophase, metaphase, anaphase and telophase and occurs as part of a meiotic cell cycle. M phase of meiotic cell cycle biological_process GO:0051327 Note that this term should not be used for direct annotation. If you are trying to make an annotation to x phase, it is likely that the correct annotation is 'regulation of x/y phase transition' or to a process which occurs during the reported phase (i.e mitotic DNA replication for mitotic S-phase). To capture the phase when a specific location or process is observed, the phase term can be used in an annotation extension (PMID:24885854) applied to a cellular component term (with the relation exists_during) or a biological process term (with the relation happens_during). meiotic M phase GO:0051327 GO:0051330 The cell cycle 'gap' phase which is the interval between the completion of DNA segregation by meiosis and the beginning of DNA synthesis. G1 phase of meiotic cell cycle biological_process GO:0051330 Note that this term should not be used for direct annotation. If you are trying to make an annotation to x phase, it is likely that the correct annotation is 'regulation of x/y phase transition' or to a process which occurs during the reported phase (i.e mitotic DNA replication for mitotic S-phase). To capture the phase when a specific location or process is observed, the phase term can be used in an annotation extension (PMID:24885854) applied to a cellular component term (with the relation exists_during) or a biological process term (with the relation happens_during). meiotic G1 phase GO:0051330 GO:0051331 The cell cycle 'gap' phase which is the interval between the completion of DNA synthesis and the beginning of DNA segregation by meiosis. G2 phase of meiotic cell cycle biological_process GO:0051331 Note that this term should not be used for direct annotation. If you are trying to make an annotation to x phase, it is likely that the correct annotation is 'regulation of x/y phase transition' or to a process which occurs during the reported phase (i.e mitotic DNA replication for mitotic S-phase). To capture the phase when a specific location or process is observed, the phase term can be used in an annotation extension (PMID:24885854) applied to a cellular component term (with the relation exists_during) or a biological process term (with the relation happens_during). meiotic G2 phase GO:0051331 GO:0051332 The cell cycle phase, following G1, during which DNA synthesis takes place as part of a meiotic cell cycle. S phase of meiotic cell cycle S-phase of meiotic cell cycle biological_process GO:0051332 Note that this term should not be used for direct annotation. If you are trying to make an annotation to x phase, it is likely that the correct annotation is 'regulation of x/y phase transition' or to a process which occurs during the reported phase (i.e mitotic DNA replication for mitotic S-phase). To capture the phase when a specific location or process is observed, the phase term can be used in an annotation extension (PMID:24885854) applied to a cellular component term (with the relation exists_during) or a biological process term (with the relation happens_during). meiotic S phase GO:0051332 GO:0051438 Any process that modulates the frequency, rate or extent of ubiquitin transferase activity. regulation of ubiquitin transferase activity APC regulator SCF complex regulator anaphase-promoting complex regulator biological_process ubiquitin transferase regulator ubiquitin-protein transferase regulator GO:0051438 regulation of ubiquitin-protein transferase activity GO:0051438 Catalysis of the reaction: C-terminal protein amino acid methyl ester + H2O = protein amino acid + methanol. Reactome:R-HSA-8856951 protein phosphatase methylesterase activity molecular_function GO:0051722 protein C-terminal methylesterase activity GO:0051722 Any process that modulates the establishment or extent of the mitochondrial membrane potential, the electric potential existing across the mitochondrial membrane arising from charges in the membrane itself and from the charges present in the media on either side of the membrane. biological_process GO:0051881 regulation of mitochondrial membrane potential GO:0051881 GO:0060964 Any process that modulates the rate, frequency, or extent of the downregulation of gene expression through the action of microRNAs (miRNAs), endogenous 21-24 nucleotide small RNAs processed from stem-loop RNA precursors (pre-miRNAs). Once incorporated into a RNA-induced silencing complex (RISC), miRNAs can downregulate gene expression by either of two posttranscriptional mechanisms: RNA (often mRNA) cleavage or mRNA translational repression. dph 2009-10-05T03:10:28Z regulation of gene silencing by microRNA biological_process GO:0060964 regulation of gene silencing by miRNA GO:0060964 GO:0061136 Any process that modulates the rate, frequency, or extent of the chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds that is mediated by the proteasome. dph 2010-05-17T01:33:20Z biological_process GO:0061136 regulation of proteasomal protein catabolic process GO:0061136 GO:0065009 Any process that modulates the frequency, rate or extent of a molecular function, an elemental biological activity occurring at the molecular level, such as catalysis or binding. regulation of a molecular function biological_process GO:0065009 regulation of molecular function GO:0065009 GO:0070265 A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues. necrosis cellular necrosis biological_process GO:0070265 Note that the word necrosis has been widely used in earlier literature to describe forms of cell death which are now known by more precise terms, such as apoptosis. Necrosis can occur in a regulated fashion, involving a precise sequence of signals; in this case, consider annotating to GO:0097300 'programmed necrotic cell death' or to its more specific child GO:0070266 'necroptotic process'. necrotic cell death GO:0070265 A series of reactions, mediated by the intracellular serine/threonine kinase protein kinase C, which occurs as a result of a single trigger reaction or compound. PKC signal transduction protein kinase C signal transduction biological_process PKC signaling cascade protein kinase C signaling cascade protein kinase C signalling cascade GO:0070528 protein kinase C signaling GO:0070528 The chemical reactions and pathways resulting in the breakdown of misfolded proteins transported from the endoplasmic reticulum and targeted to cytoplasmic proteasomes for degradation. mah 2010-03-10T12:53:27Z ER-associated misfolded protein breakdown ER-associated misfolded protein catabolism ER-associated misfolded protein degradation endoplasmic reticulum-associated misfolded protein catabolic process endoplasmic reticulum-associated misfolded protein catabolism proteasomal protein catabolism of misfolded ER proteins biological_process GO:0071712 See also the biological process terms 'unfolded protein response ; GO:0030968' and 'retrograde protein transport, ER to cytosol ; GO:0030970'. ER-associated misfolded protein catabolic process GO:0071712 Any cellular process that results in the specification or formation of a polarized intracellular organization or cell growth pattern that regulates the shape of a cell. mah 2011-06-22T03:10:08Z biological_process GO:0071964 establishment of cell polarity regulating cell shape GO:0071964 An arrangement of closely apposed microtubules running parallel to each other in the axon hillock and initial segment. pr 2012-11-07T15:37:12Z NIF_Subcellular:sao707332678 axon microtubule fascicle microtubule bundle of axon microtubule fascicle of axon cellular_component GO:1901589 axon microtubule bundle GO:1901589 NCBITaxon:10090 Mus musculus house mouse mouse Mus musculus NCBITaxon:10116 Rattus norvegicus Mus norvegicus Norway rat brown rat rat rats Rattus norvegicus NCBITaxon:10141 Cavia porcellus Cavia aperea porcellus Cavia cobaya Mus porcellus domestic guinea pig guinea pig Cavia porcellus NCBITaxon:10245 Vaccinia virus vaccinia virus VV Vaccinia virus NCBITaxon:102793 H5N1 subtype H5N1 H5N1 subtype NCBITaxon:10376 Human gammaherpesvirus 4 Epstein Barr virus Epstein-Barr virus Epstein-Barr virus EBV Human herpesvirus 4 Human herpesvirus type 4 Human gammaherpesvirus 4 NCBITaxon:10906 Bluetongue virus 10 Bluetongue virus (SEROTYPE 10) Bluetongue virus type 10 Bluetongue virus 10 NCBITaxon:11036 Venezuelan equine encephalitis virus Venezuelan equine encephalitis VEE Venezuelan equine encephalitis virus VEE Venezuelan equine encephalomyelitis virus Venezuelan equine encephalitis virus NCBITaxon:11082 West Nile virus West Nile virus NCBITaxon:11250 Human orthopneumovirus Human respiratory syncytial virus human RSV Human orthopneumovirus NCBITaxon:11676 Human immunodeficiency virus 1 AIDS virus Human immunodeficiency virus type 1 human immunodeficiency virus 1 HIV-1 human immunodeficiency virus HIV-1 human immunodeficiency virus type 1 HIV 1 human immunodeficiency virus type 1 HIV-1 human immunodeficiency virus type 1 HIV1 human immunodeficiency virus type 1, HIV-1 human immunodeficiency virus type I HIV-1 human immunodeficiency virus type-1 HIV-1 human immunodeficiency virus-1 HIV-1 Human immunodeficiency virus 1 NCBITaxon:1245 Leuconostoc mesenteroides Ascococcus mesenteroides Betacoccus arabinosaceus Leuconostoc mesenteroides NCBITaxon:1280 Staphylococcus aureus Micrococcus aureus Micrococcus pyogenes Staphlococcus pyogenes citreus Staphylococcus aureus subsp. anaerobius Staphylococcus pyogenes aureus Staphylococcus aureus NCBITaxon:1351 Enterococcus faecalis Enterococcus proteiformis Enterocoque Micrococcus ovalis Micrococcus zymogenes Streptococcus faecalis Streptococcus glycerinaceus Streptococcus liquefaciens Enterococcus faecalis NCBITaxon:1392 Bacillus anthracis Bacillus cereus var. anthracis Bacteridium anthracis anthrax anthrax bacterium Bacillus anthracis NCBITaxon:1422 Geobacillus stearothermophilus Bacillus stearothermophilus Bacillus thermoliquefaciens Geobacillus stearothermophilus NCBITaxon:1491 Clostridium botulinum Bacillus botulinus Bacillus putrificus Botulobacillus botulinus Clostridium putrificum Ermengemillus botulinus Pacinia putrifica Clostridium botulinum NCBITaxon:1710587 Photuris pensylvanica Pennsylania firefly Photuris pensylvanica NCBITaxon:1773 Mycobacterium tuberculosis Bacillus tuberculosis Bacterium tuberculosis Mycobacterium tuberculosis typus humanus Mycobacterium tuberculosis var. hominis Mycobacterium tuberculosis variant tuberculosis Mycobacterium tuberculosis NCBITaxon:208964 Pseudomonas aeruginosa PAO1 Pseudomonas sp. PAO1 Pseudomonas aeruginosa PAO1 NCBITaxon:210 Helicobacter pylori Campylobacter pylori Campylobacter pylori subsp. pylori Campylobacter pyloridis Helicobacter nemestrinae Helicobacter pylori NCBITaxon:3702 Arabidopsis thaliana Arabis thaliana mouse-ear cress thale cress thale-cress Arabidopsis thaliana NCBITaxon:373153 Streptococcus pneumoniae D39 Streptococcus pneumoniae str. D39 Streptococcus pneumoniae strain D39 Streptococcus pneumoniae D39 NCBITaxon:39947 Oryza sativa Japonica Group Japanese rice Japonica rice Oryza sativa (japonica cultivar-group) Oryza sativa subsp. japonica Oryza sativa Japonica Group NCBITaxon:469 Acinetobacter Acinetobacter NCBITaxon:4932 Saccharomyces cerevisiae Candida robusta Mycoderma cerevisiae S. cerevisiae Saccharomyces capensis Saccharomyces italicus Saccharomyces oviformis Saccharomyces uvarum var. melibiosus baker's yeast brewer's yeast Saccharomyces cerevisiae NCBITaxon:5207 Cryptococcus neoformans Blastomyces neoformans Debaryomyces neoformans Filobasidiella neoformans Lipomyces neoformans Saccharomyces neoformans Torula neoformans Torulopsis neoformans Cryptococcus neoformans NCBITaxon:5476 Candida albicans Candida albicans var. stellatoidea Candida stellatoidea Dematium albicans Endomyces albicans Monilia albicans Monilia stellatoidea Myceloblastanon albicans Mycotorula albicans Oidium albicans Parasaccharomyces albicans Procandida albicans Procandida stellatoidea Saccharomyces albicans Syringospora albicans Candida albicans NCBITaxon:562 Escherichia coli Bacillus coli Bacterium coli Bacterium coli commune E. coli Enterococcus coli Escherichia/Shigella coli Escherichia coli NCBITaxon:5664 Leishmania major Leishmania (Leishmania) major Leishmania tropica major Leishmania major NCBITaxon:5665 Leishmania mexicana Leishmania (Leishmania) mexicana Leishmania mexicana NCBITaxon:5691 Trypanosoma brucei Trypanosoma (Trypanozoon) brucei Trypanosoma brucei subgroup Trypanosoma brucei NCBITaxon:5693 Trypanosoma cruzi Trypanosoma cruzi NCBITaxon:573 Klebsiella pneumoniae 'Klebsiella aerogenes' (Kruse) Taylor et al. 1956 Bacillus pneumoniae Bacterium pneumoniae crouposae Hyalococcus pneumoniae Klebsiella pneumoniae aerogenes Klebsiella pneumoniae NCBITaxon:5833 Plasmodium falciparum Plasmodium (Laverania) falciparum malaria parasite P. falciparum Plasmodium falciparum NCBITaxon:6100 Aequorea victoria Mesonema victoria Aequorea victoria NCBITaxon:6183 Schistosoma mansoni Schistosoma mansoni NCBITaxon:6192 Fasciola hepatica liver fluke Fasciola hepatica NCBITaxon:6239 Caenorhabditis elegans Rhabditis elegans Caenorhabditis elegans NCBITaxon:6289 Haemonchus contortus barber pole worm red stomach worm Haemonchus contortus NCBITaxon:630 Yersinia enterocolitica Bacterium enterocoliticum Yersinia enterocolitica NCBITaxon:633 Yersinia pseudotuberculosis Bacillus pseudotuberkulosis Bacterium pseudotuberculosis Pasteurella lymphangitidis Pasteurella pseudotuberculosis Shigella pseudotuberculosis Yersinia pseudotuberculosis NCBITaxon:669 Vibrio harveyi Achromobacter harveyi Beneckea harveyi Beneckea neptuna Lucibacterium harveyi Photobacterium harveyi Pseudomonas harveyi Vibrio carchariae Vibrio trachuri Vibrio harveyi NCBITaxon:7054 Photinus pyralis North American firefly common eastern firefly Photinus pyralis NCBITaxon:7227 Drosophila melanogaster Sophophora melanogaster fruit fly Drosophila melanogaster NCBITaxon:7955 Danio rerio Brachydanio rerio Brachydanio rerio frankei Cyprinus rerio Danio frankei Danio rerio frankei leopard danio zebra danio zebra fish zebrafish Danio rerio NCBITaxon:8355 Xenopus laevis African clawed frog Bufo laevis clawed frog common platanna platanna Xenopus laevis NCBITaxon:90370 Salmonella enterica subsp. enterica serovar Typhi Bacillus typhi Bacterium (subgen. Eberthella) typhi Salmonella choleraesuis serovar Typhi Salmonella choleraesuis typhi Salmonella enterica ser. typhi Salmonella enterica serotype Typhi Salmonella enterica serovar Typhi Salmonella typhi Salmonella enterica subsp. enterica serovar Typhi NCBITaxon:90371 Salmonella enterica subsp. enterica serovar Typhimurium Bacillus typhimurium Salmonella choleraesuis serotype typhimurium Salmonella enterica 1,4,[5],12,:i:1,2 Salmonella enterica ser. typhimurium Salmonella enterica serotype Typhimurium Salmonella enterica serovar Typhimurium Salmonella enterica subsp. enterica serovar 1,4,[5],12:i:1,2 Salmonella typhi-murium Salmonella typhimurium Salmonella enterica subsp. enterica serovar Typhimurium NCBITaxon:9541 Macaca fascicularis Macaca cynomolgus Macaca irus Simia fascicularis crab eating macaque crab-eating macaque cynomolgus macaque cynomolgus monkey cynomolgus monkeys long-tailed macaque Macaca fascicularis NCBITaxon:9606 Homo sapiens human Homo sapiens NCBITaxon:9615 Canis lupus familiaris Canis canis Canis domesticus Canis familiaris dog dogs Canis lupus familiaris NCBITaxon:9796 Equus caballus Equus przewalskii f. caballus Equus przewalskii forma caballus domestic horse equine horse Equus caballus NCBITaxon:9823 Sus scrofa pig pigs swine wild boar Sus scrofa NCBITaxon:9913 Bos taurus Bos bovis Bos primigenius taurus bovine cattle cow dairy cow domestic cattle domestic cow ox oxen Bos taurus NCIT:C101294 A procedure that can determine the DNA sequence for nearly the entire genome of an individual. C101294 Molecular Biology Research Technique Whole Genome Sequencing Whole Genome Sequencing C3640076 CDISC CTDC CTRP GDC ICDC A DNA sequencing technique in which the entirety of the individual's genome is sequenced. WGS WGS WGS (whole genome sequencing) WHOLE GENOME SEQUENCING Whole Genome Sequencing Whole Genome Sequencing NCIT:C122936 A mouse model for human cancer studies in which a human-derived tumor sample is transplanted into an immunodeficient mouse. C122936 Experimental Model of Disease Patient Derived Xenograft Patient Derived Xenograft C4050317 CTRP PDTX PDX Patient Derived Xenograft Patient-Derived Xenograft Patient-Derived Xenograft Model Patient Derived Xenograft NCIT:C127803 A study of the effect of dose changes on the efficacy of a drug in order to determine the dose-response relationship and optimal dose of a therapy. C127803 Research Activity Dose Response Study CL509446 CDISC A study of the effect of dose changes on the efficacy of a drug in order to determine the dose-response relationship and optimal dose of a therapy. DOSE RESPONSE Dose Response Study Dose Response Study NCIT:C134270 The determination of the strength of a material, as measured by the ability to produce a specific response. The potency of a pharmacologic substance is measured by the amount needed to produce a certain effect. C134270 Laboratory Procedure Potency Assay CL521998 Potency Assay Potency Assay NCIT:C16681 The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs. In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains. C16681 Biomedical Occupation or Discipline Histology C0019638 DIPG/DMG FDA GDC PCDC The study of tissues and cells under a microscope. Histology Histology HISTOLOGY Histology Microanatomy histology Histology NCIT:C18639 Autoradiographic analysis performed in accordance with specified guidelines that will result in a defined correspondence between the intensity of the autoradiographic image and the amount of radioactivity present in the sample. This permits assignment of a value to the amount of radioactive material in the object under study. C18639 Research Activity Quantitative Autoradiography C1510991 Autoradiography_Quantitative Autoradiography, Quantitative Quantitative Autoradiography Quantitative Autoradiography NCIT:C18803 Models of human disease produced through gene knockout methods C18803 Experimental Model of Disease Gene Knock-Out Model C1517490 Gene_Knock-Out_Model Gene Knock-Out Model Gene Knock-Out Model NCIT:C19286 A technology used for preclinical research as an alternative to some animal testing. Micrometer-thin slices of various organs are incubated with various experimental compounds for assays involving toxicology, absorption, distribution, and metabolism. C19286 Research Activity Tissue Slice Technology C1519528 Tissue_Slice_Technology Tissue Slice Technology Tissue Slice Technology NCIT:C19425 An in vitro assay in which cultured cells are monitored and analyzed for their ability to move into an acellular area of a culture material. C19425 Laboratory Procedure Migration Assay C1513300 Migration_Assays Cell Migration Assay Migration Assay Migration Assays Migration Assay NCIT:C19812 An experimental system in which (usually) human tumor cells are transplanted into immunocompromised mice that do not reject human cells; cells may be implanted under the skin or into the organ type in which the tumor originated. These model systems may be used for drug development and studies of molecular biological mechanisms of cancer. C19812 Experimental Model of Disease Xenograft Model C1520166 Xenograft_Model Xenograft Model Xenograft Model NCIT:C20604 The strength of noncovalent chemical binding between two substances as measured by the dissociation constant of the complex. C20604 Qualitative Concept Affinity C1510827 In chemistry and biology, the strength of the attaction between two substances, such as two chemicals, or an antigen and an antibody. Affinity Affinity affinity Affinity NCIT:C20610 A constant symbolizing the ratio of a dissolved substance in a two-phase system. (from EPA Terminology Reference System) C20610 Quantitative Concept Partition Coefficient C1518903 Partition_Coefficient Partition Coefficient Partition Coefficient NCIT:C89775 The amount of time it take for a cessation of bleeding. It is a measurement of the ability of capillaries and platelets to interact to form a blood clot. C89775 Laboratory Procedure Bleeding Time C0005729 CDISC A measurement of the time from the start to cessation of an induced bleed. BLEEDT Bleeding Time Clotting Time Homeostasis Bleeding Time PATO:0000011 A time quality inhering in a bearer by virtue of how long the bearer has existed. quality PATO:0000011 age PATO:0000011 A composite chromatic quality composed of hue, saturation and intensity parts. PATO:0000020 colour relative color quality PATO:0000014 color PATO:0000014 An organismal quality inhering in a bearer by virtue of the bearer's ability to undergo sexual reproduction in order to differentiate the individuals or types involved. quality PATO:0000047 biological sex PATO:0000047 A quality inhering in a bearer by virtue of the bearer's possessing or displaying a distinctive feature in type or degree or effect or force. quality PATO:0000049 intensity PATO:0000049 A quality of a single physical entity inhering in the bearer by virtue of the bearer's size or shape or structure. quality PATO:0000051 morphology PATO:0000051 A morphological quality inhering in a bearer by virtue of the bearer's ratios of distances between its features (points, edges, surfaces and also holes etc). PATO:0001647 relational shape quality quality PATO:0000052 Shapes are invariant on size transformations. Shapes can be subdivided into 2D and 3D shapes, We can also make a distinction between shapes of complete self-connected objects, and shapes of parts of objects. shape PATO:0000052 A spatial quality inhering in a bearer by virtue of the bearer's exhibiting repetition of placement of its parts. PATO:0000132 PATO:0001565 distribution quality pattern PATO:0000060 spatial pattern PATO:0000060 quality PATO:0000068 TODO: define this or obsolete it and move children somewhere else. qualitative PATO:0000068 A morphology quality inhering in a bearer by virtue of the bearer's physical magnitude. quality PATO:0000117 size PATO:0000117 A 1-D extent quality which is equal to the distance between two points. quality PATO:0000122 length PATO:0000122 A morphology quality inhering in a bearer by virtue of the bearer's relative position, shape, arrangements and connectivity of an organism's various parts; the pattern underlying its form. PATO:0001452 conformation relational structural quality quality PATO:0000141 structure PATO:0000141 A morphologic quality inhering in a bearer by virtue of the bearer's relative size, organization and distribution of its surface elements or the representation or invention of the appearance of its surface; visual and tactile surface characteristics. quality PATO:0000150 texture PATO:0000150 A quality in which events occur in sequence. quality PATO:0000165 time PATO:0000165 quality PATO:0000325 obsolete bright true PATO:0000325 A biological sex quality inhering in an individual or a population that only produces gametes that can be fertilised by male gametes. quality PATO:0000383 female PATO:0000383 A biological sex quality inhering in an individual or a population whose sex organs contain only male gametes. quality PATO:0000384 male PATO:0000384 A branchiness quality inhering in a bearer by virtue of the bearer's having branches. ramified ramiform quality PATO:0000402 branched PATO:0000402 A shape quality inhering in a bearer by virtue of the bearer's being such that every part of the surface or the circumference is equidistant from the center. quality round rounded PATO:0000411 circular PATO:0000411 A quality denoting the lack of an entity. PATO:0001996 absence absent from organism quality PATO:0000462 See documentation here: http://code.google.com/p/phenotype-ontologies/wiki/ModelingOfAbsence absent PATO:0000462 A quality inhering in a bearer by virtue of the bearer's existence. quality present in organism PATO:0000467 present PATO:0000467 A length quality which is relatively large. long quality PATO:0000573 increased length PATO:0000573 A length quality which is relatively small. short quality shortened stubby PATO:0000574 decreased length PATO:0000574 A decreased size quality inhering in a bearer by virtue of the bearer's exhibiting reduced size of a cell or constituent group of cells (for example, organ). PATO:0000412 shrunken quality PATO:0000585 hypotrophic PATO:0000585 A width which is relatively small. quality narrow PATO:0000599 decreased width PATO:0000599 A width which is relatively large. quality broad wide wide/broad PATO:0000600 increased width PATO:0000600 A spatial pattern quality inhering in a bearer by virtue of the bearer's being confined or restricted to a particular location. focal localised quality PATO:0000627 localized PATO:0000627 A structural quality inhering in a bearer by virtue of the bearer's consisting of blebbing of the nucleus and DNA fragmentation due to the cell undergoing a specific form of programmed cell death termed apoptosis. GO:0006915 quality PATO:0000638 apoptotic PATO:0000638 A 3-D extent quality inhering in a bearer by virtue of the bearer's amount of 3-dimensional space it occupies. quality PATO:0000918 volume PATO:0000918 A 1-D extent quality which is equal to the distance from one side of an object to another side which is opposite. quality breadth PATO:0000921 width PATO:0000921 A permeability quality inhering in a bearer by virtue of the bearer's being capable to be permeated or pervaded by a gas or liquid (as by osmosis or diffusion). quality porous PATO:0000982 permeable PATO:0000982 PATO:0001018 A quality of a physical entity that exists through action of continuants at the physical level of organisation in relation to other entities. PATO:0002079 Wikipedia:Physical_property relational physical quality quality PATO:0001018 physical quality PATO:0001018 A quality inhering in a bearer by virtue of the bearer's length being notably higher than its width. quality PATO:0001154 elongated PATO:0001154 An EM radiation quality in which the EM radiation is within the fiat range of the spectrum visible deemed to be light. quality PATO:0001300 optical quality PATO:0001300 A 2-D extent quality inhering in a bearer by virtue of the bearer's two dimensional extent. quality PATO:0001323 area PATO:0001323 A length quality which is equal to the length of any straight line segment that passes through the center of a circle and whose endpoints are on the circular boundary. quality PATO:0001334 diameter PATO:0001334 PATO:0001396 A monadic quality of continuant that exists at the cellular level of organisation. quality PATO:0001396 cellular quality PATO:0001396 A structural quality inhering in a bearer by virtue of the bearer's being thicker or more closely packed together; pressed tightly together. PATO:0001840 compact compressed squashed quality dense PATO:0001485 condensed PATO:0001485 A quality of a single physical entity that arises by virtue of whether the bearer exhibits the ability to perform a regular function(s). quality PATO:0001509 functionality PATO:0001509 PATO:0001513 true An optical quality where light rays originating from a point on the object converge. quality PATO:0001516 focus PATO:0001516 An optical quality inhering in a bearer by virtue of the bearer's lacking focus. quality PATO:0001518 blurry PATO:0001518 A spatial pattern inhering in a bearer by virtue of the bearer's being spread out or scattered about or divided up. PATO:0001513 diffuse scattered quality PATO:0001566 distributed PATO:0001566 A spatial pattern inhering in a bearer by virtue of the bearer's being gathered or tending to gather into a mass or whole. clumped clustered quality PATO:0001629 aggregated PATO:0001629 A size quality inhering in an bearer by virtue of the bearer's extension in one dimension. 1-D size quality PATO:0001708 1-D extent PATO:0001708 A size quality inhering in an bearer by virtue of the bearer's extension in two dimensions. 2-D size quality PATO:0001709 2-D extent PATO:0001709 A size quality inhering in an bearer by virtue of the bearer's extension in three dimensions. 3D size quality PATO:0001710 3-D extent PATO:0001710 An intensity which is relatively high. high intensity quality PATO:0001782 increased intensity PATO:0001782 An intensity which is relatively low. low intensity quality PATO:0001783 decreased intensity PATO:0001783 A spatial pattern inhering in a bearer by virtue of the bearer's being confined or restricted to multiple locations. multi-focal quality PATO:0001791 multi-localised PATO:0001791 A structural quality inhering in a bearer by virtue of the bearer's forming a bundle of aligned anatomical fibers, as of muscle or nerve. fascicled quality PATO:0001861 fasciculated PATO:0001861 A texture quality inhering in a bearer by virtue of a local accumulation of fluid underneath the surface of the bearer. blistering quality PATO:0001928 blistered PATO:0001928 A structural quality inhering in a bearer by virtue of the bearer's in which bundles of aligned anatomical fibers have become separated. quality PATO:0001959 defasciculated PATO:0001959 PATO:0001995 A quality that inheres in an entire organism or part of an organism. quality PATO:0001995 organismal quality PATO:0001995 A shape quality inhering in a bearer by virtue of the bearer's being arranged like rays or radii; radiating from a common center. George Gkoutos 2009-07-01T01:48:19Z stellate quality PATO:0002065 star shaped PATO:0002065 PATO:0002182 A quality which inheres in a molecular entity, a single molecule, atom, ion, radical etc. George Gkoutos 2010-03-10T03:18:15Z PATO:0002061 relational molecular quality quality PATO:0002182 molecular quality PATO:0002182 A quality inhering in a protein or a molecule by virtue of the bearer's having a phosphate (PO4) group. george 2010-07-09T01:50:14Z quality PATO:0002220 phosphorylated PATO:0002220 A quality inhering in a protein or a molecule by virtue of the bearer's lacking a phosphate (PO4) group. george 2010-09-16T09:04:21Z quality PATO:0002263 dephosphorylated PATO:0002263 A quality of an physical object that is currently realizing one of its functions. gkoutos 2012-01-31T04:52:04Z quality PATO:0002354 active PATO:0002354 A quality of a physical object that is currently realizing none of its functions. gkoutos 2012-01-31T04:52:14Z quality PATO:0002355 inactive PATO:0002355 A quality inhering in a bearer by virtue of the bearer's length being notably lower than its width. gkoutos 2012-04-18T06:31:29Z quality PATO:0002364 shortened PATO:0002364 Lower, narrow portion of the uterus where it joins with the top end of the vagina. The narrow caudal end of the uterus that opens into the vagina. [TFD][VHOG] The evolution of mammals is associated with radical changes in their reproductive biology, particularly the structure and function of the female reproductive organs. These changes include the evolution of the uterus, cervix, vagina, placenta and specialized cell types associated with each of those structures.[well established][VHOG] cervical cervix BTO:0001421 BTO:0002249 CALOHA:TS-0134 EFO:0000979 EMAPA:29927 EV:0100114 FMA:17740 GAID:376 MA:0000392 MAT:0000292 MESH:D002584 NCIT:C12311 SCTID:181453009 UMLS:C0007874 VHOG:0001359 Wikipedia:Cervix galen:CervixUteri canalis cervicis uteri caudal segment of uterus cervical canal of uterus cervix uteri neck of uterus uterine cervix uberon cervical canal cervix of uterus UBERON:0000002 uterine cervix UBERON:0000002 https://cdn.humanatlas.io/digital-objects/ref-organ/uterus-female/v1.2/assets/3d-vh-f-uterus.glb Muscular duct that propels urine from the kidneys to the urinary bladder, or related organs. Anatomical structure consisting of long narrow duct which carries urine from the kidney to the urinary bladder.[AAO] The duct of amniotes that carries urine from a metanephric kidney to the urinary bladder. [Bemis_WE, Functional_Anatomy_of_the_Vertebrates:_An_Evolutionary_Perspective, Glossary_G-29, Grande_L, Liem_KF, Third_Edition_(2001)_Orlando_Fla.:_Harcourt_College_Publishers, Walker_WF][VHOG] The first embryonic hint of a metanephros is the formation of the metanephric duct that appears as a ureteric diverticulum arising at the base of preexisting mesonephric duct. The ureteric diverticulum grows dorsally into the posterior region of the nephric ridge. Here it enlarges and stimulates the growth of metanephric tubules that come to make up the metanephric kidney. The metanephros becomes the adult kidney of amniotes, and the metanephric duct is usually called the ureter.[well established][VHOG] ureteral ureteric in humans, consists of adventitial, muscular and mucoa layers AAO:0010254 BTO:0001409 CALOHA:TS-1084 EFO:0000930 EHDAA2:0002139 EHDAA:9341 EMAPA:17950 EV:0100097 FMA:9704 GAID:438 MA:0000378 MAT:0000120 MESH:D014513 MIAA:0000120 NCIT:C12416 SCTID:302511008 UMLS:C0041951 VHOG:0000605 Wikipedia:Ureter XAO:0000144 galen:Ureter uberon metanephric duct UBERON:0000056 ureter UBERON:0000056 https://upload.wikimedia.org/wikipedia/commons/3/30/Urinary_system.svg Material anatomical entity that is a single connected structure with inherent 3D shape generated by coordinated expression of the organism's own genome. AAO:0010825 AEO:0000003 BILA:0000003 CARO:0000003 EHDAA2:0003003 EMAPA:0 FBbt:00007001 FMA:305751 FMA:67135 GAID:781 HAO:0000003 MA:0003000 MESH:D000825 SCTID:362889002 TAO:0000037 TGMA:0001823 VHOG:0001759 XAO:0003000 ZFA:0000037 http://dbpedia.org/ontology/AnatomicalStructure biological structure connected biological structure uberon UBERON:0000061 anatomical structure UBERON:0000061 Anatomical structure that performs a specific function or group of functions [WP]. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions. CARO v1 does not include a generic 'organ' class, only simple and compound organ. CARO v2 may include organ, see https://github.com/obophenotype/caro/issues/4 BIRNLEX:4 CARO:0020004 EFO:0000634 EMAPA:35949 ENVO:01000162 FMA:67498 MA:0003001 NCIT:C13018 SCTID:272625005 UMLS:C0178784 WBbt:0003760 Wikipedia:Organ_(anatomy) uberon anatomical unit body organ element UBERON:0000062 organ UBERON:0000062 UBERON:0000068 A life cycle stage that starts with fertilization and ends with the fully formed embryo. BilaDO:0000002 EV:0300001 FBdv:00005289 FMA:72652 HsapDv:0000045 MmusDv:0000042 OGES:000000 OGES:000022 SCTID:296280003 WBls:0000003 WBls:0000092 WBls:0000102 XAO:1000012 oboInOwl:AcarDv_0000002 oboInOwl:BtauDv_0000002 oboInOwl:CfamDv_0000002 oboInOwl:CporDv_0000002 oboInOwl:DpseDv_0000002 oboInOwl:DsimDv_0000002 oboInOwl:EcabDv_0000002 oboInOwl:FcatDv_0000002 oboInOwl:GgalDv_0000002 oboInOwl:GgorDv_0000002 oboInOwl:MdomDv_0000002 oboInOwl:MmulDv_0000002 oboInOwl:OanaDv_0000002 oboInOwl:OariDv_0000002 oboInOwl:OcunDv_0000002 oboInOwl:PpanDv_0000002 oboInOwl:PtroDv_0000002 oboInOwl:RnorDv_0000002 oboInOwl:SsalDv_0000002 oboInOwl:SscrDv_0000002 embryonic stage uberon embryogenesis UBERON:0000068 embryo stage UBERON:0000068 UBERON:0000105 A spatiotemporal region encompassing some part of the life cycle of an organism. this class represents a proper part of the life cycle of an organism. The class 'life cycle' should not be placed here the WBls class 'all stages' belongs here as it is the superclass of other WBls stages we map the ZFS unknown stage here as it is logically equivalent to saying *some* life cycle stage BILS:0000105 EFO:0000399 FBdv:00007012 FMA:24120 HsapDv:0000000 MESH:D008018 MmusDv:0000000 PdumDv:0000090 WBls:0000002 XAO:1000000 ZFS:0000000 ZFS:0100000 ncithesaurus:Developmental_Stage oboInOwl:AcarDv_0000000 oboInOwl:BtauDv_0000000 oboInOwl:CfamDv_0000000 oboInOwl:CporDv_0000000 oboInOwl:DpseDv_0000000 oboInOwl:DsimDv_0000000 oboInOwl:EcabDv_0000000 oboInOwl:FcatDv_0000000 oboInOwl:GgalDv_0000000 oboInOwl:GgorDv_0000000 oboInOwl:MdomDv_0000000 oboInOwl:MmulDv_0000000 oboInOwl:OanaDv_0000000 oboInOwl:OariDv_0000000 oboInOwl:OcunDv_0000000 oboInOwl:PpanDv_0000000 oboInOwl:PtroDv_0000000 oboInOwl:RnorDv_0000000 oboInOwl:SsalDv_0000000 oboInOwl:SscrDv_0000000 developmental stage stage uberon UBERON:0000105 life cycle stage UBERON:0000105 UBERON:0000109 A stage defined by complex and coordinated series of cellular movements that occurs at the end of cleavage during embryonic development of most animals. The details of gastrulation vary from species to species, but usually result in the formation of the three primary germ layers, ectoderm, mesoderm and endoderm. BILS:0000109 BilaDO:0000008 EFO:0001296 FBdv:00005317 HsapDv:0000010 MmusDv:0000013 OGES:000004 OGES:000019 WBls:0000010 XAO:1000005 ZFS:0000047 oboInOwl:GgalDv_0000092 oboInOwl:OariDv_0000026 oboInOwl:RnorDv_0000005 oboInOwl:SsalDv_0000016 oboInOwl:SscrDv_0000090 uberon blastocystis trilaminaris stage trilaminar blastocyst stage trilaminar blastoderm stage trilaminar disk stage trilaminar germ stage trilaminar stage UBERON:0000109 gastrula stage UBERON:0000109 UBERON:0000113 The stage of being a sexually mature adult animal. adult stage BILS:0000113 EV:0300064 EV:0300070 HsapDv:0000258 MIAA:0000403 MmusDv:0000110 OGES:000026 OGES:000027 XAO:1000093 ZFS:0000044 oboInOwl:AcarDv_0000004 oboInOwl:BtauDv_0000004 oboInOwl:CfamDv_0000004 oboInOwl:CporDv_0000004 oboInOwl:EcabDv_0000004 oboInOwl:FcatDv_0000004 oboInOwl:GgalDv_0000006 oboInOwl:GgorDv_0000006 oboInOwl:MdomDv_0000006 oboInOwl:MmulDv_0000021 oboInOwl:OanaDv_0000004 oboInOwl:OariDv_0000006 oboInOwl:OcunDv_0000004 oboInOwl:PpanDv_0000016 oboInOwl:PtroDv_0000011 oboInOwl:RnorDv_0000015 oboInOwl:SsalDv_0000042 oboInOwl:SscrDv_0000006 uberon UBERON:0000113 post-juvenile adult stage https://github.com/obophenotype/uberon/issues/345 https://github.com/obophenotype/uberon/issues/499 UBERON:0000113 Segment of the alimentary canal extending from the stomach to the anus and, in humans and other mammals, consists of two segments, the small intestine and the large intestine. This class is probably too inclusive Portion of the alimentary canal bounded anteriorly by the pyloric sphincter and posteriorly by the cloacal sphincter.[AAO] The tract of the alimentary canal. [Dorian_AF, Elsevier's_encyclopaedic_dictionary_of_medicine, Part_B:_Anatomy_(1988)_Amsterdam_etc.:_Elsevier][VHOG] intestinal In zebrafish, No stomach, small intestine, or large intestine can be distinguished. However, differences can be found in the morphology of the mucosa columnar epithelial cells and the number of goblet cells, suggesting functional differentiation. The intestine has numerous folds that become progressively shorter in a rostral-to-caudal direction. Proportionally, these folds are significantly larger than the finger-like intestinal villi of mammals and other amniotes (Wallace et al. 2005). Columnar-shaped absorptive enterocytes are the most numerous in the zebrafish intestinal epithelium. Goblet cells are the second most populous epithelial cell type. AAO:0000246 ANISEED:1235303 BSA:0000093 BTO:0000648 CALOHA:TS-0490 EFO:0000834 EMAPA:32874 EV:0100071 FMA:7199 GAID:295 MA:0000328 MA:0001524 MESH:D007422 MIAA:0000043 NCIT:C12736 SCTID:256876008 TAO:0001338 UMLS:C0021853 VHOG:0000056 WBbt:0005772 Wikipedia:Intestine XAO:0000129 ZFA:0001338 galen:Intestine bowel uberon intestinal tract UBERON:0000160 intestine UBERON:0000160 A fluid that is composed of blood plasma and erythrocytes. This class excludes blood analogues, such as the insect analog of blood. See UBERON:0000179 haemolymphatic fluid. A complex mixture of cells suspended in a liquid matrix that delivers nutrients to cells and removes wastes. (Source: BioGlossary, www.Biology-Text.com)[TAO] Highly specialized circulating tissue consisting of several types of cells suspended in a fluid medium known as plasma.[AAO] relationship loss: subclass specialized connective tissue (AAO:0000571)[AAO] Recent findings strongly suggest that the molecular pathways involved in the development and function of blood cells are highly conserved among vertebrates and various invertebrates phyla. (...) There is now good reason to believe that, in vertebrates and invertebrates alike, blood cell lineages diverge from a common type of progenitor cell, the hemocytoblast.[well established][VHOG] AAO:0000046 BTO:0000089 CALOHA:TS-0079 EFO:0000296 EHDAA2:0000176 EHDAA:418 EMAPA:16332 ENVO:02000027 EV:0100047 FMA:9670 GAID:965 MA:0000059 MESH:D001769 MIAA:0000315 NCIT:C12434 TAO:0000007 UMLS:C0005767 VHOG:0000224 Wikipedia:Blood XAO:0000124 ZFA:0000007 galen:Blood portion of blood vertebrate blood uberon whole blood UBERON:0000178 blood UBERON:0000178 The upper ventral region of the torso of an organism. The breasts of a female primate's body contain the mammary glands, which secrete milk used to feed infants. Both men and women develop breasts from the same embryological tissues. However, at puberty female sex hormones, mainly estrogens, promote breast development, which does not happen with men. As a result women's breasts become more prominent than men's. BTO:0000149 CALOHA:TS-2083 EV:0100124 FMA:9601 GAID:33 MESH:D001940 NCIT:C12971 SCTID:181131000 UMLS:C0006141 Wikipedia:Breast galen:Breast mammary part of chest mammary region uberon mamma UBERON:0000310 breast UBERON:0000310 http://upload.wikimedia.org/wikipedia/commons/6/6e/Closeup_of_female_breast.jpg Material anatomical entity in a gaseous, liquid, semisolid or solid state; produced by anatomical structures or derived from inhaled and ingested substances that have been modified by anatomical structures as they pass through the body. AAO:0010839 AEO:0000004 BILA:0000004 CALOHA:TS-2101 CARO:0000004 EHDAA2:0003004 EMAPA:35178 FBbt:00007019 FMA:9669 HAO:0000004 MA:0002450 NCIT:C13236 SPD:0000008 TAO:0001487 TGMA:0001824 VHOG:0001726 XAO:0004001 ZFA:0001487 galen:BodySubstance body fluid or substance body substance organism substance portion of body substance portion of organism substance uberon UBERON:0000463 organism substance UBERON:0000463 Multicellular, connected anatomical structure that has multiple organs as parts and whose parts work together to achieve some shared function. system AAO:0000007 AEO:0000011 BILA:0000011 BIRNLEX:14 BSA:0000049 CALOHA:TS-2088 CARO:0000011 EHDAA2:0003011 EHDAA:392 EMAPA:16103 EV:0100000 FBbt:00004856 FMA:7149 HAO:0000011 IDOMAL:0002460 MA:0000003 NCIT:C12919 SCTID:278195005 TAO:0001439 TGMA:0001831 UMLS:C0460002 VHOG:0001725 WBbt:0005746 WBbt:0005763 Wikipedia:Organ_system XAO:0003002 ZFA:0001439 galen:AnatomicalSystem body system connected anatomical system organ system uberon anatomical systems UBERON:0000467 anatomical system UBERON:0000467 A gonad of a male animal. A gonad produces and releases sperm. Male reproductive organ.[TAO] (...) while it is likely that Urbilateria lacked a complex somatic reproductive system, it is at present impossible to speculate on whether or not it possessed a true gonad, let alone any other somatic adaptations for reproduction (reference 1); Examination of different vertebrate species shows that the adult gonad is remarkably similar in its morphology across different phylogenetic classes. Surprisingly, however, the cellular and molecular programs employed to create similar organs are not evolutionarily conserved (reference 2).[uncertain][VHOG] testicular The testes are descended in metatherian and eutherian mammals, first transabdominally, then inguinoscrotally UBERON:0002117 AAO:0000606 BILA:0000124 BSA:0000085 BTO:0001363 CALOHA:TS-1030 EFO:0000984 EHDAA2:0002007 EHDAA:8146 EMAPA:17972 EV:0100102 FBbt:00004928 FMA:7210 GAID:396 HAO:0001007 MA:0000411 MAT:0000132 MESH:D013737 MIAA:0000132 NCIT:C12412 SCTID:181431007 TAO:0000598 UMLS:C0039597 VHOG:0000252 WBbt:0006794 Wikipedia:Testis XAO:0000157 ZFA:0000598 galen:Testis gonad of male genitalia gonad of male reproductive system male gonad testicle uberon orchis testes testiculus UBERON:0000473 testis UBERON:0000473 http://upload.wikimedia.org/wikipedia/commons/c/c3/Gray1144.png Multicellular anatomical structure that consists of many cells of one or a few types, arranged in an extracellular matrix such that their long-range organisation is at least partly a repetition of their short-range organisation. changed label and definition to reflect CARO2 AAO:0000607 AAO:0010054 AEO:0000043 BILA:0000043 BIRNLEX:19 CALOHA:TS-2090 CARO:0000043 EHDAA2:0003043 EMAPA:35868 FBbt:00007003 FMA:9637 HAO:0000043 MA:0003002 MESH:D014024 NCIT:C12801 TAO:0001477 TGMA:0001844 UMLS:C0040300 VHOG:0001757 WBbt:0005729 XAO:0003040 ZFA:0001477 galen:Tissue portion of tissue tissue portion simple tissue uberon UBERON:0000479 tissue UBERON:0000479 An expanded region of the vertebrate alimentary tract that serves as a food storage compartment and digestive organ. A stomach is lined, in whole or in part by a glandular epithelium. Portion of alimentary canal with increased circular and longitudinal smooth muscle. Bounded posteriorly by the pyloric sphincter. Mucosal lining has increased folding.[AAO] It appears that the stomach has an ancient origin. The stomach first appears in the fish lineage. The prevertebrate chordates do not have a true stomach, whereas the cartilaginous and bony fish do. Although most fish do have a true stomach, some fish species appear to have lost the stomach secondarily. The remaining vertebrate lineages do have a true stomach (at least in the adult animal), although there is great variation in the size and shape of the stomach.[well established][VHOG] We restrict this to the vertebrate specific structure - see the grouping class 'food storage organ' for analogous structures in other species. Teleosts: Zebrafish is functionally stomach-less, but may retain ontogenic footprint. Although the precise shape and size of the stomach varies widely among different vertebrates, the relative positions of the oesophageal and duodenal openings remain relatively constant. As a result, the organ always curves somewhat to the left before curving back to meet the pyloric sphincter. However, lampreys, hagfishes, chimaeras, lungfishes, and some teleost fish have no stomach at all, with the oesophagus opening directly into the intestine. The gastric lining is usually divided into two regions, an anterior portion lined by fundic glands, and a posterior with pyloric glands. Cardiac glands are unique to mammals, and even then are absent in a number of species. The distributions of these glands vary between species, and do not always correspond with the same regions as in man. Furthermore, in many non-human mammals, a portion of the stomach anterior to the cardiac glands is lined with epithelium essentially identical to that of the oesophagus. Ruminants, in particular, have a complex stomach, the first three chambers of which are all lined with oesophageal mucosa AAO:0000579 ANISEED:1235297 BTO:0001307 CALOHA:TS-0980 EFO:0000837 EHDAA2:0001915 EHDAA:2993 EMAPA:17021 EV:0100070 FMA:7148 GAID:293 MA:0000353 MAT:0000051 MESH:D013270 MIAA:0000051 NCIT:C12391 SCTID:181246003 TAO:0002121 UMLS:C0038351 VHOG:0000408 Wikipedia:Stomach XAO:0000128 galen:Stomach stomach chamber uberon anterior intestine gaster mesenteron ventriculus UBERON:0000945 stomach UBERON:0000945 https://upload.wikimedia.org/wikipedia/commons/e/e0/Stomach_diagram.svg The brain is the center of the nervous system in all vertebrate, and most invertebrate, animals. Some primitive animals such as jellyfish and starfish have a decentralized nervous system without a brain, while sponges lack any nervous system at all. In vertebrates, the brain is located in the head, protected by the skull and close to the primary sensory apparatus of vision, hearing, balance, taste, and smell[WP]. requires review for applicability to invertebrate structures, e.g. synganglion Cavitated compound organ which is comprised of gray and white matter and surrounds the cerebral ventricular system.[TAO] Part of the central nervous system situated within the cranium and composed of both nerve cell bodies and nerve fibers.[AAO] The part of the central nervous system contained within the cranium, comprising the forebrain, midbrain, hindbrain, and metencephalon. It is derived from the anterior part of the embryonic neural tube (or the encephalon). Does not include retina. (CUMBO) (...) at some stage of its development, every chordate exhibits five uniquely derived characters or synapomorphies of the group: (...) (4) a single, tubular nerve cord that is located dorsal to the notochord (...) (reference 1); The neural tube is destined to differentiate into the brain and spinal cord (the central nervous system) (reference 2).[well established][VHOG] AAO:0010478 ABA:Brain BAMS:Br BAMS:Brain BILA:0000135 BIRNLEX:796 BTO:0000142 CALOHA:TS-0095 DHBA:10155 EFO:0000302 EHDAA2:0000183 EHDAA:2641 EHDAA:6485 EMAPA:16894 EV:0100164 FBbt:00005095 FMA:50801 GAID:571 HBA:4005 MA:0000168 MAT:0000098 MBA:8 MBA:997 MESH:D001921 MIAA:0000098 NCIT:C12439 PBA:3999 SCTID:258335003 TAO:0000008 UMLS:C0006104 UMLS:C1269537 VHOG:0000157 Wikipedia:Brain XAO:0000010 ZFA:0000008 galen:Brain neuronames:21 uberon encephalon suprasegmental levels of nervous system suprasegmental structures synganglion the brain UBERON:0000955 brain UBERON:0000955 https://cdn.humanatlas.io/digital-objects/ref-organ/brain-female/v1.4/assets/3d-allen-f-brain.glb https://cdn.humanatlas.io/digital-objects/ref-organ/brain-male/v1.4/assets/3d-allen-m-brain.glb The gonad of a female organism which contains germ cells. Either of paired female reproductive organs involved in production of ova and female sex hormones.[AAO] Female reproductive organ.[TAO] (...) while it is likely that Urbilateria lacked a complex somatic reproductive system, it is at present impossible to speculate on whether or not it possessed a true gonad, let alone any other somatic adaptations for reproduction (reference 1); Examination of different vertebrate species shows that the adult gonad is remarkably similar in its morphology across different phylogenetic classes. Surprisingly, however, the cellular and molecular programs employed to create similar organs are not evolutionarily conserved (reference 2).[uncertain][VHOG] ovarian Ovaries of some kind are found in the female reproductive system of many animals that employ sexual reproduction, including invertebrates. However, they develop in a very different way in most invertebrates than they do in vertebrates, and are not truly homologous. Many of the features found in human ovaries are common to all vertebrates, including the presence of follicular cells, tunica albuginea, and so on. However, many species produce a far greater number of eggs during their lifetime than do humans, so that, in fish and amphibians, there may be hundreds, or even millions of fertile eggs present in the ovary at any given time. In these species, fresh eggs may be developing from the germinal epithelium throughout life. Corpora lutea are found only in mammals, and in some elasmobranch fish; in other species, the remnants of the follicle are quickly resorbed by the ovary. In birds, reptiles, and monotremes, the egg is relatively large, filling the follicle, and distorting the shape of the ovary at maturity. Amphibians and reptiles have no ovarian medulla; the central part of the ovary is a hollow, lymph-filled space. The ovary of teleosts is also often hollow, but in this case, the eggs are shed into the cavity, which opens into the oviduct. Although most normal female vertebrates have two ovaries, this is not the case in all species. In birds and platypuses, the right ovary never matures, so that only the left is functional. In some elasmobranchs, the reverse is true, with only the right ovary fully developing. In the primitive jawless fish, and some teleosts, there is only one ovary, formed by the fusion of the paired organs in the embryo AAO:0000371 BILA:0000125 BSA:0000080 BTO:0000975 CALOHA:TS-0730 EFO:0000973 EHDAA2:0001360 EHDAA:8124 EMAPA:17962 EV:0100111 FBbt:00004865 FMA:7209 GAID:367 MA:0000384 MESH:D010053 MIAA:0000125 NCIT:C12404 SCTID:181464007 TAO:0000403 UMLS:C0029939 VHOG:0000251 Wikipedia:Ovary XAO:0000258 ZFA:0000403 animal ovary female gonad female organism genitalia gonad female organism genitalia gonada female organism reproductive system gonad female organism reproductive system gonada female reproductive system gonad female reproductive system gonada genitalia of female organism gonad genitalia of female organism gonada gonad of female organism genitalia gonad of female organism reproductive system gonad of female reproductive system gonad of genitalia of female organism gonad of reproductive system of female organism gonada of female organism genitalia gonada of female organism reproductive system gonada of female reproductive system gonada of genitalia of female organism gonada of reproductive system of female organism ovum-producing ovary reproductive system of female organism gonad reproductive system of female organism gonada uberon ovaries ovarium UBERON:0000992 ovary UBERON:0000992 http://upload.wikimedia.org/wikipedia/commons/d/d4/Gray589.png https://upload.wikimedia.org/wikipedia/commons/c/cb/Female_anatomy.png The female muscular organ of gestation in which the developing embryo or fetus is nourished until birth. The hollow muscular organ in female mammals in which the blastocyst normally becomes embedded and in which the developing embryo and fetus is nourished. Its cavity opens into the vagina below and into a uterine tube on either side. [TFD][VHOG] An infundibulum, uterine tube, uterus, and vagina also differentiate along the oviducts of eutherian mammals.[well established][VHOG] uterine Most animals that lay eggs, such as birds and reptiles, have an oviduct instead of a uterus. In monotremes, mammals which lay eggs and include the platypus, either the term uterus or oviduct is used to describe the same organ, but the egg does not develop a placenta within the mother and thus does not receive further nourishment after formation and fertilization. Marsupials have two uteruses, each of which connect to a lateral vagina and which both use a third, middle 'vagina' which functions as the birth canal. Marsupial embryos form a choriovitelline 'placenta' (which can be thought of as something between a monotreme egg and a 'true' placenta), in which the egg's yolk sac supplies a large part of the embryo's nutrition but also attaches to the uterine wall and takes nutrients from the mother's bloodstream. Two uteruses usually form initially in a female fetus, and in placental mammals they may partially or completely fuse into a single uterus depending on the species. In many species with two uteruses, only one is functional. Humans and other higher primates such as chimpanzees, along with horses, usually have a single completely fused uterus, although in some individuals the uteruses may not have completely fused [Wikipedia:Uterus] BTO:0001424 CALOHA:TS-1102 EFO:0000975 EMAPA:29915 EV:0100113 FMA:17558 GAID:172 MA:0000389 MAT:0000127 MESH:D014599 MIAA:0000127 NCIT:C12405 SCTID:181452004 UMLS:C0042149 VHOG:0001137 Wikipedia:Uterus galen:Uterus uberon UBERON:0000995 uterus UBERON:0000995 http://upload.wikimedia.org/wikipedia/commons/6/6a/Female_reproductive_system_lateral_nolabel.png https://cdn.humanatlas.io/digital-objects/ref-organ/uterus-female/v1.2/assets/3d-vh-f-uterus.glb https://upload.wikimedia.org/wikipedia/commons/c/cb/Female_anatomy.png External genital organs of the female mammal[WP]. The external genital organs of the female, including the labia majora, labia minora, clitoris, and vestibule of the vagina. [TFD][VHOG] vulval BTO:0003101 CALOHA:TS-1168 EFO:0000978 EMAPA:36631 EV:0100118 FMA:20462 GAID:383 MA:0000395 MAT:0000169 MESH:D014844 MIAA:0000169 NCIT:C12408 SCTID:265796001 UMLS:C0042993 VHOG:0001458 Wikipedia:Vulva galen:Vulva female pudendum mammalian vulva puboperineal region pudendum femininum vulva uberon pudendum pudendum femininum pudendum muliebre UBERON:0000997 mammalian vulva UBERON:0000997 http://upload.wikimedia.org/wikipedia/commons/d/da/Female_unshaved_genitalia.jpg The nervous system is an organ system containing predominantly neuron and glial cells. In bilaterally symmetrical organism, it is arranged in a network of tree-like structures connected to a central body. The main functions of the nervous system are to regulate and control body functions, and to receive sensory input, process this information, and generate behavior [CUMBO]. A regulatory system of the body that consists of neurons and neuroglial cells. The nervous system is divided into two parts, the central nervous system (CNS) and the peripheral nervous system (PNS). (Source: BioGlossary, www.Biology-Text.com)[TAO] Anatomical system consisting of nerve bodies and nerve fibers which regulate the response of the body to external and internal stimuli.[AAO] Nervous systems evolved in the ancestor of Eumetazoa.[well established][VHOG] nervous neural AAO:0000324 BILA:0000079 BIRNLEX:844 BTO:0001484 CALOHA:TS-1313 EFO:0000802 EHDAA2:0001246 EHDAA:826 EMAPA:16469 EV:0100162 FBbt:00005093 FMA:7157 GAID:466 MA:0000016 MAT:0000026 MESH:D009420 MIAA:0000026 NCIT:C12755 SCTID:278196006 TAO:0000396 UMLS:C0027763 VHOG:0000402 WBbt:0005735 Wikipedia:Nervous_system XAO:0000177 ZFA:0000396 neuronames:3236 neurological system nerve net uberon systema nervosum UBERON:0001016 nervous system UBERON:0001016 http://upload.wikimedia.org/wikipedia/commons/b/b2/TE-Nervous_system_diagram.svg http://upload.wikimedia.org/wikipedia/commons/b/ba/Nervous_system_diagram.png Tube that connects the pharynx to the stomach. In mammals, the oesophagus connects the buccal cavity with the stomach. The stratified squamous non-keratinised epithelium lining the buccal cavity is continued through the pharynx down into the oesophagus. The lowest part of the oesophagus (ca. 2 cm) is lined with gastric mucosa and covered by peritoneum. The main body of the oesophagus is lined with small, simple mucous glands. Each gland opens into the lumen by a long duct which pierces the muscularis mucosae (Wilson and Washington, 1989). A sphincter is situated at the point where the oesophagus enters the stomach to prevent gastro-oesophageal reflux, i.e. to prevent acidic gastric contents from reaching stratified epithelia of the oesophagus, where they can cause inflammation and irritation (Wilson and Washington, 1989; Brown et al., 1993). Anterior end of the alimentary canal lined with smooth muscle. Bounded anteriorly by a constriction in the pharynx. Bounded posteriorly by and increase in circular and/or longitudinal smooth muscle associated with the stomach.[AAO] The few structural specializations in (adult lampreys) pharynx include complex valves on the external gill openings that direct the tidal flow, and the division of the ancestral pharynx into an oesophagus and a respiratory pharynx.[well established][VHOG] esophageal esophagus NOT part of gut in MA. part of gut in ZFA. part_of gut (via UGIT) in FMA. Consider splitting. Interspecies: The human oesophagus is 25 cm long and has a diameter of ca. 2 cm. Only little information was found on the oesophagus in rat, rabbit and pig. The oesophagus of rat (75 x 2 mm) and rabbit has no mucous glands and the cardia of the stomach has a well-developed sphincter, which prevents them from vomiting (Hebel and Stromberg, 1988; Manning et al., 1994). Morphologically the oesophagus is similar in man and pig; both are omnivores and have a non-keratinised epithelium, submucous glands and similar membrane enzymes. Like in humans, pigs can suffer from reflux oesophagitis and stress ulceration of the oesophagus. The pig oesophagus may therefore be a good model for investigation compared to the human oesophagus (Christie et al., 1995) AAO:0000145 ANISEED:1235301 BTO:0000959 CALOHA:TS-0700 EFO:0000835 EHDAA2:0001285 EHDAA:2937 EMAPA:16833 EV:0100069 FMA:7131 GAID:291 MA:0000352 MAT:0000048 MESH:D004947 MIAA:0000048 NCIT:C12389 SCTID:181245004 TAO:0000204 UMLS:C0014876 VHOG:0000450 Wikipedia:Esophagus XAO:0000127 ZFA:0000204 galen:Esophagus gullet oesophagus uberon UBERON:0001043 esophagus UBERON:0001043 http://upload.wikimedia.org/wikipedia/commons/d/d4/Illu01_head_neck.jpg UBERON:0001062 Biological entity that is either an individual member of a biological species or constitutes the structural organization of an individual member of a biological species. AAO:0010841 AEO:0000000 BFO:0000004 BILA:0000000 BIRNLEX:6 CARO:0000000 EHDAA2:0002229 FBbt:10000000 FMA:62955 HAO:0000000 MA:0000001 NCIT:C12219 TAO:0100000 TGMA:0001822 UMLS:C1515976 WBbt:0000100 XAO:0000000 ZFA:0100000 uberon UBERON:0001062 anatomical entity UBERON:0001062 Distensible musculomembranous organ situated in the anterior part of the pelvic cavity in which urine collects before excretion[MP]. A saccular organ in which urine accumulates before discharge from the body. [Bemis_WE, Functional_Anatomy_of_the_Vertebrates:_An_Evolutionary_Perspective, Glossary_G-29, Grande_L, Liem_KF, Third_Edition_(2001)_Orlando_Fla.:_Harcourt_College_Publishers, Walker_WF][VHOG] Anatomical structure which consists of a membranous sac used to temporarily store urine until it is excreted from the body.[AAO] In tetrapods, the urinary bladder arises as an outpocketing of the cloaca. (...) The tetrapod urinary bladder appears first among amphibians and is present in Sphenodon, turtles, most lizards, ostriches among birds, and all mammals.[well established][VHOG] vesical The urinary bladder evolved in tetrapods. Birds to not possess a true urinary bladder, although Palaeognathae have an undifferentiated cloacal outpocketing that serves a similar function[https://github.com/obophenotype/uberon/issues/454] bladder AAO:0000623 BTO:0001418 CALOHA:TS-1090 EFO:0000290 EHDAA2:0000174 EHDAA:9328 EMAPA:18321 EV:0100098 FMA:15900 GAID:0000004 MA:0000380 MAT:0000122 MESH:D001743 MIAA:0000122 NCIT:C12414 SCTID:302512001 UMLS:C0005682 VHOG:0000740 Wikipedia:Urinary_bladder XAO:0000154 galen:UrinaryBladder vesica urinaria uberon urocyst vesica UBERON:0001255 urinary bladder UBERON:0001255 https://cdn.humanatlas.io/digital-objects/ref-organ/urinary-bladder-female/v1.2/assets/3d-vh-f-urinary-bladder.glb https://cdn.humanatlas.io/digital-objects/ref-organ/urinary-bladder-male/v1.2/assets/3d-vh-m-urinary-bladder.glb https://upload.wikimedia.org/wikipedia/commons/3/30/Urinary_system.svg An endoderm derived structure that produces precursors of digestive enzymes and blood glucose regulating hormones[GO]. Organ which secretes a fluid containing enzymes that aid in the digestion of food.[AAO] In the hagfish and lampreys (our most primitive vertebrate species of today), the first sign of 'a new organ' is found as collections of endocrine cells around the area of the bile duct connection with the duodenum. These endocrine organs are composed of 99% beta cells and 1% somatostatin-producing delta cells. Compared to the more primitive protochordates (e.g. amphioxus), this represents a stage where all previously scattered insulin-producing cells of the intestinal tissue have now quantitatively migrated to found a new organ involved in sensing blood glucose rather than gut glucose. Only later in evolution, the beta cells are joined by exocrine tissue and alpha cells (exemplified by the rat-, rabbit- and elephant-fishes). Finally, from sharks and onwards in evolution, we have the islet PP-cell entering to complete the pancreas.[well established][VHOG] pancreatic As a secretory organ serving exocrine and endocrine functions, the pancreas is specific to the vertebrates[PMID:16417468] Hagfishes and lampreys are unique in the complete separation of their endocrine pancreas (islet or- gan) and their exocrine pancreas (50). The endocrine and exocrine pancreas are coassociated in crown gnathostomes (50). In Branchiostoma and Ciona, there is no diverticulum as there is in hagfishes, lampreys, and gnathostomes, only dispersed insulin-secreting cells in the walls of the gastrointestinal tract (51, 52) The zebrafish does not have a discrete pancreas. Exocrine pancreatic tissue can be found scattered along the intestinal tract. The acinar structure of the exocrine pancreas is very similar to that of mammals and comprises cells with a very dark, basophilic cytoplasm The mature pancreas of higher vertebrates and mammals comprises two major functional units: the exocrine pancreas, which is responsible for the production of digestive enzymes to be secreted into the gut lumen, and the endocrine pancreas, which has its role in the synthesis of several hormones with key regulatory functions in food uptake and metabolism. The exocrine portion constitutes the majority of the mass of the pancreas, and contains only two different cell types, the secretory acinar cells and the ductular cells. The endocrine portion, which comprises only 1-2% of the total mass, contains five different cell types, which are organized into mixed functional assemblies referred to as the islets of Langerhans AAO:0010112 BTO:0000988 CALOHA:TS-0736 EFO:0000855 EHDAA2:0001367 EHDAA:6893 EMAPA:17503 EV:0100092 FMA:7198 GAID:334 MA:0000120 MAT:0000075 MESH:D010179 MIAA:0000075 NCIT:C12393 SCTID:181277001 TAO:0000140 UMLS:C0030274 VHOG:0000050 Wikipedia:Pancreas XAO:0000136 ZFA:0000140 galen:Pancreas uberon UBERON:0001264 pancreas UBERON:0001264 https://cdn.humanatlas.io/digital-objects/ref-organ/pancreas-female/v1.3/assets/3d-vh-f-pancreas.glb https://cdn.humanatlas.io/digital-objects/ref-organ/pancreas-male/v1.3/assets/3d-vh-m-pancreas.glb https://upload.wikimedia.org/wikipedia/commons/7/7e/Blausen_0699_PancreasAnatomy2.png Anatomical system that is a multi-element, multi-tissue anatomical cluster that consists of the skeleton and the articular system. Anatomical system consisting of multiple elements and tissues that provides physical support.[TAO] Anatomical system that is a multi-element, multi-tissue anatomical cluster that consists of the skeleton and the articular system.[VSAO] System that provides physical support to the organism.[AAO] By taking a holistic approach, integration of the evidence from molecular and developmental features of model organisms, the phylogenetic distribution in the 'new animal phylogeny' and the earliest fossilized remains of mineralized animal skeletons suggests independent origins of the skeleton at the phylum level.[debated][VHOG] skeletal GO defines skeletal system very generically: The skeleton is the bony framework of the body in vertebrates (endoskeleton) or the hard outer envelope of insects (exoskeleton or dermoskeleton) GO:0001501; however, all annotations are to vertebrates AAO:0000566 BTO:0001486 CALOHA:TS-1320 EFO:0000806 EHDAA2:0003168 EMAPA:35773 FMA:23881 MA:0000018 NCIT:C12788 TAO:0000434 UMLS:C0037253 VHOG:0001254 VSAO:0000027 XAO:0003060 ZFA:0000434 skeleton system set of all bones and joints uberon Skelettsystem UBERON:0001434 skeletal system https://github.com/obophenotype/uberon/wiki/The-skeletal-system UBERON:0001434 Skeletal element that is composed of bone tissue. Also called osseous tissue, (Latin: os). Is a type of hard endoskeletal connective tissue found in many vertebrate animals. Bone is the main tissue of body organs that support body structures, protect internal organs, (in conjunction with muscles) facilitate movement; and are involved with cell formation, calcium metabolism, and mineral storage.[AAO] Portion of tissue which is calcified connective tissue making up the structural elements of the skeletal system.[TAO] Skeletal element that is composed of bone tissue.[VSAO] relationship loss: subclass specialized connective tissue (AAO:0000571)[AAO] The 'new animal phylogeny' reveals that many of the groups known to biomineralize sit among close relatives that do not, and it favours an interpretation of convergent or parallel evolution for biomineralization in animals. (...) Whether this 'biomineralization toolkit'of genes reflects a parallel co-option of a common suite of genes or the inheritance of a skeletogenic gene regulatory network from a biomineralizing common ancestor remains an open debate.[debated][VHOG] AAO:0000047 AEO:0000082 BTO:0000140 CALOHA:TS-0088 EFO:0000298 EHDAA2:0003082 EMAPA:32782 ENVO:00002039 EV:0100140 FMA:30317 FMA:5018 GAID:92 MA:0001459 MAT:0000299 MIAA:0000299 NCIT:C12366 SCTID:90780006 TAO:0001514 UMLS:C0262950 VHOG:0001190 VSAO:0000057 Wikipedia:Bone XAO:0000169 ZFA:0001514 galen:Bone bone organ uberon bone bones UBERON:0001474 bone element UBERON:0001474 The liquid component of blood, in which erythrocytes are suspended. plasma portion of plasma BTO:0000131 CALOHA:TS-0800 EFO:0001905 EMAPA:35690 FMA:62970 GAID:1178 MA:0002501 MAT:0000052 MESH:D010949 MIAA:0000052 NCIT:C13356 UMLS:C0032105 Wikipedia:Blood_plasma blood plasm portion of blood plasma uberon UBERON:0001969 blood plasma UBERON:0001969 The portion of blood plasma that excludes clotting factors. BTO:0000133 BTO:0001239 CALOHA:TS-0923 EHDAA2:0004728 EMAPA:35770 FMA:63083 MA:0002502 MESH:D044967 NCIT:C13325 UMLS:C0229671 Wikipedia:Serum_(blood) serum uberon UBERON:0001977 blood serum UBERON:0001977 A two-lobed endocrine gland found in all vertebrates, located in front of and on either side of the trachea in humans, and producing various hormones, such as triiodothyronine and calcitonin[BTO]. Either of paired structures located in the throat which develop from the ventral wall of the pharynx and excretes hormones involved in the morphological and functional changes during metamorphosis as well as influencing other tissues.[AAO] (...) at some stage of its development, every chordate exhibits five uniquely derived characters or synapomorphies of the group: (...) (2) a groove in the pharyngeal floor known as the endostyle, or a thyroid gland derived from part of the endostyle (...).[well established][VHOG] In fish, it is usually located below the gills and is not always divided into distinct lobes. However, in some teleosts, patches of thyroid tissue are found elsewhere in the body, associated with the kidneys, spleen, heart, or eyes In larval lampreys, the thyroid originates as an exocrine gland, secreting its hormones into the gut, and associated with the larva's filter-feeding apparatus. In the adult lamprey, the gland separates from the gut, and becomes endocrine, but this path of development may reflect the evolutionary origin of the thyroid. For instance, the closest living relatives of vertebrates, the tunicates and Amphioxus, have a structure very similar to that of larval lampreys, and this also secretes iodine-containing compounds (albeit not thyroxine) In tetrapods, the thyroid is always found somewhere in the neck region. In most tetrapod species, there are two paired thyroid glands - that is, the right and left lobes are not joined together. However, there is only ever a single thyroid gland in most mammals, and the shape found in humans is common to many other species AAO:0010544 BTO:0001379 CALOHA:TS-1047 EFO:0000861 EHDAA2:0002028 EHDAA:2148 EHDAA:2975 EMAPA:17068 EV:0100133 FMA:9603 GAID:465 MA:0000129 MAT:0000081 MESH:D013961 MIAA:0000081 NCIT:C12400 SCTID:181117000 UMLS:C0040132 VHOG:0000418 Wikipedia:Thyroid XAO:0000162 galen:ThyroidGland thyroid uberon glandula thyroidea UBERON:0002046 thyroid gland UBERON:0002046 http://upload.wikimedia.org/wikipedia/commons/a/a3/Illu_thyroid_parathyroid.jpg http://upload.wikimedia.org/wikipedia/commons/c/c6/Illu_endocrine_system.jpg Respiration organ that develops as an outpocketing of the esophagus. Either of two organs which allow gas exchange absorbing oxygen from inhaled air and releasing carbon dioxide with exhaled air.[AAO] Lungs had already developed as paired ventral pockets from the intestine in the ancestor of Osteognathostomata. (...) In actinopterygian fishes, apart from Cladistia, the ventral intestinal pocket migrates dorsally and becomes the swim-bladder, a mainly hydrostatical organ (reference 1); Comparative transcriptome analyses indicate molecular homology of zebrafish swimbladder and Mammalian lung (reference 2).[well established][VHOG] pulmonary respiration organ in all air-breathing animals, including most tetrapods, a few fish and a few snails. In mammals and the more complex life forms, the two lungs are located in the chest on either side of the heart. Their principal function is to transport oxygen from the atmosphere into the bloodstream, and to release carbon dioxide from the bloodstream into the atmosphere. This exchange of gases is accomplished in the mosaic of specialized cells that form millions of tiny, exceptionally thin-walled air sacs called alveoli. // Avian lungs do not have alveoli as mammalian lungs do, they have Faveolar lungs. They contain millions of tiny passages known as para-bronchi, connected at both ends by the dorsobronchi AAO:0000275 AAO:0010567 BTO:0000763 CALOHA:TS-0568 EFO:0000934 EHDAA2:0001042 EHDAA:1554 EHDAA:2205 EMAPA:16728 EV:0100042 FMA:7195 GAID:345 MA:0000415 MAT:0000135 MESH:D008168 MIAA:0000135 NCIT:C12468 SCTID:181216001 UMLS:C0024109 Wikipedia:Lung XAO:0000119 galen:Lung pulmo uberon UBERON:0002048 Snakes and limbless lizards typically possess only the right lung as a major respiratory organ; the left lung is greatly reduced, or even absent. Amphisbaenians, however, have the opposite arrangement, with a major left lung, and a reduced or absent right lung [WP] lung https://github.com/obophenotype/uberon/issues/701 UBERON:0002048 https://cdn.humanatlas.io/digital-objects/ref-organ/lung-female/v1.4/assets/3d-vh-f-lung.glb https://cdn.humanatlas.io/digital-objects/ref-organ/lung-male/v1.4/assets/3d-vh-m-lung.glb The organ covering the body that consists of the dermis and epidermis. consider 'integumentary system' for invertebrates MA uses the term skin to refer to what is called here: zone of skin BTO:0001253 CALOHA:TS-0934 EFO:0000962 EHDAA2:0001844 EMAPA:17525 FMA:7163 MESH:D012867 MFMO:0000099 NCIT:C12470 SCTID:181469002 UMLS:C1123023 Wikipedia:Skin XAO:0000023 galen:Skin entire skin skin organ uberon entire integument integument integumental organ pelt skin UBERON:0002097 skin of body UBERON:0002097 http://upload.wikimedia.org/wikipedia/commons/6/6d/Skin.svg https://cdn.humanatlas.io/digital-objects/ref-organ/skin-female/v1.4/assets/3d-vh-f-skin.glb https://cdn.humanatlas.io/digital-objects/ref-organ/skin-male/v1.3/assets/3d-vh-m-skin.glb An exocrine gland which secretes bile and functions in metabolism of protein and carbohydrate and fat, synthesizes substances involved in the clotting of the blood, synthesizes vitamin A, detoxifies poisonous substances, stores glycogen, and breaks down worn-out erythrocytes[GO]. Organ which secretes bile and participates in formation of certain blood proteins.[AAO] relationship type change: differentiates_from endoderm (AAO:0000139) CHANGED TO: develops_from endoderm (UBERON:0000925)[AAO] All vertebrates possess a liver (reference 1); Later in craniate evolution, an anterior gill arch was transformed into jaws, and many new types of feeding subsequently evolved.(...) A liver evolved that, among its many functions, stores considerable energy as glycogen or lipid (reference 2).[well established][VHOG] hepatic An organ sometimes referred to as a liver is found associated with the digestive tract of the primitive chordate Amphioxus. However, this is an enzyme secreting gland, not a metabolic organ, and it is unclear how truly homologous it is to the vertebrate liver. The zebrafish liver differs from the mammalian liver in that the hepatocytes are not clearly organized in cords or lobules and the typical portal triads are not apparent. In addition, the zebrafish liver does not have Kuppfer cells. Furthermore, a clear distinction can be made between the male and female liver in the adult zebrafish. The female hepatocytes are very basophilic (Figure 15c) as a result of the production of vitellogenin (Van der Ven et al. 2003). The liver is found in all vertebrates, and is typically the largest visceral organ. Its form varies considerably in different species, and is largely determined by the shape and arrangement of the surrounding organs. Nonetheless, in most species it is divided into right and left lobes; exceptions to this general rule include snakes, where the shape of the body necessitates a simple cigar-like form. The internal structure of the liver is broadly similar in all vertebrates. secretes bile and functions in metabolism of protein and carbohydrate and fat, synthesizes substances involved in the clotting of the blood, synthesizes vitamin A, detoxifies poisonous substances, stores glycogen, and breaks down worn-out erythrocytes[GO]. Only ZFA considers this part_of immune system - we weaken this to an overlaps relation, as in general it's only a subset of cells that have clear immune function. AAO:0010111 BTO:0000759 CALOHA:TS-0564 EFO:0000887 EHDAA2:0000997 EHDAA:2197 EMAPA:16846 EV:0100089 FMA:7197 GAID:288 MA:0000358 MAT:0000097 MESH:D008099 MIAA:0000097 NCIT:C12392 SCTID:181268008 TAO:0000123 UMLS:C0023884 VHOG:0000257 Wikipedia:Liver XAO:0000133 ZFA:0000123 galen:Liver uberon iecur jecur UBERON:0002107 liver UBERON:0002107 https://cdn.humanatlas.io/digital-objects/ref-organ/liver-female/v1.2/assets/3d-vh-f-liver.glb https://cdn.humanatlas.io/digital-objects/ref-organ/liver-male/v1.2/assets/3d-vh-m-liver.glb https://upload.wikimedia.org/wikipedia/commons/6/64/Leber_Schaf.jpg An organ that aids digestion and stores bile produced by the liver[WP]. Membranous muscular sac in which the bile from the liver remains stored until it is required. [Dorian_AF, Elsevier's_encyclopaedic_dictionary_of_medicine, Part_B:_Anatomy_(1988)_Amsterdam_etc.:_Elsevier][VHOG] Organ attached to the liver which stores bile and empties into the duodenum via the bile duct as needed for digestion.[AAO] relationship type change: differentiates_from endoderm (AAO:0000139) CHANGED TO: develops_from endoderm (UBERON:0000925)[AAO] The presence of a gallbladder appears to be a primitive trait. It is found in most fish and all adult reptiles and amphibians and has been well conserved in mammals, for the most part.[well established][VHOG] AAO:0010114 BTO:0000493 CALOHA:TS-0394 EFO:0000853 EHDAA2:0000699 EHDAA:8062 EMAPA:17202 EV:0100090 FMA:7202 MA:0000356 MAT:0000072 MESH:D005704 MIAA:0000072 NCIT:C12377 SCTID:181269000 TAO:0000208 UMLS:C0016976 VHOG:0000221 Wikipedia:Gallbladder XAO:0000135 ZFA:0000208 galen:Gallbladder cholecyst gall bladder uberon vesica biliaris vesica fellea UBERON:0002110 Rats do not have a gallbladder, but produce bile. The bile flows directly from the liver through the (hepatic) bile duct into the small intestine (Hebel and Stromberg, 1988) gallbladder UBERON:0002110 https://upload.wikimedia.org/wikipedia/commons/b/b1/GallbladderAnatomy-en.svg https://upload.wikimedia.org/wikipedia/commons/f/f4/Abdomal_organs.svg A paired organ of the urinary tract that produces urine and maintains bodily fluid homeostasis, blood pressure, pH levels, red blood cell production and skeleton mineralization. One of either of a pair of structures lying on either side of the dorsal aorta in which fluid balance is regulated and waste is excreted out in the form of urine.[AAO] renal AAO:0000250 BTO:0000671 CALOHA:TS-0510 GAID:423 MAT:0000119 MESH:D007668 MIAA:0000119 UMLS:C0022646 Wikipedia:Kidney XAO:0003267 galen:Kidney reniculate kidney uberon UBERON:0002113 kidney UBERON:0002113 The first part of the small intestine. At the junction of the stomach and the duodenum the alimentary canal is inflected. The duodenum first goes anteriorly for a short distance, turns dorsally, and eventually caudally, thus it is a U-shaped structure with two horizontal sections (a ventral and a dorsal one). The fixed portion of the small intestine deeply lodged in the posterior wall of the abdomen and extending from the pylorus to the beginning of the jejunum. [Dorian_AF, Elsevier's_encyclopaedic_dictionary_of_medicine, Part_B:_Anatomy_(1988)_Amsterdam_etc.:_Elsevier][VHOG] duodenal In fish, the divisions of the small intestine are not as clear, and the terms anterior intestine or proximal intestine may be used instead of duodenum. In humans, the duodenum is a hollow jointed tube about 10-15 inches (25-38 centimetres) long connecting the stomach to the jejunum. It begins with the duodenal bulb and ends at the ligament of Treitz. AAO:0010402 BTO:0000365 CALOHA:TS-0214 EFO:0000851 EMAPA:18852 EV:0100073 FMA:7206 GAID:284 MA:0000338 MAT:0000044 MESH:D004386 MIAA:0000044 NCIT:C12263 SCTID:181247007 UMLS:C0013303 VHOG:0000052 Wikipedia:Duodenum XAO:0000236 galen:Duodenum uberon proximal intestine upper intestine UBERON:0002114 duodenum UBERON:0002114 http://upload.wikimedia.org/wikipedia/commons/b/b3/Tractus_intestinalis_duodenum.svg https://cdn.humanatlas.io/digital-objects/ref-organ/small-intestine-female/v1.2/assets/3d-vh-f-small-intestine.glb https://cdn.humanatlas.io/digital-objects/ref-organ/small-intestine-male/v1.2/assets/3d-vh-m-small-intestine.glb Anatomical cluster consisting of the hematopoietic system and the lymphoid system, or its analogs. CALOHA:TS-2018 EHDAA2:0004615 EMAPA:18765 FMA:74562 MA:0000013 hematolymphoid system lymphomyeloid complex uberon haemolymphoid system UBERON:0002193 hemolymphoid system UBERON:0002193 The prostate gland is a partly muscular, partly glandular body that is situated near the base of the mammalian male urethra and secretes an alkaline viscid fluid which is a major constituent of the ejaculatory fluid. TODO - FMA treats the gland as part of the prostate - see also FMA:74119. prostatic BTO:0001129 CALOHA:TS-0828 EFO:0000858 EMAPA:19287 EV:0100104 FMA:9600 GAID:392 MA:0000404 MAT:0000078 MESH:D011467 MIAA:0000078 NCIT:C12410 SCTID:181422007 UMLS:C0033572 VHOG:0001261 Wikipedia:Prostate galen:ProstateGland male prostate prostate uberon prostata UBERON:0002367 prostate gland UBERON:0002367 http://upload.wikimedia.org/wikipedia/commons/a/a1/Prostatelead.jpg https://cdn.humanatlas.io/digital-objects/ref-organ/prostate-male/v1.2/assets/3d-vh-m-prostate.glb Either of a pair of complex endocrine organs near the anterior medial border of the kidney consisting of a mesodermal cortex that produces glucocorticoid, mineralocorticoid, and androgenic hormones and an ectodermal medulla that produces epinephrine and norepinephrine[BTO]. Anatomical structure which is found on the surface of the kidney and secretes various hormones including epinephrine, norephinephrine, aldosterone, corticosterone, and cortisol.[AAO] All craniates have groups of cells homologous to the mammalian adrenocortical and chromaffin tissues, but they are scattered in and near the kidneys in fishes. (...) The cortical and chromaffin tissues come together to form adrenal glands in tetrapods.[well established][VHOG] The origin of the adrenal gland is still controversial. It is thought to share the same origin as the kidney and gonads, derived from coelomic epithelium of the urogenital ridge and/or the underlying mesenchyme (Keegan and Hammer, 2002; Morohashi, 1997). We follow Kardong and state homology at the level of the cortex and medulla rather than gland as a whole suprarenal cortex manufactures corticosteroids; suprarenal medulla manufactures epinephrine and norepinephrine; suprarenal medulla receives preganglionic sympathetic innervation from the greater thoracic splanchnic n. AAO:0010551 BTO:0000047 CALOHA:TS-0016 EFO:0000238 EMAPA:18426 EV:0100135 FMA:9604 GAID:446 MA:0000116 MAT:0000071 MESH:D000311 MIAA:0000071 NCIT:C12666 SCTID:181127006 UMLS:C0001625 Wikipedia:Adrenal_gland XAO:0000164 galen:AdrenalGland glandula adrenalis glandula suprarenalis uberon adrenal adrenal capsule adrenal medulla cell atrabiliary capsule epinephric gland epinephros glandula suprarenalis interrenal gland suprarenal capsule suprarenal gland UBERON:0002369 adrenal gland UBERON:0002369 http://upload.wikimedia.org/wikipedia/commons/9/9d/Illu_endocrine_system_New.png http://upload.wikimedia.org/wikipedia/commons/c/c6/Illu_endocrine_system.jpg Muscle tissue is a contractile tissue made up of actin and myosin fibers[GO]. One of the four types of tissue in traditional classifications. Tissue that contains cells with contractile filaments that move past each other and change the size of the cell. Muscle tissue also is separated into three distinct categories.[AAO] AAO:0000306 AEO:0000122 CALOHA:TS-0642 EHDAA2:0003122 EMAPA:32715 FMA:9641 MA:0002437 MESH:D009132 NCIT:C12435 SCTID:91727004 UMLS:C2328219 Wikipedia:Muscle_tissue galen:MuscleTissue muscular tissue portion of muscle tissue textus muscularis uberon UBERON:0002385 Vertebrate muscle is categorized into three major muscle types defined by their structural and functional properties: skeletal, cardiac and smooth. In Dmel the counterparts are somatic, heart/cardiac and visceral. Here we take a cell type based approach. muscle tissue UBERON:0002385 Lymph is the fluid that is formed when interstitial fluid enters the conduits of the lymphatic system through lymph capillaries[WP]. BTO:0000855 CALOHA:TS-0580 EFO:0000871 ENVO:02000041 EV:0100049 FMA:9671 GAID:1186 MA:0002520 MAT:0000055 MESH:D008196 MIAA:0000055 NCIT:C13252 UMLS:C0024202 VHOG:0001590 Wikipedia:Lymph ZFA:0005658 galen:Lymph uberon lympha UBERON:0002391 lymph UBERON:0002391 http://upload.wikimedia.org/wikipedia/commons/1/19/Illu_lymph_capillary.png The anteriormost subdivision of the body that includes the head, jaws, pharyngeal region and the neck (if present). In vertebrates this is the subdivision that includes the cervical vertebrae. CALOHA:TS-2356 EV:0100009 FMA:280881 MA:0000006 NCIT:C12418 SCTID:361355005 UMLS:C0460004 WikipediaCategory:Head_and_neck ZFA:0001114 galen:HeadAndNeck uberon cephalic area cephalic part of animal cephalic region head and neck head or neck UBERON:0007811 craniocervical region UBERON:0007811 An anatomical structure that has more than one cell as a part. CARO:0010000 FBbt:00100313 multicellular structure uberon UBERON:0010000 multicellular anatomical structure UBERON:0010000 UO:0000001 A unit which is a standard measure of the distance between two points. george gkoutos unit.ontology UO:0000001 length unit UO:0000001 UO:0000003 A unit which is a standard measure of the dimension in which events occur in sequence. george gkoutos UO:0000149 time derived unit unit.ontology UO:0000003 time unit UO:0000003 UO:0000005 A unit which is a standard measure of the average kinetic energy of the particles in a sample of matter. george gkoutos UO:0000126 temperature derived unit unit.ontology UO:0000005 temperature unit UO:0000005 A length unit which is equal to the length of the path traveled by light in vacuum during a time interval of 1/299 792 458 of a second. george gkoutos m metre unit.ontology UO:0000008 meter UO:0000008 A time unit which is equal to the duration of 9 192 631 770 periods of the radiation corresponding to the transition between the two hyperfine levels of the ground state of the caesium 133 atom. george gkoutos s unit.ontology UO:0000010 second UO:0000010 A thermodynamic temperature unit which is equal to the fraction 1/273.16 of the thermodynamic temperature of the triple point of water. george gkoutos K unit.ontology UO:0000012 kelvin UO:0000012 A length unit which is equal to one hundredth of a meter or 10^[-2] m. george gkoutos centimetre cm unit.ontology UO:0000015 centimeter UO:0000015 A length unit which is equal to one thousandth of a meter or 10^[-3] m. george gkoutos micrometre mm unit.ontology UO:0000016 millimeter UO:0000016 A length unit which is equal to one millionth of a meter or 10^[-6] m. george gkoutos micrometre micron um unit.ontology UO:0000017 micrometer UO:0000017 A length unit which is equal to one thousandth of one millionth of a meter or 10^[-9] m. george gkoutos nanometre nm unit.ontology UO:0000018 nanometer UO:0000018 A length unit which is equal to 10 [-10] m. george gkoutos Å unit.ontology UO:0000019 angstrom UO:0000019 A length unit which is equal to 10^[-12] m. george gkoutos picometre pm unit.ontology UO:0000020 picometer UO:0000020 A temperature unit which is equal to one kelvin degree. However, they have their zeros at different points. The centigrade scale has its zero at 273.15 K. george gkoutos C unit.ontology UO:0000027 degree Celsius UO:0000027 A time unit which is equal to one thousandth of a second or 10^[-3] s. george gkoutos ms unit.ontology UO:0000028 millisecond UO:0000028 A time unit which is equal to one millionth of a second or 10^[-6] s. george gkoutos us unit.ontology UO:0000029 microsecond UO:0000029 A time unit which is equal to 10^[-12] s. george gkoutos ps unit.ontology UO:0000030 picosecond UO:0000030 A time unit which is equal to 60 seconds. george gkoutos min unit.ontology UO:0000031 minute UO:0000031 A time unit which is equal to 3600 seconds or 60 minutes. george gkoutos h unit.ontology UO:0000032 hour UO:0000032 A time unit which is equal to 24 hours. george gkoutos unit.ontology UO:0000033 day UO:0000033 A time unit which is equal to 7 days. george gkoutos unit.ontology UO:0000034 week UO:0000034 A time unit which is approximately equal to the length of time of one of cycle of the moon's phases which in science is taken to be equal to 30 days. george gkoutos unit.ontology UO:0000035 month UO:0000035 A time unit which is equal to 12 months which is science is taken to be equal to 365.25 days. george gkoutos unit.ontology UO:0000036 year UO:0000036 UO:0000051 A unit which represents a standard measurement of how much of a given substance there is mixed with another substance. george gkoutos unit.ontology UO:0000051 concentration unit UO:0000051 A unit which is a standard measure of the number of rotations in a given time. george gkoutos unit.ontology UO:0000058 rotational frequency unit UO:0000058 UO:0000061 A concentration unit which is a standard measure of the number of moles of a given substance per liter of solution. george gkoutos unit.ontology UO:0000061 unit of molarity UO:0000061 A unit of concentration which expresses a concentration of 1 mole of solute per liter of solution (mol/L). george gkoutos M unit.ontology UO:0000062 molar UO:0000062 A unit of molarity which is equal to one thousandth of a molar or 10^[-3] M. george gkoutos mM unit.ontology UO:0000063 millimolar UO:0000063 A unit of molarity which is equal to one millionth of a molar or 10^[-6] M. george gkoutos uM unit.ontology UO:0000064 micromolar UO:0000064 A unit of molarity which is equal to one thousandth of one millionth of a molar or 10^[-9] M. george gkoutos nM unit.ontology UO:0000065 nanomolar UO:0000065 A unit of molarity which is equal to 10^[-12] M. george gkoutos pM unit.ontology UO:0000066 picomolar UO:0000066 A unit of molarity which is equal to 10^[-15] M. george gkoutos fM unit.ontology UO:0000073 femtomolar UO:0000073 A rotational frequency unit which is equal to the number complete turn in a period of time that equals to 1 second. george gkoutos 1/s one turn per second unit.ontology UO:0000092 turns per second UO:0000092 UO:0000105 A unit which is a standard measure of the number of repetitive actions in a particular time. george gkoutos unit.ontology UO:0000105 frequency unit UO:0000105 A frequency unit which is equal to 1 complete cycle of a recurring phenomenon in 1 second. george gkoutos Hz s^1 unit.ontology UO:0000106 hertz UO:0000106 A time unit which is equal to one thousandth of one millionth of a second or 10^[-9] s. george gkoutos ns unit.ontology UO:0000150 nanosecond UO:0000150 A time unit which is equal to 100 years. george gkoutos unit.ontology UO:0000151 century UO:0000151 A time unit which represents the period over which the activity or concentration of a specified chemical or element falls to half its original activity or concentration. george gkoutos unit.ontology UO:0000152 Typically applied to the half life of radioactive atoms but also applicable to any other situation where the population is of molecules of diminishing concentration or activity. half life UO:0000152 A dimensionless concentration unit which denotes the mass of a substance in a mixture as a percentage of the mass of the entire mixture. george gkoutos w/w weight-weight percentage unit.ontology UO:0000163 mass percentage UO:0000163 A concentration unit which is a standard measure of the mass of a substance in a given volume (density). george gkoutos unit.ontology UO:0000180 For units and further information look under the mass density unit. For a sample of a specific pure elemental substance, the concentration is directly proportional to the density. However, concentration is not proportional to density in general. mass per unit volume UO:0000180 UO:0000186 A unit which is a standard measure of physical quantity consisting of only a numerical number without any units. george gkoutos unit.ontology UO:0000186 dimensionless unit UO:0000186 A dimensionless ratio unit which denotes numbers as fractions of 100. george gkoutos % unit.ontology UO:0000187 percent UO:0000187 UO:0000190 A dimensionless unit which denotes an amount or magnitude of one quantity relative to another. george gkoutos unit.ontology UO:0000190 ratio UO:0000190 A temperature unit which is equal to 5/9ths of a kelvin. Negative 40 degrees Fahrenheit is equal to negative 40 degrees Celsius. george gkoutos F unit.ontology UO:0000195 In this scale, the freezing point of water is 32 degrees Fahrenheit and the boiling point is 212 degrees, placing the boiling and freezing points of water 180 degrees apart. -40 degrees Fahrenheit is equal to -40 degrees Celsius. degree Fahrenheit UO:0000195 A dimensionless concentration notation which denotes the acidity of a solution in terms of activity of hydrogen ions (H+). george gkoutos unit.ontology UO:0000196 pH UO:0000196 UO:0000200 A concentration unit which denotes the average cell number in a given volume. george gkoutos unit.ontology UO:0000200 cell concentration unit UO:0000200 A unit of cell concentration which is equal to one cell in a volume of 1 milliliter. george gkoutos cells per millilitre cells per ml unit.ontology UO:0000201 cells per milliliter UO:0000201 A concentration unit which is a standard measure of the amount of the action of a catalyst in a given volume. george gkoutos unit.ontology UO:0000202 catalytic (activity) concentration unit UO:0000202 A catalytic (activity) concentration unit which is equal to 1 katal activity of a catalyst in a given volume of one cubic meter. george gkoutos kat/m^[3] katal per cubic metre unit.ontology UO:0000203 katal per cubic meter UO:0000203 A catalytic (activity) concentration unit which is equal to 1 katal activity of a catalyst in a given volume of one thousandth of a cubic meter. george gkoutos kat/l katal per litre unit.ontology UO:0000204 katal per liter UO:0000204 A unit of cell concentration which is equal to one cell in a volume of 1 microliter. gkoutos 2013-03-12T12:34:17Z cells per microlitre cells per ul unit.ontology UO:0000316 cells per microliter UO:0000316 A unit of cell concentration which is equal to 1 cell in a well or discrete container of arbitrary volume. gkoutos 2013-03-12T12:46:20Z unit.ontology UO:0000317 cells per well UO:0000317 bao:BAO_0000001 Fluorescence resonance energy transfer (FRET) is based on the transfer of energy between two fluorophores, a donor and an acceptor, when in close proximity. The energy transfer is directed from higher-energy donor fluorophore to lower-energy acceptor fluorophore of labeled protein pairs. Target protein pairs are likely to exhibit FRET if they are no more than 10 nm apart. FRET fluorescence resonance energy transfer bao:BAO_0000002 Homogenous time resolved fluorescence (HTRF) is a technology which combines standard FRET technology with the time-resolved measurement of fluorescence. Through this, HTRF eliminates the short-lived background fluorescence. Introducing a time delay (50-150 micro seconds) between the system excitation and fluorescence measurement, which allows the signal to be cleared of all non-specific short lived emissions. HTRF homogeneous time resolved fluorescence bao:BAO_0000003 Fluorescence polarization (FP) measurements are based on the assessment of the rotational motions of species. It is used to measure binding interactions. When linear polarized light is used to excite fluorophores, only those aligned with the plane of polarization will be excited. For fluorophores attached to small, rapidly rotating molecules, the initially photoselected orientational distribution becomes randomized prior to emission, resulting in low fluorescence polarization. But binding of the low molecular weight tracer to a large, slowly rotating molecule results in high fluorescence polarization. FP fluorescence polarization bao:BAO_0000004 Time resolved-fluorescence resonance energy transfer (TR-FRET) unites TRF (Time-Resolved Fluorescence) and FRET (Fluorescence Resonance Energy Transfer) principles. This combination brings together the low background benefits of TRF with the homogeneous assay format of FRET. Introducing a time delay (50-150 micro seconds) between the system excitation and fluorescence measurement allows the signal to be cleared of all non-specific short lived emissions. TR-FRET uses lanthanide donors which are fluorophores with long emission half-lives. TR-FRET time resolved fluorescence resonance energy transfer bao:BAO_0000005 Flow cytometry uses the principles of light scattering and fluorescence from fluorochrome molecules to generate specific multi-parameter data from particles and cells in the size range of 0.5um to 40um diameter. FACS FACS assay Fluorescence-activated cell sorting flow cytometry assay flow cytometry 1 bao:BAO_0000006 It is a measure of the number of dead cells in a culture well. We consider it as a subclass of 'percent inhibition', because cell death is induced by inhibition of vital cellular processes and percent cytotoxicity increases as the number of dead cells increases. It can be estimated in the compound treated wells in comparison to vehicle-treated control wells and is expressed as a percent. The compound treatment is preferably performed in a short window of time to avoid masking the effect due to cell proliferation. Compound cytotoxicity is an important parameter to measure when developing potential human therapeutics. Cytotoxicity is determined as a measure of radioisotope (3H thymidine or 51Cr) release, lactate dehydrogenase release from damaged cells, tetrazolium salt and alamar blue reduction, fluorescent dyes that selectively stain live or dead cells, and decrease in ATP content. ATP levels are detected using a luminescence based assay kit such as CellTiter-Glo (Promega). ATP values higher than controls indicate proliferation and cultures with ATP concentrations lower than controls indicate cytotoxicity. Percent cytotoxicity = 100-percent viability % cytotoxicity percent cytotoxicity bao:BAO_0000007 They are the basic repeating units of the eukaryotic chromatin consisting of DNA wound around a histone protein core. nucleosome format bao:BAO_0000008 Categorization of bioassays based on the property or process that the assay is interrogating, e.g. ADMET, functional, etc. bioassay type bao:BAO_0000009 ADMET stands for absorption, distribution, metabolism, excretion and toxicity. Admet assays are performed for verifying the bio-availability, toxicity, metabolic stability, and drug-drug interaction potential of drugs: They quantify absorption of drugs in the intestine which is dependent on their solubility; distribution which ascertains their binding to plasma proteins, central nervous system penetration; metabolism where the in vivo clearance is monitored; and finally, toxicity in terms of inhibition of liver cytochrome p450 enzymes or hERG which could cause drug-drug interactions and cardiac arrhythmias, respectively. ADME bao:BAO_0000010 An assay where the measured signal corresponds to a direct read out of the analyte (e.g. enzyme activity) or an indirect complex response such as cell survival, proliferation, localization of a protein, nuclear translocation etc. functional assay functional bao:BAO_0000011 nucleic acid bao:BAO_0000012 PBS phosphate buffered saline bao:BAO_0000013 The quality of a biological macromolecule (DNA, RNA or protein), which could either be unmodified' (native) or modified, e.g., methylated, phosphorylated, etc. primary structure bao:BAO_0000014 secondary structure 1 bao:BAO_0000015 A set of instructions, methodology, operations, required reagents, instruments to carry out experiments for the purpose of testing the effect of a perturbing agent in a biological model system, measuring one or multiple effect(s) of the agent facilitated by an assay design method translate the perturbation into a detectable signal to arrive at one or multiple endpoint(s) that quantify or qualify the extent of the perturbation. Bioassay is described by multiple bioassay components: assay format, biology (biological participants in various role and processes), design method, physical detection method / technology, screened entity, and endpoint. Bioassay includes one or multiple measure groups to describe panel, profiling, multiparametric (or multiplexed) assays (assays that measure more than one effect of the perturbagen on the system that is screened). bioassay They are used to express the binding interactions between labeled or unlabeled ligands with protein receptors and include Bmax, Kd, etc. protein substrate and ligand constant bao:BAO_0000017 Scintillation proximity assay (SPA) eliminates the separation step of unbound radioisotopes and is performed using low energy radioisotopes (3H and 125I) as labels, which have short range electron emission. SPA involves the use of microscopic beads which are first coated with a receptor protein of interest and contain a scintillant. When stimulated by the binding of radio-labeled ligand molecules, they emit light, which is detected by the photomultiplier tube. SPA is suitable for high throughput since the protocol has no wash or separation steps. [EdgeRewiring: BAO v 2.8.14 (April 2025)] SPA scintillation proximity assay bao:BAO_0000019 Assay format is a conceptualization of assays based on the biological and / or chemical features of the experimental system. For example assay formats include biochemical assays - referring to assays with purified protein, cell-based - referring to assays in whole cells, or organism-based - referring to assays performed in an organism. assay format bao:BAO_0000020 tertiary structure bao:BAO_0000021 LysoTracker Red bao:BAO_0000022 endogenous ligand bao:BAO_0000023 synthetic small molecule ligand bao:BAO_0000024 fluorescently labeled bao:BAO_0000025 bead bao:BAO_0000026 Description of an experiment carried out for the purpose of screening a perturbing agent in a biological system, measuring the effect of the agents using specified technology, and arriving at endpoints that satisfy particular criteria. bioassay specification bao:BAO_0000027 The role of a scientist who has designed an assay and requested it to be run at a screening center. assay provider Commonly used statistical parameters for monitoring assay quality include Z and Z' factors. Prior to starting a large screen, and after assay optimization and miniaturization, pilot screens are performed to assess the quality of the assay run and to assess / validate the suitability of a assay for a high-throughput screening run. assay quality assessment method bao:BAO_0000029 The assay stage describes the purpose of the assay in an assay campaign. Assay stage also relates to the order of assays in a screening campaign. For example the primary assay, which is performed first, identifies hits. The primary hits are then confirmed in a confirmatory assay. Subsequent secondary assays are run to eliminate compounds that are not of interest or to confirm hits using an alternate design / technology, or to further characterize compounds. Whether an assay is run in single concentration or concentration response is defined in the class 'assay measurement throughput quality'. For example primary assays are typically run in single concentration with single measurements. However, the NCGC runs qHTS primary assays as concentration-response assays. assay screening campaign stage bao:BAO_0000030 Assay performed to confirm activity of compounds identified in the primary screen. It can be performed as replicate measurements at a single screening concentration or as concentration-response assay. confirmatory assay bao:BAO_0000031 The first assay performed in a in a screening campaign. The purpose of the primary assay is to identify hits, which are potentially biologically active chemical entities. Generally in this assay, the perturbagens are tested at a single concentration with only one measurement. It is followed by a confirmatory screen, which can be run at a single concentration with multiple replicates or as concentration-response assay. HitProfiling screen hit profiling primary assay SAR primary screen primary screening primary assay bao:BAO_0000032 Additional assays following the confirmatory stage to confirm the biological activity of chemical entities via a different type of assay or to eliminate certain active compounds based on their mechanism of action, toxicity or activity profile. Secondary assays can also include selectivity and specificity assays. secondary assay It is the amount of drug required to saturate a population of receptors and a measure of the number of receptors present in the sample. It is derived from Scatchard plot of binding data. It is analogous to Vmax in enzyme kinetics. The units of Bmax include cpm, sites/cell or fmol/mg. http://graphpad.com/curvefit/fitting_specific_binding_.htm Bmax Kd – is the equilibrium dissociation constant for a drug. It describes the affinity between a ligand (L) (such as a drug) and a protein (P). Ligand-protein affinities are influenced by non-covalent intermolecular interactions between the two molecules such as hydrogen bonding, electrostatic interactions, hydrophobic and Van der Waals forces. Kd = ([P] [L]) / [PL] The dissociation constant has molar units (M), which corresponds to the concentration of ligand [L] at which the binding site on a particular protein is half occupied, i.e. the concentration of ligand, at which the concentration of protein with ligand bound [PL], equals the concentration of protein with no ligand bound [P]. The smaller the dissociation constant, the more tightly bound the ligand is, or the higher the affinity between ligand and protein. http://www.graphpad.com/curvefit/law_of_mass_action.htm Kd bao:BAO_0000035 The physical method (technology) used to measure / readout the effect caused by a perturbagen in the assay environment. physical detection method bao:BAO_0000036 radiolabeled bao:BAO_0000037 labeled bao:BAO_0000038 unlabeled bao:BAO_0000040 Measure group is used to group and link multiple (different) sets of experimental results to one bioassay. Measure groups thus facilitate the description of multiparametric (or multiplexed) assays, that measure more than one effect of the perturbagen on the system that is screened. It also facilitate the definition of panel and profiling assays, e.g. assays that test compounds against multiple (protein) targets. Compare definition of bioassay. Measure group links to those classes that can vary among different measurements of a panel assay, profiling assay, multiparametric assay, e.g. target, assay design method, physical detection method, endpoint. Measure group is also used to define derived endpoints, for example concentration-response endpoints obtained by curve fitting a set of results from the same compound tested in the same assay at different concentrations. measure group bao:BAO_0000041 Binding assays are performed to understand the interaction between two molecules, e.g. perturbagen-protein, protein-protein, protein-DNA, etc. binding type binding type bao:BAO_0000042 Cue Signal Response assay Qualifies the endpoint as either the exact value (=) or less than (<) or greater than (>) the endpoint value specified. In case of less than or greater than, the endpoint cutoff is often determined manually; for example in a concentration response experiment the tested compound can be inactive at the minimum tested concentration; or a compound can still be active even at the lowest tested concentration. endpoint qualifier bao:BAO_0000044 cytokine-specific antibody bead-based method bao:BAO_0000045 The emission of light from a substance that occurs from an electronically excited state which is reached either by a physical, mechanical, or chemical mechanism. luminescence method bao:BAO_0000046 Detection techniques that use the principles of fluorescence, whereby incident light excites a fluorophore which then emits light at lower energy (higher wavelength). The emitted light is typically from the visible portion of the UV-Visible spectrum. fluorescence method bao:BAO_0000047 Syto 60 This technology relates to measurement of protein and nucleic acid conformational properties. Proteins undergo changes to their tertiary structure upon heating, binding to perturbagens, other proteins and substrates. Nucleic acids have characteristic secondary structures, which include the B-family of structures, A-form, Z-form, guanine quadruplexes, cytosine quadruplexes, triplexes, etc. Information about conformational properties of protein and nucleic acids can be obtained by circular dichroism spectroscopy, thermal shift, fluorescence resonance energy transfer (FRET), nuclear magnetic resonance (NMR), X-ray crystallography, etc. conformation determination method bao:BAO_0000049 Spectrophotometry involves the use of a spectrophotometer to measure the amount of light that a sample absorbs. The instrument operates by passing a beam of light through a sample and measuring the intensity of light reaching a detector. spectrophotometry method bao:BAO_0000050 Bioluminescence refers to the production and emission of light by a living organism. Bioluminescence is a naturally occurring form of chemiluminescence whereby energy is released by a chemical reaction in the form of light emission. The chemical reaction can occur either inside or outside the cell, and can be detected using a plate reader or a charge-coupled device (CCD) camera. bioluminescence bao:BAO_0000051 Chemiluminescence is the generation of light as a result of a chemical reaction using synthetic compounds and usually involving a highly oxidized species such as peroxide. chemiluminescence bao:BAO_0000054 For surface plasmon resonance measurements, target protein is immobilized onto a solid surface via covalent or noncovalent interaction. Binding of small molecule compounds changes the refractive index of the immobilized target, which can be detected by optical sensing. Shift in wavelength of light is proportional to mass changes near the sensor surface, with sensitivity to detect mass change being ~300 Da. SPR surface plasmon resonance bao:BAO_0000055 This method is used to detect compounds that are bound to the protein targets. The unbound compounds are separated by affinity based, size exclusion, or ultrafiltration methods. The bound compounds are eluted from the protein and detected by mass spectrometry. Based on the separation method, the throughput varies: between 200-2700 compounds can be loaded in each run for separation. Mass spectrometry is used to determine the chemical structure of molecules. The samples are vaporized, followed by ionization and then the mass to charge ratio of the particles is analyzed. MS mass spectrometry bao:BAO_0000057 These biosensors employ evanescent waves (surface plasmon resonance, resonant waveguide grating) or interference of light waves to characterize the cellular processes that are taking place at or near the sensor surface: e.g. to study the affinity of a sample to the biological receptors immobilized on the sensor surface. optical based bao:BAO_0000058 Upon heating, a protein unfolds and loses the native conformation. Binding of a small molecule can often stabilize the protein conformation, resulting in a higher unfolding temperature. The temperature shift in unfolding can be detected using a fluorescent dye, which is sensitive to the protein environment. thermal shift bao:BAO_0000060 The current clamp technique is used to measure biological voltages such as the action potential of an excitable cell with a microelectrode while keeping electrical current through the recording electrode constant. It can be used for both extracellular and intracellular recordings. current clamp bao:BAO_0000061 Impedance biosensors measure the electrical opposition of an interface in AC steady state with constant DC bias conditions. This is accomplished by imposing a small sinusoidal voltage at a particular frequency and measuring the resulting current; the process can be repeated at different frequencies. The current-voltage ratio gives the impedance. [EdgeRewiring: BAO v 2.8.14 (April 2025)] impedance bao:BAO_0000062 The patch clamping technique is refined from the voltage clamp technique, wherein a blunt electrode is placed on the surface of the cell membrane. It is a common intracellular recording technique in electrophysiology that allows either the measurement of current passing through individual ion channels in cells or through whole cells. Suction is applied via the blunt electrode (glass pipette in classical patch clamp technique) to create a high resistance (gigaohm) between the electrode and cell surface. This seal isolates the ion channels within the patch from the rest of the membrane and allows the neurophysiologist to record only from these ion channels. patch clamp bao:BAO_0000063 The voltage clamp technique is used to measure the ion currents across an excitable cell membrane, such as neuronal membrane, while holding the membrane voltage at a constant level. The neuronal membrane contains different kinds of ion channels including voltage gated ion channels. Manipulation of the membrane voltage using voltage clamping allows the current-voltage relationships of these ion channels to be studied. voltage clamp bao:BAO_0000064 This technique probes the surface of fluorescently-labeled living cells with an evanescent wave generated by a light beam traveling between two media of differing refractive indices. An incident laser beam is reflected at a critical angle (total internal reflection) when it encounters the interface between a microscope glass slide and the aqueous medium containing the cells. Only fluorophores which are within a few nanometers of the surface are excited, while those farther away are not, making possible the study the interactions at the cell surface. total internal reflection fluorescence microscopy bao:BAO_0000065 Data normalization obtained by dividing the difference of mean of the positive controls and sample measurement by the difference of the mean of the positive controls and mean of the negative control. Normalized % inhibition percent inhibition normalization bao:BAO_0000066 Bio-Layer Interferometry is a used for measuring biomolecular interactions. In this technique, the interference pattern of white light reflected from two surfaces: a layer of immobilized protein on the biosensor tip, and an internal reference layer are analyzed. Changes in the number of molecules bound to the biosensor tip cause a shift in the interference pattern, which can be measured in real-time. BLI bio layer interferometry bao:BAO_0000067 It is based on the ability of a transparent substance, such as glass to conduct some of the visible or near-visible light to its interior by means of internal reflection. fiber optic waveguide bao:BAO_0000068 The optical grating coupler sensor responds to the change of optical refractive index of the liquid or gas cover medium and to the adsorption or binding of molecules on the surface. The optical grating coupler sensor chip is based on a fine optical grating prepared on a thin waveguide layer carried by a glass substrate. The optical grating couples the light of a He-Ne laser at a given resonance angle into the waveguide layer. This incoupling angle is very sensitive to the presence of adsorbed molecules and to any change of refractive index of the medium covering the surface of the chip. By precise measurement of the incoupling angle, the amount of the adsorbed material can be determined with ultra high sensitivity. optical waveguide grating bao:BAO_0000069 Cells are directly cultured onto the surface of a resonant waveguide grating (RWG) biosensor. The mass redistribution within the bottom portion of cells, mediated by stimulus is directly measured with the biosensor. RWG biosensor utilizes an optical beam with an appropriate angular content to illuminate a waveguide film in which a grating structure is embedded. When this beam is reflected by the sensor surface, the resonant angle dominates in the output beam. The mass redistribution within the sensing volume alters the incident angle. Because of its ability for multiparameter measurements, the biosensor has potential to provide high information content for cell sensing. These parameters include the angular shift (one of the most common outputs), the intensity, the peak width at half-maximum (PWHM), and area of the resonant peaks. RWG resonant waveguide grating bao:BAO_0000070 The absorbance of a beam of collimated monochromatic radiation in a homogeneous isotropic medium is proportional to the absorption path length and to the concentration of the absorbing species. Absorbance is a logarithmic measure of the amount of light (at a specific wavelength) that is absorbed when passing through a sample. A= -log10(I/I0), where A is absorbance, I is the intensity of incident light and I0 is the intensity of light transmitted after passing through the sample. absorbance bao:BAO_0000071 The transmittance of a sample is the ratio of the intensity of the light that has passed through the sample to the intensity of the light when it entered the sample (T = Iout / Iin ). To convert between the absorbance and transmittance scales, the following equation is used: A = -log T = - log (I / Io). transmittance bao:BAO_0000072 The role of a compound that is routinely run in the same manner as the test compounds in every run of the assay. This term does not refer to the plate controls used to define the maximum and minimum responses, and they may or may not be a “literature standard” or “reference” compound. assay control bao:BAO_0000073 In a viable cell, the phospholipid, phosphatidyl serine (PS) is localized on the inner leaflet of the cell membrane facing the cytosol. When the cell is undergoing apoptosis, the cell membrane loses its phospholipid asymmetry and exposes PS on the outer layer of the membrane. Annexin V specifically binds PS. Hence, apoptotic cells can be detected by staining with FITC conjugated Annexin V followed by flow cytometry. phospholipid redistribution estimation This refers to the effect of the perturbagen on the target of an assay, whether it brings about inhibition, activation, cytotoxicity, etc. MOA mode of action Two kinds of inference errors can occur after screening at single perturbagen concentration: false positives and false negatives. To correct for this, the raw data is normalized using different statistical correction methods, namely, normalized percent distribution, Z-score, B-score, etc to derive at these endpoints. endpoint normalization method bao:BAO_0000076 screened entity bao:BAO_0000077 It is the definite magnitude of a physical quantity or of time. It has a quantity and a unit associated with it. unit of measurement bao:BAO_0000079 It is the role played by the solvent (e.g. DMSO) in which the perturbagen was dissolved. The negative control is used to determine the base-line to compare the effect of the test perturbagen. negative control bao:BAO_0000080 The role of a chemical compound or reagent used in each plate of an assay to normalize the response of the test perturbagens (by plate). Compounds that can have a positive control role are known from previous experiments or is a previously established standard. It is usually highly active resulting in a strong response of the intended effect. In an inhibition assay the positive control would usually result in the complete inhibition, which is then used for normalization (i.e. set as 100%). In an activation assay it would be activator used to normalize activity. Using controls provides an external reference and reduces the number of false negatives and false positives. positive control bao:BAO_0000082 Percent increase or decrease of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. % response percent response bao:BAO_0000084 Data measuring the biological effect of a compound, e.g. % cell death, activation of reporter gene expression, inhibition of enzyme activity, etc. ligand function mode of action In this assay, the binding of the ligand to a receptor is permanent and cannot be dissociated by changing the binding conditions such as buffer, salt concentration, etc. irreversible binding In this assay, the interaction of the ligand with a receptor can be dissociated by changing the binding conditions, e.g. buffer, salt concentration, etc. reversible binding bao:BAO_0000087 Increase of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. activation bao:BAO_0000088 A quality of a DNA or RNA residue that has a methyl group attached to it. methylated bao:BAO_0000089 The phenotype of an organism that is most common in nature and was unmodified. wild type bao:BAO_0000090 It is the toxic or cell-death inducing property of a perturbagen. Known cytotoxic agents mediate cell death commonly by necrosis, apoptosis, or autophagy. Cytotoxicity can be detected by measuring various aspects of the death process: e.g. membrane permeability, ATP concentration, DNA fragmentation, etc. cytotoxicity bao:BAO_0000091 Reduction of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. inhibition Increase of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. stimulation bao:BAO_0000094 Growth reduction of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. As a measure of viable or proliferating cells, different researchers measure different parameters, namely, protein content (by sulforhodamine B staining followed by absorbance measurement), mitochondrial dehydrogenase activity (by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide, known as MTT staining followed by absorbance measurement), expression of proliferation associated antigens (by immunostaining for Ki-67), and ATP content (by using CellTiter-Glo reagent (Promega) followed by luminescence measurement. growth inhibition 1 bao:BAO_0000096 % growth reduction of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. % growth inhibition percent growth inhibition bao:BAO_0000098 The concentration of a perturbagen used in an assay to elicit the biological effect or perturbation. This typically assumes uniform / equal distribution of the perturbagen / compound in the assay system (typically a screening well). screening concentration bao:BAO_0000099 It is the quality which allows a microorganism to survive after exposure to one or more antibiotics. antibiotic resistance bao:BAO_0000100 Assays in which the physical and chemical properties of perturbagens are measured, namely, aqueous solubility, octanol water partition, cell permeability models, for e.g. Caco2 cells, parallel artificial membrane permeability assay (PAMPA), etc. small-molecule physicochemical format bao:BAO_0000101 log10 molar bao:BAO_0000102 negative log10 molar Endpoint action correlation describes weather a low or high endpoint value corresponds to low or high activity. Specifically if the endpoint value is positively or inversely correlated with the action that corresponds to the endpoint and which is specified as 'mode of action'. For example 'percent control' can be positively correlated with enzyme activity (remaining activity) and inversely correlated with the mode of action (function) inhibition depending on how the signal is normalized. endpoint action correlation bao:BAO_0000105 The role played by a cell line in supporting the growth of another cell line (e.g., stem cell). The feeder cell, e.g., mouse embryonic fibroblasts (MEFs) provides an adhesive surface to which the stem cells can attach and also secrete factors required for their growth. feeder cell bao:BAO_0000110 It is an interaction between a protein (e.g., receptor, transcription factor) and small molecule (e.g., hormone, organic compound with a low molecular weight (<800 Da)). protein-small molecule interaction assay bao:BAO_0000114 The liquid broth used to grow cells, which is optimized for each cell type and includes additives such as growth factors, buffers, amino acids, antibiotics, etc. This information can be obtained from ATCC or found in relevant publications. culture medium bao:BAO_0000115 Hoechst 33342 bao:BAO_0000116 Hoechst bao:BAO_0000118 Dimethyl sulfoxide (DMSO) is a common organic solvent that is used to solubilize the chemical compounds prior to their addition to an assay. DMSO can have a significant impact on enzyme activity and the concentration of DMSO in the wells containing compound should be identical to the concentration of DMSO in the control wells. DMSO can also impact the solubility of a compound and its observed potency. Therefore, the concentration of DMSO should be consistent in replicate experiments. DMSO bao:BAO_0000119 iPSC induced pluripotent stem cell bao:BAO_0000123 Binding reporter technology is used to quantitate the interactions between two molecules, e.g. perturbagen-protein, protein-protein, protein-DNA, etc. The technologies used are radioligand binding, resonance energy transfer, fluorescence polarization, protein fragment complementation assay, and several label-free methods, including surface plasmon resonance, impedance, nuclear magnetic resonance, X-ray diffraction, isothermal titration calorimetry, mass spectrometry, etc. binding assessment method It describes the different methods by which an enzyme activity can be measured and the ways it is expressed. This can be measured either directly or coupled to a secondary signal. enzyme activity measurement method Inducible reporter technologies involve the use of a reporter gene to study the effect of perturbagens on gene expression. Some reporter genes can be easily detected, e.g. green fluorescence protein, and others function as selectable markers, e.g. antibiotic resistance. reporter gene method The technologies used to measure the distribution of organelles and molecules within the cell (proteins, second messengers, metal ions, dyes, etc). This is generally visualized by microscopy. translocation method molecular redistribution determination method Compound cytotoxicity is an important parameter to measure when developing potential human therapeutics. Cytotoxicity is determined as a measure of radioisotope (3H thymidine or 51Cr) release, lactate dehydrogenase release from damaged cells, tetrazolium salt and alamar blue reduction, fluorescent dyes that selectively stain live or dead cells, and decrease in ATP content. The viability reporter technologies measure cell life or death by quantitating ATP content, caspase activity, membrane potential, and so on. viability measurement method In situ refers to in place or position; undisturbed with respect to the antigen that is being tested in the immunoassay. The protein detection and localization is achieved by visualization under a microscope. in situ immunoassay It measures the concentration of a substance in a solution based on the specific binding of an antibody to that substance, which produces a measurable signal. The signal measured depends on the label that is associated with this interaction, namely radioactive element (in radioimmunoassays), fluorescent, phosphorescent and chemiluminescent dyes, etc. immunoassay bao:BAO_0000130 This technology measures the interaction of two molecules bioconjugated to donor and acceptor beads. Laser excitation leads to light emission which is directly proportional to the amount of binding, provided molecules are in proximity to cause a chemical reaction (interact). Users have modified this and coupled it to chemiluminescence emission. This technology has been adapted to study protein-protein, protein-DNA and receptor-ligand, immunoassay, phosphorylation and protease reactions. alphascreen positively correlated A competitive binding assay is based upon the competition of labeled and unlabeled ligand for a limited number of antibody binding sites. Briefly, the free antigen and antibody are incubated to form antigen-antibody complex and then the complex are bound to antigen-coated surface in the assay plate. The unbound antibody-antigen complex is washed off before adding enzyme-linked secondary antibody against the primary antibody. The substrate is then added and the antigen concentration can then be determined by the signal strength elicited by the enzyme-substrate reaction. In this assay, the enzyme-linked secondary antibody compete with the sample antigen which is associated with the primary antibody. competitive immunoassay bao:BAO_0000133 Oligonucleotides are immobilized by spotting on a solid support, such as a glass slide. They are hybridized with labeled nucleic acids from a sample and the signals measured, which reflects the composition of the sample nucleic acids. This is performed to either quantify gene expression or genomic profiling to understand genetic variation in humans. oligonucleotide array Enzyme linked immunosorbent assay or ELISA is used to detect the presence of a particular protein, either an antigen or antibody in the sample such as a body fluid. ELISA assay Enzyme linked immunosorbent assay enzyme-linked immunosorbent assay ELISA bao:BAO_0000136 High-throughput screening (HTS) is a method of scientific experiment which is used in drug discovery. It involves large scale screening of perturbagens against a biological target and requires robotics, liquid handling devices, sensitive detectors and data processing. The results of these experiments provide starting points for drug design or understanding the role of a specific biological process. In HTS, greater than 100,000 compounds are screened per assay. single repetition An antigen-down immunoassay or immunometric assay involves binding the antigen to a solid surface instead of an antibody. Antigen-down immunoassays are used to bind antibodies found in a sample. When the sample is added (such as human serum), the antibodies (IgE for example) from the sample bind to the antigen coated on the plate. antigen down assay bao:BAO_0000138 molecular structure An enzyme is a protein that acts as a catalyst for specific biochemical reaction, converting specific substrates into chemically distinct products. Enzyme activity assays quantify the kinetics of the product formation or substrate depletion in the reaction, which result in fluorescence, luminescence or colorimetric outputs. direct enzyme activity measurement method inversely correlated bao:BAO_0000141 An oxidative enzyme that catalyzes the conversion of luciferin to oxyluciferin with the concomitant emission of light (luminescence). Firefly luciferase luciferase Luciferin 4-monooxygenase This technology is used to measure the effect of a perturbagen on an enzyme activity, which is coupled to a secondary signal. E.g., the activity of a kinase determines the residual pool of ATP, with ATP being its substrate, which in turn determines the rate of a coupled enzyme luciferase, since ATP is one of its substrates too. coupled enzyme activity measurement method 1 bao:BAO_0000143 Percent control is the response relative to a reference state, typically to a high control. For example it can describe (remaining) activity of a kinase (or e.g. kinase bound to substrate). Percent control could also quantify an inhibitory action depending on control and assay method. percent control Beta galactosidase gene is attached to the regulatory sequence of a gene of interest. The effect of a perturbagen on the expression of the gene of interest could be easily monitored by the detection of the product of beta galactosidase enzyme. beta-gal induction beta galactosidase induction Beta lactamase gene is attached to the regulatory sequence of a gene of interest. The effect of a perturbagen on the expression of the gene of interest could be easily monitored by the detection of the product of beta lactamase enzyme. beta lactamase induction Luciferase gene is attached to the regulatory sequence of a gene of interest. The effect of a perturbagen on the expression of the gene of interest could be easily measured by the detection of light emitted as a product the luciferase reaction. luciferase induction Fluorescent proteins are commonly used as reporter genes to study the effect of perturbagens on gene expression. Examples include green fluorescent protein (GFP) from the jellyfish Aequorea victoria and the various modifications of it created by amino acid substitutions to either optimize the codon usage in mammalian cells or to change the spectral properties of the protein. fluorescent protein induction bao:BAO_0000156 The role played by the substrate, which is titrated without inhibitor to reflect the maximum enzyme activity at each substrate concentration. high signal control Cell viability can be assessed by the presence of cytoplasmic esterases that cleave a lipid-soluble nonfluorescent probe to yield a fluorescent product. The product is charged and is thus retained within the cell if the membrane is intact. Typical probes include fluorescein diacetate (FDA), carboxyfluorescein, and calcein. esterase activity determination bao:BAO_0000159 Chromatin condensation is one of the morphological changes that occur during apoptosis. It is also known as pyknosis and can be visualized by staining with dyes followed by microscopy. chromatin condensation visualization bao:BAO_0000160 Nuclear magnetic resonance (NMR) is used to analyze protein-small molecule interactions. This binding interaction is commonly monitored by the chemical shift of the compound. With this technique, both the binding interaction and bound compounds can be detected, which allows pools of 5-100 compounds to be tested for binding. NMR nuclear magnetic resonance bao:BAO_0000161 Circular dichroism (CD) is a technology for assessing interactions of chiral molecules with circularly polarized electromagnetic rays. Secondary and tertiary structure of proteins will impart a distinct CD to that molecule allowing the use of CD to examine the protein folding under different conditions. Information about conformational properties of nucleic acids can be obtained by CD spectroscopy. CD circular dichroism bao:BAO_0000162 Metal ions such as copper, iron, magnesium and zinc are transported between different cellular compartments to bring about specific functions. This is regulated by their influx and efflux across membranes, which could occur either by passive diffusion or active transport. metal ion redistribution assay bao:BAO_0000163 Electrical sensors are used to measure the electrical impedance, or the current-voltage relationships of these ion channels. electrical sensor ATP levels are an indicator of viable cell number. ATP values higher than controls (untreated cells) indicate proliferation and cultures with ATP concentrations lower than controls indicate cytotoxicity. ATP levels can be measured using different commercial kits. adenosine triphosphate content ATP quantitation bao:BAO_0000165 Caspases are cysteine proteases which play an important role in apoptosis. They are synthesized and stored in cells as inactive procaspases. Once apoptosis is initiated in a cell, the procaspases get activated by proteolytic cleavage. This sets in motion a caspase cascade, which leads to the activation of proteins involved in the chromatin fragmentation and finally culminates in cell death. caspase activity determination An expansion in the number of viable cells results in an increase in the overall activity of mitochondrial dehydrogenases in the sample. The internal environment of the proliferating cell is more reduced than that of non-proliferating cells. Specifically, the ratios of NADPH/NADP, FADH/FAD, FMNH/FMN, and NADH/NAD, increase during proliferation. Compounds such as tetrazolium salts and Alamar Blue, which can be reduced by these metabolic intermediates, can be used to monitor cell proliferation. Their reduction is accompanied by a measurable shift in wavelength with a corresponding change in color. dehydrogenase activity determination bao:BAO_0000167 Live cells with intact membranes have the ability to exclude dyes that easily penetrate dead or damaged cells. Examples of the dyes include propidium iodide, 7-amino actinomycin D, and trypan blue. Cells stained with the former two can be quantified by flow cytometry, while the latter is by manual counting using hemocytometer. membrane permeability assessment bao:BAO_0000168 The role played by the substrate, which is titrated without enzyme and without inhibitor. The low controls should reflect the signal expected for no enzyme activity at each substrate concentration. Depending on the composition of the inhibitor stocks, DMSO might be needed in the control wells to assure consistency across all the experiments. low signal control Cellular nuclei can be by stained with Hoechst, DAPI, etc, which is a measure of cell viability and proliferation. deoxyribonucleic acid content dna content estimation Live cells have a conserved and constitutive protease activity which serves as a biomarker of cell viability. The live-cell protease activity is measured using a fluorogenic, cell-permeant, peptide substrate (Gly-Phe-AFC). The substrate enters intact cells, where it is cleaved by the live-cell protease activity to generate a fluorescent signal proportional to the number of living cells. The live-cell protease becomes inactive upon loss of membrane integrity and leakage into the surrounding culture medium. protease activity determination bao:BAO_0000171 Lipids are a group of naturally occurring organic compounds that are soluble in nonpolar organic solvents, but insoluble in water. Examples include fatty acids, triglycerides, phospholipids, etc. Lipids function to store energy, form a component of cell membrane and as signaling molecules. lipid bao:BAO_0000172 ACTOne Membrane Potential Dye bao:BAO_0000174 Peptoids are a class of biomimetic polymers based on oligo-N-substituted glycine backbones, designed to mimic peptides and proteins. Peptoids are resistant to proteolysis and not typically denatured by solvent, temperature, or chemical denaturants. peptoid bao:BAO_0000175 A protein or polypeptide is a long polymer of amino acids joined together by peptide bonds. The sequence of the amino acids is defined by the genetic code. Here, a protein is a perturbagen whereby its ability to modulate a physiological process or a disease pathology is assessed. protein bao:BAO_0000176 Small molecule is an organic compound with a low molecular weight (<800 Da) which is used to screen against a biological target, e.g. protein, nucleic acid, cell or organism to test its ability to bind it and bring about a change in activity. It is either isolated from a natural source or is synthesized. small molecule 1 bao:BAO_0000178 Screening campaign incudes a sequence of (assay) experiments performed to identify a compound (or a series of compounds) with a specific function and it is desirable to have a known mechanism of action. It includes primary (screening at single concentration), secondary, and confirmatory (dose response) screens, structure activity relationship (SAR) studies, lead optimization, etc. screening campaign bao:BAO_0000179 The endpoint is a quantitive or qualitative interpretable standardized representation of a perturbation (a change from a defined reference state of a "closed" model system) that is measured by the bioassay. An endpoint consists of a series of data points, one for each perturbing agent (screened entity) tested the assay. endpoint result 1 1 bao:BAO_0000180 It can refer to the screening concentration (for example in a primary assay) or it can be a concentration at which the perturbagen mediates a defined response, such as IC50 or EC50. It always has one value and a concentration unit. concentration endpoint bao:BAO_0000181 Reporting the extent / magnitude of the perturbation (induced by the perturbagen) such as percent inhibition. Response-type endpoints would typically be obtained from a single concentration perturbagen measurement. response endpoint bao:BAO_0000184 High content screening (HCS) is an automated screening method using live cells to understand various aspects of their biology. HCS employs imaging (bright-field or fluorescence) and analyses in a high throughput format. HCS can be applied to monitor complex cellular aspects, namely, signaling, morphology, phenotype, proliferation, motility, intracellular trafficking, toxicology, RNAi knockdown, and receptor activation. HCS High content screening image-based readout bao:BAO_0000186 The effective concentration of a perturbagen, which produces 50% of the maximal possible response, which could mean either activation (EC50) or inhibition (IC50) for that perturbagen. Potency AC50 bao:BAO_0000187 The effective concentration of a cytotoxic compound, which produces 50% of the maximum possible cell death for that compound. Although the cytotoxic compound induces cell death, we define CC50 as subclass of IC50, because critical cellular processes are inhibited and CC50 is often used as a more specific description of IC50 for cell toxicity assays. Compound cytotoxicity is an important parameter to measure when developing potential human therapeutics. Cytotoxicity can be determined for example as a measure of radioisotope (3H thymidine or 51Cr) release, lactate dehydrogenase release from damaged cells, tetrazolium salt and alamar blue reduction, fluorescent dyes that selectively stain live or dead cells, or decrease in ATP content. ATP levels are detected using a luminescence based assay kit such as CellTiter-Glo (Promega). ATP values higher than controls (untreated cells) indicate proliferation and cultures with ATP concentrations lower than controls indicate cytotoxicity. CC50 bao:BAO_0000188 The effective concentration of an agonist, which produces 50% of the maximum possible response for that agonist. EC50 bao:BAO_0000189 The effective concentration of a growth inhibitor, which produces 50% of the maximum possible response for that inhibitor. GI50 is calculated from [(Ti-Tz)/(C-Tz)] x 100 = 50, where Tz is absorbance at time zero, Ti is absorbance in the presence of test drug, and C is absorbance in the control (untreated cells). As a measure of viable or proliferating cells, different researchers measure different parameters, namely, protein content (by sulforhodamine B staining followed by absorbance measurement), mitochondrial dehydrogenase activity (by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide, known as MTT staining followed by absorbance measurement), expression of proliferation associated antigens (by immunostaining for Ki-67), and ATP content (by using CellTiter-Glo reagent (Promega) followed by luminescence measurement). growth inhibition by 50% GI50 bao:BAO_0000190 The effective concentration of an inhibitor, which produces 50% of the maximum possible response for that inhibitor. IC50 bao:BAO_0000191 The effective concentration of an inhibitor, which produces 80% of the maximum possible response for that inhibitor. IC80 bao:BAO_0000192 Ki is the equilibrium inhibitor dissociation constant, the concentration of the competing inhibitor that results in binding to half the enzymes sites at equilibrium in the absence of substrate or other competitors. The Cheng and Prusoff equation: Ki - (IC50) / ( 1+ ([L]/Kd)) relates IC50 to Ki under conditions of competitive binding; Kd equilibrium dissociation constant of the (labeled) ligand, [L] ligand concentration. The Cheng and Prusoff equation: Ki - (IC50) / ( 1+ ([S]/Km)) relates IC50 to Ki under conditions of competitive inhibition; Ki equilibrium enzyme inhibitor dissociation constant; Km Michaelis-Menton constant, [S] substrate concentration. Ki It is the ratio of biological activity in the presence of an exogenous substance to that in its absence. The fold change is useful when comparing test compounds evaluated across multiple functional assays because varying levels of efficacy can be observed amongst the different or same reference agonists. fold change bao:BAO_0000194 TGI is total growth inhibition, which is the effective concentration of a growth inhibitor, which produces 0% relative growth for that inhibitor. Thus TGI signifies a cytostatic effect. tgi is calculated from [(Ti-Tz)/(C-Tz)] x 100 =0, where Ti = Tz and Tz is absorbance at time zero, Ti is absorbance in the presence of test drug, and C is absorbance in the control (untreated cells). As a measure of viable cells, different researchers measure different parameters, namely, protein content (by sulforhodamine B staining followed by absorbance measurement), mitochondrial dehydrogenase activity (by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide, known as MTT staining followed by absorbance measurement), and ATP content (by using CellTiter-Glo reagent (Promega) followed by luminescence measurement). total growth inhibition TGI Absolute IC50 (calculated from the curve-fit function) is the concentration corresponding to exactly 50 percent inhibition. It is obtained from the curve fit function (back-calculated IC50) and can also be extrapolated. Commonly the relative IC50 is reported; however in cell proliferation assays absolute IC50 is often used. The absolute IC50 can be more reproducible. IC50 absolute The concentration of a test substance that produces an inhibitory effect corresponding to 50% of the activity of that particular substance (i.e. 50% of the difference between top and bottom of fitted curve). It can also be described as the concentration corresponding to the inflection point of the curve. IC50 relative pIC50 is -log IC50, where IC50 is the effective concentration of an inhibitor, which produces 50% of the maximum possible response for that inhibitor. -log IC50 pIC50 1 bao:BAO_0000200 Percent increase of a measureable response relative to some baseline. Unit of Measure is always % when normalized to the dynamic range of the assay. Percent activity measures the increased activity vs. an unperturbed state, i.e. percent activation := percent activity - 100; e.g. an agonist that results in twice the activity would have percent activity = 200 and percent activation = 100. % activation percent activation 1 bao:BAO_0000201 Percent decrease of a measureable response as a consequence of compound treatment. Unit of Measure is always % when normalized to the dynamic range of the assay. Percent inhibition is expressed relative to a positive control (which results in total inhibition). percent inhibition 1 bao:BAO_0000202 It is a measure of living cells in a culture well. Unit of Measure is always % when normalized to the dynamic range of the assay. It can be estimated in the compound treated wells in comparison to vehicle-treated control wells and is expressed as a percent. Viability is determined by measuring tetrazolium salt and alamar blue reduction, staining with selective fluorescent dyes, or ATP content. ATP levels are detected using a luminescence based assay kit such as CellTiter-Glo (Promega). ATP values higher than controls indicate proliferation and cultures with ATP concentrations lower than controls indicates cytotoxicity. Percent viability = 100-percent cytotoxicity % viability percent cell viability bao:BAO_0000204 IL-6 Interleukin-6 bao:BAO_0000215 A small molecule useful to interrogate a biological system of interest. It has to be active in the system studies, i.e. cell permeable or active in vivo and be sufficiently efficacious and selective. The term probe also refers to the MLI screening effort, which has the goal to generate chemical probes. In addition, the MLI requires a novel chemical probe to be superior to the state of the art in terms of efficacy and selectivity and in-vivo properties. A list of probes generated is available here: http://mli.nih.gov/mli/mlp-probes/ small molecule probe bao:BAO_0000216 steadylite HTS Reagent bao:BAO_0000217 It is an in vitro format used to measure the activity of a biological macromolecule, either a purified protein or a nucleic acid. It is most often a homogeneous assay type, but can be heterogeneous if a solid phase such as beads is used to immobilize the macromolecule. biochemical format bao:BAO_0000218 Involves the use of a living organism, either single or multi-celled, and is a heterogeneous assay type. organism-based format bao:BAO_0000219 Involves the use of living cells of eukaryotic origin, derived from a multicellular organism, and is a heterogeneous assay type. Typically, this refers to permanent (immortal) cell lines, or primary cells, or some form of stem cells. This is distinct from a single-celled organism-based format (classically bacteria or yeast). cell based format cell-based format bao:BAO_0000220 subcellular organelles / component (not individual proteins) obtained via cell lysis and differential centrifugation (or potentially other method of purification / extraction of the organelles) subcellular format bao:BAO_0000221 Involves the use of a tissue derived from a living organism and is a heterogeneous assay type. tissue-based format bao:BAO_0000222 Includes all hydrolases except phosphatases and proteases. generic hydrolase bao:BAO_0000223 Two or more proteins interact to form a stable complex. Each of the members of this complex has a distinct role in mediating the overall function of the complex, which can be as a chaperone (DnaK, DnaJ and grpE), an enzyme (mitochondrial respiratory complexes), a signaling complex (G-proteins), etc. It can be viewed as a quaternary structure of the proteins. protein complex format bao:BAO_0000224 In this format, the perturbagen targets a protein to regulate its function. protein format bao:BAO_0000225 In this format, the perturbagen targets a nucleic acid (DNA or RNA) to regulate its function. nucleic acid format bao:BAO_0000226 PNA or protein nucleic acid is an artificially synthesized polymer whose backbone is composed of repeating N-(2-aminoethyl)-glycine units linked by peptide bonds. Since PNA does not contain charged phosphate groups in its backbone, the interaction between PNA-DNA is stronger than that between DNA-DNA due to the lack of electrostatic repulsion. protein nucleic acid PNA bao:BAO_0000228 Fusion proteins or chimeric proteins are created through the joining of two or more cDNAs which encode different proteins. Upon expression, a single polypeptide containing each of the proteins results. Generally, the protein of interest is tagged with a reporter protein, e.g. luciferase, GFP, etc, whose expression could easily be monitored. fused bao:BAO_0000230 A quality of the genetic material (DNA or RNA) that harbors a change (mutation), where one or more nucleotides are lost (spontaneously) or removed (intentionally). deleted bao:BAO_0000232 Viruses are small infectious agents that depend on the host cells to reproduce. Outside the host, they contain a protein coat called capsid that encloses their genetic material (either DNA or RNA). Viruses can infect bacteria, plants and animals and cause a number of diseases, e.g. smallpox, chickenpox, influenza, polio, rabies, etc. virus bao:BAO_0000233 It includes the baker's yeast (Saccharomyces cerevisiae) and fission yeast (Schizosaccharomyces pombe), which are unicellular. unicellular fungi bao:BAO_0000236 Tumor necrosis factor bao:BAO_0000237 The proteins located on the cell surface which are involved with the binding with other cells or the extracellular matrix. They belong to 5 families: Immunoglobulin superfamily, integrins, cadherins, selectins and the lymphocyte homing receptors. adhesion This describes the type of alterations performed on the cell line, which include plasmid transfection, viral transduction, cell fusion, etc. cell line modification method bao:BAO_0000239 Cells that are cultured from a subject (tissue or tumor) and which are not immortalized. They can undergo only a limited number of cell divisions prior to reaching senescence. primary cell Cell fusion is the formation of a hybrid cell from two different cells of same or different species. After such fusion, one of the parental cells has a dominant phenotype over the other, and the resulting hybrids will have the features of only one of the parental cells. Fusion is performed to understand the dominance of genetic material, DNA recombination events, etc. cell fusion method This refers to the introduction of cloned genes into cells by various methods, including transfection, transduction, electroporation, nucleofection, etc. It is generally performed to express the exogenously introduced gene and study its effect on the cell. In addition, DNA encoding regulatory moieties, such as siRNA is similarly introduced to inhibit the expression of a specific gene(s). genetic modification method Cell fusion is the formation of a hybrid cell from two different cells of same or different species. Fusion cybrids are created by fusing a nucleated and an enucleated (nucleus removed) cell. The resulting cybrids have one nucleus, but they contain the mitochondria from both the parental cells. This allows one to study the mitochondrial inheritance and to ascertain the role of mitochondrial DNA mutations in diseases. cybrid cell creation method Cell fusion is the formation of a hybrid cell from two different cells of same or different species. Fusion hybrids are created by fusing two nucleated cells obtained from same or different species. hybrid cell creation method This refers to the infection of cells with either a pathogenic or a modified virus, which introduces viral genome into the cells. Pathogenic viruses include the influenza virus, measles virus, Japanese encephalitis virus, etc. For recombinant expression of proteins in cells or tissues, several types of viruses are utilized, including lentivirus, retrovirus, adenovirus, etc, with each having their own advantages and disadvantages. viral transduction method This refers to the introduction of nucleic acids into cells using a construct. Plasmids constructs are created by the insertion of a gene or siRNA encoding DNA of interest into a plasmid. The engineered plasmids are introduced into cells by various means, namely, transfection, electroporation, nucleofection, etc which regulates the efficiency and location of gene transfer, for e.g., nucleofection delivers the plasmid directly into the nucleus in contrast to the other methods that deliver into the cytosol. transfection method In this method, the introduced plasmid construct is stably integrated in the cellular genome, and is hence a permanent modification of the cells. This is achieved by selecting for cells which express a plasmid-encoded selectable marker, which is commonly an antibiotic resistance protein. stable transfection It is the temporary introduction of a gene or siRNA encoding DNA of interest into a cell using various plasmids. Usually, the transiently transfected DNA remains in the cell for 2-3 days and is functional: expresses the gene of interest. There are numerous transient transfection reagents and protocols available that have been optimized for various cell lines. transient transfection bao:BAO_0000248 The title of the kit/biologicals used in the assay. assay kit bao:BAO_0000249 The thin outer covering of a cell consisting of lipid-bilayer embedded with proteins. It is semi-permeable and is also called "plasma membrane" cell membrane format bao:BAO_0000250 The fluid component of cytoplasm, without the organelles and the insoluble cytoplasmic components. cytosol format bao:BAO_0000251 Microsomes are vesicle-like structures formed as an artifact from the endoplasmic reticulum after the cell has been ruptured by homogenization. microsome format bao:BAO_0000252 An organelle found in the cytoplasm of eukaryotic cells that metabolizes glucose and other sugars to produce usable energy in the form of ATP. It contains its own genome which encodes proteins, tRNA and rRNA. mitochondrion format bao:BAO_0000253 It is a soluble extract prepared from the cellular nuclei, which are obtained by differential centrifugation of the cell lysate. nuclear extract format bao:BAO_0000254 A cell whose membrane has been ruptured, either mechanically or by freeze-thawing. The entire cell lysate is used in the assay without extensive purification (or separation). whole cell lysate format bao:BAO_0000255 The lysate contains the cellular components necessary for in vitro protein synthesis (tRNA, ribosomes, amino acids, initiation, elongation and termination factors). It is prepared from rabbit reticulocytes by lysis, followed by treatment with micrococcal nuclease to destroy endogenous mRNA for background reduction. rabbit reticulocyte lysate format Increase in perturbation (reported by the endpoint mode of action, activation) is correlated to increase in signal. signal increase corresponding to activation Increase in perturbation (reported by the endpoint mode of action, inhibition) is correlated to decrease in signal. signal decrease corresponding to inhibition bao:BAO_0000264 Any process specifically pertinent to the functioning of integrated living units: cells, tissues, organs, and organisms. A process is a collection of molecular events with a defined beginning and end (from GO). true biological process 1 bao:BAO_0000269 DNA or deoxyribonucleic acid is the genetic material in all the living things, and some viruses. It is a polymer of nucleotides, with a backbone made of deoxyribose sugar and phosphate groups joined together by ester bonds. DNA bao:BAO_0000270 RNA or ribonucleic acid is a polymer of nucleotides with a backbone made of ribose sugar and phosphate groups linked together by ester bonds. RNA has the base uracil instead of thymine, which is present in DNA. RNA bao:BAO_0000271 IFN-gamma Interferon gamma bao:BAO_0000274 mRNA or messenger RNA is a genetic intermediate between DNA and protein. It is transcribed from DNA by RNA polymerases which is further processed by other enzymes. mRNA serves as the template to synthesize proteins on the ribosomes. mRNA bao:BAO_0000275 rRNA or ribosomal RNAs are present in ribosomes in a cell. Ribosomes are protein translation machinery which can read messenger RNAs and translate that information into proteins. rRNA bao:BAO_0000276 tRNA or transfer RNA is a small RNA molecule that transfers a specific active amino acid to a growing polypeptide chain at the ribosomal site of protein synthesis. tRNA bao:BAO_0000277 They have an essential role in the regulation of protein conformation states. Molecular chaperones help nascent polypeptides fold correctly and multimeric protein complexes assemble properly, and reduce the possibility of protein aggregation. chaperone bao:BAO_0000278 It modulates the activity of an enzyme. enzyme regulator bao:BAO_0000279 Enzymes are biological catalysts involved in important pathways that allow chemical reactions to occur at higher rates (velocities) than would be possible without the enzyme. Enzymes are generally globular proteins that have one or more substrate binding sites. enzyme bao:BAO_0000280 Ion channels are present in the cell membrane. They are pore-forming protein complexes that facilitate diffusion of ions across membranes and thus establish the small voltage gradient across the plasma membrane of living cells. ion channel bao:BAO_0000281 A membrane or intracellular protein that specifically binds a known stimulus of cellular activity, such as a hormone, growth factor, antigen, neurotransmitter, drug, etc. receptor bao:BAO_0000282 It is a protein that binds to a specific sequence of DNA (upstream of the genes that it regulates) and regulates gene expression. transcription factor bao:BAO_0000283 A transporter protein is a transmembrane protein that helps transport small molecules and proteins across the membrane. This is done using facilitated diffusion or active transport. transporter bao:BAO_0000284 G protein-coupled receptors (GPCRs), comprise the largest integral membrane protein family with nearly 1000 members. They integrate extracellular signals from hormones, growth factors, neurotransmitters, etc to downstream cellular responses. They are important pharmacological targets, being associated with a number of diseases. Upon ligand binding extracellularly, the GPCR signals through a downstream heterotrimeric G protein complex, consisting of the α, β and γ subunits. G protein coupled receptor bao:BAO_0000285 Transmembrane receptors are integral membrane proteins in either the cell- or organelle-membrane. They bind specific hormones, neurotransmitters, cytokines, growth factors, etc and initiate cell signaling, which results in changes in the cell function. transmembrane receptor bao:BAO_0000286 Nuclear receptors are localized in the cytosol and mediate the activity of hormones and certain vitamins. They are all transcription factors, which upon activation by ligand binding, translocate to the nucleus, bind specific DNA sequence and activate gene expression. nuclear receptor bao:BAO_0000287 Formation of two products from a substrate by hydrolysis. hydrolase bao:BAO_0000288 Intramolecule rearrangement, i.e. isomerization changes within a single molecule. isomerase bao:BAO_0000289 Join together two molecules by synthesis of new C-O, C-S, C-N or C-C bonds with simultaneous breakdown of ATP. ligase bao:BAO_0000290 Non-hydrolytic addition or removal of groups from substrates. C-C, C-N, C-O or C-S bonds may be cleaved. lyase bao:BAO_0000291 To catalyze oxidation/reduction reactions; transfer of H and O atoms or electrons from one substance to another. oxidoreductase bao:BAO_0000292 Transfer of a functional group from one substance to another. The group may be methyl-, acyl-, amino- or phosphate group. transferase bao:BAO_0000293 Includes all transferases except kinases. generic transferase bao:BAO_0000294 A protein kinase is an enzyme that modifies other proteins by chemically adding phosphate groups to them. The substrate protein's activity, localization and overall function is modulated by the kinase reaction. kinase bao:BAO_0000295 A phosphatase is an enzyme that removes a phosphate group from its substrate by hydrolysis of phosphoric acid esters. phosphatase bao:BAO_0000297 Perkin Elmer bao:BAO_0000298 Date from BAE: 6/1/2016 PubChem AID: Steady-Glo Luciferase Assay System bao:BAO_0000299 Date from BAE: 6/1/2016 PubChem AID: Proteasome-Glo Chymotrypsin-Like Assay bao:BAO_0000303 Promega bao:BAO_0000305 Cambrex bao:BAO_0000306 Lonza bao:BAO_0000307 PKLight bao:BAO_0000310 Date from BAE: 6/1/2016 PubChem AID: P450-Glo CYP3A4 Screening System bao:BAO_0000311 Date from BAE: 6/1/2016 PubChem AID: P450-Glo CYP2D6 Screening System bao:BAO_0000313 Morpholinos are antisense oligos that bind to specific mRNAs to reduce gene expression. They are small (~25 base) and possess altered back structures compared to DNA or RNA making them resistant to cleavage by nucleases. They are used extensively as tools to investigate zebrafish, Xenopus and sea urchin embryonic development. morpholino oligonucleotide bao:BAO_0000315 cDNA or complementary DNA is complementary in sequence to a particular messenger RNA (mRNA). It is synthesized from mRNA in a reverse transcription reaction by reverse transcriptase enzyme. cDNA can be cloned in a vector and introduced into cells to bring about the expression of that particular gene in those cells. complimentary deoxyribonucleic acid cDNA bao:BAO_0000316 DNA that is linear and not circular. Examples of linear DNA include synthetic oligonucleotide, restriction endonuclease digestion product, polymerase chain reaction product, mechanically sheared genomic DNA, etc. linear deoxyribonucleic acid genomic DNA bao:BAO_0000317 Plasmid is a double stranded circular DNA molecule that can replicate independently of the chromosomal DNA. It exists naturally in bacteria and some yeast. In genetic engineering, plasmids are exploited to clone and multiply a gene of interest. Several plasmid vectors are available commercially to introduce cloned DNA into different cell types. plasmid deoxyribonucleic acid plasmid DNA bao:BAO_0000322 miRNAs or microRNAs are short RNAs (~22 nucleotides long) that bind to complementary sequences in the three prime untranslated regions (3' UTRs) of target messenger RNA transcripts (mRNAs), usually resulting in gene silencing. micro RNA micro ribonucleic acid miRNA bao:BAO_0000323 Short hairpin RNA (shRNA) can be used to achieve stable knockdown of gene expression. shRNA molecules are cloned into lentiviral or other vectors and expressed by a pol III type promoter. short hairpin RNA short hairpin ribonucleic acid shRNA bao:BAO_0000324 In the RNAi pathway, the double stranded RNAs first get processed into 20-25 nucleotide small interfering RNAs (siRNAs) by an RNase III-like enzyme called Dicer. The siRNAs enter into endoribonuclease-containing complexes known as RNA-induced silencing complexes (RISCs), and bring about the cleavage of the target mRNAs to achieve gene silencing. small interfering ribonucleic acid siRNA bao:BAO_0000325 Peptide is a short polymer of amino acids, which is generally <50 amino acids long. peptide bao:BAO_0000333 Date from BAE: 6/1/2016 PubChem AID: P450-Glo CYP2C9 Screening System bao:BAO_0000334 The role played by the reading obtained from wells to which the sample or one of the reagents was not added. This is subtracted from all the experimental readings prior to further analysis. background control 50.0 bao:BAO_0000346 50% increase of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. 50% activation 50 percent activation 50.0 bao:BAO_0000347 50% reduction of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. 50% inhibition 50 percent inhibition 80.0 bao:BAO_0000348 80% reduction of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. 80% inhibition 80 percent inhibition 50.0 bao:BAO_0000349 Assay has 50% living cells. Unit of Measure is always % when normalized to the dynamic range of the assay. 50% viability 50 percent cell viability This describes the method by which a protein is purified from its source. protein preparation method bao:BAO_0000357 one protein sequence single protein format bao:BAO_0000360 This involves cloning the cDNA of the gene of interest in a plasmid or viral vector and introducing it into a bacterial, insect or mammalian cell for expression. The expressed protein is then purified after lysing the cells followed by a series of centrifugation and, or chromatography and electrophoresis methods. recombinant expression bao:BAO_0000362 This includes animal models typically used in drug discovery for toxicity or pharmacology studies, such as mouse, rat (mammals). mammalian bao:BAO_0000363 Fluorescence intensity is the measure of fluorescence from a sample. fluorescence intensity bao:BAO_0000364 Bacteria lack membrane bound organelles and are surrounded by a rigid cell wall. Though they are unicellular, they function by aggregating into multicellular colonies. bacterium bao:BAO_0000365 Proteins localized in the cytosol, but do not belong to the transcription factor, transporter, structural, enzyme, enzyme regulator and nuclear receptor classes of proteins in the cytosol. cytosolic protein bao:BAO_0000366 This originates from a cell, but does not use intact (live) cells; does not include biochemical assays, which is one of the major formats that is categorized separately. It is most often a homogeneous assay type, but can be heterogeneous if a solid phase such as beads are used to immobilize the components. cell-free format bao:BAO_0000367 Membrane proteins are associated with the cell membrane. They can be classified into two broad categories membrane protein bao:BAO_0000368 There are two distinct G protein families, namely the heterotrimeric G proteins (consisting of the α, β and γ subunits) downstream of the G protein coupled receptors (GPCRs) and the monomeric G proteins that belong to the Ras superfamily of GTPases. Upon ligand binding, the GPCR undergoes a conformational change, which allows it to act as a guanine nucleotide exchange factor (GEF) of an associated G protein. The GTP-bound G α subunit then signals by regulating the activity of adenylate cyclase, phospholipase, or Rho GEFs. G protein bao:BAO_0000369 These proteins are translocated from the inside of the cell to the cell's exterior. Proteins targeted for secretion undergo glycosylation and other postranslational modifications in the endoplasmic reticulum and the golgi complex, and are enclosed in secretory vesicles. The fusion of vesicles to the cell membrane releases the secretory proteins to the exterior. Examples include growth factors, tumor necrosis factors, cytokines, etc. secreted bao:BAO_0000370 These proteins constitute the largest class with respect to the total protein mass. They are fibrous proteins, e.g. keratin, actin, myosin, etc whose primary function is to provide scaffolding that maintains cell shape. structural bao:BAO_0000371 It refers to whether all the assay components are in solution or some are in solid phase, which determines their ability to scatter light. assay phase characteristic bao:BAO_0000372 All assay components exist in solution phase at the time of detection (e.g. none of the components are in beads or cells). Technically no component scatters light. homogeneous phase bao:BAO_0000373 One or more assay components are present in solid phase at time of detection. (e.g.: cells, beads). heterogeneous phase The ratio of biological activity in the presence of an exogenous substance to that in its absence. This result type is used exclusively with single point (screening concentration) assays. fold activation The ratio of biological activity in the absence of an exogenous substance to that in its presence. This result type is used exclusively with single point (screening concentration) assays. fold inhibition All living cells maintain a resting membrane potential, which is the difference in voltage between the interior and exterior of the cell. Electrically active cells, such as neurons, muscle and endocrine cells undergo changes in membrane potential due to depolarization and hyperpolarization as a result of opening and closing of ion channels. Action potentials are large and rapid changes in membrane potential which are generated as a result of a large depolarization event. In neurons, action potentials are used to transmit signals across neurons, while in muscle and endocrine cells, they lead to intracellular events, such as muscle contraction and hormone release, respectively. In addition, mitochondria possess a trans-membrane potential as a result of their respiratory function. Membrane potential can be measured either by using electrophysiological techniques or by staining with dyes whose binding is dependent on the membrane potential. membrane potential measurement method bao:BAO_0000378 Cellular signaling can bring about the movement of proteins in cells. Upon receiving a cue, proteins undergo posttranslational modifications, e.g. phosphorylation, dephosphorylation, etc, which results in their activation and migration to different compartments, often to the nucleus, where they regulate gene expression. Add a relation between this class and immunoassay using a new object property 'is detected by'. protein redistribution assay bao:BAO_0000379 Second messengers relay signals from the receptors to the cell interior as part of a signaling event. In the process, they amplify the signal. Examples include cAMP, cGMP, calcium, nitric oxide, diacylglycerol, etc, which play important roles in different physiological processes. second messenger redistribution assay bao:BAO_0000382 Electrically active cells, such as neurons, muscle and endocrine cells undergo changes in membrane potential due to depolarization and hyperpolarization as a result of opening and closing of ion channels. The electrical recordings from these cells are obtained by the insertion or attaching microelectrodes to these cells. Patch clamp, voltage clamp and current clamp are three ways of studying the current-voltage relationships of these ion channels. microelectrode measurement bao:BAO_0000384 The comment deposited by the assay provider, which summarizes the screening campaign with respect to the identification of lead compounds and chemical probes. summary comment bao:BAO_0000392 This class includes membrane proteins other than g-proteins, such as regulators of g-protein, GTPases, etc. generic membrane protein bao:BAO_0000394 Protein-nucleotide interaction protein-nucleotide interaction assay bao:BAO_0000401 This assay is performed to study interaction between a radio-labeled ligand and the receptor. The reaction mixture containing the receptor and radioligand is transferred to a filter plate, washed to remove the unbound radioligand. The bound complex remains on the filter, which can be eluted into the scintillation fluid and the radioactivity measured. Filter assays differ from SPA because a separation of free radioligand and radioligand bound to the receptor is required for measurement. [EdgeRewiring: BAO v 2.8.14 (April 2025)] filter assay It is used for analysis of receptor-ligand interactions in screening applications. It utilizes a radiolabeled ligand and a source of receptor (membranes, soluble/purified). radioligand binding method bao:BAO_0000404 X-ray crystallography is used to analyze protein-small molecule interactions. This binding interaction is monitored by measuring the difference of diffraction between protein-compound binding complex and protein alone. With this technique, both the binding interaction and bound compounds can be detected, which allows pools of 5-100 compounds to be tested for binding. x ray crystallography bao:BAO_0000405 It involves the incorporation of radiolabeled precursors into uniform distribution with a liquid medium capable of converting the kinetic energy of nuclear emissions into light energy. A scintillation counter is used to measure ionizing radiation. The scintillation counter consists of a sensor, called a scintillator, made of transparent crystal or an organic liquid that fluoresces when struck by ionizing radiation. A photomultiplier is then used to measure the light emitted by the sensor and is attached to an electronic apparatus that amplifies and quantifies the radiation signal. scintillation counting This is used to study the interaction of two proteins. An enzyme or fluorescent protein is rationally dissected into two fragments and fused to two test proteins, whose interaction is being studied. Binding of the two test proteins results in the reconstitution of the enzyme or fluorescent protein from the two fragments, which can be measured. protein fragment complementation method bao:BAO_0000407 This is typically performed in HCS, where multiple parameters are measured simultaneously from a single cell / well, by the detection of several fluorescent labels. E.g., neurite length, nuclear size, protein translocation, etc. multi parameter readout bao:BAO_0000408 This assay is performed to study interaction between a radio-labeled ligand and the receptor in presence of cold ligand. The cells exposed to the radioligand and cold ligand are washed to remove the unbound ligands. They are then lysed and the bound radioactivity is counted in a liquid scintillation counter. [EdgeRewiring: BAO v 2.8.14 (April 2025)] lysate based bao:BAO_0000409 This describes whether a change in an assay is measured once at one fixed end-point or over a period of time at several time points. assay measurement type bao:BAO_0000410 Reported results do not have a time dimension, but represent a static response. This does not mean that the result is indepent from the time of measurement, such as cell viablity at 12, 24 or 72h where the time point is associated metadata. end-point assay endpoint assay bao:BAO_0000411 The measurements and reported outcome / result of the kinetic assay quantify a change / response over a time course; the reported result has a time component, for example a reaction constant or rate. This is in contrast to an endpoint that does not have a time dimension, but is associated with a time point as metadata, such as cell viablity at 12, 24 or 72 hs, but not the speed with which the cells propargate or die. binding kinetics kinetic analysis kinetics assay kinetic assay bao:BAO_0000412 Locked nucleic acid (LNA) is a nucleic acid analogue containing one or more LNA nucleotide monomers with a bicyclic furanose unit locked in an RNA mimicking sugar conformation. LNA oligonucleotides have high affinity toward complementary single-stranded RNA and complementary single- or double-stranded DNA. This makes LNA suitable for sequence specific targeting of RNA in vitro or in vivo. locked nucleic acid LNA This technique is used to detect proteins and peptides in a tissue section by binding to specific antibodies. Subsequently, a secondary antibody that is conjugated to a fluorophore or an enzyme needed for the detection of a signal is hybridized to the primary antibody. Signal is generally detected by immunofluorescence or less commonly, by a colored reaction. This allows the detection and subcellular localization of the protein of interest by visualization under a microscope. immunohistochemistry This technique is used to detect proteins and peptides in a cell by binding to specific antibodies. Subsequently, a secondary antibody that is conjugated to a fluorophore or an enzyme needed for the detection of a signal is hybridized to the primary antibody. Signal is generally detected by immunofluorescence or less commonly, by a colored reaction. This allows the detection and subcellular localization of the protein of interest by visualization under a microscope. immunocytochemistry bao:BAO_0000418 Fungi are either unicellular or multicellular and include yeasts, molds, mushrooms, etc. Several parasitic fungi exist, which infect animals and plants, e.g., Aspergillus flavus, Claviceps purpurea, Pneumocystis jirovecii, etc. fungi This refers to the correction performed on the raw data values from an assay. B-score correction is a common method used for this purpose. endpoint correction bao:BAO_0000423 Activity of the mitochondrial respiratory chain results in the generation of a proton gradient which consists of two components: a membrane potential and a pH gradient. Disruption of delta-psi has been shown to be one of the first intracellular changes following the onset of apoptosis. Delta-psi is generally quantitated by staining with specific dyes whose binding is dependent on the potential and less commonly, by electrophysiological techniques. mitochondrial membrane potential assessment Electrically active cells, such as neurons, muscle and endocrine cells undergo changes in membrane potential due to depolarization and hyperpolarization as a result of opening and closing of ion channels. The electrical recordings from these cells are obtained by the insertion or attaching microelectrodes to these cells. Patch clamp, voltage clamp and current clamp are three ways of studying the current-voltage relationships of these ion channels. electrophysiological method Most often, the mitochondrial membrane potential which is called delta-psi is quantitated by staining with specific dyes whose binding is dependent on the potential. dye binding method bao:BAO_0000427 It allows the detection of binding interactions and cell-based reactions without the need to use conventional labels, e.g., fluorescent probes. The advantages include the ability to measure a) functional activity without modifying the binding partners with labels, b) binding interactions independent of functional activity, and c) cell-Based GPCR assays without the need for engineering cell-lines to over-express given receptors. label free method bao:BAO_0000428 ITC is a thermodynamic technique that can directly measure the heat released or absorbed during a biomolecular binding event. It can measure the binding affinity (Ka), reaction stoichiometry (n), enthalpy (∆H) and entropy (ΔS) of the interaction between two or more molecules in solution.</obo:IAO_0000115> ITC isothermal titration calorimetry The B score is an analog of the Z score, but is more resistant to the presence of outliers and to differences in the measurement error distributions of the compounds. It is calculated by first computing a two-way median to account for row and column effects of the plate, which is then divided by their median absolute deviation to standardize for plate-to-plate variability. B-score bao:BAO_0000431 The (raw) measurement is normalized as a percentage of the positive control. This is typically done by plate. % control percent control normalization Random and systematic error can induce either underestimation (false negatives) or overestimation (false positives) of measured signals. Z score indicates how many standard deviations an observation is above or below the mean. For calculating this, the average of the plate values is subtracted from individual raw values and the difference divided by the standard deviation estimated from all measurements of the plate. Z-score Curve fit methods include Levenberg-Marquardt, Simplex, Linear Regression (linear least-squares), etc. The Levenberg-Marquardt method is a robust algorithm and has become the standard for non-linear regression. curve fit method bao:BAO_0000434 Has curve fit parameters, curve fit method, properties like Hill coefficient, concentration range, and measurement repetition. It involves capturing the trend in the data by assigning a single function across the entire range. The goal of curve fitting is to find the parameter values that most closely match the data. curve fit specification The Hill equation is commonly used to estimate the number of ligand molecules that are required to bind to a receptor to produce a functional effect. The Hill coefficient can be considered as an interaction coefficient, reflecting the extent of cooperativity among multiple ligand binding sites. Hill equation bao:BAO_0000441 An assay based on the competition between a labeled and an unlabeled ligand in the reaction with a receptor binding agent (e.g. antibody, receptor, transport protein). competitive binding Non-competitive ligands interact with receptors at sites distinct from the competitive ligand binding pocket, conferring multiple modes of action. non-competitive binding It identifies whether the data has been normalized (by Z and Z' factors, signal to background, signal to noise, and coefficient of variance), or if it was an immediate readout obtained from a HTS assay. input data Data can be normalized by Z and Z' factors, signal to background, signal to noise, and coefficient of variance. Plate based normalization is usually based on controls. In the absence of controls, the Z-score can be used to normalize the data by plate. normalized data The readout obtained from a HTS assay which includes measurements from the positive and negative control wells in each plate. This is the data that needs to be processed. raw data bao:BAO_0000448 The technologies used to measure the size and shape of cells and organelles (phenotype). These are detected by microscopy. morphology assessment method bao:BAO_0000449 Electron microscopy involve the diffraction, reflection, or refraction of electron beams interacting with the subject of study, and the subsequent collection of this scattered radiation in order to build up an image. EM electron microscopy bao:BAO_0000450 Fluorescence microscopy is used to image the distribution of molecules based on the properties of fluorescence emission. Excitation of fluorescent molecules with a specific wavelength results in the production of an image by the secondary fluorescence emission at longer wavelengths. fluorescence microscopy bao:BAO_0000451 Optical or light microscopy involves passing visible light transmitted through or reflected from the sample through a single or multiple lenses to allow a magnified view of the sample optical microscopy bao:BAO_0000452 The field of using microscopes to see objects that cannot be seen with the unaided eye. imaging method bao:BAO_0000453 Confocal microscopy has advantages over widefield optical microscopy, including the ability to eliminate or reduce background information away from the focal plane and collect serial optical sections from thick specimens. It uses point illumination and a spatial pinhole to eliminate out-of-focus light in specimens that are thicker than the focal plane. confocal microscopy bao:BAO_0000454 Scanning electron microscopy (SEM) visualizes details on the surfaces of cells and particles and gives a very nice 3D view. It gives results much like those of the stereo light microscope, and, akin to that, its most useful magnification is in the lower range than that of the transmission electron microscope. SEM scanning electron microscopy bao:BAO_0000455 Transmission electron microscopy (TEM) is quite similar to the compound light microscope, by sending an electron beam through a very thin slice of the specimen. The resolution limit in 2005 was approximately 0.05 nanometer and has not increased appreciably since that time. TEM transmission electron microscopy bao:BAO_0000456 Quartz crystal microbalance (QCM) technology is based on measuring the resonant frequency of piezoelectric quartz crystals. It allows measurement of important cellular parameters such as adhesion, proliferation and cytotoxicity. It is also used for the identification of protein ligands by immobilized receptors. QCM quartz crystal microbalance bao:BAO_0000457 In brightfield microscopy, sample is illuminated with transmitted white light from below and observed from above. brightfield microscopy bao:BAO_0000458 Phase contrast microscopy shows differences in refractive index as difference in contrast. Regions with higher contrast, e.g. nuclei, appear darker than the surrounding cytoplasm. phase contrast microscopy bao:BAO_0000459 It forms images of surfaces using a physical probe that scans the specimen and measuring on a fine scale, down to the level of molecules and groups of atoms. The resolution is not limited by the diffraction, but by the size of probe-sample interaction volume. Atomic force microscopy (AFM), scanning tunneling microscopy (STM), and near-field scanning optical microscopy (NSOM) are the three common scanning probe techniques. scanning probe microscopy bao:BAO_0000461 BRET is similar to FRET but has a bioluminescent protein such as aequorin as the donor and a fluorescent acceptor, e.g. GFP. The donor emits blue light in the absence of GFP, but when GFP and aequorin are associated as they are in vivo, GFP accepts the energy from aequorin and emits green light. Hence BRET eliminates the disadvantages associated with donor fluorophore activation. BRET bioluminescence resonance energy transfer bao:BAO_0000462 Chemiluminescence resonance energy transfer (CRET) is a resonance energy transfer between chemiluminescent donors and fluorescent acceptors. CRET occurs by the oxidation of a luminescent substrate, such as luminol/hydrogen peroxide reaction catalyzed by horseradish peroxidase. CRET eliminates the disadvantages associated with donor fluorophore activation. CRET chemiluminescence resonance energy transfer Following a western analysis, the individual proteins in a gel, blot, or autoradiogram are quantitated by a densitometric scan over a limited range of protein concentration per band (1-10 ug). A scanner measures the optical density of the material by directing a beam of light and measuring its transmission or reflection. densitometric scan bao:BAO_0000465 Crude protein preparation unpurified bao:BAO_0000466 Ex situ refers to out of place or position, with respect to the antigen that is being tested in the immunoassay. Usually the antigen is present in a tissue or cell lysate, or as a purified protein in the assay. ex situ immunoassay bao:BAO_0000467 This assay is performed using a different assay format with respect to the primary or confirmatory assay. alternate assay format A digital system used for quantitating proteins in gels, blots, etc. signal quantitation method This technology relates to measurement of nucleic acid conformational properties using one of the following methods: circular dichroism spectroscopy, thermal shift, fluorescence resonance energy transfer (FRET), nuclear magnetic resonance (NMR), X-ray crystallography, etc. nucleic acid conformation assessment This technology relates to measurement of protein conformational properties using one of the following methods: circular dichroism spectroscopy, thermal shift, fluorescence resonance energy transfer (FRET), nuclear magnetic resonance (NMR), X-ray crystallography, etc. protein conformation assessment bao:BAO_0000471 Carbon nanotubes (CNT) are rolled up seamless cylinders of graphene sheets, exhibiting many unique physical, mechanical and chemical properties. CNT based biosensors are used to detect protein interactions, e.g. protein-DNA, antibody-aptamer interaction, etc. carbon nanotube based sensor bao:BAO_0000473 Small molecules which are either natural or synthetic are immobilized by robotic printing on a solid support, such as a functionalized glass slide. Protein targets either purified or from a lysate are hybridized to the immobilized small molecules in an attempt to identify the natural ligands for proteins, and also molecules that could regulate their function. small molecule array bao:BAO_0000474 This contains complex samples, such as cell or tissue lysates, spotted on an array surface and interrogated with antibodies. lysate array Concepts describing the type of perturbagen interaction with the receptor. ligand binding mode of action The concentration of substrate at ½ Vmax, according to the Henri-Michaelis-Menten kinetic model. km bao:BAO_0000478 Assay employed to elucidate the specificity of biologically active chemical entities towards one or more targets that are (closely) related to the (intended) primary target. biochemical selectivity biochemical specificity selectivity selectivity profiling specificity selectivity assay The off-rate associated with the release of inhibitor from an enzyme-inhibitor complex. koff The on-rate associated with the formation of an enzyme-inhibitor complex. kon Turnover number representing the maximum number of substrate molecules converted to products per active site per unit time. kcat bao:BAO_0000482 A competitive inhibitor binds only to free enzyme. Often this binding event occurs on the active site of the target, precisely where substrate also binds. It will raise the apparent KM value for its substrate with no change in the apparent Vmax value. As a result, competitive inhibition can be overcome, observed by an increase in the apparent KI value, at higher concentrations of substrate. competitive inhibition An uncompetitive inhibitor binds exclusively to the enzyme-substrate complex yielding an inactive enzyme-substrate-inhibitor complex. When encountered, the apparent Vmax value and the apparent KM value should both decrease. uncompetitive inhibition A noncompetitive inhibitor binds equally well to both free enzyme and the enzyme-substrate complex. These binding events occur exclusively at a site distinct from the precise active site occupied by substrate. It will lower the apparent Vmax value, yet there is no effect on the apparent KM value for its substrate. Essentially, the KI of the inhibitor does not change as a function of the substrate concentration. non-competitive inhibition Describe kinetics of enzyme-catalyzed reactions. It includes the enzyme kinetic constants namely, Km and Vmax, which help to model the time course of disappearance of substrate and the production of product. enzyme kinetic constant Partial inhibition results from the formation of an enzyme-substrate-inhibitor complex that can generate product with less efficiency than the enzyme-substrate complex. partial inhibition An allosteric effector operates to enhance active site substrate affinity and/or catalysis. An allosteric inhibitor decreases activity by binding to an allosteric site, other than or in addition to the active site on the target. This interaction is characterized by a conformational change in the target enzyme that is required for inhibition. allosteric modulation In this type of inhibition, the population of free, soluble inhibitor is significantly depleted by the formation of the enzyme-inhibitor or enzyme-substrate-inhibitor complex. While tight-binding inhibitors can bind to the target enzyme in a competitive, noncompetitive, or uncompetitive manner with respect to substrate binding, they can display noncompetitive phenotypes. tight binding inhibition Time-dependent inhibitors bind slowly to the enzyme on the time scale of enzymatic turnover, and thus display a change in initial velocity with time. This has the effect of slowing the observed onset of inhibition. time dependent inhibition bao:BAO_0000492 In this method, antibodies or peptides are spotted on a support to be hybridized to analytes in complex mixtures of proteins. analytical array Chloramphenicol acetyltransferase (CAT) gene is attached to the regulatory sequence of a gene of interest. When induced to express, CAT breaks down the antibiotic chloramphenicol resulting in a resistance against that antibiotic. The effect of a perturbagen on the expression of the gene of interest could easily be monitored by the gain of antibiotic resistance by the cells. CAT induction chloramphenicol acetyltransferase induction bao:BAO_0000495 Aptamers are synthetic affinity probes. DNA aptamers are oligonucleotides that bind to a specific target molecule, such as small molecules, proteins, nucleic acids and cells. They are created by selecting them from a large random sequence pool through repeated rounds of in vitro selection. deoxyribonucleic acid aptamer DNA aptamer bao:BAO_0000496 Aptamers are synthetic affinity probes. RNA aptamers are oligonucleotides that bind to a specific target molecule such as small molecules, proteins, nucleic acids and cells. They are created by selecting them from a large random sequence pool, but natural aptamers also exist in riboswitches. ribonucleic acid aptamer RNA aptamer bao:BAO_0000497 Aptamers are synthetic affinity probes. Peptide aptamers consist of a variable peptide loop attached at both ends of a protein scaffold, such as thioredoxin-A. They bind to target proteins with high affinity, similar to that of an antibody. They are designed to inhibit the function of other protein inside the cell. peptide aptamer bao:BAO_0000498 They are part of mRNA that regulate gene expression through ligand induced changes in mRNA secondary or tertiary structure. The ligand is generally a small metabolite which binds to the aptamer part of the riboswitch. riboswitch The technologies used to measure the movement of cells and organelles (phenotype). These are detected by microscopy. cell movement measurement method bao:BAO_0000500 Molecular beacons are hairpin shaped oligonucleotide probes with an internally quenched fluorophore whose fluorescence is restored upon binding to a target nucleic acid. They are used to detect nucleic acids in solution. molecular beacon bao:BAO_0000501 In this method, many different purified proteins are spotted on a support, and used to assay biochemical functions such as protein-protein, protein-DNA, protein-small molecule interactions and enzyme activity. purified protein array bao:BAO_0000502 Antibody is a protein (immunoglobulin) produced by the immune system of an organism in response to exposure to a foreign molecule (antigen) and characterized by its specific binding to a site of that molecule (antigenic determinant or epitope). Antibodies are used extensively as tools to characterize proteins. Antibodies are either monoclonal or polyclonal. antibody bao:BAO_0000503 Highly specific antibodies produced by the clones of a single hybrid cell, which is generated by the fusion of a B cell with a tumor cell. They recognize a unique epitope of an antigen. monoclonal bao:BAO_0000504 Nucleic acids, either DNA or RNA are immobilized by spotting on a solid support such as a glass slide. They are hybridized with labeled nucleic acids from a sample and the signals measured, which reflects the composition of the sample nucleic acids. This is performed to quantify gene expression under various situations, e.g. diseases, development, etc. nucleic acid array bao:BAO_0000505 This includes spotting purified proteins, cell or tissue lysates, antibodies, or peptides in order to quantify the proteome, or study protein-protein, protein-DNA, protein-small molecule interactions and enzyme activity. protein array bao:BAO_0000506 Gene arrays include a collection of gene-specific nucleic acids that have been placed at defined locations on a solid support, either by spotting or direct synthesis. Labeled nucleic acids from a sample are hybridized with target genes on the array and the signals measured, which reflects the composition of the sample nucleic acids. gene array bao:BAO_0000507 Antibodies produced by immunizing a mammal such as a mouse, rabbit or goat with an antigen. They are a mixture of antibodies produced from different B cells raised against any of the different epitopes of that antigen. polyclonal bao:BAO_0000508 The assay is performed in a microplate, which can either be 96 well, 384 well, or 1536 well plates. microtiter plate microwell plate microplate bao:BAO_0000509 This includes fungi, vertebrates and invertebrates. Eukaryotic cells have a well-defined nucleus and membrane enveloped organelles namely, mitochondria, endoplasmic reticulum, golgi apparatus, and lysosomes. eukaryote bao:BAO_0000510 This includes animals having a vertebral column, and model organisms from this group include the zebrafish, mouse, rat, etc vertebrate bao:BAO_0000511 These animals lack a vertebral column and many of which are used as model organisms in HTS screening including Drosophila, C.elegans, sea urchin, etc. invertebrate bao:BAO_0000512 This describes the physical format such as plate density in which an assay is performed, which is generally a microplate format, but can also be an array format. assay footprint bao:BAO_0000513 This microplate contains 96 wells. It is suitable for a low throughput assay. 96 well plate bao:BAO_0000514 The immobilization of thousands of small molecules, genes or proteins on a glass slide for performing binding studies. array bao:BAO_0000515 This microplate contains 384 wells. It is suitable for a HTS assay. 384 well plate bao:BAO_0000516 This microplate contains 1536 wells. It is highly miniaturized to accommodate more wells on one plate which reduces the plate handling time and allows working with very small volumes (few microliters) that reduces the cost of an assay. 1536 well plate bao:BAO_0000517 It is a PubChem-specific assay stage. A summary assay references and summarizes the assays in PubChem that correspond to a screening campaign or a probe development project. summary assay bao:BAO_0000518 This includes vertebrate model organisms such as the Danio rerio (zebrafish), Xenopus laevis, etc which are tested generally to understand development. non-mammalian It is the trend of measured readout signal, whether it increases or decreases in perturbagen treated wells, as compared to the untreated or carrier-treated wells and the endpoint mode of action of an assay. signal direction bao:BAO_0000520 This includes the different pieces of information about a PubChem bioassay that is available at the PubChem website, namely, the assay title, assay protocol, assay description, assay provider, endpoint name, etc. assay description bao:BAO_0000521 The name of a bioassay which is associated with each assay ID (AID). It contains information about the target tested, the stage of the assay (primary or confirmatory), the assay format (biochemical or cell based), etc. assay title bao:BAO_0000522 This contains the background information and rationale for performing a bioassay and is found on the PubChem website associated with each assay ID (AID). It also includes the assay design and some information on the related bioassays. assay narrative bao:BAO_0000523 This includes the methodology used to perform a particular bioassay and is found on the PubChem website associated with each assay ID (AID). It includes the assay components and the order in which they were added, the incubation times, detection method and the kit used, etc. use cito: citesForInformation or citeAsSourceData some DOI or PMID assay protocol bao:BAO_0000524 The role of an organization or individual to add an assay to a repository, such as PubChem. assay depositor bao:BAO_0000525 This is the PubChem assay remark that can be assigned by depositors to a bioassay. assay comment It describes the assay dynamic range considering range and data variation: Z=1-{3x[StdDev(sample)+StdDev(negcontrol)]/[Avg(sample)-Avg(negcontrol)]} Not to be confused with z-score. z factor It describes the assay dynamic range considering range and data variation: Z'=1-{3x[StdDev(poscontrol)+StdDev(negcontrol)]/[Avg(poscontrol)-Avg(negcontrol)]} z-prime factor Difference of signal between positive and negative controls; assay dynamic range: SW={Avg(poscontrol)-Avg(negcontrol)-3x[StdDev(poscontrol)+StdDev(negcontrol)]}/StdDev(poscontrol). signal window Measure of signal strength. S/N=[Avg(poscontrol)-Avg(negcontrol)]/[StdDev(poscontrol)+StdDev(negcontrol)] signal to noise Measure of the signal dispersion: CV=100x[StdDev(sample)/Avg(sample)] coefficient of variation bao:BAO_0000532 Assay measurements throughput quality describes the quality of the measurements performed on each sample, such as single concentration, single repetition, concentration-response, multiple repetitions, etc. assay measurement throughput 1 bao:BAO_0000533 Regular high-throughput screening (primary screening) to identify hits. multiple repetition bao:BAO_0000534 This is a typical HTS assay, which uses a plate reader and generates one or two readouts, in contrast to high content screening, which can generate tens to hundreds of parameters. HTS single readout 1 bao:BAO_0000535 Concentration-response (dose-response) screen in which each concentration is only measured once. This is equivalent to quantitative high-throughput screening (qHTS). multiple concentration bao:BAO_0000536 Multiple measurements (typically three) are preformed at a single concentration. This is often used as a mode of confirmatory screening following a primary screen. single concentration bao:BAO_0000538 Assays performed in the lead optimization stage. They are typically concentration-response high quality assays. They can involve a number of different assays depending on the required profile of the desired lead compound. Lead ProfilingScreen LeadProfilingScreen lead optimization lead profiling assay lead profiling screen lead optimization assay bao:BAO_0000543 orthogonal assay design bao:BAO_0000544 esiRNAs are endoribonuclease-prepared siRNA pools comprised of a heterogeneous mixture of siRNAs that all target the same mRNA sequence. Endoribonuclease-prepared siRNA esiRNA This refers to the infection of cells with a modified virus, which introduces viral genome containing the foreign genes. Several types of viruses are utilized for recombinant gene expression, including lentivirus, retrovirus, adenovirus, etc, with each having their own advantages and disadvantages. recombinant virus transduction method This refers to the infection of cells with a disease-causing virus, which could effect humans, animals and plants. Pathogenic viruses include the influenza virus, measles virus, Japanese encephalitis virus, etc. pathogenic virus transduction method It is a live cell assay in which eukaryotic cells are infected with bacteria. bacterial infection method 1 bao:BAO_0000550 A brief description of the recombinant DNA created by the insertion of a gene or siRNA encoding DNA of interest into a vector. It includes information on the type of vector, the type of promoter, the selectable markers, etc., which are all considered when sub-cloning a gene of interest. The construct is transfected into cells by various methods. deoxyribonucleic acid construct DNA construct bao:BAO_0000551 The organism related to the target / meta-target of the bioassay. It includes both bacterium and eukaryote. organism bao:BAO_0000553 Most of the fungi are multicellular, e.g. molds, mushrooms, etc. They are made up of multicellular filaments known as hyphae. Several parasitic fungi exist, which infect animals and plants, e.g., Aspergillus flavus, Claviceps purpurea, Pneumocystis jirovecii, etc. multicellular fungi bao:BAO_0000558 The role of an individual or a company as a creator of an assay kit, compound library, or detection instrument. manufacturer role bao:BAO_0000562 This describes the throughput and information content generated. Categorizing multiplexed (i.e. mutiple targets measured simultaneously) and multiparametric assays and high content (image-based) and regular (plate reader) assays. assay readout content parametricity bao:BAO_0000563 Typically uses a plate reader and generates one or two readouts, in contrast to high content screening or multiplexed assays, which can generate tens to hundreds of parameters. The readout is typically from a single target / meta-target in each well. single parameter readout bao:BAO_0000564 It is a HTS assay, where the readout is measured from multiple targets from one well. E.g., several protein targets are detected simultaneously by using probes labeled with different fluorescent properties. multiplexed readout bao:BAO_0000565 A physical quality which is equal to the distance between repeating units of a wave pattern (from PATO). For fluorescence measurements, it is the wavelength at which the fluorophore is excited and the wavelength at which it emits fluorescence. In the case of absorbance, it is the wavelength at which light is absorbed by a biological entity or a dye. wavelength bao:BAO_0000566 For fluorescence measurements, it is the wavelength at which a fluorophore is excited excitation wavelength bao:BAO_0000567 For fluorescence measurements, it is the wavelength at which an excited fluorophore emits fluorescence. emission wavelength bao:BAO_0000568 In absorbance measurements, it is the wavelength at which light is absorbed by a biological entity or a dye absorbance wavelength bao:BAO_0000570 The protein is only partially purified partially purified Cells are counted to determine their viability. Cultured animal cells are counted either manually using hemocytometer, or by an automated cell counter, e.g. Coulter counter or Vi-CELL. The latter can distinguish live and dead cells by the trypan blue cell exclusion method. Yeast and bacterial cell growth is determined by measuring absorbance in a spectrophotometer, or by viable plate count. cell number determination This describes whether the perturbagens are tested individually or as mixtures / pools perturbagen delivery method The perturbagens are tested individually in an assay single perturbagen Mixtures / pools of perturbagens are tested in an assay mixture of perturbagens bao:BAO_0000576 This microplate contains 24 wells. It is suitable for a low throughput assay. 24 well plate bao:BAO_0000577 Vials are small containers that are used in biological measurements, including scintillation counting. vial bao:BAO_0000578 Cuvettes are used to measure absorbance or fluorescence in a spectrophotometer or fluorimeter, respectively using either plastic, glass or quartz cuvettes. cuvette These experiments measure specific radioligand binding at equilibrium at various concentrations of the radioligand. saturation binding Tm is defined as the midpoint temperatuere of the protein unfolding transition. It is determined by generating a thermal denaturation curve for the target molecule and taking the midpoint temperature between folding and unfolding state of the protein. In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA strands and its perfect complement are in duplex. melting temperature Tm bao:BAO_0000582 A genomic sequence, which is the unit of heredity of a living organism. It consists of regulatory regions and transcribed regions. gene Raw or qualitative data are reported as endpoints in an assay, e.g., luminescence counts, fluorescence intensity, etc. raw activity 1 1 bao:BAO_0000585 The types of endpoints that report changes in temperature as a measure of a biological reaction, e.g. tm. temperature endpoint Vmax is defined as the maximum initial velocity of an enzyme catalyzed reaction under the given conditions, and it is measured in units of quantity of substrate transformed per unit time for a given concentration of enzyme. vmax This endpoint type describes the bonding affinity between two molecules at equilibrium, e.g., drug-receptor interaction. binding constant 50.0 bao:BAO_0000588 The perturbagen mediated 50% of cells to die in an assay. 50 percent cytotoxicity bao:BAO_0000590 DNA-RNA interaction deoxyribonucleic acid-ribonucleic acid DNA-RNA interaction assay bao:BAO_0000591 Protein-DNA interaction protein-deoxyribonucleic acid protein-DNA interaction assay bao:BAO_0000593 Protein-RNA interaction protein-ribonucleic acid protein-RNA interaction assay bao:BAO_0000596 The cell culture broth used while performing an assay on cells, which is optimized for each assay type. Some interfering additives such as serum, growth factors, buffers, amino acids, antibiotics, etc. might be eliminated in this medium. assay medium The effective concentration of an agonist, which produces 30% of the maximum possible response for that agonist. EC30 bao:BAO_0000605 They are living organisms which derive their energy from photosynthesis, with the exception of parasitic plants. Plants include herbs, shrubs, trees, grasses, vines, etc. plant bao:BAO_0000607 sea urchin It is the term that describes an endpoint or result of a bioassay, which is deposited at PubChem. PubChem endpoint name bao:BAO_0000612 It is the repository (database) in which the assay was deposited, e.g., PubChem, ChEMBL, etc. assay repository bao:BAO_0000613 PubChem (http://pubchem.ncbi.nlm.nih.gov) is a public database that contains high throughput screening (HTS) data, where the assays are performed to identify small molecules effective at modulating a given biological process or disease state. The bioactivity results in PubChem are contributed by several organizations, with the majority of data coming from the screening center network under the NIH Molecular Libraries Program (MLP). PubChem bao:BAO_0000614 It is a public database that contains structure ChEMBL bao:BAO_0000615 It is a public database that contains screening data of novel psychoactive compounds for pharmacological and functional activity. PDSP bao:BAO_0000616 IUPHAR bao:BAO_0000623 This assay is performed to identify compounds that have an ability to kill the cells (cytotoxic). compound toxicity assay A mathematical model / equation to which the data is fitted (using the curve fit method / algorithm). curve fit model 3 parameter Hill equation 4 parameter Hill equation bao:BAO_0000631 Causes mild infections such as "strep throat" to severe diseases such as necrotizing fasciitis and streptococcal toxic shock syndrome. group a streptococcus bao:BAO_0000636 influenza virus bao:BAO_0000638 forskolin bao:BAO_0000639 doxorubicin bao:BAO_0000641 A quality of the genetic material (DNA or RNA) that harbors a change (mutation), where one or more nucleotides are added either spontaneously (within the cell) or intentionally (experimentally). inserted bao:BAO_0000642 A quality of the genetic material (DNA or RNA) that harbors a change (mutation), where one nucleotide is replaced by a different nucleotide either spontaneously (within the cell) or intentionally (experimentally). point mutated bao:BAO_0000643 Mutation is any alteration in a gene, which may be disease causing or a normal variant. Mutations are introduced into the genes and subsequently, introduced into cells for expression. Different types of mutations include missense, nonsense, deletions, insertions, etc. mutated bao:BAO_0000644 A quality of a protein that harbors a change (mutation), where a portion of the protein towards the carboxyl-terminal is missing either spontaneously (within the cell) or intentionally (experimentally). truncated bao:BAO_0000647 This assay is performed with the unmodified or parental cell line instead of the one modified with a DNA construct that was used in primary or confirmatory assays. parental cell line assay bao:BAO_0000648 The name of a small molecule collection from one source, which can be either commercial or academic, e.g., MLSMR, LOPAC, etc. This collection is generally diverse and contains compounds that modulate diverse biological targets. compound library bao:BAO_0000649 Calcium functions as second messenger in cell signaling. calcium redistribution assay bao:BAO_0000650 Cyclic AMP (cAMP) functions as second messenger in cell signaling. cAMP cAMP redistribution assay bao:BAO_0000651 Cyclic GMP (cGMP) functions as second messenger in cell signaling. cGMP cGMP redistribution assay bao:BAO_0000652 A protease is an enzyme that hydrolyzes the peptide bonds in a protein or a peptide. protease bao:BAO_0000653 Dye redistribution is used to study flux of molecules across membranes, e.g. calcein AM, ethidium homodimer-1, etc. dye redistribution assay 1 bao:BAO_0000656 The maximum response that can be achieved with the perturbagen as percentage of the positive control. Efficacy efficacy bao:BAO_0000657 Detection technology using radioactive tracers, e.g. filter assay, SPA, etc radiometry method bao:BAO_0000658 This includes all organisms which are made up of cells, e.g. bacteria, plants and animals. cellular organisms bao:BAO_0000659 Metazoa comprises of animals, which are multicellular eukaryotic organisms. This includes those having a vertebral column (e.g. fish, frog, snake, bird, human) and those that do not (e.g. worm, fly, star fish, etc). metazoa bao:BAO_0000661 It is a collection of perturbagens, e.g., compound, siRNA, miRNA, etc, which are sold by different vendors, or generated in academic institutions. perturbagen library bao:BAO_0000662 Protozoans are single celled organisms, some of which are parasitic, e.g., Plasmodium falciparum, Leishmania mexicana, Trypanosoma brucei, etc which cause malaria, leishmaniasis, and sleeping sickness, respectively. protozoan bao:BAO_0000663 siRNA libraries consist of large number of siRNAs, which represent a single organism, a diseased state, etc. They bring about the cleavage of the target mRNAs to achieve gene silencing. small interfering ribonucleic acid library siRNA library bao:BAO_0000664 It is a collection of miRNAs or microRNAs, which represents a single organism, a diseased state, etc. miRNAs bind the complementary sequences in the 3' UTRs of target mRNA transcripts, usually resulting in gene silencing. micro RNA library micro ribonucleic acid library miRNA library bao:BAO_0000666 An ionic compound (principally consisting of Na, K, Li, Ca, and Mg as cation) which is used as an additive in an assay. metal salt bao:BAO_0000670 Date from BAE: 6/1/2016 PubChem AID: P450-Glo CYP2C19 Screening System bao:BAO_0000672 A quality of an amino acid residue that has a moiety (e.g., phosphate, carbohydrate) attached to it after translation. posttranslationally modified bao:BAO_0000673 A quality of a protein that harbors a change (mutation), where either one or more amino acids are replaced by different ones to study the role of those amino acids in the function of the protein. amino acid substituted bao:BAO_0000674 Date from BAE: 6/1/2016 PubChem AID: P450-Glo CYP1A2 Screening System bao:BAO_0000675 Date from BAE: 6/1/2016 PubChem AID: ONE-Glo Luciferase Assay System bao:BAO_0000677 Invitrogen bao:BAO_0000678 Date from BAE: 6/1/2016 PubChem AID: Kinase-Glo Plus Luminescent Kinase Assay bao:BAO_0000679 Date from BAE: 6/1/2016 PubChem AID: Kinase-Glo Luminescent Kinase Assay bao:BAO_0000680 Date from BAE: 6/1/2016 PubChem AID: Dual-Luciferase Reporter Assay System bao:BAO_0000681 Date from BAE: 6/1/2016 PubChem AID: Chroma-Glo Luciferase Assay System bao:BAO_0000682 Date from BAE: 6/1/2016 PubChem AID: CellTiter-Glo Luminescent Cell Viability Assay bao:BAO_0000683 Date from BAE: 6/1/2016 PubChem AID: Caspase Glo 3/7 Assay bao:BAO_0000684 Artifact (aka 'artefact') assays are performed to help interpret HTS results by testing whether a 'hit' might be due to some inherent physicochemical property of the compound or perturbagen alone - in the absence of any target. Examples include fluorescence, or inhibition of the enzyme luciferase, which are part of common assay designs; another example is solubility (e.g., if a compound aggregates and interferes with an assay readout). artefact assay physicochemical profiling assay artifact assay bao:BAO_0000685 Date from BAE: 6/1/2016 PubChem AID: Bright-Glo Luciferase Assay System bao:BAO_0000686 britelite plus bao:BAO_0000687 Date from BAE: 6/1/2016 PubChem AID: Beta-Glo Assay System bao:BAO_0000688 Date from BAE: 6/1/2016 PubChem AID: BacTiter-Glo Microbial Cell Viability Assay bao:BAO_0000689 ATPLite Luminescence Assay System bao:BAO_0000690 Date from BAE: 6/1/2016 PubChem AID: ADP Glo Kinase Assay bao:BAO_0000691 ViewLux ultraHTS Microplate Imager bao:BAO_0000692 Tecan Infinite F200 is a multifunctional microplate filter-based reader with injector option, that provides high performance for the vast majority of microplate applications and research. It has been designed as a general purpose laboratory instrument for professional use, supporting common 6 to 384-well microplates. (Manufacturer description) Infinite F200 bao:BAO_0000693 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid HEPES bao:BAO_0000694 Tris (hydroxymethyl) aminomethane tris bao:BAO_0000695 MOPS bao:BAO_0000696 phosphate buffer bao:BAO_0000697 The names of equipment used for measurement/readout from an assay, e.g. FLIPR, ViewLux plate reader, PHERAstar, etc. detection instrument bao:BAO_0000698 8453 UV-Visible Spectrophotometer bao:BAO_0000699 Analyst HT bao:BAO_0000700 ELx808 Absorbance Microplate Reader bao:BAO_0000701 EnVision Multilabel Reader bao:BAO_0000702 FLx800 Fluorescence Microplate Reader bao:BAO_0000703 HTFC Screening System bao:BAO_0000705 PHERAstar Plus bao:BAO_0000706 SpectraMax M5 Multi-Mode Microplate Reader bao:BAO_0000707 VICTOR X2 Multilabel Plate Reader bao:BAO_0000708 VP-ITC Isothermal Titration Calorimeter bao:BAO_0000709 The name of the screening center organization that is affiliated with an assay or an experiment; for example the assay was developed by an individual affiliated with that organization or an assay experiment (screen) was performed by a group / in lab affiliated with that research organization. research institute bao:BAO_0000710 It is a specialized chemistry center of MLPCN. vanderbilt screening center for gpcrs, ion channels and transporters bao:BAO_0000712 Epstein-Barr virus bao:BAO_0000718 CD40 bao:BAO_0000719 Fusion protein of CD4 and TLR4. CD4-TLR4 bao:BAO_0000720 ChemBridge bao:BAO_0000721 MicroSource Discovery Systems bao:BAO_0000726 Packard Fusion Microplate Reader bao:BAO_0000727 Infinite PF200 bao:BAO_0000728 Monolight 2010 Luminometer bao:BAO_0000729 LJL BioSystems bao:BAO_0000730 Analytical Luminescence Laboratory bao:BAO_0000731 Tecan bao:BAO_0000732 Cos-7 bao:BAO_0000733 MLSMR library bao:BAO_0000734 LOPAC 1280 bao:BAO_0000735 DIVERSet bao:BAO_0000736 1-aminoanthracene bao:BAO_0000743 Schneider's Drosophila Line 2 bao:BAO_0000745 FITC-RGS12-GoLoco peptide bao:BAO_0000746 GE Healthcare bao:BAO_0000747 saponin bao:BAO_0000748 tetracycline bao:BAO_0000749 NADPH bao:BAO_0000750 Beta-galactosidase bao:BAO_0000751 Beta-lactamase bao:BAO_0000752 NINDS library bao:BAO_0000754 S-adenosyl methionine bao:BAO_0000755 coenzyme Q bao:BAO_0000758 U937 (CD59+) bao:BAO_0000759 doxycycline bao:BAO_0000760 estrogen bao:BAO_0000761 IBMX 3-isobutyl-1-methylanxthine bao:BAO_0000762 IL-3 Interleukin-3 bao:BAO_0000763 ionomycin bao:BAO_0000764 M-TriDAP MurNAc-L-Ala-gamma-D-Glu-mDAP bao:BAO_0000765 NHK 477 bao:BAO_0000766 NOD1 bao:BAO_0000767 NOD2 bao:BAO_0000769 retinoic acid bao:BAO_0000770 SFLLRN Thrombin Receptor Activator Peptide 6 bao:BAO_0000771 Thrombopoietin bao:BAO_0000772 T3 triiodothyronine bao:BAO_0000773 tunicamycin bao:BAO_0000774 MG132 Z-Leu-Leu-Leu-al bao:BAO_0000775 Adenosine diphosphate bao:BAO_0000776 ATP Adenosine triphosphate bao:BAO_0000777 4-diphosphocytidyl-2-C-methyl-D-erythritol CDP-ME bao:BAO_0000778 creatine phosphate bao:BAO_0000779 creatine phosphokinase Creatine kinase bao:BAO_0000781 deoxyluciferin bao:BAO_0000782 D-galactose bao:BAO_0000783 DYRKtide peptide bao:BAO_0000784 ethylene glycol ester of luciferin 6' methyl ether bao:BAO_0000785 Kemptide peptide bao:BAO_0000786 luciferin 6-ME bao:BAO_0000787 luciferin-PPXE bao:BAO_0000788 luciferin-BE bao:BAO_0000789 peptide-aminoluciferin bao:BAO_0000791 It is a specialized screening center of MLPCN. southern research institute bao:BAO_0000792 S6 peptide bao:BAO_0000793 Suc-LLVY-aminoluciferin bao:BAO_0000794 Z-RLRGG-aminoluciferin bao:BAO_0000795 true furafylline bao:BAO_0000796 ketoconazole bao:BAO_0000797 true quinidine bao:BAO_0000798 Mirus Bio LLC bao:BAO_0000799 lipofectin bao:BAO_0000800 TransIT-CHO kit bao:BAO_0000801 TransIT-LT1 bao:BAO_0000802 ChemDiv bao:BAO_0000803 An assay run to eliminate those hits from the primary and confirmatory assay stages that are not of interest, i.e. do not act via the MMOA of interest; for example compounds that are assay artifacts (e.g. fluorescent), promiscuously active, toxic. counter screening assay 1 bao:BAO_0000804 Maximum inhibition of an antagonist or inhibitor (relative an efficacious positive control) maximal inhibition 1 bao:BAO_0000805 The maximum percent activation of an agonist maximal activation bao:BAO_0000806 An assay using orthogonal assay design / technology run to confirm the identified hits from the primary and confirmatory assay stages. alternate confirmatory assay bao:BAO_0000807 This assay is performed with a different DNA construct than that was used in primary or confirmatory assays to modify a cell line. variant construct assay bao:BAO_0000811 wee1-like protein-luciferin 4-monooxygenase bao:BAO_0000813 It is an MLSCN (pilot phase) screening center. MLSCN center at columbia university bao:BAO_0000814 Adapta Universal Kinase Assay Kit bao:BAO_0000815 ADP Hunter Plus bao:BAO_0000816 Amplex Red Glucose/Glucose Oxidase Assay Kit bao:BAO_0000818 The role played by a soluble molecule, such as a hormone, neurotransmitter, or small molecule that binds to a biomolecular entity, such as a receptor. biological ligand bao:BAO_0000819 Radiolabeled flux assays to study ion channel activity by chemically initiating the opening of channels in the presence of a fixed amount of radiolabeled cation or anion, and a potential ion channel modulator compound. ion redistribution assay bao:BAO_0000820 1, 4 methyllumbelliferone bao:BAO_0000821 14LckpCAP394 peptide bao:BAO_0000822 3-O-methyl-fluorescein bao:BAO_0000823 3-O-methylfluorescein phosphate bao:BAO_0000824 4 methylumbelliferyl-D-pyranoside bao:BAO_0000825 5-carboxamidotryptamine bao:BAO_0000826 6,8-difluoro-4-methylumbelliferyl phosphate bao:BAO_0000827 6,8-difluoro-7-hydroxy-4-methylcoumarin bao:BAO_0000828 [125I]Y10-neuropeptide S bao:BAO_0000829 [3H]N-methylscopolamine bao:BAO_0000830 A23187 bao:BAO_0000831 AB SCIEX bao:BAO_0000832 ABD Bioquest bao:BAO_0000833 Ac-DEVD-AFC bao:BAO_0000834 Ac-DEVD-CHO is an inhibitor of caspase-3/7 (DEVDase) activity. Ac-DEVD-CHO bao:BAO_0000835 Ac-LEHD-AMC bao:BAO_0000836 Ac-WEHD-AFC bao:BAO_0000837 Ac-Trp-Glu-His-Asp-CHO Very potent reversible inhibitor of caspase-1 (ICE) that contains the optimal tetrapeptide recognition motif for this enzyme. With a Ki of 56 pM, it displays the most potent reversible, peptide-based inhibitors described for any protease. For caspase-8 a Ki of 21.1 nM has been reported. Ac-WEHD-CHO bao:BAO_0000838 acetylcholine bao:BAO_0000840 7-amino-4-trifluoromethylcoumarin bao:BAO_0000842 Agilent Technologies bao:BAO_0000843 selective calpain inhibitor AK295 AK295 peptide bao:BAO_0000844 alkaline phosphatase-cAMP bao:BAO_0000845 Alpha-D-glucose bao:BAO_0000846 7-amino-4-methylcoumarin bao:BAO_0000847 AnaSpec bao:BAO_0000848 angiotensin II bao:BAO_0000849 Apelin-13 bao:BAO_0000850 API 4000 LC/MS/MS System bao:BAO_0000851 Applied Biosystems bao:BAO_0000852 The drug aprotinin (Trasylol, Bayer), is the bovine version of the small protein basic pancreatic trypsin inhibitor, or BPTI, which inhibits trypsin and related proteolytic enzymes. aprotinin Pancreatic trypsin inhibitor bao:BAO_0000853 arachidonic acid bao:BAO_0000854 arrestin-GFP bao:BAO_0000857 AxioVert 200M Fluorescence Light Microscope bao:BAO_0000858 Bachem bao:BAO_0000859 BD Biosciences bao:BAO_0000860 beta-hydroxybutyryl coenzyme A bao:BAO_0000861 Bio-Tek Instruments bao:BAO_0000862 PKC inhibitor 3-{1-[3-(dimethylamino)propyl]-1H-indol-3-yl}-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione bisindolylmaleimide bao:BAO_0000863 BMG Labtech bao:BAO_0000864 Substrate for Factor XIIa Boc-Gln-Gly-Arg-AMC bao:BAO_0000865 Boc-Leu-Gly-Arg-AMC is a selective fluorogenic substrate for Horseshoe Crab Clotting Enzyme Boc-Leu-Gly-Arg-AMC bao:BAO_0000866 Substrate for α-Thrombin Boc-Val-Pro-Arg-AMC bao:BAO_0000867 Brij-35 is a nonionic polyoxyethylene surfactant that is most frequently used as a component of cell lysis buffers or a surfactant in various HPLC applications. Brij-35 bao:BAO_0000868 5-Hydroxy-3-(1-methylpiperidin-4-yl)-1H-indole A potent 5-ht1E/1F receptor agonist BRL-54443 bao:BAO_0000869 It is an MLPCN comprehensive screening center. broad institute bao:BAO_0000870 BTC AM Fluorescent Dye Indicator bao:BAO_0000871 It is an MLPCN comprehensive screening center. burnham center for chemical genomics bao:BAO_0000872 Calbiochem bao:BAO_0000873 Calcium 5 Assay Kit bao:BAO_0000874 calcium bao:BAO_0000875 cAMP Cyclic adenosine monophosphate bao:BAO_0000876 carbachol bao:BAO_0000877 CBF-his/runx1-biotin protein complex bao:BAO_0000878 CCD Luminometer bao:BAO_0000879 Cell Signaling bao:BAO_0000880 CHAPS is a zwitterionic detergent used in the laboratory to solubilize biological macromolecules such as proteins. It is used as a non-denaturing solvent in the process of protein purification and is especially useful in purifying membrane proteins, which are often sparingly soluble or insoluble in aqueous solution due to their native hydrophobicity. CHAPS can also be used in conjunction with nonionic detergents such as Triton X-100. CHAPS bao:BAO_0000881 Cisbio bao:BAO_0000882 coenzyme A bao:BAO_0000883 Cy5 bao:BAO_0000885 Cysteine has antioxidant properties due to the ability of thiols to undergo redox reactions. cysteine bao:BAO_0000886 IP1 inositol monophosphate inositol-1-phosphate bao:BAO_0000888 A fluorogenic FRET peptide with a substrate sequence that is optimized for calpain-1 and -2. DABCYL-Thr-Pro-Leu-Lys~Ser-Pro-Pro-Pro-Ser-Pro-Arg-EDANS bao:BAO_0000889 Dako bao:BAO_0000890 DAMGO bao:BAO_0000891 It intercalates DNA and RNA. diminazene aceturate bao:BAO_0000892 diphosphomevalonate bao:BAO_0000893 DiscoveRx bao:BAO_0000894 dopamine bao:BAO_0000895 Dithiothreitol (DTT) is the common name for a small-molecule redox reagent known as Cleland's reagent. DTT's formula is C4H10O2S2 and the molecular structure of its reduced form is shown at the right; its oxidized form is a disulfide-bonded 6-membered ring (shown below). Its name derives from the four-carbon sugar, threose. DTT bao:BAO_0000896 Dy647-pS136-Bad peptide bao:BAO_0000897 dynorphin A bao:BAO_0000898 cAMP-screen direct system bao:BAO_0000899 It is an MLSCN (pilot phase) screening center. emory university molecular libraries screening center bao:BAO_0000900 estrogen-alexa 633 bao:BAO_0000901 Eu3+-cAMP bao:BAO_0000903 FDSS6000 bao:BAO_0000904 FDSS7000 bao:BAO_0000905 FlexStation II Microplate Reader bao:BAO_0000906 FLIPR TETRA bao:BAO_0000907 fluo-4 AM calcium indicator bao:BAO_0000908 Fluo-8 No Wash Calcium Assay Kit bao:BAO_0000909 fluorescein-labeled formylmethionine-leucine-phenylalanine-lysine (fmlfk-fitc) substrate for the formylpeptide receptor (FPR) family of G-protein-coupled receptors fMLFK-FITC bao:BAO_0000910 Fluorescein Di-beta-D-Glucopyranoside bao:BAO_0000912 Fluorogenic triple-helical peptide 3 bao:BAO_0000913 Fluorometer bao:BAO_0000914 fluorophosphonate-rhodamine bao:BAO_0000915 fluozin-2 bao:BAO_0000916 fluozin bao:BAO_0000917 FluxOR Thallium Detection Kit bao:BAO_0000918 fMLFF peptide is used as a FPR-blocking peptide. fMLFF peptide bao:BAO_0000919 guanine nucleotide-binding protein G(o) subunit alpha isoform a-Alexa Fluor 488 G alpha O-Alexa Fluor 488 bao:BAO_0000920 Galanin bao:BAO_0000923 GeneBLAzer bao:BAO_0000924 Glucose bao:BAO_0000925 Glucose-6-phosphate bao:BAO_0000926 glutamate bao:BAO_0000927 Glycogen bao:BAO_0000928 GM-TriDAP (GlcNAc-MurNAc-L-Ala-D-Glu-mesoDAP), is a muropeptide found mostly in Gram-negative bacterial peptidoglycan. GM-TriDAP peptide bao:BAO_0000929 5,6,7,13-Tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile Potent protein kinase C (PKC) inhibitor (IC50 = 7.9 nM). Go6976 bao:BAO_0000931 BODIPY GTP bao:BAO_0000932 3-(3,5-Dibromo-4-hydroxy-benzylidene)-5-iodo-1,3-dihydro-indol-2-one Potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC50 = 9 nM). Displays ≥ 100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fm. GW5074 bao:BAO_0000933 An inhibitor of cyclin kinase 2 (CDK2) which prevents and/or reduces the side effects of chemotherapy (alopecia, plantar-palmar syndrome and mucositis). GW8510 bao:BAO_0000934 substrate for M1-family alanyl aminopeptidase (M1AAP) H-Leu-NHMec bao:BAO_0000935 Hamamatsu bao:BAO_0000936 High Performance PBX Calcium Assay Kit bao:BAO_0000937 HTRF cAMP Detection Kit bao:BAO_0000938 HTRF cAMP HiRange Detection Kit bao:BAO_0000939 HTRF KinEASE-TK bao:BAO_0000940 HTScan IKK-beta Kinase Assay Kit bao:BAO_0000941 HTScan PKC-beta Kinase Assay Kit bao:BAO_0000942 HTScan PKC-theta Kinase Assay Kit bao:BAO_0000943 HyperCyt High Throughput Flow Cytometry System bao:BAO_0000945 indo-1 calcium indicator bao:BAO_0000946 IntelliCyt Corporation bao:BAO_0000947 IL-8 Interleukin-8 bao:BAO_0000948 IP-One HTRF Assay bao:BAO_0000949 IGEPAL CA-630 is a nonionic, non-denaturing detergent. Its official IUPAC name is octylphenoxypolyethoxyethanol. IPEGAL bao:BAO_0000950 isoproterenol bao:BAO_0000951 It is a specialized screening center of MLPCN. john hopkins ion channel center bao:BAO_0000952 L-(+)-2-Amino-4-phosphonobutyric acid Selective group III metabotropic glutamate receptor agonist. L-AP4 bao:BAO_0000953 LANCE cAMP Detection Kit bao:BAO_0000954 LDV peptide targeted against the alpha4beta integrin VLA-4 LDV peptide bao:BAO_0000955 LI-COR Biosciences bao:BAO_0000956 Lipofectamine™ 2000 Reagent delivers DNA or siRNA with excellent transfection performance for protein expression, gene silencing, and functional assays. Superior efficiency, optimized protocols, and unparalleled success across a broad range of cell lines. lipofectamine 2000 bao:BAO_0000957 lithium chloride bao:BAO_0000958 LiveBLAzer FRET - B/G Loading Kit bao:BAO_0000960 luciferin-H bao:BAO_0000961 luciferin-H EGE bao:BAO_0000962 lysophosphatidylinositol bao:BAO_0000963 MIP3a, CCL20 peptide Macrophage inflammatory protein 3 alpha bao:BAO_0000964 Mannose-6-phosphate bao:BAO_0000965 Melanin-concentrating hormone bao:BAO_0000966 Meso Scale Discovery bao:BAO_0000967 mevalonate bao:BAO_0000968 MicroCal bao:BAO_0000969 Molecular Devices bao:BAO_0000970 Muramyl dipeptide bao:BAO_0000971 Mx3005P qPCR System bao:BAO_0000972 2-(6-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)amino)Hexanoyl-1-Hexadecanoyl-sn-Glycero-3-Phosphocholine (NBD C6-HPC) NBD C6-HPC bao:BAO_0000973 It is an MLPCN comprehensive screening center. NCGC NIH chemical genomics center bao:BAO_0000974 Neuropeptide W bao:BAO_0000975 Neuropeptide S bao:BAO_0000976 Neuropeptide Y bao:BAO_0000977 It is a specialized screening center of MLPCN. new mexico molecular libraries screening center bao:BAO_0000978 NP-40 is a commercially available detergent. The full name of NP-40 is Tergitol-type NP-40, which is nonyl phenoxypolyethoxylethanol. NP-40 bao:BAO_0000980 O-methyl-fluorescein phosphate bao:BAO_0000981 Odyssey Infrared Imager bao:BAO_0000982 Opera QEHS bao:BAO_0000983 OptEIA Human IL-8 ELISA Set bao:BAO_0000984 Orexin A bao:BAO_0000985 Oxytocin bao:BAO_0000986 para-nitrophenol bao:BAO_0000987 PNPP para-Nitrophenylphosphate (pNPP) is a chromogenic substrate for acid and alkaline phosphatase in ELISA assays. Under their influence the decay to yellow para-nitrophenol is catalysed. This product can be measured with a 405 nm spectrophotometer. para-nitrophenylphosphate bao:BAO_0000988 PathHunter Beta-Arrestin Assay bao:BAO_0000989 It is an MLSCN (pilot phase) screening center. the penn center for molecular discovery bao:BAO_0000990 It has the high-energy phosphate bond found (-61.9 kJ/mol) in living organisms, and is involved in glycolysis and gluconeogenesis. In plants, it is also involved in the biosynthesis of various aromatic compounds, and in carbon fixation; in bacteria, it is also used as the source of energy for the phosphotransferase system. phosphoenolpyruvate bao:BAO_0000991 Phosphorylethanolamine or phosphoethanolamine is an ethanolamine derivative that is used to construct sphingomyelins. phosphoethanolamine bao:BAO_0000992 phosphomevalonate bao:BAO_0000994 Photon Technology International bao:BAO_0000995 Pluronic® F-127 is a nonionic, surfactant polyol (molecular weight approximately 12,500 daltons) that has been found to facilitate the solubilization of water-insoluble dyes and other materials in physiological media. pluronic F-127 bao:BAO_0000996 phorbol myristate acetate bao:BAO_0000997 potassium phosphoenolpyruvate bao:BAO_0000998 4-(Dipropylsulfamoyl)benzoic acid Inhibitor of multidrug resistance-associated proteins (MRP). probenecid bao:BAO_0000999 profluorescent 1-AMA bao:BAO_0001000 prostaglandin bao:BAO_0001001 prostaglandin E2 bao:BAO_0001002 substrate for virus-encoded NS3 serine proteinase Pyr-RTKR-AMC bao:BAO_0001003 pyrimidine-4,6-dicarboxylic acid, bis-(4-fluoro-3-methyl-benzylamide) Degrades collagen type I. pyrimidine-4,6-dicarboxylic acid bao:BAO_0001004 The peptide sequence, PHCVPRDLSWLDLEANMCLP, named R18, was identified as an unphosphorylated peptide that binds to 14-3-3 proteins with high affinity (Kd=80 nM). It has been shown to bind to the same amphipathic groove on the surface of 14-3-3 as phosphorylated peptides. R18 can inhibit the formation of the 14-3-3-Raf-1 complex, reduce Raf-1 dependent transcriptional activity in cells and block the activation of ExoS by 14-3-3. It binds to all the 14-3-3 isoforms with equal affinities. This peptide is useful for competitive inhibition experiments. R18 peptide bao:BAO_0001005 Rauwolscine acts predominantly as a α2-adrenergic receptor antagonist. It has also been shown to function as a 5-HT1A receptor partial agonist and 5-HT2A and 5-HT2B receptor antagonist. rauwolscine bao:BAO_0001006 resorufin bao:BAO_0001007 Resorufin alpha-D-pyranoside bao:BAO_0001008 Resorufin beta-D-glucopyranoside bao:BAO_0001009 rhodamine bao:BAO_0001010 rhodamine-conjugated sulfonate ester bao:BAO_0001011 Rhodamine-RGS12-GoLoco peptide bao:BAO_0001012 4-(3-Butoxy-4-methoxyphenyl)methyl-2-imidazolidone Widely used inhibitor of cyclic nucleotide phosphodiesterase, selective for PDE4 (IC50 = 2.0 μM). Ro 20-1724 bao:BAO_0001013 Rolipram is a PDE4-inhibitor. rolipram bao:BAO_0001014 RS repeat peptide bao:BAO_0001015 SGC Oxford the structural genomics consortium bao:BAO_0001016 Sigma-Aldrich bao:BAO_0001017 A highly selective and potent non-peptide δ-opioid agonist, 2000-fold selective over μ-opioid receptors. (+)-4-[(αR)-α-((2S,5R)-4-Allyl-2,5-di methyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethyl benzamide SNC80 bao:BAO_0001018 Sodium orthovanadate is the chemical compound Na3VO4 and contains the tetrahedral VO43−. It is an inhibitor of protein tyrosine phosphatases, alkaline phosphatases and a number of ATPases, most likely acting as a phosphate analogue. The VO43- ion binds reversibly to the active sites of most protein tyrosine phosphatases. sodium orthovanadate bao:BAO_0001019 SpectraMax 190 Microplate Reader bao:BAO_0001020 Sphingosine 1-phosphate bao:BAO_0001021 Staurosporine (antibiotic AM-2282 or STS) is a natural product originally isolated in 1977 from the bacterium Streptomyces staurosporeus. staurosporine bao:BAO_0001022 The stibonic acid compound, NSC13778, also know as stibavirin, previously has been reported to inhibit the interaction between transcription factors C/EBP, C/EBPß, CREB, Fos/JunD, and VBP and their cognate DNA sequences, HIV nucleocapsid protein p7 and viral RNA, and HIV gp120 and CD4. Now, we report that this compound is a potent inhibitor of the interaction between transcription factors TFE3, Alveolar Soft Part Sarcoma (ASPS) associated fusion protein ASPL-TFE3 type 1, and ASPL-TFE3 type 2 and their cognate DNA. Proc Amer Assoc Cancer Res, Volume 47, 2006 stibavirin bao:BAO_0001023 Substrate for Chymotrypsin. Suc-Ala-Ala-Pro-Phe-AMC bao:BAO_0001024 SYPRO orange dye bao:BAO_0001025 Tango GPCR Assay System bao:BAO_0001026 texas Red bao:BAO_0001027 219479 Cdc2-Like Kinase Inhibitor, TG003 (Z)-1-(3-Ethyl-5-methoxy-2,3-dihydrobenzothiazol-2-ylidene)propan-2-one, Clk Inhibitor, TG003 TG003 bao:BAO_0001028 thallium bao:BAO_0001030 thapsigargin bao:BAO_0001031 It is an MLPCN comprehensive screening center. the scripps research institute molecular screening center bao:BAO_0001032 used for staining of senile amyloid deposits/plaques thioflavine S bao:BAO_0001033 Thyroid-stimulating hormone bao:BAO_0001034 Thyrotropin-releasing hormone bao:BAO_0001035 modulators of 14-3-3 proteins The 14-3-3 proteins are the prototype for a novel class of protein modules that can recognize phosphoserine/threonine (pS/T)-containing motifs in a variety of signaling proteins. To date, 14-3-3 proteins have been reported to bind more than 200 client proteins. Through these interactions, 14-3-3 proteins play important roles in a wide range of vital regulatory processes, such as Bad-induced apoptosis, Raf-1-mediated cell proliferation, and Cdc25-regulated cell cycle progression. TMR-pS259-Raf peptide bao:BAO_0001036 TopCount NXT Microplate Scintillation Luminescence Counter bao:BAO_0001037 Triton X-100 (C14H22O(C2H4O)n) is a nonionic surfactant which has a hydrophilic polyethylene oxide group (on average it has 9.5 ethylene oxide units) and a hydrocarbon lipophilic or hydrophobic group. triton X-100 bao:BAO_0001038 Polysorbate 20 (common commercial brand names include Alkest TW 20 and Tween 20) is a polysorbate surfactant whose stability and relative non-toxicity allows it to be used as a detergent and emulsifier in a number of domestic, scientific, and pharmacological applications. It is a polyoxyethylene derivative of sorbitan monolaurate, and is distinguished from the other members in the polysorbate range by the length of the polyoxyethylene chain and the fatty acid ester moiety. tween 20 bao:BAO_0001039 Ubiquitin-AMC is a fluorogenic substrate for a wide range of deubiquitinating enzymes (DUBs), including ubiquitin C-terminal hydrolases (UCHs) and ubiquitin specific proteases (USPs). UBIQUITIN-7-AMIDO-4-METHYLCOUMARIN Ubiquitin-AMC bao:BAO_0001040 Ubiquitin-Rho bao:BAO_0001041 For use in the detection and identification of deubiquitinylating enzymes Ubiquitin vinyl sulfone bao:BAO_0001042 This random polymer is a Tyrosine kinase substrate. ULight poly-GT bao:BAO_0001043 It is an MLSCN (pilot phase) screening center. university of pittsburgh molecular libraries screening center bao:BAO_0001044 vasopressin bao:BAO_0001045 VICTOR X3 Multilabel Plate Reader bao:BAO_0001046 ViewLux CCD Imager bao:BAO_0001048 Wallac MicroBeta Liquid Scintillation Counter bao:BAO_0001050 WIN 55,212-2 is a potent cannabinoid receptor agonist. WIN55212 bao:BAO_0001051 Selective agonist for the formyl peptide receptors FPR1, FPR2 (EC50 = 75 pM) and FPR3 (EC50 = 3 nM), expressed on immune cells. Trp-Lys-Tyr-Met-Val-D-Med-NH2 WKYMVm peptide bao:BAO_0001052 Substrate for Cathepsin B Z-Arg-Arg-AMC bao:BAO_0001053 This is a fluorescent kallikrein substrate, Abs/Em=353/442 nm. Z-Phe-Arg-AMC bao:BAO_0001054 zaprinast bao:BAO_0001055 Zeiss bao:BAO_0001060 GDP guanosine diphosphate bao:BAO_0001061 GTP guanosine triphosphate bao:BAO_0001064 This assay is performed with a different but a related target (usually from the same protein family) than that was tested in primary or confirmatory assays, e.g., SIP1 instead of SIP3. alternate target assay bao:BAO_0001065 This assay is performed with a different cell line than that was tested in primary or confirmatory assays. alternate cell line assay bao:BAO_0001066 This assay is performed with a different organism than that was tested in primary or confirmatory assays. alternate organism assay bao:BAO_0001096 This assay is performed using a different assay design or detection technology, e.g., a beta-lactamase assay performed using FRET technology instead of absorbance for measurement. orthogonal assay technology bao:BAO_0001097 This assay is a different bioassay type when compared to the primary or confirmatory assays, for e.g., a functional confirmatory assay (Ca-flux FLIPR), where the primary assay could be a binding assay. alternate assay type bao:BAO_0001098 This assay is different from the primary or confirmatory assays with respect to the use of reagents / buffer, in order to narrow the mechanism of action of a perturbagen. alternate assay conditions bao:BAO_0001099 This assay is performed to identify compounds that have a property of auto-fluorescence. compound fluorescence assay bao:BAO_0001100 This assay is performed to identify compounds that have a propensity to aggregate. compound aggregation assay bao:BAO_0001101 This assay is performed to identify compounds with redox (reducing or oxidizing) activity. compound redox activity assay 1 bao:BAO_0001103 Percent activity is the response relative to an unperturbed state; in case of inhibition the interpretation is that of remaining activity, i.e. percent inhibition := 100 - percent activity. percent activity bao:BAO_0001104 percent activation normalization 50.0 bao:BAO_0001106 50 percent growth inhibition 100.0 bao:BAO_0001108 100 percent growth inhibition bao:BAO_0001200 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 Transcreener assay kit bao:BAO_0001201 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 Lactate kit bao:BAO_0001202 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 TruPoint assay kit bao:BAO_0001213 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 Fluormone PL Far Red bao:BAO_0001215 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 Fluormone ES2 Green bao:BAO_0001216 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 Fluorescein bao:BAO_0001217 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 Amplex red reagent bao:BAO_0001218 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 Atto 495 bao:BAO_0001220 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 QuantaBlu bao:BAO_0001221 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 Sytox Orange bao:BAO_0001222 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 Ellman and apos's reagent bao:BAO_0001223 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 3H bao:BAO_0001224 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 35S bao:BAO_0001234 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 ACP-tag IRI prefix change from BAO_02000 to BAO_00012 in January 2017 EC20 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 EC150 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 EC90 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 IC95 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 MIC80 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 MIC90 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 ED IRI prefix change from BAO_02000 to BAO_00012 in January 2017 ED25 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 ED30 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 ED90 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 LD10 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 ID50 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 MinED IRI prefix change from BAO_02000 to BAO_00012 in January 2017 MTD IRI prefix change from BAO_02000 to BAO_00012 in January 2017 TD50 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 maximal effect IRI prefix change from BAO_02000 to BAO_00012 in January 2017 Increase IRI prefix change from BAO_02000 to BAO_00012 in January 2017 percent change IRI prefix change from BAO_02000 to BAO_00012 in January 2017 percent growth IRI prefix change from BAO_02000 to BAO_00012 in January 2017 percent protection IRI prefix change from BAO_02000 to BAO_00012 in January 2017 percent remaining IRI prefix change from BAO_02000 to BAO_00012 in January 2017 uptake IRI prefix change from BAO_02000 to BAO_00012 in January 2017 efflux ratio maximum rate of inactivation kinact https://doi.org/10.1177/1087057116671509 https://github.com/Scientist328455 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 Kinactivation IRI prefix change from BAO_02000 to BAO_00012 in January 2017 residence time IRI prefix change from BAO_02000 to BAO_00012 in January 2017 T IRI prefix change from BAO_02000 to BAO_00012 in January 2017 ED80 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 EC10 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 EC25 IRI prefix change from BAO_02000 to BAO_00012 in January 2017 IC75 negative allosteric modulation positive allosteric modulation bao:BAO_0002001 The role of a molecular entity of being the output of a biological reaction or process that is quantitated either directly (by the presence of a tag or probe) or indirectly in a coupled reaction. measured entity bao:BAO_0002005 kinase activity panel kinase assay kinase panel kinase profiling kinase screen kinase activity assay bao:BAO_0002006 The percentage of cells in an assay that show the hallmarks of 'programmed cell death' or apoptosis, namely, membrane asymmetry, caspase activation, nuclear fragmentation, etc. percent apoptotic cells bao:BAO_0002007 A quality of an amino acid residue that has a phosphate group attached to it. phosphorylated bao:BAO_0002010 nucleotide processing method phosphoprotein detection method preparation method bao:BAO_0002015 Import the ligands from PRO with IDs carbohydrate bao:BAO_0002016 LPS lipopolysaccharide cytokine quantitation method bao:BAO_0002018 xMap kit bao:BAO_0002021 Luminex bao:BAO_0002022 dna-coated bead based method bao:BAO_0002023 The role played by a protein in modulating immune cell function via cell signaling, subsequent to binding to its cognate cell surface receptor. cytokine bao:BAO_0002024 The role played by a protein in initiating cell division via cell signaling, subsequent to binding to its cognate cell surface receptor. growth factor bao:BAO_0002026 structure analysis method bao:BAO_0002030 The role played by a molecular entity as being the substrate for a coupled enzyme (see definition of coupled enzyme). For e.g., luciferin, which is generated by cytochrome P450 (from modified luciferin) in a coupled enzyme reaction is the coupled substrate for luciferase. coupled substrate bao:BAO_0002032 The supportive role of a protein in mediating attachment of cells to a cell culture dish, on which it is coated. cell culture substrate cell processing method cell fixation method bao:BAO_0002036 tissue processing method tissue fixation method bao:BAO_0002038 conformation bao:BAO_0002039 shRNA library bao:BAO_0002040 This represents the percentage of cells in a cell population that are in the M phase of the cell cycle. The cells in this phase can be detected using various markers, one of which is the characteristic phosphorylation of certain proteins that stain positive with MPM2 antibody. percent mitotic cells bao:BAO_0002041 cell cycle analysis endpoints: percent proliferation percent interphase percent mitosis percent G2-M arrested percent non-arrested cell cycle assay bao:BAO_0002042 This represents the percentage of cells in a cell population that are preparing for cell division and that exist in either G1, S or G2 phases of the cell cycle. This is calculated by subtracting from the total cell number, the number of cells in the M phase, apoptotic and dead cells in an assay plate. 'has marker' some (not ('DEVD-NucView 488' or 'LysoTracker Red' or 'Hoechst 33342')) percent interphase cells bao:BAO_0002043 programmed cell death apoptosis assay bao:BAO_0002044 This represents the percentage of cells in a cell population that have undergone the S phase (completed DNA replication) in preparation for mitosis, as indicated by staining positive for EdU. percent DNA replicated cells primary structure analysis method The percentage of cells in an assay that are no longer alive (viable), and show the characteristic features, such as staining with propidium iodide, blurry staining with DAPI, etc. 'has marker' some ('Hoechst 33342' and not ('DEVD-NucView 488' or 'LysoTracker Red') ) percent dead cells cell cycle progression assessment method 1 bao:BAO_0002051 The plasmid, phagemid or viral genome that is used to recombinantly clone the DNA molecule of interest to be introduced into a host cell (bacterial, eukaryotic), where it can independently replicate. DNA vector bao:BAO_0002057 The phenotype of an organism that has been derived by genetic modification. engineered bao:BAO_0002066 BSA Bovine serum albumin Serum albumin bao:BAO_0002067 A physical parameter associated with an assay measurement. assay readout type bao:BAO_0002068 calculated measurement calculated value bao:BAO_0002069 This can be moved to directly under 'assay measurement'. measured profile bao:BAO_0002070 raw measurement measured value bao:BAO_0002071 We might not need this, as 'kinetic assay' under 'measuremnt type' describes the same. time course profile extraction from natural source synthesis by a chemical process purification from natural source ATP quantitation using luciferase In molecular biology, the polymerase chain reaction (PCR) is a technique to amplify a single or few copies of a piece of DNA across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence. The method relies on thermal cycling, consisting of cycles of repeated heating and cooling of the reaction for DNA melting and enzymatic replication of the DNA. Primers (short DNA fragments) containing sequences complementary to the target region along with a DNA polymerase (after which the method is named) are key components to enable selective and repeated amplification. As PCR progresses, the DNA generated is itself used as a template for replication, setting in motion a chain reaction in which the DNA template is exponentially amplified. polymerase chain reaction bao:BAO_0002081 This represents the percentage of cells in a cell population that have undergone the DNA synthesis in the S phase as indicated by staining positive for EdU, but have not undergone the M phase as they stained negative for MDM2. In other words, these cells were arrested in the G2/M cell cycle check-points after treatment with the respective perturbagen in the assay. percent G2 arrested cells bao:BAO_0002082 This represents the percentage of cells in a cell population that have completed the mitotic cell cycle, and that have stained positive for both S phase (EdU) and M phase (MDM2) markers. In other words, these cells were not arrested in any of the cell cycle check-points after treatment with the respective perturbagen in the assay. percent non-arrested cells In molecular biology, real-time polymerase chain reaction, also called quantitative real time polymerase chain reaction (Q-PCR/qPCR) or kinetic polymerase chain reaction, is a laboratory technique based on the PCR, which is used to amplify and simultaneously quantify a targeted DNA molecule. It enables both detection and quantification (as absolute number of copies or relative amount when normalized to DNA input or additional normalizing genes) of one or more specific sequences in a DNA sample. real-time PCR bao:BAO_0002085 The role of a chemical entity to bind inside the pore of a specific type of ion channel and block the flow of ions through it, resulting in an alteration of the electrochemical gradient of the cell membrane. channel blocker bao:BAO_0002087 The molecular entity that brings about the transformation of less specialized cells to more specialized cell types, which differ morphologically and /or functionally. differentiation agent bao:BAO_0002088 The role of a molecular entity to bring about an increase of a predefined stimulus in an assay. activator Reverse transcription polymerase chain reaction (RT-PCR) is a variant of PCR in which the RNA strand is first reverse transcribed into its DNA complement (complementary DNA, or cDNA) using the enzyme reverse transcriptase, and the resulting cDNA is amplified using traditional or real-time PCR. reverse transcription PCR Quantitative reverse transcription PCR is a PCR technique used to determine the amount of cDNA in a sample. It is the most commonly used form of quantitative PCR (qPCR). This technique is also called real-time reverse transcription PCR. quantitative reverse transcription PCR bao:BAO_0002091 The name of an organization that is involved in manufacture and / or commercialization of assay kits, detection instruments, small molecule libraries, etc. commercial company bao:BAO_0002092 The role of a small molecule to act as a standard in a particular assay type, e.g., 1,4-Dioxane (for NMR), Cediranib (for Kinomescan). reference compound bao:BAO_0002093 Role of a protein in the transport of ions, small molecules, or macromolecules across a semi-permeable membrane, such as plasma membrane. carrier bao:BAO_0002094 Method based on the application of information technology to chemistry and biology. computational method bao:BAO_0002095 Method based on application of information technology to the field of molecular biology. bioinformatics method bao:BAO_0002096 The role played by an enzyme in reporting the activity of a different enzyme by being able to use the substrate or product of the latter in its own reaction (either as a substrate or cofactor). E.g., luciferase acts as a coupled enzyme for cytochrome P450, as the luciferin generated (from modified luciferin) by the latter acts as its substrate. coupled enzyme bao:BAO_0002098 The role of a molecular entity (e.g., barium chloride, acetylcholine) to change a cell's membrane potential, making it more positive. depolarizer bao:BAO_0002099 Cell line culturing describes the growth mode of a cell line, whether it grows attached to the culture dish (adherent) or floating (suspension) in the culture medium or partially attached (mixed adherent and suspension). cell growth property bao:BAO_0002100 cell growth assay bao:BAO_0002101 adherent bao:BAO_0002102 The role played by a molecular entity that is added as an ingredient to a broth that is used to culture cells. media component bao:BAO_0002104 suspension bao:BAO_0002105 The role of a molecular entity of mediating the introduction of a foreign nucleic acid into cells, e.g., Lipofectamine 2000, Fugene 6, etc. transfection agent bao:BAO_0002107 mixed bao:BAO_0002108 Microtubule-associated protein tau bao:BAO_0002109 Mitogen-activated protein kinase 14 bao:BAO_0002110 This categorizes the devices that selectively transmit light in a particular range of wavelengths, including excitation and emission filters. For optimal results, the distance between the wavelengths of the excitation and emission filter should be more than 85% of the sum of both filters’ bandwidths. fluorescence microscope filter bao:BAO_0002111 An excitation filter is an optical-glass filter used in fluorescence microscopy for selection of the excitation wavelength of light from a light source. excitation filter bao:BAO_0002112 An emission filter is an optical-glass filter used in fluorescence microscopy for selection of the emission wavelength of light from a fluorescent molecule, e.g., fluorophore or dye. emission filter 1 1 bao:BAO_0002114 An endpoint defined by a length in time at which a desired effect or observation occurs. time endpoint Half-life of drug is the time taken for the concentration of the drug to decrease by half. T1/2 An endpoint defined an effect seen in animals at a particular dosage, typically defined as a ratio of treatment to animal mass (e.g., mg/kg). dosage endpoint The median lethal dose is the dose required to kill (produce lethality) in 50% of tested population. lethal dose 50% LD50 An endpoint derived from calculus-based analysis of graphical measures. graphical calculation endpoint The maximal concentration of a drug achieved following administration (maximum point of a concentration-time curve). Cmax It is the area under the drug concentration-time curve (AUC) following a single dose or at steady state, and is expressed as weight*time/volume. area under curve AUC Slope is described as the ratio of the change in y-axis divided by the change in x-axis between two points on a line or a curve. m= y2-y1 / x2-x1 slope Endpoint values derived from an exponential growth curve, such as in a PCR reaction. amplification curve calculated endpoint Crossing point- In an exponential amplification curve (i.e., qPCR amplification) the value in number of amplification cycles at which the signal enters log phase, as determined by the maximal second derivative of the curve. crossing point Cp Quantificatoin cycle; general term, whether defined by Cp or Ct, for the value of interest determined from an exponential amplification curve (such as number of cycles in a PCR reaction). quantificatoin cycle Cq Crossing threshold; in an exponential amplification curve (i.e., qPCR amplification) the value in number of amplification cycles at which the signal crosses a defined threshold. threshold cycle Ct Endpoint values determined by a statistical measurement of the signal relative to the populations of signals observed. statistical endpoint The number of median absolute deviations outside the median of control or compound wells. MAD score bao:BAO_0002128 A measurement of an intrinsic property of a molecular entity. physical property endpoint Logarithm (log10) of the Distribution Coefficient, D, which is defined as the ratio of concentrations of a small molecule / drug distributed between octanol and water. LogD refers to the distribution of all forms of a compound between the two immiscible phases at equilibrium. It depends on pH of the aqueous phase, which is buffered to a specific value. A larger logD means the compound / drug is more hydrophobic (greasy) and a lower logD corresponds to better solubility in water. logD Logarithm (log10) of the Partition Coefficient, P, which is defined as ratio of concentrations of a small molecule / drug distributed in octanol and water. LogP refers to the distribution of un-ionized (neutral species of) compound between the two immiscible phases at equilibrium; the pH is adjusted such that the major microspecies is the un-ionized form. A larger logP means the compound / drug is more hydrophobic (greasy) and a lower logP corresponds to better solubility in water. logP pKa is the negative log10 of the acid dissociation constant (Ka) of a molecule. Ka is the equilibrium constant for dissociation of the protonated base (acid) into the free base and a proton (hydromium ion). pKa Percent purity is the ratio of mass of pure compound to the actual mass of the available/vendor supplied compound, multiplied by 100. The majority of compounds and elemental substances are only available with a larger or smaller amount of impurities, which contribute to the mass of the impure compound. percent purity This is measured to assess the transport of a drug across the cell monolayer in the apical to basolateral (A-B) direction. Typically, CaCo2 cells are used in the permeability measurements during the ADME phase, which model the intestinal epithelium.. permeability A-B This is measured to assess the transport of a drug across the cell monolayer in the basolateral to apical (B-A) direction. Typically, CaCo2 cells are used in the permeability measurements during the ADME phase, which model the intestinal epithelium. permeability B-A The ability of a chemical substance to dissolve in a solid, liquid, or gaseous solvent to form a homogeneous solution. The solubility of a given substance is dependent on the solvent used, as well as on temperature and pressure. solubility An endpoint defined by a set of measurements from a multiparametric assay. The set of measurements may be aggregated to an overall profile score, weighting each measurment in the profile relative to a desired outcome. profile endpoint computational profile endpoint gene-expression profile endpoint panel-assay profile endpoint activity threshold specification The direction of the readout signal, relative to negative controls, which is considered to be of interest for determining active perturbagents (hits). activity threshold signal direction A parameter defining the separation of the noise bands of the negative and positive controls in an experiment using robust statistics. The robust z' is defined as 1-(3*(MAD(pos)-MAD(neg))/abs(median(pos)-median(neg)) where MAD(pos) is the median absolute deviation of the positive control population and MAD(neg) is the median absolute deviation of the negative control population. Typically defined on a per-plate basis but may be defined for an overall assay. robust z-prime factor bao:BAO_0002144 The effective concentration of an inhibitor, which produces 90% of the maximum possible response for that inhibitor. IC90 It is 50% lethal concentration (the concentration that kills 50% of treated cells). LC50 The lowest concentration of an inhibitor (antimicrobial agent) required to inhibit the growth of a microorganism. minimum inhibitory concentration MIC It is a measure of the amount of radioligand that binds to its receptor in a competitive binding assay. It is the ratio of the bound to the total bound, where bound refers to the reading obtained from a binding reaction involving radioligand, receptor and a cold competitor ligand, while total bound is the reading obtained in the absence of any added competitor. percent bound In a purification assay, percent recovery is the ratio of mass of the entity obtained after the affinity purification to the mass of the unpurified entity originally added in the assay, multiplied by 100. percent recovery bao:BAO_0002149 RNA interference construct RNA interference construct preparation method Increase in perturbation (reported by the endpoint mode of action, activation) is correlated to decrease in signal. signal decrease corresponding to activation Increase in perturbation (reported by the endpoint mode of action, inhibition) is correlated to increase in signal. signal increase corresponding to inhibition silencing RNA delivery method bao:BAO_0002157 A quality of a protein of being the predominant form in an organism. canonical form native form bao:BAO_0002158 A quality of a DNA or RNA residue that has a group (e.g., methyl) attached to it after transcription. posttranscriptionally modified b-score normalization z-score normalization mad-score normalization bao:BAO_0002162 concentration response endpoint bao:BAO_0002163 solid phase bao:BAO_0002164 liquid phase silencing RNA modification method bao:BAO_0002166 computational expression analysis bao:BAO_0002167 genotoxicity assay bao:BAO_0002168 oxidative stress assay bao:BAO_0002169 assay readout content endpoint modifier Natural log (log base e) ln Log base 10 log mean median -(log10(endpoint)) p standard deviation bao:BAO_0002177 concentration throughput bao:BAO_0002178 repetition throughput bao:BAO_0002181 oxidative phosphorylation assay bao:BAO_0002182 ADME assay PK PK assay PK study pharmacokinetic assay pharmacokinetic studies pharmacokinetic study pharmacokinetics pharmacokinetic assay bao:BAO_0002183 true pharmacodynamic assay bao:BAO_0002184 QT interval study QT interval assay bao:BAO_0002185 An abstract concept to group one or more assay readout and allow description of an assay that measures one or more effect of a perturbagen on the biological entity. This does not define the physical readout method itself, which is captured in assay design, but rather classifies the data being generated by those readouts. Called 'assay measurement' in BARD. For HCS measurement, we need to define 'assay measurement' as the outcome of image analysis and is most often a calculated value. This is similar to 'parameters', such as 'intensity', 'count', 'morphology', etc which are all dependent on phenotype, e.g., intensity and count (number of bright spots) are a result of the amount of gene expression, and morphology is dependent on morphological phenotype, which is detected by the expression of a marker. measure group specification bao:BAO_0002188 DDI FDA RPS Pharmacokinetics: Drug Interactions drug-drug interaction drug-drug interaction assay drug-drug interactions drug interaction assay bao:BAO_0002189 tox assay toxicology assay toxicity assay bao:BAO_0002190 mitochondrial membrane potential assay bao:BAO_0002192 tissue culture flask bao:BAO_0002194 plasma membrane potential assay bao:BAO_0002195 nuclear membrane potential assay bao:BAO_0002196 localization assay modification method delivery method bao:BAO_0002199 T-25 bao:BAO_0002200 fluorescence anisotropy readout bao:BAO_0002201 fluorescence polarization readout bao:BAO_0002202 The assay design method describes how a biological or physical process screened / investigated in the model system is translated into a detectable signal. This relates to the technology / technologies used to make the assay system work, i.e. enable that the screened process can be detected. It typically involves some manipulation of the (biological) model system to detect the process of interest. assay design method bao:BAO_0002203 Computational methods used for analysis of microarrays, expressed cDNA sequence tag (EST) sequencing, serial analysis of gene expression (SAGE) tag sequencing, massively parallel signature sequencing (MPSS), or various applications of multiplexed in-situ hybridization. computational analysis of gene expression bao:BAO_0002204 Computational methods involved in analysis of protein microarrays and high throughput (HT) mass spectrometry (MS). computational analysis of protein expression bao:BAO_0002206 Computational methods involved in construction and interpretation of phylogenetic trees, which are used to classify the evolutionary relationships between homologous genes represented in the genomes of divergent species. computational phylogenetic analysis bao:BAO_0002207 Software for evolutionary biology, designed to help biologists analyze comparative data about organisms. Its emphasis is on phylogenetic analysis, but some of its modules concern population genetics, while others do non-phylogenetic multivariate analysis. Mesquite phylogenetic analysis bao:BAO_0002208 Program for inferring phylogenetic trees or, more generally, phylogenetic networks from various types of data such as a sequence alignment, a distance matrix or a set of trees. SplitsTree phylogenetic analysis bao:BAO_0002209 is a free computer program for the likelihood-based reconstruction of phylogenetic trees from molecular sequences. Treefinder phylogenetic analysis bao:BAO_0002210 phylogenetic analysis using parsimony bao:BAO_0002211 A free Computational phylogenetics package of programs for inferring evolutionary trees (phylogenies). phylogeny inference package bao:BAO_0002212 computational structure analysis bao:BAO_0002213 2D structure prediction bao:BAO_0002214 PREDATOR structure prediction bao:BAO_0002215 PredictProtein structure prediction bao:BAO_0002216 3D structure prediction bao:BAO_0002217 computational structure solution bao:BAO_0002218 computational NMR structure solution bao:BAO_0002219 computational X-ray structure solution bao:BAO_0002220 computational electron microscopy structure solution bao:BAO_0002221 Also known as comparative modeling of protein, refers to constructing an atomic-resolution model of the "target" protein from its amino acid sequence and an experimental three-dimensional structure of a related homologous protein (the "template"). homology modeling bao:BAO_0002222 MODELLER homology modeling bao:BAO_0002223 SwissModel homology modeling bao:BAO_0002224 A method of computational protein structure prediction used for protein sequences which have the same fold as proteins of known structures but do not have homologous proteins with known structure. protein threading bao:BAO_0002225 protein threading software used for protein structure prediction, given a primary sequence. RAPTOR protein threading bao:BAO_0002226 protein-protein docking bao:BAO_0002227 global range molecular matching bao:BAO_0002228 Structural alignment software attempts to establish equivalences between two or more polymer structures based on their shape and three-dimensional conformation. structure alignment bao:BAO_0002229 DALI breaks the input structures into hexapeptide fragments and calculates a distance matrix by evaluating the contact patterns between successive fragments. distance matrix alignment bao:BAO_0002230 matching molecular models obtained from theory bao:BAO_0002231 Computational methods used to arrange the sequences of DNA, RNA, or protein to identify regions of similarity that may be a consequence of functional, structural, or evolutionary relationships between the sequences. sequence alignment bao:BAO_0002232 sequence alignment by method bao:BAO_0002233 Global alignments, which attempt to align every residue in every sequence, are most useful when the sequences in the query set are similar and of roughly equal size. global sequence alignment bao:BAO_0002234 Pairwise global alignment with whole genomes. AVID sequence alignment bao:BAO_0002235 DIALIGN sequence alignment bao:BAO_0002236 Local alignments are more useful for dissimilar sequences that are suspected to contain regions of similarity or similar sequence motifs within their larger sequence context. local sequence alignment bao:BAO_0002237 Local search with fast k-tuple heuristic, slower but more sensitive than BLAST. FASTA local sequence alignment bao:BAO_0002238 Local search with fast k-tuple heuristic. basic local alignment search tool bao:BAO_0002239 progressive system alignment bao:BAO_0002240 Multiple sequence alignment computer program. Clustal sequence alignment bao:BAO_0002241 ClustalW sequence alignment bao:BAO_0002242 ClustalX sequence alignment bao:BAO_0002243 is a multiple sequence alignment program suitable for the alignment of large numbers of DNA sequences. MAVID sequence alignment bao:BAO_0002244 sequence alignment by type bao:BAO_0002245 Multiple sequence alignment is an extension of pairwise alignment to incorporate more than two sequences at a time. multiple sequence alignment bao:BAO_0002246 Pairwise sequence alignment methods are used to find the best-matching piecewise (local) or global alignments of two query sequences. pairwise sequence alignment bao:BAO_0002247 is an open source Java implementation of the Smith-Waterman algorithm with Gotoh's improvement for biological local pairwise sequence alignment using the affine gap penalty model. JAligner sequence alignment bao:BAO_0002248 Methods using of computer and informational techniques for problems in the field of chemistry cheminformatics method bao:BAO_0002249 Consists of the exploration of energetically favorable spatial arrangements (shapes) of a molecule (conformations). conformational search bao:BAO_0002250 distance geometry conformational search bao:BAO_0002251 random conformational search bao:BAO_0002252 cartesian conformational search bao:BAO_0002253 dihedral conformational search bao:BAO_0002254 systematic conformational search bao:BAO_0002255 database filtering bao:BAO_0002256 Set of criteria for predicting the oral bioavailability of a compound on the basis of simple molecular features (molecular weight, CLogP, numbers of hydrogen- bond donors and acceptors). Lipinski rule of 5 filtering bao:BAO_0002257 Library design enables access to the large number of drug- like molecules that could theoretically be made and can serve several purposes: for example, to generate a maximally diverse virtual library for lead generation, a biased library aimed at a specific target or target family, or a lead optimization library. library design bao:BAO_0002258 structure database search bao:BAO_0002259 exact match structure search bao:BAO_0002260 structure similarity search bao:BAO_0002261 2D structure similarity search bao:BAO_0002262 MACCS key bao:BAO_0002263 circular fingerprint search bao:BAO_0002264 3D structure similarity search bao:BAO_0002265 shape fingerprint search bao:BAO_0002266 rapid overlay of chemical structures bao:BAO_0002267 topomer search bao:BAO_0002268 substructure search bao:BAO_0002269 structure generation bao:BAO_0002270 data based structure generation bao:BAO_0002271 CORINA structure generation bao:BAO_0002272 The design of bioactive compounds by incremental construction of a ligand model within a model of the receptor or enzyme active site, the structure of which is known from X-ray or NMR data. de novo structure design bao:BAO_0002273 GROW structure design bao:BAO_0002274 Groupbuild structure design bao:BAO_0002275 LEGEND structure design bao:BAO_0002276 LUDI structure design bao:BAO_0002277 SPROUT structure design bao:BAO_0002278 fragment based structure generation bao:BAO_0002279 Chem-X structure generation bao:BAO_0002280 rule based structure generation bao:BAO_0002281 CONCORD structure generation bao:BAO_0002282 computer simulation method bao:BAO_0002283 A set of functions and parametrization used in molecular mechanics calculations. computer simulation method by force field bao:BAO_0002284 classical force field simulation bao:BAO_0002285 AMBER force field simulation bao:BAO_0002286 CHARMM force field simulation bao:BAO_0002287 GROMOS force field simulation bao:BAO_0002288 polarizable force field simulation bao:BAO_0002289 second generation force field simulation bao:BAO_0002290 CFF force field simulation bao:BAO_0002291 MM4 force field simulation bao:BAO_0002292 MMFF force field simulation bao:BAO_0002293 global minimum search bao:BAO_0002294 genetic algorithm search bao:BAO_0002295 a simulations procedure, in which the system is allowed to equilibrate at high temperatures, and then cooled down slowly to remove kinetic energy and to permit trajectories to settle into local minimum energy conformations. simulated annealing bao:BAO_0002296 local minimum search bao:BAO_0002297 energy minimization method bao:BAO_0002298 Newton-Raphson method bao:BAO_0002299 conjugate gradient method bao:BAO_0002300 steepest descent method bao:BAO_0002301 A simulation procedure consisting of the computation of the motion of atoms in a molecule or of individual atoms or molecules in solids, liquids and gases, according to Newton's laws of motion. The forces acting on the atoms, required to simulate their motions, are generally calculated using molecular mechanics force fields. molecular dynamics simulation bao:BAO_0002302 constraint molecular dynamics simulation bao:BAO_0002303 stochastic simulation bao:BAO_0002304 Monte Carlo simulation bao:BAO_0002305 Mathematical relationships linking chemical structure and pharmacological activity in a quantitative manner for a series of compounds. Methods which can be used in QSAR include various regression and pattern recognition techniques. quantitative structure activity relationship analysis bao:BAO_0002306 linear QSAR bao:BAO_0002307 partial least squares QSAR bao:BAO_0002308 regression QSAR bao:BAO_0002309 non-linear QSAR bao:BAO_0002310 neural network QSAR bao:BAO_0002311 recursive partitioning QSAR bao:BAO_0002312 Involves the analysis of the quantitative relationship between the biological activity of a set of compounds and their three- dimensional properties using statistical correlation methods. three dimensional QSAR bao:BAO_0002313 A 3D-QSAR method that uses statistical correlation techniques for the analysis of the quantitative relationship between the biological activity of a set of compounds with a specified alignment, and their three-dimensional electronic and steric properties. comparative molecular field analysis bao:BAO_0002314 comparative molecular similarity indices analysis bao:BAO_0002315 self organizing molecular field analysis bao:BAO_0002316 two dimensional QSAR bao:BAO_0002317 quantum chemistry computational method bao:BAO_0002318 Methods of quantum mechanical calculations independent of any experiment other than the determination of fundamental constants. The methods are based on the use of the full Schr ab initio quantum chemistry computational method bao:BAO_0002319 Hartree-Fock method bao:BAO_0002320 restricted open-shell Hartree-Fock bao:BAO_0002321 unrestricted Hartree-Fock bao:BAO_0002322 post Hartree-Fock method bao:BAO_0002323 configuration interaction method bao:BAO_0002324 coupled cluster method bao:BAO_0002325 quadratic configuration interaction method bao:BAO_0002326 Use parameters derived from experimental data to simplify computations. semi-empirical quantum chemistry computational method bao:BAO_0002327 pi-electron computational method bao:BAO_0002328 Pariser Parr Pople method bao:BAO_0002329 valence electron computational method bao:BAO_0002330 Zerner's intermediate neglect of differential overlap bao:BAO_0002331 austin model 1 bao:BAO_0002332 intermediate neglect of differential overlap bao:BAO_0002333 modified neglect of differential overlap bao:BAO_0002334 parameterized model number 3 bao:BAO_0002335 statistical method bao:BAO_0002336 experimental design method bao:BAO_0002337 completely randomized design bao:BAO_0002338 fractional factorial design bao:BAO_0002339 full factorial design bao:BAO_0002340 randomized block design bao:BAO_0002341 statistical classification method bao:BAO_0002342 decision tree bao:BAO_0002343 hierarchial clustering bao:BAO_0002344 k means clustering bao:BAO_0002345 neural network model bao:BAO_0002346 principal component analysis bao:BAO_0002347 systems biology method bao:BAO_0002348 pathway analysis bao:BAO_0002349 pathway analysis by knowledge base bao:BAO_0002350 automatic pathway analysis bao:BAO_0002351 natural language processing bao:BAO_0002352 Ariadne Pathway Studio bao:BAO_0002353 pathway analysis by method bao:BAO_0002354 gene list enrichment analysis bao:BAO_0002355 GOstat enrichment analysis bao:BAO_0002356 GSEA-P enrichment analysis bao:BAO_0002357 GeneTrail enrichment analysis bao:BAO_0002358 Onto-Express enrichment analysis bao:BAO_0002359 integrated pathway analysis bao:BAO_0002360 MetaDiscovery pathway analysis bao:BAO_0002361 network analysis bao:BAO_0002362 Cytoscape network analysis bao:BAO_0002363 target family knowledge analysis bao:BAO_0002364 Selection of compounds by evaluating their desirability in a computational model. virtual screening bao:BAO_0002365 ligand based virtual screening bao:BAO_0002366 The ligand-based ensemble of steric and electronic features that is necessary to ensure the optimal supramolecular interactions with a specific biological target structure and to trigger (or to block) its biological response. ligand based pharmacophore model bao:BAO_0002367 Catalyst modeling bao:BAO_0002368 DISCOtech modeling bao:BAO_0002369 distance comparison modeling bao:BAO_0002370 genetic algorithm similary program bao:BAO_0002371 scaffold hopping bao:BAO_0002372 structure based virtual screening bao:BAO_0002373 Method which predicts the preferred orientation of one molecule to a second when bound to each other to form a stable complex. molecular docking bao:BAO_0002374 molecular docking by method bao:BAO_0002375 Monte Carlo minimization method bao:BAO_0002376 internal coordinate mechanics method bao:BAO_0002377 Monte Carlo simulated annealing bao:BAO_0002378 AutoDock docking method bao:BAO_0002379 descriptor matching method bao:BAO_0002380 ADAM docking method bao:BAO_0002381 DOCK docking method bao:BAO_0002382 SLIDE docking method bao:BAO_0002383 genetic algorithm method bao:BAO_0002384 AutoDock3 docking method bao:BAO_0002385 DARWIN docking method bao:BAO_0002386 GOLD docking method bao:BAO_0002387 incremental construction method bao:BAO_0002388 DOCK4 docking method bao:BAO_0002389 FlexX docking method bao:BAO_0002390 Hummerhead docking method bao:BAO_0002391 tabu docking method bao:BAO_0002392 SFdock docking method bao:BAO_0002393 molecular docking by scoring function bao:BAO_0002394 empirical scoring function bao:BAO_0002395 AutoDock3 scoring function bao:BAO_0002396 FLOG scoring function bao:BAO_0002397 GOLD scoring function bao:BAO_0002398 force field based scoring function bao:BAO_0002399 AMBER polarizable bao:BAO_0002400 CHARMM polarizable Enzyme multiplied immunoassay technique, or EMIT, is a common method for screening urine and blood for drugs, both legal or illicit. A mix and read protocol has been developed that is exceptionally simple and rapid. The most widely used applications for EMIT are for therapeutic drug monitoring (serum) and as a primary screen for abused drugs and their metabolites (urine). enzyme-multiplied immunoassay technique bao:BAO_0002402 knowledge based scoring function bao:BAO_0002403 DrugScore scoring function bao:BAO_0002404 potentials of mean force scoring function bao:BAO_0002405 The receptor-based ensemble of steric and electronic features that is necessary to ensure the optimal supramolecular interactions with a specific biological target structure and to trigger (or to block) its biological response. receptor based pharmacophore search bao:BAO_0002406 CoMFA pharmacophore search bao:BAO_0002407 GRID pharmacophore search bao:BAO_0002408 SPROUT pharmacophore search secondary structure analysis method bao:BAO_0002410 structure activity relationship analysis In a conventional 2-site enzyme immunoassay, the antigen under assay which must have two or more epitopes, is insolubilised by reaction with an unlabelled antibody conjugated to a solid phase and reacted with an enzyme-labelled antibody directed to a different (preferably roomly-spaced) epitope of the analyte. The quantity of labelled antibody which becomes immobilised due to the complexing reaction is directly proportional to the amount of analyte present in the sample. two site enzyme immunoassay SAR by NMR Titration is a common laboratory method of quantitative chemical analysis that is used to determine the unknown concentration of a known reactant. titration method Karl Fischer titration is a classic titration method in analytical chemistry that uses coulometric or volumetric titration to determine trace amounts of water in a sample. It was invented in 1935 by the German chemist Karl Fischer. Karl Fischer titration Dot immunobinding assay (Dot Iba) is a simple and highly reproducible immunodiagnostic method. Antibody or antigen is dotted directly onto nitrocellulose membrane (NCM) discs. The diagnostic material to be checked can be incubated on this disc. Presence of antigen antibody complex in NCM discs can be directly demonstrated with enzyme-conjugated antiglobulins and substrate. Development of a purple-pink colored, insoluble substrate product in the NCM will be considered a positive result in the assay. This assay allows the processing of multiple specimens at a time. dot immunobinding assay A checkerboard titration is a single experiment in which the concentration of the two components is varied in a way that will result in a pattern. This method is often used to optimize reagent concentrations and to measure susceptibility to microbes to various agents. checkerboard titration chemiluminescence-linked immunosorbent assay dilution method The ELISPOT assay is based on, and was developed from a modified version of the ELISA immunoassay. ELISPOT assays were originally developed to enumerate B cells secreting antigen-specific antibodies, and have subsequently been adapted for various tasks, especially the identification and enumeration of cytokine-producing cells at the single cell level. Simply put, at appropriate conditions the ELISPOT assay allows visualization of the secretory product of individual activated or responding cells. Each spot that develops in the assay represents a single reactive cell. Thus, the ELISPOT assay provides both qualitative (type of immune protein) and quantitative (number of responding cells) information. ELISPOT ELISPOT assay enzyme-linked immunosorbent spot assay Fluorescence-linked immunosorbent assay (FLISA) is a technique where a fluorescent probe is used on an antibody of interest, which results in direct detecting fluorescence intensity instead of more complicated enzymatic reaction. Compared with the sandwich ELISA, FLISA has similar sensitivity and specificity, but it is much more rapid, economic and convenient. fluorescence-linked immunosorbent assay The sandwich ELISA measures the amount of antigen between two layers of antibodies. The antigens to be measured must contain at least two antigenic sites, capable of binding to antibody, since at least two antibodies act in the sandwich. So sandwich assays are restricted to the quantitation of multivalent antigens such as proteins or polysaccharides. Sandwich ELISAs for quantitation of antigens are especially valuable when the concentration of antigens is low and/or they are contained in high concentrations of contaminating protein. sandwich ELISA immunoblot The In-Cell Western Assay is an immunocytochemical assay that uses NIR fluorescence to detect and quantify proteins in fixed cells. Detecting proteins in their cellular context increases quantification precision. Proteins in fixed, cultured cells are detected directly in microplates, which yields higher throughput compared to Western blotting and eliminates typical Western blotting steps such as cell lysate preparation, electrophoresis, and membrane transfer. Using the In-Cell Western Assay kits, the cost per well for secondary screening is reduced to a fraction of the cost of typical western blots. in-cell western assay The western blot (alternatively, protein immunoblot) is an analytical technique used to detect specific proteins in a given sample of tissue homogenate or extract. It uses gel electrophoresis to separate native or denatured proteins by the length of the polypeptide (denaturing conditions) or by the 3-D structure of the protein (native/ non-denaturing conditions). The proteins are then transferred to a membrane (typically nitrocellulose or PVDF), where they are probed (detected) using antibodies specific to the target protein. western blot Immunolabeling is a means of localizing particular antigens within tissue. Immunolabeling is a methodological process where: 1) antibodies are used to identify antigens within an organism and 2) a tag (e.g. through fluorescence, gold beads, epitope tag, etc.) is added to a secondary antibody which binds to the primary antibody. immunolabeling method Immunofluorescence is the labeling of antibodies or antigens with fluorescent dyes. immunofluorescent labeling Immunolabeling method in which gold particles are conjugated to a primary or secondary antibody and used for identification of an antigen. immunogold labeling radioimmunoassay Assay supporting methods describe the methods to prepare, generate or post-process the assay system or assay screening process. Such methods include the sample preparation, labeling, data processing, etc., which are required to performing the assay, but do not constitute the actual assay (design method). assay supporting method Serial analysis of gene expression (SAGE) is a technique used by molecular biologists to produce a snapshot of the messenger RNA population in a sample of interest in the form of small tags that correspond to fragments of those transcripts. serial analysis of gene expression bao:BAO_0002431 gene expression modulation method A Knock-in refers to a genetic engineering method that involves the insertion of a protein coding cDNA sequence at a particular locus in an organism's chromosome. The difference between knock-in technology and transgenic technology is that a knock-in involves a gene inserted into a specific locus, and is a "targeted" insertion. gene knock in Gene knockdown refers to techniques by which the expression of one or more of an organism's genes is reduced, either through genetic modification (a change in the DNA of one of the organism's chromosomes) or by treatment with a reagent such as a short DNA or RNA oligonucleotide with a sequence complementary to either an mRNA transcript or a gene. gene knockdown Double-stranded RNA is synthesized with a sequence complementary to a gene of interest and introduced into a cell or organism, where it is recognized as exogenous genetic material and activates the RNAi pathway. Using this mechanism, researchers can cause a drastic decrease in the expression of a targeted gene. gene knockdown by RNA interference gene knockdown by RNA interference gene knockdown by dsRNA transfection gene knockdown by lentiviral shRNA transduction shRNA gene knockdown shRNA knockdown gene knockdown by shRNA transfection gene knockdown siRNA siRNA gene knockdown siRNA knockdown gene knockdown by siRNA transfection Antisense RNA is a single-stranded RNA that is complementary to a messenger RNA (mRNA) strand transcribed within a cell. Antisense RNA may be introduced into a cell to inhibit translation of a complementary mRNA by base pairing to it and physically obstructing the translation machinery. gene knockdown by antisense RNA Method for reducing gene expression using morpholinos. Morpholino oligomers are an antisense technology used to block access of other molecules to specific sequences within nucleic acid. Morpholinos block small (~25 base) regions of the base-pairing surfaces of ribonucleic acid (RNA). gene knockdown by morpholino treatment A gene knockout is a genetic technique in which an organism is engineered to carry genes that have been made inoperative (have been "knocked out" of the organism). gene knockout Gene overexpression refers to genetic techniques in which an organism or cell line is engineered to express increased levels of a gene. gene overexpression gene overexpression by stable transfection gene overexpression by transient transfection bao:BAO_0002445 genotyping method nucleic acid hybridization-based method nucleic acid sequencing method restriction enzyme-based method single nucleotide polymorphism genotyping A method that uses purified enzymes to isolate and then replicate specific nucleic acids to levels where they can be detected. Examples are PCR, TMA, NASBA, etc. nucleic acid amplification method Mapping is the construction of a series of chromosome descriptions that depict the position and spacing of unique, identifiable biochemical landmarks, including some genes, that occur on the DNA of chromosomes. chromosome mapping labeling method colorimetric labeling method Method in which the amount of a substance is determined by measuring the volume of a second substance that combines or reacts with the first in known proportions. volumetric titration colorimetric cell staining method The the MTS assay is a laboratory test and a standard colorimetric assay (an assay which measures changes in color) for measuring the activity of enzymes that reduce MTS + PMS to formazan, giving a purple color. MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), in the presence of phenazine methosulfate (PMS), produces a water-soluble formazan product that has an absorbance maximum at 490-500 nm in phosphate-buffered saline. It is advantageous over MTT in that (1) the reagents MTS + PMS are reduced more efficiently than MTT, and (2) the product is water soluble, decreasing toxicity to cells seen with an insoluble product. MTS reduction assay The MTT assay is a colorimetric assay that relies on the enzymatic reduction of a yellow tetrazolium salt, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), which forms a purple formazan crystal in metabolically active cells. The formazan can then be solubilized producing a concentration dependent colorimetric signal at 570 nm proportional to the cell number and activity. MTT reduction assay The XTT Cell Proliferation Assay is a colorimetric assay system which measures the reduction of a tetrazolium component (XTT) into soluble formazan product by the mitochondria of viable cells. The samples are read using an ELISA plate reader at a wavelength of 450nm. The amount of color produced is directly proportional to the number of viable cells. XTT reduction assay For spectrophotometric measurement of metabolic activity of living cells. Absorbance of converted dye is measured at a wavelength of 600 nm. Bioreduction of the dye reduces the amount of its oxidized form (blue) and concomitantly increases the fluorescent intermediate (red). resazurin reduction assay The sulforhodamine B (SRB) assay is used for cell density determination, based on the measurement of cellular protein content. sulforhodamine B staining trypan blue cell staining colorimetric protein staining method The Bradford assay, a colorimetric protein assay, is based on an absorbance shift in the dye Coomassie when the previously red form coomassie reagent changes and stabilizes into coomassie blue by the binding of protein. Bradford protein assay Coomassie dyes (also known as Coomassie Brilliant Dyes) are a family of dyes commonly used to stain proteins in sodium dodecyl sulfate and blue native polyacrylamide gel electrophoresis (SDS-PAGE and BN-PAGE, respectively) gels. Coomassie dye protein staining The Lowry protein assay is a biochemical assay for determining the total level of protein in a solution. The total protein concentration is exhibited by a color change of the sample solution in proportion to protein concentration, which can then be measured using colorimetric techniques. Lowry assay Ponceau S, Acid Red 112, or C.I. 27195 is a sodium salt of a diazo dye that may be used to prepare a stain for rapid reversible detection of protein bands on nitrocellulose or PVDF membranes (Western blotting), as well as on cellulose acetate membranes. A Ponceau S stain is easily reversed with water washes, facilitating subsequent immunological detection. Ponceau S protein staining The bicinchoninic acid assay (also known as the BCA assay or Smith assay) is a biochemical assay for determining the total level of protein in a solution, similar to Lowry protein assay, Bradford protein assay or biuret reagent. The total protein concentration is exhibited by a color change of the sample solution from green to purple in proportion to protein concentration, which can then be measured using colorimetric techniques. bicinchoninic acid assay Crystal violet is a dye derived from gentian violet that is used as a general biological stain and an acid-base indicator. crystal violet staining fluorescent labeling method fluorescent DNA hybridization probe method fluorescent DNA hydrolysis probe method fluorescent DNA intercalation method A technique for DNA detection using SYBR Green 1 stain.The fluorescence intensity of SYBR Green is enhanced over 100-fold on binding to DNA which results in bright fluorescent DNA bands against a very dark background. Using a Dark Reader transilluminator, it is possible to detect less than 100 pg of SYBR Green-stained DNA by eye and tens of picograms using a CCD system. SYBR Green I DNA staining Ethidium bromide is an intercalating agent used as a fluorescent tag (nucleic acid stain) in molecular biology laboratories for various techniques. When exposed to ultraviolet light, it will fluoresce with an orange colour, intensifying almost 20-fold after binding to DNA. ethidium bromide DNA staining The assay utilizes the displacement of ethidium bromide (or thiazole orange) from hairpin deoxyoligonucleotides. fluorescent intercalator displacement Propidium iodide (or PI) is an intercalating agent and a fluorescent molecule with a molecular mass of 668.4 Da that can be used to stain DNA. When excited by 488 nm of laser light, it can be detected with 562-588 nm band pass filter. propidium iodide DNA staining fluorescent dye transfer isotope labeling method A technique of attaching a label to the active site of a large molecule and especially a protein by using a molecule which binds loosely and reversibly to the large molecule's active site and which has an inactive part that can be converted by photolysis to a highly reactive form causing the complex of the large substrate molecule and the loosely attached label to bind more permanently. photoaffinity labeling Method that employs a stain that is capable of entering and staining a living cell without causing an injury. vital dye staining Dye staining method in which the dye is excluded from particular cells, usually due to the presence of an intact plasma membrane. dye exclusion method Dye uptake assays using neutral red, trypan blue and fluorescent compounds such as propidium iodide are traditional methods to assess cell viability and membrane damage. Trypan blue and fluorescent compounds such as propidium iodide are excluded by healthy, functional cell membranes but are able to traverse damaged cell membranes thereby preferentially staining dead cells. propidium iodide exclusion vital staining of cells vital staining of organelles reconstitution method complementation method chemical complementation genetic complementation Refers to variations on the two-hybrid technique, which measures activation of a reporter gene caused by binding between fusion proteins or other molecular entities. hybrid screening The one-hybrid variation of the hybrid screening technique is designed to investigate protein-DNA interactions and uses a single fusion protein in which the AD is linked directly to the binding domain. one-hybrid assay RNA-protein interactions have been investigated through a three-hybrid variation of the two-hybrid technique. In this case, a hybrid RNA molecule serves to adjoin together the two protein fusion domains which are not intended to interact with each other but rather the intermediary RNA molecule (through their RNA-binding domains). three-hybrid assay A molecular biology technique used to discover protein-protein interactions and protein-DNA interactions by testing for physical interactions (such as binding) between two proteins or a single protein and a DNA molecule, respectively. The premise behind the test is the activation of downstream reporter gene(s) by the binding of a transcription factor onto an upstream activating sequence (UAS). For two-hybrid screening, the transcription factor is split into two separate fragments, called the binding domain (BD) and activating domain (AD). The BD is the domain responsible for binding to the UAS and the AD is the domain responsible for the activation of transcription. two-hybrid assay Two-hybrid assay performed in mammalian cells. mammalian two-hybrid assay Two-hybrid assay performed using yeast. yeast two-hybrid assay protein complementation enzyme complementation enzyme fragment complementation liposome reconstitution PAMPA PAMPA permeability assay Parallel artificial membrane permeability Parallel artificial membrane permeability assay parallel artificial membrane permeation assay bao:BAO_0002500 separation method affinity selection antibody-based separation method using capture antibodies which are able to isolate large enzyme complexes in the their fully intact, fully active states from small samples of tissue or cells. immunocapture Test based on a strip of paper coated with an immobilized antibody specific for an antigen that is characteristic of a disease. Samples conjugated to a second antibody (which allows chromogenic detection) can be applied to the paper strip and results visualized in less than 10 minutes. By using multiple antigens at different positions on the strip, multiple diseases can be screened for in one sample. immunochromatography The removal of certain proteins by the use of antibodies. immunodepletion bao:BAO_0002506 T-75 immunomagnetic separation method It is the technique of precipitating a protein antigen out of solution using an antibody that specifically binds to that particular protein. This process can be used to isolate and concentrate a particular protein from a sample containing many thousands of different proteins. Immunoprecipitation requires that the antibody be coupled to a solid substrate at some point in the procedure. immunoprecipitation cell separation method bao:BAO_0002510 dark field microscopy bao:BAO_0002511 differential interference contrast microscopy bao:BAO_0002512 scanning near-field optical microscopy bao:BAO_0002513 vibrational spectroscopic imaging bao:BAO_0002514 T-225 bao:BAO_0002515 Raman imaging bao:BAO_0002516 infrared imaging bao:BAO_0002517 T-175 bao:BAO_0002518 near-infrared imaging bao:BAO_0002519 mid-infrared imaging bao:BAO_0002520 HYPER flask bao:BAO_0002521 triple flask bao:BAO_0002523 atomic force microscopy bao:BAO_0002524 scanning tunneling microscopy bao:BAO_0002525 tomography bao:BAO_0002526 microscopy bao:BAO_0002527 [EdgeRewiring: BAO v 2.8.14 (April 2025)] autoradiography bao:BAO_0002528 The use of photostimulated luminescence to make a form of X-ray image. [EdgeRewiring: BAO v 2.8.14 (April 2025)] phosphorimaging bao:BAO_0002529 atomic absorption spectrophotometry bao:BAO_0002530 bioavailability study bioavailability assay bao:BAO_0002531 non-specific protein binding assay bao:BAO_0002532 FDA RPS Pharmacokinetics: Distribution distribution assay drug distribution drug tissue exposure organ distribution tissue distribution tissue drug distribution tissue exposure tissue distribution assay bao:BAO_0002533 safety pharmacology assay safety pharmacology assay bao:BAO_0002534 drug abuse assay bao:BAO_0002535 metastasis assay bao:BAO_0002537 EGTA ethyleneglycol-bis(β-aminoethyl)-N,N,N′,N′-tetraacetic acid bao:BAO_0002538 EDTA ethylenediaminetetraacetic acid bao:BAO_0002539 The role of the peptide that is appended at the N- or C-terminal of a protein (e.g., GST, His, HA, Myc, etc) which allows for easy identification and/or separation of that protein. protein tag bao:BAO_0002540 ECL western blotting detection kit bao:BAO_0002541 Pierce bao:BAO_0002542 cell phenotype bao:BAO_0002544 his tag bao:BAO_0002545 myc tag bao:BAO_0002546 HA tag bao:BAO_0002547 GST tag bao:BAO_0002552 tagged bao:BAO_0002554 Two or more proteins interact to form a stable complex. Each of the members of this complex has a distinct role in mediating the overall function of the complex, which can be as a chaperone (DnaK, DnaJ and grpE), an enzyme (mitochondrial respiratory complexes), a signaling complex (G-proteins), etc. It can be viewed as a quaternary structure of the proteins. protein complex bao:BAO_0002555 The individual protein molecule of a protein complex. In the complex, it associates with other protein subunits which are either the same or different, e.g., hemoglobin, microtubule, etc. protein subunit bao:BAO_0002556 ICRM12000 atomic absorption spectrometer bao:BAO_0002557 Sector imager 6000 bao:BAO_0002558 Aurora Biomed bao:BAO_0002560 A quality of an amino acid residue that has a carbohydrate moiety attached to it. glycosylated bao:BAO_0002561 FLIPR Calcium 3 Assay Kit bao:BAO_0002562 LanthaScreen kinase activity assay kit bao:BAO_0002563 lance TR-FRET kinase assay kit bao:BAO_0002564 AlphaScreen IgG detection kit bao:BAO_0002565 AlphaScreen GST detection kit bao:BAO_0002566 AlphaScreen cAMP assay kit bao:BAO_0002567 ECL peptide assay bao:BAO_0002568 BellBrook Labs bao:BAO_0002569 LabChip EZ Reader bao:BAO_0002570 Cellomics ArrayScan bao:BAO_0002571 IN Cell Analyzer bao:BAO_0002572 Epic reader bao:BAO_0002573 Applied biosystems 8200 bao:BAO_0002574 AlphaQuest reader bao:BAO_0002575 LJL reader bao:BAO_0002576 IonWorks Quattro bao:BAO_0002577 RapidFire Mass Spec bao:BAO_0002578 Tecan Ultra bao:BAO_0002579 XTT red bao:BAO_0002580 malachite green bao:BAO_0002581 5/6 TAMRA bao:BAO_0002582 Corning pEC50 is -logEC50, where EC50 is the effective concentration of an agonist, which produces 50% of the maximum possible response for that agonist. -log EC50 pEC50 bao:BAO_0002584 'involves biological process' some 'mitotic cell cycle arrest' 'involves biological process' some 'mitotic cell cycle arrest' and 'apoptotic process' mitotic cell cycle state assay bao:BAO_0002585 meiotic cell cycle state assay bao:BAO_0002590 The role of an organization or individual in the various stages of implementation of an assay, such as manufacturing an assay kit or depositing an assay in a repository. organization role The effect of a perturbagen on an enzyme activity is coupled to a secondary signal. The activity of an enzyme, e.g. luciferase is coupled to the effect of perturbagen upon the function of a chaperone, e.g. Hsp90, as denatured luciferase could serve as a substrate for Hsp90 mediated refolding. chaperone coupled enzyme activity measurement method The effect of a perturbagen on an enzyme activity is coupled to a secondary signal. The activity of an enzyme, e.g. phospholipase A2 is dependent on the effect of perturbagen upon the function a protease, e.g. ubiquitin-specific protease-2. protease coupled enzyme activity measurement method The effect of a perturbagen on an enzyme activity is coupled to a secondary signal. The activity of an enzyme, e.g. luciferase is limited by the availability of one of its substrates (ATP or luciferin), which is coupled to the activity of another enzyme, e.g. a kinase or Cytochrome P450. substrate coupled enzyme activity measurement method The effect of a perturbagen on an enzyme activity is coupled to a secondary signal. The activity of an enzyme, e.g. luciferase is limited by the availability of one of its substrates, namely, ATP, which is coupled to the activity of another enzyme, e.g. a kinase, ATPase, etc. ATP coupled enzyme activity measurement method bao:BAO_0002595 The effect of a perturbagen on an enzyme activity is coupled to a secondary signal. The activity of an enzyme, e.g. luciferase is limited by the availability of one of its substrates, namely, luciferin, which is coupled to the activity of another enzyme, e.g. a Cytochrome P450, protease, etc. luciferin coupled enzyme activity measurement method bao:BAO_0002596 The serum used in cell culture medium. Cultured cells require serum or growth factors for growth by cell division. In the laboratory, each cell type is grown in a medium supplemented with a variable concentration of serum (up to 20%) which is optimized for its growth. Specialized sera include dextran charcoal treated serum, which lacks certain hormones, growth factors, etc, dialyzed serum, which lacks low molecular weight molecules (below 10,000 MW), such as glucose, amino acids, low molecular weight hormones, cytokines, etc. Most commonly, fetal bovine serum is used in cell culture, but other sera such as horse serum are also used. culture serum bao:BAO_0002597 The serum used in assay medium while performing a cell-based assay and is optimized for each assay type. In certain assays, the cells could be maintained at either a lower concentration of the serum or in a specialized serum, including dextran charcoal treated serum, dialyzed serum, etc. This is done to avoid interference with the assay measurements. assay serum antibody preparation method ammonium sulfate precipitation method affinity purification method protein G-based affinity purification method antigen-based affinity purification method protein A-based affinity purification method protein A/G-based affinity purification method protein L-based affinity purification method bao:BAO_0002609 The different varieties or classes of antibodies, which differ in their properties and biological functions. antibody isotype bao:BAO_0002610 IgG bao:BAO_0002611 IgA bao:BAO_0002612 IgM bao:BAO_0002613 IgD bao:BAO_0002614 IgE 1 0.0 bao:BAO_0002618 purity bao:BAO_0002619 categorical purity bao:BAO_0002624 The role of a company as a creator of an assay kit, compound library, or detection instrument. commercial vendor bao:BAO_0002625 The role of an individual, who works at an academic institution as a creator of a chemical compound. academic chemist bao:BAO_0002626 The role of a company as a creator of reagents and assay kits. biologics and screening manufacturer bao:BAO_0002627 The role of a company as a creator of a compound library. compound library manufacturer bao:BAO_0002628 The role of a company as a creator of detection instrumentation. instrumentation manufacturer bao:BAO_0002629 unfolded conformation bao:BAO_0002630 native conformation protein denaturation method protein modification method heat denaturation chemical denaturation RNA modification method bao:BAO_0002636 Bandwidth is the range of wavelength of light that it allows to pass through the filter, which is either excitation or emission type. bandwidth bao:BAO_0002639 Chlorocebus aethiops bao:BAO_0002641 cyclin B1-luciferin 4-monooxygenase bao:BAO_0002642 This categorizes the distinct roles played by antibodies in recognizing either the antigen or an antibody itself. antibody role bao:BAO_0002643 The role of an antibody to detect and bind a specific antigen in a sample (cell, tissue, protein blot). primary antibody bao:BAO_0002644 The role of an antibody to detect and bind a primary antibody in a sample (cell, tissue, protein blot). secondary antibody bao:BAO_0002646 A quality of a protein that harbors a variation from the native protein (called canonical form), which could arise due to alternative promoter usage, alternative splicing, alternative translation initiation and ribosomal frameshifting. isoform cell culture method one cell type Organoid Organoids co-culture assay co-culture bao:BAO_0002651 FuGENE 6 bao:BAO_0002652 Gilson bao:BAO_0002653 Thermo Fisher Scientific bao:BAO_0002654 Bruker bao:BAO_0002655 The NatProd Collection bao:BAO_0002656 A gene that performs the role of encoding a reporter protein, which can easily be detected in an assay, e.g., luciferase gene that encodes the luciferase protein. DNA constructs that contain reporter genes are excellent tools to understand regulation of gene expression. reporter gene bao:BAO_0002657 Infectious bronchitis virus bao:BAO_0002658 counts per second bao:BAO_0002661 luciferase reporter gene assay 90.0 bao:BAO_0002667 90% reduction of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. 90% inhibition 90 percent inhibition bao:BAO_0002670 BJ bao:BAO_0002672 fluo-8 calcium indicator bao:BAO_0002673 LYMP2-010 bao:BAO_0002674 LYMP2-001 bao:BAO_0002675 LYMP2-012 bao:BAO_0002676 LYMP2-014 bao:BAO_0002677 LYMP2-016 bao:BAO_0002678 BSC-1 bao:BAO_0002679 LYMP2-018 bao:BAO_0002680 LYMP2-020 bao:BAO_0002681 LYMP2-022 bao:BAO_0002682 LYMP2-024 bao:BAO_0002683 U3A bao:BAO_0002684 LYMP2-026 bao:BAO_0002685 MV-4-11 bao:BAO_0002686 LYMP2-007 bao:BAO_0002687 LYMP2-006 bao:BAO_0002688 LYMP2-002 bao:BAO_0002689 LYMP2-025 bao:BAO_0002690 LYMP2-023 bao:BAO_0002691 LYMP2-021 bao:BAO_0002692 LYMP2-019 bao:BAO_0002693 LYMP2-017 bao:BAO_0002694 RBL-2H3 bao:BAO_0002695 LYMP2-013 bao:BAO_0002696 LYMP2-011 bao:BAO_0002697 LYMP2-009 bao:BAO_0002698 LYMP2-005 bao:BAO_0002699 LYMP2-004 bao:BAO_0002700 LYMP2-003 bao:BAO_0002701 LYMP1-003 bao:BAO_0002702 LYMP1-002 bao:BAO_0002703 C6 bao:BAO_0002704 LYMP2-008 bao:BAO_0002705 MSC 80 bao:BAO_0002706 LYMP2-015 bao:BAO_0002707 OCI-Ly3 bao:BAO_0002708 C2C12 bao:BAO_0002709 HEC-1-A bao:BAO_0002710 WRO bao:BAO_0002711 N2a bao:BAO_0002712 SK-BR-3 bao:BAO_0002713 H4 bao:BAO_0002714 ML-2 bao:BAO_0002715 KOPN-8 bao:BAO_0002716 PPC-1 bao:BAO_0002717 CSM14.1 bao:BAO_0002718 A clone of BHK (Baby hamster kidney) cells. BSR bao:BAO_0002719 Avance III bao:BAO_0002720 2-(N-morpholino)ethanesulfonic acid MES bao:BAO_0002721 Molecular Probes bao:BAO_0002722 CyAn Flow Cytometer bao:BAO_0002723 MSD SECTOR instrument bao:BAO_0002724 AMINCO-Bowman Series 2 Luminescence Spectrometer bao:BAO_0002725 AlphaScreen Beads bao:BAO_0002726 The role played by a molecular entity that is added as an ingredient to an assay. assay component bao:BAO_0002727 ELISA cAMP Competition Assay using cAMP-Screen Direct System bao:BAO_0002728 Vybrant MTT Cell Proliferation Assay Kit bao:BAO_0002729 AAT Bioquest cofactor coupled enzyme activity measurement method bao:BAO_0002732 Phospho(Thr180/Tyr182)/Total p38 Assay Whole Cell Lysate Kit bao:BAO_0002733 HPLC System luciferase enzyme activity measurement method bao:BAO_0002735 luciferase enzyme activity assay bao:BAO_0002736 cytochrome P450 enzyme activity assay bao:BAO_0002737 regulation of catalytic activity bao:BAO_0002740 S phase assessment method bao:BAO_0002741 M phase assessment method bao:BAO_0002742 EdU bao:BAO_0002743 Recognizes a phosphorylated epitope (S/T)P found in phosphoproteins such as MAP2, HSP70, cdc25, and DNA topoisomerase IIa, most of which are phosphorylated at the onset of mitosis. The number of phosphoproteins recognized by MPM-2 varies from species to species and with the cell type. Millipore #05-368 Anti-MPM-2 Raw sample measurements are normalized relative to positive and negative control samples with known activity and inactivity. Endpoints are usually expressed as percentage, which include percent activity, percent inhibition, etc. normalization based on control Where control samples are not available, data can be normalized statistically assuming that the majority of the samples are negative, i.e. not active. An example is z-score. normalization without control Measured / detected concentration of the perturbagen / compound in the assay or a subsystem (locally) in the assay. For example measured absolute concentration in the brain. This is in contrast to screening concentration, which is the (final assumed) concentration of a compound added to the assay. measured concentration bao:BAO_0002753 assay method component Methods to process the measurement into the result type / endpoint reported as the final outcome of the assay; or other characteristics of the assay, which as data characterizing quality of an assay. Includes endpoint normalization and assay quality assessment. assay data processing method fluorescent ligand binding method bao:BAO_0002756 second messenger bao:BAO_0002757 cGMP Cyclic guanosine monophosphate volume endpoint Clearance is the volume of plasma from which the drug is completely removed per unit time, or, alternatively, the volume of plasma that would have to lose all of the drug that it contains within a unit of time to account for an observed rate of drug elimination. Drug clearance CL bao:BAO_0002760 DNA tag bao:BAO_0002761 chaperone activity assay bao:BAO_0002762 phosphatase activity assay bao:BAO_0002763 platelet activation assay bao:BAO_0002764 protease activity assay bao:BAO_0002765 An organism behavior assay evaluates an organism's response to specific stimuli or in a particular environment and how it is influenced by various factors, like genetics, environment, or drugs. [EdgeRewiring: BAO v 2.8.15 (May 2025)] https://doi.org/10.1111/j.1365-2826.2008.01772.x organism behavior assay The time taken for the concentration of the drug in a particular tissue or blood plasma to decrease by half. T1/2(in vivo) The time taken for the concentration of the drug in an in-vitro system (e.g., liver microsomes) to decrease by half. T1/2(in vitro) bao:BAO_0002769 concentration profile bao:BAO_0002770 temperature profile The area under the drug concentration-time curve following an oral dose. AUC(oral) The area under the drug concentration-time curve following an intravenous dose. AUC(iv) Clearance of the drug due to renal excretion. CL(renal) Clearance of the drug due to hepatic enzyme activity and biliary excretion. CL(hepatic) The ability of a chemical substance to dissolve in water. aqueous solubility bao:BAO_0002776 radioligand binding assay bao:BAO_0002777 beta galactosidase enzyme activity assay bao:BAO_0002778 cell permeability assay bao:BAO_0002779 protein unfolding assay bao:BAO_0002780 IP1 redistribution assay bao:BAO_0002781 IP3 inositol trisphosphate inositol 1,4,5-trisphosphate bao:BAO_0002782 P-selectin glycoprotein ligand 1 bao:BAO_0002783 [35S]GTP-gamma S bao:BAO_0002784 phosphatidylinositol (3,4,5)-triphosphate bao:BAO_0002785 This assay quantifies the expression level of the entire gene pool in a cell or a subpopulation (e.g. tissue-specific gene expression, kinases) using either microarray, bead method, RNASeq, or reporter gene method. gene expression assay gene expression assay bao:BAO_0002786 cell cycle state assay bao:BAO_0002789 Mitogen-activated protein kinase 1 bao:BAO_0002790 hydrolase activity assay ADP coupled enzyme activity measurement method bao:BAO_0002792 oxidoreductase activity assay bao:BAO_0002793 lyase activity assay bao:BAO_0002794 isomerase activity assay bao:BAO_0002795 transferase activity assay bao:BAO_0002798 detected entity fold increase fold decrease bao:BAO_0002803 neurite outgrowth assay bao:BAO_0002804 protein stability assay bao:BAO_0002805 anti-proliferation anti-proliferation assay cell proliferation cell proliferation inhibition cell proliferation inhibitor in vitro RCS proliferation assay in vitro cell proliferation inbition of cell proliferation proliferation proliferation of human breast tumor cells cell proliferation assay bao:BAO_0002806 generic hydrolase enzyme activity assay bao:BAO_0002807 percent mitotic arrested cells permeability Ka bao:BAO_0002810 physicochemical bao:BAO_0002840 on plate control bao:BAO_0002841 off plate control bao:BAO_0002842 Gram positive bao:BAO_0002843 Gram negative bao:BAO_0002844 Gram staining The concentration of compound that elicits an extension of circadian period length by 5 hours. EC 5 hour bao:BAO_0002873 A person that performs scientific research and could have the capability of synthesizing new chemical entities. chemist The compound concentration at which the fitted curve passes activity threshold 1000. AC1000 absolute The compound concentration at which the fitted curve passes activity threshold 10. AC10 absolute The compound concentration at which the fitted curve passes activity threshold 26. AC26 absolute The compound concentration at which the fitted curve passes activity threshold 35. AC35 absolute The compound concentration at which the fitted curve passes activity threshold 40. AC40 absolute The compound concentration at which the fitted curve passes activity threshold 500. AC500 absolute The compound concentration whereupon perceived activity reaches the maximum value observed (with a positive control). ECMax The compound concentration whereupon perceived activity (change in Tm) reaches the maximum value observed (with a positive control). ECMax_Tm The agonist concentration whereupon perceived activity reaches the maximum value observed (with a positive control). ECMax_Agonist The compound concentration whereupon perceived activity (fold increase) reaches the maximum value observed (with a positive control). ECMax_fold increase The compound concentration whereupon perceived activity (percent inhibition) reaches the maximum value observed (with a positive control). ECMax_percent inhibition ion redistribution determination method bao:BAO_0002889 calcium-mediated signaling using intracellular calcium bao:BAO_0002890 G-protein coupled receptor signaling bao:BAO_0002891 cAMP-mediated second messenger competitive binding assessment method bao:BAO_0002898 screening lab investigator bao:BAO_0002899 screening principal investigator bao:BAO_0002900 researcher role agonism antagonism bao:BAO_0002904 Hank's balanced salt solution HBSS allosteric inhibition partial activation Small molecule that can bind to sites other than the receptor active site and affect activity of the receptor. allosteric activation bao:BAO_0002908 KiNativ assay modulation allosteric agonism partial agonism full agonism inverse agonism full activation bao:BAO_0002925 plasmid DNA construct bao:BAO_0002927 true disease bao:BAO_0002928 quality bao:BAO_0002929 role bao:BAO_0002930 true anatomical entity bao:BAO_0002931 true cell line cell bao:BAO_0002932 screened entity role bao:BAO_0002933 experimental specification bao:BAO_0002934 Organization in BAO is the organizational affiliation of individuals / people or laboratories that develop assays or perform screens or manufacture, commercialize entities used in performing assay experiments (assay kits, instruments, etc). organization bao:BAO_0002935 automated cytometer bao:BAO_0002936 Hypercyt bao:BAO_0002937 An imageing cytometer is an instrument for image-based study or measurement of cells. (definition from OBI) imaging cytometer bao:BAO_0002938 Intelligent Imaging Innovations www.intelligent-imaging.com 3i Marianas bao:BAO_0002939 TTP LabTech http://www.ttplabtech.com/products/acumen/index.html Acumen bao:BAO_0002940 Thermo Fisher Scientific www.cellomics.com ArrayScan VTI HCS Reader bao:BAO_0002941 BD Biosciences http://www.bdbiosciences.com/instruments/pathway/index.jsp BD Pathway 435 bao:BAO_0002942 BD Biosciences http://www.bdbiosciences.com/instruments/pathway/index.jsp BD Pathway 855 bao:BAO_0002943 FLUXION http://www.fluxionbio.com/products/bioflux-live-cell-imaging-with-flow/ BioFlux 1000 bao:BAO_0002944 Brooks Life Science Systems http://www.brooks.com/products/life-science-systems/instruments-and-devices/celigo-cytometer Celigo S Imaging Cell Cytometer bao:BAO_0002945 Yokogawa http://www.yokogawa.com/scanner/products/cv1000e.htm Cell Voyager 1000 bao:BAO_0002946 Yokogawa http://www.yokogawa.com/hca/product/cv6000.htm Cell Voyager 6000 bao:BAO_0002947 Yokogawa http://www.yokogawa.com/hca/product/cv7000.htm Cell Voyager 7000 bao:BAO_0002948 Amnis https://www.amnis.com/documents/brochures/FS_Brochure_Final.pdf FlowSight bao:BAO_0002949 CompuCyte http://www.compucyte.com/icyte.htm iCyte Automated Imaging Cytometer bao:BAO_0002950 Amnis https://www.amnis.com/documents/brochures/ISX-MKII%20Brochure_Final_Web.pdf ImageStreamX Mark II Imaging Flow Cytometer bao:BAO_0002951 Molecular Devices http://www.moleculardevices.com/Products/Instruments/High-Content-Screening.html ImageXpress Micro bao:BAO_0002952 Molecular Devices http://www.moleculardevices.com/Products/Instruments/High-Content-Screening.html ImageXpress Ultra bao:BAO_0002953 formerly known as: isocyte cytometer Molecular Devices http://www.moleculardevices.com/Products/Instruments/High-Content-Screening.html ImageXpress Velos Laser Scanning Cytometer bao:BAO_0002954 GE Healthcare http://www.biacore.com/high-content-analysis/index.html IN Cell Analyzer 2000 bao:BAO_0002955 GE Healthcare http://www.biacore.com/high-content-analysis/index.html IN Cell Analyzer 6000 bao:BAO_0002956 Perkin Elmer http://www.perkinelmer.com/pages/020/cellularimaging/products/opera.xhtml Opera bao:BAO_0002957 Perkin Elmer http://www.perkinelmer.com/pages/020/cellularimaging/products/operetta.xhtml Operetta bao:BAO_0002958 life technologies http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cell-Analysis/Cellular-Imaging/imaging-cytometry/Tali-Image-Cytometer/Tali-Image-Cytometer-Specifications.html Tali Image Cytometer bao:BAO_0002959 Amnis bao:BAO_0002960 CompuCyte bao:BAO_0002961 Cyntellect bao:BAO_0002962 FLUXION bao:BAO_0002963 Leica Microsystems bao:BAO_0002964 Olympus bao:BAO_0002965 TAP Biosystems bao:BAO_0002966 TTP LabTech bao:BAO_0002967 Yokogawa bao:BAO_0002968 Life Technologies Corporation bao:BAO_0002969 assay readout parameter is the outcome of image analysis and is most often a calculated value. This includes 'parameters', such as 'intensity', 'count', 'morphology', etc which are all dependent on phenotype, e.g., intensity and count (number of bright spots) are a result of the amount of gene expression, and morphology is dependent on morphological phenotype, which is detected by the expression of a marker. measured parameter Since 'measurement' and 'parameter' are so similar in HCS, we need to decide on one term that says it all. assay readout parameter bao:BAO_0002970 counting parameter is an output of the device measuring the number of the subject. counting parameter bao:BAO_0002971 densitometric parameter is an output of the device that is the density value of the subject by measuring the amount of light or fluorescence detected on the image. densitometric parameter bao:BAO_0002972 intensity parameter is an output of the device measuring the intensity value for the light signal of the subject. intensity parameter bao:BAO_0002973 morphometric parameter is an output of image analysis measuring a structure, a concept that encompasses size and shape of the subject (cells, organisms). morphometric parameter bao:BAO_0002974 Cellomics Beta-Catenin Activation Kit bao:BAO_0002975 Cellomics BrdU and Ki67 Cell Proliferation Kit bao:BAO_0002976 Cellomics Caspase3 Activation Kit bao:BAO_0002977 Cellomics Caspase9 Activation Kit bao:BAO_0002978 Cellomics Cell Motility Kit bao:BAO_0002979 Cellomics Cell Viability Kit bao:BAO_0002980 Cellomics c-Jun Activation Kit bao:BAO_0002981 Cellomics Cytoskeletal Rearrangement Kit bao:BAO_0002982 Cellomics Mitotic Index Kit bao:BAO_0002983 Cellomics Multiparameter Cytotoxicity 1 Kit bao:BAO_0002984 Cellomics Multiplexed NFκB and c-Jun Activation Kit bao:BAO_0002985 Cellomics Multiplexed p53 and p21 Detection Kit bao:BAO_0002986 Cellomics p38 MAPK Activation Kit bao:BAO_0002989 It is performed to quantify the interactions between two molecules, e.g. small molecule-protein, protein-protein, protein-DNA, etc. ligand binding ligand binding assay binding assay bao:BAO_0002990 It is performed to quantify the interactions between two protein molecules, using methods such as protein fragment complementation assay, immunoassay, radioligand binding, etc. protein-protein interaction assay bao:BAO_0002991 It reports the size and shape of cells and organelles (phenotype). These are detected by microscopy. cell morphology assay bao:BAO_0002992 It is performed to measure the movement of cells and organelles (phenotype). These are detected by microscopy. cell motility assay bao:BAO_0002993 [EdgeRewiring: BAO v 2.8.14 (April 2025)] cytotox assay cytotoxic activity in vitro cytotoxic activity cytotoxicity assay bao:BAO_0002994 It is used to measure the effect of a perturbagen on the enzyme activity, which can be measured either directly or coupled to a secondary signal. enzymatic activities enzyme activity assay bao:BAO_0002995 This assay quantifies the expression level of the entire gene pool in a cell or a subpopulation (e.g. tissue-specific gene expression, kinases) using a bead-based method. transcriptional profile transcriptional profiling transcriptomic profiling transcriptional profiling assay bao:BAO_0002996 This reports the membrane potential of a cell by using electrophysiological techniques or by staining with dyes whose binding is dependent on the membrane potential. membrane potential assay bao:BAO_0002997 Ion channel assays are performed in electrically active cells: neurons, muscle, and endocrine cells. ion channel assay bao:BAO_0002998 This assay quantifies the protein folding/conformation using technologies, such as nuclear magnetic resonance, circular dichroism are used to determine the protein folding/conformation. protein folding assay bao:BAO_0002999 It is performed to measure the redistribution of organelles and molecules within the cell (proteins, second messengers, metal ions, dyes, etc. ). This is visualized by microscopy. redistribution assay bao:BAO_0003000 This assay quantifies the amount of a mature transcript that is produced after splicing. Splicing is a modification of an mRNA intermediate after transcription, in which introns are removed and exons are joined. It can be detected by several methods, namely, the use of a reporter gene, RNA-Seq, specialiez microarrays, etc. rna splicing assay bao:BAO_0003001 This assay allows the identification of new drugs that sensitize or desensitize the sensitivity of a cell to its signaling molecule (e.g calcium, light). The perturbagen has the role 'sensitizer' in this assay. sensitizer assay bao:BAO_0003002 This assay measures one of the series of events that are downstream to the receipt of a chemical signal at the cell cell signaling cell signaling assay cell signalling cell signalling assay signal transduction assay bao:BAO_0003003 It measures the types and amounts of cytokines that are released as the consequence of a signaling event. Cytokines can be quantitated using ELISA-based kits, PCR array, etc. cytokine release cytokine release assay cytokine secretion assay bao:BAO_0003004 This assay quantifies the modification that a protein can undergo after it is synthesized by translation. E.g. phosphorylation, acetylation, etc. The modification status is detected by one of several methods such as using modification specific antibodies followed by western blotting, imaging; mass spectrometry, etc. posttranslation modification assay bao:BAO_0003005 This assay quantifies the phosphorylation levels of a protein. The phosphorylation status is detected by one of several methods: using phosphorylation specific antibodies followed by western blotting or imaging, mass spectrometry, etc. kinase phosphorylation protein phosphorylation assay detect some (protein phosphorilation and ('catalyzed by' some kinase)) phosphorylation assay bao:BAO_0003006 Reporter gene assay measures the gene expression from a reporter gene. The reporter gene is inserted under the control of a foreign promoter or an artificial regulatory element of interest. Reporters include luciferase, beta galactosidase, beta lactamase, chloramphenicol acetyl transferase, or a fluorescent protein. reporter assay reporter assays reporter gene assays reports some ('gene expression' and ('has part' some 'reporter gene')) needs clean up to say has part gene with role of reporter. reporter gene assay bao:BAO_0003007 This assay quantifies the second messengers (calcium, cAMP, cGMP) produced in the cell as a result of a signaling event. second messenger assay bao:BAO_0003008 This assay quantifies the activity of a transporter that carries proteins, cofactors, ions, drugs, etc. across the cell membranes. Fluorescence-conjugated dyes or radiolabeled ligands are used to quantitate the various molecular entities that are being transported. drug transporter assay transporter assay bao:BAO_0003009 This assay type measures the cellular state of living or dying by measuring an indicator of life or death. Cell life indicators include ATP content, cell number, dehydrogenase activity, DNA content, esterase activity, mitochondrial membrane potential, membrane integrity, and protease activity. Cell death indicators include caspase activity, chromatin condensation, and phospholipid redistribution. viability assay viability assays cell viability assay bao:BAO_0003010 This assay quantifies the protein turnover, which is a natural phenomenon in healthy cells, but becomes aberrant in diseased cells. The protein that is needed to be degraded first undergoes ubiquitinated. Ubiquitinated proteins are degraded in the proteasome complex. The protein degradation is quantitated by using reporters, such as green fluorescent protein as proteasome substrates. protein-turnover assay bao:BAO_0003011 KINOMEScan assay bao:BAO_0003012 fluorescent protein reporter gene assay bao:BAO_0003013 beta galactosidase reporter gene assay bao:BAO_0003014 beta lactamase reporter gene assay bao:BAO_0003015 chloramphenicol acetyltransferase reporter gene assay bao:BAO_0003016 binding site bao:BAO_0003017 transcription factor binding site bao:BAO_0003018 The categorization of different functional or non-functional elements in DNA. DNA region bao:BAO_0003019 The DNA region that is involved in initiating and modulating transcription. regulatory region bao:BAO_0003020 The region of a gene that codes for RNA. transcribed region bao:BAO_0003021 A synthetic DNA element that is known to be regulated by a transcription factor/s, which is cloned upstream of a gene of interest. artificial regulatory region bao:BAO_0003022 The regulatory DNA from a non-native gene, e.g., the regulatory region from the actin gene being cloned upstream of the myosin gene in a DNA construct. foreign promoter region bao:BAO_0003023 The regulatory DNA from a native gene, e.g., the regulatory region from the actin gene being cloned upstream of the actin gene in a DNA construct. native promoter region The technologies used to quantify the expression level of the entire gene pool in a cell or a subpopulation (e.g. tissue-specific gene expression, kinases pool, etc.) using one of the three methods, namely: microarray, bead based method or RNASeq. gene expression detection method bao:BAO_0003025 phosphoprotein-specific antibody-coated bead based method Gene-specific DNA is immobilized by spotting on a solid support, such as a glass slide. The DNA is hybridized with labeled nucleic acids from a sample and the signals measured, which reflect the composition of the sample nucleic acids. This is performed to quantify gene expression under various situations,e.g. diseases, development, etc. nucleic acid array method RNA-Seq is an approach for transcriptome profiling which uses deep-sequencing technologies. RNA-Seq, also called "Whole Transcriptome Shotgun Sequencing" ("WTSS") and dubbed "a revolutionary tool for transcriptomics", refers to the use of High-throughput sequencing technologies to sequence cDNA in order to get information about a sample's RNA content, a technique that is quickly becoming invaluable in the study of diseases like cancer. Thanks to the deep coverage and base level resolution provided by next-generation sequencing instruments, RNA-Seq provides researchers with efficient ways to measure transcriptome data experimentally, allowing them to get information such as how different alleles of a gene are expressed, detect post-transcriptional mutations or identifying gene fusions. rna-seq method The methods required to perform typical screening assay. These include the assay design methods (to generate a detectable signal) and assay supporting methods. Assay methods include laboratory methods. Computational methods are not currently categorized as assay methods, although some may also be used to process the assay measurement results. assay method small molecule preparation method bao:BAO_0003030 kinase active-site binding method true quantitative PCR kinase competitive binding method mobility shift mobility shift assay mobility shift isolated enzyme assay mobility shift assessment method nucleic acid identification and quantitation method The lowest concentration of an antimicrobial agent required to inhibit the growth of 50% of organisms. MIC50 It is the dose that produces an effect in 50% of the tested population, or the dose required to produce half-maximal response. ED50 The time required for a drug to reach maximum concentration in plasma (Cmax) following administration. Tmax The negative logarithm (log10) of the molar concentration of antagonist which requires the agonist concentration to be doubled in order to achieve the original response. pA2 In the disk diffusion susceptibility test, the zone of inhibition is the clear area surrounding an antimicrobial disk where bacterial growth is inhibited, usually measured as a diameter. The diameter of the zone of inhibition is proportional to the susceptibility of the organism tested. Inhibition zone IZ Volume of Distribution is defined as the theoretical volume in which the total drug administered would need to be distributed to produce the concentration that is observed in plasma. Measured as the total amount of drug in the body divided by the concentration of drug in the plasma. Volume of distribution Vd The theoretical volume in which the total drug administered would need to be distributed to produce the concentration that is observed in plasma at steady state i.e when the rate of change of amount of drug in the body is zero. VdSS is proportional to the amount of drug in the body versus the plasma concentration of the drug at steady state (pseudo-equilibrium). Volume of distribution at steady state Vdss Bioavailability is a subcategory of absorption and is the fraction (or %) of unchanged drug that reaches the systemic circulation, thereby accessing the site of action. It is usually determined as the ratio of AUC(oral)/AUC(iv). BA Bioavailability F bao:BAO_0003043 Any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer etc., identifiable as a separately distinguishable entity (from OBI). molecular entity bao:BAO_0003044 beta galactosidase gene bao:BAO_0003045 chloramphenicol acetyl transferase gene bao:BAO_0003046 green flourescent protein gene bao:BAO_0003047 luciferase gene 1 1 bao:BAO_0003048 A cell line that is immortalized. true has associated disease some disease or is bearer of disease (relation in new RO) Disease import from DOID permanent cell line bao:BAO_0003049 P42574 Caspase-3 bao:BAO_0003050 DEVD-NucView 488 bao:BAO_0003051 TO-PRO3 bao:BAO_0003052 The part of a cell or its extracellular environment in which a gene product is located. A gene product may be located in one or more parts of a cell and its location may be as specific as a particular macromolecular complex, that is, a stable, persistent association of macromolecules that function together (from Gene Ontology). true cellular component bao:BAO_0003053 piperazine-N,N'-bis(2-ethanesulfonic acid) PIPES bao:BAO_0003054 tricine bao:BAO_0003055 n-octyl-β-D-glucoside octyl glucoside bao:BAO_0003056 TCEP tris(2-carboxyethyl)phosphine hydrochloride bao:BAO_0003057 Glutathione bao:BAO_0003058 The role of a molecular entity to initiate a biological process. E.g., interferon-gamma has an inducer role in STAT-1 mediated transcriptional activation of cells. inducer bao:BAO_0003059 The role of a molecular entity (small molecule, siRNA/shRNA, etc.) in altering the activity of proteins that serve as targets in a bioassay. perturbagen bao:BAO_0003060 The role of a molecular entity as a known activator of a target/pathway, added prior to screening the compounds for selective inhibitor indications (e.g., forskolin is a potentiator for Gi/o pathway of G-proteins). potentiator bao:BAO_0003061 The role of a protein to be easily detected in an assay by virtue of its innate properties (fluorescence) or catalyzing a reaction that result in easily measurable products, such as luminescence, colored product, etc. Examples include luciferase, GFP, beta-galactosidase, etc. reporter protein bao:BAO_0003062 The role of a compound to increase or decrease the ability of a cell to respond to its signaling molecule. sensitizer bao:BAO_0003063 The role of a molecular entity to serve as the input for an enzymatic reaction that generates a product, e.g. ATP has the role of a substrate for ATPase, which hydrolyzes it to produce ADP and Pi. substrate bao:BAO_0003064 The role of a molecular entity (protein or nucleic acid) that is the presumed subject of an assay and whose activity is being regulated by an entity with a perturbagen role in that assay. target bao:BAO_0003065 The role of a molecular entity of specifying the cell's status of being alive, e.g., ATP. viability indicator bao:BAO_0003066 A chemical entity that has the role of depolarization, which is to make the cell's membrane potential more negative. depolarization blocker bao:BAO_0003067 product bao:BAO_0003068 The role of a chemical entity to distinguish two populations of cells, e.g., ampicillin is added to culture medium to identify ampicillin resistant bacteria. selectable marker bao:BAO_0003069 purified bao:BAO_0003070 extract bao:BAO_0003071 extract fraction bao:BAO_0003072 activated bao:BAO_0003073 synthetic bao:BAO_0003074 endogenous bao:BAO_0003075 true molecular function bao:BAO_0003076 PolarScreen Competitor Assay Kit bao:BAO_0003077 HitHunter Calcium No WashPLUS Assay Kit bao:BAO_0003078 HitHunter cAMP Assay Kit bao:BAO_0003079 AlphaScreen Phosphotyrosine Assay Kit bao:BAO_0003080 AlphaScreen cGMP Detection bao:BAO_0003081 Alphascreen second messenger IP1 detection kit bao:BAO_0003082 HTRF biomarkers bao:BAO_0003083 ViaLight Plus kit bao:BAO_0003084 QuantiChrom Assay Kit bao:BAO_0003085 LanthaScreen Co-Factor Interaction Assay bao:BAO_0003086 LanthaScreen Competetive Binding Assay bao:BAO_0003087 FLIPR Calcium 5 Assay Kit bao:BAO_0003088 FLIPR Membrane Potential Assay Kit bao:BAO_0003089 CyQUANT Cell Proliferation Assay Kit bao:BAO_0003090 HTRF KinEASE bao:BAO_0003091 Fluo-4 Calcium Assay Kit bao:BAO_0003092 Calcium Assay Kit bao:BAO_0003093 ICR 8000 Ion Channel Reader bao:BAO_0003094 MicroBeta TriLux bao:BAO_0003095 SpectraMax Plus384 bao:BAO_0003096 LabChip 3000 bao:BAO_0003097 Safire bao:BAO_0003098 Infinite F500 bao:BAO_0003099 Infinite M1000 bao:BAO_0003100 LEADseeker Imaging system bao:BAO_0003101 BioAssay Systems bao:BAO_0003108 beetle luciferin bao:BAO_0003109 Kit uses for Kinome scan assays KINOMEscan kit bao:BAO_0003110 Harward Medical School HMS bao:BAO_0003111 biological macromolecule bao:BAO_0003112 assay bioassay component bao:BAO_0003113 assay format component bao:BAO_0003114 assay biology component bao:BAO_0003115 assay endpoint component assay result component bao:BAO_0003116 material entity bao:BAO_0003117 function bao:BAO_0003118 instrument bao:BAO_0003119 software bao:BAO_0003120 assay screened entity component allosteric antagonism bao:BAO_0010001 cell viability ATP quantitation assay bao:BAO_0010002 2 color apoptosis assay bao:BAO_0010003 3 color apoptosis assay bao:BAO_0010004 mitosis/apoptosis assay bao:BAO_0010005 single cell protein secretion microfluidic assay bao:BAO_0010006 A common in vitro ADME assay that tests the stability of compounds when incubated with liver microsomes (subcellular fractions which contain membrane-bound drug-metabolizing enzymes). Assay is used to measure in vitro intrinsic clearance or to identify metabolites formed. Typically liver microsomes from one or more mammalian species (mouse, rat, dog, monkey, human) are analyzed to understand differences in metabolism. Can be reported as % recovery after a set time (single timepoint), or as half-life (multiple timepoints). Date from BAE: 6/6/2016 liver microsomal stability liver microsome stability metabolic stability in liver microsomes microsomal stability microsome stability microsome stability assay PubChem AID: 504610 microsomal stability assay bao:BAO_0010007 A common in vitro ADME assay that tests the stability of compounds when incubated with plasma. Assay is used to measure stability of new chemical entities in plasma, as compounds that rapidly degrade in plasma generally show poor in vivo efficacy. Typically lplasma from one or more mammalian species (mouse, rat, dog, monkey, human) are analyzed. Can be reported as % recovery after a set time (single timepoint), or as half-life (multiple timepoints). Date from BAE: 6/6/2016 plasma stability PubChem AID: 504605 plasma stability assay bao:BAO_0010008 A common in vitro ADME assay that uses the Caco-2 cell line (derived from human colon carcinoma) to assess transport in both directions (apical to basolateral (A-B) and basolateral to apical (B-A)) across the cell monolayer), to predict the in vivo absorption of drugs across the gut wall and to investigate drug efflux. Date from BAE: 6/6/2016 Caco-2 permeability PubChem AID: 504629 Caco-2 permeability assay bao:BAO_0010009 Physicochemical assays measure inherent properties of molecules, and include turbidimetric and thermodynamic solubility (in water or PBS), chemical stability, pKa, and lipophilicity (logP and logD) Date from BAE: 6/6/2016 physicochemical assay PubChem AID: 504606 physicochemical assay bao:BAO_0010010 A physicochemical assay that measures the maximum solubility of a molecule in a particular solvent (typically water or PBS). Date from BAE: 6/6/2016 solubility assay PubChem AID: 504606 solubility assay bao:BAO_0010011 An in vivo efficacy assay is a study perfromed in a whole, living organism (usually an animal such as a mouse or rat) to test the effects of a treatment on a specific disease modeled in this animal. Date from BAE: 9/30/2016 efficacy assessed efficacy comparison efficacy study evaluate the efficacy evaluation of efficacy evaluation of the efficacies in vivo efficacies in vivo efficacy in vivo efficacy study PubChem AID: 687012 true in vivo efficacy assay bao:BAO_0010012 Date from BAE: 6/21/2016 PubChem AID: 485336 12 well plate bao:BAO_0010013 Date from BAE: 6/26/2016 PubChem AID: 2545 6 well plate bao:BAO_0010014 Date from BAE: 5/31/2016 PubChem AID: 588412 tube bao:BAO_0010015 Date from BAE: 6/1/2016 PubChem AID: 588370 microscope slide bao:BAO_0010016 Date from BAE: 5/13/2016 PubChem AID: 623915 dish bao:BAO_0010017 Date from BAE: 5/13/2016 PubChem AID: 623915 15 cm dish bao:BAO_0010018 Gel electrophoresis is a method for separation and analysis of macromolecules (DNA, RNA and proteins) and their fragments, based on their size and charge. This general method encompasses different types of matrices (gels) with different properties. The most common types are polyacrylamide and agarose, both low-throughput methods. Date from BAE: 6/2/2016 PubChem AID: 449751 gel bao:BAO_0010019 Polyacrylamide gel electrophoresis (PAGE), describes a technique to separate biological macromolecules, usually proteins or nucleic acids, according to their electrophoretic mobility. Mobility is a function of the length, conformation and charge of the molecule. Gels can be native or denaturing (urea for nucleic acids, SDS for proteins). A low-throughput method. Date from BAE: 6/2/2016 PubChem AID: 449751 PAGE bao:BAO_0010020 Agarose gel electrophoresis is a method to separate a mixed population of DNA or proteins in a matrix of agarose. The proteins may be separated by charge and/or size, and the DNA and RNA fragments by length, by applying an electric field to move the charged molecules through an agarose matrix. A low-throughput method. Date from BAE: 9/24/2016 PubChem AID: agarose gel bao:BAO_0010021 Coverslips are typically thin square pieces of glass Date from BAE: 7/2/2016 PubChem AID: 1219 coverslip bao:BAO_0010022 16 well electronic plate ('E Plate 16' (Roche Diagnostics)), used for electrophysiology Date from BAE: 7/22/2016 PubChem AID: 602291 16-well electronic plate bao:BAO_0010023 The word 'chip' is used to describe any flat surface (glass, plastic, other) that may be coated or treated to impart certain properties to help in either the immobilization and/or measurement of certain properties of varied macromolecules (protien, nucleic acid, small molecule). If an array of molecules is immobilized on a chip, the preferred term is 'array'. Date from BAE: 9/30/2016 PubChem AID: 651876 chip bao:BAO_0010024 Sensor chip CM5 is a chip used in Biacore (GE Healthcare) systems based on surface plasmon resonance (SPR) to measure molecular interactions with at least one molecule immobilized on a sensor surface. CM5 sensor chips have a matrix of carboxymethylated dextran covalently attached to a gold surface. Date from BAE: 9/30/2016 PubChem AID: 651876 Sensor chip CM5 bao:BAO_0010025 Assays performed in the pre-clinical development stage. These are assays on a lead candidate to develop it to an Investigative New Drug (IND). This stage typically includes both in vitro and in vivo assays, including thorough PK/PD profiling, toxicity, and in vivo dosing/ formulation optimization for efficacy. Date from BAE: 9/30/2016 PubChem AID: 687012 preclinical development stage bao:BAO_0010026 Protein profiling assays can be used to identify and quantify proteins together with their post-translational modifications protein profiling protein quantification assay protein profiling assay bao:BAO_0010027 An assay that is used to identify in a data-dependent mode proteins by combining the HPLC and MS methods. It is also known as liquid chromatography-coupled tandem mass spectrometry (LC-MS) shotgun MS protein profiling assay bao:BAO_0010028 Sequential window acquisition of all theoretical mass spectra (SWATH) MS is a mass spectrometrical method thatcouples data-independent acquisition is coupled with peptide spectral library match SWATH MS protein profiling assay bao:BAO_0010029 A targeted phosphoproteomic assay that uses a data-driven approach to identify and quantify a set of 96 phosphopeptide probes P100 protein profiling assay bao:BAO_0010030 Reverse phase protein array (RPPA) is a an assay that measures multiple protein expression levels in a large number of biological samples simultaneously using high quality antibodies RPPA protein profiling assay bao:BAO_0010031 Epigenetic assays that can be used to identify epigenome modifications together with the epigenetic enzymes that regulate it. The epigenetic assays are split in two categories: targeted epigenetic assays and epigenetic profiling assays depending on whether they are used to identify a modifications on a global scale or only measure and identify a predetermined list of targets epigenetic assay bao:BAO_0010032 Assays that measure a targeted and predetermined subset of the epigenetic modifications in a cell targeted epigenetic assay bao:BAO_0010033 An assay that quantifies the levels of the acetylated histones in a cell. Acetylated histones are involved in the regulation of chromatin structure and thetranscription factor recruitment acetylated histone assay bao:BAO_0010034 An assay that quantifies the levels of the methylated histones in a cell methylated histone assay bao:BAO_0010035 An assay that identifies genome-wide DNA binding sites for transcription factors and other proteins ChIP-seq assay bao:BAO_0010036 Assays that are used to capture the genome-wide epigenetic modifications in a cell epigenetic profiling assay bao:BAO_0010037 An assay that is used to determine themethylation marks in a cells genome Bisulfite Sequencing assay bao:BAO_0010038 ATAC-seq (assay for transposase-accessible chromatin using sequencing) is an assay that identifies open-chromatin sites on the whole genome level by using theTn5 transposase, which inserts sequencing adapters into accessible regions of chromatin ATAC-seq epigenetic profiling assay bao:BAO_0010039 A mass spectrometry-based assay that is used to identify and quantify post-translational modifications on histone proteins from bulk chromatin global chromatin epigenetic profiling assay bao:BAO_0010040 Assays that identify and quantify cell metabolites (metabolic analytes) metabolomic assay bao:BAO_0010041 targeted metabolomic assay bao:BAO_0010042 Assays that profile key metabolomic parameters metabolomic profiling assay bao:BAO_0010043 A high throughput live-cell microarray screening assay that is used to detect metabolic analytes such as oxygen, pH and glucose at the single-cell level Cellarium metabolomic profiling assay bao:BAO_0010044 Assays that quantify the expression of a predetermined RNA transcript / set of transcripts RNA expression targeted transcriptional assay bao:BAO_0010045 An assay that uses NGS (Next Generation Sequencing) to quantify the expression of the entire RNA transcripts in a cell / cell population RNA-seq gene expression profiling assay RNA-seq gene expression profiling assay bao:BAO_0010046 L1000 is a bead-based, high-throughput gene expression assay in which cultured cells are treated with various chemical and genetic perturbations and the corresponding transcriptional responses are measured L1000 mRNA profiling assay bao:BAO_0010047 An assay that uses barcoded hybridization probes to quantify the expression of RNA transcripts Nanostring bao:BAO_0010048 An array based method that simultaneously measures the expression of tens of thousands of RNA transcripts Microarray bao:BAO_0010049 Microwestern bao:BAO_0010050 Bead-based immunoassay for protein state bao:BAO_0010051 ELISA protein secretion profiling assay bao:BAO_0010052 ELISA protein state assay bao:BAO_0010053 Fluorescence imaging apoptosis assay bao:BAO_0010054 Fluorescence imaging cell count assay bao:BAO_0010055 Fluorescence imaging cell cycle state assay bao:BAO_0010056 Fluorescence imaging cell growth inhibition assay bao:BAO_0010057 Fluorescence imaging morphology assay bao:BAO_0010058 Fluorescence imaging multiplex cytological profiling assay bao:BAO_0010059 Fluorescence imaging protein state assay bao:BAO_0010060 MEMA cell growth assay bao:BAO_0010061 MS protein quantification assay bao:BAO_0010062 MS protein state assay bao:BAO_0010063 P100 phosphoprotein quantification assay bao:BAO_0010065 RPPA protein state assay bao:BAO_0010066 SWATH-MS protein quantification assay bao:BAO_0010067 A variant of the BRET assay utilizing Nanoluc luciferace, providing higher stability, smaller size, greater separation of donor and acceptor wavelengths, and higher fluorescence intensity, enabling more accurate and precise quantification of protein-protein interactions Protein-Protein NanoBRET Assay bao:BAO_0010068 A variant of the BRET assay utilizing Nanoluc luciferace, providing higher stability, smaller size, greater separation of donor and acceptor wavelengths, and higher fluorescence intensity, enabling more accurate and precise quantification of protein-small molecule interactions Protein-Small Molecule NanoBRET Assay bao:BAO_0010069 A specific application of protein-small molecule NanoBRET examining the interaction of small molecules with specific kinases Kinase NanoBRET Assay bao:BAO_0010070 Tandem Mass Tag (TMT) MS Protein Quantification bao:BAO_0010071 Liquid Chromatography/Mass Spectroscopy (LC/MS) protein quantification bao:BAO_0010072 A method which determines the permeability of substances from a donor compartment, through a lipid-infused artificial membrane into an acceptor compartment. At the beginning of the test, the drug is added to the donor compartment, and the acceptor compartment is drug-free. After an incubation period the amount of drug is measured in each compartment. Mass balance allows calculation of drug that remains in the membrane. It is used as an in vitro model of passive, transcellular permeation to predict oral absorption. PAMPA is an alternative to the cell-based Caco-2 permeability assay PAMPA parallel artificial membrane permeability assay bao:BAO_0010073 This descripts the relative maximum throughput of an assay in regards to its screening potential. assay screening throughput bao:BAO_0010074 high throughput screening bao:BAO_0010075 medium throughput screening bao:BAO_0010076 low throughput screening bao:BAO_0010077 GPCR assay GPCR functional assay GPCR pharmacology GPCR profiling GPCR screening assay GPCR signaling assay GPCR Signaling bao:BAO_0010078 A variant of a BRET assay wherein fluorescently tagged beta-arrestin2 is detected when in proximity of a G-protein coupled receptor with an Rluc C-terminal tag. Arrestin2 recruitment assay bao:BAO_0010079 Beta-arrestin2 fused to the TEV protease liberates a tTA molecule fused to the C-terminus of a target G-protein coupled receptor when in close proximity, resulting in a tTA-driven expression of RLuc from a genomic TETO7-RLuc locus. PRESTO-TANGO bao:BAO_0010080 Measure release of the heterotrimeric G-protein complex from G-protein coupled receptors (GPCRs). When activated GPCRs catalyze the exchange of GDP for GTP in the G-alpha subunit of the Galpha-beta-gamma heterotrimeric complex, resulting in the disassociation of these subunits from the GPCR of interest. Heterotrimeric G-protein dissassociation assay bao:BAO_0010081 Measures heterotrimer G-protein disassociation using BRET between alpha and gamma subunits. TRUPath bao:BAO_0010082 drug absorption assay SEED Project - Pistoia Alliance drug absorption assay bao:BAO_0010083 assessment of permeability bidirectional assay bidirectional assays drug permeability paracellular permeability assay permeability study permeabillity studies transcellular permeability assay SEED Project - Pistoia Alliance permeability assay bao:BAO_0010084 Ussing chamber assay Ussing chamber permeability SEED Project - Pistoia Alliance Ussing chamber permeability assay bao:BAO_0010085 BCRP assessment of permeability BCRP permeability assay BCRP-MDCK permeability SEED Project - Pistoia Alliance MDCK-BCRP permeability assay bao:BAO_0010086 MDCK assay MDCK permeability SEED Project - Pistoia Alliance MDCK permeability assay bao:BAO_0010087 RRCK assay RRCK permeability Ralph Russ Canine Kidney (RRCK) assay Ralph Russ Canine Kidney assay SEED Project - Pistoia Alliance RRCK permeability assay bao:BAO_0010088 LLCPK1 assay LLCPK1 monolayer assay LLCPK1 monolayer bidirectional permeability LLCPK1 monolayer permeability bidirectional permeability across LLCPK1 monolayers SEED Project - Pistoia Alliance LLCPK1 monolayer permeability assay bao:BAO_0010089 MDCKII assay MDCKII monolayer assay MDCKII monolayer bidirectional permeability MDCKII monolayer permeability MDCKII permeability bidirectional permeability across MDCKII monolayers SEED Project - Pistoia Alliance MDCKII monolayer permeability assay bao:BAO_0010090 FDA RPS Pharmacokinetics: Metabolism Pharmacokinetics: Metabolism In Vitro drug metabolism in vitro metabolism metabolic study metabolism - in vitro metabolism in vitro SEED Project - Pistoia Alliance drug metabolism assay bao:BAO_0010091 Met Id MetId biotransformation metabolite Id metabolite identification and profiling SEED Project - Pistoia Alliance metabolite identification and profiling assay bao:BAO_0010092 TMDD TMDD PK TMDD PK model TMDD PK modeling TMDD PK profile TMDD determination TMDD model TMDD modeling drug induced TMDD target mediated drug disposition target mediated drug disposition determination SEED Project - Pistoia Alliance target mediated drug dispositioning bao:BAO_0010093 receptor internalization SEED Project - Pistoia Alliance receptor internalization assay bao:BAO_0010094 portal vein study SEED Project - Pistoia Alliance portal vein study bao:BAO_0010095 Met Stab Metab metabolic stability SEED Project - Pistoia Alliance metabolic stability assay bao:BAO_0010096 cytosol stability cytosolic stability SEED Project - Pistoia Alliance cytosol stability assay bao:BAO_0010097 S9 fraction stability S9 metabolic stability S9 stability SEED Project - Pistoia Alliance S9 stability assay bao:BAO_0010098 blood stability blood stability assay whole blood stability SEED Project - Pistoia Alliance whole blood stability assay bao:BAO_0010099 plasma stability with inhibitor SEED Project - Pistoia Alliance plasma stability with inhibitors bao:BAO_0010100 hepatocyte clearance assay hepatocyte stability metabolic stability in hepatocytes SEED Project - Pistoia Alliance hepatocyte stability assay bao:BAO_0010101 low clearance assay low clearance hepatocyte stability low clearance relay low intrinsic clearance assay SEED Project - Pistoia Alliance hepatocyte low clearance relay assay bao:BAO_0010102 co-culture low clearance low clearance hepatocyte co-culture SEED Project - Pistoia Alliance hepatocyte co-culture low clearance assay bao:BAO_0010103 ex vivo gastric fluid stabiliy gastric fluid stability stabiity in gastric fluids SEED Project - Pistoia Alliance gastric fluid stability assay bao:BAO_0010104 simulated gastric fluid stability SEED Project - Pistoia Alliance simulated gastric fluid stability assay bao:BAO_0010105 enzymatic simulated gastric fluid stability simulated gastric fluid stability (enzymatic) stability in simulated gastric fluids with enzymes SEED Project - Pistoia Alliance simulated gastric fluid stability assay (with enzymes) bao:BAO_0010106 ex vivo intestinal fluid stability intestinal fluid stability SEED Project - Pistoia Alliance intestinal fluid stability assay bao:BAO_0010107 enzymatic simulated intestinal fluid stability SEED Project - Pistoia Alliance simulated intestinal fluid stability assay (with enzymes) bao:BAO_0010108 simulated intestinal fluid stability SEED Project - Pistoia Alliance simulated intestinal fluid stability assay bao:BAO_0010109 ex-vivo interstitial fluid stability interstitial fluid stability SEED Project - Pistoia Alliance interstitial fluid stability assay bao:BAO_0010110 simulated interstitial fluid simulated interstitial fluid stability stability in simulated interstitial fluid SEED Project - Pistoia Alliance simulated interstitial fluid stability assay bao:BAO_0010111 stability in tissue homogenate tissue homogenate stability SEED Project - Pistoia Alliance tissue homogenate stability assay bao:BAO_0010112 cell culture homogenate stability cell homogenate stability metabolic stability in cell homogenate SEED Project - Pistoia Alliance cell homogenate stability assay bao:BAO_0010113 enzymatic stability metabolic stability in enzymes SEED Project - Pistoia Alliance enzymatic stability assay bao:BAO_0010114 reaction phenotyping SEED Project - Pistoia Alliance enzyme reaction phenotyping bao:BAO_0010115 AOX reaction phenotyping AOX stability aldehyde oxidase reaction phenotyping aldehyde oxidase stability in vitro liver cytosol stability for aldehyde oxidase substrates SEED Project - Pistoia Alliance AOX reaction phenotyping bao:BAO_0010116 FMO 1 stability FMO 3 stability FMO 5 stability FMO stability flavin monooxygenases reaction phenotyping flavin-containing monooxygenase (fmo3): screening for substrates SEED Project - Pistoia Alliance FMO reaction phenotyping bao:BAO_0010117 MAO stability MAOA reaction phenotyping MAOA stability MAOB reaction phenotyping MAOB stability monoamine oxidase reaction phenotyping monoamine oxidase stability SEED Project - Pistoia Alliance MAO reaction phenotyping assay bao:BAO_0010118 hepatocyte relay with inhibitors SEED Project - Pistoia Alliance hepatocyte relay assay bao:BAO_0010119 CES stability carboxylesterase reaction phenotyping carboxylesterase stability carboxylesterases (ces1 and ces2): screening for substrate and inhibitor SEED Project - Pistoia Alliance CES reaction phenotyping bao:BAO_0010120 esterase chemical inhibitor esterase chemical inhibitors SEED Project - Pistoia Alliance esterase chemical inhibition bao:BAO_0010121 esterase metabolite formation kinetics SEED Project - Pistoia Alliance esterase metabolite formation kinetics bao:BAO_0010122 recombinant esterases SEED Project - Pistoia Alliance recombinant esterases bao:BAO_0010123 CYP identification CYP phenotyping CYP450 reaction phenotyping Cytochrome P450 phenotyping Cytochrome P450 reaction phenotyping SEED Project - Pistoia Alliance CYP reaction phenotyping assay bao:BAO_0010124 CYP chemical inhibition phenotyping CYP chemical inhibition reaction phenotyping CYP phenotyping - chem inhib CYP phenotyping- chemical inhibition true SEED Project - Pistoia Alliance CYP chemical inhibition assay bao:BAO_0010125 CYP metabolite formation kinetics SEED Project - Pistoia Alliance CYP metabolite formation kinetics bao:BAO_0010126 CYP recombinant enzymes CYP recombinant enzymes phenotyping phenotyping with recombinant CYPs phenotyping – rCYP rCYP recation phenotyping rCYPs phenotyping rCYPs recation phenotyping recombinant CYP phenotyping recombinant CYPs reaction phenotyping SEED Project - Pistoia Alliance recombinant CYP reaction phenotyping assay bao:BAO_0010127 CYP immuno inhibition CYP monoclocal antibody inhibition CYP phenotyping - mAb inhib CYP phenotyping - monoclocal antibody inhibition CYP phenotyping- immuno inhibition mAb inhibition of CYP mAb inhibitors of CYP monoclonal antibody inhibitors of CYP SEED Project - Pistoia Alliance CYP mAb inhibition bao:BAO_0010128 UGT phenotyping UGT substrate identification SEED Project - Pistoia Alliance UGT reaction phenotyping bao:BAO_0010129 UGT chem inhib UGT chemical inhibition phenotyping UGT chemical inhibition reaction phenotyping UGT phenotyping- chemical inhibition SEED Project - Pistoia Alliance UGT chemical inhibition assay bao:BAO_0010130 UGT metabolite formation kinetics SEED Project - Pistoia Alliance UGT metabolite formation kinetics bao:BAO_0010131 UGT recombinant enzymes phenotyping – rUGT rUGT phenotyping rUGT reaction phenotyping rUGTs phenotyping rUGTs reaction phenotyping recombinant UGT phenotyping recombinant UGTs reaction phenotyping SEED Project - Pistoia Alliance recombinant UGT reaction phenotyping assay bao:BAO_0010132 B/P assay RBC partitioning blood partitioning blood plasma distribution blood plasma partitioning blood to plasma partitioning blood/plasma ratio assay red blood cell partitioning SEED Project - Pistoia Alliance blood to plasma ratio assay bao:BAO_0010133 tissue binding tissue protein binding tissue protein binding assay SEED Project - Pistoia Alliance tissue binding assay bao:BAO_0010134 Placental transfer studies Placental transfer study SEED Project - Pistoia Alliance placental transfer assay bao:BAO_0010135 plasma protein binding plasma protein binding (equilibrium dialysis) SEED Project - Pistoia Alliance plasma protein binding assay bao:BAO_0010136 binding to in vitro media in vitro free fraction in vitro media binding induction media binding media binding stability in induction stability in induction media SEED Project - Pistoia Alliance media binding assay bao:BAO_0010137 2% BSA binding BSA binding binding to BSA binding to bovine serum albumin bovine serum albumin binding SEED Project - Pistoia Alliance BSA binding asssay bao:BAO_0010138 microsomal protein binding assay microsome binding microsome binding assay microsome protein binding assay SEED Project - Pistoia Alliance microsomal binding assay bao:BAO_0010139 FDA RPS Pharmacokinetics: Excretion SEED Project - Pistoia Alliance drug excretion assay bao:BAO_0010140 excretion balance excretion balance study mass balance mass balance study SEED Project - Pistoia Alliance mass balance assay bao:BAO_0010141 biliary elimination biliary excretion excretion into bile SEED Project - Pistoia Alliance biliary excretion assay bao:BAO_0010142 excretion in milk excretion into milk SEED Project - Pistoia Alliance human mammary epithelial cell permeability assay bao:BAO_0010143 renal elimination renal excretion renal excretion study SEED Project - Pistoia Alliance renal excretion assay bao:BAO_0010144 receptor induction SEED Project - Pistoia Alliance receptor induction assay bao:BAO_0010145 Fc/FcRn assay Fc/FcRn induction FcRn induction SEED Project - Pistoia Alliance Fc/FcRN induction assay bao:BAO_0010146 definitive induction SEED Project - Pistoia Alliance enzyme induction assay bao:BAO_0010147 CYP induction screen true SEED Project - Pistoia Alliance CYP induction screen bao:BAO_0010148 UGT induction assay SEED Project - Pistoia Alliance UGT induction assay bao:BAO_0010149 CYP Induction in human hepatocytes CYP induction CYP mRNA Induction CYP450 induction Cytochrome P450 Induction Induction of CYP Induction of CYP450 Induction of cytochrome P450 SEED Project - Pistoia Alliance CYP induction assay bao:BAO_0010150 CYP1A2 induction definitive CYP1A2 induction definitive CYP1A2 induction assay SEED Project - Pistoia Alliance CYP1A2 induction assay bao:BAO_0010151 CYP2B6 induction definitive CYP2B6 induction assay SEED Project - Pistoia Alliance CYP2B6 induction assay bao:BAO_0010152 CYP2C19 induction definitive CYP2C19 induction definitive CYP2C19 induction assay SEED Project - Pistoia Alliance CYP2C19 induction assay bao:BAO_0010153 CYP2C8 induction definitive CYP2C8 induction definitive CYP2C8 induction assay SEED Project - Pistoia Alliance CYP2C8 induction assay bao:BAO_0010154 CYP2C9 induction definitive CYP2C9 induction definitive CYP2C9 induction assay SEED Project - Pistoia Alliance CYP2C9 induction assay bao:BAO_0010155 CYP3A4 induction definitive CYP3A4 induction definitive CYP3A4 induction assay SEED Project - Pistoia Alliance CYP3A4 induction assay bao:BAO_0010156 3A4 Relative Induction Score CYP Induction in human hepatocytes - 3A4 Relative Induction Score (RIS) CYP Induction prediction CYP Relative Induction Score RIS determination RIS evaluation Relative Induction Score evaluation prediction of CYP induction SEED Project - Pistoia Alliance Relative Induction Score determination bao:BAO_0010157 enzyme inhibition assay SEED Project - Pistoia Alliance enzyme inhibition assay bao:BAO_0010158 MAO Inhibition inhibition MAO inhibition of MAO inhibition of monoamine oxidase SEED Project - Pistoia Alliance monoamine oxidase inhibition assay bao:BAO_0010159 CYP reversible inhibition CYP reversible inhibition assay CYP450 Inhibition CYP450 direct inhibition CYP450 reversible inhibition Cytochrome P450 Inhibition Cytochrome P450 reversible inhibition DDI- reversible Definitive DDI cytochrome P450 direct inhibition cytochrome P450 reversible inhibition inhibition of CYP inhibition of CYP450 inhibition of cytochrome P450 SEED Project - Pistoia Alliance CYP inhibition assay bao:BAO_0010160 CYP1A2 inhibition SEED Project - Pistoia Alliance CYP1A2 inhibition assay bao:BAO_0010161 CYP2B6 inhibition SEED Project - Pistoia Alliance CYP2B6 inhibition assay bao:BAO_0010162 CYP2C19 inhibition SEED Project - Pistoia Alliance CYP2C19 inhibition assay bao:BAO_0010163 CYP2C8 inhibition SEED Project - Pistoia Alliance CYP2C8 inhibition assay bao:BAO_0010164 CYP2C9 inhibition SEED Project - Pistoia Alliance CYP2C9 inhibition assay bao:BAO_0010165 CYP3A4 inhibition SEED Project - Pistoia Alliance CYP3A4 inhibition assay bao:BAO_0010166 CYP IC50 cocktail SEED Project - Pistoia Alliance CYP cocktail IC50 assay bao:BAO_0010167 CYP single point inhibition SEED Project - Pistoia Alliance CYP single point inhibition assay definitive CYP IC50 SEED Project - Pistoia Alliance definitive CYP IC50 bao:BAO_0010169 CYP time-dependent Inhibition DDI- TDI DDI- TDI Cocktail DDI-MBI Definitive TDI mechanism-based CYP inhibition mechanism-based inhibition time-dependent CYP450 Inhibition time-dependent Inhibition of CYP time-dependent Inhibition of CYP450 SEED Project - Pistoia Alliance CYP time-dependent inhibition assay bao:BAO_0010170 CYP IC50-shift assay CYP time-dependent Inhibition (IC50 shift) CYP time-dependent Inhibition shifted IC50 CYP450 time-dependent Inhibition IC50 shift Cytochrome P450 time-dependent Inhibition IC50 shift TDI IC50 shift SEED Project - Pistoia Alliance CYP time dependent inhibition IC50 shift assay bao:BAO_0010171 CYP time-dependent Inhibition (Ki/kinact) CYP time-dependent Inhibition (kinact/Ki) CYP450 time-dependent Inhibition (kinact/Ki) Cytochrome P450 time-dependent Inhibition (kinact/Ki) Ki & Kinact (TDI) SEED Project - Pistoia Alliance CYP time dependent inhibition kinact/KI assay bao:BAO_0010172 CYP time-dependent Inhibition (single point) TDI single point single point TDI single-point time dependent inhibiton time dependent inhibition single point SEED Project - Pistoia Alliance CYP time dependent inhibition single point assay bao:BAO_0010173 UGT inhibition SEED Project - Pistoia Alliance UGT inhibition assay bao:BAO_0010174 UGT1A1 with BSA SEED Project - Pistoia Alliance UGT1A1 with BSA assay bao:BAO_0010175 UGT1A1 without BSA SEED Project - Pistoia Alliance UGT1A1 without BSA assay bao:BAO_0010176 UGT1A4 with BSA SEED Project - Pistoia Alliance UGT1A4 with BSA assay bao:BAO_0010177 UGT1A4 without BSA SEED Project - Pistoia Alliance UGT1A4 without BSA assay bao:BAO_0010178 UGT1A6 with BSA SEED Project - Pistoia Alliance UGT1A6 with BSA assay bao:BAO_0010179 UGT1A6 without BSA SEED Project - Pistoia Alliance UGT1A6 without BSA assay bao:BAO_0010180 UGT1A9 with BSA SEED Project - Pistoia Alliance UGT1A9 with BSA assay bao:BAO_0010181 UGT1A9 without BSA SEED Project - Pistoia Alliance UGT1A9 without BSA assay bao:BAO_0010182 UGT2B15 with BSA SEED Project - Pistoia Alliance UGT2B15 with BSA assay bao:BAO_0010183 UGT2B15 without BSA SEED Project - Pistoia Alliance UGT2B15 without BSA assay bao:BAO_0010184 UGT2B7 with BSA SEED Project - Pistoia Alliance UGT2B7 with BSA assay bao:BAO_0010185 UGT2B7 without BSA SEED Project - Pistoia Alliance UGT2B7 without BSA assay bao:BAO_0010186 induction of transport proteins SEED Project - Pistoia Alliance transporter induction assay bao:BAO_0010187 ABCB1 induction MDR1 induction P-glycoprotein (P-gp) induction assay P-glycoprotein induction assay P-gp induction multi-drug resistance 1 induction SEED Project - Pistoia Alliance p-gp induction assay bao:BAO_0010188 transporter inhibition assay SEED Project - Pistoia Alliance transporter inhibition assay bao:BAO_0010189 efflux transporter inhibition assay SEED Project - Pistoia Alliance efflux transporter inhibition assay bao:BAO_0010190 ABCB11 inhibition BSEP inhibition bile salt export pump inhibition inhibition of bile salt export pump SEED Project - Pistoia Alliance BSEP inhibition assay bao:BAO_0010191 ABCG2 inhibition BCRP inhibition inhibition of BCRP SEED Project - Pistoia Alliance BCRP inhibition assay bao:BAO_0010192 ABCC2 inhibition MRP2 inhibition SEED Project - Pistoia Alliance MRP2 inhibition assay bao:BAO_0010193 ABCB1 inhibition MDR1 inhibition P-glycoprotein (P-gp) inhibition assay P-glycoprotein inhibition assay P-gp inhibition multi-drug resistance 1 inhibition SEED Project - Pistoia Alliance P-gp inhibition assay bao:BAO_0010194 MATE1 inhibition SLC47A1 inhibition SEED Project - Pistoia Alliance MATE1 inhibition assay bao:BAO_0010195 MATE2 inhibition MATE2-K inhibition SLC47A2 inhibition SEED Project - Pistoia Alliance MATE2 inhibition assay bao:BAO_0010196 uptake transporter inhibition SEED Project - Pistoia Alliance uptake transporter inhibition assay bao:BAO_0010197 OAT1 inhibition SLC22A6 inhibition SEED Project - Pistoia Alliance OAT1 inhibition assay bao:BAO_0010198 OAT2 inhibition SLC22A7 inhibition SEED Project - Pistoia Alliance OAT2 inhibition assay bao:BAO_0010199 OAT3 inhibition SLC22A8 inhibition SEED Project - Pistoia Alliance OAT3 inhibition assay bao:BAO_0010200 OATP1B1 inhibition SLCO1B1 inhibition SEED Project - Pistoia Alliance OATP1B1 inhibition assay bao:BAO_0010201 OATP1B3 inhibition SLCO1B3 inhibition SEED Project - Pistoia Alliance OATP1B3 inhibition assay bao:BAO_0010202 OCT1 inhibition SLC22A1 inhibition SEED Project - Pistoia Alliance OCT1 inhibition assay bao:BAO_0010203 OCT2 inhibition SLC22A inhibition SEED Project - Pistoia Alliance OCT2 inhibition assay bao:BAO_0010204 transporter substrate assay transporter substrate identification SEED Project - Pistoia Alliance transporter substrate assay bao:BAO_0010205 efflux transporter substrate identification SEED Project - Pistoia Alliance efflux transporter substrate assay bao:BAO_0010206 ABCB1 substrate ABCB1 substrate identification MDR1 substrate P-glycoprotein (P-gp) substrate assay P-gp substrate P-gp substrate assay P-gp substrate identification P-gp substrate identification assay SEED Project - Pistoia Alliance P-gp substrate assay bao:BAO_0010207 ABCC2 substrate MRP2 substrate SEED Project - Pistoia Alliance MRP2 substrate assay bao:BAO_0010208 ABCG2 substrate BCRP substrate BCRP substrate assessment BCRP substrate identification BCRP substrate identification assay SEED Project - Pistoia Alliance BCRP substrate assay bao:BAO_0010209 MATE1 substrate SLC47A1 substrate SEED Project - Pistoia Alliance MATE1 substrate assay bao:BAO_0010210 MATE2 substrate MATE2-K substrate SLC47A2 substrate SEED Project - Pistoia Alliance MATE2 substrate assay bao:BAO_0010211 uptake transporter substrate identification SEED Project - Pistoia Alliance uptake transporter substrate assay bao:BAO_0010212 OAT1 substrate OAT1 substrate assessment OAT1 substrate identification SLC22A6 substrate SEED Project - Pistoia Alliance OAT1 substrate assay bao:BAO_0010213 OAT2 substrate SLC22A7 substrate SEED Project - Pistoia Alliance OAT2 substrate assay bao:BAO_0010214 OAT3 substrate OAT3 substrate assessment OAT3 substrate identification SLC22A8 substrate SEED Project - Pistoia Alliance OAT3 substrate assay bao:BAO_0010215 OATP1B1 substrate SLCO1B1 substrate SEED Project - Pistoia Alliance OATP1B1 substrate assay bao:BAO_0010216 OATP1B3 substrate SLCO1B3 substrate SEED Project - Pistoia Alliance OATP1B3 substrate assay bao:BAO_0010217 OCT1 substrate SLC22A1 substrate SEED Project - Pistoia Alliance OCT1 substrate assay bao:BAO_0010218 OCT2 substrate OCT2 substrate identification SLC22A substrate SEED Project - Pistoia Alliance OCT2 substrate assay bao:BAO_0010219 OATP2B1 substrate SLCO2B1 substrate SEED Project - Pistoia Alliance OATP2B1 substrate assay bao:BAO_0010220 hepatic uptake hepatic uptake assay hepatocyte uptake SEED Project - Pistoia Alliance hepatocyte uptake assay bao:BAO_0010221 SCHH assay sandwich-cultured fresh hepatocytes sandwich-cultured hepatocytes sandwich-cultured human cryopreserved hepatocyte sandwich-cultured human hepatocytes SEED Project - Pistoia Alliance sandwich cultured human hepatocyte assay bao:BAO_0010222 plated human hepatocyte clearance plated human hepatocyte clearance assay plated human hepatocytes plated primary human hepatocytes SEED Project - Pistoia Alliance plated human hepatocytes assay bao:BAO_0010223 PK modeling in silico pharmacometrics pharmacometrics pharmacometrics and modeling true SEED Project - Pistoia Alliance pharmacometrics bao:BAO_0010224 PBPK PBPK model PBPK models PBPK simulations Physiologically based pharmacokinetic modeling Physiologically based pharmacokinetic modelling pharmacokinetic (PBPK) modeling physiologically based pharmacokinetic (PBPK) model SEED Project - Pistoia Alliance PBPK modeling bao:BAO_0010225 methods of analysis SEED Project - Pistoia Alliance method development and validation bao:BAO_0010226 other pharmacokinetic studies SEED Project - Pistoia Alliance other pharmacokinetic studies bao:BAO_0010227 PK non-rodent true SEED Project - Pistoia Alliance non-rodent PK bao:BAO_0010228 non-rodent urinary excretion true SEED Project - Pistoia Alliance non-rodent excretion in urine bao:BAO_0010229 non-rodent IV clearance true SEED Project - Pistoia Alliance non-rodent IV clearance bao:BAO_0010230 non-rodent IV half-life true SEED Project - Pistoia Alliance non-rodent IV half-life bao:BAO_0010231 non-rodent % F non-rodent % bioavailability non-rodent %F non-rodent (%F) non-rodent F true SEED Project - Pistoia Alliance non-rodent oral bioavailability bao:BAO_0010232 non-rodent oral half-life true SEED Project - Pistoia Alliance non-rodent oral half-life bao:BAO_0010233 non-rodent Vdss true SEED Project - Pistoia Alliance non-rodent Vdss bao:BAO_0010234 PK rodent true SEED Project - Pistoia Alliance rodent PK bao:BAO_0010235 rodent urinary excretion true SEED Project - Pistoia Alliance rodent excretion in urine bao:BAO_0010236 rodent IV clearance true SEED Project - Pistoia Alliance rodent IV clearance bao:BAO_0010237 rodent IV half-life true SEED Project - Pistoia Alliance rodent IV half-life bao:BAO_0010238 rodent % F rodent % bioavailability rodent %F rodent (%F) rodent F true SEED Project - Pistoia Alliance rodent oral bioavailability bao:BAO_0010239 rodent oral half-life true SEED Project - Pistoia Alliance rodent oral half-life bao:BAO_0010240 rodent Vdss true SEED Project - Pistoia Alliance rodent Vdss bao:BAO_0010241 Lipophilicity Lipophilicity assay LogD Shake Flask LogD assay LogD/LogP LogD/LogP assay LogD7.4 Shake Flask LogP/D SEED Project - Pistoia Alliance lipophilicity assay bao:BAO_0010242 measuring pKa values pKa assay pKa measurement SEED Project - Pistoia Alliance pKa determination bao:BAO_0010243 chemical stability SEED Project - Pistoia Alliance chemical stability assay bao:BAO_0010244 stability-pH profile SEED Project - Pistoia Alliance pH stability assay bao:BAO_0010245 GSH trapping GSH-adducts formation of GSH adduct formation of GSH adducts reactive metabolite assay SEED Project - Pistoia Alliance GSH adduct formation bao:BAO_0010246 thermodynamic (equilibrium) solubility thermodynamic solubility SEED Project - Pistoia Alliance thermodynamic solubility assay bao:BAO_0010247 turbidimetric solubility SEED Project - Pistoia Alliance turbidimetric solubility assay bao:BAO_0010248 kinome assay kinome panel kinome profiling kinome scannning kinome screen SEED Project - Pistoia Alliance kinome activity assay bao:BAO_0010249 CRISPR CRISPR editing CRISPR-Cas9 CRISPR-Cas9 editing CRISPR-Cas9-mediated gene editing CRISPR/Cas9 CRISPR/Cas9 gene editing SEED Project - Pistoia Alliance CRISPR/Cas9 method bao:BAO_0010250 cell binding SEED Project - Pistoia Alliance cell binding assay bao:BAO_0010251 biological pathway assay pathway activity pathway assay pathway biology SEED Project - Pistoia Alliance signaling pathway assay bao:BAO_0010252 protein expression assay SEED Project - Pistoia Alliance protein expression assay bao:BAO_0010253 T cell - tumor cell co-culture assay T cell activation T cell proliferation assay T-cell functional activity T-cell proliferation tumor cell - T cell co-culture assay SEED Project - Pistoia Alliance T-cell activation assay bao:BAO_0010254 mouse syngeneic mouse syngeneic tumor models syngeneic syngeneic model syngeneic models syngeneic mouse model syngeneic mouse tumor model syngeneic tumor models SEED Project - Pistoia Alliance syngeneic tumor model bao:BAO_0010255 T-cell engraftment T-cell graft SEED Project - Pistoia Alliance T-cell engraftment bao:BAO_0010256 PK/PD PK/PD analysis PK/PD assays PK/PD model PK/PD models PK/PD study pharmacokinetics and pharmacodynamics pharmacokinetics and pharmacodynamics study pharmacokinetics, pharmacodynamics pharmocokinetic/pharmocodynamic true SEED Project - Pistoia Alliance in vivo PK/PD assay bao:BAO_0010257 Dahl rat model Dahl rat models Dahl salt-sensitive (DSS) rat Dahl salt-sensitive rat SEED Project - Pistoia Alliance Dahl salt-sensitive rat model bao:BAO_0010258 concentration response concentration response assay concentration response determination concentration response relationship SEED Project - Pistoia Alliance concentration response assay bao:BAO_0010259 receptor occupancy assay target occupancy assay SEED Project - Pistoia Alliance target engagement assay bao:BAO_0010260 delayed type hypersensitivity (DTH) in mice delayed-type hypersensitivity mouse model model of delayed type hypersensitivity SEED Project - Pistoia Alliance delayed-type hypersensitivity model bao:BAO_0010261 thermofluor assay thermofluor studies thermofluor study SEED Project - Pistoia Alliance thermal shift assay bao:BAO_0010262 T-cell cytotoxicity T-cell cytotoxicity mediated killing assay immune cell killing assay in vitro hepatocyte killing tumor cell killing SEED Project - Pistoia Alliance T-cell cytotoxicity assay bao:BAO_0010263 CEREP CEREP profiling CEREP screen CEREP screening assay SEED Project - Pistoia Alliance CEREP assay bao:BAO_0010264 biosensor assay SEED Project - Pistoia Alliance biosensor method bao:BAO_0010265 Annexin V FITC apoptosis assay Annexin V FITC apoptosis detection Annexin V staining Annexin V-FITC FITC Annexin V apoptosis detection SEED Project - Pistoia Alliance Annexin V apoptosis assay bao:BAO_0010266 Epitope Mapping SEED Project - Pistoia Alliance Epitope Mapping bao:BAO_0010267 drug-protein equilibrium dialysis equilibrium dialysis equilibrium dialysis for protein binding protein binding equilibrium dialysis SEED Project - Pistoia Alliance equilibrium assay bao:BAO_0010268 orthotopic model orthotopic mouse model orthotopic tumor models SEED Project - Pistoia Alliance orthotopic tumor model bao:BAO_0010269 chemotaxis assay SEED Project - Pistoia Alliance chemotaxis assay bao:BAO_0010270 biomarker assay biomarker assessment biomarker identification SEED Project - Pistoia Alliance PD biomarker assay bao:BAO_0010271 MET and pMET immunoassay pMET immunoassay SEED Project - Pistoia Alliance MET immunoassay bao:BAO_0010272 Poly(ADP-Ribose) assay Poly(ADP-Ribose) immunoassay SEED Project - Pistoia Alliance PAR Immunoassay bao:BAO_0010273 γH2AX, pNBS1, and β-catenin γH2AX, pNBS1, and β-catenin immuno assay SEED Project - Pistoia Alliance γH2AX, pNBS1, and β-catenin Multiplex Immunofluorescence Assay bao:BAO_0010274 Phosphorylated H2Ax Assay Total H2AX assay γH2Ax immunofluoresence assay SEED Project - Pistoia Alliance γH2Ax immunoassay bao:BAO_0010275 HIF-1α assay Hypoxia Inducible Factor 1-alpha assay SEED Project - Pistoia Alliance HIF1-alpha assay bao:BAO_0010276 TOP1 Immunoassay Topoisomerase I Immunoassay SEED Project - Pistoia Alliance Total Topoisomerase I assay bao:BAO_0010277 DiscoverX G protein coupled receptor (GPCR)max pharmacology panel DiscoverX gpcrMAX assay GPCRmax pharmacology panel gpcrMAX SEED Project - Pistoia Alliance gpcrMAX℠ GPCR Assay Panel bao:BAO_0010278 In vitro, in vivo, ex vivo, or in silico experimental evaluation of hit compounds in order to determine basic information about their safety, biological efficacy, and/or ADME properties. https://www.elsevier.com/books/T/A/9780128212226 SEED Project - Pistoia Alliance preclinical study bao:BAO_0010279 A disease model is an animal or cells displaying all or some of the pathological processes that are observed in the actual human or animal disease. https://www.nature.com/subjects/disease-model SEED Project - Pistoia Alliance disease model bao:BAO_0013016 An assay where the measure signal is a direct or coupled readout of the proteins native mechanistic or conformational cycle. This can include: (1) assays that directly or indirectly measure product of an enzymatic cycle (e.g.: NADPH consumption, antibody based detection of phosphorylated peptide substrate, mass spec product detection and quantitation, electrofluidic mobility shift assay, etc); (2) assays that directly or indirectly measure the transmission of signal as a result of the interaction with a membrane bound receptor detected through fluorescent dye that detects the release of intracellular calcium, nuclear receptor, and (3) biochemical assays that measures the increase or decrease of an RNA transcript as a result of interaction with a nuclear receptor functional target-based bao:BAO_0013017 An assay where the measured signal is a phenotypic response of the system or the readout is indirect (e.g. comparing cell survival between wildtype and mutant protein). functional phenotypic bao:BAO_0013018 Toxicology, as a subdivision of pharmacology, entails the meticulous investigation of the adverse effects imparted by chemical substances on living organisms. https://www.sciencedirect.com/science/article/pii/027323008790064X?via%3Dihub https://github.com/BioAssayOntology/BAO/issues/84 toxicology bao:BAO_0013019 The rate at which a drug is removed or cleared from the whole or part of the body. http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C199688 SEED Project - Pistoia Alliance clearance bao:BAO_0013020 Intrinsic metabolic clearance is defined as ratio of maximum metabolism rate, Vmax, and the Michaelis-Menten constant, Km. http://www.owl-ontologies.com/2009/11/5/PKO.owl#CLint SEED Project - Pistoia Alliance CLint bao:BAO_0013021 Guinea pig ileum assay measures the inhibitory effect of opioid receptor activation on electrically stimulated smooth muscle contractions, reflecting the reduction in excitatory neurotransmitter release in isolate tissue (guinea pig ileum, GPI). GPI assay investigates selectivity of Mu opioid receptors in guinea pig ileum. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1073/pnas.89.24.11871 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) guinea pig ileum (GPI) assay bao:BAO_0013022 Mouse vas deferens assay measures the inhibitory effect of opioid receptor activation on electrically stimulated smooth muscle contractions, reflecting the reduction in excitatory neurotransmitter release in isolate tissue (mouse vas deferens, MVD). MVD assay investigates selectivity of delta opioid receptors in mouse vas deferens. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1073/pnas.89.24.11871 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) mouse vas deferens (MVD) assay bao:BAO_0013023 Smooth muscle contraction assay measures the inhibitory effect of opioid receptor activation on electrically stimulated smooth muscle contractions, reflecting the reduction in excitatory neurotransmitter release in isolate tissue (rabbit vas deferens, RVD assay investigates selectivity of kappa opioid receptors in mouse vas deferens). [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.3791/52324 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) rabbit vas deferens (RVD) assay bao:BAO_0013024 The term antinociception refers to the reduction of pain states observed in nonhuman animals, where evaluating the subjective experience of pain is not feasible. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1016/j.pharmthera.2021.107961 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) antinociception assay bao:BAO_0013025 Organ function assays are based on observing outcomes based on organ function such as micturition assays (urine output) or gut function assays (gut transit, or gut motility assays) in live animals. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] [EdgeRewiring: BAO v 2.8.15 (May 2025)] https://doi.org/10.1080/10790268.2019.1661697 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) organ function assay bao:BAO_0013026 Organ function assays are based on observing outcomes based on organ function such as micrition assays (urine output) or gut function assays (gut transit, or gut motility assays) in live animals. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1080/10790268.2019.1661697 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) renal function assay bao:BAO_0013027 Kidney function assays (micturition assays) are assays that measure urination or voiding behaviour of animals. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1152/ajprenal.00350.2018 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) micturition assay bao:BAO_0013028 Gut function assays in preclinical animal models evaluate parameters associated with gut function such as motility in colon sections, transit throughout the gastrointestinal system, or general status of gut microbiome. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] [EdgeRewiring: BAO v 2.8.15 (May 2025)] https://doi.org/10.1053/j.gastro.2013.01.047 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) gut function assay bao:BAO_0013029 Gut transit assays evaluate the duration of time it takes for a substance (i.e. charcoal meal in gastrointestinal motility test) to move through the entire intestestinal tract. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1038/s41598-018-23717-4 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) gut transit assay bao:BAO_0013030 Gut motility assays in isolated sections of colon monitor characteristics of migrating contractions recorded in isolated colon, but do not reflect gut transit throughout the entire gastrointestinal system. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1038/s41598-018-23717-4 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) gut motility assay bao:BAO_0013031 Accumulation assays are techniques used to measure receptor signaling activities by directly or indirectly quantifying intracellular molecules, such as second messengers. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) accumulation assay bao:BAO_0013032 Accumulation assays are techniques used to measure receptor signaling activities by directly or indirectly quantifying intracellular levels of second messengers. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) second messenger accumulation assay bao:BAO_0013033 cAMP accumulation assays are methods used to measure receptor signaling activities by directly or indirectly quantifying intracellular cAMP levels. These assays often involve forskolin-stimulated cAMP production, where forskolin activates adenylyl cyclase to amplify cAMP levels following the activation of the stimulatory G protein (Gs). [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1016/B978-0-12-381298-8.00021-6 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) cAMP accumulation assay bao:BAO_0013034 Label-free receptor assays commonly involve recording real-time, integrated signals from whole cells. These comprehensive measurements capture the complexity of receptor signaling, enabling the study of receptor systems biology, receptor cross-talk, and the integration of receptor signaling pathways. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1016/j.ddtec.2010.05.001 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) label-free receptor assay bao:BAO_0013035 Pre-clinical assays that evaluate thermal (hot and cold) pain thresholds in animals. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1093/gerona/glr210 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) thermal nociception assay bao:BAO_0013036 Pre-clinical assays that induce chemical injuries in test animals to evaluate chemical pain thresholds (more commonly chemically induced inflammation). [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1016/0304-3959(92)90003-t Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) chemical nociception assay bao:BAO_0013037 A preclinical mechanical nociception assay is used to evaluate sensitivity to mechanical stimuli, classifying responses into dynamic (triggered by brushing), punctate (triggered by touch), and static (triggered by pressure) nociception. Dynamic mechanical sensitivity is typically assessed by gently brushing the skin with tools such as a cotton bud, paintbrush, or cotton ball, mimicking conditions that may evoke nociceptive responses, including contact with clothing, bed sheets, or towels. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.3389/fnmol.2017.00284 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) mechanical nociception assay bao:BAO_0013038 The [35S]GTPγS assay is an assay that evaluates G protein activation triggered by agonist binding to a GPCR. It does so by measuring the binding of the non-hydrolyzable [35S]GTPγS analog to Gα subunits, providing a functional readout of receptor occupancy at one of the earliest receptor-mediated signaling events. This assay is done in many different formats including in cell lines, cell membrane, tissue homogenate, and SPA. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1016/j.lfs.2003.07.005 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) [35S]GTPgammaS radioligand binding assay bao:BAO_0013039 Smooth muscle assay are organ-bath based ex vivo assay that measure the inhibition or activation of electrically stimulated twitch tissue isolated in an organ bath. The assay endpoint is the measurement of the isometric contraction of an isolated smooth muscle. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://dx.doi.org/10.3791/52324-v Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) smooth muscle contraction assay bao:BAO_0013040 hERG patch clamp assay is a bioassay that uses patch clamp electrophysiology to measure the activity of hERG potassium channels in vitro. It assesses the extent to which a compound inhibits hERG channel currents, providing a functional evaluation of a drug’s potential to cause QT interval prolongation and associated cardiac arrhythmias. [NodeCreation: BAO v 2.8.14 (April 2025)] hERG automated patch clamp hERG ephys hERG patch clamp hERG patch clamp screen https://doi.org/10.1038/nature04710 Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) hERG patch clamp assay bao:BAO_0013041 hERG binding assay is a bioassay that measures the binding affinity of a compound to hERG (human Ether-à-go-go-Related Gene) potassium channels using radiolabeled ligands. This assay serves as an in vitro screening method to assess the potential of a drug to interact with hERG channels, providing early insight into the risk of drug-induced QT interval prolongation. [NodeCreation: BAO v 2.8.14 (April 2025)] hERG binding hERG dofetilide binding https://doi.org/10.1016/S0008-6363(02)00846-5 Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) hERG binding assay bao:BAO_0013042 Langendorff assay is an ex vivo bioassay that measures cardiac function by perfusing an isolated heart in a controlled system to assess the effects of compounds on parameters such as heart rate, contractility, coronary flow, and electrophysiological activity. This assay enables the evaluation of direct cardiac responses, including arrhythmogenic potential and myocardial performance, independent of systemic influences. [NodeCreation: BAO v 2.8.14 (April 2025)] Isolated guinea pig heart QT assay Isolated heart QT assay Langendorff assay lang perfused heart assay https://doi.org/10.1016/S0735-1097(02)02963-4 Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) Langendorff assay bao:BAO_0013043 Isolated aorta assay is an ex vivo bioassay that evaluates the contractile and vasorelaxant responses of isolated aortic tissue exposed to test compounds. By measuring changes in vascular tension, this assay assesses the effects of drugs on smooth muscle function, vascular reactivity, and potential cardiovascular liabilities. [NodeCreation: BAO v 2.8.14 (April 2025)] contraction assay isolated aorta assay https://doi.org/10.1161/01.ATV.0000184760.14028.54 Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) isolated aorta assay bao:BAO_0013044 Cardiomyocyte repolarization assay is a bioassay that evaluates the effects of compounds on the repolarization phase of action potentials in cardiac cells. By measuring changes in action potential duration or ionic currents in cardiomyocytes, this assay helps assess the potential for drug-induced arrhythmias, including QT interval prolongation. [NodeCreation: BAO v 2.8.14 (April 2025)] cardiomyocyte repolarization cardiomyocyte repolarization assay cardiomyocyte repolarization study myocyte repolarization myocyte repolarization assay https://doi.org/10.1016/j.celrep.2018.08.016 Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) cardiomyocyte repolarization assay bao:BAO_0013045 PTZ-induced convulsion assay is an in vivo bioassay used to evaluate the pro- or anti-convulsant effects of compounds by measuring seizure activity induced by pentylenetetrazol (PTZ), a chemical convulsant. This assay helps assess a drug’s potential impact on central nervous system excitability and seizure threshold. [NodeCreation: BAO v 2.8.14 (April 2025)] PTZ-induced convulsion PTZ-induced convulsions PTZ-induced seizure PTZ-induced seizures pentylenetetrazole-induced convusion https://doi.org/10.1016/j.ejphar.2009.03.015 Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) PTZ-induced convulsion assay bao:BAO_0013046 Platelet aggregation assay is a bioassay used to measure the extent and rate at which platelets clump together in response to agonists such as ADP, collagen, or thrombin. This assay evaluates the effects of compounds on platelet function and is commonly used to assess pro-thrombotic or anti-thrombotic potential. [NodeCreation: BAO v 2.8.14 (April 2025)] platelet aggregation platelet aggregometry assay platelet function assay Michelson, A. D. (2012). Platelets (3rd ed.). Elsevier Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) platelet aggregation assay bao:BAO_0013047 Action potential duration assay is a bioassay that measures the time course of an action potential in excitable cells, particularly cardiomyocytes or neurons, to assess how compounds affect the duration of depolarization and repolarization phases. This assay is used to evaluate drug-induced changes in cardiac or neuronal electrophysiology. [NodeCreation: BAO v 2.8.14 (April 2025)] https://doi.org/10.1038/sj.bjp.0702674 Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) action potential duration assay bao:BAO_0013048 A bioassay that evaluates the effects of compounds on multiple ion channels simultaneously to assess potential drug-induced disruptions in ion channel function. This screening approach is commonly used in safety pharmacology to predict cardiac or neurological liabilities associated with ion channel modulation. [NodeCreation: BAO v 2.8.14 (April 2025)] https://doi.org/10.1016/j.vascn.2013.01.004 Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) multichannel ion channel screening bao:BAO_0013049 A bioassay that involves continuous electrocardiogram monitoring in freely moving, conscious animals using implanted telemetry devices. This assay is used to assess cardiac electrophysiological parameters, including heart rate, rhythm, and QT interval, to evaluate the potential cardiac effects of drug candidates in a physiologically relevant, unrestrained setting. [NodeCreation: BAO v 2.8.14 (April 2025)] https://doi.org/10.1016/j.vascn.2015.04.004 Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) telemetry ECG in conscious animals bao:BAO_0013050 A bioassay that records electrical activity in the brain through electroencephalography (EEG) to monitor neuronal function and detect abnormal brain activity such as seizures. This assay is commonly used in safety pharmacology studies to evaluate the potential neurotoxic or proconvulsant effects of drug candidates. [NodeCreation: BAO v 2.8.14 (April 2025)] https://doi.org/10.1016/j.vascn.2016.03.001 Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) EEG recording assay bao:BAO_0013051 A non-invasive bioassay used to assess respiratory function by measuring parameters such as respiratory rate, tidal volume, and airflow in conscious, unrestrained animals. This method enables evaluation of drug-induced effects on pulmonary function and is commonly used in safety pharmacology for respiratory assessments. [NodeCreation: BAO v 2.8.14 (April 2025)] https://doi.org/10.1186/1465-9921-8-63 Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) whole-body plethysmography bao:BAO_0013052 A bioassay that evaluates the effect of compounds on airway constriction by measuring changes in airway resistance or smooth muscle contraction, typically in response to bronchoconstrictive agents. This assay is used to assess drug-induced effects on respiratory function, particularly in the context of asthma or airway hyperresponsiveness. [NodeCreation: BAO v 2.8.14 (April 2025)] Raeburn, D., & Giembycz, M. A. (1994). Pharmacology of airway smooth muscle. In Handbook of Experimental Pharmacology (Vol. 98, pp. 447-472). Springer Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) bronchoconstriction assay bao:BAO_0013053 A bioassay used to detect kidney injury by measuring specific biomarkers indicative of nephrotoxic effects. These assays assess the impact of compounds on renal function or structure through the quantification of biomarkers such as KIM-1, NGAL, or cystatin C, providing early and sensitive detection of drug-induced kidney toxicity. [NodeCreation: BAO v 2.8.14 (April 2025)] https://doi.org/10.4062/biomolther.2012.20.3.268 Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) nephrotoxicity biomarker assay bao:BAO_0013054 A bioassay that assesses the mutagenic potential of chemical compounds by measuring their ability to induce mutations in the DNA of Salmonella typhimurium or Escherichia coli strains that are deficient in DNA repair. This assay is widely used in drug safety testing to predict genotoxicity and potential carcinogenicity of new compounds. [NodeCreation: BAO v 2.8.14 (April 2025)] https://doi.org/10.1016/S0027-5107(00)00064-6 Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) Ames test bao:BAO_0013055 A bioassay that detects chromosomal damage by measuring the formation of micronuclei, which are small extranuclear bodies containing chromosomal fragments or whole chromosomes located in the cytoplasm of interphase cells. This assay is widely used in toxicology to assess the genotoxic potential of chemical compounds in vitro or in vivo. [NodeCreation: BAO v 2.8.14 (April 2025)] https://doi.org/10.1038/nprot.2007.77 Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) micronucleus assay bao:BAO_0013056 LDH release assay is a bioassay that measures the release of lactate dehydrogenase (LDH) from damaged or lysed cells into the extracellular environment. It is commonly used to assess cytotoxicity by quantifying the loss of membrane integrity following chemical or biological exposure. [NodeCreation: BAO v 2.8.14 (April 2025)] https://doi.org/10.1016/0022-1759(88)90310-9 Semantic Enrichment of ELN Data (SEED) (https://www.pistoiaalliance.org) - Joan Glenny Pescov (https://orcid.org/0009-0008-8186-7058) LDH release assay bao:BAO_0020002 Date from BAE: 7/19/2016 PubChem AID: 602155 liposome format bao:BAO_0020003 Plasma is the liquid part of the blood and lymphatic fluid, which makes up about half of the volume of blood. Plasma is devoid of cells and, unlike serum, has not clotted. Date from BAE: 7/6/2016 PubChem AID: 623907 plasma format bao:BAO_0020004 Serum is the clear cell-free liquid that is separated from clotted blood. Serum differs from plasma in that the blood is first allowed to clot before centrifugation (separating from cells) while plasma preparations entail preventing blood clotting. Both are cell-free and contain antibodies. Date from BAE: 7/6/2016 PubChem AID: serum format bao:BAO_0020005 experimental setting bao:BAO_0020006 ex vivo bao:BAO_0020007 in silico bao:BAO_0020008 in vitro bao:BAO_0020009 in vivo bao:BAO_0020010 Obtained by disrupting and centrifuging human liver or intestine cells, resulting in a combination of cell cytosol and microsomes. It encompasses a diverse array of drug-metabolizing enzymes and serves as a commonly utilized medium for conducting in vitro DMPK studies. S9 format https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405623/ https://github.com/BioAssayOntology/BAO/issues/84 S9 fraction format bao:BAO_0020011 The liquid component of blood devoid of cellular elements (such as red blood cells, white blood cells, and platelets) and insoluble components, typically obtained through processes like centrifugation or filtration. http://purl.org/net/OCRe/OCRe.owl#OCRE400034 SEED Project - Pistoia Alliance blood format bao:BAO_0020012 Tissue membrane format (often using morter and pestal to homogenize tissue) is considered a cell-free subcellular format that contains issues and broken down components of cells. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1016/B978-0-12-411604-7.00009-X Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) tissue membrane format bao:BAO_0020013 The synaptosomal fraction represents neuronal components, specifically crude synaptosomes, which are obtained by breaking open neural tissue and centrifuging it to separate synaptic structures (from neurons) from the soluble cytosolic material. This fraction contains synaptosomes but may also include other cellular contaminants until further purification steps are applied. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1016/j.xpro.2023.102061 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) synaptosomal fraction format bao:BAO_0020014 The P2 synaptosomal fraction is a crude neuronal sub-cellular fraction enriched in synaptosomes, obtained by centrifuging lysate at 10,000 × g to separate the cytosol (S2) from the pellet, which is resuspended in Buffer B. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1016/j.xpro.2023.102061 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) synaptosomal P2 fraction format bao:BAO_0030000 P84243 Histone H3.3 bao:BAO_0030001 cyclin-B1 P14635 G2/mitotic-specific cyclin-B1 bao:BAO_0030002 Ki67 P46013 Antigen KI-67 bao:BAO_0030003 Retinoblastoma protein P06400 Retinoblastoma-associated protein bao:BAO_0030004 c-jun P05412 Transcription factor AP-1 bao:BAO_0030005 Annexin V P08758 Annexin A5 bao:BAO_0030006 P16581 E-selectin bao:BAO_0030007 VCAM-1 P19320 Vascular cell adhesion protein 1 bao:BAO_0030008 Autophagy-related protein LC3 B Q9GZQ8 Microtubule-associated proteins 1A/1B light chain 3B bao:BAO_0030009 Tubulin beta-III Q13509 Tubulin beta-3 chain bao:BAO_0030010 Nuclear factor NF-kappa-B p65 subunit Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 Q04206 Transcription factor p65 bao:BAO_0030011 http://purl.obolibrary.org/obo/CL_0000530 primary neuron bao:BAO_0030012 A protein that has been modified with either a molecular or protein and can be used either as a method of pulling down, antibody binding, luminescense, or tracer An aldehyde oxidoreductase expressed predominantly in the LIVER; LUNGS; and KIDNEY. It catalyzes the oxidation of a variety of organic aldehydes and N-heterocyclic compounds to CARBOXYLIC ACIDS, and also oxidizes quinoline and pyridine derivatives. The enzyme utilizes molybdenum cofactor and FAD as cofactors. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://purl.bioontology.org/ontology/MESH/D042931 SEED Project - Pistoia Alliance Aldehyde oxidase bao:BAO_0030013 Broad substrate specificity ATP-binding cassette transporter ABCG2 is encoded by the human ABCG2 gene. This protein is involved in the transport of urate, heme, porphyrin and xenobiotics. http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C21253 SEED Project - Pistoia Alliance Broad substrate specificity ATP-binding cassette transporter ABCG2 bao:BAO_0030014 Bile salt export pumpis encoded by the human ABCB11 gene. This protein plays a role in bile salt secretion. http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123861 SEED Project - Pistoia Alliance Bile salt export pump bao:BAO_0030015 The protein-coding gene EST1 located on the chromosome XII. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://purl.obolibrary.org/obo/NCBIGene_850934 SEED Project - Pistoia Alliance EST1 bao:BAO_0030016 Reverse transcriptase subunit of the telomerase holoenzyme; essential for telomerase core catalytic activity, involved in other aspects of telomerase assembly and function; mutations in human homolog are associated with aplastic anemia. [EdgeRewiring: BAO v 2.8.14 (April 2025)] https://www.yeastgenome.org/locus/S000004310 SEED Project - Pistoia Alliance EST2 bao:BAO_0030017 Cytochrome P450 1A2 is encoded by the human CYP1A2 gene. This protein is involved in the hydroxylation of fatty acids, steroids and xenobiotics. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17673 SEED Project - Pistoia Alliance Cytochrome P450 1A2 bao:BAO_0030018 Cytochrome P450 2B6 is encoded by the human CYP2B6 gene. This protein plays a role in the metabolism of steroids and pharmaceuticals. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C40050 SEED Project - Pistoia Alliance Cytochrome P450 2B6 bao:BAO_0030019 Cytochrome P450 2C19 is encoded by the human CYP2C19 gene. This protein is involved in steroid, terpenoid and drug metabolism. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C25948 SEED Project - Pistoia Alliance Cytochrome P450 2C19 bao:BAO_0030020 Cytochrome P450 2C8 is encoded by the human CYP2C8 gene. This protein is involved in the oxidation of steroids, fatty acids, and xenobiotics. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C46001 SEED Project - Pistoia Alliance Cytochrome P450 2C8 bao:BAO_0030021 Cytochrome P450 2C9 is encoded by the human CYP2C9 gene. This protein is involved in the oxidation of fatty acids, steroids and xenobiotics. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C28750 SEED Project - Pistoia Alliance Cytochrome P450 2C9 bao:BAO_0030022 Cytochrome P450 3A4 is encoded by the human CYP3A4 gene. This protein is involved in the oxidation of steroids, fatty acids and xenobiotics. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17573 SEED Project - Pistoia Alliance Cytochrome P450 3A4 bao:BAO_0030023 This protein is involved in steroid, terpenoid and drug metabolism. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16484 SEED Project - Pistoia Alliance Cytochrome P450 2D12 bao:BAO_0030024 This protein is involved in steroid, terpenoid and drug metabolism. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16484 SEED Project - Pistoia Alliance Cytochrome P450 2D9 bao:BAO_0030025 Cytochrome P450 2D6 is encoded by the human CYP2D6 gene. This protein plays a role in flavoprotein metabolism. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17287 SEED Project - Pistoia Alliance Cytochrome P450 2D6 bao:BAO_0030026 Cytochrome P450 3A7 is encoded by the human CYP3A7 gene. This protein plays a role in the oxidation of steroids, fatty acids, and xenobiotics. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C46000 SEED Project - Pistoia Alliance Cytochrome P450 3A7 bao:BAO_0030027 Epoxide hydrolase 1 is encoded by the human EPHX1 gene. This protein is involved in the hydrolysis of cyclic organic compounds. http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16860 SEED Project - Pistoia Alliance Epoxide hydrolase 1 bao:BAO_0030028 Cytochrome P450 3A5 is encoded by the human CYP3A5 gene. This protein is involved in the oxidation of steroids, fatty acids, and xenobiotics. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C45999 SEED Project - Pistoia Alliance Cytochrome P450 3A5 bao:BAO_0030029 This protein is involved in steroid, terpenoid and drug metabolism. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16484 SEED Project - Pistoia Alliance Cytochrome P450 3A10 bao:BAO_0030030 This protein is involved in steroid, terpenoid and drug metabolism. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16484 SEED Project - Pistoia Alliance Cytochrome P450 2D11 bao:BAO_0030031 Multidrug and toxin extrusion protein 1 is encoded by the human SLC47A1 gene. This protein plays a role in transport of cationic drugs across membranes. http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113566 SEED Project - Pistoia Alliance Multidrug and toxin extrusion protein 1 bao:BAO_0030032 Multidrug and toxin extrusion protein 2 is encoded by the human SLC47A2 gene. This protein is involved in both excretion of toxic electrolytes and secretion of cationic drugs. http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113569 SEED Project - Pistoia Alliance Multidrug and toxin extrusion protein 2 bao:BAO_0030033 A protein that is a translation product of the human ABCB1 gene. http://purl.obolibrary.org/obo/PR_000001891 SEED Project - Pistoia Alliance ATP-dependent translocase ABCB1 bao:BAO_0030034 A protein that is a translation product of the human ABCC2 gene. http://purl.obolibrary.org/obo/PR_000003558 SEED Project - Pistoia Alliance ATP-binding cassette sub-family C member 2 bao:BAO_0030035 A protein that is a translation product of the human ABCC3 gene. http://purl.obolibrary.org/obo/PR_000003559 SEED Project - Pistoia Alliance ATP-binding cassette sub-family C member 3 bao:BAO_0030036 A protein that is a translation product of the human SLC15A1 gene. http://purl.obolibrary.org/obo/PR_000014940 SEED Project - Pistoia Alliance Solute carrier family 15 member 1 bao:BAO_0030037 The protein-coding gene FMO3 (flavin containing monooxygenase 3). [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://identifiers.org/ncbigene/2328 SEED Project - Pistoia Alliance FMO3 bao:BAO_0030038 Catalyzes the oxidative deamination of primary and some secondary amine such as neurotransmitters, with concomitant reduction of oxygen to hydrogen peroxide and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. https://www.ebi.ac.uk/interpro/protein/UniProt/P21397/ SEED Project - Pistoia Alliance Amine oxidase [flavin-containing] A bao:BAO_0030039 Catalyzes the oxidative deamination of primary and some secondary amines such as neurotransmitters, and exogenous amines including the tertiary amine, neurotoxin MPTP, with concomitant reduction of oxygen to hydrogen peroxide and participates in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. https://www.uniprot.org/uniprotkb/P27338/entry SEED Project - Pistoia Alliance Amine oxidase [flavin-containing] B bao:BAO_0030040 A protein that is a translation product of the human SLC22A6 gene. http://purl.obolibrary.org/obo/PR_000014993 SEED Project - Pistoia Alliance Solute carrier family 22 member 6 bao:BAO_0030041 A protein that is a translation product of the human SLC22A7 gene. http://purl.obolibrary.org/obo/PR_000014994 SEED Project - Pistoia Alliance Solute carrier family 22 member 7 bao:BAO_0030042 A protein that is a translation product of the SLC22A8 gene. http://purl.obolibrary.org/obo/PR_Q8R0S9 SEED Project - Pistoia Alliance Solute carrier family 22 member 8 bao:BAO_0030043 Solute carrier organic anion transporter family member 1B1 is encoded by the human SLCO1B1 gene. This protein is involved in the sodium-independent uptake of endogenous compounds in the liver. http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106616 SEED Project - Pistoia Alliance Solute carrier organic anion transporter family member 1B1 bao:BAO_0030044 A sodium-independent organic anion transporter that functions in the uptake of various drugs and endogenous compounds including estradiol; taurocholate; leukotriene c4; and methotrexate. http://purl.bioontology.org/ontology/MESH/D000074542 SEED Project - Pistoia Alliance Solute carrier organic anion transporter family member 1B3 bao:BAO_0030045 Solute carrier organic anion transporter family member 2B1 is encoded by the human SLCO2B1 gene. This protein is involved in transport of organic anions and may function in regulation of placental uptake of sulfated steroids. http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105431 SEED Project - Pistoia Alliance Solute carrier organic anion transporter family member 2B1 bao:BAO_0030046 Solute carrier family 22 member 1 is encoded by the human SLC22A1 gene. This protein is involved in bidirectional cation transport. http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105075 SEED Project - Pistoia Alliance Solute carrier family 22 member 1 bao:BAO_0030047 A protein that is a translation product of the human SLC22A24 gene. http://purl.obolibrary.org/obo/PR_000030620 SEED Project - Pistoia Alliance Steroid transmembrane transporter SLC22A24 bao:BAO_0030048 A protein that is a translation product of the human UGT1A1 gene. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://purl.obolibrary.org/obo/PR_000017048 SEED Project - Pistoia Alliance UDP-glucuronosyltransferase 1A1 bao:BAO_0030049 A protein that is a translation product of the human UGT1A3 gene. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://purl.obolibrary.org/obo/PR_000017050 SEED Project - Pistoia Alliance UDP-glucuronosyltransferase 1A3 bao:BAO_0030050 A protein that is a translation product of the human UGT1A4 gene. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://purl.obolibrary.org/obo/PR_000017051 SEED Project - Pistoia Alliance UDP-glucuronosyltransferase 1A4 bao:BAO_0030051 UDP-glucuronosyltransferase 1-6 is encoded by the human UGT1A6 gene. This protein is involved in the elimination of phenolic metabolites. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105574 SEED Project - Pistoia Alliance UDP-glucuronosyltransferase 1-6 bao:BAO_0030052 A protein that is a translation product of the mouse Ugt1a7c gene. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://purl.obolibrary.org/obo/PR_000017223 SEED Project - Pistoia Alliance UDP-glucuronosyltransferase 1A7 bao:BAO_0030053 A protein that is a translation product of the human UGT1A8 gene. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://purl.obolibrary.org/obo/PR_000017055 SEED Project - Pistoia Alliance UDP-glucuronosyltransferase 1A8 bao:BAO_0030054 A PPAR alpha and PPAR gamma target gene. The enzyme plays an important role in elimination and detoxification of drugs, xenobiotics, and metabolizing endogenous compounds, including catecholestrogens and fibrates. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://purl.bioontology.org/ontology/MESH/D000090264 SEED Project - Pistoia Alliance UDP-glucuronosyltransferase 1A9 bao:BAO_0030055 A protein that is a translation product of the human UGT1A10 gene. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://purl.obolibrary.org/obo/PR_000017049 SEED Project - Pistoia Alliance UDP-glucuronosyltransferase 1A10 bao:BAO_0030056 A protein that is a translation product of the human UGT2B4 gene [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://purl.obolibrary.org/obo/PR_000017064 SEED Project - Pistoia Alliance UDP-glucuronosyltransferase 2B4 bao:BAO_0030057 UDP-glucuronosyltransferase 2B7 is encoded by the human UGT2B7 gene. This protein plays a role in regulating the metabolism of estrogen metabolites. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105577 SEED Project - Pistoia Alliance UDP-glucuronosyltransferase 2B7 bao:BAO_0030058 A protein that is a translation product of the human UGT2B10 gene. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://purl.obolibrary.org/obo/PR_000017059 SEED Project - Pistoia Alliance UDP-glucuronosyltransferase 2B10 bao:BAO_0030059 UDP-glucuronosyltransferase 2B15 is encoded by the human UGT2B15 gene. This protein is involved in the catabolism of xenobiotics and steroids. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105422 SEED Project - Pistoia Alliance UDP-glucuronosyltransferase 2B15 bao:BAO_0030060 A protein that contains a C-terminal UDPGT domain that in active form catalyzes the transfer of glucuronic acid to a wide variety of exogenous and endogenous lipophilic substrates. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://purl.obolibrary.org/obo/PR_000024849 SEED Project - Pistoia Alliance UDP-glucuronosyltransferase 2B23 bao:BAO_0030061 A protein that is a translation product of the SLC10A1 gene http://purl.obolibrary.org/obo/PR_000014917 SEED Project - Pistoia Alliance Sodium/bile acid cotransporter bao:BAO_0030062 UDP-glucuronosyltransferase 2B17 is encoded by the human UGT2B17 gene. This protein plays a role in the metabolism of steroids and xenobiotics. [EdgeRewiring: BAO v 2.8.14 (April 2025)] http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105425 SEED Project - Pistoia Alliance UDP-glucuronosyltransferase 2B17 bao:BAO_0030063 Living multicellular organism. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1371/journal.pntd.0001762 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) whole organism image processing method image analysis method image correction Background correction is a data transformation designed to remove irrelevant contributions from the measured signal, e.g. those due to instrument noise or sample preparation. flat field correction; shading correction background correction Image resize is a process to change the size of the image data by increasing or decreasing the number of pixels within the image. Mostly used for reducing in either the horizontal or vertical dimension. image resize Image sharpening is a process to enhance the definition of object edges in an image. image sharpening Image smoothing is a set of local pre-processing methods designed to suppress image noise. image smoothing image segmentation Edge detection is the process to identify regions in a digital image where the image brightness changes sharply or the image has discontinuities. edge detection Image thresholding is a procedure that eliminates shades of gray from regions of an image above or below particular gray levels, replacing them instead with solid white or black. image thresholding Any method that simply measures the overall abundance (concentration, relative amount, etc) of a particular molecule (lipids, second messenger, nucleic acid, protein, etc.) Date from BAE: 6/28/2016 PubChem AID: molecular abundance method Second messengers relay and amplify signals from receptors to the cell interior as part of a signaling event. Examples include cAMP, cGMP, calcium, nitric oxide, diacylglycerol, etc. Levels of these second messengers are measured to reflect strength of the signaling. Date from BAE: 6/7/2016 PubChem AID: 651719 second messenger abundance Measuring lipid abundance could include mass spec-based methods and lipid droplet formation, a fluorescent intensity+image analysis assay to measure lipid stored in droplets within a cell, Date from BAE: 5/21/2016 PubChem AID: 1656 lipid abundance method Date from BAE: 6/28/2016 PubChem AID: protein abundance method Cell density, typically measured by absorbance (often indicated as A600 or OD600), is often used for bacterial or fungal cultures as an indication of cell number, viability or proliferation. Date from BAE: 6/15/2016 PubChem AID: 775 cell density determination Beta-galactosidase activity measurement method Date from BAE: 5/23/2016 PubChem AID: 652176 Beta-galactosidase activity measurement method Any method that simply measures the overall abundance (concentration, relative amount, etc) of a nucleic acid (DNA or RNA), typically via hybridization methods Date from BAE: 5/11/2016 PubChem AID: 463235 DNA or RNA abundance method Any method that simply measures the overall abundance (concentration, relative amount, etc) of a small molecule, such as LC-MS/MS or LC-UV. Typically used in both in vitro and in vivo ADME assays to monitor compound. Date from BAE: 6/6/2016 PubChem AID: 504605 small molecule abundance method Any method that measures the size and shape of whole cells. Typically detected by microscopy or flow cytometry Date from BAE: 6/6/2016 PubChem AID: 463200 cellular morphology assessment method Any method that measures the size and shape of structures or organelles within cells, such as nuclei, mitochindria, Golgi, ER or vesicles. Typically detected by microscopy or flow cytometry Date from BAE: 6/6/2016 PubChem AID: 463200 sub-cellular morphology assessment method Any study performed in a whole, living organism (usually an animal such as a mouse or rat). Date from BAE: 9/30/2016 PubChem AID: 687012 in vivo assay method Any study performed in a whole, living organism (usually an animal such as a mouse or rat), to test the effects of a treatment on a specific disease modeled in this animal. Study design and measured endpoints vary tremendously and depend on the particular aspects of the targeted disease. Ideally, the endpoints measured will correlate with how efficacy would be measured in humans. Date from BAE: 9/30/2016 PubChem AID: 687012 in vivo efficacy method Any study performed in a whole, living organism (usually an animal such as a mouse or rat) to investigate the pharmacokinetics (PK), pharmacodynamics (PD) or toxicity of a perturbagen or treatment. Date from BAE: 9/30/2016 PubChem AID: 687012 in vivo PK/PD/Tox method Changes in protein thermal stability can be induced by ligand binding, and this thermodynamic stabilization can be measured by a variety of methods, often reported as a delta Tm (or change in the melting temperature of the protein). Date from BAE: 9/30/2016 PubChem AID: 651658 thermal shift assessment method A method that uses chemilumiscence to quantify the labeled entity. For this, an enzyme converts a substrate to a product that emits photons of light chemiluminescent labeling method A method that is used to identify the precise order/sequence of the nucleotides in a dna molecule by using the shotgun method in which DNA is fragmented and then the individual frgaments are sequenced dna-seq method A method that is used to identify open / accessible genomic sites of remodeled chromatin chromatin acessibility method A method that is used to quantify various cell metabolites or metabolism-related analytes (e.g. O2, glucose, pH) metabolite abundance method epigenetic modification detection method A method that is used to identify the DNA regions that are being occupied by a predefined transcriptional factor(s) transcription factor occupancy Techniques used to separate mixtures of macromolecules based on physical size and mass size separation method NanoBRET (Nano Bioluminescence Resonance Energy Transfer) is a proximity-based assay that uses the bright, small luciferase NanoLuc (Nluc), fluorescent molecule (NCT ligand) and its substrate furimazine to monitor molecular interactions, protein conformational changes, or ligand binding in live cells. [EdgeRewiring: BAO v 2.8.15 (May 2025)] https://doi.org/10.3389/fbioe.2019.00056 NanoBRET Pistoia SEED ligand covalent binding method the lysine ligand covalent binding method is used to measure binding of an amine-reactive molecule with a lysine residue on a protein of interest. Binding assessment can be measured by protein mass spectrometry or other direct-binding methodology. Pistoia SEED lysine ligand covalent binding method the methionine ligand covalent binding method is used to measure binding of an thioether-reactive molecule with a methionine residue on a protein of interest. Binding assessment can be measured by protein mass spectrometry or other direct-binding methodology. Pistoia SEED methionine ligand covalent binding method the serine ligand covalent binding method is used to measure binding of an alcohol-reactive molecule with a serine residue on a protein of interest. Binding assessment can be measured by protein mass spectrometry or other direct-binding methodology. Pistoia SEED serine ligand covalent binding method the tyrosine ligand covalent binding method is used to measure binding of a phenol-reactive molecule with a tyrosine residue on a protein of interest. Binding assessment can be measured by protein mass spectrometry or other direct-binding methodology. Pistoia SEED tyrosine ligand covalent binding method the N-terminal ligand covalent binding method is used to measure binding of an amine-reactive molecule with the N-terminus of a protein of interest. Binding assessment can be measured by protein mass spectrometry or other direct-binding methodology. Pistoia SEED N-terminal ligand covalent binding method the threonine ligand covalent binding method is used to measure binding of an alcohol-reactive molecule with a threonine residue on a protein of interest. Binding assessment can be measured by protein mass spectrometry or other direct-binding methodology. Pistoia SEED threonine ligand covalent binding method the unnatural amino acid ligand covalent binding method is used to measure binding of a reactive molecule with a particular unnatural residue on a protein of interest. Binding assessment can be measured by protein mass spectrometry or other direct-binding methodology. Unnatural amino acids can contain a variety of ‘bioorthogonal’ chemical handles. Pistoia SEED unnatural amino acid ligand covalent binding method the cysteine ligand covalent binding method is used to measure binding of a thiol-reactive molecule with a cysteine residue on a protein of interest. Binding assessment can be measured by protein mass spectrometry or other direct-binding methodology. Pistoia SEED cysteine ligand covalent binding method A method wherein liquid chromatography is coupled to tandem mass spectrometry. http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122168 http://purl.obolibrary.org/obo/CHMO_0000701 http://purl.obolibrary.org/obo/ERO_0001349 SEED Project - Pistoia Alliance liquid chromatography-tandem mass spectrometry Luminescence ligand binding methods detect the interaction between a ligand and its binding partner by measuring light emitted during the binding event, offering a sensitive, safe, and often high-throughput alternative to traditional binding assays. [NodeCreation: BAO v 2.8.15 (May 2025)] luminescence ligand binding method The NanoBiT method detects protein-protein interactions by splitting the NanoLuc luciferase into two inactive subunits (LgBiT and SmBiT) that, when fused to interacting proteins, reconstitute to produce a measurable bioluminescent signal, allowing for sensitive and real-time analysis, especially in live cells. [NodeCreation: BAO v 2.8.15 (May 2025)] https://doi.org/10.1038/s42003-022-03163-9 NanoBIT bao:BAO_0050002 Any method entailing primarily routine examination, requiring no special instrumentation. Date from BAE: 9/30/2016 PubChem AID: 687012 visual observation method bao:BAO_0050003 Any method entailing basic measurements that require no special instrumentation. Examples are measuring a tumor size using calipers, or a subject's weight using a scale. Date from BAE: 9/30/2016 PubChem AID: 687012 simple measurement method bao:BAO_0050004 Cherenkov counting can be used for detection of hard beta-emitting radionuclides via LSC, but its counting efficiency is sensitive to color quench, and depends on the emitted ß-energy, the sample volume and its concentration, the type of counting vial, rthe efractive index and the type of photocathode. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.3390/ma14216719 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) Cherenkov counting method bao:BAO_0050005 Radiometric imaging techniques are methods used to create images by detecting the decay of radiolabeled atoms, enabling accurate visualization of the distribution of radioactive atoms on two-dimensional (2D) surfaces. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1016/B978-012379777-3/50005-4 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) radiometric imaging method bao:BAO_0050006 Method used to separate excess free ligand must be separated rapidly from the bound receptor-ligand complex. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) radiometry separation method bao:BAO_0050007 Traditionally, tissue-organ baths are used for in vitro dose response experiments, used extensively to investigate the physiology and pharmacology of tissue preparations (ring/vessel or strip) from various species (chick, toad, rabbit, rat, guinea-pig, etc.). Tissues or organs have been isolated for these studies include muscle (Smooth or Skeletal), arterial rings or strips, uterine tissue or Vas deferens, ileum, colon, atrial or Ventricle and diaphragm. Typically, these experiments are performed in a temperature controlled environment and perfused with an oxygenated physiological solution, which allows the study of evoked tissue responses to pharmacological drug/agents (Dose Response studies), electrical stimulation or both pharmacological and electrical stimulation.The recorded responses or biological activity usually are the contraction/relaxation of muscle in the tissue: Force (isometric), Displacement (isotonic). [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) organ bath method bao:BAO_0050008 Electrical field stimulation, in which the stimulating current is applied uniformly to the tissue, is useful in several experimental situations. All muscle cells are simultaneously, directly, and nearly equally stimulated. Since each cell is excited without the necessity of propagation, field stimulation ensures that all cells become activated in visceral smooth muscle, despite possible lability of cell-to-cell transmission or decremental propagation, and in normally nonpropagating multiunit smooth muscles. When recording contraction of isolated smooth muscles, field stimulation enables the maximal (for a given set of conditions) isometric developed tension to be recorded because all cells are simultaneously in their active state, and the lack of longitudinal propagation minimizes the passive series elastic element contribution from uncontracted cells in series with contracted cells. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://link.springer.com/chapter/10.1007/978-1-4684-2751-6_16 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) electrical stimulation method bao:BAO_0050009 Method used for the detection of for detecting gamma radioaction emissions. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1177/000456328001700101 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) gamma counting method bao:BAO_0050010 A process where a rotating machine exposes a specimen to centrifugal force. This process can be used to remove moisture from a specimen, to subject an organism to increased gravitational forces, or to separate the components of heterogeneous mixtures based on density differences. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://www.eionet.europa.eu/gemet/en/concept/1262 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) centrifugation bao:BAO_0050011 Procedures used in binding assays for separation of bound and free ligands. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1002/jnr.490080405 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) filter assay method bao:BAO_0050012 In ligand binding assays and immunoassays, dextran-coated charcoal is commonly used to separate free ligands or hormones from their bound forms, such as antibody-bound hormones. Dextran "coats" the charcoal, creating a sieve-like surface that facilitates this separation. This method is particularly used in immunoassays to distinguish free hormones from those bound to antibodies. Studies have also explored how small molecules interact with charcoal alone or when mixed with substances like dextran, albumin, immunoglobulin (IgG), or insulin to better understand the mechanism of differential adsorption. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1080/15321818208056986 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) dextran-coated charcoal method bao:BAO_0050013 A proximity-based method is a biophysical approach used to monitor the spatial closeness of proteins or molecules within live cells by exploiting measurable signals generated through interactions, such as energy transfer, between tagged molecular components. For example, techniques like Bioluminescence Resonance Energy Transfer (BRET) utilize the transfer of energy from a donor enzyme (e.g., luciferase) to an acceptor fluorophore, resulting in a quantifiable signal that denotes proximity. These methods are widely applied to study protein-protein interactions, protein-ligand interactions, receptor proximity, and intracellular signaling. Advances in technologies such as NanoBRET and NanoBiT have further expanded the utility and scope of proximity-based methods for various biological applications. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.3389/fbioe.2019.00056 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) proximity-based method bao:BAO_0050014 The micturition assessment method is a technique used to evaluate bladder emptying rates and overall bladder motility. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1211/002235702397 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) micturition assessment method bao:BAO_0050015 The gut transit method is a technique used to evaluate gut function by tracking the movement of a substance through the gastrointestinal tract. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1038/s41598-018-23717-4 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) gut transit method bao:BAO_0050016 Electrical impedance measurement involves determining the difference (delta change) between the applied voltage and the corresponding current. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1016/B978-0-323-98337-2.00012-2 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) electrical impedance measurement bao:BAO_0050017 Isometric tension recording is a technique used to measure tension. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1007/s11302-024-09993-y Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) isometric tension recording method bao:BAO_0070002 The Tox21 compound collection is a library of approximately 10,000 (10K) environmental chemicals and drugs (~10,500 chemicals (~8,300 unique)), also referred to as the 'Tox21 10K library'. Several publications, from NCATS and EPA. See also https://www.epa.gov/chemical-research/toxicology-testing-21st-century-tox21 or https://ncats.nih.gov/tox21/about/operations. Tox21 Compound Library The effective concentration of an inhibitor, which produces 20% of the maximum possible response for that inhibitor. IC20 The effective concentration of an inhibitor, which produces 25% of the maximum possible response for that inhibitor. IC25 The effective concentration of an inhibitor, which produces 30% of the maximum possible response for that inhibitor. IC30 phenotypic mode of action neurite blebbing neurite branching neurite elongation neurite outgrowth neurite shortening axon bundle defasciculation axon fasciculation FPKM fragments per kilobase of exon per million mapped reads need to be reviewed NF-KappaB p65 translocation bao:BAO_0080013 percent neurite outgrowth bao:BAO_0080014 percent neurite count bao:BAO_0080015 percent neurite branch point The concentration of compound required to kill 50% of a cell population (i.e., 50% inhibitory concentration in a cytotoxicity assay). Date from BAE: 6/22/2016 PubChem AID: 2649 TC50 50% Tissue Culture Infective Dose (TCID50) is the measure of infectious virus titer. This endpoint dilution assay quantifies the amount of virus required to kill 50% of infected hosts or to produce a cytopathic effect in 50% of inoculated tissue culture cells. Date from BAE: 7/21/2016 PubChem AID: 2024 TCID50 Date from BAE: 7/19/2016 PubChem AID: 588831 reversible inhibition bao:BAO_0080019 Date from BAE: 7/19/2016 PubChem AID: rate bao:BAO_0080020 Date from BAE: 7/6/2016 PubChem AID: 602462 cm/sec bao:BAO_0080021 Date from BAE: 7/19/2016 PubChem AID: 652113 nmol/sec bao:BAO_0080022 Date from BAE: 7/21/2016 PubChem AID: 2024 log change bao:BAO_0080023 A simple binary assessment, such as 'active/ inactive', 'true/ false', etc. Date from BAE: 5/30/16 PubChem AID: 449752 binary unit Any result reported as a simple binary assessment, such as 'active/ inactive', 'true/ false', etc. Date from BAE: 5/30/2016 PubChem AID: 449752 binary endpoint signal decrease signal increase protein level true quantified endpoint bao:BAO_0080029 quantified entity metabaloid profile Cell Painting Profile epigenetic profile cell profile The Transfluor assay employs a a beta-arrestin-GFP fusion protein to detect activation of GPCRs: Upon ligand binding the GPCR, cytosolic arrestin-GFP quickly translocates to the cell membrane and then to endocytic vesicles, where it 'clusters' and can be detected by fluorescent image analysis. (Developed / commercialized by Norak, then Molecular Devices) beta-arrestin clustering assay The property values are divided by the average value for the positive control wells and multiplied by 100: X' = 100*(X/PosAvg) % positive control percent postive control perturbagen / positive control ratio endpoint RIS Relative Induction Score (RIS) SEED Project - Pistoia Alliance Relative Induction Score Maximum induction effect (dimensionless) Emax This is a measurement of how strongly a chemical species attenuates light at a given wavelength. Common units are L/(mol*cm). molar attenuation coefficient The maximum observed fold increase. max fold increase The fraction of compound that does not bind to substrate (e.x. plasma proteins) fraction unbound Count of cells as an endpoint cell count A ratio endpoint is the relative relation between two quantitative results (a/b) ratio endpoint The ratio of the concentration of molecule in whole blood (i.e. contains both red blood cells and plasma) to the concentration of molecule in plasma, namely CB/CP. blood to plasma ratio Ratio of AC50 values AC50 Ratio A categorical endpoint is any result that can take one of a limited number of possible values. categorical endpoint bao:BAO_0080046 Branch of endpoints reported by electrical measurements. https://github.com/Scientist328455 https://github.com/BioAssayOntology/BAO/issues/62 electrical endpoint Electrical current density is a measure of the density of flow of electric charge; it is the electric current per unit area of cross section. Electric current density is a vector-valued quantity. https://qudt.org/vocab/quantitykind/ElectricCurrentDensity https://github.com/Scientist328455 https://github.com/BioAssayOntology/BAO/issues/62 electrical current density The fraction of the bioavailable dose which has been metabolized. http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C184704 SEED Project - Pistoia Alliance fraction metabolised Kp values are defined as the ratio of total concentration of compound in the tissue to total concentration of compound in the plasma at steady state. tissue-to-plasma concentration ratio https://github.com/BioAssayOntology/BAO/issues/103 https://github.com/Scientist328455 Kp observed rate constant https://github.com/Scientist328455 kobs A physiological endpoint is a response from either an isolated tissue or organ (i.e. smooth muscle contraction, urine output ) that also serves as an observed enpoint for a bioassay. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) physiological endpoint The amount of urine excreted. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) urine output Ratio of functional bias calculated for a test agonist compound/the measured functional bias of a reference agonist compound allowing for normalization within a single assay (parameter: ΔLog τ/KA). [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) relative bias The bias factor, defined as 10ˆΔΔLogτ/KA(assay1-assay2), quantifies the difference in relative agonist activity between two assays. A higher bias factor indicates a greater distinction in the agonist's performance across the two assays relative to the reference agonist. [DefinitionUpdate: BAO v 2.8.15 (May 2025)] [NodeCreation: BAO v 2.8.13 (March 2025)] https://doi.org/10.1016/j.cell.2017.10.035 Opioid Drug Ontology (ODO) (https://opioiddrugontology.github.io/) - Nicolette Ross (https://orcid.org/0000-0002-4677-2140) bias factor bao:BAO_0100001 A fluorinated 4-methylumbelliferyl phosphate (MUP) derivative that has a lower pKa than that of MUP, making DiFMUP an excellent substrate for continuously assaying acid phosphatases at low pH. The reaction product of DiFMUP has excitation/emission maxima of ~358/450 nm. 6,8-Difluoro-4-Methylumbelliferyl Phosphate DiFMUP (Molecular Probes) bao:BAO_0100002 alamarBlue is a cell viability assay reagent which contains the cell permeable, non-toxic, and weakly fluorescent blue indicator dye called resazurin. Alamar Blue alamarBlue bao:BAO_0100003 Fluorescent dye with an excitation/emission maxima of ~555/580 nm. Alexa Fluor 555 Alexa555 Alexa555 bao:BAO_0100004 Fluorescent dye with an excitation/emission maxima of ~578/603 nm. Alexa Fluor 568 Alexa568 Alexa568 bao:BAO_0100005 Common buffer component with the chemical formula NH4CH3CO2. AmOAc ammonium ethanoate ammonium acetate bao:BAO_0100006 Used to reduce disulfide bonds 2-mercaptoethanol 2BME BME thioglycol β-mercaptoethanol beta-mercaptoethanol bao:BAO_0100007 Common buffering agent BTM Bis-tris methane BIS-TRIS bao:BAO_0100008 Blue-fluorescent DNA stain 4',6-diamidino-2-phenylindole DAPI bao:BAO_0100009 Organic solvent which allows for the denaturation and renaturation of nucleic acids at room temperature. Often used as a quenching agent. carbamaldehyde methanamide formamide bao:BAO_0100010 Hygroscopic salt commonly used in buffers Magnesium dichloride MgCl2 chloromagnestite magnesium chloride bao:BAO_0100011 Inorganic salt commonly used in buffers KCl potassium chloride bao:BAO_0100012 Commonly used salt NaCl sodium chloride bao:BAO_0100013 GPCR arrestin complex bao:BAO_0100014 GPCR complex bao:BAO_0110000 true chemical role bao:BAO_0110001 true application bao:BAO_0110002 true biological role bao:BAO_0110003 quencher bao:BAO_0110004 detection agent bao:BAO_0110005 rescue treatment bao:BAO_0110006 protein binding ligand bao:BAO_0120000 true cellular quality bao:BAO_0120001 true molecular quality bao:BAO_0120002 true organismal quality bao:BAO_0120003 true physical quality bao:BAO_0140001 PathScan Apoptosis and Proliferation Multiplex IF Kit bao:BAO_0140002 PathScan EGF Receptor Activation Multiplex IF Kit bao:BAO_0140003 PathScan EMT Duplex IF Kit bao:BAO_0140004 PathScan Multi-Target HCA DNA Damage Kit bao:BAO_0140005 PathScan Multi-Target HCA Stress and Apoptosis Kit bao:BAO_0140006 PathScan Signaling Nodes Multiplex IF Kit bao:BAO_0140007 StemLight Pluripotency Antibody Kit bao:BAO_0140009 CytoTox-Glo Cytotoxicity Assay (Promega) uses a luminogenic peptide substrate of luciferase, the AAF-Glo Substrate, to measure dead-cell protease activity, which is released from cells that have lost membrane integrity. Date from BAE: 6/22/2016 PubChem AID: 435031 https://www.promega.com/resources/protocols/technical-bulletins/101/cytotox-glo-cytotoxicity-assay-protocol/ CytoTox-Glo (Promega) bao:BAO_0140010 The CAT ELISA is used to quantitatively measure CAT expression in eukaryotic cells that are transfected with a plasmid bearing a CAT-encoding reporter gene. Date from BAE: 6/1/2016 PubChem AID: 624301 http://www.sigmaaldrich.com/catalog/product/roche/11363727001?lang=en&region=US CAT ELISA (Roche/ Sigma-Aldrich) bao:BAO_0140011 This assay directly measures the intracellular concentration of the second messenger cAMPin living cells, in real-time. It works with cell lines that contain a proprietary exogenous Cyclic Nucleotide-Gated (CNG) channel (BD Biosciences, sold to CodexBiosolutions; both in Maryland). The channel is activated by elevated intracellular levels of cAMP, resulting in ion flux (detectable by calcium-responsive dyes) and cell membrane depolarization which can be detected with a fluorescent membrane potential (MP) dye. Date from BAE: 6/7/2016 PubChem AID: 651719 http://www.bdbiosciences.com/ds/ab/others/SF47641.pdf ACTOne cAMP biosensor assay (BD Biosciences; CodexBIosolutions) bao:BAO_0140012 The CellTiter-Blue Cell Viability Assay provides a homogeneous, fluorescent method for monitoring cell viability. The assay is based on the ability of living cells to convert a redox dye (resazurin) into a fluorescent end product (resorufin) Date from BAE: 5/27/2016 PubChem AID: 1063 https://www.promega.com/products/cell-health-and-metabolism/cell-viability-assays/celltiter_blue-cell-viability-assay/ CellTiter-Blue Cell Viability Assay (Promega) bao:BAO_0140013 The Gal-Screen assay system combines direct cell lysis with rapid, ultra-sensitive chemiluminescent detection of _-galactosidase reporter enzyme. Date from BAE: 6/22/2016 PubChem AID: 2788 https://www.thermofisher.com/order/catalog/product/T1028 Gal-Screen Beta-Galactosidase Reporter Gene Assay system bao:BAO_0140014 Real-time PCR (or RT-PCR) for quantitation of DNA (or RNA, respectively) using the fluorescent dye SYBR green that binds dsDNA and emits fluorescence only when bound. Date from BAE: 6/26/2016 PubChem AID: 504907 https://www.qiagen.com/us/shop/pcr/real-time-pcr-enzymes-and-kits/two-step-qrt-pcr/quantitect-sybr-green-pcr-kits/#orderinginformation QuantiTect SYBR Green PCR Kits (Qiagen/Thermo-Fisher) bao:BAO_0140015 Real-time PCR (or RT-PCR) for quantitation of DNA (or RNA, respectively) using a pair of unlabeled PCR primers and a 'TaqMan' fluorogenic probe labeled on the 5' end and minor groove binder (MGB) and nonfluorescent quencher (NFQ) on the 3' end, to detect target as it accumulates during PCR. Date from BAE: 6/13/2016 PubChem AID: 720492 https://www.thermofisher.com/us/en/home/life-science/pcr/real-time-pcr/real-time-pcr-assays.html TaqMan Real-Time PCR assays (Thermo-Fisher) bao:BAO_0140016 Ultra-Glo (Promega) is a thermostable recombinant luciferase that can be coupled with different luciferin-based substrates to generate a luminescent signal proportional to the substrate abundance. Date from BAE: 6/26/2016 PubChem AID: 488901 Ultra-Glo Luciferin Detection (Promega) bao:BAO_0140017 An assay system (Promega) based on the bioluminescent enzyme luciferase's catalysis of the substrate luciferin to generate light, adapted for multiple applications, such as cell viability, apoptosis, or kinase, cytochrome P450, or proteasome activity. Date from BAE: 6/1/2016 PubChem AID: 624307 Luciferase-based ('Glo') Assay System (Promega) bao:BAO_0140018 A colorimatric assay for cell viability/ proliferation based on the stable tetrazolium salt WST-1, which is cleaved to a soluble formazan by a complex cellular mechanism that occurs primarily at the cell surface. This bioreduction is largely dependent on the glycolytic production of NAD(P)H in viable cells. Date from BAE: 6/30/2016 PubChem AID: 602337 WST-1 assay (Roche) bao:BAO_0140019 Date from BAE: 7/22/2016 PubChem AID: 540282 Reverse Transcription Kit (Applied Biosystems or ABI) bao:BAO_0140020 A homogeneous bead-based proximity assay (alpha = 'amplified luminescent proximity homogeneous assay'). Binding of molecules captured on donor and acceptor beads leads to an energy transfer from one bead to the other, ultimately producing a luminescent/fluorescent signal. Ligands on the bead allow for detection of many different types of molecules. Date from BAE: 7/6/2016 PubChem AID: 2444 Alpha Screen Assay Kit (PerkinElmer) bao:BAO_0140022 A solid phase sandwich ELISA to meaasure human cytochrome c in cell lysates Date from BAE: 7/3/2016 PubChem AID: 504407 Human Cytochrome c ELISA (R&D Systems) bao:BAO_0140023 Date from BAE: 7/14/2016 PubChem AID: 1271 OptEIA human IL-2 ELISA (BD Biosciences) bao:BAO_0140024 A fluorescence polarization (FP) assay that uses an antibody against ADP and a tracer to measure the progress of any enzyme that produces ADP Date from BAE: 7/6/2016 PubChem AID: 1795 TRANSCREENER ADP2 FP Kinase Assay (BellBrook Labs) bao:BAO_0140025 A fluorescence polarization (FP) assay. Date from BAE: 7/22/2016 PubChem AID: 504453 Polar Screen PPARg Competitor Assay, Green (Invitrogen) bao:BAO_0140026 QUANTI-Blue is a colorimetric enzyme assay to measure alkaline phosphatase activity. Date from BAE: 7/14/2016 PubChem AID: 1369 http://www.invivogen.com/quanti-blue QUANTI-Blue (InvivoGen) bao:BAO_0140027 The ToxiLighte BioAssay Kit is a bioluminescent cytolysis assay kit that measures release of the enzyme, adenylate kinase (AK), from damaged cells. Date from BAE: 7/9/2016 PubChem AID: 651654 ToxiLight BioAssay Kit (Lonza) bao:BAO_0140028 TransAM Kits are DNA-binding ELISAs that facilitate the study of transcription factor activation in mammalian tissue and cell extracts. Date from BAE: 7/14/2016 PubChem AID: 1295 https://www.activemotif.com/catalog/634/transam-nf%CE%BAb TransAM Kit for NF-kB Family (Active Motif) bao:BAO_0140029 A fluorescence polarization (FP) assay that uses an antibody against AMP or GMP and a tracer to measure the progress of any enzyme that produces AMP or GMP Date from BAE: 7/6/2016 PubChem AID: 651607 TRANSCREENER AMP2/GMP2 FP Assay (BellBrook Labs) bao:BAO_0140030 A homogeneous, bioluminescent assay to measure caspase-6 activity. Date from BAE: 9/30/2016 PubChem AID: 652277 Caspase-Glo 6 Assay System (Promega) bao:BAO_0140031 CDP-Star is a chemiluminescent substrate of alkaline phosphatase, compatible with both membrane- and solution-based assays. Sold by multiple vendors. Date from BAE: 9/30/2016 PubChem AID: 518 CDP-Star alkaline phosphatase assay system bao:BAO_0140032 An assay kit for measuring hepatitits C virus (HCV) NS3/4A protease activity using a 5-FAM/QXL520 fluorescence resonance energy transfer (FRET) peptide. Called 'Enzolyte' as well as 'Sensolyte'. Date from BAE: 9/30/2016 PubChem AID: 623964 http://www.anaspec.com/products/product.asp?id=30173 Sensolyte 520 HCV Protease Assay Kit (AnaSpec) bao:BAO_0140033 An absorbance-based assay system for measuring aspartate transaminase (known as serum glutamic oxaloacetic transaminase (GOT) or aspartate aminotransferase (ASAT/AAT)), based on the quantification of oxaloacetate produced by AST. In this assay, oxaloacetate and NADH are converted to malate and NAD by the enzyme malate dehydrogenase. The decrease in NADH absorbance at 340 nm is proportionate to AST activity. Date from BAE: 9/30/2016 PubChem AID: 743184 https://www.bioassaysys.com/Aspartate-Transaminase-Assay-Kit.html EnzyChrom Aspartate Transaminase Assay Kit (BioAssay Systems) bao:BAO_0140034 FluoZin-2 AM is a cell-permeant (acetoxymymethyl (AM)) fluorescent indicator designed to detect Zn2+ concentrations that are present in synaptic vesicles and released in response to electrical stimulation or excitotoxic agonists. (Sold by Molecular Probes, Themro-Fisher) Date from BAE: 9/30/2016 PubChem AID: 623952 FluoZin-2 AM fluorescent assay of zinc concentration bao:BAO_0140035 This homogeneous (HTRF) phospho-ERK assay is based on a TR-FRET sandwich immunoassay format comprising two specific monoclonal anti-pERK1/2 antibodies (recognizing the phosphorylated residue (Thr202/Tyr204), one labeled with Eu3+-cryptate (donor) and the other labeled with d2 (acceptor). The proximity of donor and acceptor leads to a fluorescent TR-FRET signal; the signal intensity is proportional to the substrate phosphorylation. Also called 'HTRF Cellul'ERK Kit'. Date from BAE: 9/30/2016 PubChem AID: 624053 Phospho-ERK1/2 (Thr202/Tyr204) Cellular Assay Kit (Cisbio) bao:BAO_0140036 IMAP (Immobilized Metal Ion Affinity Particle) technology is a non-antibody-based assay for protein kinases in which a fluorescently labeled peptide substrate that is phosphorylated by a kinase is captured on trivalent metal-containing nanoparticles. IMAP can be adapted for either FP or TR-FRET detection. Date from BAE: 9/30/2016 PubChem AID: 624076 IMAP Assay of phosphoproteins (Molecular Devices) bao:BAO_0140037 This Insulin ELISA kit is an FDA registered in vitro diagnostic tool for the quantification of human insulin. It uses a dual-monoclonal antibody sandwich ELISA format, typically in a 96-well or other microplate format, with colorimetric (OD 450 nm) detection. Date from BAE: 9/30/2016 PubChem AID: 488951 insulin ELISA kit (Alpco) bao:BAO_0140038 An assay to monitor protein ubiquitination, using ubiquitin labeled with the LanthaScreen terbium chelate, in combination with a FRET acceptor such as fluorescein-ubiquitin or a fluorescein-labeled antibody. Date from BAE: 9/30/2016 PubChem AID: 2658 LanthaScreen Tb-Ubiquitin Assay bao:BAO_0140039 A terbium-labeled streptavidin used in combination with a fluorescent molecule to detect interaction via a TR-FRET assay. Date from BAE: 9/30/2016 PubChem AID: 588664 LanthaScreen Tb-Streptavidin Binding Assay bao:BAO_0140040 An assay system employing enzyme fragment complementation (two fragments of the beta-galactosidase enzyme), applied in U2OS cells engineered to express two appropriately tagged proteins. Inhibition of Keap1-NRF2 interaction results in Nrf2 nuclear translocation, and susbequent complementation and formation of a functional enzyme, detected using a chemiluminescent substrate of beta-galactosidase. Date from BAE: 9/30/2016 PubChem AID: 651833 PathHunter U2OS Keap1-NRF2 Nuclear Translocation Assay (DiscoverX) bao:BAO_0140041 A general kit for use in all types of qRT-PCR reactions Date from BAE: 9/30/2016 PubChem AID: 623968 qScript One-step Fast qRT-PCR kit (QuantaBioSciences) bao:BAO_0140042 A bioluminescent assay sytem for detecting sea pansy (Renilla reniformis) luciferase, an alternative to the firefly (Photinus pyralis) systems. Date from BAE: 9/30/2016 PubChem AID: 624133 Renilla-Glo luciferase assay system (Promega) bao:BAO_0140043 An assay for deubiquitination activity, employing a reporter enzyme fused to ubiquitin (making the reporter catalytically inactive). Following cleavage of the Ub-reporter system by the isopeptidase, the free reporter can act upon its fluorescent substrate. Date from BAE: 9/30/2016 PubChem AID: 652174 Ub-CHOP2-Reporter-Kit (LifeSensors Inc.) bao:BAO_0140046 The CellTiter-Fluor Cell Viability Assay measures the relative number of viable cells in a population. The assay is based on measurement of a conserved and constitutive protease activity within live cells and therefore serves as a biomarker of cell viability. The live-cell protease activity is restricted to intact viable cells and is measured using a fluorogenic, cell-permeant, peptide substrate (Gly-Phe-AFC). The substrate enters intact cells, where it is cleaved by the live-cell protease activity to generate a fluorescent signal proportional to the number of living cells. The live-cell protease becomes inactive upon loss of membrane integrity and leakage into the surrounding culture medium. (description adapted from vendor Promega) CellTiter-Fluor Cell Viability Assay Kit bao:BAO_0140047 HepatoPac kit HepatoPac® HepatoPac® micropatterned co-culture SEED Project - Pistoia Alliance HEPATOPAC® co-culture kit bao:BAO_0150000 GE Healthcare http://www.biacore.com/high-content-analysis/index.html IN Cell Analyzer 2200 bao:BAO_0150001 GE Healthcare http://www.biacore.com/high-content-analysis/index.html IN Cell Analyzer 3000 bao:BAO_0150002 CellWoRx HCS Reader bao:BAO_0150003 Thermo Fisher Scientific www.cellomics.com CellInsight NXT HCS Platform bao:BAO_0150004 Thermo Fisher Scientific Cellomics ArrayScan II HCS Reader bao:BAO_0150005 Thermo Fisher Scientific Cellomics ArrayScan 3.1 HCS Reader bao:BAO_0150006 Thermo Fisher Scientific Cellomics ArrayScan 4.0 HCS Reader bao:BAO_0150007 Cellomics http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf KineticScan HCS Reader bao:BAO_0150008 microscope bao:BAO_0150009 optical microscope bao:BAO_0150010 confocal microscope bao:BAO_0150011 laser scanning confocal microscope bao:BAO_0150012 spinning-disk confocal microscope bao:BAO_0150013 laser capture microdissection microscope bao:BAO_0150014 scanning force microscope bao:BAO_0150015 wide-field microscope bao:BAO_0150016 objective lens bao:BAO_0150017 air interface objective lens bao:BAO_0150018 glycerin immersion lens bao:BAO_0150019 oil immersion lens bao:BAO_0150020 water immersion lens bao:BAO_0150021 image acquisition device bao:BAO_0150022 area detector bao:BAO_0150023 charge coupled device bao:BAO_0150024 complementary metal oxide semiconductor bao:BAO_0150025 electron multiplying charge coupled device bao:BAO_0150026 spot detector bao:BAO_0150027 photodiode bao:BAO_0150028 photomultiplier tube bao:BAO_0150029 light source bao:BAO_0150030 arc lamp bao:BAO_0150031 mercury-vapor lamp bao:BAO_0150032 xenon lamp bao:BAO_0150033 laser bao:BAO_0150034 diode laser bao:BAO_0150035 dye laser bao:BAO_0150036 gas laser bao:BAO_0150037 ion laser bao:BAO_0150038 argon-ion laser bao:BAO_0150039 helium-neon laser bao:BAO_0150040 krypton-ion laser bao:BAO_0150041 mixed argon-krypton gas laser bao:BAO_0150042 metal vapor laser bao:BAO_0150043 helium-cadmium laser bao:BAO_0150044 nitrogen laser bao:BAO_0150045 solid state laser bao:BAO_0150046 chromium-doped lithium strontium aluminum fluoride laser bao:BAO_0150047 neodymium-yttrium aluminum garnet laser bao:BAO_0150048 titanium-doped sapphire laser bao:BAO_0150049 light-emitting diode bao:BAO_0150050 tungsten halogen lamp bao:BAO_0150052 Automated patch clamp systems for ion channel research Date from BAE: 6/26/2016 PubChem AID: 2581 https://www.moleculardevices.com/systems/automated-electrophysiology IonWorks automated electrophysiology system (Molecular Devices) bao:BAO_0150053 Assay development system (plate-reader) with four modes: fluorescence, luminescence, absorbance, and Epi-absorbance (Molecular Devices) Date from BAE: 6/25/2016 PubChem AID: 463184 Analyst AD (Molecular Devices) bao:BAO_0150054 An instument for single-channel recoding and whole-cell voltage-clamp recording (Axon Instruments/ Molecular Devices) Date from BAE: 6/26/2016 PubChem AID: 504828 https://www.moleculardevices.com/systems/axon-conventional-patch-clamp/axopatch-200b-amplifier Axopatch 200B amplifier (Molecular Devices) bao:BAO_0150055 The BD LSRII FACS is an air-cooled multi-laser benchtop flow cytometer. Date from BAE: 5/11/2016 PubChem AID: 652043 Becton Dickinson (BD) LSRII FACS bao:BAO_0150056 The Synergy 2 Multi-Mode Plate Reader's (BioTek) detection modes include fluorescence intensity, fluorescence polarization, time-resolved fluorescence, AlphaScreen, luminescence and UV-visible absorbance. Date from BAE: 6/18/2016 PubChem AID: 652216 http://www.biotek.com/products/microplate_detection/synergy2_multimode_microplate_reader.html Synergy 2 Multi-Mode Reader (BioTek) bao:BAO_0150057 BMG PHERAstar is a multi-mode benchtop plate reader; FSX and other models (BMG Labtech) Date from BAE: 6/2/2016 PubChem AID: 435018 http://www.bmglabtech.com/en/products/pherastar-fsx/#tab-product-detail BMG PHERAstar FSX plate reader (BMG Labtech, Cary NC) bao:BAO_0150058 An automated cell counting device: Countess; Countes II FL has fluorescence capabilites (Invitrogen/ ThermoFisher) Date from BAE: 6/1/2016 PubChem AID: 588370 https://www.thermofisher.com/us/en/home/life-science/cell-analysis/cell-analysis-instruments/automated-cell-counters/countess-ii-fl-automated-cell-counter.html Countess automatic cell counter bao:BAO_0150059 A flow cell_based benchtop cytometer (Becton Dickinson (BD)) Date from BAE: 6/24/2016 PubChem AID: 1758 FacSCAN flow cytometer bao:BAO_0150060 A filter-based absorbance platereader for kinetic and endpoint assays (Molecualr Devices) Date from BAE: 6/22/2016 PubChem AID: 2649 https://www.moleculardevices.com/systems/microplate-readers/absorbance-readers Molecular Devices Vmax plate reader bao:BAO_0150061 Several models of UV-visible absorbance microplate readers: SpectraMax 190; SpectraMax Plus 384; SpectraMax 340PC384 (Molecular Devices) Date from BAE: 6/22/2016 PubChem AID: 504388 https://www.moleculardevices.com/systems/microplate-readers/absorbance-readers Molecular Devices SpectraMax Plate reader bao:BAO_0150062 Several models of automated patch clamp systems for studying ion channels: QPatch8, QPAtch16, QpatchHT (Biolin Scientific) Date from BAE: 5/13/2016 PubChem AID: 623915 http://www.biolinscientific.com/product/qpatch-88x/ Qpatch automated patch clamp system (Biolin) bao:BAO_0150063 One of several models of a plate-based real-time PCR device (Roche ) Date from BAE: 6/15/2016 PubChem AID: 651770, 720492 https://lifescience.roche.com/shop/products/lightcycler14301-480-instrument-ii LightCycler 480 Real-Time PCR detection instrument bao:BAO_0150064 The Agilent Mx3005P QPCR System, a benchtop RT-PCR plate reader, has been replaced with the AriaMx system (Agilent Technologies) Date from BAE: 6/7/2016 PubChem AID: 2427 http://www.genomics.agilent.com/en/Mx3005P-Mx3000P-qPCR-Instruments-Software/Mx3005P-qPCR-System/?cid=AG-PT-199&tabId=AG-PR-1127 Mx3005P RT-PCR instrument (Agilent Technologies) bao:BAO_0150065 The Synergy HT (or HTX) is a Multi-Mode Plate Reader (BioTek) is a single-channel absorbance, fluorescence and luminescence microplate reader. Date from BAE: 6/25/2016 PubChem AID: 504653 http://www.biotek.com/products/microplate_detection/synergy2_multimode_microplate_reader.html Synergy HT Multi-Mode Reader (BioTek) bao:BAO_0150066 One of several models of luminometer, either single-tube to multiple plate readers (Promega). Some models are multimode and can also read fluorescence or absorbance in addition to luminescence ) Date from BAE: 6/1/2016 PubChem AID: 624302 GloMax luminometer (Promega) bao:BAO_0150067 A mass spectrometer Date from BAE: 6/30/2016 PubChem AID: 602339 LTQ-Orbitrap Velos (Thermo Scientific) bao:BAO_0150068 Encompasses various models--ABI-9300, ABI-7500, and QuantStudio. Date from BAE: 7/22/2016 PubChem AID: 540282 Appled Biosystems Real-Time PCR System (ThermoFisher) bao:BAO_0150069 A mass spectrometer Date from BAE: 6/30/2016 PubChem AID: 602415 Agilent 1100 series LC-MSD SL bao:BAO_0150070 Date from BAE: 7/4/2016 PubChem AID: 2692 VE-2 whole-cell patch clamp amplifier (Alembic Instruments) bao:BAO_0150071 A microplate spectrophotometer Date from BAE: 7/10/2016 PubChem AID: 624061 micro-Quant Plate Reader (BioTek) bao:BAO_0150072 Date from BAE: 7/11/2016 PubChem AID: 651896 SpectraMax Gemini XS microplate fluorometer (Molecular Devices) bao:BAO_0150073 Date from BAE: 7/1/2016 PubChem AID: 602172 Typhoon FLA 9000 laser scanner (GE Healthcare) bao:BAO_0150074 Date from BAE: 7/12/2016 PubChem AID: 720723 Fluoroskan Ascent FL Microplate Fluorometer and Luminometer (ThermoFisher) bao:BAO_0150075 Date from BAE: 7/4/2016 PubChem AID: 2719 iMIC platform/ Polychrome V imaging system, (TILL Photonics/ FEI Munic GmbH) bao:BAO_0150076 Date from BAE: 7/2/2016 PubChem AID: 602457 Infinte M200 plate reader (Tecan) bao:BAO_0150077 Date from BAE: 7/12/2016 PubChem AID: 720722 Multiskan EX plate reader (Thermo Scientific) bao:BAO_0150078 Date from BAE: 7/18/2016 PubChem AID: 1061 Wallac 1420 (Victor2) Microplate reader (PerkinElmer) bao:BAO_0150079 Date from BAE: 7/20/2016 PubChem AID: 1745 SpectraFluor Plus Microplate Reader (Tecan) bao:BAO_0150080 Date from BAE: 7/8/2016 PubChem AID: 602143 TSQ Quantum Triple Quadrupole LC-MS (Thermo Scientific) bao:BAO_0150081 A laser-based scanner that produces digital images of radioactive, fluorescent, or chemiluminescent samples Date from BAE: 7/19/2016 PubChem AID: 623937 Typhoon Trio variable-mode imager (Amersham/ GE LifeSciences) bao:BAO_0150082 Date from BAE: 7/15/2016 PubChem AID: 456 https://www.gelifesciences.com/gehcls_images/GELS/Related%20Content/Files/1314742967685/litdoc28402704_20110831020220.pdf IN Cell Analyzer 1000 bao:BAO_0150083 The xCELLigence RTCA DP instrument uses noninvasive electrical impedance monitoring to quantify cell proliferation, morphology change, and attachment quality in a label-free, real-time manner. Date from BAE: 7/22/2016 PubChem AID: 602291 http://www.aceabio.com/product/rtca-dp/ xCELLigence RTCA DP cellular impedance instrument (Acea Biosciences) bao:BAO_0150084 Date from BAE: 9/30/2016 PubChem AID: 720665 BD FACSAria flow cytometer (BD Biosciences) bao:BAO_0150085 One of several models of surface plasmon resonance (SPR) instruments. Date from BAE: 9/30/2016 PubChem AID: 651876 Biacore 3000 SPR System (GE Healthcare) bao:BAO_0150086 Imaging system based on CCD high-resolution detection, supports multiple detection methods including fluorescence, colorimetry, densitometry, chemiluminescence, and chemifluorescence. Date from BAE: 9/30/2016 PubChem AID: 652251 ChemiDoc XRS Imaging System (BioRad) bao:BAO_0150087 9Date from BAE: /30/2016 PubChem AID: 720663 FACScalibur flow cytometer (BD Biosciences) bao:BAO_0150088 Date from BAE: 9/30/2016 PubChem AID: 623961 FLUOstar Omega microplate reader (BMG Labtech) bao:BAO_0150089 Date from BAE: 9/30/2016 PubChem AID: 623974 Pico patch clamp amplifier (Tecella) bao:BAO_0150090 An imaging system for blots, gels, etc, to replace use of film; can be used for autoradiography, fluorescence, and chemifluorescence imaging. Date from BAE: 9/30/2016 PubChem AID: 2704 Storm PhosphorImager (Molecular Dynamics/ GE) bao:BAO_0150091 Date from BAE: 9/30/2016 PubChem AID: 623970 Varioskan LUX multimode microplate reader (ThermoFisher) bao:BAO_0150092 Velos-MS bao:BAO_0150093 NGS Instrument bao:BAO_0150094 Odyssey Plate Reader bao:BAO_0150095 The Luminex 100/200 System is the combination of three core xMAP® Technologies. The first is xMAP microspheres, a family of fluorescently dyed micron-sized polystyrene microspheres that act as both the identifier and the solid surface to build the assay. The second is a flow cytometry-based instrument, the Luminex 100/200 analyzer, which integrates key xMAP detection components, such as lasers, optics, fluidics, and high-speed digital signal processors. The third component is the xPONENT® software, which is designed for protocol-based data acquisition with robust data regression analysis. From https://www.luminexcorp.com/research-luminex-100200/ Luminex 200 Flow Cytometer bao:BAO_0150096 The Luminex 200 system is a compact analyzer that performs up to 100 immunoassays simultaneously using a single drop of fluid. true Luminex 200 Flow Cytometer bao:BAO_0150097 The FlexStation 3 Multi-Mode Microplate Reader measures absorbance, fluorescence intensity, fluorescence polarization, luminescence, and time-resolved fluorescence for biochemical and cell-based assays. The reader adds up to three transfers of assay reagents from a 96- or 384-well source plate to enhance assay design using integrated fluidics. FlexStation 3 FlexStation III Microplate Reader bao:BAO_0150098 IN Cell Analyzer 2500HS is a widefield high-content imaging system equipped with deconvolution. IN Cell Analyzer 2500 bao:BAO_0150099 IN Cell Analyzer 6500HS is a laser-based high-content imaging system featuring IRIS confocal technology. IN Cell Analyzer 6500 bao:BAO_0150100 Spectramax L bao:BAO_0150101 PHERAstar FSX bao:BAO_0165000 people bao:BAO_0165001 researcher bao:BAO_0170001 The molecular characteristics of a cell of tissue including expressed coding and non-coding RNAs, proteins and their post-translational modifications, lipids, carbohydrates and small molecules that characterize the state in a cell or tissue and that result from the interaction of its genotype and the environment. molecular phenotype bao:BAO_0170002 The form and structure of an organism and its parts, including cells, that result from the interaction of its genotype and the environment. morphological phenotype bao:BAO_0170003 The proteins and their post-translational modifications, lipids, carbohydrates and small molecules that characterize the state in a cell or tissue and that result from the interaction of its genotype and the environment. biochemical phenotype bao:BAO_0170004 The coding and non-coding RNAs expressed in a cell or tissue that result from the interaction of its genotype and the environment. transcriptional phenotype bao:BAO_0170005 cellular state phenotype bao:BAO_0170006 autophagic cell phenotype bao:BAO_0170007 inflamed cell phenotype bao:BAO_0170008 inflamed blood vessel cell phenotype bao:BAO_0170009 neuronal cell phenotype bao:BAO_0170010 developing neuron bao:BAO_0170011 regenerating neuron bao:BAO_0170012 dead cell phenotype bao:BAO_0170013 dying cell phenotype bao:BAO_0170014 necrotic cell phenotype bao:BAO_0170015 apoptotic cell phenotype bao:BAO_0170016 cell cycle phase phenotype bao:BAO_0170017 mitotic cell phenotype M phase mitotic cell phenotype bao:BAO_0170018 DNA replicated mitotic cell phenotype S phase mitotic cell phenotype bao:BAO_0170019 molecular localization phenotype bao:BAO_0170020 NF-KappaB p65 translocation phenotype bao:BAO_0170021 molecular expression phenotype bao:BAO_0170022 neuronal morphology phenotype bao:BAO_0170023 blebbed neurite phenotype bao:BAO_0170024 branched neurite phenotype bao:BAO_0170025 defasciculated axon bundles phenotype bao:BAO_0170026 elongated neurite phenotype bao:BAO_0170027 fasciculated axons phenotype bao:BAO_0170028 shortened neurite phenotype bao:BAO_0170029 rounded cell phenotype bao:BAO_0170030 shrunken cell phenotype bao:BAO_0170031 blebbed axon phenotype bao:BAO_0170032 blebbed dendrite phenotype bao:BAO_0180001 Perkin Elmer Acapella bao:BAO_0180002 BD AttoVision bao:BAO_0180003 BioImageXD bao:BAO_0180004 image analysis software bao:BAO_0180005 CellProfiler bao:BAO_0180006 Cellomics BioApplication bao:BAO_0180007 DCILabs bao:BAO_0180008 Fiji bao:BAO_0180009 IN Cell Investigator bao:BAO_0180010 Icy bao:BAO_0180011 ImageJ bao:BAO_0180012 MATLAB bao:BAO_0180013 MetaXpress bao:BAO_0180014 SlideBook software bao:BAO_0180015 MetaMorph bao:BAO_0180016 Perkin Elmer Volocity 3D Image Analysis Software bao:BAO_0180017 Perkin Elmer Harmony bao:BAO_0180018 sequencing data alignment software bao:BAO_0180019 Cufflinks bao:BAO_0180020 TopHat bao:BAO_0180021 Bowtie bao:BAO_0180022 sequencing data analysis software bao:BAO_0180023 Cuffcompare bao:BAO_0180024 Cuffdiff bao:BAO_0190000 It describes the most common unit used in calculating volumetric stoichiometry: molarity. Units include: molar, millimolar, micromolar, nanomolar. true concentration unit bao:BAO_0190001 true ratio bao:BAO_0190002 true temperature unit bao:BAO_0190003 true time unit bao:BAO_0190004 Negative base-10 logarithm of KI, the equilibrium dissociation constant (Ki) of an antogonist-receptor complex pKi bao:BAO_0190005 Negative base-10 logarithm of a solution's KD (drug affinity dissociation constant) pKd bao:BAO_0190006 Negative base-10 logarithm of a solution's base dissociation constant (Kb) pKb bao:BAO_0190007 true http://purl.obolibrary.org/obo/UO_0000317 duplicate: cells per microliter (UO_0000316) cells per well bao:BAO_0190008 true http://purl.obolibrary.org/obo/UO_0000316 duplicate: cells per well (UO_0000317) cells per microliter bao:BAO_0200000 A biotechnology company that develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping, gene expression, and proteomics markets. Explanation: Not currently available as a commercial company, but well known and used in next-gen sequencing circles. Illumina bao:BAO_0700003 A synthetic ligand consisting of a small molecule tethered (covalently or non-covalently) to a peptide. Date from BAE: 5/5/2016 PubChem AID: 451462 bivalent small molecule-peptide bao:BAO_0700004 Any compound library consisting solely of small molecules that have been approved by the FDA. Often used for 'drug re-purposing' assays. The specific compounds included in any given FDA-approved compound library may differ based on availability or timing. Date from BAE: 9/30/2016 PubChem AID: 1117303 FDA-approved compound library efo:EFO_0001272 A maturity quality inhering in an individual by virtue of the individual having attained sexual maturity and full growth James Malone OntologyMappingImporter following MAT:0000403 Tomasz Adamusiak EV:0300070 EVM:2990028 FBdv:00005369 MAT:0000403 MSH:D000328 NCIt:C17600 NIFSTD:birnlex_228 NIFSTD:birnlex_681 SNOMEDCT:133936004 WBls:0000041 XAO:1000009 adult stage adult efo:EFO_0001291 James Malone ZFS:0000017 Gastrula:50%-epiboly gastrula 50%-epiboly efo:EFO_0001292 James Malone ZFS:0000020 Gastrula:75%-epiboly gastrula 75%-epiboly efo:EFO_0001293 James Malone ZFS:0000021 Gastrula:90%-epiboly gastrula 90%-epiboly efo:EFO_0001323 Catherine Leroy James Malone http://purl.obolibrary.org/obo/UBERON_0000323 2.61 true use : http://purl.obolibrary.org/obo/UBERON_0000323 label : late embryo EV:0300011 EVM:2990031 FBdv:0005333 MAT:0000399 embryo late (growth) stage obsolete_fetus true efo:EFO_0002560 Jie Zheng Tomasz Adamusiak gastrula 80%-epiboly efo:EFO_0002562 mouse embryo stage at age 11.5 days Jie Zheng Tomasz Adamusiak embryonic day 11.5 efo:EFO_0002563 mouse embryo stage at age 12.5 days Jie Zheng Tomasz Adamusiak embryonic day 12.5 efo:EFO_0002564 mouse embryo stage at age 13.5 days Jie Zheng Tomasz Adamusiak embryonic day 13.5 efo:EFO_0002565 mouse embryo stage at age 14.5 days Jie Zheng Tomasz Adamusiak embryonic day 14.5 efo:EFO_0002566 mouse embryo stage at age 15.5 days Jie Zheng Tomasz Adamusiak embryonic day 15.5 efo:EFO_0002567 mouse embryo stage at age 16.5 days Jie Zheng Tomasz Adamusiak embryonic day 16.5 efo:EFO_0002568 mouse embryo stage at age 17.5 days Jie Zheng Tomasz Adamusiak embryonic day 17.5 efo:EFO_0002569 mouse embryo stage at age 18 days Jie Zheng Tomasz Adamusiak embryonic day 18 efo:EFO_0002570 mouse embryo stage at age 18.5 days Jie Zheng Tomasz Adamusiak embryonic day 18.5 efo:EFO_0002948 The stage of the mother from immediately after the birth of offspring and extending for about six weeks The time period after birth. NCIt:C81317 SNOMEDCT:263844007 postnatal owl:Thing 2.8.15 has assay design method has assay supporting method May 30, 2025 Contact: Stephan Schurer stephan dot schurer at med dot miami dot edu Created by: Caty Chung, Nicolette Ross, Joan Glenny-Pescov, Jiaming Hu, Stephan Schurer* BAO BioAssay Ontology 2.8.15 March 9, 2023 Contact: Stephan Schurer schurer at med dot miami dot edu Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Nicolette Ross, Joan Glenny-Pescov, Jiaming Hu, Caty Chung, Stephan Schurer* BAO BioAssay Ontology 2.7.5 May 30, 2025 Contact: Stephan Schurer stephan dot schurer at med dot miami dot edu Created by: Caty Chung, Nicolette Ross, Joan Glenny-Pescov, Jiaming Hu, Stephan Schurer* BAO BioAssay Ontology 2.8.15 8 Jul 2021 Contact: Stephan Schurer stephan dot schurer at gmail dot com Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* BAO BioAssay Ontology 2.7.2 May 30, 2025 Contact: Stephan Schurer stephan dot schurer at med dot miami dot edu Created by: Caty Chung, Nicolette Ross, Joan Glenny-Pescov, Jiaming Hu, Stephan Schurer* BAO BioAssay Ontology 2.8.15 8 Jul 2021 Contact: Stephan Schurer stephan dot schurer at gmail dot com Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* BAO BioAssay Ontology 2.7.2 May 30, 2025 Contact: Stephan Schurer stephan dot schurer at med dot miami dot edu Created by: Caty Chung, Nicolette Ross, Joan Glenny-Pescov, Jiaming Hu, Stephan Schurer* BAO BioAssay Ontology 2.8.15 May 30, 2025 Contact: Stephan Schurer stephan dot schurer at med dot miami dot edu Created by: Caty Chung, Nicolette Ross, Joan Glenny-Pescov, Jiaming Hu, Stephan Schurer* BAO BioAssay Ontology 2.8.15 8 Jul 2021 Contact: Stephan Schurer stephan dot schurer at gmail dot com Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* BAO BioAssay Ontology 2.7.2 10 Nov 2022 Contact: Stephan Schurer stephan dot schurer at gmail dot com Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Nicolette Ross, Joan Glenny-Pescov, Jiaming Hu, Caty Chung, Stephan Schurer* BAO BioAssay Ontology 2.7.4 29 June 2023 Contact: Stephan Schurer stephan dot schurer at med dot miami dot edu Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, add_name, Stephan Schurer* BAO BioAssay Ontology 2.8.6 May 30, 2025 Contact: Stephan Schurer stephan dot schurer at med dot miami dot edu BAO BioAssay Ontology 2.8.15 8 Jul 2021 Contact: Stephan Schurer stephan dot schurer at gmail dot com Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* BAO BioAssay Ontology 2.7.2 8 Jul 2021 Contact: Stephan Schurer stephan dot schurer at gmail dot com Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* BAO BioAssay Ontology 2.7.2 8 Jul 2021 Contact: Stephan Schurer stephan dot schurer at gmail dot com Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* BAO BioAssay Ontology 2.7.2 May 12, 2023 Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner,colette Ross, Joan Glenny-Pescov, Jiaming Hu, Caty Chung, Stephan Schurer* There is a one-to-one correspondance with rdf:label value and concept descriptions. Concept description starts with the prefix BAO_. contact: Stephan Schurer: stephan dot schurer at gmail dot com Bioassay ontology 2.8.2 8 Jul 2021 Contact: Stephan Schurer stephan dot schurer at gmail dot com Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* BAO BioAssay Ontology 2.7.2 May 30, 2025 Contact: Stephan Schurer stephan dot schurer at med dot miami dot edu BAO BioAssay Ontology 2.8.15 There is a one-to-one correspondance with rdf:label value and concept descriptions. Concept description starts with the prefix BAO_. contact: Stephan Schurer: stephan dot schurer at gmail dot com created by: Uma Vempati, Hande Küçük, Ubbo Visser, Saminda Abeyruwan, Kunie Sakurai, Vance Lemmon, Stephan Schurer* bioassay ontology 2.1 8 Jul 2021 Contact: Stephan Schurer stephan dot schurer at gmail dot com Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* BAO BioAssay Ontology 2.7.2 8 Jul 2021 Contact: Stephan Schurer stephan dot schurer at gmail dot com Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* BAO BioAssay Ontology 2.7.2 8 Jul 2021 Contact: Stephan Schurer stephan dot schurer at gmail dot com Created by: Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* BAO BioAssay Ontology 2.7.2 January 17, 2025 Contact: Stephan Schurer stephan dot schurer at med dot miami dot edu Created by: Saminda Abeyruwan, Caty Chung, Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Nicolette Ross, Joan Glenny-Pescov, Jiaming Hu, Stephan Schurer* BAO BioAssay Ontology 2.8.12